haloperidol NN 0 1 16 B-Drug
; : 0 0 2 O

While IN 0 0 12 O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
chronic JJ 0 1 6 O
phenytoin NN 0 1 16 B-Drug
or CC 0 0 12 O
carbamazepine NN 0 1 16 B-Drug
therapy NN 0 1 6 O
on IN 0 0 12 O
the DT 0 0 12 O
action NN 0 1 13 O
of IN 0 0 12 O
MIVACRON NNP 0 1 UNK B-Brand
are VBP 1 0 12 O
unknown JJ 0 1 12 O
slightly RB 0 1 3 O
shorter JJR 1 1 UNK O
durations NNS 1 1 1 O
of IN 0 0 12 O
neuromuscular JJ 0 1 6 O
block NN 0 1 3 O
may MD 0 0 1 O
be VB 0 0 12 O
anticipated VBN 1 1 1 O
and CC 0 0 12 O
infusion NN 0 1 14 O
rate NN 0 1 1 O
requirements NNS 1 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
higher JJR 1 1 1 O
. . 0 0 12 O

Although IN 0 0 12 O
a DT 0 0 12 O
causal NN 0 1 UNK O
relationship NN 0 1 12 O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
established VBN 1 1 1 O
there EX 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reports NNS 1 1 1 O
of IN 0 0 12 O
bleeding NN 0 1 6 O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
prolonged VBN 1 1 6 O
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
in IN 0 0 12 O
patients NNS 1 1 6 O
treated VBN 1 1 1 O
with IN 0 0 12 O
TRENTAL NNP 0 1 UNK B-Brand
with IN 0 0 12 O
and CC 0 0 12 O
without IN 0 0 12 O
anticoagulants NNS 1 1 13 B-Group
or CC 0 0 12 O
platelet VB 0 1 14 B-Group
aggregation NN 0 1 UNK I-Group
inhibitors NNS 1 1 14 I-Group
. . 0 0 12 O

Increasing VBG 0 1 2 O
the DT 0 0 12 O
indinavir NN 0 1 16 B-Drug
dose NN 0 1 6 O
to TO 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
every DT 0 0 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
does VBZ 1 0 12 O
not RB 0 1 12 O
compensate VB 0 1 1 O
for IN 0 0 12 O
the DT 0 0 12 O
increased VBN 1 1 1 O
indinavir NN 0 1 16 B-Drug
metabolism NN 0 1 16 O
due JJ 0 1 1 O
to TO 0 0 12 O
SUSTIVA NNP 0 1 UNK B-Brand
. . 0 0 12 O

These DT 0 0 1 O
effects NNS 1 1 1 O
were VBD 1 0 12 O
not RB 0 1 12 O
considered VBN 1 1 1 O
clinically RB 0 0 6 O
important JJ 0 1 1 O
. . 0 0 12 O

ROMAZICON NN 0 1 UNK B-Brand
blocks VBZ 1 1 3 O
the DT 0 0 12 O
central JJ 0 1 1 O
effects NNS 1 1 1 O
of IN 0 0 12 O
benzodiazepines NNS 1 1 14 B-Group
by IN 0 0 12 O
competitive JJ 0 1 UNK O
interaction NN 0 1 UNK O
at IN 0 0 12 O
the DT 0 0 12 O
receptor NN 0 1 14 O
level NN 0 1 1 O
. . 0 0 12 O

Although IN 0 0 12 O
specific JJ 0 1 1 O
drug NN 0 1 1 O
or CC 0 0 12 O
food NN 0 1 12 O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
mifepristone NN 0 1 UNK B-Drug
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
studied VBN 1 0 1 O
on IN 0 0 12 O
the DT 0 0 12 O
basis NN 0 1 1 O
of IN 0 0 12 O
this DT 0 0 12 O
drug NN 0 1 1 O
metabolism NN 0 1 16 O
by IN 0 0 12 O
CYP NNP 0 1 UNK O
9A9 CD 0 0 UNK O
it PRP 0 0 12 O
is VBZ 1 0 12 O
possible JJ 0 1 1 O
that IN 0 0 12 O
ketoconazole JJ 0 1 16 B-Drug
itraconazole JJ 0 1 0 B-Drug
erythromycin NN 0 1 0 B-Drug
and CC 0 0 12 O
grapefruit NN 0 1 3 O
juice NN 0 1 3 O
may MD 0 0 1 O
inhibit VB 0 1 13 O
its PRP$ 1 0 12 O
metabolism NN 0 1 16 O
( ( 0 0 2 O
increasing VBG 1 1 1 O
serum NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
mifepristone NN 0 1 UNK B-Drug
) ) 0 0 2 O
. . 0 0 12 O

Usually RB 0 1 UNK O
the DT 0 0 12 O
dosage NN 0 1 0 O
of IN 0 0 12 O
the DT 0 0 12 O
anticoagulant NN 0 1 13 B-Group
should MD 0 0 12 O
be VB 0 0 12 O
reduced VBN 1 1 1 O
by IN 0 0 12 O
one CD 0 1 12 O
- : 0 0 2 O
half NN 0 1 12 O
( ( 0 0 2 O
depending VBG 1 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
individual JJ 0 1 1 O
case NN 0 1 12 O
) ) 0 0 2 O
to TO 0 0 12 O
maintain VB 0 1 1 O
the DT 0 0 12 O
prothrombin NN 0 1 14 O
time NN 0 1 12 O
at IN 0 0 12 O
the DT 0 0 12 O
desired JJ 0 1 1 O
level NN 0 1 1 O
to TO 0 0 12 O
prevent VB 0 1 1 O
bleeding JJ 0 1 6 O
complications NNS 1 1 6 O
. . 0 0 12 O

In IN 0 0 2 O
general JJ 0 1 1 O
these DT 0 0 12 O
are VBP 1 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
have VBP 0 0 12 O
one CD 0 1 12 O
or CC 0 0 12 O
more JJR 0 1 12 O
pharmacologic JJ 0 1 14 O
activities NNS 1 1 1 O
similar JJ 0 1 1 O
to TO 0 0 12 O
bepridil VB 0 1 UNK B-Drug
hydrochloride JJ 0 1 0 I-Drug
including VBG 1 1 1 O
anti JJ 0 0 3 B-Group
- : 0 0 2 O
arrhythmic JJ 0 0 UNK I-Group
agents NNS 1 1 1 I-Group
such JJ 0 0 1 O
as IN 1 0 12 O
quinidine NN 0 1 16 B-Drug
and CC 0 0 12 O
procainamide JJ 0 1 16 B-Drug
cardiac JJ 0 1 6 B-Group
glycosides NNS 1 1 13 I-Group
and CC 0 0 12 O
tricyclic JJ 0 0 14 B-Group
anti SYM 0 0 3 I-Group
- : 0 0 2 O
depressants NNS 1 0 13 I-Group
. . 0 0 12 O

Ketoconazole NNP 0 1 UNK B-Drug
: : 0 0 2 O
Sensipar NN 0 1 UNK B-Brand
is VBZ 1 0 12 O
metabolized VBN 1 1 UNK O
in IN 0 0 12 O
part NN 0 1 12 O
by IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
. . 0 0 12 O

decreased VBN 1 1 1 O
antithrombin JJ 0 1 14 B-Drug
9 CD 0 0 2 I-Drug
; : 0 0 2 O

Since IN 0 1 2 O
the DT 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
with IN 0 0 12 O
amiodarone NN 0 1 0 B-Drug
increases VBZ 1 1 1 O
the DT 0 0 12 O
prothrombin NN 0 1 14 O
time NN 0 1 12 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
after IN 0 0 12 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
the DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
the DT 0 0 12 O
anticoagulant NN 0 1 13 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
reduced VBN 1 1 1 O
by IN 0 0 12 O
one CD 0 1 12 O
- : 0 0 2 O
third NN 0 1 12 O
to TO 0 0 12 O
one CD 0 1 12 O
- : 0 0 2 O
half NN 0 1 12 O
and CC 0 0 12 O
prothrombin JJ 0 1 14 O
times NNS 1 1 12 O
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
closely RB 0 0 1 O
. . 0 0 12 O

structural JJ 0 1 1 O
heart NN 0 1 12 O
disease NN 0 1 6 O
is VBZ 1 0 12 O
a DT 0 0 12 O
known JJ 0 1 12 O
risk NN 0 1 1 O
factor NN 0 1 1 O
for IN 0 0 12 O
arrhythmia NN 0 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
concomitant JJ 0 1 6 O
intake NN 0 1 3 O
of IN 0 0 12 O
alcohol NN 0 1 1 B-Drug
and CC 0 0 12 O
Acamprosate NNP 0 1 UNK B-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
affect VB 0 1 1 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
either DT 0 1 12 O
alcohol NN 0 1 1 B-Drug
or CC 0 0 12 O
acamprosate NN 0 1 13 B-Drug
. . 0 0 12 O

Therefore RB 0 0 1 O
caution NN 0 0 1 O
should MD 0 0 12 O
be VB 0 0 12 O
exercised VBN 1 1 1 O
when WRB 0 0 12 O
administering VBG 1 1 1 O
TOLECTIN NNP 0 1 UNK B-Brand
to TO 0 0 12 O
patients NNS 1 1 6 O
on IN 0 0 12 O
anticoagulants NNS 1 1 13 B-Group
. . 0 0 12 O

Patients NNS 0 1 7 O
with IN 0 0 12 O
major JJ 0 1 1 O
psychotic JJ 0 1 6 O
disorders NNS 1 1 6 O
treated VBD 1 1 1 O
with IN 0 0 12 O
neuroleptics NNS 1 1 13 B-Group
should MD 0 0 12 O
be VB 0 0 12 O
treated VBN 1 1 1 O
with IN 0 0 12 O
dopamine NN 0 1 14 B-Group
agonists NNS 1 1 UNK I-Group
only RB 0 1 12 O
if IN 0 0 12 O
the DT 0 0 12 O
potential JJ 0 1 1 O
benefits NNS 1 1 1 O
outweigh VBP 0 0 1 O
the DT 0 0 12 O
risks NNS 1 1 1 O
. . 0 0 12 O

Population NNP 0 1 UNK O
PK NNP 0 0 UNK O
analysis NN 0 1 1 O
with IN 0 0 12 O
a DT 0 0 12 O
database NN 0 1 UNK O
of IN 0 0 12 O
9 CD 0 0 2 O
patients NNS 1 1 6 O
showed VBD 1 1 12 O
that IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
rivastigmine NN 0 1 16 B-Drug
were VBD 1 0 12 O
not RB 0 1 12 O
influenced VBN 1 1 UNK O
by IN 0 0 12 O
commonly RB 0 0 UNK O
prescribed VBN 1 1 1 O
medications NNS 1 1 6 O
such JJ 0 0 1 O
as IN 1 0 12 O
antacids NNS 1 1 14 B-Group
( ( 0 0 2 O
n=9 NN 0 1 UNK O
) ) 0 0 2 O
antihypertensives VBZ 0 1 14 B-Group
( ( 0 0 2 O
n=9 NN 0 1 UNK O
) ) 0 0 2 O
calcium NN 0 1 14 B-Group
channel NN 0 1 1 I-Group
blockers NNS 1 0 6 I-Group
( ( 0 0 2 O
n=9 NN 0 1 UNK O
) ) 0 0 2 O
antidiabetics NNS 1 1 UNK B-Group
( ( 0 0 2 O
n=9 NN 0 1 UNK O
) ) 0 0 2 O
nonsteroidal FW 0 0 14 B-Group
anti SYM 0 0 3 I-Group
- : 0 0 2 O
inflammatory NN 0 1 6 I-Group
drugs NNS 1 1 6 I-Group
( ( 0 0 2 O
n=9 NN 0 1 UNK O
) ) 0 0 2 O
estrogens VBZ 0 1 16 B-Group
( ( 0 0 2 O
n=9 NN 0 1 UNK O
) ) 0 0 2 O
salicylate NN 0 1 13 B-Group
analgesics NNS 1 1 14 I-Group
( ( 0 0 2 O
n=9 NN 0 1 UNK O
) ) 0 0 2 O
antianginals NNS 0 1 UNK B-Group
( ( 0 0 2 O
n=9 NN 0 1 UNK O
) ) 0 0 2 O
and CC 0 0 12 O
antihistamines NNS 1 1 UNK B-Group
( ( 0 0 2 O
n=9 NN 0 1 UNK O
) ) 0 0 2 O
. . 0 0 12 O

Thus RB 0 0 1 O
when WRB 0 0 12 O
NSAIDs NNP 0 1 UNK B-Group
and CC 0 0 12 O
lithium NN 0 1 16 B-Drug
are VBP 1 0 12 O
administered VBN 1 1 1 O
concurrently RB 0 0 1 O
subjects NNS 1 1 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
observed VBN 1 1 1 O
carefully RB 0 0 12 O
for IN 0 0 12 O
signs NNS 1 1 12 O
of IN 0 0 12 O
lithium NN 0 1 16 B-Drug
toxicity NN 0 1 6 O
. . 0 0 12 O

Although IN 0 0 12 O
increased VBN 1 1 1 O
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
( ( 0 0 2 O
AUC NNP 0 1 UNK O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
hrs NN 1 0 16 O
) ) 0 0 2 O
of IN 0 0 12 O
loratadine NN 0 1 0 B-Drug
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
descarboethoxyloratadine NN 0 1 UNK B-Drug
were VBD 1 0 12 O
observed VBN 1 1 1 O
following VBG 1 1 1 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
loratadine NN 0 1 0 B-Drug
with IN 0 0 12 O
each DT 0 0 12 O
of IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
in IN 0 0 12 O
normal JJ 0 1 1 O
volunteers NNS 1 1 UNK O
( ( 0 0 2 O
n JJ 0 1 12 O
= NN 0 0 2 O
9 CD 0 0 2 O
in IN 0 0 12 O
each DT 0 0 12 O
study NN 0 1 1 O
) ) 0 0 2 O
there EX 0 0 12 O
were VBD 1 0 12 O
no DT 0 0 12 O
clinically RB 0 0 6 O
relevant JJ 0 1 1 O
changes NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
safety NN 0 1 1 O
profile NN 0 1 1 O
of IN 0 0 12 O
loratadine NN 0 1 0 B-Drug
as IN 1 0 12 O
assessed VBN 1 1 1 O
by IN 0 0 12 O
electrocardiographic JJ 0 1 8 O
parameters NNS 1 1 1 O
clinical JJ 0 1 6 O
laboratory NN 0 1 1 O
tests NNS 1 1 1 O
vital JJ 0 1 1 O
signs NNS 1 1 12 O
and CC 0 0 12 O
adverse JJ 0 0 1 O
events NNS 1 1 12 O
. . 0 0 12 O

Central NNP 0 1 2 B-Group
nervous JJ 0 1 6 I-Group
system NN 0 1 1 I-Group
depressant NN 0 0 UNK I-Group
( ( 0 0 2 O
CNS NNP 0 1 6 O
) ) 0 0 2 O
drugs NNS 1 1 6 O
including VBG 1 1 1 O
alcohol NN 0 1 1 B-Drug
antidepressants NNS 1 1 13 B-Group
antihistamines VBP 0 1 UNK B-Group
antipsychotics NNS 1 1 14 B-Group
blood NN 0 1 6 O
pressure NN 0 1 1 O
medications NNS 1 1 6 O
( ( 0 0 2 O
reserpine VB 0 1 UNK B-Drug
methyldopa NN 0 1 13 B-Drug
beta SYM 0 1 16 B-Group
- : 0 0 2 O
blockers NNS 1 0 6 I-Group
) ) 0 0 2 O
motion NN 0 1 1 O
sickness NN 0 1 13 O
medications NNS 1 1 6 O
muscle NN 0 1 6 B-Group
relaxants NNS 1 0 13 I-Group
narcotics VBP 0 1 1 B-Group
sedatives NNS 1 1 6 B-Group
sleeping VBG 1 1 12 O
pills NNS 1 1 6 O
and CC 0 0 12 O
tranquilizers NNS 1 1 13 B-Group

Tricyclic JJ 0 0 UNK B-Group
antidepressants NNS 1 1 13 I-Group
may MD 0 0 1 O
block VB 0 1 3 O
the DT 0 0 12 O
antihypertensive JJ 0 1 14 O
action NN 0 1 13 O
of IN 0 0 12 O
guanethidine NN 0 1 UNK B-Drug
and CC 0 0 12 O
similarly RB 0 0 1 O
acting VBG 1 1 12 O
compounds NNS 1 1 13 O
. . 0 0 12 O

Epirubicin NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
extensively RB 0 0 1 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
the DT 0 0 12 O
liver NN 0 1 6 O
. . 0 0 12 O

- : 0 0 2 O
Changes NNS 0 1 2 O
in IN 0 0 12 O
TBg NNP 0 1 UNK O
concentration NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
taken VBN 1 1 12 O
into IN 0 0 12 O
consideration NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
interpretation NN 0 1 1 O
of IN 0 0 12 O
T9 NNP 0 1 13 O
and CC 0 0 12 O
T9 NNP 0 1 13 O
values NNS 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
increase NN 0 1 1 O
of IN 0 0 12 O
phenobarbital JJ 0 1 16 B-Drug
level NN 0 1 1 O
however RB 0 0 12 O
is VBZ 1 0 12 O
small JJ 0 1 12 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
when WRB 0 0 12 O
given VBN 1 1 12 O
with IN 0 0 12 O
Trileptal NNP 0 1 UNK B-Brand
. . 0 0 12 O

Diazepam NN 0 1 UNK B-Drug
: : 0 0 2 O
The DT 0 0 2 O
co NN 0 1 12 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
Fluvoxamine NNP 0 1 UNK B-Drug
Tablets NNP 0 1 0 O
and CC 0 0 12 O
diazepam NN 0 1 0 B-Drug
is VBZ 1 0 12 O
generally RB 0 0 1 O
not RB 0 1 12 O
advisable JJ 0 0 UNK O
. . 0 0 12 O

In IN 0 0 2 O
a DT 0 0 12 O
p9 NN 0 1 UNK O
( ( 0 0 2 O
+ JJ 0 0 2 O
/ NNP 0 0 2 O
- : 0 0 2 O
) ) 0 0 2 O
mouse VBP 0 1 UNK O
carcinogenicity NN 0 1 UNK O
study NN 0 1 1 O
at IN 0 0 12 O
doses VBZ 1 1 6 O
up RB 0 0 12 O
to TO 0 0 12 O
the DT 0 0 12 O
maximum NN 0 1 1 O
tolerated VBD 1 0 1 O
dose NN 0 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
kg JJ 0 1 18 O
/ NNP 0 0 2 O
day NN 0 1 12 O
ribavirin NN 0 1 13 B-Drug
was VBD 1 0 12 O
not RB 0 1 12 O
oncogenic JJ 0 1 UNK O
. . 0 0 12 O

These DT 0 0 1 O
agents NNS 1 1 1 O
may MD 0 0 1 O
also RB 0 0 12 O
prolong VB 0 0 13 O
the DT 0 0 12 O
clinically RB 0 0 6 O
effective JJ 0 1 1 O
duration NN 0 1 1 O
of IN 0 0 12 O
action NN 0 1 13 O
and CC 0 0 12 O
decrease VB 0 1 1 O
the DT 0 0 12 O
average JJ 0 1 1 O
infusion NN 0 1 14 O
requirement NN 0 1 1 O
of IN 0 0 12 O
MIVACRON NNP 0 1 UNK B-Brand
by IN 0 0 12 O
as RB 0 0 12 O
much JJ 0 0 12 O
as IN 1 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
to TO 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

Tacrolimus NN 0 1 0 B-Drug
: : 0 0 2 O
Co NNP 0 1 2 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
tacrolimus NN 0 1 16 B-Drug
and CC 0 0 12 O
bosentan NN 0 1 13 B-Drug
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
studied VBN 1 0 1 O
in IN 0 0 12 O
man NN 0 1 12 O
. . 0 0 12 O

Therefore IN 0 0 1 O
it PRP 0 0 12 O
would MD 0 0 12 O
be VB 0 0 12 O
expected VBN 1 1 12 O
that IN 0 0 12 O
a DT 0 0 12 O
dosing VBG 1 0 14 O
schedule NN 0 1 12 O
of IN 0 0 12 O
cerivastatin NN 0 1 UNK B-Drug
sodium NN 0 1 14 I-Drug
given VBN 1 1 12 O
at IN 0 0 12 O
bedtime NN 0 1 3 O
and CC 0 0 12 O
cholestyramine VB 0 1 13 B-Drug
given VBN 1 1 12 O
before IN 0 1 12 O
the DT 0 0 12 O
evening NN 0 1 12 O
meal NN 0 1 12 O
would MD 0 0 12 O
not RB 0 1 12 O
result VB 0 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
significant JJ 0 1 1 O
decrease NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
clinical JJ 0 1 6 O
effect NN 0 1 1 O
of IN 0 0 12 O
cerivastatin NN 0 1 UNK B-Drug
sodium NN 0 1 14 I-Drug
. . 0 0 12 O

Drugs NNS 0 1 2 O
and CC 0 0 12 O
other JJ 0 0 12 O
substances NNS 1 1 1 O
demonstrated VBN 1 0 1 O
to TO 0 0 12 O
be VB 0 0 12 O
CYP NNP 0 1 UNK O
9A CD 0 1 UNK O
inhibitors NNS 1 1 14 O
on IN 0 0 12 O
the DT 0 0 12 O
basis NN 0 1 1 O
of IN 0 0 12 O
clinical JJ 0 1 6 O
studies NNS 1 1 1 O
involving VBG 1 1 1 O
benzodiazepines NNS 1 1 14 B-Group
metabolized VBD 1 1 UNK O
similarly RB 0 0 1 O
to TO 0 0 12 O
alprazolam VB 0 1 0 B-Drug
or CC 0 0 12 O
on IN 0 0 12 O
the DT 0 0 12 O
basis NN 0 1 1 O
of IN 0 0 12 O
in IN 0 0 12 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
with IN 0 0 12 O
alprazolam NN 0 1 0 B-Drug
or CC 0 0 12 O
other JJ 0 0 12 O
benzodiazepines NNS 1 1 14 B-Group
( ( 0 0 2 O
caution NN 0 0 1 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
during IN 0 0 12 O
coadministration NN 0 1 UNK O
with IN 0 0 12 O
alprazolam NN 0 1 0 B-Drug
) ) 0 0 2 O
: : 0 0 2 O
Available JJ 0 1 UNK O
data NNS 0 1 1 O
from IN 0 0 12 O
clinical JJ 0 1 6 O
studies NNS 1 1 1 O
of IN 0 0 12 O
benzodiazepines NNS 1 1 14 B-Group
other JJ 0 0 12 O
than IN 0 0 12 O
alprazolam JJ 0 1 0 B-Drug
suggest VBP 0 1 1 O
a DT 0 0 12 O
possible JJ 0 1 1 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
with IN 0 0 12 O
alprazolam NN 0 1 0 B-Drug
for IN 0 0 12 O
the DT 0 0 12 O
following NN 0 1 1 O
: : 0 0 2 O
diltiazem JJ 0 1 0 B-Drug
isoniazid NN 0 1 13 B-Drug
macrolide NN 0 1 UNK B-Group
antibiotics NNS 1 1 6 I-Group
such JJ 0 0 1 O
as IN 1 0 12 O
erythromycin NN 0 1 0 B-Drug
and CC 0 0 12 O
clarithromycin NN 0 1 13 B-Drug
and CC 0 0 12 O
grapefruit NN 0 1 3 O
juice NN 0 1 3 O
. . 0 0 12 O

ASPIRIN NNP 0 1 0 B-Brand
AND CC 0 0 11 O
OTHER NNP 0 0 11 O
SALICYLATE NNP 0 1 UNK B-Group
DRUGS NNP 0 1 UNK I-Group
WILL MD 0 0 11 O
BE VB 0 0 11 O
ADDITIVE NNP 0 1 UNK O
TO NNP 0 0 11 O
DISALCID NNP 0 1 UNK B-Brand
AND NNP 0 0 11 O
MAY NNP 0 0 11 O
INCREASE NNP 0 1 UNK O
PLASMA NNP 0 1 UNK O
CONCENTRATIONS NNP 0 1 UNK O
OF NNP 0 0 11 O
SALICYLIC NNP 0 1 UNK B-Drug
ACID NNP 0 1 11 I-Drug
TO NNP 0 0 11 O
TOXIC NNP 0 1 UNK O
LEVELS NNP 0 1 UNK O
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
not RB 0 1 12 O
to TO 0 0 12 O
exceed VB 0 0 UNK O
a DT 0 0 12 O
single JJ 0 1 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
Vardenafil NNP 0 1 UNK B-Drug
dose NN 0 1 6 O
in IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
hour NN 0 1 12 O
period NN 0 1 1 O
when WRB 0 0 12 O
used VBN 1 1 12 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
indinavir NN 0 1 16 B-Drug
. . 0 0 12 O

Antibiotics NNS 0 1 7 B-Group
: : 0 0 2 O
No DT 0 0 2 O
human JJ 0 1 1 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
with IN 0 0 12 O
antibiotics NNS 1 1 6 B-Group
were VBD 1 0 12 O
conducted VBN 1 1 1 O
. . 0 0 12 O

Potassium NN 0 1 14 B-Drug
Supplements NNS 0 1 UNK O
and CC 0 0 12 O
Potassium NNP 0 1 14 B-Group
- : 0 0 2 O
Sparing VBG 0 0 UNK I-Group
Diuretics NNS 0 1 UNK I-Group
: : 0 0 2 O
Fosinopril NNP 0 1 UNK B-Drug
sodium NN 0 1 14 I-Drug
can MD 0 0 12 O
attenuate VB 0 1 UNK O
potassium JJ 0 1 14 O
loss NN 0 1 1 O
caused VBN 1 1 1 O
by IN 0 0 12 O
thiazide JJ 0 1 UNK B-Group
diuretics NNS 1 1 14 I-Group
. . 0 0 12 O

In IN 0 0 2 O
humans NNS 1 1 UNK O
carmustine JJ 0 1 13 B-Drug
etoposide NN 0 1 13 B-Drug
and CC 0 0 12 O
cisplatin NN 0 1 14 B-Drug
do VBP 0 0 12 O
not RB 0 1 12 O
affect VB 0 1 1 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
ondansetron NN 0 1 16 B-Drug
. . 0 0 12 O

Acetazolamide NNP 0 1 0 B-Drug
reduces VBZ 1 0 UNK O
urinary JJ 0 1 6 O
excretion NN 0 1 14 O
of IN 0 0 12 O
quinidine NN 0 1 16 B-Drug
and CC 0 0 12 O
may MD 0 0 1 O
enhance VB 0 1 UNK O
its PRP$ 1 0 12 O
effect NN 0 1 1 O
. . 0 0 12 O

Naproxen NNP 0 1 0 B-Drug
may MD 0 0 1 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
some DT 0 0 12 O
urinary JJ 0 1 6 O
assays NNS 1 1 13 O
of IN 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
hydroxy NN 0 1 14 O
indoleacetic JJ 0 0 UNK O
acid NN 0 1 14 O
( ( 0 0 2 O
9HIAA CD 0 0 UNK O
) ) 0 0 2 O
. . 0 0 12 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
LaboratoryTest NNP 0 0 UNK O
Interactions NNP 0 1 UNK O
Dactinomycin NNP 0 1 UNK B-Drug
may MD 0 0 1 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
bioassay NN 0 1 UNK O
procedures NNS 1 1 1 O
for IN 0 0 12 O
the DT 0 0 12 O
determination NN 0 1 13 O
of IN 0 0 12 O
antibacterial JJ 0 1 UNK B-Group
drug NN 0 1 1 I-Group
levels NNS 1 1 1 O
. . 0 0 12 O

Other JJ 0 0 2 O
Drug NNP 0 1 2 O
Interactions NNP 0 1 UNK O
Oral NNP 0 1 2 O
Contraceptives NNP 0 1 UNK B-Group
Keppra NNP 0 1 0 B-Brand
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
twice RB 0 1 12 O
daily RB 0 1 12 O
) ) 0 0 2 O
did VBD 1 0 12 O
not RB 0 1 12 O
influence VB 0 0 UNK O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
an DT 0 0 12 O
oral JJ 0 1 6 O
contraceptive NN 0 1 13 B-Group
containing VBG 1 1 1 O
9 CD 0 0 2 O
mg JJ 0 1 0 O
ethinyl NN 0 0 13 B-Drug
estradiol NN 0 1 13 I-Drug
and CC 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
levonorgestrel NN 0 1 13 B-Drug
or CC 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
luteinizing VBG 0 0 13 O
hormone NN 0 1 6 O
and CC 0 0 12 O
progesterone NN 0 1 13 O
levels NNS 1 1 1 O
indicating VBG 1 0 1 O
that IN 0 0 12 O
impairment NN 0 1 16 O
of IN 0 0 12 O
contraceptive JJ 0 1 13 O
efficacy NN 0 1 UNK O
is VBZ 1 0 12 O
unlikely JJ 0 1 12 O
. . 0 0 12 O

Ethanol NN 0 1 13 B-Drug
: : 0 0 2 O
Clinical JJ 0 1 7 O
evidence NN 0 1 1 O
has VBZ 1 0 12 O
shown VBN 1 1 1 O
that IN 0 0 12 O
etretinate NN 0 1 UNK B-Drug
can MD 0 0 12 O
be VB 0 0 12 O
formed VBN 1 1 UNK O
with IN 0 0 12 O
concurrent JJ 0 1 1 O
ingestion NN 0 1 14 O
of IN 0 0 12 O
acitretin NN 0 1 13 B-Drug
and CC 0 0 12 O
ethanol NN 0 1 1 B-Drug
. . 0 0 12 O

Concomitant NNP 0 1 UNK O
use NN 0 1 1 O
of IN 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
with IN 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
can MD 0 0 12 O
inhibit VB 0 1 13 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
9D9 CD 0 0 UNK O
may MD 0 0 1 O
require VB 0 0 1 O
lower JJR 1 1 1 O
doses NNS 1 1 6 O
than IN 0 0 12 O
usually RB 0 1 12 O
prescribed VBN 1 1 1 O
for IN 0 0 12 O
either CC 0 1 12 O
the DT 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressant NN 0 1 6 I-Group
or CC 0 0 12 O
the DT 0 0 12 O
other JJ 0 0 12 O
drug NN 0 1 1 O
. . 0 0 12 O

Antidiabetic JJ 0 1 UNK B-Group
drug NN 0 1 1 I-Group
requirements NNS 1 1 1 O
( ( 0 0 2 O
i.e. JJ 0 1 1 O
insulin NN 0 1 14 B-Drug
) ) 0 0 2 O
may MD 0 0 1 O
be VB 0 0 12 O
altered VBN 1 1 1 O
. . 0 0 12 O

. . 0 0 12 O

In IN 0 0 2 O
addition NN 0 1 1 O
new JJ 0 1 12 O
cases NNS 1 1 UNK O
of IN 0 0 12 O
diabetes NNS 0 1 6 O
have VBP 0 0 12 O
been VBN 1 0 12 O
diagnosed VBN 1 1 6 O
during IN 0 0 12 O
retinoid JJ 0 1 UNK B-Group
therapy NN 0 1 6 O
including VBG 1 1 1 O
diabetic JJ 0 1 6 O
ketoacidosis NN 0 1 6 O
. . 0 0 12 O

Since IN 0 1 2 O
there EX 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
conflicting VBG 1 1 UNK O
results NNS 1 1 1 O
regarding VBG 1 0 1 O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
levels NNS 1 1 1 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
that IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
levels NNS 1 1 1 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
when WRB 0 0 12 O
initiating VBG 1 1 1 O
adjusting NN 0 0 1 O
and CC 0 0 12 O
discontinuing VBG 1 1 6 O
diltiazem JJ 0 1 0 B-Drug
hydrochloride NN 0 1 0 I-Drug
therapy NN 0 1 6 O
to TO 0 0 12 O
avoid VB 0 0 12 O
possible JJ 0 1 1 O
over IN 0 1 12 O
- : 0 0 2 O
or CC 0 0 12 O
under IN 0 0 12 O
- : 0 0 2 O
digitalization NN 0 1 UNK O
. . 0 0 12 O

Since IN 0 1 2 O
drowsiness NN 0 1 13 O
may MD 0 0 1 O
occur VB 0 1 1 O
with IN 0 0 12 O
use NN 0 1 1 O
of IN 0 0 12 O
this DT 0 0 12 O
drug NN 0 1 1 O
patients NNS 1 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
warned VBN 1 1 UNK O
of IN 0 0 12 O
this DT 0 0 12 O
possibility NN 0 1 1 O
and CC 0 0 12 O
cautioned VBN 1 0 UNK O
against IN 0 0 12 O
driving VBG 1 1 12 O
a DT 0 0 12 O
car NN 0 1 12 O
or CC 0 0 12 O
operating VBG 1 1 1 O
dangerous JJ 0 1 UNK O
machinery NN 0 1 13 O
while IN 0 0 12 O
taking VBG 1 0 12 O
Atarax NNP 0 1 0 B-Brand
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
advisable JJ 0 0 UNK O
to TO 0 0 12 O
check VB 0 1 12 O
coagulation NN 0 1 14 O
time NN 0 1 12 O
within IN 0 0 1 O
the DT 0 0 12 O
first JJ 0 1 12 O
few JJ 0 1 12 O
days NNS 1 1 12 O
after IN 0 0 12 O
the DT 0 0 12 O
start NN 0 1 12 O
and CC 0 0 12 O
discontinuation NN 0 1 6 O
of IN 0 0 12 O
cisapride JJ 0 1 UNK B-Drug
therapy NN 0 1 6 O
with IN 0 0 12 O
an DT 0 0 12 O
appropriate JJ 0 1 1 O
adjustment NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
anticoagulant NN 0 1 13 B-Group
dose NN 0 1 6 O
if IN 0 0 12 O
necessary JJ 0 0 1 O
. . 0 0 12 O

The DT 0 0 2 O
continued JJ 0 1 12 O
need NN 0 1 12 O
for IN 0 0 12 O
the DT 0 0 12 O
other JJ 0 0 12 O
antiarrhythmic JJ 0 1 14 B-Drug
agent NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
reviewed VBN 1 1 1 O
after IN 0 0 12 O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
amiodarone NN 0 1 0 B-Drug
have VBP 0 0 12 O
been VBN 1 0 12 O
established VBN 1 1 1 O
and CC 0 0 12 O
discontinuation NN 0 1 6 O
ordinarily RB 0 0 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
attempted VBN 1 1 12 O
. . 0 0 12 O

Anti NNP 0 0 UNK B-Group
- : 0 0 2 O
HIV NNP 0 1 6 I-Group
Reverse NNP 0 1 UNK I-Group
Transcriptase NNP 0 1 UNK I-Group
Inhibitors NNP 0 1 7 I-Group

Drug NNP 0 1 2 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
were VBD 1 0 12 O
performed VBN 1 1 1 O
with IN 0 0 12 O
azithromycin NN 0 1 0 B-Drug
and CC 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
likely JJ 0 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
. . 0 0 12 O

Urinary JJ 0 1 7 O
alkalinizing VBG 1 0 UNK O
agents NNS 1 1 1 O
increase VB 0 1 1 O
blood NN 0 1 6 O
levels NNS 1 1 1 O
and CC 0 0 12 O
decrease NN 0 1 1 O
excretion NN 0 1 14 O
of IN 0 0 12 O
amphetamines NNS 1 1 14 B-Group
. . 0 0 12 O

Such JJ 0 0 1 O
patients NNS 1 1 6 O
may MD 0 0 1 O
be VB 0 0 12 O
unresponsive JJ 0 1 6 O
to TO 0 0 12 O
the DT 0 0 12 O
usual JJ 0 1 12 O
doses NNS 1 1 6 O
of IN 0 0 12 O
epinephrine NN 0 1 14 B-Drug
used VBN 1 1 12 O
to TO 0 0 12 O
treat VB 0 1 12 O
allergic JJ 0 1 6 O
reaction NN 0 1 1 O
. . 0 0 12 O

When WRB 0 0 12 O
such JJ 0 0 1 O
drugs NNS 1 1 6 O
are VBP 1 0 12 O
withdrawn VBN 1 1 1 O
from IN 0 0 12 O
a DT 0 0 12 O
patient NN 0 1 6 O
receiving VBG 1 1 1 O
MICRONASE NNP 0 1 UNK B-Brand
the DT 0 0 12 O
patient NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
observed VBN 1 1 1 O
closely RB 0 0 1 O
for IN 0 0 12 O
hypoglycemia NN 0 1 6 O
. . 0 0 12 O

As IN 0 0 2 O
DIFFERIN NNP 0 1 UNK B-Brand
Gel NNP 0 1 2 O
has VBZ 1 0 12 O
the DT 0 0 12 O
potential JJ 0 1 1 O
to TO 0 0 12 O
produce VB 0 0 1 O
local JJ 0 1 12 O
irritation NN 0 1 6 O
in IN 0 0 12 O
some DT 0 0 12 O
patients NNS 1 1 6 O
concomitant JJ 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
other JJ 0 0 12 O
potentially RB 0 0 1 O
irritating VBG 1 0 UNK O
topical JJ 0 1 6 O
products NNS 1 1 1 O
( ( 0 0 2 O
medicated VBN 1 1 UNK O
or CC 0 0 12 O
abrasive JJ 0 0 UNK O
soaps NNS 1 1 13 O
and CC 0 0 12 O
cleansers NNS 1 1 UNK O
soaps NNS 1 1 13 O
and CC 0 0 12 O
cosmetics NNS 1 1 13 O
that WDT 0 0 12 O
have VBP 0 0 12 O
a DT 0 0 12 O
strong JJ 0 1 12 O
drying NN 0 1 3 O
effect NN 0 1 1 O
and CC 0 0 12 O
products NNS 1 1 1 O
with IN 0 0 12 O
high JJ 0 1 1 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
alcohol NN 0 1 1 O
astringents NNS 1 1 13 O
spices NNS 1 1 UNK O
or CC 0 0 12 O
lime NN 0 1 UNK O
) ) 0 0 2 O
should MD 0 0 12 O
be VB 0 0 12 O
approached VBN 1 1 UNK O
with IN 0 0 12 O
caution NN 0 0 1 O
. . 0 0 12 O

Statistically RB 0 1 UNK O
significant JJ 0 1 1 O
changes NNS 1 1 1 O
in IN 0 0 12 O
prothrombin NN 0 1 14 O
and CC 0 0 12 O
partial JJ 0 1 1 O
thromboplastin NN 0 1 14 O
times NNS 1 1 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
normal JJ 0 1 1 O
volunteers NNS 1 1 UNK O
. . 0 0 12 O

Avoid NNP 0 0 2 O
concomitant NN 0 1 6 O
use NN 0 1 1 O
unless IN 0 0 12 O
necessary JJ 0 0 1 O
to TO 0 0 12 O
control VB 0 1 1 O
side JJ 0 1 3 O
effects NNS 1 1 1 O
of IN 0 0 12 O
amphotericin NN 0 1 14 B-Drug
B NNP 0 0 2 I-Drug
. . 0 0 12 O

Angiomax NNP 0 1 UNK B-Brand
does VBZ 1 0 12 O
not RB 0 1 12 O
exhibit VB 0 1 1 O
binding VBG 1 1 1 O
to TO 0 0 12 O
plasma VB 0 1 14 O
proteins NNS 1 1 14 O
( ( 0 0 2 O
other JJ 0 0 12 O
than IN 0 0 12 O
thrombin NN 0 1 14 O
) ) 0 0 2 O
or CC 0 0 12 O
red JJ 0 1 3 O
blood NN 0 1 6 O
cells NNS 1 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
action NN 0 1 13 O
of IN 0 0 12 O
the DT 0 0 12 O
benzodiazepines NNS 1 1 14 B-Group
may MD 0 0 1 O
be VB 0 0 12 O
potentiated VBN 1 0 UNK O
by IN 0 0 12 O
anticonvulsants NNS 1 1 13 B-Group
antihistamines NNS 1 1 UNK B-Group
alcohol RB 0 1 1 B-Drug
barbiturates VBZ 0 1 14 B-Group
monoamine JJ 0 1 13 B-Group
oxidase NN 0 1 13 I-Group
inhibitors NNS 1 1 14 I-Group
narcotics VBP 0 1 1 B-Group
phenothiazines NNS 1 1 UNK B-Group
psychotropic JJ 0 1 13 B-Group
medications NNS 1 1 6 I-Group
or CC 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
that IN 0 0 12 O
produce VBP 0 0 1 O
CNS NNP 0 1 6 O
depression NN 0 1 6 O
. . 0 0 12 O

Itraconazole NNP 0 1 UNK B-Drug
Ketoconazole NNP 0 1 UNK B-Drug
Erythromycin NNP 0 1 0 B-Drug
Clarithromycin NNP 0 1 UNK B-Drug
Telithromycin NNP 0 1 UNK B-Drug
HIV NNP 0 1 6 B-Group
protease NN 0 1 13 I-Group
inhibitors NNS 1 1 14 I-Group
Nefazodone NNP 0 1 UNK B-Drug
Cyclosporine NNP 0 1 UNK B-Drug
Large NNP 0 1 2 O
quantities NNS 1 1 UNK O
of IN 0 0 12 O
grapefruit NN 0 1 3 O
juice NN 0 1 3 O
( ( 0 0 2 O
9 CD 0 0 2 O
quart RB 0 1 UNK O
daily RB 0 1 12 O
) ) 0 0 2 O

Alcohol NNP 0 1 2 B-Drug
in IN 0 0 12 O
particular NN 0 0 1 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
found VBN 1 1 12 O
to TO 0 0 12 O
exhibit VB 0 1 1 O
additive JJ 0 1 16 O
effects NNS 1 1 1 O
of IN 0 0 12 O
this DT 0 0 12 O
variety NN 0 1 1 O
. . 0 0 12 O

valproate NN 0 1 16 B-Drug
and CC 0 0 12 O
gabapentin NN 0 1 0 B-Drug
are VBP 1 0 12 O
not RB 0 1 12 O
. . 0 0 12 O

Therefore RB 0 0 1 O
fenofibrate NN 0 1 16 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
taken VBN 1 1 12 O
at IN 0 0 12 O
least JJS 0 1 12 O
9 CD 0 0 2 O
hour NN 0 1 12 O
before IN 0 1 12 O
or CC 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
after IN 0 0 12 O
a DT 0 0 12 O
bile JJ 0 1 6 B-Group
acid NN 0 1 14 I-Group
binding VBG 1 1 1 I-Group
resin NN 0 1 UNK I-Group
to TO 0 0 12 O
avoid VB 0 0 12 O
impeding VBG 1 0 UNK O
its PRP$ 1 0 12 O
absorption NN 0 1 1 O
. . 0 0 12 O

Lansoprazole NNP 0 1 0 B-Drug
is VBZ 1 0 12 O
metabolized VBN 1 1 UNK O
through IN 0 0 12 O
the DT 0 0 12 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
system NN 0 1 1 O
specifically RB 0 0 1 O
through IN 0 0 12 O
the DT 0 0 12 O
CYP9A NNP 0 0 UNK O
and CC 0 0 12 O
CYP9C9 NNP 0 0 UNK O
isozymes NNS 0 1 UNK O
. . 0 0 12 O

Since IN 0 1 2 O
hydroxyurea NN 0 1 14 B-Drug
may MD 0 0 1 O
raise VB 0 0 12 O
the DT 0 0 12 O
serum NN 0 1 14 O
uric JJ 0 0 14 O
acid JJ 0 1 14 O
level NN 0 1 1 O
dosage NN 0 1 0 O
adjustment NN 0 1 1 O
of IN 0 0 12 O
uricosuric JJ 0 0 UNK B-Group
medication NN 0 1 6 I-Group
may MD 0 0 1 O
be VB 0 0 12 O
necessary JJ 0 0 1 O

Free JJ 0 1 2 O
T9 NNP 0 1 13 O
and CC 0 0 12 O
free JJ 0 1 12 O
T9 NNP 0 1 13 O
concentrations NNS 1 1 13 O
are VBP 1 0 12 O
unaltered JJ 0 1 UNK O
. . 0 0 12 O

St NNP 0 1 2 O
. . 0 0 12 O
Johns NNP 0 0 UNK O
wort NN 0 0 UNK O
( ( 0 0 2 O
Hypericum NNP 0 1 UNK O
perforatum NN 0 0 UNK O
) ) 0 0 2 O
may MD 0 0 1 O
decrease VB 0 1 1 O
SPRYCEL NNP 0 1 UNK B-Brand
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
unpredictably RB 0 0 UNK O
. . 0 0 12 O

Levetiracetam NNP 0 1 0 B-Drug
and CC 0 0 12 O
its PRP$ 1 0 12 O
major JJ 0 1 1 O
metabolite NN 0 1 UNK O
at IN 0 0 12 O
concentrations NNS 1 1 13 O
well RB 0 1 12 O
above IN 0 1 12 O
cmax NN 0 1 UNK O
levels NNS 1 1 1 O
achieved VBN 1 0 1 O
within IN 0 0 1 O
the DT 0 0 12 O
therapeutic JJ 0 1 6 O
dose NN 0 1 6 O
range NN 0 1 1 O
are VBP 1 0 12 O
neither DT 0 0 12 O
inhibitors NNS 1 1 14 O
of IN 0 0 12 O
nor CC 0 0 12 O
high JJ 0 1 1 O
affinity NN 0 1 UNK O
substrates NNS 1 1 UNK O
for IN 0 0 12 O
human JJ 0 1 1 O
liver NN 0 1 6 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
isoforms NNS 0 1 UNK O
epoxide VBP 0 1 UNK O
hydrolase NN 0 1 UNK O
or CC 0 0 12 O
UDP NNP 0 1 UNK O
- : 0 0 2 O
glucuronidation NN 0 1 UNK O
enzymes NNS 1 1 14 O
. . 0 0 12 O

No DT 0 0 2 O
in IN 0 0 12 O
vitro JJ 0 1 UNK O
metabolism NN 0 1 16 O
studies NNS 1 1 1 O
were VBD 1 0 12 O
performed VBN 1 1 1 O
. . 0 0 12 O

Close JJ 0 1 2 O
supervision NN 0 1 1 O
and CC 0 0 12 O
careful JJ 0 1 12 O
adjustment NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
dosage NN 0 1 0 O
are VBP 1 0 12 O
required VBN 1 1 1 O
when WRB 0 0 12 O
nortriptyline JJ 0 1 16 B-Drug
hydrochloride NN 0 1 0 I-Drug
is VBZ 1 0 12 O
used VBN 1 1 12 O
with IN 0 0 12 O
other JJ 0 0 12 O
anticholinergic JJ 0 1 13 B-Group
drugs NNS 1 1 6 I-Group
or CC 0 0 12 O
sympathomimetic JJ 0 1 13 B-Group
drugs NNS 1 1 6 I-Group
. . 0 0 12 O

However RB 0 0 1 O
in IN 0 0 12 O
vivo JJ 0 1 13 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
of IN 0 0 12 O
ketoconazole NN 0 1 16 B-Drug
with IN 0 0 12 O
vitamin NN 0 1 6 B-Group
D NNP 0 1 2 I-Group
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
investigated VBN 1 1 1 O
. . 0 0 12 O

Patients NNS 0 1 7 O
using VBG 1 1 1 O
CYP9A9 NNP 0 0 UNK O
metabolized VBD 1 1 UNK O
statins NNS 1 1 UNK B-Group
should MD 0 0 12 O
have VB 0 0 12 O
cholesterol NN 0 1 6 O
levels NNS 1 1 1 O
monitored VBN 1 1 1 O
after IN 0 0 12 O
TRACLEER NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
initiated VBN 1 1 1 O
to TO 0 0 12 O
see VB 0 1 12 O
whether IN 0 0 12 O
the DT 0 0 12 O
statin NN 0 1 14 B-Group
dose NN 0 1 6 O
needs VBZ 1 1 12 O
adjustment NN 0 1 1 O
. . 0 0 12 O

Phosphate NNP 0 1 14 O
- : 0 0 2 O
Binding VBG 0 1 UNK O
Agents NNS 0 1 2 O
: : 0 0 2 O
Since IN 0 1 2 O
vitamin NN 0 1 6 B-Group
D NNP 0 1 2 I-Group
also RB 0 0 12 O
has VBZ 1 0 12 O
an DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
phosphate NN 0 1 14 O
transport NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
intestine NN 0 1 6 O
kidneys NN 1 1 6 O
and CC 0 0 12 O
bones VBZ 1 1 3 O
the DT 0 0 12 O
dosage NN 0 1 0 O
of IN 0 0 12 O
phosphate NN 0 1 14 O
- : 0 0 2 O
binding NN 0 1 1 O
agents NNS 1 1 1 O
must MD 0 0 12 O
be VB 0 0 12 O
adjusted VBN 1 1 1 O
in IN 0 0 12 O
accordance NN 0 0 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
serum NN 0 1 14 O
phosphate NN 0 1 14 O
concentration NN 0 1 1 O
. . 0 0 12 O

Therefore RB 0 0 1 O
when WRB 0 0 12 O
heparin NN 0 1 14 B-Drug
sodium NN 0 1 14 I-Drug
is VBZ 1 0 12 O
given VBN 1 1 12 O
with IN 0 0 12 O
dicumarol NN 0 1 UNK B-Drug
or CC 0 0 12 O
warfarin NN 0 1 14 B-Drug
sodium NN 0 1 14 I-Drug
a DT 0 0 12 O
period NN 0 1 1 O
of IN 0 0 12 O
at IN 0 0 12 O
least JJS 0 1 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
after IN 0 0 12 O
the DT 0 0 12 O
last JJ 0 1 12 O
intravenous JJ 0 1 14 O
dose VBD 0 1 6 O
or CC 0 0 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
after IN 0 0 12 O
the DT 0 0 12 O
last JJ 0 1 12 O
subcutaneous JJ 0 1 14 O
dose NN 0 1 6 O
should MD 0 0 12 O
elapse VB 0 1 UNK O
before IN 0 1 12 O
blood NN 0 1 6 O
is VBZ 1 0 12 O
drawn VBN 1 0 12 O
if IN 0 0 12 O
a DT 0 0 12 O
valid JJ 0 1 UNK O
prothrombin NN 0 1 14 O
time NN 0 1 12 O
is VBZ 1 0 12 O
to TO 0 0 12 O
be VB 0 0 12 O
obtained VBN 1 1 1 O
. . 0 0 12 O

Cimetidine NN 0 1 0 B-Drug
: : 0 0 2 O
In IN 0 0 2 O
the DT 0 0 12 O
presence NN 0 1 1 O
of IN 0 0 12 O
cimetidine NN 0 1 13 B-Drug
at IN 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
QID NNP 0 1 15 O
( ( 0 0 2 O
N=9 NNP 0 1 UNK O
) ) 0 0 2 O
the DT 0 0 12 O
mean JJ 0 1 12 O
apparent JJ 0 1 1 O
oral JJ 0 1 6 O
clearance NN 0 1 16 O
of IN 0 0 12 O
gabapentin NN 0 1 0 B-Drug
fell VBD 0 1 12 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
creatinine JJ 0 1 14 O
clearance NN 0 1 16 O
fell VBD 0 1 12 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

Other JJ 0 0 2 O
: : 0 0 2 O
Instances NNS 0 1 UNK O
of IN 0 0 12 O
rash NN 0 1 6 O
pruritus NN 0 1 8 O
ankle NN 0 1 3 O
edema VBP 0 1 6 O
excessive JJ 0 1 1 O
perspiration NN 0 1 UNK O
weight VBD 0 1 3 O
gain NN 0 1 1 O
nasal JJ 0 1 6 O
congestion NN 0 1 6 O
. . 0 0 12 O

Drugs NNS 0 1 2 O
That WDT 0 0 2 O
Induce NNP 0 1 UNK O
CYP9A9 NNP 0 0 UNK O
( ( 0 0 2 O
Rifampicin NNP 0 1 UNK B-Drug
) ) 0 0 2 O
Racemic NNP 0 1 UNK O
zopiclone NN 0 1 UNK B-Drug
exposure NN 0 1 1 O
was VBD 1 0 12 O
decreased VBN 1 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
by IN 0 0 12 O
concomitant JJ 0 1 6 O
useof JJ 0 0 UNK O
rifampicin NN 0 1 UNK B-Drug
a DT 0 0 12 O
potent JJ 0 1 UNK O
inducer NN 0 1 UNK O
of IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
. . 0 0 12 O

There EX 0 0 12 O
were VBD 1 0 12 O
transient JJ 0 1 1 O
increases NNS 1 1 1 O
in IN 0 0 12 O
liver NN 0 1 6 O
ALT NNP 0 1 13 O
and CC 0 0 12 O
AST NNP 0 1 13 O
when WRB 0 0 12 O
CANCIDAS NNP 0 1 UNK B-Brand
and CC 0 0 12 O
cyclosporine NN 0 1 14 B-Drug
were VBD 1 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
addition NN 0 1 1 O
certain JJ 0 1 1 O
drugs NNS 1 1 6 O
inhibit VBP 0 1 13 O
the DT 0 0 12 O
activity NN 0 1 1 O
of IN 0 0 12 O
this DT 0 0 12 O
isozyme NN 0 1 UNK O
and CC 0 0 12 O
make VB 0 1 12 O
normal JJ 0 1 1 O
metabolizers NNS 0 0 UNK O
resemble JJ 0 0 UNK O
p.o NN 0 1 UNK O
. . 0 0 12 O

Therefore RB 0 0 1 O
if IN 0 0 12 O
theophylline NN 0 1 16 B-Drug
is VBZ 1 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
with IN 0 0 12 O
fluvoxamine JJ 0 1 16 B-Drug
maleate NN 0 1 16 I-Drug
its PRP$ 1 0 12 O
dose NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
reduced VBN 1 1 1 O
to TO 0 0 12 O
one CD 0 1 12 O
third NN 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
usual JJ 0 1 12 O
daily JJ 0 1 12 O
maintenance NN 0 1 1 O
dose NN 0 1 6 O
and CC 0 0 12 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
theophylline NN 0 1 16 B-Drug
should MD 0 0 12 O
to TO 0 0 12 O
monitored VB 1 1 1 O
. . 0 0 12 O

Aprepitant NNP 0 1 UNK B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
induce VB 0 1 6 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
S NNP 0 1 2 B-Drug
- : 0 0 2 O
warfarin NN 0 1 14 I-Drug
and CC 0 0 12 O
tolbutamide NN 0 1 UNK B-Drug
which WDT 0 0 12 O
are VBP 1 0 12 O
metabolized VBN 1 1 UNK O
through IN 0 0 12 O
CYP9C9 NNP 0 0 UNK O
. . 0 0 12 O

Interactions NNS 0 1 UNK O
for IN 0 0 12 O
vitamin NN 0 1 6 B-Group
D NNP 0 1 2 I-Group
analogues NNS 1 1 UNK I-Group
( ( 0 0 2 O
Vitamin NNP 0 1 2 B-Drug
D9 NNP 0 1 UNK I-Drug
Vitamin NNP 0 1 2 B-Drug
D9 NNP 0 1 UNK I-Drug
Calcitriol NNP 0 1 0 B-Drug
and CC 0 0 12 O
Calcidiol NNP 0 1 UNK B-Drug
) ) 0 0 2 O
: : 0 0 2 O
Cholestyramine NN 0 1 UNK B-Drug
: : 0 0 2 O
Cholestyramine NN 0 1 UNK B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
reduce VB 0 0 1 O
intestinal JJ 0 1 13 O
absorption NN 0 1 1 O
of IN 0 0 12 O
fat JJ 0 1 3 B-Group
soluble JJ 0 1 16 I-Group
vitamins NNS 1 1 6 I-Group
; : 0 0 2 O

Beta NNP 0 1 2 B-Group
- : 0 0 2 O
Blockers NNS 0 0 UNK I-Group
: : 0 0 2 O
In IN 0 0 2 O
controlled JJ 0 1 1 O
clinical JJ 0 1 6 O
studies NNS 1 1 1 O
adrenergic VBP 0 1 UNK B-Group
beta SYM 0 1 16 I-Group
- : 0 0 2 O
receptor NN 0 1 14 I-Group
blockers NNS 1 0 6 I-Group
have VBP 0 0 12 O
been VBN 1 0 12 O
frequently RB 0 1 1 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
nicardipine JJ 0 1 16 B-Drug
HCl NNP 0 0 14 I-Drug
. . 0 0 12 O

The DT 0 0 2 O
use NN 0 1 1 O
of IN 0 0 12 O
NSAIDs NNP 0 1 UNK B-Group
in IN 0 0 12 O
patients NNS 1 1 6 O
who WP 0 0 12 O
are VBP 1 0 12 O
receiving VBG 1 1 1 O
ACE NNP 0 1 13 B-Group
inhibitors NNS 1 1 14 I-Group
may MD 0 0 1 O
potentiate VB 0 0 UNK O
renal JJ 0 1 6 O
disease NN 0 1 6 O
states NNS 1 1 1 O
. . 0 0 12 O

indinavir NN 0 1 16 B-Drug
concentration NN 0 1 1 O

Gemfibrozil NN 0 1 UNK B-Drug
: : 0 0 2 O
In IN 0 0 2 O
a DT 0 0 12 O
pharmacokinetic JJ 0 1 UNK O
study NN 0 1 1 O
concomitant NN 0 1 6 O
gemfibrozil JJ 0 1 16 B-Drug
administration NN 0 1 1 O
increased VBD 1 1 1 O
total JJ 0 1 1 O
ezetimibe JJ 0 1 16 B-Drug
concentrations NNS 1 1 13 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
- : 0 0 2 O
fold NN 0 1 3 O
. . 0 0 12 O

Interactions NNS 0 1 UNK O
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
this DT 0 0 12 O
enzyme NN 0 1 14 O
could MD 0 0 12 O
potentially RB 0 0 1 O
occur VB 0 1 1 O
. . 0 0 12 O

Since IN 0 1 2 O
falsely RB 0 0 1 O
elevated VBN 1 1 1 O
glucose NN 0 1 14 O
levels NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
with IN 0 0 12 O
blood NN 0 1 6 O
glucose NN 0 1 14 O
monitoring NN 0 1 1 O
devices NNS 1 1 1 O
and CC 0 0 12 O
test NN 0 1 1 O
strips NNS 1 1 3 O
that WDT 0 0 12 O
use VBP 0 1 1 O
glucose JJ 0 1 14 O
dehydrogenase NN 0 1 14 O
pyrroloquinolinequinone NN 0 0 UNK O
( ( 0 0 2 O
GDH NNP 0 0 UNK O
PQQ NNP 0 0 UNK O
) ) 0 0 2 O
- : 0 0 2 O
based VBN 1 1 1 O
methods NNS 1 1 1 O
GDH NNP 0 0 UNK O
PQQ NNP 0 0 UNK O
- : 0 0 2 O
based VBN 1 1 1 O
methods NNS 1 1 1 O
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
to TO 0 0 12 O
measure VB 0 1 1 O
glucose JJ 0 1 14 O
levels NNS 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
administered JJ 0 1 1 O
EXTRANEAL NNP 0 1 UNK B-Brand
.. NN 0 0 UNK O

Data NNS 0 1 2 O
from IN 0 0 12 O
a DT 0 0 12 O
randomized JJ 0 1 6 O
trial NN 0 1 12 O
of IN 0 0 12 O
HEXALEN NNP 0 1 UNK B-Brand
and CC 0 0 12 O
cisplatin JJ 0 1 14 B-Drug
plus CC 0 1 16 O
or CC 0 0 12 O
minus CC 0 1 3 O
pyridoxine NN 0 1 16 B-Drug
in IN 0 0 12 O
ovarian JJ 0 1 6 O
cancer NN 0 1 6 O
indicated VBD 1 1 1 O
that IN 0 0 12 O
pyridoxine NN 0 1 16 B-Drug
significantly RB 0 0 1 O
reduced VBN 1 1 1 O
neurotoxicity NN 0 1 UNK O
; : 0 0 2 O

No DT 0 0 2 O
specific JJ 0 1 1 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
- : 0 0 2 O
based VBN 1 1 1 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
conducted VBN 1 1 1 O
. . 0 0 12 O

Drug NN 0 1 2 O
Interactions NNP 0 1 UNK O
General NNP 0 1 2 O
: : 0 0 2 O
Although IN 0 0 12 O
there EX 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
no DT 0 0 12 O
formal JJ 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
intravenous JJ 0 1 14 O
fenoldopam NN 0 1 13 B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
administered VBN 1 1 1 O
safely RB 0 0 UNK O
with IN 0 0 12 O
drugs NNS 1 1 6 O
such JJ 0 0 1 O
as IN 1 0 12 O
digitalis NNS 0 1 14 B-Group
and CC 0 0 12 O
sublingual JJ 0 1 0 O
nitroglycerin NN 0 1 14 B-Drug
. . 0 0 12 O

paraldehyde NN 0 1 13 B-Drug
; : 0 0 2 O

Due JJ 0 1 2 O
to TO 0 0 12 O
the DT 0 0 12 O
slow JJ 0 1 12 O
elimination NN 0 1 UNK O
of IN 0 0 12 O
mifepristone NN 0 1 UNK B-Drug
from IN 0 0 12 O
the DT 0 0 12 O
body NN 0 1 3 O
such JJ 0 0 1 O
interaction NN 0 1 UNK O
may MD 0 0 1 O
be VB 0 0 12 O
observed VBN 1 1 1 O
for IN 0 0 12 O
a DT 0 0 12 O
prolonged JJ 0 1 6 O
period NN 0 1 1 O
after IN 0 0 12 O
its PRP$ 1 0 12 O
administration NN 0 1 1 O
. . 0 0 12 O

Following VBG 0 1 2 O
the DT 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
INAPSINE NNP 0 1 UNK B-Brand
the DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
other JJ 0 0 12 O
CNS NNP 0 1 6 B-Group
depressant NN 0 0 UNK I-Group
drugs NNS 1 1 6 I-Group
should MD 0 0 12 O
be VB 0 0 12 O
reduced VBN 1 1 1 O
. . 0 0 12 O

rifampin NN 0 1 16 B-Drug
; : 0 0 2 O

The DT 0 0 2 O
following JJ 0 1 1 O
agents NNS 1 1 1 O
may MD 0 0 1 O
increase VB 0 1 1 O
certain JJ 0 1 1 O
actions NNS 1 1 UNK O
or CC 0 0 12 O
side JJ 0 1 3 O
effects NNS 1 1 1 O
of IN 0 0 12 O
anticholinergic JJ 0 1 13 B-Group
drugs NNS 1 1 6 I-Group
. . 0 0 12 O
amantadine VB 0 1 16 B-Drug
antiarrhythmic JJ 0 1 14 B-Group
agents NNS 1 1 1 I-Group
of IN 0 0 12 O
class NN 0 1 12 O
( ( 0 0 2 O
e.g JJ 0 0 UNK O
. . 0 0 12 O
quinidine NN 0 1 16 B-Drug
) ) 0 0 2 O
antihistamines VBZ 0 1 UNK B-Group
antipsychotic JJ 0 1 UNK B-Group
agents NNS 1 1 1 I-Group
( ( 0 0 2 O
e.g NN 0 0 UNK O
. . 0 0 12 O
phenothiazines NNS 1 1 UNK B-Group
) ) 0 0 2 O
benzodiazepines NNS 1 1 14 B-Group
. . 0 0 12 O

Calcium NNP 0 1 7 B-Group
channel NN 0 1 1 I-Group
blockers NNS 1 0 6 I-Group

Neuropathy NNP 0 1 7 O
has VBZ 1 0 12 O
occurred VBN 1 1 1 O
more RBR 0 1 12 O
frequently RB 0 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
a DT 0 0 12 O
history NN 0 1 12 O
of IN 0 0 12 O
neuropathy JJ 0 1 6 O
or CC 0 0 12 O
neurotoxic JJ 0 1 UNK O
drug NN 0 1 1 O
therapy NN 0 1 6 O
including VBG 1 1 1 O
stavudine NN 0 1 13 B-Drug
and CC 0 0 12 O
these DT 0 0 12 O
patients NNS 1 1 6 O
may MD 0 0 1 O
be VB 0 0 12 O
at IN 0 0 12 O
increased JJ 0 1 1 O
risk NN 0 1 1 O
of IN 0 0 12 O
neuropathy JJ 0 1 6 O
during IN 0 0 12 O
VIDEX NNP 0 1 UNK B-Brand
therapy NN 0 1 6 O
( ( 0 0 2 O
see VB 0 1 12 O
ADVERSE NNP 0 0 11 O
REACTIONS NNP 0 1 11 O
) ) 0 0 2 O
. . 0 0 12 O

Simvastatin NNP 0 1 0 B-Drug
and CC 0 0 12 O
Other JJ 0 0 2 O
Statins NNS 0 1 UNK B-Group
: : 0 0 2 O
Co NNP 0 1 2 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
bosentan NNS 0 1 13 B-Drug
decreased VBD 1 1 1 O
the DT 0 0 12 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
simvastatin NN 0 1 0 B-Drug
( ( 0 0 2 O
a DT 0 0 12 O
CYP9A9 NNP 0 0 UNK O
substrate NN 0 1 UNK O
) ) 0 0 2 O
and CC 0 0 12 O
its PRP$ 1 0 12 O
active JJ 0 1 1 O
- : 0 0 2 O
hydroxy NN 0 1 14 O
acid IN 0 1 14 O
metabolite NN 0 1 UNK O
by IN 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

Addition NN 0 1 UNK O
or CC 0 0 12 O
deletion NN 0 1 13 O
of IN 0 0 12 O
any DT 0 0 12 O
drug NN 0 1 1 O
from IN 0 0 12 O
the DT 0 0 12 O
therapeutic JJ 0 1 6 O
regimen NNS 0 1 6 O
of IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
oral JJ 0 1 6 O
anticoagulants NNS 1 1 13 B-Group
may MD 0 0 1 O
affect VB 0 1 1 O
patient JJ 0 1 6 O
response NN 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
anticoagulant NN 0 1 13 B-Group
. . 0 0 12 O

Co NNP 0 1 2 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
single JJ 0 1 12 O
9 CD 0 0 2 O
- : 0 0 2 O
mg NN 0 1 0 O
dose JJ 0 1 6 O
warfarin NN 0 1 14 B-Drug
had VBD 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
total JJ 0 1 1 O
lenalidomide NN 0 1 UNK B-Drug
. . 0 0 12 O

Further RB 0 1 2 O
if IN 0 0 12 O
guanfacine NN 0 1 13 B-Drug
is VBZ 1 0 12 O
to TO 0 0 12 O
be VB 0 0 12 O
discontinued VBN 1 1 1 O
in IN 0 0 12 O
such JJ 0 0 1 O
patients NNS 1 1 6 O
careful JJ 0 1 12 O
tapering NN 0 1 3 O
of IN 0 0 12 O
the DT 0 0 12 O
dosage NN 0 1 0 O
may MD 0 0 1 O
be VB 0 0 12 O
necessary JJ 0 0 1 O
in IN 0 0 12 O
order NN 0 1 1 O
to TO 0 0 12 O
avoid VB 0 0 12 O
rebound NN 0 0 3 O
phenomena NN 1 1 13 O
. . 0 0 12 O

PROLEUKIN NNP 0 1 UNK B-Brand
may MD 0 0 1 O
affect VB 0 1 1 O
central JJ 0 1 1 O
nervous JJ 0 1 6 O
function NN 0 1 1 O
. . 0 0 12 O

Beta NNP 0 1 2 B-Group
- : 0 0 2 O
adrenergic NN 0 1 UNK I-Group
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
: : 0 0 2 O
Coadministration NN 0 1 UNK O
of IN 0 0 12 O
beta NN 0 1 16 B-Group
- : 0 0 2 O
adrenergic JJ 0 1 UNK I-Group
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
did VBD 1 0 12 O
not RB 0 1 12 O
have VB 0 0 12 O
any DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
either CC 0 1 12 O
the DT 0 0 12 O
safety NN 0 1 1 O
or CC 0 0 12 O
efficacy NN 0 1 UNK O
of IN 0 0 12 O
ibutilide NN 0 1 14 B-Drug
in IN 0 0 12 O
the DT 0 0 12 O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
. . 0 0 12 O

All DT 0 0 2 O
of IN 0 0 12 O
these DT 0 0 12 O
also RB 0 0 12 O
resolved VBD 1 1 1 O
9 CD 0 0 2 O
with IN 0 0 12 O
continuation NN 0 0 1 O
of IN 0 0 12 O
both DT 0 0 12 O
drugs NNS 1 1 6 O
and CC 0 0 12 O
9 CD 0 0 2 O
after IN 0 0 12 O
discontinuation NN 0 1 6 O
of IN 0 0 12 O
leflunomide NN 0 1 13 B-Drug
. . 0 0 12 O

There EX 0 0 12 O
was VBD 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
ZEBETA NNP 0 1 UNK B-Brand
on IN 0 0 12 O
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
in IN 0 0 12 O
patients NNS 1 1 6 O
on IN 0 0 12 O
stable JJ 0 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
. . 0 0 12 O

Antithrombotics NNS 0 0 UNK B-Group

Cyclosporine NN 0 1 UNK B-Drug
: : 0 0 2 O
Because IN 0 0 12 O
cyclosporine NN 0 1 14 B-Drug
can MD 0 0 12 O
produce VB 0 0 1 O
nephrotoxicity NN 0 1 UNK O
with IN 0 0 12 O
decreases NNS 1 1 UNK O
in IN 0 0 12 O
creatinine JJ 0 1 14 O
clearance NN 0 1 16 O
and CC 0 0 12 O
rises NNS 1 0 UNK O
in IN 0 0 12 O
serum JJ 0 1 14 O
creatinine NN 0 1 14 O
and CC 0 0 12 O
because IN 0 0 12 O
renal JJ 0 1 6 O
excretion NN 0 1 14 O
is VBZ 1 0 12 O
the DT 0 0 12 O
primary JJ 0 1 1 O
elimination NN 0 1 UNK O
route NN 0 1 12 O
of IN 0 0 12 O
fibrate NN 0 0 UNK B-Group
drugs NNS 1 1 6 I-Group
including VBG 1 1 1 O
TRICOR NNP 0 1 UNK B-Brand
there EX 0 0 12 O
is VBZ 1 0 12 O
a DT 0 0 12 O
risk NN 0 1 1 O
that IN 0 0 12 O
an DT 0 0 12 O
interaction NN 0 1 UNK O
will MD 0 0 12 O
lead VB 0 1 12 O
to TO 0 0 12 O
deterioration NN 0 1 1 O
. . 0 0 12 O

Of IN 0 0 2 O
over IN 0 1 12 O
9 CD 0 0 2 O
patients NNS 1 1 6 O
enrolled VBN 1 0 1 O
in IN 0 0 12 O
the DT 0 0 12 O
Ibandronate NNP 0 1 UNK B-Drug
osteoporosis NN 0 1 6 O
Treatment NNP 0 1 7 O
and CC 0 0 12 O
Prevention NNP 0 1 UNK O
Studies NNP 0 1 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
used VBN 1 1 12 O
anti JJ 0 0 3 O
- : 0 0 2 O
peptic JJ 0 1 6 O
agents NNS 1 1 1 O
( ( 0 0 2 O
primarily RB 0 0 1 O
H9 NNP 0 0 UNK B-Group
blockers NNS 1 0 6 I-Group
and CC 0 0 12 O
PPIs NNP 0 1 UNK B-Group
) ) 0 0 2 O
. . 0 0 12 O

Monitoring NN 0 1 UNK O
of IN 0 0 12 O
anticoagulation NN 0 1 14 O
levels NNS 1 1 1 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O

Oral JJ 0 1 2 O
Contraceptives NNS 0 1 UNK B-Group
: : 0 0 2 O
Coadministration NN 0 1 UNK O
of IN 0 0 12 O
atorvastatin NN 0 1 0 B-Drug
and CC 0 0 12 O
an DT 0 0 12 O
oral JJ 0 1 6 O
contraceptive NN 0 1 13 B-Group
increased VBD 1 1 1 O
AUC NNP 0 1 UNK O
values NNS 1 1 1 O
for IN 0 0 12 O
norethindrone NN 0 1 13 B-Drug
and CC 0 0 12 O
ethinyl NN 0 0 13 B-Drug
estradiol NN 0 1 13 I-Drug
by IN 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

Before IN 0 1 2 O
taking VBG 1 0 12 O
glimepiride JJ 0 1 16 B-Drug
tell VB 0 0 12 O
your PRP$ 0 0 12 O
doctor NN 0 1 12 O
if IN 0 0 12 O
you PRP 0 0 12 O
are VBP 1 0 12 O
taking VBG 1 0 12 O
any DT 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
following JJ 0 1 1 O
medicines NNS 1 1 6 O
: : 0 0 2 O
- : 0 0 2 O
aspirin NN 0 1 14 B-Brand
or CC 0 0 12 O
another DT 0 0 12 O
salicylate NN 0 1 13 B-Group
such JJ 0 0 1 O
as IN 1 0 12 O
magnesium NN 0 1 14 B-Drug
choline NN 0 1 13 I-Drug
salicylate NN 0 1 13 I-Drug
( ( 0 0 2 O
Trilisate NNP 0 1 UNK B-Brand
) ) 0 0 2 O
salsalate NN 0 1 13 B-Drug
( ( 0 0 2 O
Disalcid NNP 0 1 UNK B-Brand
others NNS 0 1 12 O
) ) 0 0 2 O
choline NN 0 1 13 B-Drug
salicylate NN 0 1 13 I-Drug
( ( 0 0 2 O
Arthropan NNP 0 1 UNK B-Drug
) ) 0 0 2 O
magnesium NN 0 1 14 B-Drug
salicylate NN 0 1 13 I-Drug
( ( 0 0 2 O
Magan NNP 0 1 UNK B-Brand
) ) 0 0 2 O
or CC 0 0 12 O
bismuth JJ 0 1 16 B-Drug
subsalicylate NN 0 0 16 I-Drug
( ( 0 0 2 O
Pepto NNP 0 0 UNK B-Brand
- : 0 0 2 O
Bismol NNP 0 0 UNK I-Brand
) ) 0 0 2 O
; : 0 0 2 O

Levothyroxine NNP 0 1 0 B-Drug
Sodium NNP 0 1 14 I-Drug
Absorption NNP 0 1 UNK O
: : 0 0 2 O
The DT 0 0 2 O
following JJ 0 1 1 O
agents NNS 1 1 1 O
may MD 0 0 1 O
bind VB 0 1 UNK O
and CC 0 0 12 O
decrease VB 0 1 1 O
absorption NN 0 1 1 O
of IN 0 0 12 O
levothyroxine JJ 0 1 0 B-Drug
sodium NN 0 1 14 I-Drug
from IN 0 0 12 O
the DT 0 0 12 O
gastrointestinal JJ 0 1 6 O
tract NN 0 1 6 O
: : 0 0 2 O
aluminum NN 0 1 16 B-Drug
hydoxide NN 0 0 UNK I-Drug
cholestyramine NN 0 1 13 B-Drug
resin NN 0 1 UNK O
colestipol NN 0 1 13 B-Drug
hydrochloride RB 0 1 0 I-Drug
ferrous JJ 0 1 14 B-Drug
sulfate NN 0 1 14 I-Drug
sodium NN 0 1 14 B-Drug
polystyrene NN 0 1 16 I-Drug
sulfonate JJ 0 1 16 I-Drug
soybean NN 0 1 UNK O
flour NN 0 1 UNK O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
infant NN 0 1 6 O
formula NN 0 1 1 O
) ) 0 0 2 O
sucralfate NN 0 1 0 B-Drug
. . 0 0 12 O

In IN 0 0 2 O
addition NN 0 1 1 O
Mitotane NNP 0 1 UNK B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
given VBN 1 1 12 O
with IN 0 0 12 O
caution NN 0 0 1 O
to TO 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
susceptible JJ 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
influence NN 0 0 UNK O
of IN 0 0 12 O
hepatic JJ 0 1 14 O
enzyme NN 0 1 14 O
induction NN 0 1 1 O
. . 0 0 12 O

therefore IN 0 0 1 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
not RB 0 1 12 O
expected VBN 1 1 12 O
to TO 0 0 12 O
affect VB 0 1 1 O
the DT 0 0 12 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
. . 0 0 12 O

Coadministration NN 0 1 UNK O
of IN 0 0 12 O
almotriptan NN 0 1 13 B-Drug
and CC 0 0 12 O
the DT 0 0 12 O
potent NN 0 1 UNK O
CYP9A9 NNP 0 0 UNK O
inhibitor NN 0 1 14 O
ketoconazole NN 0 1 16 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
q.d NN 0 0 UNK O
. . 0 0 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
) ) 0 0 2 O
resulted VBD 1 1 1 O
in IN 0 0 12 O
an DT 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
increase NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
area NN 0 1 12 O
under IN 0 0 12 O
the DT 0 0 12 O
plasma NN 0 1 14 O
concentration NN 0 1 1 O
- : 0 0 2 O
time NN 0 1 12 O
curve NN 0 1 13 O
and CC 0 0 12 O
maximal JJ 0 1 1 O
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
almotriptan NN 0 1 13 B-Drug
. . 0 0 12 O

Drug NNP 0 1 2 O
- : 0 0 2 O
Drug NN 0 1 2 O
Interactions NNS 0 1 UNK O
Cimetidine NNP 0 1 0 B-Drug
: : 0 0 2 O
Concomitant NNP 0 1 UNK O
use NN 0 1 1 O
of IN 0 0 12 O
cimetidine NN 0 1 13 B-Drug
is VBZ 1 0 12 O
contraindicated VBN 1 1 14 O
. . 0 0 12 O

Clinical JJ 0 1 7 O
Comment NN 0 1 2 O

Drug JJ 0 1 2 O
Class NN 0 1 2 O
: : 0 0 2 O
Drug NN 0 1 2 O
Name NNP 0 1 2 O
Clinical NNP 0 1 7 O
Comment NN 0 1 2 O

Caution NN 0 0 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
observed VBN 1 1 1 O
in IN 0 0 12 O
administering VBG 1 1 1 O
DEMSER NNP 0 1 UNK B-Brand
to TO 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
phenothiazines NNS 1 1 UNK B-Group
or CC 0 0 12 O
haloperidol NN 0 1 16 B-Drug
because IN 0 0 12 O
the DT 0 0 12 O
extrapyramidal JJ 0 0 13 O
effects NNS 1 1 1 O
of IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
can MD 0 0 12 O
be VB 0 0 12 O
expected VBN 1 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
potentiated VBN 1 0 UNK O
by IN 0 0 12 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
catecholamine JJ 0 1 14 O
synthesis NN 0 1 UNK O
. . 0 0 12 O

Digoxin NN 0 1 0 B-Drug
: : 0 0 2 O
Coadministration NN 0 1 UNK O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
a DT 0 0 12 O
P NNP 0 1 2 O
- : 0 0 2 O
glycoprotein NN 0 1 UNK O
substrate NN 0 1 UNK O
with IN 0 0 12 O
oral JJ 0 1 6 O
conivaptan NN 0 1 UNK B-Drug
resulted VBD 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
reduction NN 0 1 1 O
in IN 0 0 12 O
clearance NN 0 1 16 O
and CC 0 0 12 O
an DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
Cmax NNP 0 1 UNK O
and CC 0 0 12 O
AUC NNP 0 1 UNK O
values NNS 1 1 1 O
. . 0 0 12 O

No DT 0 0 2 O
specific JJ 0 1 1 O
information NN 0 1 1 O
available JJ 0 1 1 O

The DT 0 0 2 O
following JJ 0 1 1 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
with IN 0 0 12 O
etomidate NN 0 1 14 B-Drug
. . 0 0 12 O

Vardenafil NNP 0 1 UNK B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
) ) 0 0 2 O
did VBD 1 0 12 O
not RB 0 1 12 O
potentiate VB 0 0 UNK O
the DT 0 0 12 O
hypotensive JJ 0 1 14 O
effects NNS 1 1 1 O
of IN 0 0 12 O
alcohol NN 0 1 1 B-Drug
during IN 0 0 12 O
the DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
hour NN 0 1 12 O
observation NN 0 1 1 O
period NN 0 1 1 O
in IN 0 0 12 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
when WRB 0 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
alcohol NN 0 1 1 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
g NN 0 1 16 O
/ NNP 0 0 2 O
kg VBZ 0 1 18 O
body NN 0 1 3 O
weight NN 0 1 3 O
) ) 0 0 2 O
. . 0 0 12 O

Every DT 0 0 2 O
other JJ 0 0 12 O
day NN 0 1 12 O
dosing VBG 1 0 14 O
with IN 0 0 12 O
9m CD 0 0 UNK O
g NNS 0 1 16 O
/ JJ 0 0 2 O
kg NN 0 1 18 O
( ( 0 0 2 O
9m CD 0 0 UNK O
g NN 0 1 16 O
/ NNP 0 0 2 O
m9 NN 0 1 UNK O
) ) 0 0 2 O
PEGASYS NNP 0 1 UNK B-Brand
( ( 0 0 2 O
equivalent JJ 0 1 1 O
to TO 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
times NNS 1 1 12 O
the DT 0 0 12 O
recommended JJ 0 1 1 O
human NN 0 1 1 O
dose NN 0 1 6 O
) ) 0 0 2 O
had VBD 1 0 12 O
no DT 0 0 12 O
effects NNS 1 1 1 O
on IN 0 0 12 O
cycle NN 0 1 1 O
duration NN 0 1 1 O
or CC 0 0 12 O
reproductive VB 0 1 13 O
hormone NN 0 1 6 O
status NN 0 1 1 O
. . 0 0 12 O

Saquinavir NN 0 1 UNK B-Drug
: : 0 0 2 O
Coadministration NN 0 1 UNK O
of IN 0 0 12 O
saquinavir NN 0 1 13 B-Drug
( ( 0 0 2 O
using VBG 1 1 1 O
an DT 0 0 12 O
experimental JJ 0 1 UNK O
soft JJ 0 1 3 O
- : 0 0 2 O
gelatin NN 0 1 UNK O
capsule JJ 0 1 3 O
formulation NN 0 1 13 O
of IN 0 0 12 O
saquinavir $ 0 1 13 B-Drug
9mg CD 0 0 UNK O
) ) 0 0 2 O
with IN 0 0 12 O
VIRACEPT NNP 0 1 UNK B-Brand
resulted VBD 1 1 1 O
in IN 0 0 12 O
an DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
increase NN 0 1 1 O
in IN 0 0 12 O
nelfinavir JJ 0 1 16 B-Drug
plasma NN 0 1 14 O
AUC NNP 0 1 UNK O
and CC 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
fold JJ 0 1 3 O
increase NN 0 1 1 O
in IN 0 0 12 O
saquinavir JJ 0 1 13 B-Drug
plasma NN 0 1 14 O
A.C NNP 0 0 UNK O
. . 0 0 12 O

Methysergide NNP 0 1 UNK B-Drug
may MD 0 0 1 O
reverse VB 0 1 1 O
the DT 0 0 12 O
analgesic JJ 0 1 13 O
activity NN 0 1 1 O
of IN 0 0 12 O
narcotic JJ 0 1 6 B-Group
analgesics NNS 1 1 14 I-Group
. . 0 0 12 O

H9 NNP 0 0 UNK B-Group
Blockers NNP 0 0 UNK I-Group
/ NNP 0 0 2 O
Proton NNP 0 1 UNK B-Group
Pump NNP 0 1 2 I-Group
Inhibitors NNS 0 1 7 I-Group
: : 0 0 2 O
Long NNP 0 1 2 O
- : 0 0 2 O
term NN 0 1 1 O
suppression NN 0 1 1 O
of IN 0 0 12 O
gastric JJ 0 1 6 O
acid JJ 0 1 14 O
secretion NN 0 1 14 O
by IN 0 0 12 O
H9 NNP 0 0 UNK B-Group
blockers NNS 1 0 6 I-Group
or CC 0 0 12 O
proton NN 0 1 14 B-Group
pump NN 0 1 3 I-Group
inhibitors NNS 1 1 14 I-Group
( ( 0 0 2 O
eg JJ 0 1 UNK O
famotidine NN 0 1 0 B-Drug
and CC 0 0 12 O
omeprazole NN 0 1 0 B-Drug
) ) 0 0 2 O
is VBZ 1 0 12 O
likely JJ 0 1 12 O
to TO 0 0 12 O
reduce VB 0 0 1 O
dasatinib NN 0 1 13 B-Drug
exposure NN 0 1 1 O
. . 0 0 12 O

Dose NNP 0 1 7 O
adjustment NN 0 1 1 O
is VBZ 1 0 12 O
not RB 0 1 12 O
recommended.Levetiracetam JJ 0 1 UNK O
had VBD 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
carbamazepine NN 0 1 16 B-Drug
valproate NN 0 1 16 B-Drug
topiramate NN 0 1 16 B-Drug
or CC 0 0 12 O
lamotrigine NN 0 1 0 B-Drug
. . 0 0 12 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
- : 0 0 2 O
Interactions NNS 0 1 UNK O
None NN 0 0 2 O
observed VBD 1 1 1 O
. . 0 0 12 O

Cerivastatin NNP 0 1 UNK B-Drug
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
were VBD 1 0 12 O
also RB 0 0 12 O
not RB 0 1 12 O
affected VBN 1 1 1 O
by IN 0 0 12 O
co NN 0 1 12 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
. . 0 0 12 O

Established VBN 0 1 UNK O
Drug NNP 0 1 2 O
Interactions NNS 0 1 UNK O

apomorphine NN 0 1 UNK B-Drug
- : 0 0 2 O
prior JJ 0 1 1 O
ingestion NN 0 1 14 O
of IN 0 0 12 O
diphenidol NN 0 1 UNK B-Drug
may MD 0 0 1 O
decrease VB 0 1 1 O
the DT 0 0 12 O
emetic JJ 0 1 UNK B-Group
response NN 0 1 1 O
to TO 0 0 12 O
apomorphine VB 0 1 UNK B-Drug
in IN 0 0 12 O
the DT 0 0 12 O
treatment NN 0 1 6 O
of IN 0 0 12 O
poisoning NN 0 1 13 O
. . 0 0 12 O

Rare JJ 0 1 2 O
reports NNS 1 1 1 O
of IN 0 0 12 O
more JJR 0 1 12 O
severe JJ 0 1 6 O
events NNS 1 1 12 O
such JJ 0 0 1 O
as IN 1 0 12 O
phlebitis NN 0 1 8 O
cellulitis NN 0 1 6 O
induration NN 0 1 8 O
skin FW 0 1 3 O
exfoliation NN 0 1 13 O
necrosis NN 0 1 6 O
and CC 0 0 12 O
fibrosis NN 0 1 6 O
have VBP 0 0 12 O
been VBN 1 0 12 O
received VBN 1 1 12 O
as IN 1 0 12 O
part NN 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
continuing VBG 1 1 1 O
surveillance NN 0 1 1 O
of IN 0 0 12 O
TAXOL NNP 0 1 UNK B-Brand
safety NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
use NN 0 1 1 O
of IN 0 0 12 O
Nutropin NNP 0 1 UNK B-Brand
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
chronic JJ 0 1 6 O
renal JJ 0 1 6 O
insufficiency NN 0 1 6 O
receiving VBG 1 1 1 O
glucocorticoid JJ 0 1 13 O
therapy NN 0 1 6 O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
evaluated VBN 1 1 1 O
. . 0 0 12 O

Pregnancy NN 0 1 7 O
Pregnancy NN 0 1 7 O
: : 0 0 2 O
Category NNP 0 1 UNK O
C NNP 0 0 2 O
PEGASYS NNP 0 1 UNK B-Brand
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
studied VBN 1 0 1 O
for IN 0 0 12 O
its PRP$ 1 0 12 O
teratogenic JJ 0 1 UNK O
effect NN 0 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
diabetics NNS 1 1 UNK O
blood SYM 0 1 6 O
- : 0 0 2 O
sugar NN 0 1 3 O
levels NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
very RB 0 1 12 O
carefully RB 0 0 12 O
. . 0 0 12 O

Short NNP 0 1 2 O
- : 0 0 2 O
term NN 0 1 1 O
pharmacokinetic JJ 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
demonstrated VBN 1 0 1 O
that IN 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
and CC 0 0 12 O
Lodine NNP 0 1 UNK B-Brand
( ( 0 0 2 O
etodolac JJ 0 1 13 B-Drug
capsules NNS 1 1 3 O
and CC 0 0 12 O
tablets NNS 1 1 3 O
) ) 0 0 2 O
results NNS 1 1 1 O
in IN 0 0 12 O
reduced JJ 0 1 1 O
protein NN 0 1 14 O
binding NN 0 1 1 O
of IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
but CC 0 0 12 O
there EX 0 0 12 O
was VBD 1 0 12 O
no DT 0 0 12 O
change NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
clearance NN 0 1 16 O
of IN 0 0 12 O
free JJ 0 1 12 O
warfarin NN 0 1 14 B-Drug
. . 0 0 12 O

DIAMOX NNP 0 1 UNK B-Brand
modifies NNS 0 1 UNK O
phenytoin VBP 0 1 16 B-Drug
metabolism NN 0 1 16 O
with IN 0 0 12 O
increased JJ 0 1 1 O
serum NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
. . 0 0 12 O

Untreated VBN 0 1 UNK O
hypothyroidism NN 0 1 6 O
may MD 0 0 1 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
growth NN 0 1 1 O
response NN 0 1 1 O
to TO 0 0 12 O
somatrem VB 0 1 UNK B-Drug
or CC 0 0 12 O
somatropin VB 0 1 13 B-Drug
. . 0 0 12 O

9 CD 0 0 2 O
. . 0 0 12 O

Drug NN 0 1 2 O
Interactions NNS 0 1 UNK O
with IN 0 0 12 O
Antacids NNP 0 1 UNK B-Group
Administration NNP 0 1 UNK O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
of IN 0 0 12 O
fexofenadine JJ 0 1 16 B-Drug
hydrochloride NN 0 1 0 I-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
x RB 0 0 10 O
9 CD 0 0 2 O
mg JJ 0 1 0 O
capsule NN 0 1 3 O
) ) 0 0 2 O
within IN 0 0 1 O
9 CD 0 0 2 O
minutes NNS 1 1 12 O
of IN 0 0 12 O
an DT 0 0 12 O
aluminum NN 0 1 16 B-Drug
and CC 0 0 12 O
magnesium NN 0 1 14 B-Drug
containing VBG 1 1 1 O
antacid NN 0 1 UNK B-Group
( ( 0 0 2 O
Maalox NNP 0 1 0 B-Brand
) ) 0 0 2 O
decreased VBD 1 1 1 O
fexofenadine JJ 0 1 16 B-Drug
AUC NNP 0 1 UNK O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
cmax NN 0 1 UNK O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

Lipids NNS 0 1 UNK O
: : 0 0 2 O
In IN 0 0 2 O
clinical JJ 0 1 6 O
studies NNS 1 1 1 O
the DT 0 0 12 O
incidence NN 0 1 6 O
of IN 0 0 12 O
hypertriglyceridemia NN 0 1 UNK O
was VBD 1 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
hypercholesterolemia NN 0 1 14 O
was VBD 1 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
that IN 0 0 12 O
of IN 0 0 12 O
decreased JJ 0 1 1 O
HDL NNP 0 1 14 O
was VBD 1 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

Coadministration NN 0 1 UNK O
of IN 0 0 12 O
Itraconazole NNP 0 1 UNK B-Drug
with IN 0 0 12 O
oral JJ 0 1 6 O
midazolam NN 0 1 16 B-Drug
or CC 0 0 12 O
triazolam NN 0 1 13 B-Drug
has VBZ 1 0 12 O
resulted VBN 1 1 1 O
in IN 0 0 12 O
elevated JJ 0 1 1 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
the DT 0 0 12 O
latter JJ 0 0 UNK O
two CD 0 1 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

Rifampin NN 0 1 0 B-Drug

When WRB 0 0 12 O
used VBN 1 1 12 O
in IN 0 0 12 O
external JJ 0 1 1 O
subcutaneous JJ 0 1 14 O
infusion NN 0 1 14 O
pumps NNS 1 1 UNK O
for IN 0 0 12 O
insulin NN 0 1 14 B-Drug
NovoLog NNP 0 1 UNK B-Brand
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
mixed JJ 0 1 3 O
with IN 0 0 12 O
any DT 0 0 12 O
other JJ 0 0 12 O
insulins NNS 1 1 13 B-Group
or CC 0 0 12 O
diluent NN 0 1 16 O
. . 0 0 12 O

Tolbutamide NN 0 1 UNK B-Drug
: : 0 0 2 O
Aprepitant NN 0 1 UNK B-Drug
when WRB 0 0 12 O
given VBN 1 1 12 O
as IN 1 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
on IN 0 0 12 O
Day NNP 0 1 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
on IN 0 0 12 O
Days NNP 0 1 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
decreased VBD 1 1 1 O
the DT 0 0 12 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
tolbutamide NN 0 1 UNK B-Drug
( ( 0 0 2 O
a DT 0 0 12 O
CYP9C9 NNP 0 0 UNK O
substrate NN 0 1 UNK O
) ) 0 0 2 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
on IN 0 0 12 O
Day NNP 0 1 2 O
9 CD 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
on IN 0 0 12 O
Day NNP 0 1 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
on IN 0 0 12 O
Day NNP 0 1 2 O
9 CD 0 0 2 O
when WRB 0 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
tolbutamide JJ 0 1 UNK B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
was VBD 1 0 12 O
admini RB 0 0 13 O
stered VBN 0 1 UNK O
orally RB 0 1 14 O
prior JJ 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
day NN 0 1 12 O
regimen NNS 0 1 6 O
of IN 0 0 12 O
Aprepitant NNP 0 1 UNK B-Drug
and CC 0 0 12 O
on IN 0 0 12 O
Days NNP 0 1 2 O
9 CD 0 0 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
. . 0 0 12 O

Similar JJ 0 1 2 O
effects NNS 1 1 1 O
would MD 0 0 12 O
be VB 0 0 12 O
expected VBN 1 1 12 O
with IN 0 0 12 O
other JJ 0 0 12 O
potent JJ 0 1 UNK O
CYP9D9 NNP 0 0 UNK O
inhibitors NNS 1 1 14 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
fluoxetine NN 0 1 16 B-Drug
quinidine NN 0 1 16 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

This DT 0 0 2 O
product NN 0 1 1 O
can MD 0 0 12 O
affect VB 0 1 1 O
the DT 0 0 12 O
results NNS 1 1 1 O
of IN 0 0 12 O
certain JJ 0 1 1 O
lab NN 0 1 1 O
tests NNS 1 1 1 O
. . 0 0 12 O

Increasing VBG 0 1 2 O
the DT 0 0 12 O
indinavir NN 0 1 16 B-Drug
dose NN 0 1 6 O
to TO 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
every DT 0 0 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
does VBZ 1 0 12 O
not RB 0 1 12 O
compensate VB 0 1 1 O
for IN 0 0 12 O
the DT 0 0 12 O
increased VBN 1 1 1 O
indinavir NN 0 1 16 B-Drug
metabolism NN 0 1 16 O
due JJ 0 1 1 O
to TO 0 0 12 O
efavirenz VB 0 1 13 B-Drug
. . 0 0 12 O

Concomitantly RB 0 0 UNK O
administered VBN 1 1 1 O
iron NN 0 1 3 B-Drug_n
- : 0 0 2 O
fortified VBN 1 0 3 O
infant JJ 0 1 6 O
formula NN 0 1 1 O
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
elemental JJ 0 1 1 O
iron NN 0 1 3 B-Drug_n
/ VBD 0 0 2 O
9 CD 0 0 2 O
oz NN 0 1 2 O
) ) 0 0 2 O
has VBZ 1 0 12 O
no DT 0 0 12 O
significant JJ 0 1 1 O
effect NN 0 1 1 O
on IN 0 0 12 O
cefdinir NN 0 1 UNK B-Drug
pharmacokinetics NNS 0 1 UNK O
. . 0 0 12 O

Alcohol NNP 0 1 2 B-Drug
in IN 0 0 12 O
particular NN 0 0 1 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
found VBN 1 1 12 O
to TO 0 0 12 O
exhibit VB 0 1 1 O
additive JJ 0 1 16 O
effects NNS 1 1 1 O
of IN 0 0 12 O
this DT 0 0 12 O
variety NN 0 1 1 O
. . 0 0 12 O

Antidiabetic JJ 0 1 UNK B-Group
Agents NNS 0 1 2 I-Group
( ( 0 0 2 O
Insulin NNP 0 1 7 B-Drug
Sulfonylureas NNP 0 1 UNK B-Group
) ) 0 0 2 O
: : 0 0 2 O
Requirements NNS 0 1 UNK O
for IN 0 0 12 O
insulin NN 0 1 14 B-Drug
or CC 0 0 12 O
oral JJ 0 1 6 O
antidiabetic JJ 0 1 13 B-Group
agents NNS 1 1 1 I-Group
may MD 0 0 1 O
be VB 0 0 12 O
reduced VBN 1 1 1 O
in IN 0 0 12 O
hypothyroid JJ 0 1 6 O
patients NNS 1 1 6 O
with IN 0 0 12 O
diabetes NNS 0 1 6 O
mellitus NNS 0 0 6 O
and CC 0 0 12 O
may MD 0 0 1 O
subsequently VB 0 0 1 O
increase VB 0 1 1 O
with IN 0 0 12 O
the DT 0 0 12 O
initiation NN 0 1 1 O
of IN 0 0 12 O
thyroid JJ 0 1 6 O
hormone NN 0 1 6 O
replacement NN 0 1 1 O
therapy NN 0 1 6 O
. . 0 0 12 O

Inhibitors NNS 0 1 7 O
of IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
( ( 0 0 2 O
eg JJ 0 1 UNK O
ketoconazole NN 0 1 16 B-Drug
) ) 0 0 2 O
or CC 0 0 12 O
CYP9D9 NNP 0 0 UNK O
( ( 0 0 2 O
eg JJ 0 1 UNK O
quinidine NN 0 1 16 B-Drug
fluoxetine NN 0 1 16 B-Drug
or CC 0 0 12 O
paroxetine NN 0 1 16 B-Drug
) ) 0 0 2 O
can MD 0 0 12 O
inhibit VB 0 1 13 O
aripiprazole JJ 0 1 16 B-Drug
elimination NN 0 1 UNK O
and CC 0 0 12 O
cause NN 0 1 12 O
increased VBD 1 1 1 O
blood NN 0 1 6 O
levels NNS 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
bioavailability NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
capsule NN 0 1 3 O
formulation NN 0 1 13 O
of IN 0 0 12 O
cefprozil NN 0 1 UNK B-Drug
was VBD 1 0 12 O
not RB 0 1 12 O
affected VBN 1 1 1 O
when WRB 0 0 12 O
administered VBN 1 1 1 O
9 CD 0 0 2 O
minutes NNS 1 1 12 O
following VBG 1 1 1 O
an DT 0 0 12 O
antacid NN 0 1 UNK B-Group
. . 0 0 12 O

These DT 0 0 1 O
pharmacokinetic JJ 0 1 UNK O
effects NNS 1 1 1 O
seen VBN 1 1 12 O
during IN 0 0 12 O
diltiazem JJ 0 1 0 B-Drug
coadministration NN 0 1 UNK O
can MD 0 0 12 O
result VB 0 1 1 O
in IN 0 0 12 O
increased JJ 0 1 1 O
clinical JJ 0 1 6 O
effects NNS 1 1 1 O
( ( 0 0 2 O
e.g. VB 0 0 UNK O
prolonged VBN 1 1 6 O
sodation NN 0 0 UNK O
) ) 0 0 2 O
of IN 0 0 12 O
both DT 0 0 12 O
midazolam NNS 0 1 16 B-Drug
and CC 0 0 12 O
triazolam NN 0 1 13 B-Drug
. . 0 0 12 O

Etonogestrel NN 0 1 UNK B-Drug
may MD 0 0 1 O
interact VB 0 0 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
following JJ 0 1 1 O
medications NNS 1 1 6 O
: : 0 0 2 O
acetaminophen NN 0 1 16 B-Drug
( ( 0 0 2 O
Tylenol NNP 0 1 0 B-Brand
) ) 0 0 2 O
antibiotics NNS 1 1 6 B-Group
such JJ 0 0 1 O
as IN 1 0 12 O
ampicillin NN 0 1 0 B-Drug
and CC 0 0 12 O
tetracycline NN 0 1 0 B-Drug
anticonvulsants NNS 1 1 13 B-Group
( ( 0 0 2 O
Dilantin NNP 0 1 0 B-Brand
Phenobarbital NNP 0 1 0 B-Drug
Tegretol NNP 0 1 0 B-Brand
Trileptal NNP 0 1 UNK B-Brand
Topamax NNP 0 1 0 B-Brand
Felbatol NNP 0 1 UNK B-Brand
) ) 0 0 2 O
antifungals NNS 1 1 UNK B-Group
( ( 0 0 2 O
Gris NNP 0 0 UNK B-Brand
- : 0 0 2 O
PEG NNP 0 0 14 I-Brand
Nizoral NNP 0 1 UNK B-Brand
Sporanox NNP 0 1 UNK B-Brand
) ) 0 0 2 O
atorvastatin NN 0 1 0 B-Drug
( ( 0 0 2 O
Lipitor NNP 0 1 0 B-Brand
) ) 0 0 2 O
clofibrate NN 0 1 UNK B-Drug
( ( 0 0 2 O
Atromid NNP 0 1 UNK B-Brand
- : 0 0 2 O
S NN 0 1 2 I-Brand
) ) 0 0 2 O
cyclosporine NN 0 1 14 B-Drug
( ( 0 0 2 O
Neoral NNP 0 1 0 B-Brand
Sandimmune NNP 0 1 UNK B-Brand
) ) 0 0 2 O
HIV NNP 0 1 6 O
drugs NNS 1 1 6 O
classified VBD 1 1 13 O
as IN 1 0 12 O
protease NN 0 1 13 B-Group
inhibitors NNS 1 1 14 I-Group
( ( 0 0 2 O
Agenerase NNP 0 1 UNK B-Brand
Crixivan NNP 0 1 UNK B-Brand
Fortovase NNP 0 1 UNK B-Brand
Invirase NNP 0 1 UNK B-Brand
Kaletra NNP 0 1 UNK B-Brand
Norvir NNP 0 1 UNK B-Brand
Viracept NNP 0 1 UNK B-Brand
) ) 0 0 2 O
morphine NN 0 1 14 B-Drug
( ( 0 0 2 O
Astramorph NNP 0 1 UNK B-Brand
Kadian NNP 0 1 UNK B-Brand
MS NNP 0 1 2 B-Brand
Contin NNP 0 0 0 I-Brand
) ) 0 0 2 O
phenylbutazone NN 0 1 UNK B-Drug
prednisolone NN 0 1 0 B-Drug
( ( 0 0 2 O
Prelone NNP 0 1 UNK B-Brand
) ) 0 0 2 O
rifadin NN 0 1 UNK B-Brand
( ( 0 0 2 O
rifampin NN 0 1 16 B-Drug
) ) 0 0 2 O
St. NNP 0 1 2 O
Johns NNP 0 0 UNK O
wort NN 0 0 UNK O
temazepam NN 0 1 16 B-Drug
theophylline NN 0 1 16 B-Drug
( ( 0 0 2 O
Theo NNP 0 0 UNK B-Brand
- : 0 0 2 O
Dur NN 0 1 UNK I-Brand
) ) 0 0 2 O
and CC 0 0 12 O
vitamin JJ 0 1 6 B-Drug
C NNP 0 0 2 I-Drug
. . 0 0 12 O

Additionally RB 0 0 1 O
higher JJR 1 1 1 O
than IN 0 0 12 O
expected VBN 1 1 12 O
tricyclic JJ 0 0 14 B-Group
antidepressant NN 0 1 6 I-Group
levels NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
when WRB 0 0 12 O
they PRP 0 0 12 O
are VBP 1 0 12 O
begun VBN 1 1 12 O
in IN 0 0 12 O
patients NNS 1 1 6 O
already RB 0 0 12 O
taking VBG 1 0 12 O
cimetidine NN 0 1 13 B-Drug
. . 0 0 12 O

Drug NN 0 1 2 O
Interaction NNP 0 1 2 O
with IN 0 0 12 O
Erythromycin NNP 0 1 0 B-Drug
and CC 0 0 12 O
Ketoconazole NNP 0 1 UNK B-Drug
Fexofenadine NNP 0 1 UNK B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
exhibit VB 0 1 1 O
minimal JJ 0 1 1 O
( ( 0 0 2 O
ca MD 0 1 12 O
. . 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
metabolism NN 0 1 16 O
. . 0 0 12 O

Standard NNP 0 1 2 O
monitoring NN 0 1 1 O
of IN 0 0 12 O
methotrexate JJ 0 1 16 B-Drug
- : 0 0 2 O
related JJ 0 1 1 O
toxicity NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
continued VBN 1 1 12 O
if IN 0 0 12 O
VIOXX NNP 0 1 UNK B-Brand
and CC 0 0 12 O
methotrexate NN 0 1 16 B-Drug
are VBP 1 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
. . 0 0 12 O

Valproate NN 0 1 0 B-Drug
: : 0 0 2 O
Felbatol NNP 0 1 UNK B-Brand
causes VBZ 1 1 6 O
an DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
valproate NN 0 1 16 B-Drug
concentrations NNS 1 1 13 O
. . 0 0 12 O

Vaccinations NNS 0 1 UNK O
with IN 0 0 12 O
attenuated JJ 0 1 UNK O
live JJ 0 1 12 O
bacteria NNS 0 1 6 O
should MD 0 0 12 O
therefore RB 0 0 1 O
be VB 0 0 12 O
completed VBN 1 1 12 O
at IN 0 0 12 O
least JJS 0 1 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
before IN 0 1 12 O
the DT 0 0 12 O
first JJ 0 1 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
Mefloquine NNP 0 1 UNK B-Drug
. . 0 0 12 O

Intracellular JJ 0 1 UNK O
resistance NN 0 1 1 O
to TO 0 0 12 O
thyroid VB 0 1 6 B-Group
hormone NN 0 1 6 I-Group
is VBZ 1 0 12 O
quite RB 0 0 12 O
rare JJ 0 1 12 O
. . 0 0 12 O

and CC 0 0 12 O
combinations NNS 1 1 1 O
of IN 0 0 12 O
opioids NNS 0 1 14 B-Group
and CC 0 0 12 O
sedatives NNS 1 1 6 B-Group
( ( 0 0 2 O
eg JJ 0 1 UNK O
benzodiazepines NNS 1 1 14 B-Group
barbiturates VBZ 0 1 14 B-Group
chloral JJ 0 1 16 B-Drug
hydrate NN 0 1 16 I-Drug
droperidol NN 0 1 0 B-Drug
etc FW 0 1 12 O
. . 0 0 12 O
) ) 0 0 2 O
. . 0 0 12 O

In IN 0 0 2 O
one CD 0 1 12 O
controlled VBD 1 1 1 O
study NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
patients NNS 1 1 6 O
transient JJ 0 1 1 O
drowsiness NN 0 1 13 O
was VBD 1 0 12 O
observed VBN 1 1 1 O
in IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
of IN 0 0 12 O
those DT 0 0 12 O
receiving VBG 1 1 1 O
baclofen JJ 0 1 0 B-Drug
tablets NNS 1 1 3 O
compared VBN 1 1 1 O
to TO 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
of IN 0 0 12 O
those DT 0 0 12 O
in IN 0 0 12 O
the DT 0 0 12 O
placebo NN 0 1 13 O
group NN 0 1 12 O
. . 0 0 12 O

cinchophen NN 0 1 UNK B-Drug
; : 0 0 2 O

Thus NNP 0 0 1 O
concentrations NNS 1 1 13 O
which WDT 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
obtained VBN 1 1 1 O
in IN 0 0 12 O
vivo NN 0 1 13 O
clinically RB 0 0 6 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
normal JJ 0 1 1 O
renal JJ 0 1 6 O
function NN 0 1 1 O
are VBP 1 0 12 O
considerably RB 0 0 1 O
lower JJR 1 1 1 O
than IN 0 0 12 O
the DT 0 0 12 O
in IN 0 0 12 O
vitro JJ 0 1 UNK O
concentrations NNS 1 1 13 O
found VBD 1 1 12 O
to TO 0 0 12 O
induce VB 0 1 6 O
abnormalities NNS 1 1 6 O
in IN 0 0 12 O
platelet NN 0 1 14 O
function NN 0 1 1 O
tests NNS 1 1 1 O
. . 0 0 12 O

Selegiline NN 0 1 UNK B-Drug
: : 0 0 2 O
Combination NNP 0 1 UNK B-Group
hormonal JJ 0 1 6 I-Group
contraceptives NNS 1 1 13 I-Group
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
serum JJ 0 1 14 O
concentration NN 0 1 1 O
of IN 0 0 12 O
selegiline NN 0 1 13 B-Drug
. . 0 0 12 O

Given VBN 0 1 2 O
the DT 0 0 12 O
primary JJ 0 1 1 O
CNS NNP 0 1 6 O
effects NNS 1 1 1 O
of IN 0 0 12 O
paliperidone NN 0 1 16 B-Drug
INVEGA NNP 0 1 UNK B-Brand
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
with IN 0 0 12 O
caution NN 0 0 1 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
other JJ 0 0 12 O
centrally RB 0 0 UNK B-Group
acting VBG 1 1 12 I-Group
drugs NNS 1 1 6 I-Group
and CC 0 0 12 O
alcohol NN 0 1 1 B-Drug
. . 0 0 12 O

In IN 0 0 2 O
an DT 0 0 12 O
in IN 0 0 12 O
vivo NN 0 1 13 O
metabolic NN 0 1 6 O
probe NN 0 1 1 O
study NN 0 1 1 O
alosetron NN 0 1 UNK B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
inhibit VB 0 1 13 O
CYP9E9 NNP 0 0 UNK O
but CC 0 0 12 O
did VBD 1 0 12 O
produce VB 0 0 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
both DT 0 0 12 O
CYP9A9 NNP 0 0 UNK O
and CC 0 0 12 O
N NNP 0 1 2 O
- : 0 0 2 O
acetyltransferase NN 0 1 UNK O
. . 0 0 12 O

In IN 0 0 2 O
clinical JJ 0 1 6 O
studies NNS 1 1 1 O
patients NNS 1 1 6 O
on IN 0 0 12 O
opioids NNS 0 1 14 B-Group
often RB 0 1 12 O
needed VBD 1 1 12 O
higher JJR 1 1 1 O
serum NN 0 1 14 O
pegvisomant JJ 0 1 UNK B-Drug
concentrations NNS 1 1 13 O
to TO 0 0 12 O
achieve VB 0 0 1 O
appropriate JJ 0 1 1 O
IGF NNP 0 1 UNK O
- : 0 0 2 O
I PRP 0 1 12 O
suppression VBP 0 1 1 O
compared VBN 1 1 1 O
with IN 0 0 12 O
patients NNS 1 1 6 O
not RB 0 1 12 O
receiving VBG 1 1 1 O
opioids NNS 0 1 14 B-Group
. . 0 0 12 O

Although IN 0 0 12 O
there EX 0 0 12 O
is VBZ 1 0 12 O
no DT 0 0 12 O
documentation NN 0 1 13 O
of IN 0 0 12 O
such PDT 0 0 1 O
a DT 0 0 12 O
similar JJ 0 1 1 O
interaction NN 0 1 UNK O
between IN 0 0 12 O
ethotoin NN 0 1 UNK B-Drug
and CC 0 0 12 O
the DT 0 0 12 O
coumarin NN 0 1 UNK B-Group
anticoagulants NNS 1 1 13 I-Group
may MD 0 0 1 O
occur VB 0 1 1 O
. . 0 0 12 O

Concomitant JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
fenofibrate NN 0 1 16 B-Drug
( ( 0 0 2 O
equivalent JJ 0 1 1 O
to TO 0 0 12 O
9mg CD 0 0 UNK O
TRICOR NNP 0 1 UNK B-Brand
) ) 0 0 2 O
with IN 0 0 12 O
pravastatin NN 0 1 16 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
) ) 0 0 2 O
once RB 0 0 12 O
daily JJ 0 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
mean JJ 0 1 12 O
Cmax NNP 0 1 UNK O
and CC 0 0 12 O
AUC NNP 0 1 UNK O
values NNS 1 1 1 O
for IN 0 0 12 O
pravastatin NN 0 1 16 B-Drug
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
( ( 0 0 2 O
range NN 0 1 1 O
from IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
decrease NN 0 1 1 O
to TO 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
increase NN 0 1 1 O
) ) 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
( ( 0 0 2 O
range NN 0 1 1 O
from IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
decrease NN 0 1 1 O
to TO 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
increase NN 0 1 1 O
) ) 0 0 2 O
respectively RB 0 0 1 O
and CC 0 0 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
hydroxy NN 0 1 14 O
- : 0 0 2 O
iso NN 0 1 13 O
- : 0 0 2 O
pravastatin NN 0 1 16 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
( ( 0 0 2 O
range NN 0 1 1 O
from IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
decrease NN 0 1 1 O
to TO 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
increase NN 0 1 1 O
) ) 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
( ( 0 0 2 O
range NN 0 1 1 O
from IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
decrease NN 0 1 1 O
to TO 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
increase NN 0 1 1 O
) ) 0 0 2 O
respectively RB 0 0 1 O
in IN 0 0 12 O
9 CD 0 0 2 O
healthy JJ 0 1 12 O
adults NNS 1 1 13 O
. . 0 0 12 O

Potential JJ 0 1 UNK O
effect NN 0 1 1 O
on IN 0 0 12 O
anticoagulation NN 0 1 14 O
. . 0 0 12 O

Oral JJ 0 1 2 O
anticoagulants NNS 1 1 13 B-Group
may MD 0 0 1 O
potentiate VB 0 0 UNK O
the DT 0 0 12 O
hypoglycemic JJ 0 1 14 O
action NN 0 1 13 O
of IN 0 0 12 O
hypoglycemic JJ 0 1 14 B-Group
agents NNS 1 1 1 I-Group
eg JJ 0 1 UNK O
tolbutamide NN 0 1 UNK B-Drug
and CC 0 0 12 O
chlorpropamide NN 0 1 13 B-Drug
by IN 0 0 12 O
inhibiting VBG 1 1 UNK O
their PRP$ 0 0 12 O
metabolism NN 0 1 16 O
in IN 0 0 12 O
the DT 0 0 12 O
liver NN 0 1 6 O
. . 0 0 12 O

In IN 0 0 2 O
9 CD 0 0 2 O
otherwise RB 0 0 1 O
healthy JJ 0 1 12 O
subjects NNS 1 1 UNK O
with IN 0 0 12 O
epilepsy NN 0 1 13 O
ingesting VBG 1 1 UNK O
phenytoin VB 0 1 16 B-Drug
the DT 0 0 12 O
steadystate NN 0 1 UNK O
trough NN 0 1 3 O
( ( 0 0 2 O
Cmin NNP 0 1 UNK O
) ) 0 0 2 O
phenytoin VBP 0 1 16 B-Drug
plasma JJ 0 1 14 O
concentration NN 0 1 1 O
was VBD 1 0 12 O
9 CD 0 0 2 O
9 CD 0 0 2 O
micrograms NNS 1 1 14 O
/ JJ 0 0 2 O
mL NN 0 1 14 O
. . 0 0 12 O

MAO JJ 0 1 14 B-Group
Inhibitors NNS 0 1 7 I-Group
: : 0 0 2 O
Serious JJ 0 1 UNK O
side NN 0 1 3 O
effects NNS 1 1 1 O
and CC 0 0 12 O
even RB 0 0 12 O
death NN 0 1 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
following VBG 1 1 1 O
the DT 0 0 12 O
concomitant JJ 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
certain JJ 0 1 1 O
drugs NNS 1 1 6 O
with IN 0 0 12 O
MAO NNP 0 1 14 B-Group
inhibitors NNS 1 1 14 I-Group
. . 0 0 12 O

Cholinesterase NNP 0 1 UNK B-Group
Inhibitors NNS 0 1 7 I-Group
: : 0 0 2 O
Dipyridamole NNP 0 1 UNK B-Drug
may MD 0 0 1 O
counteract VB 0 0 UNK O
the DT 0 0 12 O
anticholinesterase JJ 0 1 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
cholinesterase NN 0 1 UNK B-Group
inhibitors NNS 1 1 14 I-Group
thereby RB 0 0 UNK O
potentially RB 0 0 1 O
aggravating VBG 1 1 UNK O
myasthenia NN 0 1 6 O
gravis NN 0 1 6 O
. . 0 0 12 O

Folic NNP 0 0 0 B-Drug
acid VBZ 0 1 14 I-Drug
supplements NNS 1 1 6 O
can MD 0 0 12 O
correct VB 0 1 1 O
the DT 0 0 12 O
anemia NN 0 1 6 O
associated VBN 1 1 1 O
with IN 0 0 12 O
vitamin NN 0 1 6 O
B9 NNP 0 0 UNK O
deficiency NN 0 1 6 O
. . 0 0 12 O

No DT 0 0 2 O
significant JJ 0 1 1 O
effects NNS 1 1 1 O
on IN 0 0 12 O
cisapride JJ 0 1 UNK B-Drug
metabolism NN 0 1 16 O
or CC 0 0 12 O
QT NNP 0 1 13 O
interval NN 0 1 1 O
were VBD 1 0 12 O
noted VBN 1 0 1 O
. . 0 0 12 O

L NNP 0 1 2 B-Drug
- : 0 0 2 O
glutamine NN 0 1 13 I-Drug
has VBZ 1 0 12 O
orphan VBN 0 1 UNK O
drug NN 0 1 1 O
status NN 0 1 1 O
for IN 0 0 12 O
this DT 0 0 12 O
indication NN 0 1 1 O
. . 0 0 12 O

Pediatric NNP 0 1 7 O
Use NNP 0 1 2 O
The DT 0 0 2 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
ZETIA NNP 0 1 UNK B-Brand
in IN 0 0 12 O
adolescents NNS 1 1 13 O
( ( 0 0 2 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
years NNS 1 1 12 O
) ) 0 0 2 O
have VBP 0 0 12 O
been VBN 1 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
be VB 0 0 12 O
similar JJ 0 1 1 O
to TO 0 0 12 O
that DT 0 0 12 O
in IN 0 0 12 O
adults NNS 1 1 13 O
. . 0 0 12 O

Amphotericin NNP 0 1 0 B-Drug
B NNP 0 0 2 I-Drug
or CC 0 0 12 O
Corticosteroids NNP 0 1 UNK B-Group
or CC 0 0 12 O
Corticotropin NNP 0 1 UNK B-Drug
( ( 0 0 2 O
ACTH NNP 0 1 UNK B-Drug
) ) 0 0 2 O

The DT 0 0 2 O
pharmacokinetic JJ 0 1 UNK O
interactions NNS 1 1 UNK O
listed VBN 1 1 1 O
below IN 0 0 12 O
are VBP 1 0 12 O
potentially RB 0 0 1 O
clinically RB 0 0 6 O
important JJ 0 1 1 O
. . 0 0 12 O

Diuretic JJ 0 1 UNK B-Group
agents NNS 1 1 1 I-Group
may MD 0 0 1 O
decrease VB 0 1 1 O
vascular JJ 0 1 6 O
response NN 0 1 1 O
to TO 0 0 12 O
pressor VB 0 1 14 O
drugs NNS 1 1 6 O
such JJ 0 0 1 O
as IN 1 0 12 O
epinephrine NN 0 1 14 B-Drug
. . 0 0 12 O

Drug NNP 0 1 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interactions NNS 0 1 UNK O
: : 0 0 2 O
Prolongation NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
template NN 0 1 UNK O
bleeding NN 0 1 6 O
time NN 0 1 12 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
during IN 0 0 12 O
continuous JJ 0 1 1 O
intravenous JJ 0 1 14 O
infusion NN 0 1 14 O
of IN 0 0 12 O
AMICAR NNP 0 1 UNK B-Brand
at IN 0 0 12 O
dosages NNS 1 1 14 O
exceeding VBG 1 0 1 O
9 CD 0 0 2 O
g JJ 0 1 16 O
/ NNP 0 0 2 O
day NN 0 1 12 O
. . 0 0 12 O

Currently RB 0 1 2 O
there EX 0 0 12 O
are VBP 1 0 12 O
no DT 0 0 12 O
safety NN 0 1 1 O
and CC 0 0 12 O
efficacy NN 0 1 UNK O
data NNS 0 1 1 O
available JJ 0 1 1 O
from IN 0 0 12 O
the DT 0 0 12 O
use NN 0 1 1 O
of IN 0 0 12 O
this DT 0 0 12 O
combination NN 0 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
a DT 0 0 12 O
study NN 0 1 1 O
in IN 0 0 12 O
9 CD 0 0 2 O
patients NNS 1 1 6 O
with IN 0 0 12 O
mild JJ 0 1 6 O
to TO 0 0 12 O
moderate VB 0 1 1 O
hypertension NN 0 1 6 O
where WRB 0 0 12 O
the DT 0 0 12 O
antihypertensive JJ 0 1 14 O
effects NNS 1 1 1 O
of IN 0 0 12 O
PRINIVIL NNP 0 1 UNK B-Brand
alone RB 0 1 12 O
were VBD 1 0 12 O
compared VBN 1 1 1 O
to TO 0 0 12 O
PRINIVIL VB 0 1 UNK B-Brand
given VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
indomethacin NN 0 1 14 B-Drug
the DT 0 0 12 O
use NN 0 1 1 O
of IN 0 0 12 O
indomethacin NN 0 1 14 B-Drug
was VBD 1 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
a DT 0 0 12 O
reduced JJ 0 1 1 O
antihypertensive JJ 0 1 14 O
effect NN 0 1 1 O
although IN 0 0 12 O
the DT 0 0 12 O
difference NN 0 1 UNK O
between IN 0 0 12 O
the DT 0 0 12 O
two CD 0 1 12 O
regimens NNS 1 1 UNK O
was VBD 1 0 12 O
not RB 0 1 12 O
significant JJ 0 1 1 O
. . 0 0 12 O

Drugs NNS 0 1 2 O
which WDT 0 0 12 O
may MD 0 0 1 O
potentiate VB 0 0 UNK O
the DT 0 0 12 O
release NN 0 1 12 O
of IN 0 0 12 O
neutrophils NNS 1 1 14 O
such JJ 0 0 1 O
as IN 1 0 12 O
lithium NN 0 1 16 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
with IN 0 0 12 O
caution NN 0 0 1 O
. . 0 0 12 O

Although IN 0 0 12 O
not RB 0 1 12 O
studied VBN 1 0 1 O
the DT 0 0 12 O
potent JJ 0 1 UNK O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
9A9 CD 0 0 UNK O
inhibitors NNS 1 1 14 O
ritonavir VBP 0 1 16 B-Drug
and CC 0 0 12 O
nelfinavir VBP 0 1 16 B-Drug
may MD 0 0 1 O
cause VB 0 1 12 O
intense JJ 0 1 12 O
and CC 0 0 12 O
prolonged JJ 0 1 6 O
sedation NN 0 1 6 O
and CC 0 0 12 O
respiratory NN 0 1 6 O
depression NN 0 1 6 O
due JJ 0 1 1 O
to TO 0 0 12 O
a DT 0 0 12 O
decrease NN 0 1 1 O
in IN 0 0 12 O
plasma JJ 0 1 14 O
clearance NN 0 1 16 O
of IN 0 0 12 O
midazolam NN 0 1 16 B-Drug
. . 0 0 12 O

DRUG NN 0 1 11 O
INTERACTIONS NNP 0 1 UNK O

With IN 0 0 2 O
the DT 0 0 12 O
exception NN 0 1 12 O
of IN 0 0 12 O
albuterol NN 0 1 0 B-Drug
there EX 0 0 12 O
are VBP 1 0 12 O
no DT 0 0 12 O
formal JJ 0 1 1 O
studies NNS 1 1 1 O
fully RB 0 0 1 O
evaluating VBG 1 1 1 O
the DT 0 0 12 O
interaction NN 0 1 UNK O
effects NNS 1 1 1 O
of IN 0 0 12 O
ATROVENT NNP 0 1 0 B-Brand
Inhalation NNP 0 1 7 O
Aerosol NNP 0 1 7 O
and CC 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
with IN 0 0 12 O
respect NN 0 1 1 O
to TO 0 0 12 O
effectiveness VB 0 1 UNK O
. . 0 0 12 O

halothane NN 0 1 13 B-Drug
; : 0 0 2 O

In IN 0 0 2 O
a DT 0 0 12 O
study NN 0 1 1 O
in IN 0 0 12 O
diabetics NNS 1 1 UNK O
with IN 0 0 12 O
microalbuminuria NNS 0 1 UNK O
INSPRA NNP 0 1 UNK B-Brand
9 CD 0 0 2 O
mg NN 0 1 0 O
combined VBN 1 1 1 O
with IN 0 0 12 O
the DT 0 0 12 O
ACE NNP 0 1 13 B-Group
inhibitor NN 0 1 14 I-Group
enalapril VBD 0 1 0 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
increased VBD 1 1 1 O
the DT 0 0 12 O
frequency NN 0 1 1 O
of IN 0 0 12 O
hyperkalemia NN 0 1 14 O
( ( 0 0 2 O
serum JJ 0 1 14 O
potassium NN 0 1 14 O
9 CD 0 0 2 O
mEq NN 0 1 14 O
/ NNP 0 0 2 O
L NNP 0 1 2 O
) ) 0 0 2 O
from IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
on IN 0 0 12 O
enalapril NN 0 1 0 B-Drug
alone RB 0 1 12 O
to TO 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

The DT 0 0 2 O
results NNS 1 1 1 O
indicate VBP 0 0 1 O
significant JJ 0 1 1 O
changes NNS 1 1 1 O
in IN 0 0 12 O
tamsulosin NN 0 1 16 B-Drug
HCI NNP 0 0 UNK I-Drug
clearance NN 0 1 16 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
decrease NN 0 1 1 O
) ) 0 0 2 O
and CC 0 0 12 O
AUC NNP 0 1 UNK O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
increase NN 0 1 1 O
) ) 0 0 2 O
. . 0 0 12 O

Thiazide NNP 0 1 UNK B-Group
drugs NNS 1 1 6 I-Group
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
responsiveness NN 0 1 UNK O
of IN 0 0 12 O
tubocurarine NN 0 1 UNK B-Drug
. . 0 0 12 O

Close JJ 0 1 2 O
observation NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
patient NN 0 1 6 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
when WRB 0 0 12 O
a DT 0 0 12 O
beta NN 0 1 16 B-Group
- : 0 0 2 O
blocker NN 0 0 3 I-Group
is VBZ 1 0 12 O
administered VBN 1 1 1 O
to TO 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
catecholamine JJ 0 1 14 O
- : 0 0 2 O
depleting VBG 1 1 UNK O
drugs NNS 1 1 6 O
such JJ 0 0 1 O
as IN 1 0 12 O
reserpine NN 0 1 UNK B-Drug
because IN 0 0 12 O
of IN 0 0 12 O
possible JJ 0 1 1 O
additive JJ 0 1 16 O
effects NNS 1 1 1 O
and CC 0 0 12 O
the DT 0 0 12 O
production NN 0 1 1 O
of IN 0 0 12 O
hypotension NN 0 1 6 O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
marked VBN 1 1 1 O
bradycardia IN 0 1 8 O
which WDT 0 0 12 O
may MD 0 0 1 O
produce VB 0 0 1 O
vertigo JJ 0 1 6 O
syncope NN 0 1 8 O
or CC 0 0 12 O
postural JJ 0 1 13 O
hypotension NN 0 1 6 O
. . 0 0 12 O

Dofetilide NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
metabolized VBN 1 1 UNK O
to TO 0 0 12 O
a DT 0 0 12 O
small JJ 0 1 12 O
extent NN 0 1 1 O
by IN 0 0 12 O
the DT 0 0 12 O
CYP9A9 NNP 0 0 UNK O
isoenzyme NN 0 1 13 O
of IN 0 0 12 O
the DT 0 0 12 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
system NN 0 1 1 O
. . 0 0 12 O

( ( 0 0 2 O
In IN 0 0 2 O
some DT 0 0 12 O
patients NNS 1 1 6 O
the DT 0 0 12 O
steroidal JJ 0 1 UNK B-Group
anti NN 0 0 3 I-Group
- : 0 0 2 O
inflammatory JJ 0 1 6 I-Group
agent NN 0 1 1 I-Group
can MD 0 0 12 O
reduce VB 0 0 1 O
the DT 0 0 12 O
diuretic JJ 0 1 14 O
natriuretic JJ 0 1 UNK O
and CC 0 0 12 O
antihypertensive JJ 0 1 14 O
effects NNS 1 1 1 O
of IN 0 0 12 O
loop JJ 0 1 3 B-Group
potassium NN 0 1 14 B-Group
sparing NN 0 0 6 I-Group
and CC 0 0 12 O
thiazide JJ 0 1 UNK B-Group
diuretics NNS 1 1 14 I-Group
. . 0 0 12 O

Corticosteroids NNS 0 1 UNK B-Group
. . 0 0 12 O

The DT 0 0 2 O
effects NNS 1 1 1 O
of IN 0 0 12 O
metoclopramide NN 0 1 16 B-Drug
on IN 0 0 12 O
gastrointestinal JJ 0 1 6 O
motility NN 0 1 6 O
are VBP 1 0 12 O
antagonized VBN 1 0 UNK O
by IN 0 0 12 O
anticholinergic JJ 0 1 13 B-Group
drugs NNS 1 1 6 I-Group
and CC 0 0 12 O
narcotic JJ 0 1 6 B-Group
analgesics NNS 1 1 14 I-Group
. . 0 0 12 O

insulin NN 0 1 14 B-Drug
requirements NNS 1 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
increased VBN 1 1 1 O
decreased JJ 0 1 1 O
or CC 0 0 12 O
unchanged JJ 0 1 1 O
. . 0 0 12 O
) ) 0 0 2 O

The DT 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
lower JJR 1 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
Vardenafil NNP 0 1 UNK B-Drug
with IN 0 0 12 O
alpha JJ 0 1 1 B-Group
- : 0 0 2 O
blockers NNS 1 0 6 I-Group
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
completely RB 0 1 12 O
evaluated VBN 1 1 1 O
to TO 0 0 12 O
determine VB 0 0 1 O
if IN 0 0 12 O
they PRP 0 0 12 O
can MD 0 0 12 O
be VB 0 0 12 O
safely RB 0 0 UNK O
administered VBN 1 1 1 O
together RB 0 1 12 O
. . 0 0 12 O

These DT 0 0 1 O
effects NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
attributed VBN 1 1 1 O
to TO 0 0 12 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
renal JJ 0 1 6 O
prostaglandin NN 0 1 13 O
synthesis NN 0 1 UNK O
by IN 0 0 12 O
the DT 0 0 12 O
NSAID NNP 0 1 14 B-Group
. . 0 0 12 O

Serious JJ 0 1 UNK O
arrhythmias NNS 1 1 6 O
can MD 0 0 12 O
result VB 0 1 1 O
. . 0 0 12 O

However RB 0 0 1 O
a DT 0 0 12 O
crossover NN 0 1 UNK O
study NN 0 1 1 O
in IN 0 0 12 O
healthy JJ 0 1 12 O
subjects NNS 1 1 UNK O
receiving VBG 1 1 1 O
either CC 0 1 12 O
Tagamet NNP 0 1 0 B-Brand
9 CD 0 0 2 O
mg NN 0 1 0 O
q.i.d NN 0 1 UNK O
. . 0 0 12 O
or CC 0 0 12 O
9 CD 0 0 2 O
mg JJ 0 1 0 O
h.s NN 0 1 13 O
. . 0 0 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
b.i.d NN 0 1 UNK O
. . 0 0 12 O
dosage NN 0 1 0 O
of IN 0 0 12 O
theophylline NN 0 1 16 B-Drug
( ( 0 0 2 O
Theo NNP 0 0 UNK B-Brand
- : 0 0 2 O
Dur NNP 0 1 UNK I-Brand
Key NNP 0 0 UNK O
Pharmaceuticals NNP 0 1 UNK O
Inc. NNP 0 0 UNK O
) ) 0 0 2 O
demonstrated VBD 1 0 1 O
less JJR 0 1 12 O
alteration NN 0 1 1 O
in IN 0 0 12 O
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
theophylline NN 0 1 16 B-Drug
peak NN 0 1 1 O
serum NN 0 1 14 O
levels NNS 1 1 1 O
with IN 0 0 12 O
the DT 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
h.s NN 0 1 13 O
. . 0 0 12 O
regimen NNS 0 1 6 O
particularly RB 0 0 1 O
in IN 0 0 12 O
subjects NNS 1 1 UNK O
aged VBN 1 1 12 O
9 CD 0 0 2 O
years NNS 1 1 12 O
and CC 0 0 12 O
older JJR 1 1 12 O
. . 0 0 12 O

Coadministration NN 0 1 UNK O
of IN 0 0 12 O
Aprepitant NNP 0 1 UNK B-Drug
with IN 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
induce VBP 0 1 6 O
CYP9A9 NNP 0 0 UNK O
activity NN 0 1 1 O
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
reduced JJ 0 1 1 O
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
and CC 0 0 12 O
decreased VBD 1 1 1 O
efficacy NN 0 1 UNK O
of IN 0 0 12 O
Aprepitant NNP 0 1 UNK B-Drug
. . 0 0 12 O

Certain NNP 0 1 UNK O
drugs NNS 1 1 6 O
including VBG 1 1 1 O
nonsteroidal JJ 0 0 14 B-Group
anti JJ 0 0 3 I-Group
- : 0 0 2 O
inflammatory NN 0 1 6 I-Group
agents NNS 1 1 1 I-Group
( ( 0 0 2 O
NSAIDs NNP 0 1 UNK B-Group
) ) 0 0 2 O
salicylates VBZ 0 1 13 B-Group
monoamine JJ 0 1 13 B-Group
oxidase NN 0 1 13 I-Group
inhibitors NNS 1 1 14 I-Group
and CC 0 0 12 O
non JJ 0 1 1 B-Group
- : 0 0 2 O
selective JJ 0 1 13 I-Group
beta NN 0 1 16 I-Group
- : 0 0 2 O
adrenergic JJ 0 1 UNK I-Group
- : 0 0 2 O
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
may MD 0 0 1 O
potentiate VB 0 0 UNK O
the DT 0 0 12 O
hypoglycemic JJ 0 1 14 O
action NN 0 1 13 O
of IN 0 0 12 O
Starlix NNP 0 1 UNK B-Brand
and CC 0 0 12 O
other JJ 0 0 12 O
oral JJ 0 1 6 O
antidiabetic JJ 0 1 13 B-Group
drugs NNS 1 1 6 I-Group
. . 0 0 12 O

Caffeine NNP 0 1 7 B-Drug
administered VBD 1 1 1 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
ketoprofen NN 0 1 UNK B-Drug
reduced VBD 1 1 1 O
the DT 0 0 12 O
urine JJ 0 1 6 O
volume NN 0 1 1 O
in IN 0 0 12 O
9 CD 0 0 2 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
. . 0 0 12 O

Caution NN 0 0 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
exercised VBN 1 1 1 O
during IN 0 0 12 O
the DT 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
adrenaline NN 0 1 UNK B-Drug
to TO 0 0 12 O
patients NNS 1 1 6 O
anaesthetised VBN 1 1 UNK O
with IN 0 0 12 O
FLUOTHANE NNP 0 1 UNK B-Brand
as IN 1 0 12 O
arrhythmias NN 1 1 6 O
may MD 0 0 1 O
be VB 0 0 12 O
precipitated VBN 1 1 1 O
. . 0 0 12 O

There EX 0 0 12 O
is VBZ 1 0 12 O
a DT 0 0 12 O
significant JJ 0 1 1 O
increase NN 0 1 1 O
in IN 0 0 12 O
exposure NN 0 1 1 O
to TO 0 0 12 O
imatinib VB 0 1 16 B-Drug
when WRB 0 0 12 O
Gleevec NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
ketoconazole NN 0 1 16 B-Drug
( ( 0 0 2 O
CYP9A9 NNP 0 0 UNK O
inhibitor NN 0 1 14 O
) ) 0 0 2 O
. . 0 0 12 O

Inhibitors NNS 0 1 7 O
or CC 0 0 12 O
substrates NNS 1 1 UNK O
of IN 0 0 12 O
CYP9D9 NNP 0 0 UNK O
( ( 0 0 2 O
i.e. FW 0 1 1 O
quinidine NN 0 1 16 B-Drug
selective JJ 0 1 13 B-Group
serotonin NN 0 1 13 I-Group
reuptake NN 0 1 13 I-Group
inhibitors NNS 1 1 14 I-Group
[ VBP 0 0 2 O
SSRIs NNP 0 1 UNK B-Group
] NNP 0 0 2 O
) ) 0 0 2 O
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
plasma JJ 0 1 14 O
concentration NN 0 1 1 O
of IN 0 0 12 O
doxepin NN 0 1 16 B-Drug
when WRB 0 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
. . 0 0 12 O

- : 0 0 2 O
adrenergic NN 0 1 UNK O
Blockers NNS 0 0 UNK O
: : 0 0 2 O
- : 0 0 2 O
adrenergic NN 0 1 UNK O
blockers NNS 1 0 6 O
may MD 0 0 1 O
weaken VB 0 0 UNK O
or CC 0 0 12 O
antagonise VB 0 0 UNK O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
FORADIL NNP 0 1 UNK B-Brand
. . 0 0 12 O

The DT 0 0 2 O
use NN 0 1 1 O
of IN 0 0 12 O
REGRANEX NNP 0 1 UNK B-Brand
Gel NNP 0 1 2 O
with IN 0 0 12 O
other JJ 0 0 12 O
topical JJ 0 1 6 O
drugs NNS 1 1 6 O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
studied VBN 1 0 1 O
. . 0 0 12 O

Anticoagulants NNS 0 1 UNK B-Group
oral JJ 0 1 6 O

Macrolide NNP 0 1 UNK B-Group
Antibiotics NNP 0 1 7 I-Group
( ( 0 0 2 O
e. JJ 0 0 1 O
g. NN 0 1 13 O
erythromycin NN 0 1 0 B-Drug
and CC 0 0 12 O
troleandomycin NN 0 1 UNK B-Drug
) ) 0 0 2 O
: : 0 0 2 O
Agents NNS 0 1 2 O
of IN 0 0 12 O
the DT 0 0 12 O
ergot JJ 0 1 UNK B-Group
alkaloid JJ 0 1 UNK I-Group
class NN 0 1 12 I-Group
of IN 0 0 12 O
which WDT 0 0 12 O
D.H.E NNP 0 1 UNK B-Brand
9 CD 0 0 2 I-Brand
( ( 0 0 2 O
dihydroergotamine JJ 0 1 UNK B-Drug
mesylate NN 0 1 16 I-Drug
) ) 0 0 2 O
Injection NNP 0 1 7 O
USP NNP 0 1 UNK O
is VBZ 1 0 12 O
a DT 0 0 12 O
member NN 0 1 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
interact VB 0 0 UNK O
with IN 0 0 12 O
antibiotics NNS 1 1 6 B-Group
of IN 0 0 12 O
the DT 0 0 12 O
macrolide JJ 0 1 UNK B-Group
class NN 0 1 12 I-Group
resulting VBG 1 1 1 O
in IN 0 0 12 O
increased VBN 1 1 1 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
unchanged JJ 0 1 1 O
alkaloids NNS 1 1 13 O
and CC 0 0 12 O
peripheral JJ 0 1 6 O
vasoconstriction NN 0 1 UNK O
. . 0 0 12 O

Alpha NNP 0 1 2 B-Group
- : 0 0 2 O
agonists NNS 1 1 UNK I-Group
as IN 1 0 12 O
a DT 0 0 12 O
class NN 0 1 12 O
may MD 0 0 1 O
reduce VB 0 0 1 O
pulse NN 0 1 3 O
and CC 0 0 12 O
blood NN 0 1 6 O
pressure NN 0 1 1 O
. . 0 0 12 O

Anticoagulants NNS 0 1 UNK B-Group
: : 0 0 2 O
Metolazone NN 0 1 UNK B-Drug
as RB 0 0 12 O
well RB 0 1 12 O
as IN 1 0 12 O
other JJ 0 0 12 O
thiazide IN 0 1 UNK B-Group
- : 0 0 2 O
like IN 0 0 12 I-Group
diuretics NNS 1 1 14 I-Group
may MD 0 0 1 O
affect VB 0 1 1 O
the DT 0 0 12 O
hypoprothrombinemic JJ 0 1 UNK O
response NN 0 1 1 O
to TO 0 0 12 O
anticoagulants NNS 1 1 13 B-Group
; : 0 0 2 O

decreased JJ 0 1 1 O
levels NNS 1 1 1 O
of IN 0 0 12 O
anti JJ 0 0 3 O
- : 0 0 2 O
factor NN 0 1 1 O
Xa NN 0 1 UNK O
and CC 0 0 12 O
antithrombin JJ 0 1 14 O
III NNP 0 1 2 O
decreased VBD 1 1 1 O
antithrombin JJ 0 1 14 O
III NNP 0 1 2 O
activity NN 0 1 1 O
; : 0 0 2 O

Effects NNS 0 1 UNK O
of IN 0 0 12 O
Other JJ 0 0 2 O
Antiepileptic NNP 0 1 UNK B-Group
Drugs NNP 0 1 2 I-Group
on IN 0 0 12 O
Felbatol NNP 0 1 UNK B-Brand
Phenytoin NNP 0 1 0 B-Drug
: : 0 0 2 O
Phenytoin NNP 0 1 0 B-Drug
causes VBZ 1 1 6 O
an DT 0 0 12 O
approximate JJ 0 1 1 O
doubling NN 0 1 13 O
of IN 0 0 12 O
the DT 0 0 12 O
clearance NN 0 1 16 O
of IN 0 0 12 O
Felbatol NNP 0 1 UNK B-Brand
( ( 0 0 2 O
felbamate NN 0 1 13 B-Drug
) ) 0 0 2 O
at IN 0 0 12 O
steady JJ 0 1 1 O
state NN 0 1 1 O
and CC 0 0 12 O
therefore RB 0 0 1 O
the DT 0 0 12 O
addition NN 0 1 1 O
of IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
causes VBZ 1 1 6 O
an DT 0 0 12 O
approximate JJ 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
decrease NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
trough IN 0 1 3 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
Felbatol NNP 0 1 UNK B-Brand
as IN 1 0 12 O
compared VBN 1 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
same JJ 0 1 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
Felbatol NNP 0 1 UNK B-Brand
given VBN 1 1 12 O
as IN 1 0 12 O
monotherapy NN 0 0 14 O
. . 0 0 12 O

Nevertheless RB 0 0 1 O
caution NN 0 0 1 O
is VBZ 1 0 12 O
indicated VBN 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
co NN 0 1 12 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
TCAs NNP 0 1 UNK B-Group
with IN 0 0 12 O
any DT 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
SSRIs NNP 0 1 UNK B-Group
and CC 0 0 12 O
also RB 0 0 12 O
in IN 0 0 12 O
switching VBG 1 1 UNK O
from IN 0 0 12 O
one CD 0 1 12 O
class NN 0 1 12 O
to TO 0 0 12 O
the DT 0 0 12 O
other JJ 0 0 12 O
. . 0 0 12 O

Antihistamines NNS 0 1 UNK B-Group
: : 0 0 2 O
Amphetamines NNS 0 1 UNK B-Group
may MD 0 0 1 O
counteract VB 0 0 UNK O
the DT 0 0 12 O
sedative JJ 0 1 6 O
effect NN 0 1 1 O
of IN 0 0 12 O
antihistamines NNS 1 1 UNK B-Group
. . 0 0 12 O

Sodium NNP 0 1 14 B-Drug
cephalothin NN 0 1 UNK I-Drug
may MD 0 0 1 O
enhance VB 0 1 UNK O
the DT 0 0 12 O
nephrotoxicity NN 0 1 UNK O
of IN 0 0 12 O
Coly NNP 0 1 UNK B-Brand
- : 0 0 2 O
Mycin NNP 0 0 UNK I-Brand
M NNP 0 1 2 I-Brand
Parenteral NNP 0 1 UNK O
. . 0 0 12 O

Vaccines NNS 0 1 UNK B-Group
: : 0 0 2 O
Patients NNS 0 1 7 O
on IN 0 0 12 O
corticosteroid JJ 0 1 UNK B-Group
therapy NN 0 1 6 O
may MD 0 0 1 O
exhibit VB 0 1 1 O
a DT 0 0 12 O
diminished JJ 0 1 1 O
response NN 0 1 1 O
to TO 0 0 12 O
toxoids NNS 1 1 13 O
and CC 0 0 12 O
live VBP 0 1 12 B-Group
or CC 0 0 12 O
inactivated VBN 1 0 UNK B-Group
vaccines NNS 1 1 6 I-Group
due JJ 0 1 1 O
to TO 0 0 12 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
antibody NN 0 1 14 O
response NN 0 1 1 O
. . 0 0 12 O

Cardiac NNP 0 1 7 B-Group
glycosides NNS 1 1 13 I-Group
could MD 0 0 12 O
exaggerate VB 0 1 UNK O
the DT 0 0 12 O
depression NN 0 1 6 O
of IN 0 0 12 O
AV NNP 0 0 13 O
nodal JJ 0 1 8 O
conduction NN 0 1 6 O
observed VBD 1 1 1 O
with IN 0 0 12 O
bepridil JJ 0 1 UNK B-Drug
hydrochloride NN 0 1 0 I-Drug
. . 0 0 12 O

In IN 0 0 2 O
such JJ 0 0 1 O
cases NNS 1 1 UNK O
therefore RB 0 0 1 O
more RBR 0 1 12 O
frequent JJ 0 1 1 O
dosing NN 0 0 14 O
may MD 0 0 1 O
be VB 0 0 12 O
required VBN 1 1 1 O
to TO 0 0 12 O
achieve VB 0 0 1 O
or CC 0 0 12 O
maintain VB 0 1 1 O
the DT 0 0 12 O
desired JJ 0 1 1 O
hypotensive JJ 0 1 14 O
response NN 0 1 1 O
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
that IN 0 0 12 O
these DT 0 0 12 O
tests NNS 1 1 1 O
be VB 0 0 12 O
performed VBN 1 1 1 O
at IN 0 0 12 O
weekly JJ 0 1 12 O
or CC 0 0 12 O
biweekly JJ 0 1 UNK O
intervals NNS 1 1 1 O
until IN 0 0 12 O
the DT 0 0 12 O
lipid JJ 0 1 14 O
response NN 0 1 1 O
to TO 0 0 12 O
Accutane NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
established VBN 1 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
a DT 0 0 12 O
clinical JJ 0 1 6 O
trial NN 0 1 12 O
of IN 0 0 12 O
9 CD 0 0 2 O
pediatric JJ 0 1 6 O
patients NNS 1 1 6 O
( ( 0 0 2 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
years NNS 1 1 12 O
) ) 0 0 2 O
with IN 0 0 12 O
severe JJ 0 1 6 O
recalcitrant NN 0 0 6 O
nodular JJ 0 1 8 O
acne NN 0 1 6 O
transient NN 0 1 1 O
elevations NNS 1 1 1 O
in IN 0 0 12 O
CPK NNP 0 0 15 O
were VBD 1 0 12 O
observed VBN 1 1 1 O
in IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
of IN 0 0 12 O
patients NNS 1 1 6 O
including VBG 1 1 1 O
those DT 0 0 12 O
undergoing JJ 0 0 6 O
strenuous JJ 0 0 1 O
physical JJ 0 1 1 O
activity NN 0 1 1 O
in IN 0 0 12 O
association NN 0 1 1 O
with IN 0 0 12 O
reported VBN 1 1 1 O
musculoskeletal JJ 0 1 6 O
adverse JJ 0 0 1 O
events NNS 1 1 12 O
such JJ 0 0 1 O
as IN 1 0 12 O
back JJ 0 1 12 O
pain NN 0 1 6 O
arthralgia NN 0 1 13 O
limb JJ 0 1 6 O
injury NN 0 1 6 O
or CC 0 0 12 O
muscle NN 0 1 6 O
sprain NN 0 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
conversion NN 0 1 13 O
of IN 0 0 12 O
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
deoxy NN 0 1 UNK I-Drug_n
penciclovir NN 0 1 UNK I-Drug_n
to TO 0 0 12 O
penciclovir VB 0 1 UNK B-Drug
is VBZ 1 0 12 O
catalyzed VBN 1 0 UNK O
by IN 0 0 12 O
aldehyde JJ 0 1 UNK O
oxidase NN 0 1 13 O
. . 0 0 12 O

It PRP 0 0 12 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
that IN 0 0 12 O
the DT 0 0 12 O
incidence NN 0 1 6 O
of IN 0 0 12 O
bradycardia NN 0 1 8 O
was VBD 1 0 12 O
increased VBN 1 1 1 O
when WRB 0 0 12 O
oxymorphone NN 0 1 13 B-Drug
was VBD 1 0 12 O
combined VBN 1 1 1 O
with IN 0 0 12 O
propofol NN 0 1 14 B-Drug
for IN 0 0 12 O
induction NN 0 1 1 O
of IN 0 0 12 O
anesthesia NN 0 1 6 O
. . 0 0 12 O

Since IN 0 1 2 O
blood NN 0 1 6 O
level NN 0 1 1 O
of IN 0 0 12 O
calcitriol NN 0 1 14 B-Drug
/ NNP 0 0 2 O
ergocalcitriol NN 0 0 UNK O
will MD 0 0 12 O
be VB 0 0 12 O
reduced VBN 1 1 1 O
higher JJR 1 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
Rocaltrol NNP 0 1 0 B-Brand
may MD 0 0 1 O
be VB 0 0 12 O
necessary JJ 0 0 1 O
if IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
are VBP 1 0 12 O
administered VBN 1 1 1 O
simultaneously RB 0 1 13 O
. . 0 0 12 O

Antipsychotic JJ 0 1 UNK B-Group
drugs NNS 1 1 6 I-Group
such JJ 0 0 1 O
as IN 1 0 12 O
phenothiazines NNS 1 1 UNK B-Group
or CC 0 0 12 O
haloperidol NN 0 1 16 B-Drug
; : 0 0 2 O

St NNP 0 1 2 O
. . 0 0 12 O
John NNP 0 0 19 O
Wort NNP 0 0 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
while IN 0 0 12 O
taking VBG 1 0 12 O
this DT 0 0 12 O
medicine NN 0 1 6 O
due JJ 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
additive JJ 0 1 16 O
effects NNS 1 1 1 O
of IN 0 0 12 O
serotonin NN 0 1 13 O
. . 0 0 12 O

Other JJ 0 0 2 O
Drugs NNS 0 1 2 O
: : 0 0 2 O
Drugs NNS 0 1 2 O
such JJ 0 0 1 O
as IN 1 0 12 O
quinidine JJ 0 1 16 B-Drug
disopyramide IN 0 1 16 B-Drug
procainamide JJ 0 1 16 B-Drug
phenothiazines NNS 1 1 UNK B-Group
antihistamines NNS 1 1 UNK B-Group
and CC 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
may MD 0 0 1 O
be VB 0 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
QT NNP 0 1 13 O
- : 0 0 2 O
interval NN 0 1 1 O
prolongation NN 0 1 6 O
and CC 0 0 12 O
an DT 0 0 12 O
increased VBN 1 1 1 O
risk NN 0 1 1 O
of IN 0 0 12 O
ventricular JJ 0 1 8 O
arrhythmia NN 0 1 6 O
. . 0 0 12 O

Phenothiazines NNS 0 1 UNK B-Group
and CC 0 0 12 O
butyrophenones NNS 0 1 UNK B-Group
may MD 0 0 1 O
reduce VB 0 0 1 O
or CC 0 0 12 O
reverse VB 0 1 1 O
the DT 0 0 12 O
pressor NN 0 1 14 O
effect NN 0 1 1 O
of IN 0 0 12 O
epinephrine NN 0 1 14 B-Drug
. . 0 0 12 O

Vaccines NNS 0 1 UNK B-Group
neurological JJ 0 1 6 O
complications NNS 1 1 6 O
and CC 0 0 12 O
lack NN 0 1 1 O
of IN 0 0 12 O
antibody NN 0 1 14 O
response NN 0 1 1 O
. . 0 0 12 O

consequently RB 0 0 UNK O
caution NN 0 0 1 O
is VBZ 1 0 12 O
advised VBN 1 0 12 O
if IN 0 0 12 O
dexfenfluramine NN 0 1 UNK B-Drug
and CC 0 0 12 O
such JJ 0 0 1 O
drugs NNS 1 1 6 O
are VBP 1 0 12 O
prescribed VBN 1 1 1 O
concurrently RB 0 0 1 O
. . 0 0 12 O

Another DT 0 0 2 O
study NN 0 1 1 O
at IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
mg NN 0 1 0 O
and CC 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
mg JJ 0 1 0 O
daily JJ 0 1 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
fluconazole NN 0 1 0 B-Drug
demonstrated VBD 1 0 1 O
that IN 0 0 12 O
DIFLUCAN NNP 0 1 UNK B-Brand
taken VBN 1 1 12 O
in IN 0 0 12 O
doses NNS 1 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
per IN 0 0 1 O
day NN 0 1 12 O
or CC 0 0 12 O
greater JJR 1 1 1 O
significantly RB 0 0 1 O
increases VBZ 1 1 1 O
plasma JJ 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
terfenadine NN 0 1 UNK B-Drug
when WRB 0 0 12 O
taken VBN 1 1 12 O
concomitantly RB 0 0 14 O
. . 0 0 12 O

Binding VBG 0 1 UNK O
to TO 0 0 12 O
plasma VB 0 1 14 O
protein NN 0 1 14 O
is VBZ 1 0 12 O
not RB 0 1 12 O
significantly RB 0 0 1 O
altered VBN 1 1 1 O
by IN 0 0 12 O
diazepam NN 0 1 0 B-Drug
diphenylhydantoin NN 0 1 UNK B-Drug
or CC 0 0 12 O
phenylbutazone NN 0 1 UNK B-Drug
. . 0 0 12 O

This DT 0 0 2 O
increase NN 0 1 1 O
is VBZ 1 0 12 O
greatest JJS 1 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
evening NN 0 1 12 O
. . 0 0 12 O

Because IN 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
extremely RB 0 1 12 O
high JJ 0 1 1 O
binding NN 0 1 1 O
of IN 0 0 12 O
teniposide NN 0 1 UNK B-Drug
to TO 0 0 12 O
plasma VB 0 1 14 O
proteins NNS 1 1 14 O
these DT 0 0 12 O
small JJ 0 1 12 O
decreases NNS 1 1 UNK O
in IN 0 0 12 O
binding NN 0 1 1 O
could MD 0 0 12 O
cause VB 0 1 12 O
substantial JJ 0 0 1 O
increases NNS 1 1 1 O
in IN 0 0 12 O
free JJ 0 1 12 O
drug NN 0 1 1 O
levels NNS 1 1 1 O
in IN 0 0 12 O
plasma NN 0 1 14 O
which WDT 0 0 12 O
could MD 0 0 12 O
result VB 0 1 1 O
in IN 0 0 12 O
potentiation NN 0 1 UNK O
of IN 0 0 12 O
drug NN 0 1 1 O
toxicity NN 0 1 6 O
. . 0 0 12 O

A DT 0 0 2 O
potential JJ 0 1 1 O
interaction NN 0 1 UNK O
between IN 0 0 12 O
oral JJ 0 1 6 O
miconazole NN 0 1 16 B-Drug
and CC 0 0 12 O
oral JJ 0 1 6 O
hypoglycemic JJ 0 1 14 B-Group
agents NNS 1 1 1 I-Group
leading VBG 1 1 1 O
to TO 0 0 12 O
severe JJ 0 1 6 O
hypoglycemia NN 0 1 6 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
. . 0 0 12 O

May NNP 0 1 2 O
interact NN 0 0 UNK O
with IN 0 0 12 O
cefamandole JJ 0 1 UNK B-Drug
naftate NN 0 0 UNK I-Drug
cephalothin NN 0 1 UNK B-Drug
sodium NN 0 1 14 I-Drug
magnesium NN 0 1 14 B-Drug
sulfate NN 0 1 14 I-Drug
prednisolone NN 0 1 0 B-Drug
sodium NN 0 1 14 I-Drug
succinate NN 0 1 14 I-Drug
and CC 0 0 12 O
prochlorperazine NN 0 1 16 B-Drug
edisylate NN 0 0 13 I-Drug
. . 0 0 12 O

Mineral NNP 0 1 UNK B-Drug_n
Oil NNP 0 1 UNK I-Drug_n
- : 0 0 2 O
Concomitant NNP 0 1 UNK O
intake NN 0 1 3 O
of IN 0 0 12 O
mineral JJ 0 1 3 B-Drug_n
oil NN 0 1 3 I-Drug_n
and CC 0 0 12 O
vitamin NN 0 1 6 B-Group
K NNP 0 1 2 I-Group
may MD 0 0 1 O
reduce VB 0 0 1 O
the DT 0 0 12 O
absorption NN 0 1 1 O
of IN 0 0 12 O
vitamin NN 0 1 6 B-Group
K NNP 0 1 2 I-Group
. . 0 0 12 O

WelChol NNP 0 1 UNK B-Brand
was VBD 1 0 12 O
found VBN 1 1 12 O
to TO 0 0 12 O
have VB 0 0 12 O
no DT 0 0 12 O
significant JJ 0 1 1 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
bioavailability NN 0 1 UNK O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
lovastatin NN 0 1 13 B-Drug
metoprolol NN 0 1 0 B-Drug
quinidine NN 0 1 16 B-Drug
valproic NN 0 0 16 B-Drug
acid NN 0 1 14 I-Drug
and CC 0 0 12 O
warfarin NN 0 1 14 B-Drug
. . 0 0 12 O

Two CD 0 1 2 O
percent NN 0 1 1 O
of IN 0 0 12 O
patients NNS 1 1 6 O
treated VBN 1 1 1 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
ENBREL NNP 0 1 UNK B-Brand
and CC 0 0 12 O
anakinra NN 0 1 13 B-Drug
developed VBN 1 0 1 O
neutropenia NN 0 1 14 O
( ( 0 0 2 O
ANC NNP 0 1 13 O
9 CD 0 0 2 O
x NNP 0 0 10 O
9 CD 0 0 2 O
/ NNP 0 0 2 O
L NNP 0 1 2 O
) ) 0 0 2 O
. . 0 0 12 O

Cimetidine NN 0 1 0 B-Drug
at IN 0 0 12 O
doses NNS 1 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
BID NNP 0 0 11 O
( ( 0 0 2 O
OTC NNP 0 1 UNK O
dose RB 0 1 6 O
) ) 0 0 2 O
resulted VBD 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
increase NN 0 1 1 O
in IN 0 0 12 O
dofetilide JJ 0 1 13 B-Drug
plasma NN 0 1 14 O
levels NNS 1 1 1 O
( ( 0 0 2 O
9 CD 0 0 2 O
mcg NN 0 1 0 O
single JJ 0 1 12 O
dose NN 0 1 6 O
) ) 0 0 2 O
. . 0 0 12 O

Antimycobacterial JJ 0 1 UNK B-Group
Agents NNS 0 1 2 I-Group

Salicylates NNS 0 1 UNK B-Group
- : 0 0 2 O
Salicylates VBZ 0 1 UNK B-Group
in IN 0 0 12 O
large JJ 0 1 3 O
doses NNS 1 1 6 O
may MD 0 0 1 O
inhibit VB 0 1 13 O
vitamin JJ 0 1 6 O
K NNP 0 1 2 O
epoxide NNP 0 1 UNK O
reductase NN 0 1 UNK O
resulting VBG 1 1 1 O
in IN 0 0 12 O
vitamin NN 0 1 6 O
K NNP 0 1 2 O
deficiency NN 0 1 6 O
. . 0 0 12 O

No DT 0 0 2 O
specific JJ 0 1 1 O
studies NNS 1 1 1 O
in IN 0 0 12 O
humans NNS 1 1 UNK O
have VBP 0 0 12 O
been VBN 1 0 12 O
performed VBN 1 1 1 O
and CC 0 0 12 O
caution NN 0 0 1 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O

Literature NN 0 1 UNK O
reports NNS 1 1 1 O
suggest VBP 0 1 1 O
that IN 0 0 12 O
oral JJ 0 1 6 O
calcium NN 0 1 14 B-Group
antagonists NNS 1 1 13 I-Group
may MD 0 0 1 O
be VB 0 0 12 O
used VBN 1 1 12 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
beta JJ 0 1 16 B-Group
- : 0 0 2 O
adrenergic JJ 0 1 UNK I-Group
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
when WRB 0 0 12 O
heart NN 0 1 12 O
function NN 0 1 1 O
is VBZ 1 0 12 O
normal JJ 0 1 1 O
but CC 0 0 12 O
should MD 0 0 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
impaired JJ 0 1 6 O
cardiac JJ 0 1 6 O
function NN 0 1 1 O
. . 0 0 12 O

Due JJ 0 1 2 O
to TO 0 0 12 O
its PRP$ 1 0 12 O
effects NNS 1 1 1 O
on IN 0 0 12 O
gastric JJ 0 1 6 O
emptying VBG 1 1 13 O
SYMLIN NNP 0 1 UNK B-Brand
therapy NN 0 1 6 O
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
for IN 0 0 12 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
drugs NNS 1 1 6 O
that IN 0 0 12 O
alter VBP 0 1 13 O
gastrointestinal JJ 0 1 6 O
motility NN 0 1 6 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
anticholinergic NN 0 1 13 B-Group
agents NNS 1 1 1 I-Group
such JJ 0 0 1 O
as IN 1 0 12 O
atropine NN 0 1 14 B-Drug
) ) 0 0 2 O
and CC 0 0 12 O
agents NNS 1 1 1 O
that WDT 0 0 12 O
slow VBP 0 1 12 O
the DT 0 0 12 O
intestinal JJ 0 1 13 O
absorption NN 0 1 1 O
of IN 0 0 12 O
nutrients NNS 1 1 UNK O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
alpha NN 0 1 1 B-Group
glucosidase NN 0 1 UNK I-Group
inhibitors NNS 1 1 14 I-Group
) ) 0 0 2 O
. . 0 0 12 O

Furosemide NNP 0 1 0 B-Drug
may MD 0 0 1 O
decrease VB 0 1 1 O
arterial JJ 0 1 6 O
responsiveness NN 0 1 UNK O
to TO 0 0 12 O
norepinephrine VB 0 1 14 B-Drug
. . 0 0 12 O

Non NNP 0 1 2 B-Group
- : 0 0 2 O
nucleoside JJ 0 1 UNK I-Group
reverse NN 0 1 1 I-Group
transcriptase NN 0 1 UNK I-Group
inhibitors NNS 1 1 14 I-Group
( ( 0 0 2 O
NNRTIs NNP 0 1 UNK B-Group
) ) 0 0 2 O
: : 0 0 2 O
Nevirapine NN 0 1 UNK B-Drug
may MD 0 0 1 O
decrease VB 0 1 1 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
combination NN 0 1 1 B-Group
hormonal JJ 0 1 6 I-Group
contraceptives NNS 1 1 13 I-Group
; : 0 0 2 O

Other JJ 0 0 2 O
TNFa NNP 0 1 UNK B-Group
- : 0 0 2 O
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
( ( 0 0 2 O
including VBG 1 1 1 O
REMICADE NNP 0 1 UNK B-Brand
) ) 0 0 2 O
used VBD 1 1 12 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
anakinra NN 0 1 13 B-Drug
may MD 0 0 1 O
also RB 0 0 12 O
result VB 0 1 1 O
in IN 0 0 12 O
similar JJ 0 1 1 O
toxicities NNS 1 1 UNK O
. . 0 0 12 O

Cyclopentolate NNP 0 1 UNK B-Drug
may MD 0 0 1 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
anti JJ 0 0 3 O
- : 0 0 2 O
glaucoma JJ 0 1 6 O
action NN 0 1 13 O
of IN 0 0 12 O
carbachol NN 0 1 13 B-Drug
or CC 0 0 12 O
pilocarpine NN 0 1 16 B-Drug
; : 0 0 2 O

Drugs NNS 0 1 2 O
Metabolized VBN 0 1 UNK O
by IN 0 0 12 O
Cytochrome NNP 0 1 UNK O
P9IID9 NNP 0 0 UNK O
( ( 0 0 2 O
CYP9D9 NNP 0 0 UNK O
) ) 0 0 2 O
: : 0 0 2 O
Many JJ 0 0 UNK O
drugs NNS 1 1 6 O
including VBG 1 1 1 O
most JJS 0 0 12 O
antidepressants NNS 1 1 13 B-Group
( ( 0 0 2 O
SSRIs NNP 0 1 UNK O
many JJ 0 0 12 O
tricyclics NNS 1 1 UNK B-Group
) ) 0 0 2 O
beta VBP 0 1 16 B-Group
- : 0 0 2 O
blockers NNS 1 0 6 I-Group
antiarrhythmics NNS 1 1 UNK B-Drug
and CC 0 0 12 O
antipsychotics NNS 1 1 14 B-Group
are VBP 1 0 12 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
the DT 0 0 12 O
CYP9D9 NNP 0 0 UNK O
isoenzyme NN 0 1 13 O
. . 0 0 12 O

increased JJ 0 1 1 O
levels NNS 1 1 1 O
of IN 0 0 12 O
fibrinogen NN 0 1 14 O
and CC 0 0 12 O
fibrinogen NN 0 1 14 O
activity NN 0 1 1 O
; : 0 0 2 O

Cyclosporin NNP 0 1 0 B-Drug
tacrolimus NN 0 1 16 B-Drug
sirolimus NN 0 1 16 B-Drug

An DT 0 0 2 O
association NN 0 1 1 O
between IN 0 0 12 O
prilocaine NN 0 1 UNK B-Drug
and CC 0 0 12 O
an DT 0 0 12 O
increased VBN 1 1 1 O
risk NN 0 1 1 O
of IN 0 0 12 O
methaemoglobinaemia NN 0 1 UNK O
particularly RB 0 0 1 O
in IN 0 0 12 O
infants NNS 1 1 6 O
has VBZ 1 0 12 O
specifically RB 0 0 1 O
been VBN 1 0 12 O
described VBN 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
literature NN 0 1 UNK O
case NN 0 1 12 O
report NN 0 1 1 O
. . 0 0 12 O

Rifabutin NNP 0 1 UNK B-Drug
another DT 0 0 12 O
rifamycin NN 0 1 UNK B-Drug
is VBZ 1 0 12 O
structurally RB 0 0 1 O
similar JJ 0 1 1 O
to TO 0 0 12 O
rifampin VB 0 1 16 B-Drug
and CC 0 0 12 O
may MD 0 0 1 O
possibly RB 0 1 12 O
have VB 0 0 12 O
some DT 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
same JJ 0 1 12 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
as IN 1 0 12 O
rifampin NN 0 1 16 B-Drug
. . 0 0 12 O

Electroconvulsive JJ 0 0 UNK O
Therapy NNP 0 1 2 O
( ( 0 0 2 O
ECT NNP 0 1 13 O
) ) 0 0 2 O
- : 0 0 2 O
There EX 0 0 12 O
are VBP 1 0 12 O
no DT 0 0 12 O
clinical JJ 0 1 6 O
studies NNS 1 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
combined VBN 1 1 1 O
use NN 0 1 1 O
of IN 0 0 12 O
ECT NNP 0 1 13 O
and CC 0 0 12 O
escitalopram NN 0 1 0 B-Drug
. . 0 0 12 O

There EX 0 0 12 O
was VBD 1 0 12 O
no DT 0 0 12 O
change NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
plasma NN 0 1 14 O
kinetics NNS 0 1 UNK O
of IN 0 0 12 O
teniposide NN 0 1 UNK B-Drug
when WRB 0 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
methotrexate NN 0 1 16 B-Drug
. . 0 0 12 O

Antacids NNS 0 1 UNK B-Group
: : 0 0 2 O
Absorption NN 0 1 UNK O
of IN 0 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
Myfortic NNP 0 1 UNK B-Brand
was VBD 1 0 12 O
decreased VBN 1 1 1 O
when WRB 0 0 12 O
administered VBN 1 1 1 O
to TO 0 0 12 O
9 CD 0 0 2 O
stable JJ 0 1 1 O
renal JJ 0 1 6 O
transplant NN 0 1 6 O
patients NNS 1 1 6 O
also RB 0 0 12 O
taking VBG 1 0 12 O
magnesium NN 0 1 14 B-Drug
- : 0 0 2 O
aluminum NN 0 1 16 B-Drug
containing VBG 1 1 1 O
antacids NNS 1 1 14 B-Group
( ( 0 0 2 O
9 CD 0 0 2 O
mL NN 0 1 14 O
) ) 0 0 2 O
: : 0 0 2 O
the DT 0 0 12 O
mean NN 0 1 12 O
Cmax NNP 0 1 UNK O
and CC 0 0 12 O
AUC NNP 0 1 UNK O
( ( 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
t NN 0 1 12 O
) ) 0 0 2 O
values NNS 1 1 1 O
for IN 0 0 12 O
MPA NNP 0 0 UNK O
were VBD 1 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
lower RBR 0 1 1 O
respectively RB 0 0 1 O
than IN 0 0 12 O
when WRB 0 0 12 O
Myfortic NNP 0 1 UNK B-Brand
was VBD 1 0 12 O
administered VBN 1 1 1 O
alone RB 0 1 12 O
under IN 0 0 12 O
fasting VBG 1 1 6 O
conditions NNS 1 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
the DT 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
sulfadoxine NN 0 1 UNK B-Drug
and CC 0 0 12 O
pyrimethamine NN 0 1 16 B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
alter VB 0 1 13 O
the DT 0 0 12 O
adverse JJ 0 0 1 O
reaction NN 0 1 1 O
profile NN 0 1 1 O
. . 0 0 12 O

Therefore RB 0 0 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
insulin NN 0 1 14 B-Drug
or CC 0 0 12 O
oral JJ 0 1 6 O
hypoglycemics NNS 0 1 14 B-Group
regular JJ 0 1 12 O
monitoring NN 0 1 1 O
of IN 0 0 12 O
blood NN 0 1 6 O
glucose NN 0 1 14 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O

When WRB 0 0 12 O
warfarin NN 0 1 14 B-Drug
is VBZ 1 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
with IN 0 0 12 O
nevirapine JJ 0 1 13 B-Drug
anticoagulation NN 0 1 14 O
levels NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
frequently RB 0 1 1 O
. . 0 0 12 O

therefore RB 0 0 1 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
Aprepitant NNP 0 1 UNK B-Drug
with IN 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
strongly RB 0 0 1 O
induce VBP 0 1 6 O
CYP9A9 NNP 0 0 UNK O
activity NN 0 1 1 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
rifampin NN 0 1 16 B-Drug
carbamazepine NN 0 1 16 B-Drug
phenytoin NN 0 1 16 B-Drug
) ) 0 0 2 O
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
reduced JJ 0 1 1 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
aprepitant NN 0 1 13 B-Drug
that WDT 0 0 12 O
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
decreased JJ 0 1 1 O
efficacy NN 0 1 UNK O
of IN 0 0 12 O
Aprepitant NNP 0 1 UNK B-Drug
. . 0 0 12 O

Opioid NNP 0 1 UNK B-Group
analgesics NNS 1 1 14 I-Group
Decreased VBD 0 1 7 O
antinociceptive JJ 0 0 UNK O
action NN 0 1 13 O

No DT 0 0 2 O
studies NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
performed VBN 1 1 1 O
with IN 0 0 12 O
other JJ 0 0 12 O
NNRTIs NNP 0 1 UNK B-Group
. . 0 0 12 O

Increasing VBG 0 1 2 O
the DT 0 0 12 O
felbamate NN 0 1 13 B-Drug
dose NN 0 1 6 O
to TO 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
increased VBD 1 1 1 O
the DT 0 0 12 O
steadystate NN 0 1 UNK O
valproate NN 0 1 16 B-Drug
Cmin NNP 0 1 UNK O
to TO 0 0 12 O
9 CD 0 0 2 O
9 CD 0 0 2 O
micrograms NNS 1 1 14 O
/ JJ 0 0 2 O
mL NN 0 1 14 O
. . 0 0 12 O

Furthermore RB 0 0 1 O
whenever WRB 0 0 12 O
one CD 0 1 12 O
of IN 0 0 12 O
these DT 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
is VBZ 1 0 12 O
withdrawn VBN 1 1 1 O
from IN 0 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
therapy NN 0 1 6 O
an DT 0 0 12 O
increased VBN 1 1 1 O
dose NN 0 1 6 O
of IN 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressant NN 0 1 6 I-Group
may MD 0 0 1 O
be VB 0 0 12 O
required VBN 1 1 1 O
. . 0 0 12 O

Some DT 0 0 2 O
of IN 0 0 12 O
the DT 0 0 12 O
cases NNS 1 1 UNK O
of IN 0 0 12 O
collapse NN 0 1 1 O
/ NNP 0 0 2 O
respiratory NN 0 1 6 O
arrest NN 0 1 12 O
/ NN 0 0 2 O
cardiac JJ 0 1 6 O
arrest NN 0 1 12 O
during IN 0 0 12 O
initial JJ 0 1 1 O
treatment NN 0 1 6 O
occurred VBD 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
who WP 0 0 12 O
were VBD 1 0 12 O
being VBG 1 0 12 O
administered VBN 1 1 1 O
benzodiazepines NNS 1 1 14 B-Group
; : 0 0 2 O

If IN 0 0 12 O
a DT 0 0 12 O
diuretic NN 0 1 14 B-Group
is VBZ 1 0 12 O
also RB 0 0 12 O
used VBN 1 1 12 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
lithium JJ 0 1 16 B-Drug
toxicity NN 0 1 6 O
may MD 0 0 1 O
be VB 0 0 12 O
increased VBN 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
carbamazepine NN 0 1 16 B-Drug
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
Cmin NNP 0 1 UNK O
decreased VBD 1 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
to TO 0 0 12 O
9 CD 0 0 2 O
9 CD 0 0 2 O
micrograms NNS 1 1 14 O
/ VBP 0 0 2 O
mL NN 0 1 14 O
when WRB 0 0 12 O
felbamate NN 0 1 13 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
divided VBD 1 1 1 O
into IN 0 0 12 O
three CD 0 1 12 O
doses NNS 1 1 6 O
) ) 0 0 2 O
was VBD 1 0 12 O
coadministered VBN 0 0 UNK O
. . 0 0 12 O

The DT 0 0 2 O
exact JJ 0 1 1 O
length NN 0 1 3 O
of IN 0 0 12 O
time NN 0 1 12 O
may MD 0 0 1 O
vary VB 0 0 1 O
and CC 0 0 12 O
is VBZ 1 0 12 O
dependent JJ 0 1 1 O
upon IN 0 0 12 O
the DT 0 0 12 O
particular JJ 0 0 1 O
MAO NNP 0 1 14 B-Group
inhibitor NN 0 1 14 I-Group
being VBG 1 0 12 O
used VBN 1 1 12 O
the DT 0 0 12 O
length NN 0 1 3 O
of IN 0 0 12 O
time NN 0 1 12 O
it PRP 0 0 12 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
administered VBN 1 1 1 O
and CC 0 0 12 O
the DT 0 0 12 O
dosage NN 0 1 0 O
involved VBN 1 1 12 O
. . 0 0 12 O

Therefore RB 0 0 1 O
if IN 0 0 12 O
concomitant JJ 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
these DT 0 0 12 O
agents NNS 1 1 1 O
is VBZ 1 0 12 O
indicated JJ 0 1 1 O
because IN 0 0 12 O
of IN 0 0 12 O
demonstrated JJ 0 0 1 O
hypokalemia NN 0 1 14 O
they PRP 0 0 12 O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
with IN 0 0 12 O
caution NN 0 0 1 O
and CC 0 0 12 O
with IN 0 0 12 O
frequent JJ 0 1 1 O
monitoring NN 0 1 1 O
of IN 0 0 12 O
serum JJ 0 1 14 O
potassium NN 0 1 14 O
. . 0 0 12 O

Drugs NNS 0 1 2 O
that WDT 0 0 12 O
induce VBP 0 1 6 O
hepatic JJ 0 1 14 O
enzymes NNS 1 1 14 O
such JJ 0 0 1 O
as IN 1 0 12 O
phenobarbital JJ 0 1 16 B-Drug
phenytoin NN 0 1 16 B-Drug
and CC 0 0 12 O
rifampin NN 0 1 16 B-Drug
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
clearance NN 0 1 16 O
of IN 0 0 12 O
methylprednisolone NN 0 1 16 B-Drug
and CC 0 0 12 O
may MD 0 0 1 O
require VB 0 0 1 O
increased VBN 1 1 1 O
in IN 0 0 12 O
methylprednisolone NN 0 1 16 B-Drug
dose NN 0 1 6 O
to TO 0 0 12 O
achieve VB 0 0 1 O
the DT 0 0 12 O
desired JJ 0 1 1 O
response NN 0 1 1 O
. . 0 0 12 O

Iron NNP 0 1 2 B-Group
Supplements NNP 0 1 UNK I-Group
and CC 0 0 12 O
Foods NNP 0 1 UNK O
Fortified NNP 0 0 UNK O
With IN 0 0 2 O
Iron NNP 0 1 2 B-Drug
Concomitant NNP 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
cefdinir NN 0 1 UNK B-Drug
with IN 0 0 12 O
a DT 0 0 12 O
therapeutic JJ 0 1 6 O
iron NN 0 1 3 B-Group
supplement NN 0 1 1 I-Group
containing VBG 1 1 1 O
9 CD 0 0 2 O
mg NN 0 1 0 O
of IN 0 0 12 O
elemental JJ 0 1 1 O
iron NN 0 1 3 B-Drug
( ( 0 0 2 O
as IN 1 0 12 O
FeSO9 NNP 0 0 UNK O
) ) 0 0 2 O
or CC 0 0 12 O
vitamins NNS 1 1 6 B-Group
supplemented VBN 1 1 1 O
with IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
of IN 0 0 12 O
elemental JJ 0 1 1 O
iron NN 0 1 3 B-Drug
reduced VBD 1 1 1 O
extent NN 0 1 1 O
of IN 0 0 12 O
absorption NN 0 1 1 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
respectively RB 0 0 1 O
. . 0 0 12 O

Thiazides NNS 0 1 UNK B-Group
: : 0 0 2 O
Thiazides NNS 0 1 UNK B-Group
are VBP 1 0 12 O
known VBN 1 1 12 O
to TO 0 0 12 O
induce VB 0 1 6 O
hypercalcemia NN 0 1 8 O
by IN 0 0 12 O
the DT 0 0 12 O
reduction NN 0 1 1 O
of IN 0 0 12 O
calcium NN 0 1 14 O
excretion NN 0 1 14 O
in IN 0 0 12 O
urine NN 0 1 6 O
. . 0 0 12 O

Milk NNP 0 1 2 O
milk NN 0 1 3 O
products NNS 1 1 1 O
and CC 0 0 12 O
calcium NN 0 1 14 B-Drug
- : 0 0 2 O
rich JJ 0 1 13 O
foods NNS 1 1 1 O
or CC 0 0 12 O
drugs NNS 1 1 6 O
may MD 0 0 1 O
impair VB 0 0 13 O
the DT 0 0 12 O
absorption NN 0 1 1 O
of IN 0 0 12 O
EMCYT NNP 0 1 UNK B-Brand
. . 0 0 12 O

Epinephrine NN 0 1 0 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
cautiously RB 0 0 UNK O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
hyperthyroidism NN 0 1 6 O
hypertension NN 0 1 6 O
and CC 0 0 12 O
cardiac JJ 0 1 6 O
arrhythmias NN 1 1 6 O
. . 0 0 12 O

Gentamicin NN 0 1 0 B-Drug
: : 0 0 2 O
Animal NNP 0 1 UNK O
data NNS 0 1 1 O
have VBP 0 0 12 O
suggested VBN 1 1 12 O
the DT 0 0 12 O
possibility NN 0 1 1 O
of IN 0 0 12 O
interaction NN 0 1 UNK O
between IN 0 0 12 O
perindopril NN 0 1 UNK B-Drug
and CC 0 0 12 O
gentamicin NN 0 1 14 B-Drug
. . 0 0 12 O

In IN 0 0 2 O
three CD 0 1 12 O
separate JJ 0 1 1 O
controlled VBN 1 1 1 O
parallel JJ 0 1 UNK O
group NN 0 1 12 O
clinical JJ 0 1 6 O
pharmacology NN 0 1 UNK O
studies NNS 1 1 1 O
desloratadine VBP 0 1 UNK B-Drug
at IN 0 0 12 O
the DT 0 0 12 O
clinical JJ 0 1 6 O
dose NN 0 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
azithromycin JJ 0 1 0 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
followed VBN 1 1 12 O
by IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
once RB 0 0 12 O
daily RB 0 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
( ( 0 0 2 O
n=9 JJ 0 1 UNK O
) ) 0 0 2 O
or CC 0 0 12 O
with IN 0 0 12 O
fluoxetine JJ 0 1 16 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
once RB 0 0 12 O
daily JJ 0 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
after IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
day NN 0 1 12 O
pretreatment JJ 0 1 UNK O
period NN 0 1 1 O
with IN 0 0 12 O
fluoxetine NN 0 1 16 B-Drug
( ( 0 0 2 O
n=9 JJ 0 1 UNK O
) ) 0 0 2 O
or CC 0 0 12 O
with IN 0 0 12 O
cimetidine JJ 0 1 13 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
every DT 0 0 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
( ( 0 0 2 O
n=9 JJ 0 1 UNK O
) ) 0 0 2 O
under IN 0 0 12 O
steady JJ 0 1 1 O
state NN 0 1 1 O
conditions NNS 1 1 1 O
to TO 0 0 12 O
normal JJ 0 1 1 O
healthy JJ 0 1 12 O
male NN 0 1 12 O
and CC 0 0 12 O
female JJ 0 1 12 O
volunteers NNS 1 1 UNK O
. . 0 0 12 O

In IN 0 0 2 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
diclofenac NN 0 1 16 B-Drug
and CC 0 0 12 O
lithium NN 0 1 16 B-Drug
concomitantly RB 0 0 14 O
lithium JJ 0 1 16 B-Drug
toxicity NN 0 1 6 O
may MD 0 0 1 O
develop VB 0 0 1 O
. . 0 0 12 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interactions VBZ 0 1 UNK O
A NNP 0 0 2 O
false JJ 0 1 13 O
- : 0 0 2 O
positive JJ 0 1 1 O
reaction NN 0 1 1 O
for IN 0 0 12 O
ketones NNS 1 1 14 O
in IN 0 0 12 O
the DT 0 0 12 O
urine NN 0 1 6 O
may MD 0 0 1 O
occur VB 0 1 1 O
with IN 0 0 12 O
tests NNS 1 1 1 O
using VBG 1 1 1 O
nitroprusside RB 0 1 14 B-Drug
but CC 0 0 12 O
not RB 0 1 12 O
with IN 0 0 12 O
those DT 0 0 12 O
using VBG 1 1 1 O
nitroferricyanide RB 0 1 UNK B-Drug
. . 0 0 12 O

Tolazamide NN 0 1 UNK B-Drug
: : 0 0 2 O
A DT 0 0 2 O
case NN 0 1 12 O
of IN 0 0 12 O
severe JJ 0 1 6 O
hypoglycemia NN 0 1 6 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
type NN 0 1 1 O
II NNP 0 0 2 O
diabetic JJ 0 1 6 O
patient NN 0 1 6 O
maintained VBD 1 1 1 O
on IN 0 0 12 O
tolazamide NN 0 1 13 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
gm NN 0 1 16 O
/ NNP 0 0 2 O
day NN 0 1 12 O
) ) 0 0 2 O
9 CD 0 0 2 O
days NNS 1 1 12 O
after IN 0 0 12 O
the DT 0 0 12 O
addition NN 0 1 1 O
of IN 0 0 12 O
doxepin NN 0 1 16 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
) ) 0 0 2 O
. . 0 0 12 O

Nizatidine NN 0 1 0 B-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
inhibit VB 0 1 13 O
the DT 0 0 12 O
cytochrome NN 0 1 UNK O
P NNP 0 1 2 O
- : 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
linked VBN 1 1 UNK O
drug NN 0 1 1 O
- : 0 0 2 O
metabolizing NN 0 0 UNK O
enzyme NN 0 1 14 O
system NN 0 1 1 O
; : 0 0 2 O

Tablet NN 0 1 2 O
If IN 0 0 12 O
a DT 0 0 12 O
patient NN 0 1 6 O
receiving VBG 1 1 1 O
clonidine JJ 0 1 0 B-Drug
hydrochloride NN 0 1 0 I-Drug
is VBZ 1 0 12 O
also RB 0 0 12 O
taking VBG 1 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
clonidine NN 0 1 0 B-Drug
may MD 0 0 1 O
be VB 0 0 12 O
reduced VBN 1 1 1 O
thus RB 0 0 1 O
necessitating VBG 1 0 1 O
an DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
dosage NN 0 1 0 O
. . 0 0 12 O

However RB 0 0 1 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
b.i.d NN 0 1 UNK O
. . 0 0 12 O
isradipine NN 0 1 13 B-Drug
and CC 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
b.i.d NN 0 1 UNK O
. . 0 0 12 O

cases NNS 1 1 UNK O
of IN 0 0 12 O
rhabdomyolysis NN 0 1 8 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
seriously RB 0 0 UNK O
ill JJ 0 1 12 O
patients NNS 1 1 6 O
. . 0 0 12 O

False NNP 0 1 UNK O
- : 0 0 2 O
negative JJ 0 1 1 O
results NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
dexamethasone NN 0 1 16 O
suppression NN 0 1 1 O
test NN 0 1 1 O
( ( 0 0 2 O
DST NNP 0 1 UNK O
) ) 0 0 2 O
in IN 0 0 12 O
patients NNS 1 1 6 O
being VBG 1 0 12 O
treated VBN 1 1 1 O
with IN 0 0 12 O
INDOCIN NNP 0 1 UNK B-Brand
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
. . 0 0 12 O

Esomeprazole NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
extensively RB 0 0 1 O
metabolized VBN 1 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
liver NN 0 1 6 O
by IN 0 0 12 O
CYP9C9 NNP 0 0 UNK O
and CC 0 0 12 O
CYP9A9 NNP 0 0 UNK O
. . 0 0 12 O

In IN 0 0 2 O
addition NN 0 1 1 O
under IN 0 0 12 O
the DT 0 0 12 O
influence NN 0 0 UNK O
of IN 0 0 12 O
sympatholytic JJ 0 1 UNK O
medicinal JJ 0 0 16 O
products NNS 1 1 1 O
such JJ 0 0 1 O
as IN 1 0 12 O
beta NN 0 1 16 B-Group
- : 0 0 2 O
blockers NNS 1 0 6 I-Group
clonidine VBP 0 1 0 B-Drug
guanethidine NN 0 1 UNK B-Drug
and CC 0 0 12 O
reserpine VB 0 1 UNK B-Drug
the DT 0 0 12 O
signs NNS 1 1 12 O
of IN 0 0 12 O
hypoglycemia NN 0 1 6 O
may MD 0 0 1 O
be VB 0 0 12 O
reduced VBN 1 1 1 O
or CC 0 0 12 O
absent NN 0 1 1 O
. . 0 0 12 O

- : 0 0 2 O
Cisapride NN 0 1 0 B-Drug
pimozide NN 0 1 13 B-Drug
: : 0 0 2 O
Other JJ 0 0 2 O
drugs NNS 1 1 6 O
such JJ 0 0 1 O
as IN 1 0 12 O
cisapride NN 0 1 UNK B-Drug
or CC 0 0 12 O
pimozide NN 0 1 13 B-Drug
which WDT 0 0 12 O
are VBP 1 0 12 O
metabolised VBN 1 0 UNK O
by IN 0 0 12 O
hepatic JJ 0 1 14 O
CYP9A NNP 0 0 UNK O
isozymes NNS 0 1 UNK O
have VBP 0 0 12 O
been VBN 1 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
QT NNP 0 1 13 O
interval JJ 0 1 1 O
prolongation NN 0 1 6 O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
cardiac JJ 0 1 6 O
arrythmias NN 0 1 UNK O
( ( 0 0 2 O
typically RB 0 0 UNK O
torsades VBZ 0 0 13 O
de IN 0 1 2 O
pointe NN 0 0 UNK O
) ) 0 0 2 O
as IN 1 0 12 O
a DT 0 0 12 O
result NN 0 1 1 O
of IN 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
their PRP$ 0 0 12 O
serum NN 0 1 14 O
level NN 0 1 1 O
subsequent NN 0 1 1 O
to TO 0 0 12 O
interaction NN 0 1 UNK O
with IN 0 0 12 O
significant JJ 0 1 1 O
inhibitors NNS 1 1 14 O
of IN 0 0 12 O
the DT 0 0 12 O
isozyme NN 0 1 UNK O
including VBG 1 1 1 O
some DT 0 0 12 O
macrolide NN 0 1 UNK B-Group
antibacterials NNS 1 1 UNK I-Group
. . 0 0 12 O

Therefore RB 0 0 1 O
the DT 0 0 12 O
potential JJ 0 1 1 O
exists NNS 0 1 UNK O
for IN 0 0 12 O
interaction NN 0 1 UNK O
between IN 0 0 12 O
carbamazepine NN 0 1 16 B-Drug
and CC 0 0 12 O
any DT 0 0 12 O
agent NN 0 1 1 O
that IN 0 0 12 O
inhibits VBZ 1 1 UNK O
CYP9A9 NNP 0 0 UNK O
and CC 0 0 12 O
/ NNP 0 0 2 O
or CC 0 0 12 O
epoxide JJ 0 1 UNK O
hydrolase NN 0 1 UNK O
. . 0 0 12 O

Erythromycin NNP 0 1 0 B-Drug
and CC 0 0 12 O
clarithromycin NN 0 1 13 B-Drug
( ( 0 0 2 O
and CC 0 0 12 O
possibly RB 0 1 12 O
other JJ 0 0 12 O
macrolide IN 0 1 UNK B-Group
antibiotics NNS 1 1 6 I-Group
) ) 0 0 2 O
and CC 0 0 12 O
tetracycline NN 0 1 0 B-Drug
may MD 0 0 1 O
increase VB 0 1 1 O
digoxin NN 0 1 14 B-Drug
absorption NN 0 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
who WP 0 0 12 O
inactivate VBP 0 0 UNK O
digoxin NN 0 1 14 B-Drug
by IN 0 0 12 O
bacterial JJ 0 1 6 O
metabolism NN 0 1 16 O
in IN 0 0 12 O
the DT 0 0 12 O
lower JJR 1 1 1 O
intestine NN 0 1 6 O
so IN 0 1 12 O
that DT 0 0 12 O
digitalis JJ 0 1 14 B-Group
intoxication NN 0 1 6 O
may MD 0 0 1 O
result VB 0 1 1 O
. . 0 0 12 O

Therefore RB 0 0 1 O
to TO 0 0 12 O
maximize VB 0 0 1 O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
fexofenadine NN 0 1 16 B-Drug
it PRP 0 0 12 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
that IN 0 0 12 O
ALLEGRA NNP 0 1 UNK B-Brand
should MD 0 0 12 O
be VB 0 0 12 O
taken VBN 1 1 12 O
with IN 0 0 12 O
water NN 0 1 3 O

Concurrent JJ 0 1 13 O
administration NN 0 1 1 O
of IN 0 0 12 O
oxyphenbutazone NN 0 1 UNK B-Drug
and CC 0 0 12 O
androgens NNS 1 1 13 B-Group
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
elevated JJ 0 1 1 O
serum NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
oxyphenbutazone NN 0 1 UNK B-Drug
. . 0 0 12 O

Agents NNS 0 1 2 O
Increasing VBG 0 1 2 O
Serum NNP 0 1 7 O
Potassium NN 0 1 14 O
: : 0 0 2 O
PRINIVIL NNP 0 1 UNK B-Brand
attenuates VBZ 1 1 UNK O
potassium JJ 0 1 14 O
loss NN 0 1 1 O
caused VBN 1 1 1 O
by IN 0 0 12 O
thiazide JJ 0 1 UNK B-Group
- : 0 0 2 O
type NN 0 1 1 I-Group
diuretics NNS 1 1 14 I-Group
. . 0 0 12 O

No DT 0 0 2 O
pharmacokinetic JJ 0 1 UNK O
interaction NN 0 1 UNK O
was VBD 1 0 12 O
identified VBN 1 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
a DT 0 0 12 O
study NN 0 1 1 O
in IN 0 0 12 O
which WDT 0 0 12 O
9 CD 0 0 2 O
different JJ 0 1 1 O
drugs NNS 1 1 6 O
were VBD 1 0 12 O
tested VBN 1 1 1 O
therapeutically RB 0 0 14 O
relevant JJ 0 1 1 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
tolbutamide JJ 0 1 UNK B-Drug
sodium NN 0 1 14 B-Drug
salicylate NN 0 1 13 I-Drug
and CC 0 0 12 O
sulfamethizole NN 0 1 UNK B-Drug
displaced VBD 1 1 1 O
protein JJ 0 1 14 O
- : 0 0 2 O
bound NN 0 1 12 O
teniposide NN 0 1 UNK B-Drug
in IN 0 0 12 O
fresh JJ 0 1 3 O
human JJ 0 1 1 O
serum NN 0 1 14 O
to TO 0 0 12 O
a DT 0 0 12 O
small JJ 0 1 12 O
but CC 0 0 12 O
significant JJ 0 1 1 O
extent NN 0 1 1 O
. . 0 0 12 O

Systemic JJ 0 1 7 O
exposure NN 0 1 1 O
to TO 0 0 12 O
acetaminophen VB 0 1 16 B-Drug
is VBZ 1 0 12 O
expected VBN 1 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
increased VBN 1 1 1 O
when WRB 0 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
Gleevec NNP 0 1 UNK B-Brand
. . 0 0 12 O

Reduced VBN 0 1 UNK O
efficacy NN 0 1 UNK O
and CC 0 0 12 O
increased VBD 1 1 1 O
incidence NN 0 1 6 O
of IN 0 0 12 O
breakthrough NN 0 1 1 O
bleeding NN 0 1 6 O
and CC 0 0 12 O
menstrual JJ 0 1 6 O
irregularities NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
concomitant JJ 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
rifampin NN 0 1 16 B-Drug
. . 0 0 12 O

Digoxin NN 0 1 0 B-Drug
: : 0 0 2 O
Rofecoxib NNP 0 1 UNK B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
once RB 0 0 12 O
daily JJ 0 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
does VBZ 1 0 12 O
not RB 0 1 12 O
alter VB 0 1 13 O
the DT 0 0 12 O
plasma NN 0 1 14 O
concentration NN 0 1 1 O
profile NN 0 1 1 O
or CC 0 0 12 O
renal JJ 0 1 6 O
elimination NN 0 1 UNK O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
after IN 0 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
9 CD 0 0 2 O
mg JJ 0 1 0 O
oral JJ 0 1 6 O
dose NN 0 1 6 O
. . 0 0 12 O

Cyclosporine NN 0 1 UNK B-Drug
: : 0 0 2 O
DIFLUCAN NNP 0 1 UNK B-Brand
may MD 0 0 1 O
significantly RB 0 0 1 O
increase VB 0 1 1 O
cyclosporine NN 0 1 14 B-Drug
levels NNS 1 1 1 O
in IN 0 0 12 O
renal JJ 0 1 6 O
transplant NN 0 1 6 O
patients NNS 1 1 6 O
with IN 0 0 12 O
or CC 0 0 12 O
without IN 0 0 12 O
renal JJ 0 1 6 O
impairment NN 0 1 16 O
. . 0 0 12 O

Specific JJ 0 1 UNK O
studies NNS 1 1 1 O
with IN 0 0 12 O
ibandronate NN 0 1 13 B-Drug
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
performed VBN 1 1 1 O
. . 0 0 12 O

Morphine NNP 0 1 0 B-Drug
pharmacokinetic JJ 0 1 UNK O
parameter NN 0 1 1 O
values NNS 1 1 1 O
were VBD 1 0 12 O
not RB 0 1 12 O
affected VBN 1 1 1 O
by IN 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
Neurontin NNP 0 1 0 B-Brand
9 CD 0 0 2 O
hours NNS 1 1 12 O
after IN 0 0 12 O
morphine NN 0 1 14 B-Drug
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
that IN 0 0 12 O
glucose NN 0 1 14 O
tests NNS 1 1 1 O
based VBN 1 1 1 O
on IN 0 0 12 O
enzymatic JJ 0 1 UNK O
glucose JJ 0 1 14 O
oxidase NN 0 1 13 O
reactions NNS 1 1 1 O
( ( 0 0 2 O
such JJ 0 0 1 O
as IN 1 0 12 O
Clinistix NNP 0 0 UNK O
or CC 0 0 12 O
Tes NNP 0 1 UNK O
- : 0 0 2 O
Tape NN 0 1 2 O
) ) 0 0 2 O
be VB 0 0 12 O
used VBN 1 1 12 O
. . 0 0 12 O

The DT 0 0 2 O
following NN 0 1 1 O
are VBP 1 0 12 O
examples NNS 1 1 UNK O
of IN 0 0 12 O
substances NNS 1 1 1 O
that WDT 0 0 12 O
may MD 0 0 1 O
reduce VB 0 0 1 O
the DT 0 0 12 O
blood NN 0 1 6 O
- : 0 0 2 O
glucose JJ 0 1 14 O
- : 0 0 2 O
lowering VBG 1 1 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
insulin NN 0 1 14 B-Drug
: : 0 0 2 O
corticosteroids NNS 1 1 14 B-Group
danazol VBP 0 1 13 B-Drug
diuretics NNS 1 1 14 B-Group
sympathomimetic JJ 0 1 13 B-Group
agents NNS 1 1 1 I-Group
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
epinephrine NN 0 1 14 B-Drug
albuterol NN 0 1 0 B-Drug
terbutaline NN 0 1 0 B-Drug
) ) 0 0 2 O
isoniazid NN 0 1 13 B-Drug
phenothiazine NN 0 1 UNK B-Group
derivatives NNS 1 1 13 I-Group
somatropin VBP 0 1 13 B-Drug
thyroid JJ 0 1 6 B-Group
hormones NNS 1 1 13 I-Group
estrogens NNS 1 1 16 B-Group
progestogens NNS 1 1 UNK B-Group
( ( 0 0 2 O
e.g. NN 0 0 UNK O
in IN 0 0 12 O
oral JJ 0 1 6 O
contraceptives NNS 1 1 13 B-Group
) ) 0 0 2 O
. . 0 0 12 O

No DT 0 0 2 O
dose JJ 0 1 6 O
adjustment NN 0 1 1 O
of IN 0 0 12 O
SUSTIVA NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
when WRB 0 0 12 O
given VBN 1 1 12 O
with IN 0 0 12 O
clarithromycin NN 0 1 13 B-Drug
. . 0 0 12 O

Thiazides NNS 0 1 UNK B-Group
may MD 0 0 1 O
add VB 0 1 12 O
to TO 0 0 12 O
or CC 0 0 12 O
potentiate VB 0 0 UNK O
the DT 0 0 12 O
action NN 0 1 13 O
of IN 0 0 12 O
other JJ 0 0 12 O
antihypertensive JJ 0 1 14 B-Group
drugs NNS 1 1 6 I-Group
. . 0 0 12 O

INSPRA NNP 0 1 UNK B-Brand
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
with IN 0 0 12 O
drugs NNS 1 1 6 O
described VBN 1 1 1 O
as IN 1 0 12 O
strong JJ 0 1 12 O
inhibitors NNS 1 1 14 O
of IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
in IN 0 0 12 O
their PRP$ 0 0 12 O
labeling NN 0 1 UNK O
. . 0 0 12 O

No DT 0 0 2 O
pharmacokinetic JJ 0 1 UNK O
drug NN 0 1 1 O
- : 0 0 2 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
were VBD 1 0 12 O
conducted VBN 1 1 1 O
with IN 0 0 12 O
PERSANTINE NNP 0 1 UNK B-Brand
( ( 0 0 2 O
dipyridamole JJ 0 1 0 B-Drug
USP NNP 0 1 UNK O
) ) 0 0 2 O
Tablets NNPS 0 1 0 O
. . 0 0 12 O

An DT 0 0 2 O
adjustment NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
diltiazem NN 0 1 0 B-Drug
dose NN 0 1 6 O
may MD 0 0 1 O
be VB 0 0 12 O
warranted VBN 1 0 1 O
. . 0 0 12 O

increased VBN 1 1 1 O
liver NN 0 1 6 O

Patients NNS 0 1 7 O
receiving VBG 1 1 1 O
catecholamine JJ 0 1 14 O
- : 0 0 2 O
depleting VBG 1 1 UNK O
drugs NNS 1 1 6 O
such JJ 0 0 1 O
as IN 1 0 12 O
reserpine NN 0 1 UNK B-Drug
or CC 0 0 12 O
guanethidine NN 0 1 UNK B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
closely RB 0 0 1 O
monitored VBN 1 1 1 O
because IN 0 0 12 O
the DT 0 0 12 O
added JJ 0 1 12 O
beta NN 0 1 16 O
- : 0 0 2 O
adrenergic NN 0 1 UNK O
blocking VBG 1 1 UNK O
action NN 0 1 13 O
of IN 0 0 12 O
ZEBETA NNP 0 1 UNK B-Brand
may MD 0 0 1 O
produce VB 0 0 1 O
excessive JJ 0 1 1 O
reduction NN 0 1 1 O
of IN 0 0 12 O
sympathetic JJ 0 0 13 O
activity NN 0 1 1 O
. . 0 0 12 O

Strong JJ 0 1 2 O
inducers NNS 1 1 UNK O
of IN 0 0 12 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
enzymes NNS 1 1 14 O
( ( 0 0 2 O
i.e NN 0 1 16 O
. . 0 0 12 O
carbamazepine NN 0 1 16 B-Drug
phenytoin NN 0 1 16 B-Drug
and CC 0 0 12 O
phenobarbital NN 0 1 16 B-Drug
) ) 0 0 2 O
have VBP 0 0 12 O
been VBN 1 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
decrease VB 0 1 1 O
the DT 0 0 12 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
MHD NNP 0 0 UNK B-Drug_n
( ( 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
. . 0 0 12 O

The DT 0 0 2 O
clinical JJ 0 1 6 O
significance NN 0 1 13 O
of IN 0 0 12 O
this DT 0 0 12 O
property NN 0 1 13 O
is VBZ 1 0 12 O
unknown JJ 0 1 12 O
. . 0 0 12 O

Severe NNP 0 1 7 O
toxicity NN 0 1 6 O
has VBZ 1 0 12 O
also RB 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
the DT 0 0 12 O
combination NN 0 1 1 O
of IN 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
and CC 0 0 12 O
ELDEPRYL NNP 0 1 UNK B-Brand
and CC 0 0 12 O
selective JJ 0 1 13 B-Group
serotonin NN 0 1 13 I-Group
reuptake NN 0 1 13 I-Group
inhibitors NNS 1 1 14 I-Group
and CC 0 0 12 O
ELDEPRYL NNP 0 1 UNK B-Brand
. . 0 0 12 O

The DT 0 0 2 O
physician NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
alert VBN 0 1 12 O
for IN 0 0 12 O
possible JJ 0 1 1 O
combined JJ 0 1 1 O
drug NN 0 1 1 O
actions NNS 1 1 UNK O
desirable JJ 0 0 UNK O
or CC 0 0 12 O
undesirable JJ 0 0 UNK O
involving VBG 1 1 1 O
ifosfamide NN 0 1 14 B-Drug
even RB 0 0 12 O
though IN 0 0 12 O
ifosfamide NN 0 1 14 B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
used VBN 1 1 12 O
successfully RB 0 0 1 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
including VBG 1 1 1 O
other JJ 0 0 12 O
cytotoxic NN 0 1 UNK O
drugs NNS 1 1 6 O
. . 0 0 12 O

British JJ 0 1 UNK O
Jnl NNP 0 0 UNK O
Rheum NNP 0 1 UNK O
9 CD 0 0 2 O
; : 0 0 2 O
9:9 CD 0 0 UNK O
- : 0 0 2 O
9 CD 0 0 2 O
. . 0 0 12 O

Although IN 0 0 12 O
the DT 0 0 12 O
pressor NN 0 1 14 O
activity NN 0 1 1 O
of IN 0 0 12 O
Desmopressin NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
very RB 0 1 12 O
low JJ 0 1 1 O
compared VBN 1 1 1 O
to TO 0 0 12 O
its PRP$ 1 0 12 O
antidiuretic JJ 0 1 UNK O
activity NN 0 1 1 O
large JJ 0 1 3 O
doses NNS 1 1 6 O
of IN 0 0 12 O
Desmopressin NNP 0 1 UNK B-Drug
Tablets NNP 0 1 0 O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
with IN 0 0 12 O
other JJ 0 0 12 O
pressor NN 0 1 14 O
agents NNS 1 1 1 O
only RB 0 1 12 O
with IN 0 0 12 O
careful JJ 0 1 12 O
patient JJ 0 1 6 O
monitoring NN 0 1 1 O
. . 0 0 12 O

Further RB 0 1 2 O
in IN 0 0 12 O
clinical JJ 0 1 6 O
studies NNS 1 1 1 O
with IN 0 0 12 O
PROSCAR NNP 0 1 UNK B-Brand
( ( 0 0 2 O
finasteride RB 0 1 16 B-Drug
9 CD 0 0 2 O
mg NNS 0 1 0 O
) ) 0 0 2 O
when WRB 0 0 12 O
used VBN 1 1 12 O
in IN 0 0 12 O
older JJR 1 1 12 O
men NNS 0 1 13 O
who WP 0 0 12 O
have VBP 0 0 12 O
benign VBN 0 1 6 O
prostatic JJ 0 1 6 O
hyperplasia NN 0 1 13 O
( ( 0 0 2 O
BPH NNP 0 1 6 O
) ) 0 0 2 O
PSA NNP 0 1 13 O
levels NNS 1 1 1 O
are VBP 1 0 12 O
decreased VBN 1 1 1 O
by IN 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

The DT 0 0 2 O
change NN 0 1 1 O
in IN 0 0 12 O
furosemide JJ 0 1 0 B-Drug
clearance NN 0 1 16 O
value NN 0 1 1 O
is VBZ 1 0 12 O
not RB 0 1 12 O
likely JJ 0 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
. . 0 0 12 O

Acetaminophen NN 0 1 0 B-Drug
: : 0 0 2 O
A DT 0 0 2 O
report NN 0 1 1 O
of IN 0 0 12 O
severe JJ 0 1 6 O
acetaminophen NN 0 1 16 B-Drug
toxicity NN 0 1 6 O
was VBD 1 0 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
patient NN 0 1 6 O
receiving VBG 1 1 1 O
Isoniazid NNP 0 1 UNK B-Drug
. . 0 0 12 O

This DT 0 0 2 O
effect NN 0 1 1 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
attributed VBN 1 1 1 O
to TO 0 0 12 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
renal JJ 0 1 6 O
prostaglandin NN 0 1 13 O
synthesis NN 0 1 UNK O
. . 0 0 12 O

When WRB 0 0 12 O
taken VBN 1 1 12 O
orally RB 0 1 14 O
imidazole JJ 0 1 UNK B-Group
compounds NNS 1 1 13 I-Group
like IN 0 0 12 O
ketoconazole NN 0 1 16 B-Drug
may MD 0 0 1 O
enhance VB 0 1 UNK O
the DT 0 0 12 O
anticoagulant JJ 0 1 13 O
effect NN 0 1 1 O
of IN 0 0 12 O
coumarin NN 0 1 UNK B-Group
- : 0 0 2 O
like IN 0 0 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

Cardiovascular JJ 0 1 7 O
: : 0 0 2 O
Hypotension NN 0 1 7 O
bradycardia NN 0 1 8 O
and CC 0 0 12 O
hypertension NN 0 1 6 O
have VBP 0 0 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
during IN 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
TAXOL NNP 0 1 UNK B-Brand
but CC 0 0 12 O
generally RB 0 0 1 O
do VBP 0 0 12 O
not RB 0 1 12 O
require VB 0 0 1 O
treatment NN 0 1 6 O
. . 0 0 12 O

In IN 0 0 2 O
this DT 0 0 12 O
setting VBG 1 1 1 O
cardioselective JJ 0 0 UNK B-Group
beta NN 0 1 16 I-Group
- : 0 0 2 O
blockers NNS 1 0 6 I-Group
could MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
although IN 0 0 12 O
they PRP 0 0 12 O
should MD 0 0 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
caution NN 0 0 1 O
. . 0 0 12 O

Concurrent NNP 0 1 13 O
use NN 0 1 1 O
of IN 0 0 12 O
Mexitil NNP 0 1 UNK B-Brand
and CC 0 0 12 O
theophylline NN 0 1 16 B-Drug
may MD 0 0 1 O
lead VB 0 1 12 O
to TO 0 0 12 O
increased VBN 1 1 1 O
plasma NN 0 1 14 O
theophylline NN 0 1 16 B-Drug
levels NNS 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
clinical JJ 0 1 6 O
significance NN 0 1 13 O
is VBZ 1 0 12 O
unknown JJ 0 1 12 O
. . 0 0 12 O

Terbinafine JJ 0 1 UNK B-Drug
clearance NN 0 1 16 O
is VBZ 1 0 12 O
unaffected VBN 0 1 UNK O
by IN 0 0 12 O
cyclosporine NN 0 1 14 B-Drug
. . 0 0 12 O

However RB 0 0 1 O
no DT 0 0 12 O
clinically RB 0 0 6 O
or CC 0 0 12 O
statistically RB 0 1 1 O
significant JJ 0 1 1 O
differences NNS 1 1 UNK O
in IN 0 0 12 O
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
ratio NN 0 1 1 O
or CC 0 0 12 O
warfarin VB 0 1 14 B-Drug
enantiomer JJ 0 1 UNK O
pharmacokinetics NNS 0 1 UNK O
were VBD 1 0 12 O
observed VBN 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
small JJ 0 1 12 O
study NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
healthy JJ 0 1 12 O
males NNS 1 1 UNK O
who WP 0 0 12 O
received VBD 1 1 12 O
both DT 0 0 12 O
warfarin NNS 0 1 14 B-Drug
and CC 0 0 12 O
lomefloxacin NN 0 1 UNK B-Drug
under IN 0 0 12 O
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
conditions NNS 1 1 1 O
. . 0 0 12 O

Post NNP 0 1 2 O
- : 0 0 2 O
marketing NN 0 1 UNK O
reports NNS 1 1 1 O
of IN 0 0 12 O
changes NNS 1 1 1 O
in IN 0 0 12 O
prothrombin NN 0 1 14 O
measures NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
received VBN 1 1 12 O
among IN 0 0 12 O
patients NNS 1 1 6 O
on IN 0 0 12 O
concomitant JJ 0 1 6 O
warfarin NN 0 1 14 B-Drug
and CC 0 0 12 O
esomeprazole JJ 0 1 16 B-Drug
therapy NN 0 1 6 O
. . 0 0 12 O

Levetiracetam NNP 0 1 0 B-Drug
circulates VBZ 1 1 UNK O
largely RB 0 0 1 O
unbound JJ 0 0 UNK O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
bound NN 0 1 12 O
) ) 0 0 2 O
to TO 0 0 12 O
plasma VB 0 1 14 O
proteins NNS 1 1 14 O
; : 0 0 2 O

Theophylline NN 0 1 UNK B-Drug
: : 0 0 2 O
Theophylline JJ 0 1 UNK B-Drug
clearance NN 0 1 16 O
may MD 0 0 1 O
decrease VB 0 1 1 O
in IN 0 0 12 O
hypothyroid JJ 0 1 6 O
patients NNS 1 1 6 O
and CC 0 0 12 O
return VB 0 1 12 O
toward IN 0 0 12 O
normal JJ 0 1 1 O
when WRB 0 0 12 O
a DT 0 0 12 O
euthyroid JJ 0 1 14 O
state NN 0 1 1 O
is VBZ 1 0 12 O
achieved VBN 1 0 1 O
. . 0 0 12 O

Meperidine NN 0 1 UNK B-Drug
: : 0 0 2 O
Amphetamines NNS 0 1 UNK B-Group
potentiate VBP 0 0 UNK O
the DT 0 0 12 O
analgesic JJ 0 1 13 O
effect NN 0 1 1 O
of IN 0 0 12 O
meperidine NN 0 1 16 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
preceding VBG 1 1 1 O
lists NNS 1 1 UNK O
of IN 0 0 12 O
drugs NNS 1 1 6 O
are VBP 1 0 12 O
not RB 0 1 12 O
comprehensive JJ 0 1 13 O
. . 0 0 12 O

Although IN 0 0 12 O
in IN 0 0 12 O
vivo NN 0 1 13 O
studies NNS 1 1 1 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
done VBN 1 0 12 O
to TO 0 0 12 O
see VB 0 1 12 O
if IN 0 0 12 O
etodolac JJ 0 1 13 B-Drug
clearance NN 0 1 16 O
is VBZ 1 0 12 O
changed VBN 1 1 12 O
by IN 0 0 12 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
phenylbutazone NN 0 1 UNK B-Drug
it PRP 0 0 12 O
is VBZ 1 0 12 O
not RB 0 1 12 O
recommended VBN 1 1 1 O
that IN 0 0 12 O
they PRP 0 0 12 O
be VB 0 0 12 O
coadministered VBN 0 0 UNK O
. . 0 0 12 O

Since IN 0 1 2 O
Zarontin NNP 0 1 UNK B-Brand
( ( 0 0 2 O
ethosuximide RB 0 1 13 B-Drug
) ) 0 0 2 O
may MD 0 0 1 O
interact VB 0 0 UNK O
with IN 0 0 12 O
concurrently RB 0 0 1 O
administered VBN 1 1 1 O
antiepileptic JJ 0 1 UNK B-Group
drugs NNS 1 1 6 I-Group
periodic JJ 0 1 1 O
serum VBP 0 1 14 O
level JJ 0 1 1 O
determinations NNS 1 1 UNK O
of IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
may MD 0 0 1 O
be VB 0 0 12 O
necessary JJ 0 0 1 O
( ( 0 0 2 O
eg JJ 0 1 UNK O
ethosuximide NN 0 1 13 B-Drug
may MD 0 0 1 O
elevate VB 0 1 1 O
phenytoin VB 0 1 16 B-Drug
serum NN 0 1 14 O
levels NNS 1 1 1 O
and CC 0 0 12 O
valproic NN 0 0 16 B-Drug
acid NN 0 1 14 I-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
both DT 0 0 12 O
increase NN 0 1 1 O
and CC 0 0 12 O
decrease VB 0 1 1 O
ethosuximide JJ 0 1 13 B-Drug
levels NNS 1 1 1 O
) ) 0 0 2 O
. . 0 0 12 O

Anticholinergic JJ 0 1 UNK B-Group
agents NNS 1 1 1 I-Group
may MD 0 0 1 O
potentially RB 0 0 1 O
alter VB 0 1 13 O
the DT 0 0 12 O
absorption NN 0 1 1 O
of IN 0 0 12 O
some DT 0 0 12 O
concomitantly RB 0 0 14 O
administered VBN 1 1 1 O
drugs NNS 1 1 6 O
due JJ 0 1 1 O
to TO 0 0 12 O
anticholinergic JJ 0 1 13 O
effects NNS 1 1 1 O
on IN 0 0 12 O
gastrointestinal JJ 0 1 6 O
motility NN 0 1 6 O
. . 0 0 12 O

Cytochrome NNP 0 1 UNK O
P9A9 NNP 0 0 UNK O
is VBZ 1 0 12 O
involved VBN 1 1 12 O
in IN 0 0 12 O
the DT 0 0 12 O
formation NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
hydroxy NN 0 1 14 I-Drug_n
ropivacaine VBP 0 1 16 I-Drug_n
the DT 0 0 12 O
major JJ 0 1 1 O
metabolite NN 0 1 UNK O
. . 0 0 12 O

Severe NNP 0 1 7 O
allergic JJ 0 1 6 O
reactions NNS 1 1 1 O
including VBG 1 1 1 O
anaphylaxis NNS 0 1 6 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
exposed VBN 1 1 3 O
to TO 0 0 12 O
a DT 0 0 12 O
variety NN 0 1 1 O
of IN 0 0 12 O
allergens NNS 1 1 13 O
either CC 0 1 12 O
by IN 0 0 12 O
repeated JJ 0 1 1 O
challenge NN 0 1 12 O
or CC 0 0 12 O
accidental JJ 0 1 13 O
contact NN 0 1 12 O
and CC 0 0 12 O
with IN 0 0 12 O
diagnostic JJ 0 1 6 O
or CC 0 0 12 O
therapeutic JJ 0 1 6 O
agents NNS 1 1 1 O
while IN 0 0 12 O
receiving VBG 1 1 1 O
beta SYM 0 1 16 B-Group
- : 0 0 2 O
blockers NNS 1 0 6 I-Group
. . 0 0 12 O

- : 0 0 2 O
Cholestyramine NN 0 1 UNK B-Drug
and CC 0 0 12 O
colestipol NN 0 1 13 B-Drug
resins NNS 1 1 UNK B-Group
: : 0 0 2 O
Cholestytamine NNP 0 0 UNK B-Drug
and CC 0 0 12 O
colestipol NN 0 1 13 B-Drug
resins NNS 1 1 UNK B-Group
have VBP 0 0 12 O
the DT 0 0 12 O
potential NN 0 1 1 O
of IN 0 0 12 O
binding VBG 1 1 1 O
thiazide JJ 0 1 UNK B-Group
diuretics NNS 1 1 14 I-Group
and CC 0 0 12 O
reducing VBG 1 1 1 O
diuretic JJ 0 1 14 B-Group
absorption NN 0 1 1 O
from IN 0 0 12 O
the DT 0 0 12 O
gastrointestinal JJ 0 1 6 O
tract NN 0 1 6 O

These DT 0 0 1 O
levels NNS 1 1 1 O
then RB 0 1 12 O
remained VBD 1 0 12 O
stable JJ 0 1 1 O
for IN 0 0 12 O
up IN 0 0 12 O
to TO 0 0 12 O
9 CD 0 0 2 O
year NN 0 1 12 O
of IN 0 0 12 O
therapy NN 0 1 6 O
. . 0 0 12 O

Magnesium NN 0 1 7 B-Drug
: : 0 0 2 O
Magnesium NNP 0 1 7 B-Drug
- : 0 0 2 O
containing NN 0 1 1 O
preparations NNS 1 1 13 O
( ( 0 0 2 O
eg JJ 0 1 UNK O
antacids NNS 1 1 14 B-Group
) ) 0 0 2 O
may MD 0 0 1 O
cause VB 0 1 12 O
hypermagnesemia NN 0 1 13 O
and CC 0 0 12 O
should MD 0 0 12 O
therefore VB 0 0 1 O
not RB 0 1 12 O
be VB 0 0 12 O
taken VBN 1 1 12 O
during IN 0 0 12 O
therapy NN 0 1 6 O
with IN 0 0 12 O
vitamin NN 0 1 6 B-Group
D NNP 0 1 2 I-Group
by IN 0 0 12 O
patients NNS 1 1 6 O
on IN 0 0 12 O
chronic JJ 0 1 6 O
renal JJ 0 1 6 O
dialysis NN 0 1 6 O
. . 0 0 12 O

Potential JJ 0 1 UNK O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
between IN 0 0 12 O
Keppra NNP 0 1 0 B-Brand
and CC 0 0 12 O
other JJ 0 0 12 O
AEDs NNP 0 1 UNK B-Group
( ( 0 0 2 O
carbamazepine JJ 0 1 16 B-Drug
gabapentin NN 0 1 0 B-Drug
lamotrigine NN 0 1 0 B-Drug
phenobarbital JJ 0 1 16 B-Drug
phenytoin NN 0 1 16 B-Drug
primidone NN 0 1 13 B-Drug
and CC 0 0 12 O
valproate NN 0 1 16 B-Drug
) ) 0 0 2 O
were VBD 1 0 12 O
also RB 0 0 12 O
assessed VBN 1 1 1 O
by IN 0 0 12 O
evaluating VBG 1 1 1 O
the DT 0 0 12 O
serum JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
levetiracetam NN 0 1 16 B-Drug
and CC 0 0 12 O
these DT 0 0 12 O
AEDs NNP 0 1 UNK B-Group
during IN 0 0 12 O
placebo NN 0 1 13 O
- : 0 0 2 O
controlled VBN 1 1 1 O
clinical JJ 0 1 6 O
studies NNS 1 1 1 O
. . 0 0 12 O

If IN 0 0 12 O
an DT 0 0 12 O
alternative JJ 0 1 1 O
treatment NN 0 1 6 O
is VBZ 1 0 12 O
unavailable JJ 0 1 1 O
a DT 0 0 12 O
TARCEVA NNP 0 1 UNK B-Brand
dose NN 0 1 6 O
greater JJR 1 1 1 O
than IN 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
should MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
for IN 0 0 12 O
NSCLC NNP 0 1 UNK O
patients NNS 1 1 6 O
and CC 0 0 12 O
greater JJR 1 1 1 O
than IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
considered VBN 1 1 1 O
for IN 0 0 12 O
pancreatic JJ 0 1 6 O
cancer NN 0 1 6 O
patients NNS 1 1 6 O
. . 0 0 12 O

Because IN 0 0 12 O
moderate JJ 0 1 1 O
CYP9A9 NNP 0 0 UNK O
inhibitors NNS 1 1 14 O
( ( 0 0 2 O
e.g. VB 0 0 UNK O
diltiazem NN 0 1 0 B-Drug
) ) 0 0 2 O
result NN 0 1 1 O
in IN 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
fold JJ 0 1 3 O
increase NN 0 1 1 O
in IN 0 0 12 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
aprepitant JJ 0 1 13 B-Drug
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
should MD 0 0 12 O
also RB 0 0 12 O
be VB 0 0 12 O
approached VBN 1 1 UNK O
with IN 0 0 12 O
caution NN 0 0 1 O
. . 0 0 12 O

9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O

Ethopropazine NN 0 1 UNK B-Drug
can MD 0 0 12 O
interact VB 0 0 UNK O
with IN 0 0 12 O
chlorpromazine NN 0 1 16 B-Drug
increasing VBG 1 1 1 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
chlorpromazine NN 0 1 16 B-Drug
. . 0 0 12 O

Under IN 0 0 2 O
similar JJ 0 1 1 O
conditions NNS 1 1 1 O
bexarotene VBP 0 1 UNK B-Drug
concentrations NNS 1 1 13 O
were VBD 1 0 12 O
not RB 0 1 12 O
affected VBN 1 1 1 O
by IN 0 0 12 O
concomitant JJ 0 1 6 O
atorvastatin JJ 0 1 0 B-Drug
administration NN 0 1 1 O
. . 0 0 12 O

No DT 0 0 2 O
formal JJ 0 1 1 O
studies NNS 1 1 1 O
to TO 0 0 12 O
evaluate VB 0 1 1 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
bexarotene NN 0 1 UNK B-Drug
have VBP 0 0 12 O
been VBN 1 0 12 O
conducted VBN 1 1 1 O
. . 0 0 12 O

This DT 0 0 2 O
practice NN 0 1 UNK O
resulted VBD 1 1 1 O
in IN 0 0 12 O
no DT 0 0 12 O
apparent JJ 0 1 1 O
increase NN 0 1 1 O
in IN 0 0 12 O
local JJ 0 1 12 O
breast NN 0 1 6 O
cancer NN 0 1 6 O
recurrence NN 0 1 6 O
relative NN 0 1 1 O
to TO 0 0 12 O
published VBN 1 1 UNK O
accounts NNS 1 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
literature NN 0 1 UNK O
. . 0 0 12 O

9 CD 0 0 2 O
. . 0 0 12 O

The DT 0 0 2 O
concomitant NN 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
other JJ 0 0 12 O
CYP9A9 NNP 0 0 UNK O
inhibitors NNS 1 1 14 O
such JJ 0 0 1 O
as IN 1 0 12 O
diltiazem NN 0 1 0 B-Drug
and CC 0 0 12 O
erythromycin NN 0 1 0 B-Drug
with IN 0 0 12 O
transdermal JJ 0 1 14 O
fentanyl NN 0 1 14 B-Drug
may MD 0 0 1 O
also RB 0 0 12 O
result VB 0 1 1 O
in IN 0 0 12 O
an DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
fentanyl JJ 0 1 14 B-Drug
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
which WDT 0 0 12 O
could MD 0 0 12 O
increase VB 0 1 1 O
or CC 0 0 12 O
prolong JJ 0 0 13 O
adverse JJ 0 0 1 O
drug NN 0 1 1 O
effects NNS 1 1 1 O
and CC 0 0 12 O
may MD 0 0 1 O
cause VB 0 1 12 O
serious JJ 0 1 12 O
respiratory NN 0 1 6 O
depression NN 0 1 6 O
. . 0 0 12 O

Thus RB 0 0 1 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
enoxacin NN 0 1 UNK B-Drug
and CC 0 0 12 O
bismuth NN 0 1 16 B-Drug
subsalicylate NN 0 0 16 I-Drug
should MD 0 0 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
. . 0 0 12 O

ELLENCE NN 0 1 UNK B-Brand
when WRB 0 0 12 O
used VBN 1 1 12 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
other JJ 0 0 12 O
cytotoxic JJ 0 1 UNK O
drugs NNS 1 1 6 O
may MD 0 0 1 O
show VB 0 1 12 O
on IN 0 0 12 O
- : 0 0 2 O
treatment NN 0 1 6 O
additive JJ 0 1 16 O
toxicity NN 0 1 6 O
especially RB 0 0 12 O
hematologic JJ 0 1 14 O
and CC 0 0 12 O
gastrointestinal JJ 0 1 6 O
effects NNS 1 1 1 O
. . 0 0 12 O

As IN 0 0 2 O
binding NN 0 1 1 O
of IN 0 0 12 O
MHD NNP 0 0 UNK B-Drug_n
to TO 0 0 12 O
plasma VB 0 1 14 O
proteins NNS 1 1 14 O
is VBZ 1 0 12 O
low JJ 0 1 1 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
through IN 0 0 12 O
competition NN 0 1 12 O
for IN 0 0 12 O
protein NN 0 1 14 O
binding NN 0 1 1 O
sites NNS 1 1 1 O
are VBP 1 0 12 O
unlikely JJ 0 1 12 O
. . 0 0 12 O

Beta NNP 0 1 2 B-Group
- : 0 0 2 O
adrenergic NN 0 1 UNK I-Group
blocking VBG 1 1 UNK I-Group
drugs NNS 1 1 6 I-Group
add VB 0 1 12 O
some DT 0 0 12 O
further JJ 0 1 1 O
antihypertensive JJ 0 1 14 O
effect NN 0 1 1 O
to TO 0 0 12 O
captopril VB 0 1 0 B-Drug
but CC 0 0 12 O
the DT 0 0 12 O
overall JJ 0 1 1 O
response NN 0 1 1 O
is VBZ 1 0 12 O
less JJR 0 1 12 O
than IN 0 0 12 O
additive NN 0 1 16 O
. . 0 0 12 O

disulfiram NN 0 1 13 B-Drug
; : 0 0 2 O

Since IN 0 1 2 O
fondaparinux NN 0 1 16 B-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
markedly RB 0 1 1 O
inhibit VB 0 1 13 O
CYP9s NNP 0 0 UNK O
( ( 0 0 2 O
CYP9A9 NNP 0 0 UNK O
CYP9A9 NNP 0 0 UNK O
CYP9C9 NNP 0 0 UNK O
CYP9C9 NNP 0 0 UNK O
CYP9D9 NNP 0 0 UNK O
CYP9E9 NNP 0 0 UNK O
or CC 0 0 12 O
CYP9A9 NNP 0 0 UNK O
) ) 0 0 2 O
in IN 0 0 12 O
vitro NN 0 1 UNK O
fondaparinux NN 0 1 16 B-Drug
sodium NN 0 1 14 I-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
expected VBN 1 1 12 O
to TO 0 0 12 O
significantly RB 0 0 1 O
interact VB 0 0 UNK O
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
in IN 0 0 12 O
vivo NN 0 1 13 O
by IN 0 0 12 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
metabolism NN 0 1 16 O
mediated VBN 1 1 13 O
by IN 0 0 12 O
these DT 0 0 12 O
isozymes NNS 0 1 UNK O
. . 0 0 12 O

Anticholinesterases NNS 0 1 UNK B-Group
: : 0 0 2 O
Concomitant NNP 0 1 UNK O
use NN 0 1 1 O
of IN 0 0 12 O
anticholinesterase NN 0 1 UNK B-Group
agents NNS 1 1 1 I-Group
and CC 0 0 12 O
corticosteroids NNS 1 1 14 B-Group
may MD 0 0 1 O
produce VB 0 0 1 O
severe JJ 0 1 6 O
weakness NN 0 1 6 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
myasthenia JJ 0 1 6 O
gravis NN 0 1 6 O
. . 0 0 12 O

Irinotecan JJ 0 1 UNK B-Drug
concentrations NNS 1 1 13 O
were VBD 1 0 12 O
similar JJ 0 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
bolus JJ 0 1 14 O
- : 0 0 2 O
IFL NNP 0 1 UNK O
alone RB 0 1 12 O
and CC 0 0 12 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
AVASTIN NNP 0 1 UNK B-Brand
. . 0 0 12 O

Efavirenz NNP 0 1 UNK B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
shown VBN 1 1 1 O
in IN 0 0 12 O
vivo NN 0 1 13 O
to TO 0 0 12 O
induce VB 0 1 6 O
CYP9A9 NNP 0 0 UNK O
. . 0 0 12 O

Because IN 0 0 12 O
antacids NNS 1 1 14 B-Group
may MD 0 0 1 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
absorption NN 0 1 1 O
of IN 0 0 12 O
anticholinergic JJ 0 1 13 B-Group
agents NNS 1 1 1 I-Group
simultaneous JJ 0 1 13 O
use NN 0 1 1 O
of IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
. . 0 0 12 O

Theophylline NN 0 1 UNK B-Drug
: : 0 0 2 O
Following VBG 0 1 2 O
co SYM 0 1 12 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
two CD 0 1 12 O
9 CD 0 0 2 O
- : 0 0 2 O
mg NN 0 1 0 O
dirithromycin JJ 0 1 UNK B-Drug
tablets NNS 1 1 3 O
administered VBD 1 1 1 O
once RB 0 0 12 O
daily JJ 0 1 12 O
with IN 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
mg NN 0 1 0 O
theophylline JJ 0 1 16 B-Drug
tablets NNS 1 1 3 O
administered VBN 1 1 1 O
twice RB 0 1 12 O
daily RB 0 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
to TO 0 0 12 O
9 CD 0 0 2 O
healthy JJ 0 1 12 O
subjects VBZ 1 1 UNK O
the DT 0 0 12 O
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
plasma JJ 0 1 14 O
concentration NN 0 1 1 O
of IN 0 0 12 O
theophylline NN 0 1 16 B-Drug
was VBD 1 0 12 O
not RB 0 1 12 O
significantly RB 0 0 1 O
altered VBN 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
recommended VBN 1 1 1 O
dosage NN 0 1 0 O
( ( 0 0 2 O
one CD 0 1 12 O
or CC 0 0 12 O
two CD 0 1 12 O
capsules NNS 1 1 3 O
twice RB 0 1 12 O
daily RB 0 1 12 O
morning NN 0 1 12 O
and CC 0 0 12 O
evening NN 0 1 12 O
) ) 0 0 2 O
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
exceeded VBN 1 0 UNK O
. . 0 0 12 O

The DT 0 0 2 O
concurrent NN 0 1 1 O
use NN 0 1 1 O
of IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
is VBZ 1 0 12 O
not RB 0 1 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O

Patients NNS 0 1 7 O
receiving VBG 1 1 1 O
flurbiprofen NN 0 1 16 B-Drug
and CC 0 0 12 O
furosemide NN 0 1 0 B-Drug
or CC 0 0 12 O
other JJ 0 0 12 O
diuretics NNS 1 1 14 B-Group
should MD 0 0 12 O
be VB 0 0 12 O
observed VBN 1 1 1 O
closely RB 0 0 1 O
to TO 0 0 12 O
determine VB 0 0 1 O
if IN 0 0 12 O
the DT 0 0 12 O
desired JJ 0 1 1 O
effect NN 0 1 1 O
is VBZ 1 0 12 O
obtained VBN 1 1 1 O
. . 0 0 12 O

Drugs NNS 0 1 2 O
that WDT 0 0 12 O
may MD 0 0 1 O
increase VB 0 1 1 O
dasatinib NN 0 1 13 B-Drug
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
CYP9A9 NNP 0 0 UNK O
Inhibitors NNS 0 1 7 O
: : 0 0 2 O
Dasatinib NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
a DT 0 0 12 O
CYP9A9 NNP 0 0 UNK O
substrate NN 0 1 UNK O
. . 0 0 12 O

Consequently RB 0 0 1 O
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
should MD 0 0 12 O
be VB 0 0 12 O
reassessed VBN 1 0 15 O
periodically RB 0 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
both DT 0 0 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

Interactions NNS 0 1 UNK O
for IN 0 0 12 O
Vitamin NNP 0 1 2 B-Drug
B9 NNP 0 0 UNK I-Drug
( ( 0 0 2 O
Thiamine NNP 0 1 14 B-Drug
) ) 0 0 2 O
: : 0 0 2 O
Loop JJ 0 1 UNK B-Group
Diuretics NNP 0 1 UNK I-Group
Oral NNP 0 1 2 O
Contraceptives NNP 0 1 UNK B-Group
Stavudine NNP 0 1 UNK B-Drug
Tricyclic NNP 0 0 UNK B-Group
Antidepressants NNS 0 1 UNK I-Group

Cytadren NNP 0 1 UNK B-Brand
accelerates VBZ 1 1 UNK O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
dexamethasone NN 0 1 16 B-Drug
; : 0 0 2 O

TCAs NNP 0 1 UNK B-Group
decrease VBD 0 1 1 O
the DT 0 0 12 O
hypotensive JJ 0 1 14 O
effect NN 0 1 1 O
of IN 0 0 12 O
guanfacine NN 0 1 13 B-Drug
. . 0 0 12 O

Because IN 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
increased JJ 0 1 1 O
exposure NN 0 1 1 O
to TO 0 0 12 O
nevirapine VB 0 1 13 B-Drug
caution NN 0 0 1 O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
inconcomitant JJ 0 0 UNK O
administration NN 0 1 1 O
and CC 0 0 12 O
patients NNS 1 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
closely RB 0 0 1 O
for IN 0 0 12 O
nevirapine JJ 0 1 13 O
- : 0 0 2 O
associated JJ 0 1 1 O
adverse JJ 0 0 1 O
events NNS 1 1 12 O
. . 0 0 12 O

However RB 0 0 1 O
the DT 0 0 12 O
impairment NN 0 1 16 O
of IN 0 0 12 O
cognitive JJ 0 1 1 O
and CC 0 0 12 O
motor NN 0 1 3 O
skills NNS 1 1 UNK O
produced VBN 1 0 1 O
by IN 0 0 12 O
REMERON NNP 0 1 UNK B-Brand
were VBD 1 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
be VB 0 0 12 O
additive JJ 0 1 16 O
with IN 0 0 12 O
those DT 0 0 12 O
produced VBN 1 0 1 O
by IN 0 0 12 O
alcohol NN 0 1 1 B-Drug
. . 0 0 12 O

Therefore RB 0 0 1 O
indomethacin NN 0 1 14 B-Drug
and CC 0 0 12 O
diflunisal NN 0 1 13 B-Drug
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
concomitantly RB 0 0 14 O
. . 0 0 12 O

Use NNP 0 1 2 O
of IN 0 0 12 O
a DT 0 0 12 O
nonhormonal JJ 0 0 UNK B-Group
contraceptive JJ 0 1 13 I-Group
product NN 0 1 1 I-Group
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O

A DT 0 0 2 O
pharmacokinetic JJ 0 1 UNK O
study NN 0 1 1 O
evaluating VBG 1 1 1 O
the DT 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
INSPRA NNP 0 1 UNK B-Brand
9 CD 0 0 2 O
mg NN 0 1 0 O
with IN 0 0 12 O
ketoconazole JJ 0 1 16 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
BID NNP 0 0 11 O
a DT 0 0 12 O
potent JJ 0 1 UNK O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
the DT 0 0 12 O
CYP9A9 NNP 0 0 UNK O
pathway NN 0 1 UNK O
showed VBD 1 1 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
fold JJ 0 1 3 O
increase NN 0 1 1 O
in IN 0 0 12 O
Cmax NNP 0 1 UNK O
of IN 0 0 12 O
eplerenone NN 0 1 13 B-Drug
and CC 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
fold JJ 0 1 3 O
increase NN 0 1 1 O
in IN 0 0 12 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
eplerenone NN 0 1 13 B-Drug
. . 0 0 12 O

Available JJ 0 1 UNK O
data NNS 0 1 1 O
are VBP 1 0 12 O
neither DT 0 0 12 O
sufficient JJ 0 1 1 O
to TO 0 0 12 O
rule VB 0 1 1 O
out RP 0 1 12 O
possible JJ 0 1 1 O
increases NNS 1 1 1 O
in IN 0 0 12 O
serum NN 0 1 14 O
digoxin NN 0 1 14 B-Drug
with IN 0 0 12 O
concomitant JJ 0 1 6 O
treatment NN 0 1 6 O
in IN 0 0 12 O
some DT 0 0 12 O
patients NNS 1 1 6 O
nor CC 0 0 12 O
other JJ 0 0 12 O
possible JJ 0 1 1 O
interactions NNS 1 1 UNK O
particularly RB 0 0 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
cardiac JJ 0 1 6 O
conduction NN 0 1 6 O
abnormalities NNS 1 1 6 O
( ( 0 0 2 O
Also RB 0 0 2 O
see VBP 0 1 12 O
WARNINGS NNP 0 1 UNK O
Congestive NNP 0 1 7 O
Heart NNP 0 1 2 O
Failure NNP 0 1 2 O
) ) 0 0 2 O
. . 0 0 12 O

b NN 0 0 16 O
. . 0 0 12 O

No DT 0 0 2 O
pharmacokinetic JJ 0 1 UNK O
interaction NN 0 1 UNK O
was VBD 1 0 12 O
observed VBN 1 1 1 O
between IN 0 0 12 O
rivastigmine NN 0 1 16 B-Drug
and CC 0 0 12 O
digoxin NN 0 1 14 B-Drug
warfarin NN 0 1 14 B-Drug
diazepam NN 0 1 0 B-Drug
or CC 0 0 12 O
fluoxetine NN 0 1 16 B-Drug
in IN 0 0 12 O
studies NNS 1 1 1 O
in IN 0 0 12 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
. . 0 0 12 O

There EX 0 0 12 O
was VBD 1 0 12 O
no DT 0 0 12 O
evidence NN 0 1 1 O
in IN 0 0 12 O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
of IN 0 0 12 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
concurrent JJ 0 1 1 O
medications NNS 1 1 6 O
. . 0 0 12 O

This DT 0 0 2 O
slowing VBG 1 1 1 O
potentiates NNS 0 0 UNK O
amphetamines NNS 1 1 14 B-Group
increasing VBG 1 1 1 O
their PRP$ 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
release NN 0 1 12 O
of IN 0 0 12 O
norepinephrine NN 0 1 14 O
and CC 0 0 12 O
other JJ 0 0 12 O
monoamines NNS 1 1 UNK O
from IN 0 0 12 O
adrenergic JJ 0 1 UNK O
nerve NN 0 1 6 O
endings NNS 1 1 UNK O
; : 0 0 2 O

Hydrochlorothiazide NNP 0 1 0 B-Drug
( ( 0 0 2 O
HCTZ NNP 0 1 0 B-Drug
) ) 0 0 2 O
Alone RB 0 1 UNK O
or CC 0 0 12 O
in IN 0 0 12 O
Combination NNP 0 1 UNK O
with IN 0 0 12 O
Triamterene NNP 0 1 UNK B-Drug
: : 0 0 2 O
Concomitant NNP 0 1 UNK O
use NN 0 1 1 O
of IN 0 0 12 O
HCTZ NNP 0 1 0 B-Drug
alone RB 0 1 12 O
or CC 0 0 12 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
triamterene NN 0 1 13 B-Drug
is VBZ 1 0 12 O
contraindicated VBN 1 1 14 O
. . 0 0 12 O

Agents NNS 0 1 2 O
Having VBG 0 0 2 O
Vasodilator NNP 0 1 UNK O
Activity NN 0 1 2 O
: : 0 0 2 O
Data NNS 0 1 2 O
on IN 0 0 12 O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
concomitant NN 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
other JJ 0 0 12 O
vasodilators NNS 1 1 13 B-Group
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
captopril NN 0 1 0 B-Drug
for IN 0 0 12 O
heart NN 0 1 12 O
failure NN 0 1 1 O
are VBP 1 0 12 O
not RB 0 1 12 O
available JJ 0 1 1 O
; : 0 0 2 O

Hypotension NNP 0 1 7 O
AV NNP 0 0 13 O
conduction NN 0 1 6 O
disturbances NNS 1 1 6 O
and CC 0 0 12 O
left VBD 1 1 12 O
ventricular JJ 0 1 8 O
failure NN 0 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
some DT 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
beta SYM 0 1 16 B-Group
- : 0 0 2 O
adrenergic JJ 0 1 UNK I-Group
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
when WRB 0 0 12 O
an DT 0 0 12 O
oral JJ 0 1 6 O
calcium NN 0 1 14 B-Group
antagonist NN 0 1 13 I-Group
was VBD 1 0 12 O
added VBN 1 1 12 O
to TO 0 0 12 O
the DT 0 0 12 O
treatment NN 0 1 6 O
regimen NNS 0 1 6 O
. . 0 0 12 O

Acetazolamide NNP 0 1 0 B-Drug
increases VBZ 1 1 1 O
lithium JJ 0 1 16 B-Drug
excretion NN 0 1 14 O
and CC 0 0 12 O
the DT 0 0 12 O
lithium NN 0 1 16 B-Drug
may MD 0 0 1 O
be VB 0 0 12 O
decreased VBN 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
safety NN 0 1 1 O
and CC 0 0 12 O
efficacy NN 0 1 UNK O
of IN 0 0 12 O
AMEVIVE NNP 0 1 UNK B-Brand
in IN 0 0 12 O
pediatric JJ 0 1 6 O
patients NNS 1 1 6 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
studied VBN 1 0 1 O
. . 0 0 12 O

The DT 0 0 2 O
clinical JJ 0 1 6 O
relevance NN 0 1 UNK O
is VBZ 1 0 12 O
unclear JJ 0 0 1 O
. . 0 0 12 O

Therefore RB 0 0 1 O
physicians NNS 1 1 6 O
should MD 0 0 12 O
closely RB 0 0 1 O
monitor VB 0 1 1 O
patients NNS 1 1 6 O
for IN 0 0 12 O
a DT 0 0 12 O
change NN 0 1 1 O
in IN 0 0 12 O
anticoagulant JJ 0 1 13 B-Group
dosage NN 0 1 0 O
requirements NNS 1 1 1 O
when WRB 0 0 12 O
administering VBG 1 1 1 O
Mitotane NNP 0 1 UNK B-Drug
to TO 0 0 12 O
patients NNS 1 1 6 O
on IN 0 0 12 O
coumarin JJ 0 1 UNK B-Group
- : 0 0 2 O
type NN 0 1 1 I-Group
anticoagulants NNS 1 1 13 I-Group
. . 0 0 12 O

Furthermore RB 0 0 1 O
whenever WRB 0 0 12 O
one CD 0 1 12 O
of IN 0 0 12 O
these DT 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
is VBZ 1 0 12 O
withdrawn VBN 1 1 1 O
from IN 0 0 12 O
cotherapy NN 0 1 UNK O
an DT 0 0 12 O
increased VBN 1 1 1 O
dose NN 0 1 6 O
of IN 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressant NN 0 1 6 I-Group
may MD 0 0 1 O
be VB 0 0 12 O
required VBN 1 1 1 O
. . 0 0 12 O

Both DT 0 0 2 O
the DT 0 0 12 O
magnitude NN 0 1 UNK O
and CC 0 0 12 O
duration NN 0 1 1 O
of IN 0 0 12 O
central JJ 0 1 1 O
nervous JJ 0 1 6 O
system NN 0 1 1 O
and CC 0 0 12 O
cardiovascular JJ 0 1 6 O
effects NNS 1 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
enhanced VBN 1 1 1 O
when WRB 0 0 12 O
ALFENTA NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
administered VBN 1 1 1 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
other JJ 0 0 12 O
CNS NNP 0 1 6 B-Group
depressants NNS 1 0 13 I-Group
such JJ 0 0 1 O
as IN 1 0 12 O
barbiturates NNS 1 1 14 B-Group
tranquilizers NNS 1 1 13 B-Group
opioids NNS 0 1 14 B-Group
or CC 0 0 12 O
inhalation NN 0 1 16 O
general JJ 0 1 1 O
anesthetics NNS 1 1 13 B-Group
. . 0 0 12 O

Table JJ 0 1 UNK O
9a CD 0 1 UNK O
: : 0 0 2 O
Drugs NNS 0 1 2 O
That WDT 0 0 2 O
Should MD 0 0 2 O
Not RB 0 1 2 O
Be VB 0 0 UNK O
Coadministered VBN 0 0 UNK O
With IN 0 0 2 O
SUSTIVA NNP 0 1 UNK B-Brand

The DT 0 0 2 O
gastrointestinal JJ 0 1 6 O
absorption NN 0 1 1 O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
also RB 0 0 12 O
appears VBZ 1 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
inhibited VBN 1 1 13 O
. . 0 0 12 O

The DT 0 0 2 O
clinical JJ 0 1 6 O
significance NN 0 1 13 O
of IN 0 0 12 O
this DT 0 0 12 O
interaction NN 0 1 UNK O
in IN 0 0 12 O
preterm JJ 0 1 6 O
neonates NNS 1 1 16 O
is VBZ 1 0 12 O
not RB 0 1 12 O
known VBN 1 1 12 O
. . 0 0 12 O

The DT 0 0 2 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
eszopiclone NN 0 1 13 B-Drug
was VBD 1 0 12 O
increased VBN 1 1 1 O
9 CD 0 0 2 O
- : 0 0 2 O
fold VBN 0 1 3 O
by IN 0 0 12 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
ketoconazole NN 0 1 16 B-Drug
a DT 0 0 12 O
potent JJ 0 1 UNK O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
9 CD 0 0 2 O
mg NNS 0 1 0 O
daily RB 0 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
. . 0 0 12 O

9% CD 0 0 UNK O
9% CD 0 0 UNK O
9% CD 0 0 UNK O
9% CD 0 0 UNK O

This DT 0 0 2 O
risk NN 0 1 1 O
is VBZ 1 0 12 O
present JJ 0 1 1 O
whether IN 0 0 12 O
the DT 0 0 12 O
drugs NNS 1 1 6 O
are VBP 1 0 12 O
administered VBN 1 1 1 O
as IN 1 0 12 O
oral JJ 0 1 6 O
parenteral NN 0 1 14 O
or CC 0 0 12 O
topical JJ 0 1 6 O
formulations NNS 1 1 UNK O
. . 0 0 12 O

( ( 0 0 2 O
f NN 0 1 16 O
) ) 0 0 2 O
Sulfobromophthalein NNP 0 1 UNK O
and CC 0 0 12 O
other JJ 0 0 12 O
liver NN 0 1 6 O
function NN 0 1 1 O
test NN 0 1 1 O
values NNS 1 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
increased VBN 1 1 1 O
slightly RB 0 1 3 O
. . 0 0 12 O

- : 0 0 2 O
Carmustine NN 0 1 UNK B-Drug
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
BiCNU NNP 0 1 UNK B-Brand
) ) 0 0 2 O
or CC 0 0 12 O

Drug NNP 0 1 2 O
- : 0 0 2 O
Laboratory JJ 0 1 2 O
Test NNP 0 1 2 O
Interactions NNPS 0 1 UNK O
: : 0 0 2 O
There EX 0 0 12 O
are VBP 1 0 12 O
no DT 0 0 12 O
reported JJ 0 1 1 O
drug NN 0 1 1 O
- : 0 0 2 O
laboratory NN 0 1 1 O
test NN 0 1 1 O
interactions NNS 1 1 UNK O
. . 0 0 12 O

In IN 0 0 2 O
a DT 0 0 12 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
study NN 0 1 1 O
co SYM 0 1 12 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
orally RB 0 1 14 O
inhaled VBN 1 1 14 O
ciclesonide NN 0 1 13 B-Drug
and CC 0 0 12 O
oral JJ 0 1 6 O
erythromycin NN 0 1 0 B-Drug
an DT 0 0 12 O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
9A9 CD 0 0 UNK O
had VBD 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
either DT 0 1 12 O
des NNS 1 0 13 B-Drug
- : 0 0 2 O
ciclesonide NN 0 1 13 I-Drug
or CC 0 0 12 O
erythromycin NN 0 1 0 B-Drug
. . 0 0 12 O

tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
( ( 0 0 2 O
such JJ 0 0 1 O
as IN 1 0 12 O
amitriptyline NN 0 1 16 B-Drug
) ) 0 0 2 O
; : 0 0 2 O

Simultaneous JJ 0 1 UNK O
use NN 0 1 1 O
of IN 0 0 12 O
activated JJ 0 1 1 B-Group
prothrombin NN 0 1 14 I-Group
complex JJ 0 1 1 I-Group
concentrates NNS 1 1 UNK I-Group
or CC 0 0 12 O
prothrombin NN 0 1 14 B-Group
complex JJ 0 1 1 I-Group
concentrates NNS 1 1 UNK I-Group
should MD 0 0 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
. . 0 0 12 O

Pregnancy NN 0 1 7 O
: : 0 0 2 O
Category JJ 0 1 UNK O
X NN 0 0 2 O
: : 0 0 2 O
Use NN 0 1 2 O
With IN 0 0 2 O
Ribavirin NNP 0 1 0 B-Drug
( ( 0 0 2 O
see VB 0 1 12 O
CONTRAINDICATIONS NNP 0 1 0 O
) ) 0 0 2 O
Significant NNP 0 1 2 O
teratogenic JJ 0 1 UNK O
and CC 0 0 12 O
/ JJ 0 0 2 O
or CC 0 0 12 O
embryocidal JJ 0 0 UNK O
effects NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
demonstrated VBN 1 0 1 O
in IN 0 0 12 O
all DT 0 0 12 O
animal JJ 0 1 13 O
species NNS 1 1 1 O
exposed VBN 1 1 3 O
to TO 0 0 12 O
ribavirin VB 0 1 13 B-Drug
. . 0 0 12 O

When WRB 0 0 12 O
administering VBG 1 1 1 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
concurrently RB 0 0 1 O
one CD 0 1 12 O
should MD 0 0 12 O
be VB 0 0 12 O
alert VBN 0 1 12 O
for IN 0 0 12 O
possible JJ 0 1 1 O
excessive JJ 0 1 1 O
phenytoin NN 0 1 16 B-Drug
effect NN 0 1 1 O
. . 0 0 12 O

Midazolam NN 0 1 0 B-Drug
: : 0 0 2 O
Aprepitant NN 0 1 UNK B-Drug
increased VBD 1 1 1 O
the DT 0 0 12 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
midazolam NN 0 1 16 B-Drug
a DT 0 0 12 O
sensitive JJ 0 1 1 O
CYP9A9 NNP 0 0 UNK O
substrate NN 0 1 UNK O
by IN 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
fold NN 0 1 3 O
on IN 0 0 12 O
Day NNP 0 1 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
fold NN 0 1 3 O
on IN 0 0 12 O
Day NNP 0 1 2 O
9 CD 0 0 2 O
when WRB 0 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
oral JJ 0 1 6 O
dose NN 0 1 6 O
of IN 0 0 12 O
midazolam $ 0 1 16 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
was VBD 1 0 12 O
coadministered VBN 0 0 UNK O
on IN 0 0 12 O
Day NNP 0 1 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
Day NNP 0 1 2 O
9 CD 0 0 2 O
of IN 0 0 12 O
a DT 0 0 12 O
regimen NNS 0 1 6 O
of IN 0 0 12 O
Aprepitant NNP 0 1 UNK B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
on IN 0 0 12 O
Day NNP 0 1 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
on IN 0 0 12 O
Days NNS 0 1 2 O
9 CD 0 0 2 O
through IN 0 0 12 O
9 CD 0 0 2 O
. . 0 0 12 O

High JJ 0 1 2 O
- : 0 0 2 O
dose NN 0 1 6 O
cyclosporin VBZ 0 1 14 B-Drug
A DT 0 0 2 I-Drug
resulting VBG 1 1 1 O
in IN 0 0 12 O
concentrations NNS 1 1 13 O
above IN 0 1 12 O
9 CD 0 0 2 O
ng JJ 0 1 13 O
/ NNP 0 0 2 O
mL NN 0 1 14 O
administered VBD 1 1 1 O
with IN 0 0 12 O
oral JJ 0 1 6 O
etoposide NN 0 1 13 B-Drug
has VBZ 1 0 12 O
led VBN 1 1 12 O
to TO 0 0 12 O
an DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
increase NN 0 1 1 O
in IN 0 0 12 O
etoposide JJ 0 1 13 B-Drug
exposure NN 0 1 1 O
with IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
decrease NN 0 1 1 O
in IN 0 0 12 O
total JJ 0 1 1 O
body NN 0 1 3 O
clearance NN 0 1 16 O
of IN 0 0 12 O
etoposide NN 0 1 13 B-Drug
compared VBN 1 1 1 O
to TO 0 0 12 O
etoposide VB 0 1 13 B-Drug
alone RB 0 1 12 O
. . 0 0 12 O

Flurbiprofen NNP 0 1 UNK B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
affect VB 0 1 1 O
the DT 0 0 12 O
pharmacokinetic JJ 0 1 UNK O
profile NN 0 1 1 O
of IN 0 0 12 O
either CC 0 1 12 O
drug NN 0 1 1 O
and CC 0 0 12 O
the DT 0 0 12 O
mechanism NN 0 1 13 O
under IN 0 0 12 O
lying VBG 1 1 12 O
the DT 0 0 12 O
interference NN 0 1 13 O
with IN 0 0 12 O
propranolols NNS 0 0 UNK B-Drug
hypotensive JJ 0 1 14 O
effect NN 0 1 1 O
is VBZ 1 0 12 O
unknown JJ 0 1 12 O
. . 0 0 12 O

Co NNP 0 1 2 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
ZETIA NNP 0 1 UNK B-Brand
with IN 0 0 12 O
fibrates NNS 0 1 UNK B-Group
is VBZ 1 0 12 O
not RB 0 1 12 O
recommended VBN 1 1 1 O
until IN 0 0 12 O
use NN 0 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
is VBZ 1 0 12 O
studied VBN 1 0 1 O
. . 0 0 12 O

Coadministration NN 0 1 UNK O
of IN 0 0 12 O
valdecoxib NN 0 1 13 B-Drug
and CC 0 0 12 O
Ortho NNP 0 1 7 B-Brand
- : 0 0 2 O
Novum NN 0 0 UNK I-Brand
9 CD 0 0 2 O
/ JJ 0 0 2 O
9 CD 0 0 2 O
increased VBD 1 1 1 O
the DT 0 0 12 O
exposure NN 0 1 1 O
of IN 0 0 12 O
norethindrone NN 0 1 13 B-Drug
and CC 0 0 12 O
ethinyl NN 0 0 13 B-Drug
estradiol NN 0 1 13 I-Drug
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
respectively RB 0 0 1 O
. . 0 0 12 O

Total JJ 0 1 2 O
body NN 0 1 3 O
clearance NN 0 1 16 O
of IN 0 0 12 O
Simulect NNP 0 1 UNK B-Brand
was VBD 1 0 12 O
reduced VBN 1 1 1 O
by IN 0 0 12 O
an DT 0 0 12 O
average JJ 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
when WRB 0 0 12 O
azathioprine NN 0 1 13 B-Drug
and CC 0 0 12 O
mycophenolate NN 0 1 0 B-Drug
mofetil NNS 0 0 16 I-Drug
respectively RB 0 0 1 O
were VBD 1 0 12 O
added VBN 1 1 12 O
to TO 0 0 12 O
a DT 0 0 12 O
regimen NNS 0 1 6 O
consisting VBG 1 1 1 O
of IN 0 0 12 O
cyclosporine NN 0 1 14 B-Drug
USP NNP 0 1 UNK O
( ( 0 0 2 O
MODIFIED NNP 0 1 UNK O
) ) 0 0 2 O
and CC 0 0 12 O
corticosteroids NNS 1 1 14 B-Group
. . 0 0 12 O

Bactericidal NNP 0 1 UNK O
agents NNS 1 1 1 O
work VBP 0 1 12 O
most RBS 0 0 12 O
effectively RB 0 0 1 O
against IN 0 0 12 O
the DT 0 0 12 O
immature NN 0 1 12 O
cell NN 0 1 1 O
wall NN 0 1 3 O
of IN 0 0 12 O
rapidly RB 0 1 1 O
proliferating VBG 1 1 UNK O
microorganisms NNS 1 1 13 O
. . 0 0 12 O

Since IN 0 1 2 O
barbiturates NNS 1 1 14 B-Group
are VBP 1 0 12 O
potentiated VBN 1 0 UNK O
by IN 0 0 12 O
the DT 0 0 12 O
anticholinesterases NNS 1 1 UNK B-Group
they PRP 0 0 12 O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
cautiously RB 0 0 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
treatment NN 0 1 6 O
of IN 0 0 12 O
convulsions NNS 1 1 13 O
. . 0 0 12 O

When WRB 0 0 12 O
other JJ 0 0 12 O
antiplatelet NN 0 0 13 B-Group
agents NNS 1 1 1 I-Group
or CC 0 0 12 O
anticoagulants NNS 1 1 13 B-Group
are VBP 1 0 12 O
used VBN 1 1 12 O
concomitantly RB 0 0 14 O
there EX 0 0 12 O
is VBZ 1 0 12 O
the DT 0 0 12 O
potential JJ 0 1 1 O
for IN 0 0 12 O
FLOLAN NNP 0 1 UNK B-Brand
to TO 0 0 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
bleeding NN 0 1 6 O
. . 0 0 12 O

No DT 0 0 2 O
significant JJ 0 1 1 O
interaction NN 0 1 UNK O
has VBZ 1 0 12 O
been VBN 1 0 12 O
found VBN 1 1 12 O
with IN 0 0 12 O
broad JJ 0 1 1 O
- : 0 0 2 O
spectrum NN 0 1 1 O
antibiotics NNS 1 1 6 B-Group
. . 0 0 12 O

Inhibitors NNS 0 1 7 O
of IN 0 0 12 O
this DT 0 0 12 O
isoenzyme NN 0 1 13 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
macrolide NN 0 1 UNK B-Group
antibiotics NNS 1 1 6 I-Group
azole JJ 0 1 UNK B-Group
antifungal JJ 0 1 14 I-Group
agents NNS 1 1 1 I-Group
protease JJ 0 1 13 B-Group
inhibitors NNS 1 1 14 I-Group
serotonin VBP 0 1 13 B-Group
reuptake JJ 0 1 13 I-Group
inhibitors NNS 1 1 14 I-Group
amiodarone VBP 0 1 0 B-Drug
cannabinoids NNS 0 1 UNK B-Group
diltiazem VBP 0 1 0 B-Drug
grapefruit NN 0 1 3 O
juice NN 0 1 3 O
nefazadone NN 0 0 UNK B-Drug
norfloxacin JJ 0 1 UNK B-Drug
quinine NN 0 1 16 B-Drug
zafirlukast NN 0 1 13 B-Drug
) ) 0 0 2 O
should MD 0 0 12 O
be VB 0 0 12 O
cautiously RB 0 0 UNK O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
TIKOSYN NNP 0 1 UNK B-Brand
as IN 1 0 12 O
they PRP 0 0 12 O
can MD 0 0 12 O
potentially RB 0 0 1 O
increase VB 0 1 1 O
dofetilide NN 0 1 13 B-Drug
levels NNS 1 1 1 O
. . 0 0 12 O

PROSTIN NNP 0 1 UNK B-Brand
E9 NNP 0 0 UNK I-Brand
may MD 0 0 1 O
augment VB 0 1 13 O
the DT 0 0 12 O
activity NN 0 1 1 O
of IN 0 0 12 O
other JJ 0 0 12 O
oxytocic JJ 0 1 13 B-Group
drugs NNS 1 1 6 I-Group
. . 0 0 12 O

Concurrent NNP 0 1 13 O
use NN 0 1 1 O
of IN 0 0 12 O
tetracyclines NNS 1 1 13 B-Group
with IN 0 0 12 O
oral JJ 0 1 6 O
contraceptives NNS 1 1 13 B-Group
may MD 0 0 1 O
render VB 0 0 13 O
oral JJ 0 1 6 O
contraceptives NNS 1 1 13 B-Group
less RBR 0 1 12 O
effective JJ 0 1 1 O
. . 0 0 12 O

HMG NNP 0 0 UNK B-Group
- : 0 0 2 O
CoA NNP 0 0 UNK I-Group
reductase NN 0 1 UNK I-Group
inhibitors NNS 1 1 14 I-Group
: : 0 0 2 O
The DT 0 0 2 O
combined JJ 0 1 1 O
use NN 0 1 1 O
of IN 0 0 12 O
TRICOR NNP 0 1 UNK B-Brand
and CC 0 0 12 O
HMG NNP 0 0 UNK B-Group
- : 0 0 2 O
CoA NNP 0 0 UNK I-Group
reductase NN 0 1 UNK I-Group
inhibitors NNS 1 1 14 I-Group
should MD 0 0 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
unless IN 0 0 12 O
the DT 0 0 12 O
benefit NN 0 1 1 O
of IN 0 0 12 O
further JJ 0 1 1 O
alterations NNS 1 1 1 O
in IN 0 0 12 O
lipid JJ 0 1 14 O
levels NNS 1 1 1 O
is VBZ 1 0 12 O
likely JJ 0 1 12 O
to TO 0 0 12 O
outweigh VB 0 0 1 O
the DT 0 0 12 O
increased VBN 1 1 1 O
risk NN 0 1 1 O
of IN 0 0 12 O
this DT 0 0 12 O
drug NN 0 1 1 O
combination NN 0 1 1 O
. . 0 0 12 O

Acarbose RB 0 1 UNK B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
absorption NN 0 1 1 O
or CC 0 0 12 O
disposition NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
sulfonylurea JJ 0 1 UNK B-Drug
glyburide NN 0 1 16 B-Drug
in IN 0 0 12 O
diabetic JJ 0 1 6 O
patients NNS 1 1 6 O
. . 0 0 12 O

Patients NNS 0 1 7 O
studied VBN 1 0 1 O
in IN 0 0 12 O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
of IN 0 0 12 O
TNKase NNP 0 1 UNK B-Brand
were VBD 1 0 12 O
routinely RB 0 0 1 O
treated VBN 1 1 1 O
with IN 0 0 12 O
heparin NN 0 1 14 B-Drug
and CC 0 0 12 O
aspirin NN 0 1 14 B-Brand
. . 0 0 12 O

There EX 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
greater JJR 1 1 1 O
than IN 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
fold NN 0 1 3 O
increases NNS 1 1 1 O
in IN 0 0 12 O
previously RB 0 0 1 O
stable JJ 0 1 1 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
other JJ 0 0 12 O
antidepressants NNS 1 1 13 B-Group
including VBG 1 1 1 O
nortriptyline NN 0 1 16 B-Drug
when WRB 0 0 12 O
fluoxetine NN 0 1 16 B-Drug
hydrochloride NN 0 1 0 I-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
administered VBN 1 1 1 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
these DT 0 0 12 O
agents NNS 1 1 1 O
. . 0 0 12 O

Toxicity NN 0 1 UNK O
associated VBN 1 1 1 O
with IN 0 0 12 O
concomitant JJ 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
aerosolized JJ 0 1 UNK O
pentamidine NN 0 1 14 B-Drug
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
. . 0 0 12 O

9 CD 0 0 2 O
. . 0 0 12 O

May NNP 0 1 2 O
lead NN 0 1 12 O
to TO 0 0 12 O
loss NN 0 1 1 O
of IN 0 0 12 O
virologic JJ 0 1 UNK O
response NN 0 1 1 O
and CC 0 0 12 O
possible JJ 0 1 1 O
resistance NN 0 1 1 O
to TO 0 0 12 O
CRIXIVAN NNP 0 1 UNK B-Brand
or CC 0 0 12 O
to TO 0 0 12 O
the DT 0 0 12 O
class NN 0 1 12 O
of IN 0 0 12 O
protease NN 0 1 13 B-Group
inhibitors NNS 1 1 14 I-Group
or CC 0 0 12 O
other JJ 0 0 12 O
coadministered JJ 0 0 UNK O
antiretroviral JJ 0 0 UNK B-Group
agents NNS 1 1 1 I-Group
. . 0 0 12 O

In IN 0 0 2 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
shown VBN 1 1 1 O
that IN 0 0 12 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
docetaxel NN 0 1 13 B-Drug
may MD 0 0 1 O
be VB 0 0 12 O
modified VBN 1 1 16 O
by IN 0 0 12 O
the DT 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
compounds NNS 1 1 13 O
that WDT 0 0 12 O
induce VBP 0 1 6 O
inhibit NN 0 1 13 O
or CC 0 0 12 O
are VBP 1 0 12 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
9A9 CD 0 0 UNK O
such JJ 0 0 1 O
as IN 1 0 12 O
cyclosporine JJ 0 1 14 B-Drug
terfenadine NN 0 1 UNK B-Drug
ketoconazole NN 0 1 16 B-Drug
erythromycin NN 0 1 0 B-Drug
and CC 0 0 12 O
troleandomycin NN 0 1 UNK B-Drug
. . 0 0 12 O

The DT 0 0 2 O
combination NN 0 1 1 O
is VBZ 1 0 12 O
well RB 0 1 12 O
tolerated VBN 1 0 1 O
. . 0 0 12 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interactions NNP 0 1 UNK O
As IN 0 0 2 O
a DT 0 0 12 O
result NN 0 1 1 O
of IN 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
Keflex NNP 0 1 0 B-Brand
a DT 0 0 12 O
false JJ 0 1 13 O
- : 0 0 2 O
positive JJ 0 1 1 O
reaction NN 0 1 1 O
for IN 0 0 12 O
glucose NN 0 1 14 O
in IN 0 0 12 O
the DT 0 0 12 O
urine NN 0 1 6 O
may MD 0 0 1 O
occur VB 0 1 1 O
. . 0 0 12 O

Concomitant JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
Robinul NNP 0 1 UNK B-Brand
Injection NNP 0 1 7 O
and CC 0 0 12 O
potassium NN 0 1 14 B-Drug
chloride NN 0 1 14 I-Drug
in IN 0 0 12 O
a DT 0 0 12 O
wax JJ 0 1 13 O
matrix NN 0 1 1 O
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
severity NN 0 1 6 O
of IN 0 0 12 O
potassium NN 0 1 14 O
chloride NN 0 1 14 O
- : 0 0 2 O
induced JJ 0 1 6 O
gastrointestinal JJ 0 1 6 O
lesions NNS 1 1 6 O
as IN 1 0 12 O
a DT 0 0 12 O
result NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
slower JJR 1 1 UNK O
gastrointestinal JJ 0 1 6 O
transit NN 0 1 1 O
time NN 0 1 12 O
. . 0 0 12 O

In IN 0 0 2 O
addition NN 0 1 1 O
under IN 0 0 12 O
the DT 0 0 12 O
influence NN 0 0 UNK O
of IN 0 0 12 O
sympatholytic JJ 0 1 UNK O
medicinal JJ 0 0 16 O
products NNS 1 1 1 O
such JJ 0 0 1 O
as IN 1 0 12 O
beta NN 0 1 16 B-Group
- : 0 0 2 O
blockers NNS 1 0 6 I-Group
clonidine VBP 0 1 0 B-Drug
guanethidine NN 0 1 UNK B-Drug
and CC 0 0 12 O
reserpine VB 0 1 UNK B-Drug
the DT 0 0 12 O
signs NNS 1 1 12 O
of IN 0 0 12 O
hypoglycemia NN 0 1 6 O
may MD 0 0 1 O
be VB 0 0 12 O
reduced VBN 1 1 1 O
or CC 0 0 12 O
absent NN 0 1 1 O
. . 0 0 12 O

Butalbital NNP 0 1 0 B-Drug
acetaminophen NN 0 1 16 B-Drug
and CC 0 0 12 O
caffeine NN 0 1 6 B-Drug
may MD 0 0 1 O
enhance VB 0 1 UNK O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
: : 0 0 2 O
other JJ 0 0 12 O
narcotic JJ 0 1 6 B-Group
analgesics NNS 1 1 14 I-Group
alcohol IN 0 1 1 B-Drug
general JJ 0 1 1 O
anesthetics NNS 1 1 13 B-Group
tranquilizers NNS 1 1 13 B-Group
such JJ 0 0 1 O
as IN 1 0 12 O
chlordiazepoxide NN 0 1 16 B-Drug
sedative JJ 0 1 6 B-Group
- : 0 0 2 O
hypnotics NNS 1 1 13 I-Group
or CC 0 0 12 O
other JJ 0 0 12 O
CNS NNP 0 1 6 B-Group
depressants NNS 1 0 13 I-Group
causing VBG 1 1 1 O
increased VBD 1 1 1 O
CNS NNP 0 1 6 O
depression NN 0 1 6 O
. . 0 0 12 O

Combination NN 0 1 UNK O
with IN 0 0 12 O
tramadol NN 0 1 16 B-Drug
( ( 0 0 2 O
Ultram NNP 0 1 0 B-Brand
) ) 0 0 2 O
is VBZ 1 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
increased JJ 0 1 1 O
risk NN 0 1 1 O
of IN 0 0 12 O
seizures NNS 1 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
specific JJ 0 1 1 O
pharmacokinetic JJ 0 1 UNK O
changes NNS 1 1 1 O
that WDT 0 0 12 O
occur VBP 0 1 1 O
with IN 0 0 12 O
co NN 0 1 12 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
nevirapine JJ 0 1 13 B-Drug
and CC 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
are VBP 1 0 12 O
listed VBN 1 1 1 O
in IN 0 0 12 O
CLINICAL NNP 0 1 11 O
PHARMACOLOGY NNP 0 1 UNK O
Table NNP 0 1 UNK O
9 CD 0 0 2 O
. . 0 0 12 O

Serotonergic JJ 0 0 UNK B-Group
Agents NNS 0 1 2 I-Group
: : 0 0 2 O
Co NNP 0 1 2 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
linezolid JJ 0 1 0 B-Drug
and CC 0 0 12 O
serotonergic JJ 0 0 UNK B-Group
agents NNS 1 1 1 I-Group
was VBD 1 0 12 O
not RB 0 1 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
serotonin JJ 0 1 13 O
syndrome NN 0 1 6 O
in IN 0 0 12 O
Phase NNP 0 1 UNK O
9 CD 0 0 2 O
9 CD 0 0 2 O
or CC 0 0 12 O
9 CD 0 0 2 O
studies NNS 1 1 1 O
. . 0 0 12 O

No DT 0 0 2 O
CNS NNP 0 1 6 O
lesions NNS 1 1 6 O
have VBP 0 0 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
in IN 0 0 12 O
mice NN 1 1 UNK O
after IN 0 0 12 O
chronic JJ 0 1 6 O
treatment NN 0 1 6 O
for IN 0 0 12 O
up IN 0 0 12 O
to TO 0 0 12 O
9 CD 0 0 2 O
years NNS 1 1 12 O
at IN 0 0 12 O
doses VBZ 1 1 6 O
up RB 0 0 12 O
to TO 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
kg JJ 0 1 18 O
/ JJ 0 0 2 O
day NN 0 1 12 O
or CC 0 0 12 O
in IN 0 0 12 O
rats NNS 1 1 UNK O
at IN 0 0 12 O
doses NNS 1 1 6 O
up RB 0 0 12 O
to TO 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
kg JJ 0 1 18 O
/ NNP 0 0 2 O
day NN 0 1 12 O
. . 0 0 12 O

There EX 0 0 12 O
are VBP 1 0 12 O
few JJ 0 1 12 O
data NNS 0 1 1 O
regarding VBG 1 0 1 O
the DT 0 0 12 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
radiation NN 0 1 1 O
therapy NN 0 1 6 O
and CC 0 0 12 O
epirubicin NN 0 1 13 B-Drug
. . 0 0 12 O

Grapefruit NNP 0 1 UNK O
juice NN 0 1 3 O
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
taken VBN 1 1 12 O
during IN 0 0 12 O
treatment NN 0 1 6 O
with IN 0 0 12 O
oral JJ 0 1 6 O
amiodarone NN 0 1 0 O
. . 0 0 12 O

Other JJ 0 0 2 O
drugs NNS 1 1 6 O
which WDT 0 0 12 O
may MD 0 0 1 O
enhance VB 0 1 UNK O
the DT 0 0 12 O
neuromuscular JJ 0 1 6 O
blocking VBG 1 1 UNK O
action NN 0 1 13 O
of IN 0 0 12 O
nondepolarizing VBG 0 0 UNK B-Drug
agents NNS 1 1 1 I-Drug
such JJ 0 0 1 O
as IN 1 0 12 O
MIVACRON NNP 0 1 UNK B-Brand
include VBP 0 1 1 O
certain JJ 0 1 1 O
antibiotics NNS 1 1 6 B-Group
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
aminoglycosides NNS 0 1 13 B-Group
tetracyclines NNS 1 1 13 B-Group
bacitracin VBP 0 1 16 B-Drug
polymyxins NNS 1 1 UNK B-Group
lincomycin JJ 0 1 UNK B-Drug
clindamycin NN 0 1 0 B-Drug
colistin NN 0 1 13 B-Drug
and CC 0 0 12 O
sodium NN 0 1 14 B-Drug
colistimethate NN 0 1 13 I-Drug
) ) 0 0 2 O
magnesium NN 0 1 14 B-Group
salts NNS 1 1 13 O
lithium JJ 0 1 16 B-Drug
local JJ 0 1 12 O
anesthetics NNS 1 1 13 B-Group
procainamide NN 0 1 16 B-Drug
and CC 0 0 12 O
quinidine NN 0 1 16 B-Drug
. . 0 0 12 O

Beta NNP 0 1 2 B-Group
- : 0 0 2 O
blockers NNS 1 0 6 I-Group
clonidine VBP 0 1 0 B-Drug
lithium NN 0 1 16 B-Drug
salts NNS 1 1 13 O
and CC 0 0 12 O
alcohol NN 0 1 1 B-Drug
may MD 0 0 1 O
either VB 0 1 12 O
potentiate NN 0 0 UNK O
or CC 0 0 12 O
weaken VB 0 0 UNK O
the DT 0 0 12 O
blood NN 0 1 6 O
- : 0 0 2 O
glucose JJ 0 1 14 O
- : 0 0 2 O
lowering VBG 1 1 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
insulin NN 0 1 14 B-Drug
. . 0 0 12 O

therefore RB 0 0 1 O
results NNS 1 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
test NN 0 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
inaccurate JJ 0 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
phenytoin NN 0 1 16 B-Drug
within IN 0 0 1 O
two CD 0 1 12 O
weeks NNS 1 1 12 O
before IN 0 1 12 O
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
reasonable JJ 0 0 1 O
to TO 0 0 12 O
employ VB 0 1 UNK O
appropriate JJ 0 1 1 O
clinical JJ 0 1 6 O
monitoring NN 0 1 1 O
when WRB 0 0 12 O
potent JJ 0 1 UNK O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
enzyme VBZ 0 1 14 O
inducers NNS 1 1 UNK O
such JJ 0 0 1 O
as IN 1 0 12 O
phenobarbital NN 0 1 16 B-Drug
or CC 0 0 12 O
rifampin NN 0 1 16 B-Drug
are VBP 1 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
with IN 0 0 12 O
montelukast NN 0 1 16 B-Drug
. . 0 0 12 O

Effects NNS 0 1 UNK O
of IN 0 0 12 O
Vardenafil NNP 0 1 UNK B-Drug
on IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O

Impaired NNP 0 1 UNK O
glucose VBD 0 1 14 O
tolerance NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
following JJ 0 1 1 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
with IN 0 0 12 O
erythromycin NN 0 1 0 B-Drug
products NNS 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
mechanism NN 0 1 13 O
for IN 0 0 12 O
this DT 0 0 12 O
interaction NN 0 1 UNK O
is VBZ 1 0 12 O
unknown JJ 0 1 12 O
. . 0 0 12 O

Therefore RB 0 0 1 O
when WRB 0 0 12 O
using VBG 1 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
Trileptal NNP 0 1 UNK B-Brand
greater JJR 1 1 1 O
than IN 0 0 12 O
9 CD 0 0 2 O
mg JJ 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
during IN 0 0 12 O
adjunctive JJ 0 1 13 O
therapy NN 0 1 6 O
a DT 0 0 12 O
decrease NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
may MD 0 0 1 O
be VB 0 0 12 O
required VBN 1 1 1 O
. . 0 0 12 O

Indinavir NN 0 1 UNK B-Drug

Cssmax NNP 0 0 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
metabolite JJ 0 1 UNK O
ucb JJ 0 0 UNK O
L9 NNP 0 1 UNK O
was VBD 1 0 12 O
approximately RB 0 1 1 O
doubled VBN 1 1 12 O
in IN 0 0 12 O
the DT 0 0 12 O
presence NN 0 1 1 O
of IN 0 0 12 O
probenecid NN 0 1 13 B-Drug
while IN 0 0 12 O
the DT 0 0 12 O
fraction NN 0 1 1 O
of IN 0 0 12 O
drug NN 0 1 1 O
excreted VBN 1 1 UNK O
unchanged JJ 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
urine NN 0 1 6 O
remained VBD 1 0 12 O
the DT 0 0 12 O
same JJ 0 1 12 O
. . 0 0 12 O

Since IN 0 1 2 O
symptoms NNS 1 1 6 O
of IN 0 0 12 O
anticholinesterase NN 0 1 UNK O
overdose NN 0 1 6 O
( ( 0 0 2 O
cholinergic JJ 0 1 13 O
crisis NN 0 1 12 O
) ) 0 0 2 O
may MD 0 0 1 O
mimic VB 0 0 UNK O
underdosage NN 0 0 UNK O
( ( 0 0 2 O
myasthenic JJ 0 0 13 O
weakness NN 0 1 6 O
) ) 0 0 2 O
their PRP$ 0 0 12 O
condition NN 0 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
worsened VBN 1 1 6 O
by IN 0 0 12 O
the DT 0 0 12 O
use NN 0 1 1 O
of IN 0 0 12 O
this DT 0 0 12 O
drug NN 0 1 1 O
. . 0 0 12 O

Furosemide NNP 0 1 0 B-Drug
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
ototoxic JJ 0 1 UNK O
potential NN 0 1 1 O
of IN 0 0 12 O
aminoglycoside JJ 0 1 14 B-Group
antibiotics NNS 1 1 6 I-Group
especially RB 0 0 12 O
in IN 0 0 12 O
the DT 0 0 12 O
presence NN 0 1 1 O
of IN 0 0 12 O
impaired JJ 0 1 6 O
renal JJ 0 1 6 O
function NN 0 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
FORADIL NNP 0 1 UNK B-Brand
other JJ 0 0 12 O
inhaled VBD 1 1 14 O
medications NNS 1 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
only RB 0 1 12 O
as IN 1 0 12 O
directed VBN 1 1 1 O
by IN 0 0 12 O
the DT 0 0 12 O
physician NN 0 1 6 O
. . 0 0 12 O

- : 0 0 2 O
Divalproex NN 0 1 0 B-Drug
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
Depakote NNP 0 1 0 B-Brand
) ) 0 0 2 O
or CC 0 0 12 O

Pentamidine NN 0 1 0 B-Drug
may MD 0 0 1 O
cause VB 0 1 12 O
hypoglycemia NN 0 1 6 O
which WDT 0 0 12 O
may MD 0 0 1 O
sometimes RB 0 1 12 O
be VB 0 0 12 O
followed VBN 1 1 12 O
by IN 0 0 12 O
hyperglycemia NN 0 1 14 O
. . 0 0 12 O

- : 0 0 2 O
phenytoin NN 0 1 16 B-Drug
( ( 0 0 2 O
Dilantin NNP 0 1 0 B-Brand
) ) 0 0 2 O
; : 0 0 2 O

Rifampin NN 0 1 0 B-Drug

Amiodarone NN 0 1 0 B-Drug
is VBZ 1 0 12 O
also RB 0 0 12 O
known VBN 1 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
an DT 0 0 12 O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
. . 0 0 12 O

Therefore RB 0 0 1 O
you PRP 0 0 12 O
may MD 0 0 1 O
need VB 0 1 12 O
to TO 0 0 12 O
take VB 0 1 12 O
a DT 0 0 12 O
vitamin NN 0 1 6 B-Drug
B9 NNP 0 0 UNK I-Drug
supplement NN 0 1 1 O
while IN 0 0 12 O
taking VBG 1 0 12 O
aminosalicylic JJ 0 0 UNK B-Drug
acid NN 0 1 14 I-Drug
. . 0 0 12 O

amiodarone NN 0 1 0 B-Drug
; : 0 0 2 O

Orlistat NNP 0 1 UNK B-Drug
- : 0 0 2 O
Orlistat NN 0 1 UNK B-Drug
may MD 0 0 1 O
decrease VB 0 1 1 O
the DT 0 0 12 O
absorption NN 0 1 1 O
of IN 0 0 12 O
vitamin NN 0 1 6 B-Group
K NNP 0 1 2 I-Group
. . 0 0 12 O

However RB 0 0 1 O
initial JJ 0 1 1 O
dose JJ 0 1 6 O
modification NN 0 1 1 O
is VBZ 1 0 12 O
generally RB 0 0 1 O
not RB 0 1 12 O
necessary JJ 0 0 1 O
. . 0 0 12 O

It PRP 0 0 12 O
may MD 0 0 1 O
also RB 0 0 12 O
produce VB 0 0 1 O
artifactually RB 0 0 UNK O
low JJ 0 1 1 O
results NNS 1 1 1 O
in IN 0 0 12 O
dexamethasone NN 0 1 16 O
or CC 0 0 12 O
metyrapone NN 0 1 13 O
tests NNS 1 1 1 O
. . 0 0 12 O

Anticholinergic NNP 0 1 UNK B-Group
drugs NNS 1 1 6 I-Group
may MD 0 0 1 O
antagonize VB 0 0 UNK O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
alter VBP 0 1 13 O
gastrointestinal JJ 0 1 6 O
motility NN 0 1 6 O
such JJ 0 0 1 O
as IN 1 0 12 O
metoclopramide NN 0 1 16 B-Drug
. . 0 0 12 O

Therefore RB 0 0 1 O
the DT 0 0 12 O
potential JJ 0 1 1 O
exists NNS 0 1 UNK O
for IN 0 0 12 O
interaction NN 0 1 UNK O
between IN 0 0 12 O
carbamazepine NN 0 1 16 B-Drug
and CC 0 0 12 O
any DT 0 0 12 O
agent JJ 0 1 1 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
one CD 0 1 12 O
( ( 0 0 2 O
or CC 0 0 12 O
more JJR 0 1 12 O
) ) 0 0 2 O
of IN 0 0 12 O
these DT 0 0 12 O
enzymes NNS 1 1 14 O
. . 0 0 12 O

Effect NN 0 1 UNK O
of IN 0 0 12 O
Other JJ 0 0 2 O
Drugs NNP 0 1 2 O
on IN 0 0 12 O
the DT 0 0 12 O
Metabolism NNP 0 1 UNK O
of IN 0 0 12 O
Exelon NNP 0 1 UNK B-Brand
: : 0 0 2 O
Drugs NNS 0 1 2 O
that IN 0 0 12 O
induce NN 0 1 6 O
or CC 0 0 12 O
inhibit NN 0 1 13 O
CYP9 JJ 0 0 UNK O
metabolism NN 0 1 16 O
are VBP 1 0 12 O
not RB 0 1 12 O
expected VBN 1 1 12 O
to TO 0 0 12 O
alter VB 0 1 13 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
rivastigmine NN 0 1 16 B-Drug
. . 0 0 12 O

CYP9A9 NNP 0 0 UNK B-Drug
Inhibitors NNP 0 1 7 O
Felodipine NNP 0 1 UNK O
is VBZ 1 0 12 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
CYP9A9 NNP 0 0 UNK B-Drug
. . 0 0 12 O

Drug NNP 0 1 2 O
laboratory NN 0 1 1 O
Test NNP 0 1 2 O
Interactions NNP 0 1 UNK O
Serum NNP 0 1 7 O
Salicylate NNP 0 1 UNK O
Assays NNS 0 1 UNK O
: : 0 0 2 O
Caution NN 0 0 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
in IN 0 0 12 O
interpreting VBG 1 1 UNK O
the DT 0 0 12 O
results NNS 1 1 1 O
of IN 0 0 12 O
serum JJ 0 1 14 O
salicylate NN 0 1 13 O
assays NNS 1 1 13 O
when WRB 0 0 12 O
diflunisal NN 0 1 13 B-Drug
is VBZ 1 0 12 O
present JJ 0 1 1 O
. . 0 0 12 O

Caution NN 0 0 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
exercised VBN 1 1 1 O
if IN 0 0 12 O
tacrolimus NN 0 1 16 B-Drug
and CC 0 0 12 O
bosentan NN 0 1 13 B-Drug
are VBP 1 0 12 O
used VBN 1 1 12 O
together RB 0 1 12 O
. . 0 0 12 O

Pharmacokinetic NNP 0 1 UNK O
data NNS 0 1 1 O
indicate VBP 0 0 1 O
that IN 0 0 12 O
ketoconazole NN 0 1 16 B-Drug
markedly RB 0 1 1 O
inhibits VBZ 1 1 UNK O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
terfenadine NN 0 1 UNK B-Drug
resulting VBG 1 1 1 O
in IN 0 0 12 O
elevated VBN 1 1 1 O
plasma NN 0 1 14 O
terfenadine NN 0 1 UNK B-Drug
levels NNS 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
immediate JJ 0 1 1 O
release NN 0 1 12 O
but CC 0 0 12 O
not RB 0 1 12 O
the DT 0 0 12 O
coat NN 0 1 UNK O
- : 0 0 2 O
core NN 0 1 1 O
formulation NN 0 1 13 O
of IN 0 0 12 O
nisoldipine NN 0 1 13 B-Drug
increased VBN 1 1 1 O
plasma JJ 0 1 14 O
quinidine NN 0 1 16 B-Drug
concentrations NNS 1 1 13 O
by IN 0 0 12 O
about IN 0 1 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

consideration NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
given VBN 1 1 12 O
to TO 0 0 12 O
possible JJ 0 1 1 O
CNS NNP 0 1 6 O
and CC 0 0 12 O
other JJ 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
alcohol NN 0 1 1 B-Drug
. . 0 0 12 O

If IN 0 0 12 O
at IN 0 0 12 O
all DT 0 0 12 O
possible JJ 0 1 1 O
guanethidine NN 0 1 UNK B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
discontinued VBN 1 1 1 O
well RB 0 1 12 O
before IN 0 1 12 O
minoxidil NN 0 1 16 B-Drug
is VBZ 1 0 12 O
begun VBN 1 1 12 O
. . 0 0 12 O

Co NNP 0 1 2 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
ketoconazole FW 0 1 16 B-Drug
a DT 0 0 12 O
strong JJ 0 1 12 O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
increased VBD 1 1 1 O
cinacalcet JJ 0 1 16 B-Drug
exposure NN 0 1 1 O
following VBG 1 1 1 O
a DT 0 0 12 O
single JJ 0 1 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
dose NN 0 1 6 O
of IN 0 0 12 O
Sensipar NNP 0 1 UNK B-Brand
by IN 0 0 12 O
9 CD 0 0 2 O
fold NN 0 1 3 O
. . 0 0 12 O

- : 0 0 2 O
Dapsone NN 0 1 0 B-Drug
or CC 0 0 12 O

The DT 0 0 2 O
risk NN 0 1 1 O
of IN 0 0 12 O
using VBG 1 1 1 O
loxapine NN 0 1 16 B-Drug
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
CNS NNP 0 1 6 O
- : 0 0 2 O
active JJ 0 1 1 O
drugs NNS 1 1 6 O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
systematically RB 0 0 UNK O
evaluated VBN 1 1 1 O
. . 0 0 12 O

although IN 0 0 12 O
this DT 0 0 12 O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
specifically RB 0 0 1 O
studied VBN 1 0 1 O
. . 0 0 12 O

9% CD 0 0 UNK O
9% CD 0 0 UNK O
- : 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
- : 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O

Administration NN 0 1 UNK O
of IN 0 0 12 O
valproic JJ 0 0 16 B-Drug
acid NN 0 1 14 I-Drug
decreases VBZ 1 1 UNK O
oral JJ 0 1 6 O
clearance NN 0 1 16 O
of IN 0 0 12 O
temozolomide NN 0 1 13 B-Drug
by IN 0 0 12 O
about IN 0 1 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

Therefore RB 0 0 1 O
caffeine NN 0 1 6 B-Drug
has VBZ 1 0 12 O
the DT 0 0 12 O
potential JJ 0 1 1 O
to TO 0 0 12 O
interact VB 0 0 UNK O
with IN 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
are VBP 1 0 12 O
substrates VBZ 0 1 UNK O
for IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
inhibit NN 0 1 13 O
CYP9A9 NNP 0 0 UNK O
or CC 0 0 12 O
induce VB 0 1 6 O
CYP9A9 NNP 0 0 UNK O
. . 0 0 12 O

Drug NNP 0 1 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interactions NNP 0 1 UNK O
None NNP 0 0 2 O
known VBN 1 1 12 O
. . 0 0 12 O

Decreased VBN 0 1 7 O
seizure NN 0 1 6 O
threshold NN 0 1 1 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
CYLERT NNP 0 1 UNK B-Brand
concomitantly RB 0 0 14 O
with IN 0 0 12 O
antiepileptic JJ 0 1 UNK B-Group
medications NNS 1 1 6 I-Group
. . 0 0 12 O

Concurrent JJ 0 1 13 O
therapy NN 0 1 6 O
with IN 0 0 12 O
ORENCIA NNP 0 1 UNK B-Brand
and CC 0 0 12 O
TNF NNP 0 1 UNK B-Group
antagonists NNS 1 1 13 I-Group
is VBZ 1 0 12 O
not RB 0 1 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O

Sucralfate NNP 0 1 0 B-Drug
administered VBD 1 1 1 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
before IN 0 1 12 O
lomefloxacin NN 0 1 UNK B-Drug
resulted VBD 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
slower JJR 1 1 UNK O
absorption NN 0 1 1 O
( ( 0 0 2 O
mean JJ 0 1 12 O
C NNP 0 0 2 O
max NN 0 0 3 O
decreased VBN 1 1 1 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
mean JJ 0 1 12 O
T NNP 0 1 2 O
max NN 0 0 3 O
increased VBN 1 1 1 O
by IN 0 0 12 O
9 CD 0 0 2 O
hour NN 0 1 12 O
) ) 0 0 2 O
and CC 0 0 12 O
a DT 0 0 12 O
lesser JJR 1 1 1 O
extent NN 0 1 1 O
of IN 0 0 12 O
absorption NN 0 1 1 O
( ( 0 0 2 O
mean JJ 0 1 12 O
AUC NNP 0 1 UNK O
decreased VBN 1 1 1 O
by IN 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
. . 0 0 12 O

A DT 0 0 2 O
routine JJ 0 1 1 O
dosage NN 0 1 0 O
adjustment NN 0 1 1 O
of IN 0 0 12 O
zaleplon NN 0 1 13 B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
considered VBN 1 1 1 O
necessary JJ 0 0 1 O
. . 0 0 12 O

Anticoagulants NNS 0 1 UNK B-Group
including VBG 1 1 1 O
coumarin NN 0 1 UNK O
derivatives NNS 1 1 13 O
indandione VBP 0 0 UNK O
derivatives NNS 1 1 13 O
and CC 0 0 12 O
platelet NN 0 1 14 B-Group
aggregation NN 0 1 UNK I-Group
inhibitors NNS 1 1 14 I-Group
such JJ 0 0 1 O
as IN 1 0 12 O
nonsteroidal JJ 0 0 14 B-Group
anti IN 0 0 3 I-Group
- : 0 0 2 O
inflammatory NN 0 1 6 I-Group
drugs NNS 1 1 6 I-Group
( ( 0 0 2 O
NSAIDs NNP 0 1 UNK B-Group
) ) 0 0 2 O
and CC 0 0 12 O
aspirin NN 0 1 14 B-Brand
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
bleeding VBG 1 1 6 O
when WRB 0 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
ardeparin NN 0 1 UNK B-Drug
. . 0 0 12 O

Administration NN 0 1 UNK O
of IN 0 0 12 O
dantrolene NN 0 1 16 B-Drug
may MD 0 0 1 O
potentiate VB 0 0 UNK O
vecuronium NN 0 1 16 B-Drug
- : 0 0 2 O
induced JJ 0 1 6 O
neuromuscular JJ 0 1 6 O
block NN 0 1 3 O
. . 0 0 12 O

Accordingly RB 0 0 1 O
patients NNS 1 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
advised VBN 1 0 12 O
to TO 0 0 12 O
avoid VB 0 0 12 O
diazepam NN 0 1 0 B-Drug
and CC 0 0 12 O
other JJ 0 0 12 O
similar JJ 0 1 1 O
drugs NNS 1 1 6 O
while IN 0 0 12 O
taking VBG 1 0 12 O
REMERON NNP 0 1 UNK B-Brand
SolTab NNP 0 0 UNK I-Brand
. . 0 0 12 O

Thiazides NNS 0 1 UNK B-Group
: : 0 0 2 O
Thiazides NNS 0 1 UNK B-Group
are VBP 1 0 12 O
known VBN 1 1 12 O
to TO 0 0 12 O
induce VB 0 1 6 O
hypercalcemia NN 0 1 8 O
by IN 0 0 12 O
the DT 0 0 12 O
reduction NN 0 1 1 O
of IN 0 0 12 O
calcium NN 0 1 14 B-Drug
excretion NN 0 1 14 O
in IN 0 0 12 O
urine NN 0 1 6 O
. . 0 0 12 O

Isoflurane NNP 0 1 UNK B-Drug
or CC 0 0 12 O
enflurane NN 0 1 UNK B-Drug
administered VBN 1 1 1 O
with IN 0 0 12 O
nitrous JJ 0 1 UNK B-Drug
oxide JJ 0 1 14 I-Drug
/ NN 0 0 2 O
oxygen NN 0 1 3 B-Drug
to TO 0 0 12 O
achieve VB 0 0 1 O
9 CD 0 0 2 O
MAC NNP 0 1 UNK O
[ NNP 0 0 2 O
Minimum NNP 0 1 UNK O
Alveolar NNP 0 1 UNK O
Concentration NNP 0 1 UNK O
] NNP 0 0 2 O
may MD 0 0 1 O
prolong VB 0 0 13 O
the DT 0 0 12 O
clinically RB 0 0 6 O
effective JJ 0 1 1 O
duration NN 0 1 1 O
of IN 0 0 12 O
action NN 0 1 13 O
of IN 0 0 12 O
initial JJ 0 1 1 O
and CC 0 0 12 O
maintenance NN 0 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
NIMBEX NNP 0 1 UNK B-Brand
and CC 0 0 12 O
decrease VB 0 1 1 O
the DT 0 0 12 O
required JJ 0 1 1 O
infusion NN 0 1 14 O
rate NN 0 1 1 O
of IN 0 0 12 O
NIMBEX NNP 0 1 UNK B-Brand
. . 0 0 12 O

The DT 0 0 2 O
clinical JJ 0 1 6 O
significance NN 0 1 13 O
of IN 0 0 12 O
this DT 0 0 12 O
observation NN 0 1 1 O
is VBZ 1 0 12 O
unknown JJ 0 1 12 O
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
that IN 0 0 12 O
glucose NN 0 1 14 O
tests NNS 1 1 1 O
based VBN 1 1 1 O
on IN 0 0 12 O
enzymatic JJ 0 1 UNK O
glucose JJ 0 1 14 O
oxidase NN 0 1 13 O
reactions NNS 1 1 1 O
( ( 0 0 2 O
such JJ 0 0 1 O
as IN 1 0 12 O
CLINISTIX NNP 0 0 UNK O
or CC 0 0 12 O
TES NNP 0 1 UNK O
- : 0 0 2 O
TAPE NN 0 1 UNK O
) ) 0 0 2 O
be VB 0 0 12 O
used VBN 1 1 12 O
. . 0 0 12 O

Clinical JJ 0 1 7 O
studies NNS 1 1 1 O
have VBP 0 0 12 O
shown VBN 1 1 1 O
that IN 0 0 12 O
atorvastatin NN 0 1 0 B-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
reduce VB 0 0 1 O
basal NN 0 1 6 O
plasma NN 0 1 14 O
cortisol NN 0 1 14 O
concentration NN 0 1 1 O
or CC 0 0 12 O
impair JJ 0 0 13 O
adrenal JJ 0 0 6 O
reserve NN 0 1 UNK O
. . 0 0 12 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interactions NNP 0 1 UNK O
As IN 0 0 2 O
with IN 0 0 12 O
cephalothin JJ 0 1 UNK B-Drug
high JJ 0 1 1 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
cefoxitin NN 0 1 13 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
micrograms NNS 1 1 14 O
/ NNP 0 0 2 O
mL NN 0 1 14 O
) ) 0 0 2 O
may MD 0 0 1 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
measurement NN 0 1 1 O
of IN 0 0 12 O
serum NN 0 1 14 O
and CC 0 0 12 O
urine JJ 0 1 6 O
creatinine NN 0 1 14 O
levels NNS 1 1 1 O
by IN 0 0 12 O
the DT 0 0 12 O
Jaff NNP 0 0 UNK O
reaction NN 0 1 1 O
and CC 0 0 12 O
produce VB 0 0 1 O
false JJ 0 1 13 O
increases NNS 1 1 1 O
of IN 0 0 12 O
modest JJ 0 1 1 O
degree NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
levels NNS 1 1 1 O
of IN 0 0 12 O
creatinine NN 0 1 14 O
reported VBN 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
optimal JJ 0 1 1 O
dose NN 0 1 6 O
of IN 0 0 12 O
indinavir NN 0 1 16 B-Drug
when WRB 0 0 12 O
given VBN 1 1 12 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
efavirenz NN 0 1 13 B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
known VBN 1 1 12 O
. . 0 0 12 O

Amiodarone NNP 0 1 0 B-Drug
inhibits VBZ 1 1 UNK O
CYP9D9 NNP 0 0 UNK B-Drug
. . 0 0 12 O

Animal NNP 0 1 UNK O
reproduction NN 0 1 UNK O
studies NNS 1 1 1 O
however RB 0 0 12 O
are VBP 1 0 12 O
not RB 0 1 12 O
always RB 0 1 12 O
predictive JJ 0 1 UNK O
of IN 0 0 12 O
human JJ 0 1 1 O
response NN 0 1 1 O
and CC 0 0 12 O
there EX 0 0 12 O
are VBP 1 0 12 O
no DT 0 0 12 O
adequate JJ 0 1 1 O
and CC 0 0 12 O
well RB 0 1 12 O
- : 0 0 2 O
controlled VBN 1 1 1 O
studies NNS 1 1 1 O
in IN 0 0 12 O
pregnant JJ 0 1 13 O
women NNS 1 1 UNK O
. . 0 0 12 O

. . 0 0 12 O

The DT 0 0 2 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
inhibit VBP 0 1 13 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
9D9 CD 0 0 UNK O
include VBP 0 1 1 O
some DT 0 0 12 O
that WDT 0 0 12 O
are VBP 1 0 12 O
not RB 0 1 12 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
the DT 0 0 12 O
enzyme NN 0 1 14 O
( ( 0 0 2 O
quinidine NN 0 1 16 B-Drug
; : 0 0 2 O

Therefore RB 0 0 1 O
patients NNS 1 1 6 O
concurrently RB 0 0 1 O
taking VBG 1 0 12 O
antiseizure JJ 0 0 UNK O
medication NN 0 1 6 O
and CC 0 0 12 O
Mefloquine NNP 0 1 UNK B-Drug
should MD 0 0 12 O
have VB 0 0 12 O
the DT 0 0 12 O
blood NN 0 1 6 O
level NN 0 1 1 O
of IN 0 0 12 O
their PRP$ 0 0 12 O
antiseizure NN 0 0 UNK O
medication NN 0 1 6 O
monitored VBD 1 1 1 O
and CC 0 0 12 O
the DT 0 0 12 O
dosage NN 0 1 0 O
adjusted VBD 1 1 1 O
appropriately RB 0 0 1 O
. . 0 0 12 O

. . 0 0 12 O

Sublingual JJ 0 1 0 O
nitroglycerin NN 0 1 14 B-Drug
may MD 0 0 1 O
be VB 0 0 12 O
taken VBN 1 1 12 O
if IN 0 0 12 O
necessary JJ 0 0 1 O
for IN 0 0 12 O
the DT 0 0 12 O
control NN 0 1 1 O
of IN 0 0 12 O
acute JJ 0 1 6 O
angina NN 0 1 6 O
attacks NNS 1 1 12 O
during IN 0 0 12 O
Bepridil NNP 0 1 UNK B-Drug
therapy NN 0 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
effect NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
higher JJR 1 1 1 O
ketoconazole NN 0 1 16 B-Drug
dose NN 0 1 6 O
( ( 0 0 2 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
) ) 0 0 2 O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
studied VBN 1 0 1 O
. . 0 0 12 O

Effects NNS 0 1 UNK O
were VBD 1 0 12 O
already RB 0 0 12 O
seen VBN 1 1 12 O
with IN 0 0 12 O
doses NNS 1 1 6 O
corresponding VBG 1 0 1 O
to TO 0 0 12 O
relevant VB 0 1 1 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
in IN 0 0 12 O
humans NNS 1 1 UNK O
and CC 0 0 12 O
the DT 0 0 12 O
intracellular JJ 0 1 UNK O
phosphorylation NN 0 1 UNK O
of IN 0 0 12 O
zalcitabine NN 0 1 UNK B-Drug
to TO 0 0 12 O
its PRP$ 1 0 12 O
three CD 0 1 12 O
metabolites NNS 1 1 UNK O
( ( 0 0 2 O
including VBG 1 1 1 O
the DT 0 0 12 O
active JJ 0 1 1 O
zalcitabine NN 0 1 UNK O
triphosphate NN 0 1 UNK O
metabolite NN 0 1 UNK O
) ) 0 0 2 O
was VBD 1 0 12 O
significantly RB 0 0 1 O
inhibited VBN 1 1 13 O
. . 0 0 12 O

Coadministration NN 0 1 UNK O
of IN 0 0 12 O
a DT 0 0 12 O
selective JJ 0 1 13 O
and CC 0 0 12 O
potent JJ 0 1 UNK O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
ketoconazole NNP 0 1 16 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
bid NN 0 0 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
with IN 0 0 12 O
ropivacaine JJ 0 1 16 B-Drug
infusion NN 0 1 14 O
administered VBD 1 1 1 O
9 CD 0 0 2 O
hour NN 0 1 12 O
after IN 0 0 12 O
ketoconazole NN 0 1 16 B-Drug
) ) 0 0 2 O
caused VBD 1 1 1 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
reduction NN 0 1 1 O
in IN 0 0 12 O
in IN 0 0 12 O
- : 0 0 2 O
vivo NN 0 1 13 O
plasma JJ 0 1 14 O
clearance NN 0 1 16 O
of IN 0 0 12 O
ropivacaine NN 0 1 16 B-Drug
. . 0 0 12 O

Anticholinergic JJ 0 1 UNK B-Group
agents NNS 1 1 1 I-Group
may MD 0 0 1 O
affect VB 0 1 1 O
gastrointestinal JJ 0 1 6 O
absorption NN 0 1 1 O
of IN 0 0 12 O
various JJ 0 1 1 O
drugs NNS 1 1 6 O
such JJ 0 0 1 O
as IN 1 0 12 O
slowly RB 0 1 3 O
dissolving VBG 1 1 UNK O
dosage NN 0 1 0 O
forms NNS 1 1 1 O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
; : 0 0 2 O

The DT 0 0 2 O
dosage NN 0 1 0 O
of IN 0 0 12 O
these DT 0 0 12 O
medications NNS 1 1 6 O
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
changed VBN 1 1 12 O
and CC 0 0 12 O
they PRP 0 0 12 O
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
stopped VBN 1 1 12 O
without IN 0 0 12 O
consulting VBG 1 1 13 O
the DT 0 0 12 O
physician JJ 0 1 6 O
even RB 0 0 12 O
if IN 0 0 12 O
the DT 0 0 12 O
patient NN 0 1 6 O
feels NNS 1 1 12 O
better RBR 1 1 12 O
after IN 0 0 12 O
initiating VBG 1 1 1 O
treatment NN 0 1 6 O
with IN 0 0 12 O
FORADIL NNP 0 1 UNK B-Brand
. . 0 0 12 O

increased VBN 1 1 1 O
prothrombin NN 0 1 14 O
and CC 0 0 12 O
factors NNS 1 1 1 O
VII NNP 0 1 2 O
VIII NNP 0 1 2 O
IX NNP 0 1 2 O
and CC 0 0 12 O
X NNP 0 0 2 O
; : 0 0 2 O

This DT 0 0 2 O
could MD 0 0 12 O
lead VB 0 1 12 O
to TO 0 0 12 O
decreased JJ 0 1 1 O
salicylate NN 0 1 13 B-Group
serum NN 0 1 14 O
levels NNS 1 1 1 O
or CC 0 0 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
salicylate JJ 0 1 13 B-Group
toxicity NN 0 1 6 O
when WRB 0 0 12 O
corticosteroid NN 0 1 UNK B-Group
is VBZ 1 0 12 O
withdrawn VBN 1 1 1 O
. . 0 0 12 O

For IN 0 0 2 O
patients NNS 1 1 6 O
with IN 0 0 12 O
advanced JJ 0 1 1 O
HIV NNP 0 1 6 O
disease NN 0 1 6 O
and CC 0 0 12 O
poor JJ 0 1 12 O
- : 0 0 2 O
risk NN 0 1 1 O
AIDS NNP 0 1 6 O
- : 0 0 2 O
related JJ 0 1 1 O
Kaposi NNP 0 0 UNK O
sarcoma NN 0 1 6 O
TAXOL NNP 0 1 UNK B-Brand
at IN 0 0 12 O
the DT 0 0 12 O
recommended VBN 1 1 1 O
dose NN 0 1 6 O
for IN 0 0 12 O
this DT 0 0 12 O
disease NN 0 1 6 O
can MD 0 0 12 O
be VB 0 0 12 O
initiated VBN 1 1 1 O
and CC 0 0 12 O
repeated VBN 1 1 1 O
if IN 0 0 12 O
the DT 0 0 12 O
neutrophil NN 0 1 14 O
count NN 0 1 12 O
is VBZ 1 0 12 O
at IN 0 0 12 O
least JJS 0 1 12 O
9 CD 0 0 2 O
cells NNS 1 1 6 O
/ JJ 0 0 2 O
mm9 NN 0 0 UNK O
. . 0 0 12 O

therefore RB 0 0 1 O
administration NN 0 1 1 O
of IN 0 0 12 O
these DT 0 0 12 O
agents NNS 1 1 1 O
should MD 0 0 12 O
precede VB 0 0 UNK O
lomefloxacin NN 0 1 UNK B-Drug
dosing NN 0 0 14 O
by IN 0 0 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
or CC 0 0 12 O
follow VB 0 1 12 O
lomefloxacin NN 0 1 UNK B-Drug
dosing NN 0 0 14 O
by IN 0 0 12 O
at IN 0 0 12 O
least JJS 0 1 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
. . 0 0 12 O

The DT 0 0 2 O
most RBS 0 0 12 O
potent JJ 0 1 UNK O
inhibitory NN 0 1 UNK O
activity NN 0 1 1 O
was VBD 1 0 12 O
observed VBN 1 1 1 O
for IN 0 0 12 O
vardenafil JJ 0 1 UNK O
metabolite NN 0 1 UNK O
M9 NNP 0 1 UNK O
which WDT 0 0 12 O
had VBD 1 0 12 O
a DT 0 0 12 O
Ki NNP 0 0 UNK O
of IN 0 0 12 O
9 CD 0 0 2 O
uM JJ 0 0 UNK O
toward IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
which WDT 0 0 12 O
is VBZ 1 0 12 O
about IN 0 1 12 O
9 CD 0 0 2 O
times NNS 1 1 12 O
higher JJR 1 1 1 O
than IN 0 0 12 O
the DT 0 0 12 O
M9 NNP 0 1 UNK O
Cmax NNP 0 1 UNK O
values NNS 1 1 1 O
after IN 0 0 12 O
an DT 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
Vardenafil NNP 0 1 UNK B-Drug
dose NN 0 1 6 O
. . 0 0 12 O

Non NNP 0 1 2 B-Group
- : 0 0 2 O
steroidal NN 0 1 UNK I-Group
anti SYM 0 0 3 I-Group
- : 0 0 2 O
inflammatory JJ 0 1 6 I-Group
agents NNS 1 1 1 I-Group
: : 0 0 2 O
Seizures NNS 0 1 UNK O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
enoxacin JJ 0 1 UNK B-Drug
concomitantly RB 0 0 14 O
with IN 0 0 12 O
the DT 0 0 12 O
nonsteroidal JJ 0 0 14 B-Group
anti NN 0 0 3 I-Group
- : 0 0 2 O
inflammatory JJ 0 1 6 I-Group
drug NN 0 1 1 I-Group
fenbufen NN 0 1 UNK B-Drug
. . 0 0 12 O

nalidixic JJ 0 0 UNK B-Drug
acid NN 0 1 14 I-Drug
; : 0 0 2 O

When WRB 0 0 12 O
oxandrolone NN 0 1 13 B-Drug
therapy NN 0 1 6 O
is VBZ 1 0 12 O
initiated VBN 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
patient NN 0 1 6 O
already RB 0 0 12 O
receiving VBG 1 1 1 O
treatment NN 0 1 6 O
with IN 0 0 12 O
warfarin PDT 0 1 14 B-Drug
the DT 0 0 12 O
INR NNP 0 1 13 O
or CC 0 0 12 O
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
( ( 0 0 2 O
PT NNP 0 1 2 O
) ) 0 0 2 O
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
closely RB 0 0 1 O
and CC 0 0 12 O
the DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
adjusted VBN 1 1 1 O
as IN 1 0 12 O
necessary JJ 0 0 1 O
until IN 0 0 12 O
a DT 0 0 12 O
stable JJ 0 1 1 O
target NN 0 1 1 O
INR NNP 0 1 13 O
or CC 0 0 12 O
PT NNP 0 1 2 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
achieved VBN 1 0 1 O
. . 0 0 12 O

Cancer NNP 0 1 7 O
chemotherapy NN 0 1 6 O

Patients NNS 0 1 7 O
who WP 0 0 12 O
are VBP 1 0 12 O
concomitantly RB 0 0 14 O
receiving VBG 1 1 1 O
VELCADE NNP 0 1 UNK B-Brand
and CC 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
are VBP 1 0 12 O
inhibitors NNS 1 1 14 O
or CC 0 0 12 O
inducers NNS 1 1 UNK O
of IN 0 0 12 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
9A9 CD 0 0 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
closely RB 0 0 1 O
monitored VBN 1 1 1 O
for IN 0 0 12 O
either DT 0 1 12 O
toxicities NNS 1 1 UNK O
or CC 0 0 12 O
reduced VBN 1 1 1 O
efficacy NN 0 1 UNK O
. . 0 0 12 O

Quinolones NNS 0 1 UNK B-Group
including VBG 1 1 1 O
cinoxacin NN 0 1 UNK B-Drug
may MD 0 0 1 O
enhance VB 0 1 UNK O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
oral JJ 0 1 6 O
anticoagulants NNS 1 1 13 B-Group
such JJ 0 0 1 O
as IN 1 0 12 O
warfarin NN 0 1 14 B-Drug
or CC 0 0 12 O
its PRP$ 1 0 12 O
derivatives NNS 1 1 13 O
. . 0 0 12 O

Amiodarone NN 0 1 0 B-Drug
may MD 0 0 1 O
suppress VB 0 1 1 O
certain JJ 0 1 1 O
CYP9 NNP 0 0 UNK O
enzymes NNS 1 1 14 O
including VBG 1 1 1 O
CYP9A9 NNP 0 0 UNK B-Drug
CYP9C9 NNP 0 0 UNK B-Drug
CYP9D9 NNP 0 0 UNK B-Drug
and CC 0 0 12 O
CYP9A9 NNP 0 0 UNK B-Drug
. . 0 0 12 O

Other JJ 0 0 2 O
Drugs NNS 0 1 2 O
: : 0 0 2 O
In IN 0 0 2 O
small JJ 0 1 12 O
groups NNS 1 1 1 O
of IN 0 0 12 O
patients NNS 1 1 6 O
( ( 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
/ JJ 0 0 2 O
interaction NN 0 1 UNK O
study NN 0 1 1 O
) ) 0 0 2 O
the DT 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
azathioprine JJ 0 1 13 B-Drug
gold NN 0 1 UNK B-Group
chloroquine NN 0 1 13 B-Drug
D NNP 0 1 2 B-Drug
- : 0 0 2 O
penicillamine NN 0 1 13 I-Drug
prednisolone NN 0 1 0 B-Drug
doxycycline NN 0 1 0 B-Drug
or CC 0 0 12 O
digitoxin NN 0 1 UNK B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
significantly RB 0 0 1 O
affect VBP 0 1 1 O
the DT 0 0 12 O
peak NN 0 1 1 O
levels NNS 1 1 1 O
and CC 0 0 12 O
AUC NNP 0 1 UNK O
values NNS 1 1 1 O
of IN 0 0 12 O
diclofenac NN 0 1 16 B-Drug
. . 0 0 12 O

Antihistamines NNS 0 1 UNK B-Group
may MD 0 0 1 O
enhance VB 0 1 UNK O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
barbiturates VBZ 0 1 14 B-Group
alcohol NNS 0 1 1 B-Drug
and CC 0 0 12 O
other JJ 0 0 12 O
CNS NNP 0 1 6 B-Group
depressants NNS 1 0 13 I-Group
. . 0 0 12 O

clarithromycin NN 0 1 13 B-Drug
concentration NN 0 1 1 O

Broad NNP 0 1 UNK B-Group
- : 0 0 2 O
Spectrum NN 0 1 UNK I-Group
Antibiotics NNPS 0 1 7 I-Group
- : 0 0 2 O
Broad NNP 0 1 UNK B-Group
- : 0 0 2 O
spectrum NN 0 1 1 I-Group
antibiotics NNS 1 1 6 I-Group
may MD 0 0 1 O
sterilize VB 0 1 UNK O
the DT 0 0 12 O
bowel NN 0 1 6 O
and CC 0 0 12 O
decrease VB 0 1 1 O
the DT 0 0 12 O
vitamin NN 0 1 6 B-Group
K NNP 0 1 2 I-Group
contribution NN 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
body NN 0 1 3 O
by IN 0 0 12 O
the DT 0 0 12 O
intestinal JJ 0 1 13 O
microflora NN 0 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
following JJ 0 1 1 O
medications NNS 1 1 6 O
have VBP 0 0 12 O
been VBN 1 0 12 O
administered VBN 1 1 1 O
in IN 0 0 12 O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
with IN 0 0 12 O
Simulect NNP 0 1 UNK B-Brand
with IN 0 0 12 O
no DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
adverse JJ 0 0 1 O
reactions NNS 1 1 1 O
: : 0 0 2 O
ATG NNP 0 0 UNK O
/ NNP 0 0 2 O
ALG NNP 0 1 UNK O
azathioprine NN 0 1 13 B-Drug
corticosteroids NNS 1 1 14 B-Group
cyclosporine VBP 0 1 14 B-Drug
mycophenolate NN 0 1 0 B-Drug
mofetil NN 0 0 16 I-Drug
and CC 0 0 12 O
muromonab SYM 0 0 UNK B-Drug
- : 0 0 2 O
CD9 NN 0 0 UNK I-Drug
. . 0 0 12 O

Prescribers NNS 0 0 UNK O
should MD 0 0 12 O
refer VB 0 1 1 O
to TO 0 0 12 O
national JJ 0 1 UNK O
guidelines NNS 1 1 13 O
for IN 0 0 12 O
influenza JJ 0 1 6 O
vaccination NN 0 1 6 O
. . 0 0 12 O

Laboratory JJ 0 1 2 O
Test NNP 0 1 2 O
Interactions NNP 0 1 UNK O
Scopolamine NNP 0 1 UNK B-Drug
will MD 0 0 12 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
gastric JJ 0 1 6 O
secretion NN 0 1 14 O
test NN 0 1 1 O
. . 0 0 12 O

If IN 0 0 12 O
co VBN 0 1 12 O
- : 0 0 2 O
administration NN 0 1 1 O
is VBZ 1 0 12 O
essential JJ 0 1 13 O
conduct NN 0 1 13 O
close JJ 0 1 12 O
clinical JJ 0 1 6 O
and CC 0 0 12 O
laboratory JJ 0 1 1 O
monitoring NN 0 1 1 O

Caution NN 0 0 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
exercised VBN 1 1 1 O
when WRB 0 0 12 O
taking VBG 1 0 12 O
this DT 0 0 12 O
medicine NN 0 1 6 O
certain JJ 0 1 1 O
antibiotics NNS 1 1 6 B-Group
such JJ 0 0 1 O
as IN 1 0 12 O
erythromycin JJ 0 1 0 B-Drug
clarithromycin NN 0 1 13 B-Drug
or CC 0 0 12 O
azithromycin NN 0 1 0 B-Drug
. . 0 0 12 O

In IN 0 0 2 O
TAMBOCOR NNP 0 1 UNK B-Brand
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
patients NNS 1 1 6 O
who WP 0 0 12 O
were VBD 1 0 12 O
receiving VBG 1 1 1 O
beta NN 0 1 16 B-Group
blockers NNS 1 0 6 I-Group
concurrently RB 0 0 1 O
did VBD 1 0 12 O
not RB 0 1 12 O
experience VB 0 1 12 O
an DT 0 0 12 O
increased JJ 0 1 1 O
incidence NN 0 1 6 O
of IN 0 0 12 O
side NN 0 1 3 O
effects NNS 1 1 1 O
. . 0 0 12 O

Based VBN 0 1 2 O
on IN 0 0 12 O
in IN 0 0 12 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
in IN 0 0 12 O
human JJ 0 1 1 O
liver NN 0 1 6 O
microsomes NNS 1 1 UNK O
des VBZ 0 0 13 B-Drug
- : 0 0 2 O
ciclesonide NN 0 1 13 I-Drug
appears VBZ 1 1 12 O
to TO 0 0 12 O
have VB 0 0 12 O
no DT 0 0 12 O
inhibitory NN 0 1 UNK O
or CC 0 0 12 O
induction NN 0 1 1 O
potential NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
CYP NNP 0 1 UNK O
9 CD 0 0 2 O
enzymes NNS 1 1 14 O
. . 0 0 12 O

Nursing VBG 0 1 2 O
Mothers NNS 0 1 UNK O
In IN 0 0 2 O
rat NN 0 1 13 O
studies NNS 1 1 1 O
exposure VBP 0 1 1 O
to TO 0 0 12 O
total JJ 0 1 1 O
ezetimibe NN 0 1 16 B-Drug
in IN 0 0 12 O
nursing VBG 1 1 12 O
pups NN 1 0 UNK O
was VBD 1 0 12 O
up RB 0 0 12 O
to TO 0 0 12 O
half NN 0 1 12 O
of IN 0 0 12 O
that DT 0 0 12 O
observed VBD 1 1 1 O
in IN 0 0 12 O
maternal JJ 0 1 6 O
plasma NN 0 1 14 O
. . 0 0 12 O

Albendazole NNP 0 1 UNK B-Drug
sulfoxide NN 0 1 UNK I-Drug
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
were VBD 1 0 12 O
unchanged JJ 0 1 1 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
after IN 0 0 12 O
dosing VBG 1 0 14 O
. . 0 0 12 O

The DT 0 0 2 O
following JJ 0 1 1 O
information NN 0 1 1 O
was VBD 1 0 12 O
obtained VBN 1 1 1 O
from IN 0 0 12 O
studies NNS 1 1 1 O
in IN 0 0 12 O
normal JJ 0 1 1 O
volunteers NNS 1 1 UNK O
. . 0 0 12 O

Effect NN 0 1 UNK O
of IN 0 0 12 O
Other JJ 0 0 2 O
Drugs NNP 0 1 2 O
on IN 0 0 12 O
the DT 0 0 12 O
Pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
Clonazepam NNP 0 1 0 B-Drug
: : 0 0 2 O
Literature NN 0 1 UNK O
reports NNS 1 1 1 O
suggest VBP 0 1 1 O
that IN 0 0 12 O
ranitidine VBP 0 1 0 B-Drug
an DT 0 0 12 O
agent NN 0 1 1 O
that WDT 0 0 12 O
decreases VBZ 1 1 UNK O
stomach VBP 0 1 6 O
acidity NN 0 1 UNK O
does VBZ 1 0 12 O
not RB 0 1 12 O
greatly RB 0 1 1 O
alter JJ 0 1 13 O
clonazepam NN 0 1 0 B-Drug
pharmacokinetics NNS 0 1 UNK O
. . 0 0 12 O

When WRB 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
are VBP 1 0 12 O
administered VBN 1 1 1 O
to TO 0 0 12 O
or CC 0 0 12 O
withdrawn VB 1 1 1 O
from IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
Starlix NNP 0 1 UNK B-Brand
the DT 0 0 12 O
patient NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
observed VBN 1 1 1 O
closely RB 0 0 1 O
for IN 0 0 12 O
changes NNS 1 1 1 O
in IN 0 0 12 O
glycemic JJ 0 1 14 O
control NN 0 1 1 O
. . 0 0 12 O

Antihistamines NNS 0 1 UNK B-Group
may MD 0 0 1 O
have VB 0 0 12 O
additive JJ 0 1 16 O
effects NNS 1 1 1 O
with IN 0 0 12 O
alcohol NN 0 1 1 B-Drug
and CC 0 0 12 O
other JJ 0 0 12 O
CNS NNP 0 1 6 B-Group
depressants NNS 1 0 13 I-Group
e.g. VBP 0 0 UNK O
hypnotics NNS 1 1 13 B-Group
sedatives VBZ 0 1 6 B-Group
tranquilizers NNS 1 1 13 B-Group
antianxiety NN 0 0 0 B-Group
agents NNS 1 1 1 I-Group
. . 0 0 12 O

Ranitidine NNP 0 1 0 B-Drug
produced VBD 1 0 1 O
smaller JJR 1 1 3 O
nonsignificant JJ 0 0 UNK O
increases NNS 1 1 1 O
. . 0 0 12 O

Absorption NN 0 1 UNK O
of IN 0 0 12 O
tetracyclines NNS 1 1 13 B-Group
is VBZ 1 0 12 O
impaired VBN 1 1 6 O
by IN 0 0 12 O
antacids NNS 1 1 14 B-Group
containing VBG 1 1 1 O
aluminum NN 0 1 16 B-Drug
calcium NN 0 1 14 B-Drug
or CC 0 0 12 O
magnesium NN 0 1 14 B-Drug
and CC 0 0 12 O
iron NN 0 1 3 B-Drug
- : 0 0 2 O
containing NN 0 1 1 O
preparations NNS 1 1 13 O
. . 0 0 12 O

INDOCIN NNP 0 1 UNK B-Brand
given VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
serum JJ 0 1 14 O
concentration NN 0 1 1 O
and CC 0 0 12 O
prolong VB 0 0 13 O
the DT 0 0 12 O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
. . 0 0 12 O

Aspirin NNP 0 1 0 B-Brand
may MD 0 0 1 O
decrease VB 0 1 1 O
bioavailability NN 0 1 UNK O
of IN 0 0 12 O
SKELID NNP 0 1 UNK B-Brand
by IN 0 0 12 O
up IN 0 0 12 O
to TO 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
when WRB 0 0 12 O
taken VBN 1 1 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
after IN 0 0 12 O
SKELID NNP 0 1 UNK B-Brand
. . 0 0 12 O

Potentially RB 0 0 UNK O
fatal JJ 0 1 13 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
may MD 0 0 1 O
occur VB 0 1 1 O
when WRB 0 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
as IN 1 0 12 O
this DT 0 0 12 O
may MD 0 0 1 O
enhance VB 0 1 UNK O
cardiovascular JJ 0 1 6 O
depression NN 0 1 6 O
and CC 0 0 12 O
bradyarrhythmias NN 0 1 UNK O
may MD 0 0 1 O
occur VB 0 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
Exjade NNP 0 1 UNK B-Brand
had VBD 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
. . 0 0 12 O

No DT 0 0 2 O
drug NN 0 1 1 O
nutritional JJ 0 1 6 O
supplement NN 0 1 1 O
food NN 0 1 12 O
or CC 0 0 12 O
herb NN 0 1 UNK O
interactions NNS 1 1 UNK O
are VBP 1 0 12 O
known VBN 1 1 12 O
. . 0 0 12 O

Patients NNS 0 1 7 O
on IN 0 0 12 O
Warfarin NNP 0 1 0 B-Drug
should MD 0 0 12 O
have VB 0 0 12 O
more RBR 0 1 12 O
frequent JJ 0 1 1 O
monitoring NN 0 1 1 O
of IN 0 0 12 O
prothrombin JJ 0 1 14 O
times NNS 1 1 12 O
while IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
other JJ 0 0 12 O
risk NN 0 1 1 O
factors NNS 1 1 1 O
complicated VBN 1 1 1 O
by IN 0 0 12 O
hemorrhage NN 0 1 6 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
recent JJ 0 1 12 O
surgery NN 0 1 6 O
peptic JJ 0 1 6 O
ulceration NN 0 1 8 O
) ) 0 0 2 O
should MD 0 0 12 O
have VB 0 0 12 O
periodic JJ 0 1 1 O
examinations NNS 1 1 1 O
for IN 0 0 12 O
bleeding VBG 1 1 6 O
including VBG 1 1 1 O
hematocrit NN 0 1 14 O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
hemoglobin NN 0 1 14 O
. . 0 0 12 O

Ritonavir NNP 0 1 0 B-Drug
significantly RB 0 0 1 O
prolonged VBD 1 1 6 O
the DT 0 0 12 O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
of IN 0 0 12 O
vardenafil NN 0 1 UNK B-Drug
to TO 0 0 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
. . 0 0 12 O

If IN 0 0 12 O
possible JJ 0 1 1 O
avoid NN 0 0 12 O
such JJ 0 0 1 O
combinations NNS 1 1 1 O
. . 0 0 12 O

Lithium NN 0 1 UNK B-Drug
: : 0 0 2 O
Increased VBN 0 1 7 O
serum NN 0 1 14 O
lithium NN 0 1 16 B-Drug
levels NNS 1 1 1 O
and CC 0 0 12 O
symptoms NNS 1 1 6 O
of IN 0 0 12 O
lithium NN 0 1 16 B-Drug
toxicity NN 0 1 6 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
concomitant JJ 0 1 6 O
lithium NN 0 1 16 B-Drug
and CC 0 0 12 O
ACE NNP 0 1 13 B-Group
inhibitor NN 0 1 14 I-Group
therapy NN 0 1 6 O
. . 0 0 12 O

Furosemide NN 0 1 0 B-Drug
: : 0 0 2 O
Clinical JJ 0 1 7 O
studies NNS 1 1 1 O
as RB 0 0 12 O
well RB 0 1 12 O
as IN 1 0 12 O
post NN 0 1 12 O
- : 0 0 2 O
marketing NN 0 1 UNK O
observations NNS 1 1 1 O
have VBP 0 0 12 O
shown VBN 1 1 1 O
that IN 0 0 12 O
NSAIDs NNP 0 1 UNK B-Group
can MD 0 0 12 O
reduce VB 0 0 1 O
the DT 0 0 12 O
natriuretic JJ 0 1 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
furosemide NN 0 1 0 B-Drug
and CC 0 0 12 O
thiazide NN 0 1 UNK B-Group
diuretics NNS 1 1 14 I-Group
in IN 0 0 12 O
some DT 0 0 12 O
patients NNS 1 1 6 O
. . 0 0 12 O

Phenytoin NN 0 1 0 B-Drug
: : 0 0 2 O
Isoniazid NN 0 1 UNK B-Drug
may MD 0 0 1 O
increase VB 0 1 1 O
serum NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
. . 0 0 12 O

May NNP 0 1 2 O
interact NN 0 0 UNK O
with IN 0 0 12 O
other JJ 0 0 12 O
creams JJ 0 1 3 O
lotions NNS 1 1 3 O
or CC 0 0 12 O
skin NN 0 1 3 O
medicines NNS 1 1 6 O
when WRB 0 0 12 O
placed VBN 1 1 12 O
on IN 0 0 12 O
the DT 0 0 12 O
same JJ 0 1 12 O
areas NNS 1 1 1 O
of IN 0 0 12 O
your PRP$ 0 0 12 O
skin NN 0 1 3 O
that IN 0 0 12 O
you PRP 0 0 12 O
are VBP 1 0 12 O
using VBG 1 1 1 O
bentoquatam NN 0 1 UNK B-Drug_n
. . 0 0 12 O

Cytosine NNP 0 1 UNK B-Drug
arabinoside IN 0 0 UNK I-Drug
a DT 0 0 12 O
cytostatic JJ 0 1 UNK B-Group
agent NN 0 1 1 I-Group
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
inactivate VB 0 0 UNK O
the DT 0 0 12 O
antifungal JJ 0 1 14 O
activity NN 0 1 1 O
of IN 0 0 12 O
flucytosine NN 0 1 13 B-Drug
by IN 0 0 12 O
competitive JJ 0 1 UNK O
inhibition NN 0 1 13 O
. . 0 0 12 O

Several JJ 0 1 2 O
of IN 0 0 12 O
the DT 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
have VBP 0 0 12 O
been VBN 1 0 12 O
cited VBN 1 0 UNK O
in IN 0 0 12 O
these DT 0 0 12 O
reports NNS 1 1 1 O
. . 0 0 12 O

Plasma NNP 0 1 UNK O
concentrations NNS 1 1 13 O
( ( 0 0 2 O
AUC NNP 0 1 UNK O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
hrs NN 1 0 16 O
) ) 0 0 2 O
of IN 0 0 12 O
erythromycin NN 0 1 0 B-Drug
decreased VBD 1 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
with IN 0 0 12 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
loratadine JJ 0 1 0 B-Drug
relative NN 0 1 1 O
to TO 0 0 12 O
that DT 0 0 12 O
observed VBN 1 1 1 O
with IN 0 0 12 O
erythromycin JJ 0 1 0 B-Drug
alone RB 0 1 12 O
. . 0 0 12 O

The DT 0 0 2 O
risk NN 0 1 1 O
of IN 0 0 12 O
metabolic JJ 0 1 6 O
interactions NNS 1 1 UNK O
caused VBN 1 1 1 O
by IN 0 0 12 O
an DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
an DT 0 0 12 O
individual JJ 0 1 1 O
isoform NN 0 1 UNK O
is VBZ 1 0 12 O
therefore RB 0 0 1 O
minimized VBN 1 0 1 O
. . 0 0 12 O

Concomitant NNP 0 1 UNK O
use NN 0 1 1 O
of IN 0 0 12 O
prophylactic JJ 0 1 6 O
low JJ 0 1 1 O
dose NN 0 1 6 O
heparin NN 0 1 14 B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
appear VB 0 1 12 O
to TO 0 0 12 O
affect VB 0 1 1 O
safety NN 0 1 1 O
however RB 0 0 12 O
its PRP$ 1 0 12 O
effects NNS 1 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
efficacy NN 0 1 UNK O
of IN 0 0 12 O
Xigris NNP 0 1 UNK B-Brand
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
evaluated VBN 1 1 1 O
in IN 0 0 12 O
an DT 0 0 12 O
adequate NN 0 1 1 O
and CC 0 0 12 O
well RB 0 1 12 O
- : 0 0 2 O
controlled VBD 1 1 1 O
clinical JJ 0 1 6 O
trial NN 0 1 12 O
. . 0 0 12 O

Drugs NNS 0 1 2 O
Associated VBN 0 1 2 O
With IN 0 0 2 O
Peripheral NNP 0 1 7 O
Neuropathy NNP 0 1 7 O
: : 0 0 2 O
The DT 0 0 2 O
concomitant NN 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
HIVID NNP 0 1 UNK B-Drug
with IN 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
have VBP 0 0 12 O
the DT 0 0 12 O
potential JJ 0 1 1 O
to TO 0 0 12 O
cause VB 0 1 12 O
peripheral JJ 0 1 6 O
neuropathy NNS 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
where WRB 0 0 12 O
possible JJ 0 1 1 O
. . 0 0 12 O

Therefore RB 0 0 1 O
when WRB 0 0 12 O
INDOCIN NNP 0 1 UNK B-Brand
and CC 0 0 12 O
INDOCIN NNP 0 1 UNK B-Brand
. . 0 0 12 O

Since IN 0 1 2 O
amiodarone NN 0 1 0 B-Drug
is VBZ 1 0 12 O
a DT 0 0 12 O
substrate NN 0 1 UNK O
for IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
and CC 0 0 12 O
CYP9C9 NNP 0 0 UNK O
drugs NNS 1 1 6 O
/ NNP 0 0 2 O
substances NNS 1 1 1 O
that WDT 0 0 12 O
inhibit VBP 0 1 13 O
these DT 0 0 12 O
isoenzymes NNS 0 1 14 O
may MD 0 0 1 O
decrease VB 0 1 1 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
and CC 0 0 12 O
increase VB 0 1 1 O
serum JJ 0 1 14 O
concentration NN 0 1 1 O
of IN 0 0 12 O
amiodarone NN 0 1 0 B-Drug
. . 0 0 12 O

ethinyl NN 0 0 13 B-Drug
estradiol DT 0 1 13 I-Drug
concentration NN 0 1 1 O

The DT 0 0 2 O
time NN 0 1 12 O
to TO 0 0 12 O
onset VB 0 1 6 O
of IN 0 0 12 O
maximum JJ 0 1 1 O
block NN 0 1 3 O
following VBG 1 1 1 O
NIMBEX NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
minutes NNS 1 1 12 O
faster RBR 0 1 1 O
with IN 0 0 12 O
prior JJ 0 1 1 O
administration NN 0 1 1 O
of IN 0 0 12 O
succinylcholine NN 0 1 16 B-Drug
. . 0 0 12 O

Given VBN 0 1 2 O
the DT 0 0 12 O
primary JJ 0 1 1 O
CNS NNP 0 1 6 O
effects NNS 1 1 1 O
of IN 0 0 12 O
Clozapine NNP 0 1 0 B-Drug
caution NN 0 0 1 O
is VBZ 1 0 12 O
advised VBN 1 0 12 O
in IN 0 0 12 O
using VBG 1 1 1 O
it PRP 0 0 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
other JJ 0 0 12 O
CNS NNP 0 1 6 O
- : 0 0 2 O
active JJ 0 1 1 O
drugs NNS 1 1 6 O
or CC 0 0 12 O
alcohol NN 0 1 1 B-Drug
. . 0 0 12 O

In IN 0 0 2 O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
doxazosin VBP 0 1 13 B-Drug
mesylate JJ 0 1 16 I-Drug
tablets NNS 1 1 3 O
have VBP 0 0 12 O
been VBN 1 0 12 O
administered VBN 1 1 1 O
to TO 0 0 12 O
patients NNS 1 1 6 O
on IN 0 0 12 O
a DT 0 0 12 O
variety NN 0 1 1 O
of IN 0 0 12 O
concomitant JJ 0 1 6 O
medications NNS 1 1 6 O
; : 0 0 2 O

also RB 0 0 12 O
concurrent JJ 0 1 1 O
use NN 0 1 1 O
of IN 0 0 12 O
this DT 0 0 12 O
medication NN 0 1 6 O
may MD 0 0 1 O
antagonise VB 0 0 UNK O
the DT 0 0 12 O
anti JJ 0 0 3 O
- : 0 0 2 O
glaucoma NN 0 1 6 O
and CC 0 0 12 O
miotic JJ 0 1 8 O
actions NNS 1 1 UNK O
of IN 0 0 12 O
ophthalmic JJ 0 1 6 O
cholinesterase NN 0 1 UNK B-Group
inhibitors NNS 1 1 14 I-Group
. . 0 0 12 O

While IN 0 0 12 O
taking VBG 1 0 12 O
beta JJ 0 1 16 B-Group
blockers NNS 1 0 6 I-Group
patients NNS 1 1 6 O
with IN 0 0 12 O
a DT 0 0 12 O
history NN 0 1 12 O
of IN 0 0 12 O
anaphylactic JJ 0 1 13 O
reaction NN 0 1 1 O
to TO 0 0 12 O
a DT 0 0 12 O
variety NN 0 1 1 O
of IN 0 0 12 O
allergens NNS 1 1 13 O
may MD 0 0 1 O
have VB 0 0 12 O
a DT 0 0 12 O
more RBR 0 1 12 O
severe JJ 0 1 6 O
reaction NN 0 1 1 O
on IN 0 0 12 O
repeated JJ 0 1 1 O
challenge NN 0 1 12 O
either CC 0 1 12 O
accidental JJ 0 1 13 O
diagnostic NN 0 1 6 O
or CC 0 0 12 O
therapeutic JJ 0 1 6 O
. . 0 0 12 O

When WRB 0 0 12 O
initiating VBG 1 1 1 O
a DT 0 0 12 O
multi JJ 0 1 16 O
- : 0 0 2 O
day NN 0 1 12 O
course NN 0 1 12 O
of IN 0 0 12 O
grepafloxacin NN 0 1 UNK B-Drug
in IN 0 0 12 O
a DT 0 0 12 O
patient NN 0 1 6 O
maintained VBN 1 1 1 O
on IN 0 0 12 O
theophylline NN 0 1 16 B-Drug
the DT 0 0 12 O
theophylline JJ 0 1 16 B-Drug
maintenance NN 0 1 1 O
dose NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
halved VBN 1 0 UNK O
for IN 0 0 12 O
the DT 0 0 12 O
period NN 0 1 1 O
of IN 0 0 12 O
concurrent NN 0 1 1 O
use NN 0 1 1 O
of IN 0 0 12 O
grepafloxacin NN 0 1 UNK B-Drug
and CC 0 0 12 O
monitoring NN 0 1 1 O
of IN 0 0 12 O
serum JJ 0 1 14 O
theophylline JJ 0 1 16 B-Drug
concentrations NNS 1 1 13 O
should MD 0 0 12 O
be VB 0 0 12 O
initiated VBN 1 1 1 O
as IN 1 0 12 O
a DT 0 0 12 O
guide NN 0 1 12 O
to TO 0 0 12 O
further JJ 0 1 1 O
dosage NN 0 1 0 O
adjustments NNS 1 1 1 O
. . 0 0 12 O

patients NNS 1 1 6 O
receiving VBG 1 1 1 O
lithium NN 0 1 16 B-Drug
and CC 0 0 12 O
Neulasta NNP 0 1 UNK B-Brand
should MD 0 0 12 O
have VB 0 0 12 O
more RBR 0 1 12 O
frequent JJ 0 1 1 O
monitoring NN 0 1 1 O
of IN 0 0 12 O
neutrophil JJ 0 1 14 O
counts NNS 1 1 1 O
. . 0 0 12 O

Death NN 0 1 UNK O
due JJ 0 1 1 O
to TO 0 0 12 O
fulminant VB 0 0 13 O
pancreatitis NN 0 1 6 O
possibly RB 0 1 12 O
related VBN 1 1 1 O
to TO 0 0 12 O
intravenous JJ 0 1 14 O
pentamidine NN 0 1 14 B-Drug
and CC 0 0 12 O
HIVID NNP 0 1 UNK B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
not RB 0 1 12 O
known VBN 1 1 12 O
whether IN 0 0 12 O
AMEVIVE NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
excreted VBN 1 1 UNK O
in IN 0 0 12 O
human JJ 0 1 1 O
milk NN 0 1 3 O
. . 0 0 12 O

Pediatric NNP 0 1 7 O
Use NNP 0 1 2 O
The DT 0 0 2 O
safety NN 0 1 1 O
and CC 0 0 12 O
efficacy NN 0 1 UNK O
of IN 0 0 12 O
FASLODEX NNP 0 1 UNK B-Brand
in IN 0 0 12 O
pediatric JJ 0 1 6 O
patients NNS 1 1 6 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
established VBN 1 1 1 O
. . 0 0 12 O

Cimetidine NNP 0 1 0 B-Drug
reduces VBZ 1 0 UNK O
the DT 0 0 12 O
clearance NN 0 1 16 O
of IN 0 0 12 O
ALFENTA NNP 0 1 UNK B-Brand
. . 0 0 12 O

It PRP 0 0 12 O
may MD 0 0 1 O
increase VB 0 1 1 O
excretion NN 0 1 14 O
of IN 0 0 12 O
barbiturates NNS 1 1 14 B-Group
lithium NN 0 1 16 B-Drug
and CC 0 0 12 O
ASA NNP 0 1 13 B-Drug
and CC 0 0 12 O
may MD 0 0 1 O
also RB 0 0 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
toxicity NN 0 1 6 O
of IN 0 0 12 O
salicylates NNS 1 1 13 B-Group
. . 0 0 12 O

Adenosine JJ 0 1 14 B-Drug
effects NNS 1 1 1 O
are VBP 1 0 12 O
potentiated VBN 1 0 UNK O
by IN 0 0 12 O
dipyridamole NN 0 1 0 B-Drug
. . 0 0 12 O

Studies NNS 0 1 2 O
have VBP 0 0 12 O
shown VBN 1 1 1 O
that IN 0 0 12 O
lansoprazole NN 0 1 16 B-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
have VB 0 0 12 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
the DT 0 0 12 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
system NN 0 1 1 O
such JJ 0 0 1 O
as IN 1 0 12 O
warfarin JJ 0 1 14 B-Drug
antipyrine NN 0 1 UNK B-Drug
indomethacin NN 0 1 14 B-Drug
ibuprofen NN 0 1 0 B-Drug
phenytoin NN 0 1 16 B-Drug
propranolol NN 0 1 16 B-Drug
prednisone NN 0 1 0 B-Drug
diazepam NN 0 1 0 B-Drug
clarithromycin NN 0 1 13 B-Drug
or CC 0 0 12 O
terfenadine NN 0 1 UNK B-Drug
in IN 0 0 12 O
healthy JJ 0 1 12 O
subjects NNS 1 1 UNK O
. . 0 0 12 O

9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O

St NNP 0 1 2 O
. . 0 0 12 O

Specific JJ 0 1 UNK O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
performed VBN 1 1 1 O
with IN 0 0 12 O
SUSTIVA NNP 0 1 UNK B-Brand
and CC 0 0 12 O
NRTIs NNP 0 1 UNK B-Group
other JJ 0 0 12 O
than IN 0 0 12 O
lamivudine JJ 0 1 16 B-Drug
and CC 0 0 12 O
zidovudine NN 0 1 13 B-Drug
. . 0 0 12 O

If IN 0 0 12 O
isradipine JJ 0 1 13 B-Drug
therapy NN 0 1 6 O
is VBZ 1 0 12 O
initiated VBN 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
patient NN 0 1 6 O
currently RB 0 1 12 O
receiving VBG 1 1 1 O
cimetidine NN 0 1 13 B-Drug
careful JJ 0 1 12 O
monitoring NN 0 1 1 O
for IN 0 0 12 O
adverse JJ 0 0 1 O
reactions NNS 1 1 1 O
is VBZ 1 0 12 O
advised VBN 1 0 12 O
and CC 0 0 12 O
downward RB 0 1 3 O
dose JJ 0 1 6 O
adjustment NN 0 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
required VBN 1 1 1 O
. . 0 0 12 O

CHEMET NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
not RB 0 1 12 O
known VBN 1 1 12 O
to TO 0 0 12 O
interact VB 0 0 UNK O
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
including VBG 1 1 1 O
iron NN 0 1 3 B-Drug
supplements NNS 1 1 6 O
; : 0 0 2 O

Increased VBN 0 1 7 O
metoprolol NN 0 1 0 B-Drug
plasma NN 0 1 14 O
levels NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
decreased JJ 0 1 1 O
cardioselectivity NN 0 0 UNK O
. . 0 0 12 O

sucralfate NN 0 1 0 B-Drug
or CC 0 0 12 O
divalent NN 0 0 UNK O
or CC 0 0 12 O
trivalent JJ 0 0 UNK O
cations NNS 1 1 UNK O
such JJ 0 0 1 O
as IN 1 0 12 O
iron NN 0 1 3 B-Drug
; : 0 0 2 O

Reports NNS 0 1 2 O
in IN 0 0 12 O
the DT 0 0 12 O
literature NN 0 1 UNK O
suggest VBP 0 1 1 O
that IN 0 0 12 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
doxorubicin NN 0 1 13 B-Drug
( ( 0 0 2 O
and CC 0 0 12 O
its PRP$ 1 0 12 O
active JJ 0 1 1 O
metabolite JJ 0 1 UNK O
doxorubicinol NN 0 1 UNK B-Drug_n
) ) 0 0 2 O
may MD 0 0 1 O
be VB 0 0 12 O
increased VBN 1 1 1 O
when WRB 0 0 12 O
paclitaxel NN 0 1 13 B-Drug
and CC 0 0 12 O
doxorubicin NN 0 1 13 B-Drug
are VBP 1 0 12 O
used VBN 1 1 12 O
in IN 0 0 12 O
combination NN 0 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
these DT 0 0 12 O
subjects NNS 1 1 UNK O
meloxicam VBP 0 1 13 B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
alter VB 0 1 13 O
warfarin NN 0 1 14 B-Drug
pharmacokinetics NNS 0 1 UNK O
and CC 0 0 12 O
the DT 0 0 12 O
average JJ 0 1 1 O
anticoagulant JJ 0 1 13 O
effect NN 0 1 1 O
of IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
as IN 1 0 12 O
determined VBN 1 1 1 O
by IN 0 0 12 O
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
. . 0 0 12 O

There EX 0 0 12 O
are VBP 1 0 12 O
no DT 0 0 12 O
known JJ 0 1 12 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
LEUSTATIN NNP 0 1 UNK B-Brand
Injection NNP 0 1 7 O
. . 0 0 12 O

UNIVASC NNP 0 1 UNK B-Brand
has VBZ 1 0 12 O
been VBN 1 0 12 O
used VBN 1 1 12 O
in IN 0 0 12 O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
calcium NN 0 1 14 B-Group
- : 0 0 2 O
channel NN 0 1 1 I-Group
- : 0 0 2 O
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
diuretics NNS 1 1 14 B-Group
H9 NNP 0 0 UNK B-Group
blockers NNS 1 0 6 I-Group
digoxin VBP 0 1 14 B-Drug
oral JJ 0 1 6 O
hypoglycemic JJ 0 1 14 B-Group
agents NNS 1 1 1 I-Group
and CC 0 0 12 O
cholesterol NN 0 1 6 O
- : 0 0 2 O
lowering NN 0 1 UNK O
agents NNS 1 1 1 O
. . 0 0 12 O

requirements NNS 1 1 1 O
for IN 0 0 12 O
riboflavin NN 0 1 13 B-Drug
may MD 0 0 1 O
be VB 0 0 12 O
increased VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
probenecid NN 0 1 13 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
initial JJ 0 1 1 O
dose NN 0 1 6 O
of IN 0 0 12 O
levorphanol NN 0 1 UNK B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
reduced VBN 1 1 1 O
by IN 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
or CC 0 0 12 O
more JJR 0 1 12 O
when WRB 0 0 12 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
given VBN 1 1 12 O
to TO 0 0 12 O
patients NNS 1 1 6 O
along IN 0 0 12 O
with IN 0 0 12 O
another DT 0 0 12 O
drug NN 0 1 1 O
affecting VBG 1 1 1 O
respiration NN 0 1 6 O
. . 0 0 12 O

If IN 0 0 12 O
EVISTA NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
given VBN 1 1 12 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
warfarin JJ 0 1 14 B-Drug
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
. . 0 0 12 O

Alosetron NNP 0 1 UNK B-Drug
also RB 0 0 12 O
does VBZ 1 0 12 O
not RB 0 1 12 O
appear VB 0 1 12 O
to TO 0 0 12 O
induce VB 0 1 6 O
CYP NNP 0 1 UNK O
enzymes VBZ 0 1 14 O
9E9 CD 0 0 UNK O
or CC 0 0 12 O
9C9 CD 0 0 UNK O
. . 0 0 12 O

lopinavir JJ 0 1 13 B-Drug
concentration NN 0 1 1 O

However RB 0 0 1 O
the DT 0 0 12 O
systemic JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
some DT 0 0 12 O
quinolones NNS 0 1 13 B-Group
has VBZ 1 0 12 O
been VBN 1 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
elevate VB 0 1 1 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
theophylline NN 0 1 16 B-Drug
interfere NN 0 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
caffeine NN 0 1 6 B-Drug
and CC 0 0 12 O
enhance VB 0 1 UNK O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
oral JJ 0 1 6 O
anticoagulant NN 0 1 13 B-Group
warfarin NN 0 1 14 B-Drug
and CC 0 0 12 O
its PRP$ 1 0 12 O
derivatives NNS 1 1 13 O
and CC 0 0 12 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
transient JJ 0 1 1 O
elevations NNS 1 1 1 O
in IN 0 0 12 O
serum JJ 0 1 14 O
creatinine NN 0 1 14 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
systemic JJ 0 1 6 O
cyclosporine NN 0 1 14 B-Drug
concomitantly RB 0 0 14 O
. . 0 0 12 O

Ironically RB 0 0 UNK O
benzodiazepines NNS 1 1 14 B-Group
are VBP 1 0 12 O
often RB 0 1 12 O
used VBN 1 1 12 O
in IN 0 0 12 O
the DT 0 0 12 O
treatment NN 0 1 6 O
of IN 0 0 12 O
heroin JJ 0 1 13 B-Drug
addiction NN 0 1 12 O
while IN 0 0 12 O
they PRP 0 0 12 O
cause VBP 0 1 12 O
much RB 0 0 12 O
more RBR 0 1 12 O
severe JJ 0 1 6 O
withdrawal NN 0 1 1 O
symptoms NNS 1 1 6 O
. . 0 0 12 O

Evidence NN 0 1 2 O
of IN 0 0 12 O
spontaneous JJ 0 1 1 O
recovery NN 0 1 1 O
from IN 0 0 12 O
succinylcholine NN 0 1 16 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
observed VBN 1 1 1 O
before IN 0 1 12 O
the DT 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
MIVACRON NNP 0 1 UNK B-Brand
. . 0 0 12 O

Use NN 0 1 2 O
with IN 0 0 12 O
Other JJ 0 0 2 O
Agents NNS 0 1 2 O
Affecting VBG 0 1 UNK O
Myelopoesis NN 0 0 UNK O
: : 0 0 2 O
Drugs NNP 0 1 2 O
which WDT 0 0 12 O
may MD 0 0 1 O
affect VB 0 1 1 O
leukocyte JJ 0 1 14 O
production NN 0 1 1 O
including VBG 1 1 1 O
co JJ 0 1 12 B-Brand
- : 0 0 2 O
trimoxazole NN 0 0 UNK I-Brand
may MD 0 0 1 O
lead VB 0 1 12 O
to TO 0 0 12 O
exaggerated JJ 0 1 1 O
leukopenia NN 0 1 UNK O
especially RB 0 0 12 O
in IN 0 0 12 O
renal JJ 0 1 6 O
transplant NN 0 1 6 O
recipients NNS 1 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
effect NN 0 1 1 O
of IN 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
fluconazole JJ 0 1 0 B-Drug
and CC 0 0 12 O
glipizide NN 0 1 0 B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
demonstrated VBN 1 0 1 O
in IN 0 0 12 O
a DT 0 0 12 O
placebo NN 0 1 13 O
- : 0 0 2 O
controlled VBN 1 1 1 O
crossover NN 0 1 UNK O
study NN 0 1 1 O
in IN 0 0 12 O
normal JJ 0 1 1 O
volunteers NNS 1 1 UNK O
. . 0 0 12 O

. . 0 0 12 O

Agents NNS 0 1 2 O
Affecting VBG 0 1 UNK O
Sympathetic JJ 0 0 UNK O
Activity NNP 0 1 2 O
The DT 0 0 2 O
sympathetic JJ 0 0 13 O
nervous JJ 0 1 6 O
system NN 0 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
especially RB 0 0 12 O
important JJ 0 1 1 O
in IN 0 0 12 O
supporting VBG 1 1 1 O
blood NN 0 1 6 O
pressure NN 0 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
captopril JJ 0 1 0 B-Drug
alone RB 0 1 12 O
or CC 0 0 12 O
with IN 0 0 12 O
diuretics NNS 1 1 14 B-Group
. . 0 0 12 O

Ketoconazole NN 0 1 UNK B-Drug
: : 0 0 2 O
In IN 0 0 2 O
healthy JJ 0 1 12 O
subjects NNS 1 1 UNK O
receiving VBG 1 1 1 O
ketoconazole VB 0 1 16 B-Drug
a DT 0 0 12 O
CYP9A9 NNP 0 0 UNK O
inhibitor NN 0 1 14 O
at IN 0 0 12 O
9 CD 0 0 2 O
mg JJ 0 1 0 O
twice RB 0 1 12 O
daily RB 0 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
systemic JJ 0 1 6 O
exposure NN 0 1 1 O
( ( 0 0 2 O
AUC NNP 0 1 UNK O
) ) 0 0 2 O
to TO 0 0 12 O
lapatinib VB 0 1 13 B-Drug
was VBD 1 0 12 O
increased VBN 1 1 1 O
to TO 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
- : 0 0 2 O
fold NN 0 1 3 O
of IN 0 0 12 O
control NN 0 1 1 O
and CC 0 0 12 O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
increased VBD 1 1 1 O
to TO 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
fold NN 0 1 3 O
of IN 0 0 12 O
control NN 0 1 1 O
. . 0 0 12 O

Prior NNP 0 1 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
succinylcholine NN 0 1 16 B-Drug
has VBZ 1 0 12 O
no DT 0 0 12 O
clinically RB 0 0 6 O
important JJ 0 1 1 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
neuromuscular JJ 0 1 6 O
blocking VBG 1 1 UNK O
action NN 0 1 13 O
of IN 0 0 12 O
NUROMAX NNP 0 1 UNK B-Brand
. . 0 0 12 O

Because IN 0 0 12 O
Matulane NNP 0 1 UNK B-Brand
exhibits VBZ 1 1 UNK O
some DT 0 0 12 O
monoamine JJ 0 1 13 O
oxidase JJ 0 1 13 O
inhibitory NN 0 1 UNK O
activity NN 0 1 1 O
sympathomimetic JJ 0 1 13 B-Group
drugs NNS 1 1 6 I-Group
tricyclic JJ 0 0 14 B-Group
antidepressant NN 0 1 6 I-Group
drugs NNS 1 1 6 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
amitriptyline NN 0 1 16 B-Drug
HCl NNP 0 0 14 I-Drug
imipramine NN 0 1 0 B-Drug
HCl NNP 0 0 14 I-Drug
) ) 0 0 2 O
and CC 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
and CC 0 0 12 O
foods NNS 1 1 1 O
with IN 0 0 12 O
known VBN 1 1 12 O
high JJ 0 1 1 O
tyramine NN 0 1 UNK B-Drug_n
content NN 0 1 13 O
such JJ 0 0 1 O
as IN 1 0 12 O
wine JJ 0 1 12 O
yogurt NN 0 1 UNK O
ripe NN 0 0 UNK O
cheese NN 0 1 UNK O
and CC 0 0 12 O
bananas NNS 1 1 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
. . 0 0 12 O

Changes NNS 0 1 2 O
in IN 0 0 12 O
omeprazole JJ 0 1 0 B-Drug
pharmacokinetics NNS 0 1 UNK O
were VBD 1 0 12 O
not RB 0 1 12 O
studied VBN 1 0 1 O
. . 0 0 12 O

A DT 0 0 2 O
study NN 0 1 1 O
in IN 0 0 12 O
six CD 0 1 12 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
has VBZ 1 0 12 O
shown VBN 1 1 1 O
a DT 0 0 12 O
significant JJ 0 1 1 O
increase NN 0 1 1 O
in IN 0 0 12 O
peak JJ 0 1 1 O
diltiazem NN 0 1 0 B-Drug
plasma NN 0 1 14 O
levels NNS 1 1 1 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
and CC 0 0 12 O
AUC NNP 0 1 UNK O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
after IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
week NN 0 1 12 O
course NN 0 1 12 O
of IN 0 0 12 O
cimetidine JJ 0 1 13 B-Drug
9 CD 0 0 2 O
mg JJ 0 1 0 O
/ NNP 0 0 2 O
day NN 0 1 12 O
and CC 0 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
diltiazem JJ 0 1 0 B-Drug
9mg CD 0 0 UNK O
. . 0 0 12 O

Herbal JJ 0 1 UNK O
Products NNS 0 1 2 O
: : 0 0 2 O
St. NNP 0 1 2 O
John NNP 0 0 19 O
wort NN 0 0 UNK O
( ( 0 0 2 O
hypericum JJ 0 1 UNK O
perforatum NN 0 0 UNK O
) ) 0 0 2 O
WARNING IN 0 1 11 O
coadministration NN 0 1 UNK O
may MD 0 0 1 O
lead VB 0 1 12 O
to TO 0 0 12 O
loss NN 0 1 1 O
of IN 0 0 12 O
virologic JJ 0 1 UNK O
response NN 0 1 1 O
and CC 0 0 12 O
possible JJ 0 1 1 O
resistance NN 0 1 1 O
to TO 0 0 12 O
INVIRASE NNP 0 1 UNK B-Brand
or CC 0 0 12 O
to TO 0 0 12 O
the DT 0 0 12 O
class NN 0 1 12 O
of IN 0 0 12 O
protease NN 0 1 13 O
inhibitors NNS 1 1 14 O
. . 0 0 12 O

Until IN 0 0 2 O
further JJ 0 1 1 O
data NNS 0 1 1 O
are VBP 1 0 12 O
developed VBN 1 0 1 O
regarding VBG 1 0 1 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
when WRB 0 0 12 O
azithromycin NN 0 1 0 B-Drug
and CC 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
are VBP 1 0 12 O
used VBN 1 1 12 O
concomitantly RB 0 0 14 O
careful JJ 0 1 12 O
monitoring NN 0 1 1 O
of IN 0 0 12 O
patients NNS 1 1 6 O
is VBZ 1 0 12 O
advised VBN 1 0 12 O
: : 0 0 2 O
Digoxin NN 0 1 0 B-Drug
elevated VBD 1 1 1 O
digoxin JJ 0 1 14 B-Drug
concentrations NNS 1 1 13 O
. . 0 0 12 O

Caution NN 0 0 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
when WRB 0 0 12 O
coadministering VBG 0 0 UNK O
medications NNS 1 1 6 O
that WDT 0 0 12 O
are VBP 1 0 12 O
substrates VBZ 0 1 UNK O
inhibitors NNS 1 1 14 O
or CC 0 0 12 O
inducers NNS 1 1 UNK O
of IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
or CC 0 0 12 O
potentially RB 0 0 1 O
toxic JJ 0 1 1 O
medications NNS 1 1 6 O
that WDT 0 0 12 O
are VBP 1 0 12 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
. . 0 0 12 O

These DT 0 0 1 O
reactions NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
more RBR 0 1 12 O
frequently RB 0 1 1 O
with IN 0 0 12 O
the DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
hour NN 0 1 12 O
infusion NN 0 1 14 O
than IN 0 0 12 O
with IN 0 0 12 O
the DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
hour NN 0 1 12 O
infusion NN 0 1 14 O
. . 0 0 12 O

Effect NN 0 1 UNK O

Formal JJ 0 1 2 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
conducted VBN 1 1 1 O
with IN 0 0 12 O
ORENCIA NNP 0 1 UNK B-Brand
. . 0 0 12 O

In IN 0 0 2 O
a DT 0 0 12 O
Phase NNP 0 1 UNK O
I PRP 0 1 12 O
trial NN 0 1 12 O
using VBG 1 1 1 O
escalating VBG 1 0 UNK O
doses NNS 1 1 6 O
of IN 0 0 12 O
TAXOL NNP 0 1 UNK B-Brand
( ( 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
m9 NN 0 1 UNK O
) ) 0 0 2 O
and CC 0 0 12 O
cisplatin NN 0 1 14 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
or CC 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ NNP 0 0 2 O
m9 NN 0 1 UNK O
) ) 0 0 2 O
given VBN 1 1 12 O
as IN 1 0 12 O
sequential JJ 0 1 1 O
infusions NNS 1 1 14 O
myelosuppression NN 0 1 8 O
was VBD 1 0 12 O
more RBR 0 1 12 O
profound JJ 0 1 1 O
when WRB 0 0 12 O
TAXOL NNP 0 1 UNK B-Brand
was VBD 1 0 12 O
given VBN 1 1 12 O
after IN 0 0 12 O
cisplatin NN 0 1 14 B-Drug
than IN 0 0 12 O
with IN 0 0 12 O
the DT 0 0 12 O
alternate NN 0 1 1 O
sequence NN 0 1 UNK O
( ( 0 0 2 O
ie JJ 0 0 1 O
TAXOL NNP 0 1 UNK B-Brand
before IN 0 1 12 O
cisplatin NN 0 1 14 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

Theophylline NN 0 1 UNK B-Drug
: : 0 0 2 O
Enoxacin NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
a DT 0 0 12 O
potent JJ 0 1 UNK O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
the DT 0 0 12 O
cytochrome NN 0 1 UNK O
P NNP 0 1 2 O
- : 0 0 2 O
9 CD 0 0 2 O
isozymes NNS 0 1 UNK O
responsible JJ 0 1 1 O
for IN 0 0 12 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
methylxanthines NNS 0 1 UNK B-Group
. . 0 0 12 O

Propanolol NN 0 1 0 B-Drug
: : 0 0 2 O
The DT 0 0 2 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
almotriptan NNS 0 1 13 B-Drug
were VBD 1 0 12 O
not RB 0 1 12 O
affected VBN 1 1 1 O
by IN 0 0 12 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
propranolol NN 0 1 16 B-Drug
. . 0 0 12 O

Phenobarbital NNP 0 1 0 B-Drug
which WDT 0 0 12 O
induces VBZ 1 1 UNK O
hepatic JJ 0 1 14 O
metabolism NN 0 1 16 O
decreased VBD 1 1 1 O
the DT 0 0 12 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
montelukast NN 0 1 16 B-Drug
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
following VBG 1 1 1 O
a DT 0 0 12 O
single JJ 0 1 12 O
9 CD 0 0 2 O
- : 0 0 2 O
mg NN 0 1 0 O
dose NN 0 1 6 O
of IN 0 0 12 O
montelukast NN 0 1 16 B-Drug
. . 0 0 12 O

Therefore RB 0 0 1 O
patients NNS 1 1 6 O
on IN 0 0 12 O
propranolol NN 0 1 16 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
observed VBN 1 1 1 O
when WRB 0 0 12 O
COLESTID NNP 0 1 UNK B-Brand
Tablets NNP 0 1 0 O
are VBP 1 0 12 O
either DT 0 1 12 O
added VBD 1 1 12 O
or CC 0 0 12 O
deleted VBN 1 1 16 O
from IN 0 0 12 O
a DT 0 0 12 O
therapeutic JJ 0 1 6 O
regimen NN 0 1 6 O
. . 0 0 12 O

Therefore RB 0 0 1 O
the DT 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
TRACLEER NNP 0 1 UNK B-Brand
and CC 0 0 12 O
glyburide NN 0 1 16 B-Drug
is VBZ 1 0 12 O
contraindicated VBN 1 1 14 O
and CC 0 0 12 O
alternative JJ 0 1 1 O
hypoglycemic JJ 0 1 14 B-Group
agents NNS 1 1 1 I-Group
should MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
. . 0 0 12 O

Antacids NNS 0 1 UNK B-Group
containing VBG 1 1 1 O
aluminum NN 0 1 16 B-Drug
hydroxide NN 0 1 14 I-Drug
and CC 0 0 12 O
magnesium NN 0 1 14 B-Drug
hydroxide NN 0 1 14 I-Drug
reduce VB 0 0 1 O
the DT 0 0 12 O
oral JJ 0 1 6 O
absorption NN 0 1 1 O
of IN 0 0 12 O
enoxacin NN 0 1 UNK B-Drug
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

Nevirapine NN 0 1 UNK B-Drug

Drug NN 0 1 2 O
Interactions NNS 0 1 UNK O
: : 0 0 2 O
Inhibitors NNS 0 1 7 O
of IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
Isozymes NNP 0 1 UNK O
: : 0 0 2 O
Caution NN 0 0 UNK O
is VBZ 1 0 12 O
advised VBN 1 0 12 O
when WRB 0 0 12 O
midazolam NN 0 1 16 B-Drug
is VBZ 1 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
are VBP 1 0 12 O
known VBN 1 1 12 O
to TO 0 0 12 O
inhibit VB 0 1 13 O
the DT 0 0 12 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
9A9 CD 0 0 UNK O
enzyme NN 0 1 14 O
system NN 0 1 1 O
( ( 0 0 2 O
ie VB 0 0 1 O
some DT 0 0 12 O
drugs NNS 1 1 6 O
in IN 0 0 12 O
the DT 0 0 12 O
drug NN 0 1 1 O
classes NNS 1 1 UNK O
of IN 0 0 12 O
azole JJ 0 1 UNK B-Group
antimycotics NNS 1 0 UNK I-Group
protease NN 0 1 13 B-Group
inhibitors NNS 1 1 14 I-Group
calcium VBP 0 1 14 B-Group
channel NN 0 1 1 I-Group
antagonists NNS 1 1 13 I-Group
and CC 0 0 12 O
macrolide VB 0 1 UNK B-Group
antibiotics NNS 1 1 6 I-Group
) ) 0 0 2 O
. . 0 0 12 O

The DT 0 0 2 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
inhibit VBP 0 1 13 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
9D9 CD 0 0 UNK O
include VBP 0 1 1 O
some DT 0 0 12 O
that WDT 0 0 12 O
are VBP 1 0 12 O
not RB 0 1 12 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
the DT 0 0 12 O
enzyme NN 0 1 14 O
( ( 0 0 2 O
quinidine NN 0 1 16 B-Drug
; : 0 0 2 O

The DT 0 0 2 O
effects NNS 1 1 1 O
of IN 0 0 12 O
medicinal JJ 0 0 16 O
products NNS 1 1 1 O
with IN 0 0 12 O
similar JJ 0 1 1 O
properties NNS 1 1 UNK O
such JJ 0 0 1 O
as IN 1 0 12 O
inotropes NNS 0 1 UNK O
milrinone VBP 0 1 14 B-Drug
enoximone NN 0 1 UNK B-Drug
amrinone NN 0 1 13 B-Drug
olprinone NN 0 1 UNK B-Drug_n
and CC 0 0 12 O
cilostazol NN 0 1 16 B-Drug
may MD 0 0 1 O
be VB 0 0 12 O
exacerbated VBN 1 1 1 O
by IN 0 0 12 O
anagrelide NN 0 1 13 B-Drug
. . 0 0 12 O

Concomitant JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
low JJ 0 1 1 O
- : 0 0 2 O
dose NN 0 1 6 O
aspirin NN 0 1 14 B-Brand
with IN 0 0 12 O
MOBIC NNP 0 1 UNK B-Brand
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
an DT 0 0 12 O
increased JJ 0 1 1 O
rate NN 0 1 1 O
of IN 0 0 12 O
GI NNP 0 1 6 O
ulceration NN 0 1 8 O
or CC 0 0 12 O
other JJ 0 0 12 O
complications NNS 1 1 6 O
compared VBN 1 1 1 O
to TO 0 0 12 O
use VB 0 1 1 O
of IN 0 0 12 O
MOBIC NNP 0 1 UNK B-Brand
alone RB 0 1 12 O
. . 0 0 12 O

Also RB 0 0 2 O
due JJ 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
potential NN 0 1 1 O
for IN 0 0 12 O
additive JJ 0 1 16 O
effects NNS 1 1 1 O
such JJ 0 0 1 O
as IN 1 0 12 O
bradycardia NN 0 1 8 O
and CC 0 0 12 O
AV NNP 0 0 13 O
block NN 0 1 3 O
caution NN 0 0 1 O
is VBZ 1 0 12 O
warranted VBN 1 0 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
clonidine NN 0 1 0 B-Drug
with IN 0 0 12 O
agents NNS 1 1 1 O
known VBN 1 1 12 O
to TO 0 0 12 O
affect VB 0 1 1 O
sinus NN 0 1 6 O
node JJ 0 1 1 O
function NN 0 1 1 O
or CC 0 0 12 O
AV NNP 0 0 13 O
nodal JJ 0 1 8 O
conduction NN 0 1 6 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
digitalis NN 0 1 14 B-Group
calcium NN 0 1 14 B-Group
channel NN 0 1 1 I-Group
blockers NNS 1 0 6 I-Group
and CC 0 0 12 O
beta SYM 0 1 16 B-Group
- : 0 0 2 O
blockers NNS 1 0 6 I-Group
. . 0 0 12 O
) ) 0 0 2 O

Patients NNS 0 1 7 O
receiving VBG 1 1 1 O
both DT 0 0 12 O
indomethacin NN 0 1 14 B-Drug
and CC 0 0 12 O
furosemide NN 0 1 0 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
observed VBN 1 1 1 O
closely RB 0 0 1 O
to TO 0 0 12 O
determine VB 0 0 1 O
if IN 0 0 12 O
the DT 0 0 12 O
desired VBN 1 1 1 O
diuretic JJ 0 1 14 O
and CC 0 0 12 O
/ JJ 0 0 2 O
or CC 0 0 12 O
antihypertensive JJ 0 1 14 O
effect NN 0 1 1 O
of IN 0 0 12 O
furosemide NN 0 1 0 B-Drug
is VBZ 1 0 12 O
achieved VBN 1 0 1 O
. . 0 0 12 O

Fluoxetine NN 0 1 0 B-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
affect VB 0 1 1 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
clonazepam NN 0 1 0 B-Drug
. . 0 0 12 O

anemia NN 0 1 6 O

Due JJ 0 1 2 O
to TO 0 0 12 O
the DT 0 0 12 O
possibility NN 0 1 1 O
of IN 0 0 12 O
antagonism NN 0 1 UNK O
in IN 0 0 12 O
vivo NN 0 1 13 O
particularly RB 0 0 1 O
when WRB 0 0 12 O
bactericidal NN 0 1 UNK O
activity NN 0 1 1 O
is VBZ 1 0 12 O
desired VBN 1 1 1 O
this DT 0 0 12 O
drug NN 0 1 1 O
combination NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
. . 0 0 12 O

Patients NNS 0 1 7 O
should MD 0 0 12 O
report VB 0 1 1 O
to TO 0 0 12 O
their PRP$ 0 0 12 O
practitioners NNS 1 1 UNK O
any DT 0 0 12 O
new JJ 0 1 12 O
rashes NNS 1 1 6 O
itching VBG 1 1 6 O
mouth NN 0 1 3 O
sores NNS 1 1 UNK O
or CC 0 0 12 O
unusual JJ 0 1 12 O
taste NN 0 1 13 O
while IN 0 0 12 O
taking VBG 1 0 12 O
auranofin NN 0 1 UNK B-Drug
. . 0 0 12 O

Lithium NN 0 1 UNK B-Drug
carbonate NN 0 1 14 I-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
BID NNP 0 0 11 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
) ) 0 0 2 O
had VBD 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
valdecoxib NN 0 1 13 B-Drug
pharmacokinetics NNS 0 1 UNK O
. . 0 0 12 O

Patients NNS 0 1 7 O
with IN 0 0 12 O
HACA NNP 0 0 UNK O
titers NNS 1 1 14 O
may MD 0 0 1 O
have VB 0 0 12 O
allergic NN 0 1 6 O
or CC 0 0 12 O
hypersensitivity NN 0 1 6 O
reactions NNS 1 1 1 O
when WRB 0 0 12 O
treated VBN 1 1 1 O
with IN 0 0 12 O
other JJ 0 0 12 O
diagnostic JJ 0 1 6 B-Group
or CC 0 0 12 O
therapeutic JJ 0 1 6 B-Group
monoclonal JJ 0 1 13 I-Group
antibodies NNS 1 1 14 I-Group
. . 0 0 12 O

Hemodynamic NNP 0 1 7 O
and CC 0 0 12 O
electrophysiologic JJ 0 1 13 O
interactions NNS 1 1 UNK O
have VBP 0 0 12 O
also RB 0 0 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
after IN 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
with IN 0 0 12 O
propranolol JJ 0 1 16 B-Drug
diltiazem NN 0 1 0 B-Drug
and CC 0 0 12 O
verapamil NN 0 1 0 B-Drug
. . 0 0 12 O

. . 0 0 12 O

Ritonavir NN 0 1 0 B-Drug
: : 0 0 2 O
Coadministration NN 0 1 UNK O
of IN 0 0 12 O
ritonavir NN 0 1 16 B-Drug
with IN 0 0 12 O
VIRACEPT NNP 0 1 UNK B-Brand
resulted VBD 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
increase NN 0 1 1 O
in IN 0 0 12 O
nelfinavir JJ 0 1 16 B-Drug
plasma NN 0 1 14 O
AUC NNP 0 1 UNK O
and CC 0 0 12 O
very RB 0 1 12 O
little JJ 0 1 12 O
change NN 0 1 1 O
in IN 0 0 12 O
ritonavir NN 0 1 16 B-Drug
plasma NN 0 1 14 O
A.C NNP 0 0 UNK O
. . 0 0 12 O

increased VBN 1 1 1 O
plasminogen NN 0 1 14 O
antigen NN 0 1 14 O
and CC 0 0 12 O
activity NN 0 1 1 O
. . 0 0 12 O

Additives NNS 0 1 UNK O
may MD 0 0 1 O
be VB 0 0 12 O
incompatible JJ 0 1 13 O
; : 0 0 2 O

Exogenously RB 0 0 UNK O
administered VBN 1 1 1 O
insulin NN 0 1 14 B-Drug
may MD 0 0 1 O
begin VB 0 1 12 O
to TO 0 0 12 O
act VB 0 1 13 O
before IN 0 1 12 O
food NN 0 1 12 O
has VBZ 1 0 12 O
left VBN 1 1 12 O
the DT 0 0 12 O
stomach NN 0 1 6 O
and CC 0 0 12 O
lead NN 0 1 12 O
to TO 0 0 12 O
hypoglycemia NN 0 1 6 O
. . 0 0 12 O

Because IN 0 0 12 O
of IN 0 0 12 O
its PRP$ 1 0 12 O
lack NN 0 1 1 O
of IN 0 0 12 O
platelet NN 0 1 14 O
effects NNS 1 1 1 O
CELEBREX NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
not RB 0 1 12 O
a DT 0 0 12 O
substitute NN 0 0 16 O
for IN 0 0 12 O
aspirin NN 0 1 14 B-Brand
for IN 0 0 12 O
cardiovascular JJ 0 1 6 O
prophylaxis NN 0 1 6 O
. . 0 0 12 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interactions NNP 0 1 UNK O
Increases VBZ 0 1 UNK O
in IN 0 0 12 O
lymphocyte NN 0 1 13 O
counts NNS 1 1 1 O
related VBN 1 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
pharmacologic JJ 0 1 14 O
mechanism NN 0 1 13 O
of IN 0 0 12 O
action NN 0 1 13 O
are VBP 1 0 12 O
frequently RB 0 1 1 O
observed VBN 1 1 1 O
during IN 0 0 12 O
RAPTIVA NNP 0 1 UNK B-Brand
treatment NN 0 1 6 O
. . 0 0 12 O

Additive JJ 0 1 UNK O
sedative JJ 0 1 6 O
effects NNS 1 1 1 O
and CC 0 0 12 O
confusional JJ 0 1 13 O
states NNS 1 1 1 O
may MD 0 0 1 O
emerge VB 0 0 UNK O
if IN 0 0 12 O
levomepromazine NN 0 1 UNK B-Drug
is VBZ 1 0 12 O
given VBN 1 1 12 O
with IN 0 0 12 O
benzodiazepines NNS 1 1 14 B-Group
or CC 0 0 12 O
barbiturates NNS 1 1 14 B-Group
. . 0 0 12 O

Terbinafine JJ 0 1 UNK B-Drug
clearance NN 0 1 16 O
is VBZ 1 0 12 O
increased VBN 1 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
by IN 0 0 12 O
rifampin NN 0 1 16 B-Drug
a DT 0 0 12 O
CyP9 NNP 0 0 UNK O
enzyme NN 0 1 14 O
inducer NN 0 1 UNK O
and CC 0 0 12 O
decreased VBD 1 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
by IN 0 0 12 O
cimetidine NN 0 1 13 B-Drug
a DT 0 0 12 O
CyP9 NNP 0 0 UNK O
enzyme NN 0 1 14 O
inhibitor NN 0 1 14 O
. . 0 0 12 O

Sulfapyridine NN 0 1 UNK B-Drug
may MD 0 0 1 O
interact VB 0 0 UNK O
with IN 0 0 12 O
any DT 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
following NN 0 1 1 O
: : 0 0 2 O
- : 0 0 2 O
Acetaminophen NNP 0 1 0 B-Drug
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
Tylenol NNP 0 1 0 B-Brand
) ) 0 0 2 O
( ( 0 0 2 O
with IN 0 0 12 O
long RB 0 1 12 O
- : 0 0 2 O
term NN 0 1 1 O
high JJ 0 1 1 O
- : 0 0 2 O
dose NN 0 1 6 O
use NN 0 1 1 O
) ) 0 0 2 O
or CC 0 0 12 O

Therefore RB 0 0 1 O
when WRB 0 0 12 O
INSPRA NNP 0 1 UNK B-Brand
and CC 0 0 12 O
NSAIDs NNP 0 1 UNK B-Group
are VBP 1 0 12 O
used VBN 1 1 12 O
concomitantly RB 0 0 14 O
patients NNS 1 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
observed VBN 1 1 1 O
to TO 0 0 12 O
determine VB 0 0 1 O
whether IN 0 0 12 O
the DT 0 0 12 O
desired JJ 0 1 1 O
effect NN 0 1 1 O
on IN 0 0 12 O
blood NN 0 1 6 O
pressure NN 0 1 1 O
is VBZ 1 0 12 O
obtained VBN 1 1 1 O
. . 0 0 12 O

Drugs NNS 0 1 2 O
highly RB 0 1 1 O
bound IN 0 1 12 O
to TO 0 0 12 O
albumin VB 0 1 14 O
could MD 0 0 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
unbound JJ 0 0 UNK O
fraction NN 0 1 1 O
of IN 0 0 12 O
fosphenytoin NN 0 1 16 B-Drug
. . 0 0 12 O

When WRB 0 0 12 O
administered VBN 1 1 1 O
concurrently RB 0 0 1 O
the DT 0 0 12 O
following JJ 0 1 1 O
drugs NNS 1 1 6 O
may MD 0 0 1 O
interact VB 0 0 UNK O
with IN 0 0 12 O
amphotericin JJ 0 1 14 B-Drug
B NNP 0 0 2 I-Drug
: : 0 0 2 O
Antineoplastic JJ 0 1 UNK B-Group
agents NNS 1 1 1 I-Group
: : 0 0 2 O
may MD 0 0 1 O
enhance VB 0 1 UNK O
the DT 0 0 12 O
potential NN 0 1 1 O
for IN 0 0 12 O
renal JJ 0 1 6 O
toxicity NN 0 1 6 O
bronchospasm NN 0 1 13 O
and CC 0 0 12 O
hypotension NN 0 1 6 O
. . 0 0 12 O

Data NNP 0 1 2 O
suggest NN 0 1 1 O
that IN 0 0 12 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
oral JJ 0 1 6 O
ketoconazole NN 0 1 16 B-Drug
and CC 0 0 12 O
cisapride NN 0 1 UNK B-Drug
can MD 0 0 12 O
result VB 0 1 1 O
in IN 0 0 12 O
prolongation NN 0 1 6 O
of IN 0 0 12 O
the DT 0 0 12 O
QT NNP 0 1 13 O
interval NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
ECG NNP 0 1 6 O
. . 0 0 12 O

In IN 0 0 2 O
a DT 0 0 12 O
small JJ 0 1 12 O
( ( 0 0 2 O
n=9 JJ 0 1 UNK O
) ) 0 0 2 O
combination NN 0 1 1 O
study NN 0 1 1 O
of IN 0 0 12 O
ARAVA NNP 0 1 UNK B-Brand
with IN 0 0 12 O
methotrexate NN 0 1 16 B-Drug
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
fold JJ 0 1 3 O
elevation NN 0 1 1 O
in IN 0 0 12 O
liver NN 0 1 6 O
enzymes NNS 1 1 14 O
was VBD 1 0 12 O
seen VBN 1 1 12 O
in IN 0 0 12 O
9 CD 0 0 2 O
of IN 0 0 12 O
9 CD 0 0 2 O
patients NNS 1 1 6 O
. . 0 0 12 O

Ketamine NN 0 1 UNK B-Drug
: : 0 0 2 O
When WRB 0 0 12 O
administered VBN 1 1 1 O
to TO 0 0 12 O
patients NNS 1 1 6 O
on IN 0 0 12 O
a DT 0 0 12 O
thyroid JJ 0 1 6 B-Group
preparation NN 0 1 1 I-Group
this DT 0 0 12 O
parenteral JJ 0 1 14 O
anesthetic NN 0 1 13 B-Group
may MD 0 0 1 O
cause VB 0 1 12 O
hypertension NN 0 1 6 O
and CC 0 0 12 O
tachycardia NN 0 1 8 O
. . 0 0 12 O

The DT 0 0 2 O
safety NN 0 1 1 O
and CC 0 0 12 O
efficacy NN 0 1 UNK O
of IN 0 0 12 O
anakinra NN 0 1 13 B-Drug
used VBN 1 1 12 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
HUMIRA NNP 0 1 UNK B-Brand
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
studied VBN 1 0 1 O
. . 0 0 12 O

- : 0 0 2 O
a DT 0 0 12 O
sulfa NN 0 1 0 O
- : 0 0 2 O
based VBN 1 1 1 O
drug NN 0 1 1 O
such JJ 0 0 1 O
as IN 1 0 12 O
sulfamethoxazole JJ 0 1 13 B-Drug
- : 0 0 2 O
trimethoprim NN 0 1 16 B-Drug
( ( 0 0 2 O
Bactrim NNP 0 1 0 B-Brand
Septra NNP 0 1 0 B-Brand
) ) 0 0 2 O
sulfisoxazole NN 0 1 UNK B-Drug
( ( 0 0 2 O
Gantrisin NNP 0 1 UNK B-Brand
) ) 0 0 2 O
or CC 0 0 12 O
sulfasalazine NN 0 1 0 B-Drug
( ( 0 0 2 O
Azulfidine NNP 0 1 UNK B-Brand
) ) 0 0 2 O
; : 0 0 2 O

No DT 0 0 2 O
significant JJ 0 1 1 O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
hydrochlorothiazide NN 0 1 0 B-Drug
hydralazine NN 0 1 14 B-Drug
sulfinpyrazone NN 0 1 13 B-Drug
oral JJ 0 1 6 O
contraceptives NNS 1 1 13 B-Group
tolbutamide VBP 0 1 UNK B-Drug
or CC 0 0 12 O
warfarin VBP 0 1 14 B-Drug
have VBP 0 0 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
. . 0 0 12 O

No DT 0 0 2 O
drug NN 0 1 1 O
nutritional JJ 0 1 6 O
supplement NN 0 1 1 O
food NN 0 1 12 O
or CC 0 0 12 O
herb NN 0 1 UNK O
interactions NNS 1 1 UNK O
have VBP 0 0 12 O
yet RB 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
. . 0 0 12 O

A DT 0 0 2 O
study NN 0 1 1 O
published VBN 1 1 UNK O
in IN 0 0 12 O
9 CD 0 0 2 O
found VBD 1 1 12 O
that IN 0 0 12 O
vigabatrin NN 0 1 UNK B-Drug
causes VBZ 1 1 6 O
a DT 0 0 12 O
statistically RB 0 1 1 O
significant JJ 0 1 1 O
increase NN 0 1 1 O
in IN 0 0 12 O
plasma JJ 0 1 14 O
clearance NN 0 1 16 O
of IN 0 0 12 O
carbamazepine NN 0 1 16 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
inhibiting JJ 0 1 UNK O
effects NNS 1 1 1 O
of IN 0 0 12 O
anticholinergic JJ 0 1 13 B-Group
drugs NNS 1 1 6 I-Group
on IN 0 0 12 O
gastric JJ 0 1 6 O
hydrochloric JJ 0 0 16 O
acid NN 0 1 14 O
secretion NN 0 1 14 O
are VBP 1 0 12 O
antagonized VBN 1 0 UNK O
by IN 0 0 12 O
agents NNS 1 1 1 O
used VBN 1 1 12 O
to TO 0 0 12 O
treat VB 0 1 12 O
achlorhydria NNS 0 1 13 O
and CC 0 0 12 O
those DT 0 0 12 O
used VBN 1 1 12 O
to TO 0 0 12 O
test VB 0 1 1 O
gastric JJ 0 1 6 O
secretion NN 0 1 14 O
. . 0 0 12 O

The DT 0 0 2 O
optimal JJ 0 1 1 O
dose NN 0 1 6 O
of IN 0 0 12 O
indinavir NN 0 1 16 B-Drug
when WRB 0 0 12 O
given VBN 1 1 12 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
SUSTIVA NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
not RB 0 1 12 O
known VBN 1 1 12 O
. . 0 0 12 O

. . 0 0 12 O

The DT 0 0 2 O
mechanism NN 0 1 13 O
of IN 0 0 12 O
these DT 0 0 12 O
interactions NNS 1 1 UNK O
has VBZ 1 0 12 O
been VBN 1 0 12 O
evaluated VBN 1 1 1 O
in IN 0 0 12 O
in IN 0 0 12 O
vitro NN 0 1 UNK O
in IN 0 0 12 O
situ NN 0 0 1 O
and CC 0 0 12 O
in IN 0 0 12 O
vivo NN 0 1 13 O
animal NN 0 1 13 O
models NNS 1 1 UNK O
. . 0 0 12 O

Doxepin NNP 0 1 0 B-Drug
is VBZ 1 0 12 O
primarily RB 0 0 1 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
CYP9D9 NNP 0 0 UNK O
( ( 0 0 2 O
with IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
and CC 0 0 12 O
CYP9A9 NNP 0 0 UNK O
as IN 1 0 12 O
minor JJ 0 1 1 O
pathways NNS 1 1 13 O
) ) 0 0 2 O
. . 0 0 12 O

9 CD 0 0 2 O
% NN 0 0 18 O

Since IN 0 1 2 O
iloprost NN 0 1 13 B-Drug
inhibits NNS 0 1 UNK O
platelet VBP 0 1 14 O
function NN 0 1 1 O
there EX 0 0 12 O
is VBZ 1 0 12 O
a DT 0 0 12 O
potential JJ 0 1 1 O
for IN 0 0 12 O
increased VBN 1 1 1 O
risk NN 0 1 1 O
of IN 0 0 12 O
bleeding VBG 1 1 6 O
particularly RB 0 0 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
maintained VBN 1 1 1 O
on IN 0 0 12 O
anticoagulants NNS 1 1 13 B-Group
. . 0 0 12 O

aminosalicylic JJ 0 0 UNK B-Drug
acid NN 0 1 14 I-Drug
; : 0 0 2 O

Hydrochlorothiazide NN 0 1 0 B-Drug
: : 0 0 2 O
A DT 0 0 2 O
study NN 0 1 1 O
in IN 0 0 12 O
normal JJ 0 1 1 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
has VBZ 1 0 12 O
shown VBN 1 1 1 O
that IN 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
DynaCirc NNP 0 1 UNK B-Brand
( ( 0 0 2 O
isradipine NN 0 1 13 B-Drug
) ) 0 0 2 O
and CC 0 0 12 O
hydrochlorothiazide NN 0 1 0 B-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
result VB 0 1 1 O
in IN 0 0 12 O
altered JJ 0 1 1 O
pharmacoktnetics NNS 0 0 UNK O
of IN 0 0 12 O
either DT 0 1 12 O
drug NN 0 1 1 O
. . 0 0 12 O

Prior NNP 0 1 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
succinylcholine NN 0 1 16 B-Drug
can MD 0 0 12 O
potentiate VB 0 0 UNK O
the DT 0 0 12 O
neuromuscular JJ 0 1 6 O
blocking NN 0 1 UNK O
effects NNS 1 1 1 O
of IN 0 0 12 O
nondepolarizing VBG 0 0 UNK B-Group
agents NNS 1 1 1 I-Group
. . 0 0 12 O

Methadone NNP 0 1 0 B-Drug
dose NN 0 1 6 O
was VBD 1 0 12 O
increased VBN 1 1 1 O
by IN 0 0 12 O
a DT 0 0 12 O
mean NN 0 1 12 O
of IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
to TO 0 0 12 O
alleviate VB 0 0 1 O
withdrawal NN 0 1 1 O
symptoms NNS 1 1 6 O
. . 0 0 12 O

Catecholamine NNP 0 1 UNK O
- : 0 0 2 O
depleting NN 0 1 UNK O
drugs NNS 1 1 6 O
( ( 0 0 2 O
e.g. FW 0 0 UNK O
reserpine NN 0 1 UNK B-Drug
) ) 0 0 2 O
may MD 0 0 1 O
have VB 0 0 12 O
an DT 0 0 12 O
additive JJ 0 1 16 O
effect NN 0 1 1 O
when WRB 0 0 12 O
given VBN 1 1 12 O
with IN 0 0 12 O
beta JJ 0 1 16 B-Group
- : 0 0 2 O
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
. . 0 0 12 O

Hypoglycemics NNS 0 1 UNK B-Group

Sulindac NN 0 1 UNK B-Drug
: : 0 0 2 O
The DT 0 0 2 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
diflunisal NN 0 1 13 B-Drug
and CC 0 0 12 O
sulindac NN 0 1 13 B-Drug
in IN 0 0 12 O
normal JJ 0 1 1 O
volunteers NNS 1 1 UNK O
resulted VBD 1 1 1 O
in IN 0 0 12 O
lowering NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
active JJ 0 1 1 O
sulindac NN 0 1 13 O
sulfide NN 0 1 13 O
metabolite NN 0 1 UNK O
by IN 0 0 12 O
approximately RB 0 1 1 O
one CD 0 1 12 O
- : 0 0 2 O
third NN 0 1 12 O
. . 0 0 12 O

No DT 0 0 2 O
interaction NN 0 1 UNK O
trials NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
conducted VBN 1 1 1 O
with IN 0 0 12 O
MEPRON NNP 0 1 UNK B-Brand
and CC 0 0 12 O
rifabutin NN 0 1 13 B-Drug
. . 0 0 12 O

Clofibric JJ 0 0 UNK B-Drug_n
acid NN 0 1 14 I-Drug_n
: : 0 0 2 O
Combination NNP 0 1 UNK O
hormonal JJ 0 1 6 B-Group
contraceptives NNS 1 1 13 I-Group
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
clearance NN 0 1 16 O
of IN 0 0 12 O
clofibric JJ 0 0 UNK B-Drug_n
acid NN 0 1 14 I-Drug_n
. . 0 0 12 O

Cyclosporine NNP 0 1 UNK B-Drug
- : 0 0 2 O
L NNP 0 1 2 B-Drug
- : 0 0 2 O
arginine NN 0 1 13 I-Drug
may MD 0 0 1 O
counteract VB 0 0 UNK O
the DT 0 0 12 O
antinaturetic JJ 0 0 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
cyclosporin NN 0 1 14 B-Drug
. . 0 0 12 O

Coadministration NN 0 1 UNK O
with IN 0 0 12 O
valdecoxib NN 0 1 13 B-Drug
increased VBN 1 1 1 O
exposure NN 0 1 1 O
of IN 0 0 12 O
omeprazole NN 0 1 0 B-Drug
( ( 0 0 2 O
AUC NNP 0 1 UNK O
) ) 0 0 2 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

Therefore RB 0 0 1 O
if IN 0 0 12 O
concomitant JJ 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
such JJ 0 0 1 O
agents NNS 1 1 1 O
is VBZ 1 0 12 O
indicated JJ 0 1 1 O
they PRP 0 0 12 O
should MD 0 0 12 O
be VB 0 0 12 O
given VBN 1 1 12 O
with IN 0 0 12 O
caution NN 0 0 1 O
and CC 0 0 12 O
the DT 0 0 12 O
patient NN 0 1 6 O
's POS 0 1 12 O
serum JJ 0 1 14 O
potassium NN 0 1 14 O
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
frequently RB 0 1 1 O
. . 0 0 12 O

Discontinuation NN 0 1 UNK O
of IN 0 0 12 O
cimetidine NN 0 1 13 B-Drug
in IN 0 0 12 O
well RB 0 1 12 O
- : 0 0 2 O
controlled VBN 1 1 1 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
tricyclic JJ 0 0 14 B-Drug
antidepressants NNS 1 1 13 I-Drug
and CC 0 0 12 O
cimetidine NN 0 1 13 B-Drug
may MD 0 0 1 O
decrease VB 0 1 1 O
the DT 0 0 12 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
and CC 0 0 12 O
efficacy NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
antidepressants NNS 1 1 13 B-Drug
. . 0 0 12 O

Patients NNS 0 1 7 O
receiving VBG 1 1 1 O
digoxin NN 0 1 14 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
appropriately RB 0 0 1 O
. . 0 0 12 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Tests NNP 0 1 UNK O
Interactions NNP 0 1 UNK O
Hyperaminotransferasemia NNP 0 0 UNK O
: : 0 0 2 O
Significant JJ 0 1 2 O
elevations NNS 1 1 1 O
of IN 0 0 12 O
aminotransferase NN 0 1 13 O
( ( 0 0 2 O
SGOT NNP 0 0 14 O
[ NNP 0 0 2 O
S NNP 0 1 2 O
- : 0 0 2 O
AST NNP 0 1 13 O
] NNP 0 0 2 O
and CC 0 0 12 O
SGPT NNP 0 0 14 O
[ NNP 0 0 2 O
S NNP 0 1 2 O
- : 0 0 2 O
ALT NNP 0 1 13 O
] NNP 0 0 2 O
) ) 0 0 2 O
levels NNS 1 1 1 O
have VBP 0 0 12 O
occurred VBN 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
high JJ 0 1 1 O
percentage NN 0 1 1 O
of IN 0 0 12 O
patients NNS 1 1 6 O
( ( 0 0 2 O
and CC 0 0 12 O
healthy JJ 0 1 12 O
subjects NNS 1 1 UNK O
) ) 0 0 2 O
who WP 0 0 12 O
have VBP 0 0 12 O
received VBN 1 1 12 O
heparin JJ 0 1 14 B-Drug
sodium NN 0 1 14 I-Drug
. . 0 0 12 O

Ketoconazole NNP 0 1 UNK B-Drug

Therapeutic JJ 0 1 UNK O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
warfarin NN 0 1 14 B-Drug
ibuprofen NN 0 1 0 B-Drug
naproxen JJ 0 1 16 B-Drug
piroxicam NN 0 1 13 B-Drug
acetaminophen NN 0 1 16 B-Drug
phenytoin NN 0 1 16 B-Drug
andtolbutamide RB 0 0 UNK O
did VBD 1 0 12 O
not RB 0 1 12 O
alter VB 0 1 13 O
ketorolac NN 0 1 16 B-Drug
tromethamine NN 0 1 13 I-Drug
protein NN 0 1 14 O
binding NN 0 1 1 O
. . 0 0 12 O

Ergot NNP 0 1 UNK B-Group
- : 0 0 2 O
containing VBG 1 1 1 O
drugs NNS 1 1 6 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
cause VB 0 1 12 O
prolonged JJ 0 1 6 O
vasospastic JJ 0 0 UNK O
reactions NNS 1 1 1 O
. . 0 0 12 O

Dosage NNP 0 1 UNK O
reduction NN 0 1 1 O
of IN 0 0 12 O
Cerubidine NNP 0 1 UNK B-Brand
may MD 0 0 1 O
be VB 0 0 12 O
required VBN 1 1 1 O
when WRB 0 0 12 O
used VBN 1 1 12 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
other JJ 0 0 12 O
myelosuppressive JJ 0 0 UNK O
agents NNS 1 1 1 O
. . 0 0 12 O

Therefore RB 0 0 1 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
probenecid NN 0 1 13 B-Drug
will MD 0 0 12 O
have VB 0 0 12 O
erroneously RB 0 0 UNK O
low JJ 0 1 1 O
ERPF NNP 0 1 UNK O
and CC 0 0 12 O
Tm NNP 0 1 13 O
PAH NNP 0 1 UNK B-Drug
values NNS 1 1 1 O
. . 0 0 12 O

Co NNP 0 1 2 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
tacrolimus NN 0 1 16 B-Drug
and CC 0 0 12 O
bosentan NN 0 1 13 B-Drug
resulted VBD 1 1 1 O
in IN 0 0 12 O
markedly RB 0 1 1 O
increased VBN 1 1 1 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
bosentan NN 0 1 13 B-Drug
in IN 0 0 12 O
animals NNS 1 1 12 O
. . 0 0 12 O

The DT 0 0 2 O
interaction NN 0 1 UNK O
was VBD 1 0 12 O
pharmacodynamic JJ 0 1 UNK O
; : 0 0 2 O

Cromolyn NNP 0 1 UNK B-Drug
sodium NN 0 1 14 I-Drug
alone RB 0 1 12 O
in IN 0 0 12 O
doses NNS 1 1 6 O
up RB 0 0 12 O
to TO 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
kg JJ 0 1 18 O
/ JJ 0 0 2 O
day NN 0 1 12 O
( ( 0 0 2 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
times NNS 1 1 12 O
the DT 0 0 12 O
maximum NN 0 1 1 O
recommended VBD 1 1 1 O
daily JJ 0 1 12 O
inhalation NN 0 1 16 O
dose NN 0 1 6 O
in IN 0 0 12 O
adults NNS 1 1 13 O
on IN 0 0 12 O
a DT 0 0 12 O
mg NN 0 1 0 O
/ NN 0 0 2 O
m9 JJ 0 1 UNK O
basis NN 0 1 1 O
) ) 0 0 2 O
did VBD 1 0 12 O
not RB 0 1 12 O
cause VB 0 1 12 O
significant JJ 0 1 1 O
increases NNS 1 1 1 O
in IN 0 0 12 O
resorptions NNS 1 1 UNK O
or CC 0 0 12 O
major JJ 0 1 1 O
malformations NNS 1 1 8 O
. . 0 0 12 O

Because IN 0 0 12 O
their PRP$ 0 0 12 O
vasospastic JJ 0 0 UNK O
effects NNS 1 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
additive JJ 0 1 16 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
naratriptan NN 0 1 13 B-Drug
and CC 0 0 12 O
other JJ 0 0 12 O
9 CD 0 0 2 B-Group
- : 0 0 2 O
HT9 NN 0 1 UNK I-Group
agonists NNS 1 1 UNK I-Group
within IN 0 0 1 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
of IN 0 0 12 O
each DT 0 0 12 O
other JJ 0 0 12 O
is VBZ 1 0 12 O
not RB 0 1 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O

Triprolidine NN 0 1 UNK B-Drug
may MD 0 0 1 O
enhance VB 0 1 UNK O
the DT 0 0 12 O
sedative JJ 0 1 6 O
effects NNS 1 1 1 O
of IN 0 0 12 O
central JJ 0 1 1 B-Group
nervous JJ 0 1 6 I-Group
system NN 0 1 1 I-Group
depressants NNS 1 0 13 I-Group
including VBG 1 1 1 O
alcohol NN 0 1 1 B-Drug
barbiturates NNS 1 1 14 B-Group
hypnotics NNS 1 1 13 B-Group
narcotic JJ 0 1 6 B-Group
analgesics NNS 1 1 14 I-Group
sedatives NNS 1 1 6 B-Group
and CC 0 0 12 O
tranquillisers NNS 1 1 UNK B-Group
. . 0 0 12 O

however RB 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
OH NNP 0 1 UNK O
metabolite JJ 0 1 UNK O
concentrations NNS 1 1 13 O
were VBD 1 0 12 O
increased.Because RB 0 1 UNK O
clarithromycin JJ 0 1 13 B-Drug
active JJ 0 1 1 O
metabolite NN 0 1 UNK O
has VBZ 1 0 12 O
reduced VBN 1 1 1 O
activity NN 0 1 1 O
against IN 0 0 12 O
Mycobacteriumavium NNP 0 0 UNK O
- : 0 0 2 O
intracellulare NN 0 0 UNK O
complex JJ 0 1 1 O
overallactivity NN 0 0 UNK O
against IN 0 0 12 O
this DT 0 0 12 O
pathogen NN 0 1 14 O
may MD 0 0 1 O
bealtered VB 0 0 UNK O
. . 0 0 12 O

You PRP 0 0 2 O
may MD 0 0 1 O
require VB 0 0 1 O
a DT 0 0 12 O
dosage NN 0 1 0 O
adjustment NN 0 1 1 O
or CC 0 0 12 O
special JJ 0 1 12 O
monitoring NN 0 1 1 O
if IN 0 0 12 O
you PRP 0 0 12 O
are VBP 1 0 12 O
taking VBG 1 0 12 O
any DT 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
medicines NNS 1 1 6 O
listed VBN 1 1 1 O
above RB 0 1 12 O
. . 0 0 12 O

However RB 0 0 1 O
because IN 0 0 12 O
both DT 0 0 12 O
of IN 0 0 12 O
these DT 0 0 12 O
compounds NNS 1 1 13 O
have VBP 0 0 12 O
CNS NNP 0 1 6 O
effects NNS 1 1 1 O
an DT 0 0 12 O
additive JJ 0 1 16 O
pharmacodynamic JJ 0 1 UNK O
effect NN 0 1 1 O
is VBZ 1 0 12 O
possible JJ 0 1 1 O
. . 0 0 12 O

Sympathomimetic JJ 0 1 UNK B-Group
Agents NNS 0 1 2 I-Group
: : 0 0 2 O
Possible NNP 0 1 2 O
increased VBD 1 1 1 O
risk NN 0 1 1 O
of IN 0 0 12 O
coronary JJ 0 1 6 O
insufficiency NN 0 1 6 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
coronary JJ 0 1 6 O
artery NN 0 1 6 O
disease NN 0 1 6 O
. . 0 0 12 O

Ethopropazine NN 0 1 UNK B-Drug
may MD 0 0 1 O
interact VB 0 0 UNK O
with IN 0 0 12 O
alcohol NN 0 1 1 B-Drug
or CC 0 0 12 O
other JJ 0 0 12 O
CNS NNP 0 1 6 B-Group
depressants NNS 1 0 13 I-Group
causing VBG 1 1 1 O
increased VBD 1 1 1 O
sedative JJ 0 1 6 O
effects NNS 1 1 1 O
. . 0 0 12 O

On IN 0 0 2 O
day NN 0 1 12 O
9 CD 0 0 2 O
acetaminophen NN 0 1 16 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg RB 0 1 0 O
four CD 0 1 12 O
times NNS 1 1 12 O
daily RB 0 1 12 O
) ) 0 0 2 O
was VBD 1 0 12 O
started VBN 1 1 12 O
and CC 0 0 12 O
continued VBN 1 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
. . 0 0 12 O

Metoclopramide NN 0 1 0 B-Drug
: : 0 0 2 O
When WRB 0 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
MONUROL NNP 0 1 UNK B-Brand
metoclopramide VBP 0 1 16 B-Drug
a DT 0 0 12 O
drug NN 0 1 1 O
which WDT 0 0 12 O
increases VBZ 1 1 1 O
gastrointestinal JJ 0 1 6 O
motility NN 0 1 6 O
lowers VBZ 1 1 UNK O
the DT 0 0 12 O
serum NN 0 1 14 O
concentration NN 0 1 1 O
and CC 0 0 12 O
urinary JJ 0 1 6 O
excretion NN 0 1 14 O
of IN 0 0 12 O
fosfomycin NN 0 1 13 B-Drug
. . 0 0 12 O

as IN 1 0 12 O
such JJ 0 0 1 O
it PRP 0 0 12 O
may MD 0 0 1 O
impair VB 0 0 13 O
intestinal JJ 0 1 13 O
absorption NN 0 1 1 O
of IN 0 0 12 O
any DT 0 0 12 O
of IN 0 0 12 O
vitamin NN 0 1 6 B-Group
D NNP 0 1 2 I-Group
. . 0 0 12 O

This DT 0 0 2 O
should MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
whenever WRB 0 0 12 O
these DT 0 0 12 O
agents NNS 1 1 1 O
are VBP 1 0 12 O
prescribed VBN 1 1 1 O
concomitantly RB 0 0 14 O
. . 0 0 12 O

ACE NNP 0 1 13 B-Group
Inhibitors NNP 0 1 7 I-Group
and CC 0 0 12 O
Angiotensin NNP 0 1 UNK B-Group
II NNP 0 0 2 I-Group
Receptor NNP 0 1 UNK I-Group
Antagonists NNP 0 1 UNK I-Group
( ( 0 0 2 O
Congestive NNP 0 1 7 O
Heart NNP 0 1 2 O
Failure NNP 0 1 2 O
Post NNP 0 1 2 O
- : 0 0 2 O
Myocardial NNP 0 1 7 O
Infarction NNP 0 1 7 O
) ) 0 0 2 O
- : 0 0 2 O
In IN 0 0 2 O
EPHESUS NNP 0 0 UNK O
9 CD 0 0 2 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
INSPRA NNP 0 1 UNK B-Brand
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
also RB 0 0 12 O
received VBD 1 1 12 O
ACE NNP 0 1 13 B-Group
inhibitors NNS 1 1 14 I-Group
or CC 0 0 12 O
angiotensin NN 0 1 UNK B-Group
II NNP 0 0 2 I-Group
receptor NN 0 1 14 I-Group
antagonists NNS 1 1 13 I-Group
( ( 0 0 2 O
ACEI NNP 0 0 UNK B-Group
/ NNP 0 0 2 O
ARB NNP 0 1 UNK B-Group
) ) 0 0 2 O
. . 0 0 12 O

The DT 0 0 2 O
mechanism NN 0 1 13 O
for IN 0 0 12 O
this DT 0 0 12 O
interaction NN 0 1 UNK O
is VBZ 1 0 12 O
not RB 0 1 12 O
known VBN 1 1 12 O
. . 0 0 12 O

If IN 0 0 12 O
a DT 0 0 12 O
patient NN 0 1 6 O
is VBZ 1 0 12 O
truly RB 0 0 UNK O
hypothyroid JJ 0 1 6 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
likely JJ 0 1 12 O
that IN 0 0 12 O
a DT 0 0 12 O
reduction NN 0 1 1 O
in IN 0 0 12 O
anticoagulant JJ 0 1 13 B-Group
dosage NN 0 1 0 O
will MD 0 0 12 O
be VB 0 0 12 O
required VBN 1 1 1 O
. . 0 0 12 O

dosage NN 0 1 0 O
adjustments NNS 1 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
necessary JJ 0 0 1 O
. . 0 0 12 O
) ) 0 0 2 O

No DT 0 0 2 O
clinically RB 0 0 6 O
relevant JJ 0 1 1 O
drug NN 0 1 1 O
- : 0 0 2 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
have VBP 0 0 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
with IN 0 0 12 O
drugs NNS 1 1 6 O
likely JJ 0 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
with IN 0 0 12 O
anidulafungin NN 0 1 13 B-Drug
. . 0 0 12 O

Absorption NN 0 1 UNK O
of IN 0 0 12 O
tetracycline NN 0 1 0 B-Drug
is VBZ 1 0 12 O
impaired VBN 1 1 6 O
by IN 0 0 12 O
bismuth NN 0 1 16 B-Drug
subsalicylate NN 0 0 16 I-Drug
. . 0 0 12 O

Patients NNS 0 1 7 O
treated VBN 1 1 1 O
with IN 0 0 12 O
a DT 0 0 12 O
beta NN 0 1 16 B-Group
- : 0 0 2 O
adrenergic JJ 0 1 UNK I-Group
receptor NN 0 1 14 I-Group
blocking VBG 1 1 UNK I-Group
agent JJ 0 1 1 I-Group
plus CC 0 1 16 O
a DT 0 0 12 O
catecholamine JJ 0 1 14 O
depletor NN 0 0 UNK O
should MD 0 0 12 O
therefore RB 0 0 1 O
be VB 0 0 12 O
closely RB 0 0 1 O
observed VBN 1 1 1 O
for IN 0 0 12 O
evidence NN 0 1 1 O
of IN 0 0 12 O
hypotension NN 0 1 6 O
or CC 0 0 12 O
marked VBN 1 1 1 O
bradycardia IN 0 1 8 O
which WDT 0 0 12 O
may MD 0 0 1 O
produce VB 0 0 1 O
vertigo JJ 0 1 6 O
syncope NN 0 1 8 O
or CC 0 0 12 O
postural JJ 0 1 13 O
hypotension NN 0 1 6 O
. . 0 0 12 O

Lopinavir NNP 0 1 UNK B-Drug
/ NNP 0 0 2 O
ritonavir NN 0 1 16 B-Drug

Cimetidine NN 0 1 0 B-Drug
: : 0 0 2 O
Cimetidine NN 0 1 0 B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
produce VB 0 0 1 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
fluctuations NNS 1 1 UNK O
in IN 0 0 12 O
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
serum JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
various JJ 0 1 1 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
. . 0 0 12 O

An DT 0 0 2 O
encephalopathic JJ 0 1 8 O
syndrome NN 0 1 6 O
( ( 0 0 2 O
characterized VBN 1 1 1 O
by IN 0 0 12 O
weakness NN 0 1 6 O
lethargy NN 0 1 6 O
fever NN 0 1 6 O
tremulousness NN 0 1 15 O
and CC 0 0 12 O
confusion NN 0 1 1 O
extrapyramidal NN 0 0 13 O
symptoms NNS 1 1 6 O
leukocytosis NN 0 1 8 O
elevated VBD 1 1 1 O
serum JJ 0 1 14 O
enzymes NNS 1 1 14 O
BUN NNP 0 0 14 O
and CC 0 0 12 O
FBS NNP 0 1 13 O
) ) 0 0 2 O
followed VBN 1 1 12 O
by IN 0 0 12 O
irreversible JJ 0 0 6 O
brain NN 0 1 6 O
damage NN 0 1 1 O
has VBZ 1 0 12 O
occurred VBN 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
few JJ 0 1 12 O
patients NNS 1 1 6 O
treated VBN 1 1 1 O
with IN 0 0 12 O
lithium NN 0 1 16 B-Drug
plus CC 0 1 16 O
HALDOL NNP 0 1 0 B-Brand
. . 0 0 12 O

Flurbiprofen NNP 0 1 UNK B-Drug
pretreatment NN 0 1 UNK O
attenuated VBD 1 1 UNK O
the DT 0 0 12 O
hypotensive JJ 0 1 14 O
effect NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
propranolol NN 0 1 16 B-Drug
but CC 0 0 12 O
not RB 0 1 12 O
atenolol RB 0 1 0 B-Drug
. . 0 0 12 O

Anticoagulants NNS 0 1 UNK B-Group
: : 0 0 2 O
Coagulation NN 0 1 7 O
parameters NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
tested VBN 1 1 1 O
more RBR 0 1 12 O
frequently RB 0 1 1 O
and CC 0 0 12 O
monitored VBD 1 1 1 O
regularly RB 0 0 12 O
during IN 0 0 12 O
simultaneous JJ 0 1 13 O
administration NN 0 1 1 O
of IN 0 0 12 O
high JJ 0 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
heparin JJ 0 1 14 B-Drug
oral JJ 0 1 6 O
anticoagulants NNS 1 1 13 B-Group
or CC 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
may MD 0 0 1 O
affect VB 0 1 1 O
the DT 0 0 12 O
blood NN 0 1 6 O
coagulation NN 0 1 14 O
system NN 0 1 1 O
or CC 0 0 12 O
the DT 0 0 12 O
thrombocyte JJ 0 1 13 O
function NN 0 1 1 O
. . 0 0 12 O

Concomitant JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
naproxen JJ 0 1 16 B-Drug
and CC 0 0 12 O
aspirin NN 0 1 14 B-Brand
is VBZ 1 0 12 O
not RB 0 1 12 O
recommended VBN 1 1 1 O
because IN 0 0 12 O
naproxen NN 0 1 16 B-Drug
is VBZ 1 0 12 O
displaced VBN 1 1 1 O
from IN 0 0 12 O
its PRP$ 1 0 12 O
binding NN 0 1 1 O
sites NNS 1 1 1 O
during IN 0 0 12 O
the DT 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
aspirin JJ 0 1 14 B-Brand
resulting VBG 1 1 1 O
in IN 0 0 12 O
lower JJR 1 1 1 O
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
and CC 0 0 12 O
peak VB 0 1 1 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
. . 0 0 12 O

Co NNP 0 1 2 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
BOTOX NNP 0 1 UNK B-Brand
and CC 0 0 12 O
aminoglycosides NNS 0 1 13 B-Group
or CC 0 0 12 O
other JJ 0 0 12 O
agents NNS 1 1 1 O
interfering VBG 1 1 13 O
with IN 0 0 12 O
neuromuscular JJ 0 1 6 O
transmission NN 0 1 1 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
curare NN 0 1 UNK B-Group
- : 0 0 2 O
like IN 0 0 12 I-Group
compounds NNS 1 1 13 I-Group
) ) 0 0 2 O
should MD 0 0 12 O
only RB 0 1 12 O
be VB 0 0 12 O
performed VBN 1 1 1 O
with IN 0 0 12 O
caution NN 0 0 1 O
as IN 1 0 12 O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
toxin NN 0 1 14 B-Drug
may MD 0 0 1 O
be VB 0 0 12 O
potentiated VBN 1 0 UNK O
. . 0 0 12 O

Concomitant JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
vancomycin NN 0 1 14 B-Drug
and CC 0 0 12 O
anesthetic JJ 0 1 13 B-Group
agents NNS 1 1 1 I-Group
has VBZ 1 0 12 O
been VBN 1 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
erythema NN 0 1 8 O
and CC 0 0 12 O
histamine VB 0 1 UNK O
- : 0 0 2 O
like IN 0 0 12 O
flushing VBG 1 1 13 O
and CC 0 0 12 O
anaphylactoid JJ 0 1 UNK O
reactions NNS 1 1 1 O
. . 0 0 12 O

HIV NNP 0 1 6 B-Group
Antiviral NNP 0 1 UNK I-Group
Agents NNS 0 1 2 I-Group

To TO 0 0 2 O
avoid VB 0 0 12 O
this DT 0 0 12 O
interaction NN 0 1 UNK O
delavirdine NN 0 1 13 B-Drug
or CC 0 0 12 O
indinavir NN 0 1 16 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
given VBN 1 1 12 O
9 CD 0 0 2 O
hour NN 0 1 12 O
prior RB 0 1 1 O
to TO 0 0 12 O
dosing VBG 1 0 14 O
with IN 0 0 12 O
VIDEX NNP 0 1 UNK B-Brand
. . 0 0 12 O

Dose NNP 0 1 7 O
adjustment NN 0 1 1 O
of IN 0 0 12 O
Zemplar JJ 0 1 UNK B-Brand
Capsules NNS 0 1 0 O
may MD 0 0 1 O
be VB 0 0 12 O
required VBN 1 1 1 O
and CC 0 0 12 O
iPTH JJ 0 0 UNK O
and CC 0 0 12 O
serum JJ 0 1 14 O
calcium NN 0 1 14 O
concentrations NNS 1 1 13 O
should MD 0 0 12 O
be VB 0 0 12 O
closely RB 0 0 1 O
monitored VBN 1 1 1 O
if IN 0 0 12 O
a DT 0 0 12 O
patient NN 0 1 6 O
initiates VBZ 1 1 UNK O
or CC 0 0 12 O
discontinues NNS 0 1 UNK O
therapy VBP 0 1 6 O
with IN 0 0 12 O
a DT 0 0 12 O
strong JJ 0 1 12 O
CYP9A9 NNP 0 0 UNK O
inhibitor NN 0 1 14 O
such JJ 0 0 1 O
as IN 1 0 12 O
ketoconazole NN 0 1 16 B-Drug
. . 0 0 12 O

Taking VBG 0 0 UNK O
amyl RP 0 0 13 B-Drug
nitrite RB 0 1 13 I-Drug
after IN 0 0 12 O
drinking VBG 1 1 12 O
alcohol NN 0 1 1 B-Drug
may MD 0 0 1 O
worsen VB 0 1 6 O
side NN 0 1 3 O
effects NNS 1 1 1 O
and CC 0 0 12 O
may MD 0 0 1 O
cause VB 0 1 12 O
severe JJ 0 1 6 O
hypotension NN 0 1 6 O
and CC 0 0 12 O
cardiovascular JJ 0 1 6 O
collapse NN 0 1 1 O
. . 0 0 12 O

Other JJ 0 0 2 O
Drug NNP 0 1 2 O
Interaction NNP 0 1 2 O
Information NNP 0 1 2 O
Digoxin NNP 0 1 0 B-Drug
: : 0 0 2 O
Studies NNS 0 1 2 O
in IN 0 0 12 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
have VBP 0 0 12 O
shown VBN 1 1 1 O
that IN 0 0 12 O
TIKOSYN NNP 0 1 UNK B-Brand
does VBZ 1 0 12 O
not RB 0 1 12 O
affect VB 0 1 1 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
. . 0 0 12 O

9 CD 0 0 2 O
. . 0 0 12 O

Serious JJ 0 1 UNK O
anticholinergic NN 0 1 13 O
symptoms NNS 1 1 6 O
( ( 0 0 2 O
i.e. FW 0 1 1 O
severe RB 0 1 6 O
dry JJ 0 1 3 O
mouth NN 0 1 3 O
urinary JJ 0 1 6 O
retention NN 0 1 1 O
and CC 0 0 12 O
blurred JJ 0 1 3 O
vision NN 0 1 1 O
) ) 0 0 2 O
have VBP 0 0 12 O
been VBN 1 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
elevations NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
serum NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressant NN 0 1 6 I-Group
when WRB 0 0 12 O
cimetidine NN 0 1 13 B-Drug
therapy NN 0 1 6 O
is VBZ 1 0 12 O
initiated VBN 1 1 1 O
. . 0 0 12 O

Dopamine JJ 0 1 7 B-Group
antagonists NNS 1 1 13 I-Group
: : 0 0 2 O
Since IN 0 1 2 O
pramipexole NN 0 1 16 B-Drug
is VBZ 1 0 12 O
a DT 0 0 12 O
dopamine JJ 0 1 14 B-Group
agonist NN 0 1 14 I-Group
it PRP 0 0 12 O
is VBZ 1 0 12 O
possible JJ 0 1 1 O
that IN 0 0 12 O
dopamine JJ 0 1 14 B-Group
antagonists NNS 1 1 13 I-Group
such JJ 0 0 1 O
as IN 1 0 12 O
the DT 0 0 12 O
neuroleptics NNS 1 1 13 B-Group
( ( 0 0 2 O
phenothiazines NNS 1 1 UNK B-Group
butyrophenones NNS 0 1 UNK B-Group
thioxanthenes NNS 0 1 UNK B-Group
) ) 0 0 2 O
or CC 0 0 12 O
metoclopramide NN 0 1 16 B-Group
may MD 0 0 1 O
diminish VB 0 1 UNK O
the DT 0 0 12 O
effectiveness NN 0 1 UNK O
of IN 0 0 12 O
MIRAPEX NNP 0 1 UNK B-Brand
. . 0 0 12 O

In IN 0 0 2 O
post NN 0 1 12 O
- : 0 0 2 O
marketing NN 0 1 UNK O
experience NN 0 1 12 O
as IN 1 0 12 O
with IN 0 0 12 O
other JJ 0 0 12 O
azole JJ 0 1 UNK B-Group
antifungals NNS 1 1 UNK I-Group
bleeding VBG 1 1 6 O
events NNS 1 1 12 O
( ( 0 0 2 O
bruising VBG 1 1 6 O
epistaxis RB 0 1 8 O
gastrointestinal JJ 0 1 6 O
bleeding NN 0 1 6 O
hematuria NN 0 1 8 O
and CC 0 0 12 O
melena NN 0 1 8 O
) ) 0 0 2 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
association NN 0 1 1 O
with IN 0 0 12 O
increases NNS 1 1 1 O
in IN 0 0 12 O
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
fluconazole JJ 0 1 0 B-Drug
concurrently RB 0 0 1 O
with IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
. . 0 0 12 O

Drugs NNS 0 1 2 O
Within NNP 0 0 2 O
Class NNP 0 1 2 O
Not RB 0 1 2 O
To TO 0 0 2 O
Be VB 0 0 UNK O
Coadministered VBN 0 0 UNK O
With IN 0 0 2 O
SUSTIVA NNP 0 1 UNK B-Brand

Since IN 0 1 2 O
acetaminophen NN 0 1 16 B-Drug
in IN 0 0 12 O
high JJ 0 1 1 O
doses NNS 1 1 6 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
hepatotoxicity NN 0 1 13 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
diflunisal NN 0 1 13 B-Drug
and CC 0 0 12 O
acetaminophen NN 0 1 16 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
cautiously RB 0 0 UNK O
with IN 0 0 12 O
careful JJ 0 1 12 O
monitoring NN 0 1 1 O
of IN 0 0 12 O
patients NNS 1 1 6 O
. . 0 0 12 O

Administration NN 0 1 UNK O
of IN 0 0 12 O
WELLBUTRIN NNP 0 1 0 B-Brand
Tablets NNP 0 1 0 O
to TO 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
either CC 0 1 12 O
levodopa NN 0 1 UNK B-Drug
or CC 0 0 12 O
amantadine VB 0 1 16 B-Drug
concurrently RB 0 0 1 O
should MD 0 0 12 O
be VB 0 0 12 O
undertaken VBN 1 0 1 O
with IN 0 0 12 O
caution NN 0 0 1 O
using VBG 1 1 1 O
small JJ 0 1 12 O
initial JJ 0 1 1 O
doses NNS 1 1 6 O
and CC 0 0 12 O
small JJ 0 1 12 O
gradual JJ 0 1 1 O
dose NN 0 1 6 O
increases NNS 1 1 1 O
. . 0 0 12 O

There EX 0 0 12 O
are VBP 1 0 12 O
rare JJ 0 1 12 O
reports NNS 1 1 1 O
however RB 0 0 12 O
from IN 0 0 12 O
marketing VBG 1 1 UNK O
experiences NNS 1 1 12 O
of IN 0 0 12 O
changes NNS 1 1 1 O
in IN 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
insulin NN 0 1 14 B-Drug
or CC 0 0 12 O
oral JJ 0 1 6 O
hypoglycemic JJ 0 1 14 B-Group
agents NNS 1 1 1 I-Group
in IN 0 0 12 O
the DT 0 0 12 O
presence NN 0 1 1 O
of IN 0 0 12 O
diclofenac NN 0 1 16 B-Drug
that WDT 0 0 12 O
necessitated VBD 1 0 1 O
changes NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
doses NNS 1 1 6 O
of IN 0 0 12 O
such JJ 0 0 1 O
agents NNS 1 1 1 O
. . 0 0 12 O

Acetazolamide NNP 0 1 0 B-Drug
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
other JJ 0 0 12 O
folic JJ 0 0 14 B-Group
acid NN 0 1 14 I-Group
antagonists NNS 1 1 13 I-Group
. . 0 0 12 O

Subjects NNS 0 1 UNK O
who WP 0 0 12 O
do VBP 0 0 12 O
not RB 0 1 12 O
metabolize VB 0 0 UNK O
losartan NN 0 1 0 B-Drug
to TO 0 0 12 O
active JJ 0 1 1 O
metabolite NNS 0 1 UNK O
have VBP 0 0 12 O
been VBN 1 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
have VB 0 0 12 O
a DT 0 0 12 O
specific JJ 0 1 1 O
rare JJ 0 1 12 O
defect NN 0 1 1 O
in IN 0 0 12 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
9C9 CD 0 0 UNK O
. . 0 0 12 O

Amiodarone NNP 0 1 0 B-Drug
disopyramide NN 0 1 16 B-Drug
lidocaine NN 0 1 14 B-Drug

HIV NNP 0 1 6 B-Group
Protease NNP 0 1 UNK I-Group
Inhibitors NNS 0 1 7 I-Group
: : 0 0 2 O
Indinavir NNP 0 1 UNK B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
t.i.d NN 0 1 UNK O
. . 0 0 12 O
) ) 0 0 2 O
co SYM 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
with IN 0 0 12 O
Vardenafil NNP 0 1 UNK B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
resulted VBD 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
fold JJ 0 1 3 O
increase NN 0 1 1 O
in IN 0 0 12 O
vardenafil JJ 0 1 UNK B-Drug
AUC NNP 0 1 UNK O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
fold JJ 0 1 3 O
increase NN 0 1 1 O
in IN 0 0 12 O
vardenafil JJ 0 1 UNK B-Drug
Cmax NNP 0 1 UNK O
and CC 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
fold JJ 0 1 3 O
increase NN 0 1 1 O
in IN 0 0 12 O
vardenafil JJ 0 1 UNK B-Drug
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
. . 0 0 12 O

Rifampin NN 0 1 0 B-Drug
: : 0 0 2 O
When WRB 0 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
9 CD 0 0 2 O
- : 0 0 2 O
mg NN 0 1 0 O
dose NN 0 1 6 O
of IN 0 0 12 O
Aprepitant NNP 0 1 UNK B-Drug
was VBD 1 0 12 O
administered VBN 1 1 1 O
on IN 0 0 12 O
Day9 NNP 0 0 UNK O
of IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
day NN 0 1 12 O
regimen NNS 0 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
of IN 0 0 12 O
rifampin NN 0 1 16 B-Drug
a DT 0 0 12 O
strong JJ 0 1 12 O
CYP9A9 NNP 0 0 UNK O
inducer NN 0 1 UNK O
the DT 0 0 12 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
aprepitant NN 0 1 13 B-Drug
decreased VBD 1 1 1 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
- : 0 0 2 O
fold NN 0 1 3 O
and CC 0 0 12 O
the DT 0 0 12 O
mean JJ 0 1 12 O
terminal JJ 0 1 1 O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
decreased VBD 1 1 1 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
- : 0 0 2 O
fold NN 0 1 3 O
. . 0 0 12 O

Dextromethorphan NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
a DT 0 0 12 O
substrate NN 0 1 UNK O
for IN 0 0 12 O
both DT 0 0 12 O
CYP9D9 NNP 0 0 UNK B-Drug
and CC 0 0 12 O
CYP9A9 NNP 0 0 UNK B-Drug
. . 0 0 12 O

No DT 0 0 2 O
formal JJ 0 1 1 O
assessments NNS 1 1 13 O
of IN 0 0 12 O
pharmacokinetic JJ 0 1 UNK O
drug NN 0 1 1 O
- : 0 0 2 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
between IN 0 0 12 O
TRISENOX NNP 0 1 UNK B-Brand
and CC 0 0 12 O
other JJ 0 0 12 O
agents NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
conducted VBN 1 1 1 O
. . 0 0 12 O

therefore RB 0 0 1 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
should MD 0 0 12 O
also RB 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
when WRB 0 0 12 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
given VBN 1 1 12 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
Itraconazole NNP 0 1 UNK B-Drug
. . 0 0 12 O

Anticonvulsants NNS 0 1 UNK B-Group
: : 0 0 2 O
carbamazepine NN 0 1 16 B-Drug
phenobarbital NN 0 1 16 B-Drug
phenytoin NN 0 1 16 B-Drug

Dosing VBG 0 0 UNK O
recommendations NNS 1 1 1 O
for IN 0 0 12 O
SUSTIVA NNP 0 1 UNK B-Brand
and CC 0 0 12 O
atazanavir NN 0 1 13 B-Drug
in IN 0 0 12 O
treatment NN 0 1 6 O
- : 0 0 2 O
experienced JJ 0 0 12 O
patients NNS 1 1 6 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
established VBN 1 1 1 O
. . 0 0 12 O

Drugs NNS 0 1 2 O
Metabolized VBN 0 1 UNK O
by IN 0 0 12 O
Catechol NNP 0 1 UNK O
- : 0 0 2 O
O NNP 0 1 2 O
- : 0 0 2 O
methyltransferase NN 0 1 UNK O
( ( 0 0 2 O
COMT NNP 0 0 UNK O
) ) 0 0 2 O
: : 0 0 2 O
Hormone NN 0 1 UNK O
levels NNS 1 1 1 O
: : 0 0 2 O
Levodopa NNP 0 1 0 B-Drug
is VBZ 1 0 12 O
known VBN 1 1 12 O
to TO 0 0 12 O
depress VB 0 0 13 O
prolactin JJ 0 1 13 O
secretion NN 0 1 14 O
and CC 0 0 12 O
increase VB 0 1 1 O
growth NN 0 1 1 O
hormone NN 0 1 6 O
levels NNS 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
antihypertensive JJ 0 1 14 O
effects NNS 1 1 1 O
of IN 0 0 12 O
methyldopa JJ 0 1 13 B-Drug
mecamylamine NN 0 1 UNK B-Drug
reserpine NN 0 1 UNK B-Drug
and CC 0 0 12 O
veratrum JJ 0 1 UNK B-Drug
alkaloids NNS 1 1 13 I-Drug
may MD 0 0 1 O
be VB 0 0 12 O
reduced VBN 1 1 1 O
by IN 0 0 12 O
sympathomimetics NNS 0 1 13 B-Group
. . 0 0 12 O

Sorafenib NNP 0 1 UNK B-Drug
inhibits VBZ 1 1 UNK O
CYP9B9 NNP 0 0 UNK O
and CC 0 0 12 O
CYP9C9 NNP 0 0 UNK O
in IN 0 0 12 O
vitro NN 0 1 UNK O
with IN 0 0 12 O
Ki NNP 0 0 UNK O
values NNS 1 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
? . 0 0 12 O
M NNP 0 1 2 O
respectively RB 0 0 1 O
. . 0 0 12 O

In IN 0 0 2 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
of IN 0 0 12 O
human JJ 0 1 1 O
CYP NNP 0 1 UNK O
enzymes NNS 1 1 14 O
showed VBD 1 1 12 O
that IN 0 0 12 O
entacapone NN 0 1 13 B-Drug
inhibited VBD 1 1 13 O
the DT 0 0 12 O
CYP NNP 0 1 UNK O
enzymes VBZ 0 1 14 O
9A9 CD 0 0 UNK O
9A9 CD 0 0 UNK O
9C9 CD 0 0 UNK O
9C9 CD 0 0 UNK O
9D9 CD 0 0 UNK O
9E9 CD 0 0 UNK O
and CC 0 0 12 O
9A CD 0 1 UNK O
only RB 0 1 12 O
at IN 0 0 12 O
very RB 0 1 12 O
high JJ 0 1 1 O
concentrations NNS 1 1 13 O
( ( 0 0 2 O
IC9 NNP 0 0 UNK O
from IN 0 0 12 O
9 CD 0 0 2 O
to TO 0 0 12 O
over IN 0 1 12 O
9 CD 0 0 2 O
uM NNS 0 0 UNK O
; : 0 0 2 O

Drug NNP 0 1 2 O
Class NNP 0 1 2 O
Examples NNP 0 1 UNK O
of IN 0 0 12 O
Drugs NNP 0 1 2 O

The DT 0 0 2 O
safety NN 0 1 1 O
of IN 0 0 12 O
using VBG 1 1 1 O
STADOL NNP 0 1 UNK B-Brand
NS NNP 0 1 13 I-Brand
and CC 0 0 12 O
IMITREX NNP 0 1 UNK B-Brand
( ( 0 0 2 O
sumatriptan NN 0 1 16 B-Drug
) ) 0 0 2 O
Nasal NNP 0 1 7 O
Spray NNP 0 1 2 O
during IN 0 0 12 O
the DT 0 0 12 O
same JJ 0 1 12 O
episode NN 0 1 12 O
of IN 0 0 12 O
migraine NN 0 1 6 O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
established VBN 1 1 1 O
. . 0 0 12 O

increased VBN 1 1 1 O
thyroid JJ 0 1 6 O
binding NN 0 1 1 O
globulin NN 0 1 14 O
( ( 0 0 2 O
TBG NNP 0 1 UNK O
) ) 0 0 2 O
leading VBG 1 1 1 O
to TO 0 0 12 O
increased VBN 1 1 1 O
circulating VBG 1 1 13 O
total JJ 0 1 1 O
thyroid JJ 0 1 6 O
hormone NN 0 1 6 O
as IN 1 0 12 O
measured VBN 1 1 1 O
by IN 0 0 12 O
PBI NNP 0 1 UNK O
T9 NNP 0 1 13 O
by IN 0 0 12 O
column NN 0 1 1 O
or CC 0 0 12 O
T9 NNP 0 1 13 O
by IN 0 0 12 O
radioimmunoassay NN 0 1 UNK O
. . 0 0 12 O

Skeletal JJ 0 1 UNK B-Group
muscle NN 0 1 6 I-Group
relaxants NNS 1 0 13 I-Group
nondepolarizing VBG 0 0 UNK O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
tubocurarine NN 0 1 UNK B-Drug
) ) 0 0 2 O
: : 0 0 2 O
possible JJ 0 1 1 O
increased VBD 1 1 1 O
responsiveness NN 0 1 UNK O
to TO 0 0 12 O
the DT 0 0 12 O
muscle NN 0 1 6 B-Group
relaxant NN 0 0 0 I-Group
. . 0 0 12 O

- : 0 0 2 O
Increased VBD 0 1 7 O
prothrombin NN 0 1 14 O
and CC 0 0 12 O
factors NNS 1 1 1 O
VII NNP 0 1 2 O
VIII NNP 0 1 2 O
IX NNP 0 1 2 O
and CC 0 0 12 O
X NNP 0 0 2 O
; : 0 0 2 O

9 CD 0 0 2 B-Group
- : 0 0 2 O
HT9 NN 0 1 UNK I-Group
antagonists NNS 1 1 13 I-Group
: : 0 0 2 O
In IN 0 0 2 O
clinical JJ 0 1 6 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
aprepitant VBP 0 1 13 B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
have VB 0 0 12 O
clinically RB 0 0 6 O
important JJ 0 1 1 O
effects NNS 1 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
ondansetron NN 0 1 16 B-Drug
or CC 0 0 12 O
granisetron NN 0 1 13 B-Drug
. . 0 0 12 O

Caution NN 0 0 UNK O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
hepatic JJ 0 1 14 O
impairment NN 0 1 16 O
. . 0 0 12 O

Such JJ 0 0 1 O
patients NNS 1 1 6 O
may MD 0 0 1 O
be VB 0 0 12 O
unresponsive JJ 0 1 6 O
to TO 0 0 12 O
the DT 0 0 12 O
usual JJ 0 1 12 O
doses NNS 1 1 6 O
of IN 0 0 12 O
epinephrine NN 0 1 14 B-Drug
used VBN 1 1 12 O
to TO 0 0 12 O
treat VB 0 1 12 O
allergic JJ 0 1 6 O
reaction NN 0 1 1 O
. . 0 0 12 O

Phenytoin NNP 0 1 0 B-Drug
is VBZ 1 0 12 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
hepatic JJ 0 1 14 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
enzymes NNS 1 1 14 O
and CC 0 0 12 O
is VBZ 1 0 12 O
particularly RB 0 0 1 O
susceptible JJ 0 1 1 O
to TO 0 0 12 O
inhibitory JJ 0 1 UNK O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
because IN 0 0 12 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
subject JJ 0 1 UNK O
to TO 0 0 12 O
saturable JJ 0 0 UNK O
metabolism NN 0 1 16 O
. . 0 0 12 O

positive JJ 0 1 1 O
antinuclear NN 0 0 UNK O

Alcohol NN 0 1 2 B-Drug
: : 0 0 2 O
It PRP 0 0 12 O
should MD 0 0 12 O
be VB 0 0 12 O
borne VBN 1 1 1 O
in IN 0 0 12 O
mind NN 0 1 12 O
that IN 0 0 12 O
alcohol NN 0 1 1 B-Drug
ingestion NN 0 1 14 O
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
danger NN 0 0 UNK O
inherent JJ 0 0 UNK O
in IN 0 0 12 O
any DT 0 0 12 O
intentional JJ 0 1 1 O
or CC 0 0 12 O
unintentional JJ 0 1 13 O
SINEQUAN NNP 0 1 UNK B-Brand
overdosage NN 0 0 UNK O
. . 0 0 12 O

Antimycobacterial JJ 0 1 UNK B-Group
Agents NNS 0 1 2 I-Group
: : 0 0 2 O
rifampin NN 0 1 16 B-Drug
CONTRAINDICATED NNP 0 1 UNK O
since IN 0 1 12 O
the DT 0 0 12 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
this DT 0 0 12 O
product NN 0 1 1 O
with IN 0 0 12 O
saquinavir NN 0 1 13 B-Drug
in IN 0 0 12 O
an DT 0 0 12 O
antiretroviral JJ 0 0 UNK B-Group
regimen NNS 0 1 6 O
reduces VBZ 1 0 UNK O
the DT 0 0 12 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
saquinavir NN 0 1 13 B-Drug
. . 0 0 12 O

Colchicine NNP 0 1 0 B-Drug
para NN 0 1 13 B-Drug
- : 0 0 2 O
aminosalicylic JJ 0 0 UNK I-Drug
acid NN 0 1 14 I-Drug
and CC 0 0 12 O
heavy JJ 0 1 3 O
alcohol NNS 0 1 1 B-Drug
intake VBP 0 1 3 O
for IN 0 0 12 O
longer JJR 1 1 12 O
than IN 0 0 12 O
9 CD 0 0 2 O
weeks NNS 1 1 12 O
may MD 0 0 1 O
produce VB 0 0 1 O
malabsorption NN 0 1 13 O
of IN 0 0 12 O
vitamin NN 0 1 6 B-Drug
B9 NNP 0 0 UNK I-Drug
. . 0 0 12 O

Quinolones NNS 0 1 UNK B-Group
have VBP 0 0 12 O
been VBN 1 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
caffeine NN 0 1 6 B-Drug
. . 0 0 12 O

Some DT 0 0 2 O
quinolones NNS 0 1 13 B-Group
including VBG 1 1 1 O
ciprofloxacin NN 0 1 0 B-Drug
have VBP 0 0 12 O
also RB 0 0 12 O
been VBN 1 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
caffeine NN 0 1 6 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
incidence NN 0 1 6 O
of IN 0 0 12 O
hypertriglyceridemia NN 0 1 UNK O
is VBZ 1 0 12 O
9 CD 0 0 2 O
patient NN 0 1 6 O
in IN 0 0 12 O
9 CD 0 0 2 O
on IN 0 0 12 O
Accutane NNP 0 1 UNK B-Brand
therapy NN 0 1 6 O

The DT 0 0 2 O
interaction NN 0 1 UNK O
was VBD 1 0 12 O
pharmacodynamic JJ 0 1 UNK O
with IN 0 0 12 O
no DT 0 0 12 O
alteration NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
either DT 0 1 12 O
drug NN 0 1 1 O
. . 0 0 12 O

Other JJ 0 0 2 O
strong JJ 0 1 12 O
selective JJ 0 1 13 O
CYP9A9 NNP 0 0 UNK O
inhibitors NNS 1 1 14 O
such JJ 0 0 1 O
as IN 1 0 12 O
ketoconazole NN 0 1 16 B-Drug
can MD 0 0 12 O
also RB 0 0 12 O
be VB 0 0 12 O
expected VBN 1 1 12 O
to TO 0 0 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
exposure NN 0 1 1 O
of IN 0 0 12 O
zaleplon NN 0 1 13 B-Drug
. . 0 0 12 O

Dose JJ 0 1 7 O
adjustments NNS 1 1 1 O
of IN 0 0 12 O
either DT 0 1 12 O
class NN 0 1 12 O
of IN 0 0 12 O
agents NNS 1 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
necessary JJ 0 0 1 O
. . 0 0 12 O

Butyrophenones NNS 0 1 UNK B-Group
( ( 0 0 2 O
such JJ 0 0 1 O
as IN 1 0 12 O
haloperidol NN 0 1 16 B-Drug
) ) 0 0 2 O
and CC 0 0 12 O
phenothiazines NNS 1 1 UNK B-Group
can MD 0 0 12 O
suppress VB 0 1 1 O
the DT 0 0 12 O
dopaminergic JJ 0 1 UNK O
renal NN 0 1 6 O
and CC 0 0 12 O
mesenteric JJ 0 1 8 O
vasodilation NN 0 1 14 O
induced VBN 1 1 6 O
with IN 0 0 12 O
low JJ 0 1 1 O
dose JJ 0 1 6 O
dopamine NN 0 1 14 B-Drug
infusion NN 0 1 14 O
. . 0 0 12 O

therefore RB 0 0 1 O
ZETIA NNP 0 1 UNK B-Brand
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
in IN 0 0 12 O
nursing VBG 1 1 12 O
mothers NNS 1 1 UNK O
unless IN 0 0 12 O
the DT 0 0 12 O
potential JJ 0 1 1 O
benefit NN 0 1 1 O
justifies VBZ 1 1 UNK O
the DT 0 0 12 O
potential JJ 0 1 1 O
risk NN 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
infant NN 0 1 6 O
. . 0 0 12 O

These DT 0 0 1 O
precautions NNS 1 1 1 O
probably RB 0 1 12 O
should MD 0 0 12 O
apply VB 0 1 1 O
to TO 0 0 12 O
digitoxin VB 0 1 UNK B-Drug
administration NN 0 1 1 O
as RB 0 0 12 O
well RB 0 1 12 O
. . 0 0 12 O

Monitoring VBG 0 1 UNK O
for IN 0 0 12 O
amiodarone NN 0 1 0 B-Drug
toxicity NN 0 1 6 O
and CC 0 0 12 O
serial JJ 0 1 1 O
measurement NN 0 1 1 O
of IN 0 0 12 O
amiodarone NN 0 1 0 B-Drug
serum NN 0 1 14 O
concentration NN 0 1 1 O
during IN 0 0 12 O
concomitant JJ 0 1 6 O
protease NN 0 1 13 B-Group
inhibitor NN 0 1 14 I-Group
therapy NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
. . 0 0 12 O

Salicylates NNS 0 1 UNK B-Group
may MD 0 0 1 O
enhance VB 0 1 UNK O
the DT 0 0 12 O
hypoglycemic JJ 0 1 14 O
effect NN 0 1 1 O
of IN 0 0 12 O
oral JJ 0 1 6 O
antidiabetic JJ 0 1 13 B-Group
drugs NNS 1 1 6 I-Group
of IN 0 0 12 O
the DT 0 0 12 O
sulfonylurea JJ 0 1 UNK O
class NN 0 1 12 O
. . 0 0 12 O

Lithium NN 0 1 UNK B-Drug
: : 0 0 2 O
Inhibition NN 0 1 UNK O
of IN 0 0 12 O
renal JJ 0 1 6 O
lithium NN 0 1 16 B-Drug
clearance NN 0 1 16 O
leading VBG 1 1 1 O
to TO 0 0 12 O
an DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
plasma JJ 0 1 14 O
lithium NN 0 1 16 B-Drug
concentration NN 0 1 1 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
with IN 0 0 12 O
some DT 0 0 12 O
prostaglandin NN 0 1 13 O
synthesis NN 0 1 UNK O
- : 0 0 2 O
inhibiting NN 0 1 UNK O
drugs NNS 1 1 6 O
. . 0 0 12 O

In IN 0 0 2 O
another DT 0 0 12 O
study NN 0 1 1 O
TORADOLIV NNP 0 0 UNK O
/ NNP 0 0 2 O
IM NNP 0 1 11 O
was VBD 1 0 12 O
given VBN 1 1 12 O
with IN 0 0 12 O
two CD 0 1 12 O
doses NNS 1 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
U NNP 0 0 2 O
of IN 0 0 12 O
heparin NN 0 1 14 B-Drug
to TO 0 0 12 O
9 CD 0 0 2 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
resulting VBG 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
mean JJ 0 1 12 O
template NN 0 1 UNK O
bleeding NN 0 1 6 O
time NN 0 1 12 O
of IN 0 0 12 O
9 CD 0 0 2 O
minutes NNS 1 1 12 O
( ( 0 0 2 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
min NN 0 1 16 O
) ) 0 0 2 O
compared VBN 1 1 1 O
to TO 0 0 12 O
a DT 0 0 12 O
mean NN 0 1 12 O
of IN 0 0 12 O
9 CD 0 0 2 O
minutes NNS 1 1 12 O
( ( 0 0 2 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
min NN 0 1 16 O
) ) 0 0 2 O
for IN 0 0 12 O
heparin NN 0 1 14 B-Drug
alone RB 0 1 12 O
and CC 0 0 12 O
9 CD 0 0 2 O
minutes NNS 1 1 12 O
( ( 0 0 2 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
min NN 0 1 16 O
) ) 0 0 2 O
for IN 0 0 12 O
placebo NN 0 1 13 O
. . 0 0 12 O

Drugs NNS 0 1 2 O
That WDT 0 0 2 O
Should MD 0 0 2 O
Not RB 0 1 2 O
Be VB 0 0 UNK O
Coadministered VBN 0 0 UNK O
with IN 0 0 12 O
CRIXIVAN NNP 0 1 UNK B-Brand

Appropriate JJ 0 1 2 O
dosage NN 0 1 0 O
adjustments NNS 1 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
necessary JJ 0 0 1 O
. . 0 0 12 O

Absorption NN 0 1 UNK O
of IN 0 0 12 O
drugs NNS 1 1 6 O
from IN 0 0 12 O
the DT 0 0 12 O
stomach NN 0 1 6 O
may MD 0 0 1 O
be VB 0 0 12 O
diminished VBN 1 1 1 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
digoxin NN 0 1 14 B-Drug
) ) 0 0 2 O
by IN 0 0 12 O
metoclopramide NN 0 1 16 B-Drug
whereas IN 0 0 UNK O
the DT 0 0 12 O
rate NN 0 1 1 O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
extent NN 0 1 1 O
of IN 0 0 12 O
absorption NN 0 1 1 O
of IN 0 0 12 O
drugs NNS 1 1 6 O
from IN 0 0 12 O
the DT 0 0 12 O
small JJ 0 1 12 O
bowel NN 0 1 6 O
may MD 0 0 1 O
be VB 0 0 12 O
increased VBN 1 1 1 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
acetaminophen NN 0 1 16 B-Drug
tetracycline NN 0 1 0 B-Drug
levodopa NN 0 1 UNK B-Drug
ethanol FW 0 1 1 B-Drug
cyclosporine NN 0 1 14 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

Thus RB 0 0 1 O
strong JJ 0 1 12 O
inhibitors NNS 1 1 14 O
of IN 0 0 12 O
cytochrome JJ 0 1 UNK O
P9A9 NNP 0 0 UNK O
such JJ 0 0 1 O
as IN 1 0 12 O
fluvoxamine NN 0 1 16 B-Drug
given VBN 1 1 12 O
concomitantly RB 0 0 14 O
during IN 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
Ropivacaine NNP 0 1 UNK B-Drug
can MD 0 0 12 O
interact VB 0 0 UNK O
with IN 0 0 12 O
Ropivacaine NNP 0 1 UNK B-Drug
leading VBG 1 1 1 O
to TO 0 0 12 O
increased VBN 1 1 1 O
ropivacaine NN 0 1 16 B-Drug
plasma NN 0 1 14 O
levels NNS 1 1 1 O
. . 0 0 12 O

However RB 0 0 1 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
escitalopram NN 0 1 0 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
) ) 0 0 2 O
and CC 0 0 12 O
ritonavir NN 0 1 16 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
) ) 0 0 2 O
a DT 0 0 12 O
potent JJ 0 1 UNK O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
did VBD 1 0 12 O
not RB 0 1 12 O
significantly RB 0 0 1 O
affect VBP 0 1 1 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
escitalopram NN 0 1 0 B-Drug
. . 0 0 12 O

This DT 0 0 2 O
might MD 0 0 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
methotrexate NN 0 1 16 B-Drug
toxic NN 0 1 1 O
reactions NNS 1 1 1 O
. . 0 0 12 O

Registered NNP 0 1 UNK O
trademark NN 0 1 UNK O
of IN 0 0 12 O
Ames NNP 0 1 UNK O
Company NNP 0 1 UNK O
Division NNP 0 1 2 O
of IN 0 0 12 O
Miles NNP 0 1 UNK O
Laboratories NNPS 0 1 2 O
Inc NNP 0 0 UNK O
. . 0 0 12 O

Caution NN 0 0 UNK O
is VBZ 1 0 12 O
advised VBN 1 0 12 O
for IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
high JJ 0 1 1 O
- : 0 0 2 O
dose NN 0 1 6 O
aspirin NN 0 1 14 B-Brand
and CC 0 0 12 O
methazolamide RB 0 1 13 B-Drug
concomitantly RB 0 0 14 O
as IN 1 0 12 O
anorexia JJ 0 1 6 O
tachypnea NN 0 1 8 O
lethargy NN 0 1 6 O
coma NN 0 1 6 O
and CC 0 0 12 O
death NN 0 1 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
with IN 0 0 12 O
concomitant JJ 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
high JJ 0 1 1 O
- : 0 0 2 O
dose NN 0 1 6 O
aspirin NN 0 1 14 B-Brand
and CC 0 0 12 O
carbonic JJ 0 1 13 B-Group
anhydrase NN 0 0 13 I-Group
inhibitors NNS 1 1 14 I-Group
. . 0 0 12 O

The DT 0 0 2 O
first JJ 0 1 12 O
test NN 0 1 1 O
is VBZ 1 0 12 O
obtained VBN 1 1 1 O
by IN 0 0 12 O
the DT 0 0 12 O
prescriber NN 0 0 UNK O
when WRB 0 0 12 O
the DT 0 0 12 O
decision NN 0 1 12 O
is VBZ 1 0 12 O
made VBN 1 1 12 O
to TO 0 0 12 O
pursue VB 0 0 12 O
qualification NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
patient NN 0 1 6 O
for IN 0 0 12 O
Accutane NNP 0 1 UNK B-Brand
( ( 0 0 2 O
a DT 0 0 12 O
screening NN 0 1 1 O
test NN 0 1 1 O
) ) 0 0 2 O
. . 0 0 12 O

Concomitant JJ 0 1 UNK O
medications NNS 1 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
carefully RB 0 0 12 O
assessed VBN 1 1 1 O
. . 0 0 12 O

No DT 0 0 2 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
have VBP 0 0 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
with IN 0 0 12 O
the DT 0 0 12 O
Vitrasert NNP 0 1 UNK B-Brand
Implant NNP 0 1 UNK O
. . 0 0 12 O

Other JJ 0 0 2 O
: : 0 0 2 O
Coadministration NN 0 1 UNK O
of IN 0 0 12 O
grapefruit NN 0 1 3 O
juice NN 0 1 3 O
with IN 0 0 12 O
cisapride NN 0 1 UNK B-Drug
increases VBZ 1 1 1 O
the DT 0 0 12 O
bioavailability NN 0 1 UNK O
of IN 0 0 12 O
cisapride NN 0 1 UNK B-Drug
and CC 0 0 12 O
concomitant NN 0 1 6 O
use NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
. . 0 0 12 O

Succinylcholine NN 0 1 UNK B-Drug
may MD 0 0 1 O
cause VB 0 1 12 O
a DT 0 0 12 O
sudden JJ 0 1 12 O
extrusion NN 0 1 UNK O
of IN 0 0 12 O
potassium NN 0 1 14 O
from IN 0 0 12 O
muscle NN 0 1 6 O
cells NNS 1 1 6 O
and CC 0 0 12 O
may MD 0 0 1 O
thereby RB 0 0 UNK O
cause VB 0 1 12 O
arrhythmias NN 1 1 6 O
in IN 0 0 12 O
digitalized JJ 0 1 UNK O
patients NNS 1 1 6 O
. . 0 0 12 O

In IN 0 0 2 O
these DT 0 0 12 O
cases NNS 1 1 UNK O
your PRP$ 0 0 12 O
doctor NN 0 1 12 O
may MD 0 0 1 O
want VB 0 0 12 O
to TO 0 0 12 O
change VB 0 1 1 O
the DT 0 0 12 O
dose NN 0 1 6 O
or CC 0 0 12 O
other JJ 0 0 12 O
precautions NNS 1 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
necessary JJ 0 0 1 O
. . 0 0 12 O

Interference NN 0 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
absorption NN 0 1 1 O
of IN 0 0 12 O
oral JJ 0 1 6 O
phosphate NN 0 1 14 B-Drug_n
supplements NNS 1 1 6 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
with IN 0 0 12 O
another DT 0 0 12 O
positively RB 0 0 UNK O
- : 0 0 2 O
charged VBN 1 1 UNK O
bile JJ 0 1 6 O
acid NN 0 1 14 O
sequestrant NN 0 0 UNK O
. . 0 0 12 O

No DT 0 0 2 O
interactions NNS 1 1 UNK O
were VBD 1 0 12 O
observed VBN 1 1 1 O
. . 0 0 12 O

Doxorubicin NN 0 1 UNK B-Drug
: : 0 0 2 O
Doxorubicin NNP 0 1 UNK B-Drug
caused VBD 1 1 1 O
a DT 0 0 12 O
decrease NN 0 1 1 O
in IN 0 0 12 O
zalcitabine NN 0 1 UNK B-Drug
phosphorylation NN 0 1 UNK O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
total JJ 0 1 1 O
phosphate JJ 0 1 14 O
formation NN 0 1 1 O
) ) 0 0 2 O
in IN 0 0 12 O
U9 NNP 0 0 UNK O
/ NNP 0 0 2 O
Molt NNP 0 1 UNK O
9 CD 0 0 2 O
cells NNS 1 1 6 O
. . 0 0 12 O

Beta NNP 0 1 2 O
- : 0 0 2 O
Blocking VBG 0 1 UNK O
Agents NNS 0 1 2 O
A NNP 0 0 2 O
pharmacokinetic JJ 0 1 UNK O
study NN 0 1 1 O
of IN 0 0 12 O
felodipine NN 0 1 13 B-Drug
in IN 0 0 12 O
conjunction NN 0 1 1 O
with IN 0 0 12 O
metoprolol NN 0 1 0 B-Drug
demonstrated VBD 1 0 1 O
no DT 0 0 12 O
significant JJ 0 1 1 O
effects NNS 1 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
felodipine NN 0 1 13 B-Drug
. . 0 0 12 O

See NNP 0 1 2 O
also RB 0 0 12 O
CLINICAL NNP 0 1 11 O
PHARMACOLOGY NNP 0 1 UNK O
Drug NNP 0 1 2 O
- : 0 0 2 O
Drug NN 0 1 2 O
Interactions NNS 0 1 UNK O

Ascorbic JJ 0 0 0 B-Drug
acid NN 0 1 14 I-Drug
: : 0 0 2 O
Doses NNS 0 1 0 O
of IN 0 0 12 O
ascorbic JJ 0 0 16 B-Drug
acid NN 0 1 14 I-Drug
( ( 0 0 2 O
vitamin JJ 0 1 6 B-Drug
C NNP 0 0 2 I-Drug
) ) 0 0 2 O
9 CD 0 0 2 O
g JJ 0 1 16 O
/ NNP 0 0 2 O
day NN 0 1 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
increase VB 0 1 1 O
plasma JJ 0 1 14 O
concentration NN 0 1 1 O
of IN 0 0 12 O
synthetic JJ 0 1 3 B-Group
estrogens NNS 1 1 16 I-Group
by IN 0 0 12 O
~9 NNP 0 0 UNK O
% NN 0 0 18 O
possibly RB 0 1 12 O
by IN 0 0 12 O
inhibiting VBG 1 1 UNK O
conjugation NN 0 1 14 O
; : 0 0 2 O

. . 0 0 12 O

Carbamazepine NNP 0 1 UNK B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
degree NN 0 1 1 O
of IN 0 0 12 O
heart NN 0 1 12 O
block NN 0 1 3 O
produced VBN 1 0 1 O
by IN 0 0 12 O
other JJ 0 0 12 O
agents NNS 1 1 1 O
. . 0 0 12 O

Therefore RB 0 0 1 O
monitoring NN 0 1 1 O
of IN 0 0 12 O
plasma JJ 0 1 14 O
digoxin NN 0 1 14 B-Drug
levels NNS 1 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
indicated VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
similar JJ 0 1 1 O
combination NN 0 1 1 O
chemotherapy NN 0 1 6 O
regimens NNS 1 1 UNK O
. . 0 0 12 O

Symptoms NNP 0 1 7 O
usually RB 0 1 12 O
resolve VBP 0 1 1 O
over RP 0 1 12 O
days NNS 1 1 12 O
when WRB 0 0 12 O
the DT 0 0 12 O
combination NN 0 1 1 O
is VBZ 1 0 12 O
discontinued VBN 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
extent NN 0 1 1 O
of IN 0 0 12 O
interaction NN 0 1 UNK O
depends VBZ 1 1 UNK O
on IN 0 0 12 O
the DT 0 0 12 O
variability NN 0 1 UNK O
of IN 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
CYP9D9 NNP 0 0 UNK O
. . 0 0 12 O

Dopamine NNP 0 1 7 B-Group
D9 NNP 0 1 UNK I-Group
receptor NN 0 1 14 I-Group
antagonists NNS 1 1 13 I-Group
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
phenothiazines NNS 1 1 UNK B-Group
butyrophenones NNS 0 1 UNK B-Group
risperidone NN 0 1 0 B-Drug
) ) 0 0 2 O
and CC 0 0 12 O
isoniazid NN 0 1 13 B-Drug
may MD 0 0 1 O
reduce VB 0 0 1 O
the DT 0 0 12 O
therapeutic JJ 0 1 6 O
effects NNS 1 1 1 O
of IN 0 0 12 O
levodopa NN 0 1 UNK B-Drug
. . 0 0 12 O

In IN 0 0 2 O
in IN 0 0 12 O
vivo NN 0 1 13 O
studies NNS 1 1 1 O
9 CD 0 0 2 O
- : 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
mg NN 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
doses NNS 1 1 6 O
of IN 0 0 12 O
aripiprazole NN 0 1 16 B-Drug
had VBD 1 0 12 O
no DT 0 0 12 O
significant JJ 0 1 1 O
effect NN 0 1 1 O
on IN 0 0 12 O
metabolism NN 0 1 16 O
by IN 0 0 12 O
CYP9D9 NNP 0 0 UNK O
( ( 0 0 2 O
dextromethorphan NN 0 1 16 B-Drug
) ) 0 0 2 O
CYP9C9 NNP 0 0 UNK O
( ( 0 0 2 O
warfarin NN 0 1 14 B-Drug
) ) 0 0 2 O
CYP9C9 NNP 0 0 UNK O
( ( 0 0 2 O
omeprazole JJ 0 1 0 B-Drug
warfarin NN 0 1 14 B-Drug
) ) 0 0 2 O
and CC 0 0 12 O
CYP9A9 NNP 0 0 UNK O
( ( 0 0 2 O
dextromethorphan NN 0 1 16 B-Drug
) ) 0 0 2 O
substrates VBZ 0 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
clinical JJ 0 1 6 O
significance NN 0 1 13 O
of IN 0 0 12 O
these DT 0 0 12 O
findings NNS 1 1 1 O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
established VBN 1 1 1 O
. . 0 0 12 O

Tolbutamides NNS 0 1 UNK B-Drug
conversion NN 0 1 13 O
to TO 0 0 12 O
inactive VB 0 1 1 O
metabolites NNS 1 1 UNK O
has VBZ 1 0 12 O
been VBN 1 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
be VB 0 0 12 O
catalyzed VBN 1 0 UNK O
by IN 0 0 12 O
xanthine JJ 0 1 UNK O
oxidase NN 0 1 13 O
from IN 0 0 12 O
rat NN 0 1 13 O
liver NN 0 1 6 O
. . 0 0 12 O

Aripiprazole NNP 0 1 UNK B-Drug
dose NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
reduced VBN 1 1 1 O
to TO 0 0 12 O
one CD 0 1 12 O
- : 0 0 2 O
half NN 0 1 12 O
of IN 0 0 12 O
its PRP$ 1 0 12 O
normal JJ 0 1 1 O
dose NN 0 1 6 O
when WRB 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
quinidine NN 0 1 16 B-Drug
with IN 0 0 12 O
aripiprazole JJ 0 1 16 B-Drug
occurs NNS 0 1 1 O
. . 0 0 12 O

Itraconazole NN 0 1 UNK B-Drug

A DT 0 0 2 O
single JJ 0 1 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
liquid JJ 0 1 3 O
antacid NN 0 1 UNK B-Group
did VBD 1 0 12 O
not RB 0 1 12 O
affect VB 0 1 1 O
the DT 0 0 12 O
C NNP 0 0 2 O
max NN 0 0 3 O
or CC 0 0 12 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
ceftibuten NN 0 1 UNK B-Drug
; : 0 0 2 O

Lithium NN 0 1 UNK B-Drug
: : 0 0 2 O
Nonsteroidal NNP 0 0 UNK B-Group
anti VBZ 0 0 3 I-Group
- : 0 0 2 O
inflammatory NN 0 1 6 I-Group
agents NNS 1 1 1 I-Group
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
increase VB 0 1 1 O
steadystate NN 0 1 UNK O
plasma JJ 0 1 14 O
lithium NN 0 1 16 B-Drug
levels NNS 1 1 1 O
. . 0 0 12 O

This DT 0 0 2 O
may MD 0 0 1 O
be VB 0 0 12 O
due JJ 0 1 1 O
to TO 0 0 12 O
an DT 0 0 12 O
improved VBN 1 1 1 O
glucose JJ 0 1 14 O
utilization NN 0 1 UNK O
with IN 0 0 12 O
simultaneous JJ 0 1 13 O
reduction NN 0 1 1 O
in IN 0 0 12 O
insulin NN 0 1 14 B-Drug
requirement NN 0 1 1 O

Probenecid NNP 0 1 UNK B-Drug
given VBN 1 1 12 O
concurrently RB 0 0 1 O
increases VBZ 1 1 1 O
naproxen JJ 0 1 16 B-Drug
anion NN 0 1 14 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
and CC 0 0 12 O
extends VBZ 1 1 1 O
its PRP$ 1 0 12 O
plasma NN 0 1 14 O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
significantly RB 0 0 1 O
. . 0 0 12 O

Herbal JJ 0 1 UNK O
products NNS 1 1 1 O
: : 0 0 2 O
St. NNP 0 1 2 O
John NNP 0 0 19 O
wort NN 0 0 UNK O
( ( 0 0 2 O
Hypericum NNP 0 1 UNK O
perforatum NN 0 0 UNK O
) ) 0 0 2 O

A DT 0 0 2 O
controlled VBN 1 1 1 O
study NN 0 1 1 O
found VBD 1 1 12 O
that IN 0 0 12 O
concomitant JJ 0 1 6 O
fluconazole JJ 0 1 0 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
once RB 0 0 12 O
daily JJ 0 1 12 O
and CC 0 0 12 O
cisapride JJ 0 1 UNK B-Drug
9 CD 0 0 2 O
mg RB 0 1 0 O
four CD 0 1 12 O
times NNS 1 1 12 O
a DT 0 0 12 O
day NN 0 1 12 O
yielded VBD 1 0 1 O
a DT 0 0 12 O
significant JJ 0 1 1 O
increase NN 0 1 1 O
in IN 0 0 12 O
cisapride JJ 0 1 UNK B-Drug
plasma NN 0 1 14 O
levels NNS 1 1 1 O
and CC 0 0 12 O
prolongation NN 0 1 6 O
of IN 0 0 12 O
QTc NNP 0 0 14 O
interval NN 0 1 1 O
. . 0 0 12 O

Fluconazole NN 0 1 0 B-Drug
: : 0 0 2 O
Concomitant JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
fluconazole NN 0 1 0 B-Drug
at IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
QD NNP 0 1 13 O
resulted VBD 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
two CD 0 1 12 O
- : 0 0 2 O
fold JJ 0 1 3 O
increase NN 0 1 1 O
in IN 0 0 12 O
celecoxib JJ 0 1 16 B-Drug
plasma JJ 0 1 14 O
concentration NN 0 1 1 O
. . 0 0 12 O

Lithium NN 0 1 UNK B-Drug
: : 0 0 2 O
NSAIDs NN 0 1 UNK B-Group
have VBP 0 0 12 O
produced VBN 1 0 1 O
an DT 0 0 12 O
elevation NN 0 1 1 O
of IN 0 0 12 O
plasma JJ 0 1 14 O
lithium NN 0 1 16 B-Drug
levels NNS 1 1 1 O
and CC 0 0 12 O
a DT 0 0 12 O
reduction NN 0 1 1 O
in IN 0 0 12 O
renal JJ 0 1 6 O
lithium NN 0 1 16 B-Drug
clearance NN 0 1 16 O
. . 0 0 12 O

The DT 0 0 2 O
concomitant NN 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
INDOCIN NNP 0 1 UNK B-Brand
with IN 0 0 12 O
other JJ 0 0 12 O
NSAIDs NNP 0 1 UNK B-Group
is VBZ 1 0 12 O
not RB 0 1 12 O
recommended VBN 1 1 1 O
due JJ 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
increased VBN 1 1 1 O
possibility NN 0 1 1 O
of IN 0 0 12 O
gastrointestinal JJ 0 1 6 O
toxicity NN 0 1 6 O
with IN 0 0 12 O
little JJ 0 1 12 O
or CC 0 0 12 O
no DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
efficacy NN 0 1 UNK O
. . 0 0 12 O

NSAIDs NNP 0 1 UNK B-Group
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
with IN 0 0 12 O
caution NN 0 0 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
cyclosporine NN 0 1 14 B-Drug
and CC 0 0 12 O
renal JJ 0 1 6 O
function NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
carefully RB 0 0 12 O
monitored VBN 1 1 1 O
. . 0 0 12 O

. . 0 0 12 O

However RB 0 0 1 O
the DT 0 0 12 O
peak JJ 0 1 1 O
plasma JJ 0 1 14 O
level NN 0 1 1 O
of IN 0 0 12 O
metformin NN 0 1 0 B-Drug
was VBD 1 0 12 O
reduced VBN 1 1 1 O
by IN 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
when WRB 0 0 12 O
taking VBG 1 0 12 O
Acarbose NNP 0 1 UNK B-Drug
due JJ 0 1 1 O
to TO 0 0 12 O
a DT 0 0 12 O
slight JJ 0 1 3 O
delay NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
absorption NN 0 1 1 O
of IN 0 0 12 O
metformin NN 0 1 0 B-Drug
. . 0 0 12 O

hepatotoxic NN 0 1 UNK O
drugs NNS 1 1 6 O
; : 0 0 2 O

Influenza NNP 0 1 7 O
vaccination NN 0 1 6 O
may MD 0 0 1 O
be VB 0 0 12 O
of IN 0 0 12 O
value NN 0 1 1 O
. . 0 0 12 O

Presence NN 0 1 UNK O
of IN 0 0 12 O
unchanged JJ 0 1 1 O
terfenadine NN 0 1 UNK B-Drug
is VBZ 1 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
statistically RB 0 1 1 O
significant JJ 0 1 1 O
prolongation NN 0 1 6 O
of IN 0 0 12 O
the DT 0 0 12 O
QT NNP 0 1 13 O
and CC 0 0 12 O
QTc NNP 0 0 14 O
intervals NNS 1 1 1 O
. . 0 0 12 O

therefore RB 0 0 1 O
nelfinavir NN 0 1 16 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
( ( 0 0 2 O
with IN 0 0 12 O
food NN 0 1 12 O
) ) 0 0 2 O
one CD 0 1 12 O
hour NN 0 1 12 O
after IN 0 0 12 O
or CC 0 0 12 O
more JJR 0 1 12 O
than IN 0 0 12 O
two CD 0 1 12 O
hours NNS 1 1 12 O
before IN 0 1 12 O
didanosine NN 0 1 16 B-Drug
. . 0 0 12 O

use NN 0 1 1 O
caution NN 0 0 1 O
. . 0 0 12 O

increased VBN 1 1 1 O
bilirubin NN 0 1 14 O

Reduced VBN 0 1 UNK O
efficacy NN 0 1 UNK O
and CC 0 0 12 O
increased VBD 1 1 1 O
incidence NN 0 1 6 O
of IN 0 0 12 O
breakthrough NN 0 1 1 O
bleeding NN 0 1 6 O
and CC 0 0 12 O
menstrual JJ 0 1 6 O
irregularities NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
concomitant JJ 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
rifampin NN 0 1 16 B-Drug
. . 0 0 12 O

Urinary JJ 0 1 7 O
Alkalinizers NNS 0 0 UNK O
: : 0 0 2 O
Decrease NNP 0 1 7 O
aspirin VBZ 0 1 14 B-Brand
effectiveness NN 0 1 UNK O
by IN 0 0 12 O
increasing VBG 1 1 1 O
the DT 0 0 12 O
rate NN 0 1 1 O
of IN 0 0 12 O
salicylate JJ 0 1 13 B-Group
renal JJ 0 1 6 O
excretion NN 0 1 14 O
. . 0 0 12 O

Valproate NN 0 1 0 B-Drug
: : 0 0 2 O
The DT 0 0 2 O
addition NN 0 1 1 O
of IN 0 0 12 O
tiagabine NN 0 1 13 B-Drug
to TO 0 0 12 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
valproate JJ 0 1 16 B-Drug
chronically RB 0 0 6 O
had VBD 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
tiagabine NN 0 1 13 B-Drug
pharmacokinetics NNS 0 1 UNK O
but CC 0 0 12 O
valproate VBP 0 1 16 B-Drug
significantly RB 0 0 1 O
decreased VBN 1 1 1 O
tiagabine NN 0 1 13 B-Drug
binding NN 0 1 1 O
in IN 0 0 12 O
vitro NN 0 1 UNK O
from IN 0 0 12 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
which WDT 0 0 12 O
resulted VBD 1 1 1 O
in IN 0 0 12 O
an DT 0 0 12 O
increase NN 0 1 1 O
of IN 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
in IN 0 0 12 O
the DT 0 0 12 O
free JJ 0 1 12 O
tiagabine NN 0 1 13 O
concentration NN 0 1 1 O
. . 0 0 12 O

Vasospastic JJ 0 0 UNK O
reactions NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
with IN 0 0 12 O
therapeutic JJ 0 1 6 O
doses NNS 1 1 6 O
of IN 0 0 12 O
ergotamine JJ 0 1 UNK B-Drug
- : 0 0 2 O
containing VBG 1 1 1 O
drugs NNS 1 1 6 O
when WRB 0 0 12 O
co NN 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
with IN 0 0 12 O
these DT 0 0 12 O
antibiotics NNS 1 1 6 B-Group
. . 0 0 12 O

Nevertheless RB 0 0 1 O
caution NN 0 0 1 O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
concomitant JJ 0 1 6 O
treatment NN 0 1 6 O
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
are VBP 1 0 12 O
either DT 0 1 12 O
inhibitors NNS 1 1 14 O
or CC 0 0 12 O
inducers NNS 1 1 UNK O
of IN 0 0 12 O
these DT 0 0 12 O
enzymes NNS 1 1 14 O
. . 0 0 12 O

Tacrolimus NN 0 1 0 B-Drug
: : 0 0 2 O
There EX 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reports NNS 1 1 1 O
of IN 0 0 12 O
nephrotoxicity NN 0 1 UNK O
in IN 0 0 12 O
patients NNS 1 1 6 O
to TO 0 0 12 O
whom WP 0 0 12 O
fluconazole NN 0 1 0 B-Drug
and CC 0 0 12 O
tacrolimus NN 0 1 16 B-Drug
were VBD 1 0 12 O
coadministered VBN 0 0 UNK O
. . 0 0 12 O

Concurrent NNP 0 1 13 O
use NN 0 1 1 O
of IN 0 0 12 O
DEMSER NNP 0 1 UNK B-Brand
with IN 0 0 12 O
alcohol NN 0 1 1 B-Drug
or CC 0 0 12 O
other JJ 0 0 12 O
CNS JJ 0 1 6 B-Drug
depressants NNS 1 0 13 I-Drug
can MD 0 0 12 O
increase VB 0 1 1 O
their PRP$ 0 0 12 O
sedative JJ 0 1 6 O
effects NNS 1 1 1 O
. . 0 0 12 O

Patients NNS 0 1 7 O
should MD 0 0 12 O
be VB 0 0 12 O
advised VBN 1 0 12 O
against IN 0 0 12 O
the DT 0 0 12 O
simultaneous JJ 0 1 13 O
use NN 0 1 1 O
of IN 0 0 12 O
other JJ 0 0 12 O
CNS NNP 0 1 6 B-Group
depressant NN 0 0 UNK I-Group
drugs NNS 1 1 6 I-Group
and CC 0 0 12 O
cautioned VBD 1 0 UNK O
that IN 0 0 12 O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
alcohol NN 0 1 1 B-Drug
may MD 0 0 1 O
be VB 0 0 12 O
increased VBN 1 1 1 O
. . 0 0 12 O

As IN 0 0 2 O
is VBZ 1 0 12 O
the DT 0 0 12 O
case NN 0 1 12 O
with IN 0 0 12 O
many JJ 0 0 12 O
medicinal JJ 0 0 16 O
agents NNS 1 1 1 O
propoxyphene VBP 0 1 16 B-Drug
may MD 0 0 1 O
slow VB 0 1 12 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
a DT 0 0 12 O
concomitantly RB 0 0 14 O
administered VBN 1 1 1 O
drug NN 0 1 1 O
. . 0 0 12 O

Cardiovasculars NNS 0 1 UNK O
: : 0 0 2 O
Cardiac NNP 0 1 7 B-Drug
glycosides NNS 1 1 13 I-Drug
: : 0 0 2 O
In IN 0 0 2 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
digoxin NN 0 1 14 B-Drug
therapy NN 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
oral JJ 0 1 6 O
amiodarone CD 0 1 0 B-Drug
regularly JJ 0 0 12 O
results NNS 1 1 1 O
in IN 0 0 12 O
an DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
serum JJ 0 1 14 O
digoxin NN 0 1 14 B-Drug
concentration NN 0 1 1 O
that WDT 0 0 12 O
may MD 0 0 1 O
reach VB 0 1 12 O
toxic NN 0 1 1 O
levels NNS 1 1 1 O
with IN 0 0 12 O
resultant JJ 0 0 1 O
clinical JJ 0 1 6 O
toxicity NN 0 1 6 O
. . 0 0 12 O

It PRP 0 0 12 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
that IN 0 0 12 O
sulfamethoxazole NN 0 1 13 B-Drug
may MD 0 0 1 O
prolong VB 0 0 13 O
the DT 0 0 12 O
prothrombin NN 0 1 14 O
time NN 0 1 12 O
in IN 0 0 12 O
patients NNS 1 1 6 O
who WP 0 0 12 O
are VBP 1 0 12 O
receiving VBG 1 1 1 O
the DT 0 0 12 O
anticoagulant JJ 0 1 13 B-Group
warfarin NN 0 1 14 B-Drug
. . 0 0 12 O

Therefore RB 0 0 1 O
the DT 0 0 12 O
simultaneous JJ 0 1 13 O
administration NN 0 1 1 O
of IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
. . 0 0 12 O

Because IN 0 0 12 O
Anafranil NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
highly RB 0 1 1 O
bound VBN 1 1 12 O
to TO 0 0 12 O
serum VB 0 1 14 O
protein VB 0 1 14 O
the DT 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
Anafranil NNP 0 1 UNK B-Brand
to TO 0 0 12 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
are VBP 1 0 12 O
highly RB 0 1 1 O
bound VBN 1 1 12 O
to TO 0 0 12 O
protein VB 0 1 14 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
warfarin NN 0 1 14 B-Drug
digoxin NN 0 1 14 B-Drug
) ) 0 0 2 O
may MD 0 0 1 O
cause VB 0 1 12 O
an DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
potentially RB 0 0 1 O
resulting VBG 1 1 1 O
in IN 0 0 12 O
adverse JJ 0 0 1 O
effects NNS 1 1 1 O
. . 0 0 12 O

adjust JJ 0 0 1 O
salicylate NN 0 1 13 B-Group
dosage NN 0 1 0 O
accordingly RB 0 0 1 O
if IN 0 0 12 O
effect NN 0 1 1 O
is VBZ 1 0 12 O
altered VBN 1 1 1 O
. . 0 0 12 O

Venlafaxine NN 0 1 0 B-Drug
: : 0 0 2 O
Coadministration NN 0 1 UNK O
of IN 0 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
zaleplon NN 0 1 13 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
and CC 0 0 12 O
multiple JJ 0 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
venlafaxine NN 0 1 16 B-Drug
ER NNP 0 1 2 O
( ( 0 0 2 O
extended JJ 0 1 1 O
release NN 0 1 12 O
) ) 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
did VBD 1 0 12 O
not RB 0 1 12 O
result VB 0 1 1 O
in IN 0 0 12 O
any DT 0 0 12 O
significant JJ 0 1 1 O
changes NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
either DT 0 1 12 O
zaleplon NN 0 1 13 B-Drug
or CC 0 0 12 O
venlafaxine NN 0 1 16 B-Drug
. . 0 0 12 O

However RB 0 0 1 O
because IN 0 0 12 O
some DT 0 0 12 O
quinolones NNS 0 1 13 B-Group
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
enhance VB 0 1 UNK O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
or CC 0 0 12 O
its PRP$ 1 0 12 O
derivatives NNS 1 1 13 O
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
or CC 0 0 12 O
other JJ 0 0 12 O
suitable JJ 0 1 1 O
anticoagulation NN 0 1 14 O
test NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
closely RB 0 0 1 O
if IN 0 0 12 O
a DT 0 0 12 O
quinolone NN 0 1 UNK B-Group
antimicrobial NN 0 1 14 I-Group
is VBZ 1 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
or CC 0 0 12 O
its PRP$ 1 0 12 O
derivatives NNS 1 1 13 O
. . 0 0 12 O

Systemic JJ 0 1 7 O
exposure NN 0 1 1 O
to TO 0 0 12 O
substrates NNS 1 1 UNK O
of IN 0 0 12 O
CYP9B9 NNP 0 0 UNK O
and CC 0 0 12 O
CYP9C9 NNP 0 0 UNK O
is VBZ 1 0 12 O
expected VBN 1 1 12 O
to TO 0 0 12 O
increase VB 0 1 1 O
when WRB 0 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
with IN 0 0 12 O
NEXAVAR NNP 0 1 UNK B-Brand
. . 0 0 12 O

In IN 0 0 2 O
the DT 0 0 12 O
absence NN 0 1 1 O
of IN 0 0 12 O
data NNS 0 1 1 O
regarding VBG 1 0 1 O
potential JJ 0 1 1 O
interaction NN 0 1 UNK O
between IN 0 0 12 O
ALIMTA NNP 0 1 UNK B-Brand
and CC 0 0 12 O
NSAIDs NNP 0 1 UNK B-Group
with IN 0 0 12 O
longer JJR 1 1 12 O
half NN 0 1 12 O
- : 0 0 2 O
lives VBZ 1 1 12 O
all DT 0 0 12 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
these DT 0 0 12 O
NSAIDs NNP 0 1 UNK B-Group
should MD 0 0 12 O
interrupt VB 0 1 13 O
dosing VBG 1 0 14 O
for IN 0 0 12 O
at IN 0 0 12 O
least JJS 0 1 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
before IN 0 1 12 O
the DT 0 0 12 O
day NN 0 1 12 O
of IN 0 0 12 O
and CC 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
following VBG 1 1 1 O
ALIMTA NNP 0 1 UNK B-Brand
administration NN 0 1 1 O
. . 0 0 12 O

Pindolol NNP 0 1 UNK B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
increase VB 0 1 1 O
serum JJ 0 1 14 O
thioridazine NN 0 1 13 B-Drug
levels NNS 1 1 1 O
when WRB 0 0 12 O
both DT 0 0 12 O
drugs NNS 1 1 6 O
are VBP 1 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
. . 0 0 12 O

Urinary JJ 0 1 7 B-Drug
acidifying VBG 1 0 13 I-Drug
agents NNS 1 1 1 O
decrease VB 0 1 1 O
blood NN 0 1 6 O
levels NNS 1 1 1 O
and CC 0 0 12 O
increase VB 0 1 1 O
excretion NN 0 1 14 O
of IN 0 0 12 O
amphetamines NNS 1 1 14 B-Group
. . 0 0 12 O

Selective JJ 0 1 7 B-Group
serotonin NN 0 1 13 I-Group
reuptake NN 0 1 13 I-Group
inhibitors NNS 1 1 14 I-Group
( ( 0 0 2 O
SSRIs NNP 0 1 UNK B-Group
) ) 0 0 2 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
fluoxetine NN 0 1 16 B-Drug
fluvoxamine NN 0 1 16 B-Drug
paroxetine NN 0 1 16 B-Drug
sertraline NN 0 1 16 B-Drug
) ) 0 0 2 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
rarely RB 0 1 UNK O
to TO 0 0 12 O
cause VB 0 1 12 O
weakness NN 0 1 6 O
hyperreflexia NN 0 1 8 O
and CC 0 0 12 O
incoordination NN 0 1 UNK O
when WRB 0 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
9 CD 0 0 2 B-Group
- : 0 0 2 O
HT9 NN 0 1 UNK I-Group
agonists NNS 1 1 UNK I-Group
. . 0 0 12 O

In IN 0 0 2 O
Study NNP 0 1 2 O
9 CD 0 0 2 O
patients NNS 1 1 6 O
with IN 0 0 12 O
colorectal JJ 0 1 6 O
cancer NN 0 1 6 O
were VBD 1 0 12 O
given VBN 1 1 12 O
irinotecan JJ 0 1 13 B-Drug
/ NN 0 0 2 O
9 CD 0 0 2 B-Drug
- : 0 0 2 O
FU NNP 0 1 11 I-Drug
/ NNP 0 0 2 O
leucovorin NN 0 1 16 B-Drug
( ( 0 0 2 O
bolus JJ 0 1 14 O
- : 0 0 2 O
IFL NN 0 1 UNK O
) ) 0 0 2 O
with IN 0 0 12 O
or CC 0 0 12 O
without IN 0 0 12 O
AVASTIN NNP 0 1 UNK B-Brand
. . 0 0 12 O

No DT 0 0 2 O
formal JJ 0 1 1 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
conducted VBN 1 1 1 O
with IN 0 0 12 O
Cyanokit NNP 0 1 UNK B-Brand
. . 0 0 12 O

if IN 0 0 12 O
necessary JJ 0 0 1 O
amiodarone NN 0 1 0 B-Drug
can MD 0 0 12 O
continue VB 0 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
after IN 0 0 12 O
insertion NN 0 1 3 O
of IN 0 0 12 O
a DT 0 0 12 O
pacemaker NN 0 1 6 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
severe JJ 0 1 6 O
bradycardia NN 0 1 8 O
or CC 0 0 12 O
sinus NN 0 1 6 O
arrest NN 0 1 12 O
. . 0 0 12 O

Co NNP 0 1 2 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
inhibitors NNS 1 1 14 O
( ( 0 0 2 O
eg JJ 0 1 UNK O
ketoconazole NN 0 1 16 B-Drug
itraconazole NN 0 1 0 B-Drug
erythromycin NN 0 1 0 B-Drug
grapefruit NN 0 1 3 O
juice NN 0 1 3 O
cimetidine NN 0 1 13 B-Drug
) ) 0 0 2 O
with IN 0 0 12 O
felodipine NN 0 1 13 B-Drug
may MD 0 0 1 O
lead VB 0 1 12 O
to TO 0 0 12 O
several JJ 0 1 12 O
- : 0 0 2 O
fold NN 0 1 3 O
increases NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
felodipine NN 0 1 13 B-Drug
either CC 0 1 12 O
due JJ 0 1 1 O
to TO 0 0 12 O
an DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
bioavailability NN 0 1 UNK O
or CC 0 0 12 O
due JJ 0 1 1 O
to TO 0 0 12 O
a DT 0 0 12 O
decrease NN 0 1 1 O
in IN 0 0 12 O
metabolism NN 0 1 16 O
. . 0 0 12 O

Other JJ 0 0 2 O
CNS NNP 0 1 6 B-Group
depressant NN 0 0 UNK I-Group
drugs NNS 1 1 6 I-Group
( ( 0 0 2 O
e.g NN 0 0 UNK O
. . 0 0 12 O
barbiturates VBZ 0 1 14 B-Group
tranquilizers NNS 1 1 13 B-Group
opioids NNS 0 1 14 B-Group
and CC 0 0 12 O
general JJ 0 1 1 O
anesthetics NNS 1 1 13 B-Group
) ) 0 0 2 O
have VBP 0 0 12 O
additive JJ 0 1 16 O
or CC 0 0 12 O
potentiating JJ 0 0 UNK O
effects NNS 1 1 1 O
with IN 0 0 12 O
INAPSINE NNP 0 1 UNK B-Brand
. . 0 0 12 O

This DT 0 0 2 O
can MD 0 0 12 O
lead VB 0 1 12 O
to TO 0 0 12 O
degradation NN 0 1 1 O
of IN 0 0 12 O
fibrinogen NN 0 1 14 O
in IN 0 0 12 O
blood NN 0 1 6 O
samples NNS 1 1 UNK O
removed VBD 1 1 3 O
for IN 0 0 12 O
analysis NN 0 1 1 O
. . 0 0 12 O

Caution NN 0 0 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
exercised VBN 1 1 1 O
when WRB 0 0 12 O
treating VBG 1 1 6 O
patients NNS 1 1 6 O
with IN 0 0 12 O
either DT 0 1 12 O
of IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
or CC 0 0 12 O
other JJ 0 0 12 O
highly RB 0 1 1 O
protein JJ 0 1 14 O
- : 0 0 2 O
bound NN 0 1 12 O
drugs NNS 1 1 6 O
and CC 0 0 12 O
Atromid NNP 0 1 UNK B-Brand
- : 0 0 2 O
S NN 0 1 2 I-Brand
. . 0 0 12 O

A DT 0 0 2 O
potential JJ 0 1 1 O
interaction NN 0 1 UNK O
between IN 0 0 12 O
oral JJ 0 1 6 O
miconazole NN 0 1 16 B-Drug
and CC 0 0 12 O
oral JJ 0 1 6 O
hypoglycemic JJ 0 1 14 B-Group
agents NNS 1 1 1 I-Group
leading VBG 1 1 1 O
to TO 0 0 12 O
severe JJ 0 1 6 O
hypoglycemia NN 0 1 6 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
. . 0 0 12 O

Peripheral JJ 0 1 7 O
Neuropathy NNP 0 1 7 O
: : 0 0 2 O
Medications NNS 0 1 7 O
known VBN 1 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
peripheral JJ 0 1 6 O
neuropathy NNS 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
with IN 0 0 12 O
caution NN 0 0 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
thalidomide NN 0 1 13 B-Drug
. . 0 0 12 O

Accelerated NNP 0 1 UNK O
prothrombin NN 0 1 14 O
time NN 0 1 12 O
partial JJ 0 1 1 O
thromboplastin NN 0 1 14 O
time NN 0 1 12 O
and CC 0 0 12 O
platelet VB 0 1 14 O
aggregation NN 0 1 UNK O
time NN 0 1 12 O
; : 0 0 2 O

Ketoconazole NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
a DT 0 0 12 O
known VBN 1 1 12 O
strong JJ 0 1 12 O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
. . 0 0 12 O

EDECRIN NNP 0 1 UNK B-Brand
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
ototoxic JJ 0 1 UNK O
potential NN 0 1 1 O
of IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
such JJ 0 0 1 O
as IN 1 0 12 O
aminoglycoside NN 0 1 14 B-Group
and CC 0 0 12 O
some DT 0 0 12 O
cephalosporin NN 0 1 13 B-Group
antibiotics NNS 1 1 6 I-Group
. . 0 0 12 O

Bromocriptine NNP 0 1 UNK B-Drug
mesylate NN 0 1 16 I-Drug
may MD 0 0 1 O
interact VB 0 0 UNK O
with IN 0 0 12 O
dopamine JJ 0 1 14 B-Group
antagonists NNS 1 1 13 I-Group
butyrophenones NNS 0 1 UNK B-Group
and CC 0 0 12 O
certain JJ 0 1 1 O
other JJ 0 0 12 O
agents NNS 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
clinical JJ 0 1 6 O
significance NN 0 1 13 O
of IN 0 0 12 O
these DT 0 0 12 O
effects NNS 1 1 1 O
is VBZ 1 0 12 O
presently RB 0 1 1 O
unknown JJ 0 1 12 O
. . 0 0 12 O

Because IN 0 0 12 O
there EX 0 0 12 O
are VBP 1 0 12 O
no DT 0 0 12 O
data NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
compatibility NN 0 1 UNK O
of IN 0 0 12 O
NovoLog NNP 0 1 UNK B-Brand
and CC 0 0 12 O
crystalline VB 0 1 13 O
zinc NN 0 1 14 B-Drug
insulin NN 0 1 14 I-Drug
preparations NNS 1 1 13 O
NovoLog NNP 0 1 UNK B-Brand
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
mixed JJ 0 1 3 O
with IN 0 0 12 O
these DT 0 0 12 O
preparations NNS 1 1 13 O
. . 0 0 12 O

At IN 0 0 2 O
least JJS 0 1 12 O
9 CD 0 0 2 O
weeks NNS 1 1 12 O
should MD 0 0 12 O
elapse VB 0 1 UNK O
between IN 0 0 12 O
discontinuation NN 0 1 6 O
of IN 0 0 12 O
dexfenfluramine NN 0 1 UNK B-Drug
and CC 0 0 12 O
initiation NN 0 1 1 O
of IN 0 0 12 O
treatment NN 0 1 6 O
with IN 0 0 12 O
a DT 0 0 12 O
MAO NNP 0 1 14 B-Group
inhibitor NN 0 1 14 I-Group
. . 0 0 12 O

The DT 0 0 2 O
same JJ 0 1 12 O
is VBZ 1 0 12 O
true JJ 0 1 12 O
for IN 0 0 12 O
antacids NNS 1 1 14 B-Group
; : 0 0 2 O

Concomitant NNP 0 1 UNK O
use NN 0 1 1 O
of IN 0 0 12 O
L NNP 0 1 2 B-Drug
- : 0 0 2 O
phenylalanine NN 0 1 UNK I-Drug
and CC 0 0 12 O
non JJ 0 1 1 B-Group
- : 0 0 2 O
selective JJ 0 1 13 I-Group
MAO NNP 0 1 14 I-Group
inhibitors NNS 1 1 14 I-Group
may MD 0 0 1 O
cause VB 0 1 12 O
hypertension NN 0 1 6 O
. . 0 0 12 O

Deaths NNS 0 1 UNK O
from IN 0 0 12 O
severe JJ 0 1 6 O
enterocolitis NN 0 1 13 O
diarrhea NN 0 1 6 O
and CC 0 0 12 O
dehydration NN 0 1 6 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
elderly JJ 0 1 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
weekly JJ 0 1 12 O
leucovorin NN 0 1 16 B-Drug
and CC 0 0 12 O
fluorouracil NN 0 1 13 B-Drug
. . 0 0 12 O

Lithium NN 0 1 UNK B-Drug
: : 0 0 2 O
Lithium NN 0 1 UNK B-Drug
toxicity NN 0 1 6 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
lithium NN 0 1 16 B-Drug
concomitantly RB 0 0 14 O
with IN 0 0 12 O
drugs NNS 1 1 6 O
which WDT 0 0 12 O
cause VBP 0 1 12 O
elimination NN 0 1 UNK O
of IN 0 0 12 O
sodium NN 0 1 14 O
including VBG 1 1 1 O
ACE NNP 0 1 13 B-Group
inhibitors NNS 1 1 14 I-Group
. . 0 0 12 O

As IN 0 0 2 O
MHD NNP 0 0 UNK B-Drug_n
the DT 0 0 12 O
predominant JJ 0 1 13 O
plasma NN 0 1 14 O
substrate NN 0 1 UNK O
is VBZ 1 0 12 O
only RB 0 1 12 O
a DT 0 0 12 O
weak JJ 0 1 12 O
inducer NN 0 1 UNK O
of IN 0 0 12 O
UDP NNP 0 1 UNK O
- : 0 0 2 O
glucuronyl NN 0 0 UNK O
transferase NN 0 1 14 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
unlikely JJ 0 1 12 O
to TO 0 0 12 O
have VB 0 0 12 O
an DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
are VBP 1 0 12 O
mainly RB 0 0 1 O
eliminated VBN 1 1 UNK O
by IN 0 0 12 O
conjugation NN 0 1 14 O
through IN 0 0 12 O
UDP NNP 0 1 UNK O
- : 0 0 2 O
glucuronyl NN 0 0 UNK O
transferase NN 0 1 14 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
valproic NN 0 0 16 B-Drug
acid JJ 0 1 14 I-Drug
lamotrigine NN 0 1 0 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

Therefore RB 0 0 1 O
caution NN 0 0 1 O
should MD 0 0 12 O
be VB 0 0 12 O
exercised VBN 1 1 1 O
when WRB 0 0 12 O
using VBG 1 1 1 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
together RB 0 1 12 O

Blunting NN 0 1 15 O
of IN 0 0 12 O
the DT 0 0 12 O
antihypertensive JJ 0 1 14 O
effect NN 0 1 1 O
of IN 0 0 12 O
beta NN 0 1 16 B-Group
- : 0 0 2 O
adrenoceptor NN 0 1 UNK I-Group
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
by IN 0 0 12 O
non JJ 0 1 1 B-Group
- : 0 0 2 O
steroidal JJ 0 1 UNK I-Group
antiinflammatory NN 0 1 14 I-Group
drugs NNS 1 1 6 I-Group
including VBG 1 1 1 O
INDOCIN NNP 0 1 UNK B-Brand
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
. . 0 0 12 O

Oral JJ 0 1 2 O
contraceptives NNS 1 1 13 B-Group
: : 0 0 2 O
Aprepitant NN 0 1 UNK B-Drug
when WRB 0 0 12 O
given VBN 1 1 12 O
once RB 0 0 12 O
daily JJ 0 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
as IN 1 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
mg NN 0 1 0 O
capsule NN 0 1 3 O
with IN 0 0 12 O
an DT 0 0 12 O
oral JJ 0 1 6 O
contraceptive NN 0 1 13 B-Group
containing VBG 1 1 1 O
9 CD 0 0 2 O
mcg NN 0 1 0 O
of IN 0 0 12 O
ethinyl JJ 0 0 13 B-Drug
estradiol NN 0 1 13 I-Drug
and CC 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
of IN 0 0 12 O
norethindrone NN 0 1 13 B-Drug
decreased VBD 1 1 1 O
the DT 0 0 12 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
ethinyl NN 0 0 13 B-Drug
estradiol NN 0 1 13 I-Drug
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
decreased VBD 1 1 1 O
the DT 0 0 12 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
norethindrone NN 0 1 13 B-Drug
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
; : 0 0 2 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interactions NNPS 0 1 UNK O
: : 0 0 2 O
A DT 0 0 2 O
false JJ 0 1 13 O
- : 0 0 2 O
positive JJ 0 1 1 O
reaction NN 0 1 1 O
for IN 0 0 12 O
glucose NN 0 1 14 O
in IN 0 0 12 O
the DT 0 0 12 O
urine NN 0 1 6 O
may MD 0 0 1 O
occur VB 0 1 1 O
with IN 0 0 12 O
copper NN 0 1 3 O
reduction NN 0 1 1 O
tests NNS 1 1 1 O
( ( 0 0 2 O
Benedict NNP 0 0 UNK O
or CC 0 0 12 O
Fehling NNP 0 0 UNK O
s JJ 0 1 12 O
solution NN 0 1 1 O
or CC 0 0 12 O
with IN 0 0 12 O
Clinitest NNP 0 1 UNK O
tablets NNS 1 1 3 O
) ) 0 0 2 O
but CC 0 0 12 O
not RB 0 1 12 O
with IN 0 0 12 O
enzyme SYM 0 1 14 O
- : 0 0 2 O
based VBN 1 1 1 O
tests NNS 1 1 1 O
for IN 0 0 12 O
glycosuria NN 0 1 14 O
. . 0 0 12 O

CYP9A9 JJ 0 0 UNK O
inhibitors NNS 1 1 14 O
: : 0 0 2 O
May NNP 0 1 2 O
increase VB 0 1 1 O
the DT 0 0 12 O
levels NNS 1 1 1 O
/ VBP 0 0 2 O
effects NNS 1 1 1 O
of IN 0 0 12 O
chlorpheniramine NN 0 1 16 B-Drug
. . 0 0 12 O

Renal JJ 0 1 7 O
function NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
carefully RB 0 0 12 O
if IN 0 0 12 O
high JJ 0 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
aminoglycosides NNS 0 1 13 B-Group
are VBP 1 0 12 O
to TO 0 0 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
MAXIPIME NNP 0 1 UNK B-Brand
because IN 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
increased VBN 1 1 1 O
potential NN 0 1 1 O
of IN 0 0 12 O
nephrotoxicity NN 0 1 UNK O
and CC 0 0 12 O
ototoxicity NN 0 1 UNK O
of IN 0 0 12 O
aminoglycoside JJ 0 1 14 B-Group
antibiotics NNS 1 1 6 I-Group
. . 0 0 12 O

Drug NN 0 1 2 O
Interactions NNS 0 1 UNK O
. . 0 0 12 O

Co NNP 0 1 2 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
nelfinavir NN 0 1 16 B-Drug
at IN 0 0 12 O
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
with IN 0 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
azithromycin NN 0 1 0 B-Drug
. . 0 0 12 O

This DT 0 0 2 O
increase NN 0 1 1 O
is VBZ 1 0 12 O
greatest JJS 1 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
evening NN 0 1 12 O
. . 0 0 12 O

Cyclosporin NN 0 1 0 B-Drug
: : 0 0 2 O
Reports NNS 0 1 2 O
indicate VBP 0 0 1 O
that IN 0 0 12 O
cyclosporine NN 0 1 14 B-Drug
levels NNS 1 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
increased VBN 1 1 1 O
during IN 0 0 12 O
concomitant JJ 0 1 6 O
treatment NN 0 1 6 O
with IN 0 0 12 O
allopurinol JJ 0 1 13 B-Drug
sodium NN 0 1 14 I-Drug
for IN 0 0 12 O
injection NN 0 1 3 O
. . 0 0 12 O

In IN 0 0 2 O
the DT 0 0 12 O
Duloxetine NNP 0 1 0 B-Drug
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
database VBD 0 1 UNK O
three CD 0 1 12 O
Duloxetine NNP 0 1 0 B-Drug
- : 0 0 2 O
treated VBD 1 1 1 O
patients NNS 1 1 6 O
had VBD 1 0 12 O
liver JJ 0 1 6 O
injury NN 0 1 6 O
as IN 1 0 12 O
manifested VBN 1 1 UNK O
by IN 0 0 12 O
ALT NNP 0 1 13 O
and CC 0 0 12 O
total JJ 0 1 1 O
bilirubin NN 0 1 14 O
elevations NNS 1 1 1 O
with IN 0 0 12 O
evidence NN 0 1 1 O
of IN 0 0 12 O
obstruction NN 0 1 6 O
. . 0 0 12 O

Erythromycin NNP 0 1 0 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
every DT 0 0 12 O
9 CD 0 0 2 O
hrs NN 1 0 16 O
) ) 0 0 2 O

However RB 0 0 1 O
neither DT 0 0 12 O
phenobarbital JJ 0 1 16 B-Drug
nor CC 0 0 12 O
diazepam JJ 0 1 0 B-Drug
appears VBZ 1 1 12 O
to TO 0 0 12 O
affect VB 0 1 1 O
Dantrium NNP 0 1 UNK B-Brand
metabolism NN 0 1 16 O
. . 0 0 12 O

If IN 0 0 12 O
CEFOTAN NNP 0 1 UNK B-Brand
and CC 0 0 12 O
an DT 0 0 12 O
aminoglycoside NN 0 1 14 B-Group
are VBP 1 0 12 O
used VBN 1 1 12 O
concomitantly RB 0 0 14 O
renal JJ 0 1 6 O
function NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
carefully RB 0 0 12 O
monitored VBN 1 1 1 O
because IN 0 0 12 O
nephrotoxicity NN 0 1 UNK O
may MD 0 0 1 O
be VB 0 0 12 O
potentiated VBN 1 0 UNK O
. . 0 0 12 O

Severe NNP 0 1 7 O
hypoglycemia NN 0 1 6 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
concomitantly RB 0 0 14 O
receiving VBG 1 1 1 O
azole JJ 0 1 UNK B-Group
antifungal JJ 0 1 14 I-Group
agents NNS 1 1 1 I-Group
and CC 0 0 12 O
oral JJ 0 1 6 O
hypoglycemic JJ 0 1 14 B-Group
agents NNS 1 1 1 I-Group
. . 0 0 12 O

Dexbrompheniramine NN 0 1 UNK B-Drug
can MD 0 0 12 O
interact VB 0 0 UNK O
with IN 0 0 12 O
alcohol NN 0 1 1 B-Drug
or CC 0 0 12 O
other JJ 0 0 12 O
CNS NNP 0 1 6 B-Group
depressants NNS 1 0 13 I-Group
( ( 0 0 2 O
may MD 0 0 1 O
potentiate VB 0 0 UNK O
the DT 0 0 12 O
CNS NNP 0 1 6 O
depressant JJ 0 0 UNK O
effects NNS 1 1 1 O
of IN 0 0 12 O
either CC 0 1 12 O
these DT 0 0 12 O
medications NNS 1 1 6 O
or CC 0 0 12 O
antihistamines NNS 1 1 UNK B-Group
) ) 0 0 2 O
anticholinergics NNS 1 1 13 B-Group
or CC 0 0 12 O
other JJ 0 0 12 O
medications NNS 1 1 6 O
with IN 0 0 12 O
anticholinergic JJ 0 1 13 O
activity NN 0 1 1 O
( ( 0 0 2 O
anticholinergic JJ 0 1 13 O
effects NNS 1 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
potentiated VBN 1 0 UNK O
when WRB 0 0 12 O
these DT 0 0 12 O
medications NNS 1 1 6 O
are VBP 1 0 12 O
used VBN 1 1 12 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
antihistamines NNS 1 1 UNK B-Group
) ) 0 0 2 O
and CC 0 0 12 O
monoamine JJ 0 1 13 B-Group
oxidase NN 0 1 13 I-Group
MAO NNP 0 1 14 I-Group
inhibitors NNS 1 1 14 I-Group
( ( 0 0 2 O
concurrent NN 0 1 1 O
use NN 0 1 1 O
with IN 0 0 12 O
antihistamines NNS 1 1 UNK B-Group
may MD 0 0 1 O
prolong VB 0 0 13 O
and CC 0 0 12 O
intensify VB 0 0 UNK O
the DT 0 0 12 O
anticholinergic NN 0 1 13 O
and CC 0 0 12 O
CNS NNP 0 1 6 O
depressant JJ 0 0 UNK O
effects NNS 1 1 1 O
of IN 0 0 12 O
antihistamines NNS 1 1 UNK B-Group
) ) 0 0 2 O
. . 0 0 12 O

The DT 0 0 2 O
oral JJ 0 1 6 O
dexamethasone NN 0 1 16 B-Drug
doses NNS 1 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
reduced VBN 1 1 1 O
by IN 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
when WRB 0 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
Aprepitant NNP 0 1 UNK B-Drug
to TO 0 0 12 O
achieve VB 0 0 1 O
exposures NNS 1 1 UNK O
of IN 0 0 12 O
dexamethasone NN 0 1 16 B-Drug
similar JJ 0 1 1 O
to TO 0 0 12 O
those DT 0 0 12 O
obtained VBN 1 1 1 O
when WRB 0 0 12 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
given VBN 1 1 12 O
without IN 0 0 12 O
Aprepitant NNP 0 1 UNK B-Drug
. . 0 0 12 O

Patients NNS 0 1 7 O
who WP 0 0 12 O
begin VBP 0 1 12 O
taking VBG 1 0 12 O
diclofenac NN 0 1 16 B-Drug
or CC 0 0 12 O
who WP 0 0 12 O
increase VBP 0 1 1 O
their PRP$ 0 0 12 O
diclofenac NN 0 1 16 B-Drug
dose NN 0 1 6 O
or CC 0 0 12 O
any DT 0 0 12 O
other JJ 0 0 12 O
NSAID NNP 0 1 14 B-Group
while IN 0 0 12 O
taking VBG 1 0 12 O
digoxin JJ 0 1 14 B-Drug
methotrexate NN 0 1 16 B-Drug
or CC 0 0 12 O
cyclosporine NN 0 1 14 B-Drug
may MD 0 0 1 O
develop VB 0 0 1 O
toxicity NN 0 1 6 O
characteristics NNS 1 1 UNK O
for IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

Talk NN 0 1 UNK O
to TO 0 0 12 O
your PRP$ 0 0 12 O
doctor NN 0 1 12 O
if IN 0 0 12 O
you PRP 0 0 12 O
are VBP 1 0 12 O
taking VBG 1 0 12 O
certain JJ 0 1 1 O
antibiotics NNS 1 1 6 B-Group
such JJ 0 0 1 O
as IN 1 0 12 O
erythromycin JJ 0 1 0 B-Drug
clarithromycin NN 0 1 13 B-Drug
or CC 0 0 12 O
azithromycin NN 0 1 0 B-Drug
. . 0 0 12 O

After IN 0 0 2 O
consumption NN 0 1 1 O
of IN 0 0 12 O
alcohol NN 0 1 1 B-Drug
at IN 0 0 12 O
least JJS 0 1 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
should MD 0 0 12 O
elapse VB 0 1 UNK O
before IN 0 1 12 O
these DT 0 0 12 O
determinations NNS 1 1 UNK O
are VBP 1 0 12 O
made VBN 1 1 12 O
. . 0 0 12 O

The DT 0 0 2 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
TAXOL NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
catalyzed VBN 1 0 UNK O
by IN 0 0 12 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
isoen NN 0 0 UNK O
- : 0 0 2 O
zymes NNS 0 0 UNK O
CYP9C9 NNP 0 0 UNK O
and CC 0 0 12 O
CYP9A9 NNP 0 0 UNK O
. . 0 0 12 O

Nevertheless RB 0 0 1 O
the DT 0 0 12 O
possibility NN 0 1 1 O
of IN 0 0 12 O
additive JJ 0 1 16 O
negative JJ 0 1 1 O
inotropic NN 0 0 14 O
effects NNS 1 1 1 O
of IN 0 0 12 O
beta NN 0 1 16 B-Group
blockers NNS 1 0 6 I-Group
and CC 0 0 12 O
flecainide NN 0 1 16 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
recognized VBN 1 0 13 O
. . 0 0 12 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interactions NNP 0 1 UNK O
Finasteride NNP 0 1 0 B-Drug
had VBD 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
circulating VBG 1 1 13 O
levels NNS 1 1 1 O
of IN 0 0 12 O
cortisol NN 0 1 14 O
thyroid SYM 0 1 6 O
- : 0 0 2 O
stimulating VBG 1 1 1 O
hormone NN 0 1 6 O
or CC 0 0 12 O
thyroxine VB 0 1 14 O
nor CC 0 0 12 O
did VBD 1 0 12 O
it PRP 0 0 12 O
affect VB 0 1 1 O
the DT 0 0 12 O
plasma NN 0 1 14 O
lipid JJ 0 1 14 O
profile NN 0 1 1 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
total NN 0 1 1 O
cholesterol NN 0 1 6 O
low JJ 0 1 1 O
- : 0 0 2 O
density NN 0 1 1 O
lipoproteins VBZ 0 1 UNK O
high JJ 0 1 1 O
- : 0 0 2 O
density NN 0 1 1 O
lipoproteins NNS 1 1 UNK O
and CC 0 0 12 O
triglycerides NNS 1 1 14 O
) ) 0 0 2 O
or CC 0 0 12 O
bone JJ 0 1 6 O
mineral JJ 0 1 3 O
density NN 0 1 1 O
. . 0 0 12 O

Ibandronate NNP 0 1 UNK B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
taken VBN 1 1 12 O
at IN 0 0 12 O
least JJS 0 1 12 O
9 CD 0 0 2 O
minutes NNS 1 1 12 O
before IN 0 1 12 O
any DT 0 0 12 O
oral JJ 0 1 6 O
medications NNS 1 1 6 O
containing VBG 1 1 1 O
multivalent NN 0 0 UNK O
cations NNS 1 1 UNK O
( ( 0 0 2 O
including VBG 1 1 1 O
antacids NNS 1 1 14 B-Group
supplements NNS 1 1 6 O
or CC 0 0 12 O
vitamins NNS 1 1 6 B-Group
) ) 0 0 2 O
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
important JJ 0 1 1 O
that IN 0 0 12 O
patients NNS 1 1 6 O
understand VB 0 1 12 O
how WRB 0 0 12 O
to TO 0 0 12 O
use VB 0 1 1 O
FORADIL NNP 0 1 UNK B-Brand
( ( 0 0 2 O
formoterol VB 0 1 13 B-Drug
fumarate NN 0 1 16 I-Drug
) ) 0 0 2 O
capsules VBZ 1 1 3 O
with IN 0 0 12 O
the DT 0 0 12 O
supplied JJ 0 1 UNK O
AerolizerTM NNP 0 0 UNK O
inhalation NN 0 1 16 O
device NN 0 1 1 O
and CC 0 0 12 O
how WRB 0 0 12 O
it PRP 0 0 12 O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
in IN 0 0 12 O
relation NN 0 1 13 O
to TO 0 0 12 O
other JJ 0 0 12 O
asthma NN 0 1 6 O
or CC 0 0 12 O
COPD NNP 0 1 6 O
medications NNS 1 1 6 O
they PRP 0 0 12 O
are VBP 1 0 12 O
taking VBG 1 0 12 O
. . 0 0 12 O

The DT 0 0 2 O
extent NN 0 1 1 O
to TO 0 0 12 O
which WDT 0 0 12 O
SSRI NNP 0 1 UNK B-Group
- : 0 0 2 O
TCA NNP 0 1 13 B-Group
interactions NNS 1 1 UNK O
may MD 0 0 1 O
pose VB 0 0 UNK O
clinical JJ 0 1 6 O
problems NNS 1 1 1 O
will MD 0 0 12 O
depend VB 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
degree NN 0 1 1 O
of IN 0 0 12 O
inhibition NN 0 1 13 O
and CC 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
SSRI NNP 0 1 UNK B-Group
involved VBN 1 1 12 O
. . 0 0 12 O

Therefore RB 0 0 1 O
as IN 1 0 12 O
vitamin NN 0 1 6 B-Group
K NNP 0 1 2 I-Group
absorption NN 0 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
decreased VBN 1 1 1 O
with IN 0 0 12 O
XENICAL JJ 0 1 UNK B-Brand
patients NNS 1 1 6 O
on IN 0 0 12 O
chronic JJ 0 1 6 O
stable JJ 0 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
who WP 0 0 12 O
are VBP 1 0 12 O
prescribed JJ 0 1 1 O
XENICAL NNP 0 1 UNK B-Brand
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
closely RB 0 0 1 O
for IN 0 0 12 O
changes NNS 1 1 1 O
in IN 0 0 12 O
coagulation NN 0 1 14 O
parameters NNS 1 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
healthy JJ 0 1 12 O
subjects NNS 1 1 UNK O
receiving VBG 1 1 1 O
cimetidine NN 0 1 13 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
gm NNS 0 1 16 O
daily RB 0 1 12 O
) ) 0 0 2 O
for IN 0 0 12 O
one CD 0 1 12 O
week NN 0 1 12 O
plasma NN 0 1 14 O
flecainide NN 0 1 16 B-Drug
levels NNS 1 1 1 O
increased VBN 1 1 1 O
by IN 0 0 12 O
about RB 0 1 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
increased VBN 1 1 1 O
by IN 0 0 12 O
about RB 0 1 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

Therefore RB 0 0 1 O
co SYM 0 1 12 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
bupropion NN 0 1 16 B-Drug
with IN 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
are VBP 1 0 12 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
CYP9D9 NNP 0 0 UNK O
isoenzyme NN 0 1 13 O
including VBG 1 1 1 O
certain JJ 0 1 1 O
antidepressants NNS 1 1 13 B-Group
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
nortriptyline NN 0 1 16 B-Drug
imipramine NN 0 1 0 B-Drug
desipramine NN 0 1 16 B-Drug
paroxetine NN 0 1 16 B-Drug
fluoxetine VBP 0 1 16 B-Drug
sertraline NN 0 1 16 B-Drug
) ) 0 0 2 O
antipsychotics NNS 1 1 14 B-Group
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
haloperidol NN 0 1 16 B-Drug
risperidone NN 0 1 0 B-Drug
thioridazine NN 0 1 13 B-Drug
) ) 0 0 2 O
beta NN 0 1 16 B-Group
- : 0 0 2 O
blockers NNS 1 0 6 I-Group
( ( 0 0 2 O
e.g. VB 0 0 UNK O
metoprolol NN 0 1 0 B-Drug
) ) 0 0 2 O
and CC 0 0 12 O
Type $ 0 1 2 B-Group
9C CD 0 0 UNK I-Group
antiarrhythmics NNS 1 1 UNK I-Group
( ( 0 0 2 O
e.g. VB 0 0 UNK O
propafenone NN 0 1 16 B-Drug
flecainide NN 0 1 16 B-Drug
) ) 0 0 2 O
should MD 0 0 12 O
be VB 0 0 12 O
approached VBN 1 1 UNK O
with IN 0 0 12 O
caution NN 0 0 1 O
and CC 0 0 12 O
should MD 0 0 12 O
be VB 0 0 12 O
initiated VBN 1 1 1 O
at IN 0 0 12 O
the DT 0 0 12 O
lower JJR 1 1 1 O
end NN 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
dose JJ 0 1 6 O
range NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
concomitant JJ 0 1 6 O
medication NN 0 1 6 O
. . 0 0 12 O

Use NN 0 1 2 O
with IN 0 0 12 O
caution NN 0 0 1 O
. . 0 0 12 O

In IN 0 0 2 O
a DT 0 0 12 O
single JJ 0 1 12 O
subject NN 0 1 UNK O
given VBN 1 1 12 O
one CD 0 1 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
ciprofloxacin NN 0 1 0 B-Drug
9 CD 0 0 2 O
hours NNS 1 1 12 O
after IN 0 0 12 O
a DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
didanosine JJ 0 1 16 B-Drug
- : 0 0 2 O
placebo NN 0 1 13 O
tablets VBZ 0 1 3 O
a DT 0 0 12 O
greater JJR 1 1 1 O
than IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
reduction NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
ciprofloxacin NN 0 1 0 B-Drug
was VBD 1 0 12 O
observed VBN 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
concomitant NN 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
H9 NNP 0 0 UNK B-Group
blockers NNS 1 0 6 I-Group
or CC 0 0 12 O
proton NN 0 1 14 B-Group
pump NN 0 1 3 I-Group
inhibitors NNS 1 1 14 I-Group
with IN 0 0 12 O
SPRYCEL NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
not RB 0 1 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O

Aspirin NNP 0 1 0 B-Brand
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
cautiously RB 0 0 UNK O
in IN 0 0 12 O
conjunction NN 0 1 1 O
with IN 0 0 12 O
corticosteroids NNS 1 1 14 B-Group
in IN 0 0 12 O
hypoprothrombinemia NN 0 1 UNK O
. . 0 0 12 O

However RB 0 0 1 O
caution NN 0 0 1 O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
when WRB 0 0 12 O
administering VBG 1 1 1 O
CELEBREX NNP 0 1 UNK B-Brand
with IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
since IN 0 1 12 O
these DT 0 0 12 O
patients NNS 1 1 6 O
are VBP 1 0 12 O
at IN 0 0 12 O
increased JJ 0 1 1 O
risk NN 0 1 1 O
of IN 0 0 12 O
bleeding VBG 1 1 6 O
complications NNS 1 1 6 O
. . 0 0 12 O

Diltiazem NN 0 1 0 B-Drug
: : 0 0 2 O
In IN 0 0 2 O
patients NNS 1 1 6 O
with IN 0 0 12 O
mild JJ 0 1 6 O
to TO 0 0 12 O
moderate VB 0 1 1 O
hypertension NN 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
aprepitant JJ 0 1 13 B-Drug
once RB 0 0 12 O
daily RB 0 1 12 O
as IN 1 0 12 O
a DT 0 0 12 O
tablet NN 0 1 16 O
formulation NN 0 1 13 O
comparable JJ 0 0 1 O
to TO 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
of IN 0 0 12 O
the DT 0 0 12 O
capsule NN 0 1 3 O
formulation NN 0 1 13 O
with IN 0 0 12 O
diltiazem JJ 0 1 0 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
9 CD 0 0 2 O
times NNS 1 1 12 O
daily RB 0 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
resulted VBD 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
fold JJ 0 1 3 O
increase NN 0 1 1 O
of IN 0 0 12 O
aprepitant JJ 0 1 13 B-Drug
AUC NNP 0 1 UNK O
and CC 0 0 12 O
a DT 0 0 12 O
simultaneous JJ 0 1 13 O
9 CD 0 0 2 O
- : 0 0 2 O
fold JJ 0 1 3 O
increase NN 0 1 1 O
of IN 0 0 12 O
diltiazem JJ 0 1 0 B-Drug
AUC NNP 0 1 UNK O
. . 0 0 12 O

Ketoconazole NNP 0 1 UNK B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
affect VB 0 1 1 O
the DT 0 0 12 O
conversion NN 0 1 13 O
of IN 0 0 12 O
losartan NN 0 1 0 B-Drug
to TO 0 0 12 O
the DT 0 0 12 O
active JJ 0 1 1 O
metabolite NN 0 1 UNK O
after IN 0 0 12 O
intravenous JJ 0 1 14 O
administration NN 0 1 1 O
of IN 0 0 12 O
losartan JJ 0 1 0 B-Drug
and CC 0 0 12 O
erythromycin NN 0 1 0 B-Drug
had VBD 1 0 12 O
no DT 0 0 12 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
effect NN 0 1 1 O
after IN 0 0 12 O
oral JJ 0 1 6 O
administration NN 0 1 1 O
. . 0 0 12 O

cimetidine NN 0 1 13 B-Drug
) ) 0 0 2 O
and CC 0 0 12 O
many JJ 0 0 12 O
that WDT 0 0 12 O
are VBP 1 0 12 O
substrates VBZ 0 1 UNK O
for IN 0 0 12 O
P9 NNP 0 1 UNK O
9D9 CD 0 0 UNK O
( ( 0 0 2 O
many JJ 0 0 12 O
other JJ 0 0 12 O
antidepressants NNS 1 1 13 B-Group
phenothiazines NNS 1 1 UNK B-Group
and CC 0 0 12 O
the DT 0 0 12 O
Type NNP 0 1 2 B-Group
9C CD 0 0 UNK I-Group
antiarrhythmics NNS 1 1 UNK I-Group
propafenone NN 0 1 16 B-Drug
and CC 0 0 12 O
flecainide NN 0 1 16 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

In IN 0 0 2 O
vitro JJ 0 1 UNK O
testing VBG 1 1 1 O
found VBN 1 1 12 O
no DT 0 0 12 O
protein NN 0 1 14 O
binding VBG 1 1 1 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
between IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
and CC 0 0 12 O
meloxicam NN 0 1 13 B-Drug
. . 0 0 12 O

Caution NN 0 0 UNK O
is VBZ 1 0 12 O
advised VBN 1 0 12 O
when WRB 0 0 12 O
VERSED NNP 0 1 15 B-Brand
Syrup NNP 0 1 2 I-Brand
is VBZ 1 0 12 O
used VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

Delayed NNP 0 1 7 O
Adverse NNP 0 0 UNK O
Reactions NNP 0 1 UNK O
to TO 0 0 12 O
Iodinated NNP 0 0 UNK B-Group
Contrast NNP 0 1 2 I-Group
Media NNP 0 1 UNK I-Group
: : 0 0 2 O
A DT 0 0 2 O
review NN 0 1 2 O
of IN 0 0 12 O
the DT 0 0 12 O
literature NN 0 1 UNK O
revealed VBD 1 1 12 O
that IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
( ( 0 0 2 O
range NN 0 1 1 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
of IN 0 0 12 O
9 CD 0 0 2 O
patients NNS 1 1 6 O
treated VBN 1 1 1 O
with IN 0 0 12 O
various JJ 0 1 1 O
interleukin JJ 0 1 13 B-Drug
- : 0 0 2 O
9 CD 0 0 2 I-Drug
containing VBG 1 1 1 O
regimens NNS 1 1 UNK O
who WP 0 0 12 O
were VBD 1 0 12 O
subsequently RB 0 0 1 O
administered VBN 1 1 1 O
radiographic JJ 0 1 8 B-Group
iodinated VBN 1 0 UNK I-Group
contrast NN 0 1 1 I-Group
media NNS 1 1 1 I-Group
experienced VBD 1 0 12 O
acute JJ 0 1 6 O
atypical JJ 0 1 6 O
adverse JJ 0 0 1 O
reactions NNS 1 1 1 O
. . 0 0 12 O

Concomitant JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
nephrotoxic JJ 0 1 UNK O
drugs NNS 1 1 6 O
could MD 0 0 12 O
result VB 0 1 1 O
in IN 0 0 12 O
delayed JJ 0 1 1 O
clearance NN 0 1 16 O
of IN 0 0 12 O
ALIMTA NNP 0 1 UNK B-Brand
. . 0 0 12 O

Amiodarone NN 0 1 0 B-Drug
or CC 0 0 12 O
Verapamil NN 0 1 0 B-Drug
: : 0 0 2 O
The DT 0 0 2 O
risk NN 0 1 1 O
of IN 0 0 12 O
myopathy JJ 0 1 8 O
/ JJ 0 0 2 O
rhabdomyolysis NN 0 1 8 O
is VBZ 1 0 12 O
increased VBN 1 1 1 O
when WRB 0 0 12 O
either DT 0 1 12 O
amiodarone NN 0 1 0 B-Drug
or CC 0 0 12 O
verapamil NN 0 1 0 B-Drug
is VBZ 1 0 12 O
used VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
a DT 0 0 12 O
closely RB 0 0 1 O
related JJ 0 1 1 O
member NN 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
HMG NNP 0 0 UNK B-Group
- : 0 0 2 O
CoA NNP 0 0 UNK I-Group
reductase NN 0 1 UNK I-Group
inhibitor NN 0 1 14 I-Group
class NN 0 1 12 I-Group
( ( 0 0 2 O
see VB 0 1 12 O
WARNINGS NNP 0 1 UNK O
Myopathy NNP 0 1 UNK O
/ NNP 0 0 2 O
Rhabdomyolysis NNP 0 1 UNK O
) ) 0 0 2 O
. . 0 0 12 O

Following VBG 0 1 2 O
oral JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
two CD 0 1 12 O
9 CD 0 0 2 O
- : 0 0 2 O
mg NN 0 1 0 O
sustained VBN 1 1 1 O
- : 0 0 2 O
release NN 0 1 12 O
tablets NNS 1 1 3 O
with IN 0 0 12 O
and CC 0 0 12 O
without IN 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
of IN 0 0 12 O
cimetidine NN 0 1 13 B-Drug
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
bupropion NN 0 1 16 B-Drug
and CC 0 0 12 O
hydroxybupropion NN 0 1 UNK B-Drug_n
were VBD 1 0 12 O
unaffected VBN 0 1 UNK O
. . 0 0 12 O

diuretics NNS 1 1 14 B-Group
* VBP 0 0 2 O
; : 0 0 2 O

Caution NN 0 0 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
exercised VBN 1 1 1 O
when WRB 0 0 12 O
the DT 0 0 12 O
following JJ 0 1 1 O
drugs NNS 1 1 6 O
are VBP 1 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
LODOSYN NNP 0 1 UNK B-Brand
( ( 0 0 2 O
Carbidopa NNP 0 1 0 B-Drug
) ) 0 0 2 O
given VBN 1 1 12 O
with IN 0 0 12 O
levodopa NN 0 1 UNK B-Drug
or CC 0 0 12 O
carbidopa VB 0 1 13 B-Drug
- : 0 0 2 O
levodopa NN 0 1 UNK B-Drug
combination NN 0 1 1 O
products NNS 1 1 1 O
. . 0 0 12 O

Other JJ 0 0 2 O
Potentially NNP 0 0 UNK O
Important NNP 0 1 UNK O
Drug NNP 0 1 2 O
Interactions NNS 0 1 UNK O
: : 0 0 2 O
Benzodiazepines NNS 0 1 UNK B-Group
: : 0 0 2 O
Benzodiazepines NNS 0 1 UNK B-Group
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
hepatic JJ 0 1 14 O
oxidation NN 0 1 13 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
alprazolam NN 0 1 0 B-Drug
midazolam NN 0 1 16 B-Drug
triazolam NN 0 1 13 B-Drug
elc NN 0 1 UNK O
. . 0 0 12 O
) ) 0 0 2 O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
with IN 0 0 12 O
caution NN 0 0 1 O
because IN 0 0 12 O
the DT 0 0 12 O
clearance NN 0 1 16 O
of IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
is VBZ 1 0 12 O
likely JJ 0 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
reduced VBN 1 1 1 O
by IN 0 0 12 O
fluvoxamine NN 0 1 16 B-Drug
. . 0 0 12 O

Other JJ 0 0 2 O
eye NN 0 1 3 O
drops NNS 1 1 3 O
or CC 0 0 12 O
medications NNS 1 1 6 O
such JJ 0 0 1 O
as IN 1 0 12 O
acetylcholine JJ 0 1 14 B-Drug
chloride NN 0 1 14 I-Drug
( ( 0 0 2 O
Miochol NNP 0 1 UNK B-Brand
) ) 0 0 2 O
and CC 0 0 12 O
carbachol NN 0 1 13 B-Drug
( ( 0 0 2 O
Carboptic JJ 0 1 UNK B-Brand
Isopto NNP 0 0 UNK B-Brand
Carbachol NNP 0 1 UNK I-Brand
) ) 0 0 2 O
may MD 0 0 1 O
decrease VB 0 1 1 O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
suprofen JJ 0 1 UNK B-Drug
ophthalmic JJ 0 1 6 O
. . 0 0 12 O

* NN 0 0 2 O
This DT 0 0 2 O
table NN 0 1 3 O
is VBZ 1 0 12 O
not RB 0 1 12 O
all DT 0 0 12 O
inclusive JJ 0 1 UNK O
** NNP 0 0 2 O
VIRACEPT NNP 0 1 UNK B-Brand
may MD 0 0 1 O
not RB 0 1 12 O
be VB 0 0 12 O
effective JJ 0 1 1 O
due JJ 0 1 1 O
to TO 0 0 12 O
decreased JJ 0 1 1 O
nelfinavir JJ 0 1 16 B-Drug
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
in IN 0 0 12 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
these DT 0 0 12 O
agents NNS 1 1 1 O
concomitantly RB 0 0 14 O

Observe IN 0 1 UNK O
the DT 0 0 12 O
patient NN 0 1 6 O
for IN 0 0 12 O
possible JJ 0 1 1 O
diminished JJ 0 1 1 O
effect NN 0 1 1 O
of IN 0 0 12 O
steroid NN 0 1 6 B-Group
and CC 0 0 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
steroid JJ 0 1 6 B-Group
dosage NN 0 1 0 O
accordingly RB 0 0 1 O
. . 0 0 12 O

In IN 0 0 2 O
single JJ 0 1 12 O
and CC 0 0 12 O
multiple JJ 0 1 1 O
dose JJ 0 1 6 O
studies NNS 1 1 1 O
in IN 0 0 12 O
healthy JJ 0 1 12 O
subjects NNS 1 1 UNK O
receiving VBG 1 1 1 O
both DT 0 0 12 O
warfarin NN 0 1 14 B-Drug
and CC 0 0 12 O
rofecoxib VB 0 1 16 B-Drug
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
( ( 0 0 2 O
measured VBN 1 1 1 O
as IN 1 0 12 O
INR NNP 0 1 13 O
) ) 0 0 2 O
was VBD 1 0 12 O
increased VBN 1 1 1 O
by IN 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
to TO 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

Use NN 0 1 2 O
with IN 0 0 12 O
Other JJ 0 0 2 O
Central NNP 0 1 2 B-Group
Nervous NNP 0 1 UNK I-Group
System NNP 0 1 2 I-Group
Depressants VBZ 0 0 UNK I-Group
: : 0 0 2 O
The DT 0 0 2 O
depressant JJ 0 0 UNK O
effects NNS 1 1 1 O
of IN 0 0 12 O
morphine NN 0 1 14 B-Drug
are VBP 1 0 12 O
potentiated VBN 1 0 UNK O
by IN 0 0 12 O
the DT 0 0 12 O
presence NN 0 1 1 O
of IN 0 0 12 O
other JJ 0 0 12 O
CNS NNP 0 1 6 B-Group
depressants NNS 1 0 13 I-Group
such JJ 0 0 1 O
as IN 1 0 12 O
alcohol NN 0 1 1 B-Drug
sedatives VBZ 0 1 6 B-Group
antihistaminics NNS 0 1 UNK B-Group
or CC 0 0 12 O
psychotropic NN 0 1 13 B-Group
drugs NNS 1 1 6 I-Group
. . 0 0 12 O

ranitidine NN 0 1 0 B-Drug
* NN 0 0 2 O
; : 0 0 2 O

No DT 0 0 2 O
formal JJ 0 1 1 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
with IN 0 0 12 O
anti JJ 0 0 3 B-Group
- : 0 0 2 O
neoplastic JJ 0 1 16 I-Group
agents NNS 1 1 1 I-Group
have VBP 0 0 12 O
been VBN 1 0 12 O
conducted VBN 1 1 1 O
. . 0 0 12 O

No DT 0 0 2 O
dose JJ 0 1 6 O
adjustment NN 0 1 1 O
is VBZ 1 0 12 O
necessary JJ 0 0 1 O
when WRB 0 0 12 O
Simulect NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
added VBN 1 1 12 O
to TO 0 0 12 O
triple VB 0 1 3 O
- : 0 0 2 O
immunosuppression NN 0 1 14 O
regimens VBZ 0 1 UNK O
including VBG 1 1 1 O
cyclosporine JJ 0 1 14 B-Drug
corticosteroids NNS 1 1 14 B-Group
and CC 0 0 12 O
either DT 0 1 12 O
azathioprine NN 0 1 13 B-Drug
or CC 0 0 12 O
mycophenolate NN 0 1 0 B-Drug
mofetil NNS 0 0 16 I-Drug
. . 0 0 12 O

Administration NN 0 1 UNK O
of IN 0 0 12 O
thiazide JJ 0 1 UNK B-Group
diuretics NNS 1 1 14 I-Group
to TO 0 0 12 O
hypoparathyroid VB 0 1 UNK O
patients NNS 1 1 6 O
who WP 0 0 12 O
are VBP 1 0 12 O
concurrently RB 0 0 1 O
being VBG 1 0 12 O
treated VBN 1 1 1 O
with IN 0 0 12 O
dihydrotachysterol NN 0 1 UNK B-Drug
may MD 0 0 1 O
cause VB 0 1 12 O
hypercalcemia NN 0 1 8 O
. . 0 0 12 O

The DT 0 0 2 O
effect NN 0 1 1 O
of IN 0 0 12 O
orlistat NN 0 1 UNK B-Drug
on IN 0 0 12 O
the DT 0 0 12 O
absorption NN 0 1 1 O
of IN 0 0 12 O
supplemental JJ 0 1 1 O
vitamin NN 0 1 6 B-Group
D NNP 0 1 2 I-Group
vitamin VBZ 0 1 6 B-Group
A NNP 0 0 2 I-Group
and CC 0 0 12 O
nutritionally RB 0 0 13 O
- : 0 0 2 O
derived VBN 1 1 UNK O
vitamin JJ 0 1 6 B-Group
K NNP 0 1 2 I-Group
is VBZ 1 0 12 O
not RB 0 1 12 O
known VBN 1 1 12 O
at IN 0 0 12 O
this DT 0 0 12 O
time NN 0 1 12 O
. . 0 0 12 O

Antacids NNS 0 1 UNK B-Group
Sucralfate NNP 0 1 0 B-Drug
Metal NNP 0 1 UNK O
Cations NNP 0 1 UNK O
Multivitamins NNP 0 1 0 B-Group
Quinolones NNP 0 1 UNK B-Group
form NN 0 1 1 O
chelates VBZ 1 1 UNK O
with IN 0 0 12 O
alkaline JJ 0 1 14 O
earth NN 0 1 13 O
and CC 0 0 12 O
transition NN 0 1 1 O
metal NN 0 1 3 O
cations NNS 1 1 UNK O
. . 0 0 12 O

When WRB 0 0 12 O
used VBN 1 1 12 O
in IN 0 0 12 O
therapeutic JJ 0 1 6 O
doses NNS 1 1 6 O
azithromycin VBP 0 1 0 B-Drug
had VBD 1 0 12 O
a DT 0 0 12 O
modest JJ 0 1 1 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
atorvastatin JJ 0 1 0 B-Drug
carbamazepine JJ 0 1 16 B-Drug
cetirizine NN 0 1 13 B-Drug
didanosine NN 0 1 16 B-Drug
efavirenz JJ 0 1 13 B-Drug
fluconazole JJ 0 1 0 B-Drug
indinavir NN 0 1 16 B-Drug
midazolam NN 0 1 16 B-Drug
rifabutin NN 0 1 13 B-Drug
sildenafil JJ 0 1 16 B-Drug
theophylline NN 0 1 16 B-Drug
( ( 0 0 2 O
intravenous JJ 0 1 14 O
and CC 0 0 12 O
oral JJ 0 1 6 O
) ) 0 0 2 O
triazolam NN 0 1 13 B-Drug
trimethoprim JJ 0 1 16 B-Drug
/ JJ 0 0 2 O
sulfamethoxazole NN 0 1 13 B-Drug
or CC 0 0 12 O
zidovudine NN 0 1 13 B-Drug
. . 0 0 12 O

therefore RB 0 0 1 O
concomitant JJ 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
stavudine NN 0 1 13 B-Drug
with IN 0 0 12 O
either DT 0 1 12 O
of IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
undertaken VBN 1 0 1 O
with IN 0 0 12 O
caution NN 0 0 1 O
. . 0 0 12 O

In IN 0 0 2 O
one CD 0 1 12 O
study NN 0 1 1 O
following VBG 1 1 1 O
chronic JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
bupropion NN 0 1 16 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
9 CD 0 0 2 O
times NNS 1 1 12 O
daily RB 0 1 12 O
to TO 0 0 12 O
9 CD 0 0 2 O
healthy JJ 0 1 12 O
male NN 0 1 12 O
volunteers NNS 1 1 UNK O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
there RB 0 0 12 O
was VBD 1 0 12 O
no DT 0 0 12 O
evidence NN 0 1 1 O
of IN 0 0 12 O
induction NN 0 1 1 O
of IN 0 0 12 O
its PRP$ 1 0 12 O
own JJ 0 0 12 O
metabolism NN 0 1 16 O
. . 0 0 12 O

An DT 0 0 2 O
interacting JJ 0 0 1 O
drug NN 0 1 1 O
which WDT 0 0 12 O
leads VBZ 1 1 12 O
to TO 0 0 12 O
a DT 0 0 12 O
decrease NN 0 1 1 O
in IN 0 0 12 O
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
necessitating VBG 1 0 1 O
an DT 0 0 12 O
increased VBN 1 1 1 O
dose NN 0 1 6 O
of IN 0 0 12 O
oral JJ 0 1 6 O
anticoagulant NN 0 1 13 B-Group
to TO 0 0 12 O
maintain VB 0 1 1 O
an DT 0 0 12 O
adequate JJ 0 1 1 O
degree NN 0 1 1 O
of IN 0 0 12 O
anticoagulation NN 0 1 14 O
may MD 0 0 1 O
if IN 0 0 12 O
abruptly RB 0 0 UNK O
discontinued VBN 1 1 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
subsequent JJ 0 1 1 O
bleeding NN 0 1 6 O
. . 0 0 12 O

Use NN 0 1 2 O
with IN 0 0 12 O
Cholinomimetics NNS 0 1 UNK B-Group
and CC 0 0 12 O
Other JJ 0 0 2 O
Cholinesterase NNP 0 1 UNK B-Group
Inhibitors NNS 0 1 7 I-Group
: : 0 0 2 O
A DT 0 0 2 O
synergistic JJ 0 1 UNK O
effect NN 0 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
expected VBN 1 1 12 O
when WRB 0 0 12 O
cholinesterase NN 0 1 UNK B-Group
inhibitors NNS 1 1 14 I-Group
are VBP 1 0 12 O
given VBN 1 1 12 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
succinylcholine JJ 0 1 16 B-Drug
similar JJ 0 1 1 O
neuromuscular JJ 0 1 6 B-Group
blocking NN 0 1 UNK I-Group
agents NNS 1 1 1 I-Group
or CC 0 0 12 O
cholinergic JJ 0 1 13 B-Group
agonists NNS 1 1 UNK I-Group
such JJ 0 0 1 O
as IN 1 0 12 O
bethanechol NN 0 1 0 B-Drug
. . 0 0 12 O

Antiretroviral JJ 0 0 UNK B-Group
Agents NNS 0 1 2 I-Group
: : 0 0 2 O
No DT 0 0 2 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
other JJ 0 0 12 O
antiretroviral JJ 0 0 UNK B-Group
medications NNS 1 1 6 I-Group
have VBP 0 0 12 O
been VBN 1 0 12 O
identified VBN 1 1 1 O
that WDT 0 0 12 O
would MD 0 0 12 O
warrant VB 0 0 1 O
alteration NN 0 1 1 O
of IN 0 0 12 O
either CC 0 1 12 O
the DT 0 0 12 O
enfuvirtide NN 0 1 13 B-Drug
dose NN 0 1 6 O
or CC 0 0 12 O
the DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
the DT 0 0 12 O
other JJ 0 0 12 O
antiretroviral JJ 0 0 UNK B-Group
medication NN 0 1 6 I-Group
. . 0 0 12 O

CYP9 NNP 0 0 UNK O
Metabolized NNP 0 1 UNK O
Drugs NNP 0 1 2 O
Results NNP 0 1 2 O
from IN 0 0 12 O
in IN 0 0 12 O
vitro NN 0 1 UNK O
and CC 0 0 12 O
in IN 0 0 12 O
vivo JJ 0 1 13 O
studies NNS 1 1 1 O
suggest VBP 0 1 1 O
that IN 0 0 12 O
enfuvirtide NN 0 1 13 B-Drug
is VBZ 1 0 12 O
unlikely JJ 0 1 12 O
to TO 0 0 12 O
have VB 0 0 12 O
significant JJ 0 1 1 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
concomitantly RB 0 0 14 O
administered VBN 1 1 1 O
drugs NNS 1 1 6 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
CYP9 NNP 0 0 UNK O
enzymes NNS 1 1 14 O
. . 0 0 12 O

Use NNP 0 1 2 O
of IN 0 0 12 O
potassium NN 0 1 14 B-Group
- : 0 0 2 O
sparing NN 0 0 6 I-Group
diuretics NNS 1 1 14 I-Group
( ( 0 0 2 O
spironolactone JJ 0 1 0 B-Drug
triamterene NN 0 1 13 B-Drug
amiloride NN 0 1 16 B-Drug
) ) 0 0 2 O
or CC 0 0 12 O
potassium JJ 0 1 14 B-Drug
supplements NNS 1 1 6 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
ACE NNP 0 1 13 B-Group
inhibitors NNS 1 1 14 I-Group
can MD 0 0 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
hyperkalemia NN 0 1 14 O
. . 0 0 12 O

Compounds NNS 0 1 UNK O
in IN 0 0 12 O
these DT 0 0 12 O
categories NNS 1 1 13 O
result VBP 0 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
decreased JJ 0 1 1 O
efficacy NN 0 1 UNK O
of IN 0 0 12 O
bromocriptine JJ 0 1 16 B-Drug
mesylate NN 0 1 16 I-Drug
: : 0 0 2 O
phenothiazines NNS 1 1 UNK B-Group
haloperidol VBP 0 1 16 B-Drug
metoclopramide JJ 0 1 16 B-Drug
pimozide NN 0 1 13 B-Drug
. . 0 0 12 O

No DT 0 0 2 O
other JJ 0 0 12 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
are VBP 1 0 12 O
known VBN 1 1 12 O
. . 0 0 12 O

Acetazolamide NNP 0 1 0 B-Drug
may MD 0 0 1 O
increase VB 0 1 1 O
or CC 0 0 12 O
decrease VB 0 1 1 O
blood NN 0 1 6 O
glucose NN 0 1 14 O
levels NNS 1 1 1 O
. . 0 0 12 O

Ergot NNP 0 1 UNK O
- : 0 0 2 O
containing VBG 1 1 1 O
drugs NNS 1 1 6 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
cause VB 0 1 12 O
prolonged JJ 0 1 6 O
vasospastic JJ 0 0 UNK O
reactions NNS 1 1 1 O
. . 0 0 12 O

No DT 0 0 2 O
drugs NNS 1 1 6 O
are VBP 1 0 12 O
known VBN 1 1 12 O
to TO 0 0 12 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
conversion NN 0 1 13 O
of IN 0 0 12 O
fosphenytoin NN 0 1 16 B-Drug
to TO 0 0 12 O
phenytoin VB 0 1 16 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
concurrent JJ 0 1 1 O
administration NN 0 1 1 O
of IN 0 0 12 O
allopurinol NN 0 1 13 B-Drug
and CC 0 0 12 O
ampicillin NN 0 1 0 B-Drug
increases NNS 1 1 1 O
substantially RB 0 0 1 O
the DT 0 0 12 O
incidence NN 0 1 6 O
of IN 0 0 12 O
rashes NNS 1 1 6 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
both DT 0 0 12 O
drugs NNS 1 1 6 O
as IN 1 0 12 O
compared VBN 1 1 1 O
to TO 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
ampicillin JJ 0 1 0 B-Drug
alone RB 0 1 12 O
. . 0 0 12 O

The DT 0 0 2 O
interaction NN 0 1 UNK O
is VBZ 1 0 12 O
a DT 0 0 12 O
consequence NN 0 1 1 O
of IN 0 0 12 O
blocking VBG 1 1 UNK O
hepatic JJ 0 1 14 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
vardenafil NN 0 1 UNK B-Drug
by IN 0 0 12 O
ritonavir VBG 0 1 16 B-Drug
a DT 0 0 12 O
highly RB 0 1 1 O
potent JJ 0 1 UNK O
CYP9A9 NNP 0 0 UNK O
inhibitor NN 0 1 14 O
which WDT 0 0 12 O
also RB 0 0 12 O
inhibits VBZ 1 1 UNK O
CYP9C9 NNP 0 0 UNK O
. . 0 0 12 O

Meperidine NN 0 1 UNK B-Drug
: : 0 0 2 O
Amphetamines NNS 0 1 UNK B-Group
potentiate VBP 0 0 UNK O
the DT 0 0 12 O
analgesic JJ 0 1 13 O
effect NN 0 1 1 O
of IN 0 0 12 O
meperidine NN 0 1 16 B-Drug
. . 0 0 12 O

Physicians NNS 0 1 2 O
are VBP 1 0 12 O
provided VBN 1 1 1 O
this DT 0 0 12 O
information NN 0 1 1 O
to TO 0 0 12 O
increase VB 0 1 1 O
awareness NN 0 1 13 O
of IN 0 0 12 O
the DT 0 0 12 O
potential NN 0 1 1 O
for IN 0 0 12 O
serious JJ 0 1 12 O
interactions NNS 1 1 UNK O
when WRB 0 0 12 O
cinoxacin NN 0 1 UNK B-Drug
and CC 0 0 12 O
certain JJ 0 1 1 O
nonsteroidal JJ 0 0 14 B-Group
anti SYM 0 0 3 I-Group
- : 0 0 2 O
inflammatory NN 0 1 6 I-Group
agents NNS 1 1 1 I-Group
are VBP 1 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
. . 0 0 12 O

These DT 0 0 1 O
inhalational JJ 0 1 14 O
agents NNS 1 1 1 O
can MD 0 0 12 O
also RB 0 0 12 O
be VB 0 0 12 O
expected VBN 1 1 12 O
to TO 0 0 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
anesthetic JJ 0 1 13 O
or CC 0 0 12 O
sedative JJ 0 1 6 O
and CC 0 0 12 O
cardiorespiratory JJ 0 0 13 O
effects NNS 1 1 1 O
of IN 0 0 12 O
DIPRIVAN NNP 0 1 UNK B-Brand
Injectable NNP 0 1 UNK O
Emulsion NNP 0 1 UNK O
. . 0 0 12 O

Urinary JJ 0 1 7 O
acidifying VBG 1 0 13 O
agents NNS 1 1 1 O
These DT 0 0 1 O
agents NNS 1 1 1 O
( ( 0 0 2 O
ammonium NN 0 1 13 B-Drug
chloride NN 0 1 14 I-Drug
sodium NN 0 1 14 B-Drug
acid NN 0 1 14 I-Drug
phosphate NN 0 1 14 I-Drug
etc FW 0 1 12 O
. . 0 0 12 O
) ) 0 0 2 O
increase VB 0 1 1 O
the DT 0 0 12 O
concentration NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
ionized JJ 0 1 14 O
species NNS 1 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
amphetamine NN 0 1 13 B-Drug
molecule NN 0 1 UNK O
thereby RB 0 0 UNK O
increasing VBG 1 1 1 O
urinary JJ 0 1 6 O
excretion NN 0 1 14 O
. . 0 0 12 O

Agents NNS 0 1 2 O
Increasing VBG 0 1 2 O
Serum NNP 0 1 7 O
Potassium NNP 0 1 14 O
Since IN 0 1 2 O
captopril NN 0 1 0 B-Drug
decreases VBZ 1 1 UNK O
aldosterone JJ 0 1 UNK O
production NN 0 1 1 O
elevation NN 0 1 1 O
of IN 0 0 12 O
serum JJ 0 1 14 O
potassium NN 0 1 14 O
may MD 0 0 1 O
occur VB 0 1 1 O
. . 0 0 12 O

If IN 0 0 12 O
these DT 0 0 12 O
agents NNS 1 1 1 O
are VBP 1 0 12 O
to TO 0 0 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
concurrently RB 0 0 1 O
cyclosporine JJ 0 1 14 B-Drug
concentrations NNS 1 1 13 O
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
especially RB 0 0 12 O
when WRB 0 0 12 O
diltiazem JJ 0 1 0 B-Drug
therapy NN 0 1 6 O
is VBZ 1 0 12 O
initiated VBN 1 1 1 O
adjusted JJ 0 1 1 O
or CC 0 0 12 O
discontinued VBN 1 1 1 O
. . 0 0 12 O

Because IN 0 0 12 O
eprosartan NN 0 1 UNK B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
the DT 0 0 12 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
system NN 0 1 1 O
inhibitors NNS 1 1 14 O
of IN 0 0 12 O
CYP9 NNP 0 0 UNK O
enzyme NN 0 1 14 O
would MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
expected VBN 1 1 12 O
to TO 0 0 12 O
affect VB 0 1 1 O
its PRP$ 1 0 12 O
metabolism NN 0 1 16 O
and CC 0 0 12 O
ketoconazole NN 0 1 16 B-Drug
and CC 0 0 12 O
fluconazole JJ 0 1 0 B-Drug
potent NN 0 1 UNK O
inhibitors NNS 1 1 14 O
of IN 0 0 12 O
CYP9A NNP 0 0 UNK O
and CC 0 0 12 O
9C9 CD 0 0 UNK O
respectively RB 0 0 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
have VB 0 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
eprosartan NN 0 1 UNK B-Drug
pharmacokinetics NNS 0 1 UNK O
. . 0 0 12 O

Ketoconazole NNP 0 1 UNK B-Drug
: : 0 0 2 O
Ketoconazole NNP 0 1 UNK B-Drug
may MD 0 0 1 O
inhibit VB 0 1 13 O
both DT 0 0 12 O
synthetic JJ 0 1 3 O
and CC 0 0 12 O
catabolic JJ 0 1 14 O
enzymes NNS 1 1 14 O
of IN 0 0 12 O
vitamin NN 0 1 6 B-Group
D NNP 0 1 2 I-Group
. . 0 0 12 O

Bleeding VBG 0 1 7 O
from IN 0 0 12 O
a DT 0 0 12 O
number NN 0 1 1 O
of IN 0 0 12 O
sites NNS 1 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
a DT 0 0 12 O
complication NN 0 1 6 O
of IN 0 0 12 O
warfarin JJ 0 1 14 B-Drug
treatment NN 0 1 6 O
and CC 0 0 12 O
GI NNP 0 1 6 O
bleeding VBG 1 1 6 O
a DT 0 0 12 O
complication NN 0 1 6 O
of IN 0 0 12 O
ketoprofen NN 0 1 UNK B-Drug
treatment NN 0 1 6 O
. . 0 0 12 O

Increase NNP 0 1 2 O
daily RB 0 1 12 O
dose VB 0 1 6 O
of IN 0 0 12 O
rifabutin NN 0 1 13 B-Drug
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

In IN 0 0 2 O
that DT 0 0 12 O
same JJ 0 1 12 O
study NN 0 1 1 O
aspirin IN 0 1 14 B-Brand
alone RB 0 1 12 O
produced VBN 1 0 1 O
a DT 0 0 12 O
marked JJ 0 1 1 O
inhibition NN 0 1 13 O
in IN 0 0 12 O
platelet NN 0 1 14 O
aggregation NN 0 1 UNK O
ex FW 0 1 12 O
vivo NN 0 1 13 O
. . 0 0 12 O

reliable JJ 0 1 UNK O
estimates NNS 1 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
prevalence NN 0 1 UNK O
of IN 0 0 12 O
reduced JJ 0 1 1 O
P9 NNP 0 1 UNK O
9D9 CD 0 0 UNK O
isozyme NN 0 1 UNK O
activity NN 0 1 1 O
among IN 0 0 12 O
Asian JJ 0 1 2 O
African NNP 0 1 UNK O
and CC 0 0 12 O
other JJ 0 0 12 O
populations NNS 1 1 UNK O
are VBP 1 0 12 O
not RB 0 1 12 O
yet RB 0 0 12 O
available JJ 0 1 1 O
. . 0 0 12 O

During IN 0 0 2 O
concomitant JJ 0 1 6 O
therapy NN 0 1 6 O
of IN 0 0 12 O
Ponstel NNP 0 1 UNK B-Brand
with IN 0 0 12 O
furosemide PDT 0 1 0 B-Drug
the DT 0 0 12 O
patient NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
observed VBN 1 1 1 O
closely RB 0 0 1 O
for IN 0 0 12 O
signs NNS 1 1 12 O
of IN 0 0 12 O
renal JJ 0 1 6 O
failure NN 0 1 1 O
as RB 0 0 12 O
well RB 0 1 12 O
as IN 1 0 12 O
to TO 0 0 12 O
assure VB 0 0 1 O
diuretic JJ 0 1 14 O
efficacy NN 0 1 UNK O
. . 0 0 12 O

These DT 0 0 1 O
effects NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
attributed VBN 1 1 1 O
to TO 0 0 12 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
renal JJ 0 1 6 O
prostaglandin NN 0 1 13 O
synthesis NN 0 1 UNK O
by IN 0 0 12 O
MOBIC NNP 0 1 UNK B-Brand
. . 0 0 12 O

Appropriate JJ 0 1 2 O
doses NNS 1 1 6 O
for IN 0 0 12 O
this DT 0 0 12 O
combination NN 0 1 1 O
arenot RB 0 0 UNK O
established VBN 1 1 1 O
but CC 0 0 12 O
an DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
thedosage NN 0 0 UNK O
of IN 0 0 12 O
indinavir NN 0 1 16 B-Drug
may MD 0 0 1 O
be VB 0 0 12 O
required VBN 1 1 1 O
. . 0 0 12 O

Serum NNP 0 1 7 O
potassium NN 0 1 14 O
levels NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
and CC 0 0 12 O
deficiencies NNS 1 1 13 O
corrected VBN 1 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
indicate VBP 0 0 1 O
that DT 0 0 12 O
bupropion NN 0 1 16 B-Drug
is VBZ 1 0 12 O
primarily RB 0 0 1 O
metabolized VBN 1 1 UNK O
to TO 0 0 12 O
hydroxybupropion NN 0 1 UNK B-Drug_n
by IN 0 0 12 O
the DT 0 0 12 O
CYP9B9 NNP 0 0 UNK O
isoenzyme NN 0 1 13 O
. . 0 0 12 O

In IN 0 0 2 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
with IN 0 0 12 O
several JJ 0 1 12 O
drugs NNS 1 1 6 O
which WDT 0 0 12 O
may MD 0 0 1 O
be VB 0 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
showed VBD 1 1 12 O
that IN 0 0 12 O
the DT 0 0 12 O
extent NN 0 1 1 O
of IN 0 0 12 O
flecainide NN 0 1 16 B-Drug
binding VBG 1 1 1 O
to TO 0 0 12 O
human JJ 0 1 1 O
plasma NN 0 1 14 O
proteins NNS 1 1 14 O
is VBZ 1 0 12 O
either DT 0 1 12 O
unchanged JJ 0 1 1 O
or CC 0 0 12 O
only RB 0 1 12 O
slightly RB 0 1 3 O
less RBR 0 1 12 O
. . 0 0 12 O

therefore RB 0 0 1 O
VIRACEPT NNP 0 1 UNK B-Brand
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
terfenadine NN 0 1 UNK B-Drug
because IN 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
potential NN 0 1 1 O
for IN 0 0 12 O
serious JJ 0 1 12 O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
life NN 0 1 12 O
- : 0 0 2 O
threatening JJ 0 0 12 O
cardiac JJ 0 1 6 O
arrhythmias NN 1 1 6 O
. . 0 0 12 O

Warfarin NNP 0 1 0 B-Drug
Keppra NNP 0 1 0 B-Brand
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
twice RB 0 1 12 O
daily RB 0 1 12 O
) ) 0 0 2 O
did VBD 1 0 12 O
not RB 0 1 12 O
influence VB 0 0 UNK O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
R NNP 0 1 2 B-Drug
and CC 0 0 12 O
S NNP 0 1 2 B-Drug
warfarin NN 0 1 14 I-Drug
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
likely JJ 0 1 12 O
that IN 0 0 12 O
use NN 0 1 1 O
of IN 0 0 12 O
epirubicin NN 0 1 13 B-Drug
with IN 0 0 12 O
radiotherapy NN 0 1 13 O
may MD 0 0 1 O
sensitize VB 0 0 UNK O
tissues NNS 1 1 6 O
to TO 0 0 12 O
the DT 0 0 12 O
cytotoxic JJ 0 1 UNK O
actions NNS 1 1 UNK O
of IN 0 0 12 O
irradiation NN 0 1 14 O
. . 0 0 12 O

Oral JJ 0 1 2 O
Contraceptives NNS 0 1 UNK B-Group
: : 0 0 2 O
May NNP 0 1 2 O
be VB 0 0 12 O
less RBR 0 1 12 O
effective JJ 0 1 1 O
and CC 0 0 12 O
increased VBD 1 1 1 O
breakthrough IN 0 1 1 O
bleeding NN 0 1 6 O
may MD 0 0 1 O
occur VB 0 1 1 O
. . 0 0 12 O

However RB 0 0 1 O
when WRB 0 0 12 O
any DT 0 0 12 O
additional JJ 0 1 1 O
drug NN 0 1 1 O
including VBG 1 1 1 O
INDOCIN NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
added VBN 1 1 12 O
to TO 0 0 12 O
the DT 0 0 12 O
treatment NN 0 1 6 O
of IN 0 0 12 O
patients NNS 1 1 6 O
on IN 0 0 12 O
anticoagulant JJ 0 1 13 B-Group
therapy NN 0 1 6 O
the DT 0 0 12 O
patients NNS 1 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
observed VBN 1 1 1 O
for IN 0 0 12 O
alterations NNS 1 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
. . 0 0 12 O

Other JJ 0 0 2 O
9 CD 0 0 2 B-Group
- : 0 0 2 O
HT9B9D NN 0 0 UNK I-Group
Agonists NNS 0 1 UNK I-Group
Concomitant NNP 0 1 UNK O
use NN 0 1 1 O
of IN 0 0 12 O
other JJ 0 0 12 O
9 CD 0 0 2 B-Group
- : 0 0 2 O
HT9B9D NN 0 0 UNK I-Group
agonists NNS 1 1 UNK I-Group
within IN 0 0 1 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
of IN 0 0 12 O
treatment NN 0 1 6 O
with IN 0 0 12 O
AXERT NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
contraindicated VBN 1 1 14 O
. . 0 0 12 O

Fibrates NNS 0 1 UNK B-Group
: : 0 0 2 O
The DT 0 0 2 O
safety NN 0 1 1 O
and CC 0 0 12 O
effectiveness NN 0 1 UNK O
of IN 0 0 12 O
ezetimibe NN 0 1 16 B-Drug
administered VBN 1 1 1 O
with IN 0 0 12 O
fibrates NNS 0 1 UNK B-Group
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
established VBN 1 1 1 O
. . 0 0 12 O

Massive JJ 0 1 UNK O
seizures NNS 1 1 6 O
may MD 0 0 1 O
be VB 0 0 12 O
encountered VBN 1 1 12 O
with IN 0 0 12 O
this DT 0 0 12 O
combination NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
concurrent NN 0 1 1 O
use NN 0 1 1 O
of IN 0 0 12 O
streptozocin NN 0 1 UNK B-Drug
and CC 0 0 12 O
phenytoin NN 0 1 16 B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
one CD 0 1 12 O
case NN 0 1 12 O
to TO 0 0 12 O
result VB 0 1 1 O
in IN 0 0 12 O
reduced JJ 0 1 1 O
streptozocin JJ 0 1 UNK B-Drug
cytotoxicity NN 0 1 UNK O
. . 0 0 12 O

Hormonal JJ 0 1 UNK B-Group
Contraceptives NNS 0 1 UNK I-Group
Including VBG 0 1 2 O
Oral NNP 0 1 2 O
Injectable NNP 0 1 UNK O
Transdermal NNP 0 1 7 O
and CC 0 0 12 O
Implantable JJ 0 1 UNK O
Contraceptives NNS 0 1 UNK B-Group
: : 0 0 2 O
An DT 0 0 2 O
interaction NN 0 1 UNK O
study NN 0 1 1 O
demonstrated VBD 1 0 1 O
that IN 0 0 12 O
co NN 0 1 12 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
bosentan NN 0 1 13 B-Drug
and CC 0 0 12 O
the DT 0 0 12 O
oral JJ 0 1 6 O
hormonal JJ 0 1 6 B-Group
contraceptive NN 0 1 13 I-Group
Ortho NNP 0 1 7 B-Brand
- : 0 0 2 O
Novum NNP 0 0 UNK I-Brand
produced VBD 1 0 1 O
average JJ 0 1 1 O
decreases NNS 1 1 UNK O
of IN 0 0 12 O
norethindrone NN 0 1 13 B-Drug
and CC 0 0 12 O
ethinyl VB 0 0 13 B-Drug
estradiol JJ 0 1 13 I-Drug
levels NNS 1 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
respectively RB 0 0 1 O
. . 0 0 12 O

Caution NN 0 0 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
exercised VBN 1 1 1 O
when WRB 0 0 12 O
these DT 0 0 12 O
9 CD 0 0 2 O
agents NNS 1 1 1 O
are VBP 1 0 12 O
coadministered VBN 0 0 UNK O
. . 0 0 12 O

Amiodarone NNP 0 1 0 B-Drug
taken VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
quinidine NN 0 1 16 B-Drug
increases NNS 1 1 1 O
quinidine VBP 0 1 16 B-Drug
serum JJ 0 1 14 O
concentration NN 0 1 1 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
after IN 0 0 12 O
two CD 0 1 12 O
days NNS 1 1 12 O
. . 0 0 12 O

Although IN 0 0 12 O
acid JJ 0 1 14 O
- : 0 0 2 O
base NN 0 1 3 O
and CC 0 0 12 O
electrolyte JJ 0 1 14 O
disturbances NNS 1 1 6 O
were VBD 1 0 12 O
not RB 0 1 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
with IN 0 0 12 O
dorzolamide JJ 0 1 16 B-Drug
these DT 0 0 12 O
disturbances NNS 1 1 6 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
with IN 0 0 12 O
oral JJ 0 1 6 O
carbonic JJ 0 1 13 B-Group
anhydrase NN 0 0 13 I-Group
inhibitors NNS 1 1 14 I-Group
and CC 0 0 12 O
have VBP 0 0 12 O
in IN 0 0 12 O
some DT 0 0 12 O
instances NNS 1 1 UNK O
resulted VBD 1 1 1 O
in IN 0 0 12 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
toxicity NN 0 1 6 O
associated VBN 1 1 1 O
with IN 0 0 12 O
high JJ 0 1 1 O
- : 0 0 2 O
dose JJ 0 1 6 O
salicylate JJ 0 1 13 B-Group
therapy NN 0 1 6 O
) ) 0 0 2 O
. . 0 0 12 O

Anastrozole NNP 0 1 0 B-Drug
inhibited VBD 1 1 13 O
in IN 0 0 12 O
vitro JJ 0 1 UNK O
metabolic JJ 0 1 6 O
reactions NNS 1 1 1 O
catalyzed VBN 1 0 UNK O
by IN 0 0 12 O
cytochromes NNS 1 1 UNK O
P9 NNP 0 1 UNK O
9A9 CD 0 0 UNK O
9C9 CD 0 0 UNK O
/ NN 0 0 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
9A9 CD 0 0 UNK O
but CC 0 0 12 O
only RB 0 1 12 O
at IN 0 0 12 O
relatively RB 0 0 1 O
high JJ 0 1 1 O
concentrations NNS 1 1 13 O
. . 0 0 12 O

No DT 0 0 2 O
clinically RB 0 0 6 O
relevant JJ 0 1 1 O
pharmacokinetic JJ 0 1 UNK O
interactions NNS 1 1 UNK O
between IN 0 0 12 O
anagrelide NN 0 1 13 B-Drug
and CC 0 0 12 O
acetylsalicylic JJ 0 0 UNK B-Drug
acid NN 0 1 14 I-Drug
were VBD 1 0 12 O
observed VBN 1 1 1 O
. . 0 0 12 O

Aspirin NN 0 1 0 B-Brand
: : 0 0 2 O
Concurrent JJ 0 1 13 O
administration NN 0 1 1 O
of IN 0 0 12 O
aspirin NN 0 1 14 B-Brand
may MD 0 0 1 O
lower VB 0 1 1 O
meclofenamate NN 0 1 UNK B-Drug
sodium NN 0 1 14 I-Drug
plasma NN 0 1 14 O
levels NNS 1 1 1 O
possibly RB 0 1 12 O
by IN 0 0 12 O
competing VBG 1 0 UNK O
for IN 0 0 12 O
protein NN 0 1 14 O
- : 0 0 2 O
binding NN 0 1 1 O
sites NNS 1 1 1 O
. . 0 0 12 O

No DT 0 0 2 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
were VBD 1 0 12 O
performed VBN 1 1 1 O
. . 0 0 12 O

Zalcitabine NNP 0 1 UNK B-Drug
also RB 0 0 12 O
has VBZ 1 0 12 O
no DT 0 0 12 O
significant JJ 0 1 1 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
intracellular JJ 0 1 UNK O
phosphorylation NN 0 1 UNK O
of IN 0 0 12 O
ZDV NNP 0 1 UNK B-Drug
as IN 1 0 12 O
shown VBN 1 1 1 O
in IN 0 0 12 O
vitro NN 0 1 UNK O
in IN 0 0 12 O
peripheral JJ 0 1 6 O
blood NN 0 1 6 O
mononuclear JJ 0 1 14 O
cells NNS 1 1 6 O
or CC 0 0 12 O
in IN 0 0 12 O
two CD 0 1 12 O
other JJ 0 0 12 O
cell NN 0 1 1 O
lines NNS 1 1 3 O
( ( 0 0 2 O
U9 NNP 0 0 UNK O
and CC 0 0 12 O
Molt NNP 0 1 UNK O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

Immunosuppressants NNS 0 1 UNK B-Group
: : 0 0 2 O
cyclosporine NN 0 1 14 B-Drug
tacrolimus NN 0 1 16 B-Drug
sirolimus NN 0 1 16 B-Drug

SUSTIVA NNP 0 1 UNK B-Brand
has VBZ 1 0 12 O
the DT 0 0 12 O
potential JJ 0 1 1 O
to TO 0 0 12 O
decrease VB 0 1 1 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
itraconazole NN 0 1 0 B-Drug
and CC 0 0 12 O
ketoconazole NN 0 1 16 B-Drug
. . 0 0 12 O

Metoclopramide NN 0 1 0 B-Drug
: : 0 0 2 O
Bioavailability NN 0 1 UNK O
is VBZ 1 0 12 O
mildly RB 0 1 3 O
reduced VBN 1 1 1 O
( ( 0 0 2 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
when WRB 0 0 12 O
zalcitabine NN 0 1 UNK B-Drug
and CC 0 0 12 O
metoclopramide NN 0 1 16 B-Drug
are VBP 1 0 12 O
coadministered VBN 0 0 UNK O
. . 0 0 12 O

MAO JJ 0 1 14 B-Group
Inhibitors NNS 0 1 7 I-Group
: : 0 0 2 O
Studies NNS 0 1 2 O
in IN 0 0 12 O
animals NNS 1 1 12 O
demonstrate VBP 0 0 1 O
that IN 0 0 12 O
the DT 0 0 12 O
acute JJ 0 1 6 O
toxicity NN 0 1 6 O
of IN 0 0 12 O
bupropion NN 0 1 16 B-Drug
is VBZ 1 0 12 O
enhanced VBN 1 1 1 O
by IN 0 0 12 O
the DT 0 0 12 O
MAO NNP 0 1 14 B-Group
inhibitor NN 0 1 14 I-Group
phenelzine NN 0 1 16 B-Drug
. . 0 0 12 O

Potential JJ 0 1 UNK O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
for IN 0 0 12 O
doxylamine JJ 0 1 UNK B-Drug
include VBP 0 1 1 O
increased VBN 1 1 1 O
sedation NN 0 1 6 O
if IN 0 0 12 O
doxylamine NN 0 1 UNK B-Drug
is VBZ 1 0 12 O
combined VBN 1 1 1 O
with IN 0 0 12 O
other JJ 0 0 12 O
CNS NNP 0 1 6 B-Group
depressant NN 0 0 UNK I-Group
drugs NNS 1 1 6 I-Group
. . 0 0 12 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interaction NNP 0 1 2 O
Because IN 0 0 12 O
Xigris NNP 0 1 UNK B-Brand
may MD 0 0 1 O
affect VB 0 1 1 O
the DT 0 0 12 O
APTT NNP 0 1 UNK O
assay VBP 0 1 14 O
Xigris NNP 0 1 UNK B-Brand
present NN 0 1 1 O
in IN 0 0 12 O
plasma NN 0 1 14 O
samples NNS 1 1 UNK O
may MD 0 0 1 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
one CD 0 1 12 O
- : 0 0 2 O
stage NN 0 1 12 O
coagulation NN 0 1 14 O
assays NNS 1 1 13 O
based VBN 1 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
APTT NNP 0 1 UNK O
( ( 0 0 2 O
such JJ 0 0 1 O
as IN 1 0 12 O
factor NN 0 1 1 O
VIII NNP 0 1 2 O
IX NNP 0 1 2 O
and CC 0 0 12 O
XI NNP 0 1 13 O
assays NNS 1 1 13 O
) ) 0 0 2 O
. . 0 0 12 O

In IN 0 0 2 O
clinical JJ 0 1 6 O
studies NNS 1 1 1 O
caspofungin VBP 0 1 14 B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
induce VB 0 1 6 O
the DT 0 0 12 O
CYP9A9 NNP 0 0 UNK O
metabolism NN 0 1 16 O
of IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

Of IN 0 0 2 O
particular JJ 0 0 1 O
importance NN 0 1 1 O
sufficient JJ 0 1 1 O
time NN 0 1 12 O
must MD 0 0 12 O
elapse VB 0 1 UNK O
before IN 0 1 12 O
initiating VBG 1 1 1 O
TCA NNP 0 1 13 O
treatment NN 0 1 6 O
in IN 0 0 12 O
a DT 0 0 12 O
patient NN 0 1 6 O
being VBG 1 0 12 O
withdrawn VBN 1 1 1 O
from IN 0 0 12 O
fluoxetine NN 0 1 16 B-Drug
given VBN 1 1 12 O
the DT 0 0 12 O
long JJ 0 1 12 O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
parent NN 0 1 13 O
and CC 0 0 12 O
active JJ 0 1 1 O
metabolite NN 0 1 UNK O
( ( 0 0 2 O
at IN 0 0 12 O
least JJS 0 1 12 O
9 CD 0 0 2 O
weeks NNS 1 1 12 O
may MD 0 0 1 O
be VB 0 0 12 O
necessary JJ 0 0 1 O
) ) 0 0 2 O
. . 0 0 12 O

Cardiovascular JJ 0 1 7 O
collapse NN 0 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
treated VBD 1 1 1 O
simultaneously RB 0 1 13 O
with IN 0 0 12 O
varapamil NN 0 0 UNK O
and CC 0 0 12 O
dantrolene NN 0 1 16 B-Drug
sodium NN 0 1 14 I-Drug
is VBZ 1 0 12 O
rare JJ 0 1 12 O
. . 0 0 12 O

Co NNP 0 1 2 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
multiple JJ 0 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
of IN 0 0 12 O
lenalidomide NN 0 1 UNK B-Drug
had VBD 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
single JJ 0 1 12 O
dose JJ 0 1 6 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
R NNP 0 1 2 B-Drug
- : 0 0 2 O
and CC 0 0 12 O
S NNP 0 1 2 B-Drug
- : 0 0 2 O
warfarin NN 0 1 14 I-Drug
. . 0 0 12 O

It PRP 0 0 12 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
that IN 0 0 12 O
the DT 0 0 12 O
addition NN 0 1 1 O
of IN 0 0 12 O
triamterene NN 0 1 13 B-Drug
to TO 0 0 12 O
a DT 0 0 12 O
maintenance NN 0 1 1 O
schedule NN 0 1 12 O
of IN 0 0 12 O
INDOCIN NNP 0 1 UNK B-Brand
resulted VBD 1 1 1 O
in IN 0 0 12 O
reversible JJ 0 1 3 O
acute JJ 0 1 6 O
renal JJ 0 1 6 O
failure NN 0 1 1 O
in IN 0 0 12 O
two CD 0 1 12 O
of IN 0 0 12 O
four CD 0 1 12 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
. . 0 0 12 O

Increased VBN 0 1 7 O
toxicity NN 0 1 6 O
( ( 0 0 2 O
CNS NNP 0 1 6 O
depression NN 0 1 6 O
) ) 0 0 2 O
: : 0 0 2 O
CNS JJ 0 1 6 B-Group
depressants NNS 1 0 13 I-Group
MAO NNP 0 1 14 B-Group
inhibitors NNS 1 1 14 I-Group
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
phenothiazines NNS 1 1 UNK B-Group
. . 0 0 12 O

Risk NN 0 1 2 O
of IN 0 0 12 O
Anaphylactic NNP 0 1 UNK O
Reaction NNP 0 1 UNK O
While IN 0 0 12 O
taking VBG 1 0 12 O
beta SYM 0 1 16 B-Group
- : 0 0 2 O
blockers NNS 1 0 6 I-Group
patients NNS 1 1 6 O
with IN 0 0 12 O
a DT 0 0 12 O
history NN 0 1 12 O
of IN 0 0 12 O
severe JJ 0 1 6 O
anaphylactic JJ 0 1 13 O
reaction NN 0 1 1 O
to TO 0 0 12 O
a DT 0 0 12 O
variety NN 0 1 1 O
of IN 0 0 12 O
allergens NNS 1 1 13 O
may MD 0 0 1 O
be VB 0 0 12 O
more RBR 0 1 12 O
reactive JJ 0 1 1 O
to TO 0 0 12 O
repeated VBN 1 1 1 O
challenge NN 0 1 12 O
either CC 0 1 12 O
accidental JJ 0 1 13 O
diagnostic NN 0 1 6 O
or CC 0 0 12 O
therapeutic JJ 0 1 6 O
. . 0 0 12 O

Population NNP 0 1 UNK O
pharmacokinetic JJ 0 1 UNK O
analyses NNS 1 1 UNK O
were VBD 1 0 12 O
conducted VBN 1 1 1 O
on IN 0 0 12 O
plasma JJ 0 1 14 O
concentration NN 0 1 1 O
data NNS 0 1 1 O
from IN 0 0 12 O
9 CD 0 0 2 O
patients NNS 1 1 6 O
in IN 0 0 12 O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
to TO 0 0 12 O
examine VB 0 0 1 O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
concomitant JJ 0 1 6 O
medications NNS 1 1 6 O
on IN 0 0 12 O
clearance NN 0 1 16 O
or CC 0 0 12 O
volume NN 0 1 1 O
of IN 0 0 12 O
distribution NN 0 1 1 O
of IN 0 0 12 O
dofetilide NN 0 1 13 B-Drug
. . 0 0 12 O

Administration NN 0 1 UNK O
of IN 0 0 12 O
paclitaxel NN 0 1 13 B-Drug
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
HERCEPTIN NNP 0 1 UNK B-Brand
resulted VBD 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
two CD 0 1 12 O
- : 0 0 2 O
fold JJ 0 1 3 O
decrease NN 0 1 1 O
in IN 0 0 12 O
HERCEPTIN NNP 0 1 UNK B-Brand
clearance NN 0 1 16 O
in IN 0 0 12 O
a DT 0 0 12 O
non JJ 0 1 1 O
- : 0 0 2 O
human JJ 0 1 1 O
primate NN 0 1 UNK O
study NN 0 1 1 O
and CC 0 0 12 O
in IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
fold JJ 0 1 3 O
increase NN 0 1 1 O
in IN 0 0 12 O
HERCEPTIN NNP 0 1 UNK B-Brand
serum NN 0 1 14 O
levels NNS 1 1 1 O
in IN 0 0 12 O
clinical JJ 0 1 6 O
studies NNS 1 1 1 O
. . 0 0 12 O

- : 0 0 2 O
a DT 0 0 12 O
beta NN 0 1 16 B-Group
- : 0 0 2 O
blocker NN 0 0 3 I-Group
such JJ 0 0 1 O
as IN 1 0 12 O
propranolol NN 0 1 16 B-Drug
( ( 0 0 2 O
Inderal NNP 0 1 0 B-Brand
) ) 0 0 2 O
atenolol NN 0 1 0 B-Drug
( ( 0 0 2 O
Tenormin NNP 0 1 0 B-Brand
) ) 0 0 2 O
acebutolol NN 0 1 16 B-Drug
( ( 0 0 2 O
Sectral NNP 0 1 UNK B-Brand
) ) 0 0 2 O
metoprolol NN 0 1 0 B-Drug
( ( 0 0 2 O
Lopressor NNP 0 1 0 B-Brand
) ) 0 0 2 O
and CC 0 0 12 O
others NNS 0 1 12 O
; : 0 0 2 O

Therefore RB 0 0 1 O
coagulation NN 0 1 14 O
indices NNS 1 1 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
to TO 0 0 12 O
maintain VB 0 1 1 O
the DT 0 0 12 O
desired JJ 0 1 1 O
anticoagulant JJ 0 1 13 O
effect NN 0 1 1 O
. . 0 0 12 O

However RB 0 0 1 O
the DT 0 0 12 O
pharmacodynamic JJ 0 1 UNK O
effect NN 0 1 1 O
increased VBN 1 1 1 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
( ( 0 0 2 O
QTc JJ 0 0 14 O
increase NN 0 1 1 O
over IN 0 1 12 O
time NN 0 1 12 O
) ) 0 0 2 O
and CC 0 0 12 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
( ( 0 0 2 O
maximum JJ 0 1 1 O
QTc NNP 0 0 14 O
increase NN 0 1 1 O
) ) 0 0 2 O
. . 0 0 12 O

Agents NNS 0 1 2 O
that WDT 0 0 12 O
Induce NNP 0 1 UNK O
Cytochrome NNP 0 1 UNK O
P9 NNP 0 1 UNK O
Isoenzymes NNP 0 1 UNK O
Carbamazepine NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
. . 0 0 12 O

The DT 0 0 2 O
response NN 0 1 1 O
to TO 0 0 12 O
Factrel NNP 0 1 UNK B-Brand
may MD 0 0 1 O
be VB 0 0 12 O
blunted VBN 1 1 UNK O
by IN 0 0 12 O
phenothiazines NNS 1 1 UNK B-Group
and CC 0 0 12 O
dopamine NN 0 1 14 B-Group
antagonists NNS 1 1 13 I-Group
which WDT 0 0 12 O
cause VBP 0 1 12 O
a DT 0 0 12 O
rise NN 0 0 1 O
in IN 0 0 12 O
prolactin NN 0 1 13 O
. . 0 0 12 O

Protein NNP 0 1 2 O
Binding NNP 0 1 UNK O
In IN 0 0 2 O
vitro NNP 0 1 UNK O
diclofenac NN 0 1 16 B-Drug
interferes VBZ 1 1 UNK O
minimally RB 0 0 6 O
or CC 0 0 12 O
not RB 0 1 12 O
at IN 0 0 12 O
all DT 0 0 12 O
with IN 0 0 12 O
the DT 0 0 12 O
protein NN 0 1 14 O
binding NN 0 1 1 O
of IN 0 0 12 O
salicylic JJ 0 1 UNK B-Drug
acid NN 0 1 14 I-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
decrease NN 0 1 1 O
in IN 0 0 12 O
binding VBG 1 1 1 O
) ) 0 0 2 O
tolbutamide IN 0 1 UNK B-Drug
prednisolone NN 0 1 0 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
decrease NN 0 1 1 O
in IN 0 0 12 O
binding VBG 1 1 1 O
) ) 0 0 2 O
or CC 0 0 12 O
warfarin NN 0 1 14 B-Drug
. . 0 0 12 O

Anabolic JJ 0 1 UNK B-Group
steroids NNS 1 1 6 I-Group
( ( 0 0 2 O
particularly RB 0 0 1 O
C NNP 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
alkylated JJ 0 0 UNK O
androgens NNS 1 1 13 B-Group
such JJ 0 0 1 O
as IN 1 0 12 O
oxymetholone NN 0 1 UNK B-Drug
methandrostenolone NN 0 1 UNK B-Drug
norethandrolone NN 0 1 UNK B-Drug
and CC 0 0 12 O
similar JJ 0 1 1 O
compounds NNS 1 1 13 O
) ) 0 0 2 O
enhanced VBD 1 1 1 O
tendency NN 0 0 1 O
toward IN 0 0 12 O
edema NN 0 1 6 O
. . 0 0 12 O

9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
up IN 0 0 12 O
to TO 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
increase9 JJ 0 0 UNK O
[ JJ 0 0 2 O
CI NNP 0 1 UNK O
: : 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
increase NN 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
increase NN 0 1 1 O
] NN 0 0 2 O

Pharmacodynamic NNP 0 1 UNK O
- : 0 0 2 O
related JJ 0 1 1 O
Interactions NNS 0 1 UNK O
: : 0 0 2 O
The DT 0 0 2 O
mechanism NN 0 1 13 O
of IN 0 0 12 O
Clozapine NNP 0 1 0 B-Drug
induced JJ 0 1 6 O
agranulocytosis NN 0 1 UNK O
is VBZ 1 0 12 O
unknown JJ 0 1 12 O
; : 0 0 2 O

- : 0 0 2 O
Other JJ 0 0 2 O
antihypertensive JJ 0 1 14 B-Group
drugs NNS 1 1 6 I-Group
: : 0 0 2 O
Additive JJ 0 1 UNK O
effect NN 0 1 1 O
or CC 0 0 12 O
potentiation NN 0 1 UNK O

Human NNP 0 1 2 B-Drug
growth NN 0 1 1 I-Drug
hormone NN 0 1 6 I-Drug
- : 0 0 2 O
Concomitant NNP 0 1 UNK O
use NN 0 1 1 O
of IN 0 0 12 O
L NNP 0 1 2 B-Drug
- : 0 0 2 O
glutamine NN 0 1 13 I-Drug
and CC 0 0 12 O
human JJ 0 1 1 B-Drug
growth NN 0 1 1 I-Drug
hormone NN 0 1 6 I-Drug
may MD 0 0 1 O
enhance VB 0 1 UNK O
nutrient JJ 0 1 UNK O
absorption NN 0 1 1 O
in IN 0 0 12 O
those DT 0 0 12 O
with IN 0 0 12 O
severe JJ 0 1 6 O
short JJ 0 1 12 O
bowel NN 0 1 6 O
syndrome NN 0 1 6 O
. . 0 0 12 O

Drugs NNS 0 1 2 O
which WDT 0 0 12 O
may MD 0 0 1 O
enhance VB 0 1 UNK O
the DT 0 0 12 O
neuromuscular JJ 0 1 6 O
blocking VBG 1 1 UNK O
action NN 0 1 13 O
of IN 0 0 12 O
TRACRIUM NNP 0 1 UNK B-Brand
include VBP 0 1 1 O
: : 0 0 2 O
enflurane NN 0 1 UNK B-Drug
; : 0 0 2 O

Cimetidine NN 0 1 0 B-Drug
is VBZ 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
reduce VB 0 0 1 O
hepatic JJ 0 1 14 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
certain JJ 0 1 1 O
tricyclic JJ 0 0 14 B-Drug
antidepressants NNS 1 1 13 I-Drug
thereby RB 0 0 UNK O
delaying VBG 1 1 UNK O
elimination NN 0 1 UNK O
and CC 0 0 12 O
increasing VBG 1 1 1 O
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 B-Drug
. . 0 0 12 O

Angiomax NNP 0 1 UNK B-Brand
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
with IN 0 0 12 O
caution NN 0 0 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
disease JJ 0 1 6 O
states NNS 1 1 1 O
associated VBN 1 1 1 O
with IN 0 0 12 O
an DT 0 0 12 O
increased VBN 1 1 1 O
risk NN 0 1 1 O
of IN 0 0 12 O
bleeding NN 0 1 6 O
. . 0 0 12 O

Some DT 0 0 2 O
reports NNS 1 1 1 O
have VBP 0 0 12 O
shown VBN 1 1 1 O
that IN 0 0 12 O
the DT 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
thiazides NNS 1 1 UNK B-Group
with IN 0 0 12 O
vitamin NN 0 1 6 B-Group
D NNP 0 1 2 I-Group
causes VBZ 1 1 6 O
hypercalcemia NN 0 1 8 O
. . 0 0 12 O

There EX 0 0 12 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
too RB 0 0 12 O
little JJ 0 1 12 O
experience NN 0 1 12 O
with IN 0 0 12 O
the DT 0 0 12 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
TAMBOCOR NNP 0 1 UNK B-Brand
with IN 0 0 12 O
nifedipine NN 0 1 0 B-Drug
or CC 0 0 12 O
diltiazem NN 0 1 0 B-Drug
to TO 0 0 12 O
recommend VB 0 1 12 O
concomitant NN 0 1 6 O
use NN 0 1 1 O
. . 0 0 12 O

- : 0 0 2 O
Sulfoxone NN 0 1 UNK B-Drug
( ( 0 0 2 O
e.g. VB 0 0 UNK O
Diasone NNP 0 1 UNK B-Brand
) ) 0 0 2 O
or CC 0 0 12 O

Probenecid NN 0 1 UNK B-Drug
: : 0 0 2 O
Probenecid NNP 0 1 UNK B-Drug
interferes VBZ 1 1 UNK O
with IN 0 0 12 O
renal JJ 0 1 6 O
tubular JJ 0 1 3 O
secretion NN 0 1 14 O
of IN 0 0 12 O
ciprofloxacin NN 0 1 0 B-Drug
and CC 0 0 12 O
produces VBZ 1 0 1 O
an DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
level NN 0 1 1 O
of IN 0 0 12 O
ciprofloxacin NN 0 1 0 B-Drug
in IN 0 0 12 O
serum NN 0 1 14 O
. . 0 0 12 O

However RB 0 0 1 O
caution NN 0 0 1 O
should MD 0 0 12 O
be VB 0 0 12 O
exercised VBN 1 1 1 O
because IN 0 0 12 O
there EX 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
a DT 0 0 12 O
few JJ 0 1 12 O
spontaneous JJ 0 1 1 O
reports NNS 1 1 1 O
of IN 0 0 12 O
prolonged JJ 0 1 6 O
prothrombin NN 0 1 14 O
times NNS 1 1 12 O
with IN 0 0 12 O
or CC 0 0 12 O
without IN 0 0 12 O
bleeding VBG 1 1 6 O
in IN 0 0 12 O
etodolac JJ 0 1 13 B-Drug
- : 0 0 2 O
treated JJ 0 1 1 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
concomitant JJ 0 1 6 O
warfarin NN 0 1 14 B-Drug
therapy NN 0 1 6 O
. . 0 0 12 O

Therefore RB 0 0 1 O
digoxin NN 0 1 14 B-Drug
serum NN 0 1 14 O
levels NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
. . 0 0 12 O

Beta NNP 0 1 2 B-Group
- : 0 0 2 O
adrenergic JJ 0 1 UNK I-Group
receptor NN 0 1 14 I-Group
antagonists NNS 1 1 13 I-Group
( ( 0 0 2 O
beta SYM 0 1 16 B-Group
- : 0 0 2 O
blockers NNS 1 0 6 I-Group
) ) 0 0 2 O
and CC 0 0 12 O
BROVANA NNP 0 1 UNK B-Brand
may MD 0 0 1 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
each DT 0 0 12 O
other JJ 0 0 12 O
when WRB 0 0 12 O
administered VBN 1 1 1 O
concurrently RB 0 0 1 O
. . 0 0 12 O

In IN 0 0 2 O
neither DT 0 0 12 O
case NN 0 1 12 O
were VBD 1 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
sumatriptan NN 0 1 16 B-Drug
affected VBN 1 1 1 O
by IN 0 0 12 O
coadministration NN 0 1 UNK O
with IN 0 0 12 O
STADOL NNP 0 1 UNK B-Brand
NS NNP 0 1 13 I-Brand
. . 0 0 12 O

Patients NNS 0 1 7 O
stabilized VBN 1 1 1 O
on IN 0 0 12 O
oral JJ 0 1 6 O
anticoagulants NNS 1 1 13 B-Group
who WP 0 0 12 O
are VBP 1 0 12 O
found VBN 1 1 12 O
to TO 0 0 12 O
require VB 0 0 1 O
thyroid JJ 0 1 6 B-Group
replacement NN 0 1 1 O
therapy NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
watched VBN 1 0 12 O
very RB 0 1 12 O
closely RB 0 0 1 O
when WRB 0 0 12 O
thyroid NN 0 1 6 O
is VBZ 1 0 12 O
started VBN 1 1 12 O
. . 0 0 12 O

Co NNP 0 1 2 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
bosentan NNS 0 1 13 B-Drug
decreased VBD 1 1 1 O
the DT 0 0 12 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
cyclosporine NN 0 1 14 B-Drug
A NNP 0 0 2 I-Drug
( ( 0 0 2 O
a DT 0 0 12 O
CYP9A9 NNP 0 0 UNK O
substrate NN 0 1 UNK O
) ) 0 0 2 O
by IN 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

Dimenhydrinate NNP 0 1 UNK B-Drug
may MD 0 0 1 O
decrease VB 0 1 1 O
emetic JJ 0 1 UNK B-Group
response NN 0 1 1 O
to TO 0 0 12 O
apomorphine VB 0 1 UNK B-Drug
. . 0 0 12 O

In IN 0 0 2 O
clinical JJ 0 1 6 O
studies NNS 1 1 1 O
Tilade NNP 0 1 UNK B-Brand
has VBZ 1 0 12 O
been VBN 1 0 12 O
co VBN 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
with IN 0 0 12 O
other JJ 0 0 12 O
anti JJ 0 0 3 O
- : 0 0 2 O
asthma JJ 0 1 6 O
medications NNS 1 1 6 O
including VBG 1 1 1 O
inhaled JJ 0 1 14 O
and CC 0 0 12 O
oral JJ 0 1 6 O
bronchodilators NNS 1 1 14 B-Group
and CC 0 0 12 O
inhaled JJ 0 1 14 O
corticosteroids NNS 1 1 14 B-Group
with IN 0 0 12 O
no DT 0 0 12 O
evidence NN 0 1 1 O
of IN 0 0 12 O
increased JJ 0 1 1 O
frequency NN 0 1 1 O
of IN 0 0 12 O
adverse JJ 0 0 1 O
events NNS 1 1 12 O
or CC 0 0 12 O
laboratory NN 0 1 1 O
abnormalities NNS 1 1 6 O
. . 0 0 12 O

however RB 0 0 12 O
there EX 0 0 12 O
was VBD 1 0 12 O
extensive JJ 0 1 1 O
concomitant NN 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
NSAIDs NNP 0 1 UNK B-Group
in IN 0 0 12 O
clinical JJ 0 1 6 O
studies NNS 1 1 1 O
and CC 0 0 12 O
no DT 0 0 12 O
differential JJ 0 1 1 O
effect NN 0 1 1 O
was VBD 1 0 12 O
observed VBN 1 1 1 O
. . 0 0 12 O

Ethoxzolamide NNP 0 1 UNK B-Drug
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
action NN 0 1 13 O
of IN 0 0 12 O
tricyclics NNS 1 1 UNK B-Group
amphetamines NNS 1 1 14 B-Group
procainamide RB 0 1 16 B-Drug
and CC 0 0 12 O
quinidine VB 0 1 16 B-Drug
. . 0 0 12 O

Ketoconazole NNP 0 1 UNK B-Drug
/ NNP 0 0 2 O
Itraconazole NNP 0 1 UNK B-Drug
Macrolides NNP 0 1 UNK B-Group
Including NNP 0 1 2 O
Erythromycin NNP 0 1 0 B-Drug

Should MD 0 0 2 O
this DT 0 0 12 O
occur VB 0 1 1 O
the DT 0 0 12 O
higher JJR 1 1 1 O
serum JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
that DT 0 0 12 O
drug NN 0 1 1 O
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
increased JJ 0 1 1 O
pharmacologic NN 0 1 14 O
or CC 0 0 12 O
adverse JJ 0 0 1 O
effects NNS 1 1 1 O
of IN 0 0 12 O
that DT 0 0 12 O
drug NN 0 1 1 O
. . 0 0 12 O

Cisapride NN 0 1 0 B-Drug
: : 0 0 2 O
There EX 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reports NNS 1 1 1 O
of IN 0 0 12 O
cardiac JJ 0 1 6 O
events NNS 1 1 12 O
including VBG 1 1 1 O
torsade NN 0 0 13 O
de FW 0 1 2 O
pointes NNS 0 0 UNK O
in IN 0 0 12 O
patients NNS 1 1 6 O
to TO 0 0 12 O
whom WP 0 0 12 O
fluconazole NN 0 1 0 B-Drug
and CC 0 0 12 O
cisapride NN 0 1 UNK B-Drug
were VBD 1 0 12 O
coadministered VBN 0 0 UNK O
. . 0 0 12 O

The DT 0 0 2 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
fluconazole NN 0 1 0 B-Drug
at IN 0 0 12 O
doses NNS 1 1 6 O
lower JJR 1 1 1 O
than IN 0 0 12 O
9 CD 0 0 2 O
mg JJ 0 1 0 O
/ NNP 0 0 2 O
day NN 0 1 12 O
with IN 0 0 12 O
terfenadine NN 0 1 UNK B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
carefully RB 0 0 12 O
monitored VBN 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
majority NN 0 1 1 O
of IN 0 0 12 O
patients NNS 1 1 6 O
in IN 0 0 12 O
RA NNP 0 1 13 O
clinical JJ 0 1 6 O
studies NNS 1 1 1 O
received VBD 1 1 12 O
one CD 0 1 12 O
or CC 0 0 12 O
more JJR 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
following JJ 0 1 1 O
concomitant JJ 0 1 6 O
medications NNS 1 1 6 O
with IN 0 0 12 O
ORENCIA NNP 0 1 UNK B-Brand
: : 0 0 2 O
MTX NNP 0 1 UNK B-Drug
NSAIDs NNP 0 1 UNK B-Group
corticosteroids NNS 1 1 14 B-Group
TNF NNP 0 1 UNK B-Group
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
azathioprine JJ 0 1 13 B-Drug
chloroquine VBP 0 1 13 B-Drug
gold JJ 0 1 UNK B-Drug
hydroxychloroquine NN 0 1 16 B-Drug
leflunomide NN 0 1 13 B-Drug
sulfasalazine NN 0 1 0 B-Drug
and CC 0 0 12 O
anakinra NN 0 1 13 B-Drug
. . 0 0 12 O

Because IN 0 0 12 O
ritonavir NN 0 1 16 B-Drug
is VBZ 1 0 12 O
coadministered JJ 0 0 UNK O
prescribers NNS 0 0 UNK O
should MD 0 0 12 O
also RB 0 0 12 O
refer VB 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
prescribing NN 0 1 UNK O
information NN 0 1 1 O
for IN 0 0 12 O
ritonavir NN 0 1 16 B-Drug
regarding VBG 1 0 1 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
associated VBN 1 1 1 O
with IN 0 0 12 O
this DT 0 0 12 O
agent NN 0 1 1 O
. . 0 0 12 O

Resistance NN 0 1 UNK O
to TO 0 0 12 O
the DT 0 0 12 O
neuromuscular JJ 0 1 6 O
blocking VBG 1 1 UNK O
action NN 0 1 13 O
of IN 0 0 12 O
nondepolarizing VBG 0 0 UNK B-Group
neuromuscular JJ 0 1 6 I-Group
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
has VBZ 1 0 12 O
been VBN 1 0 12 O
demonstrated VBN 1 0 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
chronically RB 0 0 6 O
administered VBN 1 1 1 O
phenytoin NN 0 1 16 B-Drug
or CC 0 0 12 O
carbamazepine NN 0 1 16 B-Drug
. . 0 0 12 O

A DT 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
fold NN 0 1 3 O
decrease NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
mean JJ 0 1 12 O
warfarin NN 0 1 14 B-Drug
dose NN 0 1 6 O
from IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
to TO 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
( ( 0 0 2 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
reduction NN 0 1 1 O
of IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
dose NN 0 1 6 O
) ) 0 0 2 O
was VBD 1 0 12 O
necessary JJ 0 0 1 O
to TO 0 0 12 O
maintain VB 0 1 1 O
a DT 0 0 12 O
target NN 0 1 1 O
INR NNP 0 1 13 O
of IN 0 0 12 O
9 CD 0 0 2 O
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
that IN 0 0 12 O
plasma JJ 0 1 14 O
lithium NN 0 1 16 B-Drug
levels NNS 1 1 1 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
when WRB 0 0 12 O
initiating VBG 1 1 1 O
adjusting NN 0 0 1 O
and CC 0 0 12 O
discontinuing VBG 1 1 6 O
FELDENE NNP 0 1 UNK B-Brand
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
known VBN 1 1 12 O
that IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
is VBZ 1 0 12 O
inhibited VBN 1 1 13 O
by IN 0 0 12 O
several JJ 0 1 12 O
medicinal JJ 0 0 16 O
products NNS 1 1 1 O
including VBG 1 1 1 O
fluvoxamine NN 0 1 16 B-Drug
and CC 0 0 12 O
such JJ 0 0 1 O
medicinal JJ 0 0 16 O
products NNS 1 1 1 O
could MD 0 0 12 O
theoretically RB 0 0 UNK O
adversely RB 0 0 UNK O
influence VB 0 0 UNK O
the DT 0 0 12 O
clearance NN 0 1 16 O
of IN 0 0 12 O
anagrelide NN 0 1 13 B-Drug
. . 0 0 12 O

Fenfluramine NN 0 1 UNK B-Drug
may MD 0 0 1 O
increase VB 0 1 1 O
slightly RB 0 1 3 O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
antihypertensive JJ 0 1 14 B-Group
drugs NNS 1 1 6 I-Group
e.g. VBP 0 0 UNK O
guanethidine NN 0 1 UNK B-Drug
methyldopa NN 0 1 13 B-Drug
reserpine NN 0 1 UNK B-Drug
. . 0 0 12 O

The DT 0 0 2 O
concomitant NN 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
other JJ 0 0 12 O
CNS NNP 0 1 6 B-Group
depressants NNS 1 0 13 I-Group
including VBG 1 1 1 O
sedatives NNS 1 1 6 B-Group
hypnotics NNS 1 1 13 B-Group
tranquilizers NNS 1 1 13 B-Group
general JJ 0 1 1 O
anesthetics NNS 1 1 13 B-Group
phenothiazines VBZ 0 1 UNK B-Group
other JJ 0 0 12 O
opioids NNS 0 1 14 B-Group
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
monoamine JJ 0 1 13 B-Group
oxidase NN 0 1 13 I-Group
MAO NNP 0 1 14 I-Group
inhibitors NNS 1 1 14 I-Group
and CC 0 0 12 O
alcohol NN 0 1 1 B-Drug
may MD 0 0 1 O
produce VB 0 0 1 O
additive JJ 0 1 16 O
CNS NNP 0 1 6 O
depressant NN 0 0 UNK O
effects NNS 1 1 1 O
. . 0 0 12 O

Concomitant JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
diltiazem NN 0 1 0 B-Drug
with IN 0 0 12 O
carbamazepine NN 0 1 16 B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
result VB 0 1 1 O
in IN 0 0 12 O
elevated JJ 0 1 1 O
serum NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
carbamazepine NN 0 1 16 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
to TO 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
increase NN 0 1 1 O
) ) 0 0 2 O
resulting VBG 1 1 1 O
in IN 0 0 12 O
toxicity NN 0 1 6 O
in IN 0 0 12 O
some DT 0 0 12 O
cases NNS 1 1 UNK O
. . 0 0 12 O

Cimetidine NN 0 1 0 B-Drug
: : 0 0 2 O
The DT 0 0 2 O
effects NNS 1 1 1 O
of IN 0 0 12 O
chronic JJ 0 1 6 O
cimetidine NN 0 1 13 B-Drug
use NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
rimantadine NN 0 1 13 B-Drug
are VBP 1 0 12 O
not RB 0 1 12 O
known VBN 1 1 12 O
. . 0 0 12 O

Propoxyphene NN 0 1 UNK B-Drug
: : 0 0 2 O
In IN 0 0 2 O
cases NNS 1 1 UNK O
of IN 0 0 12 O
propoxyphene JJ 0 1 16 B-Drug
overdosage NN 0 0 UNK O
amphetamine NN 0 1 13 B-Group
CNS NNP 0 1 6 O
stimulation NN 0 1 6 O
is VBZ 1 0 12 O
potentiated VBN 1 0 UNK O
and CC 0 0 12 O
fatal JJ 0 1 13 O
convulsions NNS 1 1 13 O
can MD 0 0 12 O
occur VB 0 1 1 O
. . 0 0 12 O

Inhibitors NNS 0 1 7 O
of IN 0 0 12 O
CYP9D9 NNP 0 0 UNK O
; : 0 0 2 O

Caution NN 0 0 UNK O
is VBZ 1 0 12 O
advised VBN 1 0 12 O
in IN 0 0 12 O
using VBG 1 1 1 O
Duloxetine NNP 0 1 0 B-Drug
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
conditions NNS 1 1 1 O
that WDT 0 0 12 O
may MD 0 0 1 O
slow VB 0 1 12 O
gastric NN 0 1 6 O
emptying VBG 1 1 13 O
( ( 0 0 2 O
e.g. VB 0 0 UNK O
some DT 0 0 12 O
diabetics NNS 1 1 UNK O
) ) 0 0 2 O
. . 0 0 12 O

The DT 0 0 2 O
optimal JJ 0 1 1 O
dosing NN 0 0 14 O
interval NN 0 1 1 O
for IN 0 0 12 O
coadministration NN 0 1 UNK O
with IN 0 0 12 O
VIDEX NNP 0 1 UNK B-Brand
should MD 0 0 12 O
be VB 0 0 12 O
determined VBN 1 1 1 O
by IN 0 0 12 O
consulting VBG 1 1 13 O
the DT 0 0 12 O
appropriate JJ 0 1 1 O
quinolone NN 0 1 UNK B-Group
package NN 0 1 13 O
insert NN 0 1 13 O
. . 0 0 12 O

Caution NN 0 0 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
when WRB 0 0 12 O
such JJ 0 0 1 O
drugs NNS 1 1 6 O
are VBP 1 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
. . 0 0 12 O

Interaction NN 0 1 2 O
of IN 0 0 12 O
GABITRIL NNP 0 1 UNK B-Brand
with IN 0 0 12 O
Other JJ 0 0 2 O
Drugs NNS 0 1 2 O
: : 0 0 2 O
Cimetidine NN 0 1 0 B-Drug
: : 0 0 2 O
Co NNP 0 1 2 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
cimetidine NN 0 1 13 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
) ) 0 0 2 O
to TO 0 0 12 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
tiagabine JJ 0 1 13 B-Drug
chronically RB 0 0 6 O
had VBD 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
tiagabine NN 0 1 13 B-Drug
pharmacokinetics NNS 0 1 UNK O
. . 0 0 12 O

dihydropyridine NN 0 1 UNK B-Group
calcium NN 0 1 14 I-Group
channel NN 0 1 1 I-Group
blockers NNS 1 0 6 I-Group
concentration NN 0 1 1 O

However RB 0 0 1 O
in IN 0 0 12 O
a DT 0 0 12 O
follow NN 0 1 12 O
- : 0 0 2 O
up RB 0 0 12 O
study NN 0 1 1 O
in IN 0 0 12 O
normal JJ 0 1 1 O
subjects NNS 1 1 UNK O
single JJ 0 1 12 O
- : 0 0 2 O
dose JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
colestipol JJ 0 1 13 B-Drug
hydrochloride NN 0 1 0 I-Drug
and CC 0 0 12 O
propranolol NN 0 1 16 B-Drug
and CC 0 0 12 O
twice RB 0 1 12 O
- : 0 0 2 O
a DT 0 0 12 O
- : 0 0 2 O
day NN 0 1 12 O
administration NN 0 1 1 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
of IN 0 0 12 O
both DT 0 0 12 O
agents NNS 1 1 1 O
did VBD 1 0 12 O
not RB 0 1 12 O
affect VB 0 1 1 O
the DT 0 0 12 O
extent NN 0 1 1 O
of IN 0 0 12 O
propranolol JJ 0 1 16 B-Drug
absorption NN 0 1 1 O
but CC 0 0 12 O
had VBD 1 0 12 O
a DT 0 0 12 O
small JJ 0 1 12 O
yet RB 0 0 12 O
statistically RB 0 1 1 O
significant JJ 0 1 1 O
effect NN 0 1 1 O
on IN 0 0 12 O
its PRP$ 1 0 12 O
rate NN 0 1 1 O
of IN 0 0 12 O
absorption NN 0 1 1 O
; : 0 0 2 O

( ( 0 0 2 O
Thiazide IN 0 1 UNK B-Group
diuretics NNS 1 1 14 I-Group
may MD 0 0 1 O
raise VB 0 0 12 O
the DT 0 0 12 O
level NN 0 1 1 O
of IN 0 0 12 O
blood NN 0 1 6 O
uric JJ 0 0 14 O
acid NN 0 1 14 O
; : 0 0 2 O

Johns NNP 0 0 UNK B-Drug_n
Wort NNP 0 0 UNK I-Drug_n
with IN 0 0 12 O
hormonal JJ 0 1 6 B-Group
contraceptive JJ 0 1 13 I-Group
agents NNS 1 1 1 I-Group
may MD 0 0 1 O
reduce VB 0 0 1 O
the DT 0 0 12 O
effectiveness NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
contraception NN 0 1 13 O
and CC 0 0 12 O
up RB 0 0 12 O
to TO 0 0 12 O
one CD 0 1 12 O
month NN 0 1 12 O
after IN 0 0 12 O
discontinuation NN 0 1 6 O
of IN 0 0 12 O
these DT 0 0 12 O
concomitant JJ 0 1 6 O
therapies NNS 1 1 6 O
. . 0 0 12 O

Both DT 0 0 2 O
acyclovir JJ 0 1 0 B-Drug
/ NN 0 0 2 O
ganciclovir NN 0 1 14 B-Drug
and CC 0 0 12 O
MPAG NNP 0 0 UNK B-Drug_n
concentrations NNS 1 1 13 O
are VBP 1 0 12 O
increased VBN 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
presence NN 0 1 1 O
of IN 0 0 12 O
renal JJ 0 1 6 O
impairment NN 0 1 16 O
their PRP$ 0 0 12 O
coexistence NN 0 0 UNK O
may MD 0 0 1 O
compete VB 0 0 UNK O
for IN 0 0 12 O
tubular JJ 0 1 3 O
secretion NN 0 1 14 O
and CC 0 0 12 O
further JJ 0 1 1 O
increase NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
the DT 0 0 12 O
two CD 0 1 12 O
. . 0 0 12 O

Thus RB 0 0 1 O
results NNS 1 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
DST NNP 0 1 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
interpreted VBN 1 1 UNK O
with IN 0 0 12 O
caution NN 0 0 1 O
in IN 0 0 12 O
these DT 0 0 12 O
patients NNS 1 1 6 O
. . 0 0 12 O

Herb NNP 0 1 UNK O
/ NNP 0 0 2 O
Nutraceutical NNP 0 1 UNK O
: : 0 0 2 O
St NNP 0 1 2 O
Johns NNP 0 0 UNK O
wort NN 0 0 UNK O
may MD 0 0 1 O
decrease VB 0 1 1 O
the DT 0 0 12 O
effectiveness NN 0 1 UNK O
of IN 0 0 12 O
combination NN 0 1 1 B-Group
hormonal JJ 0 1 6 I-Group
contraceptives NNS 1 1 13 I-Group
by IN 0 0 12 O
inducing VBG 1 1 6 O
hepatic JJ 0 1 14 O
enzymes NNS 1 1 14 O
. . 0 0 12 O

SUTENT NNP 0 1 0 B-Brand
dose JJ 0 1 6 O
modification NN 0 1 1 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
using VBG 1 1 1 O
concomitant JJ 0 1 6 O
CYP9A9 NNP 0 0 UNK O
inhibitors NNS 1 1 14 O
or CC 0 0 12 O
inducers NNS 1 1 UNK O
. . 0 0 12 O

Specific JJ 0 1 UNK O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
demonstrated VBN 1 0 1 O
the DT 0 0 12 O
following NN 0 1 1 O
: : 0 0 2 O
Cyclosporine VB 0 1 UNK B-Drug
A DT 0 0 2 I-Drug
: : 0 0 2 O
During IN 0 0 2 O
the DT 0 0 12 O
first JJ 0 1 12 O
day NN 0 1 12 O
of IN 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
trough IN 0 1 3 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
bosentan NN 0 1 13 B-Drug
were VBD 1 0 12 O
increased VBN 1 1 1 O
by IN 0 0 12 O
about IN 0 1 12 O
9 CD 0 0 2 O
- : 0 0 2 O
fold NN 0 1 3 O
. . 0 0 12 O

Neuroleptic JJ 0 1 UNK B-Group
: : 0 0 2 O
pimozide NN 0 1 13 B-Drug

If IN 0 0 12 O
TYKERB NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
are VBP 1 0 12 O
substrates NNS 1 1 UNK O
of IN 0 0 12 O
Pgp NNP 0 1 UNK O
increased VBD 1 1 1 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
the DT 0 0 12 O
substrate JJ 0 1 UNK O
drug NN 0 1 1 O
are VBP 1 0 12 O
likely JJ 0 1 12 O
and CC 0 0 12 O
caution NN 0 0 1 O
should MD 0 0 12 O
be VB 0 0 12 O
exercised VBN 1 1 1 O
. . 0 0 12 O

Population NNP 0 1 UNK O
pharmacokinetic JJ 0 1 UNK O
analyses NNS 1 1 UNK O
revealed VBD 1 1 12 O
that IN 0 0 12 O
MTX NNP 0 1 UNK B-Drug
NSAIDs NNP 0 1 UNK B-Group
corticosteroids NNS 1 1 14 B-Group
and CC 0 0 12 O
TNF NNP 0 1 UNK B-Group
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
did VBD 1 0 12 O
not RB 0 1 12 O
influence VB 0 0 UNK O
abatacept JJ 0 1 13 B-Drug
clearance NN 0 1 16 O
. . 0 0 12 O

Phenytoin NN 0 1 0 B-Drug
: : 0 0 2 O
Amphetamines NNS 0 1 UNK B-Group
may MD 0 0 1 O
delay VB 0 1 1 O
intestinal JJ 0 1 13 O
absorption NN 0 1 1 O
of IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
; : 0 0 2 O

Caffeine NN 0 1 7 B-Drug
: : 0 0 2 O
Enoxacin NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
a DT 0 0 12 O
potent JJ 0 1 UNK O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
the DT 0 0 12 O
cytochrome NN 0 1 UNK O
P NNP 0 1 2 O
- : 0 0 2 O
9 CD 0 0 2 O
isozymes NNS 0 1 UNK O
responsible JJ 0 1 1 O
for IN 0 0 12 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
methylxanthines NNS 0 1 UNK B-Group
. . 0 0 12 O

Ergot NNP 0 1 UNK B-Group
alkaloids NNS 1 1 13 I-Group

At IN 0 0 2 O
therapeutic JJ 0 1 6 O
concentrations NNS 1 1 13 O
paliperidone NN 0 1 16 B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
inhibit VB 0 1 13 O
P NNP 0 1 2 O
- : 0 0 2 O
glycoprotein NN 0 1 UNK O
. . 0 0 12 O

Use NN 0 1 2 O
with IN 0 0 12 O
Allopurinol NNP 0 1 0 B-Drug
: : 0 0 2 O
The DT 0 0 2 O
principal JJ 0 1 1 O
pathway NN 0 1 UNK O
for IN 0 0 12 O
detoxification NN 0 1 13 O
of IN 0 0 12 O
azathioprine NN 0 1 13 B-Drug
is VBZ 1 0 12 O
inhibited VBN 1 1 13 O
by IN 0 0 12 O
allopurinol NN 0 1 13 B-Drug
. . 0 0 12 O

Drugs NNS 0 1 2 O
Which NNP 0 0 UNK O
Require VBP 0 0 UNK O
a DT 0 0 12 O
Dose NNP 0 1 7 O
Reduction NNP 0 1 UNK O
When WRB 0 0 12 O
Coadminstered NNP 0 0 UNK O
With IN 0 0 2 O
VIRACEPT NNP 0 1 UNK B-Brand
Antimycobacterial NNP 0 1 UNK B-Group
agents NNS 1 1 1 I-Group
: : 0 0 2 O
rifabutin NN 0 1 13 B-Drug

Alcohol NN 0 1 2 B-Drug
: : 0 0 2 O
Alcohol NNP 0 1 2 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
g NN 0 1 16 O
/ NNP 0 0 2 O
kg VBZ 0 1 18 O
body NN 0 1 3 O
weight NN 0 1 3 O
: : 0 0 2 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
mL NNS 0 1 14 O
of IN 0 0 12 O
absolute JJ 0 1 1 O
alcohol NN 0 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
kg NNS 0 1 18 O
person NN 0 1 12 O
) ) 0 0 2 O
and CC 0 0 12 O
vardenafil $ 0 1 UNK B-Drug
plasma NN 0 1 14 O
levels NNS 1 1 1 O
were VBD 1 0 12 O
not RB 0 1 12 O
altered VBN 1 1 1 O
when WRB 0 0 12 O
dosed VBN 1 1 14 O
simultaneously RB 0 1 13 O
. . 0 0 12 O

Pharmacokinetic JJ 0 1 UNK O
studies NNS 1 1 1 O
show VBP 0 1 12 O
that IN 0 0 12 O
there EX 0 0 12 O
are VBP 1 0 12 O
no DT 0 0 12 O
significant JJ 0 1 1 O
alterations NNS 1 1 1 O
in IN 0 0 12 O
pharmacokinetic JJ 0 1 UNK O
parameters NNS 1 1 1 O
of IN 0 0 12 O
zidovudine NN 0 1 13 B-Drug
or CC 0 0 12 O
rifabutin NN 0 1 13 B-Drug
to TO 0 0 12 O
warrant VB 0 0 1 O
dosage NN 0 1 0 O
adjustment NN 0 1 1 O
when WRB 0 0 12 O
megestrol NN 0 1 16 B-Drug
acetate NN 0 1 14 I-Drug
is VBZ 1 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

avoid NN 0 0 12 O
use NN 0 1 1 O
if IN 0 0 12 O
possible JJ 0 1 1 O
or CC 0 0 12 O
closely RB 0 0 1 O
monitor JJ 0 1 1 O
cardiovascular JJ 0 1 6 O
status NN 0 1 1 O
at IN 0 0 12 O
the DT 0 0 12 O
end NN 0 1 12 O
of IN 0 0 12 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O

Coadministration NN 0 1 UNK O
of IN 0 0 12 O
oral JJ 0 1 6 O
contraceptives NNS 1 1 13 B-Group
diazepam VBP 0 1 0 B-Drug
phenytoin NN 0 1 16 B-Drug
or CC 0 0 12 O
quinidine NN 0 1 16 B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
seem VB 0 0 12 O
to TO 0 0 12 O
change VB 0 1 1 O
the DT 0 0 12 O
pharmacokinetic JJ 0 1 UNK O
profile NN 0 1 1 O
of IN 0 0 12 O
esomeprazole NN 0 1 16 B-Drug
. . 0 0 12 O

immunosuppressant JJ 0 1 14 B-Group
agents NNS 1 1 1 I-Group
concentration NN 0 1 1 O

Concurrent JJ 0 1 13 O
ingestion NN 0 1 14 O
of IN 0 0 12 O
antacid NN 0 1 UNK B-Group
( ( 0 0 2 O
9 CD 0 0 2 O
mL NN 0 1 14 O
of IN 0 0 12 O
antacid NN 0 1 UNK B-Group
containing VBG 1 1 1 O
aluminum NN 0 1 16 B-Drug
hydroxide NN 0 1 14 I-Drug
magnesium NN 0 1 14 B-Drug
hydroxide NN 0 1 14 I-Drug
and CC 0 0 12 O
simethicone NN 0 1 16 B-Drug
) ) 0 0 2 O
did VBD 1 0 12 O
not RB 0 1 12 O
significantly RB 0 0 1 O
affect VBP 0 1 1 O
the DT 0 0 12 O
exposure NN 0 1 1 O
of IN 0 0 12 O
oxybutynin NN 0 1 13 B-Drug
or CC 0 0 12 O
desethyloxybutynin NN 0 1 UNK B-Drug_n
. . 0 0 12 O

This DT 0 0 2 O
should MD 0 0 12 O
be VB 0 0 12 O
taken VBN 1 1 12 O
into IN 0 0 12 O
account NN 0 1 1 O
when WRB 0 0 12 O
evaluating VBG 1 1 1 O
serum JJ 0 1 14 O
amylase NN 0 1 14 O
levels NNS 1 1 1 O
for IN 0 0 12 O
diagnosis NN 0 1 6 O
or CC 0 0 12 O
monitoring NN 0 1 1 O
of IN 0 0 12 O
pancreatitis NN 0 1 6 O
in IN 0 0 12 O
patients NNS 1 1 6 O
using VBG 1 1 1 O
EXTRANEAL NNP 0 1 UNK B-Brand
. . 0 0 12 O

Care NN 0 1 2 O
should MD 0 0 12 O
be VB 0 0 12 O
given VBN 1 1 12 O
when WRB 0 0 12 O
administering VBG 1 1 1 O
this DT 0 0 12 O
drug NN 0 1 1 O
to TO 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
symptoms NNS 1 1 6 O
of IN 0 0 12 O
myasthenic JJ 0 0 13 O
weakness NN 0 1 6 O
who WP 0 0 12 O
are VBP 1 0 12 O
also RB 0 0 12 O
on IN 0 0 12 O
anticholinesterase NN 0 1 UNK B-Group
drugs NNS 1 1 6 I-Group
. . 0 0 12 O

Furosemide NN 0 1 0 B-Drug
: : 0 0 2 O
TORADOL NNP 0 1 UNK B-Brand
IV NNP 0 1 2 O
/ NNP 0 0 2 O
IM NNP 0 1 11 O
reduced VBD 1 1 1 O
the DT 0 0 12 O
diuretic JJ 0 1 14 B-Group
response NN 0 1 1 O
to TO 0 0 12 O
furosemide VB 0 1 0 B-Drug
in IN 0 0 12 O
normovolemic JJ 0 1 UNK O
healthy JJ 0 1 12 O
subjects NNS 1 1 UNK O
by IN 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
( ( 0 0 2 O
mean JJ 0 1 12 O
sodium NN 0 1 14 O
and CC 0 0 12 O
urinary JJ 0 1 6 O
output NN 0 1 1 O
decreased VBD 1 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
. . 0 0 12 O

Nonsteroidal NNP 0 0 UNK B-Group
anti SYM 0 0 3 I-Group
- : 0 0 2 O
inflammatory NN 0 1 6 I-Group
agents NNS 1 1 1 I-Group
( ( 0 0 2 O
NSAIDS NNP 0 1 UNK B-Group
) ) 0 0 2 O
: : 0 0 2 O
Concomitant JJ 0 1 UNK O
use NN 0 1 1 O
of IN 0 0 12 O
aspirin NN 0 1 14 B-Brand
( ( 0 0 2 O
or CC 0 0 12 O
other JJ 0 0 12 O
nonsteroidal JJ 0 0 14 B-Group
antiinflammatory NN 0 1 14 I-Group
agents NNS 1 1 1 I-Group
) ) 0 0 2 O
and CC 0 0 12 O
corticosteroids JJ 0 1 14 B-Group
increases NNS 1 1 1 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
gastrointestinal JJ 0 1 6 O
side NN 0 1 3 O
effects NNS 1 1 1 O
. . 0 0 12 O

However RB 0 0 1 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
aspirin NN 0 1 14 B-Brand
with IN 0 0 12 O
CELEBREX NNP 0 1 UNK B-Brand
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
an DT 0 0 12 O
increased JJ 0 1 1 O
rate NN 0 1 1 O
of IN 0 0 12 O
GI NNP 0 1 6 O
ulceration NN 0 1 8 O
or CC 0 0 12 O
other JJ 0 0 12 O
complications NNS 1 1 6 O
compared VBN 1 1 1 O
to TO 0 0 12 O
use VB 0 1 1 O
of IN 0 0 12 O
CELEBREX NNP 0 1 UNK B-Brand
alone RB 0 1 12 O
. . 0 0 12 O

Folinic JJ 0 0 UNK B-Drug
acid NN 0 1 14 I-Drug
( ( 0 0 2 O
leucovorin NN 0 1 16 B-Drug
) ) 0 0 2 O
should MD 0 0 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
until IN 0 0 12 O
normal JJ 0 1 1 O
hematopoiesis NN 0 1 UNK O
is VBZ 1 0 12 O
restored VBN 1 0 12 O
. . 0 0 12 O

- : 0 0 2 O
Skeletal NN 0 1 UNK B-Group
muscle NN 0 1 6 I-Group
relaxants NNS 1 0 13 I-Group
nondepolarizing VBG 0 0 UNK O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
tubocurarine NN 0 1 UNK B-Drug
) ) 0 0 2 O
: : 0 0 2 O
Possible JJ 0 1 2 O
increased VBD 1 1 1 O
responsiveness NN 0 1 UNK O
to TO 0 0 12 O
the DT 0 0 12 O
muscle NN 0 1 6 B-Group
relaxant NN 0 0 0 I-Group

The DT 0 0 2 O
color NN 0 1 3 O
reverses VBZ 1 1 UNK O
when WRB 0 0 12 O
the DT 0 0 12 O
test NN 0 1 1 O
sample NN 0 1 1 O
is VBZ 1 0 12 O
acidified VBN 1 0 UNK O
in IN 0 0 12 O
vitro NN 0 1 UNK O
to TO 0 0 12 O
a DT 0 0 12 O
pH NN 0 1 14 O
below IN 0 0 12 O
9 CD 0 0 2 O
. . 0 0 12 O

Concomitant NNP 0 1 UNK O
use NN 0 1 1 O
with IN 0 0 12 O
other JJ 0 0 12 O
oxytocic JJ 0 1 13 B-Group
agents NNS 1 1 1 I-Group
is VBZ 1 0 12 O
not RB 0 1 12 O
recommended JJ 0 1 1 O

This DT 0 0 2 O
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
increased JJ 0 1 1 O
risk NN 0 1 1 O
of IN 0 0 12 O
theophylline JJ 0 1 16 B-Drug
- : 0 0 2 O
related JJ 0 1 1 O
adverse JJ 0 0 1 O
reactions NNS 1 1 1 O
. . 0 0 12 O

Effects NNS 0 1 UNK O
of IN 0 0 12 O
Aliskiren NNP 0 1 UNK B-Drug
on IN 0 0 12 O
Other JJ 0 0 2 O
Drugs NNP 0 1 2 O
Aliskiren NNP 0 1 UNK B-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
inhibit VB 0 1 13 O
the DT 0 0 12 O
CYP9 NNP 0 0 UNK O
isoenzymes NNS 0 1 14 O
( ( 0 0 2 O
CYP9A9 NNP 0 0 UNK O
9C9 CD 0 0 UNK O
9C9 CD 0 0 UNK O
9C9 CD 0 0 UNK O
9D9 CD 0 0 UNK O
9E9 CD 0 0 UNK O
and CC 0 0 12 O
CYP NNP 0 1 UNK O
9A CD 0 1 UNK O
) ) 0 0 2 O
or CC 0 0 12 O
induce VB 0 1 6 O
CYP NNP 0 1 UNK O
9A9 CD 0 0 UNK O
. . 0 0 12 O

Theophylline NN 0 1 UNK B-Drug
: : 0 0 2 O
Theophylline JJ 0 1 UNK B-Drug
clearance NN 0 1 16 O
may MD 0 0 1 O
decrease VB 0 1 1 O
when WRB 0 0 12 O
hyperthyroid JJ 0 1 UNK O
patients NNS 1 1 6 O
on IN 0 0 12 O
a DT 0 0 12 O
stable JJ 0 1 1 O
theophylline NN 0 1 16 B-Drug
regimen NNS 0 1 6 O
become VBP 0 0 12 O
euthyroid JJ 0 1 14 O
; : 0 0 2 O

Concomitant NNP 0 1 UNK O
use NN 0 1 1 O
of IN 0 0 12 O
cimetidine NN 0 1 13 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
. . 0 0 12 O

Beta NNP 0 1 2 B-Group
Blockers NNS 0 0 UNK I-Group
: : 0 0 2 O
Although IN 0 0 12 O
the DT 0 0 12 O
results NNS 1 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
clinical JJ 0 1 6 O
study NN 0 1 1 O
did VBD 1 0 12 O
not RB 0 1 12 O
indicate VB 0 0 1 O
a DT 0 0 12 O
safe JJ 0 0 12 O
problem NN 0 1 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
the DT 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
D.H.E NNP 0 1 UNK B-Brand
9 CD 0 0 2 I-Brand
( ( 0 0 2 O
dihydroergotamine JJ 0 1 UNK B-Drug
mesylate NN 0 1 16 I-Drug
) ) 0 0 2 O
Injection NNP 0 1 7 O
USP NNP 0 1 UNK O
to TO 0 0 12 O
subjects VB 1 1 UNK O
already RB 0 0 12 O
receiving VBG 1 1 1 O
propranolol NN 0 1 16 B-Drug
there RB 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reports NNS 1 1 1 O
that IN 0 0 12 O
propranolol NN 0 1 16 B-Drug
may MD 0 0 1 O
potentiate VB 0 0 UNK O
the DT 0 0 12 O
vasoconstrictive JJ 0 0 UNK O
action NN 0 1 13 O
of IN 0 0 12 O
ergotamine NN 0 1 UNK B-Drug
by IN 0 0 12 O
blocking VBG 1 1 UNK O
the DT 0 0 12 O
vasodilating VBG 0 0 UNK O
property NN 0 1 13 O
of IN 0 0 12 O
epinephrine NN 0 1 14 O
. . 0 0 12 O

Patients NNS 0 1 7 O
receiving VBG 1 1 1 O
pindolol JJ 0 1 13 B-Drug
plus CC 0 1 16 O
a DT 0 0 12 O
catecholamine JJ 0 1 14 O
- : 0 0 2 O
depleting VBG 1 1 UNK O
agent NN 0 1 1 O
should MD 0 0 12 O
therefore RB 0 0 1 O
be VB 0 0 12 O
closely RB 0 0 1 O
observed VBN 1 1 1 O
for IN 0 0 12 O
evidence NN 0 1 1 O
of IN 0 0 12 O
hypotension NN 0 1 6 O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
marked VBN 1 1 1 O
bradycardia IN 0 1 8 O
which WDT 0 0 12 O
may MD 0 0 1 O
produce VB 0 0 1 O
vertigo JJ 0 1 6 O
syncope NN 0 1 8 O
or CC 0 0 12 O
postural JJ 0 1 13 O
hypotension NN 0 1 6 O
. . 0 0 12 O

DRUG NN 0 1 11 O
INTERACTIONS NNP 0 1 UNK O
There EX 0 0 12 O
are VBP 1 0 12 O
no DT 0 0 12 O
known JJ 0 1 12 O
drug NN 0 1 1 O
/ NNP 0 0 2 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
oral JJ 0 1 6 O
ALKERAN NNP 0 1 UNK B-Brand
Vaccinations NNP 0 1 UNK O
with IN 0 0 12 O
live JJ 0 1 12 B-Group
organism NN 0 1 1 I-Group
vaccines NNS 1 1 6 I-Group
are VBP 1 0 12 O
not RB 0 1 12 O
recommended VBN 1 1 1 O
in IN 0 0 12 O
immunocompromised JJ 0 1 13 O
individuals NNS 1 1 1 O
Nalidixic NNP 0 0 UNK B-Drug
acid VBZ 0 1 14 I-Drug
together RB 0 1 12 O
with IN 0 0 12 O
high JJ 0 1 1 O
- : 0 0 2 O
dose RB 0 1 6 O
intravenous JJ 0 1 14 O
melphalan NN 0 1 13 B-Drug
has VBZ 1 0 12 O
caused VBN 1 1 1 O
deaths NNS 1 1 UNK O
in IN 0 0 12 O
children NNS 1 1 12 O
due JJ 0 1 1 O
to TO 0 0 12 O
haemorrhagic VB 0 1 UNK O
enterocolitis NN 0 1 13 O
. . 0 0 12 O

Drug NN 0 1 2 O
interactions NNS 1 1 UNK O
between IN 0 0 12 O
NEUPOGEN NNP 0 1 UNK B-Brand
and CC 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
fully RB 0 0 1 O
evaluated VBN 1 1 1 O
. . 0 0 12 O

Certain NNP 0 1 UNK O
drugs NNS 1 1 6 O
tend VBP 0 0 12 O
to TO 0 0 12 O
produce VB 0 0 1 O
hyperglycemia NN 0 1 14 O
and CC 0 0 12 O
may MD 0 0 1 O
lead VB 0 1 12 O
to TO 0 0 12 O
loss NN 0 1 1 O
of IN 0 0 12 O
control NN 0 1 1 O
. . 0 0 12 O

Lithium JJ 0 1 UNK B-Drug
carbonate NN 0 1 14 I-Drug
: : 0 0 2 O
The DT 0 0 2 O
anorectic JJ 0 1 UNK O
and CC 0 0 12 O
stimulatory JJ 0 0 UNK O
effects NNS 1 1 1 O
of IN 0 0 12 O
amphetamines NNS 1 1 14 B-Group
may MD 0 0 1 O
be VB 0 0 12 O
inhibited VBN 1 1 13 O
by IN 0 0 12 O
lithium NN 0 1 16 B-Drug
carbonate NN 0 1 14 I-Drug
. . 0 0 12 O

A DT 0 0 2 O
two CD 0 1 12 O
- : 0 0 2 O
way NN 0 0 12 O
interaction NN 0 1 UNK O
between IN 0 0 12 O
the DT 0 0 12 O
hydantoin NN 0 1 13 B-Group
antiepileptic JJ 0 1 UNK I-Group
phenytoin NN 0 1 16 B-Drug
and CC 0 0 12 O
the DT 0 0 12 O
coumarin NN 0 1 UNK B-Group
anticoagulants NNS 1 1 13 I-Group
has VBZ 1 0 12 O
been VBN 1 0 12 O
suggested VBN 1 1 12 O
. . 0 0 12 O

Drugs NNS 0 1 2 O
that WDT 0 0 12 O
Lower JJR 0 1 2 O
Seizure NN 0 1 7 O
Threshold NN 0 1 UNK O
: : 0 0 2 O
Concurrent JJ 0 1 13 O
administration NN 0 1 1 O
of IN 0 0 12 O
WELLBUTRIN NNP 0 1 0 B-Brand
and CC 0 0 12 O
agents NNS 1 1 1 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
antipsychotics NNS 1 1 14 B-Group
other JJ 0 0 12 O
antidepressants NNS 1 1 13 B-Group
theophylline JJ 0 1 16 B-Drug
systemic JJ 0 1 6 O
steroids NNS 1 1 6 B-Group
etc FW 0 1 12 O
. . 0 0 12 O
) ) 0 0 2 O
that IN 0 0 12 O
lower JJR 1 1 1 O
seizure NN 0 1 6 O
threshold NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
undertaken VBN 1 0 1 O
only RB 0 1 12 O
with IN 0 0 12 O
extreme JJ 0 1 1 O
caution NN 0 0 1 O
. . 0 0 12 O

No DT 0 0 2 O
dosage NN 0 1 0 O
adjustment NN 0 1 1 O
is VBZ 1 0 12 O
required VBN 1 1 1 O
for IN 0 0 12 O
Fluvoxamine NNP 0 1 UNK B-Drug
Tablets NNP 0 1 0 O
. . 0 0 12 O

The DT 0 0 2 O
interaction NN 0 1 UNK O
of IN 0 0 12 O
Activase NNP 0 1 UNK B-Brand
with IN 0 0 12 O
other JJ 0 0 12 O
cardioactive JJ 0 0 UNK O
or CC 0 0 12 O
cerebroactive JJ 0 0 UNK O
drugs NNS 1 1 6 O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
studied VBN 1 0 1 O
. . 0 0 12 O

Interaction NN 0 1 2 O
with IN 0 0 12 O
phenytoin JJ 0 1 16 B-Drug
lidocaine NN 0 1 14 B-Drug
and CC 0 0 12 O
theophylline NN 0 1 16 B-Drug
has VBZ 1 0 12 O
also RB 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
produce VB 0 0 1 O
adverse JJ 0 0 1 O
clinical JJ 0 1 6 O
effects NNS 1 1 1 O
. . 0 0 12 O

allopurinol NN 0 1 13 B-Drug
; : 0 0 2 O

In IN 0 0 2 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
shown VBN 1 1 1 O
that IN 0 0 12 O
naproxen JJ 0 1 16 B-Drug
anion NN 0 1 14 O
because IN 0 0 12 O
of IN 0 0 12 O
its PRP$ 1 0 12 O
affinity NN 0 1 UNK O
for IN 0 0 12 O
protein NN 0 1 14 O
may MD 0 0 1 O
displace VB 0 0 13 O
from IN 0 0 12 O
their PRP$ 0 0 12 O
binding NN 0 1 1 O
sites VBZ 1 1 1 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
which WDT 0 0 12 O
are VBP 1 0 12 O
also RB 0 0 12 O
albumin JJ 0 1 14 O
- : 0 0 2 O
bound NN 0 1 12 O
. . 0 0 12 O

In IN 0 0 2 O
vitro JJ 0 1 UNK O
metabolism NN 0 1 16 O
studies NNS 1 1 1 O
have VBP 0 0 12 O
demonstrated VBN 1 0 1 O
that IN 0 0 12 O
tizoxanide NN 0 1 UNK B-Drug
has VBZ 1 0 12 O
no DT 0 0 12 O
significant JJ 0 1 1 O
inhibitory JJ 0 1 UNK O
effect NN 0 1 1 O
on IN 0 0 12 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
enzymes VBZ 0 1 14 O
. . 0 0 12 O

Theoretically RB 0 0 UNK O
it PRP 0 0 12 O
may MD 0 0 1 O
decrease VB 0 1 1 O
hepatic JJ 0 1 14 O
toxicity NN 0 1 6 O
in IN 0 0 12 O
the DT 0 0 12 O
case NN 0 1 12 O
of IN 0 0 12 O
other JJ 0 0 12 O
potential JJ 0 1 1 O
hepatotoxic NN 0 1 UNK O
drugs NNS 1 1 6 O
as RB 0 0 12 O
well RB 0 1 12 O
. . 0 0 12 O

Nevirapine NNP 0 1 UNK B-Drug
and CC 0 0 12 O
ketoconazole VB 0 1 16 B-Drug
should MD 0 0 12 O
not RB 0 1 12 O
beadministered VB 0 0 UNK O
concomitantly RB 0 0 14 O
becausedecreases NNS 0 0 UNK O
in IN 0 0 12 O
ketoconazole JJ 0 1 16 B-Drug
plasmaconcentrations NNS 0 0 UNK O
may MD 0 0 1 O
reduce VB 0 0 1 O
the DT 0 0 12 O
efficacy NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
drug NN 0 1 1 O
. . 0 0 12 O

Sumatriptan NNP 0 1 UNK B-Drug
- : 0 0 2 O
There EX 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
rare JJ 0 1 12 O
postmarketing VBG 0 0 UNK O
reports NNS 1 1 1 O
describing VBG 1 0 1 O
patients NNS 1 1 6 O
with IN 0 0 12 O
weakness NN 0 1 6 O
hyperreflexia NN 0 1 8 O
and CC 0 0 12 O
incoordination NN 0 1 UNK O
following VBG 1 1 1 O
the DT 0 0 12 O
use NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
selective JJ 0 1 13 B-Group
serotonin NN 0 1 13 I-Group
reuptake NN 0 1 13 I-Group
inhibitor NN 0 1 14 I-Group
( ( 0 0 2 O
SSRI NNP 0 1 UNK B-Group
) ) 0 0 2 O
and CC 0 0 12 O
sumatriptan NN 0 1 16 B-Drug
. . 0 0 12 O

Interactions NNS 0 1 UNK O
for IN 0 0 12 O
vitamin NN 0 1 6 B-Group
D NNP 0 1 2 I-Group
analogues NNS 1 1 UNK O
( ( 0 0 2 O
Vitamin NNP 0 1 2 B-Drug
D9 NNP 0 1 UNK I-Drug
Vitamin NNP 0 1 2 B-Drug
D9 NNP 0 1 UNK I-Drug
Calcitriol NNP 0 1 0 B-Drug
and CC 0 0 12 O
Calcidiol NNP 0 1 UNK B-Drug
) ) 0 0 2 O
: : 0 0 2 O
Cholestyramine NN 0 1 UNK B-Drug
: : 0 0 2 O
Cholestyramine NN 0 1 UNK B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
reduce VB 0 0 1 O
intestinal JJ 0 1 13 O
absorption NN 0 1 1 O
of IN 0 0 12 O
fat JJ 0 1 3 B-Group
soluble JJ 0 1 16 I-Group
vitamins NNS 1 1 6 I-Group
; : 0 0 2 O

- : 0 0 2 O
Drugs NNS 0 1 2 O
whose WP$ 0 0 12 O
efficacy NN 0 1 UNK O
is VBZ 1 0 12 O
impaired VBN 1 1 6 O
by IN 0 0 12 O
phenytoin JJ 0 1 16 B-Drug
include NN 0 1 1 O
: : 0 0 2 O
anticoagulants NNS 1 1 13 B-Group
corticosteroids NNS 1 1 14 B-Group
coumarin VBP 0 1 UNK B-Group
digitoxin JJ 0 1 UNK B-Drug
doxycycline NN 0 1 0 B-Drug
estrogens NNS 1 1 16 B-Group
furosemide JJ 0 1 0 B-Drug
oral JJ 0 1 6 O
contraceptives NNS 1 1 13 B-Group
rifampin VBP 0 1 16 B-Drug
quinidine JJ 0 1 16 B-Drug
theophylline NN 0 1 16 B-Drug
vitamin NN 0 1 6 B-Group
D NNP 0 1 2 I-Group
. . 0 0 12 O

Veratrum NNP 0 1 UNK B-Group
alkaloids NNS 1 1 13 I-Group
: : 0 0 2 O
Amphetamines NNS 0 1 UNK B-Group
inhibit VBP 0 1 13 O
the DT 0 0 12 O
hypotensive JJ 0 1 14 O
effect NN 0 1 1 O
of IN 0 0 12 O
veratrum NN 0 1 UNK B-Group
alkaloids NNS 1 1 13 I-Group
. . 0 0 12 O

- : 0 0 2 O
Acetohydroxamic NN 0 0 UNK B-Drug
acid NN 0 1 14 I-Drug
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
Lithostat NNP 0 1 UNK B-Brand
) ) 0 0 2 O
or CC 0 0 12 O

The DT 0 0 2 O
patient NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
informed VBN 1 1 12 O
that IN 0 0 12 O
the DT 0 0 12 O
response NN 0 1 1 O
to TO 0 0 12 O
alcohol VB 0 1 1 B-Drug
may MD 0 0 1 O
be VB 0 0 12 O
exaggerated VBN 1 1 1 O
. . 0 0 12 O

Since IN 0 1 2 O
amiodarone NN 0 1 0 B-Drug
is VBZ 1 0 12 O
a DT 0 0 12 O
substrate NN 0 1 UNK O
for IN 0 0 12 O
CYP9A9 NNP 0 0 UNK B-Drug
there EX 0 0 12 O
is VBZ 1 0 12 O
the DT 0 0 12 O
potential JJ 0 1 1 O
that IN 0 0 12 O
the DT 0 0 12 O
use NN 0 1 1 O
of IN 0 0 12 O
St. NNP 0 1 2 O
John NNP 0 0 19 O
Wort NNP 0 0 UNK O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
amiodarone NN 0 1 0 B-Drug
could MD 0 0 12 O
result VB 0 1 1 O
in IN 0 0 12 O
reduced JJ 0 1 1 O
amiodarone NN 0 1 0 B-Drug
levels NNS 1 1 1 O
. . 0 0 12 O

Evidence NN 0 1 2 O
supporting VBG 1 1 1 O
the DT 0 0 12 O
conclusion NN 0 1 12 O
that IN 0 0 12 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
inadvisable JJ 0 0 UNK O
to TO 0 0 12 O
co VB 0 1 12 O
- : 0 0 2 O
administer NN 0 1 1 O
fluvoxamine NN 0 1 16 B-Drug
and CC 0 0 12 O
diazepam NN 0 1 0 B-Drug
is VBZ 1 0 12 O
derived VBN 1 1 UNK O
from IN 0 0 12 O
a DT 0 0 12 O
study NN 0 1 1 O
in IN 0 0 12 O
which WDT 0 0 12 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
taking VBG 1 0 12 O
9 CD 0 0 2 O
mg JJ 0 1 0 O
/ NNP 0 0 2 O
day NN 0 1 12 O
of IN 0 0 12 O
fluvoxamine NN 0 1 16 B-Drug
were VBD 1 0 12 O
administered VBN 1 1 1 O
a DT 0 0 12 O
single JJ 0 1 12 O
oral JJ 0 1 6 O
dose NN 0 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
of IN 0 0 12 O
diazepam NN 0 1 0 B-Drug
. . 0 0 12 O

Administration NN 0 1 UNK O
of IN 0 0 12 O
eszopiclone $ 0 1 13 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
to TO 0 0 12 O
a DT 0 0 12 O
patient NN 0 1 6 O
taking VBG 1 0 12 O
another DT 0 0 12 O
drug NN 0 1 1 O
that WDT 0 0 12 O
is VBZ 1 0 12 O
highly RB 0 1 1 O
protein JJ 0 1 14 O
- : 0 0 2 O
bound NN 0 1 12 O
would MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
expected VBN 1 1 12 O
to TO 0 0 12 O
cause VB 0 1 12 O
an DT 0 0 12 O
alteration NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
free JJ 0 1 12 O
concentration NN 0 1 1 O
of IN 0 0 12 O
either DT 0 1 12 O
drug NN 0 1 1 O
. . 0 0 12 O

Clearance NN 0 1 UNK O
of IN 0 0 12 O
hydrodolasetron NN 0 1 UNK B-Drug_n
decreased VBN 1 1 1 O
by IN 0 0 12 O
about IN 0 1 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
when WRB 0 0 12 O
dolasetron NN 0 1 0 B-Drug
mesylate NN 0 1 16 I-Drug
was VBD 1 0 12 O
administered VBN 1 1 1 O
intravenously RB 0 0 14 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
atenolol NN 0 1 0 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
clearance NN 0 1 16 O
of IN 0 0 12 O
benzodiazepines NNS 1 1 14 B-Group
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
glucuronidation NN 0 1 UNK O
( ( 0 0 2 O
e. JJ 0 0 1 O
g. NN 0 1 13 O
lorazepam NN 0 1 0 B-Drug
oxazepam IN 0 1 16 B-Drug
temazepam NN 0 1 16 B-Drug
) ) 0 0 2 O
is VBZ 1 0 12 O
unlikely JJ 0 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
affected VBN 1 1 1 O
by IN 0 0 12 O
fluvoxamine NN 0 1 16 B-Drug
. . 0 0 12 O

Dopamine JJ 0 1 7 B-Group
antagonists NNS 1 1 13 I-Group
such JJ 0 0 1 O
as IN 1 0 12 O
the DT 0 0 12 O
neuroleptics NNS 1 1 13 B-Group
( ( 0 0 2 O
phenothiazines NNS 1 1 UNK B-Group
butyrophenones NNS 0 1 UNK B-Group
thioxanthines NNS 0 0 UNK B-Group
) ) 0 0 2 O
or CC 0 0 12 O
metoclopramide JJ 0 1 16 B-Drug
ordinarily RB 0 0 UNK O
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
Permax NNP 0 1 UNK B-Brand
( ( 0 0 2 O
a DT 0 0 12 O
dopamine NN 0 1 14 B-Group
agonist NN 0 1 14 I-Group
) ) 0 0 2 O
; : 0 0 2 O

ACE JJ 0 1 13 B-Group
Inhibitors NNS 0 1 7 I-Group
: : 0 0 2 O
Concomitant NNP 0 1 UNK O
use NN 0 1 1 O
of IN 0 0 12 O
ACE NNP 0 1 13 B-Group
inhibitors NNS 1 1 14 I-Group
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
renal JJ 0 1 6 O
impairment NN 0 1 16 O
particularly RB 0 0 1 O
in IN 0 0 12 O
volume NN 0 1 1 O
- : 0 0 2 O
depleted JJ 0 1 1 O
patients NNS 1 1 6 O
. . 0 0 12 O

In IN 0 0 2 O
addition NN 0 1 1 O
certain JJ 0 1 1 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
are VBP 1 0 12 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
this DT 0 0 12 O
isozyme JJ 0 1 UNK O
including VBG 1 1 1 O
many JJ 0 0 12 O
antidepressants NNS 1 1 13 B-Group
( ( 0 0 2 O
clozapine JJ 0 1 13 B-Drug
selective NN 0 1 13 B-Group
serotonin NN 0 1 13 I-Group
reuptake NN 0 1 13 I-Group
inhibitors NNS 1 1 14 I-Group
and CC 0 0 12 O
others NNS 0 1 12 O
) ) 0 0 2 O
may MD 0 0 1 O
inhibit VB 0 1 13 O
the DT 0 0 12 O
activity NN 0 1 1 O
of IN 0 0 12 O
this DT 0 0 12 O
isozyme NN 0 1 UNK O
and CC 0 0 12 O
thus RB 0 0 1 O
may MD 0 0 1 O
make VB 0 1 12 O
normal JJ 0 1 1 O
metabolizers NNS 0 0 UNK O
resemble JJ 0 0 UNK O
poor JJ 0 1 12 O
metabolizers NNS 0 0 UNK O
with IN 0 0 12 O
regard NN 0 0 1 O
to TO 0 0 12 O
concomitant VB 0 1 6 O
therapy NN 0 1 6 O
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
this DT 0 0 12 O
enzyme NN 0 1 14 O
system NN 0 1 1 O
leading VBG 1 1 1 O
to TO 0 0 12 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
. . 0 0 12 O

Use NNP 0 1 2 O
of IN 0 0 12 O
a DT 0 0 12 O
nonhormonal JJ 0 0 UNK B-Group
contraceptive JJ 0 1 13 I-Group
product NN 0 1 1 I-Group
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O

Effects NNS 0 1 UNK O
on IN 0 0 12 O
the DT 0 0 12 O
absorption NN 0 1 1 O
of IN 0 0 12 O
other JJ 0 0 12 O
beta NN 0 1 16 B-Group
- : 0 0 2 O
blockers NNS 1 0 6 I-Group
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
determined VBN 1 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
situations NNS 1 0 UNK O
in IN 0 0 12 O
which WDT 0 0 12 O
concurrent NN 0 1 1 O
therapy NN 0 1 6 O
is VBZ 1 0 12 O
necessary JJ 0 0 1 O
careful JJ 0 1 12 O
patient NN 0 1 6 O
monitoring NN 0 1 1 O
is VBZ 1 0 12 O
essential JJ 0 1 13 O
. . 0 0 12 O

Dolasetron NNP 0 1 0 B-Drug
mesylate NN 0 1 16 I-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
inhibit VB 0 1 13 O
the DT 0 0 12 O
antitumor NN 0 1 UNK O
activity NN 0 1 1 O
of IN 0 0 12 O
four CD 0 1 12 O
chemotherapeutic JJ 0 1 13 B-Group
agents NNS 1 1 1 I-Group
( ( 0 0 2 O
cisplatin NN 0 1 14 B-Drug
9 CD 0 0 2 B-Drug
- : 0 0 2 O
fluorouracil NN 0 1 13 I-Drug
doxorubicin JJ 0 1 13 B-Drug
cyclophosphamide NN 0 1 14 B-Drug
) ) 0 0 2 O
in IN 0 0 12 O
four CD 0 1 12 O
murine NN 0 1 13 O
models NNS 1 1 UNK O
. . 0 0 12 O

Phenytoin NNP 0 1 0 B-Drug
is VBZ 1 0 12 O
known VBN 1 1 12 O
to TO 0 0 12 O
cause VB 0 1 12 O
osteomalacia NN 0 1 13 O
. . 0 0 12 O

Because IN 0 0 12 O
there EX 0 0 12 O
is VBZ 1 0 12 O
a DT 0 0 12 O
theoretical JJ 0 1 UNK O
basis NN 0 1 1 O
that IN 0 0 12 O
these DT 0 0 12 O
effects NNS 1 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
additive JJ 0 1 16 O
use NN 0 1 1 O
of IN 0 0 12 O
ergotamine JJ 0 1 UNK B-Drug
- : 0 0 2 O
containing NN 0 1 1 O
or CC 0 0 12 O
ergot VB 0 1 UNK B-Group
- : 0 0 2 O
type NN 0 1 1 I-Group
medications NNS 1 1 6 I-Group
( ( 0 0 2 O
like IN 0 0 12 O
dihydroergotamine NN 0 1 UNK B-Drug
or CC 0 0 12 O
methysergide NN 0 1 UNK B-Drug
) ) 0 0 2 O
and CC 0 0 12 O
naratriptan $ 0 1 13 B-Drug
within IN 0 0 1 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
is VBZ 1 0 12 O
contraindicated VBN 1 1 14 O
. . 0 0 12 O

In IN 0 0 2 O
addition NN 0 1 1 O
neuromuscular JJ 0 1 6 O
blocking VBG 1 1 UNK O
action NN 0 1 13 O
is VBZ 1 0 12 O
enhanced VBN 1 1 1 O
by IN 0 0 12 O
general JJ 0 1 1 O
anesthetics NNS 1 1 13 B-Group
local JJ 0 1 12 O
anesthetics NNS 1 1 13 B-Group
like IN 0 0 12 O
lidocaine JJ 0 1 14 B-Drug
procaine NN 0 1 UNK B-Drug
beta SYM 0 1 16 B-Group
- : 0 0 2 O
blockers NNS 1 0 6 I-Group
metaclopramide VBP 0 1 UNK B-Drug
lithium NN 0 1 16 B-Drug
carbonate NN 0 1 14 I-Drug
and CC 0 0 12 O
terbutaline NN 0 1 0 B-Drug
. . 0 0 12 O

Monoamine NNP 0 1 UNK B-Group
Oxidase NNP 0 1 UNK I-Group
Inhibitors NNP 0 1 7 I-Group
and CC 0 0 12 O
Tricyclic NNP 0 0 UNK B-Group
Antidepressants NNS 0 1 UNK I-Group
: : 0 0 2 O
FORADIL NNP 0 1 UNK B-Brand
should MD 0 0 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
extreme JJ 0 1 1 O
caution NN 0 0 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
being VBG 1 0 12 O
treated VBN 1 1 1 O
with IN 0 0 12 O
monoamine JJ 0 1 13 B-Group
oxidase NN 0 1 13 I-Group
inhibitors NNS 1 1 14 I-Group
or CC 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
because IN 0 0 12 O
the DT 0 0 12 O
action NN 0 1 13 O
of IN 0 0 12 O
formoterol NN 0 1 13 B-Drug
on IN 0 0 12 O
the DT 0 0 12 O
cardiovascular JJ 0 1 6 O
system NN 0 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
potentiated VBN 1 0 UNK O
by IN 0 0 12 O
these DT 0 0 12 O
agents NNS 1 1 1 O
. . 0 0 12 O

Another DT 0 0 2 O
investigator NN 0 1 UNK O
found VBD 1 1 12 O
no DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
levels NNS 1 1 1 O
in IN 0 0 12 O
9 CD 0 0 2 O
patients NNS 1 1 6 O
with IN 0 0 12 O
coronary JJ 0 1 6 O
artery NN 0 1 6 O
disease NN 0 1 6 O
. . 0 0 12 O

Injection NN 0 1 7 O
: : 0 0 2 O
Lorazepam JJ 0 1 0 B-Drug
injection NN 0 1 3 O
like IN 0 0 12 O
other JJ 0 0 12 O
injectable JJ 0 1 UNK O
benzodiazepines NNS 1 1 14 B-Group
produces VBZ 1 0 1 O
depression NN 0 1 6 O
of IN 0 0 12 O
the DT 0 0 12 O
central JJ 0 1 1 O
nervous JJ 0 1 6 O
system NN 0 1 1 O
when WRB 0 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
ethyl JJ 0 0 13 B-Drug
alcohol NN 0 1 1 I-Drug
phenothiazines NNS 1 1 UNK B-Group
barbiturates VBZ 0 1 14 B-Group
MAO NNP 0 1 14 B-Group
inhibitors NNS 1 1 14 I-Group
and CC 0 0 12 O
other JJ 0 0 12 O
antidepressants NNS 1 1 13 B-Group
. . 0 0 12 O
When WRB 0 0 12 O
scopolamine NN 0 1 14 B-Drug
is VBZ 1 0 12 O
used VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
injectable JJ 0 1 UNK O
lorazepam NN 0 1 0 B-Drug
an DT 0 0 12 O
increased VBN 1 1 1 O
incidence NN 0 1 6 O
of IN 0 0 12 O
sedation NN 0 1 6 O
hallucinations NNS 1 1 6 O
and CC 0 0 12 O
irrational JJ 0 1 UNK O
behavior NN 0 1 1 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
. . 0 0 12 O

Cyclopropane NNP 0 1 UNK B-Drug
or CC 0 0 12 O
halogenated VBN 0 0 UNK B-Group
hydrocarbon NN 0 1 13 I-Group
anesthetics NNS 1 1 13 I-Group
increase VBP 0 1 1 O
cardiac JJ 0 1 6 O
autonomic JJ 0 1 6 O
irritability NN 0 1 6 O
and CC 0 0 12 O
may MD 0 0 1 O
sensitize VB 0 0 UNK O
the DT 0 0 12 O
myocardium NN 0 1 8 O
to TO 0 0 12 O
the DT 0 0 12 O
action NN 0 1 13 O
of IN 0 0 12 O
certain JJ 0 1 1 O
intravenously RB 0 0 14 O
administered VBN 1 1 1 O
catecholamines NNS 1 1 14 B-Group
such JJ 0 0 1 O
as IN 1 0 12 O
dopamine NN 0 1 14 B-Drug
. . 0 0 12 O

oral JJ 0 1 6 O
clearance NN 0 1 16 O
was VBD 1 0 12 O
reduced VBN 1 1 1 O
by IN 0 0 12 O
about IN 0 1 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

Antiarrhythmics NNS 0 1 UNK B-Drug
: : 0 0 2 O
Other JJ 0 0 2 O
antiarrhythmic JJ 0 1 14 B-Drug
drugs NNS 1 1 6 O
such JJ 0 0 1 O
as IN 1 0 12 O
quinidine JJ 0 1 16 B-Drug
procainamide IN 0 1 16 B-Drug
disopyramide NN 0 1 16 B-Drug
and CC 0 0 12 O
phenytoin NN 0 1 16 B-Drug
have VBP 0 0 12 O
been VBN 1 0 12 O
used VBN 1 1 12 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
amiodarone NN 0 1 0 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
clinical JJ 0 1 6 O
implication NN 0 0 UNK O
of IN 0 0 12 O
this DT 0 0 12 O
effect NN 0 1 1 O
is VBZ 1 0 12 O
not RB 0 1 12 O
known VBN 1 1 12 O
. . 0 0 12 O

naproxen NN 0 1 16 B-Drug
; : 0 0 2 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
that IN 0 0 12 O
glucose NN 0 1 14 O
tests NNS 1 1 1 O
based VBN 1 1 1 O
on IN 0 0 12 O
enzymatic JJ 0 1 UNK O
glucose JJ 0 1 14 O
oxidase NN 0 1 13 O
be VB 0 0 12 O
used VBN 1 1 12 O
. . 0 0 12 O

The DT 0 0 2 O
majority NN 0 1 1 O
of IN 0 0 12 O
patients NNS 1 1 6 O
in IN 0 0 12 O
rheumatoid JJ 0 0 6 O
arthritis NN 0 1 6 O
or CC 0 0 12 O
Crohn NNP 0 1 6 O
disease VB 0 1 6 O
clinical JJ 0 1 6 O
studies NNS 1 1 1 O
received VBD 1 1 12 O
one CD 0 1 12 O
or CC 0 0 12 O
more JJR 0 1 12 O
concomitant JJ 0 1 6 O
medications NNS 1 1 6 O
. . 0 0 12 O

Indinavir NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
. . 0 0 12 O

The DT 0 0 2 O
concurrent NN 0 1 1 O
use NN 0 1 1 O
of IN 0 0 12 O
two CD 0 1 12 O
or CC 0 0 12 O
more JJR 0 1 12 O
drugs NNS 1 1 6 O
with IN 0 0 12 O
anticholinergic JJ 0 1 13 O
activity NN 0 1 1 O
- : 0 0 2 O
- : 0 0 2 O
such JJ 0 0 1 O
as IN 1 0 12 O
an DT 0 0 12 O
antipsychotic JJ 0 1 UNK B-Group
drug NN 0 1 1 I-Group
( ( 0 0 2 O
eg JJ 0 1 UNK O
chlorpromazine NN 0 1 16 B-Drug
) ) 0 0 2 O
an DT 0 0 12 O
antiparkinsonian JJ 0 1 UNK B-Group
drug NN 0 1 1 I-Group
( ( 0 0 2 O
eg JJ 0 1 UNK O
trihexyphenidyl NN 0 1 16 B-Drug
) ) 0 0 2 O
and CC 0 0 12 O
/ $ 0 0 2 O
or CC 0 0 12 O
a DT 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressant NN 0 1 6 I-Group
( ( 0 0 2 O
eg JJ 0 1 UNK O
amitriptyline NN 0 1 16 B-Drug
) ) 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
commonly RB 0 0 UNK O
results NNS 1 1 1 O
in IN 0 0 12 O
excessive JJ 0 1 1 O
anticholinergic JJ 0 1 13 O
effects NNS 1 1 1 O
including VBG 1 1 1 O
dry JJ 0 1 3 O
mouth NN 0 1 3 O
and CC 0 0 12 O
associated VBN 1 1 1 O
dental JJ 0 1 6 O
complications NNS 1 1 6 O
blurred VBN 1 1 3 O
vision NN 0 1 1 O
and CC 0 0 12 O
in IN 0 0 12 O
patients NNS 1 1 6 O
exposed VBN 1 1 3 O
to TO 0 0 12 O
high JJ 0 1 1 O
temperature NN 0 1 3 O
and CC 0 0 12 O
humidity NN 0 1 13 O
hyperpyrexia NN 0 1 UNK O
. . 0 0 12 O

Nitroglycerin NN 0 1 0 B-Drug
: : 0 0 2 O
DynaCirc NNP 0 1 UNK B-Brand
( ( 0 0 2 O
isradipine NN 0 1 13 B-Drug
) ) 0 0 2 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
safely RB 0 0 UNK O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
nitroglycerin NN 0 1 14 B-Drug
. . 0 0 12 O

Since IN 0 1 2 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
BUSULFEX NNP 0 1 UNK B-Brand
were VBD 1 0 12 O
studied VBN 1 0 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
treated VBN 1 1 1 O
with IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
the DT 0 0 12 O
clearance NN 0 1 16 O
of IN 0 0 12 O
BUSULFEX NNP 0 1 UNK B-Brand
at IN 0 0 12 O
the DT 0 0 12 O
recommended VBN 1 1 1 O
dose NN 0 1 6 O
may MD 0 0 1 O
be VB 0 0 12 O
lower JJR 1 1 1 O
and CC 0 0 12 O
exposure NN 0 1 1 O
( ( 0 0 2 O
AUC NNP 0 1 UNK O
) ) 0 0 2 O
higher JJR 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
not RB 0 1 12 O
treated VBN 1 1 1 O
with IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
. . 0 0 12 O

Consequently RB 0 0 1 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
not RB 0 1 12 O
possible JJ 0 1 1 O
to TO 0 0 12 O
make VB 0 1 12 O
any DT 0 0 12 O
definitive JJ 0 1 1 O
statements NNS 1 1 UNK O
about IN 0 1 12 O
the DT 0 0 12 O
risks NNS 1 1 1 O
of IN 0 0 12 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
REMERON NNP 0 1 UNK B-Brand
SolTab NNP 0 0 UNK I-Brand
with IN 0 0 12 O
such JJ 0 0 1 O
drugs NNS 1 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
action NN 0 1 13 O
of IN 0 0 12 O
Mecamylamine NNP 0 1 UNK B-Drug
may MD 0 0 1 O
be VB 0 0 12 O
potentiated VBN 1 0 UNK O
by IN 0 0 12 O
anesthesia NN 0 1 6 O
other JJ 0 0 12 O
antihypertensive JJ 0 1 14 B-Group
drugs NNS 1 1 6 I-Group
and CC 0 0 12 O
alcohol NN 0 1 1 B-Drug
. . 0 0 12 O

Alcohol NN 0 1 2 B-Drug
: : 0 0 2 O
In IN 0 0 2 O
a DT 0 0 12 O
multiple JJ 0 1 1 O
- : 0 0 2 O
dose NN 0 1 6 O
study NN 0 1 1 O
in IN 0 0 12 O
9 CD 0 0 2 O
normal JJ 0 1 1 O
weight JJ 0 1 3 O
subjects NNS 1 1 UNK O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
XENICAL NNP 0 1 UNK B-Brand
and CC 0 0 12 O
9 CD 0 0 2 O
grams NNS 1 1 3 O
of IN 0 0 12 O
alcohol NN 0 1 1 B-Drug
( ( 0 0 2 O
e.g. VB 0 0 UNK O
approximately RB 0 1 1 O
9 CD 0 0 2 O
glasses NNS 1 1 3 O
of IN 0 0 12 O
wine NN 0 1 12 O
) ) 0 0 2 O
did VBD 1 0 12 O
not RB 0 1 12 O
result VB 0 1 1 O
in IN 0 0 12 O
alteration NN 0 1 1 O
of IN 0 0 12 O
alcohol NN 0 1 1 B-Drug
pharmacokinetics NNS 0 1 UNK O
orlistat VBP 0 1 UNK B-Drug
pharmacodynamics NNS 0 1 UNK O
( ( 0 0 2 O
fecal JJ 0 1 6 O
fat NN 0 1 3 O
excretion NN 0 1 14 O
) ) 0 0 2 O
or CC 0 0 12 O
systemic JJ 0 1 6 O
exposure NN 0 1 1 O
to TO 0 0 12 O
orlistat VB 0 1 UNK B-Drug
. . 0 0 12 O

Patients NNS 0 1 7 O
who WP 0 0 12 O
take VBP 0 1 12 O
both DT 0 0 12 O
ezetimibe NNS 0 1 16 B-Drug
and CC 0 0 12 O
cyclosporine NN 0 1 14 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
carefully RB 0 0 12 O
monitored VBN 1 1 1 O
. . 0 0 12 O

Since IN 0 1 2 O
trimetrexate NN 0 1 UNK B-Drug
is VBZ 1 0 12 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
a DT 0 0 12 O
P9 NNP 0 1 UNK O
enzyme NN 0 1 14 O
system NN 0 1 1 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
induce VBP 0 1 6 O
or CC 0 0 12 O
inhibit VB 0 1 13 O
this DT 0 0 12 O
drug NN 0 1 1 O
metabolizing VBG 1 0 UNK O
enzyme JJ 0 1 14 O
system NN 0 1 1 O
may MD 0 0 1 O
elicit VB 0 1 1 O
important JJ 0 1 1 O
drug NN 0 1 1 O
- : 0 0 2 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
that WDT 0 0 12 O
may MD 0 0 1 O
alter VB 0 1 13 O
trimetrexate VB 0 1 UNK B-Drug
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
. . 0 0 12 O

Anesthetics NNS 0 1 UNK B-Group
/ VBP 0 0 2 O
Sedatives VBZ 0 1 UNK B-Group
/ JJ 0 0 2 O
Hypnotics NNP 0 1 UNK B-Group
/ NNP 0 0 2 O
Opioids NNP 0 1 UNK B-Group
: : 0 0 2 O
Co NNP 0 1 2 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
PRECEDEX NNP 0 1 UNK B-Brand
with IN 0 0 12 O
anesthetics NNS 1 1 13 B-Group
sedatives NNS 1 1 6 B-Group
hypnotics NNS 1 1 13 B-Group
and CC 0 0 12 O
opioids NNS 0 1 14 B-Group
is VBZ 1 0 12 O
likely JJ 0 1 12 O
to TO 0 0 12 O
lead VB 0 1 12 O
to TO 0 0 12 O
an DT 0 0 12 O
enhancement NN 0 1 1 O
of IN 0 0 12 O
effects NNS 1 1 1 O
. . 0 0 12 O

Both DT 0 0 2 O
CYP9A9 NNP 0 0 UNK O
and CC 0 0 12 O
CYP9D9 NNP 0 0 UNK O
are VBP 1 0 12 O
responsible JJ 0 1 1 O
for IN 0 0 12 O
aripiprazole JJ 0 1 16 B-Drug
metabolism NN 0 1 16 O
. . 0 0 12 O

increased VBN 1 1 1 O
platelet NN 0 1 14 O
count NN 0 1 12 O
; : 0 0 2 O

In IN 0 0 2 O
a DT 0 0 12 O
study NN 0 1 1 O
in IN 0 0 12 O
normal JJ 0 1 1 O
volunteers NNS 1 1 UNK O
it PRP 0 0 12 O
was VBD 1 0 12 O
found VBN 1 1 12 O
that IN 0 0 12 O
chronic JJ 0 1 6 O
concurrent JJ 0 1 1 O
administration NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
g NN 0 1 16 O
of IN 0 0 12 O
aspirin JJ 0 1 14 B-Brand
per IN 0 0 1 O
day NN 0 1 12 O
decreases VBZ 1 1 UNK O
indomethacin JJ 0 1 14 B-Drug
blood NN 0 1 6 O
levels NNS 1 1 1 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

Therefore RB 0 0 1 O
the DT 0 0 12 O
combination NN 0 1 1 O
of IN 0 0 12 O
anakinra NN 0 1 13 B-Drug
with IN 0 0 12 O
other JJ 0 0 12 O
TNF NNP 0 1 UNK B-Group
- : 0 0 2 O
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
including VBG 1 1 1 O
HUMIRA NNP 0 1 UNK B-Brand
may MD 0 0 1 O
also RB 0 0 12 O
result VB 0 1 1 O
i JJ 0 1 12 O
n NNS 0 1 12 O
similar JJ 0 1 1 O
toxicities NNS 1 1 UNK O
. . 0 0 12 O

TRENTAL NNP 0 1 UNK B-Brand
has VBZ 1 0 12 O
been VBN 1 0 12 O
used VBN 1 1 12 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
antihypertensive JJ 0 1 14 B-Group
drugs NNS 1 1 6 I-Group
beta NN 0 1 16 B-Group
blockers NNS 1 0 6 I-Group
digitalis VBP 0 1 14 B-Group
diuretics NNS 1 1 14 B-Group
antidiabetic JJ 0 1 13 B-Group
agents NNS 1 1 1 I-Group
and CC 0 0 12 O
antiarrhythmics NNS 1 1 UNK B-Group
without IN 0 0 12 O
observed JJ 0 1 1 O
problems NNS 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
effect NN 0 1 1 O
of IN 0 0 12 O
meloxicam NN 0 1 13 B-Drug
on IN 0 0 12 O
the DT 0 0 12 O
anticoagulant JJ 0 1 13 O
effect NN 0 1 1 O
of IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
was VBD 1 0 12 O
studied VBN 1 0 1 O
in IN 0 0 12 O
a DT 0 0 12 O
group NN 0 1 12 O
of IN 0 0 12 O
healthy JJ 0 1 12 O
subjects NNS 1 1 UNK O
receiving VBG 1 1 1 O
daily JJ 0 1 12 O
doses NNS 1 1 6 O
of IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
that WDT 0 0 12 O
produced VBD 1 0 1 O
an DT 0 0 12 O
INR NNP 0 1 13 O
( ( 0 0 2 O
International NNP 0 1 UNK O
Normalized NNP 0 1 UNK O
Ratio NNP 0 1 2 O
) ) 0 0 2 O
between IN 0 0 12 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
. . 0 0 12 O

The DT 0 0 2 O
effect NN 0 1 1 O
of IN 0 0 12 O
methylprednisolone NN 0 1 16 B-Drug
on IN 0 0 12 O
oral JJ 0 1 6 O
anticoagulants NNS 1 1 13 B-Group
is VBZ 1 0 12 O
variable JJ 0 1 1 O
. . 0 0 12 O

Pharmacologic NNP 0 1 UNK O
studies NNS 1 1 1 O
indicate VBP 0 0 1 O
that IN 0 0 12 O
there EX 0 0 12 O
may MD 0 0 1 O
be VB 0 0 12 O
additive JJ 0 1 16 O
effects NNS 1 1 1 O
in IN 0 0 12 O
prolonging VBG 1 0 UNK O
AV NNP 0 0 13 O
conduction NN 0 1 6 O
when WRB 0 0 12 O
using VBG 1 1 1 O
beta SYM 0 1 16 B-Group
- : 0 0 2 O
blockers NNS 1 0 6 I-Group
or CC 0 0 12 O
digitalis NNS 0 1 14 B-Group
concomitantly RB 0 0 14 O
with IN 0 0 12 O
Tiazac NNP 0 1 UNK B-Brand
. . 0 0 12 O

Concomitant NNP 0 1 UNK O
use NN 0 1 1 O
of IN 0 0 12 O
ELLENCE NNP 0 1 UNK B-Brand
with IN 0 0 12 O
other JJ 0 0 12 O
cardioactive JJ 0 0 UNK O
compounds NNS 1 1 13 O
that WDT 0 0 12 O
could MD 0 0 12 O
cause VB 0 1 12 O
heart NN 0 1 12 O
failure NN 0 1 1 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
calcium NN 0 1 14 B-Group
channel NN 0 1 1 I-Group
blockers NNS 1 0 6 I-Group
) ) 0 0 2 O
requires VBZ 1 0 1 O
close JJ 0 1 12 O
monitoring NN 0 1 1 O
of IN 0 0 12 O
cardiac JJ 0 1 6 O
function NN 0 1 1 O
throughout IN 0 0 12 O
treatment NN 0 1 6 O
. . 0 0 12 O

Clidinium NN 0 1 UNK B-Drug
may MD 0 0 1 O
decrease VB 0 1 1 O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
phenothiazines NNS 1 1 UNK B-Group
levodopa NNS 0 1 UNK B-Drug
and CC 0 0 12 O
ketoconazole NN 0 1 16 B-Drug
. . 0 0 12 O

Other JJ 0 0 2 O
medicines NNS 1 1 6 O
- : 0 0 2 O
Although IN 0 0 12 O
certain JJ 0 1 1 O
medicines NNS 1 1 6 O
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
together RB 0 1 12 O
at IN 0 0 12 O
all DT 0 0 12 O
in IN 0 0 12 O
other JJ 0 0 12 O
cases NNS 1 1 UNK O
two CD 0 1 12 O
different JJ 0 1 1 O
medicines NNS 1 1 6 O
may MD 0 0 1 O
be VB 0 0 12 O
used VBN 1 1 12 O
together RB 0 1 12 O
even RB 0 0 12 O
if IN 0 0 12 O
an DT 0 0 12 O
interaction NN 0 1 UNK O
might MD 0 0 12 O
occur VB 0 1 1 O
. . 0 0 12 O

This DT 0 0 2 O
indicates VBZ 1 0 1 O
that IN 0 0 12 O
tiagabine NN 0 1 13 B-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
cause VB 0 1 12 O
induction NN 0 1 1 O
or CC 0 0 12 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
the DT 0 0 12 O
hepatic JJ 0 1 14 O
microsomal JJ 0 1 UNK O
enzyme NN 0 1 14 O
systems NNS 1 1 1 O
responsible JJ 0 1 1 O
for IN 0 0 12 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
antipyrine NN 0 1 UNK B-Drug
. . 0 0 12 O

Persons NNS 0 1 UNK O
taking VBG 1 0 12 O
most JJS 0 0 12 O
antibiotics NNS 1 1 6 B-Group
methotrexate NN 0 1 16 B-Drug
and CC 0 0 12 O
pyrimethamine NN 0 1 16 B-Drug
invalidate VBP 0 0 UNK O
folic JJ 0 0 14 B-Drug
acid NN 0 1 14 I-Drug
and CC 0 0 12 O
vitamin NN 0 1 6 B-Drug
B9 NNP 0 0 UNK I-Drug
diagnostic JJ 0 1 6 O
blood NN 0 1 6 O
assays NNS 1 1 13 O
. . 0 0 12 O

The DT 0 0 2 O
monoamine NN 0 1 13 O
oxidase NN 0 1 13 O
inhibitory JJ 0 1 UNK O
effects NNS 1 1 1 O
of IN 0 0 12 O
Isocarboxazid NNP 0 1 UNK B-Drug
may MD 0 0 1 O
persist VB 0 0 1 O
for IN 0 0 12 O
a DT 0 0 12 O
substantial JJ 0 0 1 O
period NN 0 1 1 O
after IN 0 0 12 O
discontinuation NN 0 1 6 O
of IN 0 0 12 O
the DT 0 0 12 O
drug NN 0 1 1 O
and CC 0 0 12 O
this DT 0 0 12 O
should MD 0 0 12 O
be VB 0 0 12 O
borne VBN 1 1 1 O
in IN 0 0 12 O
mind NN 0 1 12 O
when WRB 0 0 12 O
another DT 0 0 12 O
drug NN 0 1 1 O
is VBZ 1 0 12 O
prescribed VBN 1 1 1 O
following VBG 1 1 1 O
Isocarboxazid NNP 0 1 UNK B-Drug
. . 0 0 12 O

Conversely RB 0 0 UNK O
adverse JJ 0 0 1 O
effects NNS 1 1 1 O
may MD 0 0 1 O
result VB 0 1 1 O
from IN 0 0 12 O
displacement NN 0 1 1 O
of IN 0 0 12 O
protein NN 0 1 14 O
- : 0 0 2 O
bound NN 0 1 12 O
Anafranil NNP 0 1 UNK B-Brand
by IN 0 0 12 O
other JJ 0 0 12 O
highly RB 0 1 1 O
bound IN 0 1 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

Indinavir NNP 0 1 UNK B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
increase VB 0 1 1 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
combination NN 0 1 1 B-Group
hormonal JJ 0 1 6 I-Group
contraceptives NNS 1 1 13 I-Group
. . 0 0 12 O

Magnesium NN 0 1 7 B-Drug
: : 0 0 2 O
Magnesium NNP 0 1 7 B-Drug
- : 0 0 2 O
containing NN 0 1 1 O
preparations NNS 1 1 13 O
( ( 0 0 2 O
eg JJ 0 1 UNK O
antacids NNS 1 1 14 B-Group
) ) 0 0 2 O
may MD 0 0 1 O
cause VB 0 1 12 O
hypermagnesemia NN 0 1 13 O
and CC 0 0 12 O
should MD 0 0 12 O
therefore VB 0 0 1 O
not RB 0 1 12 O
be VB 0 0 12 O
taken VBN 1 1 12 O
during IN 0 0 12 O
therapy NN 0 1 6 O
with IN 0 0 12 O
vitamin NN 0 1 6 B-Group
D NNP 0 1 2 I-Group
by IN 0 0 12 O
patients NNS 1 1 6 O
on IN 0 0 12 O
chronic JJ 0 1 6 O
renal JJ 0 1 6 O
dialysis NN 0 1 6 O
. . 0 0 12 O

Antihistamines NNS 0 1 UNK B-Group

Atazanavir NN 0 1 0 B-Drug

No DT 0 0 2 O
drug NN 0 1 1 O
/ VBZ 0 0 2 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
performed VBN 1 1 1 O
. . 0 0 12 O

Curariform NNP 0 1 UNK B-Brand
muscle NN 0 1 6 I-Brand
relaxants NNS 1 0 13 I-Brand
( ( 0 0 2 O
eg JJ 0 1 UNK O
tubocurarine NN 0 1 UNK B-Drug
) ) 0 0 2 O
and CC 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
including VBG 1 1 1 O
ether RB 0 1 UNK O
succinylcholine JJ 0 1 16 B-Drug
gallamine NN 0 1 UNK B-Drug
decamethonium NN 0 1 UNK B-Drug
and CC 0 0 12 O
sodium NN 0 1 14 B-Drug
citrate NN 0 1 14 I-Drug
potentiate VBP 0 0 UNK O
the DT 0 0 12 O
neuromuscular JJ 0 1 6 O
blocking NN 0 1 UNK O
effect NN 0 1 1 O
and CC 0 0 12 O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
with IN 0 0 12 O
extreme JJ 0 1 1 O
caution NN 0 0 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
being VBG 1 0 12 O
treated VBN 1 1 1 O
with IN 0 0 12 O
Coly NNP 0 1 UNK B-Brand
- : 0 0 2 O
Mycin NNP 0 0 UNK I-Brand
M NNP 0 1 2 I-Brand
Parenteral NNP 0 1 UNK O
. . 0 0 12 O

these DT 0 0 12 O
may MD 0 0 1 O
also RB 0 0 12 O
occur VB 0 1 1 O
in IN 0 0 12 O
neonates NNS 1 1 16 O
whose WP$ 0 0 12 O
mothers NNS 1 1 UNK O
received VBD 1 1 12 O
cephalosporins NNS 1 1 14 B-Group
before IN 0 1 12 O
delivery NN 0 1 1 O
. . 0 0 12 O

During IN 0 0 2 O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
iloprost NN 0 1 13 B-Drug
was VBD 1 0 12 O
used VBN 1 1 12 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
anticoagulants NNS 1 1 13 B-Group
diuretics NNS 1 1 14 B-Group
cardiac JJ 0 1 6 B-Group
glycosides NNS 1 1 13 I-Group
calcium NN 0 1 14 B-Group
channel NN 0 1 1 I-Group
blockers NNS 1 0 6 I-Group
analgesics VBP 0 1 14 B-Group
antipyretics NNS 1 1 13 B-Group
nonsteroidal JJ 0 0 14 B-Group
antiinflammatories NNS 0 1 UNK I-Group
corticosteroids NNS 1 1 14 B-Group
and CC 0 0 12 O
other JJ 0 0 12 O
medications NNS 1 1 6 O
. . 0 0 12 O

diazoxide NN 0 1 16 B-Drug
; : 0 0 2 O

Extreme JJ 0 1 2 O
caution NN 0 0 1 O
should MD 0 0 12 O
be VB 0 0 12 O
exercised VBN 1 1 1 O
when WRB 0 0 12 O
administering VBG 1 1 1 O
TAXOL NNP 0 1 UNK B-Brand
to TO 0 0 12 O
such JJ 0 0 1 O
patients NNS 1 1 6 O
with IN 0 0 12 O
dose JJ 0 1 6 O
reduction NN 0 1 1 O
as IN 1 0 12 O
recommended VBN 1 1 1 O
in IN 0 0 12 O
DOSAGE NNP 0 1 UNK O
AND NNP 0 0 11 O
ADMINISTRATION NNP 0 1 11 O
Table NNP 0 1 UNK O
9 CD 0 0 2 O
. . 0 0 12 O

Anticoagulants NNS 0 1 UNK B-Group
: : 0 0 2 O
Combination NNP 0 1 UNK O
hormonal JJ 0 1 6 B-Group
contraceptives NNS 1 1 13 I-Group
may MD 0 0 1 O
increase VB 0 1 1 O
or CC 0 0 12 O
decrease VB 0 1 1 O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
coumarin NN 0 1 UNK B-Group
derivatives NNS 1 1 13 I-Group
. . 0 0 12 O

In IN 0 0 2 O
simultaneous JJ 0 1 13 O
treatment NN 0 1 6 O
with IN 0 0 12 O
imidazole JJ 0 1 UNK B-Group
drugs NNS 1 1 6 I-Group
and CC 0 0 12 O
coumarin NN 0 1 UNK B-Group
drugs NNS 1 1 6 I-Group
the DT 0 0 12 O
anticoagulant JJ 0 1 13 O
effect NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
carefully RB 0 0 12 O
titrated VBN 1 1 14 O
and CC 0 0 12 O
monitored VBN 1 1 1 O
. . 0 0 12 O

Response NN 0 1 UNK O
to TO 0 0 12 O
Treatment NNP 0 1 7 O
for IN 0 0 12 O
Anaphylactic NNP 0 1 UNK O
Reaction NNP 0 1 UNK O
: : 0 0 2 O
While IN 0 0 12 O
taking VBG 1 0 12 O
beta SYM 0 1 16 B-Group
- : 0 0 2 O
blockers NNS 1 0 6 I-Group
patients NNS 1 1 6 O
with IN 0 0 12 O
a DT 0 0 12 O
history NN 0 1 12 O
of IN 0 0 12 O
severe JJ 0 1 6 O
anaphylactic JJ 0 1 13 O
reaction NN 0 1 1 O
to TO 0 0 12 O
a DT 0 0 12 O
variety NN 0 1 1 O
of IN 0 0 12 O
allergens NNS 1 1 13 O
may MD 0 0 1 O
be VB 0 0 12 O
more RBR 0 1 12 O
reactive JJ 0 1 1 O
to TO 0 0 12 O
repeated VBN 1 1 1 O
challenge NN 0 1 12 O
either CC 0 1 12 O
accidental JJ 0 1 13 O
diagnostic NN 0 1 6 O
or CC 0 0 12 O
therapeutic JJ 0 1 6 O
. . 0 0 12 O

In IN 0 0 2 O
patients NNS 1 1 6 O
with IN 0 0 12 O
chronic JJ 0 1 6 O
hepatitis NN 0 1 6 O
C NNP 0 0 2 O
treated VBD 1 1 1 O
with IN 0 0 12 O
PEGASYS NNP 0 1 UNK B-Brand
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
COPEGUS NNP 0 1 UNK B-Brand
PEGASYS NNP 0 1 UNK B-Brand
treatment NN 0 1 6 O
did VBD 1 0 12 O
not RB 0 1 12 O
affect VB 0 1 1 O
ribavirin JJ 0 1 13 B-Drug
distribution NN 0 1 1 O
or CC 0 0 12 O
clearance NN 0 1 16 O
. . 0 0 12 O

Drugs NNS 0 1 2 O
which WDT 0 0 12 O
inhibit VBP 0 1 13 O
CYP NNP 0 1 UNK O
9A9 CD 0 0 UNK O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
ketoconazole NN 0 1 16 B-Drug
macrolide NN 0 1 UNK B-Group
antibiotics NNS 1 1 6 I-Group
such JJ 0 0 1 O
as IN 1 0 12 O
erythromycin NN 0 1 0 B-Drug
) ) 0 0 2 O
have VBP 0 0 12 O
the DT 0 0 12 O
potential NN 0 1 1 O
to TO 0 0 12 O
result VB 0 1 1 O
in IN 0 0 12 O
increased JJ 0 1 1 O
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
corticosteroids NNS 1 1 14 B-Group
. . 0 0 12 O

The DT 0 0 2 O
resulting VBG 1 1 1 O
increase NN 0 1 1 O
in IN 0 0 12 O
nitrofurantoin JJ 0 1 0 B-Drug
serum NN 0 1 14 O
levels NNS 1 1 1 O
may MD 0 0 1 O
increase VB 0 1 1 O
toxicity NN 0 1 6 O
and CC 0 0 12 O
the DT 0 0 12 O
decreased JJ 0 1 1 O
urinary JJ 0 1 6 O
levels NNS 1 1 1 O
could MD 0 0 12 O
lessen VB 0 0 UNK O
its PRP$ 1 0 12 O
efficacy NN 0 1 UNK O
as IN 1 0 12 O
a DT 0 0 12 O
urinary JJ 0 1 6 O
tract NN 0 1 6 O
antibacterial NN 0 1 UNK B-Group
. . 0 0 12 O

Use NN 0 1 2 O
with IN 0 0 12 O
Angiotensln NNP 0 0 UNK B-Group
Converting NNP 0 0 UNK I-Group
Enzyme NNP 0 1 UNK I-Group
Inhibitors NNS 0 1 7 I-Group
: : 0 0 2 O
The DT 0 0 2 O
use NN 0 1 1 O
of IN 0 0 12 O
angiotensin NN 0 1 UNK B-Group
converting VBG 1 0 UNK I-Group
enzyme JJ 0 1 14 I-Group
inhibitors NNS 1 1 14 I-Group
to TO 0 0 12 O
control VB 0 1 1 O
hypertension NN 0 1 6 O
in IN 0 0 12 O
patients NNS 1 1 6 O
on IN 0 0 12 O
azathioprine NN 0 1 13 B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
induce VB 0 1 6 O
severe JJ 0 1 6 O
leukopenia NN 0 1 UNK O
. . 0 0 12 O

Gold NN 0 1 UNK B-Group
is VBZ 1 0 12 O
excreted VBN 1 1 UNK O
slowly RB 0 1 3 O
from IN 0 0 12 O
the DT 0 0 12 O
body NN 0 1 3 O
. . 0 0 12 O

a DT 0 0 12 O
See NNP 0 1 2 O
Tables NNP 0 1 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
. . 0 0 12 O

The DT 0 0 2 O
effect NN 0 1 1 O
of IN 0 0 12 O
ceftibuten NN 0 1 UNK B-Drug
on IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
theophylline NN 0 1 16 B-Drug
administered VBN 1 1 1 O
orally RB 0 1 14 O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
investigated VBN 1 1 1 O
. . 0 0 12 O

No DT 0 0 2 O
pharmacokinetic JJ 0 1 UNK O
data NNS 0 1 1 O
are VBP 1 0 12 O
available JJ 0 1 1 O
. . 0 0 12 O

Ethosuximide NN 0 1 UNK B-Drug
: : 0 0 2 O
Amphetamines NNS 0 1 UNK B-Group
may MD 0 0 1 O
delay VB 0 1 1 O
intestinal JJ 0 1 13 O
absorption NN 0 1 1 O
of IN 0 0 12 O
ethosuximide NN 0 1 13 B-Drug
. . 0 0 12 O

Aspirin NNP 0 1 0 B-Brand
warfarin NN 0 1 14 B-Drug
heparin NN 0 1 14 B-Drug
NSAIDs NNP 0 1 UNK B-Group

No DT 0 0 2 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
. . 0 0 12 O

A DT 0 0 2 O
pharmacokinetic JJ 0 1 UNK O
study NN 0 1 1 O
demonstrated VBD 1 0 1 O
that IN 0 0 12 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
megestrol NN 0 1 16 B-Drug
acetate NN 0 1 14 I-Drug
and CC 0 0 12 O
indinavir JJ 0 1 16 B-Drug
results NNS 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
significant JJ 0 1 1 O
decrease NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetic JJ 0 1 UNK O
parameters NNS 1 1 1 O
( ( 0 0 2 O
~9 CD 0 0 UNK O
% NN 0 0 18 O
for IN 0 0 12 O
Cmax NNP 0 1 UNK O
and CC 0 0 12 O
~9 NNP 0 0 UNK O
% NN 0 0 18 O
for IN 0 0 12 O
AUC NNP 0 1 UNK O
) ) 0 0 2 O
of IN 0 0 12 O
indinavir NN 0 1 16 B-Drug
. . 0 0 12 O

Hematopoietic JJ 0 1 UNK O

Therefore RB 0 0 1 O
the DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
corticosteroid NN 0 1 UNK B-Group
should MD 0 0 12 O
be VB 0 0 12 O
titrated VBN 1 1 14 O
to TO 0 0 12 O
avoid VB 0 0 12 O
steroid JJ 0 1 6 O
toxicity NN 0 1 6 O
. . 0 0 12 O

Phenytoin NNP 0 1 0 B-Drug
is VBZ 1 0 12 O
a DT 0 0 12 O
potent JJ 0 1 UNK O
inducer NN 0 1 UNK O
of IN 0 0 12 O
hepatic JJ 0 1 14 O
drug NN 0 1 1 O
- : 0 0 2 O
metabolizing NN 0 0 UNK O
enzymes NNS 1 1 14 O
. . 0 0 12 O

No DT 0 0 2 O
formal JJ 0 1 1 O
drug NN 0 1 1 O
- : 0 0 2 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
however RB 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
conducted VBN 1 1 1 O
. . 0 0 12 O

Ketoconazole NNP 0 1 UNK B-Drug
increased VBD 1 1 1 O
mean JJ 0 1 12 O
alosetron NN 0 1 UNK B-Drug
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
( ( 0 0 2 O
AUC NNP 0 1 UNK O
) ) 0 0 2 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

Catecholamine NNP 0 1 UNK O
- : 0 0 2 O
depleting NN 0 1 UNK O
drugs NNS 1 1 6 O
( ( 0 0 2 O
e.g. FW 0 0 UNK O
reserpine NN 0 1 UNK B-Drug
) ) 0 0 2 O
may MD 0 0 1 O
have VB 0 0 12 O
an DT 0 0 12 O
additive JJ 0 1 16 O
effect NN 0 1 1 O
when WRB 0 0 12 O
given VBN 1 1 12 O
with IN 0 0 12 O
beta JJ 0 1 16 B-Drug
- : 0 0 2 O
blocking VBG 1 1 UNK I-Drug
agents NNS 1 1 1 O
. . 0 0 12 O

This DT 0 0 2 O
slowing VBG 1 1 1 O
potentiates NNS 0 0 UNK O
amphetamines NNS 1 1 14 B-Group
increasing VBG 1 1 1 O
their PRP$ 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
release NN 0 1 12 O
of IN 0 0 12 O
norepinephrine NN 0 1 14 O
and CC 0 0 12 O
other JJ 0 0 12 O
monoamines NNS 1 1 UNK O
from IN 0 0 12 O
adrenergic JJ 0 1 UNK O
nerve NN 0 1 6 O
endings NNS 1 1 UNK O
; : 0 0 2 O

Nevertheless RB 0 0 1 O
plasma JJ 0 1 14 O
lithium NN 0 1 16 B-Drug
levels NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
with IN 0 0 12 O
appropriate JJ 0 1 1 O
adjustment NN 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
lithium NN 0 1 16 B-Drug
dose NN 0 1 6 O
in IN 0 0 12 O
accordance NN 0 0 UNK O
with IN 0 0 12 O
standard JJ 0 1 1 O
clinical JJ 0 1 6 O
practice NN 0 1 UNK O
. . 0 0 12 O

Based VBN 0 1 2 O
on IN 0 0 12 O
the DT 0 0 12 O
literature NN 0 1 UNK O
reports VBZ 1 1 1 O
the DT 0 0 12 O
same JJ 0 1 12 O
effects NNS 1 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
extrapolated VBN 1 0 UNK O
to TO 0 0 12 O
other JJ 0 0 12 O
fruit NN 0 1 13 O
juices NNS 1 1 UNK O
such JJ 0 0 1 O
as IN 1 0 12 O
apple NN 0 1 UNK O
juice NN 0 1 3 O
. . 0 0 12 O

In IN 0 0 2 O
bioavailability NN 0 1 UNK O
studies NNS 1 1 1 O
with IN 0 0 12 O
normal JJ 0 1 1 O
subjects NNS 1 1 UNK O
the DT 0 0 12 O
concurrent JJ 0 1 1 O
administration NN 0 1 1 O
of IN 0 0 12 O
antacids NNS 1 1 14 B-Group
at IN 0 0 12 O
therapeutic JJ 0 1 6 O
levels NNS 1 1 1 O
did VBD 1 0 12 O
not RB 0 1 12 O
significantly RB 0 0 1 O
influence VB 0 0 UNK O
the DT 0 0 12 O
bioavailability NN 0 1 UNK O
of IN 0 0 12 O
TRANXENE NNP 0 1 UNK B-Brand
tablets NNS 1 1 3 O
. . 0 0 12 O

Drugs NNS 0 1 2 O
such JJ 0 0 1 O
as IN 1 0 12 O
troleandomycin NN 0 1 UNK B-Drug
and CC 0 0 12 O
ketoconazole NN 0 1 16 B-Drug
may MD 0 0 1 O
inhibit VB 0 1 13 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
corticosteroids NNS 1 1 14 B-Group
and CC 0 0 12 O
thus RB 0 0 1 O
decrease VB 0 1 1 O
their PRP$ 0 0 12 O
clearance NN 0 1 16 O
. . 0 0 12 O

. . 0 0 12 O

Sulfonamides NNS 0 1 15 B-Group
: : 0 0 2 O
Concurrent NNP 0 1 13 O
use NN 0 1 1 O
of IN 0 0 12 O
procaine NN 0 1 UNK B-Drug
hydrochloride NN 0 1 0 I-Drug
and CC 0 0 12 O
sulfonamides NNS 1 1 13 B-Group
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
reduction NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
antibacterial JJ 0 1 UNK O
action NN 0 1 13 O
of IN 0 0 12 O
the DT 0 0 12 O
sulfonamide NN 0 1 UNK B-Group
. . 0 0 12 O

Anticholinergics NNS 0 1 UNK B-Group
antagonize VBP 0 0 UNK O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
antiglaucoma NN 0 0 UNK B-Group
agents NNS 1 1 1 I-Group
. . 0 0 12 O

There EX 0 0 12 O
was VBD 1 0 12 O
no DT 0 0 12 O
evidence NN 0 1 1 O
of IN 0 0 12 O
any DT 0 0 12 O
pharmacokinetic JJ 0 1 UNK O
interactions NNS 1 1 UNK O
between IN 0 0 12 O
ERBITUX NNP 0 1 UNK B-Brand
and CC 0 0 12 O
irinotecan JJ 0 1 13 B-Drug
. . 0 0 12 O

Caution NN 0 0 UNK O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
when WRB 0 0 12 O
administering VBG 1 1 1 O
NEXAVAR NNP 0 1 UNK B-Brand
with IN 0 0 12 O
compounds NNS 1 1 13 O
that WDT 0 0 12 O
are VBP 1 0 12 O
metabolized VBN 1 1 UNK O
/ RB 0 0 2 O
eliminated VBN 1 1 UNK O
predominantly RB 0 0 1 O
by IN 0 0 12 O
the DT 0 0 12 O
UGT9A9 NNP 0 0 UNK O
pathway NN 0 1 UNK O
( ( 0 0 2 O
e.g JJ 0 0 UNK O
. . 0 0 12 O
irinotecan JJ 0 1 13 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

9 CD 0 0 2 O
- : 0 0 2 O
nc NN 0 1 3 O
denotes VBZ 1 0 UNK O
a DT 0 0 12 O
mean JJ 0 1 12 O
change NN 0 1 1 O
of IN 0 0 12 O
less JJR 0 1 12 O
than IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
9 CD 0 0 2 O
- : 0 0 2 O
Pediatrics NNS 0 1 7 O
9 CD 0 0 2 O
- : 0 0 2 O
Mean JJ 0 1 2 O
increase NN 0 1 1 O
in IN 0 0 12 O
adults NNS 1 1 13 O
at IN 0 0 12 O
high JJ 0 1 1 O
Trileptal NNP 0 1 UNK B-Brand
doses NNS 1 1 6 O
In IN 0 0 2 O
vivo NN 0 1 13 O
the DT 0 0 12 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
increased VBN 1 1 1 O
by IN 0 0 12 O
up IN 0 0 12 O
to TO 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
when WRB 0 0 12 O
Trileptal NNP 0 1 UNK B-Brand
was VBD 1 0 12 O
given VBN 1 1 12 O
at IN 0 0 12 O
doses NNS 1 1 6 O
above IN 0 1 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
. . 0 0 12 O

Poor NNP 0 1 2 O
metabolizers NNS 0 0 UNK O
have VBP 0 0 12 O
higher JJR 1 1 1 O
than IN 0 0 12 O
expected VBN 1 1 12 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
( ( 0 0 2 O
TCAs NNP 0 1 UNK B-Group
) ) 0 0 2 O
when WRB 0 0 12 O
given VBN 1 1 12 O
usual JJ 0 1 12 O
doses NNS 1 1 6 O
. . 0 0 12 O

Theophylline NN 0 1 UNK B-Drug
: : 0 0 2 O
The DT 0 0 2 O
effect NN 0 1 1 O
of IN 0 0 12 O
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
fluvoxamine NN 0 1 16 B-Drug
l9 NN 0 1 UNK O
mg FW 0 1 0 O
bid NN 0 0 12 O
on IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
Theophylline NNP 0 1 UNK B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
) ) 0 0 2 O
as IN 1 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
aminophylline NN 0 1 13 B-Drug
was VBD 1 0 12 O
evaluated VBN 1 1 1 O
in IN 0 0 12 O
9 CD 0 0 2 O
healthy JJ 0 1 12 O
non SYM 0 1 1 O
- : 0 0 2 O
smoking VBG 1 1 12 O
male JJ 0 1 12 O
volunteers NNS 1 1 UNK O
. . 0 0 12 O

However RB 0 0 1 O
9 CD 0 0 2 O
patients NNS 1 1 6 O
who WP 0 0 12 O
switched VBD 1 1 12 O
from IN 0 0 12 O
therapy NN 0 1 6 O
with IN 0 0 12 O
Interferon NNP 0 1 0 B-Drug
beta NN 0 1 16 I-Drug
to TO 0 0 12 O
COPAXONE NNP 0 1 UNK B-Brand
did VBD 1 0 12 O
not RB 0 1 12 O
report VB 0 1 1 O
any DT 0 0 12 O
serious JJ 0 1 12 O
and CC 0 0 12 O
unexpected JJ 0 1 12 O
adverse JJ 0 0 1 O
reactions NNS 1 1 1 O
thought VBD 1 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
related VBN 1 1 1 O
to TO 0 0 12 O
treatment NN 0 1 6 O
. . 0 0 12 O

Prolonged VBN 0 1 7 O
menstrual JJ 0 1 6 O
cycles NNS 1 1 1 O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
amenorrhea NN 0 1 UNK O
were VBD 1 0 12 O
observed VBN 1 1 1 O
in IN 0 0 12 O
female JJ 0 1 12 O
cynomolgus NN 0 1 UNK O
monkeys NNS 1 1 UNK O
given VBN 1 1 12 O
sc JJ 0 1 13 O
injections NNS 1 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
m NNS 0 1 2 O
g JJ 0 1 16 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
/ NN 0 0 2 O
dose NN 0 1 6 O
( ( 0 0 2 O
9 CD 0 0 2 O
m NN 0 1 2 O
g NN 0 1 16 O
/ NNP 0 0 2 O
m9 NN 0 1 UNK O
/ NNP 0 0 2 O
dose NN 0 1 6 O
) ) 0 0 2 O
of IN 0 0 12 O
PEGASYS NNP 0 1 UNK B-Brand
every DT 0 0 12 O
other JJ 0 0 12 O
day NN 0 1 12 O
for IN 0 0 12 O
one CD 0 1 12 O
month NN 0 1 12 O
at IN 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
times NNS 1 1 12 O
the DT 0 0 12 O
recommended JJ 0 1 1 O
weekly JJ 0 1 12 O
human NN 0 1 1 O
dose NN 0 1 6 O
for IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
kg NN 0 1 18 O
person NN 0 1 12 O
( ( 0 0 2 O
based VBN 1 1 1 O
on IN 0 0 12 O
body NN 0 1 3 O
surface JJ 0 1 3 O
area NN 0 1 12 O
) ) 0 0 2 O
. . 0 0 12 O

These DT 0 0 1 O
pharmacokinetic JJ 0 1 UNK O
effects NNS 1 1 1 O
did VBD 1 0 12 O
not RB 0 1 12 O
result VB 0 1 1 O
in IN 0 0 12 O
clinically RB 0 0 6 O
meaningful JJ 0 1 1 O
changes NNS 1 1 1 O
in IN 0 0 12 O
ECG NNP 0 1 6 O
heart NN 0 1 12 O
rate NN 0 1 1 O
or CC 0 0 12 O
blood NN 0 1 6 O
pressure NN 0 1 1 O
beyond IN 0 0 12 O
those DT 0 0 12 O
changes NNS 1 1 1 O
induced VBN 1 1 6 O
by IN 0 0 12 O
diltiazem NN 0 1 0 B-Drug
alone RB 0 1 12 O
. . 0 0 12 O

No DT 0 0 2 O
cases NNS 1 1 UNK O
of IN 0 0 12 O
rhabdomyolysis NN 0 1 8 O
were VBD 1 0 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
this DT 0 0 12 O
trial NN 0 1 12 O
. . 0 0 12 O

Warfarin NN 0 1 0 B-Drug
: : 0 0 2 O
Quinolones NNS 0 1 UNK B-Group
may MD 0 0 1 O
enhance VB 0 1 UNK O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
oral JJ 0 1 6 O
anticoagulant JJ 0 1 13 B-Group
warfarin NN 0 1 14 B-Drug
or CC 0 0 12 O
its PRP$ 1 0 12 O
derivatives NNS 1 1 13 O
. . 0 0 12 O

SINCE NNP 0 1 11 O
CHOLESTYRAMINE NNP 0 1 UNK B-Drug
RESIN NNP 0 1 UNK B-Group
MAY NNP 0 0 11 O
BIND NNP 0 1 UNK O
OTHER NNP 0 0 11 O
DRUGS NNP 0 1 UNK O
GIVEN NNP 0 1 11 O
CONCURRENTLY NNP 0 0 UNK O
IT NNP 0 0 UNK O
IS NNP 0 0 11 O
RECOMMENDED NNP 0 1 11 O
THAT IN 0 0 11 O
PATIENTS NNP 0 1 UNK O
TAKE NNP 0 1 11 O
OTHER NNP 0 0 11 O
DRUGS NNP 0 1 UNK O
AT NNP 0 0 11 O
LEAST NNP 0 1 UNK O
9 CD 0 0 2 O
HOUR NNP 0 1 UNK O
BEFORE NNP 0 1 11 O
OR NNP 0 0 11 O
9 CD 0 0 2 O
TO NNP 0 0 11 O
9 CD 0 0 2 O
HOURS NNP 0 1 11 O
AFTER NNP 0 0 11 O
CHOLESTYRAMINE NNP 0 1 UNK B-Drug
RESIN NNP 0 1 UNK B-Group
( ( 0 0 2 O
OR NNP 0 0 11 O
AT NNP 0 0 11 O
AS NNP 0 0 11 O
GREAT NNP 0 1 UNK O
AN NNP 0 0 11 O
INTERVAL NNP 0 1 UNK O
AS NNP 0 0 11 O
POSSIBLE NNP 0 1 UNK O
) ) 0 0 2 O
TO NNP 0 0 11 O
AVOID NNP 0 0 UNK O
IMPEDING NNP 0 0 UNK O
THEIR NNP 0 0 UNK O
ABSORPTION NNP 0 1 UNK O
. . 0 0 12 O

General NNP 0 1 2 O
In IN 0 0 2 O
vitro NN 0 1 UNK O
studies NNS 1 1 1 O
in IN 0 0 12 O
human JJ 0 1 1 O
liver NN 0 1 6 O
microsomes NNS 1 1 UNK O
demonstrated VBD 1 0 1 O
no DT 0 0 12 O
evidence NN 0 1 1 O
of IN 0 0 12 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
- : 0 0 2 O
mediated VBN 1 1 13 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
that WDT 0 0 12 O
are VBP 1 0 12 O
likely JJ 0 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
of IN 0 0 12 O
clinical JJ 0 1 6 O
relevance NN 0 1 UNK O
. . 0 0 12 O

In IN 0 0 2 O
addition NN 0 1 1 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
are VBP 1 0 12 O
actively RB 0 0 1 O
secreted VBN 1 1 14 O
via IN 0 0 1 O
this DT 0 0 12 O
route NN 0 1 12 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
triamterene NN 0 1 13 B-Drug
metformin NN 0 1 0 B-Drug
and CC 0 0 12 O
amiloride NN 0 1 16 B-Drug
) ) 0 0 2 O
should MD 0 0 12 O
be VB 0 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
with IN 0 0 12 O
care NN 0 1 12 O
as IN 1 0 12 O
they PRP 0 0 12 O
might MD 0 0 12 O
increase VB 0 1 1 O
dofetilide NN 0 1 13 B-Drug
levels NNS 1 1 1 O
. . 0 0 12 O

This DT 0 0 2 O
interference NN 0 1 13 O
has VBZ 1 0 12 O
resulted VBN 1 1 1 O
in IN 0 0 12 O
significant JJ 0 1 1 O
increases NNS 1 1 1 O
in IN 0 0 12 O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
and CC 0 0 12 O
AUC NNP 0 1 UNK O
. . 0 0 12 O

Additional NNP 0 1 2 O
dose NN 0 1 6 O
increases NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
based VBN 1 1 1 O
on IN 0 0 12 O
clinical JJ 0 1 6 O
evaluation NN 0 1 1 O
. . 0 0 12 O

therefore RB 0 0 1 O
nitroglycerin NN 0 1 14 B-Drug
or CC 0 0 12 O
other JJ 0 0 12 O
nitrates NNS 1 1 14 B-Group
( ( 0 0 2 O
as IN 1 0 12 O
used VBN 1 1 12 O
for IN 0 0 12 O
management NN 0 1 1 O
of IN 0 0 12 O
angina NN 0 1 6 O
) ) 0 0 2 O
or CC 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
having VBG 1 0 12 O
vasodilator NN 0 1 14 O
activity NN 0 1 1 O
should MD 0 0 12 O
if IN 0 0 12 O
possible JJ 0 1 1 O
be VB 0 0 12 O
discontinued VBN 1 1 1 O
before IN 0 1 12 O
starting VBG 1 1 12 O
captopril NN 0 1 0 B-Drug
. . 0 0 12 O

During IN 0 0 2 O
concomitant JJ 0 1 6 O
therapy NN 0 1 6 O
with IN 0 0 12 O
NSAIDs NNP 0 1 UNK B-Group
the DT 0 0 12 O
patient NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
observed VBN 1 1 1 O
closely RB 0 0 1 O
for IN 0 0 12 O
signs NNS 1 1 12 O
of IN 0 0 12 O
renal JJ 0 1 6 O
failure NN 0 1 1 O
as RB 0 0 12 O
well RB 0 1 12 O
as IN 1 0 12 O
to TO 0 0 12 O
assure VB 0 0 1 O
diuretic JJ 0 1 14 O
efficacy NN 0 1 UNK O
. . 0 0 12 O

ACE JJ 0 1 13 B-Group
inhibitors NNS 1 1 14 I-Group
: : 0 0 2 O
Reports NNS 0 1 2 O
suggest VBP 0 1 1 O
that IN 0 0 12 O
NSAIDs NNP 0 1 UNK B-Group
may MD 0 0 1 O
diminish VB 0 1 UNK O
the DT 0 0 12 O
antihypertensive JJ 0 1 14 O
effect NN 0 1 1 O
of IN 0 0 12 O
Angiotensin NNP 0 1 UNK B-Group
Converting NNP 0 0 UNK I-Group
Enzyme NNP 0 1 UNK I-Group
ACE NNP 0 1 13 I-Group
inhibitors NNS 1 1 14 I-Group
. . 0 0 12 O

Therefore RB 0 0 1 O
Clozapine NNP 0 1 0 B-Drug
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
with IN 0 0 12 O
other JJ 0 0 12 O
agents NNS 1 1 1 O
having VBG 1 0 12 O
a DT 0 0 12 O
well RB 0 1 12 O
- : 0 0 2 O
known VBN 1 1 12 O
potential JJ 0 1 1 O
to TO 0 0 12 O
suppress VB 0 1 1 O
bone NN 0 1 6 O
marrow NN 0 1 6 O
function NN 0 1 1 O
. . 0 0 12 O

Furthermore RB 0 0 1 O
rifampin NN 0 1 16 B-Drug
dexamethasone NN 0 1 16 B-Drug
St NNP 0 1 2 O
. . 0 0 12 O

Although IN 0 0 12 O
other JJ 0 0 12 O
hormonal JJ 0 1 6 B-Group
contraceptives NNS 1 1 13 I-Group
are VBP 1 0 12 O
highly RB 0 1 1 O
effective JJ 0 1 1 O
there EX 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reports NNS 1 1 1 O
of IN 0 0 12 O
pregnancy NN 0 1 6 O
from IN 0 0 12 O
women NNS 1 1 UNK O
who WP 0 0 12 O
have VBP 0 0 12 O
used VBN 1 1 12 O
combined VBN 1 1 1 B-Group
oral JJ 0 1 6 I-Group
contraceptives NNS 1 1 13 I-Group
as RB 0 0 12 O
well RB 0 1 12 O
as IN 1 0 12 O
topical JJ 0 1 6 O
/ NNP 0 0 2 O
injectable JJ 0 1 UNK O
/ NNP 0 0 2 O
implantable JJ 0 1 13 O
/ NNP 0 0 2 O
insertable JJ 0 0 UNK O
hormonal JJ 0 1 6 O
birth NN 0 1 12 O
control NN 0 1 1 O
products NNS 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
concurrent NN 0 1 1 O
use NN 0 1 1 O
of IN 0 0 12 O
tetracycline NN 0 1 0 B-Group
and CC 0 0 12 O
methoxyflurane NN 0 1 UNK B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
result VB 0 1 1 O
in IN 0 0 12 O
fatal JJ 0 1 13 O
renal JJ 0 1 6 O
toxicity NN 0 1 6 O
. . 0 0 12 O

Ketamine NN 0 1 UNK B-Drug
: : 0 0 2 O
Marked VBN 0 1 2 O
hypertension NN 0 1 6 O
and CC 0 0 12 O
tachycardia NN 0 1 8 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
association NN 0 1 1 O
with IN 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
levothyroxine JJ 0 1 0 B-Drug
sodium NN 0 1 14 I-Drug
and CC 0 0 12 O
ketamine NN 0 1 13 B-Drug
. . 0 0 12 O

No DT 0 0 2 O
specific JJ 0 1 1 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
conducted VBN 1 1 1 O
. . 0 0 12 O

No DT 0 0 2 O
reported VBD 1 1 1 O
interactions NNS 1 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
results NNS 1 1 1 O
from IN 0 0 12 O
a DT 0 0 12 O
study NN 0 1 1 O
in IN 0 0 12 O
which WDT 0 0 12 O
eight CD 0 1 12 O
HIV NNP 0 1 6 O
- : 0 0 2 O
infected JJ 0 1 6 O
individuals NNS 1 1 1 O
were VBD 1 0 12 O
treated VBN 1 1 1 O
with IN 0 0 12 O
zidovudine NN 0 1 13 B-Drug
9 CD 0 0 2 O
+ NN 0 0 2 O
/ NNP 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
/ NNP 0 0 2 O
day NN 0 1 12 O
showed VBD 1 1 12 O
that IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
zidovudine NN 0 1 13 B-Drug
were VBD 1 0 12 O
not RB 0 1 12 O
affected VBN 1 1 1 O
during IN 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
Itraconazole NNP 0 1 UNK B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
b.i.d NN 0 1 UNK O
. . 0 0 12 O

No DT 0 0 2 O
formal JJ 0 1 1 O
drug NN 0 1 1 O
/ NNP 0 0 2 O
laboratory NN 0 1 1 O
test NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
conducted VBN 1 1 1 O
with IN 0 0 12 O
CLOLAR NNP 0 1 UNK B-Brand
. . 0 0 12 O

Catecholamine NNP 0 1 UNK O
- : 0 0 2 O
depleting VBG 1 1 UNK O
Agents NNS 0 1 2 O
: : 0 0 2 O
Patients NNS 0 1 7 O
taking VBG 1 0 12 O
both DT 0 0 12 O
agents NNS 1 1 1 B-Group
with IN 0 0 12 I-Group
b SYM 0 0 16 I-Group
- : 0 0 2 O
blocking NN 0 1 UNK I-Group
properties NNS 1 1 UNK I-Group
and CC 0 0 12 O
a DT 0 0 12 O
drug NN 0 1 1 O
that WDT 0 0 12 O
can MD 0 0 12 O
deplete VB 0 1 13 O
catecholamines NNS 1 1 14 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
reserpine NN 0 1 UNK B-Drug
and CC 0 0 12 O
monoamine JJ 0 1 13 B-Group
oxidase NN 0 1 13 I-Group
inhibitors NNS 1 1 14 I-Group
) ) 0 0 2 O
should MD 0 0 12 O
be VB 0 0 12 O
observed VBN 1 1 1 O
closely RB 0 0 1 O
for IN 0 0 12 O
signs NNS 1 1 12 O
of IN 0 0 12 O
hypotension NN 0 1 6 O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
severe JJ 0 1 6 O
bradycardia NN 0 1 8 O
. . 0 0 12 O

Free JJ 0 1 2 O
T9 NNP 0 1 13 O
resin NN 0 1 UNK O
uptake NN 0 1 14 O
is VBZ 1 0 12 O
decreased VBN 1 1 1 O
reflecting VBG 1 1 1 O
the DT 0 0 12 O
elevated JJ 0 1 1 O
TBG NNP 0 1 UNK O
; : 0 0 2 O

When WRB 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
ketoconazole NN 0 1 16 B-Drug
with IN 0 0 12 O
aripiprazole JJ 0 1 16 B-Drug
occurs NNS 0 1 1 O
aripiprazole VBP 0 1 16 B-Drug
dose NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
reduced VBN 1 1 1 O
to TO 0 0 12 O
one CD 0 1 12 O
- : 0 0 2 O
half NN 0 1 12 O
of IN 0 0 12 O
its PRP$ 1 0 12 O
normal JJ 0 1 1 O
dose NN 0 1 6 O
. . 0 0 12 O

Nursing VBG 0 1 2 O
Mothers NNS 0 1 UNK O
It PRP 0 0 12 O
is VBZ 1 0 12 O
not RB 0 1 12 O
known VBN 1 1 12 O
whether IN 0 0 12 O
peginterferon NN 0 1 13 B-Drug
or CC 0 0 12 O
ribavirin NN 0 1 13 B-Drug
or CC 0 0 12 O
its PRP$ 1 0 12 O
components NNS 1 1 1 O
are VBP 1 0 12 O
excreted VBN 1 1 UNK O
in IN 0 0 12 O
human JJ 0 1 1 O
milk NN 0 1 3 O
. . 0 0 12 O

Frequent JJ 0 1 2 O
vital JJ 0 1 1 O
sign NN 0 1 12 O
monitoring VBG 1 1 1 O
particularly RB 0 0 1 O
during IN 0 0 12 O
the DT 0 0 12 O
first JJ 0 1 12 O
hour NN 0 1 12 O
of IN 0 0 12 O
TAXOL NNP 0 1 UNK B-Brand
infusion NN 0 1 14 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O

Clinical JJ 0 1 7 O
Comment NN 0 1 2 O

An DT 0 0 2 O
individual NN 0 1 1 O
who WP 0 0 12 O
is VBZ 1 0 12 O
stable JJ 0 1 1 O
on IN 0 0 12 O
a DT 0 0 12 O
given VBN 1 1 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
TCA NNP 0 1 13 B-Group
may MD 0 0 1 O
become VB 0 0 12 O
abruptly RB 0 0 UNK O
toxic JJ 0 1 1 O
when WRB 0 0 12 O
given VBN 1 1 12 O
one CD 0 1 12 O
of IN 0 0 12 O
these DT 0 0 12 O
inhibiting VBG 1 1 UNK O
drugs NNS 1 1 6 O
as IN 1 0 12 O
concomitant NN 0 1 6 O
therapy NN 0 1 6 O
. . 0 0 12 O

Clinical JJ 0 1 7 O
Laboratory NN 0 1 2 O

There EX 0 0 12 O
was VBD 1 0 12 O
no DT 0 0 12 O
apparent JJ 0 1 1 O
pharmacokinetic JJ 0 1 UNK O
interaction NN 0 1 UNK O
between IN 0 0 12 O
zaleplon NN 0 1 13 B-Drug
and CC 0 0 12 O
ibuprofen NN 0 1 0 B-Drug
following VBG 1 1 1 O
single JJ 0 1 12 O
dose JJ 0 1 6 O
administration NN 0 1 1 O
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
and CC 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
respectively RB 0 0 1 O
) ) 0 0 2 O
of IN 0 0 12 O
each DT 0 0 12 O
drug NN 0 1 1 O
. . 0 0 12 O

Alcohol NN 0 1 2 B-Drug
: : 0 0 2 O
Has VBZ 0 0 2 O
a DT 0 0 12 O
synergistic JJ 0 1 UNK O
effect NN 0 1 1 O
with IN 0 0 12 O
aspirin NN 0 1 14 B-Brand
in IN 0 0 12 O
causing VBG 1 1 1 O
gastrointestinal JJ 0 1 6 O
bleeding NN 0 1 6 O
. . 0 0 12 O

Gabapentin NNP 0 1 0 B-Drug
had VBD 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
naproxen JJ 0 1 16 B-Drug
pharmacokinetic JJ 0 1 UNK O
parameters NNS 1 1 1 O
. . 0 0 12 O

Oxcarbazepine NNP 0 1 UNK B-Drug
was VBD 1 0 12 O
evaluated VBN 1 1 1 O
in IN 0 0 12 O
human JJ 0 1 1 O
liver NN 0 1 6 O
microsomes NNS 1 1 UNK O
to TO 0 0 12 O
determine VB 0 0 1 O
its PRP$ 1 0 12 O
capacity NN 0 1 1 O
to TO 0 0 12 O
inhibit VB 0 1 13 O
the DT 0 0 12 O
major JJ 0 1 1 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
enzymes VBZ 0 1 14 O
responsible JJ 0 1 1 O
for IN 0 0 12 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

increased VBN 1 1 1 O
serum NN 0 1 14 O
digoxin NN 0 1 14 B-Drug
concentrations NNS 1 1 13 O
may MD 0 0 1 O
result VB 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
CNS NNP 0 1 6 O
depressant JJ 0 0 UNK O
effects NNS 1 1 1 O
of IN 0 0 12 O
oxycodone NN 0 1 0 B-Drug
hydrochloride NN 0 1 0 I-Drug
may MD 0 0 1 O
be VB 0 0 12 O
additive JJ 0 1 16 O
with IN 0 0 12 O
that DT 0 0 12 O
of IN 0 0 12 O
other JJ 0 0 12 O
CNS NNP 0 1 6 B-Group
depressants NNS 1 0 13 I-Group
.. VBP 0 0 UNK O

. . 0 0 12 O

The DT 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
naproxen NN 0 1 16 B-Drug
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
increased JJ 0 1 1 O
urinary JJ 0 1 6 O
values NNS 1 1 1 O
for IN 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
ketogenic JJ 0 1 UNK O
steroids NNS 1 1 6 O
because IN 0 0 12 O
of IN 0 0 12 O
an DT 0 0 12 O
interaction NN 0 1 UNK O
between IN 0 0 12 O
the DT 0 0 12 O
drug NN 0 1 1 O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
its PRP$ 1 0 12 O
metabolites NNS 1 1 UNK O
with IN 0 0 12 O
m JJ 0 1 2 O
- : 0 0 2 O
dinitrobenzene NN 0 1 UNK O
used VBN 1 1 12 O
in IN 0 0 12 O
this DT 0 0 12 O
assay NN 0 1 14 O
. . 0 0 12 O

Methazolamide NNP 0 1 UNK B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
with IN 0 0 12 O
caution NN 0 0 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
on IN 0 0 12 O
steroid JJ 0 1 6 O
therapy NN 0 1 6 O
because IN 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
potential NN 0 1 1 O
for IN 0 0 12 O
developing VBG 1 0 1 O
hypokalemia NN 0 1 14 O
. . 0 0 12 O

The DT 0 0 2 O
physician NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
cautious JJ 0 0 UNK O
when WRB 0 0 12 O
administering VBG 1 1 1 O
flurbiprofen NN 0 1 16 B-Drug
to TO 0 0 12 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
anticoagulants NNS 1 1 13 B-Group
. . 0 0 12 O

Familial NNP 0 1 7 O
hyper SYM 0 1 13 O
- : 0 0 2 O
or CC 0 0 12 O
hypo VB 0 0 13 O
- : 0 0 2 O
thyroxine NN 0 1 14 O
- : 0 0 2 O
binding VBG 1 1 1 O
- : 0 0 2 O
globulinemias NN 0 0 UNK O
have VBP 0 0 12 O
been VBN 1 0 12 O
described VBN 1 1 1 O
. . 0 0 12 O

Clarithromycin NN 0 1 UNK B-Drug

Psychoactive JJ 0 0 UNK B-Group
Drugs NNS 0 1 2 I-Group
: : 0 0 2 O
Hallucinations NNS 0 1 UNK O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
when WRB 0 0 12 O
TORADOL NNP 0 1 UNK B-Brand
was VBD 1 0 12 O
used VBN 1 1 12 O
in IN 0 0 12 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
psychoactive JJ 0 0 UNK B-Group
drugs NNS 1 1 6 I-Group
( ( 0 0 2 O
fluoxetine JJ 0 1 16 B-Drug
thiothixene NN 0 1 13 B-Drug
alprazolam NN 0 1 0 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

Coadministration NN 0 1 UNK O
of IN 0 0 12 O
this DT 0 0 12 O
oral JJ 0 1 6 O
contraceptive NN 0 1 13 B-Group
did VBD 1 0 12 O
not RB 0 1 12 O
influence VB 0 0 UNK O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
levetiracetam NN 0 1 16 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
results NNS 1 1 1 O
were VBD 1 0 12 O
similar JJ 0 1 1 O
with IN 0 0 12 O
and CC 0 0 12 O
without IN 0 0 12 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
thalidomide JJ 0 1 13 B-Drug
9 CD 0 0 2 O
mg JJ 0 1 0 O
/ NNP 0 0 2 O
day NN 0 1 12 O
to TO 0 0 12 O
steady VB 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
levels NNS 1 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
long RB 0 1 12 O
surgical JJ 0 1 6 O
procedures NNS 1 1 1 O
during IN 0 0 12 O
enflurane NN 0 1 UNK B-Drug
or CC 0 0 12 O
isoflurane NN 0 1 UNK B-Drug
anesthesia RB 0 1 6 O
less RBR 0 1 12 O
frequent JJ 0 1 1 O
maintenance NN 0 1 1 O
dosing VBG 1 0 14 O
lower JJR 1 1 1 O
maintenance NN 0 1 1 O
doses NNS 1 1 6 O
or CC 0 0 12 O
reduced JJ 0 1 1 O
infusion NN 0 1 14 O
rates NNS 1 1 1 O
of IN 0 0 12 O
NIMBEX NNP 0 1 UNK B-Brand
may MD 0 0 1 O
be VB 0 0 12 O
necessary JJ 0 0 1 O
. . 0 0 12 O

Correlative JJ 0 1 UNK O
clinical JJ 0 1 6 O
studies NNS 1 1 1 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
performed VBN 1 1 1 O
. . 0 0 12 O

Patients NNS 0 1 7 O
using VBG 1 1 1 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
studied VBN 1 0 1 O
in IN 0 0 12 O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
. . 0 0 12 O

Protease NN 0 1 UNK B-Group
Inhibitors NNS 0 1 7 I-Group
: : 0 0 2 O
In IN 0 0 2 O
vitro NN 0 1 UNK O
data NNS 0 1 1 O
indicate VBP 0 0 1 O
that IN 0 0 12 O
indinavir NN 0 1 16 B-Drug
and CC 0 0 12 O
ritonavir NN 0 1 16 B-Drug
markedly RB 0 1 1 O
inhibit VBZ 0 1 13 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
cisapride NN 0 1 UNK B-Drug
which WDT 0 0 12 O
can MD 0 0 12 O
result VB 0 1 1 O
in IN 0 0 12 O
an DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
plasma JJ 0 1 14 O
cisapride NN 0 1 UNK B-Drug
levels NNS 1 1 1 O
and CC 0 0 12 O
prolongation NN 0 1 6 O
of IN 0 0 12 O
the DT 0 0 12 O
QT NNP 0 1 13 O
interval NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
ECG NNP 0 1 6 O
. . 0 0 12 O

Coumarin JJ 0 1 UNK B-Group
Anticoagulants NNS 0 1 UNK I-Group
: : 0 0 2 O
In IN 0 0 2 O
a DT 0 0 12 O
small JJ 0 1 12 O
clinical JJ 0 1 6 O
trial NN 0 1 12 O
in IN 0 0 12 O
which WDT 0 0 12 O
lovastatin NN 0 1 13 B-Drug
was VBD 1 0 12 O
administered VBN 1 1 1 O
to TO 0 0 12 O
warfarin VB 0 1 14 B-Drug
treated JJ 0 1 1 O
patients NNS 1 1 6 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
prothrombin NN 0 1 14 O
time NN 0 1 12 O
was VBD 1 0 12 O
detected VBN 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
concurrent NN 0 1 1 O
use NN 0 1 1 O
of IN 0 0 12 O
Robinul NNP 0 1 UNK B-Brand
Injection NNP 0 1 7 O
with IN 0 0 12 O
other JJ 0 0 12 O
anticholinergics NNS 1 1 13 B-Group
or CC 0 0 12 O
medications NNS 1 1 6 O
with IN 0 0 12 O
anticholinergic JJ 0 1 13 O
activity NN 0 1 1 O
such JJ 0 0 1 O
as IN 1 0 12 O
phenothiazines NNS 1 1 UNK B-Group
antiparkinson VBP 0 0 UNK B-Group
drugs NNS 1 1 6 I-Group
or CC 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
may MD 0 0 1 O
intensify VB 0 0 UNK O
the DT 0 0 12 O
antimuscarinic JJ 0 1 UNK O
effects NNS 1 1 1 O
and CC 0 0 12 O
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
an DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
anticholinergic JJ 0 1 13 O
side NN 0 1 3 O
effects NNS 1 1 1 O
. . 0 0 12 O

Caution NN 0 0 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
if IN 0 0 12 O
INDOCIN NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
administered VBN 1 1 1 O
simultaneously RB 0 1 13 O
with IN 0 0 12 O
methotrexate NN 0 1 16 B-Drug
. . 0 0 12 O

Brain NNP 0 1 2 O
hemorrhage NN 0 1 6 O
and CC 0 0 12 O
optic JJ 0 1 3 O
nerve NN 0 1 6 O
vacuolation NN 0 1 UNK O
were VBD 1 0 12 O
seen VBN 1 1 12 O
in IN 0 0 12 O
another DT 0 0 12 O
female JJ 0 1 12 O
dog NN 0 1 12 O
that WDT 0 0 12 O
was VBD 1 0 12 O
sacrificed VBN 1 1 UNK O
in IN 0 0 12 O
moribund NN 0 1 UNK O
condition NN 0 1 1 O
after IN 0 0 12 O
9 CD 0 0 2 O
weeks NNS 1 1 12 O
of IN 0 0 12 O
escalating VBG 1 0 UNK O
doses NNS 1 1 6 O
up RB 0 0 12 O
to TO 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
kg JJ 0 1 18 O
/ NNP 0 0 2 O
day NN 0 1 12 O
. . 0 0 12 O

Therefore RB 0 0 1 O
linezolid NN 0 1 0 B-Drug
has VBZ 1 0 12 O
the DT 0 0 12 O
potential NN 0 1 1 O
for IN 0 0 12 O
interaction NN 0 1 UNK O
with IN 0 0 12 O
adrenergic JJ 0 1 UNK B-Group
and CC 0 0 12 O
serotonergic JJ 0 0 UNK B-Group
agents NNS 1 1 1 I-Group
. . 0 0 12 O

Probenecid NN 0 1 UNK B-Drug
: : 0 0 2 O
Probenecid NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
known VBN 1 1 12 O
to TO 0 0 12 O
interact VB 0 0 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
or CC 0 0 12 O
renal JJ 0 1 6 O
tubular JJ 0 1 3 O
excretion NN 0 1 14 O
of IN 0 0 12 O
many JJ 0 0 12 O
drugs NNS 1 1 6 O
( ( 0 0 2 O
e.g. NN 0 0 UNK O
acetaminophen NN 0 1 16 B-Drug
acyclovir NN 0 1 0 B-Drug
angiotensin SYM 0 1 UNK B-Group
- : 0 0 2 O
converting VBG 1 0 UNK I-Group
enzyme JJ 0 1 14 I-Group
inhibitors NNS 1 1 14 I-Group
aminosalicylic JJ 0 0 UNK B-Drug
acid VBP 0 1 14 I-Drug
barbiturates NNS 1 1 14 B-Group
benzodiazepines NNS 1 1 14 B-Group
bumetanide RB 0 1 16 B-Drug
clofibrate VBP 0 1 UNK B-Drug
methotrexate JJ 0 1 16 B-Drug
famotidine NN 0 1 0 B-Drug
furosemide NN 0 1 0 B-Drug
nonsteroidal IN 0 0 14 B-Group
anti JJ 0 0 3 I-Group
- : 0 0 2 O
inflammatory NN 0 1 6 I-Group
agents NNS 1 1 1 O
theophylline JJ 0 1 16 B-Drug
and CC 0 0 12 O
zidovudine NN 0 1 13 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

Probenecid NN 0 1 UNK B-Drug
: : 0 0 2 O
As IN 0 0 2 O
with IN 0 0 12 O
other JJ 0 0 12 O
b SYM 0 0 16 B-Group
- : 0 0 2 O
lactam NN 0 1 UNK I-Group
antibiotics NNS 1 1 6 I-Group
probenecid VBP 0 1 13 B-Drug
inhibits VBZ 1 1 UNK O
the DT 0 0 12 O
renal JJ 0 1 6 O
excretion NN 0 1 14 O
of IN 0 0 12 O
cefdinir NN 0 1 UNK B-Drug
resulting VBG 1 1 1 O
in IN 0 0 12 O
an DT 0 0 12 O
approximate JJ 0 1 1 O
doubling NN 0 1 13 O
in IN 0 0 12 O
A.C. NNP 0 0 UNK O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
increase NN 0 1 1 O
in IN 0 0 12 O
peak JJ 0 1 1 O
cefdinir NN 0 1 UNK B-Drug
plasma NN 0 1 14 O
levels NNS 1 1 1 O
and CC 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
prolongation NN 0 1 6 O
in IN 0 0 12 O
the DT 0 0 12 O
apparent JJ 0 1 1 O
elimination NN 0 1 UNK O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
. . 0 0 12 O

Nucleoside NNP 0 1 UNK O
Analogues NNP 0 1 UNK O
Didanosine NNP 0 1 0 B-Drug
Co NNP 0 1 2 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
COPEGUS NNP 0 1 UNK B-Brand
and CC 0 0 12 O
didanosine NN 0 1 16 B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O

- : 0 0 2 O
Drugs NNS 0 1 2 O
that WDT 0 0 12 O
may MD 0 0 1 O
either VB 0 1 12 O
increase NN 0 1 1 O
or CC 0 0 12 O
decrease VB 0 1 1 O
plasma JJ 0 1 14 O
phenytoin JJ 0 1 16 B-Drug
concentrations NNS 1 1 13 O
include VBP 0 1 1 O
: : 0 0 2 O
phenobarbital JJ 0 1 16 B-Drug
vaiproic NN 0 0 UNK O
acid NN 0 1 14 O
and CC 0 0 12 O
sodium NN 0 1 14 B-Drug
valproate NN 0 1 16 I-Drug
. . 0 0 12 O

The DT 0 0 2 O
actions NNS 1 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
benzodiazepines NNS 1 1 14 B-Group
may MD 0 0 1 O
be VB 0 0 12 O
potentiated VBN 1 0 UNK O
by IN 0 0 12 O
barbiturates NNS 1 1 14 B-Group
narcotics NNS 1 1 1 B-Group
phenothiazines NNS 1 1 UNK B-Group
monoamine VBP 0 1 13 B-Group
oxidase JJ 0 1 13 I-Group
inhibitors NNS 1 1 14 I-Group
or CC 0 0 12 O
other JJ 0 0 12 O
antidepressants NNS 1 1 13 B-Group
. . 0 0 12 O

periodic JJ 0 1 1 O
systemic JJ 0 1 6 O
blood NN 0 1 6 O
pressure NN 0 1 1 O
monitoring NN 0 1 1 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
for IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
concomitant JJ 0 1 6 O
antihypertensive JJ 0 1 14 O
therapy NN 0 1 6 O
. . 0 0 12 O

- : 0 0 2 O
a DT 0 0 12 O
nonsteroidal JJ 0 0 14 B-Group
anti NN 0 0 3 I-Group
- : 0 0 2 O
inflammatory JJ 0 1 6 I-Group
drug NN 0 1 1 I-Group
( ( 0 0 2 O
NSAID NNP 0 1 14 B-Group
) ) 0 0 2 O
such JJ 0 0 1 O
as IN 1 0 12 O
ibuprofen NN 0 1 0 B-Drug
( ( 0 0 2 O
Motrin NNP 0 1 0 B-Brand
Advil NNP 0 1 0 B-Brand
Nuprin NNP 0 1 UNK B-Brand
others NNS 0 1 12 O
) ) 0 0 2 O
ketoprofen NN 0 1 UNK B-Drug
( ( 0 0 2 O
Orudis NNP 0 1 UNK B-Brand
Orudis NNP 0 1 UNK B-Brand
KT NNP 0 1 13 I-Brand
Oruvail NNP 0 1 UNK B-Brand
) ) 0 0 2 O
diclofenac NN 0 1 16 B-Drug
( ( 0 0 2 O
Voltaren NNP 0 1 UNK B-Brand
Cataflam NNP 0 1 UNK B-Brand
) ) 0 0 2 O
etodolac NN 0 1 13 B-Drug
( ( 0 0 2 O
Lodine NNP 0 1 UNK B-Brand
) ) 0 0 2 O
indomethacin NN 0 1 14 B-Drug
( ( 0 0 2 O
Indocin NNP 0 1 0 B-Brand
) ) 0 0 2 O
nabumetone NN 0 1 13 B-Drug
( ( 0 0 2 O
Relafen NNP 0 1 0 B-Brand
) ) 0 0 2 O
oxaprozin NN 0 1 UNK B-Drug
( ( 0 0 2 O
Daypro NNP 0 1 UNK B-Brand
) ) 0 0 2 O
and CC 0 0 12 O
naproxen $ 0 1 16 B-Drug
( ( 0 0 2 O
Anaprox NNP 0 1 UNK B-Brand
Naprosyn NNP 0 1 0 B-Brand
Aleve NNP 0 1 UNK B-Brand
) ) 0 0 2 O
; : 0 0 2 O

cimetidine NN 0 1 13 B-Drug
) ) 0 0 2 O
and CC 0 0 12 O
many JJ 0 0 12 O
that WDT 0 0 12 O
are VBP 1 0 12 O
substrates VBZ 0 1 UNK O
for IN 0 0 12 O
P9 NNP 0 1 UNK O
9D9 CD 0 0 UNK O
( ( 0 0 2 O
many JJ 0 0 12 O
other JJ 0 0 12 O
antidepressants NNS 1 1 13 B-Group
phenothiazines NNS 1 1 UNK B-Group
and CC 0 0 12 O
the DT 0 0 12 O
Type NNP 0 1 2 B-Group
9C CD 0 0 UNK I-Group
antiarrhythmics NNS 1 1 UNK I-Group
propafenone NN 0 1 16 B-Drug
and CC 0 0 12 O
flecainide NN 0 1 16 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

Dose NNP 0 1 7 O
modification NN 0 1 1 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
for IN 0 0 12 O
patients NNS 1 1 6 O
who WP 0 0 12 O
are VBP 1 0 12 O
also RB 0 0 12 O
receiving VBG 1 1 1 O
a DT 0 0 12 O
potent NN 0 1 UNK O
CYP NNP 0 1 UNK O
9A9 CD 0 0 UNK O
inducer NN 0 1 UNK O
. . 0 0 12 O

sulindac NN 0 1 13 B-Drug
; : 0 0 2 O

Clarithromycin NN 0 1 UNK B-Drug

Oral JJ 0 1 2 O
Contraceptives NNS 0 1 UNK B-Group
: : 0 0 2 O
In IN 0 0 2 O
9 CD 0 0 2 O
normal JJ 0 1 1 O
- : 0 0 2 O
weight JJ 0 1 3 O
female JJ 0 1 12 O
subjects VBZ 1 1 UNK O
the DT 0 0 12 O
treatment NN 0 1 6 O
of IN 0 0 12 O
XENICAL $ 0 1 UNK B-Brand
9 CD 0 0 2 O
mg NN 0 1 0 O
three CD 0 1 12 O
times NNS 1 1 12 O
a DT 0 0 12 O
day NN 0 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
resulted VBD 1 1 1 O
in IN 0 0 12 O
no DT 0 0 12 O
changes NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
ovulation NN 0 1 13 O
- : 0 0 2 O
suppressing VBG 1 1 1 O
action NN 0 1 13 O
of IN 0 0 12 O
oral JJ 0 1 6 O
contraceptives NNS 1 1 13 B-Group
. . 0 0 12 O

The DT 0 0 2 O
mean JJ 0 1 12 O
AUC NNP 0 1 UNK O
values NNS 1 1 1 O
of IN 0 0 12 O
LNG NNP 0 0 UNK O
were VBD 1 0 12 O
decreased VBN 1 1 1 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
[ JJ 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
CI NNP 0 1 UNK O
: : 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
] NN 0 0 2 O
in IN 0 0 12 O
one CD 0 1 12 O
study NN 0 1 1 O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
[ JJ 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
CI NNP 0 1 UNK O
: : 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
] NN 0 0 2 O
in IN 0 0 12 O
another DT 0 0 12 O
study NN 0 1 1 O
. . 0 0 12 O

Warfarin NN 0 1 0 B-Drug
: : 0 0 2 O
In IN 0 0 2 O
a DT 0 0 12 O
short JJ 0 1 12 O
- : 0 0 2 O
term NN 0 1 1 O
controlled VBD 1 1 1 O
study NN 0 1 1 O
in IN 0 0 12 O
9 CD 0 0 2 O
normal JJ 0 1 1 O
volunteers NNS 1 1 UNK O
ketoprofen VBP 0 1 UNK B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
significantly RB 0 0 1 O
interfere RB 0 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
on IN 0 0 12 O
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
. . 0 0 12 O

However RB 0 0 1 O
because IN 0 0 12 O
higher JJR 1 1 1 O
doses NNS 1 1 6 O
( ( 0 0 2 O
up IN 0 0 12 O
to TO 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
QD NNP 0 1 13 O
) ) 0 0 2 O
of IN 0 0 12 O
omeprazole NN 0 1 0 B-Drug
are VBP 1 0 12 O
tolerated VBN 1 0 1 O
in IN 0 0 12 O
Zollinger NNP 0 0 UNK O
- : 0 0 2 O
Ellison NNP 0 0 19 O
( ( 0 0 2 O
ZE NNP 0 0 UNK O
) ) 0 0 2 O
patients NNS 1 1 6 O
no DT 0 0 12 O
dose JJ 0 1 6 O
adjustment NN 0 1 1 O
for IN 0 0 12 O
omeprazole NN 0 1 0 B-Drug
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
at IN 0 0 12 O
current JJ 0 1 1 O
doses NNS 1 1 6 O
. . 0 0 12 O

Clozapine NN 0 1 0 B-Drug
may MD 0 0 1 O
potentiate VB 0 0 UNK O
the DT 0 0 12 O
hypotensive JJ 0 1 14 O
effects NNS 1 1 1 O
of IN 0 0 12 O
antihypertensive JJ 0 1 14 B-Group
drugs NNS 1 1 6 I-Group
and CC 0 0 12 O
the DT 0 0 12 O
anticholinergic JJ 0 1 13 O
effects NNS 1 1 1 O
of IN 0 0 12 O
atropine JJ 0 1 14 B-Drug
- : 0 0 2 O
type NN 0 1 1 O
drugs NNS 1 1 6 O
. . 0 0 12 O

These DT 0 0 1 O
experiences NNS 1 1 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
characterized VBN 1 1 1 O
by IN 0 0 12 O
flushing VBG 1 1 13 O
rash JJ 0 1 6 O
peripheral JJ 0 1 6 O
edema NN 0 1 6 O
nausea NN 0 1 6 O
and CC 0 0 12 O
headache NN 0 1 6 O
. . 0 0 12 O

Concurrent JJ 0 1 13 O
administration NN 0 1 1 O
of IN 0 0 12 O
drugs NNS 1 1 6 O
possessing VBG 1 1 UNK O
nephrotoxic NN 0 1 UNK O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
aminoglycosides NNS 0 1 13 B-Group
indomethacin VBP 0 1 14 B-Drug
) ) 0 0 2 O
myelotoxic NN 0 0 UNK O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
cytotoxic NN 0 1 UNK B-Group
chemotherapy NN 0 1 6 O
) ) 0 0 2 O
cardiotoxic NN 0 1 UNK O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
doxorubicin NN 0 1 13 B-Drug
) ) 0 0 2 O
or CC 0 0 12 O
hepatotoxic NN 0 1 UNK O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
methotrexate NN 0 1 16 B-Drug
asparaginase NN 0 1 13 B-Drug
) ) 0 0 2 O
effects NNS 1 1 1 O
with IN 0 0 12 O
PROLEUKIN NNP 0 1 UNK B-Brand
may MD 0 0 1 O
increase VB 0 1 1 O
toxicity NN 0 1 6 O
in IN 0 0 12 O
these DT 0 0 12 O
organ JJ 0 1 6 O
systems NNS 1 1 1 O
. . 0 0 12 O

Indinavir NN 0 1 UNK B-Drug

- : 0 0 2 O
Phenothiazines NNS 0 1 UNK B-Group
( ( 0 0 2 O
acetophenazine JJ 0 1 UNK B-Drug
[ NNP 0 0 2 O
e.g. NN 0 0 UNK O
Tindal NNP 0 1 UNK B-Brand
] NNP 0 0 2 O
chlorpromazine NN 0 1 16 B-Drug
[ NNP 0 0 2 O
e.g. VBZ 0 0 UNK O
Thorazine NNP 0 1 UNK B-Brand
] NNP 0 0 2 O
fluphenazine NN 0 1 13 B-Drug
[ NNP 0 0 2 O
e.g. NN 0 0 UNK O
Prolixin NNP 0 1 UNK B-Brand
] NNP 0 0 2 O
mesoridazine NN 0 1 UNK B-Brand
[ NNP 0 0 2 O
e.g. NN 0 0 UNK O
Serentil NNP 0 1 UNK B-Brand
] NNP 0 0 2 O
perphenazine NN 0 1 13 B-Drug
[ NNP 0 0 2 O
e.g. VBZ 0 0 UNK O
Trilafon NNP 0 1 0 B-Brand
] NNP 0 0 2 O
prochlorperazine NN 0 1 16 B-Drug
[ NNP 0 0 2 O
e.g. VBZ 0 0 UNK O
Compazine NNP 0 1 0 B-Brand
] NNP 0 0 2 O
promazine NN 0 1 UNK B-Drug
[ NNP 0 0 2 O
e.g. VBZ 0 0 UNK O
Sparine NNP 0 1 UNK B-Brand
] NNP 0 0 2 O
promethazine NN 0 1 16 B-Drug
[ NNP 0 0 2 O
e.g. VBZ 0 0 UNK O
Phenergan NNP 0 1 0 B-Brand
] NNP 0 0 2 O
thioridazine NN 0 1 13 B-Drug
[ NNP 0 0 2 O
e.g. VBZ 0 0 UNK O
Mellaril NNP 0 1 UNK B-Brand
] NNP 0 0 2 O
trifluoperazine NN 0 1 13 B-Drug
[ NNP 0 0 2 O
e.g. VBZ 0 0 UNK O
Stelazine NNP 0 1 0 B-Brand
] NNP 0 0 2 O
triflupromazine NN 0 1 UNK B-Drug
[ NNP 0 0 2 O
e.g. VBZ 0 0 UNK O
Vesprin NNP 0 1 UNK B-Brand
] NNP 0 0 2 O
trimeprazine NN 0 1 UNK B-Drug
[ NNP 0 0 2 O
e.g. VBZ 0 0 UNK O
Temaril NNP 0 1 UNK B-Brand
] NNP 0 0 2 O
) ) 0 0 2 O
or CC 0 0 12 O

transaminases NNS 1 1 14 O
( ( 0 0 2 O
AST NNP 0 1 13 O

Fifteen NNP 0 1 13 O
to TO 0 0 12 O
9 CD 0 0 2 O
minutes NNS 1 1 12 O
of IN 0 0 12 O
exposure NN 0 1 1 O
to TO 0 0 12 O
9 CD 0 0 2 O
MAC NNP 0 1 UNK O
isoflurane NN 0 1 UNK B-Drug
or CC 0 0 12 O
enflurane NN 0 1 UNK B-Drug
had VBD 1 0 12 O
minimal JJ 0 1 1 O
effects NNS 1 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
duration NN 0 1 1 O
of IN 0 0 12 O
action NN 0 1 13 O
of IN 0 0 12 O
initial JJ 0 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
NIMBEX NNP 0 1 UNK B-Brand
and CC 0 0 12 O
therefore RB 0 0 1 O
no DT 0 0 12 O
adjustment NN 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
initial JJ 0 1 1 O
dose NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
necessary JJ 0 0 1 O
when WRB 0 0 12 O
NIMBEX NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
administered VBN 1 1 1 O
shortly RB 0 0 12 O
after IN 0 0 12 O
initiation NN 0 1 1 O
of IN 0 0 12 O
volatile JJ 0 1 UNK O
agents NNS 1 1 1 O
. . 0 0 12 O

Esomeprazole NN 0 1 UNK B-Drug
may MD 0 0 1 O
potentially RB 0 0 1 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
CYP9C9 NNP 0 0 UNK O
the DT 0 0 12 O
major JJ 0 1 1 O
esomeprazole NN 0 1 16 B-Drug
metabolizing VBG 1 0 UNK O
enzyme NN 0 1 14 O
. . 0 0 12 O

Patients NNS 0 1 7 O
treated VBN 1 1 1 O
with IN 0 0 12 O
proton NN 0 1 14 B-Group
pump NN 0 1 3 I-Group
inhibitors NNS 1 1 14 I-Group
and CC 0 0 12 O
warfarin NNS 0 1 14 B-Drug
concomitantly RB 0 0 14 O
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
for IN 0 0 12 O
increases NNS 1 1 1 O
in IN 0 0 12 O
INR NNP 0 1 13 O
and CC 0 0 12 O
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
. . 0 0 12 O

Although IN 0 0 12 O
clinical JJ 0 1 6 O
studies NNS 1 1 1 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
performed VBN 1 1 1 O
phenobarbital JJ 0 1 16 B-Drug
is VBZ 1 0 12 O
expected VBN 1 1 12 O
to TO 0 0 12 O
have VB 0 0 12 O
the DT 0 0 12 O
same JJ 0 1 12 O
effect NN 0 1 1 O
. . 0 0 12 O

There EX 0 0 12 O
was VBD 1 0 12 O
also RB 0 0 12 O
no DT 0 0 12 O
interaction NN 0 1 UNK O
with IN 0 0 12 O
concomitantly RB 0 0 14 O
administered VBN 1 1 1 O
antacids NNS 1 1 14 B-Group
. . 0 0 12 O

In IN 0 0 2 O
a DT 0 0 12 O
study NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
schizophrenic JJ 0 0 13 O
patients NNS 1 1 6 O
coadministered VBD 0 0 UNK O
oral JJ 0 1 6 O
haloperidol NN 0 1 16 B-Drug
and CC 0 0 12 O
rifampin NN 0 1 16 B-Drug
plasma NN 0 1 14 O
haloperidol NN 0 1 16 B-Drug
levels NNS 1 1 1 O
were VBD 1 0 12 O
decreased VBN 1 1 1 O
by IN 0 0 12 O
a DT 0 0 12 O
mean NN 0 1 12 O
of IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
mean JJ 0 1 12 O
scores NNS 1 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
Brief NNP 0 1 2 O
Psychiatric NNP 0 1 7 O
Rating NNP 0 1 UNK O
Scale NNP 0 1 2 O
were VBD 1 0 12 O
increased VBN 1 1 1 O
from IN 0 0 12 O
baseline NN 0 1 1 O
. . 0 0 12 O

Patients NNS 0 1 7 O
already RB 0 0 12 O
stabilized VBN 1 1 1 O
on IN 0 0 12 O
valdecoxib NN 0 1 13 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
closely RB 0 0 1 O
monitored VBN 1 1 1 O
for IN 0 0 12 O
loss NN 0 1 1 O
of IN 0 0 12 O
symptom JJ 0 1 6 O
control NN 0 1 1 O
with IN 0 0 12 O
phenytoin JJ 0 1 16 B-Drug
coadministration NN 0 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
possibility NN 0 1 1 O
of IN 0 0 12 O
hypotensive JJ 0 1 14 O
effects NNS 1 1 1 O
with IN 0 0 12 O
UNIVASC NNP 0 1 UNK B-Brand
can MD 0 0 12 O
be VB 0 0 12 O
minimized VBN 1 0 1 O
by IN 0 0 12 O
discontinuing VBG 1 1 6 O
diuretic JJ 0 1 14 O
therapy NN 0 1 6 O
for IN 0 0 12 O
several JJ 0 1 12 O
days NNS 1 1 12 O
or CC 0 0 12 O
cautiously RB 0 0 UNK O
increasing VBG 1 1 1 O
salt JJ 0 1 3 O
intake NN 0 1 3 O
before IN 0 1 12 O
initiation NN 0 1 1 O
of IN 0 0 12 O
treatment NN 0 1 6 O
with IN 0 0 12 O
UNIVASC NNP 0 1 UNK B-Brand
. . 0 0 12 O
If IN 0 0 12 O
this DT 0 0 12 O
is VBZ 1 0 12 O
not RB 0 1 12 O
possible JJ 0 1 1 O
the DT 0 0 12 O
starting VBG 1 1 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
moexpril NN 0 0 UNK B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
reduced.. VB 0 1 UNK O

Effects NNS 0 1 UNK O
of IN 0 0 12 O
other JJ 0 0 12 O
Antiepilepsy NNP 0 0 UNK O
Drugs NNP 0 1 2 O
( ( 0 0 2 O
AEDs NNP 0 1 UNK B-Group
) ) 0 0 2 O
on IN 0 0 12 O
GABITRIL NN 0 1 UNK B-Brand
: : 0 0 2 O
Carbamazepine NN 0 1 UNK B-Drug
: : 0 0 2 O
Population NNP 0 1 UNK O
pharmacokinetic JJ 0 1 UNK O
analyses NNS 1 1 UNK O
indicate VBP 0 0 1 O
that IN 0 0 12 O
tiagabine JJ 0 1 13 B-Drug
clearance NN 0 1 16 O
is VBZ 1 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
greater JJR 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
carbamazepine NN 0 1 16 B-Drug
with IN 0 0 12 O
or CC 0 0 12 O
without IN 0 0 12 O
other JJ 0 0 12 O
enzyme JJ 0 1 14 O
- : 0 0 2 O
inducing NN 0 1 6 O
AEDs NNP 0 1 UNK B-Group
. . 0 0 12 O

Although IN 0 0 12 O
concomitant JJ 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
Clozapine NNP 0 1 0 B-Drug
and CC 0 0 12 O
carbamazepine NN 0 1 16 B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
recommended JJ 0 1 1 O
it PRP 0 0 12 O
should MD 0 0 12 O
be VB 0 0 12 O
noted VBN 1 0 1 O
that DT 0 0 12 O
discontinuation NN 0 1 6 O
of IN 0 0 12 O
concomitant JJ 0 1 6 O
carbamazepine JJ 0 1 16 B-Drug
administration NN 0 1 1 O
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
an DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
Clozapine NNP 0 1 0 B-Drug
plasma NN 0 1 14 O
levels NNS 1 1 1 O
. . 0 0 12 O

Organic NNP 0 1 UNK O
nitrates VBZ 1 1 14 B-Group
- : 0 0 2 O
L NNP 0 1 2 B-Drug
- : 0 0 2 O
arginine NN 0 1 13 I-Drug
supplements NNS 1 1 6 O
theoretically RB 0 0 UNK O
may MD 0 0 1 O
potentiate VB 0 0 UNK O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
organic JJ 0 1 13 O
nitrates NNS 1 1 14 B-Drug
if IN 0 0 12 O
taken VBN 1 1 12 O
concomitantly RB 0 0 14 O
. . 0 0 12 O

If IN 0 0 12 O
antacids NNS 1 1 14 B-Group
are VBP 1 0 12 O
required VBN 1 1 1 O
during IN 0 0 12 O
OMNICEF NNP 0 1 UNK B-Brand
therapy NN 0 1 6 O
OMNICEF NNP 0 1 UNK B-Brand
should MD 0 0 12 O
be VB 0 0 12 O
taken VBN 1 1 12 O
at IN 0 0 12 O
least JJS 0 1 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
before IN 0 1 12 O
or CC 0 0 12 O
after IN 0 0 12 O
the DT 0 0 12 O
antacid NN 0 1 UNK B-Group
. . 0 0 12 O

If IN 0 0 12 O
such JJ 0 0 1 O
measurements NNS 1 1 1 O
are VBP 1 0 12 O
necessary JJ 0 0 1 O
the DT 0 0 12 O
use NN 0 1 1 O
of IN 0 0 12 O
other JJ 0 0 12 O
methods NNS 1 1 1 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
four CD 0 1 12 O
subjects NNS 1 1 UNK O
with IN 0 0 12 O
epilepsy NN 0 1 13 O
ingesting VBG 1 1 UNK O
valproate VBP 0 1 16 B-Drug
the DT 0 0 12 O
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
trough NN 0 1 3 O
( ( 0 0 2 O
Cmin NNP 0 1 UNK O
) ) 0 0 2 O
valproate NN 0 1 16 B-Drug
plasma NN 0 1 14 O
concentration NN 0 1 1 O
was VBD 1 0 12 O
9 CD 0 0 2 O
9 CD 0 0 2 O
micrograms NNS 1 1 14 O
/ JJ 0 0 2 O
mL NN 0 1 14 O
. . 0 0 12 O

Presumably RB 0 0 13 O
phenytoin JJ 0 1 16 B-Drug
acts NNS 1 1 UNK O
as IN 1 0 12 O
a DT 0 0 12 O
stimulator NN 0 1 6 O
of IN 0 0 12 O
coumarin JJ 0 1 UNK B-Group
metabolism NN 0 1 16 O
and CC 0 0 12 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
cause VB 0 1 12 O
decreased JJ 0 1 1 O
serum NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
coumarin NN 0 1 UNK B-Group
anticoagulants NNS 1 1 13 I-Group
and CC 0 0 12 O
increased VBD 1 1 1 O
prothrombin NN 0 1 14 O
- : 0 0 2 O
proconvertin NN 0 1 UNK O
concentrations NNS 1 1 13 O
. . 0 0 12 O

Concomitant JJ 0 1 UNK O
administrations NNS 1 1 UNK O
not RB 0 1 12 O
recommended VBD 1 1 1 O
: : 0 0 2 O
- : 0 0 2 O
Terfenadine NN 0 1 UNK B-Drug
and CC 0 0 12 O
astemizole NN 0 1 UNK B-Drug
: : 0 0 2 O
Certain NNP 0 1 UNK O
macrolides NNS 0 1 13 B-Group
interact NN 0 0 UNK O
with IN 0 0 12 O
terfenadine NN 0 1 UNK B-Drug
and CC 0 0 12 O
astemizole JJ 0 1 UNK B-Drug
leading VBG 1 1 1 O
to TO 0 0 12 O
increased VBN 1 1 1 O
serum JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
the DT 0 0 12 O
latter NN 0 0 UNK O
. . 0 0 12 O

Cimetidine NN 0 1 0 B-Drug
: : 0 0 2 O
In IN 0 0 2 O
a DT 0 0 12 O
study NN 0 1 1 O
in IN 0 0 12 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
a DT 0 0 12 O
one CD 0 1 12 O
- : 0 0 2 O
week NN 0 1 12 O
course NN 0 1 12 O
of IN 0 0 12 O
cimetidine NN 0 1 13 B-Drug
at IN 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
b.i.d NN 0 1 UNK O
. . 0 0 12 O
with IN 0 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
dose NN 0 1 6 O
of IN 0 0 12 O
isradipine NN 0 1 13 B-Drug
on IN 0 0 12 O
the DT 0 0 12 O
sixth JJ 0 1 13 O
day NN 0 1 12 O
showed VBD 1 1 12 O
an DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
isradipine JJ 0 1 13 B-Drug
mean JJ 0 1 12 O
peak NN 0 1 1 O
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
and CC 0 0 12 O
significant JJ 0 1 1 O
increase NN 0 1 1 O
in IN 0 0 12 O
area NN 0 1 12 O
under IN 0 0 12 O
the DT 0 0 12 O
curve NN 0 1 13 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
. . 0 0 12 O

Potential NNP 0 1 UNK O
for IN 0 0 12 O
Other JJ 0 0 2 O
Drugs NNP 0 1 2 O
to TO 0 0 12 O
Affect NNP 0 1 UNK O
Duloxetine NNP 0 1 0 B-Drug
: : 0 0 2 O
Both DT 0 0 2 O
CYP9A9 NNP 0 0 UNK O
and CC 0 0 12 O
CYP9D9 NNP 0 0 UNK O
are VBP 1 0 12 O
responsible JJ 0 1 1 O
for IN 0 0 12 O
duloxetine JJ 0 1 0 B-Drug
metabolism NN 0 1 16 O
. . 0 0 12 O

Rare JJ 0 1 2 O
cases NNS 1 1 UNK O
of IN 0 0 12 O
serious JJ 0 1 12 O
cardiovascular JJ 0 1 6 O
adverse JJ 0 0 1 O
events NNS 1 1 12 O
including VBG 1 1 1 O
electrocardiographic JJ 0 1 8 O
QT NNP 0 1 13 O
/ NNP 0 0 2 O
QTc NNP 0 0 14 O
interval JJ 0 1 1 O
prolongation NN 0 1 6 O
cardiac NN 0 1 6 O
arrest NN 0 1 12 O
torsades VBZ 0 0 13 O
de IN 0 1 2 O
pointes NNS 0 0 UNK O
and CC 0 0 12 O
other JJ 0 0 12 O
ventricular JJ 0 1 8 O
arrhythmias NNS 1 1 6 O
have VBP 0 0 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
. . 0 0 12 O

Consequently RB 0 0 1 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
that IN 0 0 12 O
fluvoxamine NN 0 1 16 B-Drug
not RB 0 1 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
either DT 0 1 12 O
terbinafine JJ 0 1 16 B-Drug
astemizole NN 0 1 UNK B-Drug
or CC 0 0 12 O
cisapride NN 0 1 UNK B-Drug
. . 0 0 12 O

Concomitant JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
Aprepitant NNP 0 1 UNK B-Drug
with IN 0 0 12 O
strong JJ 0 1 12 O
CYP9A9 NNP 0 0 UNK O
inhibitors NNS 1 1 14 O
should MD 0 0 12 O
be VB 0 0 12 O
approached VBN 1 1 UNK O
cautiously RB 0 0 UNK O
. . 0 0 12 O

TOBI NNP 0 1 UNK B-Brand
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
ethacrynic JJ 0 0 16 B-Drug
acid NNS 0 1 14 I-Drug
furosemide VBP 0 1 0 B-Drug
urea JJ 0 1 14 B-Drug
or CC 0 0 12 O
mannitol NN 0 1 14 B-Drug
. . 0 0 12 O

Tricyclic JJ 0 0 UNK B-Group
antidepressants NNS 1 1 13 I-Group
may MD 0 0 1 O
antagonize VB 0 0 UNK O
the DT 0 0 12 O
hypotensive JJ 0 1 14 O
effects NNS 1 1 1 O
of IN 0 0 12 O
clonidine NN 0 1 0 B-Drug
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
important JJ 0 1 1 O
to TO 0 0 12 O
recognize VB 0 0 UNK O
this DT 0 0 12 O
phenomenon NN 0 1 1 O
before IN 0 1 12 O
a DT 0 0 12 O
patient NN 0 1 6 O
with IN 0 0 12 O
a DT 0 0 12 O
possible JJ 0 1 1 O
pheochromocytoma NN 0 1 UNK O
is VBZ 1 0 12 O
subjected VBN 1 1 UNK O
to TO 0 0 12 O
surgery NN 0 1 6 O
. . 0 0 12 O

Therefore RB 0 0 1 O
caution NN 0 0 1 O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
in IN 0 0 12 O
administering VBG 1 1 1 O
VUMON NNP 0 1 UNK B-Brand
( ( 0 0 2 O
teniposide IN 0 1 UNK B-Drug
injection NN 0 1 3 O
) ) 0 0 2 O
to TO 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
these DT 0 0 12 O
other JJ 0 0 12 O
agents NNS 1 1 1 O
. . 0 0 12 O

Cimetidine NN 0 1 0 B-Drug
: : 0 0 2 O
Cimetidine NN 0 1 0 B-Drug
increases NNS 1 1 1 O
nicardipine VBP 0 1 16 B-Drug
HCl NNP 0 0 14 I-Drug
plasma NN 0 1 14 O
levels NNS 1 1 1 O
. . 0 0 12 O

When WRB 0 0 12 O
given VBN 1 1 12 O
concurrently RB 0 0 1 O
the DT 0 0 12 O
following JJ 0 1 1 O
drugs NNS 1 1 6 O
may MD 0 0 1 O
interact VB 0 0 UNK O
with IN 0 0 12 O
thiazide JJ 0 1 UNK B-Group
diuretics NNS 1 1 14 I-Group
. . 0 0 12 O

With IN 0 0 2 O
simultaneous JJ 0 1 13 O
dosing NN 0 0 14 O
of IN 0 0 12 O
Vardenafil NNP 0 1 UNK B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
and CC 0 0 12 O
terazosin NN 0 1 0 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
9 CD 0 0 2 O
of IN 0 0 12 O
9 CD 0 0 2 O
subjects NNS 1 1 UNK O
experienced VBD 1 0 12 O
a DT 0 0 12 O
standing VBG 1 1 12 O
systolic JJ 0 1 8 O
blood NN 0 1 6 O
pressure NN 0 1 1 O
of IN 0 0 12 O
less JJR 0 1 12 O
than IN 0 0 12 O
9 CD 0 0 2 O
mm JJ 0 0 18 O
Hg NNP 0 1 14 O
. . 0 0 12 O

In IN 0 0 2 O
adult JJ 0 1 12 O
diabetic JJ 0 1 6 O
patients NNS 1 1 6 O
under IN 0 0 12 O
treatment NN 0 1 6 O
with IN 0 0 12 O
either DT 0 1 12 O
sulfonylureas NNS 1 1 UNK B-Group
or CC 0 0 12 O
insulin NN 0 1 14 B-Drug
there EX 0 0 12 O
is VBZ 1 0 12 O
no DT 0 0 12 O
change NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
clinical JJ 0 1 6 O
effects NNS 1 1 1 O
of IN 0 0 12 O
either DT 0 1 12 O
TOLECTIN NNP 0 1 UNK B-Brand
or CC 0 0 12 O
the DT 0 0 12 O
hypoglycemic JJ 0 1 14 B-Group
agents NNS 1 1 1 I-Group
. . 0 0 12 O

In IN 0 0 2 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
furosemide JJ 0 1 0 B-Drug
nifedipine JJ 0 1 0 B-Drug
diltiazem NN 0 1 0 B-Drug
ACE NNP 0 1 13 B-Group
inhibitors NNS 1 1 14 I-Group
verapamil VBP 0 1 0 B-Drug
glyburide JJ 0 1 16 B-Drug
propranolol NN 0 1 16 B-Drug
and CC 0 0 12 O
various JJ 0 1 1 O
chemotherapy NN 0 1 6 O
agents VBZ 0 1 1 O
no DT 0 0 12 O
effect NN 0 1 1 O
was VBD 1 0 12 O
shown VBN 1 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
clearance NN 0 1 16 O
of IN 0 0 12 O
hydrodolasetron NN 0 1 UNK B-Drug_n
. . 0 0 12 O

Corticosteroids NNS 0 1 UNK B-Group
: : 0 0 2 O
Concomitant JJ 0 1 UNK O
administration NN 0 1 1 O
with IN 0 0 12 O
aspirin NN 0 1 14 B-Brand
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
gastrointestinal JJ 0 1 6 O
ulceration NN 0 1 8 O
and CC 0 0 12 O
may MD 0 0 1 O
reduce VB 0 0 1 O
serum VB 0 1 14 O
salicylate NN 0 1 13 O
levels NNS 1 1 1 O
. . 0 0 12 O

Vasopressors NNS 0 1 UNK B-Group
: : 0 0 2 O
Thyroxine NN 0 1 UNK B-Drug
increases VBZ 1 1 1 O
the DT 0 0 12 O
adrenergic JJ 0 1 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
catecholamines NNS 1 1 14 O
such JJ 0 0 1 O
as IN 1 0 12 O
epinephrine NN 0 1 14 B-Drug
and CC 0 0 12 O
norepinephrine NN 0 1 14 B-Drug
. . 0 0 12 O

Therefore RB 0 0 1 O
coagulation NN 0 1 14 O
indices NNS 1 1 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
frequently RB 0 1 1 O
to TO 0 0 12 O
maintain VB 0 1 1 O
the DT 0 0 12 O
desired JJ 0 1 1 O
anticoagulant JJ 0 1 13 O
effect NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
mechanism NN 0 1 13 O
of IN 0 0 12 O
this DT 0 0 12 O
interaction NN 0 1 UNK O
is VBZ 1 0 12 O
not RB 0 1 12 O
known VBN 1 1 12 O
. . 0 0 12 O

However RB 0 0 1 O
higher JJR 1 1 1 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
AMICAR NNP 0 1 UNK B-Brand
may MD 0 0 1 O
occur VB 0 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
severe JJ 0 1 6 O
renal JJ 0 1 6 O
failure NN 0 1 1 O
. . 0 0 12 O

Allopurinol NN 0 1 0 B-Drug
: : 0 0 2 O
The DT 0 0 2 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
didanosine NN 0 1 16 B-Drug
was VBD 1 0 12 O
increased VBN 1 1 1 O
about IN 0 1 12 O
9 CD 0 0 2 O
- : 0 0 2 O
fold NN 0 1 3 O
when WRB 0 0 12 O
allopurinol NN 0 1 13 B-Drug
at IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
was VBD 1 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
9 CD 0 0 2 O
- : 0 0 2 O
mg NN 0 1 0 O
dose NN 0 1 6 O
of IN 0 0 12 O
VIDEX NNP 0 1 UNK B-Brand
to TO 0 0 12 O
two CD 0 1 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
renal JJ 0 1 6 O
impairment NN 0 1 16 O
( ( 0 0 2 O
CLcr=9 NNP 0 1 UNK O
and CC 0 0 12 O
9 CD 0 0 2 O
mL NN 0 1 14 O
/ NNP 0 0 2 O
min NN 0 1 16 O
) ) 0 0 2 O
. . 0 0 12 O

Zimelidine NNP 0 1 UNK B-Drug_n
etomidate NN 0 1 14 B-Drug
antagonism NN 0 1 UNK O

- : 0 0 2 O
Anticoagulants NNS 0 1 UNK B-Group
( ( 0 0 2 O
blood NN 0 1 6 B-Group
thinners NNS 1 1 14 I-Group
) ) 0 0 2 O
or CC 0 0 12 O

It PRP 0 0 12 O
may MD 0 0 1 O
be VB 0 0 12 O
necessary JJ 0 0 1 O
to TO 0 0 12 O
adjust VB 0 0 1 O
the DT 0 0 12 O
dosage NN 0 1 0 O
of IN 0 0 12 O
oral JJ 0 1 6 O
anticoagulants NNS 1 1 13 B-Group
upon IN 0 0 12 O
beginning VBG 1 1 12 O
or CC 0 0 12 O
stopping VBG 1 1 12 O
disulfiram NN 0 1 13 B-Drug
. . 0 0 12 O
since IN 0 1 12 O
disulfiram NN 0 1 13 B-Drug
may MD 0 0 1 O
prolong VB 0 0 13 O
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
. . 0 0 12 O

However RB 0 0 1 O
increasing VBG 1 1 1 O
use NN 0 1 1 O
of IN 0 0 12 O
such JJ 0 0 1 O
preparations NNS 1 1 13 O
to TO 0 0 12 O
control VB 0 1 1 O
symptoms JJ 0 1 6 O
indicates NNS 0 0 1 O
deterioration NN 0 1 1 O
of IN 0 0 12 O
asthma JJ 0 1 6 O
control NN 0 1 1 O
and CC 0 0 12 O
the DT 0 0 12 O
need NN 0 1 12 O
to TO 0 0 12 O
reassess VB 0 0 1 O
the DT 0 0 12 O
patient NN 0 1 6 O
therapy NN 0 1 6 O
. . 0 0 12 O

Since IN 0 1 2 O
the DT 0 0 12 O
therapeutic JJ 0 1 6 O
range NN 0 1 1 O
of IN 0 0 12 O
theophylline NN 0 1 16 B-Drug
is VBZ 1 0 12 O
narrow JJ 0 1 3 O
theophylline JJ 0 1 16 B-Drug
serum NN 0 1 14 O
levels NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
closely RB 0 0 1 O
and CC 0 0 12 O
appropriate JJ 0 1 1 O
dosage NN 0 1 0 O
adjustments NNS 1 1 1 O
of IN 0 0 12 O
theophylline NN 0 1 16 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
made VBN 1 1 12 O
. . 0 0 12 O

leukopenia NN 0 1 UNK O

Local NNP 0 1 2 O
and CC 0 0 12 O
some DT 0 0 12 O
general JJ 0 1 1 O
anesthetics NNS 1 1 13 B-Group
antiarrhythmic JJ 0 1 14 B-Group
agents NNS 1 1 1 I-Group
and CC 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
interfere VBP 0 1 UNK O
with IN 0 0 12 O
neuromuscular JJ 0 1 6 O
transmission NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
cautiously RB 0 0 UNK O
if IN 0 0 12 O
at IN 0 0 12 O
all DT 0 0 12 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
myasthenia JJ 0 1 6 O
gravis NN 0 1 6 O
; : 0 0 2 O

This DT 0 0 2 O
small JJ 0 1 12 O
decrease NN 0 1 1 O
in IN 0 0 12 O
excretion NN 0 1 14 O
of IN 0 0 12 O
gabapentin NN 0 1 0 B-Drug
by IN 0 0 12 O
cimetidine NN 0 1 13 B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
expected VBN 1 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
of IN 0 0 12 O
clinical JJ 0 1 6 O
importance NN 0 1 1 O
. . 0 0 12 O

There EX 0 0 12 O
is VBZ 1 0 12 O
no DT 0 0 12 O
information NN 0 1 1 O
regarding VBG 1 0 1 O
the DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
lamivudine NN 0 1 16 B-Drug
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
higher JJR 1 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
TMP NNP 0 0 UNK B-Drug
/ NNP 0 0 2 O
SMX NNP 0 1 UNK B-Drug
such JJ 0 0 1 O
as IN 1 0 12 O
those DT 0 0 12 O
used VBN 1 1 12 O
to TO 0 0 12 O
treat VB 0 1 12 O
Pneumocystis NNP 0 1 14 O
carinii NN 0 0 14 O
pneumonia NN 0 1 6 O
. . 0 0 12 O

incomplete JJ 0 1 1 O
data NNS 0 1 1 O
for IN 0 0 12 O
efavirenz NN 0 1 13 B-Drug
. . 0 0 12 O

There EX 0 0 12 O
is VBZ 1 0 12 O
no DT 0 0 12 O
clinical JJ 0 1 6 O
evidence NN 0 1 1 O
to TO 0 0 12 O
suggest VB 0 1 1 O
that IN 0 0 12 O
anagrelide JJ 0 1 13 B-Drug
interacts NNS 0 0 UNK O
with IN 0 0 12 O
any DT 0 0 12 O
of IN 0 0 12 O
these DT 0 0 12 O
compounds NNS 1 1 13 O
. . 0 0 12 O

Reports NNS 0 1 2 O
suggest VBP 0 1 1 O
that IN 0 0 12 O
NSAIDs NNP 0 1 UNK B-Group
may MD 0 0 1 O
diminish VB 0 1 UNK O
the DT 0 0 12 O
antihypertensive JJ 0 1 14 O
effect NN 0 1 1 O
of IN 0 0 12 O
ACE NNP 0 1 13 B-Group
inhibitors NNS 1 1 14 I-Group
including VBG 1 1 1 O
lisinopril NN 0 1 0 B-Drug
. . 0 0 12 O

After IN 0 0 2 O
stopping VBG 1 1 12 O
Fluvoxamine NNP 0 1 UNK B-Drug
Tablets NNP 0 1 0 O
at IN 0 0 12 O
least JJS 0 1 12 O
9 CD 0 0 2 O
weeks NNS 1 1 12 O
should MD 0 0 12 O
be VB 0 0 12 O
allowed VBN 1 1 12 O
before IN 0 1 12 O
starting VBG 1 1 12 O
a DT 0 0 12 O
MAOI NNP 0 1 UNK B-Group
. . 0 0 12 O

Therefore RB 0 0 1 O
use NN 0 1 1 O
of IN 0 0 12 O
lamivudine NN 0 1 16 B-Drug
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
zalcitabine NN 0 1 UNK B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
recommended JJ 0 1 1 O

These DT 0 0 1 O
results NNS 1 1 1 O
would MD 0 0 12 O
seem VB 0 0 12 O
to TO 0 0 12 O
dictate VB 0 0 UNK O
against IN 0 0 12 O
the DT 0 0 12 O
clinical JJ 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
methotrexate NN 0 1 16 B-Drug
with IN 0 0 12 O
ELSPAR NNP 0 1 UNK B-Brand
or CC 0 0 12 O
during IN 0 0 12 O
the DT 0 0 12 O
period NN 0 1 1 O
following VBG 1 1 1 O
ELSPAR NNP 0 1 UNK B-Brand
therapy NN 0 1 6 O
when WRB 0 0 12 O
plasma NN 0 1 14 O
asparagine NN 0 1 UNK O
levels NNS 1 1 1 O
are VBP 1 0 12 O
below IN 0 0 12 O
normal JJ 0 1 1 O
. . 0 0 12 O

Other JJ 0 0 2 O
plasma JJ 0 1 14 O
proteins NNS 1 1 14 O
may MD 0 0 1 O
be VB 0 0 12 O
increased VBN 1 1 1 O
( ( 0 0 2 O
angiotensinogen JJ 0 1 UNK O
/ NNP 0 0 2 O
renin NN 0 1 UNK O
substrate NN 0 1 UNK O
alpha SYM 0 1 1 O
- : 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
antitrypsin NN 0 1 UNK O
ceruloplasmin NN 0 1 14 O
) ) 0 0 2 O
. . 0 0 12 O

Concomitant JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
Mefloquine NNP 0 1 UNK B-Drug
and CC 0 0 12 O
other JJ 0 0 12 O
related JJ 0 1 1 O
compounds NNS 1 1 13 O
( ( 0 0 2 O
eg JJ 0 1 UNK O
quinine NN 0 1 16 B-Drug
quinidine NN 0 1 16 B-Drug
and CC 0 0 12 O
chloroquine NN 0 1 13 B-Drug
) ) 0 0 2 O
may MD 0 0 1 O
produce VB 0 0 1 O
electrocardiographic JJ 0 1 8 O
abnormalities NNS 1 1 6 O
and CC 0 0 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
convulsions NNS 1 1 13 O
. . 0 0 12 O

Efavirenz NNP 0 1 UNK B-Drug

Concomitant NNP 0 1 UNK O
use NN 0 1 1 O
of IN 0 0 12 O
zalcitabine NN 0 1 UNK B-Drug
and CC 0 0 12 O
lamivudine NN 0 1 16 B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O

However RB 0 0 1 O
in IN 0 0 12 O
the DT 0 0 12 O
second JJ 0 1 12 O
study NN 0 1 1 O
administration NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
g NNS 0 1 16 O
cholestyramine VBP 0 1 13 B-Drug
9 CD 0 0 2 O
hour NN 0 1 12 O
before IN 0 1 12 O
the DT 0 0 12 O
evening NN 0 1 12 O
meal NN 0 1 12 O
and CC 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
cerivastatin NN 0 1 UNK B-Drug
sodium NN 0 1 14 I-Drug
approximately RB 0 1 1 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
after IN 0 0 12 O
the DT 0 0 12 O
same JJ 0 1 12 O
evening NN 0 1 12 O
meal NN 0 1 12 O
resulted VBD 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
decrease NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
cerivastatin NN 0 1 UNK B-Drug
AUC NNP 0 1 UNK O
of IN 0 0 12 O
less JJR 0 1 12 O
than IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
a DT 0 0 12 O
decrease NN 0 1 1 O
in IN 0 0 12 O
Cmax NNP 0 1 UNK O
of IN 0 0 12 O
about RB 0 1 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
when WRB 0 0 12 O
compared VBN 1 1 1 O
to TO 0 0 12 O
dosing VBG 1 0 14 O
cerivastatin JJ 0 1 UNK B-Drug
sodium NN 0 1 14 I-Drug
alone RB 0 1 12 O
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
that IN 0 0 12 O
serum JJ 0 1 14 O
lithium NN 0 1 16 B-Drug
levels NNS 1 1 1 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
frequently RB 0 1 1 O
if IN 0 0 12 O
enalapril VBN 0 1 0 B-Drug
is VBZ 1 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
lithium NN 0 1 16 B-Drug
. . 0 0 12 O

Dosage NNP 0 1 UNK O
adjustment NN 0 1 1 O
of IN 0 0 12 O
concomitant JJ 0 1 6 O
medications NNS 1 1 6 O
may MD 0 0 1 O
be VB 0 0 12 O
necessary JJ 0 0 1 O
. . 0 0 12 O

Didanosine NN 0 1 0 B-Drug
: : 0 0 2 O
It PRP 0 0 12 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
that IN 0 0 12 O
didanosine NN 0 1 16 B-Drug
be VB 0 0 12 O
administered VBN 1 1 1 O
on IN 0 0 12 O
an DT 0 0 12 O
empty JJ 0 1 3 O
stomach NN 0 1 6 O
; : 0 0 2 O

Agents NNS 0 1 2 O
that WDT 0 0 12 O
Inhibit NNP 0 1 UNK O
Cytochrome NNP 0 1 UNK O
P9 NNP 0 1 UNK O
Isoenzymes NNP 0 1 UNK O
and CC 0 0 12 O
/ NNP 0 0 2 O
or CC 0 0 12 O
Epoxide NNP 0 1 UNK O
Hydrolase NNP 0 1 UNK O
Carbamazepine NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
metabolized VBN 1 1 UNK O
mainly RB 0 0 1 O
by IN 0 0 12 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
( ( 0 0 2 O
CYP NNP 0 1 UNK O
) ) 0 0 2 O
9A9 CD 0 0 UNK O
to TO 0 0 12 O
the DT 0 0 12 O
active JJ 0 1 1 O
carbamazepine NN 0 1 16 B-Drug
9 CD 0 0 2 I-Drug
9 CD 0 0 2 I-Drug
- : 0 0 2 O
epoxide NN 0 1 UNK I-Drug
which WDT 0 0 12 O
is VBZ 1 0 12 O
further RBR 1 1 1 O
metabolized VBN 1 1 UNK O
to TO 0 0 12 O
the DT 0 0 12 O
trans NNS 0 1 3 O
- : 0 0 2 O
diol NN 0 1 UNK O
by IN 0 0 12 O
epoxide JJ 0 1 UNK O
hydrolase NN 0 1 UNK O
. . 0 0 12 O

Thyroid NNP 0 1 7 B-Group
hormone NN 0 1 6 I-Group
activity NN 0 1 1 O
may MD 0 0 1 O
also RB 0 0 12 O
be VB 0 0 12 O
enhanced VBN 1 1 1 O
. . 0 0 12 O

Trecator NN 0 1 UNK B-Brand
may MD 0 0 1 O
potentiate VB 0 0 UNK O
the DT 0 0 12 O
adverse JJ 0 0 1 O
effects NNS 1 1 1 O
of IN 0 0 12 O
other JJ 0 0 12 O
antituberculous JJ 0 0 UNK B-Group
drugs NNS 1 1 6 I-Group
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
. . 0 0 12 O

It PRP 0 0 12 O
would MD 0 0 12 O
be VB 0 0 12 O
expected VBN 1 1 12 O
that IN 0 0 12 O
laxative JJ 0 1 6 B-Group
use NN 0 1 1 O
during IN 0 0 12 O
therapy NN 0 1 6 O
with IN 0 0 12 O
CAMPTOSAR NNP 0 1 UNK B-Brand
would MD 0 0 12 O
worsen VB 0 1 6 O
the DT 0 0 12 O
incidence NN 0 1 6 O
or CC 0 0 12 O
severity NN 0 1 6 O
of IN 0 0 12 O
diarrhea NN 0 1 6 O
but CC 0 0 12 O
this DT 0 0 12 O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
studied VBN 1 0 1 O
. . 0 0 12 O

AGGRASTAT NNP 0 1 UNK B-Brand
has VBZ 1 0 12 O
been VBN 1 0 12 O
studied VBN 1 0 1 O
on IN 0 0 12 O
a DT 0 0 12 O
background NN 0 1 12 O
of IN 0 0 12 O
aspirin NN 0 1 14 B-Brand
and CC 0 0 12 O
heparin NN 0 1 14 B-Drug
. . 0 0 12 O

therefore RB 0 0 1 O
if IN 0 0 12 O
glucocorticoid JJ 0 1 13 B-Group
replacement NN 0 1 1 O
is VBZ 1 0 12 O
needed VBN 1 1 12 O
hydrocortisone NN 0 1 14 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
prescribed VBN 1 1 1 O
. . 0 0 12 O

ProAmatine NNP 0 1 UNK B-Brand
. . 0 0 12 O
Alpha NNP 0 1 2 B-Group
- : 0 0 2 O
adrenergic NN 0 1 UNK I-Group
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
such JJ 0 0 1 O
as IN 1 0 12 O
prazosin NN 0 1 16 B-Drug
terazosin NN 0 1 0 B-Drug
and CC 0 0 12 O
doxazosin NN 0 1 13 B-Drug
can MD 0 0 12 O
antagonize VB 0 0 UNK O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
ProAmatine NNP 0 1 UNK B-Brand
. . 0 0 12 O
Potential NNP 0 1 UNK O
for IN 0 0 12 O
Drug NNP 0 1 2 O
Interactions NNS 0 1 UNK O
: : 0 0 2 O
It PRP 0 0 12 O
appears VBZ 1 1 12 O
possible JJ 0 1 1 O
although IN 0 0 12 O
there EX 0 0 12 O
is VBZ 1 0 12 O
no DT 0 0 12 O
supporting VBG 1 1 1 O
experimental JJ 0 1 UNK O
evidence NN 0 1 1 O
that IN 0 0 12 O
the DT 0 0 12 O
high JJ 0 1 1 O
renal JJ 0 1 6 O
clearance NN 0 1 16 O
of IN 0 0 12 O
desglymidodrine NN 0 1 UNK B-Drug_n
( ( 0 0 2 O
a DT 0 0 12 O
base NN 0 1 3 O
) ) 0 0 2 O
is VBZ 1 0 12 O
due JJ 0 1 1 O
to TO 0 0 12 O
active JJ 0 1 1 O
tubular JJ 0 1 3 O
secretion NN 0 1 14 O
by IN 0 0 12 O
the DT 0 0 12 O
base NN 0 1 3 O
- : 0 0 2 O
secreting NN 0 1 UNK O
system NN 0 1 1 O
also RB 0 0 12 O
responsible JJ 0 1 1 O
for IN 0 0 12 O
the DT 0 0 12 O
secretion NN 0 1 14 O
of IN 0 0 12 O
such JJ 0 0 1 O
drugs NNS 1 1 6 O
as IN 1 0 12 O
metformin NN 0 1 0 B-Drug
cimetidine NN 0 1 13 B-Drug
ranitidine NN 0 1 0 B-Drug
procainamide IN 0 1 16 B-Drug
triamterene JJ 0 1 13 B-Drug
flecainide NN 0 1 16 B-Drug
and CC 0 0 12 O
quinidine NN 0 1 16 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
safety NN 0 1 1 O
of IN 0 0 12 O
using VBG 1 1 1 O
methylphenidate NN 0 1 16 B-Drug
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
clonidine NN 0 1 0 B-Drug
or CC 0 0 12 O
other JJ 0 0 12 O
centrally RB 0 0 UNK O
acting VBG 1 1 12 O
alpha SYM 0 1 1 B-Group
- : 0 0 2 O
9 CD 0 0 2 I-Group
agonists NNS 1 1 UNK I-Group
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
systemically RB 0 0 UNK O
evaluated VBN 1 1 1 O
. . 0 0 12 O

General JJ 0 1 2 O
Interactions NNS 0 1 UNK O
: : 0 0 2 O
Certain NNP 0 1 UNK O
drugs NNS 1 1 6 O
could MD 0 0 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
likelihood NN 0 1 1 O
of IN 0 0 12 O
potentially RB 0 0 1 O
serious JJ 0 1 12 O
adverse JJ 0 0 1 O
effects NNS 1 1 1 O
with IN 0 0 12 O
bepridil JJ 0 1 UNK B-Drug
hydrochloride NN 0 1 0 I-Drug
. . 0 0 12 O

A DT 0 0 2 O
dose JJ 0 1 6 O
reduction NN 0 1 1 O
of IN 0 0 12 O
beta NN 0 1 16 B-Group
- : 0 0 2 O
adrenergic JJ 0 1 UNK I-Group
blockers NNS 1 0 6 I-Group
may MD 0 0 1 O
be VB 0 0 12 O
needed VBN 1 1 12 O
when WRB 0 0 12 O
a DT 0 0 12 O
hyperthyroid JJ 0 1 UNK O
patient NN 0 1 6 O
becomes VBZ 1 0 12 O
euthyroid JJ 0 1 14 O
. . 0 0 12 O

Currently RB 0 1 2 O
no DT 0 0 12 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
Calcitonin NNP 0 1 UNK B-Drug
salmon NN 0 1 16 I-Drug
have VBP 0 0 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
. . 0 0 12 O

Also RB 0 0 2 O
there EX 0 0 12 O
were VBD 1 0 12 O
no DT 0 0 12 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
differences NNS 1 1 UNK O
in IN 0 0 12 O
adverse JJ 0 0 1 O
events NNS 1 1 12 O
when WRB 0 0 12 O
loratadine NN 0 1 0 B-Drug
was VBD 1 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
or CC 0 0 12 O
without IN 0 0 12 O
ketoconazole NN 0 1 16 B-Drug
. . 0 0 12 O

No DT 0 0 2 O
information NN 0 1 1 O
available JJ 0 1 1 O

Since IN 0 1 2 O
MEXITIL NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
a DT 0 0 12 O
substrate NN 0 1 UNK O
for IN 0 0 12 O
the DT 0 0 12 O
metabolic JJ 0 1 6 O
pathways NNS 1 1 13 O
involving VBG 1 1 1 O
CYP9D9 NNP 0 0 UNK O
and CC 0 0 12 O
CYP9A9 NNP 0 0 UNK O
enzymes VBZ 0 1 14 O
inhibition NN 0 1 13 O
or CC 0 0 12 O
induction NN 0 1 1 O
of IN 0 0 12 O
either DT 0 1 12 O
of IN 0 0 12 O
these DT 0 0 12 O
enzymes NNS 1 1 14 O
would MD 0 0 12 O
be VB 0 0 12 O
expected VBN 1 1 12 O
to TO 0 0 12 O
alter VB 0 1 13 O
mexiletine NN 0 1 16 B-Drug
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
. . 0 0 12 O

Potentiation NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
hypotensive JJ 0 1 14 O
effects NNS 1 1 1 O
of IN 0 0 12 O
nitrates NNS 1 1 14 B-Group
for IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
ischemic JJ 0 1 6 O
heart NN 0 1 12 O
disease NN 0 1 6 O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
evaluated VBN 1 1 1 O
and CC 0 0 12 O
concomitant JJ 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
Vardenafil NNP 0 1 UNK B-Drug
and CC 0 0 12 O
nitrates NNS 1 1 14 B-Group
is VBZ 1 0 12 O
contraindicated VBN 1 1 14 O
. . 0 0 12 O

Drug NNP 0 1 2 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
with IN 0 0 12 O
Xigris NNS 0 1 UNK B-Brand
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
performed VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
severe JJ 0 1 6 O
sepsis NN 0 1 6 O
. . 0 0 12 O

Coadministration NN 0 1 UNK O
with IN 0 0 12 O
aspirin JJ 0 1 14 B-Brand
results NNS 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
slight JJ 0 1 3 O
decrease NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
rate NN 0 1 1 O
of IN 0 0 12 O
salicylate NN 0 1 13 B-Group
absorption NN 0 1 1 O
that WDT 0 0 12 O
is VBZ 1 0 12 O
clinically RB 0 0 6 O
unimportant JJ 0 0 UNK O
. . 0 0 12 O

The DT 0 0 2 O
clearance NN 0 1 16 O
of IN 0 0 12 O
salicylates NNS 1 1 13 B-Group
may MD 0 0 1 O
be VB 0 0 12 O
increased VBN 1 1 1 O
with IN 0 0 12 O
concurrent NN 0 1 1 O
use NN 0 1 1 O
of IN 0 0 12 O
corticosteroids NNS 1 1 14 B-Group
. . 0 0 12 O

This DT 0 0 2 O
led VBD 1 1 12 O
to TO 0 0 12 O
statistically RB 0 1 1 O
significant JJ 0 1 1 O
increases NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
elimination NN 0 1 UNK O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
and CC 0 0 12 O
in IN 0 0 12 O
the DT 0 0 12 O
extent NN 0 1 1 O
of IN 0 0 12 O
systemic JJ 0 1 6 O
exposure NN 0 1 1 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
. . 0 0 12 O

Methotrexate NNP 0 1 0 B-Drug
- : 0 0 2 O
There EX 0 0 12 O
is VBZ 1 0 12 O
one CD 0 1 12 O
report NN 0 1 1 O
that WDT 0 0 12 O
methotrexate NN 0 1 16 B-Drug
may MD 0 0 1 O
decrease VB 0 1 1 O
the DT 0 0 12 O
possible JJ 0 1 1 O
effectiveness NN 0 1 UNK O
of IN 0 0 12 O
supplemental JJ 0 1 1 O
L NNP 0 1 2 B-Drug
- : 0 0 2 O
glutamine NN 0 1 13 I-Drug
for IN 0 0 12 O
chemotherapy NN 0 1 6 O
- : 0 0 2 O
induced JJ 0 1 6 O
mucositis NN 0 1 8 O
. . 0 0 12 O

Expected VBN 0 1 2 O
changes NNS 1 1 1 O
in IN 0 0 12 O
laboratory JJ 0 1 1 O
assessments NNS 1 1 13 O
of IN 0 0 12 O
PT NNP 0 1 2 O
and CC 0 0 12 O
INR NNP 0 1 13 O
were VBD 1 0 12 O
observed VBN 1 1 1 O
after IN 0 0 12 O
warfarin JJ 0 1 14 B-Drug
administration NN 0 1 1 O
but CC 0 0 12 O
these DT 0 0 12 O
changes NNS 1 1 1 O
were VBD 1 0 12 O
not RB 0 1 12 O
affected VBN 1 1 1 O
by IN 0 0 12 O
concomitant JJ 0 1 6 O
lenalidomide JJ 0 1 UNK B-Drug
administration NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
co NN 0 1 12 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
Natrecor NNP 0 1 UNK B-Brand
with IN 0 0 12 O
IV NNP 0 1 2 O
vasodilators NNS 1 1 13 B-Group
such JJ 0 0 1 O
as IN 1 0 12 O
nitroglycerin JJ 0 1 14 B-Drug
nitroprusside IN 0 1 14 B-Drug
milrinone NN 0 1 14 B-Drug
or CC 0 0 12 O
IV NNP 0 1 2 O
ACE NNP 0 1 13 B-Group
inhibitors NNS 1 1 14 I-Group
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
evaluated VBN 1 1 1 O
( ( 0 0 2 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
were VBD 1 0 12 O
not RB 0 1 12 O
co JJ 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
with IN 0 0 12 O
Natrecor NNP 0 1 UNK B-Brand
in IN 0 0 12 O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
) ) 0 0 2 O
. . 0 0 12 O

Sildenafil NN 0 1 UNK B-Drug

Although IN 0 0 12 O
there EX 0 0 12 O
is VBZ 1 0 12 O
little JJ 0 1 12 O
published VBN 1 1 UNK O
information NN 0 1 1 O
on IN 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
lidocaine NN 0 1 14 B-Drug
and CC 0 0 12 O
Bretylium NNP 0 1 UNK B-Drug
Tosylate NNP 0 0 UNK I-Drug
these DT 0 0 12 O
drugs NNS 1 1 6 O
are VBP 1 0 12 O
often RB 0 1 12 O
administered VBN 1 1 1 O
concurrently RB 0 0 1 O
without IN 0 0 12 O
any DT 0 0 12 O
evidence NN 0 1 1 O
of IN 0 0 12 O
interactions NNS 1 1 UNK O
resulting VBG 1 1 1 O
in IN 0 0 12 O
adverse JJ 0 0 1 O
effects NNS 1 1 1 O
or CC 0 0 12 O
diminished VBN 1 1 1 O
efficacy NN 0 1 UNK O
. . 0 0 12 O

In IN 0 0 2 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
indicate VBP 0 0 1 O
that IN 0 0 12 O
the DT 0 0 12 O
binding NN 0 1 1 O
is VBZ 1 0 12 O
not RB 0 1 12 O
easily RB 0 1 12 O
removed VBN 1 1 3 O
. . 0 0 12 O

Coadministration NN 0 1 UNK O
of IN 0 0 12 O
Aprepitant NNP 0 1 UNK B-Drug
with IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
or CC 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
are VBP 1 0 12 O
known VBN 1 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
CYP9C9 NNP 0 0 UNK O
such JJ 0 0 1 O
as IN 1 0 12 O
phenytoin NN 0 1 16 B-Drug
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
lower JJR 1 1 1 O
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

. . 0 0 12 O

Caution NN 0 0 UNK O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
when WRB 0 0 12 O
administering VBG 1 1 1 O
doxorubicin NN 0 1 13 B-Drug
with IN 0 0 12 O
NEXAVAR NNP 0 1 UNK B-Brand
. . 0 0 12 O

Other JJ 0 0 2 O
nonsteroidal JJ 0 0 14 B-Group
anti SYM 0 0 3 I-Group
- : 0 0 2 O
inflammatory NN 0 1 6 I-Group
agents NNS 1 1 1 I-Group
( ( 0 0 2 O
e.g. VB 0 0 UNK O
aspirin RB 0 1 14 B-Brand
) ) 0 0 2 O
may MD 0 0 1 O
also RB 0 0 12 O
have VB 0 0 12 O
this DT 0 0 12 O
effect NN 0 1 1 O
. . 0 0 12 O

However RB 0 0 1 O
co SYM 0 1 12 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
Duloxetine NNP 0 1 0 B-Drug
with IN 0 0 12 O
aluminum NN 0 1 16 B-Drug
- : 0 0 2 O
and CC 0 0 12 O
magnesium VB 0 1 14 B-Drug
- : 0 0 2 O
containing VBG 1 1 1 O
antacids NNS 1 1 14 B-Group
( ( 0 0 2 O
9 CD 0 0 2 O
mEq NN 0 1 14 O
) ) 0 0 2 O
or CC 0 0 12 O
Duloxetine NNP 0 1 0 B-Drug
with IN 0 0 12 O
famotidine NN 0 1 0 B-Drug
had VBD 1 0 12 O
no DT 0 0 12 O
significant JJ 0 1 1 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
rate NN 0 1 1 O
or CC 0 0 12 O
extent NN 0 1 1 O
of IN 0 0 12 O
duloxetine NN 0 1 0 B-Drug
absorption NN 0 1 1 O
after IN 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
mg NN 0 1 0 O
oral JJ 0 1 6 O
dose NN 0 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
clinical JJ 0 1 6 O
relevance NN 0 1 UNK O
of IN 0 0 12 O
this DT 0 0 12 O
finding NN 0 1 12 O
is VBZ 1 0 12 O
unclear JJ 0 0 1 O
. . 0 0 12 O

increased VBN 1 1 1 O
creatine NN 0 1 14 O

Use NNP 0 1 2 O
in IN 0 0 12 O
Ambulatory NNP 0 1 7 O
Patients NNPS 0 1 7 O
The DT 0 0 2 O
effects NNS 1 1 1 O
of IN 0 0 12 O
ROMAZICON NNP 0 1 UNK B-Brand
may MD 0 0 1 O
wear VB 0 0 3 O
off RP 0 0 12 O
before IN 0 1 12 O
a DT 0 0 12 O
long JJ 0 1 12 B-Group
- : 0 0 2 O
acting VBG 1 1 12 I-Group
benzodiazepine NN 0 1 14 I-Group
is VBZ 1 0 12 O
completely RB 0 1 12 O
cleared VBN 1 1 12 O
from IN 0 0 12 O
the DT 0 0 12 O
body NN 0 1 3 O
. . 0 0 12 O

9 CD 0 0 2 O
years NNS 1 1 12 O
of IN 0 0 12 O
age NN 0 1 12 O
. . 0 0 12 O

Potassium NNP 0 1 14 B-Group
- : 0 0 2 O
sparing VBG 1 0 6 I-Group
diuretics NNS 1 1 14 I-Group
such JJ 0 0 1 O
as IN 1 0 12 O
spironolactone NN 0 1 0 B-Drug
triamterene NN 0 1 13 B-Drug
or CC 0 0 12 O
amiloride NN 0 1 16 B-Drug
or CC 0 0 12 O
potassium NN 0 1 14 B-Drug
supplements NNS 1 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
given VBN 1 1 12 O
only RB 0 1 12 O
for IN 0 0 12 O
documented VBN 1 1 1 O
hypokalemia NN 0 1 14 O
and CC 0 0 12 O
then RB 0 1 12 O
with IN 0 0 12 O
caution NN 0 0 1 O
since IN 0 1 12 O
they PRP 0 0 12 O
may MD 0 0 1 O
lead VB 0 1 12 O
to TO 0 0 12 O
a DT 0 0 12 O
significant JJ 0 1 1 O
increase NN 0 1 1 O
of IN 0 0 12 O
serum JJ 0 1 14 O
potassium NN 0 1 14 O
. . 0 0 12 O

Aspirin NN 0 1 0 B-Brand
: : 0 0 2 O
Concomitant JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
aspirin NN 0 1 14 B-Brand
( ( 0 0 2 O
9 CD 0 0 2 O
mg RB 0 1 0 O
TID NNP 0 1 15 O
) ) 0 0 2 O
to TO 0 0 12 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
tended VBD 1 0 1 O
to TO 0 0 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
AUC NNP 0 1 UNK O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
and CC 0 0 12 O
Cmax NNP 0 1 UNK O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
of IN 0 0 12 O
meloxicam NN 0 1 13 B-Drug
. . 0 0 12 O

Pharmacokinetic NNP 0 1 UNK O
data NNS 0 1 1 O
indicate VBP 0 0 1 O
that IN 0 0 12 O
oral JJ 0 1 6 O
ketoconazole NN 0 1 16 B-Drug
inhibits VBZ 1 1 UNK O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
astemizole JJ 0 1 UNK B-Drug
resulting VBG 1 1 1 O
in IN 0 0 12 O
elevated VBN 1 1 1 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
astemizole NN 0 1 UNK B-Drug
and CC 0 0 12 O
its PRP$ 1 0 12 O
active JJ 0 1 1 O
metabolite NN 0 1 UNK O
desmethylastemizole NN 0 1 UNK B-Drug_n
which WDT 0 0 12 O
may MD 0 0 1 O
prolong VB 0 0 13 O
QT NNP 0 1 13 O
intervals NNS 1 1 1 O
. . 0 0 12 O

Beta NNP 0 1 2 B-Group
- : 0 0 2 O
adrenergic NN 0 1 UNK I-Group
Blocking VBG 0 1 UNK I-Group
Agents NNS 0 1 2 I-Group
: : 0 0 2 O
Experience NN 0 1 UNK O
in IN 0 0 12 O
over IN 0 1 12 O
9 CD 0 0 2 O
patients NNS 1 1 6 O
in IN 0 0 12 O
a DT 0 0 12 O
non JJ 0 1 1 O
- : 0 0 2 O
comparative JJ 0 0 UNK O
clinical JJ 0 1 6 O
trial NN 0 1 12 O
has VBZ 1 0 12 O
shown VBN 1 1 1 O
that IN 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
nifedipine JJ 0 1 0 B-Drug
and CC 0 0 12 O
beta JJ 0 1 16 B-Group
- : 0 0 2 O
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
is VBZ 1 0 12 O
usually RB 0 1 12 O
well RB 0 1 12 O
tolerated VBN 1 0 1 O
but CC 0 0 12 O
there EX 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
occasional JJ 0 1 12 O
literature NN 0 1 UNK O
reports NNS 1 1 1 O
suggesting VBG 1 1 1 O
that IN 0 0 12 O
the DT 0 0 12 O
combination NN 0 1 1 O
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
likelihood NN 0 1 1 O
of IN 0 0 12 O
congestive JJ 0 1 6 O
heart NN 0 1 12 O
failure NN 0 1 1 O
severe JJ 0 1 6 O
hypotension NN 0 1 6 O
or CC 0 0 12 O
exacerbation NN 0 0 6 O
of IN 0 0 12 O
angina NN 0 1 6 O
. . 0 0 12 O

Concomitant NNP 0 1 UNK O
use NN 0 1 1 O
of IN 0 0 12 O
alcohol NN 0 1 1 B-Drug
with IN 0 0 12 O
phentermine JJ 0 1 UNK B-Drug
hydrochloride NN 0 1 0 I-Drug
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
an DT 0 0 12 O
adverse JJ 0 0 1 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
. . 0 0 12 O

In IN 0 0 2 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
also RB 0 0 12 O
indicate VBP 0 0 1 O
that IN 0 0 12 O
celecoxib NN 0 1 16 B-Drug
although IN 0 0 12 O
not RB 0 1 12 O
a DT 0 0 12 O
substrate NN 0 1 UNK O
is VBZ 1 0 12 O
an DT 0 0 12 O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
9D9 CD 0 0 UNK O
. . 0 0 12 O

Free JJ 0 1 2 O
thyroid NN 0 1 6 O
hormone NN 0 1 6 O
levels NNS 1 1 1 O
remain VBP 0 0 12 O
unchanged JJ 0 1 1 O
. . 0 0 12 O

Warfarin NN 0 1 0 B-Drug
: : 0 0 2 O
In IN 0 0 2 O
subjects NNS 1 1 UNK O
receiving VBG 1 1 1 O
warfarin NN 0 1 14 B-Drug
no DT 0 0 12 O
significant JJ 0 1 1 O
change NN 0 1 1 O
in IN 0 0 12 O
clotting VBG 1 1 14 O
time NN 0 1 12 O
was VBD 1 0 12 O
observed VBN 1 1 1 O
when WRB 0 0 12 O
grepafloxacin NN 0 1 UNK B-Drug
was VBD 1 0 12 O
coadministered VBN 0 0 UNK O
. . 0 0 12 O

When WRB 0 0 12 O
administered VBN 1 1 1 O
concurrently RB 0 0 1 O
the DT 0 0 12 O
following JJ 0 1 1 O
drugs NNS 1 1 6 O
may MD 0 0 1 O
interact VB 0 0 UNK O
with IN 0 0 12 O
ampicillin NN 0 1 0 B-Drug
. . 0 0 12 O

Antineoplastic JJ 0 1 UNK B-Group
agents NNS 1 1 1 I-Group
( ( 0 0 2 O
e. JJ 0 0 1 O
g. NN 0 1 13 O
nitrogen NN 0 1 1 B-Drug
mustard NN 0 1 UNK I-Drug
etc FW 0 1 12 O
. . 0 0 12 O
) ) 0 0 2 O
should MD 0 0 12 O
be VB 0 0 12 O
given VBN 1 1 12 O
concomitantly RB 0 0 14 O
only RB 0 1 12 O
with IN 0 0 12 O
great JJ 0 1 12 O
caution NN 0 0 1 O
. . 0 0 12 O

Poor NNP 0 1 2 O
metabolizers NNS 0 0 UNK O
have VBP 0 0 12 O
higher JJR 1 1 1 O
than IN 0 0 12 O
expected VBN 1 1 12 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
( ( 0 0 2 O
TCAs NNP 0 1 UNK B-Group
) ) 0 0 2 O
when WRB 0 0 12 O
given VBN 1 1 12 O
usual JJ 0 1 12 O
doses NNS 1 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
plasma JJ 0 1 14 O
concentration NN 0 1 1 O
of IN 0 0 12 O
CMI NNP 0 0 13 B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
be VB 0 0 12 O
increased VBN 1 1 1 O
by IN 0 0 12 O
the DT 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
haloperidol NN 0 1 16 B-Drug
; : 0 0 2 O

Therefore RB 0 0 1 O
agents NNS 1 1 1 O
affecting VBG 1 1 1 O
sympathetic JJ 0 0 13 O
activity NN 0 1 1 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
ganglionic NN 0 1 UNK B-Group
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
or CC 0 0 12 O
adrenergic JJ 0 1 UNK B-Group
neuron NN 0 1 13 I-Group
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
) ) 0 0 2 O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
with IN 0 0 12 O
caution NN 0 0 1 O
. . 0 0 12 O

. . 0 0 12 O

Ketoconazole NNP 0 1 UNK B-Drug
: : 0 0 2 O
Ketoconazole NNP 0 1 UNK B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
decrease VB 0 1 1 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
certain JJ 0 1 1 O
corticosteroids NNS 1 1 14 B-Group
by IN 0 0 12 O
up IN 0 0 12 O
to TO 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
leading VBG 1 1 1 O
to TO 0 0 12 O
increased VBN 1 1 1 O
risk NN 0 1 1 O
of IN 0 0 12 O
corticosteroid JJ 0 1 UNK B-Group
side NN 0 1 3 O
effects NNS 1 1 1 O
. . 0 0 12 O

All DT 0 0 2 O
vasopressors NNS 1 1 UNK B-Group
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
cautiously RB 0 0 UNK O
in IN 0 0 12 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
monoamine JJ 0 1 13 B-Group
oxidase NN 0 1 13 I-Group
MAO NNP 0 1 14 I-Group
inhibitors NNS 1 1 14 I-Group
. . 0 0 12 O

Boric NNP 0 1 UNK B-Drug
acid NN 0 1 14 I-Drug
may MD 0 0 1 O
interact VB 0 0 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
idoxuridine JJ 0 1 UNK B-Drug
preparation NN 0 1 1 O
causing VBG 1 1 1 O
a DT 0 0 12 O
gritty JJ 0 1 UNK O
substance NN 0 1 1 O
to TO 0 0 12 O
form VB 0 1 1 O
or CC 0 0 12 O
may MD 0 0 1 O
interact VB 0 0 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
preservative NN 0 1 16 O
in IN 0 0 12 O
the DT 0 0 12 O
idoxuridine JJ 0 1 UNK B-Drug
preparation NN 0 1 1 O
causing VBG 1 1 1 O
a DT 0 0 12 O
toxic JJ 0 1 1 O
effect NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
eye NN 0 1 3 O
. . 0 0 12 O

Nonetheless RB 0 0 1 O
they PRP 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
with IN 0 0 12 O
macrolide JJ 0 1 UNK B-Group
products NNS 1 1 1 I-Group
. . 0 0 12 O

No DT 0 0 2 O
pharmacokinetic JJ 0 1 UNK O
interactions NNS 1 1 UNK O
involving VBG 1 1 1 O
other JJ 0 0 12 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
isoenzymes NNS 0 1 14 O
are VBP 1 0 12 O
known VBN 1 1 12 O
. . 0 0 12 O

No DT 0 0 2 O
dose NN 0 1 6 O
relationship NN 0 1 12 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
. . 0 0 12 O

This DT 0 0 2 O
interaction NN 0 1 UNK O
appears VBZ 1 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
related VBN 1 1 1 O
both DT 0 0 12 O
to TO 0 0 12 O
pressor NN 0 1 14 O
activity NN 0 1 1 O
and CC 0 0 12 O
to TO 0 0 12 O
beta VB 0 1 16 O
- : 0 0 2 O
adrenergic NN 0 1 UNK O
stimulating VBG 1 1 1 O
properties NNS 1 1 UNK O
of IN 0 0 12 O
these DT 0 0 12 O
catecholamines NNS 1 1 14 B-Group
and CC 0 0 12 O
may MD 0 0 1 O
produce VB 0 0 1 O
ventricular JJ 0 1 8 O
arrhythmias NNS 1 1 6 O
and CC 0 0 12 O
hypertension NN 0 1 6 O
. . 0 0 12 O

Benzodiazepines NNS 0 1 UNK B-Group

Specific JJ 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
confirmed VBN 1 1 12 O
these DT 0 0 12 O
effects NNS 1 1 1 O
with IN 0 0 12 O
sevoflurane NN 0 1 UNK B-Drug
isoflurane NN 0 1 UNK B-Drug
propofol NN 0 1 14 B-Drug
alfentanil NN 0 1 UNK B-Drug
and CC 0 0 12 O
midazolam NN 0 1 16 B-Drug
. . 0 0 12 O

While IN 0 0 12 O
all PDT 0 0 12 O
the DT 0 0 12 O
selective JJ 0 1 13 B-Group
serotonin NN 0 1 13 I-Group
reuptake NN 0 1 13 I-Group
inhibitors NNS 1 1 14 I-Group
( ( 0 0 2 O
SSRIs NNP 0 1 UNK B-Group
) ) 0 0 2 O
e.g. VBP 0 0 UNK O
fluoxetine JJ 0 1 16 B-Drug
sertraline NN 0 1 16 B-Drug
paroxetine NN 0 1 16 B-Drug
and CC 0 0 12 O
fluvoxamine JJ 0 1 16 B-Drug
inhibit NN 0 1 13 O
P9 NNP 0 1 UNK O
9D9 CD 0 0 UNK O
they PRP 0 0 12 O
may MD 0 0 1 O
vary VB 0 0 1 O
in IN 0 0 12 O
the DT 0 0 12 O
extent NN 0 1 1 O
of IN 0 0 12 O
inhibition NN 0 1 13 O
. . 0 0 12 O

- : 0 0 2 O
In IN 0 0 2 O
isolated JJ 0 1 1 O
cases NNS 1 1 UNK O
a DT 0 0 12 O
pronounced JJ 0 0 12 O
though IN 0 0 12 O
reversible JJ 0 1 3 O
impairment NN 0 1 16 O
of IN 0 0 12 O
renal JJ 0 1 6 O
function NN 0 1 1 O
( ( 0 0 2 O
accompanied VBN 1 0 12 O
by IN 0 0 12 O
a DT 0 0 12 O
corresponding JJ 0 0 1 O
increase NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
serum NN 0 1 14 O
creatinine NN 0 1 14 O
level NN 0 1 1 O
) ) 0 0 2 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
organ JJ 0 1 6 O
transplant NN 0 1 6 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
immuno JJ 0 0 13 B-Group
- : 0 0 2 O
suppressant JJ 0 0 UNK I-Group
therapy NN 0 1 6 O
and CC 0 0 12 O
concomitant JJ 0 1 6 O
bezafibrate NN 0 1 UNK B-Drug
. . 0 0 12 O

Patients NNS 0 1 7 O
receiving VBG 1 1 1 O
azathioprine NN 0 1 13 B-Drug
and CC 0 0 12 O
allopurinol NN 0 1 13 B-Drug
concomitantly RB 0 0 14 O
should MD 0 0 12 O
have VB 0 0 12 O
a DT 0 0 12 O
dose JJ 0 1 6 O
reduction NN 0 1 1 O
of IN 0 0 12 O
azathioprine NN 0 1 13 B-Drug
to TO 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
/ JJ 0 0 2 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
/ NNS 0 0 2 O
9 CD 0 0 2 O
the DT 0 0 12 O
usual JJ 0 1 12 O
dose NN 0 1 6 O
. . 0 0 12 O

GABITRIL NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
considered VBN 1 1 1 O
to TO 0 0 12 O
be VB 0 0 12 O
a DT 0 0 12 O
non JJ 0 1 1 O
- : 0 0 2 O
enzyme NN 0 1 14 O
inducing VBG 1 1 6 O
AED NNP 0 1 UNK B-Group
. . 0 0 12 O

Lethargy NNP 0 1 UNK O
and CC 0 0 12 O
somnolence NN 0 1 8 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
following JJ 0 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
REVIA NNP 0 1 UNK B-Brand
and CC 0 0 12 O
thioridazine NN 0 1 13 B-Drug
. . 0 0 12 O

v NN 0 0 16 O
. . 0 0 12 O
Patients NNS 0 1 7 O
should MD 0 0 12 O
be VB 0 0 12 O
cautioned VBN 1 0 UNK O
regarding VBG 1 0 1 O
potential JJ 0 1 1 O
adverse JJ 0 0 1 O
cardiovascular JJ 0 1 6 O
effects NNS 1 1 1 O
such JJ 0 0 1 O
as IN 1 0 12 O
palpitations NNS 1 1 6 O
or CC 0 0 12 O
chest JJS 0 1 3 O
pain NN 0 1 6 O
. . 0 0 12 O

Elevated VBN 0 1 7 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
theophylline NN 0 1 16 B-Drug
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
with IN 0 0 12 O
concomitant NN 0 1 6 O
quinolone NN 0 1 UNK B-Group
use NN 0 1 1 O
. . 0 0 12 O

Therefore RB 0 0 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
VIOXX NNP 0 1 UNK B-Brand
antiplatelet NN 0 0 13 O
therapies NNS 1 1 6 O
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
discontinued VBN 1 1 1 O
and CC 0 0 12 O
should MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
an DT 0 0 12 O
indication NN 0 1 1 O
for IN 0 0 12 O
cardiovascular JJ 0 1 6 O
prophylaxis NN 0 1 6 O
. . 0 0 12 O

9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O

Concomitant JJ 0 1 UNK O
treatment NN 0 1 6 O
with IN 0 0 12 O
potassium NN 0 1 14 B-Group
- : 0 0 2 O
sparing VBG 1 0 6 I-Group
diuretics NNS 1 1 14 I-Group
may MD 0 0 1 O
be VB 0 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
increased JJ 0 1 1 O
serum NN 0 1 14 O
potassium NN 0 1 14 O
levels NNS 1 1 1 O
. . 0 0 12 O

Substances NNS 0 1 UNK O
that WDT 0 0 12 O
are VBP 1 0 12 O
potent JJ 0 1 UNK O
inhibitors NNS 1 1 14 O
of IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
activity NN 0 1 1 O
( ( 0 0 2 O
eg JJ 0 1 UNK O
ketoconazole NN 0 1 16 B-Drug
and CC 0 0 12 O
itraconazole NN 0 1 0 B-Drug
) ) 0 0 2 O
decrease NN 0 1 1 O
gefitinib JJ 0 1 UNK B-Drug
metabolism NN 0 1 16 O
and CC 0 0 12 O
increase VB 0 1 1 O
gefitinib NN 0 1 UNK B-Drug
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
. . 0 0 12 O

If IN 0 0 12 O
you PRP 0 0 12 O
are VBP 1 0 12 O
also RB 0 0 12 O
using VBG 1 1 1 O
a DT 0 0 12 O
steroid JJ 0 1 6 B-Group
inhaler NN 0 1 0 O
take VB 0 1 12 O
bitolterol NN 0 1 UNK B-Drug
first RB 0 1 12 O
and CC 0 0 12 O
then RB 0 1 12 O
wait VB 0 1 12 O
about IN 0 1 12 O
9 CD 0 0 2 O
minutes NNS 1 1 12 O
before IN 0 1 12 O
using VBG 1 1 1 O
the DT 0 0 12 O
steroid JJ 0 1 6 B-Group
inhaler NN 0 1 0 O
. . 0 0 12 O

In IN 0 0 2 O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
mean VBP 0 1 12 O
decreases NNS 1 1 UNK O
of IN 0 0 12 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
dL NNS 0 1 14 O
were VBD 1 0 12 O
observed VBN 1 1 1 O
in IN 0 0 12 O
arthritic JJ 0 0 UNK O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
etodolac NN 0 1 13 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
to TO 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
) ) 0 0 2 O
after IN 0 0 12 O
9 CD 0 0 2 O
weeks NNS 1 1 12 O
of IN 0 0 12 O
therapy NN 0 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
data NNS 0 1 1 O
described VBN 1 1 1 O
in IN 0 0 12 O
this DT 0 0 12 O
section NN 0 1 1 O
were VBD 1 0 12 O
obtained VBN 1 1 1 O
from IN 0 0 12 O
studies NNS 1 1 1 O
involving VBG 1 1 1 O
either CC 0 1 12 O
healthy JJ 0 1 12 O
subjects NNS 1 1 UNK O
or CC 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
epilepsy NN 0 1 13 O
. . 0 0 12 O

Depending VBG 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
fraction NN 0 1 1 O
of IN 0 0 12 O
drug NN 0 1 1 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
P9 NNP 0 1 UNK O
9D9 CD 0 0 UNK O
the DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
plasma JJ 0 1 14 O
concentration NN 0 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
small JJ 0 1 12 O
or CC 0 0 12 O
quite JJ 0 0 12 O
large JJ 0 1 3 O
( ( 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
fold JJ 0 1 3 O
increase NN 0 1 1 O
in IN 0 0 12 O
plasma JJ 0 1 14 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
TCA NNP 0 1 13 O
) ) 0 0 2 O
. . 0 0 12 O

A DT 0 0 2 O
rare JJ 0 1 12 O
but CC 0 0 12 O
serious JJ 0 1 12 O
constellation NN 0 0 UNK O
of IN 0 0 12 O
symptoms NNS 1 1 6 O
termed VBN 1 1 UNK O
serotonin JJ 0 1 13 O
syndrome NN 0 1 6 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
with IN 0 0 12 O
the DT 0 0 12 O
concomitant NN 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
selective JJ 0 1 13 B-Group
serotonin NNS 0 1 13 I-Group
reuptake VBP 0 1 13 I-Group
inhibitors NNS 1 1 14 I-Group
( ( 0 0 2 O
SSRIs NNP 0 1 UNK B-Group
) ) 0 0 2 O
and CC 0 0 12 O
agents NNS 1 1 1 O
for IN 0 0 12 O
migraine JJ 0 1 6 O
therapy NN 0 1 6 O
such JJ 0 0 1 O
as IN 1 0 12 O
Imitrex NNP 0 1 0 B-Brand
( ( 0 0 2 O
sumatriptan JJ 0 1 16 B-Drug
succinate NN 0 1 14 I-Drug
) ) 0 0 2 O
and CC 0 0 12 O
dihydroergotamine NN 0 1 UNK B-Drug
. . 0 0 12 O

Live JJ 0 1 UNK B-Group
Vaccines NNS 0 1 UNK I-Group
: : 0 0 2 O
During IN 0 0 2 O
treatment NN 0 1 6 O
with IN 0 0 12 O
Myfortic NNP 0 1 UNK B-Drug
the DT 0 0 12 O
use NN 0 1 1 O
of IN 0 0 12 O
live JJ 0 1 12 B-Group
attenuated VBN 1 1 UNK I-Group
vaccines NNS 1 1 6 I-Group
should MD 0 0 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
and CC 0 0 12 O
patients NNS 1 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
advised VBN 1 0 12 O
that IN 0 0 12 O
vaccinations NNS 1 1 13 O
may MD 0 0 1 O
be VB 0 0 12 O
less RBR 0 1 12 O
effective JJ 0 1 1 O
. . 0 0 12 O

ACE JJ 0 1 13 B-Group
inhibitors NNS 1 1 14 I-Group
: : 0 0 2 O
Reports NNS 0 1 2 O
suggest VBP 0 1 1 O
that IN 0 0 12 O
NSAIDs NNP 0 1 UNK B-Group
may MD 0 0 1 O
diminish VB 0 1 UNK O
the DT 0 0 12 O
antihypertensive JJ 0 1 14 O
effect NN 0 1 1 O
of IN 0 0 12 O
Angiotensin NNP 0 1 UNK B-Group
Converting NNP 0 0 UNK I-Group
Enzyme NNP 0 1 UNK I-Group
ACE NNP 0 1 13 I-Group
inhibitors NNS 1 1 14 I-Group
. . 0 0 12 O

The DT 0 0 2 O
bioavailability NN 0 1 UNK O
of IN 0 0 12 O
SKELID NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
increased VBN 1 1 1 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
fold NN 0 1 3 O
by IN 0 0 12 O
indomethacin NN 0 1 14 B-Drug
but CC 0 0 12 O
is VBZ 1 0 12 O
not RB 0 1 12 O
significantly RB 0 0 1 O
altered VBN 1 1 1 O
by IN 0 0 12 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
diclofenac NN 0 1 16 B-Drug
. . 0 0 12 O

Therefore RB 0 0 1 O
dose JJ 0 1 6 O
adjustments NNS 1 1 1 O
of IN 0 0 12 O
concomitant JJ 0 1 6 O
medications NNS 1 1 6 O
that WDT 0 0 12 O
are VBP 1 0 12 O
predominantly RB 0 0 1 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
CYP9D9 NNP 0 0 UNK O
and CC 0 0 12 O
have VBP 0 0 12 O
a DT 0 0 12 O
narrow JJ 0 1 3 O
therapeutic JJ 0 1 6 O
index NN 0 1 1 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
flecainide RB 0 1 16 B-Drug
vinblastine JJ 0 1 13 B-Drug
thioridazine NN 0 1 13 B-Drug
and CC 0 0 12 O
most JJS 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
) ) 0 0 2 O
may MD 0 0 1 O
be VB 0 0 12 O
required VBN 1 1 1 O
. . 0 0 12 O

Hydrocodone NN 0 1 0 B-Drug
increases VBZ 1 1 1 O
gabapentin JJ 0 1 0 B-Drug
AUC NNP 0 1 UNK O
values NNS 1 1 1 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

Clinically RB 0 0 7 O
significant JJ 0 1 1 O
interactions NNS 1 1 UNK O
would MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
expected VBN 1 1 12 O
since IN 0 1 12 O
the DT 0 0 12 O
NRTIs NNP 0 1 UNK B-Group
are VBP 1 0 12 O
metabolized VBN 1 1 UNK O
via IN 0 0 1 O
a DT 0 0 12 O
different JJ 0 1 1 O
route NN 0 1 12 O
than IN 0 0 12 O
efavirenz NN 0 1 13 B-Drug
and CC 0 0 12 O
would MD 0 0 12 O
be VB 0 0 12 O
unlikely JJ 0 1 12 O
to TO 0 0 12 O
compete VB 0 0 UNK O
for IN 0 0 12 O
the DT 0 0 12 O
same JJ 0 1 12 O
metabolic JJ 0 1 6 O
enzymes NNS 1 1 14 O
and CC 0 0 12 O
elimination NN 0 1 UNK O
pathways NNS 1 1 13 O
. . 0 0 12 O

Hypertensive JJ 0 1 7 O
crises NNS 1 1 13 O
have VBP 0 0 12 O
resulted VBN 1 1 1 O
when WRB 0 0 12 O
sympathomimetic JJ 0 1 13 B-Group
amines NNS 1 1 13 I-Group
have VBP 0 0 12 O
been VBN 1 0 12 O
used VBN 1 1 12 O
concomitantly RB 0 0 14 O
within9 JJ 0 0 UNK O
days NNS 1 1 12 O
following VBG 1 1 1 O
use NN 0 1 1 O
of IN 0 0 12 O
monoamine NN 0 1 13 B-Group
oxidase NN 0 1 13 I-Group
inhibitors NNS 1 1 14 I-Group
. . 0 0 12 O

The DT 0 0 2 O
pressor NN 0 1 14 O
response NN 0 1 1 O
of IN 0 0 12 O
adrenergic JJ 0 1 UNK B-Group
agents NNS 1 1 1 I-Group
may MD 0 0 1 O
also RB 0 0 12 O
be VB 0 0 12 O
potentiated VBN 1 0 UNK O
by IN 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
. . 0 0 12 O

High JJ 0 1 2 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
cefoxitin NN 0 1 13 B-Drug
in IN 0 0 12 O
the DT 0 0 12 O
urine NN 0 1 6 O
may MD 0 0 1 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
measurement NN 0 1 1 O
of IN 0 0 12 O
urinary JJ 0 1 6 O
9 CD 0 0 2 O
- : 0 0 2 O
hydroxy NN 0 1 14 O
- : 0 0 2 O
corticosteroids NNS 1 1 14 O
by IN 0 0 12 O
the DT 0 0 12 O
Porter NNP 0 1 UNK O
- : 0 0 2 O
Silber NNP 0 0 UNK O
reaction NN 0 1 1 O
and CC 0 0 12 O
produce VB 0 0 1 O
false JJ 0 1 13 O
increases NNS 1 1 1 O
of IN 0 0 12 O
modest JJ 0 1 1 O
degree NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
levels NNS 1 1 1 O
reported VBN 1 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
vitro NNP 0 1 UNK O
data NNS 0 1 1 O
suggest VBP 0 1 1 O
that IN 0 0 12 O
itraconazole NN 0 1 0 B-Drug
when WRB 0 0 12 O
compared VBN 1 1 1 O
to TO 0 0 12 O
ketoconazole VB 0 1 16 B-Drug
has VBZ 1 0 12 O
a DT 0 0 12 O
less RBR 0 1 12 O
pronounced JJ 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
biotransformation NN 0 1 UNK O
system NN 0 1 1 O
responsible JJ 0 1 1 O
for IN 0 0 12 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
astemizole NN 0 1 UNK B-Drug
. . 0 0 12 O

Sympathomimetic JJ 0 1 UNK B-Group
amines NNS 1 1 13 I-Group
may MD 0 0 1 O
reduce VB 0 0 1 O
the DT 0 0 12 O
antihypertensive JJ 0 1 14 O
effects NNS 1 1 1 O
of IN 0 0 12 O
reserpine NN 0 1 UNK B-Drug
veratrum NN 0 1 UNK B-Group
alkaloids NNS 1 1 13 I-Group
methyldopa NN 0 1 13 B-Drug
and CC 0 0 12 O
mecamylamine NN 0 1 UNK B-Drug
. . 0 0 12 O

Methylprednisolone NN 0 1 0 B-Drug

Adjustment NN 0 1 UNK O
of IN 0 0 12 O
dosage NN 0 1 0 O
of IN 0 0 12 O
oral JJ 0 1 6 O
anticoagulants NNS 1 1 13 B-Group
may MD 0 0 1 O
be VB 0 0 12 O
required VBN 1 1 1 O
. . 0 0 12 O

However RB 0 0 1 O
another DT 0 0 12 O
HMG NNP 0 0 UNK B-Group
- : 0 0 2 O
CoA NNP 0 0 UNK I-Group
reductase NN 0 1 UNK I-Group
inhibitor NN 0 1 14 I-Group
has VBZ 1 0 12 O
been VBN 1 0 12 O
found VBN 1 1 12 O
to TO 0 0 12 O
produce VB 0 0 1 O
a DT 0 0 12 O
less JJR 0 1 12 O
than IN 0 0 12 O
two CD 0 1 12 O
- : 0 0 2 O
second JJ 0 1 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
in IN 0 0 12 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
receiving VBG 1 1 1 O
low JJ 0 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
. . 0 0 12 O

Codeine NN 0 1 0 B-Drug
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
other JJ 0 0 12 O
narcotic JJ 0 1 6 B-Group
analgesics NNS 1 1 14 I-Group
general JJ 0 1 1 O
anesthetics NNS 1 1 13 B-Group
phenothiazines VBP 0 1 UNK B-Group
tranquilizers NNS 1 1 13 B-Group
sedative JJ 0 1 6 B-Group
- : 0 0 2 O
hypnotics NNS 1 1 13 I-Group
or CC 0 0 12 O
other JJ 0 0 12 O
CNS NNP 0 1 6 B-Group
depressants NNS 1 0 13 I-Group
( ( 0 0 2 O
including VBG 1 1 1 O
alcohol NN 0 1 1 B-Drug
) ) 0 0 2 O
has VBZ 1 0 12 O
additive JJ 0 1 16 O
depressant JJ 0 0 UNK O
effects NNS 1 1 1 O
. . 0 0 12 O

Patients NNS 0 1 7 O
receiving VBG 1 1 1 O
insulin NN 0 1 14 B-Drug
or CC 0 0 12 O
oral JJ 0 1 6 O
hypoglycemics NNS 0 1 14 B-Group
should MD 0 0 12 O
be VB 0 0 12 O
closely RB 0 0 1 O
watched VBN 1 0 12 O
during IN 0 0 12 O
initiation NN 0 1 1 O
of IN 0 0 12 O
thyroid JJ 0 1 6 O
replacement NN 0 1 1 O
therapy NN 0 1 6 O
. . 0 0 12 O

- : 0 0 2 O
Antidiabetics NNS 0 1 UNK B-Group
oral JJ 0 1 6 O
( ( 0 0 2 O
diabetes VBZ 0 1 6 O
medicine NN 0 1 6 O
you PRP 0 0 12 O
take VBP 0 1 12 O
by IN 0 0 12 O
mouth NN 0 1 3 O
) ) 0 0 2 O
Use NN 0 1 2 O
of IN 0 0 12 O
oral JJ 0 1 6 O
antidiabetics NNS 1 1 UNK B-Group
with IN 0 0 12 O
sulfapyridine NN 0 1 UNK B-Drug
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
chance NN 0 1 12 O
of IN 0 0 12 O
side JJ 0 1 3 O
effects NNS 1 1 1 O
affecting VBG 1 1 1 O
the DT 0 0 12 O
blood NN 0 1 6 O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
the DT 0 0 12 O
side NN 0 1 3 O
effects NNS 1 1 1 O
or CC 0 0 12 O
oral JJ 0 1 6 O
antidiabetics NNS 1 1 UNK B-Group

Continuous JJ 0 1 2 O
cardiac JJ 0 1 6 O
monitoring NN 0 1 1 O
is VBZ 1 0 12 O
not RB 0 1 12 O
required VBN 1 1 1 O
except IN 0 0 12 O
for IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
serious JJ 0 1 12 O
conduction NN 0 1 6 O
abnormalities NNS 1 1 6 O
. . 0 0 12 O

Concomitant JJ 0 1 UNK O
administration NN 0 1 1 O
contra SYM 0 0 UNK O
- : 0 0 2 O
indicated VBN 1 1 1 O
: : 0 0 2 O
- : 0 0 2 O
Vasoconstrictive JJ 0 0 UNK O
ergot NN 0 1 UNK B-Group
alkaloids NNS 1 1 13 I-Group
. . 0 0 12 O

Concomitant NNP 0 1 UNK O
use NN 0 1 1 O
of IN 0 0 12 O
agents NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressant JJ 0 1 6 I-Group
class NN 0 1 12 I-Group
( ( 0 0 2 O
which WDT 0 0 12 O
includes VBZ 1 1 1 O
Anafranil NNP 0 1 UNK B-Brand
) ) 0 0 2 O
with IN 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
can MD 0 0 12 O
inhibit VB 0 1 13 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
9D9 CD 0 0 UNK O
may MD 0 0 1 O
require VB 0 0 1 O
lower JJR 1 1 1 O
doses NNS 1 1 6 O
than IN 0 0 12 O
usually RB 0 1 12 O
prescribed VBN 1 1 1 O
for IN 0 0 12 O
either CC 0 1 12 O
the DT 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressant JJ 0 1 6 I-Group
agent NN 0 1 1 I-Group
or CC 0 0 12 O
the DT 0 0 12 O
other JJ 0 0 12 O
drug NN 0 1 1 O
. . 0 0 12 O

There EX 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
no RB 0 0 12 O
reported JJ 0 1 1 O
cases NNS 1 1 UNK O
from IN 0 0 12 O
spontaneous JJ 0 1 1 O
reports NNS 1 1 1 O
of IN 0 0 12 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
between IN 0 0 12 O
SSRIs NNP 0 1 UNK B-Group
and CC 0 0 12 O
D.H.E NNP 0 1 UNK B-Brand
9 CD 0 0 2 I-Brand
( ( 0 0 2 O
dihydroergotamine JJ 0 1 UNK B-Drug
mesylate NN 0 1 16 I-Drug
) ) 0 0 2 O
Injection NNP 0 1 7 O
USP NNP 0 1 UNK O
. . 0 0 12 O

Immunogenicity NNP 0 1 UNK O
/ NNP 0 0 2 O
Re NNP 0 1 UNK O
- : 0 0 2 O
exposure NN 0 1 1 O
: : 0 0 2 O
In IN 0 0 2 O
in IN 0 0 12 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
Angiomax NNP 0 1 UNK B-Brand
exhibited VBD 1 1 1 O
no DT 0 0 12 O
platelet NN 0 1 14 O
aggregation NN 0 1 UNK O
response NN 0 1 1 O
against IN 0 0 12 O
sera NN 1 1 UNK O
from IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
a DT 0 0 12 O
history NN 0 1 12 O
of IN 0 0 12 O
HIT NNP 0 1 11 O
/ NNP 0 0 2 O
HITTS NNP 0 0 UNK O
. . 0 0 12 O

. . 0 0 12 O

The DT 0 0 2 O
effect NN 0 1 1 O
of IN 0 0 12 O
concurrent JJ 0 1 1 O
application NN 0 1 1 O
of IN 0 0 12 O
ALTABAX NNP 0 1 UNK B-Brand
and CC 0 0 12 O
other JJ 0 0 12 O
topical JJ 0 1 6 O
products NNS 1 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
same JJ 0 1 12 O
area NN 0 1 12 O
of IN 0 0 12 O
skin NN 0 1 3 O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
studied VBN 1 0 1 O
. . 0 0 12 O

In IN 0 0 2 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
indicate VBP 0 0 1 O
that IN 0 0 12 O
at IN 0 0 12 O
therapeutic JJ 0 1 6 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
salicylate NN 0 1 13 B-Group
( ( 0 0 2 O
9 CD 0 0 2 O
m NN 0 1 2 O
g NN 0 1 16 O
/ NNP 0 0 2 O
mL NN 0 1 14 O
) ) 0 0 2 O
the DT 0 0 12 O
binding NN 0 1 1 O
of IN 0 0 12 O
ketorolac NN 0 1 16 B-Drug
was VBD 1 0 12 O
reduced VBN 1 1 1 O
from IN 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
to TO 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
representing VBG 1 1 1 O
a DT 0 0 12 O
potential JJ 0 1 1 O
twofold NN 0 0 UNK O
increase NN 0 1 1 O
in IN 0 0 12 O
unbound JJ 0 0 UNK O
ketorolac NN 0 1 16 B-Drug
plasma NN 0 1 14 O
levels NNS 1 1 1 O
. . 0 0 12 O

Although IN 0 0 12 O
the DT 0 0 12 O
magnitude NN 0 1 UNK O
of IN 0 0 12 O
changes NNS 1 1 1 O
in IN 0 0 12 O
diazepam NN 0 1 0 B-Drug
plasma NN 0 1 14 O
exposure NN 0 1 1 O
when WRB 0 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
valdecoxib NNS 0 1 13 B-Drug
were VBD 1 0 12 O
not RB 0 1 12 O
sufficient JJ 0 1 1 O
to TO 0 0 12 O
warrant VB 0 0 1 O
dosage NN 0 1 0 O
adjustments NNS 1 1 1 O
patients NNS 1 1 6 O
may MD 0 0 1 O
experience VB 0 1 12 O
enhanced JJ 0 1 1 O
sedative JJ 0 1 6 O
side NN 0 1 3 O
effects NNS 1 1 1 O
caused VBN 1 1 1 O
by IN 0 0 12 O
increased JJ 0 1 1 O
exposure NN 0 1 1 O
of IN 0 0 12 O
diazepam NN 0 1 0 B-Drug
under IN 0 0 12 O
this DT 0 0 12 O
circumstance NN 0 0 13 O
. . 0 0 12 O

Colestipol NNP 0 1 UNK B-Drug
- : 0 0 2 O
Concomitant JJ 0 1 UNK O
intake NN 0 1 3 O
of IN 0 0 12 O
colestipol NN 0 1 13 B-Drug
and CC 0 0 12 O
vitamin NN 0 1 6 B-Group
K NNP 0 1 2 I-Group
may MD 0 0 1 O
reduce VB 0 0 1 O
the DT 0 0 12 O
absorption NN 0 1 1 O
of IN 0 0 12 O
vitamin NN 0 1 6 B-Group
K NNP 0 1 2 I-Group
. . 0 0 12 O

In IN 0 0 2 O
view NN 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
potential JJ 0 1 1 O
risk NN 0 1 1 O
of IN 0 0 12 O
dehydration NN 0 1 6 O
secondary JJ 0 1 1 O
to TO 0 0 12 O
vomiting VBG 1 1 6 O
and CC 0 0 12 O
/ NNP 0 0 2 O
or CC 0 0 12 O
diarrhea NN 0 1 6 O
induced VBN 1 1 6 O
by IN 0 0 12 O
CAMPTOSAR NNP 0 1 UNK B-Brand
the DT 0 0 12 O
physician NN 0 1 6 O
may MD 0 0 1 O
wish VB 0 1 12 O
to TO 0 0 12 O
withhold VB 0 0 UNK O
diuretics NNS 1 1 14 B-Group
during IN 0 0 12 O
dosing VBG 1 0 14 O
with IN 0 0 12 O
CAMPTOSAR NNP 0 1 UNK B-Brand
and CC 0 0 12 O
certainly RB 0 0 12 O
during IN 0 0 12 O
periods NNS 1 1 1 O
of IN 0 0 12 O
active JJ 0 1 1 O
vomiting NN 0 1 6 O
or CC 0 0 12 O
diarrhea NN 0 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
effects NNS 1 1 1 O
of IN 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
TAMBOCOR NNP 0 1 UNK B-Brand
and CC 0 0 12 O
propranolol NN 0 1 16 B-Drug
on IN 0 0 12 O
the DT 0 0 12 O
PR NNP 0 1 2 O
interval NN 0 1 1 O
were VBD 1 0 12 O
less JJR 0 1 12 O
than IN 0 0 12 O
additive NN 0 1 16 O
. . 0 0 12 O

Fulvestrant NNP 0 1 UNK B-Drug
caused VBD 1 1 1 O
an DT 0 0 12 O
increased JJ 0 1 1 O
incidence NN 0 1 6 O
of IN 0 0 12 O
fetal JJ 0 1 6 O
abnormalities NNS 1 1 6 O
in IN 0 0 12 O
rats NNS 1 1 UNK O
( ( 0 0 2 O
tarsal JJ 0 1 13 O
flexure NN 0 1 8 O
of IN 0 0 12 O
the DT 0 0 12 O
hind NN 0 1 13 O
paw NN 0 1 13 O
at IN 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
/ NNP 0 0 2 O
day NN 0 1 12 O
IM NNP 0 1 11 O
; : 0 0 2 O

In IN 0 0 2 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
in IN 0 0 12 O
human JJ 0 1 1 O
liver NN 0 1 6 O
microsomes NNS 1 1 UNK O
showed VBD 1 1 12 O
that IN 0 0 12 O
paliperidone NN 0 1 16 B-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
substantially RB 0 0 1 O
inhibit VB 0 1 13 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
drugs NNS 1 1 6 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
isozymes NNS 0 1 UNK O
including VBG 1 1 1 O
CYP9A9 NNP 0 0 UNK O
CYP9A9 NNP 0 0 UNK O
CYP9C9 NNP 0 0 UNK O
/ VBD 0 0 2 O
9 CD 0 0 2 O
/ JJ 0 0 2 O
9 CD 0 0 2 O
CYP9D9 NNP 0 0 UNK O
CYP9E9 NNP 0 0 UNK O
CYP9A9 NNP 0 0 UNK O
and CC 0 0 12 O
CYP9A9 NNP 0 0 UNK O
. . 0 0 12 O

Pharmacokinetics NNS 0 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
appropriate JJ 0 1 1 O
doses NNS 1 1 6 O
for IN 0 0 12 O
this DT 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
respect NN 0 1 1 O
to TO 0 0 12 O
efficacy NN 0 1 UNK O
and CC 0 0 12 O
safety NN 0 1 1 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
established VBN 1 1 1 O
. . 0 0 12 O

9 CD 0 0 2 O
. . 0 0 12 O

If IN 0 0 12 O
treatment NN 0 1 6 O
with IN 0 0 12 O
inhibitors NNS 1 1 14 O
of IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
activity NN 0 1 1 O
( ( 0 0 2 O
such JJ 0 0 1 O
as IN 1 0 12 O
ketoconazole JJ 0 1 16 B-Drug
intraconazole NN 0 0 UNK B-Drug
ritonavir NN 0 1 16 B-Drug
indinavir NN 0 1 16 B-Drug
saquinavir NN 0 1 13 B-Drug
erythromycin NN 0 1 0 B-Drug
etc FW 0 1 12 O
. . 0 0 12 O
) ) 0 0 2 O
is VBZ 1 0 12 O
indicated JJ 0 1 1 O
reduction NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
budesonide NN 0 1 16 B-Drug
dose NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
data NNS 0 1 1 O
do VBP 0 0 12 O
not RB 0 1 12 O
suggest VB 0 1 1 O
the DT 0 0 12 O
need NN 0 1 12 O
for IN 0 0 12 O
dose JJ 0 1 6 O
adjustment NN 0 1 1 O
of IN 0 0 12 O
either DT 0 1 12 O
HUMIRA NNP 0 1 UNK B-Brand
or CC 0 0 12 O
MTX NNP 0 1 UNK B-Drug
. . 0 0 12 O

Currently RB 0 1 2 O
there EX 0 0 12 O
are VBP 1 0 12 O
no DT 0 0 12 O
safety NN 0 1 1 O
and CC 0 0 12 O
efficacy NN 0 1 UNK O
data NNS 0 1 1 O
available JJ 0 1 1 O
from IN 0 0 12 O
the DT 0 0 12 O
use NN 0 1 1 O
of IN 0 0 12 O
this DT 0 0 12 O
combination NN 0 1 1 O
. . 0 0 12 O

No DT 0 0 2 O
dose JJ 0 1 6 O
adjustment NN 0 1 1 O
is VBZ 1 0 12 O
necessary JJ 0 0 1 O
. . 0 0 12 O

PEGASYS NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
to TO 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
during IN 0 0 12 O
pregnancy NN 0 1 6 O
only RB 0 1 12 O
if IN 0 0 12 O
the DT 0 0 12 O
potential JJ 0 1 1 O
benefit NN 0 1 1 O
justifies VBZ 1 1 UNK O
the DT 0 0 12 O
potential JJ 0 1 1 O
risk NN 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
fetus NN 0 1 13 O
. . 0 0 12 O

Erythromycin NNP 0 1 0 O
Co NNP 0 1 2 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
felodipine NN 0 1 13 B-Drug
( ( 0 0 2 O
PLENDIL NNP 0 1 UNK B-Drug
) ) 0 0 2 O
with IN 0 0 12 O
erythromycin NN 0 1 0 B-Drug
resulted VBN 1 1 1 O
in IN 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
- : 0 0 2 O
fold JJ 0 1 3 O
increase NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
AUC NNP 0 1 UNK O
and CC 0 0 12 O
Cmax NNP 0 1 UNK O
and CC 0 0 12 O
about IN 0 1 12 O
9 CD 0 0 2 O
- : 0 0 2 O
fold JJ 0 1 3 O
prolongation NN 0 1 6 O
in IN 0 0 12 O
the DT 0 0 12 O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
of IN 0 0 12 O
felodipine NN 0 1 13 B-Drug
. . 0 0 12 O

In IN 0 0 2 O
a DT 0 0 12 O
clinical JJ 0 1 6 O
pharmacology NN 0 1 UNK O
study NN 0 1 1 O
indomethacin NN 0 1 14 B-Drug
or CC 0 0 12 O
sulindac NN 0 1 13 B-Drug
was VBD 1 0 12 O
administered VBN 1 1 1 O
to TO 0 0 12 O
hypertensive JJ 0 1 6 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
VASOTEC NNP 0 1 UNK B-Brand
. . 0 0 12 O

Increased VBN 0 1 7 O
nephrotoxicity NN 0 1 UNK O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
following VBG 1 1 1 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
cephalosporins NNS 1 1 14 B-Group
and CC 0 0 12 O
aminoglycoside JJ 0 1 14 B-Group
antibiotics NNS 1 1 6 I-Group
. . 0 0 12 O

9 CD 0 0 2 O
. . 0 0 12 O

If IN 0 0 12 O
midazolam VBN 0 1 16 B-Drug
is VBZ 1 0 12 O
administered VBN 1 1 1 O
parenterally RB 0 0 UNK O
special JJ 0 1 12 O
precaution NN 0 1 1 O
is VBZ 1 0 12 O
required VBN 1 1 1 O
since IN 0 1 12 O
the DT 0 0 12 O
sedative JJ 0 1 6 O
effect NN 0 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
prolonged VBN 1 1 6 O
. . 0 0 12 O

In IN 0 0 2 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
shown VBN 1 1 1 O
that IN 0 0 12 O
precipitation NN 0 1 1 O
occurs VBZ 1 1 1 O
when WRB 0 0 12 O
eye NN 0 1 3 O
drops VBZ 1 1 3 O
containing VBG 1 1 1 O
thimerosal NN 0 1 UNK B-Drug_n
are VBP 1 0 12 O
mixed JJ 0 1 3 O
with IN 0 0 12 O
latanoprost NN 0 1 16 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
griseofulvin NN 0 1 UNK B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
reduce VB 0 0 1 O
the DT 0 0 12 O
efficacy NN 0 1 UNK O
of IN 0 0 12 O
oral JJ 0 1 6 O
contraceptives NNS 1 1 13 B-Group
and CC 0 0 12 O
to TO 0 0 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
incidence NN 0 1 6 O
of IN 0 0 12 O
breakthrough NN 0 1 1 O
bleeding NN 0 1 6 O
. . 0 0 12 O

No DT 0 0 2 O
formal JJ 0 1 1 O
assessments NNS 1 1 13 O
of IN 0 0 12 O
drug NN 0 1 1 O
- : 0 0 2 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
between IN 0 0 12 O
Vidaza NNP 0 1 UNK B-Brand
and CC 0 0 12 O
other JJ 0 0 12 O
agents NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
conducted VBN 1 1 1 O

No DT 0 0 2 O
data NN 0 1 1 O
are VBP 1 0 12 O
available JJ 0 1 1 O
on IN 0 0 12 O
potential JJ 0 1 1 O
interactions NNS 1 1 UNK O
in IN 0 0 12 O
individuals NNS 1 1 1 O
who WP 0 0 12 O
consume VBP 0 0 1 O
greater JJR 1 1 1 O
than IN 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
of IN 0 0 12 O
caffeine JJ 0 1 6 B-Drug
per IN 0 0 1 O
day NN 0 1 12 O
or CC 0 0 12 O
in IN 0 0 12 O
those DT 0 0 12 O
such JJ 0 0 1 O
as IN 1 0 12 O
the DT 0 0 12 O
geriatric JJ 0 1 UNK O
population NN 0 1 13 O
who WP 0 0 12 O
are VBP 1 0 12 O
generally RB 0 0 1 O
believed VBN 1 0 12 O
to TO 0 0 12 O
be VB 0 0 12 O
more RBR 0 1 12 O
susceptible JJ 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
development NN 0 1 1 O
of IN 0 0 12 O
drug NN 0 1 1 O
- : 0 0 2 O
induced VBN 1 1 6 O
CNS NNP 0 1 6 O
- : 0 0 2 O
related JJ 0 1 1 O
adverse JJ 0 0 1 O
effects NNS 1 1 1 O
. . 0 0 12 O

Other JJ 0 0 2 O
Agents NNS 0 1 2 O
: : 0 0 2 O
PRINIVIL NNP 0 1 UNK B-Brand
has VBZ 1 0 12 O
been VBN 1 0 12 O
used VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
nitrates NNS 1 1 14 B-Group
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
digoxin NN 0 1 14 B-Drug
without IN 0 0 12 O
evidence NN 0 1 1 O
of IN 0 0 12 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
adverse JJ 0 0 1 O
interactions NNS 1 1 UNK O
. . 0 0 12 O

In IN 0 0 2 O
addition NN 0 1 1 O
deaths NNS 1 1 UNK O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
rarely RB 0 1 UNK O
with IN 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
terfenadine NN 0 1 UNK B-Drug
and CC 0 0 12 O
erythromycin NN 0 1 0 B-Drug
. . 0 0 12 O

Vasoconstrictors NNS 0 1 UNK B-Group
: : 0 0 2 O
D.H.E NNP 0 1 UNK B-Brand
9 CD 0 0 2 I-Brand
( ( 0 0 2 O
dihydroergotamine JJ 0 1 UNK B-Drug
mesylate NN 0 1 16 I-Drug
) ) 0 0 2 O
Injection NNP 0 1 7 O
USP NNP 0 1 UNK O
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
with IN 0 0 12 O
peripheral JJ 0 1 6 B-Group
vasoconstrictors NNS 1 1 UNK I-Group
because IN 0 0 12 O
the DT 0 0 12 O
combination NN 0 1 1 O
may MD 0 0 1 O
cause VB 0 1 12 O
synergistic JJ 0 1 UNK O
elevation NN 0 1 1 O
of IN 0 0 12 O
blood NN 0 1 6 O
pressure NN 0 1 1 O
. . 0 0 12 O

Concomitant NNP 0 1 UNK O
use NN 0 1 1 O
of IN 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
with IN 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
can MD 0 0 12 O
inhibit VB 0 1 13 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
9D9 CD 0 0 UNK O
may MD 0 0 1 O
require VB 0 0 1 O
lower JJR 1 1 1 O
doses NNS 1 1 6 O
than IN 0 0 12 O
usually RB 0 1 12 O
prescribed VBN 1 1 1 O
for IN 0 0 12 O
either CC 0 1 12 O
the DT 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressant NN 0 1 6 I-Group
or CC 0 0 12 O
the DT 0 0 12 O
other JJ 0 0 12 O
drug NN 0 1 1 O
. . 0 0 12 O

N=9 NNP 0 1 UNK O
) ) 0 0 2 O
Cmax NNP 0 1 UNK O
and CC 0 0 12 O
AUC NNP 0 1 UNK O
values NNS 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
dose JJ 0 1 6 O
- : 0 0 2 O
dependent JJ 0 1 1 O
manner NN 0 0 1 O
relative JJ 0 1 1 O
to TO 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
hydrocodone NN 0 1 UNK B-Drug
alone RB 0 1 12 O
; : 0 0 2 O

Corticosteroids NNS 0 1 UNK B-Group
and CC 0 0 12 O
Corticotropin NNP 0 1 UNK B-Drug
( ( 0 0 2 O
ACTH NNP 0 1 UNK B-Group
) ) 0 0 2 O
: : 0 0 2 O
may MD 0 0 1 O
potentiate VB 0 0 UNK O
amphotericin NN 0 1 14 B-Drug
B NNP 0 0 2 I-Drug
- : 0 0 2 O
induced VBD 1 1 6 O
hypokalemia NN 0 1 14 O
which WDT 0 0 12 O
may MD 0 0 1 O
predispose VB 0 0 UNK O
the DT 0 0 12 O
patient NN 0 1 6 O
to TO 0 0 12 O
cardiac VB 0 1 6 O
dysfunction NN 0 1 6 O
. . 0 0 12 O

Diltiazem NNP 0 1 0 B-Drug
nifedipine NN 0 1 0 B-Drug
verapamil NN 0 1 0 B-Drug

Other JJ 0 0 2 O
Highly NNP 0 1 UNK O
Protein NNP 0 1 2 O
- : 0 0 2 O
Bound NNP 0 1 UNK O
Drugs NNP 0 1 2 O
: : 0 0 2 O
Raloxifene NN 0 1 UNK B-Drug
is VBZ 1 0 12 O
more JJR 0 1 12 O
than IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
bound NN 0 1 12 O
to TO 0 0 12 O
plasma VB 0 1 14 O
proteins NNS 1 1 14 O
. . 0 0 12 O

Some DT 0 0 2 O
anticonvulsants NNS 1 1 13 B-Group
may MD 0 0 1 O
interact VB 0 0 UNK O
with IN 0 0 12 O
Mephenytoin NNP 0 1 UNK B-Drug
. . 0 0 12 O

The DT 0 0 2 O
results NNS 1 1 1 O
from IN 0 0 12 O
trials NNS 1 1 1 O
using VBG 1 1 1 O
the DT 0 0 12 O
intravenous JJ 0 1 14 O
prodrug NN 0 1 UNK O
are VBP 1 0 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
this DT 0 0 12 O
section NN 0 1 1 O
as IN 1 0 12 O
they PRP 0 0 12 O
relate VBP 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
role NN 0 1 1 O
of IN 0 0 12 O
valdecoxib NN 0 1 13 B-Drug
in IN 0 0 12 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
data NNS 0 1 1 O
presently RB 0 1 1 O
available JJ 0 1 1 O
indicate NN 0 0 1 O
that IN 0 0 12 O
the DT 0 0 12 O
decreases NNS 1 1 UNK O
in IN 0 0 12 O
some DT 0 0 12 O
individual JJ 0 1 1 O
ethinyl NN 0 0 13 B-Drug
estradiol NN 0 1 13 I-Drug
and CC 0 0 12 O
levonorgestrel NN 0 1 13 B-Drug
AUC NNP 0 1 UNK O
values VBZ 1 1 1 O
with IN 0 0 12 O
fluconazole JJ 0 1 0 B-Drug
treatment NN 0 1 6 O
are VBP 1 0 12 O
likely JJ 0 1 12 O
the DT 0 0 12 O
result NN 0 1 1 O
of IN 0 0 12 O
random JJ 0 1 13 O
variation NN 0 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
eight CD 0 1 12 O
HIV NNP 0 1 6 O
- : 0 0 2 O
infected JJ 0 1 6 O
patients NNS 1 1 6 O
the DT 0 0 12 O
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
ciprofloxacin NN 0 1 0 B-Drug
was VBD 1 0 12 O
decreased VBN 1 1 1 O
an DT 0 0 12 O
average NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
CI NNP 0 1 UNK O
= NNP 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
when WRB 0 0 12 O
ciprofloxacin NN 0 1 0 B-Drug
was VBD 1 0 12 O
administered VBN 1 1 1 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
prior RB 0 1 1 O
to TO 0 0 12 O
a DT 0 0 12 O
marketed VBN 1 1 UNK O
chewable JJ 0 0 16 O
/ NN 0 0 2 O
dispersible JJ 0 0 16 O
tablet NN 0 1 16 O
formulation NN 0 1 13 O
of IN 0 0 12 O
VIDEX NNP 0 1 UNK B-Brand
. . 0 0 12 O

Aspirin NNP 0 1 0 B-Brand
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
cautiously RB 0 0 UNK O
in IN 0 0 12 O
conjunction NN 0 1 1 O
with IN 0 0 12 O
corticosteroids NNS 1 1 14 B-Group
in IN 0 0 12 O
patients NNS 1 1 6 O
suffering VBG 1 1 12 O
from IN 0 0 12 O
hypoprothrombinemia NN 0 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
potential JJ 0 1 1 O
effects NNS 1 1 1 O
of IN 0 0 12 O
fulvestrant NN 0 1 13 B-Drug
on IN 0 0 12 O
the DT 0 0 12 O
fertility NN 0 1 6 O
of IN 0 0 12 O
male JJ 0 1 12 O
animals NNS 1 1 12 O
were VBD 1 0 12 O
not RB 0 1 12 O
studied VBN 1 0 1 O
but CC 0 0 12 O
in IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
month NN 0 1 12 O
toxicology NN 0 1 6 O
study NN 0 1 1 O
male NN 0 1 12 O
rats NNS 1 1 UNK O
treated VBD 1 1 1 O
with IN 0 0 12 O
intramuscular JJ 0 1 14 O
doses NNS 1 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
kg VBP 0 1 18 O
/ JJ 0 0 2 O
9 CD 0 0 2 O
days NNS 1 1 12 O
9 CD 0 0 2 O
mg JJ 0 1 0 O
/ NNP 0 0 2 O
rat NN 0 1 13 O
/ VBD 0 0 2 O
9 CD 0 0 2 O
days NNS 1 1 12 O
or CC 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
rat VBP 0 1 13 O
/ JJ 0 0 2 O
9 CD 0 0 2 O
days NNS 1 1 12 O
fulvestrant VBP 0 1 13 B-Drug
showed VBD 1 1 12 O
a DT 0 0 12 O
loss NN 0 1 1 O
of IN 0 0 12 O
spermatozoa NN 1 1 UNK O
from IN 0 0 12 O
the DT 0 0 12 O
seminiferous JJ 0 1 UNK O
tubules NNS 1 0 UNK O
seminiferous JJ 0 1 UNK O
tubular JJ 0 1 3 O
atrophy NN 0 1 6 O
and CC 0 0 12 O
degenerative JJ 0 1 6 O
changes NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
epididymides NNS 1 1 UNK O
. . 0 0 12 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interactions NNP 0 1 UNK O
FROVA NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
not RB 0 1 12 O
known VBN 1 1 12 O
to TO 0 0 12 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
commonly RB 0 0 UNK O
employed VBN 1 1 1 O
clinical JJ 0 1 6 O
laboratory NN 0 1 1 O
tests NNS 1 1 1 O
. . 0 0 12 O

Table JJ 0 1 UNK O
9 CD 0 0 2 O
Established VBN 0 1 UNK O
Drug NNP 0 1 2 O
Interactions NNS 0 1 UNK O
: : 0 0 2 O
Alteration NN 0 1 UNK O
in IN 0 0 12 O
Dose NNP 0 1 7 O
or CC 0 0 12 O
Regimen NNP 0 1 UNK O
May NNP 0 1 2 O
Be NNP 0 0 UNK O
Recommended VBN 0 1 2 O
Based VBN 0 1 2 O
on IN 0 0 12 O
Drug NNP 0 1 2 O
Interaction NNP 0 1 2 O
Studies NNP 0 1 2 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interactions NNP 0 1 UNK O
As IN 0 0 2 O
a DT 0 0 12 O
result NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
presence NN 0 1 1 O
of IN 0 0 12 O
nitrofurantoin FW 0 1 0 B-Drug
a DT 0 0 12 O
false JJ 0 1 13 O
- : 0 0 2 O
positive JJ 0 1 1 O
reaction NN 0 1 1 O
for IN 0 0 12 O
glucose NN 0 1 14 O
in IN 0 0 12 O
the DT 0 0 12 O
urine NN 0 1 6 O
may MD 0 0 1 O
occur VB 0 1 1 O
. . 0 0 12 O

Phenobarbital NN 0 1 0 B-Drug
: : 0 0 2 O
Coadministration NN 0 1 UNK O
of IN 0 0 12 O
felbamate NN 0 1 13 B-Drug
with IN 0 0 12 O
phenobarbital JJ 0 1 16 B-Drug
causes NNS 1 1 6 O
an DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
phenobarbital JJ 0 1 16 B-Drug
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
In IN 0 0 2 O
9 CD 0 0 2 O
otherwise RB 0 0 1 O
healthy JJ 0 1 12 O
male NN 0 1 12 O
volunteers NNS 1 1 UNK O
ingesting VBG 1 1 UNK O
phenobarbital JJ 0 1 16 B-Drug
the DT 0 0 12 O
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
trough NN 0 1 3 O
( ( 0 0 2 O
Cmin NNP 0 1 UNK O
) ) 0 0 2 O
phenobarbital JJ 0 1 16 B-Drug
concentration NN 0 1 1 O
was VBD 1 0 12 O
9 CD 0 0 2 O
micrograms NNS 1 1 14 O
/ JJ 0 0 2 O
mL NN 0 1 14 O
. . 0 0 12 O

however RB 0 0 12 O
no DT 0 0 12 O
deleterious JJ 0 0 6 O
interactions NNS 1 1 UNK O
were VBD 1 0 12 O
seen VBN 1 1 12 O
when WRB 0 0 12 O
ROMAZICON NNP 0 1 UNK B-Brand
was VBD 1 0 12 O
administered VBN 1 1 1 O
after IN 0 0 12 O
narcotics NNS 1 1 1 B-Group
inhalational JJ 0 1 14 O
anesthetics NNS 1 1 13 B-Group
muscle NN 0 1 6 B-Group
relaxants NNS 1 0 13 I-Group
and CC 0 0 12 O
muscle NN 0 1 6 O
relaxant NN 0 0 0 O
antagonists NNS 1 1 13 O
administered VBD 1 1 1 O
in IN 0 0 12 O
conjunction NN 0 1 1 O
with IN 0 0 12 O
sedation NN 0 1 6 O
or CC 0 0 12 O
anesthesia NN 0 1 6 O
. . 0 0 12 O

Tablets NNS 0 1 0 O
: : 0 0 2 O
The DT 0 0 2 O
benzodiazepines NNS 1 1 14 B-Group
including VBG 1 1 1 O
lorazepam JJ 0 1 0 B-Drug
produce NN 0 0 1 O
CNS NNP 0 1 6 O
- : 0 0 2 O
depressant NN 0 0 UNK O
effects NNS 1 1 1 O
when WRB 0 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
such JJ 0 0 1 O
medications NNS 1 1 6 O
as IN 1 0 12 O
barbiturates NNS 1 1 14 B-Group
or CC 0 0 12 O
alcohol NN 0 1 1 B-Drug
. . 0 0 12 O

Heparin NNP 0 1 0 B-Drug
other JJ 0 0 12 O
anticoagulants NNS 1 1 13 B-Group
thrombolytics NNS 1 1 14 B-Group
and CC 0 0 12 O
anti JJ 0 0 3 B-Group
platelet NN 0 1 14 I-Group
agents NNS 1 1 1 I-Group
are VBP 1 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
an DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
bleeding VBG 1 1 6 O
. . 0 0 12 O

Should MD 0 0 2 O
it PRP 0 0 12 O
be VB 0 0 12 O
decided VBN 1 0 12 O
to TO 0 0 12 O
discontinue VB 0 1 1 O
therapy NN 0 1 6 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
beta SYM 0 1 16 B-Group
- : 0 0 2 O
blockers NNS 1 0 6 I-Group
and CC 0 0 12 O
clonidine NN 0 1 0 B-Drug
concurrently RB 0 0 1 O
the DT 0 0 12 O
beta NN 0 1 16 B-Group
- : 0 0 2 O
blocker NN 0 0 3 I-Group
should MD 0 0 12 O
be VB 0 0 12 O
discontinued VBN 1 1 1 O
slowly RB 0 1 3 O
over IN 0 1 12 O
several JJ 0 1 12 O
days NNS 1 1 12 O
before IN 0 1 12 O
the DT 0 0 12 O
gradual JJ 0 1 1 O
withdrawal NN 0 1 1 O
of IN 0 0 12 O
clonidine NN 0 1 0 B-Drug
. . 0 0 12 O

Fluconazole NNP 0 1 0 B-Drug
tablets NNS 1 1 3 O
coadministered VBD 0 0 UNK O
with IN 0 0 12 O
ethinyl NN 0 0 13 B-Drug
estradiol SYM 0 1 13 I-Drug
- : 0 0 2 O
and CC 0 0 12 O
levonorgestrel VB 0 1 13 B-Drug
- : 0 0 2 O
containing VBG 1 1 1 O
oral JJ 0 1 6 O
contraceptives NNS 1 1 13 B-Group
produced VBD 1 0 1 O
an DT 0 0 12 O
overall JJ 0 1 1 O
mean JJ 0 1 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
ethinyl JJ 0 0 13 B-Drug
estradiol NN 0 1 13 I-Drug
and CC 0 0 12 O
levonorgestrel NN 0 1 13 B-Drug
levels NNS 1 1 1 O
; : 0 0 2 O

Such JJ 0 0 1 O
patients NNS 1 1 6 O
may MD 0 0 1 O
be VB 0 0 12 O
unresponsive JJ 0 1 6 O
to TO 0 0 12 O
the DT 0 0 12 O
usual JJ 0 1 12 O
doses NNS 1 1 6 O
of IN 0 0 12 O
epinephrine NN 0 1 14 B-Drug
used VBN 1 1 12 O
to TO 0 0 12 O
treat VB 0 1 12 O
the DT 0 0 12 O
allergic JJ 0 1 6 O
reaction NN 0 1 1 O
. . 0 0 12 O

Methotrexate NN 0 1 0 B-Drug
: : 0 0 2 O
NSAIDs NN 0 1 UNK B-Group
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
competitively RB 0 0 UNK O
inhibit VB 0 1 13 O
methotrexate JJ 0 1 16 B-Drug
accumulation NN 0 1 1 O
in IN 0 0 12 O
rabbit NN 0 1 16 O
kidney NN 0 1 6 O
slices NNS 1 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
ECG NNP 0 1 6 O
changes NNS 1 1 1 O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
hypokalemia NN 0 1 14 O
that WDT 0 0 12 O
may MD 0 0 1 O
result VB 0 1 1 O
from IN 0 0 12 O
the DT 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
non JJ 0 1 1 B-Group
- : 0 0 2 O
potassium NN 0 1 14 I-Group
sparing VBG 1 0 6 I-Group
diuretics NNS 1 1 14 I-Group
( ( 0 0 2 O
such JJ 0 0 1 O
as IN 1 0 12 O
loop NN 0 1 3 B-Group
or CC 0 0 12 O
thiazide VB 0 1 UNK B-Group
diuretics NNS 1 1 14 I-Group
) ) 0 0 2 O
can MD 0 0 12 O
be VB 0 0 12 O
acutely RB 0 0 6 O
worsened VBN 1 1 6 O
by IN 0 0 12 O
beta NN 0 1 16 B-Group
- : 0 0 2 O
agonists NNS 1 1 UNK I-Group
especially RB 0 0 12 O
when WRB 0 0 12 O
the DT 0 0 12 O
recommended VBN 1 1 1 O
dose NN 0 1 6 O
of IN 0 0 12 O
the DT 0 0 12 O
beta NN 0 1 16 B-Group
- : 0 0 2 O
agonist NN 0 1 14 I-Group
is VBZ 1 0 12 O
exceeded VBN 1 0 UNK O
. . 0 0 12 O

This DT 0 0 2 O
increase NN 0 1 1 O
is VBZ 1 0 12 O
due JJ 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
celecoxib JJ 0 1 16 B-Drug
metabolism NN 0 1 16 O
via IN 0 0 1 O
P9 NNP 0 1 UNK O
9C9 CD 0 0 UNK O
by IN 0 0 12 O
fluconazole NN 0 1 0 B-Drug
( ( 0 0 2 O
see VB 0 1 12 O
CLINICAL NNP 0 1 11 O
PHARMACOLOGY NNP 0 1 UNK O
- : 0 0 2 O
Pharmacokinetics NNS 0 1 UNK O
: : 0 0 2 O
Metabolism NN 0 1 UNK O
) ) 0 0 2 O
. . 0 0 12 O

Fatalities NNS 0 1 UNK O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
a DT 0 0 12 O
study NN 0 1 1 O
conducted VBN 1 1 1 O
in IN 0 0 12 O
healthy JJ 0 1 12 O
subjects NNS 1 1 UNK O
mean VBP 0 1 12 O
pre JJ 0 1 1 O
- : 0 0 2 O
dose JJ 0 1 6 O
lithium NN 0 1 16 B-Drug
concentration NN 0 1 1 O
and CC 0 0 12 O
AUC NNP 0 1 UNK O
were VBD 1 0 12 O
increased VBN 1 1 1 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
in IN 0 0 12 O
subjects NNS 1 1 UNK O
receiving VBG 1 1 1 O
lithium NN 0 1 16 B-Drug
doses NNS 1 1 6 O
ranging VBG 1 1 1 O
from IN 0 0 12 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
BID NNP 0 0 11 O
with IN 0 0 12 O
meloxicam NN 0 1 13 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
QD NNP 0 1 13 O
as IN 1 0 12 O
compared VBN 1 1 1 O
to TO 0 0 12 O
subjects NNS 1 1 UNK O
receiving VBG 1 1 1 O
lithium NN 0 1 16 B-Drug
alone RB 0 1 12 O
. . 0 0 12 O

For IN 0 0 2 O
this DT 0 0 12 O
reason NN 0 1 12 O
the DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
the DT 0 0 12 O
anticoagulant NN 0 1 13 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
reduced VBN 1 1 1 O
by IN 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
at IN 0 0 12 O
the DT 0 0 12 O
start NN 0 1 12 O
of IN 0 0 12 O
treatment NN 0 1 6 O
with IN 0 0 12 O
Bezalip NNP 0 1 UNK B-Brand
or CC 0 0 12 O
Bezalip NNP 0 1 UNK B-Brand
retard NN 0 1 13 O
and CC 0 0 12 O
then RB 0 1 12 O
titrated VBD 1 1 14 O
according VBG 1 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
blood NN 0 1 6 O
clotting NN 0 1 14 O
parameters NNS 1 1 1 O

Although IN 0 0 12 O
there EX 0 0 12 O
was VBD 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
Aprepitant NNP 0 1 UNK B-Drug
on IN 0 0 12 O
the DT 0 0 12 O
plasma NN 0 1 14 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
R NNP 0 1 2 B-Drug
or CC 0 0 12 O
S NNP 0 1 2 B-Drug
- : 0 0 2 O
warfarin NN 0 1 14 I-Drug
determined VBD 1 1 1 O
on IN 0 0 12 O
Day NNP 0 1 2 O
9 CD 0 0 2 O
there EX 0 0 12 O
was VBD 1 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
decrease NN 0 1 1 O
in IN 0 0 12 O
S NNP 0 1 2 B-Drug
- : 0 0 2 O
warfarin NN 0 1 14 I-Drug
( ( 0 0 2 O
a DT 0 0 12 O
CYP9C9 NNP 0 0 UNK O
substrate NN 0 1 UNK O
) ) 0 0 2 O
trough IN 0 1 3 O
concentration NN 0 1 1 O
accompanied VBN 1 0 12 O
by IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
decrease NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
prothrombin NN 0 1 14 O
time NN 0 1 12 O
( ( 0 0 2 O
reported VBN 1 1 1 O
as IN 1 0 12 O
International NNP 0 1 UNK O
Normalized NNP 0 1 UNK O
Ratio NNP 0 1 2 O
or CC 0 0 12 O
INR NNP 0 1 13 O
) ) 0 0 2 O
9 CD 0 0 2 O
days NNS 1 1 12 O
after IN 0 0 12 O
completion NN 0 1 1 O
of IN 0 0 12 O
dosing VBG 1 0 14 O
with IN 0 0 12 O
Aprepitant NNP 0 1 UNK B-Drug
. . 0 0 12 O

In IN 0 0 2 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
another DT 0 0 12 O
serotonin NN 0 1 13 B-Group
reuptake NN 0 1 13 I-Group
inhibitor JJ 0 1 14 I-Group
drug NN 0 1 1 I-Group
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
monoamine JJ 0 1 13 B-Group
oxidase NN 0 1 13 I-Group
inhibitors NNS 1 1 14 I-Group
( ( 0 0 2 O
MAOI NNP 0 1 UNK B-Group
) ) 0 0 2 O
there EX 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reports NNS 1 1 1 O
of IN 0 0 12 O
serious JJ 0 1 12 O
sometimes NNS 0 1 12 O
fatal JJ 0 1 13 O
reactions NNS 1 1 1 O
including VBG 1 1 1 O
hyperthermia NN 0 1 13 O
rigidity NN 0 1 3 O
myoclonus VBP 0 1 13 O
autonomic JJ 0 1 6 O
instability NN 0 1 1 O
with IN 0 0 12 O
possible JJ 0 1 1 O
rapid JJ 0 1 1 O
fluctuations NNS 1 1 UNK O
of IN 0 0 12 O
vital JJ 0 1 1 O
signs NNS 1 1 12 O
and CC 0 0 12 O
mental JJ 0 1 1 O
status NN 0 1 1 O
changes NNS 1 1 1 O
that WDT 0 0 12 O
include VBP 0 1 1 O
extreme JJ 0 1 1 O
agitation NN 0 1 1 O
progressing VBG 1 1 1 O
to TO 0 0 12 O
delirium VB 0 1 6 O
and CC 0 0 12 O
coma VB 0 1 6 O
. . 0 0 12 O

In IN 0 0 2 O
addition NN 0 1 1 O
the DT 0 0 12 O
frequency NN 0 1 1 O
of IN 0 0 12 O
monitoring VBG 1 1 1 O
serum JJ 0 1 14 O
lithium JJ 0 1 16 B-Drug
concentration NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
increased VBN 1 1 1 O
at IN 0 0 12 O
the DT 0 0 12 O
outset NN 0 0 UNK O
of IN 0 0 12 O
such JJ 0 0 1 O
combination JJ 0 1 1 O
drug NN 0 1 1 O
treatment NN 0 1 6 O
. . 0 0 12 O

Patients NNS 0 1 7 O
treated VBN 1 1 1 O
with IN 0 0 12 O
proton NN 0 1 14 B-Group
pump NN 0 1 3 I-Group
inhibitors NNS 1 1 14 I-Group
and CC 0 0 12 O
warfarin NNS 0 1 14 B-Drug
concomitantly RB 0 0 14 O
may MD 0 0 1 O
need VB 0 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
for IN 0 0 12 O
increases NNS 1 1 1 O
in IN 0 0 12 O
INR NNP 0 1 13 O
and CC 0 0 12 O
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
. . 0 0 12 O

Co NNP 0 1 2 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
MYOBLOC NNP 0 1 UNK B-Brand
and CC 0 0 12 O
aminoglycosides NNS 0 1 13 B-Group
or CC 0 0 12 O
other JJ 0 0 12 O
agents NNS 1 1 1 O
interfering VBG 1 1 13 O
with IN 0 0 12 O
neuromuscular JJ 0 1 6 O
transmission NN 0 1 1 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
curare NN 0 1 UNK B-Group
- : 0 0 2 O
like IN 0 0 12 I-Group
compounds NNS 1 1 13 I-Group
) ) 0 0 2 O
should MD 0 0 12 O
only RB 0 1 12 O
be VB 0 0 12 O
performed VBN 1 1 1 O
with IN 0 0 12 O
caution NN 0 0 1 O
as IN 1 0 12 O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
toxin NN 0 1 14 B-Drug
may MD 0 0 1 O
be VB 0 0 12 O
potentiated VBN 1 0 UNK O
. . 0 0 12 O

No DT 0 0 2 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
have VBP 0 0 12 O
been VBN 1 0 12 O
identified VBN 1 1 1 O
. . 0 0 12 O

Therefore RB 0 0 1 O
concomitant JJ 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
ribavirin NN 0 1 13 B-Drug
with IN 0 0 12 O
either DT 0 1 12 O
of IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
. . 0 0 12 O

NSAIDs NN 0 1 UNK B-Group
: : 0 0 2 O
In IN 0 0 2 O
in IN 0 0 12 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
M9 NNP 0 1 UNK O
was VBD 1 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
cause VB 0 1 12 O
increases NNS 1 1 1 O
ranging VBG 1 1 1 O
from IN 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
in IN 0 0 12 O
the DT 0 0 12 O
free JJ 0 1 12 O
fraction NN 0 1 1 O
of IN 0 0 12 O
diclofenac NN 0 1 16 B-Drug
and CC 0 0 12 O
ibuprofen NN 0 1 0 B-Drug
at IN 0 0 12 O
concentrations NNS 1 1 13 O
in IN 0 0 12 O
the DT 0 0 12 O
clinical JJ 0 1 6 O
range NN 0 1 1 O
. . 0 0 12 O

Effect NN 0 1 UNK O

Furosemide NN 0 1 0 B-Drug
: : 0 0 2 O
Clinical JJ 0 1 7 O
studies NNS 1 1 1 O
as RB 0 0 12 O
well RB 0 1 12 O
as IN 1 0 12 O
post NN 0 1 12 O
- : 0 0 2 O
marketing NN 0 1 UNK O
observations NNS 1 1 1 O
have VBP 0 0 12 O
shown VBN 1 1 1 O
that IN 0 0 12 O
NSAIDs NNP 0 1 UNK B-Group
can MD 0 0 12 O
reduce VB 0 0 1 O
the DT 0 0 12 O
natriuretic JJ 0 1 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
furosemide NN 0 1 0 B-Drug
and CC 0 0 12 O
thiazides NNS 1 1 UNK B-Group
in IN 0 0 12 O
some DT 0 0 12 O
patients NNS 1 1 6 O
. . 0 0 12 O

Therefore RB 0 0 1 O
caution NN 0 0 1 O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
when WRB 0 0 12 O
administering VBG 1 1 1 O
nitazoxanide RB 0 1 13 B-Drug
concurrently RB 0 0 1 O
with IN 0 0 12 O
other JJ 0 0 12 O
highly RB 0 1 1 O
plasma JJ 0 1 14 O
protein NN 0 1 14 O
- : 0 0 2 O
bound NN 0 1 12 O
drugs NNS 1 1 6 O
with IN 0 0 12 O
narrow JJ 0 1 3 O
therapeutic JJ 0 1 6 O
indices NNS 1 1 UNK O
as IN 1 0 12 O
competition NN 0 1 12 O
for IN 0 0 12 O
binding VBG 1 1 1 O
sites NNS 1 1 1 O
may MD 0 0 1 O
occur VB 0 1 1 O
( ( 0 0 2 O
e.g. VB 0 0 UNK O
warfarin NN 0 1 14 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

Usually RB 0 1 UNK O
such JJ 0 0 1 O
inactivation NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
aminoglycoside NN 0 1 14 B-Group
is VBZ 1 0 12 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
only RB 0 1 12 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
severely RB 0 1 1 O
impaired JJ 0 1 6 O
renal JJ 0 1 6 O
function.. NN 0 1 UNK O

FELDENE NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
highly RB 0 1 1 O
protein JJ 0 1 14 O
bound NN 0 1 12 O
and CC 0 0 12 O
therefore NN 0 0 1 O
might MD 0 0 12 O
be VB 0 0 12 O
expected VBN 1 1 12 O
to TO 0 0 12 O
displace VB 0 0 13 O
other JJ 0 0 12 O
protein NN 0 1 14 O
- : 0 0 2 O
bound NN 0 1 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

Phenobarbital NNP 0 1 0 B-Drug
toxicity NN 0 1 6 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
have VB 0 0 12 O
occurred VBN 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
patient NN 0 1 6 O
on IN 0 0 12 O
chronic JJ 0 1 6 O
phenobarbital JJ 0 1 16 B-Drug
treatment NN 0 1 6 O
following VBG 1 1 1 O
the DT 0 0 12 O
initiation NN 0 1 1 O
of IN 0 0 12 O
diclofenac JJ 0 1 16 B-Drug
therapy NN 0 1 6 O
. . 0 0 12 O

. . 0 0 12 O

Anticholinergic JJ 0 1 UNK B-Group
agents NNS 1 1 1 I-Group
may MD 0 0 1 O
affect VB 0 1 1 O
gastrointestinal JJ 0 1 6 O
absorption NN 0 1 1 O
of IN 0 0 12 O
various JJ 0 1 1 O
drugs NNS 1 1 6 O
such JJ 0 0 1 O
as IN 1 0 12 O
slowly RB 0 1 3 O
dissolving VBG 1 1 UNK O
dosage NN 0 1 0 O
forms NNS 1 1 1 O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
; : 0 0 2 O

This DT 0 0 2 O
effect NN 0 1 1 O
on IN 0 0 12 O
midazolam NN 0 1 16 B-Drug
appears VBZ 1 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
more RBR 0 1 12 O
pronounced JJ 0 0 12 O
following VBG 1 1 1 O
oral JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
fluconazole JJ 0 1 0 B-Drug
than IN 0 0 12 O
with IN 0 0 12 O
fluconazole JJ 0 1 0 B-Drug
administered VBN 1 1 1 O
intravenously RB 0 0 14 O
. . 0 0 12 O

Rifabutin NN 0 1 UNK B-Drug

Since IN 0 1 2 O
bacteriostatic JJ 0 0 UNK O
drugs NNS 1 1 6 O
may MD 0 0 1 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
bactericidal JJ 0 1 UNK O
action NN 0 1 13 O
of IN 0 0 12 O
penicillin NN 0 1 14 B-Drug
it PRP 0 0 12 O
is VBZ 1 0 12 O
advisable JJ 0 0 UNK O
to TO 0 0 12 O
avoid VB 0 0 12 O
giving VBG 1 1 12 O
tetracycline JJ 0 1 0 B-Group
class NN 0 1 12 I-Group
drugs NNS 1 1 6 I-Group
in IN 0 0 12 O
conjunction NN 0 1 1 O
with IN 0 0 12 O
penicillin NN 0 1 14 B-Drug
. . 0 0 12 O

pruritus NN 0 1 8 O

Before IN 0 1 2 O
using VBG 1 1 1 O
this DT 0 0 12 O
medication NN 0 1 6 O
tell VB 0 0 12 O
your PRP$ 0 0 12 O
doctor NN 0 1 12 O
or CC 0 0 12 O
pharmacist NN 0 1 13 O
of IN 0 0 12 O
all DT 0 0 12 O
prescription NN 0 1 0 O
and CC 0 0 12 O
nonprescription NN 0 1 UNK O
products NNS 1 1 1 O
you PRP 0 0 12 O
may MD 0 0 1 O
use VB 0 1 1 O
especially RB 0 0 12 O
of IN 0 0 12 O
: : 0 0 2 O
aminoglycosides NNS 0 1 13 B-Group
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
gentamicin NN 0 1 14 B-Drug
amikacin NN 0 1 0 B-Drug
) ) 0 0 2 O
amphotericin NN 0 1 14 B-Drug
B NNP 0 0 2 I-Drug
cyclosporine NN 0 1 14 B-Drug
non NN 0 1 1 B-Group
- : 0 0 2 O
steroidal NN 0 1 UNK I-Group
anti SYM 0 0 3 I-Group
- : 0 0 2 O
inflammatory NN 0 1 6 I-Group
drugs NNS 1 1 6 O
( ( 0 0 2 O
e.g. VB 0 0 UNK O
ibuprofen NN 0 1 0 B-Drug
) ) 0 0 2 O
tacrolimus NN 0 1 16 B-Drug
vancomycin NN 0 1 14 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
safety NN 0 1 1 O
and CC 0 0 12 O
efficacy NN 0 1 UNK O
of IN 0 0 12 O
concomitant JJ 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
REVIA NNP 0 1 UNK B-Brand
and CC 0 0 12 O
disulfiram NN 0 1 13 B-Drug
is VBZ 1 0 12 O
unknown JJ 0 1 12 O
and CC 0 0 12 O
the DT 0 0 12 O
concomitant NN 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
two CD 0 1 12 O
potentially RB 0 0 1 O
hepatotoxic JJ 0 1 UNK O
medications NNS 1 1 6 O
is VBZ 1 0 12 O
not RB 0 1 12 O
ordinarily RB 0 0 UNK O
recommended VBN 1 1 1 O
unless IN 0 0 12 O
the DT 0 0 12 O
probable JJ 0 1 1 O
benefits NNS 1 1 1 O
outweigh VBP 0 0 1 O
the DT 0 0 12 O
known JJ 0 1 12 O
risks NNS 1 1 1 O
. . 0 0 12 O

however RB 0 0 12 O
the DT 0 0 12 O
total JJ 0 1 1 O
amount NN 0 1 1 O
of IN 0 0 12 O
9MNA CD 0 0 UNK B-Drug_n
in IN 0 0 12 O
the DT 0 0 12 O
plasma NN 0 1 14 O
is VBZ 1 0 12 O
unchanged JJ 0 1 1 O
. . 0 0 12 O

Efavirenz NNP 0 1 UNK B-Drug

It PRP 0 0 12 O
is VBZ 1 0 12 O
important JJ 0 1 1 O
for IN 0 0 12 O
older JJR 1 1 12 O
adults NNS 1 1 13 O
to TO 0 0 12 O
be VB 0 0 12 O
aware JJ 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
relationship NN 0 1 12 O
between IN 0 0 12 O
folic JJ 0 0 14 B-Drug
acid NN 0 1 14 I-Drug
and CC 0 0 12 O
vitamin NN 0 1 6 B-Drug
B9 NNP 0 0 UNK I-Drug
because IN 0 0 12 O
they PRP 0 0 12 O
are VBP 1 0 12 O
at IN 0 0 12 O
greater JJR 1 1 1 O
risk NN 0 1 1 O
of IN 0 0 12 O
having VBG 1 0 12 O
a DT 0 0 12 O
vitamin NN 0 1 6 O
B9 NNP 0 0 UNK O
deficiency NN 0 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
natriuretic JJ 0 1 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
furosemide NN 0 1 0 B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
be VB 0 0 12 O
inhibited VBN 1 1 13 O
by IN 0 0 12 O
some DT 0 0 12 O
drugs NNS 1 1 6 O
of IN 0 0 12 O
this DT 0 0 12 O
class NN 0 1 12 O
. . 0 0 12 O

These DT 0 0 1 O
events NNS 1 1 12 O
were VBD 1 0 12 O
also RB 0 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
occur VB 0 1 1 O
when WRB 0 0 12 O
contrast NN 0 1 1 O
media NNS 1 1 1 O
was VBD 1 0 12 O
given VBN 1 1 12 O
several JJ 0 1 12 O
months NNS 1 1 12 O
after IN 0 0 12 O
interleukin JJ 0 1 13 B-Drug
- : 0 0 2 O
9 CD 0 0 2 I-Drug
treatment NN 0 1 6 O
. . 0 0 12 O

9 CD 0 0 2 O
. . 0 0 12 O

Serum NNP 0 1 7 O
concentration NN 0 1 1 O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
and CC 0 0 12 O
digitoxin NN 0 1 UNK B-Drug
may MD 0 0 1 O
increase VB 0 1 1 O
when WRB 0 0 12 O
patients NNS 1 1 6 O
take VBP 0 1 12 O
antithyroid JJ 0 0 13 B-Group
agents NNS 1 1 1 I-Group
. . 0 0 12 O

Due JJ 0 1 2 O
to TO 0 0 12 O
their PRP$ 0 0 12 O
similar JJ 0 1 1 O
mechanism NN 0 1 13 O
of IN 0 0 12 O
action NN 0 1 13 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
expected VBN 1 1 12 O
that IN 0 0 12 O
the DT 0 0 12 O
neuromuscular JJ 0 1 6 O
blockade NN 0 1 1 O
produced VBN 1 0 1 O
by IN 0 0 12 O
any DT 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
non JJ 0 1 1 B-Group
- : 0 0 2 O
depolarizing VBG 1 0 UNK I-Group
muscle NN 0 1 6 I-Group
relaxants NNS 1 0 13 I-Group
could MD 0 0 12 O
be VB 0 0 12 O
prolonged VBN 1 1 6 O
in IN 0 0 12 O
the DT 0 0 12 O
presence NN 0 1 1 O
of IN 0 0 12 O
piperacillin NN 0 1 16 B-Drug
. . 0 0 12 O

Therefore RB 0 0 1 O
coagulation NN 0 1 14 O
indices NNS 1 1 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
to TO 0 0 12 O
maintain VB 0 1 1 O
the DT 0 0 12 O
desired JJ 0 1 1 O
anticoagulant JJ 0 1 13 O
effect NN 0 1 1 O
. . 0 0 12 O

Cisapride NNP 0 1 0 B-Drug
is VBZ 1 0 12 O
metabolized VBN 1 1 UNK O
mainly RB 0 0 1 O
via IN 0 0 1 O
the DT 0 0 12 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
9A9 CD 0 0 UNK O
enzyme NN 0 1 14 O
. . 0 0 12 O

Bisphosphonates NNS 0 1 UNK B-Group
are VBP 1 0 12 O
known VBN 1 1 12 O
to TO 0 0 12 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
use NN 0 1 1 O
of IN 0 0 12 O
bone NN 0 1 6 O
- : 0 0 2 O
imaging NN 0 1 1 O
agents NNS 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
following JJ 0 1 1 O
laboratory NN 0 1 1 O
tests NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
found VBN 1 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
abnormal JJ 0 1 6 O
in IN 0 0 12 O
a DT 0 0 12 O
few JJ 0 1 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
baclofen NN 0 1 0 B-Drug
: : 0 0 2 O
increased VBN 1 1 1 O
SGOT NNP 0 0 14 O
elevated VBD 1 1 1 O
alkaline JJ 0 1 14 O
phosphatase NN 0 1 14 O
and CC 0 0 12 O
elevation NN 0 1 1 O
of IN 0 0 12 O
blood NN 0 1 6 O
sugar NN 0 1 3 O
. . 0 0 12 O

An DT 0 0 2 O
individual NN 0 1 1 O
who WP 0 0 12 O
is VBZ 1 0 12 O
stable JJ 0 1 1 O
on IN 0 0 12 O
a DT 0 0 12 O
given VBN 1 1 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
TCA NNP 0 1 13 B-Group
may MD 0 0 1 O
become VB 0 0 12 O
abruptly RB 0 0 UNK O
toxic JJ 0 1 1 O
when WRB 0 0 12 O
given VBN 1 1 12 O
one CD 0 1 12 O
of IN 0 0 12 O
these DT 0 0 12 O
inhibiting VBG 1 1 UNK O
drugs NNS 1 1 6 O
as IN 1 0 12 O
concomitant NN 0 1 6 O
therapy NN 0 1 6 O
. . 0 0 12 O

Selective JJ 0 1 7 B-Group
Serotonin NNP 0 1 UNK I-Group
Reuptake NNP 0 1 UNK I-Group
Inhibitors NNP 0 1 7 I-Group
( ( 0 0 2 O
SSRIs NNP 0 1 UNK B-Group
) ) 0 0 2 O
: : 0 0 2 O
SSRIs NNP 0 1 UNK B-Group
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
fluoxetine NN 0 1 16 B-Drug
fluvoxamine NN 0 1 16 B-Drug
paroxetine NN 0 1 16 B-Drug
sertraline NN 0 1 16 B-Drug
) ) 0 0 2 O
have VBP 0 0 12 O
been VBN 1 0 12 O
rarely RB 0 1 UNK O
reported VBN 1 1 1 O
to TO 0 0 12 O
cause VB 0 1 12 O
weakness NN 0 1 6 O
hyperreflexia NN 0 1 8 O
and CC 0 0 12 O
incoordination NN 0 1 UNK O
when WRB 0 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
9 CD 0 0 2 B-Group
- : 0 0 2 O
HT9 NN 0 1 UNK I-Group
agonists NNS 1 1 UNK I-Group
. . 0 0 12 O

Consequently RB 0 0 1 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
not RB 0 1 12 O
to TO 0 0 12 O
exceed VB 0 0 UNK O
a DT 0 0 12 O
single JJ 0 1 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
Vardenafil NNP 0 1 UNK B-Drug
dose NN 0 1 6 O
in IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
hour NN 0 1 12 O
period NN 0 1 1 O
when WRB 0 0 12 O
used VBN 1 1 12 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
ritonavir NN 0 1 16 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
use NN 0 1 1 O
of IN 0 0 12 O
antacids NNS 1 1 14 B-Group
should MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
in IN 0 0 12 O
place NN 0 1 12 O
of IN 0 0 12 O
H9 NNP 0 0 UNK B-Group
blockers NNS 1 0 6 I-Group
or CC 0 0 12 O
proton NN 0 1 14 B-Group
pump NN 0 1 3 I-Group
inhibitors NNS 1 1 14 I-Group
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
SPRYCEL NNP 0 1 UNK B-Brand
therapy NN 0 1 6 O
. . 0 0 12 O

Dexrazoxane NNP 0 1 UNK B-Drug
was VBD 1 0 12 O
not RB 0 1 12 O
mutagenic JJ 0 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
Ames NNP 0 1 UNK O
test NN 0 1 1 O
but CC 0 0 12 O
was VBD 1 0 12 O
found VBN 1 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
clastogenic JJ 0 1 UNK O
to TO 0 0 12 O
human JJ 0 1 1 O
lymphocytes NNS 1 1 14 O
in IN 0 0 12 O
vitro NN 0 1 UNK O
and CC 0 0 12 O
to TO 0 0 12 O
mouse VB 0 1 UNK O
bone NN 0 1 6 O
marrow NN 0 1 6 O
erythrocytes VBZ 0 1 UNK O
in IN 0 0 12 O
vivo NN 0 1 13 O
( ( 0 0 2 O
micronucleus JJ 0 1 UNK O
test NN 0 1 1 O
) ) 0 0 2 O
. . 0 0 12 O

Patients NNS 0 1 7 O
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
re JJ 0 0 12 O
- : 0 0 2 O
treated VBN 1 1 1 O
with IN 0 0 12 O
subsequent JJ 0 1 1 O
cycles NNS 1 1 1 O
of IN 0 0 12 O
TAXOL NNP 0 1 UNK B-Brand
until IN 0 0 12 O
neutrophils NNS 1 1 14 O
recover VBP 0 1 1 O
to TO 0 0 12 O
a DT 0 0 12 O
level NN 0 1 1 O
9 CD 0 0 2 O
cells NNS 1 1 6 O
/ JJ 0 0 2 O
mm9 NN 0 0 UNK O
and CC 0 0 12 O
platelets NNS 1 1 14 O
recover VBP 0 1 1 O
to TO 0 0 12 O
a DT 0 0 12 O
level NN 0 1 1 O
9 CD 0 0 2 O
9 CD 0 0 2 O
cells NNS 1 1 6 O
/ JJ 0 0 2 O
mm9 NN 0 0 UNK O
. . 0 0 12 O

The DT 0 0 2 O
use NN 0 1 1 O
of IN 0 0 12 O
erythromycin NN 0 1 0 B-Drug
in IN 0 0 12 O
patients NNS 1 1 6 O
concurrently RB 0 0 1 O
taking VBG 1 0 12 O
drugs NNS 1 1 6 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
the DT 0 0 12 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
system NN 0 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
elevations NNS 1 1 1 O
in IN 0 0 12 O
serum NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
these DT 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

Because IN 0 0 12 O
fluvoxamine NN 0 1 16 B-Drug
reduces VBZ 1 0 UNK O
the DT 0 0 12 O
clearance NN 0 1 16 O
of IN 0 0 12 O
both DT 0 0 12 O
diazepam NNS 0 1 0 B-Drug
and CC 0 0 12 O
its PRP$ 1 0 12 O
active JJ 0 1 1 O
metabolite NN 0 1 UNK O
N NNP 0 1 2 B-Drug_n
- : 0 0 2 O
desmethyldiazepam NN 0 1 UNK I-Drug_n
there EX 0 0 12 O
is VBZ 1 0 12 O
a DT 0 0 12 O
strong JJ 0 1 12 O
likelihood NN 0 1 1 O
of IN 0 0 12 O
substantial JJ 0 0 1 O
accumulation NN 0 1 1 O
of IN 0 0 12 O
both DT 0 0 12 O
species NNS 1 1 1 O
during IN 0 0 12 O
chronic JJ 0 1 6 O
co NN 0 1 12 O
- : 0 0 2 O
administration NN 0 1 1 O
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
suggested VBN 1 1 12 O
to TO 0 0 12 O
monitor VB 0 1 1 O
both DT 0 0 12 O
ketoconazole NN 0 1 16 B-Drug
and CC 0 0 12 O
phenytoin NN 0 1 16 B-Drug
. . 0 0 12 O

Results NNS 0 1 2 O
from IN 0 0 12 O
limited JJ 0 1 1 O
in IN 0 0 12 O
vitro NN 0 1 UNK O
and CC 0 0 12 O
in IN 0 0 12 O
vivo JJ 0 1 13 O
drug NN 0 1 1 O
- : 0 0 2 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
between IN 0 0 12 O
tamsulosin NN 0 1 16 B-Drug
HCI NNP 0 0 UNK I-Drug
and CC 0 0 12 O
warfarin NN 0 1 14 B-Drug
are VBP 1 0 12 O
inconclusive JJ 0 1 13 O
. . 0 0 12 O

Johns NNP 0 0 UNK O
Wort NNP 0 0 UNK O
concomitantly RB 0 0 14 O
. . 0 0 12 O

Animal NNP 0 1 UNK O
studies NNS 1 1 1 O
indicate VBP 0 0 1 O
that IN 0 0 12 O
dobutamine NN 0 1 14 B-Drug
may MD 0 0 1 O
be VB 0 0 12 O
ineffective JJ 0 1 UNK O
if IN 0 0 12 O
the DT 0 0 12 O
patient NN 0 1 6 O
has VBZ 1 0 12 O
recently RB 0 1 12 O
received VBN 1 1 12 O
a DT 0 0 12 O
b SYM 0 0 16 B-Group
- : 0 0 2 O
blocking VBG 1 1 UNK I-Group
drug NN 0 1 1 I-Group
. . 0 0 12 O

Therefore RB 0 0 1 O
precaution NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
taken VBN 1 1 12 O
when WRB 0 0 12 O
coadministration NN 0 1 UNK O
is VBZ 1 0 12 O
necessary JJ 0 0 1 O
. . 0 0 12 O

Diuretic JJ 0 1 UNK B-Group
agents NNS 1 1 1 I-Group
reduce VB 0 0 1 O
the DT 0 0 12 O
renal JJ 0 1 6 O
clearance NN 0 1 16 O
of IN 0 0 12 O
lithium NN 0 1 16 B-Drug
and CC 0 0 12 O
add VB 0 1 12 O
a DT 0 0 12 O
high JJ 0 1 1 O
risk NN 0 1 1 O
of IN 0 0 12 O
lithium NN 0 1 16 B-Drug
toxicity NN 0 1 6 O
. . 0 0 12 O

Anticoagulants NNS 0 1 UNK B-Group
( ( 0 0 2 O
Oral NNP 0 1 2 O
) ) 0 0 2 O
: : 0 0 2 O
The DT 0 0 2 O
hypoprothrombinemic JJ 0 1 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
anticoagulants NNS 1 1 13 B-Group
may MD 0 0 1 O
be VB 0 0 12 O
potentiated VBN 1 0 UNK O
apparently RB 0 1 12 O
by IN 0 0 12 O
increased JJ 0 1 1 O
catabloism NN 0 0 UNK O
of IN 0 0 12 O
vitamin NN 0 1 6 O
K NNP 0 1 2 O
- : 0 0 2 O
dependent JJ 0 1 1 O
clotting NN 0 1 14 O
factors NNS 1 1 1 O
. . 0 0 12 O

clinically RB 0 0 6 O
significant JJ 0 1 1 O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
through IN 0 0 12 O
competition NN 0 1 12 O
for IN 0 0 12 O
protein NN 0 1 14 O
binding NN 0 1 1 O
sites NNS 1 1 1 O
are VBP 1 0 12 O
therefore RB 0 0 1 O
unlikely JJ 0 1 12 O
. . 0 0 12 O

- : 0 0 2 O
Oral NN 0 1 2 O
contraceptives NNS 1 1 13 B-Group
( ( 0 0 2 O
birth NN 0 1 12 O
control NN 0 1 1 O
pills NNS 1 1 6 O
) ) 0 0 2 O
containing VBG 1 1 1 O
estrogen NN 0 1 6 B-Group
or CC 0 0 12 O

Sumatriptan NN 0 1 UNK B-Drug
: : 0 0 2 O
Sumatriptan NNP 0 1 UNK B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
cause VB 0 1 12 O
coronary JJ 0 1 6 O
artery NN 0 1 6 O
vasospasm NN 0 1 8 O
and CC 0 0 12 O
its PRP$ 1 0 12 O
effect NN 0 1 1 O
could MD 0 0 12 O
be VB 0 0 12 O
additive JJ 0 1 16 O
with IN 0 0 12 O
D.H.E NNP 0 1 UNK B-Brand
9 CD 0 0 2 I-Brand
( ( 0 0 2 O
dihydroergotamine JJ 0 1 UNK B-Drug
mesylate NN 0 1 16 I-Drug
) ) 0 0 2 O
Injection NNP 0 1 7 O
USP NNP 0 1 UNK O
. . 0 0 12 O

HEMABATE NN 0 1 UNK B-Brand
may MD 0 0 1 O
augment VB 0 1 13 O
the DT 0 0 12 O
activity NN 0 1 1 O
of IN 0 0 12 O
other JJ 0 0 12 O
oxytocic JJ 0 1 13 B-Group
agents NNS 1 1 1 I-Group
. . 0 0 12 O

This DT 0 0 2 O
indicates VBZ 1 0 1 O
that IN 0 0 12 O
gabapentin NN 0 1 0 B-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
undergo JJ 0 0 1 O
renal JJ 0 1 6 O
tubular JJ 0 1 3 O
secretion NN 0 1 14 O
by IN 0 0 12 O
the DT 0 0 12 O
pathway NN 0 1 UNK O
that WDT 0 0 12 O
is VBZ 1 0 12 O
blocked VBN 1 1 13 O
by IN 0 0 12 O
probenecid NN 0 1 13 B-Drug
. . 0 0 12 O

In IN 0 0 2 O
Study NNP 0 1 2 O
9 CD 0 0 2 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
bolus JJ 0 1 14 O
- : 0 0 2 O
IFL NNP 0 1 UNK O
plus CC 0 1 16 O
AVASTIN NNP 0 1 UNK B-Brand
had VBD 1 0 12 O
a DT 0 0 12 O
higher JJR 1 1 1 O
incidence NN 0 1 6 O
of IN 0 0 12 O
Grade NNP 0 1 2 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
diarrhea NN 0 1 6 O
and CC 0 0 12 O
neutropenia NN 0 1 14 O
. . 0 0 12 O

In IN 0 0 2 O
addition NN 0 1 1 O
most JJS 0 0 12 O
macrolides NNS 0 1 13 B-Group
are VBP 1 0 12 O
contraindicated VBN 1 1 14 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
terfenadine JJ 0 1 UNK B-Drug
therapy NN 0 1 6 O
who WP 0 0 12 O
have VBP 0 0 12 O
pre VBN 0 1 1 O
- : 0 0 2 O
existing VBG 1 1 1 O
cardiac JJ 0 1 6 O
abnormalities NNS 1 1 6 O
( ( 0 0 2 O
arrhythmia JJ 0 1 6 O
bradycardia NN 0 1 8 O
QT NNP 0 1 13 O
c VBZ 0 0 16 O
interval JJ 0 1 1 O
prolongation NN 0 1 6 O
ischemic JJ 0 1 6 O
heart NN 0 1 12 O
disease NN 0 1 6 O
congestive JJ 0 1 6 O
heart NN 0 1 12 O
failure NN 0 1 1 O
etc FW 0 1 12 O
. . 0 0 12 O
) ) 0 0 2 O
or CC 0 0 12 O
electrolyte JJ 0 1 14 O
disturbances NNS 1 1 6 O
. . 0 0 12 O

Using VBG 0 1 2 O
calcium NN 0 1 14 B-Drug
acetate NN 0 1 14 I-Drug
with IN 0 0 12 O
digitalis NN 0 1 14 B-Group
glycosides NNS 1 1 13 I-Group
( ( 0 0 2 O
heart NN 0 1 12 O
medicine NN 0 1 6 O
) ) 0 0 2 O
may MD 0 0 1 O
cause VB 0 1 12 O
hypercalcemia NN 0 1 8 O
( ( 0 0 2 O
too RB 0 0 12 O
much JJ 0 0 12 O
calcium NN 0 1 14 B-Drug
in IN 0 0 12 O
the DT 0 0 12 O
blood NN 0 1 6 O
) ) 0 0 2 O
which WDT 0 0 12 O
could MD 0 0 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
chance NN 0 1 12 O
of IN 0 0 12 O
developing VBG 1 0 1 O
an DT 0 0 12 O
irregular JJ 0 1 3 O
heartbeat NN 0 1 UNK O
. . 0 0 12 O

These DT 0 0 1 O
drugs NNS 1 1 6 O
include VBP 0 1 1 O
the DT 0 0 12 O
thiazides NNS 1 1 UNK B-Group
and CC 0 0 12 O
other JJ 0 0 12 O
diuretics NNS 1 1 14 B-Group
corticosteroids NNS 1 1 14 B-Group
phenothiazines NNS 1 1 UNK B-Group
thyroid JJ 0 1 6 O
products NNS 1 1 1 O
estrogens VBZ 0 1 16 B-Group
oral JJ 0 1 6 O
contraceptives NNS 1 1 13 B-Group
phenytoin VBP 0 1 16 B-Drug
nicotinic JJ 0 1 13 B-Drug
acid NN 0 1 14 I-Drug
sympathomimetics NNS 0 1 13 B-Group
calcium JJ 0 1 14 B-Group
channel NNS 0 1 1 I-Group
blocking VBG 1 1 UNK I-Group
drugs NNS 1 1 6 I-Group
and CC 0 0 12 O
isoniazid NN 0 1 13 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
effect NN 0 1 1 O
of IN 0 0 12 O
desflurane NN 0 1 UNK B-Drug
on IN 0 0 12 O
the DT 0 0 12 O
disposition NN 0 1 1 O
of IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
determined VBN 1 1 1 O
. . 0 0 12 O

Hypersensitivity NNP 0 1 7 O
Reactions NNS 0 1 UNK O
: : 0 0 2 O
Patients NNS 0 1 7 O
with IN 0 0 12 O
a DT 0 0 12 O
history NN 0 1 12 O
of IN 0 0 12 O
severe JJ 0 1 6 O
hypersensitivity NN 0 1 6 O
reactions NNS 1 1 1 O
to TO 0 0 12 O
products NNS 1 1 1 O
containing VBG 1 1 1 O
Cremophor NNP 0 1 UNK O
EL NNP 0 1 UNK O
( ( 0 0 2 O
eg JJ 0 1 UNK O
cyclosporin NN 0 1 14 B-Drug
for IN 0 0 12 O
injection NN 0 1 3 O
concentrate NN 0 1 1 O
and CC 0 0 12 O
teniposide NN 0 1 UNK B-Drug
for IN 0 0 12 O
injection NN 0 1 3 O
concentrate NN 0 1 1 O
) ) 0 0 2 O
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
treated VBN 1 1 1 O
with IN 0 0 12 O
TAXOL NNP 0 1 UNK B-Brand
. . 0 0 12 O

Furosemide NN 0 1 0 B-Drug
: : 0 0 2 O
single JJ 0 1 12 O
and CC 0 0 12 O
multiple JJ 0 1 1 O
dose NN 0 1 6 O
pharmacodynamics NNS 0 1 UNK O
and CC 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
are VBP 1 0 12 O
not RB 0 1 12 O
affected VBN 1 1 1 O
by IN 0 0 12 O
multiple JJ 0 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
meloxicam NN 0 1 13 B-Drug
. . 0 0 12 O

These DT 0 0 1 O
drugs NNS 1 1 6 O
include VBP 0 1 1 O
the DT 0 0 12 O
thiazides NNS 1 1 UNK B-Group
and CC 0 0 12 O
other JJ 0 0 12 O
diuretics NNS 1 1 14 B-Group
corticosteroids NNS 1 1 14 B-Group
phenothiazines NNS 1 1 UNK B-Group
thyroid JJ 0 1 6 B-Group
products NNS 1 1 1 I-Group
estrogens VBZ 0 1 16 B-Group
oral JJ 0 1 6 O
contraceptives NNS 1 1 13 B-Group
phenytoin VBP 0 1 16 B-Drug
nicotinic JJ 0 1 13 B-Drug
acid NN 0 1 14 I-Drug
sympathomimetics NNS 0 1 13 B-Group
calcium JJ 0 1 14 B-Group
channel NNS 0 1 1 I-Group
blocking VBG 1 1 UNK I-Group
drugs NNS 1 1 6 I-Group
and CC 0 0 12 O
isoniazid NN 0 1 13 B-Drug
. . 0 0 12 O

9 CD 0 0 2 O
% NN 0 0 18 O
increase NN 0 1 1 O
[ NNP 0 0 2 O
CI NNP 0 1 UNK O
: : 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
increase NN 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
increase NN 0 1 1 O
] VBZ 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
decrease NN 0 1 1 O
[ NNP 0 0 2 O
CI NNP 0 1 UNK O
: : 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
decrease NN 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
decrease NN 0 1 1 O
] NN 0 0 2 O

The DT 0 0 2 O
clinical JJ 0 1 6 O
significance NN 0 1 13 O
of IN 0 0 12 O
this DT 0 0 12 O
increased VBN 1 1 1 O
bioavailability NN 0 1 UNK O
and CC 0 0 12 O
whether IN 0 0 12 O
similar JJ 0 1 1 O
increases NNS 1 1 1 O
will MD 0 0 12 O
occur VB 0 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
given VBN 1 1 12 O
oral JJ 0 1 6 O
H9 NNP 0 0 UNK B-Group
- : 0 0 2 O
antagonists NNS 1 1 13 I-Group
is VBZ 1 0 12 O
unknown JJ 0 1 12 O
; : 0 0 2 O

Lipids NNS 0 1 UNK O
: : 0 0 2 O
Pretreatment NN 0 1 UNK O
and CC 0 0 12 O
follow VB 0 1 12 O
- : 0 0 2 O
up RB 0 0 12 O
blood NN 0 1 6 O
lipids NNS 1 1 14 O
should MD 0 0 12 O
be VB 0 0 12 O
obtained VBN 1 1 1 O
under IN 0 0 12 O
fasting VBG 1 1 6 O
conditions NNS 1 1 1 O
. . 0 0 12 O

Concomitant JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
alosetron NN 0 1 UNK B-Drug
and CC 0 0 12 O
moderate JJ 0 1 1 O
CYP9A9 NNP 0 0 UNK O
inhibitors NNS 1 1 14 O
including VBG 1 1 1 O
quinolone NN 0 1 UNK B-Group
antibiotics NNS 1 1 6 I-Group
and CC 0 0 12 O
cimetidine NN 0 1 13 B-Drug
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
evaluated VBN 1 1 1 O
but CC 0 0 12 O
should MD 0 0 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
unless IN 0 0 12 O
clinically RB 0 0 6 O
necessary JJ 0 0 1 O
because IN 0 0 12 O
of IN 0 0 12 O
similar JJ 0 1 1 O
potential JJ 0 1 1 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
. . 0 0 12 O

Consequently RB 0 0 1 O
TRACLEER NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
not RB 0 1 12 O
expected VBN 1 1 12 O
to TO 0 0 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
drugs NNS 1 1 6 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
these DT 0 0 12 O
enzymes NNS 1 1 14 O
. . 0 0 12 O

Concomitant NNP 0 1 UNK O
use NN 0 1 1 O
with IN 0 0 12 O
other JJ 0 0 12 O
oxytocic JJ 0 1 13 B-Group
agents NNS 1 1 1 I-Group
is VBZ 1 0 12 O
not RB 0 1 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O

Cyclophosphamide NN 0 1 UNK B-Drug

In IN 0 0 2 O
these DT 0 0 12 O
patients NNS 1 1 6 O
the DT 0 0 12 O
mixed JJ 0 1 3 O
agonist NN 0 1 14 O
/ NNP 0 0 2 O
antagonist NN 0 1 13 O
may MD 0 0 1 O
alter VB 0 1 13 O
the DT 0 0 12 O
analgesic JJ 0 1 13 O
effect NN 0 1 1 O
or CC 0 0 12 O
may MD 0 0 1 O
precipitate VB 0 1 13 O
withdrawal NN 0 1 1 O
symptoms NNS 1 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
combination NN 0 1 1 O
of IN 0 0 12 O
therapeutic JJ 0 1 6 O
doses NNS 1 1 6 O
of IN 0 0 12 O
intravenous JJ 0 1 14 O
dantrolene NN 0 1 16 B-Drug
sodium NN 0 1 14 I-Drug
and CC 0 0 12 O
verapamil NN 0 1 0 B-Drug
in IN 0 0 12 O
halothane NN 0 1 13 B-Drug
a DT 0 0 12 O
- : 0 0 2 O
chloralose NN 0 1 UNK O
anesthetized JJ 0 1 13 O
swine NN 0 1 UNK O
has VBZ 1 0 12 O
resulted VBN 1 1 1 O
in IN 0 0 12 O
ventricular JJ 0 1 8 O
fibrillation NN 0 1 6 O
and CC 0 0 12 O
cardiovascular JJ 0 1 6 O
collapse NN 0 1 1 O
in IN 0 0 12 O
association NN 0 1 1 O
with IN 0 0 12 O
marked JJ 0 1 1 O
hyperkalemia NN 0 1 14 O
. . 0 0 12 O

therefore RB 0 0 1 O
doses VBZ 1 1 6 O
greater JJR 1 1 1 O
than IN 0 0 12 O
the DT 0 0 12 O
normal JJ 0 1 1 O
antiasthmatic JJ 0 1 UNK O
dose NN 0 1 6 O
of IN 0 0 12 O
beta NN 0 1 16 B-Group
- : 0 0 2 O
agonist NN 0 1 14 I-Group
bronchodilator NN 0 1 UNK I-Group
drugs NNS 1 1 6 I-Group
may MD 0 0 1 O
be VB 0 0 12 O
required VBN 1 1 1 O
. . 0 0 12 O

Ketoconazole NNS 0 1 UNK B-Drug
: : 0 0 2 O
When WRB 0 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
9 CD 0 0 2 O
- : 0 0 2 O
mg NN 0 1 0 O
dose NN 0 1 6 O
of IN 0 0 12 O
Aprepitant NNP 0 1 UNK B-Drug
was VBD 1 0 12 O
administered VBN 1 1 1 O
on IN 0 0 12 O
Day9 NNP 0 0 UNK O
of IN 0 0 12 O
a DT 0 0 12 O

Interaction NN 0 1 2 O
with IN 0 0 12 O
Mixed NNP 0 1 UNK B-Group
Agonist NNP 0 1 UNK I-Group
Antagonist NNP 0 1 UNK I-Group
Opioid NNP 0 1 UNK I-Group
Analgesics NNPS 0 1 UNK I-Group
: : 0 0 2 O
Agonist NNP 0 1 UNK B-Group
antagonist NN 0 1 13 I-Group
analgesics NNS 1 1 14 I-Group
( ( 0 0 2 O
i.e. FW 0 1 1 O
pentazocine NN 0 1 UNK B-Drug
nalbuphine NN 0 1 16 B-Drug
butorphanol NN 0 1 13 B-Drug
or CC 0 0 12 O
buprenorphine NN 0 1 13 B-Drug
) ) 0 0 2 O
should MD 0 0 12 O
NOT NNP 0 1 11 O
be VB 0 0 12 O
administered VBN 1 1 1 O
to TO 0 0 12 O
patients NNS 1 1 6 O
who WP 0 0 12 O
have VBP 0 0 12 O
received VBN 1 1 12 O
or CC 0 0 12 O
are VBP 1 0 12 O
receiving VBG 1 1 1 O
a DT 0 0 12 O
course NN 0 1 12 O
of IN 0 0 12 O
therapy NN 0 1 6 O
with IN 0 0 12 O
a DT 0 0 12 O
proof NN 0 1 1 O
opioid JJ 0 1 13 B-Group
agonist NN 0 1 14 I-Group
analgesic NN 0 1 13 I-Group
. . 0 0 12 O

Some DT 0 0 2 O
clinicians NNS 1 1 UNK O
have VBP 0 0 12 O
noted VBN 1 0 1 O
that IN 0 0 12 O
these DT 0 0 12 O
reactions NNS 1 1 1 O
resemble VBP 0 0 UNK O
the DT 0 0 12 O
immediate JJ 0 1 1 O
side NN 0 1 3 O
effects NNS 1 1 1 O
caused VBN 1 1 1 O
by IN 0 0 12 O
interleukin JJ 0 1 13 B-Drug
- : 0 0 2 O
9 CD 0 0 2 I-Drug
administration NN 0 1 1 O
however RB 0 0 12 O
the DT 0 0 12 O
cause NN 0 1 12 O
of IN 0 0 12 O
contrast NN 0 1 1 O
reactions NNS 1 1 1 O
after IN 0 0 12 O
interleukin JJ 0 1 13 O
- : 0 0 2 O
9 CD 0 0 2 O
therapy NN 0 1 6 O
is VBZ 1 0 12 O
unknown JJ 0 1 12 O
. . 0 0 12 O

Pentamidine NN 0 1 0 B-Drug
may MD 0 0 1 O
cause VB 0 1 12 O
hypoglycemia NN 0 1 6 O
which WDT 0 0 12 O
may MD 0 0 1 O
sometimes RB 0 1 12 O
be VB 0 0 12 O
followed VBN 1 1 12 O
by IN 0 0 12 O
hyperglycemia NN 0 1 14 O
. . 0 0 12 O

Penicillin NNP 0 1 0 B-Group
blood NN 0 1 6 O
levels NNS 1 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
prolonged VBN 1 1 6 O
by IN 0 0 12 O
concurrent JJ 0 1 1 O
administration NN 0 1 1 O
of IN 0 0 12 O
probenecid NN 0 1 13 B-Drug
which WDT 0 0 12 O
blocks VBZ 1 1 3 O
the DT 0 0 12 O
renal JJ 0 1 6 O
tubular JJ 0 1 3 O
secretion NN 0 1 14 O
of IN 0 0 12 O
penicillins NNS 1 1 14 B-Group
. . 0 0 12 O

Rates NNS 0 1 2 O
of IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
maximum JJ 0 1 1 O
potassium NN 0 1 14 O
levels NNS 1 1 1 O
9 CD 0 0 2 O
mEq NN 0 1 14 O
/ NN 0 0 2 O
L NNP 0 1 2 O
were VBD 1 0 12 O
similar JJ 0 1 1 O
regardless NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
use NN 0 1 1 O
of IN 0 0 12 O
ACEI NNP 0 0 UNK B-Group
/ NNP 0 0 2 O
ARB NNP 0 1 UNK B-Group
. . 0 0 12 O

There EX 0 0 12 O
are VBP 1 0 12 O
no DT 0 0 12 O
known JJ 0 1 12 O
drug NN 0 1 1 O
/ NNP 0 0 2 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
chlorambucil NN 0 1 13 B-Drug
. . 0 0 12 O

Hormonal JJ 0 1 UNK B-Group
Contraceptives NNS 0 1 UNK I-Group
: : 0 0 2 O
It PRP 0 0 12 O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
established VBN 1 1 1 O
if IN 0 0 12 O
there EX 0 0 12 O
is VBZ 1 0 12 O
a DT 0 0 12 O
pharmacokinetic JJ 0 1 UNK O
interaction NN 0 1 UNK O
between IN 0 0 12 O
acitretin NN 0 1 13 B-Drug
and CC 0 0 12 O
combined VBN 1 1 1 B-Group
oral JJ 0 1 6 I-Group
contraceptives NNS 1 1 13 I-Group
. . 0 0 12 O

Minimal JJ 0 1 2 O
metabolism NN 0 1 16 O
occurs VBZ 1 1 1 O
via IN 0 0 1 O
the DT 0 0 12 O
major JJ 0 1 1 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
isoenzymes NNS 0 1 14 O
. . 0 0 12 O

this DT 0 0 12 O
can MD 0 0 12 O
cause VB 0 1 12 O
headaches NNS 1 1 6 O
and CC 0 0 12 O
other JJ 0 0 12 O
signs NNS 1 1 12 O
of IN 0 0 12 O
hypertensive JJ 0 1 6 O
crisis NN 0 1 12 O
. . 0 0 12 O

Less NNP 0 1 2 O
potent JJ 0 1 UNK O
CYP NNP 0 1 UNK O
9A9 CD 0 0 UNK O
inhibitors NNS 1 1 14 O
should MD 0 0 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
caution NN 0 0 1 O
. . 0 0 12 O

Aspirin NN 0 1 0 B-Brand
: : 0 0 2 O
Concurrent JJ 0 1 13 O
administration NN 0 1 1 O
of IN 0 0 12 O
aspirin NN 0 1 14 B-Brand
and CC 0 0 12 O
flurbiprofen NN 0 1 16 B-Drug
resulted VBD 1 1 1 O
in IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
lower JJR 1 1 1 O
serum NN 0 1 14 O
flurbiprofen JJ 0 1 16 B-Drug
concentrations NNS 1 1 13 O
. . 0 0 12 O

These DT 0 0 1 O
small JJ 0 1 12 O
changes NNS 1 1 1 O
are VBP 1 0 12 O
not RB 0 1 12 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
and CC 0 0 12 O
no DT 0 0 12 O
dose JJ 0 1 6 O
adjustment NN 0 1 1 O
is VBZ 1 0 12 O
necessary JJ 0 0 1 O
. . 0 0 12 O

Postoperative JJ 0 1 7 O
respiratory NN 0 1 6 O
depression NN 0 1 6 O
may MD 0 0 1 O
be VB 0 0 12 O
enhanced VBN 1 1 1 O
or CC 0 0 12 O
prolonged VBN 1 1 6 O
by IN 0 0 12 O
these DT 0 0 12 O
agents NNS 1 1 1 O
. . 0 0 12 O

For IN 0 0 2 O
example NN 0 1 1 O
since IN 0 1 12 O
cholestyramine NN 0 1 13 B-Drug
may MD 0 0 1 O
reduce VB 0 0 1 O
the DT 0 0 12 O
gastrointestinal JJ 0 1 6 O
absorption NN 0 1 1 O
of IN 0 0 12 O
both CC 0 0 12 O
the DT 0 0 12 O
oral JJ 0 1 6 O
anticoagulants NNS 1 1 13 B-Group
and CC 0 0 12 O
vitamin NN 0 1 6 B-Group
K NNP 0 1 2 I-Group
the DT 0 0 12 O
net JJ 0 1 1 O
effects NNS 1 1 1 O
are VBP 1 0 12 O
unpredictable JJ 0 0 UNK O
. . 0 0 12 O

These DT 0 0 1 O
increased VBD 1 1 1 O
exposures NNS 1 1 UNK O
of IN 0 0 12 O
norethindrone NN 0 1 13 B-Drug
and CC 0 0 12 O
ethinyl JJ 0 0 13 B-Drug
estradiol NN 0 1 13 I-Drug
should MD 0 0 12 O
be VB 0 0 12 O
taken VBN 1 1 12 O
into IN 0 0 12 O
consideration NN 0 1 1 O
when WRB 0 0 12 O
selecting VBG 1 1 UNK O
an DT 0 0 12 O
oral JJ 0 1 6 O
contraceptive NN 0 1 13 B-Group
for IN 0 0 12 O
women NNS 1 1 UNK O
taking VBG 1 0 12 O
valdecoxib NN 0 1 13 B-Drug
. . 0 0 12 O

Avoid IN 0 0 2 O
the DT 0 0 12 O
concomitant JJ 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
chlorprothixene NN 0 1 UNK B-Drug
and CC 0 0 12 O
tramadol NN 0 1 16 B-Drug
( ( 0 0 2 O
Ultram NNP 0 1 0 B-Brand
) ) 0 0 2 O
. . 0 0 12 O

Effect NN 0 1 UNK O
of IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
on IN 0 0 12 O
Sensipar NN 0 1 UNK B-Brand
: : 0 0 2 O
Sensipar NN 0 1 UNK B-Brand
is VBZ 1 0 12 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
multiple JJ 0 1 1 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
enzymes VBZ 0 1 14 O
primarily RB 0 0 1 O
CYP9A9 NNP 0 0 UNK O
CYP9D9 NNP 0 0 UNK O
and CC 0 0 12 O
CYP9A9 NNP 0 0 UNK O
. . 0 0 12 O

Monitor NNP 0 1 2 O
for IN 0 0 12 O
symptoms NNS 1 1 6 O
of IN 0 0 12 O
hyperglycemia NN 0 1 14 O
; : 0 0 2 O

Concurrent NNP 0 1 13 O
use NN 0 1 1 O
of IN 0 0 12 O
alcohol NN 0 1 1 B-Drug
and CC 0 0 12 O
other JJ 0 0 12 O
CNS NNP 0 1 6 B-Group
depression NN 0 1 6 I-Group
- : 0 0 2 O
producing VBG 1 0 1 I-Group
drugs NNS 1 1 6 I-Group
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
CNS NNP 0 1 6 O
depressant JJ 0 0 UNK O
effects NNS 1 1 1 O
of IN 0 0 12 O
methyprylon NN 0 1 UNK B-Drug
or CC 0 0 12 O
these DT 0 0 12 O
other JJ 0 0 12 O
medications NNS 1 1 6 O
. . 0 0 12 O

Carcinogenesis NNP 0 1 UNK O
Mutagenesis NNP 0 1 UNK O
and CC 0 0 12 O
Fertility NNP 0 1 7 O

If IN 0 0 12 O
ProSom NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
given VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
acting VBG 1 1 12 O
on IN 0 0 12 O
the DT 0 0 12 O
central JJ 0 1 1 O
nervous JJ 0 1 6 O
system NN 0 1 1 O
careful JJ 0 1 12 O
consideration NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
given VBN 1 1 12 O
to TO 0 0 12 O
the DT 0 0 12 O
pharmacology NN 0 1 UNK O
of IN 0 0 12 O
all DT 0 0 12 O
agents NNS 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
injection NN 0 1 3 O
should MD 0 0 12 O
be VB 0 0 12 O
made VBN 1 1 12 O
immediately RB 0 1 12 O
after IN 0 0 12 O
mixing VBG 1 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
effects NNS 1 1 1 O
of IN 0 0 12 O
HMG NNP 0 0 UNK B-Group
- : 0 0 2 O
CoA NNP 0 0 UNK I-Group
reductase NN 0 1 UNK I-Group
inhibitors NNS 1 1 14 I-Group
on IN 0 0 12 O
male NN 0 1 12 O
fertility NN 0 1 6 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
studied VBN 1 0 1 O
in IN 0 0 12 O
adequate JJ 0 1 1 O
numbers NNS 1 1 1 O
of IN 0 0 12 O
patients NNS 1 1 6 O
. . 0 0 12 O

Although IN 0 0 12 O
the DT 0 0 12 O
interactions NNS 1 1 UNK O
observed VBD 1 1 1 O
in IN 0 0 12 O
these DT 0 0 12 O
studies NNS 1 1 1 O
do VBP 0 0 12 O
not RB 0 1 12 O
appear VB 0 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
of IN 0 0 12 O
major JJ 0 1 1 O
clinical JJ 0 1 6 O
importance NN 0 1 1 O
BREVIBLOC NNP 0 1 UNK B-Brand
should MD 0 0 12 O
be VB 0 0 12 O
titrated VBN 1 1 14 O
with IN 0 0 12 O
caution NN 0 0 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
being VBG 1 0 12 O
treated VBN 1 1 1 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
morphine NN 0 1 14 B-Drug
succinylcholine NN 0 1 16 B-Drug
or CC 0 0 12 O
warfarin NN 0 1 14 B-Drug
. . 0 0 12 O

Multiple NNP 0 1 2 O
- : 0 0 2 O
dose JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
potent NN 0 1 UNK O
CYP9A9 NNP 0 0 UNK O
inducer NN 0 1 UNK O
rifampin NN 0 1 16 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
every DT 0 0 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
q9h VBP 0 1 UNK O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
) ) 0 0 2 O
however RB 0 0 12 O
reduced VBN 1 1 1 O
zaleplon NN 0 1 13 B-Drug
Cmax NNP 0 1 UNK O
and CC 0 0 12 O
AUC NNP 0 1 UNK O
by IN 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

At IN 0 0 2 O
least JJS 0 1 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
should MD 0 0 12 O
elapse VB 0 1 UNK O
between IN 0 0 12 O
discontinuation NN 0 1 6 O
of IN 0 0 12 O
a DT 0 0 12 O
MAO NNP 0 1 14 B-Group
inhibitor NN 0 1 14 I-Group
and CC 0 0 12 O
initiation NN 0 1 1 O
of IN 0 0 12 O
treatment NN 0 1 6 O
with IN 0 0 12 O
dexfenfluramine NN 0 1 UNK B-Drug
. . 0 0 12 O

The DT 0 0 2 O
potential JJ 0 1 1 O
for IN 0 0 12 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
EMTRIVA NNP 0 1 UNK B-Brand
has VBZ 1 0 12 O
been VBN 1 0 12 O
studied VBN 1 0 1 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
indinavir JJ 0 1 16 B-Drug
stavudine NN 0 1 13 B-Drug
famciclovir NN 0 1 13 B-Drug
and CC 0 0 12 O
tenofovir NN 0 1 16 B-Drug
disoproxil NN 0 0 16 I-Drug
fumarate NN 0 1 16 I-Drug
. . 0 0 12 O

Because IN 0 0 12 O
the DT 0 0 12 O
risk NN 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
development NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
fetal JJ 0 1 6 O
immune NN 0 1 6 O
system NN 0 1 1 O
and CC 0 0 12 O
postnatal JJ 0 1 13 O
immune NN 0 1 6 O
function NN 0 1 1 O
in IN 0 0 12 O
humans NNS 1 1 UNK O
is VBZ 1 0 12 O
unknown JJ 0 1 12 O
AMEVIVE NNP 0 1 UNK B-Brand
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
during IN 0 0 12 O
pregnancy NN 0 1 6 O
only RB 0 1 12 O
if IN 0 0 12 O
clearly RB 0 0 12 O
needed VBN 1 1 12 O
. . 0 0 12 O

Therefore RB 0 0 1 O
ketoconazole NN 0 1 16 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
caution NN 0 0 1 O
with IN 0 0 12 O
intranasal JJ 0 1 13 O
ciclesonide NN 0 1 13 B-Drug
. . 0 0 12 O

Patients NNS 0 1 7 O
taking VBG 1 0 12 O
coumarin JJ 0 1 UNK B-Group
- : 0 0 2 O
derivative JJ 0 1 13 I-Group
anticoagulants NNS 1 1 13 I-Group
concomitantly RB 0 0 14 O
with IN 0 0 12 O
capecitabine NN 0 1 13 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
regularly RB 0 0 12 O
for IN 0 0 12 O
alterations NNS 1 1 1 O
in IN 0 0 12 O
their PRP$ 0 0 12 O
coagulation NN 0 1 14 O
parameters NNS 1 1 1 O
( ( 0 0 2 O
PT NNP 0 1 2 O
or CC 0 0 12 O
INR NNP 0 1 13 O
) ) 0 0 2 O
. . 0 0 12 O

Systemic JJ 0 1 7 O
exposure NN 0 1 1 O
to TO 0 0 12 O
substrates NNS 1 1 UNK O
of IN 0 0 12 O
CYP9D9 NNP 0 0 UNK O
is VBZ 1 0 12 O
expected VBN 1 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
increased VBN 1 1 1 O
when WRB 0 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
Gleevec NNP 0 1 UNK O
. . 0 0 12 O

Patients NNS 0 1 7 O
who WP 0 0 12 O
are VBP 1 0 12 O
applying VBG 1 1 1 O
Panretin NNP 0 1 UNK B-Brand
gel NN 0 1 3 O
should MD 0 0 12 O
not RB 0 1 12 O
concurrently VB 0 0 1 O
use NN 0 1 1 O
products NNS 1 1 1 O
that WDT 0 0 12 O
contain VBP 0 1 UNK O
DEET NNP 0 1 UNK B-Drug
( ( 0 0 2 O
N NNP 0 1 2 O
N NNP 0 1 2 B-Drug
- : 0 0 2 O
diethyl NN 0 0 UNK I-Drug
- : 0 0 2 O
m NN 0 1 2 I-Drug
- : 0 0 2 O
toluamide NN 0 0 UNK I-Drug
) ) 0 0 2 O
a DT 0 0 12 O
common JJ 0 1 1 O
component NN 0 1 1 O
of IN 0 0 12 O
insect JJ 0 1 13 O
repellent NN 0 1 UNK O
products NNS 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
results NNS 1 1 1 O
of IN 0 0 12 O
assays NNS 1 1 13 O
using VBG 1 1 1 O
red JJ 0 1 3 O
cells NNS 1 1 6 O
from IN 0 0 12 O
healthy JJ 0 1 12 O
subjects NNS 1 1 UNK O
to TO 0 0 12 O
determine VB 0 0 1 O
whether IN 0 0 12 O
ceftibuten NN 0 1 UNK B-Drug
would MD 0 0 12 O
cause VB 0 1 12 O
direct JJ 0 1 1 O
Coombs NNP 0 1 19 O
reactions NNS 1 1 1 O
in IN 0 0 12 O
vitro NN 0 1 UNK O
showed VBD 1 1 12 O
no DT 0 0 12 O
positive JJ 0 1 1 O
reaction NN 0 1 1 O
at IN 0 0 12 O
ceftibuten JJ 0 1 UNK B-Drug
concentrations NNS 1 1 13 O
as RB 0 0 12 O
high JJ 0 1 1 O
as IN 1 0 12 O
9 CD 0 0 2 O
g NN 0 1 16 O
/ NNP 0 0 2 O
mL NN 0 1 14 O
. . 0 0 12 O

Cimetidine NN 0 1 0 B-Drug

If IN 0 0 12 O
pregnancy NN 0 1 6 O
occurs VBZ 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
patient NN 0 1 6 O
or CC 0 0 12 O
partner NN 0 1 12 O
of IN 0 0 12 O
a DT 0 0 12 O
patient NN 0 1 6 O
during IN 0 0 12 O
treatment NN 0 1 6 O
or CC 0 0 12 O
during IN 0 0 12 O
the DT 0 0 12 O
9 CD 0 0 2 O
months NNS 1 1 12 O
after IN 0 0 12 O
treatment NN 0 1 6 O
cessation NN 0 1 6 O
such JJ 0 0 1 O
cases NNS 1 1 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
COPEGUS NNP 0 1 UNK B-Brand
Pregnancy NNP 0 1 7 O
Registry NNP 0 1 UNK O
at IN 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
. . 0 0 12 O

. . 0 0 12 O

No DT 0 0 2 O
formal JJ 0 1 1 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
performed VBN 1 1 1 O
with IN 0 0 12 O
RAPTIVA NNP 0 1 UNK B-Brand
. . 0 0 12 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interactions NNP 0 1 UNK O
Certain NNP 0 1 UNK O
endocrine NN 0 1 6 O
and CC 0 0 12 O
liver JJ 0 1 6 O
function NN 0 1 1 O
tests NNS 1 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
affected VBN 1 1 1 O
by IN 0 0 12 O
estrogen NN 0 1 6 B-Group
- : 0 0 2 O
containing VBG 1 1 1 O
oral JJ 0 1 6 O
contraceptives NNS 1 1 13 B-Group
. . 0 0 12 O

Poor NNP 0 1 2 O
metabolizers NNS 0 0 UNK O
have VBP 0 0 12 O
higher JJR 1 1 1 O
than IN 0 0 12 O
expected VBN 1 1 12 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
( ( 0 0 2 O
TCAs NNP 0 1 UNK B-Group
) ) 0 0 2 O
when WRB 0 0 12 O
given VBN 1 1 12 O
usual JJ 0 1 12 O
doses NNS 1 1 6 O
. . 0 0 12 O

An DT 0 0 2 O
adequate JJ 0 1 1 O
period NN 0 1 1 O
of IN 0 0 12 O
observation NN 0 1 1 O
must MD 0 0 12 O
be VB 0 0 12 O
provided VBN 1 1 1 O
for IN 0 0 12 O
any DT 0 0 12 O
patient NN 0 1 6 O
in IN 0 0 12 O
whom WP 0 0 12 O
either DT 0 1 12 O
long JJ 0 1 12 B-Group
- : 0 0 2 O
acting VBG 1 1 12 I-Group
benzodiazepines NNS 1 1 14 I-Group
( ( 0 0 2 O
such JJ 0 0 1 O
as IN 1 0 12 O
diazepam NN 0 1 0 B-Drug
) ) 0 0 2 O
or CC 0 0 12 O
large JJ 0 1 3 O
doses NNS 1 1 6 O
of IN 0 0 12 O
short JJ 0 1 12 B-Group
- : 0 0 2 O
acting VBG 1 1 12 I-Group
benzodiazepines NNS 1 1 14 I-Group
( ( 0 0 2 O
such JJ 0 0 1 O
as IN 1 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
of IN 0 0 12 O
midazolam NN 0 1 16 B-Drug
) ) 0 0 2 O
have VBP 0 0 12 O
been VBN 1 0 12 O
used VBN 1 1 12 O
. . 0 0 12 O

Respiratory NNP 0 1 7 O
depression NN 0 1 6 O
hypotension NN 0 1 6 O
and CC 0 0 12 O
profound JJ 0 1 1 O
sedation NN 0 1 6 O
or CC 0 0 12 O
coma NN 0 1 6 O
may MD 0 0 1 O
occur VB 0 1 1 O
. . 0 0 12 O

Dopamine NNP 0 1 7 B-Drug
- : 0 0 2 O
induced VBD 1 1 6 O
renal JJ 0 1 6 O
and CC 0 0 12 O
mesenteric JJ 0 1 8 O
vasodilation NN 0 1 14 O
is VBZ 1 0 12 O
not RB 0 1 12 O
antagonized VBN 1 0 UNK O
by IN 0 0 12 O
either DT 0 1 12 O
alpha JJ 0 1 1 B-Group
- : 0 0 2 O
or CC 0 0 12 O
beta VB 0 1 16 B-Drug
- : 0 0 2 O
adrenergic NN 0 1 UNK I-Drug
blocking VBG 1 1 UNK I-Drug
agents NNS 1 1 1 I-Drug
. . 0 0 12 O

However RB 0 0 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
decreases NNS 1 1 UNK O
in IN 0 0 12 O
prothrombin NN 0 1 14 O
time NN 0 1 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
in IN 0 0 12 O
single JJ 0 1 12 O
- : 0 0 2 O
dose JJ 0 1 6 O
studies NNS 1 1 1 O
. . 0 0 12 O

No DT 0 0 2 O
data NN 0 1 1 O
for IN 0 0 12 O
delavirdine NN 0 1 13 B-Drug
; : 0 0 2 O

Although IN 0 0 12 O
BETAGAN NNP 0 1 UNK B-Brand
used VBD 1 1 12 O
alone RB 0 1 12 O
has VBZ 1 0 12 O
little JJ 0 1 12 O
or CC 0 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
pupil NN 0 1 1 O
size NN 0 1 3 O
mydriasis NN 0 1 13 O
resulting VBG 1 1 1 O
from IN 0 0 12 O
concomitant JJ 0 1 6 O
therapy NN 0 1 6 O
with IN 0 0 12 O
BETAGAN NNP 0 1 UNK B-Brand
and CC 0 0 12 O
epinephrine NN 0 1 14 B-Drug
may MD 0 0 1 O
occur VB 0 1 1 O
. . 0 0 12 O

Drug NNP 0 1 2 O
monitoring NN 0 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
of IN 0 0 12 O
assistance NN 0 1 1 O
in IN 0 0 12 O
detecting VBG 1 1 UNK O
alterations NNS 1 1 1 O
in IN 0 0 12 O
carbamazepine NN 0 1 16 B-Drug
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
. . 0 0 12 O

These DT 0 0 1 O
effects NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
when WRB 0 0 12 O
anticholinergic JJ 0 1 13 O
properties NNS 1 1 UNK O
may MD 0 0 1 O
be VB 0 0 12 O
contributing VBG 1 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
therapeutic JJ 0 1 6 O
effect NN 0 1 1 O
of IN 0 0 12 O
concomitant JJ 0 1 6 O
medication NN 0 1 6 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
atropine NN 0 1 14 B-Drug
inhaled VBD 1 1 14 O
ipratropium NN 0 1 0 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

ZADAXIN NNP 0 1 UNK B-Brand
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
mixed JJ 0 1 3 O
with IN 0 0 12 O
any DT 0 0 12 O
other JJ 0 0 12 O
drug NN 0 1 1 O
. . 0 0 12 O

With IN 0 0 2 O
simultaneous JJ 0 1 13 O
dosing NN 0 0 14 O
of IN 0 0 12 O
Vardenafil NNP 0 1 UNK B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
and CC 0 0 12 O
terazosin NN 0 1 0 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
9 CD 0 0 2 O
of IN 0 0 12 O
9 CD 0 0 2 O
subjects NNS 1 1 UNK O
experienced VBD 1 0 12 O
a DT 0 0 12 O
standing VBG 1 1 12 O
systolic JJ 0 1 8 O
blood NN 0 1 6 O
pressure NN 0 1 1 O
of IN 0 0 12 O
less JJR 0 1 12 O
than IN 0 0 12 O
9 CD 0 0 2 O
mm JJ 0 0 18 O
Hg NNP 0 1 14 O
. . 0 0 12 O

Oral JJ 0 1 2 O
Anticoagulants NNS 0 1 UNK B-Group
: : 0 0 2 O
Interaction NN 0 1 2 O
studies NNS 1 1 1 O
with IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
failed VBD 1 1 12 O
to TO 0 0 12 O
identify VB 0 0 1 O
any DT 0 0 12 O
clinically RB 0 0 6 O
important JJ 0 1 1 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
serum JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
the DT 0 0 12 O
anticoagulant NN 0 1 13 B-Group
or CC 0 0 12 O
on IN 0 0 12 O
its PRP$ 1 0 12 O
anticoagulant JJ 0 1 13 O
effect NN 0 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
shown VBN 1 1 1 O
CASODEX NNP 0 1 UNK B-Brand
can MD 0 0 12 O
displace VB 0 0 13 O
coumarin JJ 0 1 UNK B-Group
anticoagulants NNS 1 1 13 I-Group
such JJ 0 0 1 O
as IN 1 0 12 O
warfarin NN 0 1 14 B-Drug
from IN 0 0 12 O
their PRP$ 0 0 12 O
protein NN 0 1 14 O
- : 0 0 2 O
binding NN 0 1 1 O
sites NNS 1 1 1 O
. . 0 0 12 O

When WRB 0 0 12 O
increases NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
INDOCIN NNP 0 1 UNK B-Brand
are VBP 1 0 12 O
made VBN 1 1 12 O
they PRP 0 0 12 O
should MD 0 0 12 O
be VB 0 0 12 O
made VBN 1 1 12 O
carefully RB 0 0 12 O
and CC 0 0 12 O
in IN 0 0 12 O
small JJ 0 1 12 O
increments NNS 1 1 UNK O
. . 0 0 12 O

Therefore RB 0 0 1 O
when WRB 0 0 12 O
hydroflumethiazide NN 0 1 UNK B-Drug
and CC 0 0 12 O
nonsteroidal JJ 0 0 14 B-Group
anti NN 0 0 3 I-Group
- : 0 0 2 O
inflammatory NN 0 1 6 I-Group
agents NNS 1 1 1 I-Group
are VBP 1 0 12 O
used VBN 1 1 12 O
concomitantly RB 0 0 14 O
the DT 0 0 12 O
patient NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
observed VBN 1 1 1 O
closely RB 0 0 1 O
to TO 0 0 12 O
determine VB 0 0 1 O
if IN 0 0 12 O
the DT 0 0 12 O
desired JJ 0 1 1 O
effect NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
diuretic JJ 0 1 14 B-Group
is VBZ 1 0 12 O
obtained VBN 1 1 1 O
. . 0 0 12 O
) ) 0 0 2 O

Nevertheless RB 0 0 1 O
caution NN 0 0 1 O
is VBZ 1 0 12 O
indicated VBN 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
escitalopram NN 0 1 0 B-Drug
and CC 0 0 12 O
drugs NNS 1 1 6 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
CYP9D9 NNP 0 0 UNK O
. . 0 0 12 O

Lithium NNP 0 1 UNK B-Drug
generally RB 0 0 1 O
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
given VBN 1 1 12 O
with IN 0 0 12 O
diuretics NNS 1 1 14 B-Group
because IN 0 0 12 O
they PRP 0 0 12 O
reduce VB 0 0 1 O
its PRP$ 1 0 12 O
renal JJ 0 1 6 O
clearance NN 0 1 16 O
and CC 0 0 12 O
add VB 0 1 12 O
a DT 0 0 12 O
high JJ 0 1 1 O
risk NN 0 1 1 O
of IN 0 0 12 O
lithium NN 0 1 16 O
toxicity NN 0 1 6 O
. . 0 0 12 O

Lithium NNP 0 1 UNK B-Drug
Reversible JJ 0 1 UNK O
increases NNS 1 1 1 O
in IN 0 0 12 O
serum JJ 0 1 14 O
lithium NN 0 1 16 B-Drug
concentrations NNS 1 1 13 O
and CC 0 0 12 O
toxicity NN 0 1 6 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
during IN 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
lithium NN 0 1 16 B-Drug
with IN 0 0 12 O
ACE NNP 0 1 13 B-Group
inhibitors NNS 1 1 14 I-Group
and CC 0 0 12 O
with IN 0 0 12 O
some DT 0 0 12 O
angiotensin NN 0 1 UNK B-Group
II NNP 0 0 2 I-Group
receptor NN 0 1 14 I-Group
antagonists NNS 1 1 13 I-Group
. . 0 0 12 O

- : 0 0 2 O
Decreased VBD 0 1 7 O
pregnanediol JJ 0 1 UNK O
excretion NN 0 1 14 O

In IN 0 0 2 O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
similar JJ 0 1 1 O
changes NNS 1 1 1 O
in IN 0 0 12 O
carbamazepine NN 0 1 16 B-Drug
and CC 0 0 12 O
carbamazepine NN 0 1 16 B-Drug_n
epoxide NN 0 1 UNK I-Drug_n
were VBD 1 0 12 O
seen VBN 1 1 12 O
. . 0 0 12 O

Animal NNP 0 1 UNK O
data NNS 0 1 1 O
indicated VBD 1 1 1 O
that IN 0 0 12 O
bupropion NN 0 1 16 B-Drug
may MD 0 0 1 O
be VB 0 0 12 O
an DT 0 0 12 O
inducer NN 0 1 UNK O
of IN 0 0 12 O
drug NN 0 1 1 O
- : 0 0 2 O
metabolizing NN 0 0 UNK O
enzymes NNS 1 1 14 O
in IN 0 0 12 O
humans NNS 1 1 UNK O
. . 0 0 12 O

Eprosartan NNP 0 1 UNK B-Drug
( ( 0 0 2 O
up IN 0 0 12 O
to TO 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
b.i.d NN 0 1 UNK O
. . 0 0 12 O
or CC 0 0 12 O
9 CD 0 0 2 O
mg JJ 0 1 0 O
q.d NN 0 0 UNK O
. . 0 0 12 O
) ) 0 0 2 O
doses NNS 1 1 6 O
have VBP 0 0 12 O
been VBN 1 0 12 O
safely RB 0 0 UNK O
used VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
a DT 0 0 12 O
thiazide JJ 0 1 UNK B-Group
diuretic NN 0 1 14 I-Group
( ( 0 0 2 O
hydrochlorothiazide NN 0 1 0 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

Amphetamines NNS 0 1 UNK B-Group
may MD 0 0 1 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
urinary JJ 0 1 6 O
steroid JJ 0 1 6 O
determinations NNS 1 1 UNK O
. . 0 0 12 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interactions NNP 0 1 UNK O
AMERGE NNP 0 1 UNK B-Brand
Tablets NNP 0 1 0 O
are VBP 1 0 12 O
not RB 0 1 12 O
known VBN 1 1 12 O
to TO 0 0 12 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
commonly RB 0 0 UNK O
employed VBN 1 1 1 O
clinical JJ 0 1 6 O
laboratory NN 0 1 1 O
tests NNS 1 1 1 O
. . 0 0 12 O

Drug NNP 0 1 2 O
- : 0 0 2 O
Drug NN 0 1 2 O
Interactions NNS 0 1 UNK O
Given VBP 0 1 2 O
the DT 0 0 12 O
primary JJ 0 1 1 O
CNS NNP 0 1 6 O
effects NNS 1 1 1 O
of IN 0 0 12 O
aripiprazole JJ 0 1 16 B-Drug
caution NN 0 0 1 O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
when WRB 0 0 12 O
ABILIFY NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
taken VBN 1 1 12 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
other JJ 0 0 12 O
centrally RB 0 0 UNK B-Group
acting VBG 1 1 12 I-Group
drugs NNS 1 1 6 I-Group
and CC 0 0 12 O
alcohol NN 0 1 1 B-Drug
. . 0 0 12 O

In IN 0 0 2 O
another DT 0 0 12 O
formal JJ 0 1 1 O
study NN 0 1 1 O
( ( 0 0 2 O
n JJ 0 1 12 O
= $ 0 0 2 O
9 CD 0 0 2 O
extensive JJ 0 1 1 O
and CC 0 0 12 O
n JJ 0 1 12 O
= NN 0 0 2 O
9 CD 0 0 2 O
poor JJ 0 1 12 O
metabolizers NNS 0 0 UNK O
of IN 0 0 12 O
CYP9D9 NNP 0 0 UNK O
) ) 0 0 2 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
propafenone NN 0 1 16 B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
alter VB 0 1 13 O
the DT 0 0 12 O
kinetics NNS 0 1 UNK O
of IN 0 0 12 O
mexiletine NN 0 1 16 B-Drug
in IN 0 0 12 O
the DT 0 0 12 O
poor JJ 0 1 12 O
CYP9D9 NNP 0 0 UNK O
metabolizer NN 0 0 UNK O
group NN 0 1 12 O
. . 0 0 12 O

Patients NNS 0 1 7 O
treated VBN 1 1 1 O
with IN 0 0 12 O
acebutolol JJ 0 1 16 B-Drug
plus CC 0 1 16 O
catecholamine JJ 0 1 14 B-Group
depletors NNS 0 0 UNK I-Group
should MD 0 0 12 O
therefore RB 0 0 1 O
be VB 0 0 12 O
observed VBN 1 1 1 O
closely RB 0 0 1 O
for IN 0 0 12 O
evidence NN 0 1 1 O
of IN 0 0 12 O
marked JJ 0 1 1 O
bradycardia NN 0 1 8 O
or CC 0 0 12 O
hypotension NN 0 1 6 O
which WDT 0 0 12 O
may MD 0 0 1 O
present VB 0 1 1 O
as IN 1 0 12 O
vertigo JJ 0 1 6 O
syncope NN 0 1 8 O
/ NNP 0 0 2 O
presyncope NN 0 1 8 O
or CC 0 0 12 O
orthostatic JJ 0 1 8 O
changes NNS 1 1 1 O
in IN 0 0 12 O
blood NN 0 1 6 O
pressure NN 0 1 1 O
without IN 0 0 12 O
compensatory JJ 0 1 13 O
tachycardia NN 0 1 8 O
. . 0 0 12 O

Adequate NNP 0 1 UNK O
monitoring NN 0 1 1 O
of IN 0 0 12 O
theophylline JJ 0 1 16 B-Drug
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
should MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
when WRB 0 0 12 O
therapy NN 0 1 6 O
with IN 0 0 12 O
VIOXX NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
initiated VBN 1 1 1 O
or CC 0 0 12 O
changed VBN 1 1 12 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
theophylline NN 0 1 16 B-Drug
. . 0 0 12 O

No DT 0 0 2 O
data NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
level NN 0 1 1 O
of IN 0 0 12 O
circulating VBG 1 1 13 O
catecholamines NNS 1 1 14 O
after IN 0 0 12 O
ALPHAGAN NNP 0 1 0 B-Brand
P NNP 0 1 2 I-Brand
administration NN 0 1 1 O
are VBP 1 0 12 O
available JJ 0 1 1 O
. . 0 0 12 O

Oral JJ 0 1 2 O
Anticoagulants NNS 0 1 UNK B-Group
: : 0 0 2 O
Thyroid NNP 0 1 7 B-Group
hormones NNS 1 1 13 I-Group
appear VBP 0 1 12 O
to TO 0 0 12 O
increase VB 0 1 1 O
catabolism NN 0 1 UNK O
of IN 0 0 12 O
vitamin NN 0 1 6 O
K NNP 0 1 2 O
- : 0 0 2 O
dependent JJ 0 1 1 O
clotting NN 0 1 14 O
factors NNS 1 1 1 O
. . 0 0 12 O

When WRB 0 0 12 O
such JJ 0 0 1 O
combined VBN 1 1 1 O
therapy NN 0 1 6 O
is VBZ 1 0 12 O
contemplated VBN 1 0 UNK O
the DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
one CD 0 1 12 O
or CC 0 0 12 O
both DT 0 0 12 O
agents NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
reduced VBN 1 1 1 O
. . 0 0 12 O

( ( 0 0 2 O
c NN 0 0 16 O
) ) 0 0 2 O
SHBG NNP 0 0 UNK O
concentrations NNS 1 1 13 O
are VBP 1 0 12 O
decreased VBN 1 1 1 O
. . 0 0 12 O

Montelukast NN 0 1 0 B-Drug
at IN 0 0 12 O
Doses NNP 0 1 0 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg JJ 0 1 0 O
Daily NNP 0 1 2 O
Dosed VBD 0 1 UNK O
to TO 0 0 12 O
Pharmacokinetic NNP 0 1 UNK O
Steady NNP 0 1 UNK O
State NNP 0 1 2 O
: : 0 0 2 O
- : 0 0 2 O
did VBD 1 0 12 O
not RB 0 1 12 O
significantly RB 0 0 1 O
alter VB 0 1 13 O
the DT 0 0 12 O
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
either DT 0 1 12 O
component NN 0 1 1 O
of IN 0 0 12 O
an DT 0 0 12 O
oral JJ 0 1 6 O
contraceptive NN 0 1 13 B-Group
containing VBG 1 1 1 O
norethindrone RB 0 1 13 B-Drug
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
ethinyl VBP 0 0 13 O
estradiol $ 0 1 13 B-Drug
9 CD 0 0 2 O
mcg NN 0 1 0 O
. . 0 0 12 O

Concurrent NNP 0 1 13 O
use NN 0 1 1 O
of IN 0 0 12 O
these DT 0 0 12 O
agents NNS 1 1 1 O
should MD 0 0 12 O
generally RB 0 0 1 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
. . 0 0 12 O

In IN 0 0 2 O
addition NN 0 1 1 O
higher JJR 1 1 1 O
- : 0 0 2 O
than IN 0 0 12 O
expected VBN 1 1 12 O
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
serum JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
have VBP 0 0 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
when WRB 0 0 12 O
therapy NN 0 1 6 O
is VBZ 1 0 12 O
initiated VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
already RB 0 0 12 O
taking VBG 1 0 12 O
cimetidine NN 0 1 13 B-Drug
. . 0 0 12 O

Diflunisal NNP 0 1 UNK B-Drug
decreased VBD 1 1 1 O
the DT 0 0 12 O
hyperuricemic JJ 0 1 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
hydrochlorothiazide NN 0 1 0 B-Drug
. . 0 0 12 O

Concomitant JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
alosetron NN 0 1 UNK B-Drug
and CC 0 0 12 O
fluvoxamine NN 0 1 16 B-Drug
is VBZ 1 0 12 O
contraindicated VBN 1 1 14 O
. . 0 0 12 O

The DT 0 0 2 O
drugs NNS 1 1 6 O
may MD 0 0 1 O
however RB 0 0 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
alternately RB 0 0 UNK O
provided VBD 1 1 1 O
a DT 0 0 12 O
proper JJ 0 0 1 O
interval NN 0 1 1 O
has VBZ 1 0 12 O
elapsed VBN 1 1 UNK O
between IN 0 0 12 O
doses NNS 1 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
benefits NNS 1 1 1 O
and CC 0 0 12 O
risks NNS 1 1 1 O
of IN 0 0 12 O
using VBG 1 1 1 O
TRICOR NNP 0 1 UNK B-Brand
with IN 0 0 12 O
immunosuppressants NNS 1 1 UNK B-Group
and CC 0 0 12 O
other JJ 0 0 12 O
potentially RB 0 0 1 O
nephrotoxic JJ 0 1 UNK O
agents NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
carefully RB 0 0 12 O
considered VBN 1 1 1 O
and CC 0 0 12 O
the DT 0 0 12 O
lowest JJS 1 1 13 O
effective JJ 0 1 1 O
dose NN 0 1 6 O
employed VBD 1 1 1 O

No DT 0 0 2 O
autoinduction NN 0 0 UNK O
has VBZ 1 0 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
with IN 0 0 12 O
Trileptal NNP 0 1 UNK B-Brand
. . 0 0 12 O

Methyldopa NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
recommended VBN 1 1 1 O
for IN 0 0 12 O
the DT 0 0 12 O
treatment NN 0 1 6 O
of IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
pheochromocytoma NN 0 1 UNK O
. . 0 0 12 O

co SYM 0 1 12 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
may MD 0 0 1 O
produce VB 0 0 1 O
a DT 0 0 12 O
synergistic JJ 0 1 UNK O
anticonvulsant JJ 0 1 14 O
action NN 0 1 13 O
. . 0 0 12 O

Cytochrome NNP 0 1 UNK O
P NNP 0 1 2 O
- : 0 0 2 O
9 CD 0 0 2 O
inducers NNS 1 1 UNK O
such JJ 0 0 1 O
as IN 1 0 12 O
phenytoin JJ 0 1 16 B-Drug
carbamazepine NN 0 1 16 B-Drug
and CC 0 0 12 O
phenobarbital JJ 0 1 16 B-Drug
induce NN 0 1 6 O
clonazepam NN 0 1 0 B-Drug
metabolism NN 0 1 16 O
causing VBG 1 1 1 O
an DT 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
decrease NN 0 1 1 O
in IN 0 0 12 O
plasma JJ 0 1 14 O
clonazepam NN 0 1 0 B-Drug
levels NNS 1 1 1 O
. . 0 0 12 O

as IN 1 0 12 O
such JJ 0 0 1 O
it PRP 0 0 12 O
may MD 0 0 1 O
impair VB 0 0 13 O
intestinal JJ 0 1 13 O
absorption NN 0 1 1 O
of IN 0 0 12 O
any DT 0 0 12 O
of IN 0 0 12 O
vitamin NN 0 1 6 B-Group
D NNP 0 1 2 I-Group
. . 0 0 12 O

This DT 0 0 2 O
effect NN 0 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
mediated VBN 1 1 13 O
by IN 0 0 12 O
the DT 0 0 12 O
known JJ 0 1 12 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
hepatic JJ 0 1 14 O
cytochrome NN 0 1 UNK O
P NNP 0 1 2 O
- : 0 0 2 O
9 CD 0 0 2 O
by IN 0 0 12 O
cimetidine NN 0 1 13 B-Drug
which WDT 0 0 12 O
could MD 0 0 12 O
decrease VB 0 1 1 O
first JJ 0 1 12 O
pass NN 1 1 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
nimodipine NN 0 1 16 B-Drug
. . 0 0 12 O

Since IN 0 1 2 O
methyldopa NN 0 1 13 B-Drug
causes NNS 1 1 6 O
fluorescence NN 0 1 13 O
in IN 0 0 12 O
urine JJ 0 1 6 O
samples NNS 1 1 UNK O
at IN 0 0 12 O
the DT 0 0 12 O
same JJ 0 1 12 O
wave JJ 0 1 3 O
lengths NNS 1 1 UNK O
as IN 1 0 12 O
catecholamines NNS 1 1 14 O
falsely RB 0 0 1 O
high JJ 0 1 1 O
levels NNS 1 1 1 O
of IN 0 0 12 O
urinary JJ 0 1 6 O
catecholamines NNS 1 1 14 O
may MD 0 0 1 O
be VB 0 0 12 O
reported VBN 1 1 1 O
. . 0 0 12 O

as IN 1 0 12 O
measured VBN 1 1 1 O
by IN 0 0 12 O
PBI NNP 0 1 UNK O
T9 NNP 0 1 13 O
by IN 0 0 12 O
column NN 0 1 1 O
or CC 0 0 12 O
T9 NNP 0 1 13 O
by IN 0 0 12 O
radioimmunoassay NN 0 1 UNK O
. . 0 0 12 O

CYP JJ 0 1 UNK O
interactions NNS 1 1 UNK O
: : 0 0 2 O
Inhibitors NNS 0 1 7 O
of IN 0 0 12 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
enzymes NNS 1 1 14 O
would MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
expected VBN 1 1 12 O
to TO 0 0 12 O
affect VB 0 1 1 O
pramipexole JJ 0 1 16 B-Drug
elimination NN 0 1 UNK O
because IN 0 0 12 O
pramipexole NN 0 1 16 B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
appreciably RB 0 0 UNK O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
these DT 0 0 12 O
enzymes NNS 1 1 14 O
in IN 0 0 12 O
vivo NN 0 1 13 O
or CC 0 0 12 O
in IN 0 0 12 O
vitro NN 0 1 UNK O
. . 0 0 12 O

Didanosine NN 0 1 0 B-Drug

methyldopa NN 0 1 13 B-Drug
; : 0 0 2 O

There EX 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reports NNS 1 1 1 O
of IN 0 0 12 O
theophylline JJ 0 1 16 B-Drug
- : 0 0 2 O
related JJ 0 1 1 O
side NN 0 1 3 O
effects NNS 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
on IN 0 0 12 O
concomitant JJ 0 1 6 O
therapy NN 0 1 6 O
with IN 0 0 12 O
quinolones NNS 0 1 13 B-Group
and CC 0 0 12 O
theophylline NN 0 1 16 B-Drug
. . 0 0 12 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Tests NNP 0 1 UNK O
Interactions NNP 0 1 UNK O
No NNP 0 0 2 O
clinically RB 0 0 6 O
relevant JJ 0 1 1 O
changes NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
results NNS 1 1 1 O
of IN 0 0 12 O
clinical JJ 0 1 6 O
laboratory NN 0 1 1 O
tests NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
. . 0 0 12 O

Drug NNP 0 1 2 O
- : 0 0 2 O
Laboratory JJ 0 1 2 O
Test NNP 0 1 2 O
Interactions NNPS 0 1 UNK O
There EX 0 0 12 O
are VBP 1 0 12 O
no DT 0 0 12 O
reported JJ 0 1 1 O
drug NN 0 1 1 O
- : 0 0 2 O
laboratory NN 0 1 1 O
test NN 0 1 1 O
interactions NNS 1 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
inhibit VBP 0 1 13 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
9D9 CD 0 0 UNK O
include VBP 0 1 1 O
some DT 0 0 12 O
that WDT 0 0 12 O
are VBP 1 0 12 O
not RB 0 1 12 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
the DT 0 0 12 O
enzyme NN 0 1 14 O
( ( 0 0 2 O
quinidine NN 0 1 16 B-Drug
; : 0 0 2 O

When WRB 0 0 12 O
atropine NN 0 1 14 B-Drug
and CC 0 0 12 O
pralidoxime NN 0 1 13 B-Drug
are VBP 1 0 12 O
used VBN 1 1 12 O
together RB 0 1 12 O
the DT 0 0 12 O
signs NNS 1 1 12 O
of IN 0 0 12 O
atropinization NN 0 1 UNK O
( ( 0 0 2 O
flushing VBG 1 1 13 O
mydriasis NN 0 1 13 O
tachycardia NN 0 1 8 O
dryness NN 0 1 6 O
of IN 0 0 12 O
the DT 0 0 12 O
mouth NN 0 1 3 O
and CC 0 0 12 O
nose RB 0 1 3 O
) ) 0 0 2 O
may MD 0 0 1 O
occur VB 0 1 1 O
earlier JJR 1 1 12 O
than IN 0 0 12 O
might MD 0 0 12 O
be VB 0 0 12 O
expected VBN 1 1 12 O
when WRB 0 0 12 O
atropine NN 0 1 14 B-Drug
is VBZ 1 0 12 O
used VBN 1 1 12 O
alone RB 0 1 12 O
. . 0 0 12 O

The DT 0 0 2 O
effects NNS 1 1 1 O
of IN 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
cimetidine NN 0 1 13 B-Drug
on IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
bupropion NN 0 1 16 B-Drug
and CC 0 0 12 O
its PRP$ 1 0 12 O
active JJ 0 1 1 O
metabolites NNS 1 1 UNK O
were VBD 1 0 12 O
studied VBN 1 0 1 O
in IN 0 0 12 O
9 CD 0 0 2 O
healthy JJ 0 1 12 O
young JJ 0 1 12 O
male NN 0 1 12 O
volunteers NNS 1 1 UNK O
. . 0 0 12 O

nc9 RB 0 0 UNK O
9 CD 0 0 2 O
% NN 0 0 18 O
decrease NN 0 1 1 O
[ NNP 0 0 2 O
CI NNP 0 1 UNK O
: : 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
decrease NN 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
decrease NN 0 1 1 O
] NN 0 0 2 O

Cholestyramine NNP 0 1 UNK B-Drug
resin NN 0 1 UNK B-Group
may MD 0 0 1 O
delay VB 0 1 1 O
or CC 0 0 12 O
reduce VB 0 0 1 O
the DT 0 0 12 O
absorption NN 0 1 1 O
of IN 0 0 12 O
concomitant JJ 0 1 6 O
oral JJ 0 1 6 O
medication NN 0 1 6 O
such JJ 0 0 1 O
as IN 1 0 12 O
phenylbutazone NN 0 1 UNK B-Group
warfarin NN 0 1 14 B-Drug
thiazide IN 0 1 UNK B-Group
diuretics NNS 1 1 14 I-Group
( ( 0 0 2 O
acidic JJ 0 1 UNK O
) ) 0 0 2 O
or CC 0 0 12 O
propranolol NN 0 1 16 B-Drug
( ( 0 0 2 O
basic JJ 0 1 1 O
) ) 0 0 2 O
as RB 0 0 12 O
well RB 0 1 12 O
as IN 1 0 12 O
tetracycline NN 0 1 0 B-Drug
penicillin NN 0 1 14 B-Drug
G NNP 0 1 2 I-Drug
phenobarbital NN 0 1 16 B-Drug
thyroid NN 0 1 6 O
and CC 0 0 12 O
thyroxine JJ 0 1 14 B-Drug
preparations NNS 1 1 13 O
estrogens NNS 1 1 16 B-Group
and CC 0 0 12 O
progestins NNS 1 1 UNK B-Group
and CC 0 0 12 O
digitalis NN 0 1 14 B-Group
. . 0 0 12 O

In IN 0 0 2 O
vitro PDT 0 1 UNK O
the DT 0 0 12 O
UDP NNP 0 1 UNK O
- : 0 0 2 O
glucuronyl NN 0 0 UNK O
transferase NN 0 1 14 O
level NN 0 1 1 O
was VBD 1 0 12 O
increased VBN 1 1 1 O
indicating VBG 1 0 1 O
induction NN 0 1 1 O
of IN 0 0 12 O
this DT 0 0 12 O
enzyme NN 0 1 14 O
. . 0 0 12 O

Carbamazepine NN 0 1 UNK B-Drug
: : 0 0 2 O
Elevated VBN 0 1 7 O
carbamazepine NN 0 1 16 B-Drug
levels NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
postmarketing VBG 0 0 UNK O
experience NN 0 1 12 O
when WRB 0 0 12 O
SUPRAX NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
. . 0 0 12 O

AED NNP 0 1 UNK B-Group
Co NNP 0 1 2 O
- : 0 0 2 O
administered VBD 1 1 1 O

Additionally RB 0 0 1 O
BREVIBLOC NNP 0 1 UNK B-Brand
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
to TO 0 0 12 O
control VB 0 1 1 O
supraventricular JJ 0 0 8 O
tachycardia NN 0 1 8 O
in IN 0 0 12 O
the DT 0 0 12 O
presence NN 0 1 1 O
of IN 0 0 12 O
agents NNS 1 1 1 O
which WDT 0 0 12 O
are VBP 1 0 12 O
vasoconstrictive JJ 0 0 UNK O
and CC 0 0 12 O
inotropic JJ 0 0 14 O
such JJ 0 0 1 O
as IN 1 0 12 O
dopamine JJ 0 1 14 B-Drug
epinephrine NN 0 1 14 B-Drug
and CC 0 0 12 O
norepinephrine NN 0 1 14 B-Drug
because IN 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
danger NN 0 0 UNK O
of IN 0 0 12 O
blocking VBG 1 1 UNK O
cardiac JJ 0 1 6 O
contractility NN 0 1 13 O
when WRB 0 0 12 O
systemic JJ 0 1 6 O
vascular NN 0 1 6 O
resistance NN 0 1 1 O
is VBZ 1 0 12 O
high JJ 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
sedative JJ 0 1 6 O
effect NN 0 1 1 O
of IN 0 0 12 O
VERSED NNP 0 1 15 B-Brand
Syrup NNP 0 1 2 I-Brand
is VBZ 1 0 12 O
accentuated VBN 1 1 UNK O
by IN 0 0 12 O
any DT 0 0 12 O
concomitantly RB 0 0 14 O
administered VBN 1 1 1 O
medication NN 0 1 6 O
which WDT 0 0 12 O
depresses VBZ 1 0 UNK O
the DT 0 0 12 O
central JJ 0 1 1 O
nervous JJ 0 1 6 O
system NN 0 1 1 O
particularly RB 0 0 1 O
narcotics NNS 1 1 1 B-Group
( ( 0 0 2 O
eg JJ 0 1 UNK O
morphine NN 0 1 14 B-Drug
meperidine NN 0 1 16 B-Drug
and CC 0 0 12 O
fentanyl NN 0 1 14 B-Drug
) ) 0 0 2 O
propofol NN 0 1 14 B-Drug
ketamine VBP 0 1 13 B-Drug
nitrous JJ 0 1 UNK B-Drug
oxide IN 0 1 14 I-Drug
secobarbital JJ 0 1 UNK B-Drug
and CC 0 0 12 O
droperidol NN 0 1 0 B-Drug
. . 0 0 12 O

In IN 0 0 2 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
shown VBN 1 1 1 O
that IN 0 0 12 O
fenoprofen NN 0 1 UNK B-Drug
because IN 0 0 12 O
of IN 0 0 12 O
its PRP$ 1 0 12 O
affinity NN 0 1 UNK O
for IN 0 0 12 O
albumin NN 0 1 14 O
may MD 0 0 1 O
displace VB 0 0 13 O
from IN 0 0 12 O
their PRP$ 0 0 12 O
binding NN 0 1 1 O
sites VBZ 1 1 1 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
are VBP 1 0 12 O
also RB 0 0 12 O
albumin JJ 0 1 14 O
bound NN 0 1 12 O
and CC 0 0 12 O
this DT 0 0 12 O
may MD 0 0 1 O
lead VB 0 1 12 O
to TO 0 0 12 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
. . 0 0 12 O

Patients NNS 0 1 7 O
with IN 0 0 12 O
Severe NNP 0 1 7 O
Hepatic NNP 0 1 7 O
or CC 0 0 12 O
Renal NNP 0 1 7 O
Impairment NNP 0 1 UNK O
Caution NNP 0 0 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
exercised VBN 1 1 1 O
when WRB 0 0 12 O
TEMODAR NNP 0 1 UNK B-Brand
Capsules NNP 0 1 0 O
are VBP 1 0 12 O
administered VBN 1 1 1 O
to TO 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
severe JJ 0 1 6 O
hepatic JJ 0 1 14 O
or CC 0 0 12 O
renal JJ 0 1 6 O
impairment NN 0 1 16 O
. . 0 0 12 O

Furthermore RB 0 0 1 O
whenever WRB 0 0 12 O
one CD 0 1 12 O
of IN 0 0 12 O
these DT 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
is VBZ 1 0 12 O
withdrawn VBN 1 1 1 O
from IN 0 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
therapy NN 0 1 6 O
an DT 0 0 12 O
increased VBN 1 1 1 O
dose NN 0 1 6 O
of IN 0 0 12 O
tricyclic JJ 0 0 14 B-Drug
antidepressant NN 0 1 6 I-Drug
may MD 0 0 1 O
be VB 0 0 12 O
required VBN 1 1 1 O
. . 0 0 12 O

Serum NNP 0 1 7 O
lithium NN 0 1 16 B-Drug
levels NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
frequently RB 0 1 1 O
if IN 0 0 12 O
INSPRA NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
lithium NN 0 1 16 B-Drug
. . 0 0 12 O

Anticonvulsants NNS 0 1 UNK B-Group
: : 0 0 2 O
In IN 0 0 2 O
a DT 0 0 12 O
pharmacokinetic JJ 0 1 UNK O
study NN 0 1 1 O
maximum JJ 0 1 1 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
felodipine NN 0 1 13 B-Drug
were VBD 1 0 12 O
considerably RB 0 0 1 O
lower JJR 1 1 1 O
in IN 0 0 12 O
epileptic JJ 0 1 13 O
patients NNS 1 1 6 O
on IN 0 0 12 O
long JJ 0 1 12 O
- : 0 0 2 O
term NN 0 1 1 O
anticonvulsant JJ 0 1 14 B-Group
therapy NN 0 1 6 O
( ( 0 0 2 O
eg JJ 0 1 UNK O
phenytoin NN 0 1 16 B-Drug
carbamazepine NN 0 1 16 B-Drug
or CC 0 0 12 O
phenobarbital NN 0 1 16 B-Drug
) ) 0 0 2 O
than IN 0 0 12 O
in IN 0 0 12 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
. . 0 0 12 O

Concurrent NNP 0 1 13 O
use NN 0 1 1 O
of IN 0 0 12 O
tetracycline NN 0 1 0 B-Drug
may MD 0 0 1 O
render VB 0 0 13 O
oral JJ 0 1 6 O
contraceptives NNS 1 1 13 B-Group
less RBR 0 1 12 O
effective JJ 0 1 1 O
. . 0 0 12 O

Lithium NN 0 1 UNK B-Drug
: : 0 0 2 O
In IN 0 0 2 O
a DT 0 0 12 O
study NN 0 1 1 O
conducted VBN 1 1 1 O
in IN 0 0 12 O
healthy JJ 0 1 12 O
subjects NNS 1 1 UNK O
mean VBP 0 1 12 O
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
lithium NN 0 1 16 B-Drug
plasma NN 0 1 14 O
levels NNS 1 1 1 O
increased VBD 1 1 1 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
in IN 0 0 12 O
subjects NNS 1 1 UNK O
receiving VBG 1 1 1 O
lithium NN 0 1 16 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
BID NNP 0 0 11 O
with IN 0 0 12 O
CELEBREX NNP 0 1 UNK B-Brand
9 CD 0 0 2 O
mg NN 0 1 0 O
BID NNP 0 0 11 O
as IN 1 0 12 O
compared VBN 1 1 1 O
to TO 0 0 12 O
subjects NNS 1 1 UNK O
receiving VBG 1 1 1 O
lithium NN 0 1 16 B-Drug
alone RB 0 1 12 O
. . 0 0 12 O

Patients NNS 0 1 7 O
taking VBG 1 0 12 O
disopyramide JJ 0 1 16 B-Drug
phosphate NN 0 1 14 I-Drug
and CC 0 0 12 O
erythromycin VB 0 1 0 B-Drug
concomitantly RB 0 0 14 O
may MD 0 0 1 O
develop VB 0 0 1 O
increased JJ 0 1 1 O
serum NN 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
disopyramide NN 0 1 16 B-Drug
resulting VBG 1 1 1 O
in IN 0 0 12 O
excessive JJ 0 1 1 O
widening NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
QRS NNP 0 0 8 O
complex NN 0 1 1 O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
prolongation NN 0 1 6 O
of IN 0 0 12 O
the DT 0 0 12 O
Q NNP 0 0 2 O
- : 0 0 2 O
T NNP 0 1 2 O
interval NN 0 1 1 O
. . 0 0 12 O

Valproate NN 0 1 0 B-Drug
: : 0 0 2 O
A DT 0 0 2 O
recent JJ 0 1 12 O
case NN 0 1 12 O
study NN 0 1 1 O
has VBZ 1 0 12 O
shown VBN 1 1 1 O
a DT 0 0 12 O
possible JJ 0 1 1 O
increase NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
plasma JJ 0 1 14 O
level NN 0 1 1 O
of IN 0 0 12 O
valproate NN 0 1 16 B-Drug
when WRB 0 0 12 O
co NN 0 1 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
isoniazid NN 0 1 13 B-Drug
. . 0 0 12 O

In IN 0 0 2 O
two CD 0 1 12 O
combined VBD 1 1 1 O
9 CD 0 0 2 O
- : 0 0 2 O
week NN 0 1 12 O
placebo NN 0 1 13 O
controlled VBD 1 1 1 O
trials NNS 1 1 1 O
that WDT 0 0 12 O
included VBD 1 1 1 O
BROVANA NNP 0 1 UNK B-Brand
doses NNS 1 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
mcg JJ 0 1 0 O
twice RB 0 1 12 O
daily RB 0 1 12 O
9 CD 0 0 2 O
mcg JJ 0 1 0 O
twice RB 0 1 12 O
daily RB 0 1 12 O
and CC 0 0 12 O
9 CD 0 0 2 O
mcg NN 0 1 0 O
once RB 0 0 12 O
daily JJ 0 1 12 O
9 CD 0 0 2 O
of IN 0 0 12 O
9 CD 0 0 2 O
BROVANA NNP 0 1 UNK B-Brand
- : 0 0 2 O
treated JJ 0 1 1 O
subjects NNS 1 1 UNK O
received VBD 1 1 12 O
concomitant JJ 0 1 6 O
theophylline NN 0 1 16 B-Drug
at IN 0 0 12 O
study NN 0 1 1 O
entry NN 0 1 1 O
. . 0 0 12 O

Alcohol NNP 0 1 2 B-Drug
Barbiturates NNP 0 1 UNK B-Group
and CC 0 0 12 O
Narcotics NNPS 0 1 13 B-Group
: : 0 0 2 O
The DT 0 0 2 O
hypotensive JJ 0 1 14 O
effects NNS 1 1 1 O
of IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
may MD 0 0 1 O
be VB 0 0 12 O
potentiated VBN 1 0 UNK O
by IN 0 0 12 O
the DT 0 0 12 O
volume NN 0 1 1 O
contraction NN 0 1 6 O
that WDT 0 0 12 O
may MD 0 0 1 O
be VB 0 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
metolazone NN 0 1 16 B-Drug
therapy NN 0 1 6 O
. . 0 0 12 O

Concomitant NNP 0 1 UNK O
single JJ 0 1 12 O
dose JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
valdecoxib $ 0 1 13 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
with IN 0 0 12 O
multiple JJ 0 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
ketoconazole NN 0 1 16 B-Drug
and CC 0 0 12 O
fluconazole NN 0 1 0 B-Drug
produced VBD 1 0 1 O
a DT 0 0 12 O
significant JJ 0 1 1 O
increase NN 0 1 1 O
in IN 0 0 12 O
exposure NN 0 1 1 O
of IN 0 0 12 O
valdecoxib NN 0 1 13 B-Drug
. . 0 0 12 O

Differences NNS 0 1 UNK O
in IN 0 0 12 O
clearance NN 0 1 16 O
between IN 0 0 12 O
patients NNS 1 1 6 O
on IN 0 0 12 O
these DT 0 0 12 O
medications NNS 1 1 6 O
( ( 0 0 2 O
at IN 0 0 12 O
any DT 0 0 12 O
occasion NN 0 0 12 O
in IN 0 0 12 O
the DT 0 0 12 O
study NN 0 1 1 O
) ) 0 0 2 O
and CC 0 0 12 O
those DT 0 0 12 O
off RP 0 0 12 O
medications NNS 1 1 6 O
varied VBD 1 1 1 O
between IN 0 0 12 O
- : 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
9% CD 0 0 UNK O
. . 0 0 12 O

Accordingly RB 0 0 1 O
diazepam JJ 0 1 0 B-Drug
and CC 0 0 12 O
fluvoxamine NN 0 1 16 B-Drug
should MD 0 0 12 O
not RB 0 1 12 O
ordinarily RB 0 0 UNK O
be VB 0 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
. . 0 0 12 O

griseofulvin NN 0 1 UNK B-Drug
; : 0 0 2 O

Saquinavir NN 0 1 UNK B-Drug

No DT 0 0 2 O
significant JJ 0 1 1 O
interactions NNS 1 1 UNK O
were VBD 1 0 12 O
found VBN 1 1 12 O
between IN 0 0 12 O
nisoldipine NN 0 1 13 B-Drug
and CC 0 0 12 O
warfarin NN 0 1 14 B-Drug
or CC 0 0 12 O
digoxin NN 0 1 14 B-Drug
. . 0 0 12 O

Consider VB 0 1 2 O
doubling VBG 1 1 13 O
the DT 0 0 12 O
rifabutin NN 0 1 13 B-Drug
dose NN 0 1 6 O
in IN 0 0 12 O
regimens NNS 1 1 UNK O
where WRB 0 0 12 O
rifabutin NN 0 1 13 B-Drug
is VBZ 1 0 12 O
given VBN 1 1 12 O
9 CD 0 0 2 O
or CC 0 0 12 O
9 CD 0 0 2 O
times NNS 1 1 12 O
a DT 0 0 12 O
week NN 0 1 12 O
. . 0 0 12 O

As IN 0 0 2 O
there EX 0 0 12 O
is VBZ 1 0 12 O
in IN 0 0 12 O
vitro JJ 0 1 UNK O
evidence NN 0 1 1 O
that IN 0 0 12 O
aminosalicylate NN 0 1 UNK B-Group
derivatives NNS 1 1 13 I-Group
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
olsalazine NN 0 1 13 B-Drug
mesalazine NN 0 1 UNK B-Drug
or CC 0 0 12 O
sulphasalazine NN 0 1 UNK B-Drug
) ) 0 0 2 O
inhibit VBZ 0 1 13 O
the DT 0 0 12 O
TPMT NNP 0 1 UNK O
enzyme NN 0 1 14 O
they PRP 0 0 12 O
should MD 0 0 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
caution NN 0 0 1 O
to TO 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
concurrent JJ 0 1 1 O
thioguanine NN 0 1 UNK B-Drug
therapy NN 0 1 6 O
. . 0 0 12 O

9 CD 0 0 2 O
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
that IN 0 0 12 O
buspirone NN 0 1 16 B-Drug
hydrochloride NN 0 1 0 I-Drug
not RB 0 1 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
MAO NNP 0 1 14 B-Group
inhibitors NNS 1 1 14 I-Group
Because IN 0 0 12 O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
buspirone NN 0 1 16 B-Drug
HCl NNP 0 0 14 I-Drug
with IN 0 0 12 O
most JJS 0 0 12 O
other JJ 0 0 12 O
psychotropic NN 0 1 13 B-Group
drugs NNS 1 1 6 I-Group
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
studied VBN 1 0 1 O
the DT 0 0 12 O
concomitant NN 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
buspirone NN 0 1 16 B-Drug
HCl NNP 0 0 14 I-Drug
with IN 0 0 12 O
other JJ 0 0 12 O
CNS NNP 0 1 6 O
- : 0 0 2 O
active JJ 0 1 1 O
drugs NNS 1 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
approached VBN 1 1 UNK O
with IN 0 0 12 O
caution NN 0 0 1 O
. . 0 0 12 O

Disopyramide NNP 0 1 UNK B-Drug
increases VBZ 1 1 1 O
QT NNP 0 1 13 O
prolongation NN 0 1 6 O
which WDT 0 0 12 O
could MD 0 0 12 O
cause VB 0 1 12 O
arrhythmia NN 0 1 6 O
. . 0 0 12 O

Therefore RB 0 0 1 O
caution NN 0 0 1 O
should MD 0 0 12 O
be VB 0 0 12 O
exercised VBN 1 1 1 O
when WRB 0 0 12 O
using VBG 1 1 1 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
together RB 0 1 12 O
. . 0 0 12 O

Calcium NN 0 1 7 B-Drug
Supplements NNS 0 1 UNK O
: : 0 0 2 O
Uncontrolled VBN 0 1 UNK O
intake NN 0 1 3 O
of IN 0 0 12 O
additional JJ 0 1 1 O
calcium NN 0 1 14 B-Drug
- : 0 0 2 O
containing VBG 1 1 1 O
preparations NNS 1 1 13 O
should MD 0 0 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
. . 0 0 12 O

As IN 0 0 2 O
a DT 0 0 12 O
consequence NN 0 1 1 O
when WRB 0 0 12 O
INDOCIN NNP 0 1 UNK B-Brand
and CC 0 0 12 O
lithium NN 0 1 16 B-Drug
are VBP 1 0 12 O
given VBN 1 1 12 O
concomitantly RB 0 0 14 O
the DT 0 0 12 O
patient NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
carefully RB 0 0 12 O
observed VBN 1 1 1 O
for IN 0 0 12 O
signs NNS 1 1 12 O
of IN 0 0 12 O
lithium NN 0 1 16 B-Drug
toxicity NN 0 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
adrenergic JJ 0 1 UNK O
receptors NNS 1 1 13 O
remain VBP 0 0 12 O
sensitive JJ 0 1 1 O
during IN 0 0 12 O
treatment NN 0 1 6 O
with IN 0 0 12 O
methyldopa NN 0 1 13 B-Drug
. . 0 0 12 O

- : 0 0 2 O
Daunorubicin NN 0 1 UNK B-Drug
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
Cerubidine NNP 0 1 UNK B-Brand
) ) 0 0 2 O
or CC 0 0 12 O

In IN 0 0 2 O
two CD 0 1 12 O
clinical JJ 0 1 6 O
studies NNS 1 1 1 O
cyclosporine VBP 0 1 14 B-Drug
( ( 0 0 2 O
one CD 0 1 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
dose NN 0 1 6 O
or CC 0 0 12 O
two CD 0 1 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
kg VBP 0 1 18 O
doses NNS 1 1 6 O
) ) 0 0 2 O
increased VBD 1 1 1 O
the DT 0 0 12 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
caspofungin NN 0 1 14 B-Drug
by IN 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

Thrombolytic JJ 0 1 UNK B-Group
agents NNS 1 1 1 I-Group
: : 0 0 2 O
The DT 0 0 2 O
safety NN 0 1 1 O
and CC 0 0 12 O
effectiveness NN 0 1 UNK O
of IN 0 0 12 O
Argatroban NNP 0 1 0 B-Drug
with IN 0 0 12 O
thrombolytic JJ 0 1 14 B-Group
agents NNS 1 1 1 I-Group
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
established VBN 1 1 1 O
. . 0 0 12 O

Antihistamines NNS 0 1 UNK B-Drug
: : 0 0 2 O
astemizole JJ 0 1 UNK B-Drug
* NNP 0 0 2 O
terfenadine NN 0 1 UNK B-Drug
* NN 0 0 2 O
CONTRAINDICATED NNP 0 1 UNK O
due JJ 0 1 1 O
to TO 0 0 12 O
potential JJ 0 1 1 O
for IN 0 0 12 O
serious JJ 0 1 12 O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
life NN 0 1 12 O
- : 0 0 2 O
threatening JJ 0 0 12 O
cardiac JJ 0 1 6 O
arrhythmias NN 1 1 6 O
. . 0 0 12 O

As IN 0 0 2 O
with IN 0 0 12 O
other JJ 0 0 12 O
antihypertensive JJ 0 1 14 B-Group
agents NNS 1 1 1 I-Group
the DT 0 0 12 O
antihypertensive JJ 0 1 14 O
effect NN 0 1 1 O
of IN 0 0 12 O
losartan NN 0 1 0 B-Drug
may MD 0 0 1 O
be VB 0 0 12 O
blunted VBN 1 1 UNK O
by IN 0 0 12 O
the DT 0 0 12 O
non JJ 0 1 1 B-Group
- : 0 0 2 O
steroidal NN 0 1 UNK I-Group
anti SYM 0 0 3 I-Group
- : 0 0 2 O
inflammatory JJ 0 1 6 I-Group
drug NN 0 1 1 I-Group
indomethacin NN 0 1 14 B-Drug

However RB 0 0 1 O
the DT 0 0 12 O
pharmacodynamic JJ 0 1 UNK O
effect NN 0 1 1 O
increased VBN 1 1 1 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
( ( 0 0 2 O
QTc JJ 0 0 14 O
increase NN 0 1 1 O
over IN 0 1 12 O
time NN 0 1 12 O
) ) 0 0 2 O
and CC 0 0 12 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
( ( 0 0 2 O
Maximum NNP 0 1 2 O
QTc NNP 0 0 14 O
increase NN 0 1 1 O
) ) 0 0 2 O
. . 0 0 12 O

Quinolones NNS 0 1 UNK B-Group
including VBG 1 1 1 O
nalidixic JJ 0 0 UNK B-Drug
acid NN 0 1 14 I-Drug
may MD 0 0 1 O
enhance VB 0 1 UNK O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
oral JJ 0 1 6 O
anticoagulant JJ 0 1 13 B-Group
warfarin NN 0 1 14 B-Drug
or CC 0 0 12 O
its PRP$ 1 0 12 O
derivatives NNS 1 1 13 O
. . 0 0 12 O

Stavudine NNP 0 1 UNK B-Drug
and CC 0 0 12 O
Zidovudine NNP 0 1 UNK B-Drug
Ribavirin NNP 0 1 0 B-Drug
can MD 0 0 12 O
antagonize VB 0 0 UNK O
the DT 0 0 12 O
in IN 0 0 12 O
vitro JJ 0 1 UNK O
antiviral JJ 0 1 13 O
activity NN 0 1 1 O
of IN 0 0 12 O
stavudine NN 0 1 13 B-Drug
and CC 0 0 12 O
zidovudine NN 0 1 13 B-Drug
against IN 0 0 12 O
HIV NNP 0 1 6 O
. . 0 0 12 O

No DT 0 0 2 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
performed VBN 1 1 1 O
with IN 0 0 12 O
Calcitonin NNP 0 1 UNK B-Drug
salmon NN 0 1 16 I-Drug
nasal NN 0 1 6 O
spray NN 0 1 3 O
ingredients NNS 1 1 UNK O
. . 0 0 12 O

Tell VB 0 0 UNK O
your PRP$ 0 0 12 O
doctor NN 0 1 12 O
if IN 0 0 12 O
you PRP 0 0 12 O
are VBP 1 0 12 O
taking VBG 1 0 12 O
guanethidine NN 0 1 UNK B-Drug
. . 0 0 12 O

Additionally RB 0 0 1 O
in IN 0 0 12 O
one CD 0 1 12 O
controlled VBD 1 1 1 O
study NN 0 1 1 O
in IN 0 0 12 O
five CD 0 1 12 O
normal JJ 0 1 1 O
subjects NNS 1 1 UNK O
and CC 0 0 12 O
seven CD 0 1 12 O
patients NNS 1 1 6 O
the DT 0 0 12 O
clearance NN 0 1 16 O
of IN 0 0 12 O
caffeine NN 0 1 6 B-Drug
was VBD 1 0 12 O
decreased VBN 1 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
following VBG 1 1 1 O
the DT 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
Mexitil NNP 0 1 UNK B-Brand
. . 0 0 12 O

Amphotericin NNP 0 1 0 B-Drug
B NNP 0 0 2 I-Drug
injection NN 0 1 3 O
and CC 0 0 12 O
potassium NN 0 1 14 O
- : 0 0 2 O
depleting VBG 1 1 UNK O
agents NNS 1 1 1 O
: : 0 0 2 O
When WRB 0 0 12 O
corticosteroids NNS 1 1 14 B-Group
are VBP 1 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
potassium NN 0 1 14 O
- : 0 0 2 O
depleting NN 0 1 UNK O
agents NNS 1 1 1 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
amphotericin NN 0 1 14 B-Drug
B NNP 0 0 2 I-Drug
diuretics NNS 1 1 14 B-Group
) ) 0 0 2 O
patients NNS 1 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
observed VBN 1 1 1 O
closely RB 0 0 1 O
for IN 0 0 12 O
development NN 0 1 1 O
of IN 0 0 12 O
hypokalemia NN 0 1 14 O
. . 0 0 12 O

cholestyramine NN 0 1 13 B-Drug
; : 0 0 2 O

The DT 0 0 2 O
data NN 0 1 1 O
inTables VBZ 0 0 UNK O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
are VBP 1 0 12 O
based VBN 1 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
results NNS 1 1 1 O
of IN 0 0 12 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
conducted VBN 1 1 1 O
in IN 0 0 12 O
HIV NNP 0 1 6 O
- : 0 0 2 O
9 CD 0 0 2 O
seropositive JJ 0 1 UNK O
subjects NNS 1 1 UNK O
unless IN 0 0 12 O
otherwise RB 0 0 1 O
indicated VBN 1 1 1 O
. . 0 0 12 O

Gabapentin NNP 0 1 0 B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
appreciably RB 0 0 UNK O
metabolized VBN 1 1 UNK O
nor CC 0 0 12 O
does VBZ 1 0 12 O
it PRP 0 0 12 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
commonly RB 0 0 UNK O
coadministered VBN 0 0 UNK O
antiepileptic JJ 0 1 UNK B-Group
drugs NNS 1 1 6 I-Group
. . 0 0 12 O

Caution NN 0 0 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
when WRB 0 0 12 O
NSAIDs NNP 0 1 UNK B-Group
are VBP 1 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
methotrexate NN 0 1 16 B-Drug
. . 0 0 12 O

This DT 0 0 2 O
may MD 0 0 1 O
potentiate VB 0 0 UNK O
and CC 0 0 12 O
prolong VB 0 0 13 O
hypnotic JJ 0 1 13 O
and CC 0 0 12 O
sedative JJ 0 1 6 O
effects NNS 1 1 1 O
. . 0 0 12 O

Tagamet NNP 0 1 0 B-Brand
apparently RB 0 1 12 O
through IN 0 0 12 O
an DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
certain JJ 0 1 1 O
microsomal JJ 0 1 UNK O
enzyme NN 0 1 14 O
systems NNS 1 1 1 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
reduce VB 0 0 1 O
the DT 0 0 12 O
hepatic JJ 0 1 14 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
warfarin JJ 0 1 14 B-Group
- : 0 0 2 O
type NN 0 1 1 I-Group
anticoagulants NNS 1 1 13 I-Group
phenytoin VBP 0 1 16 B-Drug
propranolol JJ 0 1 16 B-Drug
nifedipine JJ 0 1 0 B-Drug
chlordiazepoxide NN 0 1 16 B-Drug
diazepam NN 0 1 0 B-Drug
certain JJ 0 1 1 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
lidocaine JJ 0 1 14 B-Drug
theophylline NN 0 1 16 B-Drug
and CC 0 0 12 O
metronidazole JJ 0 1 0 B-Drug
thereby NN 0 0 UNK O
delaying VBG 1 1 UNK O
elimination NN 0 1 UNK O
and CC 0 0 12 O
increasing VBG 1 1 1 O
blood NN 0 1 6 O
levels NNS 1 1 1 O
of IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

Epinephrine NNP 0 1 0 B-Drug
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
other JJ 0 0 12 O
sympathomimetic JJ 0 1 13 B-Group
drugs NNS 1 1 6 I-Group
( ( 0 0 2 O
such JJ 0 0 1 O
as IN 1 0 12 O
isoproterenol NN 0 1 13 B-Drug
) ) 0 0 2 O
because IN 0 0 12 O
of IN 0 0 12 O
possible JJ 0 1 1 O
additive JJ 0 1 16 O
effects NNS 1 1 1 O
and CC 0 0 12 O
increased JJ 0 1 1 O
toxicity NN 0 1 6 O
. . 0 0 12 O

However RB 0 0 1 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
infusions NNS 1 1 14 O
of IN 0 0 12 O
FLOLAN NNP 0 1 UNK B-Brand
in IN 0 0 12 O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
were VBD 1 0 12 O
maintained VBN 1 1 1 O
on IN 0 0 12 O
anticoagulants NNS 1 1 13 B-Group
without IN 0 0 12 O
evidence NN 0 1 1 O
of IN 0 0 12 O
increased JJ 0 1 1 O
bleeding NN 0 1 6 O
. . 0 0 12 O

Because IN 0 0 12 O
there EX 0 0 12 O
is VBZ 1 0 12 O
a DT 0 0 12 O
theoretical JJ 0 1 UNK O
basis NN 0 1 1 O
that IN 0 0 12 O
these DT 0 0 12 O
effects NNS 1 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
additive JJ 0 1 16 O
use NN 0 1 1 O
of IN 0 0 12 O
ergotamine JJ 0 1 UNK B-Drug
- : 0 0 2 O
containing NN 0 1 1 O
or CC 0 0 12 O
ergot VB 0 1 UNK B-Group
- : 0 0 2 O
type NN 0 1 1 I-Group
medications NNS 1 1 6 I-Group
( ( 0 0 2 O
like IN 0 0 12 O
dihydroergotamine NN 0 1 UNK B-Drug
or CC 0 0 12 O
methysergide NN 0 1 UNK B-Drug
) ) 0 0 2 O
and CC 0 0 12 O
sumatriptan VB 0 1 16 B-Drug
within IN 0 0 1 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
of IN 0 0 12 O
each DT 0 0 12 O
other JJ 0 0 12 O
should MD 0 0 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
. . 0 0 12 O

Single NNP 0 1 2 O
dose JJ 0 1 6 O
bioavailability NN 0 1 UNK O
studies NNS 1 1 1 O
in IN 0 0 12 O
normal JJ 0 1 1 O
volunteers NNS 1 1 UNK O
have VBP 0 0 12 O
failed VBN 1 1 12 O
to TO 0 0 12 O
wshow VB 0 0 UNK O
an DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
aspirin NN 0 1 14 B-Brand
on IN 0 0 12 O
ibuprofen JJ 0 1 0 B-Drug
blood NN 0 1 6 O
levels NNS 1 1 1 O
. . 0 0 12 O

Wait $ 0 1 UNK O
9 CD 0 0 2 O
weeks NNS 1 1 12 O
after IN 0 0 12 O
stopping VBG 1 1 12 O
an DT 0 0 12 O
MAO NNP 0 1 14 B-Group
inhibitor NN 0 1 14 I-Group
before IN 0 1 12 O
starting VBG 1 1 12 O
escitalopram NN 0 1 0 B-Drug
. . 0 0 12 O

This DT 0 0 2 O
response NN 0 1 1 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
attributed VBN 1 1 1 O
to TO 0 0 12 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
renal JJ 0 1 6 O
prostaglandin NN 0 1 13 O
synthesis NN 0 1 UNK O
. . 0 0 12 O

Agents NNS 0 1 2 O
that WDT 0 0 12 O
induce VBP 0 1 6 O
CYP9A9 NNP 0 0 UNK O
( ( 0 0 2 O
eg JJ 0 1 UNK O
carbamazepine NN 0 1 16 B-Drug
) ) 0 0 2 O
could MD 0 0 12 O
cause VB 0 1 12 O
an DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
aripiprazole JJ 0 1 16 B-Drug
clearance NN 0 1 16 O
and CC 0 0 12 O
lower JJR 1 1 1 O
blood NN 0 1 6 O
levels NNS 1 1 1 O
. . 0 0 12 O

http NN 0 1 UNK O
: : 0 0 2 O
/ JJ 0 0 2 O
/ NNP 0 0 2 O
www.rxlist.com NN 0 1 UNK O
/ NNP 0 0 2 O
cgi NN 0 1 UNK O
/ NNP 0 0 2 O
generic9 NN 0 0 UNK O
/ NNP 0 0 2 O
guanethidine_od.htm NN 0 1 UNK O

The DT 0 0 2 O
use NN 0 1 1 O
of IN 0 0 12 O
dextromethorphan NNS 0 1 16 B-Drug
hydrobromide VBP 0 0 16 I-Drug
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
additive JJ 0 1 16 O
CNS NNP 0 1 6 O
depressant NN 0 0 UNK O
effects NNS 1 1 1 O
when WRB 0 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
alcohol NN 0 1 1 B-Drug
antihistamines NNS 1 1 UNK B-Group
psychotropics NNS 0 1 UNK B-Group
or CC 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
that IN 0 0 12 O
produce VBP 0 0 1 O
CNS NNP 0 1 6 O
depression NN 0 1 6 O
. . 0 0 12 O

Gleevec NNP 0 1 UNK B-Brand
will MD 0 0 12 O
increase VB 0 1 1 O
plasmaconcentration NN 0 0 UNK O
of IN 0 0 12 O
other JJ 0 0 12 O
CYP9A9 NNP 0 0 UNK O
metabolized VBN 1 1 UNK O
drugs NNS 1 1 6 O
( ( 0 0 2 O
e.g. NN 0 0 UNK O
triazolo SYM 0 0 UNK O
- : 0 0 2 O
benzodiazepines NNS 1 1 14 B-Group
dihydropyridine VBP 0 1 UNK B-Group
calcium NN 0 1 14 I-Group
channel NN 0 1 1 I-Group
blockers NNS 1 0 6 I-Group
certain JJ 0 1 1 O
HMG NNP 0 0 UNK B-Group
- : 0 0 2 O
CoA NNP 0 0 UNK I-Group
reductase NN 0 1 UNK I-Group
inhibitors NNS 1 1 14 I-Group
etc VBP 0 1 12 O
. . 0 0 12 O
) ) 0 0 2 O
. . 0 0 12 O

( ( 0 0 2 O
9 CD 0 0 2 O
mg RB 0 1 0 O
Q9h NNP 0 1 UNK O
) ) 0 0 2 O

There EX 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
postmarketing VBG 0 0 UNK O
reports NNS 1 1 1 O
of IN 0 0 12 O
increased VBN 1 1 1 O
INR NNP 0 1 13 O
and CC 0 0 12 O
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
proton JJ 0 1 14 B-Group
pump NN 0 1 3 I-Group
inhibitors NNS 1 1 14 I-Group
including VBG 1 1 1 O
pantoprazole NN 0 1 16 B-Drug
and CC 0 0 12 O
warfarin NN 0 1 14 B-Drug
concomitantly RB 0 0 14 O
. . 0 0 12 O

However RB 0 0 1 O
interactions NNS 1 1 UNK O
may MD 0 0 1 O
be VB 0 0 12 O
expected VBN 1 1 12 O
and CC 0 0 12 O
UROXATRAL NNP 0 1 UNK B-Brand
should MD 0 0 12 O
NOT NNP 0 1 11 O
be VB 0 0 12 O
used VBN 1 1 12 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
other JJ 0 0 12 O
alpha JJ 0 1 1 B-Group
- : 0 0 2 O
blockers NNS 1 0 6 I-Group
. . 0 0 12 O

- : 0 0 2 O
Pressor NN 0 1 UNK O
amines NNS 1 1 13 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
norepinephrine NN 0 1 14 B-Drug
) ) 0 0 2 O
: : 0 0 2 O
Possible JJ 0 1 2 O
decreased JJ 0 1 1 O
response NN 0 1 1 O
to TO 0 0 12 O
pressor VB 0 1 14 O
amines NNS 1 1 13 O
but CC 0 0 12 O
not RB 0 1 12 O
sufficient JJ 0 1 1 O
to TO 0 0 12 O
preclude VB 0 0 UNK O
their PRP$ 0 0 12 O
use NN 0 1 1 O

Thus RB 0 0 1 O
if IN 0 0 12 O
a DT 0 0 12 O
patient NN 0 1 6 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
titrated VBN 1 1 14 O
to TO 0 0 12 O
a DT 0 0 12 O
stable JJ 0 1 1 O
dosage NN 0 1 0 O
on IN 0 0 12 O
one CD 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
agents NNS 1 1 1 O
in IN 0 0 12 O
this DT 0 0 12 O
category NN 0 1 16 O
and CC 0 0 12 O
then RB 0 1 12 O
begins VBZ 1 1 12 O
a DT 0 0 12 O
course NN 0 1 12 O
of IN 0 0 12 O
treatment NN 0 1 6 O
with IN 0 0 12 O
EQUETROTM NNP 0 0 UNK B-Brand
it PRP 0 0 12 O
is VBZ 1 0 12 O
reasonable JJ 0 0 1 O
to TO 0 0 12 O
expect VB 0 0 12 O
that IN 0 0 12 O
a DT 0 0 12 O
dose JJ 0 1 6 O
adjustment NN 0 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
necessary JJ 0 0 1 O
. . 0 0 12 O

A DT 0 0 2 O
number NN 0 1 1 O
of IN 0 0 12 O
drugs NNS 1 1 6 O
including VBG 1 1 1 O
ethacrynic JJ 0 0 16 B-Drug
acid NNS 0 1 14 I-Drug
have VBP 0 0 12 O
been VBN 1 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
displace VB 0 0 13 O
warfarin NN 0 1 14 B-Drug
from IN 0 0 12 O
plasma JJ 0 1 14 O
protein NN 0 1 14 O
; : 0 0 2 O

The DT 0 0 2 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
quinolones NNS 0 1 13 B-Group
including VBG 1 1 1 O
norfloxacin NN 0 1 UNK B-Drug
with IN 0 0 12 O
glyburide NN 0 1 16 B-Drug
( ( 0 0 2 O
a DT 0 0 12 O
sulfonylurea NN 0 1 UNK B-Group
agent NN 0 1 1 I-Group
) ) 0 0 2 O
has VBZ 1 0 12 O
on IN 0 0 12 O
rare JJ 0 1 12 O
occasions NNS 1 0 12 O
resulted VBD 1 1 1 O
in IN 0 0 12 O
severe JJ 0 1 6 O
hypoglycemia NN 0 1 6 O
. . 0 0 12 O

Potentiation NN 0 1 UNK O
occurs VBZ 1 1 1 O
with IN 0 0 12 O
ganglionic JJ 0 1 UNK B-Group
or CC 0 0 12 O
peripheral JJ 0 1 6 B-Group
adrenergic JJ 0 1 UNK I-Group
blocking VBG 1 1 UNK I-Group
drugs NNS 1 1 6 I-Group
. . 0 0 12 O

Combinations NNS 0 1 UNK O
of IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
studied VBN 1 0 1 O
and CC 0 0 12 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
CRIXIVAN NNP 0 1 UNK B-Brand
and CC 0 0 12 O
atazanavir NN 0 1 13 B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O

Results NNS 0 1 2 O
of IN 0 0 12 O
studies NNS 1 1 1 O
in IN 0 0 12 O
multiple JJ 0 1 1 O
sclerosis NN 0 1 6 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
TYSABRI NNP 0 1 UNK B-Brand
and CC 0 0 12 O
concomitant JJ 0 1 6 O
interferon NN 0 1 14 B-Drug
beta SYM 0 1 16 I-Drug
- : 0 0 2 O
9a CD 0 1 UNK I-Drug
( ( 0 0 2 O
AVONEX NNP 0 1 UNK B-Brand
9 CD 0 0 2 O
mcg NN 0 1 0 O
IM NNP 0 1 11 O
once RB 0 0 12 O
weekly RB 0 1 12 O
) ) 0 0 2 O
or CC 0 0 12 O
glatiramer JJ 0 1 16 B-Drug
acetate NN 0 1 14 I-Drug
were VBD 1 0 12 O
inconclusive JJ 0 1 13 O
with IN 0 0 12 O
regard NN 0 0 1 O
to TO 0 0 12 O
the DT 0 0 12 O
need NN 0 1 12 O
for IN 0 0 12 O
dose JJ 0 1 6 O
adjustment NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
beta NN 0 1 16 B-Drug
- : 0 0 2 O
interferon NN 0 1 14 I-Drug
or CC 0 0 12 O
glatiramer NN 0 1 16 B-Drug
acetate NN 0 1 14 I-Drug
. . 0 0 12 O

Other JJ 0 0 2 O
drugs NNS 1 1 6 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
C.P.A NNP 0 0 UNK O
. . 0 0 12 O

Laboratory NN 0 1 2 O
Tests NNS 0 1 UNK O
If IN 0 0 12 O
significant JJ 0 1 1 O
abnormal JJ 0 1 6 O
laboratory NN 0 1 1 O
results NNS 1 1 1 O
are VBP 1 0 12 O
obtained VBN 1 1 1 O
either RB 0 1 12 O
dosage JJ 0 1 0 O
reduction NN 0 1 1 O
with IN 0 0 12 O
careful JJ 0 1 12 O
monitoring NN 0 1 1 O
or CC 0 0 12 O
treatment NN 0 1 6 O
discontinuation NN 0 1 6 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
depending VBG 1 1 1 O
on IN 0 0 12 O
clinical JJ 0 1 6 O
judgement NN 0 1 13 O
. . 0 0 12 O

No DT 0 0 2 O
information NN 0 1 1 O
is VBZ 1 0 12 O
available JJ 0 1 1 O
about IN 0 1 12 O
the DT 0 0 12 O
interaction NN 0 1 UNK O
of IN 0 0 12 O
cephalexin NN 0 1 16 B-Drug
and CC 0 0 12 O
metformin NN 0 1 0 B-Drug
following VBG 1 1 1 O
multiple JJ 0 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
either DT 0 1 12 O
drug NN 0 1 1 O
. . 0 0 12 O

Digoxin NN 0 1 0 B-Drug
: : 0 0 2 O
Some DT 0 0 2 O
calcium NN 0 1 14 B-Group
blockers NNS 1 0 6 I-Group
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
concentration NN 0 1 1 O
of IN 0 0 12 O
digitalis JJ 0 1 14 B-Group
preparations NNS 1 1 13 I-Group
in IN 0 0 12 O
the DT 0 0 12 O
blood NN 0 1 6 O
. . 0 0 12 O

Although IN 0 0 12 O
not RB 0 1 12 O
studied VBN 1 0 1 O
systematically RB 0 0 UNK O
in IN 0 0 12 O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
no DT 0 0 12 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
were VBD 1 0 12 O
observed VBN 1 1 1 O
when WRB 0 0 12 O
vecuronium NN 0 1 16 B-Drug
pancuronium NN 0 1 16 B-Drug
or CC 0 0 12 O
atracurium NN 0 1 13 B-Drug
were VBD 1 0 12 O
administered VBN 1 1 1 O
following VBG 1 1 1 O
varying VBG 1 0 1 O
degrees NNS 1 1 1 O
of IN 0 0 12 O
recovery NN 0 1 1 O
from IN 0 0 12 O
single JJ 0 1 12 O
doses NNS 1 1 6 O
or CC 0 0 12 O
infusions NNS 1 1 14 O
of IN 0 0 12 O
NIMBEX NNP 0 1 UNK B-Brand
. . 0 0 12 O

Patients NNS 0 1 7 O
with IN 0 0 12 O
ACTH NNP 0 1 UNK O
deficiency NN 0 1 6 O
should MD 0 0 12 O
have VB 0 0 12 O
their PRP$ 0 0 12 O
glucocorticoid JJ 0 1 13 B-Group
- : 0 0 2 O
replacement NN 0 1 1 O
dose NN 0 1 6 O
carefully RB 0 0 12 O
adjusted VBN 1 1 1 O
to TO 0 0 12 O
avoid VB 0 0 12 O
an DT 0 0 12 O
inhibitory JJ 0 1 UNK O
effect NN 0 1 1 O
on IN 0 0 12 O
growth NN 0 1 1 O
. . 0 0 12 O

If IN 0 0 12 O
concomitant JJ 0 1 6 O
use NN 0 1 1 O
can MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
serum JJ 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
theophylline NN 0 1 16 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
and CC 0 0 12 O
dosage NN 0 1 0 O
adjustments NNS 1 1 1 O
made VBN 1 1 12 O
as IN 1 0 12 O
appropriate JJ 0 1 1 O
. . 0 0 12 O

An DT 0 0 2 O
appropriate JJ 0 1 1 O
adjustment NN 0 1 1 O
in IN 0 0 12 O
theophylline NN 0 1 16 B-Drug
dose NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
. . 0 0 12 O

Dosage NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
anticoagulant NN 0 1 13 B-Group
may MD 0 0 1 O
require VB 0 0 1 O
reduction NN 0 1 1 O
in IN 0 0 12 O
order NN 0 1 1 O
to TO 0 0 12 O
maintain VB 0 1 1 O
satisfactory JJ 0 1 1 O
therapeutic JJ 0 1 6 O
hypoprothrombinemia NN 0 1 UNK O
. . 0 0 12 O

Alcohol NN 0 1 2 B-Drug
: : 0 0 2 O
In IN 0 0 2 O
post NN 0 1 12 O
- : 0 0 2 O
marketing NN 0 1 UNK O
experience NN 0 1 12 O
there RB 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
rare JJ 0 1 12 O
reports NNS 1 1 1 O
of IN 0 0 12 O
adverse JJ 0 0 1 O
neuropsychiatric JJ 0 0 UNK O
events NNS 1 1 12 O
or CC 0 0 12 O
reduced VBN 1 1 1 O
alcohol JJ 0 1 1 B-Drug
tolerance NN 0 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
who WP 0 0 12 O
were VBD 1 0 12 O
drinking VBG 1 1 12 O
alcohol NN 0 1 1 B-Drug
during IN 0 0 12 O
treatment NN 0 1 6 O
with IN 0 0 12 O
WELLBUTRIN NNP 0 1 0 B-Brand
. . 0 0 12 O

Therefore RB 0 0 1 O
cyclosporine JJ 0 1 14 B-Drug
serum NN 0 1 14 O
levels NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
and CC 0 0 12 O
appropriate JJ 0 1 1 O
cyclosporine NN 0 1 14 B-Drug
dosage NN 0 1 0 O
adjustments NNS 1 1 1 O
made VBD 1 1 12 O
when WRB 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
are VBP 1 0 12 O
used VBN 1 1 12 O
concomitantly RB 0 0 14 O
. . 0 0 12 O

Anticholinergic JJ 0 1 UNK B-Group
agents NNS 1 1 1 I-Group
: : 0 0 2 O
Although IN 0 0 12 O
ipratropium NN 0 1 0 B-Drug
bromide NN 0 1 16 I-Drug
is VBZ 1 0 12 O
minimally RB 0 0 6 O
absorbed VBN 1 0 3 O
into IN 0 0 12 O
the DT 0 0 12 O
systemic JJ 0 1 6 O
circulation NN 0 1 1 O
there EX 0 0 12 O
is VBZ 1 0 12 O
some DT 0 0 12 O
potential JJ 0 1 1 O
for IN 0 0 12 O
an DT 0 0 12 O
additive JJ 0 1 16 O
interaction NN 0 1 UNK O
with IN 0 0 12 O
concomitantly RB 0 0 14 O
used VBN 1 1 12 O
anticholinergic JJ 0 1 13 B-Group
medications NNS 1 1 6 I-Group
. . 0 0 12 O

Based VBN 0 1 2 O
on IN 0 0 12 O
adult NN 0 1 12 O
data NNS 0 1 1 O
lower JJR 1 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
caffeine NN 0 1 6 B-Drug
may MD 0 0 1 O
be VB 0 0 12 O
needed VBN 1 1 12 O
following VBG 1 1 1 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
drugs NNS 1 1 6 O
which WDT 0 0 12 O
are VBP 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
decrease VB 0 1 1 O
caffeine JJ 0 1 6 B-Drug
elimination NN 0 1 UNK O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
cimetidine NN 0 1 13 B-Drug
and CC 0 0 12 O
ketoconazole NN 0 1 16 B-Drug
) ) 0 0 2 O
and CC 0 0 12 O
higher JJR 1 1 1 O
caffeine NN 0 1 6 B-Drug
doses NNS 1 1 6 O
may MD 0 0 1 O
be VB 0 0 12 O
needed VBN 1 1 12 O
following VBG 1 1 1 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
increase VBP 0 1 1 O
caffeine JJ 0 1 6 B-Drug
elimination NN 0 1 UNK O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
phenobarbital NN 0 1 16 B-Drug
and CC 0 0 12 O
phenytoin NN 0 1 16 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

In IN 0 0 2 O
a DT 0 0 12 O
single JJ 0 1 12 O
study NN 0 1 1 O
rats NNS 1 1 UNK O
given VBN 1 1 12 O
high JJ 0 1 1 O
intraperitoneal NN 0 1 14 O
doses NNS 1 1 6 O
of IN 0 0 12 O
an DT 0 0 12 O
MAO NNP 0 1 14 B-Group
inhibitor NN 0 1 14 I-Group
plus CC 0 1 16 O
disulfiram NN 0 1 13 B-Drug
experienced VBN 1 0 12 O
severe JJ 0 1 6 O
toxicity NN 0 1 6 O
including VBG 1 1 1 O
convulsions NNS 1 1 13 O
and CC 0 0 12 O
death NN 0 1 12 O
. . 0 0 12 O

Such JJ 0 0 1 O
patients NNS 1 1 6 O
may MD 0 0 1 O
be VB 0 0 12 O
unresponsive JJ 0 1 6 O
to TO 0 0 12 O
the DT 0 0 12 O
usual JJ 0 1 12 O
doses NNS 1 1 6 O
of IN 0 0 12 O
epinephrine NN 0 1 14 B-Drug
used VBN 1 1 12 O
to TO 0 0 12 O
treat VB 0 1 12 O
allergic JJ 0 1 6 O
reactions NNS 1 1 1 O
. . 0 0 12 O

Other JJ 0 0 2 O
significant JJ 0 1 1 O
inhibitors NNS 1 1 14 O
of IN 0 0 12 O
CYP9D9 NNP 0 0 UNK O
such JJ 0 0 1 O
as IN 1 0 12 O
fluoxetine NN 0 1 16 B-Drug
or CC 0 0 12 O
paroxetine NN 0 1 16 B-Drug
would MD 0 0 12 O
be VB 0 0 12 O
expected VBN 1 1 12 O
to TO 0 0 12 O
have VB 0 0 12 O
similar JJ 0 1 1 O
effects NNS 1 1 1 O
and CC 0 0 12 O
therefore NN 0 0 1 O
should MD 0 0 12 O
be VB 0 0 12 O
accompanied VBN 1 0 12 O
by IN 0 0 12 O
similar JJ 0 1 1 O
dose NN 0 1 6 O
reductions NNS 1 1 1 O
. . 0 0 12 O

Because IN 0 0 12 O
lithium NN 0 1 16 B-Drug
may MD 0 0 1 O
enhance VB 0 1 UNK O
the DT 0 0 12 O
serotonergic JJ 0 0 UNK O
effects NNS 1 1 1 O
of IN 0 0 12 O
escitalopram JJ 0 1 0 B-Drug
caution NN 0 0 1 O
should MD 0 0 12 O
be VB 0 0 12 O
exercised VBN 1 1 1 O
when WRB 0 0 12 O
LEXAPRO NNP 0 1 UNK B-Brand
and CC 0 0 12 O
lithium NN 0 1 16 B-Drug
are VBP 1 0 12 O
coadministered VBN 0 0 UNK O
. . 0 0 12 O

When WRB 0 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
SUSTIVA NNP 0 1 UNK B-Brand
in IN 0 0 12 O
treatment NN 0 1 6 O
- : 0 0 2 O
naive JJ 0 0 UNK O
patients NNS 1 1 6 O
the DT 0 0 12 O
recommended VBN 1 1 1 O
dose NN 0 1 6 O
of IN 0 0 12 O
atazanavir NN 0 1 13 B-Drug
is VBZ 1 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
with IN 0 0 12 O
ritonavir JJ 0 1 16 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
and CC 0 0 12 O
SUSTIVA NNP 0 1 UNK B-Brand
9 CD 0 0 2 O
mg NN 0 1 0 O
( ( 0 0 2 O
all DT 0 0 12 O
once RB 0 0 12 O
daily JJ 0 1 12 O
) ) 0 0 2 O
. . 0 0 12 O

Mexitil NNP 0 1 UNK B-Brand
does VBZ 1 0 12 O
not RB 0 1 12 O
alter VB 0 1 13 O
serum NN 0 1 14 O
digoxin NN 0 1 14 B-Drug
levels NNS 1 1 1 O
but CC 0 0 12 O
magnesium NN 0 1 14 B-Drug
- : 0 0 2 O
aluminum NN 0 1 16 I-Drug
hydroxide NN 0 1 14 I-Drug
when WRB 0 0 12 O
used VBN 1 1 12 O
to TO 0 0 12 O
treat VB 0 1 12 O
gastrointestinal JJ 0 1 6 O
symptoms NNS 1 1 6 O
due JJ 0 1 1 O
to TO 0 0 12 O
Mexitil NNP 0 1 UNK B-Brand
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
lower VB 0 1 1 O
serum NN 0 1 14 O
digoxin NN 0 1 14 B-Drug
levels NNS 1 1 1 O
. . 0 0 12 O

Immediate NNP 0 1 UNK O
and CC 0 0 12 O
Extended NNP 0 1 2 O
Release NNP 0 1 2 O
Tablets VBZ 0 1 0 O
The DT 0 0 2 O
hypoglycemic JJ 0 1 14 O
action NN 0 1 13 O
of IN 0 0 12 O
sulfonylureas NNS 1 1 UNK B-Group
may MD 0 0 1 O
be VB 0 0 12 O
potentiated VBN 1 0 UNK O
by IN 0 0 12 O
certain JJ 0 1 1 O
drugs NNS 1 1 6 O
including VBG 1 1 1 O
nonsteroidal JJ 0 0 14 B-Group
anti JJ 0 0 3 I-Group
- : 0 0 2 O
inflammatory NN 0 1 6 I-Group
agents NNS 1 1 1 I-Group
some DT 0 0 12 O
azoles NNS 0 1 UNK B-Group
and CC 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
are VBP 1 0 12 O
highly RB 0 1 1 O
protein JJ 0 1 14 O
bound NN 0 1 12 O
salicylates VBZ 0 1 13 B-Group
sulfonamides NNS 1 1 13 B-Group
chloramphenicol JJ 0 1 14 B-Drug
probenecid NN 0 1 13 B-Drug
coumarins NNS 0 1 UNK B-Group
monoamine JJ 0 1 13 B-Group
oxidase NN 0 1 13 I-Group
inhibitors NNS 1 1 14 I-Group
and CC 0 0 12 O
beta NN 0 1 16 B-Group
adrenergic NNS 0 1 UNK I-Group
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
. . 0 0 12 O

Oral JJ 0 1 2 O
Anticoagulants NNPS 0 1 UNK B-Group
Interaction NNP 0 1 2 O
studies NNS 1 1 1 O
with IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
and CC 0 0 12 O
acenocoumarol NN 0 1 UNK B-Drug
failed VBD 1 1 12 O
to TO 0 0 12 O
identify VB 0 0 1 O
any DT 0 0 12 O
clinically RB 0 0 6 O
important JJ 0 1 1 O
effects NNS 1 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
serum NN 0 1 14 O
concentrations NNS 1 1 13 O
or CC 0 0 12 O
clinical JJ 0 1 6 O
effects NNS 1 1 1 O
of IN 0 0 12 O
these DT 0 0 12 O
anticoagulants NNS 1 1 13 B-Group
. . 0 0 12 O

In IN 0 0 2 O
rats NNS 1 1 UNK O
simultaneous JJ 0 1 13 O
ingestion NN 0 1 14 O
of IN 0 0 12 O
disulfiram NN 0 1 13 B-Drug
and CC 0 0 12 O
nitrite NN 0 1 13 B-Drug
in IN 0 0 12 O
the DT 0 0 12 O
diet NN 0 1 6 O
for IN 0 0 12 O
9 CD 0 0 2 O
weeks NNS 1 1 12 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
cause VB 0 1 12 O
tumors NNS 1 1 6 O
and CC 0 0 12 O
it PRP 0 0 12 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
suggested VBN 1 1 12 O
that IN 0 0 12 O
disulfiram NN 0 1 13 B-Drug
may MD 0 0 1 O
react VB 0 0 13 O
with IN 0 0 12 O
nitrites NNS 1 1 UNK B-Group
in IN 0 0 12 O
the DT 0 0 12 O
rat NN 0 1 13 O
stomach NN 0 1 6 O
to TO 0 0 12 O
form VB 0 1 1 O
a DT 0 0 12 O
nitrosamine NN 0 1 UNK O
which WDT 0 0 12 O
is VBZ 1 0 12 O
tumorigenic JJ 0 1 UNK O
. . 0 0 12 O

Data NNS 0 1 2 O
from IN 0 0 12 O
several JJ 0 1 12 O
studies NNS 1 1 1 O
ie VBP 0 0 1 O
TIMI NNP 0 0 UNK O
- : 0 0 2 O
II NNP 0 0 2 O
ISIS NNP 0 1 UNK O
- : 0 0 2 O
9 CD 0 0 2 O
currently RB 0 1 12 O
do VBP 0 0 12 O
not RB 0 1 12 O
suggest VB 0 1 1 O
any DT 0 0 12 O
clinical JJ 0 1 6 O
interaction NN 0 1 UNK O
between IN 0 0 12 O
aspirin NN 0 1 14 B-Brand
and CC 0 0 12 O
beta NN 0 1 16 B-Group
blockers NNS 1 0 6 I-Group
in IN 0 0 12 O
the DT 0 0 12 O
acute JJ 0 1 6 O
myocardial JJ 0 1 6 O
infarction NN 0 1 6 O
setting NN 0 1 1 O
. . 0 0 12 O

Short NNP 0 1 2 B-Group
- : 0 0 2 O
Acting VBG 0 1 UNK I-Group
beta9 SYM 0 0 UNK I-Group
- : 0 0 2 O
agonists NNS 1 1 UNK I-Group
: : 0 0 2 O
Aerosol NNP 0 1 7 O
bronchodilators NNS 1 1 14 B-Group
of IN 0 0 12 O
the DT 0 0 12 O
short JJ 0 1 12 O
- : 0 0 2 O
acting VBG 1 1 12 O
adrenergic JJ 0 1 UNK O
stimulant JJ 0 1 13 O
type NN 0 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
used VBN 1 1 12 O
for IN 0 0 12 O
relief NN 0 1 1 O
of IN 0 0 12 O
breakthrough NN 0 1 1 O
symptoms NNS 1 1 6 O
while IN 0 0 12 O
using VBG 1 1 1 O
formoterol NN 0 1 13 B-Drug
. . 0 0 12 O

Cimetidine NNP 0 1 0 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
b.i.d NN 0 1 UNK O
. . 0 0 12 O
) ) 0 0 2 O
had VBD 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
vardenafil NN 0 1 UNK B-Drug
bioavailability NN 0 1 UNK O
( ( 0 0 2 O
AUC NNP 0 1 UNK O
) ) 0 0 2 O
and CC 0 0 12 O
maximum JJ 0 1 1 O
concentration NN 0 1 1 O
( ( 0 0 2 O
Cmax NNP 0 1 UNK O
) ) 0 0 2 O
of IN 0 0 12 O
vardenafil NN 0 1 UNK B-Drug
when WRB 0 0 12 O
co NN 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
with IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
Vardenafil NNP 0 1 UNK B-Drug
in IN 0 0 12 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
. . 0 0 12 O

Animal NNP 0 1 UNK O
toxicology NN 0 1 6 O
studies NNS 1 1 1 O
showed VBD 1 1 12 O
increased JJ 0 1 1 O
DEET NNP 0 1 UNK B-Drug
toxicity NN 0 1 6 O
when WRB 0 0 12 O
DEET NNP 0 1 UNK B-Drug
was VBD 1 0 12 O
included VBN 1 1 1 O
as IN 1 0 12 O
proof NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
formulation NN 0 1 13 O
. . 0 0 12 O

Concomitant NNP 0 1 UNK O
use NN 0 1 1 O
of IN 0 0 12 O
clozapine NN 0 1 13 B-Drug
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
9D9 CD 0 0 UNK O
may MD 0 0 1 O
require VB 0 0 1 O
lower JJR 1 1 1 O
doses NNS 1 1 6 O
than IN 0 0 12 O
usually RB 0 1 12 O
prescribed VBN 1 1 1 O
for IN 0 0 12 O
either DT 0 1 12 O
clozapine NN 0 1 13 B-Drug
or CC 0 0 12 O
the DT 0 0 12 O
other JJ 0 0 12 O
drug NN 0 1 1 O
. . 0 0 12 O

APRD99_IN NNP 0 0 UNK O
txt NN 0 1 UNK O

Aspirin NN 0 1 0 B-Brand
: : 0 0 2 O
Vardenafil NNP 0 1 UNK B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
and CC 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
) ) 0 0 2 O
did VBD 1 0 12 O
not RB 0 1 12 O
potentiate VB 0 0 UNK O
the DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
bleeding JJ 0 1 6 O
time NN 0 1 12 O
caused VBN 1 1 1 O
by IN 0 0 12 O
aspirin NN 0 1 14 B-Brand
( ( 0 0 2 O
two CD 0 1 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
tablets NNS 1 1 3 O
) ) 0 0 2 O
. . 0 0 12 O

When WRB 0 0 12 O
administered VBN 1 1 1 O
concurrently RB 0 0 1 O
testolactone NN 0 1 UNK B-Drug
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
oral JJ 0 1 6 O
anticoagulants NNS 1 1 13 B-Group
; : 0 0 2 O

Some DT 0 0 2 O
quinolones NNS 0 1 13 B-Group
including VBG 1 1 1 O
ciprofloxacin NNS 0 1 0 B-Drug
have VBP 0 0 12 O
been VBN 1 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
transient JJ 0 1 1 O
elevations NNS 1 1 1 O
in IN 0 0 12 O
serum JJ 0 1 14 O
creatinine NN 0 1 14 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
cyclosporine NN 0 1 14 B-Drug
concomitantly RB 0 0 14 O
. . 0 0 12 O

Caution NN 0 0 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
if IN 0 0 12 O
ibuprofen NN 0 1 0 B-Drug
is VBZ 1 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
methotrexate NN 0 1 16 B-Drug
. . 0 0 12 O

Therefore RB 0 0 1 O
when WRB 0 0 12 O
initiating VBG 1 1 1 O
pressor NN 0 1 14 O
therapy NN 0 1 6 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
the DT 0 0 12 O
initial JJ 0 1 1 O
dose NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
small JJ 0 1 12 O
and CC 0 0 12 O
given VBN 1 1 12 O
with IN 0 0 12 O
caution NN 0 0 1 O
. . 0 0 12 O

. . 0 0 12 O

Loop JJ 0 1 UNK B-Group
Diuretics NNS 0 1 UNK I-Group
: : 0 0 2 O
Furosemide NNP 0 1 0 B-Drug
administered VBD 1 1 1 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
captopril NN 0 1 0 B-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
alter VB 0 1 13 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
captopril NN 0 1 0 B-Drug
in IN 0 0 12 O
renally RB 0 0 14 O
impaired JJ 0 1 6 O
hypertensive JJ 0 1 6 O
patients NNS 1 1 6 O
. . 0 0 12 O

Probenecid NN 0 1 UNK B-Drug
: : 0 0 2 O
Probenecid NN 0 1 UNK B-Drug
increases NNS 1 1 1 O
both DT 0 0 12 O
free JJ 0 1 12 O
and CC 0 0 12 O
bound JJ 0 1 12 O
ketoprofen NN 0 1 UNK B-Drug
by IN 0 0 12 O
reducing VBG 1 1 1 O
the DT 0 0 12 O
plasma JJ 0 1 14 O
clearance NN 0 1 16 O
of IN 0 0 12 O
ketoprofen NN 0 1 UNK B-Drug
to TO 0 0 12 O
about IN 0 1 12 O
one CD 0 1 12 O
- : 0 0 2 O
third NN 0 1 12 O
as RB 0 0 12 O
well RB 0 1 12 O
as IN 1 0 12 O
decreasing VBG 1 1 1 O
its PRP$ 1 0 12 O
protein NN 0 1 14 O
binding NN 0 1 1 O
. . 0 0 12 O

When WRB 0 0 12 O
administered VBN 1 1 1 O
concurrently RB 0 0 1 O
the DT 0 0 12 O
following JJ 0 1 1 O
drugs NNS 1 1 6 O
may MD 0 0 1 O
interact VB 0 0 UNK O
with IN 0 0 12 O
beta NN 0 1 16 B-Group
- : 0 0 2 O
adrenergic JJ 0 1 UNK I-Group
receptor NN 0 1 14 I-Group
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
: : 0 0 2 O
Anesthetics NNPS 0 1 UNK B-Group
general JJ 0 1 1 O
: : 0 0 2 O
exaggeration NN 0 0 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
hypotension NN 0 1 6 O
induced VBN 1 1 6 O
by IN 0 0 12 O
general JJ 0 1 1 O
anesthetics NNS 1 1 13 B-Group
. . 0 0 12 O

Interactions NNS 0 1 UNK O
with IN 0 0 12 O
Other JJ 0 0 2 O
Antiretroviral JJ 0 0 UNK B-Group
Drugs NNS 0 1 2 I-Group
: : 0 0 2 O
Significant NN 0 1 2 O
decreases VBZ 1 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
delavirdine NN 0 1 13 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
and CC 0 0 12 O
indinavir NN 0 1 16 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
occurred VBD 1 1 1 O
following VBG 1 1 1 O
simultaneous JJ 0 1 13 O
administration NN 0 1 1 O
of IN 0 0 12 O
these DT 0 0 12 O
agents NNS 1 1 1 O
with IN 0 0 12 O
VIDEX NNP 0 1 UNK B-Brand
. . 0 0 12 O

Alcohol NNP 0 1 2 B-Drug
barbiturates VBZ 0 1 14 B-Group
or CC 0 0 12 O
narcotics NNS 1 1 1 B-Group
: : 0 0 2 O
potentiation NN 0 1 UNK O
of IN 0 0 12 O
orthostatic JJ 0 1 8 O
hypotension NN 0 1 6 O
may MD 0 0 1 O
occur VB 0 1 1 O
. . 0 0 12 O

When WRB 0 0 12 O
the DT 0 0 12 O
CYP9A9 NNP 0 0 UNK O
inhibitor NN 0 1 14 O
is VBZ 1 0 12 O
withdrawn VBN 1 1 1 O
from IN 0 0 12 O
the DT 0 0 12 O
combination NN 0 1 1 O
therapy NN 0 1 6 O
aripiprazole NN 0 1 16 B-Drug
dose NN 0 1 6 O
should MD 0 0 12 O
then RB 0 1 12 O
be VB 0 0 12 O
increased VBN 1 1 1 O
. . 0 0 12 O

because IN 0 0 12 O
of IN 0 0 12 O
this DT 0 0 12 O
the DT 0 0 12 O
dosage NN 0 1 0 O
of IN 0 0 12 O
flecainide NN 0 1 16 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
adjusted VBN 1 1 1 O
when WRB 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 B-Drug
are VBP 1 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
. . 0 0 12 O

Caffeine NNP 0 1 7 B-Drug
and CC 0 0 12 O
/ NNP 0 0 2 O
or CC 0 0 12 O
stimulantes NNS 0 0 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
ephedrine NN 0 1 13 B-Drug
/ NNP 0 0 2 O
amphetamine NN 0 1 13 B-Drug
type NN 0 1 1 O
may MD 0 0 1 O
counteract VB 0 0 UNK O
the DT 0 0 12 O
specific JJ 0 1 1 O
actions NNS 1 1 UNK O
of IN 0 0 12 O
levomepromazine NN 0 1 UNK B-Drug
. . 0 0 12 O

In IN 0 0 2 O
studies NNS 1 1 1 O
with IN 0 0 12 O
finasteride JJ 0 1 16 B-Drug
no DT 0 0 12 O
clinically RB 0 0 6 O
meaningful JJ 0 1 1 O
changes NNS 1 1 1 O
in IN 0 0 12 O
luteinizing VBG 0 0 13 O
hormone NN 0 1 6 O
( ( 0 0 2 O
LH NNP 0 1 13 O
) ) 0 0 2 O
follicle NN 0 1 13 O
- : 0 0 2 O
stimulating VBG 1 1 1 O
hormone NN 0 1 6 O
( ( 0 0 2 O
FSH NNP 0 0 14 O
) ) 0 0 2 O
or CC 0 0 12 O
prolactin NN 0 1 13 O
were VBD 1 0 12 O
detected VBN 1 1 1 O
. . 0 0 12 O

Rifabutin NNP 0 1 UNK B-Drug
and CC 0 0 12 O
its PRP$ 1 0 12 O
metabolite NN 0 1 UNK O
concentrationswere RB 0 0 UNK O
moderately RB 0 1 3 O
increased VBN 1 1 1 O
. . 0 0 12 O

Lupus NNP 0 1 7 O
- : 0 0 2 O
like IN 0 0 12 O
syndrome NN 0 1 6 O

The DT 0 0 2 O
effect NN 0 1 1 O
of IN 0 0 12 O
TORADOL NNP 0 1 UNK B-Brand
on IN 0 0 12 O
methotrexate NN 0 1 16 B-Drug
clearance NN 0 1 16 O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
studied VBN 1 0 1 O
. . 0 0 12 O

Serum NNP 0 1 7 O
infliximab JJ 0 1 13 B-Drug
concentrations NNS 1 1 13 O
appeared VBD 1 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
unaffected VBN 0 1 UNK O
by IN 0 0 12 O
baseline NN 0 1 1 O
use NN 0 1 1 O
of IN 0 0 12 O
medications NNS 1 1 6 O
for IN 0 0 12 O
the DT 0 0 12 O
treatment NN 0 1 6 O
of IN 0 0 12 O
Crohn NNP 0 1 6 O
disease NN 0 1 6 O
including VBG 1 1 1 O
corticosteroids NNS 1 1 14 B-Group
antibiotics NNS 1 1 6 B-Group
( ( 0 0 2 O
metronidazole NN 0 1 0 B-Drug
or CC 0 0 12 O
ciprofloxacin NN 0 1 0 B-Drug
) ) 0 0 2 O
and CC 0 0 12 O
aminosalicylates VBZ 0 1 UNK O
. . 0 0 12 O

Of IN 0 0 2 O
particular JJ 0 0 1 O
importance NN 0 1 1 O
sufficient JJ 0 1 1 O
time NN 0 1 12 O
must MD 0 0 12 O
elapse VB 0 1 UNK O
before IN 0 1 12 O
initiating VBG 1 1 1 O
TCA NNP 0 1 13 O
treatment NN 0 1 6 O
in IN 0 0 12 O
a DT 0 0 12 O
patient NN 0 1 6 O
being VBG 1 0 12 O
withdrawn VBN 1 1 1 O
from IN 0 0 12 O
fluoxetine NN 0 1 16 B-Drug
given VBN 1 1 12 O
the DT 0 0 12 O
long JJ 0 1 12 O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
parent NN 0 1 13 O
and CC 0 0 12 O
active JJ 0 1 1 O
metabolite NN 0 1 UNK O
( ( 0 0 2 O
at IN 0 0 12 O
least JJS 0 1 12 O
9 CD 0 0 2 O
weeks NNS 1 1 12 O
may MD 0 0 1 O
be VB 0 0 12 O
necessary JJ 0 0 1 O
) ) 0 0 2 O
. . 0 0 12 O

Caution NN 0 0 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
exercised VBN 1 1 1 O
when WRB 0 0 12 O
administering VBG 1 1 1 O
ZADAXIN NNP 0 1 UNK B-Brand
therapy NN 0 1 6 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
other JJ 0 0 12 O
immunomodulating VBG 0 0 UNK B-Group
drugs NNS 1 1 6 I-Group
. . 0 0 12 O

Warning VBG 0 1 UNK O
signs NNS 1 1 12 O
irrespective NN 0 0 UNK O
of IN 0 0 12 O
cause NN 0 1 12 O
are VBP 1 0 12 O
: : 0 0 2 O
dryness NN 0 1 6 O
of IN 0 0 12 O
mouth NN 0 1 3 O
thirst JJ 0 1 13 O
weakness NN 0 1 6 O
lethargy NN 0 1 6 O
drowsiness NN 0 1 13 O
restlessness NN 0 1 13 O
muscle NN 0 1 6 O
pains NNS 1 1 6 O
or CC 0 0 12 O
cramps NNS 1 1 6 O
muscular JJ 0 1 6 O
fatigue JJ 0 1 6 O
hypotension NN 0 1 6 O
oliguria IN 0 1 8 O
tachycardia NN 0 1 8 O
and CC 0 0 12 O
gastrointestinal JJ 0 1 6 O
disturbances NNS 1 1 6 O
such JJ 0 0 1 O
as IN 1 0 12 O
nausea NN 0 1 6 O
and CC 0 0 12 O
vomiting NN 0 1 6 O
. . 0 0 12 O

Salicylate NNP 0 1 UNK B-Group
competes NNS 0 0 UNK O
with IN 0 0 12 O
a DT 0 0 12 O
number NN 0 1 1 O
of IN 0 0 12 O
drugs NNS 1 1 6 O
for IN 0 0 12 O
protein NN 0 1 14 O
binding NN 0 1 1 O
sites VBZ 1 1 1 O
notably RB 0 0 1 O
penicillin JJ 0 1 14 B-Drug
thiopental JJ 0 1 13 B-Drug
thyroxine NN 0 1 14 B-Drug
triiodothyronine NN 0 1 13 B-Drug
phenytoin NN 0 1 16 B-Drug
sulfinpyrazone NN 0 1 13 B-Drug
naproxen JJ 0 1 16 B-Drug
warfarin NN 0 1 14 B-Drug
methotrexate NN 0 1 16 B-Drug
and CC 0 0 12 O
possibly RB 0 1 12 O
corticosteroids NNS 1 1 14 B-Group
. . 0 0 12 O

Elevated VBN 0 1 7 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
theophylline NN 0 1 16 B-Drug
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
with IN 0 0 12 O
concomitant JJ 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
some DT 0 0 12 O
quinolones NNS 0 1 13 B-Group
. . 0 0 12 O

Insulin NNP 0 1 7 O
parameters NNS 1 1 1 O
were VBD 1 0 12 O
not RB 0 1 12 O
affected VBN 1 1 1 O
. . 0 0 12 O

Special JJ 0 1 2 O
attention NN 0 1 12 O
should MD 0 0 12 O
be VB 0 0 12 O
given VBN 1 1 12 O
to TO 0 0 12 O
electrolyte VB 0 1 14 O
and CC 0 0 12 O
acid VB 0 1 14 O
- : 0 0 2 O
base NN 0 1 3 O
balance NN 0 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
experiencing VBG 1 1 12 O
severe JJ 0 1 6 O
or CC 0 0 12 O
prolonged JJ 0 1 6 O
diarrhea NN 0 1 6 O
or CC 0 0 12 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
concomitant JJ 0 1 6 O
diuretics NNS 1 1 14 B-Drug
. . 0 0 12 O

Agents NNS 0 1 2 O
with IN 0 0 12 O
Decreased JJ 0 1 7 O
Levels NNS 0 1 2 O
in IN 0 0 12 O
the DT 0 0 12 O
Presence NNP 0 1 UNK O
of IN 0 0 12 O
Carbamazepine NNP 0 1 UNK B-Drug
due JJ 0 1 1 O
to TO 0 0 12 O
Induction NNP 0 1 UNK O
of IN 0 0 12 O
Cytochrome NNP 0 1 UNK O
P9 NNP 0 1 UNK O
Enzymes NNP 0 1 7 O
Carbamazepine NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
known VBN 1 1 12 O
to TO 0 0 12 O
induce VB 0 1 6 O
CYP9A9 NNP 0 0 UNK O
and CC 0 0 12 O
CYP9A9 NNP 0 0 UNK O
. . 0 0 12 O

Tacrolimus NNP 0 1 0 O
Felodipine NNP 0 1 UNK B-Drug
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
blood NN 0 1 6 O
concentration NN 0 1 1 O
of IN 0 0 12 O
tacrolimus NN 0 1 16 B-Drug
. . 0 0 12 O

Trimethoprim NNP 0 1 0 B-Drug
may MD 0 0 1 O
inhibit VB 0 1 13 O
the DT 0 0 12 O
hepatic JJ 0 1 14 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
. . 0 0 12 O

Coumarin NNP 0 1 UNK B-Group
- : 0 0 2 O
type NN 0 1 1 I-Group
anticoagulants NNS 1 1 13 I-Group
: : 0 0 2 O
Prothrombin NNP 0 1 7 O
time NN 0 1 12 O
may MD 0 0 1 O
be VB 0 0 12 O
increased VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
concomitant JJ 0 1 6 O
DIFLUCAN NNP 0 1 UNK B-Brand
and CC 0 0 12 O
coumarin VB 0 1 UNK B-Group
- : 0 0 2 O
type NN 0 1 1 I-Group
anticoagulants NNS 1 1 13 I-Group
. . 0 0 12 O

Thus RB 0 0 1 O
if IN 0 0 12 O
a DT 0 0 12 O
patient NN 0 1 6 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
titrated VBN 1 1 14 O
to TO 0 0 12 O
a DT 0 0 12 O
stable JJ 0 1 1 O
dosage NN 0 1 0 O
on IN 0 0 12 O
one CD 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
agents NNS 1 1 1 O
in IN 0 0 12 O
this DT 0 0 12 O
category NN 0 1 16 O
and CC 0 0 12 O
then RB 0 1 12 O
begins VBZ 1 1 12 O
a DT 0 0 12 O
course NN 0 1 12 O
of IN 0 0 12 O
treatment NN 0 1 6 O
with IN 0 0 12 O
EQUETROTM NNP 0 0 UNK B-Brand
it PRP 0 0 12 O
is VBZ 1 0 12 O
reasonable JJ 0 0 1 O
to TO 0 0 12 O
expect VB 0 0 12 O
that IN 0 0 12 O
a DT 0 0 12 O
dose JJ 0 1 6 O
increase NN 0 1 1 O
for IN 0 0 12 O
the DT 0 0 12 O
concomitant JJ 0 1 6 O
agent NN 0 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
necessary JJ 0 0 1 O
. . 0 0 12 O

These DT 0 0 1 O
reactions NNS 1 1 1 O
consisted VBD 1 1 1 O
of IN 0 0 12 O
erythema NN 0 1 8 O
pruritus NN 0 1 8 O
and CC 0 0 12 O
hypotension NN 0 1 6 O
and CC 0 0 12 O
occurred VBD 1 1 1 O
within IN 0 0 1 O
hours NNS 1 1 12 O
of IN 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
chemotherapy NN 0 1 6 O
. . 0 0 12 O

Interactions NNS 0 1 UNK O
for IN 0 0 12 O
Vitamin NNP 0 1 2 B-Drug
B9 NNP 0 0 UNK I-Drug
( ( 0 0 2 O
Niacin NNP 0 1 0 B-Drug
) ) 0 0 2 O
: : 0 0 2 O
Antihypertensive JJ 0 1 7 B-Group
Therapy NN 0 1 2 O
: : 0 0 2 O
Nicotinic JJ 0 1 UNK B-Drug
acid NN 0 1 14 I-Drug
may MD 0 0 1 O
potentiate VB 0 0 UNK O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
ganglionic JJ 0 1 UNK B-Group
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
and CC 0 0 12 O
vasoactive JJ 0 1 14 O
drugs NNS 1 1 6 O
resulting VBG 1 1 1 O
in IN 0 0 12 O
postural JJ 0 1 13 O
hypotension NN 0 1 6 O
. . 0 0 12 O

Valproate NNP 0 1 0 B-Drug
** NN 0 0 2 O

Since IN 0 1 2 O
indomethacin NN 0 1 14 B-Drug
and CC 0 0 12 O
potassium NN 0 1 14 B-Group
- : 0 0 2 O
sparing VBG 1 0 6 I-Group
diuretics NNS 1 1 14 I-Group
including VBG 1 1 1 O
MIDAMOR NNP 0 1 UNK B-Brand
may MD 0 0 1 O
each DT 0 0 12 O
be VB 0 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
increased JJ 0 1 1 O
serum NN 0 1 14 O
potassium NN 0 1 14 O
levels NNS 1 1 1 O
the DT 0 0 12 O
potential JJ 0 1 1 O
effects NNS 1 1 1 O
on IN 0 0 12 O
potassium NN 0 1 14 O
kinetics NNS 0 1 UNK O
and CC 0 0 12 O
renal JJ 0 1 6 O
function NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
when WRB 0 0 12 O
these DT 0 0 12 O
agents NNS 1 1 1 O
are VBP 1 0 12 O
administered VBN 1 1 1 O
concurrently RB 0 0 1 O
. . 0 0 12 O

Therefore RB 0 0 1 O
FORADIL NNP 0 1 UNK B-Brand
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
given VBN 1 1 12 O
together RB 0 1 12 O
with IN 0 0 12 O
- : 0 0 2 O
adrenergic NN 0 1 UNK O
blockers NNS 1 0 6 O
( ( 0 0 2 O
including VBG 1 1 1 O
eye NN 0 1 3 O
drops NNS 1 1 3 O
) ) 0 0 2 O
unless IN 0 0 12 O
there EX 0 0 12 O
are VBP 1 0 12 O
compelling VBG 1 0 UNK O
reasons NNS 1 1 12 O
for IN 0 0 12 O
their PRP$ 0 0 12 O
use NN 0 1 1 O
. . 0 0 12 O

9% CD 0 0 UNK O
9% CD 0 0 UNK O
9% CD 0 0 UNK O
9% CD 0 0 UNK O

Substantial JJ 0 0 UNK O
intercurrent NN 0 0 UNK O
ethanol NN 0 1 1 B-Drug
use NN 0 1 1 O
was VBD 1 0 12 O
present JJ 0 1 1 O
in IN 0 0 12 O
each DT 0 0 12 O
of IN 0 0 12 O
these DT 0 0 12 O
cases NNS 1 1 UNK O
and CC 0 0 12 O
this DT 0 0 12 O
may MD 0 0 1 O
have VB 0 0 12 O
contributed VBN 1 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
abnormalities NNS 1 1 6 O
seen VBN 1 1 12 O
. . 0 0 12 O

These DT 0 0 1 O
antibiotics NNS 1 1 6 B-Group
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
in IN 0 0 12 O
the DT 0 0 12 O
myasthenic JJ 0 0 13 O
patient NN 0 1 6 O
only RB 0 1 12 O
where WRB 0 0 12 O
definitely RB 0 1 UNK O
indicated VBN 1 1 1 O
and CC 0 0 12 O
then RB 0 1 12 O
careful JJ 0 1 12 O
adjustment NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
made VBN 1 1 12 O
of IN 0 0 12 O
adjunctive JJ 0 1 13 O
anticholinesterase NN 0 1 UNK B-Group
dosage NN 0 1 0 O
. . 0 0 12 O

When WRB 0 0 12 O
Mefloquine NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
taken VBN 1 1 12 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
oral JJ 0 1 6 O
live JJ 0 1 12 B-Group
typhoid NN 0 1 13 I-Group
vaccines NNS 1 1 6 I-Group
attenuation NN 0 1 1 O
of IN 0 0 12 O
immunization NN 0 1 6 O
can MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
excluded VBN 1 1 1 O
. . 0 0 12 O

There EX 0 0 12 O
are VBP 1 0 12 O
reports NNS 1 1 1 O
of IN 0 0 12 O
enhanced VBN 1 1 1 O
as RB 0 0 12 O
well RB 0 1 12 O
as IN 1 0 12 O
diminished JJ 0 1 1 O
effects NNS 1 1 1 O
of IN 0 0 12 O
anticoagulants NNS 1 1 13 B-Group
when WRB 0 0 12 O
given VBN 1 1 12 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
corticosteroids NNS 1 1 14 B-Group
. . 0 0 12 O

interactions NNS 1 1 UNK O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
systematically RB 0 0 UNK O
studied VBN 1 0 1 O
. . 0 0 12 O

If IN 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
an DT 0 0 12 O
NSAID NNP 0 1 14 B-Group
is VBZ 1 0 12 O
necessary JJ 0 0 1 O
patients NNS 1 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
closely RB 0 0 1 O
for IN 0 0 12 O
toxicity NN 0 1 6 O
especially RB 0 0 12 O
myelosuppression JJ 0 1 8 O
renal JJ 0 1 6 O
and CC 0 0 12 O
gastrointestinal JJ 0 1 6 O
toxicity NN 0 1 6 O
. . 0 0 12 O

Warfarin NN 0 1 0 B-Drug
: : 0 0 2 O
In IN 0 0 2 O
a DT 0 0 12 O
study NN 0 1 1 O
in IN 0 0 12 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
no DT 0 0 12 O
clinically RB 0 0 6 O
relevant JJ 0 1 1 O
pharmacokinetic JJ 0 1 UNK O
or CC 0 0 12 O
pharmacodynamic JJ 0 1 UNK O
interaction NN 0 1 UNK O
between IN 0 0 12 O
isradipine NN 0 1 13 B-Drug
and CC 0 0 12 O
racemic JJ 0 1 14 O
warfarin NN 0 1 14 B-Drug
was VBD 1 0 12 O
seen VBN 1 1 12 O
when WRB 0 0 12 O
two CD 0 1 12 O
single JJ 0 1 12 O
oral JJ 0 1 6 O
doses NNS 1 1 6 O
of IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg VBZ 0 1 18 O
body NN 0 1 3 O
weight NN 0 1 3 O
) ) 0 0 2 O
were VBD 1 0 12 O
administered VBN 1 1 1 O
during IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
of IN 0 0 12 O
multipledose JJ 0 0 UNK O
treatment NN 0 1 6 O
with IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
b.i.d NN 0 1 UNK O
. . 0 0 12 O
isradipine NN 0 1 13 B-Drug
. . 0 0 12 O

Caution NN 0 0 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
observed VBN 1 1 1 O
when WRB 0 0 12 O
anileridine NN 0 1 UNK B-Drug
is VBZ 1 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
other JJ 0 0 12 O
opioids NNS 0 1 14 B-Group
sedatives NNS 1 1 6 B-Group
phenothiazines NNS 1 1 UNK B-Group
or CC 0 0 12 O
anesthetics NNS 1 1 13 B-Group
as IN 1 0 12 O
these DT 0 0 12 O
agents NNS 1 1 1 O
may MD 0 0 1 O
increase VB 0 1 1 O
respiratory NN 0 1 6 O
and CC 0 0 12 O
circulatory JJ 0 1 6 O
depression NN 0 1 6 O
. . 0 0 12 O

Alosetron NNP 0 1 UNK B-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
appear VB 0 1 12 O
to TO 0 0 12 O
induce VB 0 1 6 O
the DT 0 0 12 O
major JJ 0 1 1 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
( ( 0 0 2 O
CYP NNP 0 1 UNK O
) ) 0 0 2 O
drug NN 0 1 1 O
metabolizing VBG 1 0 UNK O
enzyme JJ 0 1 14 O
9A CD 0 1 UNK O
. . 0 0 12 O

This DT 0 0 2 O
is VBZ 1 0 12 O
especially RB 0 0 12 O
true JJ 0 1 12 O
if IN 0 0 12 O
the DT 0 0 12 O
total JJ 0 1 1 O
dose NN 0 1 6 O
of IN 0 0 12 O
atropine NN 0 1 14 B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
large JJ 0 1 3 O
and CC 0 0 12 O
the DT 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
pralidoxime NN 0 1 13 B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
delayed VBN 1 1 1 O
. . 0 0 12 O

Phenytoin NN 0 1 0 B-Drug
: : 0 0 2 O
In IN 0 0 2 O
a DT 0 0 12 O
single JJ 0 1 12 O
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
) ) 0 0 2 O
and CC 0 0 12 O
multiple JJ 0 1 1 O
dose NN 0 1 6 O
( ( 0 0 2 O
9 CD 0 0 2 O
mg RB 0 1 0 O
TID NNP 0 1 15 O
) ) 0 0 2 O
study NN 0 1 1 O
of IN 0 0 12 O
Neurontin NNP 0 1 0 B-Brand
in IN 0 0 12 O
epileptic JJ 0 1 13 O
patients NNS 1 1 6 O
( ( 0 0 2 O
N=9 NNP 0 1 UNK O
) ) 0 0 2 O
maintained VBD 1 1 1 O
on IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
monotherapy NN 0 0 14 O
for IN 0 0 12 O
at IN 0 0 12 O
least JJS 0 1 12 O
9 CD 0 0 2 O
months NNS 1 1 12 O
gabapentin NN 0 1 0 B-Drug
had VBD 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
trough IN 0 1 3 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
and CC 0 0 12 O
phenytoin NN 0 1 16 B-Drug
had VBD 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
gabapentin NN 0 1 0 B-Drug
pharmacokinetics NNS 0 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
aspirin NN 0 1 14 B-Brand
decreases VBZ 1 1 UNK O
the DT 0 0 12 O
biologic JJ 0 1 16 O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
of IN 0 0 12 O
fenoprofen NN 0 1 UNK B-Drug
because IN 0 0 12 O
of IN 0 0 12 O
an DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
metabolic JJ 0 1 6 O
clearance NN 0 1 16 O
that WDT 0 0 12 O
results NNS 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
greater JJR 1 1 1 O
amount NN 0 1 1 O
of IN 0 0 12 O
hydroxylated VBN 0 0 UNK B-Drug_n
fenoprofen NN 0 1 UNK I-Drug_n
in IN 0 0 12 O
the DT 0 0 12 O
urine NN 0 1 6 O
. . 0 0 12 O

Methotrexate NNP 0 1 0 B-Drug
Renal NNP 0 1 7 O
tubular JJ 0 1 3 O
transport NN 0 1 1 O
of IN 0 0 12 O
methotrexate NN 0 1 16 B-Drug
may MD 0 0 1 O
be VB 0 0 12 O
inhibited VBN 1 1 13 O
by IN 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
ciprofloxacin NN 0 1 0 B-Drug
potentially RB 0 0 1 O
leading JJ 0 1 1 O
to TO 0 0 12 O
increased VBN 1 1 1 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
methotrexate NN 0 1 16 B-Drug
. . 0 0 12 O

While IN 0 0 12 O
not RB 0 1 12 O
systematically RB 0 0 UNK O
studied VBN 1 0 1 O
certain JJ 0 1 1 O
drugs NNS 1 1 6 O
may MD 0 0 1 O
induce VB 0 1 6 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
bupropion NN 0 1 16 B-Drug
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
carbamazepine NN 0 1 16 B-Drug
phenobarbital JJ 0 1 16 B-Drug
phenytoin NN 0 1 16 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

Uricosuric JJ 0 0 UNK B-Group
drugs NNS 1 1 6 I-Group
such JJ 0 0 1 O
as IN 1 0 12 O
probenecid NN 0 1 13 B-Drug
and CC 0 0 12 O
sulfinpyrazone NN 0 1 13 B-Drug
can MD 0 0 12 O
inhibit VB 0 1 13 O
renal JJ 0 1 6 O
tubular JJ 0 1 3 O
secretion NN 0 1 14 O
of IN 0 0 12 O
nitrofurantoin NN 0 1 0 B-Drug
. . 0 0 12 O

Reduced VBN 0 1 UNK O
response NN 0 1 1 O
to TO 0 0 12 O
metyrapone VB 0 1 13 O
test NN 0 1 1 O
. . 0 0 12 O

Poor NNP 0 1 2 O
metabolizers NNS 0 0 UNK O
have VBP 0 0 12 O
higher JJR 1 1 1 O
than IN 0 0 12 O
expected VBN 1 1 12 O
lasma JJ 0 0 UNK O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
( ( 0 0 2 O
TCAs NNP 0 1 UNK B-Group
) ) 0 0 2 O
when WRB 0 0 12 O
given VBN 1 1 12 O
usual JJ 0 1 12 O
doses NNS 1 1 6 O
. . 0 0 12 O

Lithium NN 0 1 UNK B-Drug
: : 0 0 2 O
NSAIDs NN 0 1 UNK B-Group
have VBP 0 0 12 O
produced VBN 1 0 1 O
an DT 0 0 12 O
elevation NN 0 1 1 O
of IN 0 0 12 O
plasma JJ 0 1 14 O
lithium NN 0 1 16 B-Drug
levels NNS 1 1 1 O
and CC 0 0 12 O
a DT 0 0 12 O
reduction NN 0 1 1 O
in IN 0 0 12 O
renal JJ 0 1 6 O
lithium NN 0 1 16 B-Drug
clearance NN 0 1 16 O
. . 0 0 12 O

Calcium NNP 0 1 7 B-Drug
particularly RB 0 0 1 O
if IN 0 0 12 O
administered VBN 1 1 1 O
rapidly RB 0 1 1 O
by IN 0 0 12 O
the DT 0 0 12 O
intravenous JJ 0 1 14 O
route NN 0 1 12 O
may MD 0 0 1 O
produce VB 0 0 1 O
serious JJ 0 1 12 O
arrhythmias NNS 1 1 6 O
in IN 0 0 12 O
digitalized JJ 0 1 UNK O
patients NNS 1 1 6 O
. . 0 0 12 O

Dicumarol NN 0 1 UNK B-Drug
: : 0 0 2 O
It PRP 0 0 12 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
that IN 0 0 12 O
allopurinol JJ 0 1 13 B-Drug
prolongs NNS 0 0 UNK O
the DT 0 0 12 O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
anticoagulant JJ 0 1 13 B-Group
dicumarol NN 0 1 UNK B-Drug
. . 0 0 12 O

Caution NN 0 0 UNK O
is VBZ 1 0 12 O
warranted VBN 1 0 1 O
and CC 0 0 12 O
therapeutic JJ 0 1 6 O
concentration NN 0 1 1 O
monitoring NN 0 1 1 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
for IN 0 0 12 O
antiarrhythmics NNS 1 1 UNK B-Group
when WRB 0 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
CRIXIVAN NNP 0 1 UNK B-Brand
. . 0 0 12 O

Therefore RB 0 0 1 O
amiodarone NN 0 1 0 B-Drug
has VBZ 1 0 12 O
the DT 0 0 12 O
potential NN 0 1 1 O
for IN 0 0 12 O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
drugs NNS 1 1 6 O
or CC 0 0 12 O
substances NNS 1 1 1 O
that WDT 0 0 12 O
may MD 0 0 1 O
be VB 0 0 12 O
substrates JJ 0 1 UNK O
inhibitors NNS 1 1 14 O
or CC 0 0 12 O
inducers NNS 1 1 UNK O
of IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
. . 0 0 12 O

therefore RB 0 0 1 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
mediated VBN 1 1 13 O
by IN 0 0 12 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
hepatic JJ 0 1 14 O
metabolism NN 0 1 16 O
are VBP 1 0 12 O
not RB 0 1 12 O
expected VBN 1 1 12 O
to TO 0 0 12 O
occur VB 0 1 1 O
. . 0 0 12 O

- : 0 0 2 O
Perhexiline NN 0 1 UNK B-Drug
hydrogen NN 0 1 13 I-Drug
maleate NN 0 1 16 I-Drug
or CC 0 0 12 O
MAO NNP 0 1 14 B-Group
- : 0 0 2 O
inhibitors NNS 1 1 14 I-Group
( ( 0 0 2 O
with IN 0 0 12 O
hepatotoxic NN 0 1 UNK O
potential NN 0 1 1 O
) ) 0 0 2 O
must MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
together RB 0 1 12 O
with IN 0 0 12 O
Bezalip NNP 0 1 UNK B-Brand
or CC 0 0 12 O
Bezalip NNP 0 1 UNK B-Brand
retard NN 0 1 13 I-Brand
. . 0 0 12 O

Pharmacokinetic JJ 0 1 UNK O
data NNS 0 1 1 O
from IN 0 0 12 O
these DT 0 0 12 O
patients NNS 1 1 6 O
demonstrated VBD 1 0 1 O
a DT 0 0 12 O
decrease NN 0 1 1 O
in IN 0 0 12 O
paclitaxel JJ 0 1 13 B-Drug
clearance NN 0 1 16 O
of IN 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
when WRB 0 0 12 O
TAXOL NNP 0 1 UNK B-Brand
was VBD 1 0 12 O
administered VBN 1 1 1 O
following VBG 1 1 1 O
cisplatin NN 0 1 14 B-Drug
. . 0 0 12 O

Sedative JJ 0 1 UNK B-Group
/ NN 0 0 2 O
hypnotics NNS 1 1 13 B-Group
: : 0 0 2 O
midazolam NN 0 1 16 B-Drug
triazolam NN 0 1 13 B-Drug

Corticosteroids NNS 0 1 UNK B-Group
: : 0 0 2 O
A DT 0 0 2 O
relationship NN 0 1 12 O
of IN 0 0 12 O
functional JJ 0 1 1 O
antagonism NN 0 1 UNK O
exists VBZ 1 1 UNK O
between IN 0 0 12 O
vitamin NN 0 1 6 B-Group
D NNP 0 1 2 I-Group
analogues VBZ 0 1 UNK I-Group
which WDT 0 0 12 O
promote VBP 0 1 1 O
calcium NN 0 1 14 O
absorption NN 0 1 1 O
and CC 0 0 12 O
corticosteroids NNS 1 1 14 B-Group
which WDT 0 0 12 O
inhibit VBP 0 1 13 O
calcium JJ 0 1 14 O
absorption NN 0 1 1 O
. . 0 0 12 O

Such JJ 0 0 1 O
concomitant NN 0 1 6 O
use NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
under IN 0 0 12 O
careful JJ 0 1 12 O
medical JJ 0 1 1 O
supervision NN 0 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
clinical JJ 0 1 6 O
studies NNS 1 1 1 O
where WRB 0 0 12 O
patients NNS 1 1 6 O
were VBD 1 0 12 O
on IN 0 0 12 O
chronic JJ 0 1 6 O
theophylline NN 0 1 16 B-Drug
therapy NN 0 1 6 O
lomefloxacin NN 0 1 UNK B-Drug
had VBD 1 0 12 O
no DT 0 0 12 O
measurable JJ 0 1 1 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
mean JJ 0 1 12 O
distribution NN 0 1 1 O
of IN 0 0 12 O
theophylline JJ 0 1 16 B-Drug
concentrations NNS 1 1 13 O
or CC 0 0 12 O
the DT 0 0 12 O
mean JJ 0 1 12 O
estimates NNS 1 1 UNK O
of IN 0 0 12 O
theophylline JJ 0 1 16 B-Drug
clearance NN 0 1 16 O
. . 0 0 12 O

Precipitation NN 0 1 UNK O
or CC 0 0 12 O
haze NN 0 0 UNK O
may MD 0 0 1 O
result VB 0 1 1 O
from IN 0 0 12 O
sodium NN 0 1 14 O
bicarbonate NN 0 1 14 O
- : 0 0 2 O
calcium NN 0 1 14 O
admixtures NNS 1 1 UNK O
. . 0 0 12 O

An DT 0 0 2 O
alternative NN 0 1 1 O
or CC 0 0 12 O
additional JJ 0 1 1 O
method NN 0 1 13 O
of IN 0 0 12 O
contraception NN 0 1 13 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O

These DT 0 0 1 O
agents NNS 1 1 1 O
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
taken VBN 1 1 12 O
within IN 0 0 1 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
before IN 0 1 12 O
or CC 0 0 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
after IN 0 0 12 O
grepafloxacin JJ 0 1 UNK B-Drug
administration NN 0 1 1 O
. . 0 0 12 O

Interactions NNS 0 1 UNK O
with IN 0 0 12 O
lipid JJ 0 1 14 O
- : 0 0 2 O
lowering VBG 1 1 UNK O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
can MD 0 0 12 O
cause VB 0 1 12 O
myopathy JJ 0 1 8 O
when WRB 0 0 12 O
given VBN 1 1 12 O
alone RB 0 1 12 O
. . 0 0 12 O

There EX 0 0 12 O
were VBD 1 0 12 O
no DT 0 0 12 O
clinically RB 0 0 6 O
relevant JJ 0 1 1 O
alterations NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
either DT 0 1 12 O
agent NN 0 1 1 O
. . 0 0 12 O

Inhibition NN 0 1 UNK O
of IN 0 0 12 O
these DT 0 0 12 O
isoenzymes NNS 0 1 14 O
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
plasma JJ 0 1 14 O
concentration NN 0 1 1 O
of IN 0 0 12 O
bosentan NN 0 1 13 B-Drug
. . 0 0 12 O

Do NNP 0 0 2 O
not RB 0 1 12 O
exceed VB 0 0 UNK O
a DT 0 0 12 O
9 CD 0 0 2 O
mg JJ 0 1 0 O
daily JJ 0 1 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
VESIcare NNP 0 1 UNK B-Brand
when WRB 0 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
therapeutic JJ 0 1 6 O
doses NNS 1 1 6 O
of IN 0 0 12 O
ketoconazole NN 0 1 16 B-Drug
or CC 0 0 12 O
other JJ 0 0 12 O
potent JJ 0 1 UNK O
CYP9A9 NNP 0 0 UNK O
inhibitors NNS 1 1 14 O
. . 0 0 12 O

Caution NN 0 0 UNK O
is VBZ 1 0 12 O
indicated VBN 1 1 1 O
when WRB 0 0 12 O
piperacillin NN 0 1 16 B-Drug
is VBZ 1 0 12 O
used VBN 1 1 12 O
perioperatively RB 0 0 8 O
. . 0 0 12 O

The DT 0 0 2 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
midazolam NN 0 1 16 B-Drug
on IN 0 0 12 O
Day NNP 0 1 2 O
9 CD 0 0 2 O
was VBD 1 0 12 O
similar JJ 0 1 1 O
to TO 0 0 12 O
that DT 0 0 12 O
observed VBN 1 1 1 O
at IN 0 0 12 O
baseline NN 0 1 1 O
. . 0 0 12 O

Pregnancy NN 0 1 7 O
estrogens NNS 1 1 16 B-Group
and CC 0 0 12 O
estrogen SYM 0 1 6 B-Group
- : 0 0 2 O
containing VBG 1 1 1 O
oral JJ 0 1 6 O
contraceptives NNS 1 1 13 B-Group
increase VBP 0 1 1 O
TBg NNP 0 1 UNK O
concentrations NNS 1 1 13 O
. . 0 0 12 O

9 CD 0 0 2 O
. . 0 0 12 O

Nephrotoxicity NN 0 1 UNK O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
following VBG 1 1 1 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
other JJ 0 0 12 O
cephalosporins NNS 1 1 14 B-Group
with IN 0 0 12 O
potent JJ 0 1 UNK O
diuretics NNS 1 1 14 B-Group
such JJ 0 0 1 O
as IN 1 0 12 O
furosemide NN 0 1 0 B-Drug
. . 0 0 12 O

Digitalis NNS 0 1 15 B-Group

astemizole JJ 0 1 UNK B-Drug
midazolam NN 0 1 16 B-Drug
triazolam NN 0 1 13 B-Drug
cisapride NN 0 1 UNK B-Drug
ergot VBD 0 1 UNK O
derivatives NNS 1 1 13 O
voriconazole NN 0 1 14 B-Drug

When WRB 0 0 12 O
amiodarone NN 0 1 0 B-Drug
is VBZ 1 0 12 O
added VBN 1 1 12 O
to TO 0 0 12 O
flecainide VB 0 1 16 B-Drug
therapy NN 0 1 6 O
plasma NN 0 1 14 O
flecainide NN 0 1 16 B-Drug
levels NNS 1 1 1 O
may MD 0 0 1 O
increase VB 0 1 1 O
two CD 0 1 12 O
- : 0 0 2 O
fold NN 0 1 3 O
or CC 0 0 12 O
more RBR 0 1 12 O
in IN 0 0 12 O
some DT 0 0 12 O
patients NNS 1 1 6 O
if IN 0 0 12 O
flecainide JJ 0 1 16 B-Drug
dosage NN 0 1 0 O
is VBZ 1 0 12 O
not RB 0 1 12 O
reduced VBN 1 1 1 O
. . 0 0 12 O

this DT 0 0 12 O
interaction NN 0 1 UNK O
is VBZ 1 0 12 O
not RB 0 1 12 O
expected VBN 1 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
of IN 0 0 12 O
clinical JJ 0 1 6 O
importance NN 0 1 1 O
. . 0 0 12 O

No DT 0 0 2 O
carcinogenicity NN 0 1 UNK O
or CC 0 0 12 O
fertility NN 0 1 6 O
studies NNS 1 1 1 O
were VBD 1 0 12 O
conducted VBN 1 1 1 O
. . 0 0 12 O

( ( 0 0 2 O
Thiazide IN 0 1 UNK B-Group
diuretics NNS 1 1 14 I-Group
may MD 0 0 1 O
raise VB 0 0 12 O
blood NN 0 1 6 O
glucose JJ 0 1 14 O
levels NNS 1 1 1 O
; : 0 0 2 O

Nephrotoxicity NN 0 1 UNK O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
following VBG 1 1 1 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
cephalosporins NNS 1 1 14 B-Group
with IN 0 0 12 O
aminoglycoside JJ 0 1 14 B-Group
antibiotics NNS 1 1 6 I-Group
or CC 0 0 12 O
potent JJ 0 1 UNK O
diuretics NNS 1 1 14 B-Group
such JJ 0 0 1 O
as IN 1 0 12 O
furosemide NN 0 1 0 B-Drug
. . 0 0 12 O

An DT 0 0 2 O
increase NN 0 1 1 O
in IN 0 0 12 O
serum JJ 0 1 14 O
lithium NN 0 1 16 B-Drug
concentration NN 0 1 1 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
during IN 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
lithium NN 0 1 16 B-Drug
with IN 0 0 12 O
ATACAND NNP 0 1 UNK B-Brand
so RB 0 1 12 O
careful JJ 0 1 12 O
monitoring NN 0 1 1 O
of IN 0 0 12 O
serum JJ 0 1 14 O
lithium NN 0 1 16 B-Drug
levels NNS 1 1 1 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
during IN 0 0 12 O
concomitant NN 0 1 6 O
use NN 0 1 1 O
. . 0 0 12 O

This DT 0 0 2 O
was VBD 1 0 12 O
expected VBN 1 1 12 O
because RB 0 0 12 O
zaleplon NN 0 1 13 B-Drug
is VBZ 1 0 12 O
primarily RB 0 0 1 O
metabolized VBN 1 1 UNK O
and CC 0 0 12 O
renal JJ 0 1 6 O
excretion NN 0 1 14 O
of IN 0 0 12 O
unchanged JJ 0 1 1 O
zaleplon NN 0 1 13 B-Drug
accounts NNS 1 1 UNK O
for IN 0 0 12 O
less JJR 0 1 12 O
than IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
of IN 0 0 12 O
the DT 0 0 12 O
administered VBN 1 1 1 O
dose NN 0 1 6 O
. . 0 0 12 O

Clinical JJ 0 1 7 O
experience NN 0 1 12 O
in IN 0 0 12 O
the DT 0 0 12 O
concurrent JJ 0 1 1 O
administration NN 0 1 1 O
of IN 0 0 12 O
ECT NNP 0 1 13 O
and CC 0 0 12 O
antidepressant JJ 0 1 6 B-Group
drugs NNS 1 1 6 I-Group
is VBZ 1 0 12 O
limited VBN 1 1 1 O
. . 0 0 12 O

Although IN 0 0 12 O
clinical JJ 0 1 6 O
studies NNS 1 1 1 O
have VBP 0 0 12 O
not RB 0 1 12 O
established VBN 1 1 1 O
a DT 0 0 12 O
cause NN 0 1 12 O
and CC 0 0 12 O
effect NN 0 1 1 O
relationship NN 0 1 12 O
physicians NNS 1 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
aware JJ 0 1 12 O
that IN 0 0 12 O
variable JJ 0 1 1 O
effects NNS 1 1 1 O
an DT 0 0 12 O
blood NN 0 1 6 O
coagulation NN 0 1 14 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
very RB 0 1 12 O
rarely RB 0 1 UNK O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
oral JJ 0 1 6 O
anticoagulants NNS 1 1 13 B-Group
and CC 0 0 12 O
chlordiazepoxide NN 0 1 16 B-Drug
. . 0 0 12 O

Use NNP 0 1 2 O
of IN 0 0 12 O
MAO NNP 0 1 14 B-Group
inhibitors NNS 1 1 14 I-Group
may MD 0 0 1 O
cause VB 0 1 12 O
an DT 0 0 12 O
excessive JJ 0 1 1 O
increase NN 0 1 1 O
in IN 0 0 12 O
blood NN 0 1 6 O
pressure NN 0 1 1 O
and CC 0 0 12 O
heart NN 0 1 12 O
stimulation NN 0 1 6 O
. . 0 0 12 O

Lithium NN 0 1 UNK B-Drug
: : 0 0 2 O
Serum NNP 0 1 7 O
lithium NN 0 1 16 B-Drug
levels NNS 1 1 1 O
may MD 0 0 1 O
increase VB 0 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
elderly JJ 0 1 12 O
patients NNS 1 1 6 O
concurrently RB 0 0 1 O
receiving VBG 1 1 1 O
certain JJ 0 1 1 O
diuretics NNS 1 1 14 B-Group
primarily RB 0 0 1 O
thiazides IN 1 1 UNK B-Group
an DT 0 0 12 O
increased JJ 0 1 1 O
incidence NN 0 1 6 O
of IN 0 0 12 O
thrombopenia NN 0 1 UNK O
with IN 0 0 12 O
purpura NN 0 1 8 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
. . 0 0 12 O

Salicylates NNS 0 1 UNK B-Group
and CC 0 0 12 O
Other JJ 0 0 2 O
Non NNP 0 1 2 B-Group
- : 0 0 2 O
Steroidal NNP 0 1 UNK I-Group
Anti NNP 0 0 UNK I-Group
- : 0 0 2 O
Inflammatory NN 0 1 UNK I-Group
Drugs NNS 0 1 2 I-Group
: : 0 0 2 O
May NNP 0 1 2 O
decrease VB 0 1 1 O
the DT 0 0 12 O
antihypertensive JJ 0 1 14 O
effects NNS 1 1 1 O
of IN 0 0 12 O
MYKROX NNP 0 1 UNK B-Brand
Tablets NNP 0 1 0 O
. . 0 0 12 O

When WRB 0 0 12 O
phenobarbital NN 0 1 16 B-Drug
is VBZ 1 0 12 O
added VBN 1 1 12 O
to TO 0 0 12 O
or CC 0 0 12 O
withdrawn VB 1 1 1 O
from IN 0 0 12 O
treatment NN 0 1 6 O
dosage NN 0 1 0 O
adjustment NN 0 1 1 O
of IN 0 0 12 O
Nalfon NNP 0 1 UNK B-Brand
may MD 0 0 1 O
be VB 0 0 12 O
required VBN 1 1 1 O
. . 0 0 12 O

Specific JJ 0 1 UNK O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
conducted VBN 1 1 1 O
with IN 0 0 12 O
Levofloxacin NNP 0 1 0 B-Drug
. . 0 0 12 O

Caution NN 0 0 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
when WRB 0 0 12 O
CYP9A9 NNP 0 0 UNK B-Drug
inhibitors NNS 1 1 14 O
are VBP 1 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
with IN 0 0 12 O
felodipine NN 0 1 13 B-Drug
. . 0 0 12 O

Use NNP 0 1 2 O
of IN 0 0 12 O
a DT 0 0 12 O
nonhormonal JJ 0 0 UNK B-Group
contraceptive JJ 0 1 13 I-Group
product NN 0 1 1 I-Group
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
clinical JJ 0 1 6 O
studies NNS 1 1 1 O
with IN 0 0 12 O
PROPECIA NNP 0 1 UNK B-Brand
( ( 0 0 2 O
finasteride RB 0 1 16 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
) ) 0 0 2 O
in IN 0 0 12 O
men NNS 0 1 13 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
years NNS 1 1 12 O
of IN 0 0 12 O
age NN 0 1 12 O
the DT 0 0 12 O
mean JJ 0 1 12 O
value NN 0 1 1 O
of IN 0 0 12 O
serum NN 0 1 14 O
prostate NN 0 1 6 O
- : 0 0 2 O
specific JJ 0 1 1 O
antigen NN 0 1 14 O
( ( 0 0 2 O
PSA NNP 0 1 13 O
) ) 0 0 2 O
decreased VBD 1 1 1 O
from IN 0 0 12 O
9 CD 0 0 2 O
ng JJ 0 1 13 O
/ NN 0 0 2 O
mL NN 0 1 14 O
at IN 0 0 12 O
baseline NN 0 1 1 O
to TO 0 0 12 O
9 CD 0 0 2 O
ng NNS 0 1 13 O
/ JJ 0 0 2 O
mL NNS 0 1 14 O
at IN 0 0 12 O
Month NNP 0 1 UNK O
9 CD 0 0 2 O
. . 0 0 12 O

No DT 0 0 2 O
information NN 0 1 1 O
provided VBD 1 1 1 O

Drugs NNS 0 1 2 O
that WDT 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
diminish VB 0 1 UNK O
oral JJ 0 1 6 O
anticoagulant JJ 0 1 13 B-Group
response NN 0 1 1 O
ie NN 0 0 1 O
decreased VBD 1 1 1 O
prothrom IN 0 0 UNK O
- : 0 0 2 O
bin NN 0 1 UNK O
time NN 0 1 12 O
response NN 0 1 1 O
in IN 0 0 12 O
man NN 0 1 12 O
significantly RB 0 0 1 O
include VBP 0 1 1 O
: : 0 0 2 O
adrenocortical JJ 0 1 UNK B-Group
steroids NNS 1 1 6 I-Group
; : 0 0 2 O
alcohol NN 0 1 1 B-Drug
* NN 0 0 2 O
; : 0 0 2 O
antacids NNS 1 1 14 B-Group
; : 0 0 2 O
antihistamines NNS 1 1 UNK B-Group
; : 0 0 2 O
barbiturates NNS 1 1 14 B-Group
; : 0 0 2 O
carbamazepine NN 0 1 16 B-Drug
; : 0 0 2 O
chloral JJ 0 1 16 B-Drug
hydrate NN 0 1 16 I-Drug
* NN 0 0 2 O
; : 0 0 2 O
chlordiazepoxide NN 0 1 16 B-Drug
; : 0 0 2 O
cholestyramine NN 0 1 13 B-Drug
; : 0 0 2 O
diet JJ 0 1 6 O
high JJ 0 1 1 O
in IN 0 0 12 O
vitamin JJ 0 1 6 B-Group
K NNP 0 1 2 I-Group
; : 0 0 2 O
diuretics NNS 1 1 14 B-Group
* VBP 0 0 2 O
; : 0 0 2 O
ethchlorvynol CC 0 1 UNK B-Drug
; : 0 0 2 O
glutethimide NN 0 1 13 B-Drug
; : 0 0 2 O
griseofulvin NN 0 1 UNK B-Drug
; : 0 0 2 O
haloperidol NN 0 1 16 B-Drug
; : 0 0 2 O
meprobamate NN 0 1 UNK B-Drug
; : 0 0 2 O
oral JJ 0 1 6 O
contraceptives NNS 1 1 13 B-Group
; : 0 0 2 O
paraldehyde NN 0 1 13 B-Drug
; : 0 0 2 O
primidone NN 0 1 13 B-Drug
; : 0 0 2 O
ranitidine JJ 0 1 0 B-Drug
* NN 0 0 2 O
; : 0 0 2 O
rifampin NN 0 1 16 B-Drug
; : 0 0 2 O
unreliable JJ 0 1 1 O
prothrombin NN 0 1 14 O
time NN 0 1 12 O
determinations NNS 1 1 UNK O
; : 0 0 2 O
vitamin NNP 0 1 6 B-Drug
C NNP 0 0 2 I-Drug
; : 0 0 2 O
warfarin JJ 0 1 14 B-Drug
sodium NN 0 1 14 I-Drug
under IN 0 0 12 O
- : 0 0 2 O
dosage NN 0 1 0 O
. . 0 0 12 O

This DT 0 0 2 O
is VBZ 1 0 12 O
especially RB 0 0 12 O
true JJ 0 1 12 O
in IN 0 0 12 O
patients NNS 1 1 6 O
who WP 0 0 12 O
may MD 0 0 1 O
subject VB 0 1 UNK O
themselves PRP 0 0 UNK O
to TO 0 0 12 O
an DT 0 0 12 O
overdosage NN 0 0 UNK O
of IN 0 0 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

PEGASYS NNP 0 1 UNK B-Brand
contains VBZ 1 1 1 O
benzyl JJ 0 0 UNK B-Drug_n
alcohol NN 0 1 1 I-Drug_n
. . 0 0 12 O

Inducers NNS 0 1 UNK O
of IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
Isozymes NNP 0 1 UNK O
: : 0 0 2 O
Cytochrome NNP 0 1 UNK O
P9 NNP 0 1 UNK O
inducers NNS 1 1 UNK O
such JJ 0 0 1 O
as IN 1 0 12 O
rifampin NN 0 1 16 B-Drug
carbamazepine NN 0 1 16 B-Drug
and CC 0 0 12 O
phenytoin NN 0 1 16 B-Drug
induce VBP 0 1 6 O
metabolism NN 0 1 16 O
and CC 0 0 12 O
caused VBD 1 1 1 O
a DT 0 0 12 O
markedly RB 0 1 1 O
decreased VBN 1 1 1 O
C NNP 0 0 2 O
max NN 0 0 3 O
and CC 0 0 12 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
oral JJ 0 1 6 O
midazolam NN 0 1 16 B-Drug
in IN 0 0 12 O
adult NN 0 1 12 O
studies NNS 1 1 1 O
. . 0 0 12 O

b NN 0 0 16 O
This DT 0 0 2 O
table NN 0 1 3 O
is VBZ 1 0 12 O
not RB 0 1 12 O
all DT 0 0 12 O
- : 0 0 2 O
inclusive NN 0 1 UNK O
. . 0 0 12 O

Reciprocal JJ 0 1 UNK O
interactions NNS 1 1 UNK O
may MD 0 0 1 O
occur VB 0 1 1 O
with IN 0 0 12 O
concomitant JJ 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
Antizol NNP 0 1 UNK B-Brand
and CC 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
increase VBP 0 1 1 O
or CC 0 0 12 O
inhibit VBP 0 1 13 O
the DT 0 0 12 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
system NN 0 1 1 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
phenytoin NN 0 1 16 B-Drug
carbamazepine NN 0 1 16 B-Drug
cimetidine NN 0 1 13 B-Drug
ketoconazole NN 0 1 16 B-Drug
) ) 0 0 2 O
though IN 0 0 12 O
this DT 0 0 12 O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
studied VBN 1 0 1 O

The DT 0 0 2 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
bosentan NN 0 1 13 B-Drug
were VBD 1 0 12 O
also RB 0 0 12 O
decreased VBN 1 1 1 O
by IN 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

Ketoconazole NNP 0 1 UNK B-Drug
: : 0 0 2 O
Ketoconazole NNP 0 1 UNK B-Drug
9 CD 0 0 2 O
mg JJ 0 1 0 O
daily RB 0 1 12 O
did VBD 1 0 12 O
not RB 0 1 12 O
have VB 0 0 12 O
any DT 0 0 12 O
clinically RB 0 0 6 O
important JJ 0 1 1 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
rofecoxib NN 0 1 16 B-Drug
. . 0 0 12 O

Drugs NNS 0 1 2 O
That WDT 0 0 2 O
Should MD 0 0 2 O
Not RB 0 1 2 O
Be VB 0 0 UNK O
Coadministered VBN 0 0 UNK O
With IN 0 0 2 O
VIRACEPT NNP 0 1 UNK B-Brand
Antiarrhythmics NNPS 0 1 UNK B-Group
: : 0 0 2 O
amiodarone NN 0 1 0 B-Drug
quinidine NN 0 1 16 B-Drug
Antihistamines NNS 0 1 UNK B-Group
: : 0 0 2 O
astemizole JJ 0 1 UNK B-Drug
terfenadine NN 0 1 UNK B-Drug
Antimigraine NNP 0 0 UNK O
: : 0 0 2 O
ergot NN 0 1 UNK B-Group
derivatives NNS 1 1 13 I-Group
Antimycobacterial JJ 0 1 UNK B-Group
agents NNS 1 1 1 I-Group
: : 0 0 2 O
rifampin NN 0 1 16 B-Drug
Benzodiazepines NNP 0 1 UNK B-Group
midazolam NN 0 1 16 B-Drug
triazolam NN 0 1 13 B-Drug
GI NNP 0 1 6 O
motility NN 0 1 6 O
agents NNS 1 1 1 O
: : 0 0 2 O
cisapride NN 0 1 UNK B-Drug

However RB 0 0 1 O
co JJ 0 1 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
fexofenadine JJ 0 1 16 B-Drug
hydrochloride NN 0 1 0 I-Drug
with IN 0 0 12 O
either DT 0 1 12 O
ketoconazole NN 0 1 16 B-Drug
or CC 0 0 12 O
erythromycin NN 0 1 0 B-Drug
led VBN 1 1 12 O
to TO 0 0 12 O
increased VBN 1 1 1 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
fexofenadine NN 0 1 16 B-Drug
. . 0 0 12 O

In IN 0 0 2 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
mercaptopurine NN 0 1 13 B-Drug
( ( 0 0 2 O
Purinethol NNP 0 1 UNK B-Brand
) ) 0 0 2 O
or CC 0 0 12 O
azathioprine NN 0 1 13 B-Drug
( ( 0 0 2 O
Imuran NNP 0 1 0 B-Brand
) ) 0 0 2 O
the DT 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
of IN 0 0 12 O
allopurinol JJ 0 1 13 B-Drug
per IN 0 0 1 O
day NN 0 1 12 O
will MD 0 0 12 O
require VB 0 0 1 O
a DT 0 0 12 O
reduction NN 0 1 1 O
in IN 0 0 12 O
dose NN 0 1 6 O
to TO 0 0 12 O
approximately RB 0 1 1 O
one CD 0 1 12 O
- : 0 0 2 O
third NN 0 1 12 O
to TO 0 0 12 O
one CD 0 1 12 O
- : 0 0 2 O
fourth JJ 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
usual JJ 0 1 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
mercaptopurine NN 0 1 13 B-Drug
or CC 0 0 12 O
azathioprine NN 0 1 13 B-Drug
. . 0 0 12 O

Drugs NNS 0 1 2 O
which WDT 0 0 12 O
induce VBP 0 1 6 O
CYP9A9 NNP 0 0 UNK O
activity NN 0 1 1 O
( ( 0 0 2 O
eg JJ 0 1 UNK O
phenobarbital NN 0 1 16 B-Drug
rifampin NN 0 1 16 B-Drug
rifabutin NN 0 1 13 B-Drug
) ) 0 0 2 O
would MD 0 0 12 O
be VB 0 0 12 O
expected VBN 1 1 12 O
to TO 0 0 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
clearance NN 0 1 16 O
of IN 0 0 12 O
efavirenz JJ 0 1 13 B-Drug
resulting VBG 1 1 1 O
in IN 0 0 12 O
lowered VBN 1 1 3 O
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
. . 0 0 12 O

Warfarin NN 0 1 0 B-Drug
: : 0 0 2 O
In IN 0 0 2 O
9 CD 0 0 2 O
normal JJ 0 1 1 O
- : 0 0 2 O
weight NN 0 1 3 O
subjects VBZ 1 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
XENICAL $ 0 1 UNK B-Brand
9 CD 0 0 2 O
mg NN 0 1 0 O
three CD 0 1 12 O
times NNS 1 1 12 O
a DT 0 0 12 O
day NN 0 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
did VBD 1 0 12 O
not RB 0 1 12 O
result VB 0 1 1 O
in IN 0 0 12 O
any DT 0 0 12 O
change NN 0 1 1 O
in IN 0 0 12 O
either DT 0 1 12 O
warfarin NN 0 1 14 B-Drug
pharmacokinetics NNS 0 1 UNK O
( ( 0 0 2 O
both DT 0 0 12 O
R NNP 0 1 2 O
- : 0 0 2 O
and CC 0 0 12 O
S NNP 0 1 2 O
- : 0 0 2 O
enantiomers NNS 1 1 UNK O
) ) 0 0 2 O
or CC 0 0 12 O
pharmacodynamics NNS 0 1 UNK O
( ( 0 0 2 O
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
and CC 0 0 12 O
serum JJ 0 1 14 O
Factor NNP 0 1 2 O
VII NNP 0 1 2 O
) ) 0 0 2 O
. . 0 0 12 O

The DT 0 0 2 O
use NN 0 1 1 O
of IN 0 0 12 O
dexfenfluramine NN 0 1 UNK B-Drug
with IN 0 0 12 O
other JJ 0 0 12 O
CNS NNP 0 1 6 O
- : 0 0 2 O
active JJ 0 1 1 O
drugs NNS 1 1 6 O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
systematically RB 0 0 UNK O
evaluated VBN 1 1 1 O
; : 0 0 2 O

include VBP 0 1 1 O
terfenadine JJ 0 1 UNK B-Drug
astemizole JJ 0 1 UNK B-Drug
cisapride NN 0 1 UNK B-Drug
midazolam NN 0 1 16 B-Drug
and CC 0 0 12 O
triazolam NN 0 1 13 B-Drug
. . 0 0 12 O

When WRB 0 0 12 O
encountered VBD 1 1 12 O
such JJ 0 0 1 O
arrhythmias NNS 1 1 6 O
may MD 0 0 1 O
respond VB 0 0 1 O
to TO 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
beta NN 0 1 16 B-Group
- : 0 0 2 O
adrenergic JJ 0 1 UNK I-Group
blocking JJ 0 1 UNK I-Group
drug NN 0 1 1 I-Group
. . 0 0 12 O

nonetheless RB 0 0 UNK O
the DT 0 0 12 O
possibility NN 0 1 1 O
that WDT 0 0 12 O
causative JJ 0 0 UNK O
factors NNS 1 1 1 O
may MD 0 0 1 O
interact VB 0 0 UNK O
synergistically RB 0 0 UNK O
to TO 0 0 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
risk NN 0 1 1 O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
severity NN 0 1 6 O
of IN 0 0 12 O
bone NN 0 1 6 O
marrow NN 0 1 6 O
suppression NN 0 1 1 O
warrants NNS 1 0 UNK O
consideration NN 0 1 1 O
. . 0 0 12 O

These DT 0 0 1 O
would MD 0 0 12 O
include VB 0 1 1 O
a DT 0 0 12 O
variety NN 0 1 1 O
of IN 0 0 12 O
preparations NNS 1 1 13 O
which WDT 0 0 12 O
contain VBP 0 1 UNK O
androgens NNS 1 1 13 B-Group
estrogens VBZ 0 1 16 B-Group
progestins NNS 1 1 UNK B-Group
or CC 0 0 12 O
glucocorticoids NNS 1 1 UNK B-Group
. . 0 0 12 O

while IN 0 0 12 O
no DT 0 0 12 O
formal JJ 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
conducted VBN 1 1 1 O
no DT 0 0 12 O
interactions NNS 1 1 UNK O
were VBD 1 0 12 O
observed VBN 1 1 1 O
. . 0 0 12 O

Results NNS 0 1 2 O
with IN 0 0 12 O
warfarin JJ 0 1 14 B-Drug
wshow NN 0 0 UNK O
no DT 0 0 12 O
evidence NN 0 1 1 O
of IN 0 0 12 O
interaction NN 0 1 UNK O
with IN 0 0 12 O
either DT 0 1 12 O
single JJ 0 1 12 O
or CC 0 0 12 O
repeated JJ 0 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
Trileptal NNP 0 1 UNK B-Brand
. . 0 0 12 O

Catecholamine NNP 0 1 UNK O
- : 0 0 2 O
depleting NN 0 1 UNK O
drugs NNS 1 1 6 O
( ( 0 0 2 O
e.g. FW 0 0 UNK O
reserpine NN 0 1 UNK B-Drug
) ) 0 0 2 O
may MD 0 0 1 O
have VB 0 0 12 O
an DT 0 0 12 O
additive JJ 0 1 16 O
effect NN 0 1 1 O
when WRB 0 0 12 O
given VBN 1 1 12 O
with IN 0 0 12 O
beta JJ 0 1 16 B-Group
- : 0 0 2 O
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
. . 0 0 12 O

9 CD 0 0 2 O
. . 0 0 12 O

INCREASED NNP 0 1 11 O
PHENYTOIN NNP 0 1 UNK B-Drug
LEVELS NNP 0 1 UNK O
SHOULD NNP 0 0 UNK O
BE NNP 0 0 11 O
TREATED NNP 0 1 11 O
WITH NNP 0 0 11 O
APPROPRIATE NNP 0 1 UNK O
DOSAGE NNP 0 1 UNK O
ADJUSTMENT NNP 0 1 UNK O
. . 0 0 12 O

Reduced VBN 0 1 UNK O
absorption NN 0 1 1 O
of IN 0 0 12 O
folic JJ 0 0 14 B-Drug
acid NN 0 1 14 I-Drug
and CC 0 0 12 O
digoxin NN 0 1 14 B-Drug
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
when WRB 0 0 12 O
those DT 0 0 12 O
agents NNS 1 1 1 O
were VBD 1 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
sulfasalazine NN 0 1 0 B-Drug
. . 0 0 12 O

While IN 0 0 12 O
taking VBG 1 0 12 O
beta JJ 0 1 16 B-Group
blockers NNS 1 0 6 I-Group
patients NNS 1 1 6 O
with IN 0 0 12 O
a DT 0 0 12 O
history NN 0 1 12 O
of IN 0 0 12 O
severe JJ 0 1 6 O
anaphylactic JJ 0 1 13 O
reaction NN 0 1 1 O
to TO 0 0 12 O
a DT 0 0 12 O
variety NN 0 1 1 O
of IN 0 0 12 O
allergens NNS 1 1 13 O
may MD 0 0 1 O
be VB 0 0 12 O
more RBR 0 1 12 O
reactive JJ 0 1 1 O
to TO 0 0 12 O
repeated VBN 1 1 1 O
challenge NN 0 1 12 O
either CC 0 1 12 O
accidental JJ 0 1 13 O
diagnostic NN 0 1 6 O
or CC 0 0 12 O
therapeutic JJ 0 1 6 O
. . 0 0 12 O

Melatonin NNP 0 1 UNK B-Drug
may MD 0 0 1 O
interact VB 0 0 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
following VBG 1 1 1 O
drugs NNS 1 1 6 O
: : 0 0 2 O
aspirin NN 0 1 14 B-Brand
and CC 0 0 12 O
other JJ 0 0 12 O
NSAIDs NNP 0 1 UNK B-Group
( ( 0 0 2 O
may MD 0 0 1 O
lower VB 0 1 1 O
melatonin NN 0 1 13 B-Drug
levels NNS 1 1 1 O
) ) 0 0 2 O
fluvoxamine NN 0 1 16 B-Drug
( ( 0 0 2 O
bioavailability NN 0 1 UNK O
of IN 0 0 12 O
oral JJ 0 1 6 O
melatonin NN 0 1 13 B-Drug
is VBZ 1 0 12 O
increased VBN 1 1 1 O
with IN 0 0 12 O
coadministration NN 0 1 UNK O
) ) 0 0 2 O
beta NN 0 1 16 B-Group
blockers NNS 1 0 6 I-Group
( ( 0 0 2 O
may MD 0 0 1 O
decrease VB 0 1 1 O
melatonin NN 0 1 13 B-Drug
levels NNS 1 1 1 O
) ) 0 0 2 O
fluoxetine VBP 0 1 16 B-Drug
( ( 0 0 2 O
reports NNS 1 1 1 O
of IN 0 0 12 O
psychotic JJ 0 1 6 O
episodes NNS 1 1 12 O
when WRB 0 0 12 O
coadministered VBN 0 0 UNK O
) ) 0 0 2 O
progestin NN 0 1 UNK B-Group
( ( 0 0 2 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
melatonin NN 0 1 13 B-Drug
with IN 0 0 12 O
progestin NN 0 1 UNK B-Group
can MD 0 0 12 O
inhibit VB 0 1 13 O
ovarian JJ 0 1 6 O
function NN 0 1 1 O
in IN 0 0 12 O
women NNS 1 1 UNK O
) ) 0 0 2 O
benzodiazepenes NNS 0 0 UNK B-Group
and CC 0 0 12 O
other JJ 0 0 12 O
sedating VBG 1 1 14 O
drugs NNS 1 1 6 O
( ( 0 0 2 O
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
additive JJ 0 1 16 O
sedation NN 0 1 6 O
and CC 0 0 12 O
an DT 0 0 12 O
increased JJ 0 1 1 O
incidence NN 0 1 6 O
of IN 0 0 12 O
adverse JJ 0 0 1 O
effects NNS 1 1 1 O
) ) 0 0 2 O
and CC 0 0 12 O
corticosteroids NNS 1 1 14 B-Group
( ( 0 0 2 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
melatonin NN 0 1 13 B-Drug
and CC 0 0 12 O
corticosteroids NNS 1 1 14 B-Group
may MD 0 0 1 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
efficacy NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
corticosteroids NNS 1 1 14 B-Group
) ) 0 0 2 O
. . 0 0 12 O

Therefore IN 0 0 1 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
advisable JJ 0 0 UNK O
to TO 0 0 12 O
be VB 0 0 12 O
particularly RB 0 0 1 O
cautious JJ 0 0 UNK O
in IN 0 0 12 O
patients NNS 1 1 6 O
whose WP$ 0 0 12 O
plasma JJ 0 1 14 O
digoxin NN 0 1 14 B-Drug
levels NNS 1 1 1 O
are VBP 1 0 12 O
above IN 0 1 12 O
or CC 0 0 12 O
suspected VBN 1 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
above IN 0 1 12 O
the DT 0 0 12 O
usual JJ 0 1 12 O
therapeutic JJ 0 1 6 O
range NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
possibility NN 0 1 1 O
of IN 0 0 12 O
hypotensive JJ 0 1 14 O
effects NNS 1 1 1 O
with IN 0 0 12 O
PRINIVIL NNP 0 1 UNK B-Brand
can MD 0 0 12 O
be VB 0 0 12 O
minimized VBN 1 0 1 O
by IN 0 0 12 O
either DT 0 1 12 O
discontinuing VBG 1 1 6 O
the DT 0 0 12 O
diuretic JJ 0 1 14 B-Group
or CC 0 0 12 O
increasing VBG 1 1 1 O
the DT 0 0 12 O
salt NN 0 1 3 O
intake VB 0 1 3 O
prior JJ 0 1 1 O
to TO 0 0 12 O
initiation NN 0 1 1 O
of IN 0 0 12 O
treatment NN 0 1 6 O
with IN 0 0 12 O
PRINIVIL NNP 0 1 UNK B-Brand
. . 0 0 12 O

ZANOSAR NNP 0 1 UNK B-Brand
may MD 0 0 1 O
demonstrate VB 0 0 1 O
additive JJ 0 1 16 O
toxicity NN 0 1 6 O
when WRB 0 0 12 O
used VBN 1 1 12 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
other JJ 0 0 12 O
cytotoxic NN 0 1 UNK O
drugs NNS 1 1 6 O
. . 0 0 12 O

Plasma NNP 0 1 UNK O
levels NNS 1 1 1 O
of IN 0 0 12 O
piroxicam NN 0 1 13 B-Drug
are VBP 1 0 12 O
depressed VBN 1 1 12 O
to TO 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
of IN 0 0 12 O
their PRP$ 0 0 12 O
normal JJ 0 1 1 O
values NNS 1 1 1 O
when WRB 0 0 12 O
FELDENE NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
administered VBN 1 1 1 O
in IN 0 0 12 O
conjunction NN 0 1 1 O
with IN 0 0 12 O
aspirin NN 0 1 14 B-Brand
( ( 0 0 2 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
) ) 0 0 2 O
but CC 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
antacids NNS 1 1 14 B-Group
has VBZ 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
piroxicam NN 0 1 13 B-Drug
plasma NN 0 1 14 O
levels NNS 1 1 1 O
. . 0 0 12 O
Nonsteroidal NNP 0 0 UNK B-Group
anti SYM 0 0 3 I-Group
- : 0 0 2 O
inflammatory JJ 0 1 6 I-Group
agents NNS 1 1 1 I-Group
including VBG 1 1 1 O
FELDENE NNP 0 1 UNK B-Brand
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
increase VB 0 1 1 O
steady JJ 0 1 1 O
state NN 0 1 1 O
plasma NN 0 1 14 O
lithium NN 0 1 16 B-Drug
levels NNS 1 1 1 O
. . 0 0 12 O

Use NNP 0 1 2 O
of IN 0 0 12 O
Antithrombotics NNP 0 0 UNK B-Group
Aspirin NNP 0 1 0 B-Brand
and CC 0 0 12 O
heparin NNS 0 1 14 B-Drug
have VBP 0 0 12 O
been VBN 1 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
and CC 0 0 12 O
following VBG 1 1 1 O
infusions NNS 1 1 14 O
of IN 0 0 12 O
Activase NNP 0 1 UNK B-Brand
in IN 0 0 12 O
the DT 0 0 12 O
management NN 0 1 1 O
of IN 0 0 12 O
acute JJ 0 1 6 O
myocardial JJ 0 1 6 O
infarction NN 0 1 6 O
or CC 0 0 12 O
pulmonary JJ 0 1 6 O
embolism NN 0 1 8 O
. . 0 0 12 O

Carbamazepine NN 0 1 UNK B-Drug
: : 0 0 2 O
Isoniazid NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
known VBN 1 1 12 O
to TO 0 0 12 O
slow VB 0 1 12 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
carbamazepine NN 0 1 16 B-Drug
and CC 0 0 12 O
increase VB 0 1 1 O
its PRP$ 1 0 12 O
serum NN 0 1 14 O
levels NNS 1 1 1 O
Carbamazepine NNP 0 1 UNK B-Drug
levels NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
determined VBN 1 1 1 O
prior RB 0 1 1 O
to TO 0 0 12 O
concurrent VB 0 1 1 O
administration NN 0 1 1 O
with IN 0 0 12 O
isoniazid JJ 0 1 13 B-Drug
signs NNS 1 1 12 O
and CC 0 0 12 O
symptoms NNS 1 1 6 O
of IN 0 0 12 O
carbamazepine JJ 0 1 16 B-Drug
toxicity NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
closely RB 0 0 1 O
and CC 0 0 12 O
appropriate JJ 0 1 1 O
dosage NN 0 1 0 O
adjustment NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
anticonvulsant NN 0 1 14 B-Group
should MD 0 0 12 O
be VB 0 0 12 O
made VBN 1 1 12 O
. . 0 0 12 O

In IN 0 0 2 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
mg NN 0 1 0 O
dose NN 0 1 6 O
of IN 0 0 12 O
butorphanol NN 0 1 13 B-Drug
administered VBN 1 1 1 O
as IN 1 0 12 O
STADOL NNP 0 1 UNK B-Brand
NS NNP 0 1 13 I-Brand
were VBD 1 0 12 O
not RB 0 1 12 O
affected VBN 1 1 1 O
by IN 0 0 12 O
the DT 0 0 12 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
9 CD 0 0 2 O
- : 0 0 2 O
mg NN 0 1 0 O
subcutaneous JJ 0 1 14 O
dose NN 0 1 6 O
of IN 0 0 12 O
sumatriptan NN 0 1 16 B-Drug
. . 0 0 12 O

International NNP 0 1 UNK O
Normalized NNP 0 1 UNK O
Ratio NNP 0 1 2 O
( ( 0 0 2 O
INR NNP 0 1 13 O
) ) 0 0 2 O
elevations NNS 1 1 1 O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
bleeding VBG 1 1 6 O
events NNS 1 1 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
some DT 0 0 12 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
warfarin NN 0 1 14 B-Drug
while IN 0 0 12 O
on IN 0 0 12 O
IRESSA NNP 0 1 UNK B-Brand
therapy NN 0 1 6 O
. . 0 0 12 O

Digoxin NN 0 1 0 B-Drug
: : 0 0 2 O
When WRB 0 0 12 O
multiple JJ 0 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
atorvastatin NN 0 1 0 B-Drug
and CC 0 0 12 O
digoxin NN 0 1 14 B-Drug
were VBD 1 0 12 O
coadministered VBN 0 0 UNK O
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
plasma NN 0 1 14 O
digoxin NN 0 1 14 B-Drug
concentrations NNS 1 1 13 O
increased VBN 1 1 1 O
by IN 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

Whether IN 0 0 12 O
this DT 0 0 12 O
interaction NN 0 1 UNK O
also RB 0 0 12 O
occurs VBZ 1 1 1 O
with IN 0 0 12 O
the DT 0 0 12 O
intravenous JJ 0 1 14 O
topical JJ 0 1 6 O
or CC 0 0 12 O
vaginal JJ 0 1 6 O
preparations NNS 1 1 13 O
of IN 0 0 12 O
miconazole NN 0 1 16 B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
known VBN 1 1 12 O
. . 0 0 12 O

Glibenclamide NN 0 1 UNK B-Drug
: : 0 0 2 O
In IN 0 0 2 O
a DT 0 0 12 O
study NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
healthy JJ 0 1 12 O
male NN 0 1 12 O
volunteers NNS 1 1 UNK O
acitretin VBP 0 1 13 B-Drug
treatment NN 0 1 6 O
potentiated VBD 1 0 UNK O
the DT 0 0 12 O
blood NN 0 1 6 O
glucose NN 0 1 14 O
lowering VBG 1 1 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
glibenclamide NN 0 1 UNK B-Drug
( ( 0 0 2 O
a DT 0 0 12 O
sulfonylurea NN 0 1 UNK B-Group
similar JJ 0 1 1 O
to TO 0 0 12 O
chlorpropamide VB 0 1 13 B-Drug
) ) 0 0 2 O
in IN 0 0 12 O
9 CD 0 0 2 O
of IN 0 0 12 O
the DT 0 0 12 O
9 CD 0 0 2 O
subjects NNS 1 1 UNK O
. . 0 0 12 O

Drugs NNS 0 1 2 O
That WDT 0 0 2 O
Alter NNP 0 1 UNK O
Renal NNP 0 1 7 O
Excretion NNP 0 1 UNK O
Ibuprofen NNP 0 1 0 B-Drug
: : 0 0 2 O
Ibuprofen NNP 0 1 0 B-Drug
is VBZ 1 0 12 O
known VBN 1 1 12 O
to TO 0 0 12 O
affect VB 0 1 1 O
renal JJ 0 1 6 O
function NN 0 1 1 O
and CC 0 0 12 O
consequently RB 0 0 UNK O
alter VB 0 1 13 O
the DT 0 0 12 O
renal JJ 0 1 6 O
excretion NN 0 1 14 O
of IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

Insulin NN 0 1 7 B-Drug
requirements NNS 1 1 1 O
in IN 0 0 12 O
diabetic JJ 0 1 6 O
patients NNS 1 1 6 O
may MD 0 0 1 O
be VB 0 0 12 O
increased VBN 1 1 1 O
decreased JJ 0 1 1 O
or CC 0 0 12 O
unchanged JJ 0 1 1 O
. . 0 0 12 O

Phenytoin NNP 0 1 0 B-Drug
/ NNP 0 0 2 O
Phenobarbital NNP 0 1 0 B-Drug
: : 0 0 2 O
The DT 0 0 2 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
or CC 0 0 12 O
phenobarbital NN 0 1 16 B-Drug
will MD 0 0 12 O
not RB 0 1 12 O
affect VB 0 1 1 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
vitamin NN 0 1 6 B-Group
D NNP 0 1 2 I-Group
but CC 0 0 12 O
may MD 0 0 1 O
reduce VB 0 0 1 O
endogenous JJ 0 1 14 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
calcitriol NN 0 1 14 B-Drug
/ NNP 0 0 2 O
ergocalcitriol NN 0 0 UNK O
by IN 0 0 12 O
accelerating VBG 1 1 UNK O
metabolism NN 0 1 16 O
. . 0 0 12 O

The DT 0 0 2 O
intake NN 0 1 3 O
of IN 0 0 12 O
furosemide NN 0 1 0 B-Drug
and CC 0 0 12 O
sucralfate NN 0 1 0 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
separated VBN 1 1 3 O
by IN 0 0 12 O
at IN 0 0 12 O
least JJS 0 1 12 O
two CD 0 1 12 O
hours NNS 1 1 12 O
. . 0 0 12 O

Co NNP 0 1 2 O
- : 0 0 2 O
treatment NN 0 1 6 O
with IN 0 0 12 O
the DT 0 0 12 O
potent NN 0 1 UNK O
CYP9A9 NNP 0 0 UNK O
inhibitor NN 0 1 14 O
ketoconazole NN 0 1 16 B-Drug
increases NNS 1 1 1 O
erlotinib VBP 0 1 13 B-Drug
AUC NNP 0 1 UNK O
by IN 0 0 12 O
9 CD 0 0 2 O
/ JJ 0 0 2 O
9 CD 0 0 2 O
. . 0 0 12 O

an DT 0 0 12 O
interval NN 0 1 1 O
of IN 0 0 12 O
at IN 0 0 12 O
least JJS 0 1 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
between IN 0 0 12 O
intake NN 0 1 3 O
of IN 0 0 12 O
these DT 0 0 12 O
agents NNS 1 1 1 O
and CC 0 0 12 O
chloroquine NN 0 1 13 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
observed VBN 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
duration NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
period NN 0 1 1 O
following VBG 1 1 1 O
treatment NN 0 1 6 O
with IN 0 0 12 O
AMEVIVE NNP 0 1 UNK B-Brand
before IN 0 1 12 O
one CD 0 1 12 O
should MD 0 0 12 O
consider VB 0 1 12 O
starting VBG 1 1 12 O
other JJ 0 0 12 O
immunosuppressive JJ 0 1 14 B-Group
therapy NN 0 1 6 O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
evaluated VBN 1 1 1 O
. . 0 0 12 O

chlorpropamide NN 0 1 13 B-Drug
; : 0 0 2 O

All DT 0 0 2 O
patients NNS 1 1 6 O
in IN 0 0 12 O
whom WP 0 0 12 O
this DT 0 0 12 O
effect NN 0 1 1 O
was VBD 1 0 12 O
observed VBN 1 1 1 O
remained JJ 0 0 12 O
asymptomatic JJ 0 1 6 O
. . 0 0 12 O

On IN 0 0 2 O
day NN 0 1 12 O
9 CD 0 0 2 O
aspirin NN 0 1 14 B-Brand
( ( 0 0 2 O
9 CD 0 0 2 O
mg RB 0 1 0 O
four CD 0 1 12 O
times NNS 1 1 12 O
daily RB 0 1 12 O
) ) 0 0 2 O
was VBD 1 0 12 O
started VBN 1 1 12 O
and CC 0 0 12 O
continued VBN 1 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
. . 0 0 12 O

Cmax NNP 0 1 UNK O
and CC 0 0 12 O
AUC NNP 0 1 UNK O
values NNS 1 1 1 O
are VBP 1 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
to TO 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
lower RBR 0 1 1 O
respectively RB 0 0 1 O
after IN 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
Neurontin NNP 0 1 0 B-Brand
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
to TO 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
lower RBR 0 1 1 O
respectively RB 0 0 1 O
after IN 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
Neurontin NNP 0 1 0 B-Brand
. . 0 0 12 O

Less JJR 0 1 2 O
than IN 0 0 12 O
the DT 0 0 12 O
usual JJ 0 1 12 O
amounts NNS 1 1 1 O
of IN 0 0 12 O
these DT 0 0 12 O
medicines NNS 1 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
. . 0 0 12 O

magnesium NN 0 1 14 B-Drug
salts NNS 1 1 13 O
; : 0 0 2 O

There EX 0 0 12 O
is VBZ 1 0 12 O
no DT 0 0 12 O
significant JJ 0 1 1 O
change NN 0 1 1 O
in IN 0 0 12 O
platelet NN 0 1 14 O
count NN 0 1 12 O
prothrombin NN 0 1 14 O
time NN 0 1 12 O
partial JJ 0 1 1 O
thromboplastin NN 0 1 14 O
time NN 0 1 12 O
or CC 0 0 12 O
thrombin JJ 0 1 14 O
time NN 0 1 12 O
. . 0 0 12 O

Additional JJ 0 1 2 O
reductions NNS 1 1 1 O
in IN 0 0 12 O
blood NN 0 1 6 O
pressure NN 0 1 1 O
may MD 0 0 1 O
occur VB 0 1 1 O
when WRB 0 0 12 O
FLOLAN NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
diuretics NNS 1 1 14 B-Group
antihypertensive JJ 0 1 14 B-Group
agents NNS 1 1 1 I-Group
or CC 0 0 12 O
other JJ 0 0 12 O
vasodilators NNS 1 1 13 B-Group
. . 0 0 12 O

Cimetidine NN 0 1 0 B-Drug
: : 0 0 2 O
A DT 0 0 2 O
study NN 0 1 1 O
in IN 0 0 12 O
9 CD 0 0 2 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
has VBZ 1 0 12 O
shown VBN 1 1 1 O
a DT 0 0 12 O
significant JJ 0 1 1 O
increase NN 0 1 1 O
in IN 0 0 12 O
peak JJ 0 1 1 O
nifedipine JJ 0 1 0 B-Drug
plasma NN 0 1 14 O
levels NNS 1 1 1 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
and CC 0 0 12 O
area NN 0 1 12 O
- : 0 0 2 O
under IN 0 0 12 O
- : 0 0 2 O
the DT 0 0 12 O
- : 0 0 2 O
curve NN 0 1 13 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
after IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
week NN 0 1 12 O
course NN 0 1 12 O
of IN 0 0 12 O
cimetidine NN 0 1 13 B-Drug
at IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
per IN 0 0 1 O
day NN 0 1 12 O
and CC 0 0 12 O
nifedipine NN 0 1 0 B-Drug
at IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
per IN 0 0 1 O
day NN 0 1 12 O
. . 0 0 12 O

Exaggerated JJ 0 1 7 O
hypertensive JJ 0 1 6 O
responses NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
from IN 0 0 12 O
the DT 0 0 12 O
combined VBN 1 1 1 O
use NN 0 1 1 O
of IN 0 0 12 O
beta NN 0 1 16 B-Group
- : 0 0 2 O
adrenergic JJ 0 1 UNK I-Group
antagonists NNS 1 1 13 I-Group
and CC 0 0 12 O
alpha SYM 0 1 1 B-Group
- : 0 0 2 O
adrenergic JJ 0 1 UNK I-Group
stimulants NNS 1 1 13 I-Group
including VBG 1 1 1 O
those DT 0 0 12 O
contained VBN 1 1 1 O
in IN 0 0 12 O
proprietary JJ 0 1 UNK O
cold NN 0 1 3 O
remedies NNS 1 0 6 O
and CC 0 0 12 O
vasoconstrictive JJ 0 0 UNK O
nasal NN 0 1 6 O
drops NNS 1 1 3 O
. . 0 0 12 O

- : 0 0 2 O
Corticosteroids NNS 0 1 UNK B-Group
ACTH VBP 0 1 UNK B-Drug
: : 0 0 2 O
Intensified NNP 0 0 UNK O
electrolyte VBZ 0 1 14 O
depletion NN 0 1 1 O
particularly RB 0 0 1 O
hypokalemia NN 0 1 14 O

Therefore RB 0 0 1 O
positive JJ 0 1 1 O
test NN 0 1 1 O
results NNS 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
piperacillin NN 0 1 16 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
interpreted VBN 1 1 UNK O
cautiously RB 0 0 UNK O
and CC 0 0 12 O
confirmed VBN 1 1 12 O
by IN 0 0 12 O
other JJ 0 0 12 O
diagnostic JJ 0 1 6 O
methods NNS 1 1 1 O
. . 0 0 12 O

Frequent JJ 0 1 2 O
determination NN 0 1 13 O
of IN 0 0 12 O
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
and CC 0 0 12 O
close JJ 0 1 12 O
monitoring NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
patient NN 0 1 6 O
is VBZ 1 0 12 O
essential JJ 0 1 13 O
to TO 0 0 12 O
ascertain VB 0 0 1 O
when WRB 0 0 12 O
adjustment NN 0 1 1 O
of IN 0 0 12 O
dosage NN 0 1 0 O
of IN 0 0 12 O
anticoagulant NN 0 1 13 B-Group
may MD 0 0 1 O
be VB 0 0 12 O
needed VBN 1 1 12 O
. . 0 0 12 O

In IN 0 0 2 O
hematologic JJ 0 1 14 O
studies NNS 1 1 1 O
or CC 0 0 12 O
in IN 0 0 12 O
transfusion NN 0 1 6 O
cross NN 0 1 12 O
- : 0 0 2 O
matching NN 0 1 UNK O
procedures NNS 1 1 1 O
when WRB 0 0 12 O
anti SYM 0 0 3 O
- : 0 0 2 O
globulin NN 0 1 14 O
tests NNS 1 1 1 O
are VBP 1 0 12 O
performed VBN 1 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
minor JJ 0 1 1 O
side NN 0 1 3 O
or CC 0 0 12 O
in IN 0 0 12 O
Coombs NNP 0 1 19 O
testing NN 0 1 1 O
of IN 0 0 12 O
newborns NNS 1 1 UNK O
whose WP$ 0 0 12 O
mothers NNS 1 1 UNK O
have VBP 0 0 12 O
received VBN 1 1 12 O
cephalosporin JJ 0 1 13 B-Group
antibiotics NNS 1 1 6 I-Group
before IN 0 1 12 O
parturition NN 0 1 UNK O
it PRP 0 0 12 O
should MD 0 0 12 O
be VB 0 0 12 O
recognized VBN 1 0 13 O
that IN 0 0 12 O
a DT 0 0 12 O
positive JJ 0 1 1 O
Coombs NNP 0 1 19 O
test NN 0 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
due JJ 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
drug NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
effect NN 0 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
mediated VBN 1 1 13 O
by IN 0 0 12 O
the DT 0 0 12 O
known JJ 0 1 12 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
cimetidine NN 0 1 13 B-Drug
on IN 0 0 12 O
hepatic JJ 0 1 14 O
cytochrome NN 0 1 UNK O
P NNP 0 1 2 O
- : 0 0 2 O
9 CD 0 0 2 O
the DT 0 0 12 O
enzyme NN 0 1 14 O
system NN 0 1 1 O
probably RB 0 1 12 O
responsible JJ 0 1 1 O
for IN 0 0 12 O
the DT 0 0 12 O
first JJ 0 1 12 O
- : 0 0 2 O
pass NN 1 1 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
nifedipine NN 0 1 0 B-Drug
. . 0 0 12 O

Patients NNS 0 1 7 O
receiving VBG 1 1 1 O
both DT 0 0 12 O
drugs NNS 1 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
under IN 0 0 12 O
careful JJ 0 1 12 O
observation NN 0 1 1 O
. . 0 0 12 O

Nonsteroidal NNP 0 0 UNK B-Group
anti SYM 0 0 3 I-Group
- : 0 0 2 O
inflammatory NN 0 1 6 I-Group
drugs NNS 1 1 6 I-Group
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
decrease VB 0 1 1 O
the DT 0 0 12 O
tubular JJ 0 1 3 O
secretion NN 0 1 14 O
of IN 0 0 12 O
methotrexate NN 0 1 16 B-Drug
and CC 0 0 12 O
to TO 0 0 12 O
potentiate VB 0 0 UNK O
its PRP$ 1 0 12 O
toxicity NN 0 1 6 O
. . 0 0 12 O

Propoxyphene NN 0 1 UNK B-Drug
: : 0 0 2 O
The DT 0 0 2 O
concurrent JJ 0 1 1 O
administration NN 0 1 1 O
of IN 0 0 12 O
propoxyphene JJ 0 1 16 B-Drug
hydrochloride NN 0 1 0 I-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
affect VB 0 1 1 O
the DT 0 0 12 O
bioavailability NN 0 1 UNK O
of IN 0 0 12 O
meclofenamate NN 0 1 UNK B-Drug
sodium NN 0 1 14 I-Drug
. . 0 0 12 O

Concomitant NNP 0 1 UNK O
use NN 0 1 1 O
of IN 0 0 12 O
prostaglandin JJ 0 1 13 O
synthase NN 0 1 UNK O
inhibiting VBG 1 1 UNK O
drugs NNS 1 1 6 O
eg JJ 0 1 UNK O
indomethacin NN 0 1 14 B-Drug
may MD 0 0 1 O
decrease VB 0 1 1 O
the DT 0 0 12 O
hypotensive JJ 0 1 14 O
effects NNS 1 1 1 O
of IN 0 0 12 O
beta NN 0 1 16 B-Group
blockers NNS 1 0 6 I-Group
. . 0 0 12 O

In IN 0 0 2 O
9 CD 0 0 2 O
Drs NNP 0 1 UNK O
Rimmer NNP 0 0 UNK O
and CC 0 0 12 O
Richens NNP 0 0 UNK O
at IN 0 0 12 O
the DT 0 0 12 O
University NNP 0 1 2 O
of IN 0 0 12 O
Wales NNP 0 1 UNK O
reported VBD 1 1 1 O
that IN 0 0 12 O
administering VBG 1 1 1 O
vigabatrin NN 0 1 UNK B-Drug
with IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
lowered VBD 1 1 3 O
the DT 0 0 12 O
serum NN 0 1 14 O
phenytoin NN 0 1 16 B-Drug
concentration NN 0 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
treatment NN 0 1 6 O
- : 0 0 2 O
resistant JJ 0 1 3 O
epilepsy NN 0 1 13 O
. . 0 0 12 O

Antithyroid JJ 0 0 UNK B-Group
agents NNS 1 1 1 I-Group
may MD 0 0 1 O
decrease VB 0 1 1 O
thyroidal JJ 0 1 UNK O
uptake NN 0 1 14 O
of IN 0 0 12 O
sodium NN 0 1 14 B-Drug
iodide NN 0 1 16 I-Drug
I9 NNP 0 0 UNK I-Drug
a DT 0 0 12 O
rebound NN 0 0 3 O
in IN 0 0 12 O
uptake NN 0 1 14 O
may MD 0 0 1 O
occur VB 0 1 1 O
up RP 0 0 12 O
to TO 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
after IN 0 0 12 O
sudden JJ 0 1 12 O
withdrawal NN 0 1 1 O
of IN 0 0 12 O
Carbimazole NNP 0 1 UNK B-Drug
. . 0 0 12 O

In IN 0 0 2 O
an DT 0 0 12 O
analysis NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
supraventricular JJ 0 0 8 O
arrhythmia NN 0 1 6 O
and CC 0 0 12 O
DIAMOND NNP 0 1 UNK O
patient NN 0 1 6 O
populations NNS 1 1 UNK O
the DT 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
verapamil NN 0 1 0 B-Drug
with IN 0 0 12 O
dofetilide NN 0 1 13 B-Drug
was VBD 1 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
a DT 0 0 12 O
higher JJR 1 1 1 O
occurrence NN 0 1 1 O
of IN 0 0 12 O
torsade NN 0 0 13 O
de FW 0 1 2 O
pointes NNS 0 0 UNK O
. . 0 0 12 O

Laboratory JJ 0 1 2 O
Test NNP 0 1 2 O
Interactions NNPS 0 1 UNK O
There EX 0 0 12 O
are VBP 1 0 12 O
no DT 0 0 12 O
reported JJ 0 1 1 O
laboratory NN 0 1 1 O
test NN 0 1 1 O
interactions NNS 1 1 UNK O
. . 0 0 12 O

Therefore RB 0 0 1 O
the DT 0 0 12 O
combined VBN 1 1 1 O
use NN 0 1 1 O
of IN 0 0 12 O
lovastatin NN 0 1 13 B-Drug
with IN 0 0 12 O
fibrates NNS 0 1 UNK B-Group
should MD 0 0 12 O
generally RB 0 0 1 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
. . 0 0 12 O

However RB 0 0 1 O
the DT 0 0 12 O
co JJ 0 1 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
SPIRIVA NNP 0 1 0 B-Brand
with IN 0 0 12 O
other JJ 0 0 12 O
anticholinergic JJ 0 1 13 B-Group
containing VBG 1 1 1 O
drugs NNS 1 1 6 O
( ( 0 0 2 O
e.g. VB 0 0 UNK O
ipratropium NN 0 1 0 B-Drug
) ) 0 0 2 O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
studied VBN 1 0 1 O
and CC 0 0 12 O
is VBZ 1 0 12 O
therefore RB 0 0 1 O
not RB 0 1 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O

Quinolones NNS 0 1 UNK B-Group
have VBP 0 0 12 O
also RB 0 0 12 O
been VBN 1 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
caffeine NN 0 1 6 B-Drug
. . 0 0 12 O

This DT 0 0 2 O
effect NN 0 1 1 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
attributed VBN 1 1 1 O
to TO 0 0 12 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
prostaglandin JJ 0 1 13 O
synthesis NN 0 1 UNK O
. . 0 0 12 O

Phenytoin NN 0 1 0 B-Drug
: : 0 0 2 O
Etodolac NNP 0 1 UNK B-Drug
has VBZ 1 0 12 O
no DT 0 0 12 O
apparent JJ 0 1 1 O
pharmacokinetic JJ 0 1 UNK O
interaction NN 0 1 UNK O
when WRB 0 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
. . 0 0 12 O

Reported VBN 0 1 2 O
examples NNS 1 1 UNK O
of IN 0 0 12 O
this DT 0 0 12 O
interaction NN 0 1 UNK O
include VBP 0 1 1 O
the DT 0 0 12 O
following JJ 0 1 1 O
: : 0 0 2 O
Antibiotics NNS 0 1 7 B-Drug
: : 0 0 2 O
Rifampin NNP 0 1 0 B-Drug
is VBZ 1 0 12 O
a DT 0 0 12 O
potent JJ 0 1 UNK O
inducer NN 0 1 UNK O
of IN 0 0 12 O
CYP9A9 NNP 0 0 UNK B-Drug
. . 0 0 12 O

Therefore RB 0 0 1 O
the DT 0 0 12 O
use NN 0 1 1 O
of IN 0 0 12 O
sumatriptan JJ 0 1 16 B-Drug
succinate NN 0 1 14 I-Drug
tablets NNS 1 1 3 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
MAO NNP 0 1 14 B-Group
- : 0 0 2 O
A DT 0 0 2 I-Group
inhibitors NNS 1 1 14 I-Group
is VBZ 1 0 12 O
contraindicated VBN 1 1 14 O
. . 0 0 12 O
Selective JJ 0 1 7 B-Group
serotonin NN 0 1 13 I-Group
reuptake NN 0 1 13 I-Group
inhibitors NNS 1 1 14 I-Group
( ( 0 0 2 O
SSRIs NNP 0 1 UNK B-Group
) ) 0 0 2 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
fluoxetine NN 0 1 16 B-Drug
fluvoxamine NN 0 1 16 B-Drug
paroxetine NN 0 1 16 B-Drug
sertraline NN 0 1 16 B-Drug
) ) 0 0 2 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
rarely RB 0 1 UNK O
to TO 0 0 12 O
cause VB 0 1 12 O
weakness NN 0 1 6 O
hyperreflexia NN 0 1 8 O
and CC 0 0 12 O
incoordination NN 0 1 UNK O
when WRB 0 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
sumatriptan NN 0 1 16 B-Drug
. . 0 0 12 O

Geriatric NNP 0 1 7 O
Use NNP 0 1 2 O

Patients NNS 0 1 7 O
undergoing VBG 1 0 6 O
systemic JJ 0 1 6 O
anticholinesterase NN 0 1 UNK O
treatment NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
warned VBN 1 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
possible JJ 0 1 1 O
additive JJ 0 1 16 O
effects NNS 1 1 1 O
of IN 0 0 12 O
Phospholine NNP 0 1 UNK B-Drug
Iodide NNP 0 1 UNK I-Drug
. . 0 0 12 O

If IN 0 0 12 O
other JJ 0 0 12 O
muscle NN 0 1 6 B-Group
relaxants NNS 1 0 13 I-Group
are VBP 1 0 12 O
used VBN 1 1 12 O
during IN 0 0 12 O
the DT 0 0 12 O
same JJ 0 1 12 O
procedure NN 0 1 1 O
the DT 0 0 12 O
possibility NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
synergistic JJ 0 1 UNK O
or CC 0 0 12 O
antagonist JJ 0 1 13 O
effect NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
. . 0 0 12 O

Caution NN 0 0 UNK O
is VBZ 1 0 12 O
therefore RB 0 0 1 O
advised VBN 1 0 12 O
in IN 0 0 12 O
the DT 0 0 12 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
ATROVENT NNP 0 1 0 B-Brand
Inhalation NNP 0 1 7 O
Aerosol NNP 0 1 7 O
with IN 0 0 12 O
other JJ 0 0 12 O
anticholinergic JJ 0 1 13 B-Group
- : 0 0 2 O
containing VBG 1 1 1 O
drugs NNS 1 1 6 O
. . 0 0 12 O

In IN 0 0 2 O
occasional JJ 0 1 12 O
susceptible JJ 0 1 1 O
patients NNS 1 1 6 O
or CC 0 0 12 O
in IN 0 0 12 O
those DT 0 0 12 O
receiving VBG 1 1 1 O
anticholinergic JJ 0 1 13 B-Group
drugs NNS 1 1 6 I-Group
( ( 0 0 2 O
including VBG 1 1 1 O
antiparkinsonism NN 0 0 UNK O
agents NNS 1 1 1 O
) ) 0 0 2 O
in IN 0 0 12 O
addition NN 0 1 1 O
the DT 0 0 12 O
atropine JJ 0 1 14 O
- : 0 0 2 O
like IN 0 0 12 O
effects NNS 1 1 1 O
may MD 0 0 1 O
become VB 0 0 12 O
more RBR 0 1 12 O
pronounced JJ 0 0 12 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
paralytic JJ 0 0 13 O
ileus NN 0 1 8 O
) ) 0 0 2 O
. . 0 0 12 O

Adverse JJ 0 0 UNK O
reactions NNS 1 1 1 O
related VBN 1 1 1 O
to TO 0 0 12 O
alpha VB 0 1 1 B-Drug
interferons NNS 1 1 UNK I-Drug
such JJ 0 0 1 O
as IN 1 0 12 O
CNS NNP 0 1 6 O
cardiac NN 0 1 6 O
and CC 0 0 12 O
systemic JJ 0 1 6 O
( ( 0 0 2 O
eg JJ 0 1 UNK O
flu SYM 0 1 6 O
- : 0 0 2 O
like IN 0 0 12 O
) ) 0 0 2 O
effects NNS 1 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
more JJR 0 1 12 O
severe JJ 0 1 6 O
in IN 0 0 12 O
the DT 0 0 12 O
elderly JJ 0 1 12 O
and CC 0 0 12 O
caution NN 0 0 1 O
should MD 0 0 12 O
be VB 0 0 12 O
exercised VBN 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
use NN 0 1 1 O
of IN 0 0 12 O
PEGASYS NNP 0 1 UNK B-Brand
in IN 0 0 12 O
this DT 0 0 12 O
population NN 0 1 13 O
. . 0 0 12 O

No DT 0 0 2 O
information NN 0 1 1 O
available JJ 0 1 1 O
. . 0 0 12 O

Caution NN 0 0 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
exercised VBN 1 1 1 O
when WRB 0 0 12 O
considering VBG 1 1 12 O
the DT 0 0 12 O
use NN 0 1 1 O
of IN 0 0 12 O
BREVIBLOC NNP 0 1 UNK B-Brand
and CC 0 0 12 O
verapamil NN 0 1 0 B-Drug
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
depressed JJ 0 1 12 O
myocardial JJ 0 1 6 O
function NN 0 1 1 O
. . 0 0 12 O

Rifampin NN 0 1 0 B-Drug
: : 0 0 2 O
Coadministration NN 0 1 UNK O
of IN 0 0 12 O
rifampin NN 0 1 16 B-Drug
and CC 0 0 12 O
VIRACEPT NNP 0 1 UNK B-Brand
resulted VBD 1 1 1 O
in IN 0 0 12 O
an DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
decrease NN 0 1 1 O
in IN 0 0 12 O
nelfinavir JJ 0 1 16 B-Drug
plasma NN 0 1 14 O
A.C NNP 0 0 UNK O
. . 0 0 12 O

Mild NNP 0 1 7 O
hepatotoxicity NN 0 1 13 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
some DT 0 0 12 O
patients NNS 1 1 6 O
when WRB 0 0 12 O
lorazepam NN 0 1 0 B-Drug
and CC 0 0 12 O
pyrimethamine NN 0 1 16 B-Drug
were VBD 1 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
. . 0 0 12 O

One CD 0 1 2 O
controlled VBN 1 1 1 O
study NN 0 1 1 O
in IN 0 0 12 O
eight CD 0 1 12 O
normal JJ 0 1 1 O
subjects NNS 1 1 UNK O
showed VBD 1 1 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
mean JJ 0 1 12 O
increase NN 0 1 1 O
( ( 0 0 2 O
range VB 0 1 1 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
in IN 0 0 12 O
plasma JJ 0 1 14 O
theophylline NN 0 1 16 B-Drug
levels NNS 1 1 1 O
. . 0 0 12 O

exfoliative JJ 0 1 UNK O
dermatitis NN 0 1 13 O

Combination NNP 0 1 UNK O
hormonal JJ 0 1 6 B-Group
contraceptives NNS 1 1 13 I-Group
may MD 0 0 1 O
also RB 0 0 12 O
decrease VB 0 1 1 O
the DT 0 0 12 O
plasma JJ 0 1 14 O
concentration NN 0 1 1 O
of IN 0 0 12 O
acetaminophen NN 0 1 16 B-Drug
. . 0 0 12 O

Therefore RB 0 0 1 O
co SYM 0 1 12 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
Duloxetine NNP 0 1 0 B-Drug
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
are VBP 1 0 12 O
extensively RB 0 0 1 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
this DT 0 0 12 O
isozyme NN 0 1 UNK O
and CC 0 0 12 O
which WDT 0 0 12 O
have VBP 0 0 12 O
a DT 0 0 12 O
narrow JJ 0 1 3 O
therapeutic JJ 0 1 6 O
index NN 0 1 1 O
including VBG 1 1 1 O
certain JJ 0 1 1 O
antidepressants NNS 1 1 13 B-Group
( ( 0 0 2 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
[ VBP 0 0 2 O
TCAs NNP 0 1 UNK B-Group
] NNP 0 0 2 O
such JJ 0 0 1 O
as IN 1 0 12 O
nortriptyline JJ 0 1 16 B-Drug
amitriptyline NN 0 1 16 B-Drug
and CC 0 0 12 O
imipramine NN 0 1 0 B-Drug
) ) 0 0 2 O
phenothiazines NNS 1 1 UNK B-Group
and CC 0 0 12 O
Type NNP 0 1 2 B-Group
9C CD 0 0 UNK I-Group
antiarrhythmics NNS 1 1 UNK I-Group
( ( 0 0 2 O
e.g. VB 0 0 UNK O
propafenone NN 0 1 16 B-Drug
flecainide NN 0 1 16 B-Drug
) ) 0 0 2 O
should MD 0 0 12 O
be VB 0 0 12 O
approached VBN 1 1 UNK O
with IN 0 0 12 O
caution NN 0 0 1 O
. . 0 0 12 O

Because IN 0 0 12 O
of IN 0 0 12 O
reports NNS 1 1 1 O
of IN 0 0 12 O
prolongation NN 0 1 6 O
of IN 0 0 12 O
the DT 0 0 12 O
prothrombin NN 0 1 14 O
time NN 0 1 12 O
beyond IN 0 0 12 O
the DT 0 0 12 O
therapeutic JJ 0 1 6 O
range NN 0 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
concurrent JJ 0 1 1 O
levamisole NN 0 1 UNK B-Drug
and CC 0 0 12 O
warfarin NN 0 1 14 B-Drug
sodium NN 0 1 14 I-Drug
it PRP 0 0 12 O
is VBZ 1 0 12 O
suggested VBN 1 1 12 O
that IN 0 0 12 O
the DT 0 0 12 O
prothrombin NN 0 1 14 O
time NN 0 1 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
carefully RB 0 0 12 O
and CC 0 0 12 O
the DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
warfarin JJ 0 1 14 B-Drug
sodium NN 0 1 14 I-Drug
or CC 0 0 12 O
other JJ 0 0 12 O
coumarin JJ 0 1 UNK B-Group
- : 0 0 2 O
like IN 0 0 12 O
drugs NNS 1 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
adjusted VBN 1 1 1 O
accordingly RB 0 0 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
both DT 0 0 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
naratriptan JJ 0 1 13 B-Drug
with IN 0 0 12 O
other JJ 0 0 12 O
9 CD 0 0 2 B-Group
- : 0 0 2 O
HT9 NN 0 1 UNK I-Group
agonists NNS 1 1 UNK I-Group
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
evaluated VBN 1 1 1 O
in IN 0 0 12 O
migraine NN 0 1 6 O
patients NNS 1 1 6 O
. . 0 0 12 O

Although IN 0 0 12 O
there EX 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
no DT 0 0 12 O
reports NNS 1 1 1 O
of IN 0 0 12 O
such JJ 0 0 1 O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
methylergonovine NN 0 1 16 B-Drug
alone RB 0 1 12 O
potent JJ 0 1 UNK O
CYP NNP 0 1 UNK O
9A9 CD 0 0 UNK O
inhibitors NNS 1 1 14 O
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
methylergonovine NN 0 1 16 O
. . 0 0 12 O

In IN 0 0 2 O
addition NN 0 1 1 O
steady JJ 0 1 1 O
state NN 0 1 1 O
levels NNS 1 1 1 O
of IN 0 0 12 O
racemic JJ 0 1 14 O
citalopram NNS 0 1 16 B-Drug
were VBD 1 0 12 O
not RB 0 1 12 O
significantly RB 0 0 1 O
different JJ 0 1 1 O
in IN 0 0 12 O
poor JJ 0 1 12 O
metabolizers NNS 0 0 UNK O
and CC 0 0 12 O
extensive JJ 0 1 1 O
CYP9D9 NNP 0 0 UNK O
metabolizers NNS 0 0 UNK O
after IN 0 0 12 O
multiple JJ 0 1 1 O
- : 0 0 2 O
dose JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
citalopram JJ 0 1 16 B-Drug
suggesting NN 0 1 1 O
that IN 0 0 12 O
coadministration NN 0 1 UNK O
with IN 0 0 12 O
escitalopram NN 0 1 0 B-Drug
of IN 0 0 12 O
a DT 0 0 12 O
drug NN 0 1 1 O
that WDT 0 0 12 O
inhibits VBZ 1 1 UNK O
CYP9D9 NNP 0 0 UNK O
is VBZ 1 0 12 O
unlikely JJ 0 1 12 O
to TO 0 0 12 O
have VB 0 0 12 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
effects NNS 1 1 1 O
on IN 0 0 12 O
escitalopram JJ 0 1 0 B-Drug
metabolism NN 0 1 16 O
. . 0 0 12 O

Drugs NNS 0 1 2 O
That WDT 0 0 2 O
Inhibit NNP 0 1 UNK O
Aldehyde NNP 0 1 UNK O
Oxidase NNP 0 1 UNK O
The DT 0 0 2 O
aldehyde JJ 0 1 UNK O
oxidase NN 0 1 13 O
enzyme NN 0 1 14 O
system NN 0 1 1 O
is VBZ 1 0 12 O
less RBR 0 1 12 O
well RB 0 1 12 O
studied VBN 1 0 1 O
than IN 0 0 12 O
the DT 0 0 12 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
enzyme NN 0 1 14 O
system NN 0 1 1 O
. . 0 0 12 O

As IN 0 0 2 O
with IN 0 0 12 O
all DT 0 0 12 O
drugs NNS 1 1 6 O
the DT 0 0 12 O
potential JJ 0 1 1 O
exists NNS 0 1 UNK O
for IN 0 0 12 O
interaction NN 0 1 UNK O
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
by IN 0 0 12 O
a DT 0 0 12 O
variety NN 0 1 1 O
of IN 0 0 12 O
mechanisms NNS 1 1 UNK O
. . 0 0 12 O

In IN 0 0 2 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
indicate VBP 0 0 1 O
that IN 0 0 12 O
celecoxib NN 0 1 16 B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
an DT 0 0 12 O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
9C9 CD 0 0 UNK O
9C9 CD 0 0 UNK O
or CC 0 0 12 O
9A9 CD 0 0 UNK O
. . 0 0 12 O

If IN 0 0 12 O
these DT 0 0 12 O
preparations NNS 1 1 13 O
have VBP 0 0 12 O
been VBN 1 0 12 O
used VBN 1 1 12 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
advisable JJ 0 0 UNK O
not RB 0 1 12 O
to TO 0 0 12 O
start VB 0 1 12 O
therapy NN 0 1 6 O
with IN 0 0 12 O
DIFFERIN NNP 0 1 UNK B-Brand
Gel NNP 0 1 2 O
until IN 0 0 12 O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
such JJ 0 0 1 O
preparations NNS 1 1 13 O
in IN 0 0 12 O
the DT 0 0 12 O
skin NN 0 1 3 O
have VBP 0 0 12 O
subsided VBN 1 0 3 O
. . 0 0 12 O

Therefore RB 0 0 1 O
the DT 0 0 12 O
combination NN 0 1 1 O
of IN 0 0 12 O
ketoprofen NN 0 1 UNK B-Drug
and CC 0 0 12 O
probenecid NN 0 1 13 B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O

A DT 0 0 2 O
subset NN 0 1 UNK O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
- : 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
of IN 0 0 12 O
the DT 0 0 12 O
population NN 0 1 13 O
has VBZ 1 0 12 O
reduced VBN 1 1 1 O
activity NN 0 1 1 O
of IN 0 0 12 O
certain JJ 0 1 1 O
drug NN 0 1 1 O
metabolizing VBG 1 0 UNK O
enzymes NNS 1 1 14 O
such JJ 0 0 1 O
as IN 1 0 12 O
the DT 0 0 12 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
isozyme NN 0 1 UNK O
P9 NNP 0 1 UNK O
9D9 CD 0 0 UNK O
. . 0 0 12 O

When WRB 0 0 12 O
therapeutic JJ 0 1 6 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
furosemide JJ 0 1 0 B-Drug
propranolol JJ 0 1 16 B-Drug
dipyridamole NN 0 1 0 B-Drug
warfarin NN 0 1 14 B-Drug
quinidine NN 0 1 16 B-Drug
or CC 0 0 12 O
naproxen NN 0 1 16 B-Drug
were VBD 1 0 12 O
added VBN 1 1 12 O
to TO 0 0 12 O
human JJ 0 1 1 O
plasma NN 0 1 14 O
( ( 0 0 2 O
in IN 0 0 12 O
vitro NN 0 1 UNK O
) ) 0 0 2 O
the DT 0 0 12 O
plasma NN 0 1 14 O
protein NN 0 1 14 O
binding NN 0 1 1 O
of IN 0 0 12 O
nicardipine JJ 0 1 16 B-Drug
HCl NNP 0 0 14 I-Drug
was VBD 1 0 12 O
not RB 0 1 12 O
altered VBN 1 1 1 O
. . 0 0 12 O

Theophylline NN 0 1 UNK B-Drug
: : 0 0 2 O
DIFLUCAN NN 0 1 UNK B-Brand
increases VBZ 1 1 1 O
the DT 0 0 12 O
serum JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
theophylline NN 0 1 16 B-Drug
. . 0 0 12 O

Non NNP 0 1 2 B-Group
- : 0 0 2 O
steroidal NN 0 1 UNK I-Group
anti SYM 0 0 3 I-Group
- : 0 0 2 O
inflammatory NN 0 1 6 I-Group
drugs NNS 1 1 6 I-Group
( ( 0 0 2 O
but CC 0 0 12 O
not RB 0 1 12 O
aspirin JJ 0 1 14 B-Brand
) ) 0 0 2 O
: : 0 0 2 O
These DT 0 0 1 O
drugs NNS 1 1 6 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
very RB 0 1 12 O
high JJ 0 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
quinolones NNS 0 1 13 B-Group
have VBP 0 0 12 O
been VBN 1 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
provoke VB 0 0 UNK O
convulsions NNS 1 1 13 O
in IN 0 0 12 O
pre NN 0 1 1 O
- : 0 0 2 O
clinical JJ 0 1 6 O
studies NNS 1 1 1 O
. . 0 0 12 O

Ketoconazole NNP 0 1 UNK B-Drug
: : 0 0 2 O
Concomitant NNP 0 1 UNK O
use NN 0 1 1 O
of IN 0 0 12 O
ketoconazole NN 0 1 16 B-Drug
is VBZ 1 0 12 O
contraindicated VBN 1 1 14 O
. . 0 0 12 O

Warfarin NNP 0 1 0 B-Drug
and CC 0 0 12 O
Anticoagulants NNS 0 1 UNK B-Group
: : 0 0 2 O
Increased VBN 0 1 7 O
prothrombin NN 0 1 14 O
time NN 0 1 12 O
with IN 0 0 12 O
or CC 0 0 12 O
without IN 0 0 12 O
clinical JJ 0 1 6 O
bleeding NN 0 1 6 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
when WRB 0 0 12 O
cefixime NN 0 1 13 B-Drug
is VBZ 1 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
. . 0 0 12 O

Salicylates NNS 0 1 UNK B-Group
antagonize VBP 0 0 UNK O
the DT 0 0 12 O
uricosuric JJ 0 0 UNK O
action NN 0 1 13 O
of IN 0 0 12 O
. . 0 0 12 O
drugs NNS 1 1 6 O
used VBD 1 1 12 O
to TO 0 0 12 O
treat VB 0 1 12 O
gout NN 0 1 6 O
. . 0 0 12 O

Other JJ 0 0 2 O
strong JJ 0 1 12 O
inhibitors NNS 1 1 14 O
of IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
itraconazole NN 0 1 0 B-Drug
clarithromycin NN 0 1 13 B-Drug
nefazodone NN 0 1 16 B-Drug
troleandomycin NN 0 1 UNK B-Drug
ritonavir NN 0 1 16 B-Drug
nelfinavir NN 0 1 16 B-Drug
) ) 0 0 2 O
would MD 0 0 12 O
be VB 0 0 12 O
expected VBN 1 1 12 O
to TO 0 0 12 O
behave VB 0 0 UNK O
similarly RB 0 0 1 O
. . 0 0 12 O

The DT 0 0 2 O
clinical JJ 0 1 6 O
significance NN 0 1 13 O
of IN 0 0 12 O
this DT 0 0 12 O
interaction NN 0 1 UNK O
with IN 0 0 12 O
doxepin NN 0 1 16 B-Drug
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
systematically RB 0 0 UNK O
evaluated VBN 1 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
studies NNS 1 1 1 O
in IN 0 0 12 O
normal JJ 0 1 1 O
volunteers NNS 1 1 UNK O
there EX 0 0 12 O
was VBD 1 0 12 O
no DT 0 0 12 O
pharmacodynamic JJ 0 1 UNK O
interaction NN 0 1 UNK O
between IN 0 0 12 O
intravenous JJ 0 1 14 O
iloprost NN 0 1 13 B-Drug
and CC 0 0 12 O
either DT 0 1 12 O
nifedipine JJ 0 1 0 B-Drug
diltiazem NN 0 1 0 B-Drug
or CC 0 0 12 O
captopril NN 0 1 0 B-Drug
. . 0 0 12 O

These DT 0 0 1 O
drugs NNS 1 1 6 O
include VBP 0 1 1 O
the DT 0 0 12 O
thiazides NNS 1 1 UNK B-Group
and CC 0 0 12 O
other JJ 0 0 12 O
diuretics NNS 1 1 14 B-Group
corticosteroids NNS 1 1 14 B-Group
phenothiazines NNS 1 1 UNK B-Group
thyroid JJ 0 1 6 B-Group
products NNS 1 1 1 I-Group
estrogens VBZ 0 1 16 B-Group
oral JJ 0 1 6 O
contraceptives NNS 1 1 13 B-Group
phenytoin VBP 0 1 16 B-Drug
nicotinic JJ 0 1 13 B-Drug
acid NN 0 1 14 I-Drug
sympathomimetics NNS 0 1 13 B-Group
calcium NN 0 1 14 B-Group
channel SYM 0 1 1 I-Group
- : 0 0 2 O
blocking VBG 1 1 UNK I-Group
drugs NNS 1 1 6 I-Group
and CC 0 0 12 O
isoniazid NN 0 1 13 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
presence NN 0 1 1 O
of IN 0 0 12 O
food NN 0 1 12 O
in IN 0 0 12 O
the DT 0 0 12 O
stomach NN 0 1 6 O
does VBZ 1 0 12 O
not RB 0 1 12 O
alter VB 0 1 13 O
the DT 0 0 12 O
bioavailability NN 0 1 UNK O
of IN 0 0 12 O
PRINIVIL NNP 0 1 UNK B-Brand
. . 0 0 12 O

Therefore RB 0 0 1 O
such JJ 0 0 1 O
combined JJ 0 1 1 O
treatment NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
approached VBN 1 1 UNK O
with IN 0 0 12 O
caution NN 0 0 1 O
and CC 0 0 12 O
patients NNS 1 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
closely RB 0 0 1 O
when WRB 0 0 12 O
Clozapine NNP 0 1 0 B-Drug
is VBZ 1 0 12 O
combined VBN 1 1 1 O
with IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
particularly RB 0 0 1 O
with IN 0 0 12 O
fluvoxamine NN 0 1 16 B-Drug
. . 0 0 12 O

. . 0 0 12 O

The DT 0 0 2 O
effects NNS 1 1 1 O
of IN 0 0 12 O
indinavir JJ 0 1 16 B-Drug
zidovudine NN 0 1 13 B-Drug
or CC 0 0 12 O
rifabutin NN 0 1 13 B-Drug
on IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
megestrol NN 0 1 16 B-Drug
acetate NN 0 1 14 I-Drug
were VBD 1 0 12 O
not RB 0 1 12 O
studied VBN 1 0 1 O
. . 0 0 12 O

Exjade NNP 0 1 UNK B-Brand
tablets NNS 1 1 3 O
for IN 0 0 12 O
oral JJ 0 1 6 O
suspension NN 0 1 3 O
can MD 0 0 12 O
be VB 0 0 12 O
dispersed VBN 1 1 UNK O
in IN 0 0 12 O
water NN 0 1 3 O
orange NN 0 1 16 O
juice NN 0 1 3 O
or CC 0 0 12 O
apple NN 0 1 UNK O
juice NN 0 1 3 O
. . 0 0 12 O

Anagrelide NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
metabolized VBN 1 1 UNK O
at IN 0 0 12 O
least JJS 0 1 12 O
in IN 0 0 12 O
part NN 0 1 12 O
by IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
. . 0 0 12 O

Coadministration NN 0 1 UNK O
of IN 0 0 12 O
LEXAPRO NNP 0 1 UNK B-Brand
and CC 0 0 12 O
metoprolol NN 0 1 0 B-Drug
had VBD 1 0 12 O
no DT 0 0 12 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
effects NNS 1 1 1 O
on IN 0 0 12 O
blood NN 0 1 6 O
pressure NN 0 1 1 O
or CC 0 0 12 O
heart NN 0 1 12 O
rate NN 0 1 1 O
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
not RB 0 1 12 O
clear JJ 0 1 12 O
whether IN 0 0 12 O
this DT 0 0 12 O
represents VBZ 1 1 1 O
an DT 0 0 12 O
interaction NN 0 1 UNK O
with IN 0 0 12 O
TIKOSYN NNP 0 1 UNK B-Brand
or CC 0 0 12 O
the DT 0 0 12 O
presence NN 0 1 1 O
of IN 0 0 12 O
more JJR 0 1 12 O
severe JJ 0 1 6 O
structural JJ 0 1 1 O
heart NN 0 1 12 O
disease NN 0 1 6 O
in IN 0 0 12 O
patients NNS 1 1 6 O
on IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
; : 0 0 2 O

FLUOTHANE NNP 0 1 UNK B-Brand
augments VBZ 1 1 UNK O
the DT 0 0 12 O
action NN 0 1 13 O
of IN 0 0 12 O
non JJ 0 1 1 B-Group
- : 0 0 2 O
depolarising VBG 1 0 UNK I-Group
muscle NN 0 1 6 I-Group
relaxants NNS 1 0 13 I-Group
and CC 0 0 12 O
the DT 0 0 12 O
muscle NN 0 1 6 O
relaxant JJ 0 0 0 O
effects NNS 1 1 1 O
of IN 0 0 12 O
aminoglycosides NNS 0 1 13 B-Group
. . 0 0 12 O

Concomitant JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
FACTIVE NNP 0 1 UNK B-Brand
and CC 0 0 12 O
calcium NN 0 1 14 B-Drug
carbonate NN 0 1 14 I-Drug
cimetidine NN 0 1 13 B-Drug
omeprazole NN 0 1 0 B-Drug
or CC 0 0 12 O
an DT 0 0 12 O
estrogen NN 0 1 6 B-Group
/ NN 0 0 2 O
progesterone NN 0 1 13 B-Drug
oral JJ 0 1 6 O
contraceptive NN 0 1 13 B-Group
produced VBN 1 0 1 O
minor JJ 0 1 1 O
changes NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
gemifloxacin NN 0 1 UNK B-Drug
which WDT 0 0 12 O
were VBD 1 0 12 O
considered VBN 1 1 1 O
to TO 0 0 12 O
be VB 0 0 12 O
without IN 0 0 12 O
clinical JJ 0 1 6 O
significance NN 0 1 13 O
. . 0 0 12 O

Similarly RB 0 0 1 O
of IN 0 0 12 O
over IN 0 1 12 O
9 CD 0 0 2 O
patients NNS 1 1 6 O
enrolled VBN 1 0 1 O
in IN 0 0 12 O
a DT 0 0 12 O
study NN 0 1 1 O
comparing VBG 1 1 UNK O
once RB 0 0 12 O
- : 0 0 2 O
monthly JJ 0 1 1 O
with IN 0 0 12 O
daily JJ 0 1 12 O
dosing VBG 1 0 14 O
regimens NNS 1 1 UNK O
of IN 0 0 12 O
ibandronate JJ 0 1 13 B-Drug
9 CD 0 0 2 O
% NN 0 0 18 O
of IN 0 0 12 O
patients NNS 1 1 6 O
used VBN 1 1 12 O
anti JJ 0 0 3 O
- : 0 0 2 O
peptic JJ 0 1 6 O
agents NNS 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
results NNS 1 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
study NN 0 1 1 O
of IN 0 0 12 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
ethambutol NN 0 1 16 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
) ) 0 0 2 O
with IN 0 0 12 O
an DT 0 0 12 O
aluminum NN 0 1 16 B-Drug
hydroxide NN 0 1 14 I-Drug
containing VBG 1 1 1 O
antacid NN 0 1 UNK B-Group
to TO 0 0 12 O
9 CD 0 0 2 O
patients NNS 1 1 6 O
with IN 0 0 12 O
tuberculosis NN 0 1 6 O
showed VBD 1 1 12 O
a DT 0 0 12 O
reduction NN 0 1 1 O
of IN 0 0 12 O
mean JJ 0 1 12 O
serum NN 0 1 14 O
concentrations NNS 1 1 13 O
and CC 0 0 12 O
urinary JJ 0 1 6 O
excretion NN 0 1 14 O
of IN 0 0 12 O
ethambutol NN 0 1 16 B-Drug
of IN 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
respectively RB 0 0 1 O
suggesting VBG 1 1 1 O
that IN 0 0 12 O
the DT 0 0 12 O
oral JJ 0 1 6 O
absorption NN 0 1 1 O
of IN 0 0 12 O
ethambutol NN 0 1 16 B-Drug
may MD 0 0 1 O
be VB 0 0 12 O
reduced VBN 1 1 1 O
by IN 0 0 12 O
these DT 0 0 12 O
antacid JJ 0 1 UNK B-Group
products NNS 1 1 1 I-Group
. . 0 0 12 O

The DT 0 0 2 O
AUC NNP 0 1 UNK O
and CC 0 0 12 O
Cmax NNP 0 1 UNK O
of IN 0 0 12 O
descarboethoxyloratadine NN 0 1 UNK B-Drug_n
an DT 0 0 12 O
active JJ 0 1 1 O
metabolite NN 0 1 UNK O
averaged VBD 1 1 18 O
9 CD 0 0 2 O
% NN 0 0 18 O
( ( 0 0 2 O
9 CD 0 0 2 O
S.D NNP 0 1 UNK O
. . 0 0 12 O
) ) 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
( ( 0 0 2 O
9 CD 0 0 2 O
S.D NNP 0 1 UNK O
. . 0 0 12 O
) ) 0 0 2 O
respectively RB 0 0 1 O
. . 0 0 12 O

Drug NN 0 1 2 O
Effect NN 0 1 UNK O

The DT 0 0 2 O
cause NN 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
reported VBN 1 1 1 O
association NN 0 1 1 O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
established VBN 1 1 1 O
. . 0 0 12 O

Digitalis NNP 0 1 15 B-Group
Glycosides NNP 0 1 UNK I-Group
: : 0 0 2 O
Diuretic JJ 0 1 UNK B-Group
- : 0 0 2 O
induced JJ 0 1 6 O
hypokalemia NN 0 1 14 O
can MD 0 0 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
sensitivity NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
myocardium NN 0 1 8 O
to TO 0 0 12 O
digitalis VB 0 1 14 B-Group
. . 0 0 12 O

Nitrates NNS 0 1 UNK B-Group
: : 0 0 2 O
The DT 0 0 2 O
concomitant NN 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
Bepridil NNP 0 1 UNK B-Drug
with IN 0 0 12 O
long JJ 0 1 12 O
- : 0 0 2 O
and CC 0 0 12 O
short JJ 0 1 12 O
- : 0 0 2 O
acting VBG 1 1 12 O
nitrates NNS 1 1 14 B-Group
has VBZ 1 0 12 O
been VBN 1 0 12 O
safely RB 0 0 UNK O
tolerated VBN 1 0 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
stable JJ 0 1 1 O
angina JJ 0 1 6 O
pectoris NN 0 0 8 O
. . 0 0 12 O

Others NNS 0 1 UNK O
reported VBD 1 1 1 O
: : 0 0 2 O
Neuropsychiatric NN 0 0 UNK O
: : 0 0 2 O
Confusion NN 0 1 UNK O
( ( 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
headache NN 0 1 6 O
( ( 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
insomnia NN 0 1 6 O
( ( 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
; : 0 0 2 O

- : 0 0 2 O
Chloroquine NN 0 1 UNK B-Drug
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
Aralen NNP 0 1 UNK B-Brand
) ) 0 0 2 O
or CC 0 0 12 O

Urinary JJ 0 1 7 B-Group
acidifying VBG 1 0 13 I-Group
agents NNS 1 1 1 I-Group
( ( 0 0 2 O
ammonium NN 0 1 13 B-Drug
chloride NN 0 1 14 I-Drug
sodium NN 0 1 14 B-Drug
acid NN 0 1 14 I-Drug
phosphate NN 0 1 14 I-Drug
etc FW 0 1 12 O
. . 0 0 12 O
) ) 0 0 2 O
increase VB 0 1 1 O
the DT 0 0 12 O
concentration NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
ionized JJ 0 1 14 O
species NNS 1 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
amphetamine NN 0 1 13 B-Drug
molecule NN 0 1 UNK O
thereby RB 0 0 UNK O
increasing VBG 1 1 1 O
urinary JJ 0 1 6 O
excretion NN 0 1 14 O
. . 0 0 12 O

A DT 0 0 2 O
similar JJ 0 1 1 O
effect NN 0 1 1 O
would MD 0 0 12 O
be VB 0 0 12 O
expected VBN 1 1 12 O
with IN 0 0 12 O
eszopiclone NN 0 1 13 B-Drug
. . 0 0 12 O

Acarbose NNP 0 1 UNK B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
change VB 0 1 1 O
the DT 0 0 12 O
bioavailabillty NN 0 0 UNK O
digoxin NN 0 1 14 B-Drug
when WRB 0 0 12 O
they PRP 0 0 12 O
are VBP 1 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
administered VBD 1 1 1 O
which WDT 0 0 12 O
may MD 0 0 1 O
require VB 0 0 1 O
digoxin NN 0 1 14 B-Drug
dose JJ 0 1 6 O
adjustment NN 0 1 1 O
. . 0 0 12 O

Aspirin NN 0 1 0 B-Brand
: : 0 0 2 O
In IN 0 0 2 O
normal JJ 0 1 1 O
volunteers NNS 1 1 UNK O
a DT 0 0 12 O
small JJ 0 1 12 O
decrease NN 0 1 1 O
in IN 0 0 12 O
diflunisal NN 0 1 13 B-Drug
levels NNS 1 1 1 O
was VBD 1 0 12 O
observed VBN 1 1 1 O
when WRB 0 0 12 O
multiple JJ 0 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
diflunisal NN 0 1 13 B-Drug
and CC 0 0 12 O
aspirin NN 0 1 14 B-Brand
were VBD 1 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
. . 0 0 12 O

For IN 0 0 2 O
example NN 0 1 1 O
when WRB 0 0 12 O
vitamin NN 0 1 6 B-Group
K NNP 0 1 2 I-Group
antagonists NNS 1 1 13 I-Group
are VBP 1 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
nilutamide JJ 0 1 UNK B-Drug
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
should MD 0 0 12 O
be VB 0 0 12 O
carefully RB 0 0 12 O
monitored VBN 1 1 1 O
and CC 0 0 12 O
if IN 0 0 12 O
necessary JJ 0 0 1 O
the DT 0 0 12 O
dosage NN 0 1 0 O
of IN 0 0 12 O
vitamin NN 0 1 6 B-Group
K NNP 0 1 2 I-Group
antagonists NNS 1 1 13 I-Group
should MD 0 0 12 O
be VB 0 0 12 O
reduced VBN 1 1 1 O
. . 0 0 12 O

Possible JJ 0 1 2 O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
drugs NNS 1 1 6 O
known VBN 1 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
via IN 0 0 1 O
competitive JJ 0 1 UNK O
inhibition NN 0 1 13 O
such JJ 0 0 1 O
as IN 1 0 12 O
theophylline NN 0 1 16 B-Drug
and CC 0 0 12 O
imipramine NN 0 1 0 B-Drug
may MD 0 0 1 O
also RB 0 0 12 O
occur VB 0 1 1 O
. . 0 0 12 O

Physicians NNS 0 1 2 O
needing VBG 1 1 12 O
to TO 0 0 12 O
treatpatients NNS 0 0 UNK O
co VB 0 1 12 O
- : 0 0 2 O
infected VBN 1 1 6 O
with IN 0 0 12 O
tuberculosis NN 0 1 6 O
andusing VBG 0 0 UNK O
a DT 0 0 12 O
nevirapine JJ 0 1 13 B-Drug
containing VBG 1 1 1 O
regimen NNS 0 1 6 O
mayuse RB 0 0 UNK O
rifabutin JJ 0 1 13 B-Drug
instead RB 0 0 12 O
. . 0 0 12 O

Formal JJ 0 1 2 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
of IN 0 0 12 O
TNKase NNP 0 1 UNK B-Brand
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
performed VBN 1 1 1 O
. . 0 0 12 O

Effect NN 0 1 UNK O
of IN 0 0 12 O
Clonazepam NNP 0 1 0 B-Drug
on IN 0 0 12 O
the DT 0 0 12 O
Pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
Other JJ 0 0 2 O
Drugs NNS 0 1 2 O
: : 0 0 2 O
Clonazepam NN 0 1 0 B-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
appear VB 0 1 12 O
to TO 0 0 12 O
alter VB 0 1 13 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
phenytoin JJ 0 1 16 B-Drug
carbamazepine NN 0 1 16 B-Drug
or CC 0 0 12 O
phenobarbital NN 0 1 16 B-Drug
. . 0 0 12 O

An DT 0 0 2 O
individual NN 0 1 1 O
who WP 0 0 12 O
is VBZ 1 0 12 O
stable JJ 0 1 1 O
on IN 0 0 12 O
a DT 0 0 12 O
given VBN 1 1 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
TCA NNP 0 1 13 B-Group
may MD 0 0 1 O
become VB 0 0 12 O
abruptly RB 0 0 UNK O
toxic JJ 0 1 1 O
when WRB 0 0 12 O
given VBN 1 1 12 O
one CD 0 1 12 O
of IN 0 0 12 O
these DT 0 0 12 O
inhibiting VBG 1 1 UNK O
drugs NNS 1 1 6 O
as IN 1 0 12 O
concomitant NN 0 1 6 O
therapy NN 0 1 6 O
. . 0 0 12 O

- : 0 0 2 O
Probenecid NN 0 1 UNK B-Drug
: : 0 0 2 O
Pretreatment NN 0 1 UNK O
with IN 0 0 12 O
probenecid NN 0 1 13 B-Drug
reduces NNS 0 0 UNK O
both CC 0 0 12 O
the DT 0 0 12 O
natriuresis NN 0 1 UNK O
and CC 0 0 12 O
hyperreninemia NN 0 1 UNK O
produced VBN 1 0 1 O
by IN 0 0 12 O
bumetanide NN 0 1 16 B-Drug
. . 0 0 12 O

DISULFIRAM NNP 0 1 UNK B-Drug
SHOULD NNP 0 0 UNK O
BE NNP 0 0 11 O
USED NNP 0 1 11 O
WITH NNP 0 0 11 O
CAUTION NNP 0 0 UNK O
IN NNP 0 0 11 O
THOSE NNP 0 0 UNK O
PATIENTS NNP 0 1 UNK O
REVEIVING NNP 0 0 UNK O
PHENYTOIN NNP 0 1 UNK B-Drug
AND NNP 0 0 11 O
ITS NNP 0 0 UNK O
CONGENERS NNP 0 1 UNK O
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
not RB 0 1 12 O
known VBN 1 1 12 O
whether IN 0 0 12 O
ezetimibe NN 0 1 16 B-Drug
is VBZ 1 0 12 O
excreted VBN 1 1 UNK O
into IN 0 0 12 O
human JJ 0 1 1 O
breast NN 0 1 6 O
milk NN 0 1 3 O
; : 0 0 2 O

Other JJ 0 0 2 O
Drugs NNS 0 1 2 O
: : 0 0 2 O
Based VBN 0 1 2 O
on IN 0 0 12 O
the DT 0 0 12 O
results NNS 1 1 1 O
of IN 0 0 12 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
no DT 0 0 12 O
dosage NN 0 1 0 O
adjustment NN 0 1 1 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
when WRB 0 0 12 O
SUSTIVA NNP 0 1 UNK B-Brand
( ( 0 0 2 O
efavirenz NN 0 1 13 B-Drug
) ) 0 0 2 O
is VBZ 1 0 12 O
given VBN 1 1 12 O
with IN 0 0 12 O
the DT 0 0 12 O
following NN 0 1 1 O
: : 0 0 2 O
aluminum NN 0 1 16 B-Group
magnesium NN 0 1 14 I-Group
hydroxide NN 0 1 14 I-Group
antacids NNS 1 1 14 I-Group
azithromycin VBP 0 1 0 B-Drug
cetirizine JJ 0 1 13 B-Drug
famotidine JJ 0 1 0 B-Drug
fluconazole JJ 0 1 0 B-Drug
lamivudine NN 0 1 16 B-Drug
lorazepam NN 0 1 0 B-Drug
nelfinavir JJ 0 1 16 B-Drug
paroxetine NN 0 1 16 B-Drug
and CC 0 0 12 O
zidovudine NN 0 1 13 B-Drug
. . 0 0 12 O

Amphotericin NNP 0 1 0 B-Drug
B NNP 0 0 2 I-Drug
or CC 0 0 12 O
potassium NN 0 1 14 B-Group
- : 0 0 2 O
depleting NN 0 1 UNK I-Group
diuretics NNS 1 1 14 I-Group
( ( 0 0 2 O
benzothiadiazines NNS 0 1 UNK B-Group
and CC 0 0 12 O
related JJ 0 1 1 O
drugs NNS 1 1 6 O
ethacrynic JJ 0 0 16 B-Drug
acid NN 0 1 14 I-Drug
and CC 0 0 12 O
furosemide NN 0 1 0 B-Drug
) ) 0 0 2 O
enhanced VBD 1 1 1 O
hypokalemia NN 0 1 14 O
. . 0 0 12 O

Paroxetine NN 0 1 0 B-Drug
: : 0 0 2 O
Coadministration NN 0 1 UNK O
of IN 0 0 12 O
single JJ 0 1 12 O
doses NNS 1 1 6 O
of IN 0 0 12 O
eszopiclone NN 0 1 13 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
and CC 0 0 12 O
paroxetine NN 0 1 16 B-Drug
9 CD 0 0 2 O
mg JJ 0 1 0 O
daily RB 0 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
produced VBD 1 0 1 O
no DT 0 0 12 O
pharmacokinetic JJ 0 1 UNK O
or CC 0 0 12 O
pharmacodynamic JJ 0 1 UNK O
interaction NN 0 1 UNK O
. . 0 0 12 O

These DT 0 0 1 O
results NNS 1 1 1 O
suggest VBP 0 1 1 O
that IN 0 0 12 O
the DT 0 0 12 O
analgesic JJ 0 1 13 O
effect NN 0 1 1 O
of IN 0 0 12 O
STADOL NNP 0 1 UNK B-Brand
NS NNP 0 1 13 I-Brand
may MD 0 0 1 O
be VB 0 0 12 O
diminished VBN 1 1 1 O
when WRB 0 0 12 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
administered VBN 1 1 1 O
shortly RB 0 0 12 O
after IN 0 0 12 O
sumatriptan JJ 0 1 16 B-Drug
nasal NN 0 1 6 O
spray NN 0 1 3 O
but CC 0 0 12 O
by IN 0 0 12 O
9 CD 0 0 2 O
minutes NNS 1 1 12 O
any DT 0 0 12 O
such JJ 0 0 1 O
reduction NN 0 1 1 O
in IN 0 0 12 O
effect NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
minimal JJ 0 1 1 O
. . 0 0 12 O

Patients NNS 0 1 7 O
currently RB 0 1 12 O
receiving VBG 1 1 1 O
diltiazem NNS 0 1 0 B-Drug
therapy NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
carefully RB 0 0 12 O
monitored VBN 1 1 1 O
for IN 0 0 12 O
a DT 0 0 12 O
change NN 0 1 1 O
in IN 0 0 12 O
pharmacological JJ 0 1 14 O
effect NN 0 1 1 O
when WRB 0 0 12 O
initiating NN 0 1 1 O
and CC 0 0 12 O
discontinuing VBG 1 1 6 O
therapy NN 0 1 6 O
with IN 0 0 12 O
cimetidine NN 0 1 13 B-Drug
. . 0 0 12 O

( ( 0 0 2 O
9 CD 0 0 2 O
mg RB 0 1 0 O
Q9h NNP 0 1 UNK O
) ) 0 0 2 O

Theophylline NNP 0 1 UNK B-Drug
serum NN 0 1 14 O
levels NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
and CC 0 0 12 O
appropriate JJ 0 1 1 O
dose NN 0 1 6 O
adjustments NNS 1 1 1 O
considered VBN 1 1 1 O
for IN 0 0 12 O
patients NNS 1 1 6 O
given VBN 1 1 12 O
both DT 0 0 12 O
theophylline NN 0 1 16 B-Drug
and CC 0 0 12 O
PEGASYS NNP 0 1 UNK B-Brand
. . 0 0 12 O

The DT 0 0 2 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
nelfinavir NNS 0 1 16 B-Drug
are VBP 1 0 12 O
not RB 0 1 12 O
altered VBN 1 1 1 O
to TO 0 0 12 O
a DT 0 0 12 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
degree NN 0 1 1 O
when WRB 0 0 12 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
a DT 0 0 12 O
light JJ 0 1 3 O
meal NN 0 1 12 O
9 CD 0 0 2 O
hour NN 0 1 12 O
after IN 0 0 12 O
VIDEX NNP 0 1 UNK B-Brand
. . 0 0 12 O

AMEVIVE NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
not RB 0 1 12 O
indicated VBN 1 1 1 O
for IN 0 0 12 O
pediatric JJ 0 1 6 O
patients NNS 1 1 6 O
. . 0 0 12 O

cimetidine NN 0 1 13 B-Drug
) ) 0 0 2 O
and CC 0 0 12 O
many JJ 0 0 12 O
that WDT 0 0 12 O
are VBP 1 0 12 O
substrates VBZ 0 1 UNK O
for IN 0 0 12 O
P9 NNP 0 1 UNK O
9D9 CD 0 0 UNK O
( ( 0 0 2 O
many JJ 0 0 12 O
other JJ 0 0 12 O
antidepressants NNS 1 1 13 B-Group
phenothiazines NNS 1 1 UNK B-Group
and CC 0 0 12 O
the DT 0 0 12 O
Type NNP 0 1 2 O
9C CD 0 0 UNK O
antiarrhythrnics NNS 0 0 UNK O
propatenone NN 0 0 UNK O
and CC 0 0 12 O
flecainide NN 0 1 16 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

Chloramphenicol NNP 0 1 UNK B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
be VB 0 0 12 O
antagonistic JJ 0 1 UNK O
to TO 0 0 12 O
beta VB 0 1 16 B-Group
- : 0 0 2 O
lactam NN 0 1 UNK I-Group
antibiotics NNS 1 1 6 I-Group
including VBG 1 1 1 O
ceftazidime NN 0 1 14 B-Drug
based VBN 1 1 1 O
on IN 0 0 12 O
in IN 0 0 12 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
and CC 0 0 12 O
time NN 0 1 12 O
kill VB 0 1 12 O
curves NNS 1 1 UNK O
with IN 0 0 12 O
enteric JJ 0 1 14 O
gram NN 0 1 16 O
- : 0 0 2 O
negative JJ 0 1 1 O
bacilli NN 1 1 16 O
. . 0 0 12 O

. . 0 0 12 O

Clinical JJ 0 1 7 O
comments NNS 1 1 12 O
about IN 0 1 12 O
possible JJ 0 1 1 O
dosage NN 0 1 0 O
modifications NNS 1 1 UNK O
based VBN 1 1 1 O
on IN 0 0 12 O
these DT 0 0 12 O
pharmacokinetic JJ 0 1 UNK O
changes NNS 1 1 1 O
are VBP 1 0 12 O
listed VBN 1 1 1 O
in IN 0 0 12 O
Table JJ 0 1 UNK O
9 CD 0 0 2 O
. . 0 0 12 O

Therefore RB 0 0 1 O
caution NN 0 0 1 O
should MD 0 0 12 O
be VB 0 0 12 O
exercised VBN 1 1 1 O
with IN 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
and CC 0 0 12 O
FLOMAX NNP 0 1 UNK B-Brand
capsules NNS 1 1 3 O
. . 0 0 12 O

Ergot NNP 0 1 UNK B-Group
- : 0 0 2 O
Containing VBG 0 1 2 I-Group
Drugs NNS 0 1 2 I-Group
: : 0 0 2 O
These DT 0 0 1 O
drugs NNS 1 1 6 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
cause VB 0 1 12 O
prolonged JJ 0 1 6 O
vasospastic JJ 0 0 UNK O
reactions NNS 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
risk NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
potential JJ 0 1 1 O
interaction NN 0 1 UNK O
between IN 0 0 12 O
NovoSeven NNP 0 1 UNK B-Brand
and CC 0 0 12 O
coagulation NN 0 1 14 B-Group
factor NN 0 1 1 I-Group
concentrates NNS 1 1 UNK O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
adequately RB 0 0 1 O
evaluated VBN 1 1 1 O
in IN 0 0 12 O
preclinical JJ 0 1 UNK O
or CC 0 0 12 O
clinical JJ 0 1 6 O
studies NNS 1 1 1 O
. . 0 0 12 O

one CD 0 1 12 O
fatality NN 0 1 UNK O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
from IN 0 0 12 O
hypoglycemia NN 0 1 6 O
in IN 0 0 12 O
association NN 0 1 1 O
with IN 0 0 12 O
combined JJ 0 1 1 O
DIFLUCAN NNP 0 1 UNK B-Brand
and CC 0 0 12 O
glyburide NN 0 1 16 B-Drug
use NN 0 1 1 O
. . 0 0 12 O

Coadministration NN 0 1 UNK O
of IN 0 0 12 O
VIRACEPT NNP 0 1 UNK B-Brand
and CC 0 0 12 O
drugs NNS 1 1 6 O
primarily RB 0 0 1 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
CYP9A NNP 0 0 UNK O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
dihydropyridine NN 0 1 UNK B-Group
calcium NN 0 1 14 I-Group
channel NN 0 1 1 I-Group
blockers NNS 1 0 6 I-Group
) ) 0 0 2 O
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
increased JJ 0 1 1 O
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
the DT 0 0 12 O
other JJ 0 0 12 O
drug NN 0 1 1 O
that WDT 0 0 12 O
could MD 0 0 12 O
increase VB 0 1 1 O
or CC 0 0 12 O
prolong VB 0 0 13 O
both DT 0 0 12 O
its PRP$ 1 0 12 O
therapeutic NN 0 1 6 O
and CC 0 0 12 O
adverse JJ 0 0 1 O
effects NNS 1 1 1 O
. . 0 0 12 O

Propranolol NNP 0 1 0 B-Drug
increases VBZ 1 1 1 O
hydralazines NNS 1 0 UNK B-Drug
serum JJ 0 1 14 O
concentrations NNS 1 1 13 O
. . 0 0 12 O

The DT 0 0 2 O
effect NN 0 1 1 O
of IN 0 0 12 O
foods NNS 1 1 1 O
highly RB 0 1 1 O
fortified VBN 1 0 3 O
with IN 0 0 12 O
elemental JJ 0 1 1 O
iron NN 0 1 3 B-Drug_n
( ( 0 0 2 O
primarily RB 0 0 1 O
iron VBZ 0 1 3 B-Drug_n
- : 0 0 2 O
fortified VBN 1 0 3 O
breakfast NN 0 1 12 O
cereals NNS 1 1 UNK O
) ) 0 0 2 O
on IN 0 0 12 O
cefdinir NN 0 1 UNK B-Drug
absorption NN 0 1 1 O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
studied VBN 1 0 1 O
. . 0 0 12 O

HMG NNP 0 0 UNK B-Group
- : 0 0 2 O
CoA NNP 0 0 UNK I-Group
Reductase NNP 0 1 UNK I-Group
inhibitors NNS 1 1 14 I-Group
: : 0 0 2 O
lovastatin NN 0 1 13 B-Drug
simvastatin NN 0 1 0 B-Drug

Calcium NNP 0 1 7 B-Group
Channel NNP 0 1 2 I-Group
Blockers NNP 0 0 UNK I-Group
Dihydropyridine NNP 0 1 UNK B-Group
: : 0 0 2 O
e.g. JJ 0 0 UNK O
felodipine NN 0 1 13 B-Drug
nifedipine NN 0 1 0 B-Drug
nicardipine NN 0 1 16 B-Drug

The DT 0 0 2 O
clinical JJ 0 1 6 O
significance NN 0 1 13 O
of IN 0 0 12 O
this DT 0 0 12 O
finding NN 0 1 12 O
is VBZ 1 0 12 O
not RB 0 1 12 O
clear JJ 0 1 12 O
. . 0 0 12 O

or CC 0 0 12 O
with IN 0 0 12 O
multivitamins NNS 1 1 14 B-Group
containing VBG 1 1 1 O
zinc NN 0 1 14 B-Drug
may MD 0 0 1 O
substantially RB 0 0 1 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
drug NN 0 1 1 O
absorption NN 0 1 1 O
and CC 0 0 12 O
result NN 0 1 1 O
in IN 0 0 12 O
insufficient JJ 0 1 1 O
plasma NN 0 1 14 O
and CC 0 0 12 O
tissue NN 0 1 6 O
quinolone NN 0 1 UNK B-Group
concentrations NNS 1 1 13 O
. . 0 0 12 O

Agents NNS 0 1 2 O
Causing VBG 0 1 7 O
Renin NNP 0 1 UNK O
Release NN 0 1 2 O
: : 0 0 2 O
The DT 0 0 2 O
antihypertensive JJ 0 1 14 O
effect NN 0 1 1 O
of IN 0 0 12 O
enalapril NN 0 1 0 B-Drug
and CC 0 0 12 O
enalapril NN 0 1 0 B-Drug
IV NNP 0 1 2 O
is VBZ 1 0 12 O
augmented VBN 1 1 1 O
by IN 0 0 12 O
antihypertensive JJ 0 1 14 B-Group
agents NNS 1 1 1 I-Group
that WDT 0 0 12 O
cause VBP 0 1 12 O
renin JJ 0 1 UNK O
release NN 0 1 12 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
diuretics NNS 1 1 14 B-Group
) ) 0 0 2 O
. . 0 0 12 O

Even RB 0 0 UNK O
so RB 0 1 12 O
dextromethorphan JJ 0 1 16 B-Drug
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
in IN 0 0 12 O
the DT 0 0 12 O
presence NN 0 1 1 O
of IN 0 0 12 O
high JJ 0 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
valdecoxib NN 0 1 13 B-Drug
were VBD 1 0 12 O
almost RB 0 1 12 O
9 CD 0 0 2 O
- : 0 0 2 O
fold NN 0 1 3 O
lower JJR 1 1 1 O
than IN 0 0 12 O
those DT 0 0 12 O
seen VBN 1 1 12 O
in IN 0 0 12 O
CYP NNP 0 1 UNK O
9D9 CD 0 0 UNK O
poor JJ 0 1 12 O
metabolizers NNS 0 0 UNK O
suggesting VBG 1 1 1 O
that IN 0 0 12 O
dose JJ 0 1 6 O
adjustment NN 0 1 1 O
is VBZ 1 0 12 O
not RB 0 1 12 O
necessary JJ 0 0 1 O
. . 0 0 12 O

Ethinyl NNP 0 0 UNK B-Drug
estradiol VBZ 0 1 13 I-Drug
Norethindrone NN 0 1 UNK B-Drug

Binding VBG 0 1 UNK O
to TO 0 0 12 O
plasma VB 0 1 14 O
proteins NNS 1 1 14 O
is VBZ 1 0 12 O
reduced VBN 1 1 1 O
by IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
and CC 0 0 12 O
clotibrate NN 0 0 UNK O
and CC 0 0 12 O
increased VBN 1 1 1 O
by IN 0 0 12 O
tolbutamide NN 0 1 UNK B-Drug
. . 0 0 12 O

Some DT 0 0 2 O
reports NNS 1 1 1 O
have VBP 0 0 12 O
shown VBN 1 1 1 O
that IN 0 0 12 O
the DT 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
thiazides NNS 1 1 UNK B-Group
with IN 0 0 12 O
vitamin NN 0 1 6 B-Group
D NNP 0 1 2 I-Group
causes VBZ 1 1 6 O
hypercalcemia NN 0 1 8 O
. . 0 0 12 O

Reported VBN 0 1 2 O
examples NNS 1 1 UNK O
include VBP 0 1 1 O
the DT 0 0 12 O
following JJ 0 1 1 O
: : 0 0 2 O
Protease JJ 0 1 UNK B-Group
Inhibitors NNS 0 1 7 I-Group
: : 0 0 2 O
Protease NN 0 1 UNK B-Group
inhibitors NNS 1 1 14 I-Group
are VBP 1 0 12 O
known VBN 1 1 12 O
to TO 0 0 12 O
inhibit VB 0 1 13 O
CYP9A9 NNP 0 0 UNK O
to TO 0 0 12 O
varying VBG 1 0 1 O
degrees NNS 1 1 1 O
. . 0 0 12 O

Studies NNS 0 1 2 O
in IN 0 0 12 O
vitro NN 0 1 UNK O
show NN 0 1 12 O
that IN 0 0 12 O
caspofungin NN 0 1 14 B-Drug
acetate NN 0 1 14 I-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
an DT 0 0 12 O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
any DT 0 0 12 O
enzyme NN 0 1 14 O
in IN 0 0 12 O
the DT 0 0 12 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
( ( 0 0 2 O
CYP NNP 0 1 UNK O
) ) 0 0 2 O
system NN 0 1 1 O
. . 0 0 12 O

No DT 0 0 2 O
well NN 0 1 12 O
- : 0 0 2 O
known VBN 1 1 12 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
glutamic JJ 0 0 14 B-Drug
acid NN 0 1 14 I-Drug

Since IN 0 1 2 O
blood NN 0 1 6 O
level NN 0 1 1 O
of IN 0 0 12 O
calcitriol NN 0 1 14 B-Drug
/ NNP 0 0 2 O
ergocalcitriol NN 0 0 UNK O
will MD 0 0 12 O
be VB 0 0 12 O
reduced VBN 1 1 1 O
higher JJR 1 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
Rocaltrol NNP 0 1 0 B-Brand
may MD 0 0 1 O
be VB 0 0 12 O
necessary JJ 0 0 1 O
if IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
are VBP 1 0 12 O
administered VBN 1 1 1 O
simultaneously RB 0 1 13 O
. . 0 0 12 O

This DT 0 0 2 O
may MD 0 0 1 O
lead VB 0 1 12 O
to TO 0 0 12 O
low JJ 0 1 1 O
amiodarone NN 0 1 0 B-Drug
serum NN 0 1 14 O
levels NNS 1 1 1 O
and CC 0 0 12 O
potential JJ 0 1 1 O
decrease NN 0 1 1 O
in IN 0 0 12 O
efficacy NN 0 1 UNK O
. . 0 0 12 O

Certain NNP 0 1 UNK O
drugs NNS 1 1 6 O
including VBG 1 1 1 O
thiazides NNS 1 1 UNK B-Group
corticosteroids NNS 1 1 14 B-Group
thyroid JJ 0 1 6 B-Group
products NNS 1 1 1 I-Group
and CC 0 0 12 O
sympathomimetics NNS 0 1 13 B-Group
may MD 0 0 1 O
reduce VB 0 0 1 O
the DT 0 0 12 O
hypoglycemic JJ 0 1 14 O
action NN 0 1 13 O
of IN 0 0 12 O
Starlix NNP 0 1 UNK B-Brand
and CC 0 0 12 O
other JJ 0 0 12 O
oral JJ 0 1 6 O
antidiabetic JJ 0 1 13 B-Group
drugs NNS 1 1 6 I-Group
. . 0 0 12 O

Furosemide NNP 0 1 0 B-Drug
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
ethacrynic JJ 0 0 16 B-Drug
acid NN 0 1 14 I-Drug
because IN 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
possibility NN 0 1 1 O
of IN 0 0 12 O
ototoxicity NN 0 1 UNK O
. . 0 0 12 O

In IN 0 0 2 O
these DT 0 0 12 O
patients NNS 1 1 6 O
approximately RB 0 1 1 O
half NN 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
CPK NNP 0 0 15 O
elevations NNS 1 1 1 O
returned VBD 1 1 12 O
to TO 0 0 12 O
normal JJ 0 1 1 O
within IN 0 0 1 O
9 CD 0 0 2 O
weeks NNS 1 1 12 O
and CC 0 0 12 O
half NN 0 1 12 O
returned VBN 1 1 12 O
to TO 0 0 12 O
normal JJ 0 1 1 O
within IN 0 0 1 O
9 CD 0 0 2 O
weeks NNS 1 1 12 O
. . 0 0 12 O

Albuterol NNP 0 1 0 B-Drug
Antihistamines NNP 0 1 UNK B-Group
antidiabetic JJ 0 1 13 B-Group
drugs NNS 1 1 6 I-Group
diuretics NNS 1 1 14 B-Group
digitalis NNS 0 1 14 B-Group
. . 0 0 12 O

The DT 0 0 2 O
benefits NNS 1 1 1 O
of IN 0 0 12 O
Mefloquine NNP 0 1 UNK B-Drug
therapy NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
weighed VBN 1 0 12 O
against IN 0 0 12 O
the DT 0 0 12 O
possibility NN 0 1 1 O
of IN 0 0 12 O
adverse JJ 0 0 1 O
effects NNS 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
cardiac JJ 0 1 6 O
disease NN 0 1 6 O
. . 0 0 12 O

Laboratory JJ 0 1 2 O
Test NNP 0 1 2 O
In IN 0 0 2 O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
no DT 0 0 12 O
clinically RB 0 0 6 O
relevant JJ 0 1 1 O
laboratory NN 0 1 1 O
test NN 0 1 1 O
abnormalities NNS 1 1 6 O
were VBD 1 0 12 O
identified VBN 1 1 1 O
as IN 1 0 12 O
causally RB 0 0 UNK O
related VBN 1 1 1 O
to TO 0 0 12 O
drug NN 0 1 1 O
during IN 0 0 12 O
short JJ 0 1 12 O
- : 0 0 2 O
term NN 0 1 1 O
treatment NN 0 1 6 O
with IN 0 0 12 O
guanfacine NN 0 1 13 B-Drug
. . 0 0 12 O

Dopamine JJ 0 1 7 B-Group
Antagonists NNS 0 1 UNK I-Group
: : 0 0 2 O
Since IN 0 1 2 O
apomorphine NN 0 1 UNK B-Drug
is VBZ 1 0 12 O
a DT 0 0 12 O
dopamine JJ 0 1 14 B-Group
agonist NN 0 1 14 I-Group
it PRP 0 0 12 O
is VBZ 1 0 12 O
possible JJ 0 1 1 O
that IN 0 0 12 O
dopamine JJ 0 1 14 B-Group
antagonists NNS 1 1 13 I-Group
such JJ 0 0 1 O
as IN 1 0 12 O
the DT 0 0 12 O
neuroleptics NNS 1 1 13 B-Group
( ( 0 0 2 O
phenothiazines NNS 1 1 UNK B-Group
butyrophenones NNS 0 1 UNK B-Group
thioxanthenes NNS 0 1 UNK B-Group
) ) 0 0 2 O
or CC 0 0 12 O
metoclopramide NN 0 1 16 B-Drug
may MD 0 0 1 O
diminish VB 0 1 UNK O
the DT 0 0 12 O
effectiveness NN 0 1 UNK O
of IN 0 0 12 O
APOKYN NNP 0 1 UNK B-Brand
. . 0 0 12 O

procainamide NN 0 1 16 B-Drug
; : 0 0 2 O

Data NNP 0 1 2 O
beyond IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
are VBP 1 0 12 O
not RB 0 1 12 O
available JJ 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
increased VBD 1 1 1 O
from IN 0 0 12 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
. . 0 0 12 O

and CC 0 0 12 O
rarely RB 0 1 UNK O
dry JJ 0 1 3 O
mouth NN 0 1 3 O
anorexia JJ 0 1 6 O
taste NN 0 1 13 O
disorder NN 0 1 6 O
abdominal JJ 0 1 6 O
pain NN 0 1 6 O
vomiting VBG 1 1 6 O
diarrhea NN 0 1 6 O
and CC 0 0 12 O
positive JJ 0 1 1 O
test NN 0 1 1 O
for IN 0 0 12 O
occult NN 0 1 6 O
blood NN 0 1 6 O
in IN 0 0 12 O
stool NN 0 1 3 O
. . 0 0 12 O

The DT 0 0 2 O
steady JJ 0 1 1 O
state NN 0 1 1 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
imipramine NN 0 1 0 B-Drug
and CC 0 0 12 O
desipramine NN 0 1 16 B-Drug
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
be VB 0 0 12 O
increased VBN 1 1 1 O
an DT 0 0 12 O
average NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
respectively RB 0 0 1 O
by IN 0 0 12 O
the DT 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
alprazolam JJ 0 1 0 B-Drug
tablets NNS 1 1 3 O
in IN 0 0 12 O
doses NNS 1 1 6 O
up RB 0 0 12 O
to TO 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
. . 0 0 12 O

no DT 0 0 12 O
change NN 0 1 1 O
in IN 0 0 12 O
pravastatin NN 0 1 16 B-Drug
AUC NNP 0 1 UNK O
and CC 0 0 12 O
Cmax NNP 0 1 UNK O
was VBD 1 0 12 O
observed VBN 1 1 1 O
during IN 0 0 12 O
diltiazem JJ 0 1 0 B-Drug
coadministration NN 0 1 UNK O
. . 0 0 12 O

No DT 0 0 2 O
significant JJ 0 1 1 O
adverse JJ 0 0 1 O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
common JJ 0 1 1 O
premedications NNS 0 1 UNK O
( ( 0 0 2 O
such JJ 0 0 1 O
as IN 1 0 12 O
atropine JJ 0 1 14 B-Drug
scopolamine NN 0 1 14 B-Drug
glycopyrrolate NN 0 1 16 B-Drug
diazepam NN 0 1 0 B-Drug
hydroxyzine NN 0 1 16 B-Drug
and CC 0 0 12 O
other JJ 0 0 12 O
muscle NN 0 1 6 B-Group
relaxants NNS 1 0 13 I-Group
) ) 0 0 2 O
or CC 0 0 12 O
local JJ 0 1 12 O
anesthetics NNS 1 1 13 B-Group
have VBP 0 0 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
. . 0 0 12 O

Therefore RB 0 0 1 O
the DT 0 0 12 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
probenecid NN 0 1 13 B-Drug
with IN 0 0 12 O
meropenem NN 0 1 14 B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O

Clinical JJ 0 1 7 O
studies NNS 1 1 1 O
have VBP 0 0 12 O
shown VBN 1 1 1 O
increased JJ 0 1 1 O
sedation NN 0 1 6 O
with IN 0 0 12 O
concurrent JJ 0 1 1 O
hypnotic JJ 0 1 13 B-Group
medications NNS 1 1 6 I-Group
. . 0 0 12 O

Clarithromycin NNP 0 1 UNK B-Drug
9OH CD 0 0 UNK O
- : 0 0 2 O
clarithromycin NN 0 1 13 O

Vindesine NN 0 1 UNK B-Drug
can MD 0 0 12 O
interact VB 0 0 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
drugs NNS 1 1 6 O
of IN 0 0 12 O
the DT 0 0 12 O
following JJ 0 1 1 O
categories NNS 1 1 13 O
: : 0 0 2 O
- : 0 0 2 O
Blood NN 0 1 2 O
dyscrasia NN 0 1 UNK O
: : 0 0 2 O
can MD 0 0 12 O
cause VB 0 1 12 O
unpredictable JJ 0 0 UNK O
myelotoxicity NN 0 0 UNK O
- : 0 0 2 O
Bone NN 0 1 2 O
marrow NN 0 1 6 O
depressants NNS 1 0 13 O
: : 0 0 2 O
can MD 0 0 12 O
cause VB 0 1 12 O
a DT 0 0 12 O
predictable JJ 0 1 UNK O
dose JJ 0 1 6 O
- : 0 0 2 O
related JJ 0 1 1 O
myelotoxicity NN 0 0 UNK O
- : 0 0 2 O
Radiation NN 0 1 7 O
therapy NN 0 1 6 O
: : 0 0 2 O
may MD 0 0 1 O
cause VB 0 1 12 O
marrow NN 0 1 6 O
depression NN 0 1 6 O
- : 0 0 2 O
Neurotoxic JJ 0 1 UNK O
medications NNS 1 1 6 O
: : 0 0 2 O
can MD 0 0 12 O
cause VB 0 1 12 O
neurologic JJ 0 1 6 O
toxicity NN 0 1 6 O
- : 0 0 2 O
Phenytoin NN 0 1 0 B-Drug
: : 0 0 2 O
can MD 0 0 12 O
increase VB 0 1 1 O
seizure NN 0 1 6 O
activity NN 0 1 1 O
- : 0 0 2 O
Live JJ 0 1 UNK B-Group
virus NN 0 1 6 I-Group
vaccines NNS 1 1 6 I-Group
: : 0 0 2 O
may MD 0 0 1 O
potentiate VB 0 0 UNK O
the DT 0 0 12 O
replication NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
vaccine NN 0 1 6 B-Drug
virus NN 0 1 6 O
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
side JJ 0 1 3 O
effects NNS 1 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
vaccination NN 0 1 6 O
and CC 0 0 12 O
decrease NN 0 1 1 O
patient NN 0 1 6 O
's POS 0 1 12 O
response NN 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
vaccine NN 0 1 6 O
- : 0 0 2 O
Mitomycin NNP 0 1 UNK B-Drug
- : 0 0 2 O
C NN 0 0 2 I-Drug
: : 0 0 2 O
may MD 0 0 1 O
cause VB 0 1 12 O
shortness NN 0 1 6 O
of IN 0 0 12 O
breath NN 0 1 3 O
and CC 0 0 12 O
bronchospasm SYM 0 1 13 O
- : 0 0 2 O
Killed VBN 0 1 UNK B-Group
virus NN 0 1 6 I-Group
vaccines NNS 1 1 6 I-Group
: : 0 0 2 O
may MD 0 0 1 O
decrease VB 0 1 1 O
patient NN 0 1 6 O
's POS 0 1 12 O
response NN 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
vaccine NN 0 1 6 B-Group

Patients NNS 0 1 7 O
receiving VBG 1 1 1 O
SPRYCEL NNP 0 1 UNK B-Brand
should MD 0 0 12 O
not RB 0 1 12 O
take VB 0 1 12 O
St. NNP 0 1 2 O
Johns NNP 0 0 UNK O
wort NN 0 0 UNK O
. . 0 0 12 O

Valproic NNP 0 0 UNK B-Drug
Acid NNP 0 1 2 I-Drug
: : 0 0 2 O
The DT 0 0 2 O
mean NN 0 1 12 O
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
trough IN 0 1 3 O
serum NN 0 1 14 O
valproic NN 0 0 16 B-Drug
acid NN 0 1 14 I-Drug
concentrations NNS 1 1 13 O
prior VBP 0 1 1 O
to TO 0 0 12 O
and CC 0 0 12 O
during IN 0 0 12 O
concomitant JJ 0 1 6 O
gabapentin JJ 0 1 0 B-Drug
administration NN 0 1 1 O
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
TID NNP 0 1 15 O
; : 0 0 2 O

however RB 0 0 12 O
as IN 1 0 12 O
with IN 0 0 12 O
other JJ 0 0 12 O
NSAIDs NNP 0 1 UNK B-Group
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
meloxicam NN 0 1 13 B-Drug
and CC 0 0 12 O
aspirin NN 0 1 14 B-Brand
is VBZ 1 0 12 O
not RB 0 1 12 O
generally RB 0 0 1 O
recommended VBN 1 1 1 O
because IN 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
potential JJ 0 1 1 O
for IN 0 0 12 O
increased JJ 0 1 1 O
adverse JJ 0 0 1 O
effects NNS 1 1 1 O
. . 0 0 12 O

Patients NNS 0 1 7 O
with IN 0 0 12 O
Crohn NNP 0 1 6 O
disease NN 0 1 6 O
who WP 0 0 12 O
received VBD 1 1 12 O
immunosuppressants NNS 1 1 UNK B-Group
tended VBD 1 0 1 O
to TO 0 0 12 O
experience VB 0 1 12 O
fewer JJR 1 1 UNK O
infusion NN 0 1 14 O
reactions NNS 1 1 1 O
compared VBN 1 1 1 O
to TO 0 0 12 O
patients NNS 1 1 6 O
on IN 0 0 12 O
no DT 0 0 12 O
immunosuppressants NNS 1 1 UNK B-Group
. . 0 0 12 O

The DT 0 0 2 O
onset NN 0 1 6 O
of IN 0 0 12 O
symptoms NNS 1 1 6 O
usually RB 0 1 12 O
occurred VBD 1 1 1 O
within IN 0 0 1 O
hours NNS 1 1 12 O
( ( 0 0 2 O
most RBS 0 0 12 O
commonly RB 0 0 UNK O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
) ) 0 0 2 O
following VBG 1 1 1 O
the DT 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
contrast NN 0 1 1 O
media NNS 1 1 1 O
. . 0 0 12 O

If IN 0 0 12 O
desipramine JJ 0 1 16 B-Drug
hydrochloride NN 0 1 0 I-Drug
is VBZ 1 0 12 O
to TO 0 0 12 O
be VB 0 0 12 O
combined VBN 1 1 1 O
with IN 0 0 12 O
other JJ 0 0 12 O
psychotropic NN 0 1 13 B-Group
agents NNS 1 1 1 I-Group
such JJ 0 0 1 O
as IN 1 0 12 O
tranquilizers NNS 1 1 13 B-Group
or CC 0 0 12 O
sedative JJ 0 1 6 B-Group
/ NN 0 0 2 O
hypnotics NNS 1 1 13 B-Group
careful JJ 0 1 12 O
consideration NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
given VBN 1 1 12 O
to TO 0 0 12 O
the DT 0 0 12 O
pharmacology NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
agents NNS 1 1 1 O
employed VBN 1 1 1 O
since IN 0 1 12 O
the DT 0 0 12 O
sedative JJ 0 1 6 O
effects NNS 1 1 1 O
of IN 0 0 12 O
desipramine NN 0 1 16 B-Drug
and CC 0 0 12 O
benzodiazepines NNS 1 1 14 B-Group
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
chlordiazepoxide NN 0 1 16 B-Drug
or CC 0 0 12 O
diazepam NN 0 1 0 B-Drug
) ) 0 0 2 O
are VBP 1 0 12 O
additive JJ 0 1 16 O
. . 0 0 12 O

Ketoconazole NNP 0 1 UNK B-Drug
: : 0 0 2 O
Coadministration NN 0 1 UNK O
of IN 0 0 12 O
ketoconazole NN 0 1 16 B-Drug
with IN 0 0 12 O
VIRACEPT NNP 0 1 UNK B-Brand
resulted VBD 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
increase NN 0 1 1 O
in IN 0 0 12 O
nelfinavir JJ 0 1 16 B-Drug
plasma NN 0 1 14 O
A.C NNP 0 0 UNK O
. . 0 0 12 O

For IN 0 0 2 O
information NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
Gemzar NNP 0 1 UNK B-Brand
and CC 0 0 12 O
cisplatin NN 0 1 14 B-Drug
in IN 0 0 12 O
combination NN 0 1 1 O
see VBP 0 1 12 O
Drug JJ 0 1 2 O
Interactions NNP 0 1 UNK O
under IN 0 0 12 O
CLINICAL NNP 0 1 11 O
PHARMACOLOGY NNP 0 1 UNK O
section NN 0 1 1 O
. . 0 0 12 O

Magnesium NNP 0 1 7 B-Drug
/ NNP 0 0 2 O
Aluminum NNP 0 1 2 B-Drug
- : 0 0 2 O
containing VBG 1 1 1 O
Antacid NNP 0 1 UNK B-Group
Products NNPS 0 1 2 I-Group
: : 0 0 2 O
Absorption NN 0 1 UNK O
of IN 0 0 12 O
zalcitabine NN 0 1 UNK B-Drug
is VBZ 1 0 12 O
moderately RB 0 1 3 O
reduced VBN 1 1 1 O
( ( 0 0 2 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
when WRB 0 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
magnesium NN 0 1 14 B-Drug
/ NN 0 0 2 O
aluminum NN 0 1 16 B-Drug
- : 0 0 2 O
containing VBG 1 1 1 O
antacid NN 0 1 UNK B-Group
products NNS 1 1 1 I-Group
. . 0 0 12 O

twice RB 0 1 12 O
the DT 0 0 12 O
human JJ 0 1 1 O
dose NN 0 1 6 O
on IN 0 0 12 O
BSA NNP 0 0 13 O
) ) 0 0 2 O
and CC 0 0 12 O
non $ 0 1 1 O
- : 0 0 2 O
ossification NN 0 1 8 O
of IN 0 0 12 O
the DT 0 0 12 O
odontoid NN 0 0 8 O
and CC 0 0 12 O
ventral JJ 0 1 8 O
tubercle NN 0 1 16 O
of IN 0 0 12 O
the DT 0 0 12 O
first JJ 0 1 12 O
cervical JJ 0 1 6 O
vertebra NN 0 1 8 O
at IN 0 0 12 O
doses NNS 1 1 6 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
kg JJ 0 1 18 O
/ NNP 0 0 2 O
day NN 0 1 12 O
IM NNP 0 1 11 O
( ( 0 0 2 O
approximately RB 0 1 1 O
one CD 0 1 12 O
- : 0 0 2 O
tenth NN 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
human JJ 0 1 1 O
dose NN 0 1 6 O
on IN 0 0 12 O
BSA NNP 0 0 13 O
) ) 0 0 2 O
when WRB 0 0 12 O
administered VBN 1 1 1 O
during IN 0 0 12 O
the DT 0 0 12 O
period NN 0 1 1 O
of IN 0 0 12 O
organogenesis NN 0 1 UNK O
. . 0 0 12 O

Other JJ 0 0 2 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
Cimetidine NNP 0 1 0 B-Drug
erythromycin NN 0 1 0 B-Drug
and CC 0 0 12 O
dextropropoxyphene NN 0 1 UNK B-Drug
had VBD 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
MHD NNP 0 0 UNK B-Drug_n
. . 0 0 12 O

Therefore IN 0 0 1 O
it PRP 0 0 12 O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
in IN 0 0 12 O
caution NN 0 0 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
such JJ 0 0 1 O
agents NNS 1 1 1 O
. . 0 0 12 O

A DT 0 0 2 O
case NN 0 1 12 O
report NN 0 1 1 O
of IN 0 0 12 O
one CD 0 1 12 O
patient NN 0 1 6 O
taking VBG 1 0 12 O
amiodarone JJ 0 1 0 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
and CC 0 0 12 O
indinavir $ 0 1 16 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
three CD 0 1 12 O
times NNS 1 1 12 O
a DT 0 0 12 O
day NN 0 1 12 O
resulted VBD 1 1 1 O
in IN 0 0 12 O
increases NNS 1 1 1 O
in IN 0 0 12 O
amiodarone JJ 0 1 0 B-Drug
concentrations NNS 1 1 13 O
from IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
L NNP 0 1 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
L NNP 0 1 2 O
. . 0 0 12 O

More JJR 0 1 UNK O
than IN 0 0 12 O
9 CD 0 0 2 O
Parkinsons NNS 0 1 7 O
disease NN 0 1 6 O
patients NNS 1 1 6 O
in IN 0 0 12 O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
have VBP 0 0 12 O
used VBN 1 1 12 O
selegiline NN 0 1 13 B-Drug
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
entacapone NN 0 1 13 B-Drug
and CC 0 0 12 O
levodopa JJ 0 1 UNK B-Drug
/ NNP 0 0 2 O
dopa NN 0 1 14 B-Group
decarboxylase NN 0 1 UNK I-Group
inhibitor NN 0 1 14 I-Group
. . 0 0 12 O

INFORMATION NN 0 1 11 O
TO NNP 0 0 11 O
BE NNP 0 0 11 O
PROVIDED NNP 0 1 UNK O
TO NNP 0 0 11 O
THE NNP 0 0 11 O
PATIENT NNP 0 1 11 O
OR NNP 0 0 11 O
GUARDIAN NNP 0 1 UNK O
See NNP 0 1 2 O
illustrated JJ 0 0 UNK O
Information NNP 0 1 2 O
For IN 0 0 2 O
The DT 0 0 2 O
Patient NNP 0 1 7 O
or CC 0 0 12 O
Guardian JJ 0 1 2 O
section NN 0 1 1 O
. . 0 0 12 O

Drug NNP 0 1 2 O
- : 0 0 2 O
Laboratory JJ 0 1 2 O
Test NNP 0 1 2 O
Interactions NNPS 0 1 UNK O
There EX 0 0 12 O
are VBP 1 0 12 O
no DT 0 0 12 O
known JJ 0 1 12 O
interactions NNS 1 1 UNK O
between IN 0 0 12 O
ELLENCE NNP 0 1 UNK B-Brand
and CC 0 0 12 O
laboratory NN 0 1 1 O
tests NNS 1 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
humans NNS 1 1 UNK O
two CD 0 1 12 O
inhibitors NNS 1 1 14 O
of IN 0 0 12 O
P9 NNP 0 1 UNK O
9A9 CD 0 0 UNK O
have VBP 0 0 12 O
been VBN 1 0 12 O
studied VBN 1 0 1 O
. . 0 0 12 O

There EX 0 0 12 O
was VBD 1 0 12 O
a DT 0 0 12 O
small JJ 0 1 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
capecitabine NN 0 1 13 B-Drug
and CC 0 0 12 O
one CD 0 1 12 O
metabolite NN 0 1 UNK O
( ( 0 0 2 O
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
DFCR NN 0 0 UNK I-Drug_n
) ) 0 0 2 O
; : 0 0 2 O

These DT 0 0 1 O
drugs NNS 1 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
caution NN 0 0 1 O
and CC 0 0 12 O
frequent JJ 0 1 1 O
monitoring NN 0 1 1 O
of IN 0 0 12 O
serum JJ 0 1 14 O
lithium NN 0 1 16 B-Drug
levels NNS 1 1 1 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
patients NNS 1 1 6 O
on IN 0 0 12 O
chronic JJ 0 1 6 O
warfarin NN 0 1 14 B-Drug
therapy VBD 0 1 6 O
the DT 0 0 12 O
prothrombin NN 0 1 14 O
time NN 0 1 12 O
( ( 0 0 2 O
INR NNP 0 1 13 O
) ) 0 0 2 O
should MD 0 0 12 O
be VB 0 0 12 O
closely RB 0 0 1 O
monitored VBN 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
week NN 0 1 12 O
period NN 0 1 1 O
particularly RB 0 0 1 O
at IN 0 0 12 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
following VBG 1 1 1 O
initiation NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
day NN 0 1 12 O
regimen NNS 0 1 6 O
of IN 0 0 12 O
Aprepitant NNP 0 1 UNK B-Drug
with IN 0 0 12 O
each DT 0 0 12 O
chemotherapy NN 0 1 6 O
cycle NN 0 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
post NN 0 1 12 O
- : 0 0 2 O
marketing NN 0 1 UNK O
experience NN 0 1 12 O
there RB 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reports NNS 1 1 1 O
of IN 0 0 12 O
increases NNS 1 1 1 O
in IN 0 0 12 O
plasma JJ 0 1 14 O
lithium NN 0 1 16 B-Drug
levels NNS 1 1 1 O
. . 0 0 12 O

If IN 0 0 12 O
such JJ 0 0 1 O
drugs NNS 1 1 6 O
are VBP 1 0 12 O
used VBN 1 1 12 O
they PRP 0 0 12 O
should MD 0 0 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
an DT 0 0 12 O
interval NN 0 1 1 O
of IN 0 0 12 O
at IN 0 0 12 O
least JJS 0 1 12 O
9 CD 0 0 2 O
minutes NNS 1 1 12 O
between IN 0 0 12 O
applications NNS 1 1 UNK O
. . 0 0 12 O

Methotrexate NN 0 1 0 B-Drug
: : 0 0 2 O
Ibuprofen NN 0 1 0 B-Drug
as RB 0 0 12 O
well RB 0 1 12 O
as IN 1 0 12 O
other JJ 0 0 12 O
nonsteroidal JJ 0 0 14 B-Group
anti SYM 0 0 3 I-Group
- : 0 0 2 O
inflammatory NN 0 1 6 I-Group
drugs NNS 1 1 6 I-Group
probably RB 0 1 12 O
reduces VBZ 1 0 UNK O
the DT 0 0 12 O
tubular JJ 0 1 3 O
secretion NN 0 1 14 O
of IN 0 0 12 O
methotrexate NN 0 1 16 B-Drug
based VBN 1 1 1 O
on IN 0 0 12 O
in IN 0 0 12 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
in IN 0 0 12 O
rabbit NN 0 1 16 O
kidney NN 0 1 6 O
slices NNS 1 1 UNK O
. . 0 0 12 O

Treatment NN 0 1 7 O
with IN 0 0 12 O
PEGASYS NNP 0 1 UNK B-Brand
once RB 0 0 12 O
weekly VBD 0 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
weeks NNS 1 1 12 O
in IN 0 0 12 O
healthy JJ 0 1 12 O
subjects NNS 1 1 UNK O
was VBD 1 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
an DT 0 0 12 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
P9 NNP 0 1 UNK O
9A9 CD 0 0 UNK O
and CC 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
increase NN 0 1 1 O
in IN 0 0 12 O
theophylline JJ 0 1 16 B-Drug
AUC NNP 0 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
clinical JJ 0 1 6 O
significance NN 0 1 13 O
of IN 0 0 12 O
this DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
doxazosin JJ 0 1 13 B-Drug
AUC NNP 0 1 UNK O
is VBZ 1 0 12 O
unknown JJ 0 1 12 O
. . 0 0 12 O

Preliminary NNP 0 1 2 O
data NNS 0 1 1 O
which WDT 0 0 12 O
suggest VBP 0 1 1 O
that IN 0 0 12 O
dapsone NN 0 1 13 B-Drug
may MD 0 0 1 O
inhibit VB 0 1 13 O
the DT 0 0 12 O
anti JJ 0 0 3 O
- : 0 0 2 O
inflammatory JJ 0 1 6 O
activity NN 0 1 1 O
of IN 0 0 12 O
Lamprene NNP 0 1 UNK B-Brand
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
confirmed VBN 1 1 12 O
. . 0 0 12 O

Drug JJ 0 1 2 O
Class NN 0 1 2 O
: : 0 0 2 O
Drug NN 0 1 2 O
Name NNP 0 1 2 O
Clinical NNP 0 1 7 O
Comment NN 0 1 2 O

No DT 0 0 2 O
changes NNS 1 1 1 O
were VBD 1 0 12 O
observed VBN 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
degree NN 0 1 1 O
of IN 0 0 12 O
anticoagulation NN 0 1 14 O
. . 0 0 12 O

Coumarin NNP 0 1 UNK B-Group
Anticoagulants NNP 0 1 UNK I-Group
Altered NNP 0 1 13 O
coagulation NN 0 1 14 O
parameters NNS 1 1 1 O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
bleeding NN 0 1 6 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
capecitabine JJ 0 1 13 B-Drug
concomitantly RB 0 0 14 O
with IN 0 0 12 O
coumarin JJ 0 1 UNK B-Group
- : 0 0 2 O
derivative JJ 0 1 13 I-Group
anticoagulants NNS 1 1 13 I-Group
such JJ 0 0 1 O
as IN 1 0 12 O
warfarin NN 0 1 14 B-Drug
and CC 0 0 12 O
phenprocoumon NN 0 1 UNK B-Drug
. . 0 0 12 O

Tablets NNS 0 1 0 O
Simultaneous JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
sucralfate NN 0 1 0 B-Drug
and CC 0 0 12 O
furosemide JJ 0 1 0 B-Drug
tablets NNS 1 1 3 O
may MD 0 0 1 O
reduce VB 0 0 1 O
the DT 0 0 12 O
natriuretic JJ 0 1 UNK O
and CC 0 0 12 O
antihypertensive JJ 0 1 14 O
effects NNS 1 1 1 O
of IN 0 0 12 O
furosemide NN 0 1 0 B-Drug
. . 0 0 12 O

Consequently RB 0 0 1 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
Aprepitant NNP 0 1 UNK B-Drug
with IN 0 0 12 O
strong JJ 0 1 12 O
CYP9A9 NNP 0 0 UNK O
inhibitors NNS 1 1 14 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
ketoconazole NN 0 1 16 B-Drug
itraconazole NN 0 1 0 B-Drug
nefazodone NN 0 1 16 B-Drug
troleandomycin NN 0 1 UNK B-Drug
clarithromycin NN 0 1 13 B-Drug
ritonavir NN 0 1 16 B-Drug
nelfinavir NN 0 1 16 B-Drug
) ) 0 0 2 O
should MD 0 0 12 O
be VB 0 0 12 O
approached VBN 1 1 UNK O
with IN 0 0 12 O
caution NN 0 0 1 O
. . 0 0 12 O

PEGASYS NNP 0 1 UNK B-Brand
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
with IN 0 0 12 O
caution NN 0 0 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
creatinine JJ 0 1 14 O
clearance NN 0 1 16 O
9 CD 0 0 2 O
mL NN 0 1 14 O
/ NNP 0 0 2 O
min NN 0 1 16 O
and CC 0 0 12 O
COPEGUS NNP 0 1 UNK B-Brand
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
to TO 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
creatinine JJ 0 1 14 O
clearance NN 0 1 16 O
9 CD 0 0 2 O
mL NN 0 1 14 O
/ CD 0 0 2 O
min NN 0 1 16 O

eosinophilia NNS 0 1 8 O

Furosemide NN 0 1 0 B-Drug
: : 0 0 2 O
Clinical JJ 0 1 7 O
studies NNS 1 1 1 O
as RB 0 0 12 O
well RB 0 1 12 O
as IN 1 0 12 O
post NN 0 1 12 O
- : 0 0 2 O
marketing NN 0 1 UNK O
observations NNS 1 1 1 O
have VBP 0 0 12 O
shown VBN 1 1 1 O
that IN 0 0 12 O
NSAIDs NNP 0 1 UNK B-Group
can MD 0 0 12 O
reduce VB 0 0 1 O
the DT 0 0 12 O
natriuretic JJ 0 1 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
furosemide NN 0 1 0 B-Drug
and CC 0 0 12 O
thiazides NNS 1 1 UNK B-Group
in IN 0 0 12 O
some DT 0 0 12 O
patients NNS 1 1 6 O
. . 0 0 12 O

However RB 0 0 1 O
the DT 0 0 12 O
concomitant NN 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
Argatroban NNP 0 1 0 B-Drug
and CC 0 0 12 O
warfarin NN 0 1 14 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
mg JJ 0 1 0 O
initial JJ 0 1 1 O
oral JJ 0 1 6 O
dose NN 0 1 6 O
followed VBN 1 1 12 O
by IN 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
mg JJ 0 1 0 O
/ NNP 0 0 2 O
day NN 0 1 12 O
orally RB 0 1 14 O
for IN 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
days NNS 1 1 12 O
) ) 0 0 2 O
results NNS 1 1 1 O
in IN 0 0 12 O
prolongation NN 0 1 6 O
of IN 0 0 12 O
the DT 0 0 12 O
prothrombin NN 0 1 14 O
time NN 0 1 12 O
( ( 0 0 2 O
PT NNP 0 1 2 O
) ) 0 0 2 O
and CC 0 0 12 O
International NNP 0 1 UNK O
Normalized NNP 0 1 UNK O
Ratio NNP 0 1 2 O
( ( 0 0 2 O
INR NNP 0 1 13 O
) ) 0 0 2 O
. . 0 0 12 O

Concurrent JJ 0 1 13 O
therapy NN 0 1 6 O
with IN 0 0 12 O
bumetanide NN 0 1 16 B-Drug
is VBZ 1 0 12 O
thus RB 0 0 1 O
not RB 0 1 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O

Because IN 0 0 12 O
the DT 0 0 12 O
incidence NN 0 1 6 O
of IN 0 0 12 O
infections NNS 1 1 6 O
and CC 0 0 12 O
certain JJ 0 1 1 O
malignancies NNS 1 1 16 O
is VBZ 1 0 12 O
higher JJR 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
elderly JJ 0 1 12 O
population NN 0 1 13 O
in IN 0 0 12 O
general JJ 0 1 1 O
caution NN 0 0 1 O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
in IN 0 0 12 O
treating VBG 1 1 6 O
the DT 0 0 12 O
elderly JJ 0 1 12 O
. . 0 0 12 O

Lithium NN 0 1 UNK B-Drug
: : 0 0 2 O
Valdecoxib NNP 0 1 UNK B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
BID NNP 0 0 11 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
produced VBD 1 0 1 O
significant JJ 0 1 1 O
decreases NNS 1 1 UNK O
in IN 0 0 12 O
lithium NN 0 1 16 B-Drug
serum NN 0 1 14 O
clearance NN 0 1 16 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
and CC 0 0 12 O
renal JJ 0 1 6 O
clearance NN 0 1 16 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
with IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
higher JJR 1 1 1 O
serum NN 0 1 14 O
exposure NN 0 1 1 O
compared VBN 1 1 1 O
to TO 0 0 12 O
lithium VB 0 1 16 B-Drug
alone RB 0 1 12 O
. . 0 0 12 O

Hepatic JJ 0 1 7 O
Impairment NNP 0 1 UNK O
There EX 0 0 12 O
are VBP 1 0 12 O
currently RB 0 1 12 O
no DT 0 0 12 O
clinical JJ 0 1 6 O
studies NNS 1 1 1 O
with IN 0 0 12 O
SPRYCEL NNP 0 1 UNK B-Brand
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
impaired JJ 0 1 6 O
liver NN 0 1 6 O
function NN 0 1 1 O
( ( 0 0 2 O
clinical JJ 0 1 6 O
studies NNS 1 1 1 O
have VBP 0 0 12 O
excluded VBN 1 1 1 O
patients NNS 1 1 6 O
with IN 0 0 12 O
ALT NNP 0 1 13 O
and CC 0 0 12 O
/ NNP 0 0 2 O
or CC 0 0 12 O
AST NNP 0 1 13 O
9 CD 0 0 2 O
times NNS 1 1 12 O
the DT 0 0 12 O
upper JJ 0 1 3 O
limit NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
normal JJ 0 1 1 O
range NN 0 1 1 O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
total JJ 0 1 1 O
bilirubin NN 0 1 14 O
9 CD 0 0 2 O
times NNS 1 1 12 O
the DT 0 0 12 O
upper JJ 0 1 3 O
limit NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
normal JJ 0 1 1 O
range NN 0 1 1 O
) ) 0 0 2 O
. . 0 0 12 O

Antiarrhythmic JJ 0 1 UNK B-Drug
agents NNS 1 1 1 I-Drug
class NN 0 1 12 I-Drug
I PRP 0 1 12 I-Drug
( ( 0 0 2 O
such JJ 0 0 1 O
as IN 1 0 12 O
flecainide JJ 0 1 16 B-Drug
lidocaine NN 0 1 14 B-Drug
or CC 0 0 12 O
quinidine NN 0 1 16 B-Drug
) ) 0 0 2 O
: : 0 0 2 O
concurrent NN 0 1 1 O
use NN 0 1 1 O
with IN 0 0 12 O
arbutamine NN 0 1 UNK B-Drug
may MD 0 0 1 O
have VB 0 0 12 O
a DT 0 0 12 O
proarrhythmic JJ 0 0 UNK O
effect NN 0 1 1 O
. . 0 0 12 O

Drugs NNS 0 1 2 O
Metabolized VBN 0 1 UNK O
by IN 0 0 12 O
P9 NNP 0 1 UNK O
9D9 CD 0 0 UNK O
: : 0 0 2 O
The DT 0 0 2 O
biochemical JJ 0 1 UNK O
activity NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
drug NN 0 1 1 O
metabolizing VBG 1 0 UNK O
isozyme JJ 0 1 UNK O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
9D9 CD 0 0 UNK O
( ( 0 0 2 O
debrisoquin JJ 0 1 UNK O
hydroxylase NN 0 1 UNK O
) ) 0 0 2 O
is VBZ 1 0 12 O
reduced VBN 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
subset NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
aucasian JJ 0 0 UNK O
population NN 0 1 13 O
( ( 0 0 2 O
about IN 0 1 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
- : 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
of IN 0 0 12 O
Caucasians NNPS 0 1 UNK O
are VBP 1 0 12 O
so RB 0 1 12 O
- : 0 0 2 O
called VBN 1 1 12 O
poor JJ 0 1 12 O
metabolizers NNS 0 0 UNK O
) ) 0 0 2 O
; : 0 0 2 O

In IN 0 0 2 O
patients NNS 1 1 6 O
who WP 0 0 12 O
have VBP 0 0 12 O
received VBN 1 1 12 O
general JJ 0 1 1 O
anesthesia NN 0 1 6 O
utilizing VBG 1 0 1 O
a DT 0 0 12 O
volatile JJ 0 1 UNK O
agent NN 0 1 1 O
known VBN 1 1 12 O
to TO 0 0 12 O
sensitize VB 0 0 UNK O
the DT 0 0 12 O
myocardium NN 0 1 8 O
to TO 0 0 12 O
catecholamines VB 0 1 14 O
administration NN 0 1 1 O
of IN 0 0 12 O
doxapram NN 0 1 UNK B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
delayed VBN 1 1 1 O
until IN 0 0 12 O
the DT 0 0 12 O
volatile JJ 0 1 UNK O
agent NN 0 1 1 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
excreted VBN 1 1 UNK O
in IN 0 0 12 O
order NN 0 1 1 O
to TO 0 0 12 O
lessen VB 0 0 UNK O
the DT 0 0 12 O
potential NN 0 1 1 O
for IN 0 0 12 O
arrhythmias JJ 0 1 6 O
including VBG 1 1 1 O
ventricular JJ 0 1 8 O
tachycardia NN 0 1 8 O
and CC 0 0 12 O
ventricular JJ 0 1 8 O
fibrillation NN 0 1 6 O
. . 0 0 12 O

In IN 0 0 2 O
geriatric JJ 0 1 UNK O
subjects NNS 1 1 UNK O
( ( 0 0 2 O
n=9 NN 0 1 UNK O
) ) 0 0 2 O
there EX 0 0 12 O
was VBD 1 0 12 O
a DT 0 0 12 O
reduction NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
rate NN 0 1 1 O
but CC 0 0 12 O
not RB 0 1 12 O
the DT 0 0 12 O
extent NN 0 1 1 O
of IN 0 0 12 O
flurbiprofen JJ 0 1 16 B-Drug
absorption NN 0 1 1 O
. . 0 0 12 O

Lithium NN 0 1 UNK B-Drug
: : 0 0 2 O
Increased VBN 0 1 7 O
serum NN 0 1 14 O
lithium NN 0 1 16 B-Drug
levels NNS 1 1 1 O
and CC 0 0 12 O
symptoms NNS 1 1 6 O
of IN 0 0 12 O
lithium NN 0 1 16 B-Drug
toxicity NN 0 1 6 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
ACE NNP 0 1 13 B-Group
inhibitors NNS 1 1 14 I-Group
during IN 0 0 12 O
therapy NN 0 1 6 O
with IN 0 0 12 O
lithium NN 0 1 16 B-Drug
. . 0 0 12 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interactions NNPS 0 1 UNK O
: : 0 0 2 O
It PRP 0 0 12 O
is VBZ 1 0 12 O
not RB 0 1 12 O
known VBN 1 1 12 O
if IN 0 0 12 O
MEPRON NNP 0 1 UNK B-Brand
interferes VBZ 1 1 UNK O
with IN 0 0 12 O
clinical JJ 0 1 6 O
laboratory NN 0 1 1 O
test NN 0 1 1 O
or CC 0 0 12 O
assay NN 0 1 14 O
results NNS 1 1 1 O
. . 0 0 12 O

This DT 0 0 2 O
may MD 0 0 1 O
lead VB 0 1 12 O
to TO 0 0 12 O
reduced JJ 0 1 1 O
clearance NN 0 1 16 O
of IN 0 0 12 O
caffeine NN 0 1 6 B-Drug
and CC 0 0 12 O
a DT 0 0 12 O
prolongation NN 0 1 6 O
of IN 0 0 12 O
its PRP$ 1 0 12 O
serum NN 0 1 14 O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
. . 0 0 12 O

Patients NNS 0 1 7 O
receiving VBG 1 1 1 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
zalcitabine NN 0 1 UNK B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
for IN 0 0 12 O
signs NNS 1 1 12 O
of IN 0 0 12 O
toxicity NN 0 1 6 O
and CC 0 0 12 O
the DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
zalcitabine NN 0 1 UNK B-Drug
reduced VBN 1 1 1 O
if IN 0 0 12 O
warranted VBN 1 0 1 O
. . 0 0 12 O

In IN 0 0 2 O
vitro JJ 0 1 UNK O
nilutamide NN 0 1 UNK B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
inhibit VB 0 1 13 O
the DT 0 0 12 O
activity NN 0 1 1 O
of IN 0 0 12 O
liver NN 0 1 6 O
cytochrome NN 0 1 UNK O
P NNP 0 1 2 O
- : 0 0 2 O
9 CD 0 0 2 O
isoenzymes NNS 0 1 14 O
and CC 0 0 12 O
therefore NN 0 0 1 O
may MD 0 0 1 O
reduce VB 0 0 1 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
compounds NNS 1 1 13 O
requiring VBG 1 0 1 O
these DT 0 0 12 O
systems NNS 1 1 1 O
. . 0 0 12 O

Zidovudine NNP 0 1 UNK B-Drug
competitively RB 0 0 UNK O
inhibits VBZ 1 1 UNK O
the DT 0 0 12 O
intracellular JJ 0 1 UNK O
phosphorylation NN 0 1 UNK O
of IN 0 0 12 O
stavudine NN 0 1 13 B-Drug
. . 0 0 12 O

Agents NNS 0 1 2 O
that WDT 0 0 12 O
might MD 0 0 12 O
be VB 0 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
trimetrexate NN 0 1 UNK B-Drug
in IN 0 0 12 O
AIDS NNP 0 1 6 O
patients NNS 1 1 6 O
for IN 0 0 12 O
other JJ 0 0 12 O
indications NNS 1 1 1 O
that WDT 0 0 12 O
could MD 0 0 12 O
elicit VB 0 1 1 O
this DT 0 0 12 O
activity NN 0 1 1 O
include VBP 0 1 1 O
erythromycin JJ 0 1 0 B-Drug
rifampin NN 0 1 16 B-Drug
rifabutin NN 0 1 13 B-Drug
ketoconazole NN 0 1 16 B-Drug
and CC 0 0 12 O
fluconazole NN 0 1 0 B-Drug
. . 0 0 12 O

mefenamic JJ 0 0 UNK B-Drug
acid NN 0 1 14 I-Drug
; : 0 0 2 O

If IN 0 0 12 O
signs NNS 1 1 12 O
and CC 0 0 12 O
symptoms NNS 1 1 6 O
suggestive NN 0 1 6 O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
toxicity NN 0 1 6 O
occur VBP 0 1 1 O
when WRB 0 0 12 O
enoxacin NN 0 1 UNK B-Drug
and CC 0 0 12 O
digoxin NN 0 1 14 B-Drug
are VBP 1 0 12 O
given VBN 1 1 12 O
concomitantly RB 0 0 14 O
physicians NNS 1 1 6 O
are VBP 1 0 12 O
advised VBN 1 0 12 O
to TO 0 0 12 O
obtain VB 0 1 1 O
serum JJ 0 1 14 O
digoxin NN 0 1 14 B-Drug
levels NNS 1 1 1 O
and CC 0 0 12 O
adjust VBP 0 0 1 O
digoxin NN 0 1 14 B-Drug
doses NNS 1 1 6 O
appropriately RB 0 0 1 O
. . 0 0 12 O

Because IN 0 0 12 O
of IN 0 0 12 O
its PRP$ 1 0 12 O
lack NN 0 1 1 O
of IN 0 0 12 O
platelet NN 0 1 14 O
effects NNS 1 1 1 O
VIOXX NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
not RB 0 1 12 O
a DT 0 0 12 O
substitute NN 0 0 16 O
for IN 0 0 12 O
aspirin NN 0 1 14 B-Brand
for IN 0 0 12 O
cardiovascular JJ 0 1 6 O
prophylaxis NN 0 1 6 O
. . 0 0 12 O

In IN 0 0 2 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
indicate VBP 0 0 1 O
that IN 0 0 12 O
ertapenem NN 0 1 16 B-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
inhibit VB 0 1 13 O
P NNP 0 1 2 O
- : 0 0 2 O
glycoprotein NN 0 1 UNK O
- : 0 0 2 O
mediated VBN 1 1 13 O
transport NN 0 1 1 O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
or CC 0 0 12 O
vinblastine NN 0 1 13 B-Drug
and CC 0 0 12 O
that DT 0 0 12 O
ertapenem NN 0 1 16 B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
a DT 0 0 12 O
substrate NN 0 1 UNK O
for IN 0 0 12 O
P NNP 0 1 2 O
- : 0 0 2 O
glycoprotein NN 0 1 UNK O
- : 0 0 2 O
mediated VBN 1 1 13 O
transport NN 0 1 1 O
. . 0 0 12 O

Since IN 0 1 2 O
aminotransferase NN 0 1 13 O
determinations NNS 1 1 UNK O
are VBP 1 0 12 O
important JJ 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
differential JJ 0 1 1 O
diagnosis NN 0 1 6 O
of IN 0 0 12 O
myocardial JJ 0 1 6 O
infarction NN 0 1 6 O
liver NN 0 1 6 O
disease NN 0 1 6 O
and CC 0 0 12 O
pulmonary JJ 0 1 6 O
emboli NN 1 1 8 O
rises VBZ 1 0 UNK O
that WDT 0 0 12 O
might MD 0 0 12 O
be VB 0 0 12 O
caused VBN 1 1 1 O
by IN 0 0 12 O
drugs NNS 1 1 6 O
( ( 0 0 2 O
heparin VB 0 1 14 B-Drug
sodium NN 0 1 14 I-Drug
) ) 0 0 2 O
should MD 0 0 12 O
be VB 0 0 12 O
interpreted VBN 1 1 UNK O
with IN 0 0 12 O
caution NN 0 0 1 O
. . 0 0 12 O

Caution NN 0 0 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
when WRB 0 0 12 O
administering VBG 1 1 1 O
MOBIC NNP 0 1 UNK B-Brand
with IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
since IN 0 1 12 O
patients NNS 1 1 6 O
on IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
may MD 0 0 1 O
experience VB 0 1 12 O
changes NNS 1 1 1 O
in IN 0 0 12 O
INR NNP 0 1 13 O
and CC 0 0 12 O
an DT 0 0 12 O
increased VBN 1 1 1 O
risk NN 0 1 1 O
of IN 0 0 12 O
bleeding VBG 1 1 6 O
complications NNS 1 1 6 O
when WRB 0 0 12 O
a DT 0 0 12 O
new JJ 0 1 12 O
medication NN 0 1 6 O
is VBZ 1 0 12 O
introduced VBN 1 1 12 O
. . 0 0 12 O

However RB 0 0 1 O
no DT 0 0 12 O
related JJ 0 1 1 O
changes NNS 1 1 1 O
were VBD 1 0 12 O
noted VBN 1 0 1 O
in IN 0 0 12 O
the DT 0 0 12 O
QT9 NNP 0 0 UNK O
on IN 0 0 12 O
ECG NNP 0 1 6 O
taken VBN 1 1 12 O
at IN 0 0 12 O
9 CD 0 0 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
after IN 0 0 12 O
the DT 0 0 12 O
coadministration NN 0 1 UNK O
. . 0 0 12 O

This DT 0 0 2 O
included VBD 1 1 1 O
post NN 0 1 12 O
myocardial JJ 0 1 6 O
infarction NN 0 1 6 O
patients NNS 1 1 6 O
who WP 0 0 12 O
were VBD 1 0 12 O
receiving VBG 1 1 1 O
intravenous JJ 0 1 14 O
or CC 0 0 12 O
transdermal JJ 0 1 14 O
nitroglycerin NN 0 1 14 B-Drug
. . 0 0 12 O

Due JJ 0 1 2 O
to TO 0 0 12 O
its PRP$ 1 0 12 O
potential JJ 0 1 1 O
to TO 0 0 12 O
cause VB 0 1 12 O
neutropenia NN 0 1 14 O
and CC 0 0 12 O
lymphopenia JJ 0 1 8 O
proper JJ 0 0 1 O
monitoring NN 0 1 1 O
of IN 0 0 12 O
patients NNS 1 1 6 O
is VBZ 1 0 12 O
required VBN 1 1 1 O
if IN 0 0 12 O
Rebif NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
given VBN 1 1 12 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
myelosuppressive JJ 0 0 UNK O
agents NNS 1 1 1 O
. . 0 0 12 O

Cyclosporine NNP 0 1 UNK O
Digoxin NNP 0 1 0 O
Methotrexate NNP 0 1 0 O
Lodine NNP 0 1 UNK B-Brand
like IN 0 0 12 O
other JJ 0 0 12 O
NSAIDs NNP 0 1 UNK B-Group
through IN 0 0 12 O
effects NNS 1 1 1 O
on IN 0 0 12 O
renal JJ 0 1 6 O
prostaglandins NNS 1 1 UNK O
may MD 0 0 1 O
cause VB 0 1 12 O
changes NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
elimination NN 0 1 UNK O
of IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
leading VBG 1 1 1 O
to TO 0 0 12 O
elevated VBN 1 1 1 O
serum NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
cyclosporine NN 0 1 14 B-Drug
digoxin NN 0 1 14 B-Drug
methotrexate NN 0 1 16 B-Drug
and CC 0 0 12 O
increased JJ 0 1 1 O
toxicity NN 0 1 6 O
. . 0 0 12 O

dextrothyroxine NN 0 1 UNK B-Drug
; : 0 0 2 O

Few JJ 0 1 2 O
data NNS 0 1 1 O
exist VBP 0 1 UNK O
on IN 0 0 12 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
caffeine NN 0 1 6 B-Drug
in IN 0 0 12 O
preterm JJ 0 1 6 O
neonates NNS 1 1 16 O
. . 0 0 12 O

Of IN 0 0 2 O
particular JJ 0 0 1 O
importance NN 0 1 1 O
sufficient JJ 0 1 1 O
time NN 0 1 12 O
must MD 0 0 12 O
elapse VB 0 1 UNK O
before IN 0 1 12 O
initiating VBG 1 1 1 O
TCA NNP 0 1 13 O
treatment NN 0 1 6 O
in IN 0 0 12 O
a DT 0 0 12 O
patient NN 0 1 6 O
being VBG 1 0 12 O
withdrawn VBN 1 1 1 O
from IN 0 0 12 O
fluoxetine NN 0 1 16 B-Drug
given VBN 1 1 12 O
the DT 0 0 12 O
long JJ 0 1 12 O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
parent NN 0 1 13 O
and CC 0 0 12 O
active JJ 0 1 1 O
metabolite NN 0 1 UNK O
( ( 0 0 2 O
at IN 0 0 12 O
least JJS 0 1 12 O
9 CD 0 0 2 O
weeks NNS 1 1 12 O
may MD 0 0 1 O
be VB 0 0 12 O
necessary JJ 0 0 1 O
) ) 0 0 2 O
. . 0 0 12 O

Interactions NNS 0 1 UNK O
for IN 0 0 12 O
vitamin NN 0 1 6 B-Group
D NNP 0 1 2 I-Group
analogues NNS 1 1 UNK I-Group
( ( 0 0 2 O
Vitamin NNP 0 1 2 B-Drug
D9 NNP 0 1 UNK I-Drug
Vitamin NNP 0 1 2 B-Drug
D9 NNP 0 1 UNK I-Drug
Calcitriol NNP 0 1 0 B-Drug
and CC 0 0 12 O
Calcidiol NNP 0 1 UNK B-Drug
) ) 0 0 2 O
: : 0 0 2 O
Cholestyramine NN 0 1 UNK B-Drug
: : 0 0 2 O
Cholestyramine NN 0 1 UNK B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
reduce VB 0 0 1 O
intestinal JJ 0 1 13 O
absorption NN 0 1 1 O
of IN 0 0 12 O
fat JJ 0 1 3 B-Group
soluble JJ 0 1 16 I-Group
vitamins NNS 1 1 6 I-Group
; : 0 0 2 O

Methotrexate NN 0 1 0 B-Drug
: : 0 0 2 O
Piperacillin NNP 0 1 0 B-Drug
sodium NN 0 1 14 I-Drug
may MD 0 0 1 O
reduce VB 0 0 1 O
the DT 0 0 12 O
excretion NN 0 1 14 O
of IN 0 0 12 O
methotrexate NN 0 1 16 B-Drug
. . 0 0 12 O

Ethanol NNP 0 1 13 B-Drug
or CC 0 0 12 O
Triazolam NNP 0 1 UNK B-Drug
: : 0 0 2 O
No DT 0 0 2 O
significant JJ 0 1 1 O
differences NNS 1 1 UNK O
were VBD 1 0 12 O
observed VBN 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
triazolam NN 0 1 13 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
) ) 0 0 2 O
and CC 0 0 12 O
tiagabine NN 0 1 13 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
) ) 0 0 2 O
when WRB 0 0 12 O
given VBN 1 1 12 O
together RB 0 1 12 O
as IN 1 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
dose NN 0 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
possibility NN 0 1 1 O
of IN 0 0 12 O
hypotensive JJ 0 1 14 O
effects NNS 1 1 1 O
with IN 0 0 12 O
Lotensin NNP 0 1 UNK B-Brand
can MD 0 0 12 O
be VB 0 0 12 O
minimized VBN 1 0 1 O
by IN 0 0 12 O
either DT 0 1 12 O
discontinuing VBG 1 1 6 O
the DT 0 0 12 O
diuretic JJ 0 1 14 B-Group
or CC 0 0 12 O
increasing VBG 1 1 1 O
the DT 0 0 12 O
salt NN 0 1 3 O
intake VB 0 1 3 O
prior JJ 0 1 1 O
to TO 0 0 12 O
initiation NN 0 1 1 O
of IN 0 0 12 O
treatment NN 0 1 6 O
with IN 0 0 12 O
Lotensin NNP 0 1 UNK B-Brand
. . 0 0 12 O

The DT 0 0 2 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
bosentan NNS 0 1 13 B-Drug
were VBD 1 0 12 O
not RB 0 1 12 O
affected VBN 1 1 1 O
. . 0 0 12 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interactions NNP 0 1 UNK O
There EX 0 0 12 O
are VBP 1 0 12 O
no DT 0 0 12 O
known JJ 0 1 12 O
interactions NNS 1 1 UNK O
between IN 0 0 12 O
APOKYN NNP 0 1 UNK B-Brand
and CC 0 0 12 O
laboratory NN 0 1 1 O
tests NNS 1 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
female JJ 0 1 12 O
rats NNS 1 1 UNK O
fulvestrant VBP 0 1 13 B-Drug
administered VBN 1 1 1 O
at IN 0 0 12 O
doses NNS 1 1 6 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
kg JJ 0 1 18 O
/ JJ 0 0 2 O
day NN 0 1 12 O
( ( 0 0 2 O
approximately RB 0 1 1 O
one CD 0 1 12 O
- : 0 0 2 O
hundredth NN 0 0 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
human NN 0 1 1 O
recommended VBD 1 1 1 O
dose RB 0 1 6 O
based VBN 1 1 1 O
on IN 0 0 12 O
body NN 0 1 3 O
surface JJ 0 1 3 O
area NN 0 1 12 O
[ NNP 0 0 2 O
BSA NNP 0 0 13 O
] NNP 0 0 2 O
for IN 0 0 12 O
9 CD 0 0 2 O
weeks NNS 1 1 12 O
prior RB 0 1 1 O
to TO 0 0 12 O
and CC 0 0 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
week NN 0 1 12 O
following VBG 1 1 1 O
mating NN 0 1 UNK O
caused VBD 1 1 1 O
a DT 0 0 12 O
reduction NN 0 1 1 O
in IN 0 0 12 O
fertility NN 0 1 6 O
and CC 0 0 12 O
embryonic JJ 0 1 13 O
survival NN 0 1 1 O
. . 0 0 12 O

Coffee NN 0 1 UNK O
and CC 0 0 12 O
black JJ 0 1 3 O
tea NN 0 1 13 O
should MD 0 0 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
because IN 0 0 12 O
they PRP 0 0 12 O
decrease VBP 0 1 1 O
the DT 0 0 12 O
absorption NN 0 1 1 O
of IN 0 0 12 O
levomepromazine NN 0 1 UNK B-Drug
considerably RB 0 0 1 O
. . 0 0 12 O

The DT 0 0 2 O
effects NNS 1 1 1 O
of IN 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
on IN 0 0 12 O
clonidines NNS 1 0 UNK B-Drug
analgesic JJ 0 1 13 O
actions NNS 1 1 UNK O
are VBP 1 0 12 O
not RB 0 1 12 O
known VBN 1 1 12 O
. . 0 0 12 O

Methadone NN 0 1 0 B-Drug
: : 0 0 2 O
Coadministration NN 0 1 UNK O
of IN 0 0 12 O
amprenavir NN 0 1 13 B-Drug
and CC 0 0 12 O
methadone NN 0 1 6 B-Drug
can MD 0 0 12 O
decrease VB 0 1 1 O
plasma JJ 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
methadone NN 0 1 6 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
clinical JJ 0 1 6 O
significance NN 0 1 13 O
of IN 0 0 12 O
this DT 0 0 12 O
finding NN 0 1 12 O
is VBZ 1 0 12 O
unknown JJ 0 1 12 O
. . 0 0 12 O

. . 0 0 12 O

Aspirin NNP 0 1 0 B-Brand
increased VBD 1 1 1 O
ulcerogenic JJ 0 1 UNK O
effect NN 0 1 1 O
; : 0 0 2 O

Digitalis NNP 0 1 15 B-Group
toxicity NN 0 1 6 O
may MD 0 0 1 O
be VB 0 0 12 O
aggravated VBN 1 1 6 O
by IN 0 0 12 O
the DT 0 0 12 O
initial JJ 0 1 1 O
release NN 0 1 12 O
of IN 0 0 12 O
norepinephrine NN 0 1 14 O
caused VBN 1 1 1 O
by IN 0 0 12 O
Bretylium NNP 0 1 UNK B-Drug
Tosylate NNP 0 0 UNK I-Drug
Injection NNP 0 1 7 O
. . 0 0 12 O

Azithromycin NNP 0 1 0 B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
affect VB 0 1 1 O
the DT 0 0 12 O
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
response NN 0 1 1 O
to TO 0 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
. . 0 0 12 O

Tadalafil NN 0 1 UNK B-Drug

Conflicting VBG 0 1 UNK O
results NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
regarding VBG 1 0 1 O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
EPA NNP 0 0 UNK B-Drug
supplements NNS 1 1 6 O
on IN 0 0 12 O
glycemic JJ 0 1 14 O
control NN 0 1 1 O
in IN 0 0 12 O
non JJ 0 1 1 O
- : 0 0 2 O
diabetics NNS 1 1 UNK O
with IN 0 0 12 O
glucose JJ 0 1 14 O
intolerance NN 0 1 6 O
and CC 0 0 12 O
those DT 0 0 12 O
with IN 0 0 12 O
type JJ 0 1 1 O
9 CD 0 0 2 O
diabetes NNS 0 1 6 O
. . 0 0 12 O

If IN 0 0 12 O
the DT 0 0 12 O
usual JJ 0 1 12 O
amounts NNS 1 1 1 O
of IN 0 0 12 O
nondepolarizing NN 0 0 UNK O
relaxants NNS 1 0 13 O
are VBP 1 0 12 O
given VBN 1 1 12 O
the DT 0 0 12 O
time NN 0 1 12 O
for IN 0 0 12 O
recovery NN 0 1 1 O
from IN 0 0 12 O
neuromuscular JJ 0 1 6 O
blockade NN 0 1 1 O
will MD 0 0 12 O
be VB 0 0 12 O
longer RBR 0 1 12 O
in IN 0 0 12 O
the DT 0 0 12 O
presence NN 0 1 1 O
of IN 0 0 12 O
Enflurane NNP 0 1 UNK B-Drug
than IN 0 0 12 O
when WRB 0 0 12 O
halothane NN 0 1 13 B-Drug
or CC 0 0 12 O
nitrous JJ 0 1 UNK B-Drug
oxide NN 0 1 14 I-Drug
with IN 0 0 12 O
a DT 0 0 12 O
balanced VBN 1 1 1 O
technique NN 0 1 1 O
are VBP 1 0 12 O
used VBN 1 1 12 O
. . 0 0 12 O

Certain NNP 0 1 UNK O
antibiotics NNS 1 1 6 B-Group
especially RB 0 0 12 O
neomycin JJ 0 1 16 B-Drug
streptomycin NN 0 1 13 B-Drug
and CC 0 0 12 O
kanamycin NNS 0 1 UNK B-Drug
have VBP 0 0 12 O
a DT 0 0 12 O
mild NN 0 1 6 O
but CC 0 0 12 O
definite JJ 0 1 1 O
nondepolarizing NN 0 0 UNK O
blocking VBG 1 1 UNK O
action NN 0 1 13 O
which WDT 0 0 12 O
may MD 0 0 1 O
accentuate VB 0 0 UNK O
neuromuscular JJ 0 1 6 O
block NN 0 1 3 O
. . 0 0 12 O

The DT 0 0 2 O
renal JJ 0 1 6 O
effects NNS 1 1 1 O
of IN 0 0 12 O
nephrotoxic JJ 0 1 UNK O
compounds NNS 1 1 13 O
may MD 0 0 1 O
be VB 0 0 12 O
potentiated VBN 1 0 UNK O
by IN 0 0 12 O
Carboplatin NNP 0 1 0 B-Drug
. . 0 0 12 O

Specific JJ 0 1 UNK O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
including VBG 1 1 1 O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
MTX NNP 0 1 UNK B-Drug
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
conducted VBN 1 1 1 O
. . 0 0 12 O

Valproate NN 0 1 0 B-Drug
: : 0 0 2 O
Available JJ 0 1 UNK O
data NNS 0 1 1 O
suggest VBP 0 1 1 O
that IN 0 0 12 O
there EX 0 0 12 O
is VBZ 1 0 12 O
no DT 0 0 12 O
significant JJ 0 1 1 O
effect NN 0 1 1 O
of IN 0 0 12 O
valproate NN 0 1 16 B-Drug
on IN 0 0 12 O
the DT 0 0 12 O
clearance NN 0 1 16 O
of IN 0 0 12 O
Felbatol NNP 0 1 UNK B-Brand
at IN 0 0 12 O
steady JJ 0 1 1 O
state NN 0 1 1 O
Therefore IN 0 0 1 O
the DT 0 0 12 O
addition NN 0 1 1 O
of IN 0 0 12 O
valproate NN 0 1 16 B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
expected VBN 1 1 12 O
to TO 0 0 12 O
cause VB 0 1 12 O
a DT 0 0 12 O
clinically RB 0 0 6 O
important JJ 0 1 1 O
effect NN 0 1 1 O
on IN 0 0 12 O
Felbatol NNP 0 1 UNK B-Brand
( ( 0 0 2 O
felbamate NN 0 1 13 B-Drug
) ) 0 0 2 O
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
. . 0 0 12 O

- : 0 0 2 O
Antithyroid NN 0 0 UNK B-Group
agents NNS 1 1 1 I-Group
( ( 0 0 2 O
medicine NN 0 1 6 O
for IN 0 0 12 O
overactive JJ 0 1 UNK O
thyroid NN 0 1 6 O
) ) 0 0 2 O
or CC 0 0 12 O

Concomitant JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
TRENTAL NNP 0 1 UNK B-Brand
and CC 0 0 12 O
theophylline VB 0 1 16 B-Drug
- : 0 0 2 O
containing VBG 1 1 1 O
drugs NNS 1 1 6 O
leads VBZ 1 1 12 O
to TO 0 0 12 O
increased VBN 1 1 1 O
theophylline NN 0 1 16 B-Drug
levels NNS 1 1 1 O
and CC 0 0 12 O
theophylline NN 0 1 16 B-Drug
toxicity NN 0 1 6 O
in IN 0 0 12 O
some DT 0 0 12 O
individuals NNS 1 1 1 O
. . 0 0 12 O

Substrate NNP 0 1 UNK O
of IN 0 0 12 O
CYP9D9 NNP 0 0 UNK O
( ( 0 0 2 O
minor JJ 0 1 1 O
) ) 0 0 2 O
9A9 CD 0 0 UNK O
( ( 0 0 2 O
major JJ 0 1 1 O
) ) 0 0 2 O
; : 0 0 2 O

Drug NNP 0 1 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interactions NNP 0 1 UNK O
Interactions NNP 0 1 UNK O
between IN 0 0 12 O
darifenacin NN 0 1 13 B-Drug
and CC 0 0 12 O
laboratory NN 0 1 1 O
tests NNS 1 1 1 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
studied VBN 1 0 1 O
. . 0 0 12 O

The DT 0 0 2 O
following NN 0 1 1 O
are VBP 1 0 12 O
examples NNS 1 1 UNK O
of IN 0 0 12 O
substances NNS 1 1 1 O
that WDT 0 0 12 O
may MD 0 0 1 O
reduce VB 0 0 1 O
the DT 0 0 12 O
blood NN 0 1 6 O
- : 0 0 2 O
glucose JJ 0 1 14 O
- : 0 0 2 O
lowering VBG 1 1 UNK O
effect NN 0 1 1 O
: : 0 0 2 O
corticosteroids NNS 1 1 14 B-Group
niacin VBP 0 1 14 B-Drug
danazol JJ 0 1 13 B-Drug
diuretics NNS 1 1 14 B-Group
sympathomimetic JJ 0 1 13 B-Group
agents NNS 1 1 1 I-Group
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
epinephrine NN 0 1 14 B-Drug
salbutamol NN 0 1 UNK B-Drug
terbutaline NN 0 1 0 B-Drug
) ) 0 0 2 O
isoniazid NN 0 1 13 B-Drug
phenothiazine NN 0 1 UNK B-Group
derivatives NNS 1 1 13 I-Group
somatropin VBP 0 1 13 B-Drug
thyroid JJ 0 1 6 B-Group
hormones NNS 1 1 13 I-Group
estrogens NNS 1 1 16 B-Group
progestogens NNS 1 1 UNK B-Group
( ( 0 0 2 O
e.g. NN 0 0 UNK O
in IN 0 0 12 O
oral JJ 0 1 6 O
contraceptives NNS 1 1 13 B-Group
) ) 0 0 2 O
. . 0 0 12 O

phenytoin NN 0 1 16 B-Drug
; : 0 0 2 O

Erythromycin NN 0 1 0 B-Drug

Drugs NNS 0 1 2 O
that WDT 0 0 12 O
Inhibit NNP 0 1 UNK O
Drug NNP 0 1 2 O
Transport NNP 0 1 UNK O
Systems NNP 0 1 UNK O
Lapatinib NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
a DT 0 0 12 O
substrate NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
efflux NN 0 0 UNK O
transporter NN 0 1 UNK O
P NNP 0 1 2 O
- : 0 0 2 O
glycoprotein NN 0 1 UNK O
( ( 0 0 2 O
Pgp NNP 0 1 UNK O
ABCB9 NNP 0 1 UNK O
) ) 0 0 2 O
. . 0 0 12 O

Induction NN 0 1 UNK O
of IN 0 0 12 O
such JJ 0 0 1 O
tumors NNS 1 1 6 O
is VBZ 1 0 12 O
consistent JJ 0 1 1 O
with IN 0 0 12 O
the DT 0 0 12 O
pharmacology NN 0 1 UNK O
- : 0 0 2 O
related JJ 0 1 1 O
endocrine JJ 0 1 6 O
feedback NN 0 1 UNK O
alterations NNS 1 1 1 O
in IN 0 0 12 O
gonadotropin NN 0 1 13 O
levels NNS 1 1 1 O
caused VBN 1 1 1 O
by IN 0 0 12 O
an DT 0 0 12 O
antiestrogen NN 0 1 UNK B-Group
. . 0 0 12 O

indinavir NN 0 1 16 B-Drug
concentration NN 0 1 1 O

Conversely RB 0 0 UNK O
decreases VBZ 1 1 UNK O
in IN 0 0 12 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
upon IN 0 0 12 O
discontinuation NN 0 1 6 O
of IN 0 0 12 O
cimetidine NN 0 1 13 B-Drug
which WDT 0 0 12 O
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
loss NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
therapeutic JJ 0 1 6 O
efficacy NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressant JJ 0 1 6 I-Group
9 CD 0 0 2 O
. . 0 0 12 O

The DT 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
SUPRAX NNP 0 1 UNK B-Brand
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
false JJ 0 1 13 O
- : 0 0 2 O
positive JJ 0 1 1 O
reaction NN 0 1 1 O
for IN 0 0 12 O
glucose NN 0 1 14 O
in IN 0 0 12 O
the DT 0 0 12 O
urine JJ 0 1 6 O
using VBG 1 1 1 O
Clinitest NNP 0 1 UNK O
** NNP 0 0 2 O
Benedict NNP 0 0 UNK O
solution NN 0 1 1 O
or CC 0 0 12 O
Fehling VBG 0 0 UNK O
s JJ 0 1 12 O
solution NN 0 1 1 O
. . 0 0 12 O

Drugs NNS 0 1 2 O
which WDT 0 0 12 O
impair VBP 0 0 13 O
glomerular JJ 0 1 UNK O
filtration NN 0 1 3 O
may MD 0 0 1 O
prolong VB 0 0 13 O
the DT 0 0 12 O
biological JJ 0 1 13 O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
of IN 0 0 12 O
flucytosine NN 0 1 13 B-Drug
. . 0 0 12 O

Coadministration NN 0 1 UNK O
of IN 0 0 12 O
gly RB 0 1 UNK O
- : 0 0 2 O
buride NN 0 0 UNK O
and CC 0 0 12 O
metformin NN 0 1 0 B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
result VB 0 1 1 O
in IN 0 0 12 O
any DT 0 0 12 O
changes NNS 1 1 1 O
in IN 0 0 12 O
either DT 0 1 12 O
metformin NN 0 1 0 B-Drug
pharmacokinetics NNS 0 1 UNK O
or CC 0 0 12 O
pharmaco VB 0 0 UNK O
- : 0 0 2 O
dynamics NNS 1 1 UNK O
. . 0 0 12 O

Inhibitors NNS 0 1 7 O
of IN 0 0 12 O
renal JJ 0 1 6 O
cationic JJ 0 1 UNK O
secretion NN 0 1 14 O
are VBP 1 0 12 O
contraindicated VBN 1 1 14 O
with IN 0 0 12 O
TIKOSYN NNP 0 1 UNK B-Brand
. . 0 0 12 O

These DT 0 0 1 O
potential JJ 0 1 1 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
are VBP 1 0 12 O
listed VBN 1 1 1 O
in IN 0 0 12 O
Table JJ 0 1 UNK O
9 CD 0 0 2 O
. . 0 0 12 O

Laboratory NN 0 1 2 O
Tests NNS 0 1 UNK O
Pregnancy NNP 0 1 7 O
Test NNP 0 1 2 O
Female NNP 0 1 2 O
patients NNS 1 1 6 O
of IN 0 0 12 O
childbearing VBG 0 0 UNK O
potential JJ 0 1 1 O
must MD 0 0 12 O
have VB 0 0 12 O
negative JJ 0 1 1 O
results NNS 1 1 1 O
from IN 0 0 12 O
9 CD 0 0 2 O
urine NN 0 1 6 O
or CC 0 0 12 O
serum JJ 0 1 14 O
pregnancy NN 0 1 6 O
tests NNS 1 1 1 O
with IN 0 0 12 O
a DT 0 0 12 O
sensitivity NN 0 1 1 O
of IN 0 0 12 O
at IN 0 0 12 O
least JJS 0 1 12 O
9 CD 0 0 2 O
mIU JJ 0 1 UNK O
/ NNP 0 0 2 O
mL NN 0 1 14 O
before IN 0 1 12 O
receiving VBG 1 1 1 O
the DT 0 0 12 O
initial JJ 0 1 1 O
Accutane NNP 0 1 UNK B-Brand
prescription NN 0 1 0 O
. . 0 0 12 O

Warfarin NN 0 1 0 B-Drug
: : 0 0 2 O
The DT 0 0 2 O
effects NNS 1 1 1 O
of IN 0 0 12 O
aliskiren NNS 0 1 13 B-Drug
on IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
pharmacokinetics NNS 0 1 UNK O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
evaluated VBN 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
well NN 0 1 12 O
- : 0 0 2 O
controlled VBN 1 1 1 O
clinical JJ 0 1 6 O
trial NN 0 1 12 O
. . 0 0 12 O

Diuretics NNS 0 1 UNK B-Group
: : 0 0 2 O
Patients NNS 0 1 7 O
on IN 0 0 12 O
diuretics NNS 1 1 14 B-Group
and CC 0 0 12 O
especially RB 0 0 12 O
those DT 0 0 12 O
started VBN 1 1 12 O
recently RB 0 1 12 O
may MD 0 0 1 O
occasionally RB 0 1 12 O
experience VB 0 1 12 O
an DT 0 0 12 O
excessive JJ 0 1 1 O
reduction NN 0 1 1 O
of IN 0 0 12 O
blood NN 0 1 6 O
pressure NN 0 1 1 O
after IN 0 0 12 O
initiation NN 0 1 1 O
of IN 0 0 12 O
ACEON NNP 0 1 UNK B-Brand
Tablets NNP 0 1 0 O
therapy NN 0 1 6 O
. . 0 0 12 O

Cardiac NNP 0 1 7 B-Group
glycosides NNS 1 1 13 I-Group

Esomeprazole NNP 0 1 UNK B-Drug
inhibits VBZ 1 1 UNK O
gastric JJ 0 1 6 O
acid JJ 0 1 14 O
secretion NN 0 1 14 O
. . 0 0 12 O

Thus RB 0 0 1 O
probenecid NN 0 1 13 B-Drug
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
bumetanide NN 0 1 16 B-Drug
. . 0 0 12 O

An DT 0 0 2 O
in IN 0 0 12 O
vivo NN 0 1 13 O
interaction NN 0 1 UNK O
study NN 0 1 1 O
in IN 0 0 12 O
humans NNS 1 1 UNK O
demonstrated VBD 1 0 1 O
that IN 0 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
9mg CD 0 0 UNK O
dose NN 0 1 6 O
of IN 0 0 12 O
anagrelide NN 0 1 13 B-Drug
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
dose NN 0 1 6 O
of IN 0 0 12 O
aspirin NN 0 1 14 B-Brand
was VBD 1 0 12 O
generally RB 0 0 1 O
well RB 0 1 12 O
tolerated VBN 1 0 1 O
. . 0 0 12 O

After IN 0 0 2 O
multiple JJ 0 1 1 O
dosing VBG 1 0 14 O
interferon NN 0 1 14 B-Drug
beta NN 0 1 16 I-Drug
- : 0 0 2 O
9a CD 0 1 UNK I-Drug
( ( 0 0 2 O
AVONEX NNP 0 1 UNK B-Brand
9 CD 0 0 2 O
mcg NN 0 1 0 O
IM NNP 0 1 11 O
once RB 0 0 12 O
weekly RB 0 1 12 O
) ) 0 0 2 O
reduced VBD 1 1 1 O
TYSABRI NNP 0 1 UNK B-Brand
clearance NN 0 1 16 O
by IN 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

9 CD 0 0 2 O
. . 0 0 12 O

Anticoagulants NNS 0 1 UNK B-Group
: : 0 0 2 O
Warfarin NN 0 1 0 B-Drug

9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O

Lithium JJ 0 1 UNK B-Drug
carbonate NN 0 1 14 I-Drug
: : 0 0 2 O
The DT 0 0 2 O
stimulatory JJ 0 0 UNK O
effects NNS 1 1 1 O
of IN 0 0 12 O
amphetamines NNS 1 1 14 B-Group
may MD 0 0 1 O
be VB 0 0 12 O
inhibited VBN 1 1 13 O
by IN 0 0 12 O
lithium NN 0 1 16 B-Drug
carbonate NN 0 1 14 I-Drug
. . 0 0 12 O

is VBZ 1 0 12 O
a DT 0 0 12 O
possibility NN 0 1 1 O
. . 0 0 12 O

When WRB 0 0 12 O
patients NNS 1 1 6 O
being VBG 1 0 12 O
treated VBN 1 1 1 O
with IN 0 0 12 O
labetalol NNS 0 1 0 B-Drug
have VBP 0 0 12 O
a DT 0 0 12 O
positive JJ 0 1 1 O
urine JJ 0 1 6 O
test NN 0 1 1 O
for IN 0 0 12 O
amphetamine NN 0 1 13 B-Drug
using VBG 1 1 1 O
these DT 0 0 12 O
techniques NNS 1 1 13 O
confirmation NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
made VBN 1 1 12 O
by IN 0 0 12 O
using VBG 1 1 1 O
more JJR 0 1 12 O
specific JJ 0 1 1 O
methods NNS 1 1 1 O
such JJ 0 0 1 O
as IN 1 0 12 O
a DT 0 0 12 O
gas NN 0 1 3 O
chromatographic JJ 0 1 UNK O
- : 0 0 2 O
mass NN 0 1 1 O
spectrometer NN 0 1 UNK O
technique NN 0 1 1 O
. . 0 0 12 O

Talk NN 0 1 UNK O
to TO 0 0 12 O
your PRP$ 0 0 12 O
doctor NN 0 1 12 O
and CC 0 0 12 O
pharmacist NN 0 1 13 O
before IN 0 1 12 O
taking VBG 1 0 12 O
any DT 0 0 12 O
prescription NN 0 1 0 O
or CC 0 0 12 O
over IN 0 1 12 O
- : 0 0 2 O
the DT 0 0 12 O
- : 0 0 2 O
counter NN 0 1 3 O
medicines NNS 1 1 6 O
including VBG 1 1 1 O
herbal JJ 0 1 6 O
products NNS 1 1 1 O
. . 0 0 12 O

Although IN 0 0 12 O
additional JJ 0 1 1 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
conducted VBN 1 1 1 O
the DT 0 0 12 O
most RBS 0 0 12 O
common JJ 0 1 1 O
medications NNS 1 1 6 O
used VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
anagrelide NN 0 1 13 B-Drug
in IN 0 0 12 O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
were VBD 1 0 12 O
aspirin JJ 0 1 14 B-Brand
acetaminophen JJ 0 1 16 B-Drug
furosemide NN 0 1 0 B-Drug
iron NN 0 1 3 B-Drug
ranitidine NN 0 1 0 B-Drug
hydroxyurea NN 0 1 14 B-Drug
and CC 0 0 12 O
allopurinol NN 0 1 13 B-Drug
. . 0 0 12 O

Many JJ 0 0 UNK O
other JJ 0 0 12 O
medicines NNS 1 1 6 O
may MD 0 0 1 O
increase VB 0 1 1 O
or CC 0 0 12 O
decrease VB 0 1 1 O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
glimepiride NN 0 1 16 B-Drug
or CC 0 0 12 O
affect VB 0 1 1 O
your PRP$ 0 0 12 O
condition NN 0 1 1 O
. . 0 0 12 O

However RB 0 0 1 O
in IN 0 0 12 O
vivo JJ 0 1 13 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
of IN 0 0 12 O
ketoconazole NN 0 1 16 B-Drug
with IN 0 0 12 O
vitamin NN 0 1 6 B-Group
D NNP 0 1 2 I-Group
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
investigated VBN 1 1 1 O
. . 0 0 12 O

Lithium NNP 0 1 UNK B-Drug
renal JJ 0 1 6 O
clearance NN 0 1 16 O
is VBZ 1 0 12 O
reduced VBN 1 1 1 O
by IN 0 0 12 O
thiazides NNS 1 1 UNK B-Group
increasing VBG 1 1 1 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
lithium NN 0 1 16 B-Drug
toxicity NN 0 1 6 O
. . 0 0 12 O

No DT 0 0 2 O
formal JJ 0 1 1 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
conducted VBN 1 1 1 O
with IN 0 0 12 O
VELCADE NNP 0 1 UNK B-Brand
. . 0 0 12 O

Digoxin NN 0 1 0 B-Drug
: : 0 0 2 O
Supraventricular JJ 0 0 7 O
arrhythmias NN 1 1 6 O
may MD 0 0 1 O
mask VB 0 1 3 O
the DT 0 0 12 O
cardiotoxicity NN 0 1 UNK O
associated VBN 1 1 1 O
with IN 0 0 12 O
excessive JJ 0 1 1 O
digoxin NN 0 1 14 B-Drug
levels NNS 1 1 1 O
. . 0 0 12 O

Nevertheless RB 0 0 1 O
caution NN 0 0 1 O
is VBZ 1 0 12 O
indicated VBN 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
co NN 0 1 12 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
TCA9 NNP 0 0 UNK O
with IN 0 0 12 O
any DT 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
SSRIs NNP 0 1 UNK B-Group
and CC 0 0 12 O
also RB 0 0 12 O
in IN 0 0 12 O
switching VBG 1 1 UNK O
from IN 0 0 12 O
one CD 0 1 12 O
class NN 0 1 12 O
to TO 0 0 12 O
the DT 0 0 12 O
other JJ 0 0 12 O
. . 0 0 12 O

Flurbiprofen NNP 0 1 UNK B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
appear VB 0 1 12 O
to TO 0 0 12 O
affect VB 0 1 1 O
the DT 0 0 12 O
beta NN 0 1 16 O
- : 0 0 2 O
blocker NN 0 0 3 O
- : 0 0 2 O
mediated VBN 1 1 13 O
reduction NN 0 1 1 O
in IN 0 0 12 O
heart NN 0 1 12 O
rate NN 0 1 1 O
. . 0 0 12 O

There EX 0 0 12 O
is VBZ 1 0 12 O
insufficient JJ 0 1 1 O
experience NN 0 1 12 O
to TO 0 0 12 O
assess VB 0 1 1 O
the DT 0 0 12 O
safety NN 0 1 1 O
and CC 0 0 12 O
efficacy NN 0 1 UNK O
of IN 0 0 12 O
ORENCIA NNP 0 1 UNK B-Brand
administered VBD 1 1 1 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
anakinra NN 0 1 13 B-Drug
and CC 0 0 12 O
therefore RB 0 0 1 O
such JJ 0 0 1 O
use NN 0 1 1 O
is VBZ 1 0 12 O
not RB 0 1 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O

When WRB 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
either DT 0 1 12 O
of IN 0 0 12 O
these DT 0 0 12 O
two CD 0 1 12 O
drugs NNS 1 1 6 O
with IN 0 0 12 O
mexiletine NN 0 1 16 B-Drug
is VBZ 1 0 12 O
initiated VBN 1 1 1 O
the DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
mexiletine NN 0 1 16 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
slowly RB 0 1 3 O
titrated VBN 1 1 14 O
to TO 0 0 12 O
desired VB 1 1 1 O
effect NN 0 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
addition NN 0 1 1 O
the DT 0 0 12 O
transfusion NN 0 1 6 O
practices NNS 1 1 UNK O
for IN 0 0 12 O
such JJ 0 0 1 O
patients NNS 1 1 6 O
may MD 0 0 1 O
need VB 0 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
modified VBN 1 1 16 O
given VBN 1 1 12 O
the DT 0 0 12 O
increased VBN 1 1 1 O
risk NN 0 1 1 O
of IN 0 0 12 O
bleeding NN 0 1 6 O
. . 0 0 12 O

combination NN 0 1 1 O
therapy NN 0 1 6 O
is VBZ 1 0 12 O
contemplated VBN 1 0 UNK O
the DT 0 0 12 O
dosage NN 0 1 0 O
of IN 0 0 12 O
one CD 0 1 12 O
or CC 0 0 12 O
both DT 0 0 12 O
agents NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
reduced VBN 1 1 1 O
. . 0 0 12 O

These DT 0 0 1 O
in IN 0 0 12 O
vitro NN 0 1 UNK O
studies NNS 1 1 1 O
suggest VBP 0 1 1 O
that IN 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
zalcitabine NN 0 1 UNK B-Drug
and CC 0 0 12 O
lamivudine NN 0 1 16 B-Drug
in IN 0 0 12 O
humans NNS 1 1 UNK O
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
sub JJ 0 1 1 O
- : 0 0 2 O
therapeutic JJ 0 1 6 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
active JJ 0 1 1 O
phosphorylated VBN 0 0 UNK O
zalcitabine NN 0 1 UNK B-Drug
which WDT 0 0 12 O
may MD 0 0 1 O
lead VB 0 1 12 O
to TO 0 0 12 O
a DT 0 0 12 O
decreased JJ 0 1 1 O
antiretroviral JJ 0 0 UNK B-Group
effect NN 0 1 1 O
of IN 0 0 12 O
zalcitabine NN 0 1 UNK B-Drug
. . 0 0 12 O

These DT 0 0 1 O
agents NNS 1 1 1 O
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
in IN 0 0 12 O
patients NNS 1 1 6 O
treated VBN 1 1 1 O
with IN 0 0 12 O
NIZORAL NNP 0 1 UNK B-Brand
Tablets NNPS 0 1 0 O
. . 0 0 12 O

These DT 0 0 1 O
medications NNS 1 1 6 O
included VBD 1 1 1 O
thyroid JJ 0 1 6 B-Group
hormones NNS 1 1 13 I-Group
sedative JJ 0 1 6 B-Group
hypnotics NNS 1 1 13 I-Group
non SYM 0 1 1 B-Group
- : 0 0 2 O
steroidal NN 0 1 UNK I-Group
anti SYM 0 0 3 I-Group
- : 0 0 2 O
inflammatory NN 0 1 6 I-Group
agents NNS 1 1 1 I-Group
benzodiazepines NNS 1 1 14 B-Group
and CC 0 0 12 O
decongestants NNS 1 1 UNK B-Group
. . 0 0 12 O

No DT 0 0 2 O
formal JJ 0 1 1 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
conducted VBN 1 1 1 O
with IN 0 0 12 O
Rebif NNP 0 1 UNK B-Brand
. . 0 0 12 O

Hypotension NNP 0 1 7 O
- : 0 0 2 O
Patients NNS 0 1 7 O
on IN 0 0 12 O
Diuretic JJ 0 1 UNK O
Therapy NN 0 1 2 O
: : 0 0 2 O
Patients NNS 0 1 7 O
on IN 0 0 12 O
diuretics NNS 1 1 14 B-Group
and CC 0 0 12 O
especially RB 0 0 12 O
those DT 0 0 12 O
in IN 0 0 12 O
whom WP 0 0 12 O
diuretic JJ 0 1 14 O
therapy NN 0 1 6 O
was VBD 1 0 12 O
recently RB 0 1 12 O
instituted VBN 1 1 1 O
may MD 0 0 1 O
occasionally RB 0 1 12 O
experience VB 0 1 12 O
an DT 0 0 12 O
excessive JJ 0 1 1 O
reduction NN 0 1 1 O
of IN 0 0 12 O
blood NN 0 1 6 O
pressure NN 0 1 1 O
after IN 0 0 12 O
initiation NN 0 1 1 O
of IN 0 0 12 O
therapy NN 0 1 6 O
with IN 0 0 12 O
PRINIVIL NNP 0 1 UNK B-Brand
. . 0 0 12 O

In IN 0 0 2 O
these DT 0 0 12 O
subjects NNS 1 1 UNK O
( ( 0 0 2 O
R= NNP 0 1 UNK O
B NNP 0 0 2 O
) ) 0 0 2 O
the DT 0 0 12 O
clearance NN 0 1 16 O
of IN 0 0 12 O
diazepam NN 0 1 0 B-Drug
was VBD 1 0 12 O
reduced VBN 1 1 1 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
that IN 0 0 12 O
of IN 0 0 12 O
N NNP 0 1 2 B-Drug_n
- : 0 0 2 O
desmethyldiazepam NN 0 1 UNK I-Drug_n
to TO 0 0 12 O
a DT 0 0 12 O
level NN 0 1 1 O
that WDT 0 0 12 O
was VBD 1 0 12 O
too RB 0 0 12 O
low JJ 0 1 1 O
to TO 0 0 12 O
measure VB 0 1 1 O
over IN 0 1 12 O
the DT 0 0 12 O
course NN 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
9 CD 0 0 2 O
week NN 0 1 12 O
long RB 0 1 12 O
study NN 0 1 1 O
. . 0 0 12 O

Caution NN 0 0 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
exercised VBN 1 1 1 O
and CC 0 0 12 O
dose JJ 0 1 6 O
reduction NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
concomitant JJ 0 1 6 O
substrate JJ 0 1 UNK O
drug NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
when WRB 0 0 12 O
dosing VBG 1 0 14 O
lapatinib RB 0 1 13 B-Drug
concurrently RB 0 0 1 O
with IN 0 0 12 O
medications NNS 1 1 6 O
with IN 0 0 12 O
narrow JJ 0 1 3 O
therapeutic JJ 0 1 6 O
windows NNS 1 1 3 O
that WDT 0 0 12 O
are VBP 1 0 12 O
substrates NNS 1 1 UNK O
of IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
or CC 0 0 12 O
CYP9C9 NNP 0 0 UNK O
. . 0 0 12 O

Other JJ 0 0 2 O
compounds NNS 1 1 13 O
that WDT 0 0 12 O
are VBP 1 0 12 O
substrates NNS 1 1 UNK O
of IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
may MD 0 0 1 O
have VB 0 0 12 O
decreased VBN 1 1 1 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
when WRB 0 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
SUSTIVA NNP 0 1 UNK B-Brand
( ( 0 0 2 O
efavirenz NN 0 1 13 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

The DT 0 0 2 O
possibility NN 0 1 1 O
of IN 0 0 12 O
hypotensive JJ 0 1 14 O
effects NNS 1 1 1 O
can MD 0 0 12 O
be VB 0 0 12 O
minimized VBN 1 0 1 O
by IN 0 0 12 O
either DT 0 1 12 O
discontinuing VBG 1 1 6 O
the DT 0 0 12 O
diuretic JJ 0 1 14 B-Group
or CC 0 0 12 O
increasing VBG 1 1 1 O
the DT 0 0 12 O
salt NN 0 1 3 O
intake VB 0 1 3 O
prior JJ 0 1 1 O
to TO 0 0 12 O
initiation NN 0 1 1 O
of IN 0 0 12 O
treatment NN 0 1 6 O
with IN 0 0 12 O
perindopril NN 0 1 UNK B-Drug
. . 0 0 12 O

Nonsteroidal NNP 0 0 UNK B-Group
Anti NNP 0 0 UNK I-Group
- : 0 0 2 O
Inflammatory NN 0 1 UNK I-Group
Drugs NNP 0 1 2 I-Group
( ( 0 0 2 O
NSAIDs NNP 0 1 UNK B-Group
) ) 0 0 2 O
- : 0 0 2 O
A DT 0 0 2 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
study NN 0 1 1 O
of IN 0 0 12 O
eplerenone NN 0 1 13 B-Drug
with IN 0 0 12 O
an DT 0 0 12 O
NSAID NNP 0 1 14 B-Group
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
conducted VBN 1 1 1 O
. . 0 0 12 O

Increases NNS 0 1 UNK O
of IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
with IN 0 0 12 O
MHD NNP 0 0 UNK B-Drug_n
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
with IN 0 0 12 O
oxcarbazepine NN 0 1 16 B-Drug
were VBD 1 0 12 O
observed VBN 1 1 1 O
. . 0 0 12 O

Systemic JJ 0 1 7 B-Group
Corticosteroids NNS 0 1 UNK I-Group
: : 0 0 2 O
Systemic JJ 0 1 7 B-Group
corticosteroids NNS 1 1 14 I-Group
are VBP 1 0 12 O
known VBN 1 1 12 O
to TO 0 0 12 O
cause VB 0 1 12 O
osteoporosis NN 0 1 6 O
. . 0 0 12 O

indomethacin NN 0 1 14 B-Drug
; : 0 0 2 O

Concurrent NN 0 1 13 O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
sequential JJ 0 1 1 O
use NN 0 1 1 O
of IN 0 0 12 O
TOBI NNP 0 1 UNK B-Brand
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
with IN 0 0 12 O
neurotoxic NN 0 1 UNK O
or CC 0 0 12 O
ototoxic JJ 0 1 UNK O
potential NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
. . 0 0 12 O

ACE NNP 0 1 13 B-Group
Inhibitors NNP 0 1 7 I-Group
and CC 0 0 12 O
Angiotensin NNP 0 1 UNK B-Group
II NNP 0 0 2 I-Group
Receptor NNP 0 1 UNK I-Group
Antagonists NNP 0 1 UNK I-Group
( ( 0 0 2 O
Hypertension NNP 0 1 7 O
) ) 0 0 2 O
- : 0 0 2 O
In IN 0 0 2 O
clinical JJ 0 1 6 O
studies NNS 1 1 1 O
of IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
hypertension NN 0 1 6 O
the DT 0 0 12 O
addition NN 0 1 1 O
of IN 0 0 12 O
INSPRA NNP 0 1 UNK B-Brand
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
to TO 0 0 12 O
ACE NNP 0 1 13 B-Group
inhibitors NNS 1 1 14 I-Group
and CC 0 0 12 O
angiotensin NN 0 1 UNK B-Group
II NNP 0 0 2 I-Group
receptor NN 0 1 14 I-Group
antagonists NNS 1 1 13 I-Group
increased VBD 1 1 1 O
mean JJ 0 1 12 O
serum NN 0 1 14 O
potassium NN 0 1 14 O
slightly RB 0 1 3 O
( ( 0 0 2 O
about IN 0 1 12 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
mEq NN 0 1 14 O
/ NNP 0 0 2 O
L NNP 0 1 2 O
) ) 0 0 2 O
. . 0 0 12 O

Digoxin NNP 0 1 0 B-Drug
- : 0 0 2 O
In IN 0 0 2 O
subjects NNS 1 1 UNK O
who WP 0 0 12 O
had VBD 1 0 12 O
received VBN 1 1 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
racemic JJ 0 1 14 O
citalopram NN 0 1 16 B-Drug
combined VBN 1 1 1 O
administration NN 0 1 1 O
of IN 0 0 12 O
citalopram NN 0 1 16 B-Drug
and CC 0 0 12 O
digoxin NN 0 1 14 B-Drug
( ( 0 0 2 O
single JJ 0 1 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
) ) 0 0 2 O
did VBD 1 0 12 O
not RB 0 1 12 O
significantly RB 0 0 1 O
affect VBP 0 1 1 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
either DT 0 1 12 O
citalopram NN 0 1 16 B-Drug
or CC 0 0 12 O
digoxin NN 0 1 14 B-Drug
. . 0 0 12 O

May NNP 0 1 2 O
interact NN 0 0 UNK O
anticoagulants NNS 1 1 13 B-Group
( ( 0 0 2 O
altered VBN 1 1 1 O
hypo SYM 0 0 13 O
- : 0 0 2 O
prothrombinemic JJ 0 0 UNK O
effect NN 0 1 1 O
) ) 0 0 2 O
barbiturates VBZ 0 1 14 B-Group
rifampin NN 0 1 16 B-Drug
and CC 0 0 12 O
other JJ 0 0 12 O
inducers NNS 1 1 UNK O
of IN 0 0 12 O
hepatic JJ 0 1 14 O
microsomal JJ 0 1 UNK O
enzyme NN 0 1 14 O
oxidation NN 0 1 13 O
system NN 0 1 1 O
( ( 0 0 2 O
decreased JJ 0 1 1 O
effect NN 0 1 1 O
of IN 0 0 12 O
diethylstilbestrol NN 0 1 13 B-Drug
) ) 0 0 2 O
corticosteroids NNS 1 1 14 B-Group
( ( 0 0 2 O
increased JJ 0 1 1 O
effect NN 0 1 1 O
of IN 0 0 12 O
corticosteroids NNS 1 1 14 B-Group
) ) 0 0 2 O
. . 0 0 12 O

Close JJ 0 1 2 O
supervision NN 0 1 1 O
and CC 0 0 12 O
careful JJ 0 1 12 O
adjustment NN 0 1 1 O
of IN 0 0 12 O
dosage NN 0 1 0 O
are VBP 1 0 12 O
required VBN 1 1 1 O
when WRB 0 0 12 O
Anafranil NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
anticholinergic NN 0 1 13 B-Group
or CC 0 0 12 O
sympathomimetic JJ 0 1 13 B-Group
drugs NNS 1 1 6 I-Group
. . 0 0 12 O

Tenecteplase NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
an DT 0 0 12 O
enzyme NN 0 1 14 O
that IN 0 0 12 O
when WRB 0 0 12 O
present JJ 0 1 1 O
in IN 0 0 12 O
blood NN 0 1 6 O
in IN 0 0 12 O
pharmacologic JJ 0 1 14 O
concentrations NNS 1 1 13 O
remains VBZ 1 0 12 O
active JJ 0 1 1 O
under IN 0 0 12 O
in IN 0 0 12 O
vitro JJ 0 1 UNK O
conditions NNS 1 1 1 O
. . 0 0 12 O

However RB 0 0 1 O
LDL NNP 0 0 14 O
- : 0 0 2 O
C NNP 0 0 2 O
reduction NN 0 1 1 O
was VBD 1 0 12 O
not RB 0 1 12 O
altered VBN 1 1 1 O
. . 0 0 12 O

Consult NN 0 1 UNK O
with IN 0 0 12 O
pharmacist NN 0 1 13 O
if IN 0 0 12 O
available JJ 0 1 1 O
. . 0 0 12 O

Concomitant NNP 0 1 UNK O
glucocorticoid JJ 0 1 13 O
therapy NN 0 1 6 O
may MD 0 0 1 O
inhibit VB 0 1 13 O
the DT 0 0 12 O
growth NN 0 1 1 O
- : 0 0 2 O
promoting VBG 1 1 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
Nutropin NNP 0 1 UNK B-Brand
. . 0 0 12 O

Digitalis NNS 0 1 15 B-Group
: : 0 0 2 O
Vitamin NNP 0 1 2 B-Group
D NNP 0 1 2 I-Group
dosage NN 0 1 0 O
must MD 0 0 12 O
be VB 0 0 12 O
determined VBN 1 1 1 O
with IN 0 0 12 O
care NN 0 1 12 O
in IN 0 0 12 O
patients NNS 1 1 6 O
undergoing VBG 1 0 6 O
treatment NN 0 1 6 O
with IN 0 0 12 O
digitalis NN 0 1 14 B-Group
as IN 1 0 12 O
hypercalcemia NN 0 1 8 O
in IN 0 0 12 O
such JJ 0 0 1 O
patients NNS 1 1 6 O
may MD 0 0 1 O
precipitate VB 0 1 13 O
cardiac JJ 0 1 6 O
arrhythmias NN 1 1 6 O
. . 0 0 12 O

Administration NN 0 1 UNK O
of IN 0 0 12 O
a DT 0 0 12 O
higher JJR 1 1 1 O
dose NN 0 1 6 O
of IN 0 0 12 O
indinavir NN 0 1 16 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
when WRB 0 0 12 O
coadministering VBG 0 0 UNK O
with IN 0 0 12 O
megestrol NN 0 1 16 B-Drug
acetate NN 0 1 14 I-Drug
. . 0 0 12 O

There EX 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
rare JJ 0 1 12 O
reports NNS 1 1 1 O
of IN 0 0 12 O
significant JJ 0 1 1 O
respiratory JJ 0 1 6 O
depression NN 0 1 6 O
stupor NN 0 1 16 O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
hypotension NN 0 1 6 O
with IN 0 0 12 O
the DT 0 0 12 O
concomitant NN 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
loxapine NN 0 1 16 B-Drug
and CC 0 0 12 O
lorazepam NN 0 1 0 B-Drug
. . 0 0 12 O

Aminoglycosides NNS 0 1 UNK B-Group
: : 0 0 2 O
The DT 0 0 2 O
mixing NN 0 1 UNK O
of IN 0 0 12 O
piperacillin NN 0 1 16 B-Drug
with IN 0 0 12 O
an DT 0 0 12 O
aminoglycoside NN 0 1 14 B-Group
in IN 0 0 12 O
vitro NN 0 1 UNK O
can MD 0 0 12 O
result VB 0 1 1 O
in IN 0 0 12 O
substantial JJ 0 0 1 O
inactivation NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
aminoglycoside NN 0 1 14 B-Group
. . 0 0 12 O

Cevimeline NN 0 1 UNK B-Drug
might MD 0 0 12 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
desirable JJ 0 0 UNK O
antimuscarinic JJ 0 1 UNK O
effects NNS 1 1 1 O
of IN 0 0 12 O
drugs NNS 1 1 6 O
used VBN 1 1 12 O
concomitantly RB 0 0 14 O
. . 0 0 12 O

cimetidine NN 0 1 13 B-Drug
) ) 0 0 2 O
and CC 0 0 12 O
many JJ 0 0 12 O
that WDT 0 0 12 O
are VBP 1 0 12 O
substrates VBZ 0 1 UNK O
for IN 0 0 12 O
P9 NNP 0 1 UNK O
9D9 CD 0 0 UNK O
( ( 0 0 2 O
many JJ 0 0 12 O
other JJ 0 0 12 O
antidepressants NNS 1 1 13 B-Group
phenothiazines NNS 1 1 UNK B-Group
and CC 0 0 12 O
the DT 0 0 12 O
Type NNP 0 1 2 B-Group
9C CD 0 0 UNK I-Group
antiarrhythmics NNS 1 1 UNK I-Group
propafenone NN 0 1 16 B-Drug
and CC 0 0 12 O
flecainide NN 0 1 16 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

therefore IN 0 0 1 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
theoretically RB 0 0 UNK O
possible JJ 0 1 1 O
that IN 0 0 12 O
lansoprazole NN 0 1 16 B-Drug
may MD 0 0 1 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
absorption NN 0 1 1 O
of IN 0 0 12 O
drugs NNS 1 1 6 O
where WRB 0 0 12 O
gastric NN 0 1 6 O
pH NN 0 1 14 O
is VBZ 1 0 12 O
an DT 0 0 12 O
important JJ 0 1 1 O
determinant NN 0 1 UNK O
of IN 0 0 12 O
bioavailability NN 0 1 UNK O
( ( 0 0 2 O
e.g JJ 0 0 UNK O
. . 0 0 12 O
ketoconazole JJ 0 1 16 B-Drug
ampicillin NN 0 1 0 B-Drug
esters NNS 1 1 UNK O
iron VBP 0 1 3 B-Drug
salts NNS 1 1 13 O
digoxin NN 0 1 14 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

ZEBETA NNP 0 1 UNK B-Brand
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
with IN 0 0 12 O
care NN 0 1 12 O
when WRB 0 0 12 O
myocardial JJ 0 1 6 B-Group
depressants NNS 1 0 13 I-Group
or CC 0 0 12 O
inhibitors NNS 1 1 14 O
of IN 0 0 12 O
AV NNP 0 0 13 O
conduction NN 0 1 6 O
such JJ 0 0 1 O
as IN 1 0 12 O
certain JJ 0 1 1 O
calcium NN 0 1 14 B-Group
antagonists NNS 1 1 13 I-Group
( ( 0 0 2 O
particularly RB 0 0 1 O
of IN 0 0 12 O
the DT 0 0 12 O
phenylalkylamine NN 0 1 UNK B-Group
[ NNP 0 0 2 O
verapamil NN 0 1 0 B-Drug
] NN 0 0 2 O
and CC 0 0 12 O
benzothiazepine NN 0 1 UNK B-Group
[ NNP 0 0 2 O
diltiazem VBZ 0 1 0 B-Drug
] NNP 0 0 2 O
classes NNS 1 1 UNK O
) ) 0 0 2 O
or CC 0 0 12 O
antiarrhythmic JJ 0 1 14 B-Group
agents NNS 1 1 1 I-Group
such JJ 0 0 1 O
as IN 1 0 12 O
disopyramide NN 0 1 16 B-Drug
are VBP 1 0 12 O
used VBN 1 1 12 O
concurrently RB 0 0 1 O
. . 0 0 12 O

Drugs NNS 0 1 2 O
with IN 0 0 12 O
parasympathomimetic JJ 0 1 UNK O
effects NNS 1 1 1 O
administered VBN 1 1 1 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
pilocarpine NN 0 1 16 B-Drug
would MD 0 0 12 O
be VB 0 0 12 O
expected VBN 1 1 12 O
to TO 0 0 12 O
result VB 0 1 1 O
in IN 0 0 12 O
additive JJ 0 1 16 O
pharmacologic JJ 0 1 14 O
effects NNS 1 1 1 O
. . 0 0 12 O

Choose NNP 0 1 UNK O
particular JJ 0 0 1 O
low JJ 0 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

Transient NNP 0 1 7 O
delirium NN 0 1 6 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
who WP 0 0 12 O
were VBD 1 0 12 O
treated VBN 1 1 1 O
with IN 0 0 12 O
one CD 0 1 12 O
gram NN 0 1 16 O
of IN 0 0 12 O
ethchlorvynol NN 0 1 UNK B-Drug
and CC 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
of IN 0 0 12 O
amitriptyline JJ 0 1 16 B-Drug
HCl NNP 0 0 14 I-Drug
. . 0 0 12 O

Morphine NN 0 1 0 B-Drug
: : 0 0 2 O
A DT 0 0 2 O
literature NN 0 1 UNK O
article NN 0 1 UNK O
reported VBD 1 1 1 O
that IN 0 0 12 O
when WRB 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
mg NN 0 1 0 O
controlled VBD 1 1 1 O
- : 0 0 2 O
release NN 0 1 12 O
morphine NN 0 1 14 B-Drug
capsule NN 0 1 3 O
was VBD 1 0 12 O
administered VBN 1 1 1 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
prior RB 0 1 1 O
to TO 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
mg NN 0 1 0 O
Neurontin NNP 0 1 0 B-Brand
capsule NN 0 1 3 O
( ( 0 0 2 O
N=9 NNP 0 1 UNK O
) ) 0 0 2 O
mean VBP 0 1 12 O
gabapentin JJ 0 1 0 B-Drug
AUC NNP 0 1 UNK O
increased VBN 1 1 1 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
compared VBN 1 1 1 O
to TO 0 0 12 O
gabapentin VB 0 1 0 B-Drug
administered VBN 1 1 1 O
without IN 0 0 12 O
morphine NN 0 1 14 B-Drug
. . 0 0 12 O

Concomitant NNP 0 1 UNK O
use NN 0 1 1 O
with IN 0 0 12 O
iron NN 0 1 3 B-Group
supplements NNS 1 1 6 I-Group
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
reduced JJ 0 1 1 O
absorption NN 0 1 1 O
of IN 0 0 12 O
iron NN 0 1 3 B-Drug
. . 0 0 12 O

Clonidine NNP 0 1 0 B-Drug
therapy NN 0 1 6 O
can MD 0 0 12 O
then RB 0 1 12 O
be VB 0 0 12 O
discontinued VBN 1 1 1 O
several JJ 0 1 12 O
days NNS 1 1 12 O
later RB 0 1 12 O
by IN 0 0 12 O
gradually RB 0 0 1 O
decreasing VBG 1 1 1 O
the DT 0 0 12 O
dosage NN 0 1 0 O
. . 0 0 12 O

Concomitant JJ 0 1 UNK O
medications NNS 1 1 6 O
were VBD 1 0 12 O
grouped VBN 1 1 UNK O
as IN 1 0 12 O
ACE NNP 0 1 13 B-Group
inhibitors NNS 1 1 14 I-Group
oral JJ 0 1 6 O
anticoagulants NNS 1 1 13 B-Group
calcium JJ 0 1 14 B-Group
channel NN 0 1 1 I-Group
blockers NNS 1 0 6 I-Group
beta VBP 0 1 16 B-Group
blockers NNS 1 0 6 I-Group
cardiac VBP 0 1 6 B-Group
glycosides NNS 1 1 13 I-Group
inducers NNS 1 1 UNK O
of IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
substrates NNS 1 1 UNK O
and CC 0 0 12 O
inhibitors NNS 1 1 14 O
of IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
substrates NNS 1 1 UNK O
and CC 0 0 12 O
inhibitors NNS 1 1 14 O
of IN 0 0 12 O
P NNP 0 1 2 O
- : 0 0 2 O
glycoprotein NN 0 1 UNK O
nitrates VBZ 1 1 14 B-Group
sulphonylureas JJ 0 1 UNK B-Group
loop NN 0 1 3 B-Group
diuretics NNS 1 1 14 I-Group
potassium VBP 0 1 14 B-Group
sparing VBG 1 0 6 I-Group
diuretics NNS 1 1 14 I-Group
thiazide IN 0 1 UNK B-Group
diuretics NNS 1 1 14 I-Group
substrates NNS 1 1 UNK O
and CC 0 0 12 O
inhibitors NNS 1 1 14 O
of IN 0 0 12 O
tubular JJ 0 1 3 O
organic JJ 0 1 13 O
cation NN 0 1 UNK O
transport NN 0 1 1 O
and CC 0 0 12 O
QTc NNP 0 0 14 O
- : 0 0 2 O
prolonging NN 0 0 UNK O
drugs NNS 1 1 6 O
. . 0 0 12 O

Other JJ 0 0 2 O
antiarrhythmic JJ 0 1 14 B-Group
drugs NNS 1 1 6 I-Group
( ( 0 0 2 O
eg JJ 0 1 UNK O
quinidine NN 0 1 16 B-Drug
procainamide NN 0 1 16 B-Drug
lidocaine NN 0 1 14 B-Drug
propranolol NN 0 1 16 B-Drug
) ) 0 0 2 O
have VBP 0 0 12 O
occasionally RB 0 1 12 O
been VBN 1 0 12 O
used VBN 1 1 12 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
Norpace NNP 0 1 0 B-Brand
. . 0 0 12 O

Immunosuppressants NNS 0 1 UNK B-Group

. . 0 0 12 O

This DT 0 0 2 O
did VBD 1 0 12 O
not RB 0 1 12 O
result VB 0 1 1 O
in IN 0 0 12 O
any DT 0 0 12 O
statistically RB 0 1 1 O
or CC 0 0 12 O
clinically RB 0 0 6 O
relevant JJ 0 1 1 O
changes NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetic JJ 0 1 UNK O
parameters NNS 1 1 1 O
of IN 0 0 12 O
either DT 0 1 12 O
caffeine NN 0 1 6 B-Drug
or CC 0 0 12 O
its PRP$ 1 0 12 O
major JJ 0 1 1 O
metabolite JJ 0 1 UNK O
paraxanthine NN 0 1 UNK B-Drug_n
. . 0 0 12 O

Coadministration NN 0 1 UNK O
of IN 0 0 12 O
diltiazem NN 0 1 0 B-Drug
with IN 0 0 12 O
rifampin NN 0 1 16 B-Drug
or CC 0 0 12 O
any DT 0 0 12 O
known JJ 0 1 12 O
CYP9A9 NNP 0 0 UNK O
inducer NN 0 1 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
when WRB 0 0 12 O
possible JJ 0 1 1 O
and CC 0 0 12 O
alternative JJ 0 1 1 O
therapy NN 0 1 6 O
considered VBN 1 1 1 O
. . 0 0 12 O

If IN 0 0 12 O
digitalis JJ 0 1 14 B-Drug
treatment NN 0 1 6 O
is VBZ 1 0 12 O
continued VBN 1 1 12 O
serum JJ 0 1 14 O
levels NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
closely RB 0 0 1 O
monitored JJ 0 1 1 O
and CC 0 0 12 O
patients NNS 1 1 6 O
observed VBD 1 1 1 O
for IN 0 0 12 O
clinical JJ 0 1 6 O
evidence NN 0 1 1 O
of IN 0 0 12 O
toxicity NN 0 1 6 O
. . 0 0 12 O

Patients NNS 0 1 7 O
receiving VBG 1 1 1 O
tacrolimus NN 0 1 16 B-Drug
and CC 0 0 12 O
fluconazole JJ 0 1 0 B-Drug
concomitantly RB 0 0 14 O
should MD 0 0 12 O
be VB 0 0 12 O
carefully RB 0 0 12 O
monitored VBN 1 1 1 O
. . 0 0 12 O

Drug NNP 0 1 2 O
- : 0 0 2 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
In IN 0 0 2 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
using VBG 1 1 1 O
human JJ 0 1 1 O
liver NN 0 1 6 O
microsomes NNS 1 1 UNK O
indicate VBP 0 0 1 O
that IN 0 0 12 O
fenofibrate NN 0 1 16 B-Drug
and CC 0 0 12 O
fenofibric JJ 0 0 13 B-Drug_n
acid NNS 0 1 14 I-Drug_n
are VBP 1 0 12 O
not RB 0 1 12 O
inhibitors NNS 1 1 14 O
of IN 0 0 12 O
cytochrome NN 0 1 UNK O
( ( 0 0 2 O
CYP NNP 0 1 UNK O
) ) 0 0 2 O
P9 NNP 0 1 UNK O
isoforms VBZ 0 1 UNK O
CYP9A9 NNP 0 0 UNK O
CYP9D9 NNP 0 0 UNK O
CYP9E9 NNP 0 0 UNK O
or CC 0 0 12 O
CYP9A9 NNP 0 0 UNK O
. . 0 0 12 O

these DT 0 0 12 O
enzymes NNS 1 1 14 O
would MD 0 0 12 O
therefore VB 0 0 1 O
not RB 0 1 12 O
be VB 0 0 12 O
expected VBN 1 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
inhibited VBN 1 1 13 O
in IN 0 0 12 O
clinical JJ 0 1 6 O
use NN 0 1 1 O
. . 0 0 12 O

Additional JJ 0 1 2 O
clinical JJ 0 1 6 O
experience NN 0 1 12 O
may MD 0 0 1 O
reveal VB 0 1 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
affected VBN 1 1 1 O
by IN 0 0 12 O
the DT 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
Tagamet NNP 0 1 0 B-Brand
. . 0 0 12 O

Drugs NNS 0 1 2 O
That WDT 0 0 2 O
Inhibit NNP 0 1 UNK O
Both NNP 0 0 2 O
Aldehyde NNP 0 1 UNK O
Oxidase NNP 0 1 UNK O
and CC 0 0 12 O
CYP9A9 NNP 0 0 UNK O
Cimetidine NNP 0 1 0 B-Drug
: : 0 0 2 O
Cimetidine NN 0 1 0 B-Drug
inhibits VBZ 1 1 UNK O
both DT 0 0 12 O
aldehyde JJ 0 1 UNK O
oxidase NN 0 1 13 O
( ( 0 0 2 O
in IN 0 0 12 O
vitro NN 0 1 UNK O
) ) 0 0 2 O
and CC 0 0 12 O
CYP9A9 NNP 0 0 UNK O
( ( 0 0 2 O
in IN 0 0 12 O
vitro NN 0 1 UNK O
and CC 0 0 12 O
in IN 0 0 12 O
vivo NN 0 1 13 O
) ) 0 0 2 O
the DT 0 0 12 O
primary JJ 0 1 1 O
and CC 0 0 12 O
secondary JJ 0 1 1 O
enzymes NNS 1 1 14 O
respectively RB 0 0 1 O
responsible JJ 0 1 1 O
for IN 0 0 12 O
zaleplon NN 0 1 13 B-Drug
metabolism NN 0 1 16 O
. . 0 0 12 O

No DT 0 0 2 O
significant JJ 0 1 1 O
drug NN 0 1 1 O
- : 0 0 2 O
drug NN 0 1 1 O
pharmacokinetic JJ 0 1 UNK O
( ( 0 0 2 O
or CC 0 0 12 O
pharmacodynamic VB 0 1 UNK O
) ) 0 0 2 O
interactions NNS 1 1 UNK O
have VBP 0 0 12 O
been VBN 1 0 12 O
found VBN 1 1 12 O
in IN 0 0 12 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
with IN 0 0 12 O
hydrochlorothiazide JJ 0 1 0 B-Drug
digoxin NN 0 1 14 B-Drug
warfarin NN 0 1 14 B-Drug
and CC 0 0 12 O
nifedipine NN 0 1 0 B-Drug
. . 0 0 12 O

Multivitamins NNS 0 1 0 B-Group
or CC 0 0 12 O
other JJ 0 0 12 O
products NNS 1 1 1 O
containing VBG 1 1 1 O
iron NN 0 1 3 B-Drug
or CC 0 0 12 O
zinc NN 0 1 14 B-Drug
antacids NNS 1 1 14 B-Group
or CC 0 0 12 O
sucralfate NN 0 1 0 B-Drug
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
or CC 0 0 12 O
within IN 0 0 1 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
norfloxacin NNS 0 1 UNK B-Drug
because IN 0 0 12 O
they PRP 0 0 12 O
may MD 0 0 1 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
absorption NN 0 1 1 O
resulting VBG 1 1 1 O
in IN 0 0 12 O
lower JJR 1 1 1 O
serum NN 0 1 14 O
and CC 0 0 12 O
urine JJ 0 1 6 O
levels NNS 1 1 1 O
of IN 0 0 12 O
norfloxacin NN 0 1 UNK B-Drug
. . 0 0 12 O

Interactions NNS 0 1 UNK O
with IN 0 0 12 O
Mixed NNP 0 1 UNK B-Group
Agonist NNP 0 1 UNK I-Group
/ NNP 0 0 2 O
Antagonist NNP 0 1 UNK I-Group
Opioid NNP 0 1 UNK I-Group
Analgesics NNPS 0 1 UNK I-Group
: : 0 0 2 O
Agonist NNP 0 1 UNK B-Group
/ NNP 0 0 2 O
antagonist NN 0 1 13 I-Group
analgesics NNS 1 1 14 I-Group
( ( 0 0 2 O
eg JJ 0 1 UNK O
pentazocine NN 0 1 UNK B-Drug
nalbuphine NN 0 1 16 B-Drug
butorphanol NN 0 1 13 B-Drug
dezocine NN 0 1 UNK B-Drug
and CC 0 0 12 O
buprenorphine NN 0 1 13 B-Drug
) ) 0 0 2 O
should MD 0 0 12 O
NOT NNP 0 1 11 O
be VB 0 0 12 O
administered VBN 1 1 1 O
to TO 0 0 12 O
a DT 0 0 12 O
patient NN 0 1 6 O
who WP 0 0 12 O
has VBZ 1 0 12 O
received VBN 1 1 12 O
or CC 0 0 12 O
is VBZ 1 0 12 O
receiving VBG 1 1 1 O
a DT 0 0 12 O
course NN 0 1 12 O
of IN 0 0 12 O
therapy NN 0 1 6 O
with IN 0 0 12 O
a DT 0 0 12 O
pure JJ 0 1 13 B-Group
agonist NN 0 1 14 I-Group
opioid JJ 0 1 13 I-Group
analgesic JJ 0 1 13 I-Group
such JJ 0 0 1 O
as IN 1 0 12 O
Levo NNP 0 1 15 B-Brand
- : 0 0 2 O
Dromoran NN 0 0 UNK I-Brand
. . 0 0 12 O

The DT 0 0 2 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
theophylline NN 0 1 16 B-Drug
were VBD 1 0 12 O
not RB 0 1 12 O
altered VBN 1 1 1 O
. . 0 0 12 O

Digoxin NN 0 1 0 B-Drug
: : 0 0 2 O
Concomitant JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
tiagabine NN 0 1 13 B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
affect VB 0 1 1 O
the DT 0 0 12 O
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
or CC 0 0 12 O
the DT 0 0 12 O
mean JJ 0 1 12 O
daily JJ 0 1 12 O
trough IN 0 1 3 O
serum JJ 0 1 14 O
level NN 0 1 1 O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
. . 0 0 12 O

Due JJ 0 1 2 O
to TO 0 0 12 O
highintersubject VB 0 0 UNK O
variability NN 0 1 UNK O
however RB 0 0 12 O
somepatients NNS 0 0 UNK O
may MD 0 0 1 O
experience VB 0 1 12 O
large JJ 0 1 3 O
increases NNS 1 1 1 O
in IN 0 0 12 O
rifabutin NN 0 1 13 B-Drug
exposure NN 0 1 1 O
and CC 0 0 12 O
may MD 0 0 1 O
be VB 0 0 12 O
at IN 0 0 12 O
higher JJR 1 1 1 O
riskfor NN 0 0 UNK O
rifabutin NN 0 1 13 O
toxicity NN 0 1 6 O
. . 0 0 12 O

Vitamin NNP 0 1 2 B-Group
D NNP 0 1 2 I-Group
: : 0 0 2 O
The DT 0 0 2 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
any DT 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
vitamin NN 0 1 6 B-Group
D NNP 0 1 2 I-Group
analogues NNS 1 1 UNK I-Group
should MD 0 0 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
as IN 1 0 12 O
this DT 0 0 12 O
could MD 0 0 12 O
create VB 0 1 13 O
possible JJ 0 1 1 O
additive JJ 0 1 16 O
effects NNS 1 1 1 O
and CC 0 0 12 O
hypercalcemia NN 0 1 8 O
. . 0 0 12 O

Drugs NNS 0 1 2 O
that WDT 0 0 12 O
Inhibit NNP 0 1 UNK O
or CC 0 0 12 O
Induce NNP 0 1 UNK O
Cytochrome NNP 0 1 UNK O
P9 NNP 0 1 UNK O
9A9 CD 0 0 UNK O
Enzymes NNP 0 1 7 O
Lapatinib NNP 0 1 UNK B-Drug
undergoes NNS 0 0 UNK O
extensive JJ 0 1 1 O
metabolism NN 0 1 16 O
by IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
and CC 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
strong JJ 0 1 12 O
inhibitors NNS 1 1 14 O
or CC 0 0 12 O
inducers NNS 1 1 UNK O
of IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
alter NN 0 1 13 O
lapatinib NN 0 1 13 B-Drug
concentrations NNS 1 1 13 O
significantly RB 0 0 1 O
. . 0 0 12 O

This DT 0 0 2 O
response NN 0 1 1 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
attributed VBN 1 1 1 O
to TO 0 0 12 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
renal JJ 0 1 6 O
prostaglandin NN 0 1 13 O
synthesis NN 0 1 UNK O
. . 0 0 12 O

Based VBN 0 1 2 O
on IN 0 0 12 O
the DT 0 0 12 O
above JJ 0 1 12 O
data NN 0 1 1 O
from IN 0 0 12 O
in IN 0 0 12 O
vitro NN 0 1 UNK O
and CC 0 0 12 O
in IN 0 0 12 O
vivo JJ 0 1 13 O
studies NNS 1 1 1 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
unlikely JJ 0 1 12 O
that IN 0 0 12 O
alosetron NN 0 1 UNK B-Drug
will MD 0 0 12 O
inhibit VB 0 1 13 O
the DT 0 0 12 O
hepatic JJ 0 1 14 O
metabolic JJ 0 1 6 O
clearance NN 0 1 16 O
of IN 0 0 12 O
drugs NNS 1 1 6 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
the DT 0 0 12 O
major JJ 0 1 1 O
CYP NNP 0 1 UNK O
enzyme RB 0 1 14 O
9A9 CD 0 0 UNK O
as RB 0 0 12 O
well RB 0 1 12 O
as IN 1 0 12 O
the DT 0 0 12 O
CYP NNP 0 1 UNK O
enzymes VBZ 0 1 14 O
9D9 CD 0 0 UNK O
9C9 CD 0 0 UNK O
9C9 CD 0 0 UNK O
9E9 CD 0 0 UNK O
or CC 0 0 12 O
9A9 CD 0 0 UNK O
. . 0 0 12 O

Sildenafil NNP 0 1 UNK B-Drug
dose NN 0 1 6 O
should MD 0 0 12 O
not RB 0 1 12 O
exceed VB 0 0 UNK O
a DT 0 0 12 O
maximum NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
in IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
hour NN 0 1 12 O
period NN 0 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
concomitant JJ 0 1 6 O
indinavir JJ 0 1 16 B-Drug
therapy NN 0 1 6 O
. . 0 0 12 O

While IN 0 0 12 O
there EX 0 0 12 O
is VBZ 1 0 12 O
evidence NN 0 1 1 O
that IN 0 0 12 O
fluconazole NN 0 1 0 B-Drug
can MD 0 0 12 O
inhibit VB 0 1 13 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
ethinyl JJ 0 0 13 B-Drug
estradiol NN 0 1 13 I-Drug
and CC 0 0 12 O
levonorgestrel NN 0 1 13 B-Drug
there EX 0 0 12 O
is VBZ 1 0 12 O
no DT 0 0 12 O
evidence NN 0 1 1 O
that IN 0 0 12 O
fluconazole NN 0 1 0 B-Drug
is VBZ 1 0 12 O
a DT 0 0 12 O
net JJ 0 1 1 O
inducer NN 0 1 UNK O
of IN 0 0 12 O
ethinyl JJ 0 0 13 B-Drug
estradiol NN 0 1 13 I-Drug
or CC 0 0 12 O
levonorgestrel JJ 0 1 13 B-Drug
metabolism NN 0 1 16 O
. . 0 0 12 O

Anti NNP 0 0 UNK B-Group
- : 0 0 2 O
HIV NNP 0 1 6 I-Group
protease NN 0 1 13 I-Group
inhibitors NNS 1 1 14 I-Group
: : 0 0 2 O
Saquinavir NNP 0 1 UNK B-Drug
/ NNP 0 0 2 O
ritonavir NN 0 1 16 B-Drug
combination NN 0 1 1 O

Antipyrine NN 0 1 UNK B-Drug
: : 0 0 2 O
Antipyrine JJ 0 1 UNK B-Drug
pharmacokinetics NNS 0 1 UNK O
were VBD 1 0 12 O
not RB 0 1 12 O
significantly RB 0 0 1 O
different JJ 0 1 1 O
before IN 0 1 12 O
and CC 0 0 12 O
after IN 0 0 12 O
tiagabine JJ 0 1 13 B-Drug
multiple JJ 0 1 1 O
- : 0 0 2 O
dose NN 0 1 6 O
regimens NNS 1 1 UNK O
. . 0 0 12 O

CNS NNP 0 1 6 O
vascular JJ 0 1 6 O
lesions NNS 1 1 6 O
characterized VBN 1 1 1 O
by IN 0 0 12 O
perivascular JJ 0 1 UNK O
hemorrhages NNS 1 1 8 O
edema VBP 0 1 6 O
and CC 0 0 12 O
mononuclear VBP 0 1 14 O
cell NN 0 1 1 O
infiltration NN 0 1 1 O
of IN 0 0 12 O
perivascular JJ 0 1 UNK O
spaces NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
in IN 0 0 12 O
dogs NNS 1 1 UNK O
treated VBN 1 1 1 O
with IN 0 0 12 O
other JJ 0 0 12 O
members NNS 1 1 12 O
of IN 0 0 12 O
this DT 0 0 12 O
class NN 0 1 12 O
. . 0 0 12 O

Other JJ 0 0 2 O
antihypertensive JJ 0 1 14 B-Group
drugs NNS 1 1 6 I-Group
: : 0 0 2 O
additive JJ 0 1 16 O
effect NN 0 1 1 O
or CC 0 0 12 O
potentiation NN 0 1 UNK O
. . 0 0 12 O

May NNP 0 1 2 O
interact NN 0 0 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
following NN 0 1 1 O
: : 0 0 2 O
cholestyramine NN 0 1 13 B-Drug
colestipol NN 0 1 13 B-Drug
( ( 0 0 2 O
use NN 0 1 1 O
with IN 0 0 12 O
thiazide JJ 0 1 UNK B-Group
diuretics NNS 1 1 14 I-Group
may MD 0 0 1 O
prevent VB 0 1 1 O
the DT 0 0 12 O
diuretic JJ 0 1 14 B-Group
from IN 0 0 12 O
working VBG 1 1 12 O
properly RB 0 0 UNK O
; : 0 0 2 O

The DT 0 0 2 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
CYP NNP 0 1 UNK O
- : 0 0 2 O
9C9 CD 0 0 UNK O
by IN 0 0 12 O
OXC NNP 0 0 UNK B-Drug
and CC 0 0 12 O
MHD NNP 0 0 UNK B-Drug_n
however RB 0 0 12 O
is VBZ 1 0 12 O
clinically RB 0 0 6 O
relevant JJ 0 1 1 O
. . 0 0 12 O

Probenecid NNP 0 1 UNK B-Drug
or CC 0 0 12 O
Cimetidine NNP 0 1 0 B-Drug
: : 0 0 2 O
Concomitant JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
probenecid NN 0 1 13 B-Drug
or CC 0 0 12 O
cimetidine NN 0 1 13 B-Drug
decreases VBZ 1 1 UNK O
the DT 0 0 12 O
elimination NN 0 1 UNK O
of IN 0 0 12 O
zalcitabine NN 0 1 UNK B-Drug
most RBS 0 0 12 O
likely JJ 0 1 12 O
by IN 0 0 12 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
renal JJ 0 1 6 O
tubular JJ 0 1 3 O
secretion NN 0 1 14 O
of IN 0 0 12 O
zalcitabine NN 0 1 UNK B-Drug
. . 0 0 12 O

Example JJ 0 1 UNK O
inhibitors NNS 1 1 14 O
include VBP 0 1 1 O
azole JJ 0 1 UNK B-Group
antifungals NNS 1 1 UNK I-Group
ciprofloxacin VBP 0 1 0 B-Drug
clarithromycin JJ 0 1 13 B-Drug
diclofenac NN 0 1 16 B-Drug
doxycycline NN 0 1 0 B-Drug
erythromycin NN 0 1 0 B-Drug
imatinib NN 0 1 16 B-Drug
isoniazid NN 0 1 13 B-Drug
nefazodone CD 0 1 16 B-Drug
nicardipine JJ 0 1 16 B-Drug
propofol NN 0 1 14 B-Drug
protease NN 0 1 13 B-Group
inhibitors NNS 1 1 14 I-Group
quinidine VBP 0 1 16 B-Drug
and CC 0 0 12 O
verapamil VBP 0 1 0 B-Drug
. . 0 0 12 O

Perioperative JJ 0 1 7 O
administration NN 0 1 1 O
of IN 0 0 12 O
drugs NNS 1 1 6 O
affecting VBG 1 1 1 O
hepatic JJ 0 1 14 O
blood NN 0 1 6 O
flow NN 0 1 1 O
or CC 0 0 12 O
enzyme JJ 0 1 14 O
function NN 0 1 1 O
may MD 0 0 1 O
reduce VB 0 0 1 O
plasma JJ 0 1 14 O
clearance NN 0 1 16 O
and CC 0 0 12 O
prolong JJ 0 0 13 O
recovery NN 0 1 1 O
. . 0 0 12 O

Microdosed VBN 0 0 UNK O
minipill NN 0 1 UNK O
progestin NN 0 1 UNK B-Drug
preparations NNS 1 1 13 O
are VBP 1 0 12 O
not RB 0 1 12 O
recommended VBN 1 1 1 O
for IN 0 0 12 O
use NN 0 1 1 O
with IN 0 0 12 O
Soriatane NNP 0 1 UNK B-Drug
. . 0 0 12 O

Nonetheless RB 0 0 1 O
the DT 0 0 12 O
range NN 0 1 1 O
of IN 0 0 12 O
individual JJ 0 1 1 O
Simulect NNP 0 1 UNK B-Brand
clearance NN 0 1 16 O
values NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
presence NN 0 1 1 O
of IN 0 0 12 O
azathioprine NN 0 1 13 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
mL NN 0 1 14 O
/ NNP 0 0 2 O
h NN 0 1 16 O
) ) 0 0 2 O
or CC 0 0 12 O
mycophenolate VB 0 1 0 B-Drug
mofetil NNS 0 0 16 I-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
mL NN 0 1 14 O
/ NNP 0 0 2 O
h NN 0 1 16 O
) ) 0 0 2 O
did VBD 1 0 12 O
not RB 0 1 12 O
extend VB 0 1 1 O
outside IN 0 1 12 O
the DT 0 0 12 O
range NN 0 1 1 O
observed VBD 1 1 1 O
with IN 0 0 12 O
dual JJ 0 1 3 O
therapy NN 0 1 6 O
( ( 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
mL NN 0 1 14 O
/ NNP 0 0 2 O
h NN 0 1 16 O
) ) 0 0 2 O
. . 0 0 12 O

No DT 0 0 2 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
conducted VBN 1 1 1 O
for IN 0 0 12 O
COLAZAL NNP 0 1 UNK B-Brand
however RB 0 0 12 O
the DT 0 0 12 O
use NN 0 1 1 O
of IN 0 0 12 O
orally RB 0 1 14 O
administered VBN 1 1 1 O
antibiotics NNS 1 1 6 B-Group
could MD 0 0 12 O
theoretically RB 0 0 UNK O
interfere VB 0 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
release NN 0 1 12 O
of IN 0 0 12 O
mesalamine NN 0 1 16 B-Drug
in IN 0 0 12 O
the DT 0 0 12 O
colon NN 0 1 6 O
. . 0 0 12 O

Cholestyramine NN 0 1 UNK B-Drug
: : 0 0 2 O
Concomitant NNP 0 1 UNK O
cholestyramine NN 0 1 13 B-Drug
administration NN 0 1 1 O
decreased VBD 1 1 1 O
the DT 0 0 12 O
mean JJ 0 1 12 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
total JJ 0 1 1 O
ezetimibe NN 0 1 16 B-Drug
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

Although IN 0 0 12 O
glucocorticoids NNS 1 1 UNK B-Group
have VBP 0 0 12 O
been VBN 1 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
reduce VB 0 0 1 O
PROLEUKIN NNP 0 1 UNK B-Brand
- : 0 0 2 O
induced JJ 0 1 6 O
side NN 0 1 3 O
effects NNS 1 1 1 O
including VBG 1 1 1 O
fever JJ 0 1 6 O
renal JJ 0 1 6 O
insufficiency NN 0 1 6 O
hyperbilirubinemia NN 0 1 8 O
confusion NN 0 1 1 O
and CC 0 0 12 O
dyspnea NN 0 1 8 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
these DT 0 0 12 O
agents NNS 1 1 1 O
with IN 0 0 12 O
PROLEUKIN NNP 0 1 UNK B-Brand
may MD 0 0 1 O
reduce VB 0 0 1 O
the DT 0 0 12 O
antitumor NN 0 1 UNK O
effectiveness NN 0 1 UNK O
of IN 0 0 12 O
PROLEUKIN NNP 0 1 UNK B-Brand
and CC 0 0 12 O
thus RB 0 0 1 O
should MD 0 0 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
. . 0 0 12 O
9 CD 0 0 2 O
Beta NNP 0 1 2 B-Group
- : 0 0 2 O
blockers NNS 1 0 6 I-Group
and CC 0 0 12 O
other JJ 0 0 12 O
antihypertensives NNS 1 1 14 B-Group
may MD 0 0 1 O
potentiate VB 0 0 UNK O
the DT 0 0 12 O
hypotension NN 0 1 6 O
seen VBN 1 1 12 O
with IN 0 0 12 O
PROLEUKIN NNP 0 1 UNK B-Brand
. . 0 0 12 O

In IN 0 0 2 O
order NN 0 1 1 O
to TO 0 0 12 O
maintain VB 0 1 1 O
phenytoin JJ 0 1 16 B-Drug
levels NNS 1 1 1 O
limit VBP 0 1 1 O
adverse JJ 0 0 1 O
experiences NNS 1 1 12 O
and CC 0 0 12 O
achieve VBP 0 0 1 O
the DT 0 0 12 O
felbamate NN 0 1 13 B-Drug
dose NN 0 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
a DT 0 0 12 O
phenytoin NN 0 1 16 B-Drug
dose JJ 0 1 6 O
reduction NN 0 1 1 O
of IN 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
was VBD 1 0 12 O
necessary JJ 0 0 1 O
for IN 0 0 12 O
eight CD 0 1 12 O
of IN 0 0 12 O
these DT 0 0 12 O
9 CD 0 0 2 O
subjects NNS 1 1 UNK O
. . 0 0 12 O

Consequently RB 0 0 1 O
drugs NNS 1 1 6 O
with IN 0 0 12 O
a DT 0 0 12 O
low JJ 0 1 1 O
therapeutic JJ 0 1 6 O
margin NN 0 1 1 O
such JJ 0 0 1 O
as IN 1 0 12 O
vitamin NN 0 1 6 B-Group
K NNP 0 1 2 I-Group
antagonists VBZ 0 1 13 I-Group
phenytoin NN 0 1 16 B-Drug
and CC 0 0 12 O
theophylline NN 0 1 16 B-Drug
could MD 0 0 12 O
have VB 0 0 12 O
a DT 0 0 12 O
delayed VBN 1 1 1 O
elimination NN 0 1 UNK O
and CC 0 0 12 O
increases NNS 1 1 1 O
in IN 0 0 12 O
their PRP$ 0 0 12 O
serum NN 0 1 14 O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
leading VBG 1 1 1 O
to TO 0 0 12 O
a DT 0 0 12 O
toxic JJ 0 1 1 O
level NN 0 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
a DT 0 0 12 O
study NN 0 1 1 O
with IN 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
aspirin NN 0 1 14 B-Brand
and CC 0 0 12 O
fosinopril JJ 0 1 13 B-Drug
sodium NN 0 1 14 I-Drug
the DT 0 0 12 O
bioavailability NN 0 1 UNK O
of IN 0 0 12 O
unbound JJ 0 0 UNK O
fosinoprilat NN 0 1 UNK B-Drug_n
was VBD 1 0 12 O
not RB 0 1 12 O
altered VBN 1 1 1 O
. . 0 0 12 O

Those DT 0 0 12 O
anticonvulsants NNS 1 1 13 B-Group
include VBP 0 1 1 O
divalproex JJ 0 1 16 B-Drug
sodium NN 0 1 14 I-Drug
valproic NN 0 0 16 B-Drug
acid NN 0 1 14 I-Drug
and CC 0 0 12 O
phenobarbital NN 0 1 16 B-Drug
. . 0 0 12 O

No DT 0 0 2 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
data NNS 0 1 1 O
are VBP 1 0 12 O
available JJ 0 1 1 O
on IN 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
Panretin NNP 0 1 UNK B-Brand
gel NN 0 1 3 O
and CC 0 0 12 O
systemic JJ 0 1 6 O
anti NN 0 0 3 O
- : 0 0 2 O
KS NNP 0 1 2 O
agents NNS 1 1 1 O
. . 0 0 12 O

As IN 0 0 2 O
with IN 0 0 12 O
other JJ 0 0 12 O
antipsychotic JJ 0 1 UNK B-Group
agents NNS 1 1 1 I-Group
it PRP 0 0 12 O
should MD 0 0 12 O
be VB 0 0 12 O
noted VBN 1 0 1 O
that IN 0 0 12 O
HALDOL NNP 0 1 0 B-Brand
may MD 0 0 1 O
be VB 0 0 12 O
capable JJ 0 1 UNK O
of IN 0 0 12 O
potentiating VBG 1 0 UNK O
CNS NNP 0 1 6 B-Group
depressants NNS 1 0 13 I-Group
such JJ 0 0 1 O
as IN 1 0 12 O
anesthetics NNS 1 1 13 B-Group
opiates NNS 1 1 6 B-Group
and CC 0 0 12 O
alcohol NN 0 1 1 B-Drug
. . 0 0 12 O

ibuprofen NN 0 1 0 B-Drug
; : 0 0 2 O

The DT 0 0 2 O
extent NN 0 1 1 O
of IN 0 0 12 O
plasma NN 0 1 14 O
protein NN 0 1 14 O
binding NN 0 1 1 O
of IN 0 0 12 O
atovaquone NN 0 1 16 B-Drug
in IN 0 0 12 O
human JJ 0 1 1 O
plasma NN 0 1 14 O
is VBZ 1 0 12 O
not RB 0 1 12 O
affected VBN 1 1 1 O
by IN 0 0 12 O
the DT 0 0 12 O
presence NN 0 1 1 O
of IN 0 0 12 O
therapeutic JJ 0 1 6 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mcg NN 0 1 0 O
/ NNP 0 0 2 O
mL NN 0 1 14 O
) ) 0 0 2 O
nor CC 0 0 12 O
is VBZ 1 0 12 O
the DT 0 0 12 O
binding NN 0 1 1 O
of IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
affected VBN 1 1 1 O
by IN 0 0 12 O
the DT 0 0 12 O
presence NN 0 1 1 O
of IN 0 0 12 O
atovaquone NN 0 1 16 B-Drug
. . 0 0 12 O

In IN 0 0 2 O
these DT 0 0 12 O
patients NNS 1 1 6 O
whose WP$ 0 0 12 O
hypertension NN 0 1 6 O
was VBD 1 0 12 O
controlled VBN 1 1 1 O
with IN 0 0 12 O
nifedipine JJ 0 1 0 B-Drug
Vardenafil NNP 0 1 UNK B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
produced VBN 1 0 1 O
mean JJ 0 1 12 O
additional JJ 0 1 1 O
supine NN 0 1 8 O
systolic JJ 0 1 8 O
/ NNP 0 0 2 O
diastolic NN 0 1 8 O
blood NN 0 1 6 O
pressure NN 0 1 1 O
reductions NNS 1 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
/ JJ 0 0 2 O
9 CD 0 0 2 O
mm NN 0 0 18 O
Hg NNP 0 1 14 O
compared VBN 1 1 1 O
to TO 0 0 12 O
placebo VB 0 1 13 O
. . 0 0 12 O

No DT 0 0 2 O
information NN 0 1 1 O
is VBZ 1 0 12 O
available JJ 0 1 1 O
about IN 0 1 12 O
the DT 0 0 12 O
use NN 0 1 1 O
of IN 0 0 12 O
butorphanol NNS 0 1 13 B-Drug
concurrently RB 0 0 1 O
with IN 0 0 12 O
MAO NNP 0 1 14 B-Group
inhibitors NNS 1 1 14 I-Group
. . 0 0 12 O

an DT 0 0 12 O
oral JJ 0 1 6 O
9 CD 0 0 2 O
mg NN 0 1 0 O
dose NN 0 1 6 O
achieves VBZ 1 0 1 O
a DT 0 0 12 O
highest JJS 1 1 1 O
level NN 0 1 1 O
of IN 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
uM JJ 0 0 UNK O
in IN 0 0 12 O
people NNS 0 1 12 O
) ) 0 0 2 O
; : 0 0 2 O

The DT 0 0 2 O
physician NN 0 1 6 O
is VBZ 1 0 12 O
advised VBN 1 0 12 O
to TO 0 0 12 O
monitor VB 0 1 1 O
plasma JJ 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
and CC 0 0 12 O
to TO 0 0 12 O
decrease VB 0 1 1 O
the DT 0 0 12 O
dose NN 0 1 6 O
if IN 0 0 12 O
necessary JJ 0 0 1 O
. . 0 0 12 O

Anagrelide NNP 0 1 UNK B-Drug
alone RB 0 1 12 O
had VBD 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
platelet NN 0 1 14 O
aggregation NN 0 1 UNK O
but CC 0 0 12 O
did VBD 1 0 12 O
slightly RB 0 1 3 O
enhance VB 0 1 UNK O
the DT 0 0 12 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
platelet NN 0 1 14 O
aggregation NN 0 1 UNK O
by IN 0 0 12 O
aspirin NN 0 1 14 B-Brand
. . 0 0 12 O

Pindolol NNP 0 1 UNK B-Drug
levels NNS 1 1 1 O
may MD 0 0 1 O
also RB 0 0 12 O
be VB 0 0 12 O
increased VBN 1 1 1 O
with IN 0 0 12 O
this DT 0 0 12 O
combination NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
potential JJ 0 1 1 O
for IN 0 0 12 O
increased VBN 1 1 1 O
sedation NN 0 1 6 O
when WRB 0 0 12 O
guanfacine NN 0 1 13 B-Drug
is VBZ 1 0 12 O
given VBN 1 1 12 O
with IN 0 0 12 O
other JJ 0 0 12 O
CNS NNP 0 1 6 B-Group
- : 0 0 2 O
depressant JJ 0 0 UNK I-Group
drug NN 0 1 1 I-Group
should MD 0 0 12 O
be VB 0 0 12 O
appreciated VBN 1 0 12 O
. . 0 0 12 O

Although IN 0 0 12 O
a DT 0 0 12 O
causal NN 0 1 UNK O
mechanism NN 0 1 13 O
and CC 0 0 12 O
a DT 0 0 12 O
cause NN 0 1 12 O
- : 0 0 2 O
and CC 0 0 12 O
- : 0 0 2 O
effect NN 0 1 1 O
relationship NN 0 1 12 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
established VBN 1 1 1 O
current JJ 0 1 1 O
evidence NN 0 1 1 O
suggests VBZ 1 1 1 O
that IN 0 0 12 O
renal JJ 0 1 6 O
function NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
on IN 0 0 12 O
thiazide JJ 0 1 UNK B-Group
diuretics NNS 1 1 14 I-Group
and CC 0 0 12 O
allopurinol VB 0 1 13 B-Drug
even RB 0 0 12 O
in IN 0 0 12 O
the DT 0 0 12 O
absence NN 0 1 1 O
of IN 0 0 12 O
renal JJ 0 1 6 O
failure NN 0 1 1 O
and CC 0 0 12 O
dosage NN 0 1 0 O
levels NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
even RB 0 0 12 O
more RBR 0 1 12 O
conservatively RB 0 0 1 O
adjusted VBN 1 1 1 O
in IN 0 0 12 O
those DT 0 0 12 O
patients NNS 1 1 6 O
on IN 0 0 12 O
such JJ 0 0 1 O
combined VBN 1 1 1 O
therapy NN 0 1 6 O
if IN 0 0 12 O
diminished VBN 1 1 1 O
renal JJ 0 1 6 O
function NN 0 1 1 O
is VBZ 1 0 12 O
detected.. JJ 0 1 UNK O

In IN 0 0 2 O
the DT 0 0 12 O
DIAMOND NNP 0 1 UNK O
trials NNS 1 1 1 O
9 CD 0 0 2 O
patients NNS 1 1 6 O
were VBD 1 0 12 O
treated VBN 1 1 1 O
with IN 0 0 12 O
TIKOSYN NNP 0 1 UNK B-Brand
and CC 0 0 12 O
diuretics NNS 1 1 14 B-Group
concomitantly RB 0 0 14 O
of IN 0 0 12 O
whom WP 0 0 12 O
9 CD 0 0 2 O
died VBD 1 1 12 O
compared VBN 1 1 1 O
to TO 0 0 12 O
9 CD 0 0 2 O
deaths NNS 1 1 UNK O
among IN 0 0 12 O
the DT 0 0 12 O
9 CD 0 0 2 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
placebo NN 0 1 13 O
and CC 0 0 12 O
diuretics NNS 1 1 14 B-Group
. . 0 0 12 O

This DT 0 0 2 O
change NN 0 1 1 O
was VBD 1 0 12 O
not RB 0 1 12 O
considered VBN 1 1 1 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
and CC 0 0 12 O
no DT 0 0 12 O
dose JJ 0 1 6 O
adjustment NN 0 1 1 O
is VBZ 1 0 12 O
needed VBN 1 1 12 O
when WRB 0 0 12 O
ketoconazole NN 0 1 16 B-Drug
and CC 0 0 12 O
VIRACEPT NNP 0 1 UNK B-Brand
are VBP 1 0 12 O
coadministered VBN 0 0 UNK O
. . 0 0 12 O

barbiturates NNS 1 1 14 B-Group
; : 0 0 2 O

diuretics NNS 1 1 14 B-Group
* VBP 0 0 2 O
; : 0 0 2 O

certain JJ 0 1 1 O
tetracyclic JJ 0 0 13 B-Group
antidepressants NNS 1 1 13 I-Group
( ( 0 0 2 O
such JJ 0 0 1 O
as IN 1 0 12 O
maprotiline NN 0 1 13 B-Drug
) ) 0 0 2 O
; : 0 0 2 O

Rifampin NN 0 1 0 B-Drug
: : 0 0 2 O
Rifampin NN 0 1 0 B-Drug
increases VBZ 1 1 1 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
ethinyl JJ 0 0 13 B-Drug
estradiol NN 0 1 13 I-Drug
and CC 0 0 12 O
some DT 0 0 12 O
progestins NNS 1 1 UNK B-Group
( ( 0 0 2 O
norethindrone NN 0 1 13 B-Drug
) ) 0 0 2 O
resulting VBG 1 1 1 O
in IN 0 0 12 O
decreased JJ 0 1 1 O
contraceptive JJ 0 1 13 O
effectiveness NN 0 1 UNK O
and CC 0 0 12 O
increased VBD 1 1 1 O
menstrual JJ 0 1 6 O
irregularities NNS 1 1 1 O
. . 0 0 12 O

Antifungals NNS 0 1 UNK B-Group
: : 0 0 2 O
Itraconazole NNP 0 1 UNK B-Drug
Ketoconazole NNP 0 1 UNK B-Drug

On IN 0 0 2 O
the DT 0 0 12 O
basis NN 0 1 1 O
of IN 0 0 12 O
limited JJ 0 1 1 O
available JJ 0 1 1 O
data NNS 0 1 1 O
no DT 0 0 12 O
dosage NN 0 1 0 O
adjustment NN 0 1 1 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
for IN 0 0 12 O
patients NNS 1 1 6 O
on IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

In IN 0 0 2 O
a DT 0 0 12 O
chronic JJ 0 1 6 O
toxicity NN 0 1 6 O
study NN 0 1 1 O
cynomolgus JJ 0 1 UNK O
monkeys NNS 1 1 UNK O
were VBD 1 0 12 O
dosed JJ 0 1 14 O
weekly JJ 0 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
weeks NNS 1 1 12 O
with IN 0 0 12 O
intravenous JJ 0 1 14 O
alefacept NNS 0 1 UNK B-Drug
at IN 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NNP 0 1 18 O
/ NNP 0 0 2 O
dose VBD 0 1 6 O
or CC 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
kg FW 0 1 18 O
/ FW 0 0 2 O
dose NN 0 1 6 O
. . 0 0 12 O

An DT 0 0 2 O
immune JJ 0 1 6 O
response NN 0 1 1 O
to TO 0 0 12 O
Campath NNP 0 1 0 B-Brand
may MD 0 0 1 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
subsequent JJ 0 1 1 O
diagnostic JJ 0 1 6 O
serum NN 0 1 14 O
tests NNS 1 1 1 O
that WDT 0 0 12 O
utilize VBP 0 0 1 O
antibodies NNS 1 1 14 B-Group

Patients NNS 0 1 7 O
taking VBG 1 0 12 O
disopyramide JJ 0 1 16 B-Drug
phosphate NN 0 1 14 I-Drug
and CC 0 0 12 O
hepatic JJ 0 1 14 O
enzyme NN 0 1 14 O
inhibitors NNS 1 1 14 O
concomitantly RB 0 0 14 O
should MD 0 0 12 O
be VB 0 0 12 O
closely RB 0 0 1 O
monitored VBN 1 1 1 O
. . 0 0 12 O

Digoxin NN 0 1 0 B-Drug
: : 0 0 2 O
The DT 0 0 2 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
DynaCirc NNP 0 1 UNK B-Brand
( ( 0 0 2 O
isradipine NN 0 1 13 B-Drug
) ) 0 0 2 O
and CC 0 0 12 O
digoxin NN 0 1 14 B-Drug
in IN 0 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
- : 0 0 2 O
dose JJ 0 1 6 O
pharmacokinetic JJ 0 1 UNK O
study NN 0 1 1 O
did VBD 1 0 12 O
not RB 0 1 12 O
affect VB 0 1 1 O
renal JJ 0 1 6 O
nonrenal JJ 0 0 13 O
and CC 0 0 12 O
total JJ 0 1 1 O
body NN 0 1 3 O
clearance NN 0 1 16 O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
. . 0 0 12 O

When WRB 0 0 12 O
such JJ 0 0 1 O
drugs NNS 1 1 6 O
are VBP 1 0 12 O
withdrawn VBN 1 1 1 O
from IN 0 0 12 O
a DT 0 0 12 O
patient NN 0 1 6 O
receiving VBG 1 1 1 O
DIABINESE NNP 0 1 UNK B-Brand
the DT 0 0 12 O
patient NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
observed VBN 1 1 1 O
closely RB 0 0 1 O
for IN 0 0 12 O
loss NN 0 1 1 O
of IN 0 0 12 O
control NN 0 1 1 O
. . 0 0 12 O

Other JJ 0 0 2 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
are VBP 1 0 12 O
specific JJ 0 1 1 O
substrates NNS 1 1 UNK O
inhibitors NNS 1 1 14 O
or CC 0 0 12 O
inducers NNS 1 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
enzyme NN 0 1 14 O
system NN 0 1 1 O
may MD 0 0 1 O
have VB 0 0 12 O
a DT 0 0 12 O
significant JJ 0 1 1 O
impact NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
efficacy NN 0 1 UNK O
and CC 0 0 12 O
side NN 0 1 3 O
effect NN 0 1 1 O
profile NN 0 1 1 O
of IN 0 0 12 O
diltiazem NN 0 1 0 B-Drug
. . 0 0 12 O

Since IN 0 1 2 O
there EX 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
isolated VBN 1 1 1 O
reports NNS 1 1 1 O
of IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
elevated JJ 0 1 1 O
digoxin NN 0 1 14 B-Drug
levels NNS 1 1 1 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
that IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
levels NNS 1 1 1 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
when WRB 0 0 12 O
initiating VBG 1 1 1 O
adjusting NN 0 0 1 O
and CC 0 0 12 O
discontinuing VBG 1 1 6 O
nifedipine NN 0 1 0 B-Drug
to TO 0 0 12 O
avoid VB 0 0 12 O
possible JJ 0 1 1 O
over IN 0 1 12 O
- : 0 0 2 O
or CC 0 0 12 O
under IN 0 0 12 O
- : 0 0 2 O
digitalization NN 0 1 UNK O
. . 0 0 12 O

Other JJ 0 0 2 O
CYP9A9 NNP 0 0 UNK O
inducers NNS 1 1 UNK O
include VBP 0 1 1 O
but CC 0 0 12 O
are VBP 1 0 12 O
not RB 0 1 12 O
limited VBN 1 1 1 O
to TO 0 0 12 O
rifabutin VB 0 1 13 B-Drug
rifapentine JJ 0 1 UNK B-Drug
phenytoin NN 0 1 16 B-Drug
carbamazepine NN 0 1 16 B-Drug
phenobarbital NN 0 1 16 B-Drug
and CC 0 0 12 O
St. NNP 0 1 2 O
Johns NNP 0 0 UNK O
Wort NNP 0 0 UNK O
. . 0 0 12 O

Therefore RB 0 0 1 O
careful JJ 0 1 12 O
monitoring NN 0 1 1 O
of IN 0 0 12 O
blood NN 0 1 6 O
glucose NN 0 1 14 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
when WRB 0 0 12 O
these DT 0 0 12 O
agents NNS 1 1 1 O
are VBP 1 0 12 O
coadministered VBN 0 0 UNK O
. . 0 0 12 O

Excessive JJ 0 1 UNK O
ethanol NN 0 1 1 B-Drug
ingestion NN 0 1 14 O
should MD 0 0 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
because IN 0 0 12 O
a DT 0 0 12 O
psychotic JJ 0 1 6 O
reaction NN 0 1 1 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
therefore RB 0 0 1 O
advisable JJ 0 0 UNK O
to TO 0 0 12 O
monitor VB 0 1 1 O
digoxin JJ 0 1 14 B-Drug
concentrations NNS 1 1 13 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
ketoconazole NN 0 1 16 B-Drug
. . 0 0 12 O

Glyburide NN 0 1 0 B-Drug
: : 0 0 2 O
Etodolac NNP 0 1 UNK B-Drug
has VBZ 1 0 12 O
no DT 0 0 12 O
apparent JJ 0 1 1 O
pharmacokinetic JJ 0 1 UNK O
interaction NN 0 1 UNK O
when WRB 0 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
glyburide NN 0 1 16 B-Drug
. . 0 0 12 O

increased VBN 1 1 1 O
serum NN 0 1 14 O
triglyceride NN 0 1 14 O
and CC 0 0 12 O
phospholipid JJ 0 1 UNK O
concentration NN 0 1 1 O
. . 0 0 12 O

Lithium NNP 0 1 UNK B-Drug
serum NN 0 1 14 O
concentrations NNS 1 1 13 O
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
closely RB 0 0 1 O
when WRB 0 0 12 O
initiating VBG 1 1 1 O
or CC 0 0 12 O
changing VBG 1 1 1 O
therapy NN 0 1 6 O
with IN 0 0 12 O
BEXTRA NNP 0 1 UNK B-Brand
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
lithium NN 0 1 16 B-Drug
. . 0 0 12 O

Effects NNS 0 1 UNK O
of IN 0 0 12 O
Lapatinib NNP 0 1 UNK B-Drug
on IN 0 0 12 O
Drug NNP 0 1 2 O
Metabolizing NNP 0 0 UNK O
Enzymes NNP 0 1 7 O
and CC 0 0 12 O
Drug NNP 0 1 2 O
Transport NNP 0 1 UNK O
Systems NNP 0 1 UNK O
Lapatinib NNP 0 1 UNK B-Drug
inhibits VBZ 1 1 UNK O
CYP9A9 NNP 0 0 UNK O
and CC 0 0 12 O
CYP9C9 NNP 0 0 UNK O
in IN 0 0 12 O
vitro NN 0 1 UNK O
at IN 0 0 12 O
clinically RB 0 0 6 O
relevant JJ 0 1 1 O
concentrations NNS 1 1 13 O
. . 0 0 12 O

Lapatinib NNP 0 1 UNK B-Drug
inhibits VBZ 1 1 UNK O
human JJ 0 1 1 O
P NNP 0 1 2 O
- : 0 0 2 O
glycoprotein NN 0 1 UNK O
. . 0 0 12 O

Mequitazine NN 0 1 UNK B-Drug
can MD 0 0 12 O
interact VB 0 0 UNK O
with IN 0 0 12 O
CNS NNP 0 1 6 B-Group
depressant NN 0 0 UNK I-Group
antichlolinergic NN 0 0 UNK B-Group
TCA NNP 0 1 13 B-Group
MAOIs NNP 0 1 UNK B-Group
and CC 0 0 12 O
alcohol NN 0 1 1 B-Drug
. . 0 0 12 O

In IN 0 0 2 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
also RB 0 0 12 O
shown VBN 1 1 1 O
that IN 0 0 12 O
terbinafine NN 0 1 16 B-Drug
inhibits NNS 0 1 UNK O
CYP9D9 NNP 0 0 UNK O
- : 0 0 2 O
mediated VBD 1 1 13 O
metabolism NN 0 1 16 O
. . 0 0 12 O

Hepatic JJ 0 1 7 O
Enzyme NNP 0 1 UNK O
Inducers NNP 0 1 UNK O
Inhibitors NNP 0 1 7 O
and CC 0 0 12 O
Substrates NNS 0 1 UNK O
: : 0 0 2 O
Drugs NNP 0 1 2 O
which WDT 0 0 12 O
induce VBP 0 1 6 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
9A9 CD 0 0 UNK O
( ( 0 0 2 O
CYP NNP 0 1 UNK O
9A9 CD 0 0 UNK O
) ) 0 0 2 O
enzyme NN 0 1 14 O
activity NN 0 1 1 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
barbiturates NNS 1 1 14 B-Group
phenytoin VBP 0 1 16 B-Drug
carbamazepine JJ 0 1 16 B-Drug
rifampin NN 0 1 16 B-Drug
) ) 0 0 2 O
may MD 0 0 1 O
enhance VB 0 1 UNK O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
corticosteroids NNS 1 1 14 B-Group
and CC 0 0 12 O
require VB 0 0 1 O
that IN 0 0 12 O
the DT 0 0 12 O
dosage NN 0 1 0 O
of IN 0 0 12 O
the DT 0 0 12 O
corticosteroid JJ 0 1 UNK B-Group
be VB 0 0 12 O
increased VBN 1 1 1 O
. . 0 0 12 O

Fenbufen NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
approved VBN 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
United NNP 0 0 2 O
States NNPS 0 1 2 O
at IN 0 0 12 O
this DT 0 0 12 O
time NN 0 1 12 O
. . 0 0 12 O

Ketoconazole NNP 0 1 UNK B-Drug

Your PRP$ 0 0 2 O
doctor NN 0 1 12 O
or CC 0 0 12 O
pharmacist NN 0 1 13 O
can MD 0 0 12 O
give VB 0 1 12 O
you PRP 0 0 12 O
more JJR 0 1 12 O
information NN 0 1 1 O
on IN 0 0 12 O
MAO NNP 0 1 14 B-Group
inhibitors NNS 1 1 14 I-Group
. . 0 0 12 O

Excessive JJ 0 1 UNK O
glucocorticoid NN 0 1 13 O
therapy NN 0 1 6 O
will MD 0 0 12 O
inhibit VB 0 1 13 O
the DT 0 0 12 O
growth NN 0 1 1 O
- : 0 0 2 O
promoting VBG 1 1 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
human JJ 0 1 1 B-Drug
GH NNP 0 1 13 I-Drug
. . 0 0 12 O

Administration NN 0 1 UNK O
of IN 0 0 12 O
CMI NNP 0 0 13 B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
plasma JJ 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
phenobarbital NN 0 1 16 B-Drug
if IN 0 0 12 O
given VBN 1 1 12 O
concomitantly RB 0 0 14 O
. . 0 0 12 O

No DT 0 0 2 O
confirmed JJ 0 1 12 O
interactions NNS 1 1 UNK O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
between IN 0 0 12 O
ZOLADEX NNP 0 1 UNK B-Brand
and CC 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O

At IN 0 0 2 O
a DT 0 0 12 O
median JJ 0 1 1 O
follow NN 0 1 12 O
- : 0 0 2 O
up IN 0 0 12 O
of IN 0 0 12 O
9 CD 0 0 2 O
months NNS 1 1 12 O
the DT 0 0 12 O
combination NN 0 1 1 O
of IN 0 0 12 O
ARIMIDEX NNP 0 1 UNK B-Brand
and CC 0 0 12 O
tamoxifen NN 0 1 0 B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
demonstrate VB 0 0 1 O
any DT 0 0 12 O
efficacy NN 0 1 UNK O
benefit NN 0 1 1 O
when WRB 0 0 12 O
compared VBN 1 1 1 O
with IN 0 0 12 O
tamoxifen NN 0 1 0 B-Drug
in IN 0 0 12 O
all DT 0 0 12 O
patients NNS 1 1 6 O
as RB 0 0 12 O
well RB 0 1 12 O
as IN 1 0 12 O
in IN 0 0 12 O
the DT 0 0 12 O
hormone NN 0 1 6 O
receptor NN 0 1 14 O
- : 0 0 2 O
positive JJ 0 1 1 O
subpopulation NN 0 1 UNK O
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
unknown JJ 0 1 12 O
whether IN 0 0 12 O
the DT 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
proton JJ 0 1 14 B-Group
pump NN 0 1 3 I-Group
inhibitors NNS 1 1 14 I-Group
affects VBZ 1 1 1 O
duloxetine JJ 0 1 0 B-Drug
absorption NN 0 1 1 O
. . 0 0 12 O

Therefore RB 0 0 1 O
unless IN 0 0 12 O
otherwise RB 0 0 1 O
specified VBN 1 1 13 O
appropriate JJ 0 1 1 O
dosage NN 0 1 0 O
adjustments NNS 1 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
necessary JJ 0 0 1 O
. . 0 0 12 O

If IN 0 0 12 O
concomitant JJ 0 1 6 O
treatment NN 0 1 6 O
with IN 0 0 12 O
frovatriptan NN 0 1 UNK B-Drug
and CC 0 0 12 O
an DT 0 0 12 O
SSRI NNP 0 1 UNK B-Group
is VBZ 1 0 12 O
clinically RB 0 0 6 O
warranted JJ 0 0 1 O
appropriate JJ 0 1 1 O
observation NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
patient NN 0 1 6 O
is VBZ 1 0 12 O
advised VBN 1 0 12 O
. . 0 0 12 O

Accutane NNP 0 1 UNK B-Brand
use NN 0 1 1 O
is VBZ 1 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
depression NN 0 1 6 O
in IN 0 0 12 O
some DT 0 0 12 O
patients NNS 1 1 6 O
. . 0 0 12 O

MAO JJ 0 1 14 B-Group
inhibitors NNS 1 1 14 I-Group
: : 0 0 2 O
MAOI NNP 0 1 UNK B-Group
antidepressants NNS 1 1 13 I-Group
as RB 0 0 12 O
well RB 0 1 12 O
as IN 1 0 12 O
a DT 0 0 12 O
metabolite NN 0 1 UNK O
of IN 0 0 12 O
furazolidone NN 0 1 UNK B-Drug
slow JJ 0 1 12 O
amphetamine NN 0 1 13 B-Group
metabolism NN 0 1 16 O
. . 0 0 12 O

Studies NNS 0 1 2 O
with IN 0 0 12 O
ACE NNP 0 1 13 B-Group
inhibitors NNS 1 1 14 I-Group
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
diuretics NNS 1 1 14 B-Group
indicate VBP 0 0 1 O
that IN 0 0 12 O
the DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
the DT 0 0 12 O
ACE NNP 0 1 13 B-Group
inhibitor NN 0 1 14 I-Group
can MD 0 0 12 O
be VB 0 0 12 O
reduced VBN 1 1 1 O
when WRB 0 0 12 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
given VBN 1 1 12 O
with IN 0 0 12 O
a DT 0 0 12 O
diuretic JJ 0 1 14 B-Group
. . 0 0 12 O

In IN 0 0 2 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
demonstrated VBD 1 0 1 O
no DT 0 0 12 O
evidence NN 0 1 1 O
of IN 0 0 12 O
incompatibility NN 0 1 13 O
of IN 0 0 12 O
heparin NN 0 1 14 B-Drug
with IN 0 0 12 O
EXTRANEAL NNP 0 1 UNK B-Brand
. . 0 0 12 O

A DT 0 0 2 O
causal NN 0 1 UNK O
relationship NN 0 1 12 O
between IN 0 0 12 O
these DT 0 0 12 O
events NNS 1 1 12 O
and CC 0 0 12 O
the DT 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
lithium NN 0 1 16 B-Drug
and CC 0 0 12 O
HALDOL NNP 0 1 0 B-Brand
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
established VBN 1 1 1 O
; : 0 0 2 O

When WRB 0 0 12 O
Vardenafil NNP 0 1 UNK B-Drug
dosing NN 0 0 14 O
was VBD 1 0 12 O
separated VBN 1 1 3 O
from IN 0 0 12 O
terazosin NN 0 1 0 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
by IN 0 0 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
9 CD 0 0 2 O
of IN 0 0 12 O
9 CD 0 0 2 O
subjects NNS 1 1 UNK O
who WP 0 0 12 O
received VBD 1 1 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
of IN 0 0 12 O
Vardenafil NNP 0 1 UNK B-Drug
experienced VBD 1 0 12 O
a DT 0 0 12 O
decrease NN 0 1 1 O
in IN 0 0 12 O
standing VBG 1 1 12 O
systolic JJ 0 1 8 O
blood NN 0 1 6 O
pressure NN 0 1 1 O
below IN 0 0 12 O
9 CD 0 0 2 O
mm NN 0 0 18 O
Hg NNP 0 1 14 O
. . 0 0 12 O

Based VBN 0 1 2 O
on IN 0 0 12 O
anecdotal JJ 0 1 UNK O
reports NNS 1 1 1 O
there EX 0 0 12 O
may MD 0 0 1 O
be VB 0 0 12 O
an DT 0 0 12 O
interaction NN 0 1 UNK O
between IN 0 0 12 O
buprenorphine NN 0 1 13 B-Drug
and CC 0 0 12 O
benzodiazepines NNS 1 1 14 B-Group
. . 0 0 12 O

Acetaminophen NNS 0 1 0 B-Drug
: : 0 0 2 O
May NNP 0 1 2 O
increase VB 0 1 1 O
plasma JJ 0 1 14 O
concentration NN 0 1 1 O
of IN 0 0 12 O
synthetic JJ 0 1 3 B-Group
estrogens NNS 1 1 16 I-Group
possibly RB 0 1 12 O
by IN 0 0 12 O
inhibiting VBG 1 1 UNK O
conjugation NN 0 1 14 O
. . 0 0 12 O

Digoxin NN 0 1 0 B-Drug
: : 0 0 2 O
In IN 0 0 2 O
a DT 0 0 12 O
study NN 0 1 1 O
in IN 0 0 12 O
9 CD 0 0 2 O
patients NNS 1 1 6 O
with IN 0 0 12 O
congestive JJ 0 1 6 O
heart NN 0 1 12 O
failure NN 0 1 1 O
where WRB 0 0 12 O
ketoprofen NN 0 1 UNK B-Drug
and CC 0 0 12 O
digoxin NN 0 1 14 B-Drug
were VBD 1 0 12 O
concomitantly RB 0 0 14 O
administered VBN 1 1 1 O
ketoprofen NN 0 1 UNK B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
alter VB 0 1 13 O
the DT 0 0 12 O
serum NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
. . 0 0 12 O

Therefore RB 0 0 1 O
FLOMAX NNP 0 1 UNK B-Brand
capsules NNS 1 1 3 O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
with IN 0 0 12 O
caution NN 0 0 1 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
cimetidine JJ 0 1 13 B-Drug
particularly RB 0 0 1 O
at IN 0 0 12 O
doses NNS 1 1 6 O
higher JJR 1 1 1 O
than IN 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
. . 0 0 12 O

In IN 0 0 2 O
addition NN 0 1 1 O
ketoconazole FW 0 1 16 B-Drug
alone RB 0 1 12 O
can MD 0 0 12 O
inhibit VB 0 1 13 O
adrenal JJ 0 0 6 O
corticosteroid NN 0 1 UNK B-Drug
synthesis NN 0 1 UNK O
and CC 0 0 12 O
may MD 0 0 1 O
cause VB 0 1 12 O
adrenal JJ 0 0 6 O
insufficiency NN 0 1 6 O
during IN 0 0 12 O
corticosteroid JJ 0 1 UNK O
withdrawal NN 0 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
a DT 0 0 12 O
patient NN 0 1 6 O
with IN 0 0 12 O
a DT 0 0 12 O
nonfunctioning JJ 0 1 UNK O
thyroid JJ 0 1 6 O
gland NN 0 1 6 O
who WP 0 0 12 O
is VBZ 1 0 12 O
receiving VBG 1 1 1 O
thyroid JJ 0 1 6 O
replacement NN 0 1 1 O
therapy NN 0 1 6 O
free JJ 0 1 12 O
levothyroxine NN 0 1 0 B-Drug
may MD 0 0 1 O
be VB 0 0 12 O
decreased VBN 1 1 1 O
when WRB 0 0 12 O
estrogens NNS 1 1 16 B-Group
are VBP 1 0 12 O
started VBN 1 1 12 O
thus RB 0 0 1 O
increasing VBG 1 1 1 O
thyroid NN 0 1 6 B-Group
requirements NNS 1 1 1 O
. . 0 0 12 O

Omeprazole NN 0 1 0 B-Drug
: : 0 0 2 O
No DT 0 0 2 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
changes NNS 1 1 1 O
in IN 0 0 12 O
lomefloxacin NN 0 1 UNK B-Drug
pharmacokinetics NNS 0 1 UNK O
( ( 0 0 2 O
AUC NNP 0 1 UNK O
C NNP 0 0 2 O
max NN 0 0 3 O
or CC 0 0 12 O
T NNP 0 1 2 O
max NN 0 0 3 O
) ) 0 0 2 O
were VBD 1 0 12 O
observed VBN 1 1 1 O
when WRB 0 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
lomefloxacin JJ 0 1 UNK B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
was VBD 1 0 12 O
given VBN 1 1 12 O
after IN 0 0 12 O
multiple JJ 0 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
omeprazole NN 0 1 0 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg RB 0 1 0 O
qd NN 0 1 14 O
) ) 0 0 2 O
in IN 0 0 12 O
9 CD 0 0 2 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
. . 0 0 12 O

Drug NNP 0 1 2 O
- : 0 0 2 O
Drug NN 0 1 2 O
Interactions NNS 0 1 UNK O
: : 0 0 2 O
The DT 0 0 2 O
pharmacokinetic JJ 0 1 UNK O
and CC 0 0 12 O
pharmacodynamic JJ 0 1 UNK O
interactions NNS 1 1 UNK O
between IN 0 0 12 O
FLOMAX NNP 0 1 UNK B-Brand
capsules NNS 1 1 3 O
and CC 0 0 12 O
other JJ 0 0 12 O
alpha JJ 0 1 1 B-Group
- : 0 0 2 O
adrenergic JJ 0 1 UNK I-Group
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
determined VBN 1 1 1 O
. . 0 0 12 O

HMG NNP 0 0 UNK B-Group
- : 0 0 2 O
CoA NNP 0 0 UNK I-Group
reductase NN 0 1 UNK I-Group
inhibitors NNS 1 1 14 I-Group
: : 0 0 2 O
No DT 0 0 2 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
pharmacokinetic JJ 0 1 UNK O
interactions NNS 1 1 UNK O
were VBD 1 0 12 O
seen VBN 1 1 12 O
when WRB 0 0 12 O
ezetimibe NN 0 1 16 B-Drug
was VBD 1 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
with IN 0 0 12 O
atorvastatin NN 0 1 0 B-Drug
simvastatin NN 0 1 0 B-Drug
pravastatin NN 0 1 16 B-Drug
lovastatin NN 0 1 13 B-Drug
or CC 0 0 12 O
fluvastatin NN 0 1 13 B-Drug
. . 0 0 12 O

Interference NN 0 1 UNK O
with IN 0 0 12 O
spectrophotometric JJ 0 1 UNK O
methods NNS 1 1 1 O
for IN 0 0 12 O
SGOT NNP 0 0 14 O
analysis NN 0 1 1 O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
. . 0 0 12 O

Women NNS 0 1 2 O
of IN 0 0 12 O
childbearing VBG 0 0 UNK O
potential JJ 0 1 1 O
make VBP 0 1 12 O
up RP 0 0 12 O
a DT 0 0 12 O
considerable JJ 0 0 1 O
segment NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
patient JJ 0 1 6 O
population NN 0 1 13 O
affected VBN 1 1 1 O
by IN 0 0 12 O
psoriasis NN 0 1 6 O
. . 0 0 12 O

No DT 0 0 2 O
evidence NN 0 1 1 O
of IN 0 0 12 O
mutagenicity NN 0 1 UNK O
was VBD 1 0 12 O
observed VBN 1 1 1 O
in IN 0 0 12 O
vitro NN 0 1 UNK O
in IN 0 0 12 O
a DT 0 0 12 O
microbial JJ 0 1 UNK O
mutagenicity NN 0 1 UNK O
( ( 0 0 2 O
Ames NNP 0 1 UNK O
) ) 0 0 2 O
test NN 0 1 1 O
with IN 0 0 12 O
Salmonella NNP 0 1 UNK O
typhimurium NN 0 0 UNK O
and CC 0 0 12 O
Escherichia NNP 0 1 14 O
coli VBP 0 0 14 O
with IN 0 0 12 O
or CC 0 0 12 O
without IN 0 0 12 O
metabolic JJ 0 1 6 O
activation NN 0 1 13 O
. . 0 0 12 O

Patients NNS 0 1 7 O
with IN 0 0 12 O
Hepatic NNP 0 1 7 O
Impairment NNP 0 1 UNK O
In IN 0 0 2 O
vitro NN 0 1 UNK O
and CC 0 0 12 O
in IN 0 0 12 O
vivo JJ 0 1 13 O
evidence NN 0 1 1 O
suggest VBP 0 1 1 O
that IN 0 0 12 O
erlotinib NN 0 1 13 B-Drug
is VBZ 1 0 12 O
cleared VBN 1 1 12 O
primarily RB 0 0 1 O
by IN 0 0 12 O
the DT 0 0 12 O
liver NN 0 1 6 O
. . 0 0 12 O

Patients NNS 0 1 7 O
who WP 0 0 12 O
have VBP 0 0 12 O
previously RB 0 0 1 O
received VBN 1 1 12 O
pelvic JJ 0 1 6 O
/ NNP 0 0 2 O
abdominal JJ 0 1 6 O
irradiation NN 0 1 14 O
are VBP 1 0 12 O
at IN 0 0 12 O
increased JJ 0 1 1 O
risk NN 0 1 1 O
of IN 0 0 12 O
severe JJ 0 1 6 O
myelosuppression NN 0 1 8 O
following VBG 1 1 1 O
the DT 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
CAMPTOSAR NNP 0 1 UNK B-Brand
. . 0 0 12 O

MAO NNP 0 1 14 B-Group
inhibitors NNS 1 1 14 I-Group
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
with IN 0 0 12 O
caution NN 0 0 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
hydralazine NN 0 1 14 B-Drug
. . 0 0 12 O

A DT 0 0 2 O
number NN 0 1 1 O
of IN 0 0 12 O
substances NNS 1 1 1 O
affect VBP 0 1 1 O
glucose JJ 0 1 14 O
metabolism NN 0 1 16 O
and CC 0 0 12 O
may MD 0 0 1 O
require VB 0 0 1 O
insulin NN 0 1 14 B-Drug
dose JJ 0 1 6 O
adjustment NN 0 1 1 O
and CC 0 0 12 O
particularly RB 0 0 1 O
close JJ 0 1 12 O
monitoring NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
data NNS 0 1 1 O
described VBN 1 1 1 O
in IN 0 0 12 O
this DT 0 0 12 O
section NN 0 1 1 O
were VBD 1 0 12 O
obtained VBN 1 1 1 O
from IN 0 0 12 O
controlled JJ 0 1 1 O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
and CC 0 0 12 O
studies NNS 1 1 1 O
involving VBG 1 1 1 O
otherwise RB 0 0 1 O
healthy JJ 0 1 12 O
adults NNS 1 1 13 O
with IN 0 0 12 O
epilepsy NN 0 1 13 O
. . 0 0 12 O

. . 0 0 12 O

There EX 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
isolated VBN 1 1 1 O
reports NNS 1 1 1 O
of IN 0 0 12 O
patients NNS 1 1 6 O
experiencing VBG 1 1 12 O
increases NNS 1 1 1 O
in IN 0 0 12 O
their PRP$ 0 0 12 O
prothrombin NN 0 1 14 O
times NNS 1 1 12 O
when WRB 0 0 12 O
etidronate NN 0 1 0 B-Drug
was VBD 1 0 12 O
added VBN 1 1 12 O
to TO 0 0 12 O
warfarin VB 0 1 14 B-Drug
therapy NN 0 1 6 O
. . 0 0 12 O

- : 0 0 2 O
a DT 0 0 12 O
diuretic JJ 0 1 14 B-Group
( ( 0 0 2 O
water NN 0 1 3 O
pill NN 0 1 6 O
) ) 0 0 2 O
such JJ 0 0 1 O
as IN 1 0 12 O
hydrochlorothiazide NN 0 1 0 B-Drug
( ( 0 0 2 O
HCTZ NNP 0 1 0 B-Drug
Hydrodiuril NNP 0 1 UNK B-Brand
) ) 0 0 2 O
chlorothiazide NN 0 1 16 B-Drug
( ( 0 0 2 O
Diuril NNP 0 1 UNK B-Brand
) ) 0 0 2 O
and CC 0 0 12 O
others NNS 0 1 12 O
; : 0 0 2 O

Close JJ 0 1 2 O
observation NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
patient NN 0 1 6 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
when WRB 0 0 12 O
a DT 0 0 12 O
beta NN 0 1 16 B-Group
- : 0 0 2 O
blocker NN 0 0 3 I-Group
is VBZ 1 0 12 O
administered VBN 1 1 1 O
to TO 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
catecholamine JJ 0 1 14 O
- : 0 0 2 O
depleting VBG 1 1 UNK O
drugs NNS 1 1 6 O
such JJ 0 0 1 O
as IN 1 0 12 O
reserpine NN 0 1 UNK B-Drug
because IN 0 0 12 O
of IN 0 0 12 O
possible JJ 0 1 1 O
additive JJ 0 1 16 O
effects NNS 1 1 1 O
and CC 0 0 12 O
the DT 0 0 12 O
production NN 0 1 1 O
of IN 0 0 12 O
hypotension NN 0 1 6 O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
marked VBN 1 1 1 O
bradycardia IN 0 1 8 O
which WDT 0 0 12 O
may MD 0 0 1 O
produce VB 0 0 1 O
vertigo JJ 0 1 6 O
syncope NN 0 1 8 O
or CC 0 0 12 O
postural JJ 0 1 13 O
hypotension NN 0 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
possibility NN 0 1 1 O
of IN 0 0 12 O
hypotensive JJ 0 1 14 O
effects NNS 1 1 1 O
can MD 0 0 12 O
be VB 0 0 12 O
minimized VBN 1 0 1 O
by IN 0 0 12 O
either DT 0 1 12 O
discontinuing VBG 1 1 6 O
the DT 0 0 12 O
diuretic JJ 0 1 14 B-Group
or CC 0 0 12 O
increasing VBG 1 1 1 O
salt JJ 0 1 3 O
intake NN 0 1 3 O
prior RB 0 1 1 O
to TO 0 0 12 O
initiation NN 0 1 1 O
of IN 0 0 12 O
treatment NN 0 1 6 O
with IN 0 0 12 O
fosinopril JJ 0 1 13 B-Drug
sodium NN 0 1 14 I-Drug
. . 0 0 12 O

- : 0 0 2 O
did VBD 1 0 12 O
not RB 0 1 12 O
change VB 0 1 1 O
the DT 0 0 12 O
pharmacokinetic JJ 0 1 UNK O
profile NN 0 1 1 O
or CC 0 0 12 O
urinary JJ 0 1 6 O
excretion NN 0 1 14 O
of IN 0 0 12 O
immunoreactive JJ 0 0 UNK O
digoxin NN 0 1 14 B-Drug
. . 0 0 12 O

No DT 0 0 2 O
evidence NN 0 1 1 O
of IN 0 0 12 O
interaction NN 0 1 UNK O
of IN 0 0 12 O
PROCRIT NNP 0 1 UNK B-Brand
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
was VBD 1 0 12 O
observed VBN 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
course NN 0 1 12 O
of IN 0 0 12 O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
. . 0 0 12 O

Physiological JJ 0 1 UNK O
changes NNS 1 1 1 O
resulting VBG 1 1 1 O
from IN 0 0 12 O
smoking VBG 1 1 12 O
cessation NN 0 1 6 O
with IN 0 0 12 O
or CC 0 0 12 O
without IN 0 0 12 O
nicotine JJ 0 1 6 B-Drug
replacement NN 0 1 1 O
may MD 0 0 1 O
alter VB 0 1 13 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
certain JJ 0 1 1 O
concomitant JJ 0 1 6 O
medications NNS 1 1 6 O
such JJ 0 0 1 O
as IN 1 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
and CC 0 0 12 O
theophylline NN 0 1 16 B-Drug
. . 0 0 12 O

phosphokinase NN 0 1 8 O

Impaired NNP 0 1 UNK O
glucose VBD 0 1 14 O
tolerance NN 0 1 1 O
. . 0 0 12 O

Estrogen NNP 0 1 7 B-Group
Oral NNP 0 1 2 O
Contraceptives NNS 0 1 UNK B-Group
: : 0 0 2 O
Estrogens NNS 0 1 0 B-Group
tend VBP 0 0 12 O
to TO 0 0 12 O
increase VB 0 1 1 O
serum NN 0 1 14 O
thyroxine JJ 0 1 14 O
- : 0 0 2 O
binding NN 0 1 1 O
globulin NN 0 1 14 O
( ( 0 0 2 O
TBg NNP 0 1 UNK O
) ) 0 0 2 O
. . 0 0 12 O

Oral JJ 0 1 2 O
metronidazole NN 0 1 0 B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
potentiate VB 0 0 UNK O
the DT 0 0 12 O
anticoagulant JJ 0 1 13 O
effect NN 0 1 1 O
of IN 0 0 12 O
coumarin NN 0 1 UNK B-Group
and CC 0 0 12 O
warfarin NN 0 1 14 B-Drug
resulting VBG 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
prolongation NN 0 1 6 O
of IN 0 0 12 O
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
. . 0 0 12 O

Patients NNS 0 1 7 O
receiving VBG 1 1 1 O
other JJ 0 0 12 O
narcotic JJ 0 1 6 B-Group
analgesics NNS 1 1 14 I-Group
general JJ 0 1 1 O
anesthetics NNS 1 1 13 B-Group
phenothiazines VBP 0 1 UNK B-Group
tranquilizers NNS 1 1 13 B-Group
sedative JJ 0 1 6 B-Group
- : 0 0 2 O
hypnotics NNS 1 1 13 I-Group
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
or CC 0 0 12 O
other JJ 0 0 12 O
CNS NNP 0 1 6 B-Group
depressants NNS 1 0 13 I-Group
( ( 0 0 2 O
including VBG 1 1 1 O
alcohol NN 0 1 1 B-Drug
) ) 0 0 2 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
DILAUDID NNP 0 1 UNK B-Brand
may MD 0 0 1 O
exhibit VB 0 1 1 O
an DT 0 0 12 O
additive JJ 0 1 16 O
CNS NNP 0 1 6 O
depression NN 0 1 6 O
. . 0 0 12 O

Such JJ 0 0 1 O
patients NNS 1 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
closely RB 0 0 1 O
monitored VBN 1 1 1 O
for IN 0 0 12 O
signs NNS 1 1 12 O
of IN 0 0 12 O
toxicity NN 0 1 6 O
and CC 0 0 12 O
have VBP 0 0 12 O
their PRP$ 0 0 12 O
theophylline JJ 0 1 16 B-Drug
dosage NN 0 1 0 O
adjusted VBN 1 1 1 O
as IN 1 0 12 O
necessary JJ 0 0 1 O
. . 0 0 12 O

ECG JJ 0 1 6 O
intervals NNS 1 1 1 O
( ( 0 0 2 O
PR NNP 0 1 2 O
QRS NNP 0 0 8 O
and CC 0 0 12 O
QT NNP 0 1 13 O
) ) 0 0 2 O
were VBD 1 0 12 O
not RB 0 1 12 O
affected VBN 1 1 1 O
by IN 0 0 12 O
concurrent NN 0 1 1 O
Mexitil NNP 0 1 UNK B-Brand
and CC 0 0 12 O
digoxin NN 0 1 14 B-Drug
diuretics NNS 1 1 14 B-Group
or CC 0 0 12 O
propranolol NN 0 1 16 B-Drug
. . 0 0 12 O

Pravastatin NN 0 1 0 B-Drug
: : 0 0 2 O
In IN 0 0 2 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
way NN 0 0 12 O
crossover NN 0 1 UNK O
study NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
normal JJ 0 1 1 O
- : 0 0 2 O
weight NN 0 1 3 O
mildly RB 0 1 3 O
hypercholesterolemic JJ 0 0 UNK O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
XENICAL JJ 0 1 UNK B-Brand
9 CD 0 0 2 O
mg NN 0 1 0 O
three CD 0 1 12 O
times NNS 1 1 12 O
a DT 0 0 12 O
day NN 0 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
XENICAL RB 0 1 UNK B-Brand
did VBD 1 0 12 O
not RB 0 1 12 O
affect VB 0 1 1 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
pravastatin NN 0 1 16 B-Drug
. . 0 0 12 O

Anticonvulsants NNS 0 1 UNK B-Group
: : 0 0 2 O
Phenytoin NNP 0 1 0 B-Drug
Phenobarbital NNP 0 1 0 B-Drug
Carbamazepine NNP 0 1 UNK B-Drug

. . 0 0 12 O

9 CD 0 0 2 O
. . 0 0 12 O

Drugs NNS 0 1 2 O
affecting VBG 1 1 1 O
pituitary NN 0 1 6 O
or CC 0 0 12 O
adrenocortical JJ 0 1 UNK O
function NN 0 1 1 O
including VBG 1 1 1 O
all DT 0 0 12 O
corticosteroid JJ 0 1 UNK O
therapy NN 0 1 6 O
must MD 0 0 12 O
be VB 0 0 12 O
discontinued VBN 1 1 1 O
prior JJ 0 1 1 O
to TO 0 0 12 O
and CC 0 0 12 O
during IN 0 0 12 O
testing VBG 1 1 1 O
with IN 0 0 12 O
Metopirone NNP 0 1 UNK B-Brand
. . 0 0 12 O

A DT 0 0 2 O
pregnancy NN 0 1 6 O
test NN 0 1 1 O
must MD 0 0 12 O
be VB 0 0 12 O
repeated VBN 1 1 1 O
each DT 0 0 12 O
month NN 0 1 12 O
prior RB 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
female JJ 0 1 12 O
patient NN 0 1 6 O
receiving VBG 1 1 1 O
each DT 0 0 12 O
prescription NN 0 1 0 O

Corticosteroids NNS 0 1 UNK B-Group
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
clearance NN 0 1 16 O
of IN 0 0 12 O
chronic JJ 0 1 6 O
high JJ 0 1 1 O
dose NN 0 1 6 O
aspirin NN 0 1 14 B-Brand
. . 0 0 12 O

If IN 0 0 12 O
you PRP 0 0 12 O
are VBP 1 0 12 O
taking VBG 1 0 12 O
medications NNS 1 1 6 O
for IN 0 0 12 O
migraines NNS 1 1 6 O
such JJ 0 0 1 O
as IN 1 0 12 O
Imitrex NNP 0 1 0 B-Brand
talk NN 0 1 12 O
to TO 0 0 12 O
your PRP$ 0 0 12 O
doctor NN 0 1 12 O
before IN 0 1 12 O
starting VBG 1 1 12 O
this DT 0 0 12 O
medicine NN 0 1 6 O
. . 0 0 12 O

Patients NNS 0 1 7 O
with IN 0 0 12 O
mild JJ 0 1 6 O
to TO 0 0 12 O
moderate VB 0 1 1 O
renal JJ 0 1 6 O
insufficiency NN 0 1 6 O
should MD 0 0 12 O
avoid VB 0 0 12 O
taking VBG 1 0 12 O
NSAIDs NNP 0 1 UNK B-Group
with IN 0 0 12 O
short JJ 0 1 12 O
elimination NN 0 1 UNK O
half NN 0 1 12 O
- : 0 0 2 O
lives VBZ 1 1 12 O
for IN 0 0 12 O
a DT 0 0 12 O
period NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
before IN 0 1 12 O
the DT 0 0 12 O
day NN 0 1 12 O
of IN 0 0 12 O
and CC 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
following VBG 1 1 1 O
administration NN 0 1 1 O
of IN 0 0 12 O
ALIMTA NNP 0 1 UNK B-Brand
. . 0 0 12 O

H9 NNP 0 0 UNK B-Group
Receptor NNP 0 1 UNK I-Group
Antagonists VBZ 0 1 UNK I-Group
: : 0 0 2 O
Cimetidine JJ 0 1 0 B-Drug
coadministration NN 0 1 UNK O
leads VBZ 1 1 12 O
to TO 0 0 12 O
an DT 0 0 12 O
increased VBN 1 1 1 O
peak NN 0 1 1 O
plasma NN 0 1 14 O
concentration NN 0 1 1 O
and CC 0 0 12 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
cisapride NN 0 1 UNK B-Drug
there EX 0 0 12 O
is VBZ 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
cisapride NN 0 1 UNK B-Drug
absorption NN 0 1 1 O
when WRB 0 0 12 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
ranitidine NN 0 1 0 B-Drug
. . 0 0 12 O

Valproate NNP 0 1 0 B-Drug
Keppra NNP 0 1 0 B-Brand
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
twice RB 0 1 12 O
daily RB 0 1 12 O
) ) 0 0 2 O
did VBD 1 0 12 O
not RB 0 1 12 O
alter VB 0 1 13 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
valproate NN 0 1 16 B-Drug
in IN 0 0 12 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
. . 0 0 12 O

Furthermore RB 0 0 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
both DT 0 0 12 O
drugs NNS 1 1 6 O
careful JJ 0 1 12 O
monitoring NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
INR NNP 0 1 13 O
or CC 0 0 12 O
PT NNP 0 1 2 O
and CC 0 0 12 O
adjustment NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
warfarin NN 0 1 14 B-Drug
dosage NN 0 1 0 O
if IN 0 0 12 O
indicated VBN 1 1 1 O
are VBP 1 0 12 O
recommended VBN 1 1 1 O
when WRB 0 0 12 O
the DT 0 0 12 O
oxandrolone NN 0 1 13 B-Drug
dose NN 0 1 6 O
is VBZ 1 0 12 O
changed VBN 1 1 12 O
or CC 0 0 12 O
discontinued VBN 1 1 1 O
. . 0 0 12 O

MAO NNP 0 1 14 B-Group
inhibitors NNS 1 1 14 I-Group
prolong RB 0 0 13 O
and CC 0 0 12 O
intensify VB 0 0 UNK O
the DT 0 0 12 O
anticholinergic JJ 0 1 13 O
effects NNS 1 1 1 O
of IN 0 0 12 O
antihistamines NNS 1 1 UNK B-Group
. . 0 0 12 O

While IN 0 0 12 O
all PDT 0 0 12 O
the DT 0 0 12 O
selective JJ 0 1 13 B-Group
serotonin NN 0 1 13 I-Group
reuptake NN 0 1 13 I-Group
inhibitors NNS 1 1 14 I-Group
( ( 0 0 2 O
SSRIs NNP 0 1 UNK B-Group
) ) 0 0 2 O
e.g. VBP 0 0 UNK O
fluoxetine JJ 0 1 16 B-Drug
seriraline NN 0 0 UNK O
and CC 0 0 12 O
paroxetine JJ 0 1 16 B-Drug
inhibit NN 0 1 13 O
P9 NNP 0 1 UNK O
9D9 CD 0 0 UNK O
they PRP 0 0 12 O
may MD 0 0 1 O
vary VB 0 0 1 O
in IN 0 0 12 O
the DT 0 0 12 O
extent NN 0 1 1 O
of IN 0 0 12 O
inhibition NN 0 1 13 O
. . 0 0 12 O

Integumentary JJ 0 1 UNK O

If IN 0 0 12 O
NovoLog NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
mixed JJ 0 1 3 O
with IN 0 0 12 O
NPH NNP 0 1 14 B-Drug
human JJ 0 1 1 I-Drug
insulin NN 0 1 14 I-Drug
NovoLog NNP 0 1 UNK B-Brand
should MD 0 0 12 O
be VB 0 0 12 O
drawn VBN 1 0 12 O
into IN 0 0 12 O
the DT 0 0 12 O
syringe NN 0 1 3 O
first RB 0 1 12 O
. . 0 0 12 O

Cholestyramine NNP 0 1 UNK B-Drug
resin NN 0 1 UNK B-Group
may MD 0 0 1 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
undergo VBP 0 0 1 O
enterohepatic JJ 0 0 UNK O
circulation NN 0 1 1 O
The DT 0 0 2 O
discontinuance NN 0 0 15 O
of IN 0 0 12 O
cholestyramine NN 0 1 13 B-Drug
resin NN 0 1 UNK B-Group
could MD 0 0 12 O
pose VB 0 0 UNK O
a DT 0 0 12 O
hazard NN 0 1 13 O
to TO 0 0 12 O
health NN 0 1 1 O
if IN 0 0 12 O
a DT 0 0 12 O
potentially RB 0 0 1 O
toxic JJ 0 1 1 O
drug NN 0 1 1 O
such JJ 0 0 1 O
as IN 1 0 12 O
digitalis NN 0 1 14 B-Group
has VBZ 1 0 12 O
been VBN 1 0 12 O
filtrated VBN 1 0 UNK O
to TO 0 0 12 O
a DT 0 0 12 O
maintenance NN 0 1 1 O
level NN 0 1 1 O
while IN 0 0 12 O
the DT 0 0 12 O
patient NN 0 1 6 O
was VBD 1 0 12 O
taking VBG 1 0 12 O
cholestyramine JJ 0 1 13 B-Drug
resin NN 0 1 UNK B-Group
. . 0 0 12 O

Ganciclovir NNP 0 1 UNK B-Drug
: : 0 0 2 O
Administration NN 0 1 UNK O
of IN 0 0 12 O
VIDEX NNP 0 1 UNK B-Brand
9 CD 0 0 2 O
hours NNS 1 1 12 O
prior RB 0 1 1 O
to TO 0 0 12 O
or CC 0 0 12 O
concurrent NN 0 1 1 O
with IN 0 0 12 O
oral JJ 0 1 6 O
ganciclovir NN 0 1 14 B-Drug
was VBD 1 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
( ( 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
% NN 0 0 18 O
increase NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
didanosine NN 0 1 16 B-Drug
( ( 0 0 2 O
n JJ 0 1 12 O
= NNP 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

Phenobarbital NNP 0 1 0 B-Drug
or CC 0 0 12 O
Primidone NNP 0 1 UNK B-Drug
: : 0 0 2 O
No DT 0 0 2 O
formal JJ 0 1 1 O
pharmacokinetic JJ 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
performed VBN 1 1 1 O
examining VBG 1 1 UNK O
the DT 0 0 12 O
addition NN 0 1 1 O
of IN 0 0 12 O
tiagabine NN 0 1 13 B-Drug
to TO 0 0 12 O
regimens VB 0 1 UNK O
containing VBG 1 1 1 O
phenobarbital JJ 0 1 16 B-Drug
or CC 0 0 12 O
primidone NN 0 1 13 B-Drug
. . 0 0 12 O

If IN 0 0 12 O
nifedipine JJ 0 1 0 B-Drug
therapy NN 0 1 6 O
is VBZ 1 0 12 O
initiated VBN 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
patient NN 0 1 6 O
currently RB 0 1 12 O
receiving VBG 1 1 1 O
cimetidine NN 0 1 13 B-Drug
cautious JJ 0 0 UNK O
titration NN 0 1 14 O
is VBZ 1 0 12 O
advised VBN 1 0 12 O
. . 0 0 12 O

however RB 0 0 12 O
it PRP 0 0 12 O
adversely RB 0 0 UNK O
affected VBD 1 1 1 O
response NN 0 1 1 O
duration NN 0 1 1 O
suggesting VBG 1 1 1 O
that IN 0 0 12 O
pyridoxine NN 0 1 16 B-Drug
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
HEXALEN NNP 0 1 UNK B-Brand
and CC 0 0 12 O
/ NNP 0 0 2 O
or CC 0 0 12 O
cisplatin NN 0 1 14 B-Drug
.9 NN 0 0 18 O

Although IN 0 0 12 O
the DT 0 0 12 O
relevance NN 0 1 UNK O
of IN 0 0 12 O
these DT 0 0 12 O
reports NNS 1 1 1 O
and CC 0 0 12 O
any DT 0 0 12 O
mechanism NN 0 1 13 O
of IN 0 0 12 O
coagulation NN 0 1 14 O
alterations NNS 1 1 1 O
is VBZ 1 0 12 O
unclear JJ 0 0 1 O
patients NNS 1 1 6 O
on IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
should MD 0 0 12 O
have VB 0 0 12 O
their PRP$ 0 0 12 O
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
monitored VBD 1 1 1 O
. . 0 0 12 O

Patients NNS 0 1 7 O
on IN 0 0 12 O
lithium JJ 0 1 16 B-Drug
treatment NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
closely RB 0 0 1 O
monitored VBN 1 1 1 O
when WRB 0 0 12 O
CELEBREX NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
introduced VBN 1 1 12 O
or CC 0 0 12 O
withdrawn VBN 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
following VBG 1 1 1 O
specific JJ 0 1 1 O
interactions NNS 1 1 UNK O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
: : 0 0 2 O
Itraconazole NNP 0 1 UNK O
Co NNP 0 1 2 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
another DT 0 0 12 O
extended JJ 0 1 1 O
release NN 0 1 12 O
formulation NN 0 1 13 O
of IN 0 0 12 O
felodipine NN 0 1 13 B-Drug
with IN 0 0 12 O
itraconazole JJ 0 1 0 B-Drug
resulted VBN 1 1 1 O
in IN 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
- : 0 0 2 O
fold JJ 0 1 3 O
increase NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
AUC NNP 0 1 UNK O
more JJR 0 1 12 O
than IN 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
fold JJ 0 1 3 O
increase NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
Cmax NNP 0 1 UNK O
and CC 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
fold JJ 0 1 3 O
prolongation NN 0 1 6 O
in IN 0 0 12 O
the DT 0 0 12 O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
of IN 0 0 12 O
felodipine NN 0 1 13 B-Drug
. . 0 0 12 O

Because IN 0 0 12 O
busulfan NN 0 1 13 B-Drug
is VBZ 1 0 12 O
eliminated VBN 1 1 UNK O
from IN 0 0 12 O
the DT 0 0 12 O
body NN 0 1 3 O
via IN 0 0 1 O
conjugation NN 0 1 14 O
with IN 0 0 12 O
glutathione NN 0 1 13 O
use NN 0 1 1 O
of IN 0 0 12 O
acetaminophen NN 0 1 16 B-Drug
prior RB 0 1 1 O
to TO 0 0 12 O
( ( 0 0 2 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
) ) 0 0 2 O
or CC 0 0 12 O
concurrent NN 0 1 1 O
with IN 0 0 12 O
BUSULFEX NNP 0 1 UNK B-Brand
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
reduced JJ 0 1 1 O
busulfan NN 0 1 13 B-Drug
clearance NN 0 1 16 O
based VBN 1 1 1 O
upon IN 0 0 12 O
the DT 0 0 12 O
known JJ 0 1 12 O
property NN 0 1 13 O
of IN 0 0 12 O
acetaminophen NN 0 1 16 B-Drug
to TO 0 0 12 O
decrease VB 0 1 1 O
glutathione NN 0 1 13 O
levels NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
blood NN 0 1 6 O
and CC 0 0 12 O
tissues NNS 1 1 6 O
. . 0 0 12 O

Nifedipine NN 0 1 0 B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
alter VB 0 1 13 O
the DT 0 0 12 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
Vardenafil NNP 0 1 UNK B-Drug
when WRB 0 0 12 O
taken VBN 1 1 12 O
in IN 0 0 12 O
combination NN 0 1 1 O
. . 0 0 12 O

Intensive JJ 0 1 2 O
monitoring NN 0 1 1 O
of IN 0 0 12 O
renal JJ 0 1 6 O
function NN 0 1 1 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
requiring VBG 1 0 1 O
any DT 0 0 12 O
combination NN 0 1 1 O
of IN 0 0 12 O
nephrotoxic JJ 0 1 UNK O
medications NNS 1 1 6 O
. . 0 0 12 O

However RB 0 0 1 O
serious JJ 0 1 12 O
opportunistic JJ 0 0 1 O
infections NNS 1 1 6 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
and CC 0 0 12 O
no DT 0 0 12 O
complications NNS 1 1 6 O
have VBP 0 0 12 O
specifically RB 0 0 1 O
been VBN 1 0 12 O
attributed VBN 1 1 1 O
to TO 0 0 12 O
lymphocytopenia VB 0 1 13 O
. . 0 0 12 O

Dose JJ 0 1 7 O
adjustments NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
and CC 0 0 12 O
possible JJ 0 1 1 O
prolongation NN 0 1 6 O
and CC 0 0 12 O
intensity NN 0 1 1 O
of IN 0 0 12 O
effect NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
anticipated VBN 1 1 1 O
. . 0 0 12 O

Aspirin NN 0 1 0 B-Brand
: : 0 0 2 O
Concomitant JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
low JJ 0 1 1 O
- : 0 0 2 O
dose NN 0 1 6 O
aspirin NN 0 1 14 B-Brand
with IN 0 0 12 O
VIOXX NNP 0 1 UNK B-Brand
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
an DT 0 0 12 O
increased JJ 0 1 1 O
rate NN 0 1 1 O
of IN 0 0 12 O
GI NNP 0 1 6 O
ulceration NN 0 1 8 O
or CC 0 0 12 O
other JJ 0 0 12 O
complications NNS 1 1 6 O
compared VBN 1 1 1 O
to TO 0 0 12 O
use VB 0 1 1 O
of IN 0 0 12 O
VIOXX NNP 0 1 UNK B-Brand
alone RB 0 1 12 O
. . 0 0 12 O

Human NNP 0 1 2 O
pharmacologic NN 0 1 14 O
studies NNS 1 1 1 O
have VBP 0 0 12 O
shown VBN 1 1 1 O
that IN 0 0 12 O
Ritalin NNP 0 1 0 B-Brand
may MD 0 0 1 O
inhibit VB 0 1 13 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
coumarin JJ 0 1 UNK B-Group
anticoagulants NNS 1 1 13 I-Group
anticonvulsants NNS 1 1 13 B-Group
( ( 0 0 2 O
phenobarbital JJ 0 1 16 B-Drug
diphenylhydantoin NN 0 1 UNK B-Drug
primidone NN 0 1 13 B-Drug
) ) 0 0 2 O
phenylbutazone NN 0 1 UNK B-Drug
and CC 0 0 12 O
tricyclic JJ 0 0 14 B-Group
drugs NNS 1 1 6 I-Group
( ( 0 0 2 O
imipramine JJ 0 1 0 B-Drug
clomipramine NN 0 1 13 B-Drug
desipramine NN 0 1 16 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

9 CD 0 0 2 O
. . 0 0 12 O

Glyburide NN 0 1 0 B-Drug
: : 0 0 2 O
In IN 0 0 2 O
a DT 0 0 12 O
randomized JJ 0 1 6 O
multiple JJ 0 1 1 O
- : 0 0 2 O
dose NN 0 1 6 O
crossover NN 0 1 UNK O
study NN 0 1 1 O
patients NNS 1 1 6 O
with IN 0 0 12 O
Type NNP 0 1 2 O
9 CD 0 0 2 O
diabetes NNS 0 1 6 O
were VBD 1 0 12 O
administered VBN 1 1 1 O
9 CD 0 0 2 O
mg NN 0 1 0 O
Starlix NNP 0 1 UNK B-Brand
three CD 0 1 12 O
times NNS 1 1 12 O
a DT 0 0 12 O
day NN 0 1 12 O
before IN 0 1 12 O
meals NNS 1 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
day NN 0 1 12 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
glyburide JJ 0 1 16 B-Drug
9 CD 0 0 2 O
mg JJ 0 1 0 O
daily RB 0 1 12 O
. . 0 0 12 O

In IN 0 0 2 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
treatment NN 0 1 6 O
with IN 0 0 12 O
finasteride NN 0 1 16 B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
alter VB 0 1 13 O
the DT 0 0 12 O
response NN 0 1 1 O
of IN 0 0 12 O
LH NNP 0 1 13 O
and CC 0 0 12 O
FSH NNP 0 0 14 O
to TO 0 0 12 O
gonadotropin VB 0 1 13 O
- : 0 0 2 O
releasing VBG 1 1 UNK O
hormone NN 0 1 6 O
indicating NN 0 0 1 O
that IN 0 0 12 O
the DT 0 0 12 O
hypothalamic JJ 0 1 13 O
- : 0 0 2 O
pituitary JJ 0 1 6 O
- : 0 0 2 O
testicular JJ 0 1 13 O
axis NN 0 1 3 O
was VBD 1 0 12 O
not RB 0 1 12 O
affected VBN 1 1 1 O
. . 0 0 12 O

Racemic JJ 0 1 UNK O
citalopram NN 0 1 16 B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
alter VB 0 1 13 O
the DT 0 0 12 O
mean JJ 0 1 12 O
AUC NNP 0 1 UNK O
or CC 0 0 12 O
Cmax NNP 0 1 UNK O
of IN 0 0 12 O
pimozide NN 0 1 13 B-Drug
. . 0 0 12 O

Glyburide NN 0 1 0 B-Drug
: : 0 0 2 O
The DT 0 0 2 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
ciprofloxacin NN 0 1 0 B-Drug
with IN 0 0 12 O
the DT 0 0 12 O
sulfonylurea NN 0 1 UNK B-Group
glyburide NN 0 1 16 B-Drug
has VBZ 1 0 12 O
on IN 0 0 12 O
rare JJ 0 1 12 O
occasions NNS 1 0 12 O
resulted VBD 1 1 1 O
in IN 0 0 12 O
severe JJ 0 1 6 O
hypoglycemia NN 0 1 6 O
. . 0 0 12 O

Further JJ 0 1 2 O
misoprostol NN 0 1 13 B-Drug
is VBZ 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
have VB 0 0 12 O
a DT 0 0 12 O
synergistic JJ 0 1 UNK O
effect NN 0 1 1 O
with IN 0 0 12 O
this DT 0 0 12 O
combination NN 0 1 1 O
in IN 0 0 12 O
ameliorating VBG 1 0 UNK O
intestinal JJ 0 1 13 O
permeability NN 0 1 UNK O
. . 0 0 12 O

No DT 0 0 2 O
pharmacokinetic JJ 0 1 UNK O
- : 0 0 2 O
based VBN 1 1 1 O
drug NN 0 1 1 O
- : 0 0 2 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
conducted VBN 1 1 1 O
with IN 0 0 12 O
SYNAREL NNP 0 1 UNK B-Brand
. . 0 0 12 O

Metabolism NN 0 1 UNK O
of IN 0 0 12 O
dasatinib NN 0 1 13 B-Drug
is VBZ 1 0 12 O
mainly RB 0 0 1 O
hepatic JJ 0 1 14 O
. . 0 0 12 O

Methotrexate NN 0 1 0 B-Drug
: : 0 0 2 O
A DT 0 0 2 O
study NN 0 1 1 O
in IN 0 0 12 O
9 CD 0 0 2 O
rheumatoid NN 0 0 6 O
arthritis NN 0 1 6 O
( ( 0 0 2 O
RA NNP 0 1 13 O
) ) 0 0 2 O
patients NNS 1 1 6 O
evaluated VBD 1 1 1 O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
multiple JJ 0 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
meloxicam NN 0 1 13 B-Drug
on IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
methotrexate NN 0 1 16 B-Drug
taken VBN 1 1 12 O
once RB 0 0 12 O
weekly JJ 0 1 12 O
. . 0 0 12 O

9 CD 0 0 2 O
% NN 0 0 18 O

These DT 0 0 1 O
include VBP 0 1 1 O
probenecid NNS 0 1 13 B-Drug
cholestyramine NN 0 1 13 B-Drug
and CC 0 0 12 O
some DT 0 0 12 O
antibiotics NNS 1 1 6 B-Group
( ( 0 0 2 O
e.g NN 0 0 UNK O
. . 0 0 12 O
erythromycin CC 0 1 0 B-Drug
rifamipicin JJ 0 0 UNK O
ampicillin NN 0 1 0 B-Drug
and CC 0 0 12 O
chloramphenicol NN 0 1 14 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

This DT 0 0 2 O
interaction NN 0 1 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
given VBN 1 1 12 O
consideration NN 0 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
NSAIDs NNP 0 1 UNK B-Group
concomitantly RB 0 0 14 O
with IN 0 0 12 O
ACE NNP 0 1 13 B-Group
inhibitors NNS 1 1 14 I-Group
. . 0 0 12 O

The DT 0 0 2 O
potential JJ 0 1 1 O
effects NNS 1 1 1 O
of IN 0 0 12 O
INDOCIN NNP 0 1 UNK B-Brand
and CC 0 0 12 O
potassium NN 0 1 14 B-Group
- : 0 0 2 O
sparing VBG 1 0 6 I-Group
diuretics NNS 1 1 14 I-Group
on IN 0 0 12 O
potassium NN 0 1 14 O
kinetics NNS 0 1 UNK O
and CC 0 0 12 O
renal JJ 0 1 6 O
function NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
when WRB 0 0 12 O
these DT 0 0 12 O
agents NNS 1 1 1 O
are VBP 1 0 12 O
administered VBN 1 1 1 O
concurrently RB 0 0 1 O
. . 0 0 12 O

This DT 0 0 2 O
drug NN 0 1 1 O
may MD 0 0 1 O
interact VB 0 0 UNK O
with IN 0 0 12 O
alcohol NN 0 1 1 B-Drug
or CC 0 0 12 O
other JJ 0 0 12 O
CNS NNP 0 1 6 B-Group
depressants NNS 1 0 13 I-Group
( ( 0 0 2 O
may MD 0 0 1 O
potentiate VB 0 0 UNK O
the DT 0 0 12 O
CNS NNP 0 1 6 O
depressant JJ 0 0 UNK O
effects NNS 1 1 1 O
of IN 0 0 12 O
either CC 0 1 12 O
these DT 0 0 12 O
medications NNS 1 1 6 O
or CC 0 0 12 O
antihistamines NNS 1 1 UNK B-Group
) ) 0 0 2 O
anticholinergics NNS 1 1 13 B-Group
or CC 0 0 12 O
other JJ 0 0 12 O
medications NNS 1 1 6 O
with IN 0 0 12 O
anticholinergic JJ 0 1 13 O
activity NN 0 1 1 O
( ( 0 0 2 O
anticholinergic JJ 0 1 13 O
effects NNS 1 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
potentiated VBN 1 0 UNK O
when WRB 0 0 12 O
these DT 0 0 12 O
medications NNS 1 1 6 O
are VBP 1 0 12 O
used VBN 1 1 12 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
antihistamines NNS 1 1 UNK B-Group
) ) 0 0 2 O
and CC 0 0 12 O
monoamine JJ 0 1 13 B-Group
oxidase NN 0 1 13 I-Group
MAO NNP 0 1 14 I-Group
inhibitors NNS 1 1 14 I-Group
( ( 0 0 2 O
concurrent NN 0 1 1 O
use NN 0 1 1 O
with IN 0 0 12 O
antihistamines NNS 1 1 UNK B-Group
may MD 0 0 1 O
prolong VB 0 0 13 O
and CC 0 0 12 O
intensify VB 0 0 UNK O
the DT 0 0 12 O
anticholinergic NN 0 1 13 O
and CC 0 0 12 O
CNS NNP 0 1 6 O
depressant JJ 0 0 UNK O
effects NNS 1 1 1 O
of IN 0 0 12 O
antihistamines NNS 1 1 UNK B-Group
) ) 0 0 2 O
. . 0 0 12 O

atazanavir NN 0 1 13 B-Drug

Renal JJ 0 1 7 O
function NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
carefully RB 0 0 12 O
monitored VBN 1 1 1 O
especially RB 0 0 12 O
if IN 0 0 12 O
higher JJR 1 1 1 O
dosages NNS 1 1 14 O
of IN 0 0 12 O
the DT 0 0 12 O
aminoglycosides NNS 0 1 13 B-Group
are VBP 1 0 12 O
to TO 0 0 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
or CC 0 0 12 O
if IN 0 0 12 O
therapy NN 0 1 6 O
is VBZ 1 0 12 O
prolonged VBN 1 1 6 O
because IN 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
potential JJ 0 1 1 O
nephrotoxicity NN 0 1 UNK O
and CC 0 0 12 O
ototoxicity NN 0 1 UNK O
of IN 0 0 12 O
aminoglycosidic JJ 0 1 UNK B-Group
antibiotics NNS 1 1 6 I-Group
. . 0 0 12 O

Coadministration NN 0 1 UNK O
of IN 0 0 12 O
propoxyphene NN 0 1 16 B-Drug
decreased VBD 1 1 1 O
the DT 0 0 12 O
maximum JJ 0 1 1 O
plasma JJ 0 1 14 O
concentration NN 0 1 1 O
of IN 0 0 12 O
alprazolam NN 0 1 0 B-Drug
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
decreased VBN 1 1 1 O
clearance NN 0 1 16 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
increased VBD 1 1 1 O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

. . 0 0 12 O

The DT 0 0 2 O
prior JJ 0 1 1 O
administration NN 0 1 1 O
of IN 0 0 12 O
succinylcholine NN 0 1 16 B-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
enhance VB 0 1 UNK O
the DT 0 0 12 O
duration NN 0 1 1 O
but CC 0 0 12 O
quickens VBZ 1 1 UNK O
the DT 0 0 12 O
onset NN 0 1 6 O
and CC 0 0 12 O
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
depth NN 0 1 13 O
of IN 0 0 12 O
neuromuscular JJ 0 1 6 O
block NN 0 1 3 O
induced VBN 1 1 6 O
by IN 0 0 12 O
TRACRIUM NNP 0 1 UNK B-Brand
. . 0 0 12 O

If IN 0 0 12 O
the DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
lovastatin NN 0 1 13 B-Drug
is VBZ 1 0 12 O
changed VBN 1 1 12 O
the DT 0 0 12 O
same JJ 0 1 12 O
procedure NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
repeated VBN 1 1 1 O
. . 0 0 12 O

Drugs NNS 0 1 2 O
possessing VBG 1 1 UNK O
beta NN 0 1 16 O
- : 0 0 2 O
blocking NN 0 1 UNK O
properties NNS 1 1 UNK O
can MD 0 0 12 O
blunt VB 0 1 3 O
the DT 0 0 12 O
bronchodilator NN 0 1 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
beta NN 0 1 16 B-Group
- : 0 0 2 O
receptor NN 0 1 14 I-Group
agonist NN 0 1 14 I-Group
drugs NNS 1 1 6 I-Group
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
bronchospasm NN 0 1 13 O
; : 0 0 2 O

VIRACEPT NNP 0 1 UNK B-Brand
and CC 0 0 12 O
rifampin NN 0 1 16 B-Drug
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
coadministered VBN 0 0 UNK O
. . 0 0 12 O

Therefore RB 0 0 1 O
concomitant JJ 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
TORADOL NNP 0 1 UNK B-Brand
and CC 0 0 12 O
probenecid NN 0 1 13 B-Drug
is VBZ 1 0 12 O
contraindicated VBN 1 1 14 O
. . 0 0 12 O

Since IN 0 1 2 O
apraclonidine NN 0 1 16 B-Drug
may MD 0 0 1 O
reduce VB 0 0 1 O
pulse NN 0 1 3 O
and CC 0 0 12 O
blood NN 0 1 6 O
pressure NN 0 1 1 O
caution NN 0 0 1 O
in IN 0 0 12 O
using VBG 1 1 1 O
drugs NNS 1 1 6 O
such JJ 0 0 1 O
as IN 1 0 12 O
beta NN 0 1 16 B-Group
- : 0 0 2 O
blockers NNS 1 0 6 I-Group
( ( 0 0 2 O
ophthalmic JJ 0 1 6 O
and CC 0 0 12 O
systemic JJ 0 1 6 O
) ) 0 0 2 O
antihypertensives NNS 1 1 14 B-Group
and CC 0 0 12 O
cardiac JJ 0 1 6 B-Group
glycosides NNS 1 1 13 I-Group
is VBZ 1 0 12 O
advised VBN 1 0 12 O
. . 0 0 12 O

Labetalol NNP 0 1 0 B-Drug
HCl NNP 0 0 14 I-Drug
blunts VBZ 1 1 UNK O
the DT 0 0 12 O
reflex JJ 0 1 6 O
tachycardia NN 0 1 8 O
produced VBN 1 0 1 O
by IN 0 0 12 O
nitroglycerin NN 0 1 14 B-Drug
without IN 0 0 12 O
preventing VBG 1 1 1 O
its PRP$ 1 0 12 O
hypotensive JJ 0 1 14 O
effect NN 0 1 1 O
. . 0 0 12 O

Analgesic JJ 0 1 7 B-Group
/ NN 0 0 2 O
anti SYM 0 0 3 B-Group
- : 0 0 2 O
inflammatory NN 0 1 6 I-Group
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
acetaminophen NN 0 1 16 B-Drug
aspirin NN 0 1 14 B-Brand
codeine NN 0 1 0 B-Drug
and CC 0 0 12 O
codeine NN 0 1 0 B-Drug
combinations NNS 1 1 1 O
ibuprofen VBP 0 1 0 B-Drug
indomethacin NN 0 1 14 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

No DT 0 0 2 O
formal JJ 0 1 1 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
performed VBN 1 1 1 O
. . 0 0 12 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interactions NNS 0 1 UNK O

Diclofenac NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
a DT 0 0 12 O
prostaglandin JJ 0 1 13 O
synthetase NN 0 1 UNK O
inhibitor NN 0 1 14 O
however RB 0 0 12 O
and CC 0 0 12 O
all DT 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
inhibit VBP 0 1 13 O
prostaglandin JJ 0 1 13 O
synthesis NN 0 1 UNK O
interfere RB 0 1 UNK O
with IN 0 0 12 O
platelet NN 0 1 14 O
function NN 0 1 1 O
to TO 0 0 12 O
some DT 0 0 12 O
degree NN 0 1 1 O
; : 0 0 2 O

Phenytoin NN 0 1 0 B-Drug
may MD 0 0 1 O
also RB 0 0 12 O
cause VB 0 1 12 O
increased VBD 1 1 1 O
serum JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
glucose JJ 0 1 14 O
alkaline JJ 0 1 14 O
phosphatase NN 0 1 14 O
and CC 0 0 12 O
gamma NN 0 1 14 O
glutamyl NN 0 0 14 O
transpeptidase NN 0 1 UNK O
( ( 0 0 2 O
GGT NNP 0 1 UNK O
) ) 0 0 2 O
. . 0 0 12 O

Cimetidine NN 0 1 0 B-Drug
: : 0 0 2 O
Co NNP 0 1 2 O
- : 0 0 2 O
administration NN 0 1 1 O
with IN 0 0 12 O
high JJ 0 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
cimetidine NN 0 1 13 B-Drug
[ $ 0 0 2 O
9 CD 0 0 2 O
mg JJ 0 1 0 O
twice RB 0 1 12 O
daily JJ 0 1 12 O
] NNS 0 0 2 O
increased VBD 1 1 1 O
the DT 0 0 12 O
Cmax NNP 0 1 UNK O
of IN 0 0 12 O
rofecoxib NN 0 1 16 B-Drug
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
the DT 0 0 12 O
AUC9 NNP 0 0 UNK O
- : 0 0 2 O
9hr CD 0 0 UNK O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
the DT 0 0 12 O
t9 NN 0 1 13 O
/ VBD 0 0 2 O
9 CD 0 0 2 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interactions NNS 0 1 UNK O
: : 0 0 2 O
The DT 0 0 2 O
presence NN 0 1 1 O
of IN 0 0 12 O
sulfasalazine NN 0 1 0 B-Drug
or CC 0 0 12 O
its PRP$ 1 0 12 O
metabolites NNS 1 1 UNK O
in IN 0 0 12 O
body NN 0 1 3 O
fluids NNS 1 1 6 O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
laboratory JJ 0 1 1 O
test NN 0 1 1 O
procedures NNS 1 1 1 O
. . 0 0 12 O

no DT 0 0 12 O
evidence NN 0 1 1 O
of IN 0 0 12 O
mutagenicity NN 0 1 UNK O
was VBD 1 0 12 O
observed VBN 1 1 1 O
. . 0 0 12 O

Concomitant JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
clarithromycin NN 0 1 13 B-Drug
with IN 0 0 12 O
pimozide NN 0 1 13 B-Drug
is VBZ 1 0 12 O
contraindicated VBN 1 1 14 O
. . 0 0 12 O

Co NNP 0 1 2 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
aliskiren NNS 0 1 13 B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
significantly RB 0 0 1 O
affect VBP 0 1 1 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
lovastatin NN 0 1 13 B-Drug
digoxin NN 0 1 14 B-Drug
valsartan FW 0 1 0 B-Drug
amlodipine NN 0 1 0 B-Drug
metformin NN 0 1 0 B-Drug
celecoxib NN 0 1 16 B-Drug
atenolol NN 0 1 0 B-Drug
atorvastatin NN 0 1 0 B-Drug
ramipril NN 0 1 16 B-Drug
or CC 0 0 12 O
hydrochlorothiazide NN 0 1 0 B-Drug
. . 0 0 12 O

convulsions NNS 1 1 13 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
with IN 0 0 12 O
concurrent NN 0 1 1 O
use NN 0 1 1 O
of IN 0 0 12 O
methylprednisolone NN 0 1 16 B-Drug
and CC 0 0 12 O
cyclosporin NN 0 1 14 B-Drug
. . 0 0 12 O

Co NNP 0 1 2 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
and CC 0 0 12 O
cerivastatin NN 0 1 UNK B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
alter VB 0 1 13 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
cerivastatin NN 0 1 UNK B-Drug
sodium NN 0 1 14 I-Drug
. . 0 0 12 O

Barbiturates NNS 0 1 UNK B-Group
may MD 0 0 1 O
decrease VB 0 1 1 O
the DT 0 0 12 O
effectiveness NN 0 1 UNK O
of IN 0 0 12 O
oral JJ 0 1 6 O
contraceptives NNS 1 1 13 B-Group
certain JJ 0 1 1 O
antibiotics NNS 1 1 6 B-Group
quinidine VBP 0 1 16 B-Group
theophylline JJ 0 1 16 B-Drug
corticosteroids NNS 1 1 14 B-Group
anticoagulants NNS 1 1 13 B-Group
and CC 0 0 12 O
beta NN 0 1 16 B-Group
blockers NNS 1 0 6 I-Group
. . 0 0 12 O

Drug NNP 0 1 2 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
of IN 0 0 12 O
mefenamic JJ 0 0 UNK B-Drug
acid NN 0 1 14 I-Drug
and CC 0 0 12 O
these DT 0 0 12 O
compounds NNS 1 1 13 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
conducted VBN 1 1 1 O
. . 0 0 12 O

Nicardipine NNP 0 1 UNK B-Drug
HCl NNP 0 0 14 I-Drug
usually RB 0 1 12 O
does VBZ 1 0 12 O
not RB 0 1 12 O
alter VB 0 1 13 O
the DT 0 0 12 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
however RB 0 0 12 O
serum JJ 0 1 14 O
digoxin NN 0 1 14 B-Drug
levels NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
evaluated VBN 1 1 1 O
after IN 0 0 12 O
concomitant JJ 0 1 6 O
therapy NN 0 1 6 O
with IN 0 0 12 O
nicardipine JJ 0 1 16 B-Drug
HCl NNP 0 0 14 I-Drug
is VBZ 1 0 12 O
initiated VBN 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
extent NN 0 1 1 O
to TO 0 0 12 O
which WDT 0 0 12 O
SSRI NNP 0 1 UNK B-Group
- : 0 0 2 O
TCA NNP 0 1 13 B-Group
interactions NNS 1 1 UNK O
may MD 0 0 1 O
pose VB 0 0 UNK O
clinical JJ 0 1 6 O
problems NNS 1 1 1 O
will MD 0 0 12 O
depend VB 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
degree NN 0 1 1 O
of IN 0 0 12 O
inhibition NN 0 1 13 O
and CC 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
SSRI NNP 0 1 UNK B-Group
involved VBN 1 1 12 O
. . 0 0 12 O

Colestipol NN 0 1 UNK B-Drug
: : 0 0 2 O
Plasma NNP 0 1 UNK O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
atorvastatin NN 0 1 0 B-Drug
decreased VBD 1 1 1 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
when WRB 0 0 12 O
colestipol NN 0 1 13 B-Drug
and CC 0 0 12 O
atorvastatin NN 0 1 0 B-Drug
were VBD 1 0 12 O
coadministered VBN 0 0 UNK O
. . 0 0 12 O

Following VBG 0 1 2 O
a DT 0 0 12 O
9 CD 0 0 2 O
g NN 0 1 16 O
bolus NN 0 1 14 O
of IN 0 0 12 O
AMICAR NNP 0 1 UNK B-Brand
transient NN 0 1 1 O
peak NN 0 1 1 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
9 CD 0 0 2 O
mMol NNS 0 1 UNK O
/ JJ 0 0 2 O
L NNP 0 1 2 O
or CC 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
mL NNS 0 1 14 O
have VBP 0 0 12 O
been VBN 1 0 12 O
obtained VBN 1 1 1 O
. . 0 0 12 O

Simultaneous JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
SPRYCEL NNP 0 1 UNK B-Brand
with IN 0 0 12 O
antacids NNS 1 1 14 B-Group
should MD 0 0 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
. . 0 0 12 O

ketoconazole NN 0 1 16 B-Drug
) ) 0 0 2 O
macrolide NN 0 1 UNK B-Group
antibiotics NNS 1 1 6 I-Group
( ( 0 0 2 O
e.g NN 0 0 UNK O
. . 0 0 12 O
erythromycin NN 0 1 0 B-Drug
) ) 0 0 2 O
and CC 0 0 12 O
HIV NNP 0 1 6 B-Group
protease NN 0 1 13 I-Group
inhibitors NNS 1 1 14 I-Group
( ( 0 0 2 O
e.g NN 0 0 UNK O
. . 0 0 12 O
ritonavir VB 0 1 16 B-Drug
indinavir NN 0 1 16 B-Drug
and CC 0 0 12 O
saquinavir NN 0 1 13 B-Drug
) ) 0 0 2 O
should MD 0 0 12 O
have VB 0 0 12 O
their PRP$ 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
SUBUTEX NNP 0 1 UNK B-Brand
or CC 0 0 12 O
SUBOXONE NNP 0 1 UNK B-Brand
adjusted VBD 1 1 1 O
. . 0 0 12 O

Therefore NNP 0 0 1 O
interactions NNS 1 1 UNK O
could MD 0 0 12 O
occur VB 0 1 1 O
following VBG 1 1 1 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
psychotropic NN 0 1 13 B-Group
drugs NNS 1 1 6 I-Group
( ( 0 0 2 O
e.g. VB 0 0 UNK O
narcotics NNS 1 1 1 B-Group
analgesics NNS 1 1 14 B-Group
antiemetics NNS 1 1 14 B-Group
sedatives NNS 1 1 6 B-Group
tranquilizers NNS 1 1 13 B-Group
) ) 0 0 2 O
. . 0 0 12 O

Oral JJ 0 1 2 O
Contraceptives NNS 0 1 UNK B-Group

Co NNP 0 1 2 O
- : 0 0 2 O
administration NN 0 1 1 O
: : 0 0 2 O
Concomitant JJ 0 1 UNK O
use NN 0 1 1 O
of IN 0 0 12 O
Argatroban NNP 0 1 0 B-Drug
with IN 0 0 12 O
antiplatelet NN 0 0 13 B-Group
agents NNS 1 1 1 I-Group
thrombolytics NNS 1 1 14 B-Group
and CC 0 0 12 O
other JJ 0 0 12 O
anticoagulants NNS 1 1 13 B-Group
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
bleeding NN 0 1 6 O
. . 0 0 12 O

In IN 0 0 2 O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
antacids NNS 1 1 14 B-Group
were VBD 1 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
lansoprazole JJ 0 1 16 B-Drug
delayed VBN 1 1 1 O
- : 0 0 2 O
release NN 0 1 12 O
capsules NNS 1 1 3 O
; : 0 0 2 O

Mylotarg NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
not RB 0 1 12 O
known VBN 1 1 12 O
to TO 0 0 12 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
any DT 0 0 12 O
routine JJ 0 1 1 O
diagnostic JJ 0 1 6 O
tests NNS 1 1 1 O
. . 0 0 12 O

Such JJ 0 0 1 O
patients NNS 1 1 6 O
may MD 0 0 1 O
be VB 0 0 12 O
unresponsive JJ 0 1 6 O
to TO 0 0 12 O
the DT 0 0 12 O
usual JJ 0 1 12 O
doses NNS 1 1 6 O
of IN 0 0 12 O
epinephrine NN 0 1 14 B-Drug
used VBN 1 1 12 O
to TO 0 0 12 O
treat VB 0 1 12 O
allergic JJ 0 1 6 O
reaction NN 0 1 1 O
. . 0 0 12 O

Coadministration NN 0 1 UNK O
of IN 0 0 12 O
VIRACEPT NNP 0 1 UNK B-Brand
and CC 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
induce VBP 0 1 6 O
CYP9A NNP 0 0 UNK O
may MD 0 0 1 O
decrease VB 0 1 1 O
nelfinavir JJ 0 1 16 B-Drug
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
and CC 0 0 12 O
reduce VB 0 0 1 O
its PRP$ 1 0 12 O
therapeutic JJ 0 1 6 O
effect NN 0 1 1 O
. . 0 0 12 O

Ketoconazole NNP 0 1 UNK B-Drug
: : 0 0 2 O
Coadministration NN 0 1 UNK O
of IN 0 0 12 O
ketoconazole NN 0 1 16 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
) ) 0 0 2 O
with IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
mg NN 0 1 0 O
single JJ 0 1 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
aripiprazole NN 0 1 16 B-Drug
increased VBD 1 1 1 O
the DT 0 0 12 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
aripiprazole NN 0 1 16 B-Drug
and CC 0 0 12 O
its PRP$ 1 0 12 O
active JJ 0 1 1 O
metabolite NN 0 1 UNK O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
respectively RB 0 0 1 O
. . 0 0 12 O

The DT 0 0 2 O
gonadotropin NN 0 1 13 O
levels NNS 1 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
transiently RB 0 0 14 O
elevated VBN 1 1 1 O
by IN 0 0 12 O
spironolactone NN 0 1 0 B-Drug
minimally RB 0 0 6 O
elevated VBN 1 1 1 O
by IN 0 0 12 O
levodopa NN 0 1 UNK B-Drug
and CC 0 0 12 O
suppressed VBN 1 1 1 O
by IN 0 0 12 O
oral JJ 0 1 6 O
contraceptives NNS 1 1 13 B-Group
and CC 0 0 12 O
digoxin NN 0 1 14 B-Drug
. . 0 0 12 O

Warfarin NN 0 1 0 B-Drug
: : 0 0 2 O
A DT 0 0 2 O
multidose JJ 0 0 UNK O
study NN 0 1 1 O
of IN 0 0 12 O
oxandrolone NN 0 1 13 B-Drug
given VBN 1 1 12 O
as IN 1 0 12 O
9 CD 0 0 2 O
or CC 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
BID NNP 0 0 11 O
in IN 0 0 12 O
9 CD 0 0 2 O
healthy JJ 0 1 12 O
subjects NNS 1 1 UNK O
concurrently RB 0 0 1 O
treated VBN 1 1 1 O
with IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
resulted VBN 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
mean JJ 0 1 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
S NNP 0 1 2 B-Drug
- : 0 0 2 O
warfarin NN 0 1 14 I-Drug
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
from IN 0 0 12 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
and CC 0 0 12 O
AUC NNP 0 1 UNK O
from IN 0 0 12 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
ng*hr NNS 0 1 UNK O
/ JJ 0 0 2 O
mL NN 0 1 14 O
: : 0 0 2 O
similar JJ 0 1 1 O
increases NNS 1 1 1 O
in IN 0 0 12 O
R NNP 0 1 2 B-Drug
- : 0 0 2 O
warfarin NN 0 1 14 I-Drug
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
and CC 0 0 12 O
AUC NNP 0 1 UNK O
were VBD 1 0 12 O
also RB 0 0 12 O
detected VBN 1 1 1 O
. . 0 0 12 O

Elevated VBN 0 1 7 O
serum NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
cyclosporine NN 0 1 14 B-Drug
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
with IN 0 0 12 O
concomitant JJ 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
cyclosporine NN 0 1 14 B-Drug
with IN 0 0 12 O
norfloxacin NN 0 1 UNK B-Drug
. . 0 0 12 O

Patients NNS 0 1 7 O
taking VBG 1 0 12 O
warfarin NN 0 1 14 B-Drug
or CC 0 0 12 O
other JJ 0 0 12 O
coumarin JJ 0 1 UNK B-Group
- : 0 0 2 O
derivative JJ 0 1 13 I-Group
anticoagulants NNS 1 1 13 I-Group
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
regularly RB 0 0 12 O
for IN 0 0 12 O
changes NNS 1 1 1 O
in IN 0 0 12 O
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
or CC 0 0 12 O
INR NN 0 1 13 O

The DT 0 0 2 O
interaction NN 0 1 UNK O
was VBD 1 0 12 O
pharmacodynamic JJ 0 1 UNK O
with IN 0 0 12 O
no DT 0 0 12 O
alteration NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
either DT 0 1 12 O
drug NN 0 1 1 O
. . 0 0 12 O

Nursing VBG 0 1 2 O
Mothers NNP 0 1 UNK O
Fulvestrant NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
found VBN 1 1 12 O
in IN 0 0 12 O
rat NN 0 1 13 O
milk NN 0 1 3 O
at IN 0 0 12 O
levels NNS 1 1 1 O
significantly RB 0 0 1 O
higher JJR 1 1 1 O
( ( 0 0 2 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
- : 0 0 2 O
fold NN 0 1 3 O
) ) 0 0 2 O
than IN 0 0 12 O
plasma NN 0 1 14 O
after IN 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
kg NN 0 1 18 O
. . 0 0 12 O

Preliminary JJ 0 1 2 O
investigations NNS 1 1 1 O
indicate VBP 0 0 1 O
that IN 0 0 12 O
icodextrin NN 0 1 UNK B-Drug
and CC 0 0 12 O
its PRP$ 1 0 12 O
metabolites NNS 1 1 UNK O
interfere RB 0 1 UNK O
with IN 0 0 12 O
enzymatic JJ 0 1 UNK O
- : 0 0 2 O
based VBN 1 1 1 O
amylase NN 0 1 14 O
assays NNS 1 1 13 O
resulting VBG 1 1 1 O
in IN 0 0 12 O
inaccurately RB 0 0 UNK O
low JJ 0 1 1 O
values NNS 1 1 1 O
. . 0 0 12 O

Therefore RB 0 0 1 O
CYP9A9 NNP 0 0 UNK O
substrates VBZ 0 1 UNK O
known VBN 1 1 12 O
to TO 0 0 12 O
have VB 0 0 12 O
a DT 0 0 12 O
narrow JJ 0 1 3 O
therapeutic JJ 0 1 6 O
index NN 0 1 1 O
such JJ 0 0 1 O
as IN 1 0 12 O
alfentanil JJ 0 1 UNK B-Drug
astemizole JJ 0 1 UNK B-Drug
terfenadine NN 0 1 UNK B-Drug
cisapride NN 0 1 UNK B-Drug
cyclosporine NN 0 1 14 B-Drug
fentanyl NN 0 1 14 B-Drug
pimozide IN 0 1 13 B-Drug
quinidine JJ 0 1 16 B-Drug
sirolimus NN 0 1 16 B-Drug
tacrolimus NN 0 1 16 B-Drug
or CC 0 0 12 O
ergot JJ 0 1 UNK B-Group
alkaloids NNS 1 1 13 I-Group
( ( 0 0 2 O
ergotamine JJ 0 1 UNK B-Drug
dihydroergotamine NN 0 1 UNK B-Drug
) ) 0 0 2 O
should MD 0 0 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
caution NN 0 0 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
SPRYCEL NNP 0 1 UNK B-Brand
. . 0 0 12 O

Pharmacokinetic JJ 0 1 UNK O
interactions NNS 1 1 UNK O
between IN 0 0 12 O
nisoldipine NN 0 1 13 B-Drug
and CC 0 0 12 O
beta NN 0 1 16 B-Group
- : 0 0 2 O
blockers NNS 1 0 6 I-Group
( ( 0 0 2 O
atenolol JJ 0 1 0 B-Drug
propranolol NN 0 1 16 B-Drug
) ) 0 0 2 O
were VBD 1 0 12 O
variable JJ 0 1 1 O
and CC 0 0 12 O
not RB 0 1 12 O
significant JJ 0 1 1 O
. . 0 0 12 O

Consideration NN 0 1 2 O
should MD 0 0 12 O
be VB 0 0 12 O
taken VBN 1 1 12 O
in IN 0 0 12 O
patients NNS 1 1 6 O
being VBG 1 0 12 O
treated VBN 1 1 1 O
with IN 0 0 12 O
antidiabetic JJ 0 1 13 B-Drug
agents NNS 1 1 1 O
. . 0 0 12 O

Although IN 0 0 12 O
there EX 0 0 12 O
was VBD 1 0 12 O
a DT 0 0 12 O
slight JJ 0 1 3 O
reduction NN 0 1 1 O
in IN 0 0 12 O
blood NN 0 1 6 O
sugar NN 0 1 3 O
concentrations NNS 1 1 13 O
during IN 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
flurbiprofen NN 0 1 16 B-Drug
and CC 0 0 12 O
hypoglycemic JJ 0 1 14 B-Group
agents NNS 1 1 1 I-Group
there EX 0 0 12 O
were VBD 1 0 12 O
no DT 0 0 12 O
signs NNS 1 1 12 O
or CC 0 0 12 O
symptoms NNS 1 1 6 O
of IN 0 0 12 O
hypoglycemia NN 0 1 6 O
. . 0 0 12 O

Methotrexate NN 0 1 0 B-Drug
: : 0 0 2 O
Valdecoxib NNP 0 1 UNK B-Drug
9 CD 0 0 2 I-Drug
mg NN 0 1 0 I-Drug
BID NNP 0 0 11 O
did VBD 1 0 12 O
not RB 0 1 12 O
show VB 0 1 12 O
a DT 0 0 12 O
significant JJ 0 1 1 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
plasma NN 0 1 14 O
exposure NN 0 1 1 O
or CC 0 0 12 O
renal JJ 0 1 6 O
clearance NN 0 1 16 O
of IN 0 0 12 O
methotrexate NN 0 1 16 B-Drug
. . 0 0 12 O

Other JJ 0 0 2 O
Potentially NNP 0 0 UNK O
Clinically NNP 0 0 7 O
Significant NNP 0 1 2 O
Drug NNP 0 1 2 O
or CC 0 0 12 O
Herbal NNP 0 1 UNK O
Product NNP 0 1 UNK O
Interactions NNP 0 1 UNK O
With IN 0 0 2 O
SUSTIVAb NNP 0 0 UNK O

Particular JJ 0 0 UNK O
caution NN 0 0 1 O
should MD 0 0 12 O
be VB 0 0 12 O
exercised VBN 1 1 1 O
in IN 0 0 12 O
using VBG 1 1 1 O
preparations NNS 1 1 13 O
containing VBG 1 1 1 O
sulfur JJ 0 1 13 B-Drug
resorcinol NN 0 1 UNK B-Drug
or CC 0 0 12 O
salicylic JJ 0 1 UNK B-Drug
acid NN 0 1 14 I-Drug
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
DIFFERIN NNP 0 1 UNK B-Brand
Gel NNP 0 1 2 O
. . 0 0 12 O

Digitalis NNP 0 1 15 B-Group
glycosides NNS 1 1 13 I-Group
: : 0 0 2 O
Serum NNP 0 1 7 O
digitalis NN 0 1 14 O
levels NNS 1 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
increased VBN 1 1 1 O
when WRB 0 0 12 O
hyperthyroid JJ 0 1 UNK O
patients NNS 1 1 6 O
on IN 0 0 12 O
a DT 0 0 12 O
stable JJ 0 1 1 O
digitalis NN 0 1 14 B-Group
glycoside JJ 0 1 UNK I-Group
regimen NNS 0 1 6 O
become VBP 0 0 12 O
euthyroid JJ 0 1 14 O
; : 0 0 2 O

In IN 0 0 2 O
a DT 0 0 12 O
multiple NN 0 1 1 O
dose NN 0 1 6 O
study NN 0 1 1 O
of IN 0 0 12 O
theophylline NN 0 1 16 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
once RB 0 0 12 O
daily JJ 0 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
) ) 0 0 2 O
and CC 0 0 12 O
cetirizine NN 0 1 13 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
once RB 0 0 12 O
daily JJ 0 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
) ) 0 0 2 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
decrease NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
clearance NN 0 1 16 O
of IN 0 0 12 O
cetirizine NN 0 1 13 B-Drug
was VBD 1 0 12 O
observed VBN 1 1 1 O
. . 0 0 12 O

Interaction NN 0 1 2 O
with IN 0 0 12 O
Guanethidine NNP 0 1 UNK B-Drug
: : 0 0 2 O
Although IN 0 0 12 O
minoxidil NN 0 1 16 B-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
itself PRP 0 0 UNK O
cause VBP 0 1 12 O
orthostatic JJ 0 1 8 O
hypotension NN 0 1 6 O
its PRP$ 1 0 12 O
administration NN 0 1 1 O
to TO 0 0 12 O
patients NNS 1 1 6 O
already RB 0 0 12 O
receiving VBG 1 1 1 O
guanethidine NN 0 1 UNK B-Drug
can MD 0 0 12 O
result VB 0 1 1 O
in IN 0 0 12 O
profound JJ 0 1 1 O
orthostatic JJ 0 1 8 O
effects NNS 1 1 1 O
. . 0 0 12 O

Based VBN 0 1 2 O
on IN 0 0 12 O
in IN 0 0 12 O
vitro NNP 0 1 UNK O
data NN 0 1 1 O
no DT 0 0 12 O
interaction NN 0 1 UNK O
would MD 0 0 12 O
be VB 0 0 12 O
expected VBN 1 1 12 O
with IN 0 0 12 O
drugs NNS 1 1 6 O
whose WP$ 0 0 12 O
metabolism NN 0 1 16 O
is VBZ 1 0 12 O
dependent JJ 0 1 1 O
upon IN 0 0 12 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
isozymes VBZ 0 1 UNK O
9A9 CD 0 0 UNK O
9A9 CD 0 0 UNK O
9A9 CD 0 0 UNK O
9B9 CD 0 0 UNK O
9D9 CD 0 0 UNK O
9E9 CD 0 0 UNK O
or CC 0 0 12 O
9A9 CD 0 0 UNK O
. . 0 0 12 O

Should MD 0 0 2 O
not RB 0 1 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
as IN 1 0 12 O
sole JJ 0 1 UNK O
protease NN 0 1 13 B-Group
inhibitor NN 0 1 14 I-Group
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
SUSTIVA NNP 0 1 UNK B-Brand
. . 0 0 12 O

Known VBN 0 1 2 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
include VBP 0 1 1 O
barbiturates VBZ 0 1 14 B-Group
tranquilizers NNS 1 1 13 B-Group
and CC 0 0 12 O
alcohol NN 0 1 1 B-Drug
. . 0 0 12 O

Therefore RB 0 0 1 O
monitoring NN 0 1 1 O
of IN 0 0 12 O
theophylline JJ 0 1 16 B-Drug
plasma NN 0 1 14 O
levels NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
and CC 0 0 12 O
dosage NN 0 1 0 O
of IN 0 0 12 O
theophylline NN 0 1 16 B-Drug
adjusted VBN 1 1 1 O
as IN 1 0 12 O
required VBN 1 1 1 O
. . 0 0 12 O

No DT 0 0 2 O
formal JJ 0 1 1 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
conducted VBN 1 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
addition NN 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
interactions NNS 1 1 UNK O
noted VBD 1 0 1 O
above IN 0 1 12 O
chronic NN 0 1 6 O
( ( 0 0 2 O
9 CD 0 0 2 O
weeks NNS 1 1 12 O
) ) 0 0 2 O
oral VBP 0 1 6 O
Cordarone NNP 0 1 UNK B-Drug
administration NN 0 1 1 O
impairs VBZ 1 0 UNK O
metabolism NN 0 1 16 O
of IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
dextromethorphan NN 0 1 16 B-Drug
and CC 0 0 12 O
methotrexate NN 0 1 16 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
possibility NN 0 1 1 O
of IN 0 0 12 O
hypotensive JJ 0 1 14 O
effects NNS 1 1 1 O
with IN 0 0 12 O
captopril NN 0 1 0 B-Drug
can MD 0 0 12 O
be VB 0 0 12 O
minimized VBN 1 0 1 O
by IN 0 0 12 O
either DT 0 1 12 O
discontinuing VBG 1 1 6 O
the DT 0 0 12 O
diuretic JJ 0 1 14 B-Group
or CC 0 0 12 O
increasing VBG 1 1 1 O
the DT 0 0 12 O
salt NN 0 1 3 O
intake VB 0 1 3 O
approximately RB 0 1 1 O
one CD 0 1 12 O
week NN 0 1 12 O
prior RB 0 1 1 O
to TO 0 0 12 O
initiation NN 0 1 1 O
of IN 0 0 12 O
treatment NN 0 1 6 O
with IN 0 0 12 O
captopril NN 0 1 0 B-Drug
( ( 0 0 2 O
captopril JJ 0 1 0 B-Drug
tablets NNS 1 1 3 O
USP NNP 0 1 UNK O
) ) 0 0 2 O
or CC 0 0 12 O
initiating VBG 1 1 1 O
therapy NN 0 1 6 O
with IN 0 0 12 O
small JJ 0 1 12 O
doses NNS 1 1 6 O
( ( 0 0 2 O
9 CD 0 0 2 O
or CC 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
) ) 0 0 2 O
. . 0 0 12 O

Astemizole NN 0 1 UNK B-Drug
: : 0 0 2 O
The DT 0 0 2 O
use NN 0 1 1 O
of IN 0 0 12 O
fluconazole NN 0 1 0 B-Drug
in IN 0 0 12 O
patients NNS 1 1 6 O
concurrently RB 0 0 1 O
taking VBG 1 0 12 O
astemizole NN 0 1 UNK B-Drug
or CC 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
the DT 0 0 12 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
system NN 0 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
elevations NNS 1 1 1 O
in IN 0 0 12 O
serum NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

Thus RB 0 0 1 O
smaller JJR 1 1 3 O
doses NNS 1 1 6 O
of IN 0 0 12 O
adenosine NN 0 1 14 B-Drug
may MD 0 0 1 O
be VB 0 0 12 O
effective JJ 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
presence NN 0 1 1 O
of IN 0 0 12 O
dipyridamole NN 0 1 0 B-Drug
. . 0 0 12 O

Anticoagulants NNS 0 1 UNK B-Group
( ( 0 0 2 O
oral JJ 0 1 6 O
) ) 0 0 2 O
: : 0 0 2 O
The DT 0 0 2 O
activity NN 0 1 1 O
of IN 0 0 12 O
oral JJ 0 1 6 O
anticoagulants NNS 1 1 13 B-Group
may MD 0 0 1 O
be VB 0 0 12 O
potentiated VBN 1 0 UNK O
by IN 0 0 12 O
anti JJ 0 0 3 O
- : 0 0 2 O
vitamin NN 0 1 6 O
- : 0 0 2 O
K NNP 0 1 2 O
activity NN 0 1 1 O
attributed VBD 1 1 1 O
to TO 0 0 12 O
methimazole VB 0 1 16 B-Drug
. . 0 0 12 O

Atorvastatin NN 0 1 0 B-Drug
: : 0 0 2 O
Atorvastatin NN 0 1 0 B-Drug
increases VBZ 1 1 1 O
the DT 0 0 12 O
AUC NNP 0 1 UNK O
for IN 0 0 12 O
norethindrone NN 0 1 13 B-Drug
and CC 0 0 12 O
ethinyl JJ 0 0 13 B-Drug
estradiol NN 0 1 13 I-Drug
. . 0 0 12 O

No DT 0 0 2 O
rashes NNS 1 1 6 O
were VBD 1 0 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
these DT 0 0 12 O
patients NNS 1 1 6 O
. . 0 0 12 O

Antihistamines NNS 0 1 UNK B-Group
: : 0 0 2 O
Benzodiazepines NNS 0 1 UNK B-Group
GI NNP 0 1 6 O
Motility NNP 0 1 UNK O
Agents NNP 0 1 2 O
Anti NNP 0 0 UNK B-Group
- : 0 0 2 O
Migraine NNP 0 1 UNK I-Group
Antifungal NNP 0 1 UNK B-Group

Cimetidine NN 0 1 0 B-Drug
at IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
BID NNP 0 0 11 O
( ( 0 0 2 O
the DT 0 0 12 O
usual JJ 0 1 12 O
prescription NN 0 1 0 O
dose NN 0 1 6 O
) ) 0 0 2 O
co NN 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
with IN 0 0 12 O
TIKOSYN NNP 0 1 UNK B-Brand
( ( 0 0 2 O
9 CD 0 0 2 O
mcg RB 0 1 0 O
BID NNP 0 0 11 O
) ) 0 0 2 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
increase VB 0 1 1 O
dofetilide JJ 0 1 13 B-Drug
plasma NN 0 1 14 O
levels NNS 1 1 1 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

For IN 0 0 2 O
patients NNS 1 1 6 O
with IN 0 0 12 O
amenorrhea PDT 0 1 UNK O
the DT 0 0 12 O
second JJ 0 1 12 O
test NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
done VBN 1 0 12 O
at IN 0 0 12 O
least JJS 0 1 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
after IN 0 0 12 O
the DT 0 0 12 O
last JJ 0 1 12 O
act NN 0 1 13 O
of IN 0 0 12 O
unprotected JJ 0 0 UNK O
sexual JJ 0 1 12 O
intercourse NN 0 1 6 O
( ( 0 0 2 O
without IN 0 0 12 O
using VBG 1 1 1 O
9 CD 0 0 2 O
effective JJ 0 1 1 O
forms NNS 1 1 1 O
of IN 0 0 12 O
contraception NN 0 1 13 O
) ) 0 0 2 O
. . 0 0 12 O

Cisapride NN 0 1 0 B-Drug

. . 0 0 12 O

and CC 0 0 12 O
/ PRP 0 0 2 O
or CC 0 0 12 O
Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interactions NNP 0 1 UNK O
See NNP 0 1 2 O
CLINICAL NNP 0 1 11 O
PHARMACOLOGY NNP 0 1 UNK O
Pharmacokinetics NNP 0 1 UNK O
and CC 0 0 12 O
Drug NNP 0 1 2 O
Interactions NNP 0 1 UNK O
. . 0 0 12 O

Pregnancies NNS 0 1 UNK O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
by IN 0 0 12 O
users NNS 1 1 UNK O
of IN 0 0 12 O
combined JJ 0 1 1 B-Group
hormonal JJ 0 1 6 I-Group
contraceptives NNS 1 1 13 I-Group
who WP 0 0 12 O
also RB 0 0 12 O
used VBD 1 1 12 O
some DT 0 0 12 O
form NN 0 1 1 O
of IN 0 0 12 O
St. NNP 0 1 2 O
Johns NNP 0 0 UNK O
Wort NNP 0 0 UNK O
. . 0 0 12 O

Therefore RB 0 0 1 O
COLESTlD NNP 0 0 UNK B-Brand
Tablets NNP 0 1 0 O
may MD 0 0 1 O
delay VB 0 1 1 O
or CC 0 0 12 O
reduce VB 0 0 1 O
the DT 0 0 12 O
absorption NN 0 1 1 O
of IN 0 0 12 O
concomitant JJ 0 1 6 O
oral JJ 0 1 6 O
medication NN 0 1 6 O
. . 0 0 12 O

Retrospective JJ 0 1 UNK O
analysis NN 0 1 1 O
of IN 0 0 12 O
side NN 0 1 3 O
effects NNS 1 1 1 O
in IN 0 0 12 O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
showed VBD 1 1 12 O
that IN 0 0 12 O
poor JJ 0 1 12 O
9D9 CD 0 0 UNK O
metabolizers NNS 0 0 UNK O
had VBD 1 0 12 O
a DT 0 0 12 O
higher JJR 1 1 1 O
rate NN 0 1 1 O
of IN 0 0 12 O
dizziness NN 0 1 6 O
during IN 0 0 12 O
up RP 0 0 12 O
- : 0 0 2 O
titration NN 0 1 14 O
presumably RB 0 0 12 O
resulting VBG 1 1 1 O
from IN 0 0 12 O
vasodilating VBG 0 0 UNK O
effects NNS 1 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
higher JJR 1 1 1 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
the DT 0 0 12 O
a DT 0 0 12 O
- : 0 0 2 O
blocking NN 0 1 UNK O
R NNP 0 1 2 O
( ( 0 0 2 O
+ NNP 0 0 2 O
) ) 0 0 2 O
enantiomer NN 0 1 UNK O
. . 0 0 12 O

Oral JJ 0 1 2 O
Contraceptives NNS 0 1 UNK B-Group
: : 0 0 2 O
The DT 0 0 2 O
effect NN 0 1 1 O
of IN 0 0 12 O
oral JJ 0 1 6 O
contraceptives NNS 1 1 13 B-Group
on IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
D.H.E NNP 0 1 UNK B-Brand
9 CD 0 0 2 I-Brand
( ( 0 0 2 O
dihydroergotamine JJ 0 1 UNK B-Drug
mesylate NN 0 1 16 I-Drug
) ) 0 0 2 O
Injection NNP 0 1 7 O
USP NNP 0 1 UNK O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
studied VBN 1 0 1 O
. . 0 0 12 O

Pressor NN 0 1 UNK O
agents NNS 1 1 1 O
- : 0 0 2 O
Because IN 0 0 12 O
of IN 0 0 12 O
possible JJ 0 1 1 O
effects NNS 1 1 1 O
on IN 0 0 12 O
blood NN 0 1 6 O
pressure NN 0 1 1 O
STRATTERA NNP 0 1 UNK B-Brand
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
cautiously RB 0 0 UNK O
with IN 0 0 12 O
pressor NN 0 1 14 O
agents NNS 1 1 1 O
. . 0 0 12 O

To TO 0 0 2 O
avoid VB 0 0 12 O
phenytoin JJ 0 1 16 B-Drug
intoxication NN 0 1 6 O
appropriate JJ 0 1 1 O
adjustment NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
anticonvulsant NN 0 1 14 B-Group
should MD 0 0 12 O
be VB 0 0 12 O
made VBN 1 1 12 O
. . 0 0 12 O

Additionally RB 0 0 1 O
aripiprazole JJ 0 1 16 B-Drug
and CC 0 0 12 O
dehydroaripiprazole NN 0 1 UNK B-Drug_n
did VBD 1 0 12 O
not RB 0 1 12 O
show VB 0 1 12 O
potential JJ 0 1 1 O
for IN 0 0 12 O
altering VBG 1 1 1 O
CYP9A9 NNP 0 0 UNK O
- : 0 0 2 O
mediated VBD 1 1 13 O
metabolism NN 0 1 16 O
in IN 0 0 12 O
vitro NN 0 1 UNK O
. . 0 0 12 O

DOXIL NNP 0 1 UNK B-Brand
may MD 0 0 1 O
interact VB 0 0 UNK O
with IN 0 0 12 O
drugs NNS 1 1 6 O
known VBN 1 1 12 O
to TO 0 0 12 O
interact VB 0 0 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
conventional JJ 0 1 1 O
formulation NN 0 1 13 O
of IN 0 0 12 O
doxorubicin NN 0 1 13 B-Drug
HCl NNP 0 0 14 I-Drug
. . 0 0 12 O

certain JJ 0 1 1 O
protease NN 0 1 13 B-Group
inhibitors NNS 1 1 14 I-Group
e.g. VBP 0 0 UNK O
ritanovir NN 0 0 UNK O
; : 0 0 2 O

Phenytoin NN 0 1 0 B-Drug
: : 0 0 2 O
In IN 0 0 2 O
post NN 0 1 12 O
- : 0 0 2 O
marketing NN 0 1 UNK O
experience NN 0 1 12 O
there RB 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reports NNS 1 1 1 O
of IN 0 0 12 O
both DT 0 0 12 O
increases NNS 1 1 1 O
and CC 0 0 12 O
decreases NNS 1 1 UNK O
in IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
levels NNS 1 1 1 O
with IN 0 0 12 O
dexamethasone NN 0 1 16 B-Drug
co NN 0 1 12 O
- : 0 0 2 O
administration NN 0 1 1 O
leading VBG 1 1 1 O
to TO 0 0 12 O
alterations NNS 1 1 1 O
in IN 0 0 12 O
seizure NN 0 1 6 O
control NN 0 1 1 O
. . 0 0 12 O

Oral JJ 0 1 2 O
Contraceptives NNS 0 1 UNK B-Group
: : 0 0 2 O
In IN 0 0 2 O
9 CD 0 0 2 O
healthy JJ 0 1 12 O
women NNS 1 1 UNK O
the DT 0 0 12 O
pharmacokinetic JJ 0 1 UNK O
profiles NNS 1 1 UNK O
of IN 0 0 12 O
norethindrone NN 0 1 13 B-Drug
and CC 0 0 12 O
ethinyl JJ 0 0 13 B-Drug
estradiol NN 0 1 13 I-Drug
following VBG 1 1 1 O
administration NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
dose NN 0 1 6 O
containing VBG 1 1 1 O
9 CD 0 0 2 O
mg NN 0 1 0 O
of IN 0 0 12 O
norethindrone NN 0 1 13 B-Drug
acetate NN 0 1 14 I-Drug
and CC 0 0 12 O
9 CD 0 0 2 O
g NN 0 1 16 O
of IN 0 0 12 O
ethinyl JJ 0 0 13 B-Drug
estradiol NNS 0 1 13 I-Drug
were VBD 1 0 12 O
studied VBN 1 0 1 O
. . 0 0 12 O

As IN 0 0 2 O
plasma JJ 0 1 14 O
protein IN 0 1 14 O
binding VBG 1 1 1 O
of IN 0 0 12 O
decitabine NN 0 1 13 B-Drug
is VBZ 1 0 12 O
negligible JJ 0 1 UNK O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
interactions NNS 1 1 UNK O
due JJ 0 1 1 O
to TO 0 0 12 O
displacement VB 0 1 1 O
of IN 0 0 12 O
more JJR 0 1 12 O
highly RB 0 1 1 O
protein JJ 0 1 14 O
bound NN 0 1 12 O
drugs NNS 1 1 6 O
from IN 0 0 12 O
plasma NN 0 1 14 O
proteins NNS 1 1 14 O
are VBP 1 0 12 O
not RB 0 1 12 O
expected VBN 1 1 12 O
. . 0 0 12 O

Thus RB 0 0 1 O
when WRB 0 0 12 O
VIOXX NNP 0 1 UNK B-Brand
and CC 0 0 12 O
lithium NN 0 1 16 B-Drug
are VBP 1 0 12 O
administered VBN 1 1 1 O
concurrently RB 0 0 1 O
subjects NNS 1 1 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
observed VBN 1 1 1 O
carefully RB 0 0 12 O
for IN 0 0 12 O
signs NNS 1 1 12 O
of IN 0 0 12 O
lithium NN 0 1 16 B-Drug
toxicity NN 0 1 6 O
. . 0 0 12 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interactions NNP 0 1 UNK O
As IN 0 0 2 O
with IN 0 0 12 O
other JJ 0 0 12 O
penicillins NNS 1 1 14 B-Drug
the DT 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
PIPRACIL NNP 0 1 UNK B-Brand
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
false JJ 0 1 13 O
- : 0 0 2 O
positive JJ 0 1 1 O
reaction NN 0 1 1 O
for IN 0 0 12 O
glucose NN 0 1 14 O
in IN 0 0 12 O
the DT 0 0 12 O
urine NN 0 1 6 O
using VBG 1 1 1 O
a DT 0 0 12 O
copper NN 0 1 3 O
- : 0 0 2 O
reduction NN 0 1 1 O
method NN 0 1 13 O
. . 0 0 12 O

In IN 0 0 2 O
these DT 0 0 12 O
trials NNS 1 1 1 O
heart NN 0 1 12 O
rate NN 0 1 1 O
and CC 0 0 12 O
systolic JJ 0 1 8 O
blood NN 0 1 6 O
pressure NN 0 1 1 O
were VBD 1 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
bpm NN 0 0 13 O
and CC 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
mm NN 0 0 18 O
Hg NNP 0 1 14 O
higher RBR 0 1 1 O
respectively RB 0 0 1 O
in IN 0 0 12 O
subjects NNS 1 1 UNK O
on IN 0 0 12 O
concomitant JJ 0 1 6 O
theophylline NN 0 1 16 B-Drug
compared VBN 1 1 1 O
with IN 0 0 12 O
the DT 0 0 12 O
overall JJ 0 1 1 O
population NN 0 1 13 O
. . 0 0 12 O

The DT 0 0 2 O
concomitant NN 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
heparin NN 0 1 14 B-Drug
or CC 0 0 12 O
aspirin NN 0 1 14 B-Brand
during IN 0 0 12 O
the DT 0 0 12 O
first JJ 0 1 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
following VBG 1 1 1 O
symptom JJ 0 1 6 O
onset VBN 0 1 6 O
were VBD 1 0 12 O
prohibited VBN 1 1 UNK O
in IN 0 0 12 O
The DT 0 0 2 O
NINDS NNP 0 1 UNK O
t SYM 0 1 12 O
- : 0 0 2 O
PA NNP 0 1 2 O
Stroke NNP 0 1 7 O
Trial NNP 0 1 2 O
. . 0 0 12 O

Drug NNP 0 1 2 O
Interaction NNP 0 1 2 O
During IN 0 0 2 O
Pregnancy NNP 0 1 7 O
: : 0 0 2 O
Cromolyn NNP 0 1 UNK B-Drug
sodium NN 0 1 14 I-Drug
and CC 0 0 12 O
isoproterenol NN 0 1 13 B-Drug
were VBD 1 0 12 O
studied VBN 1 0 1 O
following VBG 1 1 1 O
subcutaneous JJ 0 1 14 O
injections NNS 1 1 6 O
in IN 0 0 12 O
pregnant JJ 0 1 13 O
mice NN 1 1 UNK O
. . 0 0 12 O

These DT 0 0 1 O
effects NNS 1 1 1 O
are VBP 1 0 12 O
clinically RB 0 0 6 O
insignificant JJ 0 0 1 O
. . 0 0 12 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Tests VBZ 0 1 UNK O
Interaction NN 0 1 2 O
: : 0 0 2 O
Succimer NN 0 1 UNK B-Drug
may MD 0 0 1 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
serum NN 0 1 14 O
and CC 0 0 12 O
urinary JJ 0 1 6 O
laboratory NN 0 1 1 O
tests NNS 1 1 1 O
. . 0 0 12 O

Review NN 0 1 2 O
of IN 0 0 12 O
these DT 0 0 12 O
case NN 0 1 12 O
reports NNS 1 1 1 O
indicates VBZ 1 0 1 O
that IN 0 0 12 O
the DT 0 0 12 O
patients NNS 1 1 6 O
were VBD 1 0 12 O
mainly RB 0 0 1 O
receiving VBG 1 1 1 O
thiazide NN 0 1 UNK B-Group
diuretics NNS 1 1 14 I-Group
for IN 0 0 12 O
hypertension NN 0 1 6 O
and CC 0 0 12 O
that DT 0 0 12 O
tests VBZ 1 1 1 O
to TO 0 0 12 O
rule VB 0 1 1 O
out RP 0 1 12 O
decreased VBN 1 1 1 O
renal JJ 0 1 6 O
function NN 0 1 1 O
secondary JJ 0 1 1 O
to TO 0 0 12 O
hypertensive VB 0 1 6 O
nephropathy NNS 0 1 14 O
were VBD 1 0 12 O
not RB 0 1 12 O
often RB 0 1 12 O
performed VBN 1 1 1 O
. . 0 0 12 O

weaker NN 0 1 1 O
inhibitors NNS 1 1 14 O
( ( 0 0 2 O
erythromycin JJ 0 1 0 B-Drug
grapefruit NN 0 1 3 O
juice NN 0 1 3 O
) ) 0 0 2 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
studied VBN 1 0 1 O
. . 0 0 12 O

Therefore RB 0 0 1 O
coagulation NN 0 1 14 O
indices NNS 1 1 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
to TO 0 0 12 O
maintain VB 0 1 1 O
the DT 0 0 12 O
desired JJ 0 1 1 O
anticoagulant JJ 0 1 13 O
effect NN 0 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
Europe NNP 0 1 UNK O
Nimotop NNP 0 1 UNK B-Brand
was VBD 1 0 12 O
observed VBN 1 1 1 O
to TO 0 0 12 O
occasionally RB 0 1 12 O
intensify VB 0 0 UNK O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
antihypertensive JJ 0 1 14 B-Group
compounds NNS 1 1 13 I-Group
taken VBN 1 1 12 O
concomitantly RB 0 0 14 O
by IN 0 0 12 O
patients NNS 1 1 6 O
suffering VBG 1 1 12 O
from IN 0 0 12 O
hypertension NN 0 1 6 O
; : 0 0 2 O

Rifampin NN 0 1 0 B-Drug
: : 0 0 2 O
Coadministration NN 0 1 UNK O
of IN 0 0 12 O
rifampin NN 0 1 16 B-Drug
and CC 0 0 12 O
MEPRON NNP 0 1 UNK B-Brand
Suspension NNP 0 1 2 O
results NNS 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
significant JJ 0 1 1 O
decrease NN 0 1 1 O
in IN 0 0 12 O
average JJ 0 1 1 O
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
plasma NN 0 1 14 O
atovaquone NN 0 1 16 B-Drug
concentrations NNS 1 1 13 O
. . 0 0 12 O

Increases NNS 0 1 UNK O
of IN 0 0 12 O
9 CD 0 0 2 B-Drug
- : 0 0 2 O
FU NNP 0 1 11 I-Drug
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
by IN 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
have VBP 0 0 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
with IN 0 0 12 O
doses NNS 1 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
m9 NN 0 1 UNK O
ELOXATIN NNP 0 1 UNK B-Brand
dosed VBD 1 1 14 O
every DT 0 0 12 O
9 CD 0 0 2 O
weeks NNS 1 1 12 O
. . 0 0 12 O

- : 0 0 2 O
Non NN 0 1 2 B-Group
- : 0 0 2 O
steroidal NN 0 1 UNK I-Group
Anti NNP 0 0 UNK I-Group
- : 0 0 2 O
inflammatory NN 0 1 6 I-Group
Drugs NNS 0 1 2 I-Group
: : 0 0 2 O
In IN 0 0 2 O
some DT 0 0 12 O
patients NNS 1 1 6 O
the DT 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
non JJ 0 1 1 B-Group
- : 0 0 2 O
steroidal NN 0 1 UNK I-Group
anti SYM 0 0 3 I-Group
- : 0 0 2 O
inflammatory JJ 0 1 6 I-Group
agent NN 0 1 1 I-Group
can MD 0 0 12 O
reduce VB 0 0 1 O
the DT 0 0 12 O
diuretic JJ 0 1 14 O
natriuretic JJ 0 1 UNK O
and CC 0 0 12 O
antihypertensive JJ 0 1 14 O
effects NNS 1 1 1 O
of IN 0 0 12 O
loop NN 0 1 3 B-Group
potassium NN 0 1 14 B-Group
- : 0 0 2 O
sparing NN 0 0 6 I-Group
and CC 0 0 12 O
thiazide JJ 0 1 UNK B-Drug
diuretics NNS 1 1 14 I-Drug
. . 0 0 12 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interactions NNP 0 1 UNK O
Cephalosporins NNP 0 1 15 B-Group
including VBG 1 1 1 O
cefotaxime JJ 0 1 14 B-Drug
sodium NN 0 1 14 I-Drug
are VBP 1 0 12 O
known VBN 1 1 12 O
to TO 0 0 12 O
occasionally RB 0 1 12 O
induce VB 0 1 6 O
a DT 0 0 12 O
positive JJ 0 1 1 O
direct JJ 0 1 1 O
Coombs NNP 0 1 19 O
test NN 0 1 1 O
. . 0 0 12 O

Aspirin NN 0 1 0 B-Brand
: : 0 0 2 O
Concomitant JJ 0 1 UNK O
aspirin NN 0 1 14 B-Brand
may MD 0 0 1 O
decrease VB 0 1 1 O
the DT 0 0 12 O
metabolic JJ 0 1 6 O
clearance NN 0 1 16 O
of IN 0 0 12 O
nicotinic JJ 0 1 13 B-Drug
acid NN 0 1 14 I-Drug
. . 0 0 12 O

Administration NN 0 1 UNK O
of IN 0 0 12 O
thiazide JJ 0 1 UNK B-Group
diuretics NNS 1 1 14 I-Group
to TO 0 0 12 O
hypoparathyroid VB 0 1 UNK O
patients NNS 1 1 6 O
who WP 0 0 12 O
are VBP 1 0 12 O
concurrently RB 0 0 1 O
being VBG 1 0 12 O
treated VBN 1 1 1 O
with IN 0 0 12 O
ergocalciferol NN 0 1 13 B-Drug
may MD 0 0 1 O
cause VB 0 1 12 O
hypercalcemia NN 0 1 8 O
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
that IN 0 0 12 O
these DT 0 0 12 O
tests NNS 1 1 1 O
be VB 0 0 12 O
performed VBN 1 1 1 O
weekly JJ 0 1 12 O
or CC 0 0 12 O
every DT 0 0 12 O
other JJ 0 0 12 O
week NN 0 1 12 O
until IN 0 0 12 O
the DT 0 0 12 O
lipid JJ 0 1 14 O
response NN 0 1 1 O
to TO 0 0 12 O
Soriatane NNP 0 1 UNK B-Brand
has VBZ 1 0 12 O
stabilized VBN 1 1 1 O
. . 0 0 12 O

Aprepitant NN 0 1 UNK B-Drug
when WRB 0 0 12 O
given VBN 1 1 12 O
as IN 1 0 12 O
a DT 0 0 12 O
regimen NN 0 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
on IN 0 0 12 O
Day NNP 0 1 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
on IN 0 0 12 O
Days NNP 0 1 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
increased VBD 1 1 1 O
the DT 0 0 12 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
methylprednisolone NN 0 1 16 B-Drug
a DT 0 0 12 O
CYP9A9 NNP 0 0 UNK O
substrate NN 0 1 UNK O
by IN 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
fold NN 0 1 3 O
on IN 0 0 12 O
Day NNP 0 1 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
by IN 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
fold NN 0 1 3 O
on IN 0 0 12 O
Day NNP 0 1 2 O
9 CD 0 0 2 O
when WRB 0 0 12 O
methylprednisolone NN 0 1 16 B-Drug
was VBD 1 0 12 O
coadministered VBN 0 0 UNK O
intravenously RB 0 0 14 O
as IN 1 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
on IN 0 0 12 O
Day NNP 0 1 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
orally RB 0 1 14 O
as IN 1 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
on IN 0 0 12 O
Days NNP 0 1 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
. . 0 0 12 O

Latent NNP 0 1 UNK O
diabetes VBZ 0 1 6 O
mellitus NN 0 0 6 O
may MD 0 0 1 O
become VB 0 0 12 O
manifest JJS 0 1 1 O
during IN 0 0 12 O
chlorthalidone NN 0 1 13 B-Drug
administration NN 0 1 1 O
. . 0 0 12 O

These DT 0 0 1 O
lists NNS 1 1 UNK O
are VBP 1 0 12 O
not RB 0 1 12 O
exhaustive JJ 0 1 UNK O
and CC 0 0 12 O
the DT 0 0 12 O
prescriber NN 0 0 UNK O
should MD 0 0 12 O
consider VB 0 1 12 O
the DT 0 0 12 O
effects NNS 1 1 1 O
on IN 0 0 12 O
CYP NNP 0 1 UNK O
9A9 CD 0 0 UNK O
of IN 0 0 12 O
other JJ 0 0 12 O
agents NNS 1 1 1 O
being VBG 1 0 12 O
considered VBN 1 1 1 O
for IN 0 0 12 O
concomitant NN 0 1 6 O
use NN 0 1 1 O
with IN 0 0 12 O
methylergonovine NN 0 1 16 B-Drug
. . 0 0 12 O

Nelfinavir NN 0 1 UNK B-Drug

When WRB 0 0 12 O
these DT 0 0 12 O
products NNS 1 1 1 O
are VBP 1 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
or CC 0 0 12 O
other JJ 0 0 12 O
suitable JJ 0 1 1 O
coagulation NN 0 1 14 O
tests NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
. . 0 0 12 O

Because IN 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
variability NN 0 1 UNK O
of IN 0 0 12 O
individual JJ 0 1 1 O
patient NN 0 1 6 O
response NN 0 1 1 O
multiple NN 0 1 1 O
interacting VBG 1 0 1 O
mechanisms NNS 1 1 UNK O
with IN 0 0 12 O
some DT 0 0 12 O
drugs NNS 1 1 6 O
the DT 0 0 12 O
dependency NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
extent NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
interaction NN 0 1 UNK O
on IN 0 0 12 O
the DT 0 0 12 O
dosage NN 0 1 0 O
and CC 0 0 12 O
duration NN 0 1 1 O
of IN 0 0 12 O
therapy NN 0 1 6 O
and CC 0 0 12 O
the DT 0 0 12 O
possible JJ 0 1 1 O
administration NN 0 1 1 O
of IN 0 0 12 O
several JJ 0 1 12 O
interacting VBG 1 0 1 O
drugs NNS 1 1 6 O
simultaneously RB 0 1 13 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
difficult JJ 0 1 12 O
to TO 0 0 12 O
predict VB 0 0 UNK O
the DT 0 0 12 O
direction NN 0 1 1 O
and CC 0 0 12 O
degree NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
ultimate JJ 0 0 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
concomitant JJ 0 1 6 O
medications NNS 1 1 6 O
on IN 0 0 12 O
anticoagulant JJ 0 1 13 B-Group
response NN 0 1 1 O
. . 0 0 12 O

Established VBN 0 1 UNK O
and CC 0 0 12 O
Other JJ 0 0 2 O
Potentially NNP 0 0 UNK O
Significant NNP 0 1 2 O
Drug NNP 0 1 2 O
Interactions NNS 0 1 UNK O
: : 0 0 2 O
Alteration NN 0 1 UNK O
in IN 0 0 12 O
Dose NNP 0 1 7 O
or CC 0 0 12 O
Regimen NNP 0 1 UNK O
May NNP 0 1 2 O
Be NNP 0 0 UNK O
Recommended VBN 0 1 2 O
Based VBN 0 1 2 O
on IN 0 0 12 O
Drug NNP 0 1 2 O
Interaction NNP 0 1 2 O
Studies NNP 0 1 2 O
or CC 0 0 12 O
Predicted VBN 0 1 UNK O
Interaction NN 0 1 2 O

Azithromycin NN 0 1 0 B-Drug

A DT 0 0 2 O
dose JJ 0 1 6 O
increase NN 0 1 1 O
of IN 0 0 12 O
lopinavir JJ 0 1 13 B-Drug
/ NNP 0 0 2 O
ritonavir NN 0 1 16 B-Drug
to TO 0 0 12 O
9 CD 0 0 2 O
/ NNS 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
( ( 0 0 2 O
9 CD 0 0 2 O
capsules NNS 1 1 3 O
or CC 0 0 12 O
9 CD 0 0 2 O
mL NN 0 1 14 O
) ) 0 0 2 O
twice RB 0 1 12 O
daily RB 0 1 12 O
taken VBN 1 1 12 O
with IN 0 0 12 O
food NN 0 1 12 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
when WRB 0 0 12 O
used VBN 1 1 12 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
SUSTIVA NNP 0 1 UNK B-Brand
. . 0 0 12 O

In IN 0 0 2 O
addition NN 0 1 1 O
Fondaparinux NNP 0 1 UNK B-Drug
neither CC 0 0 12 O
influenced VBD 1 1 UNK O
the DT 0 0 12 O
pharmacodynamics NNS 0 1 UNK O
of IN 0 0 12 O
warfarin JJ 0 1 14 B-Drug
acetylsalicylic JJ 0 0 UNK B-Drug
acid NN 0 1 14 I-Drug
piroxicam NN 0 1 13 B-Drug
and CC 0 0 12 O
digoxin NN 0 1 14 B-Drug
nor CC 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
at IN 0 0 12 O
steady JJ 0 1 1 O
state NN 0 1 1 O
. . 0 0 12 O

Additive JJ 0 1 UNK O
sedative JJ 0 1 6 O
effects NNS 1 1 1 O
can MD 0 0 12 O
occur VB 0 1 1 O
when WRB 0 0 12 O
metoclopramide NN 0 1 16 B-Drug
is VBZ 1 0 12 O
given VBN 1 1 12 O
with IN 0 0 12 O
alcohol NN 0 1 1 B-Drug
sedatives NNS 1 1 6 B-Group
hypnotics VBP 0 1 13 B-Group
narcotics NNS 1 1 1 B-Group
or CC 0 0 12 O
tranquilizers NNS 1 1 13 B-Group
. . 0 0 12 O

The DT 0 0 2 O
physician NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
alert VBN 0 1 12 O
for IN 0 0 12 O
possible JJ 0 1 1 O
combined JJ 0 1 1 O
drug NN 0 1 1 O
actions NNS 1 1 UNK O
desirable JJ 0 0 UNK O
or CC 0 0 12 O
undesirable JJ 0 0 UNK O
involving VBG 1 1 1 O
cyclophosphamide NN 0 1 14 B-Drug
even RB 0 0 12 O
though IN 0 0 12 O
cyclophosphamide NN 0 1 14 B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
used VBN 1 1 12 O
successfully RB 0 0 1 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
including VBG 1 1 1 O
other JJ 0 0 12 O
cytotoxic NN 0 1 UNK O
drugs NNS 1 1 6 O
. . 0 0 12 O

ii NN 0 0 13 O
. . 0 0 12 O

This DT 0 0 2 O
interaction NN 0 1 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
given VBN 1 1 12 O
consideration NN 0 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
BEXTRA NNP 0 1 UNK B-Brand
concomitantly RB 0 0 14 O
with IN 0 0 12 O
ACE NNP 0 1 13 B-Group
- : 0 0 2 O
inhibitors NNS 1 1 14 I-Group
. . 0 0 12 O

These DT 0 0 1 O
stimulants NNS 1 1 13 O
are VBP 1 0 12 O
commonly RB 0 0 UNK O
found VBN 1 1 12 O
in IN 0 0 12 O
coffee NN 0 1 12 O
and CC 0 0 12 O
tea NN 0 1 13 O
respectively RB 0 0 1 O
. . 0 0 12 O

There EX 0 0 12 O
does VBZ 1 0 12 O
not RB 0 1 12 O
appear VB 0 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
an DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
adverse JJ 0 0 1 O
events NNS 1 1 12 O
in IN 0 0 12 O
subjects NNS 1 1 UNK O
who WP 0 0 12 O
received VBD 1 1 12 O
oral JJ 0 1 6 O
contraceptives NNS 1 1 13 B-Group
and CC 0 0 12 O
loratadine NN 0 1 0 B-Drug
. . 0 0 12 O

Oral JJ 0 1 2 O
Hypoglycemics NNS 0 1 UNK B-Group
: : 0 0 2 O
Bepridil NNP 0 1 UNK B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
safely RB 0 0 UNK O
used VBN 1 1 12 O
in IN 0 0 12 O
diabetic JJ 0 1 6 O
patients NNS 1 1 6 O
without IN 0 0 12 O
significantly RB 0 0 1 O
lowering VBG 1 1 UNK O
their PRP$ 0 0 12 O
blood NN 0 1 6 O
glucose NN 0 1 14 O
levels NNS 1 1 1 O
or CC 0 0 12 O
altering VBG 1 1 1 O
their PRP$ 0 0 12 O
need NN 0 1 12 O
for IN 0 0 12 O
insulin NN 0 1 14 B-Drug
or CC 0 0 12 O
oral JJ 0 1 6 O
hypoglycemic JJ 0 1 14 B-Group
agents NNS 1 1 1 I-Group
. . 0 0 12 O

Because IN 0 0 12 O
both DT 0 0 12 O
of IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
have VBP 0 0 12 O
negative JJ 0 1 1 O
inotropic NN 0 0 14 O
properties NNS 1 1 UNK O
and CC 0 0 12 O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
coadministration NN 0 1 UNK O
with IN 0 0 12 O
TAMBOCOR NNP 0 1 UNK B-Brand
are VBP 1 0 12 O
unknown JJ 0 1 12 O
neither DT 0 0 12 O
disopyramide JJ 0 1 16 B-Drug
nor CC 0 0 12 O
verapamil JJ 0 1 0 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
TAMBOCOR NNP 0 1 UNK B-Brand
unless IN 0 0 12 O
in IN 0 0 12 O
the DT 0 0 12 O
judgment NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
physician NN 0 1 6 O
the DT 0 0 12 O
benefits NNS 1 1 1 O
of IN 0 0 12 O
this DT 0 0 12 O
combination NN 0 1 1 O
outweigh VBZ 0 0 1 O
the DT 0 0 12 O
risks NNS 1 1 1 O
. . 0 0 12 O

Carcinogenesis NNP 0 1 UNK O
Mutagenesis NNP 0 1 UNK O
and CC 0 0 12 O
Impairment NNP 0 1 UNK O
of IN 0 0 12 O
Fertility NNP 0 1 7 O
A NNP 0 0 2 O
two CD 0 1 12 O
- : 0 0 2 O
year NN 0 1 12 O
carcinogenesis NN 0 1 UNK O
study NN 0 1 1 O
was VBD 1 0 12 O
conducted VBN 1 1 1 O
in IN 0 0 12 O
female JJ 0 1 12 O
and CC 0 0 12 O
male JJ 0 1 12 O
rats NNS 1 1 UNK O
at IN 0 0 12 O
intramuscular JJ 0 1 14 O
doses NNS 1 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
kg VBP 0 1 18 O
/ JJ 0 0 2 O
9 CD 0 0 2 O
days NNS 1 1 12 O
9 CD 0 0 2 O
mg JJ 0 1 0 O
/ NNP 0 0 2 O
rat NN 0 1 13 O
/ VBD 0 0 2 O
9 CD 0 0 2 O
days NNS 1 1 12 O
and CC 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
rat NN 0 1 13 O
/ VBD 0 0 2 O
9 CD 0 0 2 O
days NNS 1 1 12 O
. . 0 0 12 O

There EX 0 0 12 O
are VBP 1 0 12 O
no DT 0 0 12 O
clinical JJ 0 1 6 O
data NNS 0 1 1 O
on IN 0 0 12 O
concomitant NN 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
NUROMAX NNP 0 1 UNK B-Brand
and CC 0 0 12 O
other JJ 0 0 12 O
nondepolarizing VBG 0 0 UNK O
neuromuscular JJ 0 1 6 B-Group
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
. . 0 0 12 O

However RB 0 0 1 O
if IN 0 0 12 O
Argatroban NNP 0 1 0 B-Drug
is VBZ 1 0 12 O
to TO 0 0 12 O
be VB 0 0 12 O
initiated VBN 1 1 1 O
after IN 0 0 12 O
cessation NN 0 1 6 O
of IN 0 0 12 O
heparin NN 0 1 14 B-Drug
therapy NN 0 1 6 O
allow VB 0 1 1 O
sufficient JJ 0 1 1 O
time NN 0 1 12 O
for IN 0 0 12 O
heparins NNS 1 1 UNK O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
aPTT NN 0 1 UNK O
to TO 0 0 12 O
decrease VB 0 1 1 O
prior RB 0 1 1 O
to TO 0 0 12 O
initiation NN 0 1 1 O
of IN 0 0 12 O
Argatroban NNP 0 1 0 B-Drug
therapy NN 0 1 6 O
. . 0 0 12 O

Lithium NN 0 1 UNK B-Drug
: : 0 0 2 O
Increased VBN 0 1 7 O
serum NN 0 1 14 O
lithium NN 0 1 16 B-Drug
levels NNS 1 1 1 O
and CC 0 0 12 O
symptoms NNS 1 1 6 O
of IN 0 0 12 O
lithium NN 0 1 16 B-Drug
toxicity NN 0 1 6 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
ACE NNP 0 1 13 B-Group
inhibitors NNS 1 1 14 I-Group
during IN 0 0 12 O
therapy NN 0 1 6 O
with IN 0 0 12 O
lithium NN 0 1 16 B-Drug
. . 0 0 12 O

Drug NNP 0 1 2 O
- : 0 0 2 O
Drug NN 0 1 2 O
Interactions NNS 0 1 UNK O
Effect NNP 0 1 UNK O
of IN 0 0 12 O
Exelon NNP 0 1 UNK B-Brand
( ( 0 0 2 O
rivastigmine VB 0 1 16 B-Drug
tartrate NN 0 1 16 I-Drug
) ) 0 0 2 O
on IN 0 0 12 O
the DT 0 0 12 O
Metabolism NNP 0 1 UNK O
of IN 0 0 12 O
Other JJ 0 0 2 O
Drugs NNS 0 1 2 O
: : 0 0 2 O
Rivastigmine NN 0 1 UNK B-Drug
is VBZ 1 0 12 O
primarily RB 0 0 1 O
metabolized VBN 1 1 UNK O
through IN 0 0 12 O
hydrolysis NN 0 1 UNK O
by IN 0 0 12 O
esterases NNS 0 1 UNK O
. . 0 0 12 O

( ( 0 0 2 O
Read NNP 0 1 2 O
circulars NNS 1 1 UNK O
for IN 0 0 12 O
lithium NN 0 1 16 B-Drug
preparations NNS 1 1 13 O
before IN 0 1 12 O
use NN 0 1 1 O
of IN 0 0 12 O
such JJ 0 0 1 O
concomitant JJ 0 1 6 O
therapy NN 0 1 6 O
. . 0 0 12 O
) ) 0 0 2 O

REFERENCES $ 0 1 UNK O
9.Farr CD 0 1 UNK O
M NNP 0 1 2 O
et FW 0 0 13 O
al NN 0 1 16 O
. . 0 0 12 O

Immunodeficiency NNP 0 1 UNK O
- : 0 0 2 O
associated VBN 1 1 1 O
lymphocyte NN 0 1 13 O
disorders NNS 1 1 6 O
( ( 0 0 2 O
plasmacytic JJ 0 1 UNK O
hyperplasia NN 0 1 13 O
polymorphic JJ 0 1 13 O
proliferation NN 0 1 1 O
and CC 0 0 12 O
B NNP 0 0 2 O
- : 0 0 2 O
cell NN 0 1 1 O
lymphomas NN 1 1 13 O
) ) 0 0 2 O
occur VBP 0 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
who WP 0 0 12 O
have VBP 0 0 12 O
congenital NN 0 1 6 O
or CC 0 0 12 O
acquired VBN 1 1 1 O
immunodeficiencies NNS 1 1 UNK O
including VBG 1 1 1 O
those DT 0 0 12 O
resulting VBG 1 1 1 O
from IN 0 0 12 O
immunosuppressive JJ 0 1 14 B-Group
therapy NN 0 1 6 O
. . 0 0 12 O

Eprosartan NNP 0 1 UNK B-Drug
doses NNS 1 1 6 O
of IN 0 0 12 O
up IN 0 0 12 O
to TO 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
b.i.d NN 0 1 UNK O
. . 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
safely RB 0 0 UNK O
used VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
sustained VBN 1 1 1 O
- : 0 0 2 O
release NN 0 1 12 O
calcium NN 0 1 14 B-Group
channel NN 0 1 1 I-Group
blockers NNS 1 0 6 I-Group
( ( 0 0 2 O
sustained VBN 1 1 1 O
- : 0 0 2 O
release NN 0 1 12 O
nifedipine NN 0 1 0 B-Drug
) ) 0 0 2 O
with IN 0 0 12 O
no DT 0 0 12 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
adverse JJ 0 0 1 O
interactions NNS 1 1 UNK O
. . 0 0 12 O

Corticosteroids NNS 0 1 UNK B-Group
: : 0 0 2 O
A DT 0 0 2 O
relationship NN 0 1 12 O
of IN 0 0 12 O
functional JJ 0 1 1 O
antagonism NN 0 1 UNK O
exists VBZ 1 1 UNK O
between IN 0 0 12 O
vitamin NN 0 1 6 B-Group
D NNP 0 1 2 I-Group
analogues VBZ 0 1 UNK O
which WDT 0 0 12 O
promote VBP 0 1 1 O
calcium NN 0 1 14 O
absorption NN 0 1 1 O
and CC 0 0 12 O
corticosteroids NNS 1 1 14 B-Group
which WDT 0 0 12 O
inhibit VBP 0 1 13 O
calcium JJ 0 1 14 O
absorption NN 0 1 1 O
. . 0 0 12 O

Co NNP 0 1 2 O
- : 0 0 2 O
medications NNS 1 1 6 O
that IN 0 0 12 O
induce VBP 0 1 6 O
CYP9A9 NNP 0 0 UNK O
( ( 0 0 2 O
e.g. VB 0 0 UNK O
dexamethasone NN 0 1 16 B-Drug
phenytoin NN 0 1 16 B-Drug
carbamazepine NN 0 1 16 B-Drug
rifampin NN 0 1 16 B-Drug
phenobarbital NN 0 1 16 B-Drug
or CC 0 0 12 O
St NNP 0 1 2 O
. . 0 0 12 O

Therefore RB 0 0 1 O
caution NN 0 0 1 O
should MD 0 0 12 O
be VB 0 0 12 O
exercised VBN 1 1 1 O
when WRB 0 0 12 O
mifepristone NN 0 1 UNK B-Drug
is VBZ 1 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
are VBP 1 0 12 O
CYP NNP 0 1 UNK O
9A9 CD 0 0 UNK O
substrates NNS 1 1 UNK O
and CC 0 0 12 O
have VBP 0 0 12 O
narrow VBN 0 1 3 O
therapeutic JJ 0 1 6 O
range NN 0 1 1 O
including VBG 1 1 1 O
some DT 0 0 12 O
agents NNS 1 1 1 O
used VBN 1 1 12 O
during IN 0 0 12 O
general JJ 0 1 1 O
anesthesia NN 0 1 6 O
. . 0 0 12 O

These DT 0 0 1 O
effects NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
attributed VBN 1 1 1 O
to TO 0 0 12 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
renal JJ 0 1 6 O
prostaglandin NN 0 1 13 O
synthesis NN 0 1 UNK O
by IN 0 0 12 O
the DT 0 0 12 O
NSAID NNP 0 1 14 B-Group
. . 0 0 12 O

Oils NNS 0 1 UNK O
may MD 0 0 1 O
enhance VB 0 1 UNK O
absorption NN 0 1 1 O
. . 0 0 12 O

Accordingly RB 0 0 1 O
patients NNS 1 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
advised VBN 1 0 12 O
to TO 0 0 12 O
avoid VB 0 0 12 O
alcohol NN 0 1 1 B-Drug
while IN 0 0 12 O
taking VBG 1 0 12 O
REMERON NNP 0 1 UNK B-Brand
SolTab NNP 0 0 UNK I-Brand
. . 0 0 12 O
Diazepam NN 0 1 UNK B-Drug
: : 0 0 2 O
Concomitant JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
diazepam NN 0 1 0 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
) ) 0 0 2 O
had VBD 1 0 12 O
a DT 0 0 12 O
minimal JJ 0 1 1 O
effect NN 0 1 1 O
on IN 0 0 12 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
mirtazapine NN 0 1 0 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
) ) 0 0 2 O
in IN 0 0 12 O
9 CD 0 0 2 O
healthy JJ 0 1 12 O
subjects NNS 1 1 UNK O
. . 0 0 12 O

This DT 0 0 2 O
response NN 0 1 1 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
attributed VBN 1 1 1 O
to TO 0 0 12 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
renal JJ 0 1 6 O
prostaglandin NN 0 1 13 O
synthesis NN 0 1 UNK O
. . 0 0 12 O

Non NNP 0 1 2 B-Group
- : 0 0 2 O
steroidal NN 0 1 UNK I-Group
Anti NNP 0 0 UNK I-Group
- : 0 0 2 O
inflammatory NN 0 1 6 I-Group
Agents NNS 0 1 2 I-Group
: : 0 0 2 O
In IN 0 0 2 O
some DT 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
compromised JJ 0 0 1 O
renal JJ 0 1 6 O
function NN 0 1 1 O
who WP 0 0 12 O
are VBP 1 0 12 O
being VBG 1 0 12 O
treated VBN 1 1 1 O
with IN 0 0 12 O
non JJ 0 1 1 B-Group
- : 0 0 2 O
steroidal NN 0 1 UNK I-Group
anti SYM 0 0 3 I-Group
- : 0 0 2 O
inflammatory NN 0 1 6 I-Group
drugs NNS 1 1 6 I-Group
the DT 0 0 12 O
co NN 0 1 12 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
lisinopril NN 0 1 0 B-Drug
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
further JJ 0 1 1 O
deterioration NN 0 1 1 O
of IN 0 0 12 O
renal JJ 0 1 6 O
function NN 0 1 1 O
. . 0 0 12 O

Allopurinol NN 0 1 0 B-Drug
: : 0 0 2 O
In IN 0 0 2 O
a DT 0 0 12 O
study NN 0 1 1 O
of IN 0 0 12 O
healthy JJ 0 1 12 O
male NN 0 1 12 O
volunteers NNS 1 1 UNK O
no DT 0 0 12 O
significant JJ 0 1 1 O
pharmacokinetic JJ 0 1 UNK O
interaction NN 0 1 UNK O
occurred VBD 1 1 1 O
when WRB 0 0 12 O
captopril NN 0 1 0 B-Drug
and CC 0 0 12 O
allopurinol NN 0 1 13 B-Drug
were VBD 1 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
. . 0 0 12 O

In IN 0 0 2 O
patients NNS 1 1 6 O
with IN 0 0 12 O
impaired JJ 0 1 6 O
cardiac JJ 0 1 6 O
function NN 0 1 1 O
simultaneous JJ 0 1 13 O
use NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
altogether RB 0 0 12 O
. . 0 0 12 O

Serious JJ 0 1 UNK O
cardiac NN 0 1 6 O
dysrhythmias NN 0 1 13 O
some DT 0 0 12 O
resulting VBG 1 1 1 O
in IN 0 0 12 O
death NN 0 1 12 O
have VBP 0 0 12 O
occurred VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
terfenadine NN 0 1 UNK B-Drug
concomitantly RB 0 0 14 O
with IN 0 0 12 O
other JJ 0 0 12 O
macrolide JJ 0 1 UNK B-Group
antibiotics NNS 1 1 6 I-Group
. . 0 0 12 O

Antidiabetic JJ 0 1 UNK B-Group
Agents NNS 0 1 2 I-Group
: : 0 0 2 O
Disturbances NNS 0 1 UNK O
of IN 0 0 12 O
blood NN 0 1 6 O
glucose NN 0 1 14 O
including VBG 1 1 1 O
hyperglycemia NN 0 1 14 O
and CC 0 0 12 O
hypoglycemia NN 0 1 6 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
treated VBN 1 1 1 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
quinolones NNS 0 1 13 B-Group
and CC 0 0 12 O
an DT 0 0 12 O
antidiabetic JJ 0 1 13 B-Group
agent NN 0 1 1 I-Group
. . 0 0 12 O

As IN 0 0 2 O
a DT 0 0 12 O
false JJ 0 1 13 O
- : 0 0 2 O
negative JJ 0 1 1 O
result NN 0 1 1 O
may MD 0 0 1 O
occur VB 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
ferricyanide JJ 0 1 UNK O
test NN 0 1 1 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
that IN 0 0 12 O
either CC 0 1 12 O
the DT 0 0 12 O
glucose JJ 0 1 14 O
oxidase NN 0 1 13 O
or CC 0 0 12 O
hexokinase NN 0 1 UNK O
method NN 0 1 13 O
be VB 0 0 12 O
used VBN 1 1 12 O
to TO 0 0 12 O
determine VB 0 0 1 O
blood NN 0 1 6 O
plasma NN 0 1 14 O
glucose NN 0 1 14 O
levels NNS 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
cefuroxime NN 0 1 0 B-Drug
. . 0 0 12 O

with IN 0 0 12 O
divalent NN 0 0 UNK O
or CC 0 0 12 O
trivalent JJ 0 0 UNK O
cations NNS 1 1 UNK O
such JJ 0 0 1 O
as IN 1 0 12 O
iron NN 0 1 3 B-Drug
; : 0 0 2 O

Furosemide NNP 0 1 0 B-Drug
may MD 0 0 1 O
add VB 0 1 12 O
to TO 0 0 12 O
or CC 0 0 12 O
potentiate VB 0 0 UNK O
the DT 0 0 12 O
therapeutic JJ 0 1 6 O
effect NN 0 1 1 O
of IN 0 0 12 O
other JJ 0 0 12 O
antihypertensive JJ 0 1 14 B-Group
drugs NNS 1 1 6 I-Group
. . 0 0 12 O

monoamine NN 0 1 13 B-Group
oxidase NN 0 1 13 I-Group
inhibitors NNS 1 1 14 I-Group
; : 0 0 2 O

Therefore RB 0 0 1 O
monitoring NN 0 1 1 O
of IN 0 0 12 O
theophylline JJ 0 1 16 B-Drug
plasma NN 0 1 14 O
levels NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
and CC 0 0 12 O
dosage NN 0 1 0 O
of IN 0 0 12 O
theophylline NN 0 1 16 B-Drug
adjusted VBN 1 1 1 O
as IN 1 0 12 O
required VBN 1 1 1 O
. . 0 0 12 O

Alternatives NNS 0 1 UNK O
to TO 0 0 12 O
clarithromycin VB 0 1 13 B-Drug
such JJ 0 0 1 O
as IN 1 0 12 O
azithromycin NN 0 1 0 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
vitro NN 0 1 UNK O
at IN 0 0 12 O
total JJ 0 1 1 O
drug NN 0 1 1 O
concentrations NNS 1 1 13 O
9 CD 0 0 2 O
- : 0 0 2 O
fold NN 0 1 3 O
higher JJR 1 1 1 O
than IN 0 0 12 O
peak JJ 0 1 1 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
observed VBN 1 1 1 O
with IN 0 0 12 O
the DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
mg NN 0 1 0 O
dosage NN 0 1 0 O
alosetron NN 0 1 UNK B-Drug
inhibited VBD 1 1 13 O
CYP NNP 0 1 UNK O
enzymes VBZ 0 1 14 O
9A9 CD 0 0 UNK O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
and CC 0 0 12 O
9E9 CD 0 0 UNK O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
. . 0 0 12 O

In IN 0 0 2 O
screening VBG 1 1 1 O
patients NNS 1 1 6 O
suspected VBN 1 1 12 O
of IN 0 0 12 O
having VBG 1 0 12 O
a DT 0 0 12 O
pheochromocytoma NN 0 1 UNK O
and CC 0 0 12 O
being VBG 1 0 12 O
treated VBN 1 1 1 O
with IN 0 0 12 O
labetalol JJ 0 1 0 B-Drug
HCl NNP 0 0 14 I-Drug
a DT 0 0 12 O
specific JJ 0 1 1 O
method NN 0 1 13 O
such JJ 0 0 1 O
as IN 1 0 12 O
a DT 0 0 12 O
high JJ 0 1 1 O
performance NN 0 1 13 O
liquid NN 0 1 3 O
chromatographic JJ 0 1 UNK O
assay NN 0 1 14 O
with IN 0 0 12 O
solid JJ 0 1 3 O
phase NN 0 1 1 O
extraction NN 0 1 1 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
J NNP 0 0 19 O
Chromatogr NNP 0 0 UNK O
9:9 CD 0 0 UNK O
9 CD 0 0 2 O
) ) 0 0 2 O
should MD 0 0 12 O
be VB 0 0 12 O
employed VBN 1 1 1 O
in IN 0 0 12 O
determining VBG 1 0 UNK O
levels NNS 1 1 1 O
of IN 0 0 12 O
catecholamines NNS 1 1 14 O
. . 0 0 12 O

COPAXONE NNP 0 1 UNK B-Brand
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
formally RB 0 0 1 O
evaluated VBN 1 1 1 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
Interferon NNP 0 1 0 B-Drug
beta NN 0 1 16 I-Drug
. . 0 0 12 O

Concurrent NN 0 1 13 O
use NN 0 1 1 O
with IN 0 0 12 O
general JJ 0 1 1 O
anesthetics NNS 1 1 13 B-Group
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
arrhythmias NN 1 1 6 O
. . 0 0 12 O

No DT 0 0 2 O
dosage NN 0 1 0 O
adjustment NN 0 1 1 O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
or CC 0 0 12 O
JANUVIA NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O

Drug NN 0 1 2 O
Interactions NNS 0 1 UNK O
: : 0 0 2 O
The DT 0 0 2 O
central JJ 0 1 1 O
anticholinergic JJ 0 1 13 B-Group
syndrome NN 0 1 6 O
can MD 0 0 12 O
occur VB 0 1 1 O
when WRB 0 0 12 O
anticholinergic JJ 0 1 13 O
agents NNS 1 1 1 O
such JJ 0 0 1 O
as IN 1 0 12 O
AKINETON NNP 0 1 UNK B-Brand
are VBP 1 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
have VBP 0 0 12 O
secondary JJ 0 1 1 O
anticholinergic JJ 0 1 13 O
actions NNS 1 1 UNK O
e.g. VBP 0 0 UNK O
certain JJ 0 1 1 O
narcotic JJ 0 1 6 B-Group
analgesics NNS 1 1 14 I-Group
such JJ 0 0 1 O
as IN 1 0 12 O
meperidine NN 0 1 16 B-Drug
the DT 0 0 12 O
phenothiazines NNS 1 1 UNK B-Group
and CC 0 0 12 O
other JJ 0 0 12 O
antipsychotics NNS 1 1 14 B-Group
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
certain JJ 0 1 1 O
antiarrhythmics NNS 1 1 UNK B-Group
such JJ 0 0 1 O
as IN 1 0 12 O
the DT 0 0 12 O
quinidine NN 0 1 16 B-Drug
salts NNS 1 1 13 O
and CC 0 0 12 O
antihistamines NNS 1 1 UNK B-Group
. . 0 0 12 O

BROVANA NNP 0 1 UNK B-Brand
as IN 1 0 12 O
with IN 0 0 12 O
other JJ 0 0 12 O
beta9 SYM 0 0 UNK B-Group
- : 0 0 2 O
agonists NNS 1 1 UNK I-Group
should MD 0 0 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
extreme JJ 0 1 1 O
caution NN 0 0 1 O
to TO 0 0 12 O
patients NNS 1 1 6 O
being VBG 1 0 12 O
treated VBN 1 1 1 O
with IN 0 0 12 O
monoamine JJ 0 1 13 B-Group
oxidase NN 0 1 13 I-Group
inhibitors NNS 1 1 14 I-Group
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
or CC 0 0 12 O
drugs NNS 1 1 6 O
known VBN 1 1 12 O
to TO 0 0 12 O
prolong VB 0 0 13 O
the DT 0 0 12 O
QTc NNP 0 0 14 O
interval NN 0 1 1 O
because IN 0 0 12 O
the DT 0 0 12 O
action NN 0 1 13 O
of IN 0 0 12 O
adrenergic JJ 0 1 UNK B-Group
agonists NNS 1 1 UNK I-Group
on IN 0 0 12 O
the DT 0 0 12 O
cardiovascular JJ 0 1 6 O
system NN 0 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
potentiated VBN 1 0 UNK O
by IN 0 0 12 O
these DT 0 0 12 O
agents NNS 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
effects NNS 1 1 1 O
of IN 0 0 12 O
mixing VBG 1 1 UNK O
NovoLog NNP 0 1 UNK B-Brand
with IN 0 0 12 O
insulins NNS 1 1 13 B-Group
of IN 0 0 12 O
animal JJ 0 1 13 O
source NN 0 1 1 O
or CC 0 0 12 O
insulin NN 0 1 14 B-Drug
preparations NNS 1 1 13 O
produced VBN 1 0 1 O
by IN 0 0 12 O
other JJ 0 0 12 O
manufacturers NNS 1 1 UNK O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
studied VBN 1 0 1 O
. . 0 0 12 O

Paliperidone NN 0 1 UNK B-Drug
is VBZ 1 0 12 O
also RB 0 0 12 O
not RB 0 1 12 O
expected VBN 1 1 12 O
to TO 0 0 12 O
have VB 0 0 12 O
enzyme VBN 0 1 14 O
inducing VBG 1 1 6 O
properties NNS 1 1 UNK O
. . 0 0 12 O

Magnesium NNP 0 1 7 B-Drug
- : 0 0 2 O
and CC 0 0 12 O
/ VB 0 0 2 O
or CC 0 0 12 O
aluminum VB 0 1 16 B-Drug
- : 0 0 2 O
containing VBG 1 1 1 O
antacids NNS 1 1 14 B-Group
products NNS 1 1 1 O
containing VBG 1 1 1 O
ferrous JJ 0 1 14 B-Drug
sulfate NN 0 1 14 I-Drug
( ( 0 0 2 O
iron NN 0 1 3 B-Drug
) ) 0 0 2 O
multivitamin NN 0 1 14 B-Group
preparations NNS 1 1 13 I-Group
containing VBG 1 1 1 O
zinc NN 0 1 14 B-Drug
or CC 0 0 12 O
other JJ 0 0 12 O
metal JJ 0 1 3 O
cations NNS 1 1 UNK O
or CC 0 0 12 O
Videx NNP 0 1 UNK B-Brand
( ( 0 0 2 O
didanosine NN 0 1 16 B-Drug
) ) 0 0 2 O
chewable JJ 0 0 16 O
/ NN 0 0 2 O
buffered VBD 1 1 16 O
tablets NNS 1 1 3 O
or CC 0 0 12 O
the DT 0 0 12 O
pediatric JJ 0 1 6 O
powder NN 0 1 3 O
for IN 0 0 12 O
oral JJ 0 1 6 O
solution NN 0 1 1 O
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
taken VBN 1 1 12 O
within IN 0 0 1 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
before IN 0 1 12 O
or CC 0 0 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
after IN 0 0 12 O
FACTIVE NNP 0 1 UNK B-Brand
. . 0 0 12 O

Therefore RB 0 0 1 O
a DT 0 0 12 O
possible JJ 0 1 1 O
lack NN 0 1 1 O
of IN 0 0 12 O
desired JJ 0 1 1 O
effect NN 0 1 1 O
of IN 0 0 12 O
treatment NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
taken VBN 1 1 12 O
into IN 0 0 12 O
consideration NN 0 1 1 O
before IN 0 1 12 O
such JJ 0 0 1 O
drugs NNS 1 1 6 O
are VBP 1 0 12 O
given VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
lactulose NN 0 1 14 B-Drug
. . 0 0 12 O

There EX 0 0 12 O
was VBD 1 0 12 O
no DT 0 0 12 O
evidence NN 0 1 1 O
of IN 0 0 12 O
toxicity NN 0 1 6 O
. . 0 0 12 O

phenylbutazone NN 0 1 UNK B-Drug
; : 0 0 2 O

Patients NNS 0 1 7 O
taking VBG 1 0 12 O
REVIA NNP 0 1 UNK B-Brand
may MD 0 0 1 O
not RB 0 1 12 O
benefit VB 0 1 1 O
from IN 0 0 12 O
opioid JJ 0 1 13 B-Group
containing VBG 1 1 1 O
medicines NNS 1 1 6 O
such JJ 0 0 1 O
as IN 1 0 12 O
cough NN 0 1 6 O
and CC 0 0 12 O
cold JJ 0 1 3 O
preparations NNS 1 1 13 O
antidiarrheal VBP 0 1 13 O
preparations NNS 1 1 13 O
and CC 0 0 12 O
opioid JJ 0 1 13 B-Group
analgesics NNS 1 1 14 I-Group
. . 0 0 12 O

Caution NN 0 0 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
exercised VBN 1 1 1 O
when WRB 0 0 12 O
administering VBG 1 1 1 O
nabumetone RB 0 1 13 B-Drug
with IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
since IN 0 1 12 O
interactions NNS 1 1 UNK O
have VBP 0 0 12 O
been VBN 1 0 12 O
seen VBN 1 1 12 O
with IN 0 0 12 O
other JJ 0 0 12 O
NSAIDs NNP 0 1 UNK B-Group
. . 0 0 12 O

increased VBN 1 1 1 O
platelet NN 0 1 14 O
count NN 0 1 12 O
; : 0 0 2 O

The DT 0 0 2 O
depression NN 0 1 6 O
of IN 0 0 12 O
cardiac JJ 0 1 6 O
contractility NN 0 1 13 O
conductivity NN 0 1 UNK O
and CC 0 0 12 O
automaticity NN 0 1 UNK O
as RB 0 0 12 O
well RB 0 1 12 O
as IN 1 0 12 O
the DT 0 0 12 O
vascular JJ 0 1 6 O
dilation NN 0 1 6 O
associated VBN 1 1 1 O
with IN 0 0 12 O
anesthetics NNS 1 1 13 B-Group
may MD 0 0 1 O
be VB 0 0 12 O
potentiated VBN 1 0 UNK O
by IN 0 0 12 O
calcium NN 0 1 14 B-Group
channel NN 0 1 1 I-Group
blockers NNS 1 0 6 I-Group
. . 0 0 12 O

Cholestyramine NN 0 1 UNK B-Drug
: : 0 0 2 O
Cholestyramine NN 0 1 UNK B-Drug
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
clearance NN 0 1 16 O
of IN 0 0 12 O
corticosteroids NNS 1 1 14 B-Group
. . 0 0 12 O

In IN 0 0 2 O
controlled JJ 0 1 1 O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
however RB 0 0 12 O
beta VBP 0 1 16 B-Drug
blockers NNS 1 0 6 I-Drug
including VBG 1 1 1 O
metoprolol NN 0 1 0 B-Drug
were VBD 1 0 12 O
concurrently RB 0 0 1 O
administered VBN 1 1 1 O
with IN 0 0 12 O
felodipine NN 0 1 13 B-Drug
and CC 0 0 12 O
were VBD 1 0 12 O
well RB 0 1 12 O
tolerated VBN 1 0 1 O
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
that IN 0 0 12 O
the DT 0 0 12 O
combination NN 0 1 1 O
of IN 0 0 12 O
intravenous JJ 0 1 14 O
dantrolene NN 0 1 16 B-Drug
sodium NN 0 1 14 I-Drug
and CC 0 0 12 O
calcium NN 0 1 14 B-Group
channel NN 0 1 1 I-Group
blockers NNS 1 0 6 I-Group
such JJ 0 0 1 O
as IN 1 0 12 O
verapamil NN 0 1 0 B-Drug
not RB 0 1 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
together RB 0 1 12 O
during IN 0 0 12 O
the DT 0 0 12 O
management NN 0 1 1 O
of IN 0 0 12 O
malignant JJ 0 1 6 O
hyperthermia NN 0 1 13 O
crisis NN 0 1 12 O
until IN 0 0 12 O
the DT 0 0 12 O
relevance NN 0 1 UNK O
of IN 0 0 12 O
these DT 0 0 12 O
findings NNS 1 1 1 O
to TO 0 0 12 O
humans NNS 1 1 UNK O
is VBZ 1 0 12 O
established VBN 1 1 1 O
. . 0 0 12 O

There EX 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
inconsistent JJ 0 1 1 O
reports NNS 1 1 1 O
regarding VBG 1 0 1 O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
quinine NN 0 1 16 B-Drug
penicillamine NN 0 1 13 B-Drug
) ) 0 0 2 O
on IN 0 0 12 O
serum NN 0 1 14 O
digoxin NN 0 1 14 B-Drug
concentration NN 0 1 1 O
. . 0 0 12 O

These DT 0 0 1 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
increased JJ 0 1 1 O
and CC 0 0 12 O
prolonged JJ 0 1 6 O
sedation NN 0 1 6 O
due JJ 0 1 1 O
to TO 0 0 12 O
a DT 0 0 12 O
decrease NN 0 1 1 O
in IN 0 0 12 O
plasma JJ 0 1 14 O
clearance NN 0 1 16 O
of IN 0 0 12 O
midazolam NN 0 1 16 B-Drug
. . 0 0 12 O

MAO JJ 0 1 14 B-Group
Inhibitors NNS 0 1 7 I-Group
: : 0 0 2 O
DURAGESIC NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
not RB 0 1 12 O
recommended VBN 1 1 1 O
for IN 0 0 12 O
use NN 0 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
who WP 0 0 12 O
have VBP 0 0 12 O
received VBN 1 1 12 O
MAOI NNP 0 1 UNK B-Group
within IN 0 0 1 O
9 CD 0 0 2 O
days NNS 1 1 12 O
because IN 0 0 12 O
severe JJ 0 1 6 O
and CC 0 0 12 O
unpredictable JJ 0 0 UNK O
potentiation NN 0 1 UNK O
by IN 0 0 12 O
MAO NNP 0 1 14 B-Group
inhibitors NNS 1 1 14 I-Group
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
with IN 0 0 12 O
opioid JJ 0 1 13 B-Group
analgesics NNS 1 1 14 I-Group

FACTIVE NNP 0 1 UNK B-Brand
had VBD 1 0 12 O
no DT 0 0 12 O
significant JJ 0 1 1 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
anticoagulant JJ 0 1 13 O
effect NN 0 1 1 O
of IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
in IN 0 0 12 O
healthy JJ 0 1 12 O
subjects NNS 1 1 UNK O
on IN 0 0 12 O
stable JJ 0 1 1 O
warfarin JJ 0 1 14 B-Drug
therapy NN 0 1 6 O
. . 0 0 12 O

however RB 0 0 12 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
not RB 0 1 12 O
known VBN 1 1 12 O
if IN 0 0 12 O
other JJ 0 0 12 O
phenothiazines NNS 1 1 UNK B-Group
produce VBP 0 0 1 O
a DT 0 0 12 O
similar JJ 0 1 1 O
response NN 0 1 1 O
. . 0 0 12 O

Other JJ 0 0 2 O
macrolide JJ 0 1 UNK B-Group
antibiotics NNS 1 1 6 I-Group
such JJ 0 0 1 O
as IN 1 0 12 O
erythromycin NNS 0 1 0 B-Drug
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
studied VBN 1 0 1 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
SUSTIVA NNP 0 1 UNK B-Brand
. . 0 0 12 O

Caution NN 0 0 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
when WRB 0 0 12 O
administering VBG 1 1 1 O
or CC 0 0 12 O
taking VBG 1 0 12 O
TARCEVA RP 0 1 UNK B-Brand
with IN 0 0 12 O
ketoconazole NN 0 1 16 B-Drug
and CC 0 0 12 O
other JJ 0 0 12 O
strong JJ 0 1 12 O
CYP9A9 NNP 0 0 UNK O
inhibitors NNS 1 1 14 O
such JJ 0 0 1 O
as IN 1 0 12 O
but CC 0 0 12 O
not RB 0 1 12 O
limited JJ 0 1 1 O
to TO 0 0 12 O
atazanavir VB 0 1 13 B-Drug
clarithromycin JJ 0 1 13 B-Drug
indinavir JJ 0 1 16 B-Drug
itraconazole NN 0 1 0 B-Drug
nefazodone NN 0 1 16 B-Drug
nelfinavir JJ 0 1 16 B-Drug
ritonavir NN 0 1 16 B-Drug
saquinavir NN 0 1 13 B-Drug
telithromycin NN 0 1 UNK B-Drug
troleandomycin NN 0 1 UNK B-Drug
( ( 0 0 2 O
TAO NNP 0 1 UNK B-Drug
) ) 0 0 2 O
and CC 0 0 12 O
voriconazole NN 0 1 14 B-Drug
. . 0 0 12 O

Corticosteroids NNS 0 1 UNK B-Group
may MD 0 0 1 O
also RB 0 0 12 O
potentiate VB 0 0 UNK O
the DT 0 0 12 O
replication NN 0 1 UNK O
of IN 0 0 12 O
some DT 0 0 12 O
organisms NNS 1 1 1 O
contained VBN 1 1 1 O
in IN 0 0 12 O
live JJ 0 1 12 B-Group
attenuated JJ 0 1 UNK I-Group
vaccines NNS 1 1 6 I-Group
. . 0 0 12 O

However RB 0 0 1 O
the DT 0 0 12 O
relationship NN 0 1 12 O
to TO 0 0 12 O
nifedipine VB 0 1 0 B-Drug
therapy NN 0 1 6 O
is VBZ 1 0 12 O
uncertain JJ 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
hypoglycemic JJ 0 1 14 O
effect NN 0 1 1 O
of IN 0 0 12 O
tolbutamide NN 0 1 UNK B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
increase VB 0 1 1 O
when WRB 0 0 12 O
Atromid NNP 0 1 UNK B-Brand
- : 0 0 2 O
S NN 0 1 2 I-Brand
is VBZ 1 0 12 O
given VBN 1 1 12 O
concurrently RB 0 0 1 O
. . 0 0 12 O

Elevated VBN 0 1 7 O
International NNP 0 1 UNK O
Normalized NNP 0 1 UNK O
Ratio NNP 0 1 2 O
and CC 0 0 12 O
Potential NNP 0 1 UNK O
Bleeding NNP 0 1 7 O
International NNP 0 1 UNK O
Normalized NNP 0 1 UNK O
Ratio NNP 0 1 2 O
( ( 0 0 2 O
INR NNP 0 1 13 O
) ) 0 0 2 O
elevations NNS 1 1 1 O
and CC 0 0 12 O
infrequent JJ 0 1 1 O
reports NNS 1 1 1 O
of IN 0 0 12 O
bleeding VBG 1 1 6 O
events NNS 1 1 12 O
including VBG 1 1 1 O
gastrointestinal JJ 0 1 6 O
and CC 0 0 12 O
non JJ 0 1 1 O
- : 0 0 2 O
gastrointestinal JJ 0 1 6 O
bleedings NNS 1 1 UNK O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
clinical JJ 0 1 6 O
studies NNS 1 1 1 O
some DT 0 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
concomitant JJ 0 1 6 O
warfarin JJ 0 1 14 B-Drug
administration NN 0 1 1 O
. . 0 0 12 O

When WRB 0 0 12 O
these DT 0 0 12 O
products NNS 1 1 1 O
are VBP 1 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
or CC 0 0 12 O
other JJ 0 0 12 O
suitable JJ 0 1 1 O
coagulation NN 0 1 14 O
tests NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
closely RB 0 0 1 O
monitored VBN 1 1 1 O
. . 0 0 12 O

Mitotane NNP 0 1 UNK B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
accelerate VB 0 1 UNK O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
by IN 0 0 12 O
the DT 0 0 12 O
mechanism NN 0 1 13 O
of IN 0 0 12 O
hepatic JJ 0 1 14 O
microsomal JJ 0 1 UNK O
enzyme NN 0 1 14 O
induction NN 0 1 1 O
leading VBG 1 1 1 O
to TO 0 0 12 O
an DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
dosage NN 0 1 0 O
requirements NNS 1 1 1 O
for IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
. . 0 0 12 O

Therefore IN 0 0 1 O
patients NNS 1 1 6 O
under IN 0 0 12 O
methotrexate JJ 0 1 16 B-Drug
therapy NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
carefully RB 0 0 12 O
monitored VBN 1 1 1 O
when WRB 0 0 12 O
concomitant JJ 0 1 6 O
ciprofloxacin NN 0 1 0 B-Drug
therapy NN 0 1 6 O
is VBZ 1 0 12 O
indicated VBN 1 1 1 O
. . 0 0 12 O

No DT 0 0 2 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
adverse JJ 0 0 1 O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
commonly RB 0 0 UNK O
used VBN 1 1 12 O
preanesthetic JJ 0 0 UNK O
drugs NNS 1 1 6 O
or CC 0 0 12 O
drugs NNS 1 1 6 O
used VBN 1 1 12 O
during IN 0 0 12 O
anesthesia NN 0 1 6 O
( ( 0 0 2 O
muscle NN 0 1 6 B-Group
relaxants NNS 1 0 13 I-Group
intravenous JJ 0 1 14 O
agents NNS 1 1 1 O
and CC 0 0 12 O
local JJ 0 1 12 O
anesthetic JJ 0 1 13 B-Group
agents NNS 1 1 1 I-Group
) ) 0 0 2 O
were VBD 1 0 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
. . 0 0 12 O

Tricyclic JJ 0 0 UNK B-Group
Antidepressants NNS 0 1 UNK I-Group
: : 0 0 2 O
Concurrent NNP 0 1 13 O
use NN 0 1 1 O
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
therapeutic JJ 0 1 6 O
and CC 0 0 12 O
toxic JJ 0 1 1 O
effects NNS 1 1 1 O
of IN 0 0 12 O
both DT 0 0 12 O
drugs NNS 1 1 6 O
possibly RB 0 1 12 O
due JJ 0 1 1 O
to TO 0 0 12 O
increased VBN 1 1 1 O
catecholamine NN 0 1 14 O
sensitivity NN 0 1 1 O
. . 0 0 12 O

While IN 0 0 12 O
all PDT 0 0 12 O
the DT 0 0 12 O
selective JJ 0 1 13 B-Group
serotonin NN 0 1 13 I-Group
reuptake NN 0 1 13 I-Group
inhibitors NNS 1 1 14 I-Group
( ( 0 0 2 O
SSRIs NNP 0 1 UNK B-Group
) ) 0 0 2 O
e.g. VBP 0 0 UNK O
citalopram JJ 0 1 16 B-Drug
escitalopram FW 0 1 0 B-Drug
fluoxetine JJ 0 1 16 B-Drug
sertraline NN 0 1 16 B-Drug
and CC 0 0 12 O
paroxetine JJ 0 1 16 B-Drug
inhibit NN 0 1 13 O
P9 NNP 0 1 UNK O
9D9 CD 0 0 UNK O
they PRP 0 0 12 O
may MD 0 0 1 O
vary VB 0 0 1 O
in IN 0 0 12 O
the DT 0 0 12 O
extent NN 0 1 1 O
of IN 0 0 12 O
inhibition NN 0 1 13 O
. . 0 0 12 O

the DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
Prostigmin NNP 0 1 UNK B-Brand
may MD 0 0 1 O
have VB 0 0 12 O
to TO 0 0 12 O
be VB 0 0 12 O
increased VBN 1 1 1 O
accordingly RB 0 0 1 O
. . 0 0 12 O

However RB 0 0 1 O
there EX 0 0 12 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
one CD 0 1 12 O
report NN 0 1 1 O
of IN 0 0 12 O
prolonged JJ 0 1 6 O
prothrombin NN 0 1 14 O
time NN 0 1 12 O
when WRB 0 0 12 O
buspirone NN 0 1 16 B-Drug
was VBD 1 0 12 O
added VBN 1 1 12 O
to TO 0 0 12 O
the DT 0 0 12 O
regimen NNS 0 1 6 O
of IN 0 0 12 O
a DT 0 0 12 O
patient NN 0 1 6 O
treated VBN 1 1 1 O
with IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
. . 0 0 12 O

Geriatric NNP 0 1 7 O
Use NNP 0 1 2 O
When WRB 0 0 12 O
tumor NN 0 1 6 O
response NN 0 1 1 O
was VBD 1 0 12 O
considered VBN 1 1 1 O
by IN 0 0 12 O
age NN 0 1 12 O
objective JJ 0 1 13 O
responses NNS 1 1 1 O
were VBD 1 0 12 O
seen VBN 1 1 12 O
in IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
of IN 0 0 12 O
patients NNS 1 1 6 O
under IN 0 0 12 O
9 CD 0 0 2 O
years NNS 1 1 12 O
of IN 0 0 12 O
age NN 0 1 12 O
and CC 0 0 12 O
in IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
of IN 0 0 12 O
patients NNS 1 1 6 O
9 CD 0 0 2 O
years NNS 1 1 12 O
of IN 0 0 12 O
age NN 0 1 12 O
and CC 0 0 12 O
older JJR 1 1 12 O
who WP 0 0 12 O
were VBD 1 0 12 O
treated VBN 1 1 1 O
with IN 0 0 12 O
FASLODEX NNP 0 1 UNK B-Brand
in IN 0 0 12 O
the DT 0 0 12 O
European NNP 0 1 UNK O
and CC 0 0 12 O
North NNP 0 1 2 O
American JJ 0 1 2 O
trials NNS 1 1 1 O
respectively RB 0 0 1 O
. . 0 0 12 O

This DT 0 0 2 O
diminution NN 0 1 1 O
is VBZ 1 0 12 O
not RB 0 1 12 O
sufficient JJ 0 1 1 O
to TO 0 0 12 O
preclude VB 0 0 UNK O
effectiveness NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
pressor NN 0 1 14 O
agent NN 0 1 1 O
for IN 0 0 12 O
therapeutic JJ 0 1 6 O
use NN 0 1 1 O
. . 0 0 12 O

Based VBN 0 1 2 O
on IN 0 0 12 O
in IN 0 0 12 O
vitro NN 0 1 UNK O
P9 NNP 0 1 UNK O
inhibition NN 0 1 13 O
studies NNS 1 1 1 O
and CC 0 0 12 O
the DT 0 0 12 O
low JJ 0 1 1 O
systemic JJ 0 1 6 O
exposure NN 0 1 1 O
observed VBD 1 1 1 O
following VBG 1 1 1 O
topical JJ 0 1 6 O
application NN 0 1 1 O
of IN 0 0 12 O
ALTABAX NNP 0 1 UNK B-Brand
retapamulin NN 0 1 UNK B-Drug
is VBZ 1 0 12 O
unlikely JJ 0 1 12 O
to TO 0 0 12 O
affect VB 0 1 1 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
other JJ 0 0 12 O
P9 NNP 0 1 UNK O
substrates NNS 1 1 UNK O
. . 0 0 12 O

Therefore RB 0 0 1 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
ketoconazole JJ 0 1 16 B-Drug
tablets NNS 1 1 3 O
with IN 0 0 12 O
cisapride NN 0 1 UNK B-Drug
is VBZ 1 0 12 O
contraindicated VBN 1 1 14 O
. . 0 0 12 O

Studies NNS 0 1 2 O
with IN 0 0 12 O
other JJ 0 0 12 O
oral JJ 0 1 6 O
or CC 0 0 12 O
implant JJ 0 1 6 O
contraceptives NNS 1 1 13 B-Group
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
conducted VBN 1 1 1 O
. . 0 0 12 O

TAXOL NNP 0 1 UNK B-Brand
contains NNS 0 1 1 O
dehydrated VBD 1 1 3 O
alcohol NN 0 1 1 O
USP NNP 0 1 UNK O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
mL NN 0 1 14 O
; : 0 0 2 O

Toxicologic NNP 0 1 UNK O
and CC 0 0 12 O
toxicokinetic JJ 0 1 UNK O
studies NNS 1 1 1 O
in IN 0 0 12 O
rats NNS 1 1 UNK O
did VBD 1 0 12 O
not RB 0 1 12 O
demonstrate VB 0 0 1 O
any DT 0 0 12 O
alterations NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
clearance NN 0 1 16 O
or CC 0 0 12 O
toxicologic JJ 0 1 13 O
profile NN 0 1 1 O
of IN 0 0 12 O
either DT 0 1 12 O
methotrexate NN 0 1 16 B-Drug
or CC 0 0 12 O
Kineret NNP 0 1 UNK B-Brand
when WRB 0 0 12 O
the DT 0 0 12 O
two CD 0 1 12 O
agents NNS 1 1 1 O
were VBD 1 0 12 O
administered VBN 1 1 1 O
together RB 0 1 12 O
. . 0 0 12 O

Patients NNS 0 1 7 O
should MD 0 0 12 O
be VB 0 0 12 O
warned VBN 1 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
potential JJ 0 1 1 O
danger NN 0 0 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
intravenous JJ 0 1 14 O
self NN 0 1 12 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
benzodiazepines NNS 1 1 14 B-Group
while IN 0 0 12 O
under IN 0 0 12 O
treatment NN 0 1 6 O
with IN 0 0 12 O
SUBOXONE NNP 0 1 UNK B-Brand
or CC 0 0 12 O
SUBUTEX NNP 0 1 UNK B-Brand
. . 0 0 12 O

Amitriptyline NNP 0 1 0 B-Drug
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
clonidine JJ 0 1 0 B-Drug
enhances NNS 0 1 UNK O
the DT 0 0 12 O
manifestation NN 0 1 13 O
of IN 0 0 12 O
corneal JJ 0 1 6 O
lesions NNS 1 1 6 O
in IN 0 0 12 O
rats NNS 1 1 UNK O
Epidural NNP 0 1 7 O
Injection NNP 0 1 7 O
Clonidine NNP 0 1 0 B-Drug
may MD 0 0 1 O
potentiate VB 0 0 UNK O
the DT 0 0 12 O
CNS NNP 0 1 6 O
- : 0 0 2 O
depressive JJ 0 0 13 O
effect NN 0 1 1 O
of IN 0 0 12 O
alcohol NN 0 1 1 B-Drug
barbiturates NNS 1 1 14 B-Group
or CC 0 0 12 O
other JJ 0 0 12 O
sedating VBG 1 1 14 B-Group
drugs NNS 1 1 6 I-Group
. . 0 0 12 O

Mixing VBG 0 1 UNK O
SYMLIN NNP 0 1 UNK B-Brand
and CC 0 0 12 O
Insulin NNP 0 1 7 B-Drug
The DT 0 0 2 O
pharmacokinetic JJ 0 1 UNK O
parameters NNS 1 1 1 O
of IN 0 0 12 O
SYMLIN NNP 0 1 UNK B-Brand
were VBD 1 0 12 O
altered VBN 1 1 1 O
when WRB 0 0 12 O
mixed JJ 0 1 3 O
with IN 0 0 12 O
regular JJ 0 1 12 O
NPH NNP 0 1 14 O
and CC 0 0 12 O
9 CD 0 0 2 O
/ NNS 0 0 2 O
9 CD 0 0 2 O
premixed JJ 0 0 UNK O
formulations NNS 1 1 UNK O
of IN 0 0 12 O
recombinant JJ 0 1 13 O
human JJ 0 1 1 B-Drug
insulin NN 0 1 14 I-Drug
immediately RB 0 1 12 O
prior JJ 0 1 1 O
to TO 0 0 12 O
injection NN 0 1 3 O
. . 0 0 12 O

Diuretics NNS 0 1 UNK B-Group
: : 0 0 2 O
Studies NNS 0 1 2 O
in IN 0 0 12 O
normal JJ 0 1 1 O
volunteers NNS 1 1 UNK O
have VBP 0 0 12 O
shown VBN 1 1 1 O
that IN 0 0 12 O
flurbiprofen NN 0 1 16 B-Drug
like IN 0 0 12 O
other JJ 0 0 12 O
nonsteroidal JJ 0 0 14 B-Group
anti SYM 0 0 3 I-Group
- : 0 0 2 O
inflammatory NN 0 1 6 I-Group
drugs NNS 1 1 6 I-Group
can MD 0 0 12 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
furosemide NN 0 1 0 B-Drug
. . 0 0 12 O

No DT 0 0 2 O
cross NN 0 1 12 O
- : 0 0 2 O
resistance NN 0 1 1 O
with IN 0 0 12 O
other JJ 0 0 12 O
chemotherapeutic JJ 0 1 13 B-Group
agents NNS 1 1 1 I-Group
radiotherapy VBP 0 1 13 O
or CC 0 0 12 O
steroids NNS 1 1 6 B-Group
has VBZ 1 0 12 O
been VBN 1 0 12 O
demonstrated VBN 1 0 1 O
. . 0 0 12 O

In IN 0 0 2 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
HCTZ NNP 0 1 0 B-Drug
alone RB 0 1 12 O
dofetilide RB 0 1 13 B-Drug
AUC NNP 0 1 UNK O
increased VBN 1 1 1 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
Cmax NNP 0 1 UNK O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

In IN 0 0 2 O
post NN 0 1 12 O
- : 0 0 2 O
marketing NN 0 1 UNK O
experience NN 0 1 12 O
bleeding NN 0 1 6 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
on IN 0 0 12 O
concomitant JJ 0 1 6 O
treatment NN 0 1 6 O
with IN 0 0 12 O
anticoagulants NNS 1 1 13 B-Group
and CC 0 0 12 O
INDOCIN NNP 0 1 UNK B-Brand
. . 0 0 12 O

Potential JJ 0 1 UNK O
Drug NNP 0 1 2 O
Interactions NNP 0 1 UNK O
Dofetilide NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
eliminated VBN 1 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
kidney NN 0 1 6 O
by IN 0 0 12 O
cationic JJ 0 1 UNK O
secretion NN 0 1 14 O
. . 0 0 12 O

Based VBN 0 1 2 O
on IN 0 0 12 O
studies NNS 1 1 1 O
evaluating VBG 1 1 1 O
possible JJ 0 1 1 O
interactions NNS 1 1 UNK O
of IN 0 0 12 O
pantoprazole NN 0 1 16 B-Drug
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
no DT 0 0 12 O
dosage NN 0 1 0 O
adjustment NN 0 1 1 O
is VBZ 1 0 12 O
needed VBN 1 1 12 O
with IN 0 0 12 O
concomitant JJ 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
following NN 0 1 1 O
: : 0 0 2 O
theophylline JJ 0 1 16 B-Drug
cisapride NN 0 1 UNK B-Drug
antipyrine NN 0 1 UNK B-Drug
caffeine NN 0 1 6 B-Drug
carbamazepine NN 0 1 16 B-Drug
diazepam NN 0 1 0 B-Drug
( ( 0 0 2 O
and CC 0 0 12 O
its PRP$ 1 0 12 O
active JJ 0 1 1 O
metabolite JJ 0 1 UNK O
desmethyldiazepam NN 0 1 UNK B-Drug_n
) ) 0 0 2 O
diclofenac NN 0 1 16 B-Drug
naproxen JJ 0 1 16 B-Drug
piroxicam NN 0 1 13 B-Drug
digoxin NN 0 1 14 B-Drug
ethanol NN 0 1 1 B-Drug
glyburide VBP 0 1 16 B-Drug
an DT 0 0 12 O
oral JJ 0 1 6 O
contraceptive NN 0 1 13 B-Group
( ( 0 0 2 O
levonorgestrel JJ 0 1 13 B-Drug
/ NNP 0 0 2 O
ethinyl NN 0 0 13 B-Drug
estradiol NN 0 1 13 I-Drug
) ) 0 0 2 O
metoprolol FW 0 1 0 B-Drug
nifedipine JJ 0 1 0 B-Drug
phenytoin NN 0 1 16 B-Drug
warfarin NN 0 1 14 B-Drug
midazolam NN 0 1 16 B-Drug
clarithromycin NN 0 1 13 B-Drug
metronidazole NN 0 1 0 B-Drug
or CC 0 0 12 O
amoxicillin NN 0 1 0 B-Drug
. . 0 0 12 O

Plasma NNP 0 1 UNK O
concentrations NNS 1 1 13 O
may MD 0 0 1 O
be VB 0 0 12 O
increased VBN 1 1 1 O
by IN 0 0 12 O
CRIXIVAN NNP 0 1 UNK B-Brand
. . 0 0 12 O

Although IN 0 0 12 O
no DT 0 0 12 O
specific JJ 0 1 1 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
topical JJ 0 1 6 O
glaucoma NN 0 1 6 O
drugs NNS 1 1 6 O
or CC 0 0 12 O
systemic JJ 0 1 6 O
medications NNS 1 1 6 O
were VBD 1 0 12 O
identified VBN 1 1 1 O
in IN 0 0 12 O
clinical JJ 0 1 6 O
studies NNS 1 1 1 O
of IN 0 0 12 O
IOPIDINE NNP 0 1 UNK B-Brand
9 CD 0 0 2 O
% NN 0 0 18 O
Ophthalmic NNP 0 1 7 O
Solution NNP 0 1 2 O
the DT 0 0 12 O
possibility NN 0 1 1 O
of IN 0 0 12 O
an DT 0 0 12 O
additive JJ 0 1 16 O
or CC 0 0 12 O
potentiating VBG 1 0 UNK O
effect NN 0 1 1 O
with IN 0 0 12 O
CNS NNP 0 1 6 B-Group
depressants NNS 1 0 13 I-Group
( ( 0 0 2 O
alcohol NN 0 1 1 B-Drug
barbiturates VBZ 0 1 14 B-Group
opiates VBZ 0 1 6 B-Group
sedatives NNS 1 1 6 B-Group
anesthetics NNS 1 1 13 B-Group
) ) 0 0 2 O
should MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
. . 0 0 12 O

No DT 0 0 2 O
data NN 0 1 1 O
for IN 0 0 12 O
saquinavir NN 0 1 13 B-Drug
. . 0 0 12 O

Ketamine NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
clinically RB 0 0 6 O
compatible JJ 0 1 1 O
with IN 0 0 12 O
the DT 0 0 12 O
commonly RB 0 0 UNK O
used VBN 1 1 12 O
general JJ 0 1 1 O
and CC 0 0 12 O
local JJ 0 1 12 O
anesthetic JJ 0 1 13 B-Group
agents NNS 1 1 1 I-Group
when WRB 0 0 12 O
an DT 0 0 12 O
adequate JJ 0 1 1 O
respiratory NN 0 1 6 O
exchange NN 0 1 1 O
is VBZ 1 0 12 O
maintained VBN 1 1 1 O
. . 0 0 12 O

Skeletal JJ 0 1 UNK B-Group
muscle NN 0 1 6 I-Group
relaxants NNS 1 0 13 I-Group
: : 0 0 2 O
amphotericin NN 0 1 14 B-Drug
B NNP 0 0 2 I-Drug
- : 0 0 2 O
induced JJ 0 1 6 O
hypokalemia NN 0 1 14 O
may MD 0 0 1 O
enhance VB 0 1 UNK O
the DT 0 0 12 O
curariform NN 0 1 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
skeletal JJ 0 1 13 B-Group
muscle NN 0 1 6 I-Group
relaxants NNS 1 0 13 I-Group
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
tubocurarine NN 0 1 UNK B-Drug
) ) 0 0 2 O
. . 0 0 12 O

Three CD 0 1 2 O
patients NNS 1 1 6 O
met VBD 1 1 12 O
ACR NNP 0 1 UNK O
criteria NNS 1 1 1 O
for IN 0 0 12 O
liver NN 0 1 6 O
biopsy NN 0 1 6 O
( ( 0 0 2 O
9 CD 0 0 2 O
: : 0 0 2 O
Roegnik NNP 0 0 UNK O
Grade NNP 0 1 2 O
I PRP 0 1 12 O
9 CD 0 0 2 O
: : 0 0 2 O
Roegnik NNP 0 0 UNK O
Grade NNP 0 1 2 O
IIIa NNP 0 0 UNK O
) ) 0 0 2 O
. . 0 0 12 O

Administration NN 0 1 UNK O
of IN 0 0 12 O
doxapram NN 0 1 UNK B-Drug
to TO 0 0 12 O
patients NNS 1 1 6 O
who WP 0 0 12 O
are VBP 1 0 12 O
receiving VBG 1 1 1 O
sympathomimetic JJ 0 1 13 B-Group
or CC 0 0 12 O
monoamine JJ 0 1 13 B-Group
oxidase NN 0 1 13 I-Group
inhibiting VBG 1 1 UNK I-Group
drugs NNS 1 1 6 I-Group
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
an DT 0 0 12 O
additive JJ 0 1 16 O
pressor NN 0 1 14 O
effect NN 0 1 1 O
. . 0 0 12 O

Dolasetron NNP 0 1 0 B-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
influence VB 0 0 UNK O
anesthesia JJ 0 1 6 O
recovery NN 0 1 1 O
time NN 0 1 12 O
in IN 0 0 12 O
patients NNS 1 1 6 O
. . 0 0 12 O

As IN 0 0 2 O
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
primarily RB 0 0 1 O
being VBG 1 0 12 O
metabolized VBN 1 1 UNK O
through IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
ingestion NN 0 1 14 O
of IN 0 0 12 O
grapefruit NN 0 1 3 O
or CC 0 0 12 O
grapefruit NN 0 1 3 O
juice NN 0 1 3 O
should MD 0 0 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
in IN 0 0 12 O
connection NN 0 1 1 O
with IN 0 0 12 O
budesonide JJ 0 1 16 B-Drug
administration NN 0 1 1 O
. . 0 0 12 O

Gabapentin NNP 0 1 0 B-Drug
pharmacokinetic JJ 0 1 UNK O
parameters NNS 1 1 1 O
without IN 0 0 12 O
and CC 0 0 12 O
with IN 0 0 12 O
probenecid NNS 0 1 13 B-Drug
were VBD 1 0 12 O
comparable JJ 0 0 1 O
. . 0 0 12 O

Because IN 0 0 12 O
a DT 0 0 12 O
similar JJ 0 1 1 O
interaction NN 0 1 UNK O
is VBZ 1 0 12 O
likely JJ 0 1 12 O
VIRACEPT NNP 0 1 UNK B-Brand
should MD 0 0 12 O
also RB 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
astemizole NN 0 1 UNK B-Drug
. . 0 0 12 O

meprobamate NN 0 1 UNK B-Drug
; : 0 0 2 O

There EX 0 0 12 O
were VBD 1 0 12 O
no DT 0 0 12 O
significant JJ 0 1 1 O
effects NNS 1 1 1 O
on IN 0 0 12 O
QTc NNP 0 0 14 O
intervals NNS 1 1 1 O
and CC 0 0 12 O
no DT 0 0 12 O
reports NNS 1 1 1 O
of IN 0 0 12 O
sedation NN 0 1 6 O
or CC 0 0 12 O
syncope NN 0 1 8 O
. . 0 0 12 O

In IN 0 0 2 O
rabbits NNS 1 1 UNK O
treated VBN 1 1 1 O
with IN 0 0 12 O
ezetimibe DT 0 1 16 B-Drug
an DT 0 0 12 O
increased JJ 0 1 1 O
incidence NN 0 1 6 O
of IN 0 0 12 O
extra JJ 0 0 3 O
thoracic NN 0 0 8 O
ribs NN 1 1 3 O
was VBD 1 0 12 O
observed VBN 1 1 1 O
at IN 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
/ NNP 0 0 2 O
day NN 0 1 12 O
( ( 0 0 2 O
9 CD 0 0 2 O
times NNS 1 1 12 O
the DT 0 0 12 O
human JJ 0 1 1 O
exposure NN 0 1 1 O
at IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
daily RB 0 1 12 O
based VBN 1 1 1 O
on IN 0 0 12 O
AUC9 NNP 0 0 UNK O
- : 0 0 2 O
9hr CD 0 0 UNK O
for IN 0 0 12 O
total JJ 0 1 1 O
ezetimibe NN 0 1 16 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

Concomitant JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
Sonata NNP 0 1 UNK B-Brand
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
) ) 0 0 2 O
and CC 0 0 12 O
cimetidine NN 0 1 13 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
) ) 0 0 2 O
produced VBD 1 0 1 O
an DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
increase NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
mean NN 0 1 12 O
Cmax NNP 0 1 UNK O
and CC 0 0 12 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
zaleplon NN 0 1 13 B-Drug
. . 0 0 12 O

ProAmatine NNP 0 1 UNK B-Brand
has VBZ 1 0 12 O
been VBN 1 0 12 O
used VBN 1 1 12 O
in IN 0 0 12 O
patients NNS 1 1 6 O
concomitantly RB 0 0 14 O
treated VBN 1 1 1 O
with IN 0 0 12 O
salt NN 0 1 3 O
- : 0 0 2 O
retaining VBG 1 1 1 O
steroid JJ 0 1 6 O
therapy NN 0 1 6 O
( ( 0 0 2 O
i.e. JJ 0 1 1 O
fludrocortisone NN 0 1 0 B-Drug
acetate NN 0 1 14 I-Drug
) ) 0 0 2 O
with IN 0 0 12 O
or CC 0 0 12 O
without IN 0 0 12 O
salt JJ 0 1 3 O
supplementation NN 0 1 14 O
. . 0 0 12 O

( ( 0 0 2 O
Both DT 0 0 2 O
drugs NNS 1 1 6 O
were VBD 1 0 12 O
thus RB 0 0 1 O
dosed VBN 1 1 14 O
to TO 0 0 12 O
steady JJ 0 1 1 O
state NN 0 1 1 O
. . 0 0 12 O
) ) 0 0 2 O

Poor NNP 0 1 2 O
metabolizers NNS 0 0 UNK O
have VBP 0 0 12 O
higher JJR 1 1 1 O
than IN 0 0 12 O
expected VBN 1 1 12 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
( ( 0 0 2 O
TCAs NNP 0 1 UNK B-Group
) ) 0 0 2 O
when WRB 0 0 12 O
given VBN 1 1 12 O
usual JJ 0 1 12 O
doses NNS 1 1 6 O
. . 0 0 12 O

Administration NN 0 1 UNK O
of IN 0 0 12 O
diltiazem JJ 0 1 0 B-Drug
hydrochloride NN 0 1 0 I-Drug
with IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
in IN 0 0 12 O
9 CD 0 0 2 O
healthy JJ 0 1 12 O
male JJ 0 1 12 O
subjects NNS 1 1 UNK O
increased VBD 1 1 1 O
plasma NN 0 1 14 O
digoxin NN 0 1 14 B-Drug
concentrations NNS 1 1 13 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

No DT 0 0 2 O
pharmacokinetic JJ 0 1 UNK O
interaction NN 0 1 UNK O
between IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
m9 NN 0 1 UNK O
ELOXATIN NNP 0 1 UNK B-Brand
and CC 0 0 12 O
infusional JJ 0 1 UNK O
9 CD 0 0 2 B-Drug
- : 0 0 2 O
FU NN 0 1 11 I-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
treated VBN 1 1 1 O
every DT 0 0 12 O
9 CD 0 0 2 O
weeks NNS 1 1 12 O
. . 0 0 12 O

The DT 0 0 2 O
mean JJ 0 1 12 O
QT NNP 0 1 13 O
c NN 0 0 16 O
interval NN 0 1 1 O
( ( 0 0 2 O
msec NN 0 1 14 O
) ) 0 0 2 O
was VBD 1 0 12 O
9 CD 0 0 2 O
with IN 0 0 12 O
terfenadine NN 0 1 UNK B-Drug
alone RB 0 1 12 O
and CC 0 0 12 O
9 CD 0 0 2 O
with IN 0 0 12 O
terfenadine JJ 0 1 UNK B-Drug
plus CC 0 1 16 O
dirithromycin NN 0 1 UNK B-Drug
. . 0 0 12 O

This DT 0 0 2 O
may MD 0 0 1 O
be VB 0 0 12 O
of IN 0 0 12 O
concern NN 0 1 1 O
for IN 0 0 12 O
drugs NNS 1 1 6 O
with IN 0 0 12 O
a DT 0 0 12 O
narrow JJ 0 1 3 O
therapeutic JJ 0 1 6 O
index NN 0 1 1 O
. . 0 0 12 O

Grapefruit NNP 0 1 UNK O
juice NN 0 1 3 O
increases NNS 1 1 1 O
ethinyl VBP 0 0 13 B-Drug
estradiol JJ 0 1 13 I-Drug
concentrations NNS 1 1 13 O
and CC 0 0 12 O
would MD 0 0 12 O
be VB 0 0 12 O
expected VBN 1 1 12 O
to TO 0 0 12 O
increase VB 0 1 1 O
progesterone NN 0 1 13 B-Drug
serum NN 0 1 14 O
levels NNS 1 1 1 O
as IN 1 0 12 O
well RB 0 1 12 O
; : 0 0 2 O

Phenytoin NN 0 1 0 B-Drug
: : 0 0 2 O
Altered NNP 0 1 13 O
serum NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
( ( 0 0 2 O
increased VBN 1 1 1 O
and CC 0 0 12 O
decreased VBN 1 1 1 O
) ) 0 0 2 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
concomitant JJ 0 1 6 O
ciprofloxacin NN 0 1 0 B-Drug
. . 0 0 12 O

Xigris JJ 0 1 UNK B-Brand
present NN 0 1 1 O
in IN 0 0 12 O
plasma NN 0 1 14 O
samples NNS 1 1 UNK O
does VBZ 1 0 12 O
not RB 0 1 12 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
one CD 0 1 12 O
- : 0 0 2 O
stage NN 0 1 12 O
factor NN 0 1 1 O
assays NNS 1 1 13 O
based VBN 1 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
PT NNP 0 1 2 O
( ( 0 0 2 O
such JJ 0 0 1 O
as IN 1 0 12 O
factor NN 0 1 1 O
II NNP 0 0 2 O
V NNP 0 0 2 O
VII NNP 0 1 2 O
and CC 0 0 12 O
X NNP 0 0 2 O
assays NNS 1 1 13 O
) ) 0 0 2 O
. . 0 0 12 O

Therefore IN 0 0 1 O
it PRP 0 0 12 O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
with IN 0 0 12 O
caution NN 0 0 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
such JJ 0 0 1 O
agents NNS 1 1 1 O
. . 0 0 12 O

Symptoms NNS 0 1 7 O
resolved VBD 1 1 1 O
within IN 0 0 1 O
a DT 0 0 12 O
few JJ 0 1 12 O
hours NNS 1 1 12 O
. . 0 0 12 O

The DT 0 0 2 O
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
Cmin NNP 0 1 UNK O
concentration NN 0 1 1 O
increased VBD 1 1 1 O
to TO 0 0 12 O
9 CD 0 0 2 O
micrograms NNS 1 1 14 O
/ VBP 0 0 2 O
mL NN 0 1 14 O
when WRB 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
of IN 0 0 12 O
felbamate NN 0 1 13 B-Drug
was VBD 1 0 12 O
coadministered VBN 0 0 UNK O
for IN 0 0 12 O
one CD 0 1 12 O
week NN 0 1 12 O
. . 0 0 12 O

Plasma NN 0 1 UNK O
exposure NN 0 1 1 O
( ( 0 0 2 O
AUC NNP 0 1 UNK O
) ) 0 0 2 O
to TO 0 0 12 O
valdecoxib VB 0 1 13 B-Drug
was VBD 1 0 12 O
increased VBN 1 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
when WRB 0 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
fluconazole NN 0 1 0 B-Drug
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
when WRB 0 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
ketoconazole NN 0 1 16 B-Drug
. . 0 0 12 O

Insulin NN 0 1 7 B-Drug
: : 0 0 2 O
A DT 0 0 2 O
clinical JJ 0 1 6 O
study NN 0 1 1 O
in IN 0 0 12 O
9 CD 0 0 2 O
insulin NN 0 1 14 O
- : 0 0 2 O
dependent JJ 0 1 1 O
diabetic JJ 0 1 6 O
patients NNS 1 1 6 O
demonstrated VBD 1 0 1 O
no DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
EXTRANEAL NNP 0 1 UNK B-Brand
on IN 0 0 12 O
insulin NN 0 1 14 B-Drug
absorption NN 0 1 1 O
from IN 0 0 12 O
the DT 0 0 12 O
peritoneal JJ 0 1 8 O
cavity NN 0 1 3 O
or CC 0 0 12 O
on IN 0 0 12 O
insulins NNS 1 1 13 B-Drug
ability NN 0 1 1 O
to TO 0 0 12 O
control VB 0 1 1 O
blood NN 0 1 6 O
glucose NN 0 1 14 O
when WRB 0 0 12 O
insulin NN 0 1 14 B-Drug
was VBD 1 0 12 O
administered VBN 1 1 1 O
intraperitoneally RB 0 0 UNK O
with IN 0 0 12 O
EXTRANEAL NNP 0 1 UNK B-Brand
. . 0 0 12 O

Bismuth NN 0 1 UNK B-Drug
: : 0 0 2 O
Bismuth NNP 0 1 UNK B-Drug
subsalicylate VB 0 0 16 I-Drug
given VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
enoxacin NN 0 1 UNK B-Drug
or CC 0 0 12 O
9 CD 0 0 2 O
minutes NNS 1 1 12 O
following VBG 1 1 1 O
enoxacin JJ 0 1 UNK B-Drug
administration NN 0 1 1 O
decreased VBD 1 1 1 O
enoxacin JJ 0 1 UNK B-Drug
bioavailability NN 0 1 UNK O
by IN 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

While IN 0 0 12 O
co SYM 0 1 12 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
ZAVESCA NNP 0 1 UNK B-Brand
appeared VBD 1 1 12 O
to TO 0 0 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
clearance NN 0 1 16 O
of IN 0 0 12 O
Cerezyme NNP 0 1 UNK B-Brand
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
these DT 0 0 12 O
results NNS 1 1 1 O
are VBP 1 0 12 O
not RB 0 1 12 O
conclusive JJ 0 1 UNK O
because IN 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
small JJ 0 1 12 O
number NN 0 1 1 O
of IN 0 0 12 O
subjects NNS 1 1 UNK O
studied VBN 1 0 1 O
and CC 0 0 12 O
because IN 0 0 12 O
patients NNS 1 1 6 O
took VBD 1 1 12 O
variable JJ 0 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
Cerezyme NNP 0 1 UNK B-Brand
. . 0 0 12 O

reduced VBN 1 1 1 O
dosage NN 0 1 0 O
of IN 0 0 12 O
digitalis NNS 0 1 14 B-Group
glycosides NNS 1 1 13 I-Group
may MD 0 0 1 O
be VB 0 0 12 O
required VBN 1 1 1 O
. . 0 0 12 O

Thiazide IN 0 1 UNK B-Group
Diuretics NNS 0 1 UNK I-Group
: : 0 0 2 O
The DT 0 0 2 O
reports NNS 1 1 1 O
that IN 0 0 12 O
the DT 0 0 12 O
concomitant NN 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
allopurinol NN 0 1 13 B-Drug
and CC 0 0 12 O
thiazide JJ 0 1 UNK B-Group
diuretics NNS 1 1 14 I-Group
may MD 0 0 1 O
contribute VB 0 1 UNK O
to TO 0 0 12 O
the DT 0 0 12 O
enhancement NN 0 1 1 O
of IN 0 0 12 O
allopurinol JJ 0 1 13 B-Drug
toxicity NN 0 1 6 O
in IN 0 0 12 O
some DT 0 0 12 O
patients NNS 1 1 6 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reviewed VBN 1 1 1 O
in IN 0 0 12 O
an DT 0 0 12 O
attempt NN 0 1 12 O
to TO 0 0 12 O
establish VB 0 1 UNK O
a DT 0 0 12 O
cause NN 0 1 12 O
- : 0 0 2 O
and CC 0 0 12 O
- : 0 0 2 O
effect NN 0 1 1 O
relationship NN 0 1 12 O
and CC 0 0 12 O
a DT 0 0 12 O
mechanism NN 0 1 13 O
of IN 0 0 12 O
causation NN 0 1 UNK O
. . 0 0 12 O

Plasma NNP 0 1 UNK O
concentrations NNS 1 1 13 O
increased VBN 1 1 1 O
by IN 0 0 12 O
SUSTIVA NNP 0 1 UNK B-Brand
( ( 0 0 2 O
efavirenz NN 0 1 13 B-Drug
) ) 0 0 2 O
; : 0 0 2 O

Co NNP 0 1 2 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
naltrexone NN 0 1 13 B-Drug
with IN 0 0 12 O
Acamprosate NNP 0 1 UNK B-Drug
produced VBD 1 0 1 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
increase NN 0 1 1 O
in IN 0 0 12 O
AUC NNP 0 1 UNK O
and CC 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
increase NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
Cmax NNP 0 1 UNK O
of IN 0 0 12 O
acamprosate NN 0 1 13 B-Drug
. . 0 0 12 O

If IN 0 0 12 O
a DT 0 0 12 O
diuretic NN 0 1 14 B-Group
is VBZ 1 0 12 O
also RB 0 0 12 O
used VBN 1 1 12 O
it PRP 0 0 12 O
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
lithium NN 0 1 16 B-Drug
toxicity NN 0 1 6 O
. . 0 0 12 O

Diuretics NNS 0 1 UNK B-Group
: : 0 0 2 O
Excessive JJ 0 1 UNK O
reductions NNS 1 1 1 O
in IN 0 0 12 O
blood NN 0 1 6 O
pressure NN 0 1 1 O
may MD 0 0 1 O
occur VB 0 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
on IN 0 0 12 O
diuretic JJ 0 1 14 O
therapy NN 0 1 6 O
when WRB 0 0 12 O
ACE NNP 0 1 13 B-Group
inhibitors NNS 1 1 14 I-Group
are VBP 1 0 12 O
started VBN 1 1 12 O
. . 0 0 12 O

Omniscan JJ 0 1 UNK B-Brand
interferes NNS 0 1 UNK O
with IN 0 0 12 O
serum JJ 0 1 14 O
calcium NN 0 1 14 O
measurements NNS 1 1 1 O
with IN 0 0 12 O
some DT 0 0 12 O
colorimetric NN 0 1 UNK O
( ( 0 0 2 O
complexometric JJ 0 0 UNK O
) ) 0 0 2 O
methods NNS 1 1 1 O
commonly RB 0 0 UNK O
used VBN 1 1 12 O
in IN 0 0 12 O
hospitals NNS 1 1 1 O
resulting VBG 1 1 1 O
in IN 0 0 12 O
serum NN 0 1 14 O
calcium NN 0 1 14 O
concentrations NNS 1 1 13 O
lower JJR 1 1 1 O
than IN 0 0 12 O
the DT 0 0 12 O
true JJ 0 1 12 O
values NNS 1 1 1 O
. . 0 0 12 O

Corticosteroids NNS 0 1 UNK B-Group
: : 0 0 2 O
Dexamethasone NN 0 1 0 B-Drug
: : 0 0 2 O
Aprepitant NN 0 1 UNK B-Drug
when WRB 0 0 12 O
given VBN 1 1 12 O
as IN 1 0 12 O
a DT 0 0 12 O
regimen NN 0 1 6 O
of IN 0 0 12 O
9mg CD 0 0 UNK O
with IN 0 0 12 O
dexamethasone NN 0 1 16 B-Drug
coadministered VBN 0 0 UNK O
orally RB 0 1 14 O
as IN 1 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
on IN 0 0 12 O
Day NNP 0 1 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
Aprepitant NNP 0 1 UNK B-Drug
when WRB 0 0 12 O
given VBN 1 1 12 O
as IN 1 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
with IN 0 0 12 O
dexamethasone NN 0 1 16 B-Drug
coadministered VBN 0 0 UNK O
orally RB 0 1 14 O
as IN 1 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
on IN 0 0 12 O
Days NNS 0 1 2 O
9 CD 0 0 2 O
through IN 0 0 12 O
9 CD 0 0 2 O
increased VBD 1 1 1 O
the DT 0 0 12 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
dexamethasone NN 0 1 16 B-Drug
a DT 0 0 12 O
CYP9A9 NNP 0 0 UNK O
substrate NN 0 1 UNK O
by IN 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
fold NN 0 1 3 O
on IN 0 0 12 O
Days NNP 0 1 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
. . 0 0 12 O

Recurrence NN 0 1 UNK O
of IN 0 0 12 O
skin JJ 0 1 3 O
reactions NNS 1 1 1 O
at IN 0 0 12 O
a DT 0 0 12 O
site NN 0 1 12 O
of IN 0 0 12 O
previous JJ 0 1 12 O
extravasation NN 0 1 8 O
following VBG 1 1 1 O
administration NN 0 1 1 O
of IN 0 0 12 O
TAXOL NNP 0 1 UNK B-Brand
at IN 0 0 12 O
a DT 0 0 12 O
different JJ 0 1 1 O
site NN 0 1 12 O
ie NN 0 0 1 O
recall NN 0 1 12 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
rarely RB 0 1 UNK O
. . 0 0 12 O

Medroxyprogesterone NN 0 1 UNK B-Drug
Acetate NNP 0 1 0 I-Drug
- : 0 0 2 O
L NNP 0 1 2 B-Drug
- : 0 0 2 O
histidine NN 0 1 13 I-Drug
was VBD 1 0 12 O
observed VBN 1 1 1 O
to TO 0 0 12 O
enhance VB 0 1 UNK O
( ( 0 0 2 O
in IN 0 0 12 O
tissue NN 0 1 6 O
culture NN 0 1 1 O
) ) 0 0 2 O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
medroxyprogesterone NN 0 1 16 B-Drug
acetate NN 0 1 14 I-Drug
in IN 0 0 12 O
reducing VBG 1 1 1 O
the DT 0 0 12 O
number NN 0 1 1 O
of IN 0 0 12 O
human JJ 0 1 1 O
breast NN 0 1 6 O
cancer NN 0 1 6 O
cells NNS 1 1 6 O
that WDT 0 0 12 O
were VBD 1 0 12 O
in IN 0 0 12 O
the DT 0 0 12 O
S NNP 0 1 2 O
phase NN 0 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
9 CD 0 0 2 O
other JJ 0 0 12 O
schizophrenic JJ 0 0 13 O
patients NNS 1 1 6 O
treated VBN 1 1 1 O
with IN 0 0 12 O
oral JJ 0 1 6 O
haloperidol NN 0 1 16 B-Drug
and CC 0 0 12 O
rifampin JJ 0 1 16 B-Drug
discontinuation NN 0 1 6 O
of IN 0 0 12 O
rifampin NN 0 1 16 B-Drug
produced VBD 1 0 1 O
a DT 0 0 12 O
mean JJ 0 1 12 O
9 CD 0 0 2 O
- : 0 0 2 O
fold JJ 0 1 3 O
increase NN 0 1 1 O
in IN 0 0 12 O
haloperidol JJ 0 1 16 B-Drug
concentrations NNS 1 1 13 O
. . 0 0 12 O

Promethazine NN 0 1 0 B-Drug
: : 0 0 2 O
Coadministration NN 0 1 UNK O
of IN 0 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
zaleplon NN 0 1 13 B-Drug
and CC 0 0 12 O
promethazine NN 0 1 16 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
respectively RB 0 0 1 O
) ) 0 0 2 O
resulted VBD 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
decrease NN 0 1 1 O
in IN 0 0 12 O
maximal JJ 0 1 1 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
zaleplon NN 0 1 13 B-Drug
but CC 0 0 12 O
no DT 0 0 12 O
change NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
area NN 0 1 12 O
under IN 0 0 12 O
the DT 0 0 12 O
plasma NN 0 1 14 O
concentration NN 0 1 1 O
- : 0 0 2 O
time NN 0 1 12 O
curve NN 0 1 13 O
. . 0 0 12 O

Digitalis NNS 0 1 15 B-Group
: : 0 0 2 O
Vitamin NNP 0 1 2 B-Group
D NNP 0 1 2 I-Group
dosage NN 0 1 0 O
must MD 0 0 12 O
be VB 0 0 12 O
determined VBN 1 1 1 O
with IN 0 0 12 O
care NN 0 1 12 O
in IN 0 0 12 O
patients NNS 1 1 6 O
undergoing VBG 1 0 6 O
treatment NN 0 1 6 O
with IN 0 0 12 O
digitalis NN 0 1 14 B-Group
as IN 1 0 12 O
hypercalcemia NN 0 1 8 O
in IN 0 0 12 O
such JJ 0 0 1 O
patients NNS 1 1 6 O
may MD 0 0 1 O
precipitate VB 0 1 13 O
cardiac JJ 0 1 6 O
arrhythmias NN 1 1 6 O
. . 0 0 12 O

Drug NN 0 1 2 O
Interactions NNS 0 1 UNK O
: : 0 0 2 O
Flupenthixol NNP 0 1 UNK B-Drug
may MD 0 0 1 O
interact VB 0 0 UNK O
with IN 0 0 12 O
some DT 0 0 12 O
drugs NNS 1 1 6 O
like IN 0 0 12 O
Monoamine NNP 0 1 UNK B-Group
oxidase NN 0 1 13 I-Group
inhibitors NNS 1 1 14 I-Group
( ( 0 0 2 O
MAOI NNP 0 1 UNK B-Group
) ) 0 0 2 O
: : 0 0 2 O
MAOI NN 0 1 UNK B-Group
could MD 0 0 12 O
theoretically RB 0 0 UNK O
affect VB 0 1 1 O
flupenthixol NN 0 1 UNK B-Drug
pharmacodynamics NNS 0 1 UNK O
- : 0 0 2 O
Arecoline NNP 0 1 UNK B-Drug_n
- : 0 0 2 O
Eproxindine NNP 0 1 UNK O
- : 0 0 2 O
Ethanol NN 0 1 13 B-Drug
: : 0 0 2 O
Flupenthixol NNP 0 1 UNK B-Drug
and CC 0 0 12 O
Ethanol NNP 0 1 13 B-Drug
cause VBP 0 1 12 O
additive JJ 0 1 16 O
CNS NNP 0 1 6 O
depression NN 0 1 6 O
- : 0 0 2 O
Tricyclic JJ 0 0 UNK B-Group
antidepressants NNS 1 1 13 I-Group
: : 0 0 2 O
Flupenthixol NNP 0 1 UNK B-Drug
increases VBZ 1 1 1 O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
Tricyclic NNP 0 0 UNK B-Group
antidepressants NNS 1 1 13 I-Group

Lamivudine NNP 0 1 UNK B-Drug
and CC 0 0 12 O
zalcitabine NN 0 1 UNK B-Drug
may MD 0 0 1 O
inhibit VB 0 1 13 O
the DT 0 0 12 O
intracellular JJ 0 1 UNK O
phosphorylation NN 0 1 UNK O
of IN 0 0 12 O
one CD 0 1 12 O
another DT 0 0 12 O
. . 0 0 12 O

The DT 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
local JJ 0 1 12 O
anesthetic JJ 0 1 13 B-Group
solutions NNS 1 1 UNK I-Group
containing VBG 1 1 1 O
epinephrine NN 0 1 14 B-Drug
or CC 0 0 12 O
norepinephrine NN 0 1 14 B-Drug
to TO 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
monoamine JJ 0 1 13 B-Group
oxidase NN 0 1 13 I-Group
inhibitors NNS 1 1 14 I-Group
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
or CC 0 0 12 O
phenothiazines NNS 1 1 UNK B-Group
may MD 0 0 1 O
produce VB 0 0 1 O
severe JJ 0 1 6 O
prolonged VBN 1 1 6 O
hypotension NN 0 1 6 O
or CC 0 0 12 O
hypertension NN 0 1 6 O
. . 0 0 12 O

Drugs NNS 0 1 2 O
Metabolized VBN 0 1 UNK O
by IN 0 0 12 O
CYP9D9 NNP 0 0 UNK O
: : 0 0 2 O
Duloxetine NN 0 1 0 B-Drug
is VBZ 1 0 12 O
a DT 0 0 12 O
moderate JJ 0 1 1 O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
CYP9D9 NNP 0 0 UNK O
. . 0 0 12 O

If IN 0 0 12 O
used VBN 1 1 12 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
saquinavir JJ 0 1 13 B-Drug
hard JJ 0 1 12 O
gelatin NN 0 1 UNK O
capsules NNS 1 1 3 O
at IN 0 0 12 O
the DT 0 0 12 O
recommended JJ 0 1 1 O
dose NN 0 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
tid JJ 0 1 13 O
no DT 0 0 12 O
dose JJ 0 1 6 O
adjustments NNS 1 1 1 O
are VBP 1 0 12 O
needed VBN 1 1 12 O
. . 0 0 12 O

However RB 0 0 1 O
caution NN 0 0 1 O
must MD 0 0 12 O
be VB 0 0 12 O
exercised VBN 1 1 1 O
in IN 0 0 12 O
extrapolating VBG 1 0 UNK O
these DT 0 0 12 O
findings NNS 1 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
clinical JJ 0 1 6 O
situation NN 0 0 12 O
and CC 0 0 12 O
in IN 0 0 12 O
the DT 0 0 12 O
use NN 0 1 1 O
of IN 0 0 12 O
glipizide NN 0 1 0 B-Drug
with IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
risk NN 0 1 1 O
of IN 0 0 12 O
myopathy JJ 0 1 8 O
during IN 0 0 12 O
treatment NN 0 1 6 O
with IN 0 0 12 O
drugs NNS 1 1 6 O
of IN 0 0 12 O
this DT 0 0 12 O
class NN 0 1 12 O
is VBZ 1 0 12 O
increased VBN 1 1 1 O
with IN 0 0 12 O
concurrent JJ 0 1 1 O
administration NN 0 1 1 O
of IN 0 0 12 O
cyclosporine JJ 0 1 14 B-Drug
fibric JJ 0 0 UNK B-Group
acid NN 0 1 14 I-Group
derivatives NNS 1 1 13 I-Group
niacin VBP 0 1 14 B-Drug
( ( 0 0 2 O
nicotinic JJ 0 1 13 B-Drug
acid NN 0 1 14 I-Drug
) ) 0 0 2 O
erythromycin VBZ 0 1 0 B-Drug
azole JJ 0 1 UNK B-Group
antifungals NNS 1 1 UNK I-Group
. . 0 0 12 O

If IN 0 0 12 O
you PRP 0 0 12 O
are VBP 1 0 12 O
9 CD 0 0 2 O
years NNS 1 1 12 O
of IN 0 0 12 O
age NN 0 1 12 O
or CC 0 0 12 O
older JJR 1 1 12 O
ask VB 0 0 12 O
your PRP$ 0 0 12 O
physician NN 0 1 6 O
to TO 0 0 12 O
check VB 0 1 12 O
your PRP$ 0 0 12 O
B9 NNP 0 0 UNK O
status NN 0 1 1 O
before IN 0 1 12 O
you PRP 0 0 12 O
take VBP 0 1 12 O
a DT 0 0 12 O
supplement NN 0 1 1 O
that WDT 0 0 12 O
contains VBZ 1 1 1 O
folic JJ 0 0 14 B-Drug
acid NN 0 1 14 I-Drug
. . 0 0 12 O

Pilocarpine NN 0 1 0 B-Drug
might MD 0 0 12 O
antagonize VB 0 0 UNK O
the DT 0 0 12 O
anticholinergic JJ 0 1 13 O
effects NNS 1 1 1 O
of IN 0 0 12 O
drugs NNS 1 1 6 O
used VBN 1 1 12 O
concomitantly RB 0 0 14 O
. . 0 0 12 O

Thyroid NNP 0 1 7 O
Physiology NNP 0 1 UNK O
: : 0 0 2 O
The DT 0 0 2 O
following JJ 0 1 1 O
agents NNS 1 1 1 O
may MD 0 0 1 O
alter VB 0 1 13 O
thyroid VB 0 1 6 O
hormone NN 0 1 6 O
or CC 0 0 12 O
TSH NN 0 0 14 O
levels NNS 1 1 1 O
generally RB 0 0 1 O
by IN 0 0 12 O
effects NNS 1 1 1 O
on IN 0 0 12 O
thyroid NN 0 1 6 O
hormone NN 0 1 6 O
synthesis NN 0 1 UNK O
secretion NN 0 1 14 O
distribution NN 0 1 1 O
metabolism NN 0 1 16 O
hormone CD 0 1 6 O
action NN 0 1 13 O
or CC 0 0 12 O
elimination NN 0 1 UNK O
or CC 0 0 12 O
altered VBN 1 1 1 O
TSH NNP 0 0 14 O
secretion NN 0 1 14 O
: : 0 0 2 O
aminoglutethimide NN 0 1 UNK B-Drug
p IN 0 1 2 B-Drug
- : 0 0 2 O
aminosalicylic JJ 0 0 UNK I-Drug
acid VBP 0 1 14 I-Drug
amiodarone NN 0 1 0 B-Drug
androgens NNS 1 1 13 B-Group
and CC 0 0 12 O
related JJ 0 1 1 O
anabolic JJ 0 1 13 O
hormones NNS 1 1 13 O
complex JJ 0 1 1 O
anions NNS 1 1 UNK O
( ( 0 0 2 O
thiocyanate VB 0 1 UNK B-Drug
perchlorate NN 0 1 UNK B-Drug
pertechnetate NN 0 1 UNK B-Drug
) ) 0 0 2 O
antithyroid NN 0 0 13 B-Group
drugs NNS 1 1 6 I-Group
b SYM 0 0 16 B-Group
- : 0 0 2 O
adrenergic JJ 0 1 UNK I-Group
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
carbamazepine JJ 0 1 16 B-Drug
chloral JJ 0 1 16 B-Drug
hydrate NN 0 1 16 I-Drug
diazepam NN 0 1 0 B-Drug
dopamine NN 0 1 14 B-Drug
and CC 0 0 12 O
dopamine NN 0 1 14 B-Group
agonists NNS 1 1 UNK I-Group
ethionamide VBP 0 1 UNK B-Drug
glucocorticoids NNS 1 1 UNK B-Group
heparin RBR 0 1 14 B-Drug
hepatic JJ 0 1 14 O
enzyme NN 0 1 14 O
inducers NNS 1 1 UNK O
insulin VBP 0 1 14 B-Drug
iodinated JJ 0 0 UNK O
cholestographic JJ 0 0 UNK O
agents NNS 1 1 1 O
iodine JJ 0 1 14 B-Group
- : 0 0 2 O
containing VBG 1 1 1 I-Group
compounds NNS 1 1 13 I-Group
levodopa JJ 0 1 UNK B-Drug
lovastatin JJ 0 1 13 B-Drug
lithium NN 0 1 16 B-Drug
9 CD 0 0 2 B-Drug
- : 0 0 2 O
mercaptopurine NN 0 1 13 I-Drug
metoclopramide IN 0 1 16 B-Drug
mitotane NN 0 1 13 B-Drug
nitroprusside IN 0 1 14 B-Drug
phenobarbital JJ 0 1 16 B-Drug
phenytoin NN 0 1 16 B-Drug
resorcinol NN 0 1 UNK B-Drug
rifampin NN 0 1 16 B-Drug
somatostatin NN 0 1 14 B-Group
analogs NNS 1 1 UNK I-Group
sulfonamides VBZ 0 1 13 B-Group
sulfonylureas JJ 0 1 UNK B-Group
thiazide IN 0 1 UNK B-Group
diuretics NNS 1 1 14 I-Group
. . 0 0 12 O

Anticoagulation NN 0 1 7 O
and CC 0 0 12 O
Antiplatelets NNS 0 0 UNK B-Group
After IN 0 0 2 O
Treatment NNP 0 1 7 O
for IN 0 0 12 O
Myocardial NNP 0 1 7 O
Infarction NNP 0 1 7 O
- : 0 0 2 O
- : 0 0 2 O
In IN 0 0 2 O
the DT 0 0 12 O
treatment NN 0 1 6 O
of IN 0 0 12 O
acute JJ 0 1 6 O
myocardial JJ 0 1 6 O
infarction NN 0 1 6 O
the DT 0 0 12 O
use NN 0 1 1 O
of IN 0 0 12 O
aspirin NN 0 1 14 B-Brand
has VBZ 1 0 12 O
been VBN 1 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
reduce VB 0 0 1 O
the DT 0 0 12 O
incidence NN 0 1 6 O
of IN 0 0 12 O
reinfarction NN 0 0 UNK O
and CC 0 0 12 O
stroke NN 0 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
effects NNS 1 1 1 O
of IN 0 0 12 O
prior JJ 0 1 1 O
use NN 0 1 1 O
of IN 0 0 12 O
diphosphonates NNS 0 1 UNK B-Group
in IN 0 0 12 O
postmenopausal JJ 0 1 6 O
osteoporosis NN 0 1 6 O
patients NNS 1 1 6 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
assessed VBN 1 1 1 O
; : 0 0 2 O

9 CD 0 0 2 O
. . 0 0 12 O

Cyclosporine NN 0 1 UNK B-Drug

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interactions NNP 0 1 UNK O
None NNP 0 0 2 O
known VBN 1 1 12 O
. . 0 0 12 O

Diuretics NNS 0 1 UNK B-Group
: : 0 0 2 O
Furosemide NNP 0 1 0 B-Drug
and CC 0 0 12 O
probably RB 0 1 12 O
other JJ 0 0 12 O
loop JJ 0 1 3 B-Group
diuretics NNS 1 1 14 I-Group
given VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
metolazone NN 0 1 16 B-Drug
can MD 0 0 12 O
cause VB 0 1 12 O
unusually RB 0 0 1 O
large JJ 0 1 3 O
or CC 0 0 12 O
prolonged JJ 0 1 6 O
losses NNS 1 1 1 O
of IN 0 0 12 O
fluid NN 0 1 3 O
and CC 0 0 12 O
electrolytes NNS 1 1 14 O
. . 0 0 12 O

Conversely RB 0 0 UNK O
the DT 0 0 12 O
coumarin NN 0 1 UNK B-Group
anticoagulants NNS 1 1 13 I-Group
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
serum NN 0 1 14 O
levels NNS 1 1 1 O
and CC 0 0 12 O
prolong VB 0 0 13 O
the DT 0 0 12 O
serum NN 0 1 14 O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
of IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
by IN 0 0 12 O
inhibiting VBG 1 1 UNK O
its PRP$ 1 0 12 O
metabolism NN 0 1 16 O
. . 0 0 12 O

In IN 0 0 2 O
addition NN 0 1 1 O
certain JJ 0 1 1 O
drugs NNS 1 1 6 O
inhibit VBP 0 1 13 O
the DT 0 0 12 O
activity NN 0 1 1 O
of IN 0 0 12 O
this DT 0 0 12 O
isozyme NN 0 1 UNK O
and CC 0 0 12 O
make VB 0 1 12 O
normal JJ 0 1 1 O
metabolizers NNS 0 0 UNK O
resemble JJ 0 0 UNK O
p.o NN 0 1 UNK O
. . 0 0 12 O

HCTZ $ 0 1 0 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
QD NNP 0 1 13 O
or CC 0 0 12 O
HCTZ NNP 0 1 0 B-Drug
/ NNP 0 0 2 O
triamterene VBD 0 1 13 B-Drug
9 CD 0 0 2 O
/ JJ 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
QD NNP 0 1 13 O
was VBD 1 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
with IN 0 0 12 O
TIKOSYN NNP 0 1 UNK B-Brand
( ( 0 0 2 O
9 CD 0 0 2 O
mcg RB 0 1 0 O
BID NNP 0 0 11 O
) ) 0 0 2 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
( ( 0 0 2 O
following VBG 1 1 1 O
9 CD 0 0 2 O
days NNS 1 1 12 O
of IN 0 0 12 O
diuretic JJ 0 1 14 B-Group
use NN 0 1 1 O
at IN 0 0 12 O
half PDT 0 1 12 O
dose JJ 0 1 6 O
) ) 0 0 2 O
. . 0 0 12 O

pregnancies NNS 1 1 6 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
. . 0 0 12 O

There EX 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
rare JJ 0 1 12 O
postmarketing VBG 0 0 UNK O
reports NNS 1 1 1 O
of IN 0 0 12 O
rhabdomyolysis NN 0 1 8 O
some DT 0 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
strenuous JJ 0 0 1 O
physical JJ 0 1 1 O
activity NN 0 1 1 O
. . 0 0 12 O

Maprotiline NN 0 1 UNK B-Drug
: : 0 0 2 O
Risk NN 0 1 2 O
of IN 0 0 12 O
cardiac JJ 0 1 6 O
arrhythmias NN 1 1 6 O
may MD 0 0 1 O
increase VB 0 1 1 O
. . 0 0 12 O

Antihypertensive JJ 0 1 7 O
effects NNS 1 1 1 O
of IN 0 0 12 O
guanethidine NN 0 1 UNK B-Drug
and CC 0 0 12 O
related JJ 0 1 1 O
compounds NNS 1 1 13 O
may MD 0 0 1 O
be VB 0 0 12 O
counteracted VBN 1 0 UNK O
when WRB 0 0 12 O
phenothiazines NNS 1 1 UNK B-Group
are VBP 1 0 12 O
used VBN 1 1 12 O
concomitantly RB 0 0 14 O
. . 0 0 12 O

Co NNP 0 1 2 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
atorvastatin NN 0 1 0 B-Drug
resulted VBN 1 1 1 O
in IN 0 0 12 O
about IN 0 1 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
increase NN 0 1 1 O
in IN 0 0 12 O
aliskiren JJ 0 1 13 B-Drug
Cmax NNP 0 1 UNK O
and CC 0 0 12 O
AUC NNP 0 1 UNK O
after IN 0 0 12 O
multiple JJ 0 1 1 O
dosing NN 0 0 14 O
. . 0 0 12 O

The DT 0 0 2 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
rimantadine NN 0 1 13 B-Drug
were VBD 1 0 12 O
assessed VBN 1 1 1 O
on IN 0 0 12 O
days NNS 1 1 12 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
. . 0 0 12 O

An DT 0 0 2 O
individual NN 0 1 1 O
who WP 0 0 12 O
is VBZ 1 0 12 O
stable JJ 0 1 1 O
on IN 0 0 12 O
a DT 0 0 12 O
given VBN 1 1 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
TCA NNP 0 1 13 B-Group
may MD 0 0 1 O
become VB 0 0 12 O
abruptly RB 0 0 UNK O
toxic JJ 0 1 1 O
when WRB 0 0 12 O
given VBN 1 1 12 O
one CD 0 1 12 O
of IN 0 0 12 O
these DT 0 0 12 O
inhibiting VBG 1 1 UNK O
drugs NNS 1 1 6 O
as IN 1 0 12 O
concomitant NN 0 1 6 O
therapy NN 0 1 6 O
. . 0 0 12 O

However RB 0 0 1 O
under IN 0 0 12 O
certain JJ 0 1 1 O
circumstances NNS 1 0 1 O
e.g. VBP 0 0 UNK O
as IN 1 0 12 O
prophylaxis NN 0 1 6 O
after IN 0 0 12 O
myocardial JJ 0 1 6 O
infarction NN 0 1 6 O
there EX 0 0 12 O
may MD 0 0 1 O
be VB 0 0 12 O
no DT 0 0 12 O
acceptable JJ 0 1 1 O
alternatives NNS 1 1 UNK O
to TO 0 0 12 O
the DT 0 0 12 O
use NN 0 1 1 O
of IN 0 0 12 O
beta NN 0 1 16 B-Group
- : 0 0 2 O
blockers NNS 1 0 6 I-Group
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
COPD NNP 0 1 6 O
. . 0 0 12 O

In IN 0 0 2 O
the DT 0 0 12 O
presence NN 0 1 1 O
of IN 0 0 12 O
these DT 0 0 12 O
methylxanthines NNS 0 1 UNK B-Group
larger JJR 1 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
adenosine NN 0 1 14 B-Drug
may MD 0 0 1 O
be VB 0 0 12 O
required VBN 1 1 1 O
or CC 0 0 12 O
adenosine VB 0 1 14 B-Drug
may MD 0 0 1 O
not RB 0 1 12 O
be VB 0 0 12 O
effective JJ 0 1 1 O
. . 0 0 12 O

Coadministration NN 0 1 UNK O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
have VB 0 0 12 O
effects NNS 1 1 1 O
on IN 0 0 12 O
either CC 0 1 12 O
the DT 0 0 12 O
safety NN 0 1 1 O
or CC 0 0 12 O
efficacy NN 0 1 UNK O
of IN 0 0 12 O
ibutilide NN 0 1 14 B-Drug
in IN 0 0 12 O
the DT 0 0 12 O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
. . 0 0 12 O

If IN 0 0 12 O
SPRYCEL NNP 0 1 UNK B-Brand
must MD 0 0 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
a DT 0 0 12 O
CYP9A9 NNP 0 0 UNK O
inducer NN 0 1 UNK O
a DT 0 0 12 O
dose JJ 0 1 6 O
increase NN 0 1 1 O
in IN 0 0 12 O
SPRYCEL NNP 0 1 UNK B-Brand
should MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
. . 0 0 12 O

Pressor NNP 0 1 UNK O
amines NNS 1 1 13 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
norepinephrine NN 0 1 14 B-Drug
) ) 0 0 2 O
: : 0 0 2 O
possible JJ 0 1 1 O
decreased JJ 0 1 1 O
response NN 0 1 1 O
to TO 0 0 12 O
pressor VB 0 1 14 O
amines NNS 1 1 13 O
but CC 0 0 12 O
not RB 0 1 12 O
sufficient JJ 0 1 1 O
to TO 0 0 12 O
preclude VB 0 0 UNK O
their PRP$ 0 0 12 O
use NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
concurrent JJ 0 1 1 O
administration NN 0 1 1 O
of IN 0 0 12 O
potent JJ 0 1 UNK O
inhalational JJ 0 1 14 O
agents NNS 1 1 1 O
( ( 0 0 2 O
eg JJ 0 1 UNK O
isoflurane NN 0 1 UNK B-Drug
enflurane NN 0 1 UNK B-Drug
and CC 0 0 12 O
halothane NN 0 1 13 B-Drug
) ) 0 0 2 O
during IN 0 0 12 O
maintenance NN 0 1 1 O
with IN 0 0 12 O
DIPRIVAN NNP 0 1 UNK B-Brand
Injectable NNP 0 1 UNK O
Emulsion NNP 0 1 UNK O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
extensively RB 0 0 1 O
evaluated VBN 1 1 1 O
. . 0 0 12 O

Nonetheless RB 0 0 1 O
individual JJ 0 1 1 O
patients NNS 1 1 6 O
may MD 0 0 1 O
require VB 0 0 1 O
additional JJ 0 1 1 O
titration NN 0 1 14 O
of IN 0 0 12 O
their PRP$ 0 0 12 O
theophylline NN 0 1 16 B-Drug
dosage NN 0 1 0 O
when WRB 0 0 12 O
lansoprazole NN 0 1 16 B-Drug
is VBZ 1 0 12 O
started VBN 1 1 12 O
or CC 0 0 12 O
stopped VBN 1 1 12 O
to TO 0 0 12 O
ensure VB 0 1 1 O
clinically RB 0 0 6 O
effective JJ 0 1 1 O
blood NN 0 1 6 O
levels NNS 1 1 1 O
. . 0 0 12 O

Terbinafine NN 0 1 UNK B-Drug
increases VBZ 1 1 1 O
the DT 0 0 12 O
clearance NN 0 1 16 O
of IN 0 0 12 O
cyclosporine NN 0 1 14 B-Drug
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

Ergot NNP 0 1 UNK B-Group
Derivatives NNS 0 1 UNK I-Group
: : 0 0 2 O
Dihydroergotamine NNP 0 1 UNK B-Drug
ergonovine VBP 0 1 UNK B-Drug
ergotamine JJ 0 1 UNK B-Drug
methylergonovine NN 0 1 16 B-Drug
CONTRAINDICATED NNP 0 1 UNK O
due JJ 0 1 1 O
to TO 0 0 12 O
potential JJ 0 1 1 O
for IN 0 0 12 O
serious JJ 0 1 12 O
and CC 0 0 12 O
life NN 0 1 12 O
- : 0 0 2 O
threatening VBG 1 0 12 O
reactions NNS 1 1 1 O
such JJ 0 0 1 O
as IN 1 0 12 O
acute JJ 0 1 6 O
ergot FW 0 1 UNK B-Group
toxicity NN 0 1 6 O
characterized VBN 1 1 1 O
by IN 0 0 12 O
peripheral JJ 0 1 6 O
vasospasm NN 0 1 8 O
and CC 0 0 12 O
ischemia NN 0 1 8 O
of IN 0 0 12 O
the DT 0 0 12 O
extremities NNS 1 1 6 O
and CC 0 0 12 O
other JJ 0 0 12 O
tissues NNS 1 1 6 O
. . 0 0 12 O

Because IN 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
danger NN 0 0 UNK O
of IN 0 0 12 O
a DT 0 0 12 O
potentially RB 0 0 1 O
fatal JJ 0 1 13 O
prolongation NN 0 1 6 O
of IN 0 0 12 O
the DT 0 0 12 O
QTc NNP 0 0 14 O
interval JJ 0 1 1 O
halofantrine NN 0 1 UNK B-Drug
must MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
given VBN 1 1 12 O
simultaneously RB 0 1 13 O
with IN 0 0 12 O
or CC 0 0 12 O
subsequent JJ 0 1 1 O
to TO 0 0 12 O
Mefloquine NNP 0 1 UNK B-Drug
. . 0 0 12 O

Other JJ 0 0 2 O
concomitant JJ 0 1 6 O
therapies NNS 1 1 6 O
: : 0 0 2 O
In IN 0 0 2 O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
the DT 0 0 12 O
safety NN 0 1 1 O
profile NN 0 1 1 O
in IN 0 0 12 O
subjects NNS 1 1 UNK O
treated VBN 1 1 1 O
with IN 0 0 12 O
Acamprosate NNP 0 1 UNK B-Drug
concomitantly RB 0 0 14 O
with IN 0 0 12 O
anxiolytics NNS 1 1 UNK B-Group
hypnotics NNS 1 1 13 B-Group
and CC 0 0 12 O
sedatives NNS 1 1 6 B-Group
( ( 0 0 2 O
including VBG 1 1 1 O
benzodiazepines NNS 1 1 14 B-Group
) ) 0 0 2 O
or CC 0 0 12 O
non JJ 0 1 1 B-Group
- : 0 0 2 O
opioid NN 0 1 13 I-Group
analgesics NNS 1 1 14 I-Group
was VBD 1 0 12 O
similar JJ 0 1 1 O
to TO 0 0 12 O
that DT 0 0 12 O
of IN 0 0 12 O
subjects NNS 1 1 UNK O
taking VBG 1 0 12 O
placebo NN 0 1 13 O
with IN 0 0 12 O
these DT 0 0 12 O
concomitant JJ 0 1 6 O
medications NNS 1 1 6 O
. . 0 0 12 O

Most JJS 0 0 2 O
events NNS 1 1 12 O
were VBD 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
occur VB 0 1 1 O
when WRB 0 0 12 O
contrast NN 0 1 1 O
media NNS 1 1 1 O
was VBD 1 0 12 O
given VBN 1 1 12 O
within IN 0 0 1 O
9 CD 0 0 2 O
weeks NNS 1 1 12 O
after IN 0 0 12 O
the DT 0 0 12 O
last JJ 0 1 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
interleukin JJ 0 1 13 B-Drug
- : 0 0 2 O
9 CD 0 0 2 I-Drug
. . 0 0 12 O

The DT 0 0 2 O
daily JJ 0 1 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
dexamethasone NN 0 1 16 B-Drug
administered VBN 1 1 1 O
in IN 0 0 12 O
clinical JJ 0 1 6 O
studies NNS 1 1 1 O
with IN 0 0 12 O
Aprepitant NNP 0 1 UNK B-Drug
reflects VBZ 1 1 UNK O
an DT 0 0 12 O
approximate JJ 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
reduction NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
dexamethasone NN 0 1 16 B-Drug
. . 0 0 12 O

. . 0 0 12 O

When WRB 0 0 12 O
administering VBG 1 1 1 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
concurrently RB 0 0 1 O
one CD 0 1 12 O
should MD 0 0 12 O
be VB 0 0 12 O
alert VBN 0 1 12 O
for IN 0 0 12 O
possible JJ 0 1 1 O
excessive JJ 0 1 1 O
phenytoin NN 0 1 16 B-Drug
effect NN 0 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
addition NN 0 1 1 O
other JJ 0 0 12 O
quinolones NNS 0 1 13 B-Group
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
decrease VB 0 1 1 O
the DT 0 0 12 O
CYP9A9 NNP 0 0 UNK O
- : 0 0 2 O
mediated VBD 1 1 13 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
cyclosporine NN 0 1 14 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
acceleration NN 0 1 UNK O
of IN 0 0 12 O
gastric JJ 0 1 6 O
emptying NN 0 1 13 O
by IN 0 0 12 O
cisapride NN 0 1 UNK B-Drug
could MD 0 0 12 O
affect VB 0 1 1 O
the DT 0 0 12 O
rate NN 0 1 1 O
of IN 0 0 12 O
absorption NN 0 1 1 O
of IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
not RB 0 1 12 O
known VBN 1 1 12 O
whether IN 0 0 12 O
the DT 0 0 12 O
concurrent NN 0 1 1 O
use NN 0 1 1 O
of IN 0 0 12 O
these DT 0 0 12 O
agents NNS 1 1 1 O
with IN 0 0 12 O
apraclonidine NN 0 1 16 B-Drug
can MD 0 0 12 O
lead VB 0 1 12 O
to TO 0 0 12 O
a DT 0 0 12 O
reduction NN 0 1 1 O
in IN 0 0 12 O
IOP NNP 0 1 UNK O
lowering VBG 1 1 UNK O
effect NN 0 1 1 O
. . 0 0 12 O

A DT 0 0 2 O
drug NN 0 1 1 O
- : 0 0 2 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
study NN 0 1 1 O
evaluated VBD 1 1 1 O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
use NN 0 1 1 O
of IN 0 0 12 O
ACZONE NNP 0 1 UNK B-Brand
Gel NNP 0 1 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
double JJ 0 1 3 O
strength NN 0 1 1 O
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ VBD 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
) ) 0 0 2 O
trimethoprim NN 0 1 16 B-Drug
/ JJ 0 0 2 O
sulfamethoxazole NN 0 1 13 B-Drug
( ( 0 0 2 O
TMP NNP 0 0 UNK B-Drug
/ NNP 0 0 2 O
SMX NNP 0 1 UNK B-Drug
) ) 0 0 2 O
. . 0 0 12 O

Although IN 0 0 12 O
specific JJ 0 1 1 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
in IN 0 0 12 O
HIV NNP 0 1 6 O
- : 0 0 2 O
9 CD 0 0 2 O
seropositive JJ 0 1 UNK O
subjects NNS 1 1 UNK O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
conducted VBN 1 1 1 O
for IN 0 0 12 O
the DT 0 0 12 O
classes NNS 1 1 UNK O
of IN 0 0 12 O
drugs NNS 1 1 6 O
listed VBN 1 1 1 O
in IN 0 0 12 O
Table JJ 0 1 UNK O
9 CD 0 0 2 O
additional JJ 0 1 1 O
clinical JJ 0 1 6 O
monitoring NN 0 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
warranted VBN 1 0 1 O
when WRB 0 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
administering VBG 1 1 1 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

However RB 0 0 1 O
in IN 0 0 12 O
vivo JJ 0 1 13 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
of IN 0 0 12 O
ketoconazole NN 0 1 16 B-Drug
with IN 0 0 12 O
vitamin NN 0 1 6 B-Group
D NNP 0 1 2 I-Group
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
investigated VBN 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
gradual JJ 0 1 1 O
withdrawal NN 0 1 1 O
of IN 0 0 12 O
guafacine NN 0 0 UNK B-Drug
or CC 0 0 12 O
a DT 0 0 12 O
cardioselective JJ 0 0 UNK B-Group
beta NN 0 1 16 I-Group
- : 0 0 2 O
blocker NN 0 0 3 I-Group
could MD 0 0 12 O
be VB 0 0 12 O
substituted VBN 1 0 UNK O
. . 0 0 12 O

Therefore DT 0 0 1 O
injection NN 0 1 3 O
of IN 0 0 12 O
these DT 0 0 12 O
agents NNS 1 1 1 O
into IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
thyroid JJ 0 1 6 B-Group
preparations NNS 1 1 13 I-Group
increases VBZ 1 1 1 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
precipitating VBG 1 1 14 O
coronary JJ 0 1 6 O
insufficiency NN 0 1 6 O
especially RB 0 0 12 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
coronary JJ 0 1 6 O
artery NN 0 1 6 O
disease NN 0 1 6 O
. . 0 0 12 O

In IN 0 0 2 O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
perindopril NN 0 1 UNK B-Drug
was VBD 1 0 12 O
generally RB 0 0 1 O
administered VBN 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
non JJ 0 1 1 O
- : 0 0 2 O
fasting VBG 1 1 6 O
state NN 0 1 1 O
. . 0 0 12 O

- : 0 0 2 O
a DT 0 0 12 O
monoamine JJ 0 1 13 B-Group
oxidase NN 0 1 13 I-Group
inhibitor NN 0 1 14 I-Group
( ( 0 0 2 O
MAOI NNP 0 1 UNK B-Group
) ) 0 0 2 O
such JJ 0 0 1 O
as IN 1 0 12 O
isocarboxazid NN 0 1 UNK B-Drug
( ( 0 0 2 O
Marplan NNP 0 1 UNK B-Brand
) ) 0 0 2 O
tranylcypromine NN 0 1 13 B-Drug
( ( 0 0 2 O
Parnate NNP 0 1 UNK B-Brand
) ) 0 0 2 O
or CC 0 0 12 O
phenelzine NN 0 1 16 B-Drug
( ( 0 0 2 O
Nardil NNP 0 1 UNK B-Brand
) ) 0 0 2 O
; : 0 0 2 O

Lopinavir NNP 0 1 UNK B-Drug
/ NNP 0 0 2 O
Ritonavir NNP 0 1 0 B-Drug

Drugs NNS 0 1 2 O
whose WP$ 0 0 12 O
absorption NN 0 1 1 O
is VBZ 1 0 12 O
sensitive JJ 0 1 1 O
to TO 0 0 12 O
pH VB 0 1 14 O
may MD 0 0 1 O
be VB 0 0 12 O
negatively RB 0 0 1 O
impacted VBN 1 1 1 O
by IN 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
omeprazole JJ 0 1 0 B-Drug
and CC 0 0 12 O
valdecoxib NN 0 1 13 B-Drug
. . 0 0 12 O

Concurrent JJ 0 1 13 O
administration NN 0 1 1 O
of IN 0 0 12 O
cimetidine NN 0 1 13 B-Drug
and CC 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
can MD 0 0 12 O
produce VB 0 0 1 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
increases NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
. . 0 0 12 O

Increased VBN 0 1 7 O
ectopic JJ 0 1 6 O
pacemaker NN 0 1 6 O
activity NN 0 1 1 O
can MD 0 0 12 O
occur VB 0 1 1 O
when WRB 0 0 12 O
pseudoephedrine NN 0 1 16 B-Drug
is VBZ 1 0 12 O
used VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
digitalis NNS 0 1 14 B-Group
. . 0 0 12 O

Nonsteroidal NNP 0 0 UNK B-Drug
Antiinflammatory NNP 0 1 UNK I-Drug
Agents NNS 0 1 2 O
: : 0 0 2 O
Aspirin NNP 0 1 0 B-Drug
is VBZ 1 0 12 O
contraindicated VBN 1 1 14 O
in IN 0 0 12 O
patients NNS 1 1 6 O
who WP 0 0 12 O
are VBP 1 0 12 O
hypersensitive JJ 0 1 UNK O
to TO 0 0 12 O
nonsteroidal VB 0 0 14 B-Drug
anti JJ 0 0 3 I-Drug
- : 0 0 2 O
inflammatory NN 0 1 6 I-Drug
agents NNS 1 1 1 O
. . 0 0 12 O

Drugs NNS 0 1 2 O
That WDT 0 0 2 O
Inhibit NNP 0 1 UNK O
CYP9A9 NNP 0 0 UNK O
CYP9A9 NNP 0 0 UNK O
is VBZ 1 0 12 O
a DT 0 0 12 O
minor JJ 0 1 1 O
metabolic JJ 0 1 6 O
pathway NN 0 1 UNK O
for IN 0 0 12 O
the DT 0 0 12 O
elimination NN 0 1 UNK O
of IN 0 0 12 O
zaleplon NN 0 1 13 B-Drug
because IN 0 0 12 O
the DT 0 0 12 O
sum NN 0 1 13 O
of IN 0 0 12 O
desethylzaleplon NN 0 0 UNK O
( ( 0 0 2 O
formed VBN 1 1 UNK O
via IN 0 0 1 O
CYP9A9 NNP 0 0 UNK O
in IN 0 0 12 O
vitro NN 0 1 UNK O
) ) 0 0 2 O
and CC 0 0 12 O
its PRP$ 1 0 12 O
metabolites NNS 1 1 UNK O
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
oxo NN 0 1 UNK I-Drug_n
- : 0 0 2 O
desethylzaleplon NN 0 0 UNK I-Drug_n
and CC 0 0 12 O
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
oxo NN 0 1 UNK I-Drug_n
- : 0 0 2 O
desethylzaleplon NN 0 0 UNK I-Drug_n
glucuronide NN 0 1 UNK I-Drug_n
account NN 0 1 1 O
for IN 0 0 12 O
only RB 0 1 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
of IN 0 0 12 O
the DT 0 0 12 O
urinary JJ 0 1 6 O
recovery NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
zaleplon NN 0 1 13 B-Drug
dose NN 0 1 6 O
. . 0 0 12 O

Patients NNS 0 1 7 O
who WP 0 0 12 O
have VBP 0 0 12 O
developed VBN 1 0 1 O
severe JJ 0 1 6 O
hypersensitivity NN 0 1 6 O
reactions NNS 1 1 1 O
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
rechallenged VBN 0 1 UNK O
with IN 0 0 12 O
TAXOL NNP 0 1 UNK B-Brand
. . 0 0 12 O

Because IN 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
increased VBN 1 1 1 O
risk NN 0 1 1 O
of IN 0 0 12 O
adverse JJ 0 0 1 O
reactions NNS 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
who WP 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
taking VBG 1 0 12 O
benzodiazepines NNS 1 1 14 B-Group
on IN 0 0 12 O
a DT 0 0 12 O
regular JJ 0 1 12 O
basis NN 0 1 1 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
particularly RB 0 0 1 O
important JJ 0 1 1 O
that IN 0 0 12 O
physicians VBZ 0 1 6 O
query JJ 0 1 UNK O
patients NNS 1 1 6 O
or CC 0 0 12 O
their PRP$ 0 0 12 O
guardians NNS 1 1 UNK O
carefully RB 0 0 12 O
about IN 0 1 12 O
benzodiazepine NN 0 1 14 B-Group
alcohol NN 0 1 1 B-Drug
and CC 0 0 12 O
sedative JJ 0 1 6 B-Group
use NN 0 1 1 O
as IN 1 0 12 O
part NN 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
history NN 0 1 12 O
prior RB 0 1 1 O
to TO 0 0 12 O
any DT 0 0 12 O
procedure NN 0 1 1 O
in IN 0 0 12 O
which WDT 0 0 12 O
the DT 0 0 12 O
use NN 0 1 1 O
of IN 0 0 12 O
ROMAZICON NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
planned VBN 1 1 12 O
. . 0 0 12 O

( ( 0 0 2 O
See VB 0 1 2 O
CLINICAL NNP 0 1 11 O
PHARMACOLOGY NNP 0 1 UNK O
: : 0 0 2 O
Drug NNP 0 1 2 O
Interaction NNP 0 1 2 O
Studies NNP 0 1 2 O
. . 0 0 12 O
) ) 0 0 2 O

There EX 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
no DT 0 0 12 O
formal JJ 0 1 1 O
drug NN 0 1 1 O
- : 0 0 2 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
performed VBN 1 1 1 O
with IN 0 0 12 O
Mylotarg NNP 0 1 UNK B-Brand
. . 0 0 12 O

Potential NNP 0 1 UNK O
for IN 0 0 12 O
Interaction NNP 0 1 2 O
with IN 0 0 12 O
Drugs NNP 0 1 2 O
that WDT 0 0 12 O
Affect NNP 0 1 UNK O
Gastric NNP 0 1 7 O
Acidity NNP 0 1 UNK O
: : 0 0 2 O
Duloxetine NNP 0 1 0 B-Drug
has VBZ 1 0 12 O
an DT 0 0 12 O
enteric JJ 0 1 14 O
coating NN 0 1 UNK O
that WDT 0 0 12 O
resists VBZ 1 0 UNK O
dissolution NN 0 0 UNK O
until IN 0 0 12 O
reaching VBG 1 1 12 O
a DT 0 0 12 O
segment NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
gastrointestinal JJ 0 1 6 O
tract NN 0 1 6 O
where WRB 0 0 12 O
the DT 0 0 12 O
pH NN 0 1 14 O
exceeds VBZ 1 0 UNK O
9 CD 0 0 2 O
. . 0 0 12 O

Vitamin NNP 0 1 2 B-Group
D NNP 0 1 2 I-Group
: : 0 0 2 O
The DT 0 0 2 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
any DT 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
vitamin NN 0 1 6 B-Group
D NNP 0 1 2 I-Group
analogues NNS 1 1 UNK I-Group
should MD 0 0 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
as IN 1 0 12 O
this DT 0 0 12 O
could MD 0 0 12 O
create VB 0 1 13 O
possible JJ 0 1 1 O
additive JJ 0 1 16 O
effects NNS 1 1 1 O
and CC 0 0 12 O
hypercalcemia NN 0 1 8 O
. . 0 0 12 O

. . 0 0 12 O

There EX 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
greater JJR 1 1 1 O
than IN 0 0 12 O
two CD 0 1 12 O
- : 0 0 2 O
fold NN 0 1 3 O
increases NNS 1 1 1 O
of IN 0 0 12 O
previously RB 0 0 1 O
stable JJ 0 1 1 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
when WRB 0 0 12 O
fluoxetine NN 0 1 16 B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
administered VBN 1 1 1 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
these DT 0 0 12 O
agents NNS 1 1 1 O
. . 0 0 12 O

Drugs NNS 0 1 2 O
that WDT 0 0 12 O
inhibit VBP 0 1 13 O
or CC 0 0 12 O
Induce NNP 0 1 UNK O
CYP NNP 0 1 UNK O
9D9 CD 0 0 UNK O
and CC 0 0 12 O
CYP NNP 0 1 UNK O
9A9 CD 0 0 UNK O
may MD 0 0 1 O
affect VB 0 1 1 O
the DT 0 0 12 O
concentration NN 0 1 1 O
on IN 0 0 12 O
Aricept NNP 0 1 0 B-Brand
. . 0 0 12 O

Response NN 0 1 UNK O
to TO 0 0 12 O
sympathomimetic JJ 0 1 13 B-Group
agents NNS 1 1 1 I-Group
may MD 0 0 1 O
be VB 0 0 12 O
enhanced VBN 1 1 1 O
by IN 0 0 12 O
colchicine NN 0 1 0 B-Drug
. . 0 0 12 O

In IN 0 0 2 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
Nalfon NNP 0 1 UNK B-Brand
and CC 0 0 12 O
a DT 0 0 12 O
steroid JJ 0 1 6 B-Group
concomitantly RB 0 0 14 O
any DT 0 0 12 O
reduction NN 0 1 1 O
in IN 0 0 12 O
steroid JJ 0 1 6 B-Group
dosage NN 0 1 0 O
should MD 0 0 12 O
be VB 0 0 12 O
gradual JJ 0 1 1 O
in IN 0 0 12 O
order NN 0 1 1 O
to TO 0 0 12 O
avoid VB 0 0 12 O
the DT 0 0 12 O
possible JJ 0 1 1 O
complications NNS 1 1 6 O
of IN 0 0 12 O
sudden JJ 0 1 12 O
steroid NN 0 1 6 B-Group
withdrawal NN 0 1 1 O
. . 0 0 12 O

No DT 0 0 2 O
significant JJ 0 1 1 O
adverse JJ 0 0 1 O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
commonly RB 0 0 UNK O
used VBN 1 1 12 O
premedications NNS 0 1 UNK O
or CC 0 0 12 O
drugs NNS 1 1 6 O
used VBN 1 1 12 O
during IN 0 0 12 O
anesthesia NN 0 1 6 O
or CC 0 0 12 O
sedation NN 0 1 6 O
( ( 0 0 2 O
including VBG 1 1 1 O
a DT 0 0 12 O
range NN 0 1 1 O
of IN 0 0 12 O
muscle NN 0 1 6 B-Group
relaxants NNS 1 0 13 I-Group
inhalational JJ 0 1 14 O
agents NNS 1 1 1 O
analgesic JJ 0 1 13 B-Group
agents NNS 1 1 1 I-Group
and CC 0 0 12 O
local JJ 0 1 12 O
anesthetic JJ 0 1 13 B-Group
agents NNS 1 1 1 I-Group
) ) 0 0 2 O
have VBP 0 0 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
. . 0 0 12 O

Drugs NNS 0 1 2 O
such JJ 0 0 1 O
as IN 1 0 12 O
lithium NN 0 1 16 B-Drug
may MD 0 0 1 O
potentiate VB 0 0 UNK O
the DT 0 0 12 O
release NN 0 1 12 O
of IN 0 0 12 O
neutrophils NNS 1 1 14 O
; : 0 0 2 O

Profound NNP 0 1 UNK O
hypotensive JJ 0 1 14 O
episodes NNS 1 1 12 O
may MD 0 0 1 O
occur VB 0 1 1 O
when WRB 0 0 12 O
diazoxide JJ 0 1 16 B-Drug
infection NN 0 1 6 O
and CC 0 0 12 O
hydralazine NN 0 1 14 B-Drug
are VBP 1 0 12 O
used VBN 1 1 12 O
concomitantly RB 0 0 14 O
. . 0 0 12 O

While IN 0 0 12 O
no DT 0 0 12 O
in IN 0 0 12 O
vivo JJ 0 1 13 O
drug NN 0 1 1 O
- : 0 0 2 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
were VBD 1 0 12 O
conducted VBN 1 1 1 O
between IN 0 0 12 O
estazolam NN 0 1 13 B-Drug
and CC 0 0 12 O
inducers NNS 1 1 UNK O
of IN 0 0 12 O
CYP9A NNP 0 0 UNK O
compounds NNS 1 1 13 O
that WDT 0 0 12 O
are VBP 1 0 12 O
potent JJ 0 1 UNK O
CYP9A NNP 0 0 UNK O
inducers NNS 1 1 UNK O
( ( 0 0 2 O
such JJ 0 0 1 O
as IN 1 0 12 O
carbamazepine NN 0 1 16 B-Drug
phenytoin NN 0 1 16 B-Drug
rifampin NN 0 1 16 B-Drug
and CC 0 0 12 O
barbiturates NNS 1 1 14 B-Group
) ) 0 0 2 O
would MD 0 0 12 O
be VB 0 0 12 O
expected VBN 1 1 12 O
to TO 0 0 12 O
decrease VB 0 1 1 O
estazolam JJ 0 1 13 B-Drug
concentrations NNS 1 1 13 O
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
that IN 0 0 12 O
gabapentin NN 0 1 0 B-Drug
be VB 0 0 12 O
taken VBN 1 1 12 O
at IN 0 0 12 O
least JJS 0 1 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
following VBG 1 1 1 O
Maalox NNP 0 1 0 B-Brand
administration NN 0 1 1 O
. . 0 0 12 O

Concomitant NNP 0 1 UNK O
use NN 0 1 1 O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
and CC 0 0 12 O
sympathomimetics NNS 0 1 13 B-Group
increases VBZ 1 1 1 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
cardiac JJ 0 1 6 O
arrhythmias NN 1 1 6 O
. . 0 0 12 O

Although IN 0 0 12 O
metoclopramide NN 0 1 16 B-Drug
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
bioavailability NN 0 1 UNK O
of IN 0 0 12 O
levodopa NN 0 1 UNK B-Drug
by IN 0 0 12 O
increasing VBG 1 1 1 O
gastric JJ 0 1 6 O
emptying VBG 1 1 13 O
metoclopramide NN 0 1 16 B-Drug
may MD 0 0 1 O
also RB 0 0 12 O
adversely RB 0 0 UNK O
affect JJ 0 1 1 O
disease NN 0 1 6 O
control NN 0 1 1 O
by IN 0 0 12 O
its PRP$ 1 0 12 O
dopamine NN 0 1 14 O
receptor NN 0 1 14 O
antagonistic JJ 0 1 UNK O
properties NNS 1 1 UNK O
. . 0 0 12 O

Other JJ 0 0 2 O
Drug NNP 0 1 2 O
Interactions NNS 0 1 UNK O
: : 0 0 2 O
No DT 0 0 2 O
pharmacokinetic JJ 0 1 UNK O
interactions NNS 1 1 UNK O
were VBD 1 0 12 O
observed VBN 1 1 1 O
between IN 0 0 12 O
vardenafil NN 0 1 UNK B-Drug
and CC 0 0 12 O
the DT 0 0 12 O
following JJ 0 1 1 O
drugs NNS 1 1 6 O
: : 0 0 2 O
glyburide NN 0 1 16 B-Drug
warfarin NN 0 1 14 B-Drug
digoxin NN 0 1 14 B-Drug
Maalox NNP 0 1 0 B-Brand
and CC 0 0 12 O
ranitidine NN 0 1 0 B-Drug
. . 0 0 12 O

Caffeine NNP 0 1 7 B-Drug
Theobromine NNP 0 1 UNK B-Drug
Grepafloxacin NNP 0 1 UNK B-Drug
like IN 0 0 12 O
other JJ 0 0 12 O
quinolones NNS 0 1 13 B-Group
may MD 0 0 1 O
inhibit VB 0 1 13 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
caffeine NN 0 1 6 B-Drug
and CC 0 0 12 O
theobromine NN 0 1 UNK B-Drug
. . 0 0 12 O

primidone NN 0 1 13 B-Drug
; : 0 0 2 O

Therefore RB 0 0 1 O
do VBP 0 0 12 O
not RB 0 1 12 O
administer VB 0 1 1 O
Myfortic NNP 0 1 UNK B-Drug
with IN 0 0 12 O
cholestyramine NN 0 1 13 B-Drug
or CC 0 0 12 O
other JJ 0 0 12 O
agents NNS 1 1 1 O
that WDT 0 0 12 O
may MD 0 0 1 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
enterohepatic JJ 0 0 UNK O
recirculation NN 0 0 UNK O
or CC 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
may MD 0 0 1 O
bind VB 0 1 UNK O
bile JJ 0 1 6 O
acids NNS 1 1 14 O
for IN 0 0 12 O
example NN 0 1 1 O
bile NN 0 1 6 O
acid NN 0 1 14 O
sequestrates VBZ 1 0 UNK O
or CC 0 0 12 O
oral JJ 0 1 6 O
activated VBN 1 1 1 B-Drug
charcoal NN 0 1 3 I-Drug
because IN 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
potential JJ 0 1 1 O
to TO 0 0 12 O
reduce VB 0 0 1 O
the DT 0 0 12 O
efficacy NN 0 1 UNK O
of IN 0 0 12 O
Myfortic NNP 0 1 UNK B-Brand
. . 0 0 12 O

Use NNP 0 1 2 O
in IN 0 0 12 O
Conjunction NNP 0 1 UNK O
with IN 0 0 12 O
Other JJ 0 0 2 O
Antiepileptic JJ 0 1 UNK B-Group
Drugs NNS 0 1 2 I-Group
: : 0 0 2 O
The DT 0 0 2 O
addition NN 0 1 1 O
of IN 0 0 12 O
Felbatol NNP 0 1 UNK B-Brand
to TO 0 0 12 O
antiepileptic VB 0 1 UNK B-Group
drugs NNS 1 1 6 I-Group
( ( 0 0 2 O
AEDs NNP 0 1 UNK B-Group
) ) 0 0 2 O
affects VBZ 1 1 1 O
the DT 0 0 12 O
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
AEDs NNP 0 1 UNK B-Group
. . 0 0 12 O

CYP9D9 NNP 0 0 UNK O
inhibitors NNS 1 1 14 O
- : 0 0 2 O
Atomoxetine NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
primarily RB 0 0 1 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
the DT 0 0 12 O
CYP9D9 NNP 0 0 UNK O
pathway NN 0 1 UNK O
to TO 0 0 12 O
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
hydroxyatomoxetine NN 0 0 UNK I-Drug_n
. . 0 0 12 O

Naproxen NNP 0 1 0 B-Drug
and CC 0 0 12 O
other JJ 0 0 12 O
NSAIDs NNP 0 1 UNK B-Group
can MD 0 0 12 O
reduce VB 0 0 1 O
the DT 0 0 12 O
antihypertensive JJ 0 1 14 O
effect NN 0 1 1 O
of IN 0 0 12 O
propranolol NN 0 1 16 B-Drug
and CC 0 0 12 O
other JJ 0 0 12 O
beta NN 0 1 16 B-Group
- : 0 0 2 O
blockers NNS 1 0 6 I-Group
. . 0 0 12 O

Adenosine NN 0 1 14 B-Drug
: : 0 0 2 O
Dipyridamole NNP 0 1 UNK B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
and CC 0 0 12 O
cardiovascular JJ 0 1 6 O
effects NNS 1 1 1 O
of IN 0 0 12 O
adenosine NN 0 1 14 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
gastrointestinal JJ 0 1 6 O
absorption NN 0 1 1 O
of IN 0 0 12 O
cimetidine NN 0 1 13 B-Drug
and CC 0 0 12 O
ranitidine NN 0 1 0 B-Drug
is VBZ 1 0 12 O
accelerated VBN 1 1 1 O
when WRB 0 0 12 O
they PRP 0 0 12 O
are VBP 1 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
cisapride NN 0 1 UNK B-Drug
. . 0 0 12 O

Anticholinergics NNS 0 1 UNK B-Group
or CC 0 0 12 O
other JJ 0 0 12 O
medications NNS 1 1 6 O
with IN 0 0 12 O
anticholinergic JJ 0 1 13 O
activity NN 0 1 1 O
when WRB 0 0 12 O
used VBN 1 1 12 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
opioid JJ 0 1 13 B-Group
analgesics NNS 1 1 14 I-Group
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
increased JJ 0 1 1 O
risk NN 0 1 1 O
of IN 0 0 12 O
urinary JJ 0 1 6 O
retention NN 0 1 1 O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
severe JJ 0 1 6 O
constipation NN 0 1 6 O
which WDT 0 0 12 O
may MD 0 0 1 O
lead VB 0 1 12 O
to TO 0 0 12 O
paralytic JJ 0 0 13 O
ileus NN 0 1 8 O
. . 0 0 12 O

Antifungals NNS 0 1 UNK B-Group
: : 0 0 2 O
In IN 0 0 2 O
vitro NN 0 1 UNK O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
in IN 0 0 12 O
vivo JJ 0 1 13 O
data NNS 0 1 1 O
indicate VBP 0 0 1 O
that IN 0 0 12 O
fluconazole JJ 0 1 0 B-Drug
itraconazole NN 0 1 0 B-Drug
and CC 0 0 12 O
oral JJ 0 1 6 O
ketoconazole NN 0 1 16 B-Drug
markedly RB 0 1 1 O
inhibit VBZ 0 1 13 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
cisapride NN 0 1 UNK B-Drug
which WDT 0 0 12 O
can MD 0 0 12 O
result VB 0 1 1 O
in IN 0 0 12 O
an DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
plasma JJ 0 1 14 O
cisapride NN 0 1 UNK B-Drug
levels NNS 1 1 1 O
and CC 0 0 12 O
prolongation NN 0 1 6 O
of IN 0 0 12 O
the DT 0 0 12 O
QT NNP 0 1 13 O
interval NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
ECG NNP 0 1 6 O
. . 0 0 12 O

Ethyl NNP 0 0 UNK B-Drug
alcohol NN 0 1 1 I-Drug
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
since IN 0 1 12 O
there EX 0 0 12 O
may MD 0 0 1 O
be VB 0 0 12 O
an DT 0 0 12 O
Antabuse NNP 0 1 UNK O
( ( 0 0 2 O
disulfiram NN 0 1 13 O
) ) 0 0 2 O
- : 0 0 2 O
like IN 0 0 12 O
reaction NN 0 1 1 O
. . 0 0 12 O

This DT 0 0 2 O
interaction NN 0 1 UNK O
which WDT 0 0 12 O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
investigated VBN 1 1 1 O
using VBG 1 1 1 O
higher JJR 1 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
fluvoxamine NN 0 1 16 B-Drug
may MD 0 0 1 O
be VB 0 0 12 O
more JJR 0 1 12 O
pronounced JJ 0 0 12 O
if IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
mg JJ 0 1 0 O
daily JJ 0 1 12 O
dose NN 0 1 6 O
is VBZ 1 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
particularly RB 0 0 1 O
since IN 0 1 12 O
fluvoxamine NN 0 1 16 B-Drug
exhibits NNS 1 1 UNK O
non VBP 0 1 1 O
- : 0 0 2 O
linear JJ 0 1 1 O
pharmacokinetics NNS 0 1 UNK O
over IN 0 1 12 O
the DT 0 0 12 O
dosage NN 0 1 0 O
range NN 0 1 1 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
. . 0 0 12 O
If IN 0 0 12 O
alprazolam NN 0 1 0 B-Drug
is VBZ 1 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
with IN 0 0 12 O
Fluvoxamine NNP 0 1 UNK B-Drug
Tablets NNPS 0 1 0 O
the DT 0 0 12 O
initial JJ 0 1 1 O
alprazolam JJ 0 1 0 B-Drug
dosage NN 0 1 0 O
should MD 0 0 12 O
be VB 0 0 12 O
at IN 0 0 12 O
least JJS 0 1 12 O
halved JJ 0 0 UNK O
and CC 0 0 12 O
titration NN 0 1 14 O
to TO 0 0 12 O
the DT 0 0 12 O
lowest JJS 1 1 13 O
effective JJ 0 1 1 O
dose NN 0 1 6 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
CYP9A9 NNP 0 0 UNK O
isoenzyme NN 0 1 13 O
is VBZ 1 0 12 O
present JJ 0 1 1 O
in IN 0 0 12 O
both DT 0 0 12 O
the DT 0 0 12 O
liver NN 0 1 6 O
and CC 0 0 12 O
intestines NNS 1 1 6 O
. . 0 0 12 O

No DT 0 0 2 O
clinically RB 0 0 6 O
important JJ 0 1 1 O
pharmacokinetic JJ 0 1 UNK O
interactions NNS 1 1 UNK O
occurred VBD 1 1 1 O
when WRB 0 0 12 O
PRINIVIL NNP 0 1 UNK B-Brand
was VBD 1 0 12 O
used VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
propranolol NN 0 1 16 B-Drug
or CC 0 0 12 O
hydrochlorothiazide NN 0 1 0 B-Drug
. . 0 0 12 O

Thus RB 0 0 1 O
in IN 0 0 12 O
order NN 0 1 1 O
to TO 0 0 12 O
avoid VB 0 0 12 O
bleeding NN 0 1 6 O
reduced JJ 0 1 1 O
dosage NN 0 1 0 O
of IN 0 0 12 O
heparin NN 0 1 14 B-Drug
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
during IN 0 0 12 O
treatment NN 0 1 6 O
with IN 0 0 12 O
antithrombin JJ 0 1 14 B-Drug
III NNP 0 1 2 I-Drug
( ( 0 0 2 O
human JJ 0 1 1 O
) ) 0 0 2 O
. . 0 0 12 O

In IN 0 0 2 O
well RB 0 1 12 O
- : 0 0 2 O
controlled VBN 1 1 1 O
patients NNS 1 1 6 O
undergoing JJ 0 0 6 O
concurrent JJ 0 1 1 O
therapy NN 0 1 6 O
with IN 0 0 12 O
cimetidine NN 0 1 13 B-Drug
a DT 0 0 12 O
decrease NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
serum JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
may MD 0 0 1 O
occur VB 0 1 1 O
when WRB 0 0 12 O
cime NN 0 0 UNK O
- : 0 0 2 O
tidine NN 0 0 UNK O
therapy NN 0 1 6 O
is VBZ 1 0 12 O
discontinued VBN 1 1 1 O
. . 0 0 12 O

Antacids NNP 0 1 UNK B-Group
( ( 0 0 2 O
aluminum SYM 0 1 16 B-Drug
- : 0 0 2 O
or CC 0 0 12 O
magnesium VB 0 1 14 B-Drug
- : 0 0 2 O
containing VBG 1 1 1 O
) ) 0 0 2 O
: : 0 0 2 O
Concomitant JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
mg NN 0 1 0 O
cefdinir NN 0 1 UNK B-Drug
capsules NNS 1 1 3 O
with IN 0 0 12 O
9 CD 0 0 2 O
mL NNS 0 1 14 O
Maalox NNP 0 1 0 B-Brand
TC NNP 0 1 13 I-Brand
suspension NN 0 1 3 O
reduces VBZ 1 0 UNK O
the DT 0 0 12 O
rate NN 0 1 1 O
( ( 0 0 2 O
Cmax NNP 0 1 UNK O
) ) 0 0 2 O
and CC 0 0 12 O
extent NN 0 1 1 O
( ( 0 0 2 O
AUC NNP 0 1 UNK O
) ) 0 0 2 O
of IN 0 0 12 O
absorption NN 0 1 1 O
by IN 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

Tricyclic JJ 0 0 UNK B-Group
antidepressants NNS 1 1 13 I-Group
may MD 0 0 1 O
enhance VB 0 1 UNK O
the DT 0 0 12 O
seizure NN 0 1 6 O
risk NN 0 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
tramadol NN 0 1 16 B-Drug

anaphylaxis NN 0 1 6 O

Drugs NNS 0 1 2 O
that WDT 0 0 12 O
are VBP 1 0 12 O
known VBN 1 1 12 O
to TO 0 0 12 O
prolong VB 0 0 13 O
the DT 0 0 12 O
QTc NNP 0 0 14 O
interval NN 0 1 1 O
have VBP 0 0 12 O
an DT 0 0 12 O
increased VBN 1 1 1 O
risk NN 0 1 1 O
of IN 0 0 12 O
ventricular JJ 0 1 8 O
arrhythmias NNS 1 1 6 O
. . 0 0 12 O

Monitor NNP 0 1 2 O
prothrombin NN 0 1 14 O
levels NNS 1 1 1 O
and CC 0 0 12 O
adjust VBP 0 0 1 O
anticoagulant JJ 0 1 13 B-Group
dosage NN 0 1 0 O
accordingly RB 0 0 1 O
. . 0 0 12 O

A DT 0 0 2 O
false JJ 0 1 13 O
- : 0 0 2 O
positive JJ 0 1 1 O
direct JJ 0 1 1 O
Coombs NNP 0 1 19 O
test NN 0 1 1 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
during IN 0 0 12 O
treatment NN 0 1 6 O
with IN 0 0 12 O
other JJ 0 0 12 O
cephalosporin JJ 0 1 13 B-Group
antibiotics NNS 1 1 6 I-Group
; : 0 0 2 O

Pharmacokinetic JJ 0 1 UNK O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
with IN 0 0 12 O
cetirizine NN 0 1 13 B-Drug
in IN 0 0 12 O
adults NNS 1 1 13 O
were VBD 1 0 12 O
conducted VBN 1 1 1 O
with IN 0 0 12 O
pseudoephedrine JJ 0 1 16 B-Drug
antipyrine JJ 0 1 UNK B-Drug
ketoconazole NN 0 1 16 B-Drug
erythromycin NN 0 1 0 B-Drug
and CC 0 0 12 O
azithromycin NN 0 1 0 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
pharmacodynamic JJ 0 1 UNK O
consequences NNS 1 1 UNK O
of IN 0 0 12 O
concomitant JJ 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
losartan NN 0 1 0 B-Drug
and CC 0 0 12 O
inhibitors NNS 1 1 14 O
of IN 0 0 12 O
P9 NNP 0 1 UNK O
9C9 CD 0 0 UNK O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
examined VBN 1 1 1 O
. . 0 0 12 O

Calcium NN 0 1 7 B-Drug
Supplements NNS 0 1 UNK O
: : 0 0 2 O
Uncontrolled VBN 0 1 UNK O
intake NN 0 1 3 O
of IN 0 0 12 O
additional JJ 0 1 1 O
calcium NN 0 1 14 B-Drug
- : 0 0 2 O
containing VBG 1 1 1 O
preparations NNS 1 1 13 O
should MD 0 0 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
. . 0 0 12 O

The DT 0 0 2 O
CNS NNP 0 1 6 O
effects NNS 1 1 1 O
of IN 0 0 12 O
butalbital NN 0 1 UNK B-Drug
may MD 0 0 1 O
be VB 0 0 12 O
enhanced VBN 1 1 1 O
by IN 0 0 12 O
monoamine NN 0 1 13 B-Group
oxidase NN 0 1 13 I-Group
MAO NNP 0 1 14 I-Group
inhibitors NNS 1 1 14 I-Group
. . 0 0 12 O

Monitoring NN 0 1 UNK O
of IN 0 0 12 O
Mexitil NNP 0 1 UNK B-Brand
plasma NN 0 1 14 O
levels NNS 1 1 1 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
during IN 0 0 12 O
such JJ 0 0 1 O
concurrent JJ 0 1 1 O
use NN 0 1 1 O
to TO 0 0 12 O
avoid VB 0 0 12 O
ineffective JJ 0 1 UNK O
therapy NN 0 1 6 O
. . 0 0 12 O

In IN 0 0 2 O
addition NN 0 1 1 O
oxcarbazepine NN 0 1 16 B-Drug
and CC 0 0 12 O
MHD NNP 0 0 UNK B-Drug_n
induce VB 0 1 6 O
a DT 0 0 12 O
subgroup NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
9A CD 0 1 UNK O
family NN 0 1 12 O
( ( 0 0 2 O
CYP9A9 NNP 0 0 UNK O
and CC 0 0 12 O
CYP9A9 NNP 0 0 UNK O
) ) 0 0 2 O
responsible JJ 0 1 1 O
for IN 0 0 12 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
dihydropyridine JJ 0 1 UNK B-Group
calcium NN 0 1 14 I-Group
antagonists NNS 1 1 13 I-Group
and CC 0 0 12 O
oral JJ 0 1 6 O
contraceptives NNS 1 1 13 B-Group
resulting VBG 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
lower JJR 1 1 1 O
plasma JJ 0 1 14 O
concentration NN 0 1 1 O
of IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

Calcium NN 0 1 7 B-Drug
Supplements NNS 0 1 UNK O
: : 0 0 2 O
Uncontrolled VBN 0 1 UNK O
intake NN 0 1 3 O
of IN 0 0 12 O
additional JJ 0 1 1 O
calcium NN 0 1 14 B-Drug
- : 0 0 2 O
containing VBG 1 1 1 O
preparations NNS 1 1 13 O
should MD 0 0 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
. . 0 0 12 O

For IN 0 0 2 O
information NN 0 1 1 O
on IN 0 0 12 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
associated VBN 1 1 1 O
with IN 0 0 12 O
ranitidine NN 0 1 0 B-Drug
refer NN 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
ZANTAC NNP 0 1 0 B-Brand
package NN 0 1 13 O
insert NN 0 1 13 O
. . 0 0 12 O

Digoxin NNP 0 1 0 B-Drug
Keppra NNP 0 1 0 B-Brand
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
twice RB 0 1 12 O
daily RB 0 1 12 O
) ) 0 0 2 O
did VBD 1 0 12 O
not RB 0 1 12 O
influence VB 0 0 UNK O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
and CC 0 0 12 O
pharmacodynamics NNS 0 1 UNK O
( ( 0 0 2 O
ECG NNP 0 1 6 O
) ) 0 0 2 O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
given VBN 1 1 12 O
as IN 1 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
dose JJ 0 1 6 O
every DT 0 0 12 O
day NN 0 1 12 O
. . 0 0 12 O

Cyclosporine NN 0 1 UNK B-Drug
: : 0 0 2 O
Preliminary JJ 0 1 2 O
data NNS 0 1 1 O
from IN 0 0 12 O
a DT 0 0 12 O
XENICAL NN 0 1 UNK B-Brand
and CC 0 0 12 O
cyclosporine JJ 0 1 14 B-Drug
drug NN 0 1 1 O
interaction NN 0 1 UNK O
study NN 0 1 1 O
indicate VBP 0 0 1 O
a DT 0 0 12 O
reduction NN 0 1 1 O
in IN 0 0 12 O
cyclosporine NN 0 1 14 B-Drug
plasma NN 0 1 14 O
levels NNS 1 1 1 O
when WRB 0 0 12 O
XENICAL NN 0 1 UNK B-Brand
was VBD 1 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
cyclosporine NN 0 1 14 B-Drug
. . 0 0 12 O

vasculitis NN 0 1 13 O

Beta NNP 0 1 2 B-Group
- : 0 0 2 O
blockers NNS 1 0 6 I-Group
( ( 0 0 2 O
metoprolol VB 0 1 0 B-Drug
propranolol NN 0 1 16 B-Drug
) ) 0 0 2 O
serum NN 0 1 14 O
concentrations NNS 1 1 13 O
and CC 0 0 12 O
pharmacologic JJ 0 1 14 O
effects NNS 1 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
increased VBN 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
physician NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
informed VBN 1 1 12 O
that IN 0 0 12 O
certain JJ 0 1 1 O
endocrine NN 0 1 6 O
and CC 0 0 12 O
liver JJ 0 1 6 O
function NN 0 1 1 O
tests NNS 1 1 1 O
and CC 0 0 12 O
blood NN 0 1 6 O
components NNS 1 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
affected VBN 1 1 1 O
by IN 0 0 12 O
progestin JJ 0 1 UNK O
therapy NN 0 1 6 O
: : 0 0 2 O
( ( 0 0 2 O
a DT 0 0 12 O
) ) 0 0 2 O
Plasma NNP 0 1 UNK O
and CC 0 0 12 O
urinary JJ 0 1 6 O
steroid NN 0 1 6 O
levels NNS 1 1 1 O
are VBP 1 0 12 O
decreased VBN 1 1 1 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
progesterone NN 0 1 13 O
estradiol NN 0 1 13 O
pregnanediol NN 0 1 UNK O
testosterone NN 0 1 6 O
cortisol NN 0 1 14 O
) ) 0 0 2 O
. . 0 0 12 O

A DT 0 0 2 O
direct JJ 0 1 1 O
causal NN 0 1 UNK O
relationship NN 0 1 12 O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
established VBN 1 1 1 O
but CC 0 0 12 O
physicians NNS 1 1 6 O
should MD 0 0 12 O
consider VB 0 1 12 O
the DT 0 0 12 O
possibility NN 0 1 1 O
that IN 0 0 12 O
diclofenac NN 0 1 16 B-Drug
may MD 0 0 1 O
alter VB 0 1 13 O
a DT 0 0 12 O
diabetic JJ 0 1 6 O
patient NN 0 1 6 O
response NN 0 1 1 O
to TO 0 0 12 O
insulin VB 0 1 14 B-Drug
or CC 0 0 12 O
oral JJ 0 1 6 O
hypoglycemic JJ 0 1 14 B-Group
agents NNS 1 1 1 I-Group
. . 0 0 12 O

Phenobarbital NN 0 1 0 B-Drug

Uricosuric JJ 0 0 UNK B-Group
Agents NNS 0 1 2 I-Group
: : 0 0 2 O
Aspirin NNP 0 1 0 B-Brand
may MD 0 0 1 O
decrease VB 0 1 1 O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
probenecid NN 0 1 13 B-Drug
sulfinpyrazone NN 0 1 13 B-Drug
and CC 0 0 12 O
phenylbutazone NN 0 1 UNK B-Drug
. . 0 0 12 O

Hepatotoxic NNP 0 1 UNK O
Drugs NNP 0 1 2 O
Increased VBD 0 1 7 O
side NN 0 1 3 O
effects NNS 1 1 1 O
may MD 0 0 1 O
occur VB 0 1 1 O
when WRB 0 0 12 O
leflunomide NN 0 1 13 B-Drug
is VBZ 1 0 12 O
given VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
hepatotoxic JJ 0 1 UNK O
substances NNS 1 1 1 O
. . 0 0 12 O

If IN 0 0 12 O
bupropion NN 0 1 16 B-Drug
is VBZ 1 0 12 O
added VBN 1 1 12 O
to TO 0 0 12 O
the DT 0 0 12 O
treatment NN 0 1 6 O
regimen NNS 0 1 6 O
of IN 0 0 12 O
a DT 0 0 12 O
patient NN 0 1 6 O
already RB 0 0 12 O
receiving VBG 1 1 1 O
a DT 0 0 12 O
drug NN 0 1 1 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
CYP9D9 NNP 0 0 UNK O
the DT 0 0 12 O
need NN 0 1 12 O
to TO 0 0 12 O
decrease VB 0 1 1 O
the DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
the DT 0 0 12 O
original JJ 0 1 12 O
medication NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
particularly RB 0 0 1 O
for IN 0 0 12 O
those DT 0 0 12 O
concomitant JJ 0 1 6 O
medications NNS 1 1 6 O
with IN 0 0 12 O
a DT 0 0 12 O
narrow JJ 0 1 3 O
therapeutic JJ 0 1 6 O
index NN 0 1 1 O
. . 0 0 12 O

SUBSEQUENT NNP 0 1 UNK O
TO NNP 0 0 11 O
INITIATION NNP 0 1 UNK O
OF NNP 0 0 11 O
DISULFIRAM NNP 0 1 UNK B-Drug
THERAPY NNP 0 1 UNK O
. . 0 0 12 O

norepinephrine NN 0 1 14 B-Drug
and CC 0 0 12 O
dobutamine NN 0 1 14 B-Drug
are VBP 1 0 12 O
incompatible JJ 0 1 13 O
with IN 0 0 12 O
sodium NN 0 1 14 B-Drug
bicarbonate NN 0 1 14 I-Drug
solution NN 0 1 1 O
. . 0 0 12 O

( ( 0 0 2 O
9 CD 0 0 2 O
mg RB 0 1 0 O
QD NNP 0 1 13 O
) ) 0 0 2 O

Agents NNS 0 1 2 O
Increasing VBG 0 1 2 O
Serum NNP 0 1 7 O
Potassium NN 0 1 14 O
: : 0 0 2 O
Enalapril NNP 0 1 0 B-Drug
and CC 0 0 12 O
enalapril VB 0 1 0 B-Drug
IV NNP 0 1 2 O
attenuate JJ 0 1 UNK O
potassium NN 0 1 14 O
loss NN 0 1 1 O
caused VBN 1 1 1 O
by IN 0 0 12 O
thiazide JJ 0 1 UNK B-Group
- : 0 0 2 O
type NN 0 1 1 I-Group
diuretics NNS 1 1 14 I-Group
. . 0 0 12 O

These DT 0 0 1 O
drugs NNS 1 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
caution NN 0 0 1 O
and CC 0 0 12 O
frequent JJ 0 1 1 O
monitoring NN 0 1 1 O
of IN 0 0 12 O
serum JJ 0 1 14 O
lithium NN 0 1 16 B-Drug
concentration NN 0 1 1 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O

No DT 0 0 2 O
adverse JJ 0 0 1 O
effects NNS 1 1 1 O
on IN 0 0 12 O
female JJ 0 1 12 O
fertility NN 0 1 6 O
and CC 0 0 12 O
embryonic JJ 0 1 13 O
survival NN 0 1 1 O
were VBD 1 0 12 O
evident JJ 0 1 1 O
in IN 0 0 12 O
female JJ 0 1 12 O
animals NNS 1 1 12 O
dosed VBD 1 1 14 O
at IN 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
/ NNP 0 0 2 O
day NN 0 1 12 O
( ( 0 0 2 O
approximately RB 0 1 1 O
one CD 0 1 12 O
- : 0 0 2 O
thousandth NN 0 0 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
human JJ 0 1 1 O
dose NN 0 1 6 O
based VBN 1 1 1 O
on IN 0 0 12 O
BSA NNP 0 0 13 O
) ) 0 0 2 O
. . 0 0 12 O

Paralytic JJ 0 0 UNK O
ileus NN 0 1 8 O
may MD 0 0 1 O
occur VB 0 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
tricyclic JJ 0 0 14 B-Drug
antidepressants NNS 1 1 13 I-Drug
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
anticholinergic JJ 0 1 13 B-Drug
- : 0 0 2 O
type NN 0 1 1 O
drugs NNS 1 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
clinical JJ 0 1 6 O
significance NN 0 1 13 O
of IN 0 0 12 O
these DT 0 0 12 O
observations NNS 1 1 1 O
is VBZ 1 0 12 O
unknown JJ 0 1 12 O
. . 0 0 12 O

however RB 0 0 12 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
Paget NNP 0 0 UNK O
's POS 0 1 12 O
Disease NNP 0 1 7 O
prior RB 0 1 1 O
diphosphonate NN 0 1 UNK B-Group
use NN 0 1 1 O
appears VBZ 1 1 12 O
to TO 0 0 12 O
reduce VB 0 0 1 O
the DT 0 0 12 O
anti NN 0 0 3 O
- : 0 0 2 O
resorptive JJ 0 1 UNK O
response NN 0 1 1 O
to TO 0 0 12 O
Calcitonin NNP 0 1 UNK B-Drug
salmon NN 0 1 16 I-Drug
nasal NN 0 1 6 O
spray NN 0 1 3 O
. . 0 0 12 O

The DT 0 0 2 O
following JJ 0 1 1 O
precautions NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
kept VBN 1 1 12 O
in IN 0 0 12 O
mind NN 0 1 12 O
in IN 0 0 12 O
the DT 0 0 12 O
treatment NN 0 1 6 O
of IN 0 0 12 O
anticholinesterase NN 0 1 UNK O
poisoning VBG 1 1 13 O
although IN 0 0 12 O
they PRP 0 0 12 O
do VBP 0 0 12 O
not RB 0 1 12 O
bear VB 0 1 12 O
directly RB 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
use NN 0 1 1 O
of IN 0 0 12 O
atropine NN 0 1 14 B-Drug
and CC 0 0 12 O
pralidoxime NN 0 1 13 B-Drug
. . 0 0 12 O

No DT 0 0 2 O
special JJ 0 1 12 O
precautions NNS 1 1 1 O
appear VBP 0 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
necessary JJ 0 0 1 O
when WRB 0 0 12 O
oral JJ 0 1 6 O
anticoagulant JJ 0 1 13 O
therapy NN 0 1 6 O
is VBZ 1 0 12 O
begun VBN 1 1 12 O
in IN 0 0 12 O
a DT 0 0 12 O
patient NN 0 1 6 O
already RB 0 0 12 O
stabilized VBN 1 1 1 O
on IN 0 0 12 O
maintenance NN 0 1 1 O
thyroid JJ 0 1 6 O
replacement NN 0 1 1 O
therapy NN 0 1 6 O
. . 0 0 12 O

Rarely RB 0 1 UNK O
when WRB 0 0 12 O
urine NN 0 1 6 O
is VBZ 1 0 12 O
exposed VBN 1 1 3 O
to TO 0 0 12 O
air NN 0 1 3 O
after IN 0 0 12 O
voiding VBG 1 1 6 O
it PRP 0 0 12 O
may MD 0 0 1 O
darken VB 0 0 UNK O
because IN 0 0 12 O
of IN 0 0 12 O
breakdown NN 0 1 1 O
of IN 0 0 12 O
methyldopa NN 0 1 13 B-Drug
or CC 0 0 12 O
its PRP$ 1 0 12 O
metabolites NNS 1 1 UNK O
. . 0 0 12 O

In IN 0 0 2 O
about RB 0 1 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
of IN 0 0 12 O
patients NNS 1 1 6 O
the DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
cyclosporine NN 0 1 14 B-Drug
had VBD 1 0 12 O
to TO 0 0 12 O
be VB 0 0 12 O
reduced VBN 1 1 1 O
in IN 0 0 12 O
order NN 0 1 1 O
to TO 0 0 12 O
maintain VB 0 1 1 O
cyclosporine JJ 0 1 14 B-Drug
concentrations NNS 1 1 13 O
within IN 0 0 1 O
the DT 0 0 12 O
therapeutic JJ 0 1 6 O
range NN 0 1 1 O
while IN 0 0 12 O
in IN 0 0 12 O
the DT 0 0 12 O
remainder NN 0 0 1 O
no DT 0 0 12 O
adjustment NN 0 1 1 O
was VBD 1 0 12 O
needed VBN 1 1 12 O
. . 0 0 12 O

Estazolam NN 0 1 UNK B-Drug
: : 0 0 2 O
Interaction NN 0 1 2 O
with IN 0 0 12 O
Drugs NNP 0 1 2 O
that WDT 0 0 12 O
Inhibit NNP 0 1 UNK O
Metabolism NNP 0 1 UNK O
via IN 0 0 1 O
Cytochrome NNP 0 1 UNK O
P9 NNP 0 1 UNK O
9A CD 0 1 UNK O
( ( 0 0 2 O
CYP9A NNP 0 0 UNK O
) ) 0 0 2 O
: : 0 0 2 O
The DT 0 0 2 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
estazolam NN 0 1 13 B-Drug
to TO 0 0 12 O
the DT 0 0 12 O
major JJ 0 1 1 O
circulating VBG 1 1 13 O
metabolite RB 0 1 UNK O
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
hydroxy NN 0 1 14 I-Drug_n
- : 0 0 2 O
estazolam NN 0 1 13 I-Drug_n
and CC 0 0 12 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
other JJ 0 0 12 O
triazolobenzodiazepines NNS 0 0 UNK B-Group
is VBZ 1 0 12 O
catalyzed VBN 1 0 UNK O
by IN 0 0 12 O
CYP9A NNP 0 0 UNK O
. . 0 0 12 O

In IN 0 0 2 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
indicated VBN 1 1 1 O
that IN 0 0 12 O
colestipol NN 0 1 13 B-Drug
hydrochloride NN 0 1 0 I-Drug
binds VBZ 1 1 UNK O
a DT 0 0 12 O
number NN 0 1 1 O
of IN 0 0 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

Alternatives NNS 0 1 UNK O
to TO 0 0 12 O
rifampin VB 0 1 16 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
during IN 0 0 12 O
the DT 0 0 12 O
course NN 0 1 12 O
of IN 0 0 12 O
PCP NNP 0 1 13 O
treatment NN 0 1 6 O
with IN 0 0 12 O
MEPRON NNP 0 1 UNK B-Brand
. . 0 0 12 O

This DT 0 0 2 O
may MD 0 0 1 O
increase VB 0 1 1 O
or CC 0 0 12 O
enhance VB 0 1 UNK O
the DT 0 0 12 O
occurrence NN 0 1 1 O
of IN 0 0 12 O
osteomalacia NN 0 1 13 O
in IN 0 0 12 O
some DT 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
chronic JJ 0 1 6 O
phenytoin NN 0 1 16 B-Drug
therapy NN 0 1 6 O
. . 0 0 12 O

Repeated VBN 0 1 7 O
doses NNS 1 1 6 O
of IN 0 0 12 O
colestipol NN 0 1 13 B-Drug
hydrochloride NN 0 1 0 I-Drug
given VBN 1 1 12 O
prior RB 0 1 1 O
to TO 0 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
propranolol NN 0 1 16 B-Drug
in IN 0 0 12 O
human JJ 0 1 1 O
trials NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
decrease VB 0 1 1 O
propranolol JJ 0 1 16 B-Drug
absorption NN 0 1 1 O
. . 0 0 12 O

bone NN 0 1 6 O
marrow NN 0 1 6 O
hypoplasia NN 0 1 13 O

A DT 0 0 2 O
return NN 0 1 12 O
to TO 0 0 12 O
normal JJ 0 1 1 O
menstrual JJ 0 1 6 O
rhythm NN 0 1 3 O
followed VBD 1 1 12 O
cessation NN 0 1 6 O
of IN 0 0 12 O
treatment NN 0 1 6 O
. . 0 0 12 O

Caution NN 0 0 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
exercised VBN 1 1 1 O
if IN 0 0 12 O
LEUSTATIN NNP 0 1 UNK B-Brand
Injection NNP 0 1 7 O
is VBZ 1 0 12 O
administered VBN 1 1 1 O
before IN 0 1 12 O
after IN 0 0 12 O
or CC 0 0 12 O
in IN 0 0 12 O
conjunction NN 0 1 1 O
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
known VBN 1 1 12 O
to TO 0 0 12 O
cause VB 0 1 12 O
immunosuppression NN 0 1 14 O
or CC 0 0 12 O
myelosuppression NN 0 1 8 O
. . 0 0 12 O

In IN 0 0 2 O
addition NN 0 1 1 O
several JJ 0 1 12 O
AED NNP 0 1 UNK B-Group
that WDT 0 0 12 O
are VBP 1 0 12 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
inducers NNS 1 1 UNK O
can MD 0 0 12 O
decrease VB 0 1 1 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
oxcarbazepine NN 0 1 16 B-Drug
and CC 0 0 12 O
MHD NNP 0 0 UNK B-Drug_n
. . 0 0 12 O

Non NNP 0 1 2 B-Group
- : 0 0 2 O
nucleoside JJ 0 1 UNK I-Group
reverse NN 0 1 1 I-Group
transcriptase NN 0 1 UNK I-Group
inhibitors NNS 1 1 14 I-Group

Phenylbutazone NN 0 1 UNK B-Drug
: : 0 0 2 O
Phenylbutazone NN 0 1 UNK B-Drug
causes VBZ 1 1 6 O
increase NN 0 1 1 O
( ( 0 0 2 O
by IN 0 0 12 O
about RB 0 1 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
in IN 0 0 12 O
the DT 0 0 12 O
free JJ 0 1 12 O
fraction NN 0 1 1 O
of IN 0 0 12 O
etodolac NN 0 1 13 B-Drug
. . 0 0 12 O

Addition NN 0 1 UNK O
of IN 0 0 12 O
mexiletine NN 0 1 16 B-Drug
to TO 0 0 12 O
propafenone VB 0 1 16 B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
lead VB 0 1 12 O
to TO 0 0 12 O
further JJ 0 1 1 O
electrocardiographic JJ 0 1 8 O
parameters NNS 1 1 1 O
changes NNS 1 1 1 O
of IN 0 0 12 O
QRS NNP 0 0 8 O
QTc NNP 0 0 14 O
RR NNP 0 0 13 O
and CC 0 0 12 O
PR NNP 0 1 2 O
intervals NNS 1 1 1 O
than IN 0 0 12 O
propafenone NN 0 1 16 B-Drug
alone RB 0 1 12 O
. . 0 0 12 O

Barbiturates NNS 0 1 UNK B-Group
may MD 0 0 1 O
decrease VB 0 1 1 O
the DT 0 0 12 O
effectiveness NN 0 1 UNK O
of IN 0 0 12 O
oral JJ 0 1 6 O
contraceptives NNS 1 1 13 B-Group
certain JJ 0 1 1 O
antibiotics NNS 1 1 6 B-Group
quinidine VBP 0 1 16 B-Drug
theophylline JJ 0 1 16 B-Drug
corticosteroids NNS 1 1 14 B-Group
anticoagulants NNS 1 1 13 B-Group
and CC 0 0 12 O
beta NN 0 1 16 B-Group
blockers NNS 1 0 6 I-Group
. . 0 0 12 O

If IN 0 0 12 O
any DT 0 0 12 O
signs NNS 1 1 12 O
or CC 0 0 12 O
symptoms NNS 1 1 6 O
occur VBP 0 1 1 O
physicians NNS 1 1 6 O
should MD 0 0 12 O
consider VB 0 1 12 O
discontinuation NN 0 1 6 O
of IN 0 0 12 O
either CC 0 1 12 O
one CD 0 1 12 O
or CC 0 0 12 O
both DT 0 0 12 O
agents NNS 1 1 1 O
( ( 0 0 2 O
ZYVOX NNP 0 1 UNK B-Brand
or CC 0 0 12 O
concomitant JJ 0 1 6 O
serotonergic JJ 0 0 UNK B-Group
agents NNS 1 1 1 I-Group
) ) 0 0 2 O
. . 0 0 12 O

Drug NN 0 1 2 O
Class NN 0 1 2 O

Potential NNP 0 1 UNK O
pharmacokinetic JJ 0 1 UNK O
interactions NNS 1 1 UNK O
were VBD 1 0 12 O
assessed VBN 1 1 1 O
in IN 0 0 12 O
clinical JJ 0 1 6 O
pharmacokinetic JJ 0 1 UNK O
studies NNS 1 1 1 O
( ( 0 0 2 O
phenytoin VB 0 1 16 B-Drug
valproate RB 0 1 16 B-Drug
oral JJ 0 1 6 O
contraceptive NN 0 1 13 B-Group
digoxin NN 0 1 14 B-Drug
warfarin IN 0 1 14 B-Drug
probenecid NN 0 1 13 B-Drug
) ) 0 0 2 O
and CC 0 0 12 O
through IN 0 0 12 O
pharmacokinetic JJ 0 1 UNK O
screening NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
placebo NN 0 1 13 O
- : 0 0 2 O
controlled VBN 1 1 1 O
clinical JJ 0 1 6 O
studies NNS 1 1 1 O
in IN 0 0 12 O
epilepsy NN 0 1 13 O
patients NNS 1 1 6 O
. . 0 0 12 O

In IN 0 0 2 O
vitro JJ 0 1 UNK O
mixing NN 0 1 UNK O
of IN 0 0 12 O
an DT 0 0 12 O
aminoglycoside NN 0 1 14 B-Group
with IN 0 0 12 O
beta NN 0 1 16 O
- : 0 0 2 O
lactamtype NN 0 0 UNK O
antibiotics NNS 1 1 6 B-Group
( ( 0 0 2 O
penicillins NNS 1 1 14 B-Group
or CC 0 0 12 O
cephalosporins NNS 1 1 14 B-Group
) ) 0 0 2 O
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
significant JJ 0 1 1 O
mutual JJ 0 1 UNK O
inactivation NN 0 1 UNK O
. . 0 0 12 O

Anticholinesterases NNS 0 1 UNK B-Group
( ( 0 0 2 O
neostgmine JJ 0 0 UNK O
physostigmine NN 0 1 13 B-Drug
) ) 0 0 2 O
lignocaine NN 0 1 UNK B-Drug
quinine JJ 0 1 16 B-Drug
procainamide NN 0 1 16 B-Drug
can MD 0 0 12 O
enhance VB 0 1 UNK O
toxicity NN 0 1 6 O
and CC 0 0 12 O
cause NN 0 1 12 O
cardio NN 0 1 13 O
respiratory NN 0 1 6 O
depression NN 0 1 6 O
. . 0 0 12 O

- : 0 0 2 O
The DT 0 0 2 O
persistence NN 0 1 1 O
of IN 0 0 12 O
clinical JJ 0 1 6 O
and CC 0 0 12 O
laboratory JJ 0 1 1 O
evidence NN 0 1 1 O
of IN 0 0 12 O
hypothyroidism NN 0 1 6 O
in IN 0 0 12 O
spite NN 0 0 UNK O
of IN 0 0 12 O
adequate JJ 0 1 1 O
dosage NN 0 1 0 O
replacement NN 0 1 1 O
indicates VBZ 1 0 1 O
either DT 0 1 12 O
poor JJ 0 1 12 O
patient NN 0 1 6 O
compliance NN 0 1 1 O
poor JJ 0 1 12 O
absorption NN 0 1 1 O
excessive JJ 0 1 1 O
fecal JJ 0 1 6 O
loss NN 0 1 1 O
or CC 0 0 12 O
inactivity NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
preparation NN 0 1 1 O
. . 0 0 12 O

However RB 0 0 1 O
no DT 0 0 12 O
adverse JJ 0 0 1 O
effects NNS 1 1 1 O
on IN 0 0 12 O
fertility NN 0 1 6 O
were VBD 1 0 12 O
observed VBN 1 1 1 O
in IN 0 0 12 O
male JJ 0 1 12 O
Rhesus NNP 0 1 UNK O
monkeys NNS 1 1 UNK O
treated VBD 1 1 1 O
with IN 0 0 12 O
non JJ 0 1 1 O
- : 0 0 2 O
pegylated VBN 0 0 UNK B-Drug
interferon NN 0 1 14 I-Drug
alfa NN 0 1 16 I-Drug
- : 0 0 2 O
9a CD 0 1 UNK I-Drug
for IN 0 0 12 O
9 CD 0 0 2 O
months NNS 1 1 12 O
at IN 0 0 12 O
doses VBZ 1 1 6 O
up RB 0 0 12 O
to TO 0 0 12 O
9 CD 0 0 2 O
x NNS 0 0 10 O
9 CD 0 0 2 O
IU NNP 0 1 13 O
/ NNP 0 0 2 O
kg VBD 0 1 18 O
/ NNP 0 0 2 O
day NN 0 1 12 O
. . 0 0 12 O

The DT 0 0 2 O
potential JJ 0 1 1 O
effects NNS 1 1 1 O
of IN 0 0 12 O
increased JJ 0 1 1 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
midazolam NN 0 1 16 B-Drug
or CC 0 0 12 O
other JJ 0 0 12 O
benzodiazepines NNS 1 1 14 B-Group
metabolized VBN 1 1 UNK O
via IN 0 0 1 O
CYP9A9 NNP 0 0 UNK O
( ( 0 0 2 O
alprazolam JJ 0 1 0 B-Drug
triazolam NN 0 1 13 B-Drug
) ) 0 0 2 O
should MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
when WRB 0 0 12 O
coadministering VBG 0 0 UNK O
these DT 0 0 12 O
agents NNS 1 1 1 O
with IN 0 0 12 O
Aprepitant NNP 0 1 UNK B-Drug
. . 0 0 12 O

Hyaluronidase NN 0 1 UNK B-Drug
: : 0 0 2 O
Hyaluronidase NN 0 1 UNK B-Drug
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
diffusion NN 0 1 1 O
rate NN 0 1 1 O
of IN 0 0 12 O
procaine NN 0 1 UNK B-Drug
hydrochloride NN 0 1 0 I-Drug
resulting VBG 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
decreased JJ 0 1 1 O
time NN 0 1 12 O
of IN 0 0 12 O
onset NN 0 1 6 O
but CC 0 0 12 O
an DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
systemic JJ 0 1 6 O
toxicity NN 0 1 6 O
. . 0 0 12 O

Since IN 0 1 2 O
blood NN 0 1 6 O
level NN 0 1 1 O
of IN 0 0 12 O
calcitriol NN 0 1 14 B-Drug
/ NNP 0 0 2 O
ergocalcitriol NN 0 0 UNK O
will MD 0 0 12 O
be VB 0 0 12 O
reduced VBN 1 1 1 O
higher JJR 1 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
Rocaltrol NNP 0 1 0 B-Brand
may MD 0 0 1 O
be VB 0 0 12 O
necessary JJ 0 0 1 O
if IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
are VBP 1 0 12 O
administered VBN 1 1 1 O
simultaneously RB 0 1 13 O
. . 0 0 12 O

Lithium NN 0 1 UNK B-Drug
: : 0 0 2 O
Increased VBN 0 1 7 O
serum NN 0 1 14 O
lithium NN 0 1 16 B-Drug
levels NNS 1 1 1 O
and CC 0 0 12 O
symptoms NNS 1 1 6 O
of IN 0 0 12 O
lithium NN 0 1 16 B-Drug
toxicity NN 0 1 6 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
ACE NNP 0 1 13 B-Group
inhibitors NNS 1 1 14 I-Group
during IN 0 0 12 O
therapy NN 0 1 6 O
with IN 0 0 12 O
lithium NN 0 1 16 B-Drug
. . 0 0 12 O

Special JJ 0 1 2 O
attention NN 0 1 12 O
should MD 0 0 12 O
be VB 0 0 12 O
paid VBN 1 1 12 O
to TO 0 0 12 O
potential JJ 0 1 1 O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
drugs NNS 1 1 6 O
having VBG 1 0 12 O
anticholinergic NN 0 1 13 O
properties NNS 1 1 UNK O
; : 0 0 2 O

Auranofin NNP 0 1 UNK B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
by IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
a DT 0 0 12 O
history NN 0 1 12 O
of IN 0 0 12 O
serious JJ 0 1 12 O
reaction NN 0 1 1 O
to TO 0 0 12 O
any DT 0 0 12 O
gold JJ 0 1 UNK B-Group
medication NN 0 1 6 I-Group
including VBG 1 1 1 O
Solganal NNP 0 1 UNK B-Brand
and CC 0 0 12 O
Myochrysine NNP 0 1 UNK B-Brand
. . 0 0 12 O

An DT 0 0 2 O
increased JJ 0 1 1 O
incidence NN 0 1 6 O
of IN 0 0 12 O
benign JJ 0 1 6 O
ovarian JJ 0 1 6 O
granulosa NN 0 1 UNK O
cell NN 0 1 1 O
tumors NNS 1 1 6 O
and CC 0 0 12 O
testicular JJ 0 1 13 O
Leydig NNP 0 0 UNK O
cell NN 0 1 1 O
tumors NNS 1 1 6 O
was VBD 1 0 12 O
evident JJ 0 1 1 O
in IN 0 0 12 O
females NNS 1 1 UNK O
dosed VBN 1 1 14 O
at IN 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
rat NN 0 1 13 O
/ VBD 0 0 2 O
9 CD 0 0 2 O
days NNS 1 1 12 O
and CC 0 0 12 O
males NNS 1 1 UNK O
dosed VBN 1 1 14 O
at IN 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
rat NN 0 1 13 O
/ VBD 0 0 2 O
9 CD 0 0 2 O
days NNS 1 1 12 O
respectively RB 0 0 1 O
. . 0 0 12 O

If IN 0 0 12 O
combination NN 0 1 1 O
therapy NN 0 1 6 O
is VBZ 1 0 12 O
initiated VBN 1 1 1 O
or CC 0 0 12 O
withdrawn VBN 1 1 1 O
in IN 0 0 12 O
conjunction NN 0 1 1 O
with IN 0 0 12 O
propranolol NN 0 1 16 B-Drug
an DT 0 0 12 O
adjustment NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
propranolol NN 0 1 16 B-Drug
dose NN 0 1 6 O
may MD 0 0 1 O
be VB 0 0 12 O
warranted VBN 1 0 1 O
. . 0 0 12 O

Reports NNS 0 1 2 O
of IN 0 0 12 O
fatal JJ 0 1 13 O
hepatic JJ 0 1 14 O
failure NN 0 1 1 O
as RB 0 0 12 O
well RB 0 1 12 O
as IN 1 0 12 O
peripheral JJ 0 1 6 O
neuropathy JJ 0 1 6 O
pancreatitis NN 0 1 6 O
and CC 0 0 12 O
symptomatic JJ 0 1 6 O
hyperlactatemia NN 0 1 UNK O
/ NNP 0 0 2 O
lactic JJ 0 1 14 O
acidosis NN 0 1 14 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
. . 0 0 12 O

Therefore RB 0 0 1 O
diflunisal NN 0 1 13 B-Drug
and CC 0 0 12 O
INDOCIN NNP 0 1 UNK B-Brand
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
concomitantly RB 0 0 14 O
. . 0 0 12 O

While IN 0 0 12 O
no DT 0 0 12 O
formal JJ 0 1 1 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
performed VBN 1 1 1 O
the DT 0 0 12 O
following VBG 1 1 1 O
concomitant NN 0 1 6 O
drugs NNS 1 1 6 O
were VBD 1 0 12 O
used VBN 1 1 12 O
in IN 0 0 12 O
at IN 0 0 12 O
least JJS 0 1 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
of IN 0 0 12 O
patients NNS 1 1 6 O
in IN 0 0 12 O
either DT 0 1 12 O
or CC 0 0 12 O
both DT 0 0 12 O
Sj NNP 0 1 UNK O
grens NNS 0 0 UNK O
efficacy NN 0 1 UNK O
studies NNS 1 1 1 O
: : 0 0 2 O
acetylsalicylic JJ 0 0 UNK B-Drug
acid VBP 0 1 14 I-Drug
artificial JJ 0 1 1 O
tears NNS 1 1 3 O
calcium NN 0 1 14 B-Drug
conjugated VBD 1 1 14 B-Drug
estrogens NNS 1 1 16 I-Drug
hydroxychloroquine JJ 0 1 16 B-Drug
sulfate NN 0 1 14 I-Drug
ibuprofen NN 0 1 0 B-Drug
levothyroxine NN 0 1 0 B-Drug
sodium NN 0 1 14 I-Drug
medroxyprogesterone NN 0 1 16 B-Drug
acetate NN 0 1 14 I-Drug
methotrexate NN 0 1 16 B-Drug
multivitamins NNS 1 1 14 B-Group
naproxen JJ 0 1 16 B-Drug
omeprazole JJ 0 1 0 B-Drug
paracetamol NN 0 1 UNK B-Drug
and CC 0 0 12 O
prednisone NN 0 1 0 B-Drug
. . 0 0 12 O

- : 0 0 2 O
Lofexidine NN 0 1 UNK B-Drug
may MD 0 0 1 O
enhance VB 0 1 UNK O
the DT 0 0 12 O
CNS NNP 0 1 6 O
depressive JJ 0 0 13 O
effects NNS 1 1 1 O
of IN 0 0 12 O
alcohol NN 0 1 1 B-Drug
barbiturates NNS 1 1 14 B-Group
and CC 0 0 12 O
other JJ 0 0 12 O
sedatives NNS 1 1 6 B-Group

Other JJ 0 0 2 O
HDAC NNP 0 1 UNK B-Group
Inhibitors NNPS 0 1 7 I-Group
Severe NNP 0 1 7 O
thrombocytopenia NN 0 1 14 O
and CC 0 0 12 O
gastrointestinal JJ 0 1 6 O
bleeding NN 0 1 6 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
with IN 0 0 12 O
concomitant JJ 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
ZOLINZA NNP 0 1 UNK B-Brand
and CC 0 0 12 O
other JJ 0 0 12 O
HDAC NNP 0 1 UNK B-Group
inhibitors NNS 1 1 14 I-Group
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
valproic NN 0 0 16 B-Drug
acid NN 0 1 14 I-Drug
) ) 0 0 2 O
. . 0 0 12 O

Urinary JJ 0 1 7 O
excretion NN 0 1 14 O
and CC 0 0 12 O
renal JJ 0 1 6 O
clearance NN 0 1 16 O
were VBD 1 0 12 O
correspondingly RB 0 0 UNK O
reduced VBN 1 1 1 O
. . 0 0 12 O

Diminished NNP 0 1 UNK O
urinary JJ 0 1 6 O
excretion NN 0 1 14 O
of IN 0 0 12 O
norfloxacin NN 0 1 UNK B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
during IN 0 0 12 O
the DT 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
probenecid NN 0 1 13 B-Drug
and CC 0 0 12 O
norfloxacin NN 0 1 UNK B-Drug
. . 0 0 12 O

co SYM 0 1 12 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
phenobarbital NN 0 1 16 B-Drug
may MD 0 0 1 O
produce VB 0 0 1 O
a DT 0 0 12 O
synergistic JJ 0 1 UNK O
anticonvulsant JJ 0 1 14 O
action NN 0 1 13 O
. . 0 0 12 O

In IN 0 0 2 O
a DT 0 0 12 O
formal JJ 0 1 1 O
single JJ 0 1 12 O
- : 0 0 2 O
dose JJ 0 1 6 O
interaction NN 0 1 UNK O
study NN 0 1 1 O
( ( 0 0 2 O
n JJ 0 1 12 O
= $ 0 0 2 O
9 CD 0 0 2 O
males NNS 1 1 UNK O
) ) 0 0 2 O
the DT 0 0 12 O
clearance NN 0 1 16 O
of IN 0 0 12 O
mexiletine NN 0 1 16 B-Drug
was VBD 1 0 12 O
decreased VBN 1 1 1 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
following VBG 1 1 1 O
the DT 0 0 12 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
fluvoxamine NN 0 1 16 B-Drug
an DT 0 0 12 O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
. . 0 0 12 O

It PRP 0 0 12 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
that IN 0 0 12 O
results NNS 1 1 1 O
of IN 0 0 12 O
studies NNS 1 1 1 O
in IN 0 0 12 O
animals NNS 1 1 12 O
indicate VBP 0 0 1 O
that IN 0 0 12 O
dopamine NN 0 1 14 B-Drug
- : 0 0 2 O
induced JJ 0 1 6 O
ventricular JJ 0 1 8 O
arrhythmias NN 1 1 6 O
during IN 0 0 12 O
anesthesia NN 0 1 6 O
can MD 0 0 12 O
be VB 0 0 12 O
reversed VBN 1 1 1 O
by IN 0 0 12 O
propranolol NN 0 1 16 B-Drug
. . 0 0 12 O

Amphetamines NNS 0 1 UNK B-Group
may MD 0 0 1 O
decrease VB 0 1 1 O
the DT 0 0 12 O
hypotensive JJ 0 1 14 O
effect NN 0 1 1 O
of IN 0 0 12 O
antihypertensives NNS 1 1 14 B-Group
. . 0 0 12 O

Lovastatin NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
but CC 0 0 12 O
has VBZ 1 0 12 O
no DT 0 0 12 O
CYP9A9 NNP 0 0 UNK O
inhibitory NN 0 1 UNK O
activity NN 0 1 1 O
; : 0 0 2 O

This DT 0 0 2 O
may MD 0 0 1 O
lead VB 0 1 12 O
to TO 0 0 12 O
reduced JJ 0 1 1 O
clearance NN 0 1 16 O
of IN 0 0 12 O
caffeine NN 0 1 6 B-Drug
and CC 0 0 12 O
a DT 0 0 12 O
prolongation NN 0 1 6 O
of IN 0 0 12 O
its PRP$ 1 0 12 O
plasma NN 0 1 14 O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
. . 0 0 12 O

Caution NN 0 0 UNK O
in IN 0 0 12 O
using VBG 1 1 1 O
concomitant JJ 0 1 6 O
drugs NNS 1 1 6 O
such JJ 0 0 1 O
as IN 1 0 12 O
beta NN 0 1 16 B-Group
- : 0 0 2 O
blockers NNS 1 0 6 I-Group
( ( 0 0 2 O
ophthalmic JJ 0 1 6 O
and CC 0 0 12 O
systemic JJ 0 1 6 O
) ) 0 0 2 O
anti SYM 0 0 3 B-Group
- : 0 0 2 O
hypertensives NNS 1 1 UNK I-Group
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
cardiac JJ 0 1 6 B-Group
glycosides NNS 1 1 13 I-Group
is VBZ 1 0 12 O
advised VBN 1 0 12 O
. . 0 0 12 O

The DT 0 0 2 O
use NN 0 1 1 O
of IN 0 0 12 O
NIMBEX NNP 0 1 UNK B-Brand
before IN 0 1 12 O
succinylcholine NN 0 1 16 B-Drug
to TO 0 0 12 O
attenuate VB 0 1 UNK O
some DT 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
side NN 0 1 3 O
effects NNS 1 1 1 O
of IN 0 0 12 O
succinylcholine NN 0 1 16 B-Drug
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
studied VBN 1 0 1 O
. . 0 0 12 O

Terfenadine NN 0 1 UNK B-Drug
: : 0 0 2 O
Administration NN 0 1 UNK O
of IN 0 0 12 O
terfenadine NN 0 1 UNK B-Drug
with IN 0 0 12 O
VIRACEPT NNP 0 1 UNK B-Brand
resulted VBD 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
appearance NN 0 1 12 O
of IN 0 0 12 O
unchanged JJ 0 1 1 O
terfenadine NN 0 1 UNK B-Drug
in IN 0 0 12 O
plasma NN 0 1 14 O
; : 0 0 2 O

however RB 0 0 12 O
the DT 0 0 12 O
clinical JJ 0 1 6 O
significance NN 0 1 13 O
of IN 0 0 12 O
this DT 0 0 12 O
interaction NN 0 1 UNK O
is VBZ 1 0 12 O
not RB 0 1 12 O
well RB 0 1 12 O
documented VBN 1 1 1 O
. . 0 0 12 O

Patients NNS 0 1 7 O
receiving VBG 1 1 1 O
oral JJ 0 1 6 O
anticoagulant JJ 0 1 13 O
therapy NN 0 1 6 O
require VBP 0 0 1 O
close JJ 0 1 12 O
monitoring NN 0 1 1 O
especially RB 0 0 12 O
when WRB 0 0 12 O
anabolic JJ 0 1 13 B-Group
steroids NNS 1 1 6 I-Group
are VBP 1 0 12 O
started VBN 1 1 12 O
or CC 0 0 12 O
stopped VBN 1 1 12 O
. . 0 0 12 O

ERYTHROMYCIN NN 0 1 UNK B-Drug
: : 0 0 2 O
In IN 0 0 2 O
hypercholesterolemic JJ 0 0 UNK O
patients NNS 1 1 6 O
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
cerivastatin NN 0 1 UNK B-Drug
AUC NNP 0 1 UNK O
and CC 0 0 12 O
Cmax NNP 0 1 UNK O
increased VBD 1 1 1 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
respectively RB 0 0 1 O
after IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
with IN 0 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
erythromycin FW 0 1 0 B-Drug
a DT 0 0 12 O
known VBN 1 1 12 O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
9A9 CD 0 0 UNK O
. . 0 0 12 O

Because IN 0 0 12 O
of IN 0 0 12 O
its PRP$ 1 0 12 O
lack NN 0 1 1 O
of IN 0 0 12 O
anti JJ 0 0 3 O
- : 0 0 2 O
platelet NN 0 1 14 O
effect NN 0 1 1 O
valdecoxib NN 0 1 13 B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
a DT 0 0 12 O
substitute NN 0 0 16 O
for IN 0 0 12 O
aspirin NN 0 1 14 B-Brand
for IN 0 0 12 O
cardiovascular JJ 0 1 6 O
prophylaxis NN 0 1 6 O
. . 0 0 12 O

Therefore RB 0 0 1 O
there EX 0 0 12 O
is VBZ 1 0 12 O
a DT 0 0 12 O
potential JJ 0 1 1 O
for IN 0 0 12 O
an DT 0 0 12 O
in IN 0 0 12 O
vivo JJ 0 1 13 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
with IN 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
are VBP 1 0 12 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
P9 NNP 0 1 UNK O
9D9 CD 0 0 UNK O
. . 0 0 12 O

In IN 0 0 2 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
week NN 0 1 12 O
endoscopy NN 0 1 6 O
study NN 0 1 1 O
conducted VBN 1 1 1 O
in IN 0 0 12 O
OA NNP 0 1 13 O
patients NNS 1 1 6 O
there EX 0 0 12 O
was VBD 1 0 12 O
no DT 0 0 12 O
difference NN 0 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
cumulative JJ 0 1 13 O
incidence NN 0 1 6 O
of IN 0 0 12 O
endoscopic JJ 0 1 8 O
gastroduodenal JJ 0 1 8 O
ulcers NNS 1 1 6 O
in IN 0 0 12 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
low JJ 0 1 1 O
- : 0 0 2 O
dose NN 0 1 6 O
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
) ) 0 0 2 O
enteric NN 0 1 14 O
coated VBN 1 1 3 O
aspirin JJ 0 1 14 B-Brand
plus CC 0 1 16 O
VIOXX JJ 0 1 UNK B-Brand
9 CD 0 0 2 O
mg JJ 0 1 0 O
daily RB 0 1 12 O
as IN 1 0 12 O
compared VBN 1 1 1 O
to TO 0 0 12 O
those DT 0 0 12 O
taking VBG 1 0 12 O
ibuprofen JJ 0 1 0 B-Drug
9 CD 0 0 2 O
mg JJ 0 1 0 O
daily JJ 0 1 12 O
alone RB 0 1 12 O
. . 0 0 12 O

Mercaptopurine NNP 0 1 UNK B-Drug
/ NNP 0 0 2 O
Azathioprine NNP 0 1 UNK B-Drug
: : 0 0 2 O
Allopurinol NNP 0 1 0 B-Drug
inhibits VBZ 1 1 UNK O
the DT 0 0 12 O
enzymatic JJ 0 1 UNK O
oxidation NN 0 1 13 O
of IN 0 0 12 O
mercaptopurine NN 0 1 13 B-Drug
and CC 0 0 12 O
azathioprine NN 0 1 13 B-Drug
to TO 0 0 12 O
9 CD 0 0 2 B-Drug
- : 0 0 2 O
thiouric JJ 0 0 UNK I-Drug
acid NN 0 1 14 I-Drug
. . 0 0 12 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interactions NNP 0 1 UNK O
There EX 0 0 12 O
are VBP 1 0 12 O
no DT 0 0 12 O
reported JJ 0 1 1 O
drug NN 0 1 1 O
- : 0 0 2 O
laboratory NN 0 1 1 O
test NN 0 1 1 O
interactions NNS 1 1 UNK O
. . 0 0 12 O

Ethinyl NNP 0 0 UNK B-Drug
Estradiol NNP 0 1 UNK I-Drug
and CC 0 0 12 O
Norethindrone NNP 0 1 UNK B-Drug
: : 0 0 2 O
Coadministration NN 0 1 UNK O
of IN 0 0 12 O
VIRACEPT NNP 0 1 UNK B-Brand
with IN 0 0 12 O
OVCON NNP 0 1 UNK B-Brand
- : 0 0 2 O
9 CD 0 0 2 I-Brand
resulted VBD 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
decrease NN 0 1 1 O
in IN 0 0 12 O
ethinyl JJ 0 0 13 B-Drug
estradiol NN 0 1 13 I-Drug
and CC 0 0 12 O
an DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
decrease NN 0 1 1 O
in IN 0 0 12 O
norethindrone NN 0 1 13 B-Drug
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
. . 0 0 12 O

When WRB 0 0 12 O
ertapenem NN 0 1 16 B-Drug
is VBZ 1 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
with IN 0 0 12 O
probenecid NN 0 1 13 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
p.o NN 0 1 UNK O
. . 0 0 12 O
every DT 0 0 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
) ) 0 0 2 O
probenecid VBP 0 1 13 B-Drug
competes NNS 0 0 UNK O
for IN 0 0 12 O
active JJ 0 1 1 O
tubular JJ 0 1 3 O
secretion NN 0 1 14 O
and CC 0 0 12 O
reduces VBZ 1 0 UNK O
the DT 0 0 12 O
renal JJ 0 1 6 O
clearance NN 0 1 16 O
of IN 0 0 12 O
ertapenem NN 0 1 16 B-Drug
. . 0 0 12 O

triclofos JJ 0 1 UNK B-Drug
sodium NN 0 1 14 I-Drug
; : 0 0 2 O

Of IN 0 0 2 O
the DT 0 0 12 O
9 CD 0 0 2 O
patients NNS 1 1 6 O
who WP 0 0 12 O
received VBD 1 1 12 O
AMEVIVE NNP 0 1 UNK B-Brand
in IN 0 0 12 O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
a DT 0 0 12 O
total NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
patients NNS 1 1 6 O
were VBD 1 0 12 O

Coadministration NN 0 1 UNK O
with IN 0 0 12 O
valdecoxib NN 0 1 13 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
BID NNP 0 0 11 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
) ) 0 0 2 O
resulted VBD 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
significant JJ 0 1 1 O
increase NN 0 1 1 O
in IN 0 0 12 O
dextromethorphan JJ 0 1 16 B-Drug
plasma NN 0 1 14 O
levels NNS 1 1 1 O
suggesting VBG 1 1 1 O
that IN 0 0 12 O
at IN 0 0 12 O
these DT 0 0 12 O
doses NNS 1 1 6 O
valdecoxib VBP 0 1 13 B-Drug
is VBZ 1 0 12 O
a DT 0 0 12 O
weak JJ 0 1 12 O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
9D9 CD 0 0 UNK O
. . 0 0 12 O

Curariform NNP 0 1 UNK B-Group
Drugs NNP 0 1 2 I-Group
: : 0 0 2 O
Diuretic NNP 0 1 UNK B-Group
- : 0 0 2 O
induced VBD 1 1 6 O
hypokalemia NN 0 1 14 O
may MD 0 0 1 O
enhance VB 0 1 UNK O
neuromuscular JJ 0 1 6 O
blocking VBG 1 1 UNK O
effects NNS 1 1 1 O
of IN 0 0 12 O
curariform NN 0 1 UNK B-Group
drugs NNS 1 1 6 I-Group
( ( 0 0 2 O
such JJ 0 0 1 O
as IN 1 0 12 O
tubocurarine NN 0 1 UNK B-Drug
) ) 0 0 2 O
the DT 0 0 12 O
most RBS 0 0 12 O
serious JJ 0 1 12 O
effect NN 0 1 1 O
would MD 0 0 12 O
be VB 0 0 12 O
respiratory JJ 0 1 6 O
depression NN 0 1 6 O
which WDT 0 0 12 O
could MD 0 0 12 O
proceed VB 0 0 1 O
to TO 0 0 12 O
apnea VB 0 1 6 O
. . 0 0 12 O

Also RB 0 0 2 O
bleeding VBG 1 1 6 O
and CC 0 0 12 O
/ JJ 0 0 2 O
or CC 0 0 12 O
increased JJ 0 1 1 O
prothrombin NN 0 1 14 O
time NN 0 1 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
few JJ 0 1 12 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
coumarin JJ 0 1 UNK B-Group
anticoagulants NNS 1 1 13 I-Group
concomitantly RB 0 0 14 O
with IN 0 0 12 O
lovastatin NN 0 1 13 B-Drug
. . 0 0 12 O

Thus RB 0 0 1 O
the DT 0 0 12 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
would MD 0 0 12 O
increase VB 0 1 1 O
meaning VBG 1 1 UNK O
side JJ 0 1 3 O
effects NNS 1 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
seen VBN 1 1 12 O
. . 0 0 12 O

Antacids NNS 0 1 UNK B-Group
: : 0 0 2 O
In IN 0 0 2 O
a DT 0 0 12 O
single JJ 0 1 12 O
dose NN 0 1 6 O
study NN 0 1 1 O
( ( 0 0 2 O
n=9 JJ 0 1 UNK O
) ) 0 0 2 O
ingestion NN 0 1 14 O
of IN 0 0 12 O
an DT 0 0 12 O
antacid NN 0 1 UNK B-Group
containing VBG 1 1 1 O
9 CD 0 0 2 O
- : 0 0 2 O
gram NN 0 1 16 O
of IN 0 0 12 O
magnesium NN 0 1 14 B-Drug
hydroxide NN 0 1 14 I-Drug
with IN 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
mg NN 0 1 0 O
of IN 0 0 12 O
mefenamic JJ 0 0 UNK B-Drug
acid NN 0 1 14 I-Drug
increased VBD 1 1 1 O
the DT 0 0 12 O
Cmax NNP 0 1 UNK O
and CC 0 0 12 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
mefenamic JJ 0 0 UNK B-Drug
acid NN 0 1 14 I-Drug
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
respectively RB 0 0 1 O
. . 0 0 12 O
A DT 0 0 2 O
number NN 0 1 1 O
of IN 0 0 12 O
compounds NNS 1 1 13 O
are VBP 1 0 12 O
inhibitors NNS 1 1 14 O
of IN 0 0 12 O
CYP9C9 NNP 0 0 UNK O
including VBG 1 1 1 O
fluconazole JJ 0 1 0 B-Drug
lovastatin NN 0 1 13 B-Drug
and CC 0 0 12 O
trimethoprim NN 0 1 16 B-Drug
. . 0 0 12 O

Monitoring NN 0 1 UNK O
of IN 0 0 12 O
liver NN 0 1 6 O
enzymes NNS 1 1 14 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
when WRB 0 0 12 O
SUSTIVA NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
used VBN 1 1 12 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
ritonavir NN 0 1 16 B-Drug
. . 0 0 12 O

Asubnormal JJ 0 0 UNK O
response NN 0 1 1 O
may MD 0 0 1 O
occur VB 0 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
on IN 0 0 12 O
estrogen NN 0 1 6 O
therapy NN 0 1 6 O
. . 0 0 12 O

Imipramine NNP 0 1 UNK B-Drug
hydrochloride NN 0 1 0 I-Drug
may MD 0 0 1 O
potentiate VB 0 0 UNK O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
CNS NNP 0 1 6 B-Group
depressant NN 0 0 UNK I-Group
drugs NNS 1 1 6 I-Group
. . 0 0 12 O

As IN 0 0 2 O
with IN 0 0 12 O
other JJ 0 0 12 O
agents NNS 1 1 1 B-Group
with IN 0 0 12 I-Group
b SYM 0 0 16 I-Group
- : 0 0 2 O
blocking NN 0 1 UNK I-Group
properties NNS 1 1 UNK I-Group
if IN 0 0 12 O
COREG NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
to TO 0 0 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
orally RB 0 1 14 O
with IN 0 0 12 O
calcium NN 0 1 14 B-Group
channel NN 0 1 1 I-Group
blockers NNS 1 0 6 I-Group
of IN 0 0 12 O
the DT 0 0 12 O
verapamil NN 0 1 0 B-Drug
or CC 0 0 12 O
diltiazem NN 0 1 0 B-Drug
type NN 0 1 1 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
that IN 0 0 12 O
ECG NNP 0 1 6 O
and CC 0 0 12 O
blood NN 0 1 6 O
pressure NN 0 1 1 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
incidence NN 0 1 6 O
of IN 0 0 12 O
akathisia NN 0 1 UNK O
however RB 0 0 12 O
is VBZ 1 0 12 O
within IN 0 0 1 O
the DT 0 0 12 O
range NN 0 1 1 O
reported VBD 1 1 1 O
for IN 0 0 12 O
use NN 0 1 1 O
of IN 0 0 12 O
prochlorperazine NN 0 1 16 B-Drug
when WRB 0 0 12 O
given VBN 1 1 12 O
as IN 1 0 12 O
a DT 0 0 12 O
premedication NN 0 1 UNK O
for IN 0 0 12 O
other JJ 0 0 12 O
chemotherapies NNS 1 1 UNK O
. . 0 0 12 O

Among IN 0 0 UNK O
these DT 0 0 12 O
patients NNS 1 1 6 O
the DT 0 0 12 O
incidence NN 0 1 6 O
of IN 0 0 12 O
upper JJ 0 1 3 O
gastrointestinal JJ 0 1 6 O
adverse JJ 0 0 1 O
experiences NNS 1 1 12 O
in IN 0 0 12 O
the DT 0 0 12 O
patients NNS 1 1 6 O
treated VBN 1 1 1 O
with IN 0 0 12 O
Ibandronate NNP 0 1 UNK B-Drug
was VBD 1 0 12 O
similar JJ 0 1 1 O
to TO 0 0 12 O
that DT 0 0 12 O
in IN 0 0 12 O
placebo NN 0 1 13 O
- : 0 0 2 O
treated JJ 0 1 1 O
patients NNS 1 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
incremental JJ 0 1 UNK O
LDL NNP 0 0 14 O
- : 0 0 2 O
C NNP 0 0 2 O
reduction NN 0 1 1 O
due JJ 0 1 1 O
to TO 0 0 12 O
adding VBG 1 1 1 O
ezetimibe NN 0 1 16 B-Drug
to TO 0 0 12 O
cholestyramine VB 0 1 13 B-Drug
may MD 0 0 1 O
be VB 0 0 12 O
reduced VBN 1 1 1 O
by IN 0 0 12 O
this DT 0 0 12 O
interaction NN 0 1 UNK O
. . 0 0 12 O

INDOCIN NNP 0 1 UNK B-Brand
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
decrease VB 0 1 1 O
the DT 0 0 12 O
tubular JJ 0 1 3 O
secretion NN 0 1 14 O
of IN 0 0 12 O
methotrexate NN 0 1 16 B-Drug
and CC 0 0 12 O
to TO 0 0 12 O
potentiate VB 0 0 UNK O
its PRP$ 1 0 12 O
toxicity NN 0 1 6 O
. . 0 0 12 O

Based VBN 0 1 2 O
on IN 0 0 12 O
these DT 0 0 12 O
data NNS 0 1 1 O
Vardenafil NNP 0 1 UNK B-Drug
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
in IN 0 0 12 O
patients NNS 1 1 6 O
on IN 0 0 12 O
alpha JJ 0 1 1 B-Group
- : 0 0 2 O
blocker NN 0 0 3 I-Group
therapy NN 0 1 6 O
. . 0 0 12 O

Amprenavir NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
metabolized VBN 1 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
liver NN 0 1 6 O
by IN 0 0 12 O
the DT 0 0 12 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
enzyme NN 0 1 14 O
system NN 0 1 1 O
. . 0 0 12 O

Warfarin NN 0 1 0 B-Drug
: : 0 0 2 O
The DT 0 0 2 O
effect NN 0 1 1 O
of IN 0 0 12 O
celecoxib NN 0 1 16 B-Drug
on IN 0 0 12 O
the DT 0 0 12 O
anti JJ 0 0 3 O
- : 0 0 2 O
coagulant JJ 0 1 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
was VBD 1 0 12 O
studied VBN 1 0 1 O
in IN 0 0 12 O
a DT 0 0 12 O
group NN 0 1 12 O
of IN 0 0 12 O
healthy JJ 0 1 12 O
subjects NNS 1 1 UNK O
receiving VBG 1 1 1 O
daily JJ 0 1 12 O
doses NNS 1 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
of IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
. . 0 0 12 O

Phosphate NNP 0 1 14 O
- : 0 0 2 O
Binding VBG 0 1 UNK O
Agents NNS 0 1 2 O
: : 0 0 2 O
Since IN 0 1 2 O
vitamin NN 0 1 6 B-Group
D NNP 0 1 2 I-Group
also RB 0 0 12 O
has VBZ 1 0 12 O
an DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
phosphate NN 0 1 14 O
transport NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
intestine NN 0 1 6 O
kidneys NN 1 1 6 O
and CC 0 0 12 O
bones VBZ 1 1 3 O
the DT 0 0 12 O
dosage NN 0 1 0 O
of IN 0 0 12 O
phosphate NN 0 1 14 O
- : 0 0 2 O
binding NN 0 1 1 O
agents NNS 1 1 1 O
must MD 0 0 12 O
be VB 0 0 12 O
adjusted VBN 1 1 1 O
in IN 0 0 12 O
accordance NN 0 0 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
serum NN 0 1 14 O
phosphate NN 0 1 14 O
concentration NN 0 1 1 O
. . 0 0 12 O

If IN 0 0 12 O
hypotension NN 0 1 6 O
occurs VBZ 1 1 1 O
the DT 0 0 12 O
patient NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
placed VBN 1 1 12 O
in IN 0 0 12 O
a DT 0 0 12 O
supine JJ 0 1 8 O
position NN 0 1 1 O
and CC 0 0 12 O
if IN 0 0 12 O
necessary JJ 0 0 1 O
receive VBP 0 1 1 O
an DT 0 0 12 O
intravenous JJ 0 1 14 O
infusion NN 0 1 14 O
of IN 0 0 12 O
normal JJ 0 1 1 O
saline NN 0 1 14 O
. . 0 0 12 O

A DT 0 0 2 O
potential JJ 0 1 1 O
interaction NN 0 1 UNK O
between IN 0 0 12 O
oral JJ 0 1 6 O
miconazole NN 0 1 16 B-Drug
and CC 0 0 12 O
oral JJ 0 1 6 O
hypoglycemic JJ 0 1 14 B-Group
agents NNS 1 1 1 I-Group
leading VBG 1 1 1 O
to TO 0 0 12 O
severe JJ 0 1 6 O
hypoglycemia NN 0 1 6 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
. . 0 0 12 O

Cholestyramine NN 0 1 UNK B-Drug
: : 0 0 2 O
Cholestyramine NNP 0 1 UNK B-Drug
causes VBZ 1 1 6 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
reduction NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
absorption NN 0 1 1 O
and CC 0 0 12 O
enterohepatic JJ 0 0 UNK O
cycling NN 0 1 UNK O
of IN 0 0 12 O
raloxifene NN 0 1 13 B-Drug
and CC 0 0 12 O
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
EVISTA NNP 0 1 UNK B-Brand
. . 0 0 12 O

poor JJ 0 1 12 O
metabolizers NNS 0 0 UNK O
of IN 0 0 12 O
debrisoquin NN 0 1 UNK B-Drug
: : 0 0 2 O
Interactions NNS 0 1 UNK O
of IN 0 0 12 O
carvedilol NN 0 1 16 B-Drug
with IN 0 0 12 O
strong JJ 0 1 12 O
inhibitors NNS 1 1 14 O
of IN 0 0 12 O
CYP9D9 NNP 0 0 UNK O
( ( 0 0 2 O
such JJ 0 0 1 O
as IN 1 0 12 O
quinidine JJ 0 1 16 B-Drug
fluoxetine NN 0 1 16 B-Drug
paroxetine NN 0 1 16 B-Drug
and CC 0 0 12 O
propafenone NN 0 1 16 B-Drug
) ) 0 0 2 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
studied VBN 1 0 1 O
but CC 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
would MD 0 0 12 O
be VB 0 0 12 O
expected VBN 1 1 12 O
to TO 0 0 12 O
increase VB 0 1 1 O
blood NN 0 1 6 O
levels NNS 1 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
R NNP 0 1 2 O
( ( 0 0 2 O
+ NNP 0 0 2 O
) ) 0 0 2 O
enantiomer NN 0 1 UNK O
of IN 0 0 12 O
carvedilol NN 0 1 16 B-Drug
. . 0 0 12 O

Nelfinavir NNP 0 1 UNK B-Drug
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
Cmax NNP 0 1 UNK O
A.C. NNP 0 0 UNK O
and CC 0 0 12 O
Cmin NNP 0 1 UNK O
were VBD 1 0 12 O
increased VBN 1 1 1 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
respectively RB 0 0 1 O
by IN 0 0 12 O
concomitant JJ 0 1 6 O
amprenavir NN 0 1 13 B-Drug
. . 0 0 12 O

Omeprazole NN 0 1 0 B-Drug
: : 0 0 2 O
The DT 0 0 2 O
rate NN 0 1 1 O
and CC 0 0 12 O
extent NN 0 1 1 O
of IN 0 0 12 O
absorption NN 0 1 1 O
of IN 0 0 12 O
ciprofloxacin NN 0 1 0 B-Drug
was VBD 1 0 12 O
bioequivalent JJ 0 1 UNK O
when WRB 0 0 12 O
Proquin NNP 0 1 UNK B-Brand
XR NNP 0 1 0 I-Brand
was VBD 1 0 12 O
given VBN 1 1 12 O
alone RB 0 1 12 O
or CC 0 0 12 O
when WRB 0 0 12 O
Proquin NNP 0 1 UNK B-Brand
XR NNP 0 1 0 I-Brand
was VBD 1 0 12 O
given VBN 1 1 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
after IN 0 0 12 O
omeprazole NN 0 1 0 B-Drug
at IN 0 0 12 O
the DT 0 0 12 O
dose NN 0 1 6 O
that WDT 0 0 12 O
maximally RB 0 0 1 O
suppresses VBZ 1 1 UNK O
gastric JJ 0 1 6 O
acid JJ 0 1 14 O
secretion NN 0 1 14 O
. . 0 0 12 O

Table JJ 0 1 UNK O
9 CD 0 0 2 O

Phenobarbital NN 0 1 0 B-Drug

Drugs NNS 0 1 2 O
that WDT 0 0 12 O
reportedly RB 0 0 12 O
may MD 0 0 1 O
increase VB 0 1 1 O
oral JJ 0 1 6 O
anticoagulant JJ 0 1 13 B-Group
response NN 0 1 1 O
ie NN 0 0 1 O
increased VBD 1 1 1 O
prothrombin JJ 0 1 14 O
response NN 0 1 1 O
in IN 0 0 12 O
man NN 0 1 12 O
include VBP 0 1 1 O
: : 0 0 2 O
alcohol NN 0 1 1 B-Drug
* NN 0 0 2 O
; : 0 0 2 O

Intravenous JJ 0 1 7 O
Pentamidine NN 0 1 0 B-Drug
: : 0 0 2 O
Treatment NN 0 1 7 O
with IN 0 0 12 O
HIVID NNP 0 1 UNK B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
interrupted VBN 1 1 12 O
when WRB 0 0 12 O
the DT 0 0 12 O
use NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
drug NN 0 1 1 O
that WDT 0 0 12 O
has VBZ 1 0 12 O
the DT 0 0 12 O
potential JJ 0 1 1 O
to TO 0 0 12 O
cause VB 0 1 12 O
pancreatitis NN 0 1 6 O
is VBZ 1 0 12 O
required VBN 1 1 1 O
. . 0 0 12 O

Leucovorin NNP 0 1 UNK B-Drug
may MD 0 0 1 O
enhance VB 0 1 UNK O
the DT 0 0 12 O
toxicity NN 0 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 B-Drug
- : 0 0 2 O
fluorouracil NN 0 1 13 I-Drug
. . 0 0 12 O

Drug NNP 0 1 2 O
- : 0 0 2 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
Mefloquine NNP 0 1 UNK B-Drug
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
explored VBN 1 0 1 O
in IN 0 0 12 O
detail NN 0 1 1 O
. . 0 0 12 O

Hypokalemia NNP 0 1 7 O
can MD 0 0 12 O
sensitize VB 0 0 UNK O
or CC 0 0 12 O
exaggerate VB 0 1 UNK O
the DT 0 0 12 O
response NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
heart NN 0 1 12 O
to TO 0 0 12 O
the DT 0 0 12 O
toxic JJ 0 1 1 O
effects NNS 1 1 1 O
of IN 0 0 12 O
digitalis NN 0 1 14 B-Group
( ( 0 0 2 O
e.g. NN 0 0 UNK O
increased VBD 1 1 1 O
ventricular JJ 0 1 8 O
irritability NN 0 1 6 O
) ) 0 0 2 O
. . 0 0 12 O

In IN 0 0 2 O
a DT 0 0 12 O
study NN 0 1 1 O
in IN 0 0 12 O
hypertensive JJ 0 1 6 O
patients NNS 1 1 6 O
addition NN 0 1 1 O
of IN 0 0 12 O
isradipine NN 0 1 13 B-Drug
to TO 0 0 12 O
existing VBG 1 1 1 O
hydrochlorothiazide JJ 0 1 0 B-Drug
therapy NN 0 1 6 O
did VBD 1 0 12 O
not RB 0 1 12 O
result VB 0 1 1 O
in IN 0 0 12 O
any DT 0 0 12 O
unexpected JJ 0 1 12 O
adverse JJ 0 0 1 O
effects NNS 1 1 1 O
and CC 0 0 12 O
isradipine NN 0 1 13 B-Drug
had VBD 1 0 12 O
an DT 0 0 12 O
additional JJ 0 1 1 O
antihypertensive JJ 0 1 14 O
effect NN 0 1 1 O
. . 0 0 12 O

Zidovudine NNP 0 1 UNK B-Drug
should MD 0 0 12 O
either RB 0 1 12 O
be VB 0 0 12 O
temporarily RB 0 0 1 O
discontinued VBN 1 1 1 O
or CC 0 0 12 O
decreased VBN 1 1 1 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
when WRB 0 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
probenecid NN 0 1 13 B-Drug
on IN 0 0 12 O
the DT 0 0 12 O
day NN 0 1 12 O
of IN 0 0 12 O
VISTIDE NNP 0 1 UNK B-Brand
infusion NN 0 1 14 O
. . 0 0 12 O

Anticonvulsants NNS 0 1 UNK B-Group

Although IN 0 0 12 O
the DT 0 0 12 O
interaction NN 0 1 UNK O
between IN 0 0 12 O
almotriptan NN 0 1 13 B-Drug
and CC 0 0 12 O
other JJ 0 0 12 O
potent NN 0 1 UNK O
CYP9A9 NNP 0 0 UNK O
inhibitors NNS 1 1 14 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
itraconazole NN 0 1 0 B-Drug
ritonavir NN 0 1 16 B-Drug
and CC 0 0 12 O
erythromycin NN 0 1 0 B-Drug
) ) 0 0 2 O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
studied VBN 1 0 1 O
increased JJ 0 1 1 O
exposures NNS 1 1 UNK O
to TO 0 0 12 O
almotriptan VB 0 1 13 B-Drug
may MD 0 0 1 O
be VB 0 0 12 O
expected VBN 1 1 12 O
when WRB 0 0 12 O
almotriptan NN 0 1 13 B-Drug
is VBZ 1 0 12 O
used VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
these DT 0 0 12 O
medications NNS 1 1 6 O
. . 0 0 12 O

( ( 0 0 2 O
Read NNP 0 1 2 O
circulars NNS 1 1 UNK O
for IN 0 0 12 O
lithium NN 0 1 16 B-Drug
preparation NN 0 1 1 O
before IN 0 1 12 O
use NN 0 1 1 O
of IN 0 0 12 O
such JJ 0 0 1 O
concurrent JJ 0 1 1 O
therapy NN 0 1 6 O
) ) 0 0 2 O
. . 0 0 12 O

Patients NNS 0 1 7 O
should MD 0 0 12 O
be VB 0 0 12 O
closely RB 0 0 1 O
monitored VBN 1 1 1 O
for IN 0 0 12 O
signs NNS 1 1 12 O
and CC 0 0 12 O
symptoms NNS 1 1 6 O
of IN 0 0 12 O
occult NN 0 1 6 O
bleeding NN 0 1 6 O
. . 0 0 12 O

Nevertheless RB 0 0 1 O
during IN 0 0 12 O
concomitant JJ 0 1 6 O
therapy NN 0 1 6 O
with IN 0 0 12 O
furosemide NN 0 1 0 B-Drug
and CC 0 0 12 O
MOBIC NNP 0 1 UNK B-Brand
patients NNS 1 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
observed VBN 1 1 1 O
closely RB 0 0 1 O
for IN 0 0 12 O
signs NNS 1 1 12 O
of IN 0 0 12 O
declining VBG 1 1 1 O
renal JJ 0 1 6 O
function NN 0 1 1 O
as RB 0 0 12 O
well RB 0 1 12 O
as IN 1 0 12 O
to TO 0 0 12 O
assure VB 0 0 1 O
diuretic JJ 0 1 14 O
efficacy NN 0 1 UNK O
. . 0 0 12 O

Capsules NNP 0 1 0 O
INDOCIN NNP 0 1 UNK B-Brand
9 CD 0 0 2 O
mg NN 0 1 0 O
t.i.d NN 0 1 UNK O
. . 0 0 12 O
produced VBD 1 0 1 O
a DT 0 0 12 O
clinically RB 0 0 6 O
relevant JJ 0 1 1 O
elevation NN 0 1 1 O
of IN 0 0 12 O
plasma JJ 0 1 14 O
lithium NN 0 1 16 B-Drug
and CC 0 0 12 O
reduction NN 0 1 1 O
in IN 0 0 12 O
renal JJ 0 1 6 O
lithium NN 0 1 16 B-Drug
clearance NN 0 1 16 O
in IN 0 0 12 O
psychiatric JJ 0 1 6 O
patients NNS 1 1 6 O
and CC 0 0 12 O
normal JJ 0 1 1 O
subjects NNS 1 1 UNK O
with IN 0 0 12 O
steady JJ 0 1 1 O
state NN 0 1 1 O
plasma NN 0 1 14 O
lithium NN 0 1 16 B-Drug
concentrations NNS 1 1 13 O
. . 0 0 12 O

Cyclosporine NN 0 1 UNK B-Drug
: : 0 0 2 O
When WRB 0 0 12 O
studied VBN 1 0 1 O
in IN 0 0 12 O
stable JJ 0 1 1 O
renal JJ 0 1 6 O
transplant NN 0 1 6 O
patients NNS 1 1 6 O
cyclosporine VBP 0 1 14 B-Drug
USP NNP 0 1 UNK O
( ( 0 0 2 O
MODIFIED NNP 0 1 UNK O
) ) 0 0 2 O
pharmacokinetics NNS 0 1 UNK O
were VBD 1 0 12 O
unaffected VBN 0 1 UNK O
by IN 0 0 12 O
steady JJ 0 1 1 O
state NN 0 1 1 O
dosing NN 0 0 14 O
of IN 0 0 12 O
Myfortic NNP 0 1 UNK B-Brand
. . 0 0 12 O

When WRB 0 0 12 O
s.c NN 0 1 UNK O
. . 0 0 12 O

Clinical JJ 0 1 7 O
Comment NN 0 1 2 O

Concomitant JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
terfenadine NN 0 1 UNK B-Drug
with IN 0 0 12 O
clarithromycin JJ 0 1 13 B-Drug
erythromycin NN 0 1 0 B-Drug
or CC 0 0 12 O
troleandomycin NN 0 1 UNK B-Drug
is VBZ 1 0 12 O
contraindicated VBN 1 1 14 O
: : 0 0 2 O
Pending VBG 0 0 2 O
full JJ 0 1 12 O
characterization NN 0 1 UNK O
of IN 0 0 12 O
potential JJ 0 1 1 O
interactions NNS 1 1 UNK O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
terfenadine NN 0 1 UNK B-Drug
with IN 0 0 12 O
other JJ 0 0 12 O
macrolide JJ 0 1 UNK B-Group
antibiotics NNS 1 1 6 I-Group
including VBG 1 1 1 O
azithromycin NN 0 1 0 B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O

Administration NN 0 1 UNK O
of IN 0 0 12 O
rifampin NNS 0 1 16 B-Drug
concomitantly RB 0 0 14 O
with IN 0 0 12 O
oral JJ 0 1 6 O
amiodarone NN 0 1 0 B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
result VB 0 1 1 O
in IN 0 0 12 O
decreases NNS 1 1 UNK O
in IN 0 0 12 O
serum JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
amiodarone NN 0 1 0 B-Drug
and CC 0 0 12 O
desethylamiodarone NN 0 1 UNK B-Drug
. . 0 0 12 O

No DT 0 0 2 O
information NN 0 1 1 O
available JJ 0 1 1 O
. . 0 0 12 O

Potassium NNP 0 1 14 B-Group
- : 0 0 2 O
sparing VBG 1 0 6 I-Group
diuretics NNS 1 1 14 I-Group
( ( 0 0 2 O
e.g. VB 0 0 UNK O
spironolactone NN 0 1 0 B-Drug
triamterene NN 0 1 13 B-Drug
or CC 0 0 12 O
amiloride NN 0 1 16 B-Drug
) ) 0 0 2 O
potassium NN 0 1 14 B-Drug
supplements NNS 1 1 6 O
or CC 0 0 12 O
potassium NN 0 1 14 B-Drug
- : 0 0 2 O
containing NN 0 1 1 O
salt NN 0 1 3 O
substitutes NNS 1 0 13 O
may MD 0 0 1 O
lead VB 0 1 12 O
to TO 0 0 12 O
significant JJ 0 1 1 O
increases NNS 1 1 1 O
in IN 0 0 12 O
serum JJ 0 1 14 O
potassium NN 0 1 14 O
. . 0 0 12 O

Other JJ 0 0 2 O
substances NNS 1 1 1 O
including VBG 1 1 1 O
herbal JJ 0 1 6 O
preparations NNS 1 1 13 O
: : 0 0 2 O
St. NNP 0 1 2 O
John NNP 0 0 19 O
Wort NNP 0 0 UNK O
( ( 0 0 2 O
Hypericum NNP 0 1 UNK O
perforatum NN 0 0 UNK O
) ) 0 0 2 O
induces VBZ 1 1 UNK O
CYP9A9 NNP 0 0 UNK O
. . 0 0 12 O

There EX 0 0 12 O
is VBZ 1 0 12 O
no DT 0 0 12 O
experience NN 0 1 12 O
with IN 0 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
Angiomax NNP 0 1 UNK B-Brand
and CC 0 0 12 O
plasma JJ 0 1 14 O
expanders NNS 0 1 UNK O
such JJ 0 0 1 O
as IN 1 0 12 O
dextran NN 0 1 14 B-Drug
. . 0 0 12 O

An DT 0 0 2 O
individual NN 0 1 1 O
who WP 0 0 12 O
is VBZ 1 0 12 O
stable JJ 0 1 1 O
on IN 0 0 12 O
a DT 0 0 12 O
given VBN 1 1 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
TCA NNP 0 1 13 B-Group
may MD 0 0 1 O
become VB 0 0 12 O
abruptly RB 0 0 UNK O
toxic JJ 0 1 1 O
when WRB 0 0 12 O
given VBN 1 1 12 O
one CD 0 1 12 O
of IN 0 0 12 O
these DT 0 0 12 O
inhibiting VBG 1 1 UNK O
drugs NNS 1 1 6 O
as IN 1 0 12 O
concomitant NN 0 1 6 O
therapy NN 0 1 6 O
. . 0 0 12 O

Catecholamine NNP 0 1 UNK B-Group
- : 0 0 2 O
depleting VBG 1 1 UNK I-Group
drugs NNS 1 1 6 I-Group
such JJ 0 0 1 O
as IN 1 0 12 O
reserpine NN 0 1 UNK B-Drug
may MD 0 0 1 O
have VB 0 0 12 O
an DT 0 0 12 O
additive JJ 0 1 16 O
effect NN 0 1 1 O
when WRB 0 0 12 O
given VBN 1 1 12 O
with IN 0 0 12 O
beta JJ 0 1 16 B-Group
- : 0 0 2 O
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
. . 0 0 12 O

Although IN 0 0 12 O
no DT 0 0 12 O
studies NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
conducted VBN 1 1 1 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
Itraconazole NNP 0 1 UNK B-Drug
and CC 0 0 12 O
phenytoin NN 0 1 16 B-Drug
may MD 0 0 1 O
alter VB 0 1 13 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
; : 0 0 2 O

The DT 0 0 2 O
clinical JJ 0 1 6 O
significance NN 0 1 13 O
of IN 0 0 12 O
these DT 0 0 12 O
changes NNS 1 1 1 O
is VBZ 1 0 12 O
unknown JJ 0 1 12 O
. . 0 0 12 O

Certain NNP 0 1 UNK O
drugs NNS 1 1 6 O
tend VBP 0 0 12 O
to TO 0 0 12 O
produce VB 0 0 1 O
hyperglycemia NN 0 1 14 O
and CC 0 0 12 O
may MD 0 0 1 O
lead VB 0 1 12 O
to TO 0 0 12 O
loss NN 0 1 1 O
of IN 0 0 12 O
blood NN 0 1 6 O
glucose NN 0 1 14 O
control NN 0 1 1 O
. . 0 0 12 O

Other JJ 0 0 2 O
reported VBD 1 1 1 O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
amiodarone NN 0 1 0 B-Drug
: : 0 0 2 O
Fentanyl NNP 0 1 0 B-Drug
( ( 0 0 2 O
CYP9A9 NNP 0 0 UNK B-Drug
substrate NN 0 1 UNK O
) ) 0 0 2 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
amiodarone NN 0 1 0 B-Drug
may MD 0 0 1 O
cause VB 0 1 12 O
hypotension NN 0 1 6 O
bradycardia NN 0 1 8 O
and CC 0 0 12 O
decreased JJ 0 1 1 O
cardiac NN 0 1 6 O
output NN 0 1 1 O
. . 0 0 12 O

Concomitant JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
propranolol NN 0 1 16 B-Drug
with IN 0 0 12 O
phenothiazines NNS 1 1 UNK B-Group
results NNS 1 1 1 O
in IN 0 0 12 O
increased JJ 0 1 1 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
both DT 0 0 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

Drug NN 0 1 2 O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
clomiphene JJ 0 1 UNK B-Drug
citrate JJ 0 1 14 I-Drug
tablets NNS 1 1 3 O
USP NNP 0 1 UNK O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
documented VBN 1 1 1 O
. . 0 0 12 O

These DT 0 0 1 O
studies NNS 1 1 1 O
indicate VBP 0 0 1 O
that IN 0 0 12 O
ketoconazole NN 0 1 16 B-Drug
or CC 0 0 12 O
erythromycin VB 0 1 0 B-Drug
co SYM 0 1 12 O
- : 0 0 2 O
administration NN 0 1 1 O
enhances VBZ 1 1 UNK O
fexofenadine JJ 0 1 16 B-Drug
gastrointestinal JJ 0 1 6 O
absorption NN 0 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
nonselective JJ 0 0 UNK O
monoamine NN 0 1 13 B-Group
oxidase NN 0 1 13 I-Group
inhibitors NNS 1 1 14 I-Group
( ( 0 0 2 O
MAOIs NNP 0 1 UNK B-Group
) ) 0 0 2 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
selegiline NN 0 1 13 B-Drug
hydrochloride NN 0 1 0 I-Drug
) ) 0 0 2 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
serotoninergic JJ 0 0 UNK B-Group
agents NNS 1 1 1 I-Group
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
fluoxetine NN 0 1 16 B-Drug
fluvoxamine NN 0 1 16 B-Drug
paroxetine NN 0 1 16 B-Drug
sertraline NN 0 1 16 B-Drug
venlafaxine NN 0 1 16 B-Drug
) ) 0 0 2 O
there EX 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reports NNS 1 1 1 O
of IN 0 0 12 O
serious JJ 0 1 12 O
sometimes NNS 0 1 12 O
fatal JJ 0 1 13 O
reactions NNS 1 1 1 O
. . 0 0 12 O

Interaction NN 0 1 2 O
with IN 0 0 12 O
central JJ 0 1 1 B-Group
nervous JJ 0 1 6 I-Group
system NN 0 1 1 I-Group
depressants VBZ 0 0 13 I-Group
other JJ 0 0 12 O
than IN 0 0 12 O
benzodiazepines NNS 1 1 14 B-Group
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
specifically RB 0 0 1 O
studied VBN 1 0 1 O
; : 0 0 2 O

Coadministration NN 0 1 UNK O
of IN 0 0 12 O
ethoxzolamide NN 0 1 UNK B-Drug
with IN 0 0 12 O
other JJ 0 0 12 O
diuretics NNS 1 1 14 B-Group
amphotericin VBP 0 1 14 B-Drug
B NNP 0 0 2 I-Drug
and CC 0 0 12 O
corticosteroids NNS 1 1 14 B-Group
may MD 0 0 1 O
cause VB 0 1 12 O
hypokalemia NN 0 1 14 O
. . 0 0 12 O

Formal JJ 0 1 2 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
with IN 0 0 12 O
Abciximab NNP 0 1 UNK B-Drug
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
conducted VBN 1 1 1 O
. . 0 0 12 O

Triazolam NN 0 1 UNK B-Drug
: : 0 0 2 O
Erythromycin NN 0 1 0 B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
decrease VB 0 1 1 O
the DT 0 0 12 O
clearance NN 0 1 16 O
of IN 0 0 12 O
triazolam NN 0 1 13 B-Drug
and CC 0 0 12 O
thus RB 0 0 1 O
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
pharmacologic JJ 0 1 14 O
effect NN 0 1 1 O
of IN 0 0 12 O
triazolam NN 0 1 13 B-Drug
. . 0 0 12 O

Nevirapine NNP 0 1 UNK B-Drug
and CC 0 0 12 O
rifampin NN 0 1 16 B-Drug
should MD 0 0 12 O
not RB 0 1 12 O
beadministered VB 0 0 UNK O
concomitantly RB 0 0 14 O
becausedecreases NNS 0 0 UNK O
in IN 0 0 12 O
nevirapine JJ 0 1 13 B-Drug
plasmaconcentrations NNS 0 0 UNK O
may MD 0 0 1 O
reduce VB 0 0 1 O
the DT 0 0 12 O
efficacy NN 0 1 UNK O
ofthe JJ 0 0 1 O
drug NN 0 1 1 O
. . 0 0 12 O

Other JJ 0 0 2 O
No NNP 0 0 2 O
clinically RB 0 0 6 O
important JJ 0 1 1 O
pharmacokinetic JJ 0 1 UNK O
interactions NNS 1 1 UNK O
occurred VBD 1 1 1 O
when WRB 0 0 12 O
Lotensin NNP 0 1 UNK B-Brand
was VBD 1 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
hydrochlorothiazide JJ 0 1 0 B-Drug
chlorthalidone NN 0 1 13 B-Drug
furosemide NN 0 1 0 B-Drug
digoxin NN 0 1 14 B-Drug
propranolol NN 0 1 16 B-Drug
atenolol NN 0 1 0 B-Drug
naproxen NN 0 1 16 B-Drug
or CC 0 0 12 O
cimetidine NN 0 1 13 B-Drug
. . 0 0 12 O

Eprosartan NNP 0 1 UNK B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
have VB 0 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
and CC 0 0 12 O
the DT 0 0 12 O
pharmacodynamics NNS 0 1 UNK O
of IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
and CC 0 0 12 O
glyburide NN 0 1 16 B-Drug
. . 0 0 12 O

Phenytoin NN 0 1 0 B-Drug
: : 0 0 2 O
Accutane NNP 0 1 UNK B-Brand
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
alter VB 0 1 13 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
in IN 0 0 12 O
a DT 0 0 12 O
study NN 0 1 1 O
in IN 0 0 12 O
seven CD 0 1 12 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
. . 0 0 12 O

Therefore RB 0 0 1 O
MAO NNP 0 1 14 B-Group
inhibitors NNS 1 1 14 I-Group
should MD 0 0 12 O
be VB 0 0 12 O
discontinued VBN 1 1 1 O
at IN 0 0 12 O
least JJS 0 1 12 O
two CD 0 1 12 O
weeks NNS 1 1 12 O
prior RB 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
cautious JJ 0 0 UNK O
initiation NN 0 1 1 O
of IN 0 0 12 O
therapy NN 0 1 6 O
with IN 0 0 12 O
SINEQUAN NNP 0 1 UNK B-Brand
. . 0 0 12 O

Food NNP 0 1 2 O
has VBZ 1 0 12 O
no DT 0 0 12 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
bioavailability NN 0 1 UNK O
of IN 0 0 12 O
anagrelide NN 0 1 13 B-Drug
. . 0 0 12 O

Certain NNP 0 1 UNK O
drugs NNS 1 1 6 O
tend VBP 0 0 12 O
to TO 0 0 12 O
produce VB 0 0 1 O
hyperglycemia NN 0 1 14 O
and CC 0 0 12 O
may MD 0 0 1 O
lead VB 0 1 12 O
to TO 0 0 12 O
loss NN 0 1 1 O
of IN 0 0 12 O
control NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
IV NNP 0 1 2 O
methylprednisolone NN 0 1 16 B-Drug
dose NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
reduced VBN 1 1 1 O
by IN 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
the DT 0 0 12 O
oral JJ 0 1 6 O
methylprednisolone NN 0 1 16 B-Drug
dose NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
reduced VBN 1 1 1 O
by IN 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
when WRB 0 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
Aprepitant NNP 0 1 UNK B-Drug
to TO 0 0 12 O
achieve VB 0 0 1 O
exposures NNS 1 1 UNK O
of IN 0 0 12 O
methylprednisolone NN 0 1 16 B-Drug
similar JJ 0 1 1 O
to TO 0 0 12 O
those DT 0 0 12 O
obtained VBN 1 1 1 O
when WRB 0 0 12 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
given VBN 1 1 12 O
without IN 0 0 12 O
Aprepitant NNP 0 1 UNK B-Drug
. . 0 0 12 O

Physicians NNS 0 1 2 O
should MD 0 0 12 O
carefully RB 0 0 12 O
monitor VB 0 1 1 O
PT NNP 0 1 2 O
and CC 0 0 12 O
INR NNP 0 1 13 O
in IN 0 0 12 O
patients NNS 1 1 6 O
concurrently RB 0 0 1 O
administered VBN 1 1 1 O
ZOLINZA NNP 0 1 UNK B-Brand
and CC 0 0 12 O
coumarin JJ 0 1 UNK B-Group
derivatives NNS 1 1 13 I-Group
. . 0 0 12 O

SUBUTEX NNP 0 1 UNK B-Brand
and CC 0 0 12 O
SUBOXONE NNP 0 1 UNK B-Brand
should MD 0 0 12 O
be VB 0 0 12 O
prescribed VBN 1 1 1 O
with IN 0 0 12 O
caution NN 0 0 1 O
to TO 0 0 12 O
patients NNS 1 1 6 O
on IN 0 0 12 O
benzodiazepines NNS 1 1 14 B-Group
or CC 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
act VBP 0 1 13 O
on IN 0 0 12 O
the DT 0 0 12 O
central JJ 0 1 1 O
nervous JJ 0 1 6 O
system NN 0 1 1 O
regardless NN 0 1 UNK O
of IN 0 0 12 O
whether IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
are VBP 1 0 12 O
taken VBN 1 1 12 O
on IN 0 0 12 O
the DT 0 0 12 O
advice NN 0 1 16 O
of IN 0 0 12 O
a DT 0 0 12 O
physician NN 0 1 6 O
or CC 0 0 12 O
are VBP 1 0 12 O
taken VBN 1 1 12 O
as IN 1 0 12 O
drugs NNS 1 1 6 O
of IN 0 0 12 O
abuse NN 0 1 12 O
. . 0 0 12 O

Monitor NNP 0 1 2 O
platelet NN 0 1 14 O
count NN 0 1 12 O
every DT 0 0 12 O
9 CD 0 0 2 O
weeks NNS 1 1 12 O
for IN 0 0 12 O
the DT 0 0 12 O
first JJ 0 1 12 O
9 CD 0 0 2 O
months NNS 1 1 12 O
. . 0 0 12 O

During IN 0 0 2 O
concomitant JJ 0 1 6 O
therapy NN 0 1 6 O
with IN 0 0 12 O
ibuprofen PDT 0 1 0 B-Drug
the DT 0 0 12 O
patient NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
observed VBN 1 1 1 O
closely RB 0 0 1 O
for IN 0 0 12 O
signs NNS 1 1 12 O
of IN 0 0 12 O
renal JJ 0 1 6 O
failure NN 0 1 1 O
as RB 0 0 12 O
well RB 0 1 12 O
as IN 1 0 12 O
to TO 0 0 12 O
assure VB 0 0 1 O
diuretic JJ 0 1 14 B-Group
efficacy NN 0 1 UNK O
. . 0 0 12 O

Phase NNP 0 1 UNK O
II NNP 0 0 2 O
clinical JJ 0 1 6 O
trial NN 0 1 12 O
data NNS 0 1 1 O
where WRB 0 0 12 O
IRESSA NNP 0 1 UNK B-Brand
and CC 0 0 12 O
vinorelbine NN 0 1 13 B-Drug
have VBP 0 0 12 O
been VBN 1 0 12 O
used VBN 1 1 12 O
concomitantly RB 0 0 14 O
indicate VBP 0 0 1 O
that IN 0 0 12 O
IRESSA NNP 0 1 UNK B-Brand
may MD 0 0 1 O
exacerbate VB 0 1 UNK O
the DT 0 0 12 O
neutropenic JJ 0 0 8 O
effect NN 0 1 1 O
of IN 0 0 12 O
vinorelbine NN 0 1 13 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
majority NN 0 1 1 O
of IN 0 0 12 O
these DT 0 0 12 O
reports NNS 1 1 1 O
concerned VBD 1 0 12 O
variable JJ 0 1 1 O
elevations NNS 1 1 1 O
in IN 0 0 12 O
prothrombin NN 0 1 14 O
times NNS 1 1 12 O
without IN 0 0 12 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
sequelae NN 1 1 6 O
. . 0 0 12 O

Plasma NNP 0 1 UNK O
TCA NNP 0 1 13 B-Group
concentrations NNS 1 1 13 O
may MD 0 0 1 O
need VB 0 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
and CC 0 0 12 O
the DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
the DT 0 0 12 O
TCA NNP 0 1 13 B-Group
may MD 0 0 1 O
need VB 0 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
reduced VBN 1 1 1 O
if IN 0 0 12 O
a DT 0 0 12 O
TCA NNP 0 1 13 B-Group
is VBZ 1 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
with IN 0 0 12 O
Duloxetine NNP 0 1 0 B-Drug
. . 0 0 12 O

Antibiotics NNS 0 1 7 B-Group
: : 0 0 2 O
Macrolide NNP 0 1 UNK B-Group
antibiotics NNS 1 1 6 I-Group
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
cause VB 0 1 12 O
a DT 0 0 12 O
significant JJ 0 1 1 O
decrease NN 0 1 1 O
in IN 0 0 12 O
corticosteroid JJ 0 1 UNK B-Group
clearance NN 0 1 16 O
. . 0 0 12 O

If IN 0 0 12 O
TRANXENE NNP 0 1 UNK B-Brand
tablets NNS 1 1 3 O
are VBP 1 0 12 O
used VBN 1 1 12 O
to TO 0 0 12 O
treat VB 0 1 12 O
anxiety NN 0 1 6 O
associated VBN 1 1 1 O
with IN 0 0 12 O
somatic JJ 0 1 13 O
disease NN 0 1 6 O
states NNS 1 1 1 O
careful JJ 0 1 12 O
attention NN 0 1 12 O
must MD 0 0 12 O
be VB 0 0 12 O
paid VBN 1 1 12 O
to TO 0 0 12 O
possible JJ 0 1 1 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
with IN 0 0 12 O
concomitant JJ 0 1 6 O
medication NN 0 1 6 O
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
not RB 0 1 12 O
known VBN 1 1 12 O
if IN 0 0 12 O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
butorphanol NN 0 1 13 B-Drug
are VBP 1 0 12 O
altered VBN 1 1 1 O
by IN 0 0 12 O
concomitant JJ 0 1 6 O
medications NNS 1 1 6 O
that WDT 0 0 12 O
affect VBP 0 1 1 O
hepatic JJ 0 1 14 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
drugs NNS 1 1 6 O
( ( 0 0 2 O
erythromycin JJ 0 1 0 B-Drug
etc NN 0 1 12 O
. . 0 0 12 O
) ) 0 0 2 O
but CC 0 0 12 O
physicians NNS 1 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
alert JJ 0 1 12 O
to TO 0 0 12 O
the DT 0 0 12 O
possibility NN 0 1 1 O
that IN 0 0 12 O
a DT 0 0 12 O
smaller JJR 1 1 3 O
initial JJ 0 1 1 O
dose NN 0 1 6 O
and CC 0 0 12 O
longer JJR 1 1 12 O
intervals NNS 1 1 1 O
between IN 0 0 12 O
doses NNS 1 1 6 O
may MD 0 0 1 O
be VB 0 0 12 O
needed VBN 1 1 12 O
. . 0 0 12 O

- : 0 0 2 O
Naltrexone NN 0 1 UNK B-Drug
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
Trexan NNP 0 1 UNK B-Brand
) ) 0 0 2 O
( ( 0 0 2 O
with IN 0 0 12 O
long RB 0 1 12 O
- : 0 0 2 O
term NN 0 1 1 O
high JJ 0 1 1 O
- : 0 0 2 O
dose NN 0 1 6 O
use NN 0 1 1 O
) ) 0 0 2 O
or CC 0 0 12 O

Tolbutamide NN 0 1 UNK B-Drug
: : 0 0 2 O
In IN 0 0 2 O
diabetic JJ 0 1 6 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
diflunisal NN 0 1 13 B-Drug
and CC 0 0 12 O
tolbutamide VB 0 1 UNK B-Drug
no DT 0 0 12 O
significant JJ 0 1 1 O
effects NNS 1 1 1 O
were VBD 1 0 12 O
seen VBN 1 1 12 O
on IN 0 0 12 O
tolbutamide JJ 0 1 UNK B-Drug
plasma NN 0 1 14 O
levels NNS 1 1 1 O
or CC 0 0 12 O
fasting VBG 1 1 6 O
blood NN 0 1 6 O
glucose NN 0 1 14 O
. . 0 0 12 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interactions NNS 0 1 UNK O
: : 0 0 2 O
Physiologic NNP 0 1 7 O
effects NNS 1 1 1 O
of IN 0 0 12 O
testolactone NN 0 1 UNK B-Drug
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
decreased JJ 0 1 1 O
estradiol NN 0 1 13 O
concentrations NNS 1 1 13 O
with IN 0 0 12 O
radioimmunoassays NNS 1 1 UNK O
for IN 0 0 12 O
estradiol NN 0 1 13 O
increased VBD 1 1 1 O
plasma JJ 0 1 14 O
calcium NN 0 1 14 O
concentrations NNS 1 1 13 O
and CC 0 0 12 O
increased VBD 1 1 1 O
9 CD 0 0 2 O
- : 0 0 2 O
hour NN 0 1 12 O
urinary JJ 0 1 6 O
excretion NN 0 1 14 O
of IN 0 0 12 O
creatine NN 0 1 14 O
and CC 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
ketosteroids NNS 1 1 UNK O
. . 0 0 12 O

- : 0 0 2 O
rifampin NN 0 1 16 B-Drug
( ( 0 0 2 O
Rifadin NNP 0 1 UNK B-Brand
Rifamate NNP 0 1 UNK B-Brand
) ) 0 0 2 O
; : 0 0 2 O

Drugs NNS 0 1 2 O
that WDT 0 0 12 O
reduce VB 0 0 1 O
the DT 0 0 12 O
number NN 0 1 1 O
of IN 0 0 12 O
blood NN 0 1 6 O
platelets NNS 1 1 14 O
by IN 0 0 12 O
causing VBG 1 1 1 O
bone NN 0 1 6 O
marrow NN 0 1 6 O
depression NN 0 1 6 O
( ( 0 0 2 O
such JJ 0 0 1 O
as IN 1 0 12 O
antineoplastic JJ 0 1 13 B-Group
agents NNS 1 1 1 I-Group
) ) 0 0 2 O
or CC 0 0 12 O
drugs NNS 1 1 6 O
which WDT 0 0 12 O
inhibit VBP 0 1 13 O
platelet NN 0 1 14 O
function NN 0 1 1 O
( ( 0 0 2 O
eg JJ 0 1 UNK O
aspirin NN 0 1 14 B-Brand
and CC 0 0 12 O
other JJ 0 0 12 O
non JJ 0 1 1 B-Group
- : 0 0 2 O
steroidal NN 0 1 UNK I-Group
anti SYM 0 0 3 I-Group
- : 0 0 2 O
inflammatory NN 0 1 6 I-Group
drugs NNS 1 1 6 I-Group
dipyridamole JJ 0 1 0 B-Drug
hydrochloroquine NN 0 0 UNK B-Drug
clofibrate NN 0 1 UNK B-Drug
dextran NN 0 1 14 B-Drug
) ) 0 0 2 O
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
bleeding NN 0 1 6 O
tendency NN 0 0 1 O
produced VBN 1 0 1 O
by IN 0 0 12 O
anticoagulants NNS 1 1 13 B-Group
without IN 0 0 12 O
altering VBG 1 1 1 O
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
determinations NNS 1 1 UNK O
. . 0 0 12 O

Montelukast NNP 0 1 0 B-Drug
at IN 0 0 12 O
a DT 0 0 12 O
Dose NNP 0 1 7 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
Once RB 0 0 12 O
Daily NNP 0 1 2 O
Dosed VBD 0 1 UNK O
to TO 0 0 12 O
Pharmacokinetic NNP 0 1 UNK O
Steady NNP 0 1 UNK O
State NNP 0 1 2 O
- : 0 0 2 O
did VBD 1 0 12 O
not RB 0 1 12 O
cause VB 0 1 12 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
changes NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
kinetics NNS 0 1 UNK O
of IN 0 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
intravenous JJ 0 1 14 O
dose NN 0 1 6 O
of IN 0 0 12 O
theophylline NN 0 1 16 B-Drug
( ( 0 0 2 O
predominantly RB 0 0 1 O
a DT 0 0 12 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
9A9 CD 0 0 UNK O
substrate NN 0 1 UNK O
) ) 0 0 2 O
. . 0 0 12 O

Concurrent NNP 0 1 13 O
use NN 0 1 1 O
of IN 0 0 12 O
hydroxyurea NN 0 1 14 B-Drug
and CC 0 0 12 O
other JJ 0 0 12 O
myelosuppressive JJ 0 0 UNK O
agents NNS 1 1 1 O
or CC 0 0 12 O
radiation NN 0 1 1 O
therapy NN 0 1 6 O
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
likelihood NN 0 1 1 O
of IN 0 0 12 O
bone NN 0 1 6 O
marrow NN 0 1 6 O
depression NN 0 1 6 O
or CC 0 0 12 O
other JJ 0 0 12 O
adverse JJ 0 0 1 O
events NNS 1 1 12 O
. . 0 0 12 O

The DT 0 0 2 O
effects NNS 1 1 1 O
of IN 0 0 12 O
Mefloquineuine NNP 0 0 UNK O
on IN 0 0 12 O
the DT 0 0 12 O
compromised VBN 1 0 1 O
cardiovascular NN 0 1 6 O
system NN 0 1 1 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
evaluated VBN 1 1 1 O
. . 0 0 12 O

No DT 0 0 2 O
pharmacodynamic JJ 0 1 UNK O
effects NNS 1 1 1 O
of IN 0 0 12 O
either DT 0 1 12 O
histamine NN 0 1 UNK B-Group
H9 NNP 0 0 UNK I-Group
receptor NN 0 1 14 I-Group
antagonist NN 0 1 13 I-Group
were VBD 1 0 12 O
observed VBN 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
concomitant NN 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
ENABLEX NNP 0 1 UNK B-Brand
with IN 0 0 12 O
other JJ 0 0 12 O
anticholinergic JJ 0 1 13 B-Group
agents NNS 1 1 1 I-Group
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
frequency NN 0 1 1 O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
severity NN 0 1 6 O
of IN 0 0 12 O
dry JJ 0 1 3 O
mouth NN 0 1 3 O
constipation NN 0 1 6 O
blurred VBN 1 1 3 O
vision NN 0 1 1 O
and CC 0 0 12 O
other JJ 0 0 12 O
anticholinergic JJ 0 1 13 O
pharmacological JJ 0 1 14 O
effects NNS 1 1 1 O
. . 0 0 12 O

Bosentan NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
also RB 0 0 12 O
expected VBN 1 1 12 O
to TO 0 0 12 O
reduce VB 0 0 1 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
other JJ 0 0 12 O
statins NNS 1 1 UNK B-Group
that WDT 0 0 12 O
have VBP 0 0 12 O
significant JJ 0 1 1 O
metabolism NN 0 1 16 O
by IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
such JJ 0 0 1 O
as IN 1 0 12 O
lovastatin NN 0 1 13 B-Drug
and CC 0 0 12 O
atorvastatin NN 0 1 0 B-Drug
. . 0 0 12 O

There EX 0 0 12 O
were VBD 1 0 12 O
no DT 0 0 12 O
reports NNS 1 1 1 O
of IN 0 0 12 O
skeletal JJ 0 1 13 O
myopathy NN 0 1 8 O
in IN 0 0 12 O
a DT 0 0 12 O
placebo NN 0 1 13 O
- : 0 0 2 O
controlled JJ 0 1 1 O
Phase NNP 0 1 UNK O
I PRP 0 1 12 O
trial NN 0 1 12 O
in IN 0 0 12 O
which WDT 0 0 12 O
9 CD 0 0 2 O
healthy JJ 0 1 12 O
subjects NNS 1 1 UNK O
on IN 0 0 12 O
stable JJ 0 1 1 O
simvastatin NN 0 1 0 B-Drug
therapy NN 0 1 6 O
were VBD 1 0 12 O
treated VBN 1 1 1 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
daptomycin NN 0 1 16 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
once RB 0 0 12 O
every DT 0 0 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
) ) 0 0 2 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
. . 0 0 12 O

Synergism NN 0 1 UNK O
between IN 0 0 12 O
xanthine JJ 0 1 UNK B-Group
bronchodilators NNS 1 1 14 I-Group
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
theophylline NN 0 1 16 B-Drug
) ) 0 0 2 O
ephedrine NN 0 1 13 B-Drug
and CC 0 0 12 O
other JJ 0 0 12 O
sympathomimetic JJ 0 1 13 B-Group
bronchodilators NNS 1 1 14 I-Group
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
. . 0 0 12 O

These DT 0 0 1 O
data NNS 0 1 1 O
suggest VBP 0 1 1 O
that IN 0 0 12 O
rofecoxib NN 0 1 16 B-Drug
may MD 0 0 1 O
produce VB 0 0 1 O
a DT 0 0 12 O
modest JJ 0 1 1 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
( ( 0 0 2 O
CYP NNP 0 1 UNK O
) ) 0 0 2 O
9A9 CD 0 0 UNK O
. . 0 0 12 O

Some DT 0 0 2 O
early JJ 0 1 12 O
studies NNS 1 1 1 O
indicated VBD 1 1 1 O
that IN 0 0 12 O
EPA NNP 0 0 UNK B-Drug
supplements NNS 1 1 6 O
might MD 0 0 12 O
have VB 0 0 12 O
detrimental JJ 0 0 UNK O
effects NNS 1 1 1 O
in IN 0 0 12 O
those DT 0 0 12 O
groups NNS 1 1 1 O
. . 0 0 12 O

These DT 0 0 1 O
increases NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
when WRB 0 0 12 O
selecting VBG 1 1 UNK O
an DT 0 0 12 O
oral JJ 0 1 6 O
contraceptive NN 0 1 13 B-Group
for IN 0 0 12 O
a DT 0 0 12 O
woman NN 0 1 12 O
taking VBG 1 0 12 O
atorvastatin NN 0 1 0 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
cefdinir NN 0 1 UNK B-Drug
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
false JJ 0 1 13 O
- : 0 0 2 O
positive JJ 0 1 1 O
reaction NN 0 1 1 O
for IN 0 0 12 O
glucose NN 0 1 14 O
in IN 0 0 12 O
urine JJ 0 1 6 O
using VBG 1 1 1 O
Clinitest NNP 0 1 UNK O
Benedict NNP 0 0 UNK O
solution NN 0 1 1 O
or CC 0 0 12 O
Fehlings NNP 0 0 UNK O
solution NN 0 1 1 O
. . 0 0 12 O

A DT 0 0 2 O
number NN 0 1 1 O
of IN 0 0 12 O
substances NNS 1 1 1 O
affect VBP 0 1 1 O
glucose JJ 0 1 14 O
metabolism NN 0 1 16 O
and CC 0 0 12 O
may MD 0 0 1 O
require VB 0 0 1 O
insulin NN 0 1 14 B-Drug
dose JJ 0 1 6 O
adjustment NN 0 1 1 O
and CC 0 0 12 O
particularly RB 0 0 1 O
close JJ 0 1 12 O
monitoring NN 0 1 1 O
. . 0 0 12 O

Increases NNS 0 1 UNK O
in IN 0 0 12 O
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
noted VBN 1 0 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
long JJ 0 1 12 O
- : 0 0 2 O
term NN 0 1 1 O
warfarin NN 0 1 14 B-Drug
therapy NN 0 1 6 O
after IN 0 0 12 O
flutamide NN 0 1 13 B-Drug
was VBD 1 0 12 O
initiated VBN 1 1 1 O
. . 0 0 12 O

therefore RB 0 0 1 O
caution NN 0 0 1 O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
when WRB 0 0 12 O
administering VBG 1 1 1 O
CYP9A9 NNP 0 0 UNK O
inhibitors NNS 1 1 14 O
with IN 0 0 12 O
IRESSA NNP 0 1 UNK B-Brand
. . 0 0 12 O

Scopolamine NN 0 1 UNK B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
with IN 0 0 12 O
care NN 0 1 12 O
in IN 0 0 12 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
are VBP 1 0 12 O
capable JJ 0 1 UNK O
of IN 0 0 12 O
causing VBG 1 1 1 O
CNS NNP 0 1 6 O
effects NNS 1 1 1 O
such JJ 0 0 1 O
as IN 1 0 12 O
sedatives NNS 1 1 6 B-Group
tranquilizers NNS 1 1 13 B-Group
or CC 0 0 12 O
alcohol NN 0 1 1 B-Drug
. . 0 0 12 O

Sirolimus NNP 0 1 UNK B-Drug
AUC NNP 0 1 UNK O
was VBD 1 0 12 O
increased VBN 1 1 1 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
with IN 0 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
Cmax NNP 0 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
presence NN 0 1 1 O
of IN 0 0 12 O
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
MYCAMINE NNP 0 1 UNK B-Brand
compared VBN 1 1 1 O
with IN 0 0 12 O
sirolimus JJ 0 1 16 B-Drug
alone RB 0 1 12 O
. . 0 0 12 O

DRUG NN 0 1 11 O
/ NNP 0 0 2 O
LABORATORY NNP 0 1 11 O
TEST NNP 0 1 11 O
INTERACTIONS NNP 0 1 UNK O
: : 0 0 2 O
EFFECT NN 0 1 UNK O
ON NNP 0 0 11 O
BLOOD NNP 0 1 11 O
COAGULATION NNP 0 1 15 O
Ketoprofen NNP 0 1 UNK B-Drug
decreases VBZ 1 1 UNK O
platelet NN 0 1 14 O
adhesion NN 0 1 13 O
and CC 0 0 12 O
aggregation NN 0 1 UNK O
. . 0 0 12 O

No DT 0 0 2 O
evidence NN 0 1 1 O
of IN 0 0 12 O
clastogenicity NN 0 1 UNK O
was VBD 1 0 12 O
observed VBN 1 1 1 O
in IN 0 0 12 O
vitro NN 0 1 UNK O
in IN 0 0 12 O
a DT 0 0 12 O
chromosomal JJ 0 1 13 O
aberration NN 0 1 UNK O
assay NN 0 1 14 O
in IN 0 0 12 O
human JJ 0 1 1 O
peripheral JJ 0 1 6 O
blood NN 0 1 6 O
lymphocytes NNS 1 1 14 O
with IN 0 0 12 O
or CC 0 0 12 O
without IN 0 0 12 O
metabolic JJ 0 1 6 O
activation NN 0 1 13 O
. . 0 0 12 O

saquinavir NN 0 1 13 B-Drug
concentration NN 0 1 1 O

. . 0 0 12 O

Benzyl NNP 0 0 UNK B-Drug_n
alcohol NN 0 1 1 I-Drug_n
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
be VB 0 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
an DT 0 0 12 O
increased JJ 0 1 1 O
incidence NN 0 1 6 O
of IN 0 0 12 O
neurological JJ 0 1 6 O
and CC 0 0 12 O
other JJ 0 0 12 O
complications NNS 1 1 6 O
in IN 0 0 12 O
neonates NNS 1 1 16 O
and CC 0 0 12 O
infants NNS 1 1 6 O
which WDT 0 0 12 O
are VBP 1 0 12 O
sometimes RB 0 1 12 O
fatal JJ 0 1 13 O
. . 0 0 12 O

oxyphenbutazone NN 0 1 UNK B-Drug
; : 0 0 2 O

Monoamine NNP 0 1 UNK B-Group
Oxidase NNP 0 1 UNK I-Group
Inhibitors NNS 0 1 7 I-Group
: : 0 0 2 O
Coadministration NN 0 1 UNK O
of IN 0 0 12 O
moclobemide NN 0 1 UNK B-Drug
resulted VBD 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
decrease NN 0 1 1 O
in IN 0 0 12 O
almotriptan JJ 0 1 13 B-Drug
clearance NN 0 1 16 O
and CC 0 0 12 O
an DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
Cmax NNP 0 1 UNK O
of IN 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
desirable JJ 0 0 UNK O
to TO 0 0 12 O
monitor VB 0 1 1 O
TCA NNP 0 1 13 B-Group
plasma NN 0 1 14 O
levels NNS 1 1 1 O
whenever WRB 0 0 12 O
a DT 0 0 12 O
TCA NNP 0 1 13 B-Group
is VBZ 1 0 12 O
going VBG 1 0 12 O
to TO 0 0 12 O
be VB 0 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
another DT 0 0 12 O
drug NN 0 1 1 O
known VBN 1 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
an DT 0 0 12 O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
P9 NNP 0 1 UNK O
9D9 CD 0 0 UNK O
. . 0 0 12 O

CYP9A9 NNP 0 0 UNK O
and CC 0 0 12 O
- : 0 0 2 O
9C9 CD 0 0 UNK O
Inhibitors NNPS 0 1 7 O
- : 0 0 2 O
In IN 0 0 2 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
indicated VBD 1 1 1 O
that IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
and CC 0 0 12 O
- : 0 0 2 O
9C9 CD 0 0 UNK O
are VBP 1 0 12 O
the DT 0 0 12 O
primary JJ 0 1 1 O
enzymes NNS 1 1 14 O
involved VBN 1 1 12 O
in IN 0 0 12 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
escitalopram NN 0 1 0 B-Drug
. . 0 0 12 O

Iodine NNP 0 1 7 B-Drug
or CC 0 0 12 O
iodine JJ 0 1 14 B-Drug
excess NN 0 1 1 O
may MD 0 0 1 O
decrease VB 0 1 1 O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
Carbimazole NNP 0 1 UNK B-Drug
and CC 0 0 12 O
an DT 0 0 12 O
iodine JJ 0 1 14 B-Drug
deficiency NN 0 1 6 O
can MD 0 0 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
Carbimazole NNP 0 1 UNK B-Drug
. . 0 0 12 O

Alkalinizing VBG 0 0 UNK O
agents NNS 1 1 1 O
: : 0 0 2 O
Gastrointestinal NNP 0 1 7 O
alkalinizing VBG 1 0 UNK O
agents NNS 1 1 1 O
( ( 0 0 2 O
sodium NN 0 1 14 B-Drug
bicarbonate NN 0 1 14 I-Drug
etc FW 0 1 12 O
. . 0 0 12 O
) ) 0 0 2 O
increase NN 0 1 1 O
absorption NN 0 1 1 O
of IN 0 0 12 O
amphetamines NNS 1 1 14 B-Drug
. . 0 0 12 O

Oral JJ 0 1 2 O
Anticoagulants NNS 0 1 UNK B-Group
CAUTION NNP 0 0 UNK O
SHOULD NNP 0 0 UNK O
BE NNP 0 0 11 O
EXERCISED NNP 0 1 UNK O
WHEN NNP 0 0 UNK O
COUMARIN NNP 0 1 UNK B-Group
ANTICOAGULANTS NNP 0 1 UNK I-Group
ARE NNP 0 0 UNK O
GIVEN NNP 0 1 11 O
IN NNP 0 0 11 O
CONJUNCTION NNP 0 1 UNK O
WITH NNP 0 0 11 O
TRICOR NNP 0 1 UNK B-Brand
. . 0 0 12 O

May NNP 0 1 2 O
interact NN 0 0 UNK O
with IN 0 0 12 O
skin JJ 0 1 3 O
products NNS 1 1 1 O
or CC 0 0 12 O
shampoos NN 1 1 13 O
for IN 0 0 12 O
dandruff NN 0 1 UNK O
or CC 0 0 12 O
psoriasis NN 0 1 6 O
. . 0 0 12 O

ERGAMISOL NNP 0 1 UNK B-Brand
( ( 0 0 2 O
levamisole JJ 0 1 UNK B-Drug
hydrochloride NN 0 1 0 I-Drug
) ) 0 0 2 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
produce VB 0 0 1 O
ANTABUSE NNP 0 1 UNK O
- : 0 0 2 O
like IN 0 0 12 O
side NN 0 1 3 O
effects NNS 1 1 1 O
when WRB 0 0 12 O
given VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
alcohol NN 0 1 1 B-Drug
. . 0 0 12 O

In IN 0 0 2 O
such JJ 0 0 1 O
cases NNS 1 1 UNK O
the DT 0 0 12 O
unbound NN 0 0 UNK O
( ( 0 0 2 O
free JJ 0 1 12 O
) ) 0 0 2 O
hormone NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
measured VBN 1 1 1 O
. . 0 0 12 O

When WRB 0 0 12 O
catecholamines NNS 1 1 14 B-Group
are VBP 1 0 12 O
administered VBN 1 1 1 O
dilute JJ 0 1 16 O
solutions NNS 1 1 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
and CC 0 0 12 O
blood JJ 0 1 6 O
pressure NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
closely RB 0 0 1 O
. . 0 0 12 O

Omeprazole NNP 0 1 0 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
taken VBN 1 1 12 O
as IN 1 0 12 O
directed JJ 0 1 1 O
and CC 0 0 12 O
Proquin NNP 0 1 UNK B-Brand
XR NNP 0 1 0 I-Brand
should MD 0 0 12 O
be VB 0 0 12 O
taken VBN 1 1 12 O
with IN 0 0 12 O
a DT 0 0 12 O
main JJ 0 1 12 O
meal NN 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
day NN 0 1 12 O
preferably RB 0 0 UNK O
the DT 0 0 12 O
evening NN 0 1 12 O
meal.. NN 0 1 UNK O

Pharmacokinetic NNP 0 1 UNK O
data NNS 0 1 1 O
suggest VBP 0 1 1 O
that IN 0 0 12 O
absorption NN 0 1 1 O
metabolism NN 0 1 16 O
and CC 0 0 12 O
elimination NN 0 1 UNK O
of IN 0 0 12 O
each DT 0 0 12 O
of IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
are VBP 1 0 12 O
unchanged JJ 0 1 1 O
when WRB 0 0 12 O
they PRP 0 0 12 O
are VBP 1 0 12 O
used VBN 1 1 12 O
together RB 0 1 12 O
. . 0 0 12 O

Beta NNP 0 1 2 B-Group
- : 0 0 2 O
blockers NNS 1 0 6 I-Group
not RB 0 1 12 O
only RB 0 1 12 O
block VB 0 1 3 O
the DT 0 0 12 O
therapeutic JJ 0 1 6 O
effects NNS 1 1 1 O
of IN 0 0 12 O
beta NN 0 1 16 B-Group
- : 0 0 2 O
agonists NNS 1 1 UNK I-Group
but CC 0 0 12 O
may MD 0 0 1 O
produce VB 0 0 1 O
severe JJ 0 1 6 O
bronchospasm NN 0 1 13 O
in IN 0 0 12 O
COPD NNP 0 1 6 O
patients NNS 1 1 6 O
. . 0 0 12 O

Chlorthalidone NN 0 1 UNK B-Drug
and CC 0 0 12 O
related JJ 0 1 1 O
drugs NNS 1 1 6 O
may MD 0 0 1 O
decrease VB 0 1 1 O
arterial JJ 0 1 6 O
responsiveness NN 0 1 UNK O
to TO 0 0 12 O
norepinephrine VB 0 1 14 B-Drug
. . 0 0 12 O

tadalafil NN 0 1 UNK B-Drug
concentration NN 0 1 1 O

Concomitant NNP 0 1 UNK O
use NN 0 1 1 O
of IN 0 0 12 O
barbiturates NNS 1 1 14 B-Group
usually RB 0 1 12 O
depresses VBZ 1 0 UNK O
griseofulvin JJ 0 1 UNK B-Drug
activity NN 0 1 1 O
and CC 0 0 12 O
may MD 0 0 1 O
necessitate VB 0 0 UNK O
raising VBG 1 0 UNK O
the DT 0 0 12 O
dosage NN 0 1 0 O
. . 0 0 12 O

Propranolol NN 0 1 0 B-Drug
: : 0 0 2 O
In IN 0 0 2 O
a DT 0 0 12 O
single JJ 0 1 12 O
dose NN 0 1 6 O
study NN 0 1 1 O
in IN 0 0 12 O
normal JJ 0 1 1 O
volunteers NNS 1 1 UNK O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
propranolol NN 0 1 16 B-Drug
had VBD 1 0 12 O
a DT 0 0 12 O
small JJ 0 1 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
rate NN 0 1 1 O
but CC 0 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
extent NN 0 1 1 O
of IN 0 0 12 O
isradipine JJ 0 1 13 B-Drug
bioavailability NN 0 1 UNK O
. . 0 0 12 O

Inhibitors NNS 0 1 7 O
of IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
- : 0 0 2 O
Eplerenone NN 0 1 UNK B-Drug
metabolism NN 0 1 16 O
is VBZ 1 0 12 O
predominantly RB 0 0 1 O
mediated VBN 1 1 13 O
via IN 0 0 1 O
CYP9A9 NNP 0 0 UNK O
. . 0 0 12 O

The DT 0 0 2 O
risk NN 0 1 1 O
of IN 0 0 12 O
myopathy NN 0 1 8 O
is VBZ 1 0 12 O
also RB 0 0 12 O
increased VBN 1 1 1 O
by IN 0 0 12 O
the DT 0 0 12 O
following VBG 1 1 1 O
lipid JJ 0 1 14 O
- : 0 0 2 O
lowering VBG 1 1 UNK O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
are VBP 1 0 12 O
not RB 0 1 12 O
potent JJ 0 1 UNK O
CYP9A9 NNP 0 0 UNK O
inhibitors NNS 1 1 14 O
but CC 0 0 12 O
which WDT 0 0 12 O
can MD 0 0 12 O
cause VB 0 1 12 O
myopathy JJ 0 1 8 O
when WRB 0 0 12 O
given VBN 1 1 12 O
alone RB 0 1 12 O
. . 0 0 12 O

Due JJ 0 1 2 O
to TO 0 0 12 O
the DT 0 0 12 O
potential NN 0 1 1 O
for IN 0 0 12 O
additive JJ 0 1 16 O
effects NNS 1 1 1 O
caution NN 0 0 1 O
and CC 0 0 12 O
careful JJ 0 1 12 O
titration NN 0 1 14 O
are VBP 1 0 12 O
warranted VBN 1 0 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
diltiazem JJ 0 1 0 B-Drug
hydrochloride NN 0 1 0 I-Drug
concomitantly RB 0 0 14 O
with IN 0 0 12 O
other JJ 0 0 12 O
agents NNS 1 1 1 O
known VBN 1 1 12 O
to TO 0 0 12 O
affect VB 0 1 1 O
cardiac JJ 0 1 6 O
contractility NN 0 1 13 O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
conduction NN 0 1 6 O
. . 0 0 12 O

In IN 0 0 2 O
the DT 0 0 12 O
case NN 0 1 12 O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
serum NN 0 1 14 O
levels NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
. . 0 0 12 O

Careful JJ 0 1 UNK O
observation NN 0 1 1 O
is VBZ 1 0 12 O
required VBN 1 1 1 O
. . 0 0 12 O

Careful JJ 0 1 UNK O
patient NN 0 1 6 O
monitoring NN 0 1 1 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
such JJ 0 0 1 O
drugs NNS 1 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
beneficial JJ 0 0 UNK O
effects NNS 1 1 1 O
on IN 0 0 12 O
arterial JJ 0 1 6 O
thrombus NN 0 1 8 O
formation NN 0 1 1 O
from IN 0 0 12 O
combined VBN 1 1 1 O
therapy NN 0 1 6 O
with IN 0 0 12 O
antiplatelet NN 0 0 13 B-Group
and CC 0 0 12 O
anticoagulant JJ 0 1 13 B-Group
medication NN 0 1 6 I-Group
must MD 0 0 12 O
be VB 0 0 12 O
weighed VBN 1 0 12 O
against IN 0 0 12 O
an DT 0 0 12 O
increased JJ 0 1 1 O
risk NN 0 1 1 O
of IN 0 0 12 O
inducing VBG 1 1 6 O
hemorrhage NN 0 1 6 O
. . 0 0 12 O

It PRP 0 0 12 O
may MD 0 0 1 O
also RB 0 0 12 O
interact VB 0 0 UNK O
with IN 0 0 12 O
thiazides NNS 1 1 UNK B-Group
( ( 0 0 2 O
increased VBN 1 1 1 O
thrombocytopenia NN 0 1 14 O
) ) 0 0 2 O
cyclosporine NN 0 1 14 B-Drug
( ( 0 0 2 O
increased JJ 0 1 1 O
nephrotoxicity NN 0 1 UNK O
) ) 0 0 2 O
sulfonylurea NN 0 1 UNK B-Group
agents NNS 1 1 1 I-Group
( ( 0 0 2 O
increased VBN 1 1 1 O
hypoglycemic JJ 0 1 14 O
response NN 0 1 1 O
) ) 0 0 2 O
warfarin NN 0 1 14 B-Drug
( ( 0 0 2 O
increased VBN 1 1 1 O
anticoagulant RB 0 1 13 O
effect NN 0 1 1 O
) ) 0 0 2 O
methotrexate NN 0 1 16 B-Drug
( ( 0 0 2 O
decreased JJ 0 1 1 O
renal JJ 0 1 6 O
excretion NN 0 1 14 O
of IN 0 0 12 O
methotrexate NN 0 1 16 B-Drug
) ) 0 0 2 O
phenytoin NN 0 1 16 B-Drug
( ( 0 0 2 O
decreased VBN 1 1 1 O
hepatic JJ 0 1 14 O
clearance NN 0 1 16 O
of IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

No DT 0 0 2 O
depressant JJ 0 0 UNK O
effect NN 0 1 1 O
on IN 0 0 12 O
blood NN 0 1 6 O
levels NNS 1 1 1 O
in IN 0 0 12 O
humans NNS 1 1 UNK O
was VBD 1 0 12 O
noted VBN 1 0 1 O
when WRB 0 0 12 O
colestipol JJ 0 1 13 B-Drug
hydrochloride NN 0 1 0 I-Drug
was VBD 1 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
any DT 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
following JJ 0 1 1 O
drugs NNS 1 1 6 O
: : 0 0 2 O
aspirin NN 0 1 14 B-Brand
clindamycin NN 0 1 0 B-Brand
clofibrate NN 0 1 UNK B-Drug
methyldopa NN 0 1 13 B-Drug
nicotinic JJ 0 1 13 B-Drug
acid NN 0 1 14 I-Drug
( ( 0 0 2 O
niacin JJ 0 1 14 B-Drug
) ) 0 0 2 O
tolbutamide NN 0 1 UNK B-Drug
phenytoin NN 0 1 16 B-Drug
or CC 0 0 12 O
warfarin NN 0 1 14 B-Drug
. . 0 0 12 O

9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O

FLEXERIL NNP 0 1 0 B-Brand
may MD 0 0 1 O
enhance VB 0 1 UNK O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
alcohol NN 0 1 1 B-Drug
barbiturates NNS 1 1 14 B-Group
and CC 0 0 12 O
other JJ 0 0 12 O
CNS NNP 0 1 6 B-Group
depressants NNS 1 0 13 I-Group
. . 0 0 12 O

metabolizers NNS 0 0 UNK O
. . 0 0 12 O

Anticoagulants NNS 0 1 UNK B-Group
Anabolic NNP 0 1 UNK B-Group
steroids NNS 1 1 6 I-Group
may MD 0 0 1 O
increase VB 0 1 1 O
sensitivity NN 0 1 1 O
to TO 0 0 12 O
oral JJ 0 1 6 O
anticoagulants NNS 1 1 13 B-Group
. . 0 0 12 O

Duloxetine NN 0 1 0 B-Drug
May NNP 0 1 2 O
Have VBP 0 0 UNK O
a DT 0 0 12 O
Clinically NNP 0 0 7 O
Important NNP 0 1 UNK O
Interaction NNP 0 1 2 O
with IN 0 0 12 O
the DT 0 0 12 O
Following VBG 0 1 2 O
Other JJ 0 0 2 O
Drugs NNS 0 1 2 O
: : 0 0 2 O
Alcohol NN 0 1 2 B-Drug
: : 0 0 2 O
When WRB 0 0 12 O
Duloxetine NNP 0 1 0 B-Drug
and CC 0 0 12 O
ethanol NN 0 1 1 B-Drug
were VBD 1 0 12 O
administered VBN 1 1 1 O
several JJ 0 1 12 O
hours NNS 1 1 12 O
apart RB 0 0 12 O
so IN 0 1 12 O
that IN 0 0 12 O
peak JJ 0 1 1 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
each DT 0 0 12 O
would MD 0 0 12 O
coincide VB 0 0 UNK O
Duloxetine NNP 0 1 0 B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
impairment NN 0 1 16 O
of IN 0 0 12 O
mental JJ 0 1 1 O
and CC 0 0 12 O
motor NN 0 1 3 O
skills NNS 1 1 UNK O
caused VBN 1 1 1 O
by IN 0 0 12 O
alcohol NN 0 1 1 B-Drug
. . 0 0 12 O

No DT 0 0 2 O
formal JJ 0 1 1 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
performed VBN 1 1 1 O
with IN 0 0 12 O
ZEVALIN NNP 0 1 UNK B-Brand
. . 0 0 12 O

Acebutolol NNP 0 1 UNK B-Drug
atenolol NN 0 1 0 B-Drug
and CC 0 0 12 O
nadolol NN 0 1 0 B-Drug
( ( 0 0 2 O
low JJ 0 1 1 O
hepatic JJ 0 1 14 O
clearance NN 0 1 16 O
or CC 0 0 12 O
no DT 0 0 12 O
first JJ 0 1 12 O
- : 0 0 2 O
pass NN 1 1 12 O
metabolism NN 0 1 16 O
) ) 0 0 2 O
are VBP 1 0 12 O
unlikely JJ 0 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
affected VBN 1 1 1 O
. . 0 0 12 O

Benzodiazepines NNS 0 1 UNK B-Group
: : 0 0 2 O
Combination NNP 0 1 UNK O
hormonal JJ 0 1 6 B-Group
contraceptives NNS 1 1 13 I-Group
may MD 0 0 1 O
decrease VB 0 1 1 O
the DT 0 0 12 O
clearance NN 0 1 16 O
of IN 0 0 12 O
some DT 0 0 12 O
benzodiazepines NNS 1 1 14 B-Group
( ( 0 0 2 O
alprazolam JJ 0 1 0 B-Drug
chlordiazepoxide NN 0 1 16 B-Drug
diazepam NN 0 1 0 B-Drug
) ) 0 0 2 O
and CC 0 0 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
clearance NN 0 1 16 O
of IN 0 0 12 O
others NNS 0 1 12 O
( ( 0 0 2 O
lorazepam JJ 0 1 0 B-Drug
oxazepam RB 0 1 16 B-Drug
temazepam NN 0 1 16 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

Drugs NNS 0 1 2 O
Whose NNP 0 0 UNK O
Absorption NNP 0 1 UNK O
Can MD 0 0 2 O
Be VB 0 0 UNK O
Affected VBN 0 1 UNK O
by IN 0 0 12 O
the DT 0 0 12 O
Level NNP 0 1 2 O
of IN 0 0 12 O
Acidity NNP 0 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
Stomach NN 0 1 7 O
: : 0 0 2 O
Drugs NNS 0 1 2 O
such JJ 0 0 1 O
as IN 1 0 12 O
ketoconazole NN 0 1 16 B-Drug
and CC 0 0 12 O
itraconazole NN 0 1 0 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
at IN 0 0 12 O
least JJS 0 1 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
prior RB 0 1 1 O
to TO 0 0 12 O
dosing VBG 1 0 14 O
with IN 0 0 12 O
VIDEX NNP 0 1 UNK B-Brand
. . 0 0 12 O

Other JJ 0 0 2 O
Agents NNS 0 1 2 O

reduced VBN 1 1 1 O
response NN 0 1 1 O
to TO 0 0 12 O
metyrapone VB 0 1 13 O
test NN 0 1 1 O
; : 0 0 2 O

The DT 0 0 2 O
incidence NN 0 1 6 O
of IN 0 0 12 O
TBg NNP 0 1 UNK O
deficiency NN 0 1 6 O
approximates VBZ 1 1 UNK O
9 CD 0 0 2 O
in IN 0 0 12 O
9 CD 0 0 2 O
. . 0 0 12 O

With IN 0 0 2 O
some DT 0 0 12 O
agents NNS 1 1 1 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
may MD 0 0 1 O
be VB 0 0 12 O
induced VBN 1 1 6 O
resulting VBG 1 1 1 O
in IN 0 0 12 O
decreased JJ 0 1 1 O
concentrations NNS 1 1 13 O
. . 0 0 12 O

Cimetidine NN 0 1 0 B-Drug
: : 0 0 2 O
Cimetidine NN 0 1 0 B-Drug
can MD 0 0 12 O
inhibit VB 0 1 13 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
chloroquine NN 0 1 13 B-Drug
increasing VBG 1 1 1 O
its PRP$ 1 0 12 O
plasma NN 0 1 14 O
level NN 0 1 1 O
. . 0 0 12 O

There EX 0 0 12 O
is VBZ 1 0 12 O
evidence NN 0 1 1 O
that IN 0 0 12 O
the DT 0 0 12 O
use NN 0 1 1 O
of IN 0 0 12 O
halofantrine NN 0 1 UNK B-Drug
after IN 0 0 12 O
Mefloquineuine NNP 0 0 UNK O
causes VBZ 1 1 6 O
a DT 0 0 12 O
significant JJ 0 1 1 O
lengthening NN 0 1 13 O
of IN 0 0 12 O
the DT 0 0 12 O
QTc NNP 0 0 14 O
interval NN 0 1 1 O
. . 0 0 12 O

These DT 0 0 1 O
data NNS 0 1 1 O
suggest VBP 0 1 1 O
that IN 0 0 12 O
GH NNP 0 1 13 B-Drug
administration NN 0 1 1 O
may MD 0 0 1 O
alter VB 0 1 13 O
the DT 0 0 12 O
clearance NN 0 1 16 O
of IN 0 0 12 O
compounds NNS 1 1 13 O
known VBN 1 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
CP9 NNP 0 0 UNK O
liver NN 0 1 6 O
enzymes NNS 1 1 14 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
corticosteroids NNS 1 1 14 B-Group
sex NN 0 1 13 B-Group
steroids NNS 1 1 6 I-Group
anticonvulsants NNS 1 1 13 B-Group
cyclosporin NN 0 1 14 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

Smokers NNS 0 1 UNK O
have VBP 0 0 12 O
an DT 0 0 12 O
increased VBN 1 1 1 O
clearance NN 0 1 16 O
of IN 0 0 12 O
benzodiazepines NNS 1 1 14 B-Group
as IN 1 0 12 O
compared VBN 1 1 1 O
to TO 0 0 12 O
nonsmokers NNS 1 1 UNK O
; : 0 0 2 O

- : 0 0 2 O
Concomitant NN 0 1 UNK O
use NN 0 1 1 O
of IN 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
may MD 0 0 1 O
reduce VB 0 0 1 O
the DT 0 0 12 O
efficacy NN 0 1 UNK O
of IN 0 0 12 O
lofexidine NN 0 1 UNK B-Drug
. . 0 0 12 O

The DT 0 0 2 O
potential NN 0 1 1 O
for IN 0 0 12 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
drug NN 0 1 1 O
- : 0 0 2 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
posed VBN 1 0 UNK O
by IN 0 0 12 O
dolasetron NN 0 1 0 B-Drug
and CC 0 0 12 O
hydrodolasetron NN 0 1 UNK B-Drug_n
appears VBZ 1 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
low JJ 0 1 1 O
for IN 0 0 12 O
drugs NNS 1 1 6 O
commonly RB 0 0 UNK O
used VBN 1 1 12 O
in IN 0 0 12 O
chemotherapy NN 0 1 6 O
or CC 0 0 12 O
surgery NN 0 1 6 O
because IN 0 0 12 O
hydrodolasetron NN 0 1 UNK B-Drug_n
is VBZ 1 0 12 O
eliminated VBN 1 1 UNK O
by IN 0 0 12 O
multiple JJ 0 1 1 O
routes NNS 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
terfenadine NN 0 1 UNK B-Drug
and CC 0 0 12 O
its PRP$ 1 0 12 O
acid NN 0 1 14 O
metabolite NN 0 1 UNK O
and CC 0 0 12 O
the DT 0 0 12 O
electrocardiographic JJ 0 1 8 O
QT NNP 0 1 13 O
c NN 0 0 16 O
interval NN 0 1 1 O
were VBD 1 0 12 O
measured VBN 1 1 1 O
during IN 0 0 12 O
both DT 0 0 12 O
periods NNS 1 1 1 O
: : 0 0 2 O
with IN 0 0 12 O
terfenadine NN 0 1 UNK B-Drug
alone RB 0 1 12 O
and CC 0 0 12 O
with IN 0 0 12 O
terfenadine JJ 0 1 UNK B-Drug
plus CC 0 1 16 O
dirithromycin NN 0 1 UNK B-Drug
. . 0 0 12 O

Concurrent NNP 0 1 13 O
use NN 0 1 1 O
of IN 0 0 12 O
these DT 0 0 12 O
agents NNS 1 1 1 O
should MD 0 0 12 O
generally RB 0 0 1 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
. . 0 0 12 O

Probenecid NN 0 1 UNK B-Drug
: : 0 0 2 O
Probenecid VB 0 1 UNK B-Drug
a DT 0 0 12 O
known JJ 0 1 12 O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
renal JJ 0 1 6 O
tubular JJ 0 1 3 O
secretion NN 0 1 14 O
of IN 0 0 12 O
organic JJ 0 1 13 O
acids NNS 1 1 14 O
via IN 0 0 1 O
the DT 0 0 12 O
aruonic JJ 0 0 UNK O
transporter NN 0 1 UNK O
did VBD 1 0 12 O
not RB 0 1 12 O
noticeably RB 0 0 3 O
influence VB 0 0 UNK O
pramipexole JJ 0 1 16 B-Drug
pharmacokinetics NNS 0 1 UNK O
( ( 0 0 2 O
N= NNP 0 1 UNK O
9 CD 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

Antihistamines NNS 0 1 UNK B-Group
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
chlorpheniramine NN 0 1 16 B-Group
) ) 0 0 2 O
. . 0 0 12 O

On IN 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
oral JJ 0 1 6 O
amiodarone NN 0 1 0 B-Drug
the DT 0 0 12 O
need NN 0 1 12 O
for IN 0 0 12 O
digitalis JJ 0 1 14 B-Group
therapy NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
reviewed VBN 1 1 1 O
and CC 0 0 12 O
the DT 0 0 12 O
dose NN 0 1 6 O
reduced VBN 1 1 1 O
by IN 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
or CC 0 0 12 O
discontinued VBN 1 1 1 O
. . 0 0 12 O

Pindolol NNP 0 1 UNK B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
used VBN 1 1 12 O
with IN 0 0 12 O
a DT 0 0 12 O
variety NN 0 1 1 O
of IN 0 0 12 O
antihypertensive JJ 0 1 14 B-Group
agents NNS 1 1 1 I-Group
including VBG 1 1 1 O
hydrochlorothiazide JJ 0 1 0 B-Drug
hydralazine NN 0 1 14 B-Drug
and CC 0 0 12 O
guanethidine NN 0 1 UNK B-Drug
without IN 0 0 12 O
unexpected JJ 0 1 12 O
adverse JJ 0 0 1 O
interactions NNS 1 1 UNK O
. . 0 0 12 O

Other JJ 0 0 2 O
: : 0 0 2 O
Concomitant JJ 0 1 UNK O
alcohol NN 0 1 1 B-Drug
or CC 0 0 12 O
hot JJ 0 1 3 O
drinks NNS 1 1 12 O
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
side JJ 0 1 3 O
effects NNS 1 1 1 O
of IN 0 0 12 O
flushing NN 0 1 13 O
and CC 0 0 12 O
pruritus NN 0 1 8 O
and CC 0 0 12 O
should MD 0 0 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
at IN 0 0 12 O
the DT 0 0 12 O
time NN 0 1 12 O
of IN 0 0 12 O
drug NN 0 1 1 O
ingestion NN 0 1 14 O
. . 0 0 12 O

Somatrem NNP 0 1 UNK B-Drug
/ NNP 0 0 2 O
Somatropin NNP 0 1 UNK B-Drug
: : 0 0 2 O
Excessive JJ 0 1 UNK O
concurrent NN 0 1 1 O
use NN 0 1 1 O
of IN 0 0 12 O
thyroid JJ 0 1 6 B-Group
hormone NN 0 1 6 I-Group
may MD 0 0 1 O
accelerate VB 0 1 UNK O
epiphyseal JJ 0 1 13 O
closure NN 0 1 3 O
. . 0 0 12 O

No DT 0 0 2 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
between IN 0 0 12 O
Prostin NNP 0 1 UNK B-Brand
VR NNP 0 1 UNK I-Brand
Pediatric NNP 0 1 7 I-Brand
and CC 0 0 12 O
the DT 0 0 12 O
therapy JJ 0 1 6 O
standard NN 0 1 1 O
in IN 0 0 12 O
neonates NNS 1 1 16 O
with IN 0 0 12 O
restricted JJ 0 1 1 O
pulmonary NN 0 1 6 O
or CC 0 0 12 O
systemic JJ 0 1 6 O
blood NN 0 1 6 O
flow NN 0 1 1 O
. . 0 0 12 O

Anagrelide NNP 0 1 UNK B-Drug
demonstrates VBZ 1 1 1 O
some DT 0 0 12 O
limited JJ 0 1 1 O
inhibitory NN 0 1 UNK O
activity NN 0 1 1 O
towards NNS 0 0 12 O
CYP9A9 NNP 0 0 UNK O
which WDT 0 0 12 O
may MD 0 0 1 O
present VB 0 1 1 O
a DT 0 0 12 O
theoretical JJ 0 1 UNK O
potential NN 0 1 1 O
for IN 0 0 12 O
interaction NN 0 1 UNK O
with IN 0 0 12 O
other JJ 0 0 12 O
coadministered VBD 0 0 UNK O
medicinal JJ 0 0 16 O
products NNS 1 1 1 O
sharing VBG 1 1 UNK O
that IN 0 0 12 O
clearance NN 0 1 16 O
mechanism NN 0 1 13 O
e.g NN 0 0 UNK O
. . 0 0 12 O

Agents NNS 0 1 2 O
that WDT 0 0 12 O
are VBP 1 0 12 O
CYP9A9 NNP 0 0 UNK O
inhibitors NNS 1 1 14 O
that WDT 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
found VBN 1 1 12 O
or CC 0 0 12 O
are VBP 1 0 12 O
expected VBN 1 1 12 O
to TO 0 0 12 O
increase VB 0 1 1 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
EQUETROTM NNP 0 0 UNK B-Brand
are VBP 1 0 12 O
the DT 0 0 12 O
following JJ 0 1 1 O
: : 0 0 2 O
Acetazolamide JJ 0 1 0 B-Drug
azole JJ 0 1 UNK B-Group
antifungals NNS 1 1 UNK I-Group
cimetidine VBP 0 1 13 B-Drug
clarithromycin NN 0 1 13 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
dalfopristin NN 0 1 13 B-Drug
danazol JJ 0 1 13 B-Drug
delavirdine NN 0 1 13 B-Drug
diltiazem NN 0 1 0 B-Drug
erythromycin NN 0 1 0 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
fluoxetine NN 0 1 16 B-Drug
fluvoxamine NN 0 1 16 B-Drug
grapefruit NN 0 1 3 O
juice NN 0 1 3 O
isoniazid JJ 0 1 13 B-Drug
itraconazole JJ 0 1 0 B-Drug
ketoconazole NN 0 1 16 B-Drug
loratadine NN 0 1 0 B-Drug
nefazodone NN 0 1 16 B-Drug
niacinamide JJ 0 1 13 B-Drug
nicotinamide JJ 0 1 UNK B-Drug
protease NN 0 1 13 B-Group
inhibitors NNS 1 1 14 I-Group
propoxyphene VBP 0 1 16 B-Drug
quinine JJ 0 1 16 B-Drug
quinupristin NN 0 1 13 B-Drug
troleandomycin NN 0 1 UNK B-Drug
valproate NN 0 1 16 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
verapamil NN 0 1 0 B-Drug
zileuton NN 0 1 13 B-Drug
. . 0 0 12 O

Dicumarol NNP 0 1 UNK B-Drug
and CC 0 0 12 O
warfarin NN 0 1 14 B-Drug
may MD 0 0 1 O
decrease VB 0 1 1 O
hypoprothrombinemic JJ 0 1 UNK O
effect NN 0 1 1 O
. . 0 0 12 O

Products NNS 0 1 2 O
containing VBG 1 1 1 O
calcium NN 0 1 14 B-Drug
and CC 0 0 12 O
other JJ 0 0 12 O
multivalent NN 0 0 UNK O
cations NNS 1 1 UNK O
( ( 0 0 2 O
such JJ 0 0 1 O
as IN 1 0 12 O
aluminum NN 0 1 16 B-Drug
magnesium NN 0 1 14 B-Drug
iron NN 0 1 3 B-Drug
) ) 0 0 2 O
are VBP 1 0 12 O
likely JJ 0 1 12 O
to TO 0 0 12 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
absorption NN 0 1 1 O
of IN 0 0 12 O
Ibandronate NNP 0 1 UNK B-Drug
. . 0 0 12 O

Carbamazepine NN 0 1 UNK B-Drug
: : 0 0 2 O
Tiagabine NN 0 1 UNK B-Drug
had VBD 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
carbamazepine NN 0 1 16 B-Drug
or CC 0 0 12 O
its PRP$ 1 0 12 O
epoxide JJ 0 1 UNK O
metabolite NN 0 1 UNK O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
epilepsy NN 0 1 13 O
. . 0 0 12 O

Based VBN 0 1 2 O
on IN 0 0 12 O
in IN 0 0 12 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
no DT 0 0 12 O
pharmacokinetic JJ 0 1 UNK O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
drugs NNS 1 1 6 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
the DT 0 0 12 O
following JJ 0 1 1 O
isoenzyme NN 0 1 13 O
systems NNS 1 1 1 O
are VBP 1 0 12 O
expected VBN 1 1 12 O
: : 0 0 2 O
CYP9A9 NNP 0 0 UNK O
CYP9D9 NNP 0 0 UNK O
CYP9A9 NNP 0 0 UNK O
/ VBD 0 0 2 O
9 CD 0 0 2 O
CYP9E9 NNP 0 0 UNK O
CYP9C9 NNP 0 0 UNK O
CYP9C9 NNP 0 0 UNK O
or CC 0 0 12 O
CYP9C9 NNP 0 0 UNK O
. . 0 0 12 O

Risk NN 0 1 2 O
of IN 0 0 12 O
Anaphylactic JJ 0 1 UNK O
Reaction NN 0 1 UNK O
: : 0 0 2 O
While IN 0 0 12 O
taking VBG 1 0 12 O
beta SYM 0 1 16 B-Group
- : 0 0 2 O
blockers NNS 1 0 6 I-Group
patients NNS 1 1 6 O
with IN 0 0 12 O
a DT 0 0 12 O
history NN 0 1 12 O
of IN 0 0 12 O
severe JJ 0 1 6 O
anaphylactic JJ 0 1 13 O
reaction NN 0 1 1 O
to TO 0 0 12 O
a DT 0 0 12 O
variety NN 0 1 1 O
of IN 0 0 12 O
allergens NNS 1 1 13 O
may MD 0 0 1 O
be VB 0 0 12 O
more RBR 0 1 12 O
reactive JJ 0 1 1 O
to TO 0 0 12 O
repeated VBN 1 1 1 O
challenge NN 0 1 12 O
either CC 0 1 12 O
accidental JJ 0 1 13 O
diagnostic NN 0 1 6 O
or CC 0 0 12 O
therapeutic JJ 0 1 6 O
. . 0 0 12 O

oxolinic JJ 0 1 UNK B-Drug
acid NN 0 1 14 I-Drug
; : 0 0 2 O

The DT 0 0 2 O
concurrent JJ 0 1 1 O
administration NN 0 1 1 O
of IN 0 0 12 O
CAMPTOSAR NNP 0 1 UNK B-Brand
with IN 0 0 12 O
irradiation NN 0 1 14 O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
adequately RB 0 0 1 O
studied VBN 1 0 1 O
and CC 0 0 12 O
is VBZ 1 0 12 O
not RB 0 1 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O

atorvastatin NN 0 1 0 B-Drug
concentration NN 0 1 1 O

In IN 0 0 2 O
utero JJ 0 1 6 O
serum NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
exposure NN 0 1 1 O
in IN 0 0 12 O
these DT 0 0 12 O
monkeys NNS 1 1 UNK O
were VBD 1 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
of IN 0 0 12 O
maternal JJ 0 1 6 O
serum NN 0 1 14 O
levels NNS 1 1 1 O
. . 0 0 12 O

Erythromycin NNP 0 1 0 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg RB 0 1 0 O
t.i.d NN 0 1 UNK O
) ) 0 0 2 O
produced VBD 1 0 1 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
fold JJ 0 1 3 O
increase NN 0 1 1 O
in IN 0 0 12 O
vardenafil JJ 0 1 UNK B-Drug
AUC NNP 0 1 UNK O
and CC 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
fold JJ 0 1 3 O
increase NN 0 1 1 O
in IN 0 0 12 O
Cmax NNP 0 1 UNK O
when WRB 0 0 12 O
co NN 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
with IN 0 0 12 O
Vardenafil NNP 0 1 UNK B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
in IN 0 0 12 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
. . 0 0 12 O

Coadministration NN 0 1 UNK O
of IN 0 0 12 O
valdecoxib NN 0 1 13 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
BID NNP 0 0 11 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
) ) 0 0 2 O
with IN 0 0 12 O
glyburide NN 0 1 16 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
QD NNP 0 1 13 O
or CC 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
BID NNP 0 0 11 O
) ) 0 0 2 O
did VBD 1 0 12 O
not RB 0 1 12 O
affect VB 0 1 1 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
( ( 0 0 2 O
exposure NN 0 1 1 O
) ) 0 0 2 O
of IN 0 0 12 O
glyburide NN 0 1 16 B-Drug
. . 0 0 12 O

Prothrombin NNP 0 1 7 O
time NN 0 1 12 O
was VBD 1 0 12 O
not RB 0 1 12 O
affected VBN 1 1 1 O
. . 0 0 12 O

Therefore RB 0 0 1 O
if IN 0 0 12 O
concomitant JJ 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
such JJ 0 0 1 O
agents NNS 1 1 1 O
is VBZ 1 0 12 O
indicated JJ 0 1 1 O
they PRP 0 0 12 O
should MD 0 0 12 O
be VB 0 0 12 O
given VBN 1 1 12 O
with IN 0 0 12 O
caution NN 0 0 1 O
and CC 0 0 12 O
the DT 0 0 12 O
patient NN 0 1 6 O
's POS 0 1 12 O
serum JJ 0 1 14 O
potassium NN 0 1 14 O
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
frequently RB 0 1 1 O
. . 0 0 12 O

ACE NNP 0 1 13 B-Group
- : 0 0 2 O
inhibitors NNS 1 1 14 I-Group
Reports VBP 0 1 2 O
suggest NN 0 1 1 O
that IN 0 0 12 O
NSAIDs NNP 0 1 UNK B-Group
may MD 0 0 1 O
diminish VB 0 1 UNK O
the DT 0 0 12 O
antihypertensive JJ 0 1 14 O
effect NN 0 1 1 O
of IN 0 0 12 O
ACE NNP 0 1 13 B-Group
- : 0 0 2 O
inhibitors NNS 1 1 14 I-Group
. . 0 0 12 O

Verapamil NN 0 1 0 B-Drug
: : 0 0 2 O
Coadministration NN 0 1 UNK O
of IN 0 0 12 O
almotriptan NN 0 1 13 B-Drug
and CC 0 0 12 O
verapamil NN 0 1 0 B-Drug
resulted VBD 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
increase NN 0 1 1 O
in IN 0 0 12 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
almotriptan NN 0 1 13 B-Drug
. . 0 0 12 O

No DT 0 0 2 O
dosage NN 0 1 0 O
adjustment NN 0 1 1 O
for IN 0 0 12 O
montelukast NN 0 1 16 B-Drug
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O

- : 0 0 2 O
Primaquine NN 0 1 0 B-Drug
or CC 0 0 12 O

Lamivudine NN 0 1 UNK B-Drug
: : 0 0 2 O
In IN 0 0 2 O
vitro NN 0 1 UNK O
studies NNS 1 1 1 O
in IN 0 0 12 O
peripheral JJ 0 1 6 O
blood NN 0 1 6 O
mononuclear NN 0 1 14 O
cells NNS 1 1 6 O
U9 NNP 0 0 UNK O
and CC 0 0 12 O
Molt NNP 0 1 UNK O
- : 0 0 2 O
9 CD 0 0 2 O
cells NNS 1 1 6 O
revealed VBD 1 1 12 O
that IN 0 0 12 O
lamivudine NN 0 1 16 B-Drug
significantly RB 0 0 1 O
inhibited VBN 1 1 13 O
zalcitabine CD 0 1 UNK B-Drug
phosphorylation NN 0 1 UNK O
in IN 0 0 12 O
a DT 0 0 12 O
dose JJ 0 1 6 O
dependent JJ 0 1 1 O
manner NN 0 0 1 O
. . 0 0 12 O

They PRP 0 0 12 O
can MD 0 0 12 O
either VB 0 1 12 O
increase VB 0 1 1 O
or CC 0 0 12 O
decrease VB 0 1 1 O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
Mephenytoin NNP 0 1 UNK B-Drug
. . 0 0 12 O

TBg NN 0 1 UNK O
may MD 0 0 1 O
also RB 0 0 12 O
be VB 0 0 12 O
increased VBN 1 1 1 O
during IN 0 0 12 O
infectious JJ 0 1 6 O
hepatitis NN 0 1 6 O
. . 0 0 12 O

Indinavir NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
an DT 0 0 12 O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
the DT 0 0 12 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
isoform NN 0 1 UNK O
CYP9A9 NNP 0 0 UNK O
. . 0 0 12 O

Onset NNP 0 1 7 O
of IN 0 0 12 O
action NN 0 1 13 O
of IN 0 0 12 O
tricyclics NNS 1 1 UNK B-Group
may MD 0 0 1 O
be VB 0 0 12 O
accelerated VBN 1 1 1 O
. . 0 0 12 O

therefore RB 0 0 1 O
the DT 0 0 12 O
efficacy NN 0 1 UNK O
of IN 0 0 12 O
oral JJ 0 1 6 O
contraceptives NNS 1 1 13 B-Group
during IN 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
Aprepitant NNP 0 1 UNK B-Drug
may MD 0 0 1 O
be VB 0 0 12 O
reduced VBN 1 1 1 O
. . 0 0 12 O

ethchlorvynol NN 0 1 UNK B-Drug
; : 0 0 2 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interactions NNPS 0 1 UNK O
The DT 0 0 2 O
presence NN 0 1 1 O
of IN 0 0 12 O
labetalol NN 0 1 0 O
metabolites NNS 1 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
urine NN 0 1 6 O
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
falsely RB 0 0 1 O
elevated JJ 0 1 1 O
levels NNS 1 1 1 O
of IN 0 0 12 O
urinary JJ 0 1 6 O
catecholamines NNS 1 1 14 O
metanephrine VBP 0 1 UNK O
normetanephrine NN 0 1 UNK O
and CC 0 0 12 O
vanillylmandelic JJ 0 0 UNK O
acid NN 0 1 14 O
when WRB 0 0 12 O
measured VBN 1 1 1 O
by IN 0 0 12 O
fluorimetric JJ 0 1 UNK O
or CC 0 0 12 O
photometric JJ 0 1 UNK O
methods NNS 1 1 1 O
. . 0 0 12 O

Caution NN 0 0 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
if IN 0 0 12 O
TOLECTIN NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
methotrexate NN 0 1 16 B-Drug
. . 0 0 12 O

Patients NNS 0 1 7 O
taking VBG 1 0 12 O
warfarin NN 0 1 14 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
regularly RB 0 0 12 O
for IN 0 0 12 O
changes NNS 1 1 1 O
in IN 0 0 12 O
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
or CC 0 0 12 O
INR NNP 0 1 13 O
. . 0 0 12 O

Indinavir NN 0 1 UNK B-Drug
: : 0 0 2 O
Coadministration NN 0 1 UNK O
of IN 0 0 12 O
indinavir NN 0 1 16 B-Drug
with IN 0 0 12 O
VIRACEPT NNP 0 1 UNK B-Brand
resulted VBD 1 1 1 O
in IN 0 0 12 O
an DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
increase NN 0 1 1 O
in IN 0 0 12 O
nelfinavir JJ 0 1 16 B-Drug
plasma NN 0 1 14 O
AUC NNP 0 1 UNK O
and CC 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
increase NN 0 1 1 O
in IN 0 0 12 O
indinavir JJ 0 1 16 B-Drug
plasma NN 0 1 14 O
A.C NNP 0 0 UNK O
. . 0 0 12 O

See VB 0 1 2 O
WARNINGS NNP 0 1 UNK O
Myopathy NNP 0 1 UNK O
/ NNP 0 0 2 O
Rhabdomyolysis NNP 0 1 UNK O
. . 0 0 12 O

These DT 0 0 1 O
agents NNS 1 1 1 O
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
taken VBN 1 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
before IN 0 1 12 O
or CC 0 0 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
after IN 0 0 12 O
enoxacin DT 0 1 UNK B-Drug
administration NN 0 1 1 O
. . 0 0 12 O

increased VBN 1 1 1 O
factors NNS 1 1 1 O
II NNP 0 0 2 O
VII NNP 0 1 2 O
antigen NN 0 1 14 O
VIII NNP 0 1 2 O
antigen NN 0 1 14 O
VIII NNP 0 1 2 O
coagulant NN 0 1 UNK O
activity NN 0 1 1 O
IX NNP 0 1 2 O
X NNP 0 0 2 O
XII NNP 0 0 13 O
VII NNP 0 1 2 O
- : 0 0 2 O
X NN 0 0 2 O
complex JJ 0 1 1 O
II NNP 0 0 2 O
- : 0 0 2 O
VII NNP 0 1 2 O
- : 0 0 2 O
X NN 0 0 2 O
complex NN 0 1 1 O
and CC 0 0 12 O
beta NN 0 1 16 O
- : 0 0 2 O
thromboglobulin NN 0 1 UNK O
; : 0 0 2 O

Therefore RB 0 0 1 O
a DT 0 0 12 O
slower JJR 1 1 UNK O
onset NN 0 1 6 O
can MD 0 0 12 O
be VB 0 0 12 O
anticipated VBN 1 1 1 O
if IN 0 0 12 O
STADOL NNP 0 1 UNK B-Brand
NS NNP 0 1 13 I-Brand
is VBZ 1 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
or CC 0 0 12 O
immediately RB 0 1 12 O
following VBG 1 1 1 O
a DT 0 0 12 O
nasal JJ 0 1 6 B-Group
vasoconstrictor NN 0 1 UNK I-Group
. . 0 0 12 O

The DT 0 0 2 O
mean JJ 0 1 12 O
changes NNS 1 1 1 O
were VBD 1 0 12 O
observed VBN 1 1 1 O
to TO 0 0 12 O
be VB 0 0 12 O
less JJR 0 1 12 O
than IN 0 0 12 O
9 CD 0 0 2 O
second JJ 0 1 12 O
in IN 0 0 12 O
both DT 0 0 12 O
instances NNS 1 1 UNK O
however RB 0 0 12 O
and CC 0 0 12 O
are VBP 1 0 12 O
unlikely JJ 0 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
clinically RB 0 0 6 O
important JJ 0 1 1 O
. . 0 0 12 O

Rare JJ 0 1 2 O
cases NNS 1 1 UNK O
of IN 0 0 12 O
elevated JJ 0 1 1 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
. . 0 0 12 O

Administration NN 0 1 UNK O
of IN 0 0 12 O
epinephrine NN 0 1 14 B-Drug
to TO 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
cyclopropane NN 0 1 UNK B-Drug
or CC 0 0 12 O
halogenated VBN 0 0 UNK B-Group
hydrocarbon NN 0 1 13 I-Group
general JJ 0 1 1 I-Group
anesthetics NNS 1 1 13 I-Group
such JJ 0 0 1 O
as IN 1 0 12 O
halothane NN 0 1 13 B-Drug
which WDT 0 0 12 O
sensitize VBP 0 0 UNK O
the DT 0 0 12 O
myocardium NN 0 1 8 O
may MD 0 0 1 O
induce VB 0 1 6 O
cardiac JJ 0 1 6 O
arrhythmia NN 0 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
use NN 0 1 1 O
of IN 0 0 12 O
AGGRASTAT NNP 0 1 UNK B-Brand
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
heparin NN 0 1 14 B-Drug
and CC 0 0 12 O
aspirin NN 0 1 14 B-Brand
has VBZ 1 0 12 O
been VBN 1 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
an DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
bleeding VBG 1 1 6 O
compared VBN 1 1 1 O
to TO 0 0 12 O
heparin VB 0 1 14 B-Drug
and CC 0 0 12 O
aspirin VB 0 1 14 B-Drug
alone RB 0 1 12 O
( ( 0 0 2 O
see VB 0 1 12 O

Potassium NN 0 1 14 B-Drug
Supplements NNS 0 1 UNK O
and CC 0 0 12 O
Potassium NNP 0 1 14 B-Group
- : 0 0 2 O
Sparing VBG 0 0 UNK I-Group
Diuretics NNS 0 1 UNK I-Group
: : 0 0 2 O
ACEON NNP 0 1 UNK B-Brand
Tablets NNP 0 1 0 O
may MD 0 0 1 O
increase VB 0 1 1 O
serum NN 0 1 14 O
potassium NN 0 1 14 O
because IN 0 0 12 O
of IN 0 0 12 O
its PRP$ 1 0 12 O
potential JJ 0 1 1 O
to TO 0 0 12 O
decrease VB 0 1 1 O
aldosterone JJ 0 1 UNK O
production NN 0 1 1 O
. . 0 0 12 O

Alcohol NN 0 1 2 B-Drug
: : 0 0 2 O
Concomitant JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
alcohol NN 0 1 1 B-Drug
( ( 0 0 2 O
equivalent JJ 0 1 1 O
to TO 0 0 12 O
9 CD 0 0 2 O
g NN 0 1 16 O
) ) 0 0 2 O
had VBD 1 0 12 O
a DT 0 0 12 O
minimal JJ 0 1 1 O
effect NN 0 1 1 O
on IN 0 0 12 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
mirtazapine NN 0 1 0 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
) ) 0 0 2 O
in IN 0 0 12 O
9 CD 0 0 2 O
healthy JJ 0 1 12 O
male JJ 0 1 12 O
subjects NNS 1 1 UNK O
. . 0 0 12 O

Administration NN 0 1 UNK O
of IN 0 0 12 O
reserpine NN 0 1 UNK B-Drug
during IN 0 0 12 O
therapy NN 0 1 6 O
with IN 0 0 12 O
a DT 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressant NN 0 1 6 I-Group
has VBZ 1 0 12 O
been VBN 1 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
produce VB 0 0 1 O
a DT 0 0 12 O
stimulating JJ 0 1 1 O
effect NN 0 1 1 O
in IN 0 0 12 O
some DT 0 0 12 O
depressed JJ 0 1 12 O
patients NNS 1 1 6 O
. . 0 0 12 O

Valproic NNP 0 0 UNK B-Drug
acid NN 0 1 14 I-Drug

Experience NN 0 1 UNK O
with IN 0 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
HMG NNP 0 0 UNK B-Group
- : 0 0 2 O
CoA NNP 0 0 UNK I-Group
reductase NN 0 1 UNK I-Group
inhibitors NNS 1 1 14 I-Group
and CC 0 0 12 O
Fentanyl NNP 0 1 0 B-Drug
in IN 0 0 12 O
patients NNS 1 1 6 O
is VBZ 1 0 12 O
limited JJ 0 1 1 O
therefore IN 0 0 1 O
consideration NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
given VBN 1 1 12 O
to TO 0 0 12 O
temporarily RB 0 0 1 O
suspending VBG 1 1 UNK O
use NN 0 1 1 O
of IN 0 0 12 O
HMG NNP 0 0 UNK B-Group
- : 0 0 2 O
CoA NNP 0 0 UNK I-Group
reductase NN 0 1 UNK I-Group
inhibitors NNS 1 1 14 I-Group
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
Fentanyl NNP 0 1 0 B-Drug
. . 0 0 12 O

Use NN 0 1 2 O
with IN 0 0 12 O
Anticholinergics NNS 0 1 UNK B-Group
: : 0 0 2 O
Because IN 0 0 12 O
of IN 0 0 12 O
their PRP$ 0 0 12 O
mechanism NN 0 1 13 O
of IN 0 0 12 O
action NN 0 1 13 O
cholinesterase NN 0 1 UNK B-Group
inhibitors NNS 1 1 14 I-Group
have VBP 0 0 12 O
the DT 0 0 12 O
potential JJ 0 1 1 O
to TO 0 0 12 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
activity NN 0 1 1 O
of IN 0 0 12 O
anticholinergic JJ 0 1 13 B-Group
medications NNS 1 1 6 I-Group
. . 0 0 12 O

Particular JJ 0 0 UNK O
caution NN 0 0 1 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
when WRB 0 0 12 O
administering VBG 1 1 1 O
Gleevec NNP 0 1 UNK B-Brand
with IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
substrates NNS 1 1 UNK O
that WDT 0 0 12 O
have VBP 0 0 12 O
a DT 0 0 12 O
narrow JJ 0 1 3 O
therapeutic JJ 0 1 6 O
window NN 0 1 3 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
cyclosporine NN 0 1 14 B-Drug
or CC 0 0 12 O
pimozide NN 0 1 13 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

Furosemide NN 0 1 0 B-Drug
: : 0 0 2 O
In IN 0 0 2 O
normal JJ 0 1 1 O
volunteers NNS 1 1 UNK O
the DT 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
diflunisal NN 0 1 13 B-Drug
and CC 0 0 12 O
furosemide NN 0 1 0 B-Drug
had VBD 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
diuretic JJ 0 1 14 O
activity NN 0 1 1 O
of IN 0 0 12 O
furosemide NN 0 1 0 B-Drug
. . 0 0 12 O

However RB 0 0 1 O
the DT 0 0 12 O
pharmacodynamics NNS 0 1 UNK O
of IN 0 0 12 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
zaleplon NN 0 1 13 B-Drug
and CC 0 0 12 O
promethazine NN 0 1 16 B-Drug
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
evaluated VBN 1 1 1 O
. . 0 0 12 O

CNS NNP 0 1 6 O
- : 0 0 2 O
Active JJ 0 1 2 O
Drugs NNP 0 1 2 O
Ethanol NNP 0 1 13 B-Drug
: : 0 0 2 O
Sonata NNP 0 1 UNK B-Brand
9 CD 0 0 2 O
mg NN 0 1 0 O
potentiated VBD 1 0 UNK O
the DT 0 0 12 O
CNS NNP 0 1 6 O
- : 0 0 2 O
impairing VBG 1 1 UNK O
effects NNS 1 1 1 O
of IN 0 0 12 O
ethanol JJ 0 1 1 B-Drug
9 CD 0 0 2 O
g NN 0 1 16 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
on IN 0 0 12 O
balance NN 0 1 1 O
testing NN 0 1 1 O
and CC 0 0 12 O
reaction NN 0 1 1 O
time NN 0 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
hour NN 0 1 12 O
after IN 0 0 12 O
ethanol JJ 0 1 1 B-Drug
administration NN 0 1 1 O
and CC 0 0 12 O
on IN 0 0 12 O
the DT 0 0 12 O
digit JJ 0 1 1 O
symbol NN 0 1 UNK O
substitution NN 0 1 13 O
test NN 0 1 1 O
( ( 0 0 2 O
DSST NNP 0 1 UNK O
) ) 0 0 2 O
symbol NN 0 1 UNK O
copying VBG 1 1 1 O
test NN 0 1 1 O
and CC 0 0 12 O
the DT 0 0 12 O
variability NN 0 1 UNK O
component NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
divided JJ 0 1 1 O
attention NN 0 1 12 O
test NN 0 1 1 O
for IN 0 0 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
after IN 0 0 12 O
ethanol DT 0 1 1 B-Drug
administration NN 0 1 1 O
. . 0 0 12 O

Rifampin NNP 0 1 0 B-Drug
may MD 0 0 1 O
decrease VB 0 1 1 O
serum NN 0 1 14 O
digoxin NN 0 1 14 B-Drug
concentration NN 0 1 1 O
especially RB 0 0 12 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
renal JJ 0 1 6 O
dysfunction NN 0 1 6 O
by IN 0 0 12 O
increasing VBG 1 1 1 O
the DT 0 0 12 O
non NN 0 1 1 O
- : 0 0 2 O
renal JJ 0 1 6 O
clearance NN 0 1 16 O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
. . 0 0 12 O

Oral JJ 0 1 2 O
Hypoglycemic NNP 0 1 UNK B-Group
Agents NNS 0 1 2 I-Group
: : 0 0 2 O
In IN 0 0 2 O
one CD 0 1 12 O
study NN 0 1 1 O
flurbiprofen NN 0 1 16 B-Drug
was VBD 1 0 12 O
given VBN 1 1 12 O
to TO 0 0 12 O
adult VB 0 1 12 O
diabetics NNS 1 1 UNK O
who WP 0 0 12 O
were VBD 1 0 12 O
already RB 0 0 12 O
receiving VBG 1 1 1 O
glyburide NN 0 1 16 B-Drug
( ( 0 0 2 O
n=9 JJ 0 1 UNK O
) ) 0 0 2 O
metformin NN 0 1 0 B-Drug
( ( 0 0 2 O
n=9 JJ 0 1 UNK O
) ) 0 0 2 O
chlorpropamide NN 0 1 13 B-Drug
with IN 0 0 12 O
phenformin NN 0 1 UNK B-Drug
( ( 0 0 2 O
n= JJ 0 1 UNK O
9 CD 0 0 2 O
) ) 0 0 2 O
or CC 0 0 12 O
glyburide NN 0 1 16 B-Drug
with IN 0 0 12 O
phenformin NN 0 1 UNK B-Drug
( ( 0 0 2 O
n=9 JJ 0 1 UNK O
) ) 0 0 2 O
. . 0 0 12 O

The DT 0 0 2 O
clinical JJ 0 1 6 O
relevance NN 0 1 UNK O
of IN 0 0 12 O
such JJ 0 0 1 O
potential JJ 0 1 1 O
interactions NNS 1 1 UNK O
is VBZ 1 0 12 O
not RB 0 1 12 O
known VBN 1 1 12 O
. . 0 0 12 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Tests NNP 0 1 UNK O
Interactions NNP 0 1 UNK O
There EX 0 0 12 O
are VBP 1 0 12 O
no DT 0 0 12 O
known VBN 1 1 12 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
interactions NNS 1 1 UNK O
of IN 0 0 12 O
CLOLAR NNP 0 1 UNK B-Brand
with IN 0 0 12 O
other JJ 0 0 12 O
medications NNS 1 1 6 O
or CC 0 0 12 O
laboratory NN 0 1 1 O
tests NNS 1 1 1 O
. . 0 0 12 O

Acellular JJ 0 0 UNK B-Group
live JJ 0 1 12 B-Group
and CC 0 0 12 O
live JJ 0 1 12 B-Group
- : 0 0 2 O
attenuated JJ 0 1 UNK I-Group
vaccines NNS 1 1 6 I-Group
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
during IN 0 0 12 O
RAPTIVA NNP 0 1 UNK B-Brand
treatment NN 0 1 6 O
. . 0 0 12 O

saquinavir NN 0 1 13 B-Drug
concentration NN 0 1 1 O

Free JJ 0 1 2 O
hormone NN 0 1 6 O
concentrations NNS 1 1 13 O
may MD 0 0 1 O
be VB 0 0 12 O
decreased VBN 1 1 1 O
. . 0 0 12 O

A DT 0 0 2 O
single JJ 0 1 12 O
tonic JJ 0 1 6 O
convulsion NN 0 1 UNK O
was VBD 1 0 12 O
seen VBN 1 1 12 O
in IN 0 0 12 O
each DT 0 0 12 O
of IN 0 0 12 O
9 CD 0 0 2 O
male JJ 0 1 12 O
dogs NNS 1 1 UNK O
( ( 0 0 2 O
one CD 0 1 12 O
treated VBN 1 1 1 O
at IN 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
/ NNP 0 0 2 O
day NN 0 1 12 O
and CC 0 0 12 O
one CD 0 1 12 O
at IN 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
/ NNP 0 0 2 O
day NN 0 1 12 O
) ) 0 0 2 O
in IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
year NN 0 1 12 O
study NN 0 1 1 O
. . 0 0 12 O

However RB 0 0 1 O
interactions NNS 1 1 UNK O
may MD 0 0 1 O
be VB 0 0 12 O
expected VBN 1 1 12 O
and CC 0 0 12 O
FLOMAX NNP 0 1 UNK B-Brand
capsules NNS 1 1 3 O
should MD 0 0 12 O
NOT NNP 0 1 11 O
be VB 0 0 12 O
used VBN 1 1 12 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
other JJ 0 0 12 O
alpha JJ 0 1 1 B-Group
- : 0 0 2 O
adrenergic JJ 0 1 UNK I-Group
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
. . 0 0 12 O

Displacement NN 0 1 UNK O
of IN 0 0 12 O
penicillin NN 0 1 14 B-Group
from IN 0 0 12 O
plasma JJ 0 1 14 O
protein NN 0 1 14 O
binding VBG 1 1 1 O
sites NNS 1 1 1 O
will MD 0 0 12 O
elevate VB 0 1 1 O
the DT 0 0 12 O
level NN 0 1 1 O
of IN 0 0 12 O
free JJ 0 1 12 O
penicillin NN 0 1 14 B-Group
in IN 0 0 12 O
the DT 0 0 12 O
serum NN 0 1 14 O
. . 0 0 12 O

These DT 0 0 1 O
compounds NNS 1 1 13 O
are VBP 1 0 12 O
metabolized VBN 1 1 UNK O
through IN 0 0 12 O
various JJ 0 1 1 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
isozymes NNS 0 1 UNK O
including VBG 1 1 1 O
CYP9A9 NNP 0 0 UNK O
CYP9C9 NNP 0 0 UNK O
CYP9C9 NNP 0 0 UNK O
CYP9D9 NNP 0 0 UNK O
and CC 0 0 12 O
CYP9A NNP 0 0 UNK O
. . 0 0 12 O

( ( 0 0 2 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
day NN 0 1 12 O
9 CD 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
QD NNP 0 1 13 O
9 CD 0 0 2 O
days NNS 1 1 12 O
) ) 0 0 2 O

Drug NNP 0 1 2 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
performed VBN 1 1 1 O
with IN 0 0 12 O
Soliris NNP 0 1 UNK B-Brand
. . 0 0 12 O

However RB 0 0 1 O
in IN 0 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
in IN 0 0 12 O
vivo JJ 0 1 13 O
rodent NN 0 1 UNK O
study NN 0 1 1 O
denileukin FW 0 1 UNK B-Drug
diftitox NN 0 0 UNK I-Drug
had VBD 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
P9 NNP 0 1 UNK O
levels NNS 1 1 1 O
. . 0 0 12 O

HMG NNP 0 0 UNK B-Group
- : 0 0 2 O
CoA NNP 0 0 UNK I-Group
Reductase NNP 0 1 UNK I-Group
Inhibitor NNP 0 1 7 I-Group
: : 0 0 2 O
atorvastatin NN 0 1 0 B-Drug

Their PRP$ 0 0 UNK O
concurrent NN 0 1 1 O
use NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
. . 0 0 12 O

Epidemiological JJ 0 1 UNK O
studies NNS 1 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
case NN 0 1 12 O
- : 0 0 2 O
control NN 0 1 1 O
and CC 0 0 12 O
cohort NN 0 1 UNK O
design NN 0 1 UNK O
that WDT 0 0 12 O
have VBP 0 0 12 O
demonstrated VBN 1 0 1 O
an DT 0 0 12 O
association NN 0 1 1 O
between IN 0 0 12 O
use NN 0 1 1 O
of IN 0 0 12 O
psychotropic NN 0 1 13 B-Group
drugs NNS 1 1 6 I-Group
that WDT 0 0 12 O
interfere VBP 0 1 UNK O
with IN 0 0 12 O
serotonin JJ 0 1 13 O
reuptake NN 0 1 13 O
and CC 0 0 12 O
the DT 0 0 12 O
occurrence NN 0 1 1 O
of IN 0 0 12 O
upper JJ 0 1 3 O
gastrointestinal JJ 0 1 6 O
bleeding NN 0 1 6 O
have VBP 0 0 12 O
also RB 0 0 12 O
shown VBN 1 1 1 O
that IN 0 0 12 O
concurrent NN 0 1 1 O
use NN 0 1 1 O
of IN 0 0 12 O
an DT 0 0 12 O
NSAID NNP 0 1 14 B-Group
or CC 0 0 12 O
aspirin RB 0 1 14 B-Brand
potentiated VBD 1 0 UNK O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
bleeding NN 0 1 6 O
. . 0 0 12 O

Anticholinergics NNS 0 1 UNK B-Group
antagonize VBP 0 0 UNK O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
antiglaucoma NN 0 0 UNK B-Group
agents NNS 1 1 1 I-Group
. . 0 0 12 O

Caution NN 0 0 UNK O
is VBZ 1 0 12 O
advised VBN 1 0 12 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
concomitant JJ 0 1 6 O
high JJ 0 1 1 O
- : 0 0 2 O
dose NN 0 1 6 O
aspirin NN 0 1 14 B-Brand
and CC 0 0 12 O
carbonic JJ 0 1 13 B-Group
anhydrase NN 0 0 13 I-Group
inhibitors NNS 1 1 14 I-Group
as IN 1 0 12 O
anorexia JJ 0 1 6 O
tachypnea NN 0 1 8 O
lethargy NN 0 1 6 O
and CC 0 0 12 O
coma NN 0 1 6 O
have VBP 0 0 12 O
been VBN 1 0 12 O
rarely RB 0 1 UNK O
reported VBN 1 1 1 O
due JJ 0 1 1 O
to TO 0 0 12 O
a DT 0 0 12 O
possible JJ 0 1 1 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
following JJ 0 1 1 O
information NN 0 1 1 O
was VBD 1 0 12 O
obtained VBN 1 1 1 O
from IN 0 0 12 O
the DT 0 0 12 O
literature NN 0 1 UNK O
. . 0 0 12 O

Co NNP 0 1 2 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
irbesartan NN 0 1 16 B-Drug
reduced VBN 1 1 1 O
aliskiren NNS 0 1 13 B-Drug
Cmax NNP 0 1 UNK O
up RB 0 0 12 O
to TO 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
after IN 0 0 12 O
multiple JJ 0 1 1 O
dosing NN 0 0 14 O
. . 0 0 12 O

Coadministration NN 0 1 UNK O
of IN 0 0 12 O
valdecoxib NN 0 1 13 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
BID NNP 0 0 11 O
( ( 0 0 2 O
day NN 0 1 12 O
9 CD 0 0 2 O
) ) 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
QD NNP 0 1 13 O
( ( 0 0 2 O
days NNS 1 1 12 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
) ) 0 0 2 O
with IN 0 0 12 O
glyburide NN 0 1 16 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg RB 0 1 0 O
QD NNP 0 1 13 O
) ) 0 0 2 O
did VBD 1 0 12 O
not RB 0 1 12 O
affect VB 0 1 1 O
either CC 0 1 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
( ( 0 0 2 O
exposure NN 0 1 1 O
) ) 0 0 2 O
or CC 0 0 12 O
the DT 0 0 12 O
pharmacodynamics NNS 0 1 UNK O
( ( 0 0 2 O
blood NN 0 1 6 O
glucose NN 0 1 14 O
and CC 0 0 12 O
insulin NN 0 1 14 O
levels NNS 1 1 1 O
) ) 0 0 2 O
of IN 0 0 12 O
glyburide NN 0 1 16 B-Drug
. . 0 0 12 O

ZINECARD NNP 0 1 UNK B-Brand
does VBZ 1 0 12 O
not RB 0 1 12 O
influence VB 0 0 UNK O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
doxorubicin NN 0 1 13 B-Drug
. . 0 0 12 O

metabolizers NNS 0 0 UNK O
. . 0 0 12 O

Cytochrome NNP 0 1 UNK O
P NNP 0 1 2 O
- : 0 0 2 O
9 CD 0 0 2 O
is VBZ 1 0 12 O
not RB 0 1 12 O
known VBN 1 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
involved VBN 1 1 12 O
in IN 0 0 12 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
Plenaxis NNP 0 1 UNK B-Brand
. . 0 0 12 O

RAPTIVA NNP 0 1 UNK B-Brand
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
with IN 0 0 12 O
other JJ 0 0 12 O
immunosuppressive JJ 0 1 14 B-Group
drugs NNS 1 1 6 I-Group
. . 0 0 12 O

Some DT 0 0 2 O
of IN 0 0 12 O
the DT 0 0 12 O
CNS NNP 0 1 6 O
and CC 0 0 12 O
genitourinary JJ 0 1 8 O
symptoms NNS 1 1 6 O
may MD 0 0 1 O
be VB 0 0 12 O
related VBN 1 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
underlying JJ 0 0 1 O
disease NN 0 1 6 O
rather RB 0 0 12 O
than IN 0 0 12 O
to TO 0 0 12 O
drug NN 0 1 1 O
therapy NN 0 1 6 O
. . 0 0 12 O

When WRB 0 0 12 O
the DT 0 0 12 O
CYP9D9 NNP 0 0 UNK O
inhibitor NN 0 1 14 O
is VBZ 1 0 12 O
withdrawn VBN 1 1 1 O
from IN 0 0 12 O
the DT 0 0 12 O
combination NN 0 1 1 O
therapy NN 0 1 6 O
aripiprazole NN 0 1 16 B-Drug
dose NN 0 1 6 O
should MD 0 0 12 O
then RB 0 1 12 O
be VB 0 0 12 O
increased VBN 1 1 1 O
. . 0 0 12 O

ACE JJ 0 1 13 B-Group
inhibitors NNS 1 1 14 I-Group
: : 0 0 2 O
Reports NNS 0 1 2 O
suggest VBP 0 1 1 O
that IN 0 0 12 O
NSAIDs NNP 0 1 UNK B-Group
may MD 0 0 1 O
diminish VB 0 1 UNK O
the DT 0 0 12 O
antihypertensive JJ 0 1 14 O
effect NN 0 1 1 O
of IN 0 0 12 O
ACE NNP 0 1 13 B-Group
inhibitors NNS 1 1 14 I-Group
. . 0 0 12 O

Drugs NNS 0 1 2 O
That WDT 0 0 2 O
Should MD 0 0 2 O
Not RB 0 1 2 O
Be VB 0 0 UNK O
Coadministered VBN 0 0 UNK O
With IN 0 0 2 O
INVIRASE NNP 0 1 UNK B-Brand
/ NNP 0 0 2 O
Ritonavir NNP 0 1 0 B-Drug

Other JJ 0 0 2 O
: : 0 0 2 O
There EX 0 0 12 O
appears VBZ 1 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
no DT 0 0 12 O
pharmacokinetic JJ 0 1 UNK O
interaction NN 0 1 UNK O
between IN 0 0 12 O
acitretin NN 0 1 13 B-Drug
and CC 0 0 12 O
cimetidine NN 0 1 13 B-Drug
digoxin NN 0 1 14 B-Drug
or CC 0 0 12 O
glyburide NN 0 1 16 B-Drug
. . 0 0 12 O

Changes NNS 0 1 2 O
in IN 0 0 12 O
insulin NN 0 1 14 B-Drug
and CC 0 0 12 O
other JJ 0 0 12 O
diabetes NNS 0 1 6 O
drug NN 0 1 1 O
therapies NNS 1 1 6 O
may MD 0 0 1 O
be VB 0 0 12 O
necessary JJ 0 0 1 O
during IN 0 0 12 O
treatment NN 0 1 6 O
with IN 0 0 12 O
mazindol NN 0 1 UNK B-Drug
. . 0 0 12 O

The DT 0 0 2 O
effects NNS 1 1 1 O
if IN 0 0 12 O
any DT 0 0 12 O
on IN 0 0 12 O
the DT 0 0 12 O
pituitary JJ 0 1 6 O
- : 0 0 2 O
gonadal NN 0 1 13 O
axis NN 0 1 3 O
in IN 0 0 12 O
premenopausal JJ 0 1 13 O
women NNS 1 1 UNK O
are VBP 1 0 12 O
unknown JJ 0 1 12 O
. . 0 0 12 O

Most JJS 0 0 2 O
automated JJ 0 1 1 O
equipment NN 0 1 13 O
for IN 0 0 12 O
measurement NN 0 1 1 O
of IN 0 0 12 O
creatinine NN 0 1 14 O
makes VBZ 1 1 12 O
use NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
Jaffe NNP 0 0 UNK O
reaction NN 0 1 1 O
. . 0 0 12 O

Other JJ 0 0 2 O
: : 0 0 2 O
Neither CC 0 0 12 O
fosinopril JJ 0 1 13 B-Drug
sodium NN 0 1 14 I-Drug
nor CC 0 0 12 O
its PRP$ 1 0 12 O
metabolites NNS 1 1 UNK O
have VBP 0 0 12 O
been VBN 1 0 12 O
found VBN 1 1 12 O
to TO 0 0 12 O
interact VB 0 0 UNK O
with IN 0 0 12 O
food NN 0 1 12 O
. . 0 0 12 O

Coumarin NNP 0 1 UNK B-Group
- : 0 0 2 O
Derivative JJ 0 1 UNK I-Group
Anticoagulants NNS 0 1 UNK I-Group
: : 0 0 2 O
Prolongation NN 0 1 UNK O
of IN 0 0 12 O
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
( ( 0 0 2 O
PT NNP 0 1 2 O
) ) 0 0 2 O
and CC 0 0 12 O
International NNP 0 1 UNK O
Normalized NNP 0 1 UNK O
Ratio NNP 0 1 2 O
( ( 0 0 2 O
INR NNP 0 1 13 O
) ) 0 0 2 O
were VBD 1 0 12 O
observed VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
ZOLINZA NNP 0 1 UNK B-Brand
concomitantly RB 0 0 14 O
with IN 0 0 12 O
coumarin JJ 0 1 UNK B-Group
- : 0 0 2 O
derivative JJ 0 1 13 I-Group
anticoagulants NNS 1 1 13 I-Group
. . 0 0 12 O

Coadminstration NN 0 0 UNK O
with IN 0 0 12 O
agents NNS 1 1 1 O
that WDT 0 0 12 O
induce VBP 0 1 6 O
9A9 CD 0 0 UNK O
activity NN 0 1 1 O
may MD 0 0 1 O
reduce VB 0 0 1 O
the DT 0 0 12 O
efficacy NN 0 1 UNK O
of IN 0 0 12 O
DURAGESIC NNP 0 1 UNK B-Brand
. . 0 0 12 O

increased VBN 1 1 1 O
factors NNS 1 1 1 O
II NNP 0 0 2 O
VII NNP 0 1 2 O
antigen NN 0 1 14 O
VIII NNP 0 1 2 O
antigen NN 0 1 14 O
VIII NNP 0 1 2 O
coagulant NN 0 1 UNK O
activity NN 0 1 1 O
IX NNP 0 1 2 O
X NNP 0 0 2 O
XII NNP 0 0 13 O
VII NNP 0 1 2 O
- : 0 0 2 O
X NN 0 0 2 O
complex JJ 0 1 1 O
II NNP 0 0 2 O
- : 0 0 2 O
VII NNP 0 1 2 O
- : 0 0 2 O
X NN 0 0 2 O
complex NN 0 1 1 O
and CC 0 0 12 O
beta NN 0 1 16 O
- : 0 0 2 O
thromboglobulin NN 0 1 UNK O
; : 0 0 2 O

( ( 0 0 2 O
See VB 0 1 2 O
< IN 0 0 16 O
a DT 0 0 12 O
href= NN 0 0 UNK O
`` `` 0 0 13 O
flucon_cp.htm JJ 0 1 UNK O
# # 0 0 2 O
CP NNP 0 1 13 O
'' '' 0 0 13 O
> NNP 0 0 2 O
CLINICAL NNP 0 1 11 O
PHARMACOLOGY NNP 0 1 UNK O
: : 0 0 2 O
Drug NNP 0 1 2 O
Interaction NNP 0 1 2 O
Studies NNP 0 1 2 O
. . 0 0 12 O
) ) 0 0 2 O

Inducers NNS 0 1 UNK O
and CC 0 0 12 O
Inhibitors NNS 0 1 7 O
of IN 0 0 12 O
Hepatic JJ 0 1 7 O
Metabolism NN 0 1 UNK O
: : 0 0 2 O
Rifampin NNP 0 1 0 B-Drug
reduced VBD 1 1 1 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
carvedilol NN 0 1 16 B-Drug
by IN 0 0 12 O
about IN 0 1 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

Concomitant JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
Kerlone NNP 0 1 UNK B-Brand
with IN 0 0 12 O
the DT 0 0 12 O
oral JJ 0 1 6 O
anticoagulant NN 0 1 13 B-Group
warfarin NN 0 1 14 B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
shown VBN 1 1 1 O
not RB 0 1 12 O
to TO 0 0 12 O
potentiate VB 0 0 UNK O
the DT 0 0 12 O
anticoagulant JJ 0 1 13 O
effect NN 0 1 1 O
of IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
. . 0 0 12 O

Careful JJ 0 1 UNK O
monitoring NN 0 1 1 O
of IN 0 0 12 O
cyclosporine JJ 0 1 14 B-Drug
concentrations NNS 1 1 13 O
and CC 0 0 12 O
serum JJ 0 1 14 O
creatinine NN 0 1 14 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
DIFLUCAN NNP 0 1 UNK B-Brand
and CC 0 0 12 O
cyclosporine NN 0 1 14 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
oral JJ 0 1 6 O
bioavailability NN 0 1 UNK O
of IN 0 0 12 O
enoxacin NN 0 1 UNK B-Drug
is VBZ 1 0 12 O
reduced VBN 1 1 1 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
with IN 0 0 12 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
ranitidine NN 0 1 0 B-Drug
. . 0 0 12 O

D NNP 0 1 2 O
. . 0 0 12 O

*Not NN 0 1 UNK O
administered VBN 1 1 1 O
but CC 0 0 12 O
an DT 0 0 12 O
active JJ 0 1 1 O
metabolite NN 0 1 UNK O
of IN 0 0 12 O
carbamazepine NN 0 1 16 B-Drug
. . 0 0 12 O

Dexfenfluramine NNP 0 1 UNK B-Drug
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
other JJ 0 0 12 O
serotoninergic JJ 0 0 UNK B-Group
agents NNS 1 1 1 I-Group
. . 0 0 12 O

In IN 0 0 2 O
such PDT 0 0 1 O
a DT 0 0 12 O
case NN 0 1 12 O
the DT 0 0 12 O
peripheral JJ 0 1 6 O
vascular JJ 0 1 6 O
resistance NN 0 1 1 O
may MD 0 0 1 O
increase VB 0 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
a DT 0 0 12 O
preclinical JJ 0 1 UNK O
study NN 0 1 1 O
in IN 0 0 12 O
dogs NNS 1 1 UNK O
ezetimibe VBP 0 1 16 B-Drug
increased VBN 1 1 1 O
cholesterol NN 0 1 6 O
in IN 0 0 12 O
the DT 0 0 12 O
gallbladder NN 0 1 6 O
bile NN 0 1 6 O
. . 0 0 12 O

Uricosuric JJ 0 0 UNK B-Group
Agents NNS 0 1 2 I-Group
: : 0 0 2 O
Since IN 0 1 2 O
the DT 0 0 12 O
excretion NN 0 1 14 O
of IN 0 0 12 O
oxipurinol NN 0 1 UNK B-Drug
is VBZ 1 0 12 O
similar JJ 0 1 1 O
to TO 0 0 12 O
that DT 0 0 12 O
of IN 0 0 12 O
urate JJ 0 1 UNK O
uricosuric JJ 0 0 UNK B-Group
agents NNS 1 1 1 I-Group
which WDT 0 0 12 O
increase VBP 0 1 1 O
the DT 0 0 12 O
excretion NN 0 1 14 O
of IN 0 0 12 O
urate NN 0 1 UNK O
are VBP 1 0 12 O
also RB 0 0 12 O
likely JJ 0 1 12 O
to TO 0 0 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
excretion NN 0 1 14 O
of IN 0 0 12 O
oxipurinol NN 0 1 UNK B-Drug
and CC 0 0 12 O
thus RB 0 0 1 O
lower JJR 1 1 1 O
the DT 0 0 12 O
degree NN 0 1 1 O
of IN 0 0 12 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
xanthine JJ 0 1 UNK O
oxidase NN 0 1 13 O
. . 0 0 12 O

Accordingly RB 0 0 1 O
it PRP 0 0 12 O
may MD 0 0 1 O
be VB 0 0 12 O
advisable JJ 0 0 UNK O
to TO 0 0 12 O
discontinue VB 0 1 1 O
MYKROX NNP 0 1 UNK B-Brand
Tablets NNP 0 1 0 O
three CD 0 1 12 O
days NNS 1 1 12 O
before IN 0 1 12 O
elective JJ 0 1 1 O
surgery NN 0 1 6 O
. . 0 0 12 O

With IN 0 0 2 O
drugs NNS 1 1 6 O
inhibiting VBG 1 1 UNK O
CYP9A NNP 0 0 UNK O
to TO 0 0 12 O
a DT 0 0 12 O
lesser JJR 1 1 1 O
but CC 0 0 12 O
still RB 0 0 12 O
significant JJ 0 1 1 O
degree JJ 0 1 1 O
estazolam NN 0 1 13 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
only RB 0 1 12 O
with IN 0 0 12 O
caution NN 0 0 1 O
and CC 0 0 12 O
consideration NN 0 1 1 O
of IN 0 0 12 O
appropriate JJ 0 1 1 O
dosage NN 0 1 0 O
reduction NN 0 1 1 O
. . 0 0 12 O

Excessive JJ 0 1 UNK O
widening NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
QRS NNP 0 0 8 O
complex NN 0 1 1 O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
prolongation NN 0 1 6 O
of IN 0 0 12 O
the DT 0 0 12 O
Q NNP 0 0 2 O
- : 0 0 2 O
T NNP 0 1 2 O
interval NN 0 1 1 O
may MD 0 0 1 O
occur VB 0 1 1 O
in IN 0 0 12 O
these DT 0 0 12 O
situations NNS 1 0 UNK O
. . 0 0 12 O

Plasma NNP 0 1 UNK O
levels NNS 1 1 1 O
of IN 0 0 12 O
anticonvulsant JJ 0 1 14 B-Group
agents NNS 1 1 1 I-Group
may MD 0 0 1 O
become VB 0 0 12 O
subtherapeutic JJ 0 0 14 O
during IN 0 0 12 O
cisplatin JJ 0 1 14 B-Drug
therapy NN 0 1 6 O
. . 0 0 12 O

In IN 0 0 2 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
show VBP 0 1 12 O
significant JJ 0 1 1 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
the DT 0 0 12 O
formation NN 0 1 1 O
of IN 0 0 12 O
oxidized JJ 0 1 UNK O
irbesartan NN 0 1 16 O
metabolites NNS 1 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
known VBN 1 1 12 O
cytochrome NN 0 1 UNK O
CYP NNP 0 1 UNK O
9C9 CD 0 0 UNK O
substrates NNS 1 1 UNK O
/ JJ 0 0 2 O
inhibitors NNS 1 1 14 O
sulphenazole JJ 0 0 UNK B-Drug
tolbutamide NN 0 1 UNK B-Drug
and CC 0 0 12 O
nifedipine NN 0 1 0 B-Drug
. . 0 0 12 O

Because IN 0 0 12 O
the DT 0 0 12 O
action NN 0 1 13 O
of IN 0 0 12 O
metoclopramide NN 0 1 16 B-Drug
will MD 0 0 12 O
influence VB 0 0 UNK O
the DT 0 0 12 O
delivery NN 0 1 1 O
of IN 0 0 12 O
food NN 0 1 12 O
to TO 0 0 12 O
the DT 0 0 12 O
intestines NNS 1 1 6 O
and CC 0 0 12 O
thus RB 0 0 1 O
the DT 0 0 12 O
rate NN 0 1 1 O
of IN 0 0 12 O
absorption NN 0 1 1 O
insulin NN 0 1 14 B-Drug
dosage NN 0 1 0 O
or CC 0 0 12 O
timing NN 0 1 UNK O
of IN 0 0 12 O
dosage NN 0 1 0 O
may MD 0 0 1 O
require VB 0 0 1 O
adjustment NN 0 1 1 O
. . 0 0 12 O

As IN 0 0 2 O
with IN 0 0 12 O
other JJ 0 0 12 O
cephalosporins NNS 1 1 14 B-Group
high JJ 0 1 1 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
cefotetan NN 0 1 14 B-Drug
may MD 0 0 1 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
measurement NN 0 1 1 O
of IN 0 0 12 O
serum NN 0 1 14 O
and CC 0 0 12 O
urine JJ 0 1 6 O
creatinine NN 0 1 14 O
levels NNS 1 1 1 O
by IN 0 0 12 O
Jaffe NNP 0 0 UNK O
reaction NN 0 1 1 O
and CC 0 0 12 O
produce VB 0 0 1 O
false JJ 0 1 13 O
increases NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
levels NNS 1 1 1 O
of IN 0 0 12 O
creatinine NN 0 1 14 O
reported VBN 1 1 1 O
. . 0 0 12 O

Opiate NN 0 1 UNK B-Group
agonists NNS 1 1 UNK I-Group

Additional NNP 0 1 2 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
are VBP 1 0 12 O
not RB 0 1 12 O
recommended VBN 1 1 1 O
for IN 0 0 12 O
coadministration NN 0 1 UNK O
with IN 0 0 12 O
INVIRASE NNP 0 1 UNK B-Brand
and CC 0 0 12 O
ritonavir NN 0 1 16 B-Drug
are VBP 1 0 12 O
included VBN 1 1 1 O
below IN 0 0 12 O
. . 0 0 12 O

Although IN 0 0 12 O
ROMAZICON NNP 0 1 UNK B-Brand
exerts VBZ 1 1 UNK O
a DT 0 0 12 O
slight JJ 0 1 3 O
intrinsic JJ 0 1 1 O
anticonvulsant JJ 0 1 14 O
effect NN 0 1 1 O
its PRP$ 1 0 12 O
abrupt JJ 0 1 UNK O
suppression NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
protective JJ 0 0 3 O
effect NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
benzodiazepine JJ 0 1 14 B-Group
agonist NN 0 1 14 O
can MD 0 0 12 O
give VB 0 1 12 O
rise NN 0 0 1 O
to TO 0 0 12 O
convulsions NNS 1 1 13 O
in IN 0 0 12 O
epileptic JJ 0 1 13 O
patients NNS 1 1 6 O
. . 0 0 12 O

Even RB 0 0 UNK O
though IN 0 0 12 O
such JJ 0 0 1 O
interactions NNS 1 1 UNK O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
seen VBN 1 1 12 O
in IN 0 0 12 O
clinical JJ 0 1 6 O
studies NNS 1 1 1 O
with IN 0 0 12 O
DynaCirc NNP 0 1 UNK B-Brand
( ( 0 0 2 O
isradipine NN 0 1 13 B-Drug
) ) 0 0 2 O
an DT 0 0 12 O
increased JJ 0 1 1 O
volume NN 0 1 1 O
of IN 0 0 12 O
circulating VBG 1 1 13 O
fluids NNS 1 1 6 O
might MD 0 0 12 O
be VB 0 0 12 O
required VBN 1 1 1 O
if IN 0 0 12 O
such JJ 0 0 1 O
an DT 0 0 12 O
interaction NN 0 1 UNK O
were VBD 1 0 12 O
to TO 0 0 12 O
occur VB 0 1 1 O
. . 0 0 12 O

Potassium NN 0 1 14 O
sparing VBG 1 0 6 O
agents NNS 1 1 1 O
should MD 0 0 12 O
generally RB 0 0 1 O
not RB 0 1 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
heart NN 0 1 12 O
failure NN 0 1 1 O
who WP 0 0 12 O
are VBP 1 0 12 O
receiving VBG 1 1 1 O
PRINIVIL NNP 0 1 UNK B-Brand
. . 0 0 12 O

DIGOXIN NN 0 1 0 B-Drug
: : 0 0 2 O
Plasma NNP 0 1 UNK O
digoxin NN 0 1 14 B-Drug
levels NNS 1 1 1 O
and CC 0 0 12 O
digoxin NN 0 1 14 B-Drug
clearance NN 0 1 16 O
at IN 0 0 12 O
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
were VBD 1 0 12 O
not RB 0 1 12 O
affected VBN 1 1 1 O
by IN 0 0 12 O
co NN 0 1 12 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
cerivastatin NN 0 1 UNK B-Drug
sodium NN 0 1 14 I-Drug
. . 0 0 12 O

Oral JJ 0 1 2 O
contraceptives NNS 1 1 13 B-Group
and CC 0 0 12 O
other JJ 0 0 12 O
hormonalmethods NNS 0 0 UNK O
of IN 0 0 12 O
birth NN 0 1 12 O
control NN 0 1 1 O
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
usedas JJ 0 0 UNK O
the DT 0 0 12 O
sole JJ 0 1 UNK O
method NN 0 1 13 O
of IN 0 0 12 O
contraception NN 0 1 13 O
inwomen NNS 0 0 UNK O
taking VBG 1 0 12 O
nevirapine JJ 0 1 13 B-Drug
since IN 0 1 12 O
nevirapinemay NN 0 0 UNK O
lower RBR 0 1 1 O
the DT 0 0 12 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
thesemedications NNS 0 0 UNK O
. . 0 0 12 O

Breakthrough IN 0 1 UNK O
bleeding NN 0 1 6 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O

Hepatotoxicity NNP 0 1 UNK O
Asymptomatic NNP 0 1 UNK O
increases NNS 1 1 1 O
in IN 0 0 12 O
liver NN 0 1 6 O
transaminases NNS 1 1 14 O
have VBP 0 0 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
in IN 0 0 12 O
TARCEVA NNP 0 1 UNK B-Brand
treated VBD 1 1 1 O
patients NNS 1 1 6 O
; : 0 0 2 O

Digoxin NN 0 1 0 B-Drug
: : 0 0 2 O
In IN 0 0 2 O
9 CD 0 0 2 O
normal JJ 0 1 1 O
- : 0 0 2 O
weight NN 0 1 3 O
subjects NNS 1 1 UNK O
receiving VBG 1 1 1 O
XENICAL JJ 0 1 UNK B-Brand
9 CD 0 0 2 O
mg NN 0 1 0 O
three CD 0 1 12 O
times NNS 1 1 12 O
a DT 0 0 12 O
day NN 0 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
XENICAL RB 0 1 UNK B-Brand
did VBD 1 0 12 O
not RB 0 1 12 O
alter VB 0 1 13 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
. . 0 0 12 O

No DT 0 0 2 O
clinical JJ 0 1 6 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
conducted VBN 1 1 1 O
. . 0 0 12 O

Drug NN 0 1 2 O
Name NN 0 1 2 O

Although IN 0 0 12 O
it PRP 0 0 12 O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
established VBN 1 1 1 O
that IN 0 0 12 O
there EX 0 0 12 O
is VBZ 1 0 12 O
an DT 0 0 12 O
interaction NN 0 1 UNK O
between IN 0 0 12 O
Clozapine NNP 0 1 0 B-Drug
and CC 0 0 12 O
benzodiazepines NNS 1 1 14 B-Group
or CC 0 0 12 O
other JJ 0 0 12 O
psychotropics NNS 0 1 UNK B-Group
caution NN 0 0 1 O
is VBZ 1 0 12 O
advised VBN 1 0 12 O
when WRB 0 0 12 O
clozapine NN 0 1 13 B-Drug
is VBZ 1 0 12 O
initiated VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
a DT 0 0 12 O
benzodiazepine NN 0 1 14 B-Group
or CC 0 0 12 O
any DT 0 0 12 O
other JJ 0 0 12 O
psychotropic JJ 0 1 13 B-Group
drug NN 0 1 1 I-Group
. . 0 0 12 O

Risk NN 0 1 2 O
of IN 0 0 12 O
Anaphylactic JJ 0 1 UNK O
Reaction NN 0 1 UNK O
: : 0 0 2 O
Although IN 0 0 12 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
known VBN 1 1 12 O
that IN 0 0 12 O
patients NNS 1 1 6 O
on IN 0 0 12 O
beta NN 0 1 16 B-Group
- : 0 0 2 O
blockers NNS 1 0 6 I-Group
may MD 0 0 1 O
be VB 0 0 12 O
refractory NN 0 1 6 O
to TO 0 0 12 O
epinephrine VB 0 1 14 B-Drug
in IN 0 0 12 O
the DT 0 0 12 O
treatment NN 0 1 6 O
of IN 0 0 12 O
anaphylactic JJ 0 1 13 O
shock NN 0 1 3 O
beta SYM 0 1 16 B-Group
- : 0 0 2 O
blockers NNS 1 0 6 I-Group
can MD 0 0 12 O
in IN 0 0 12 O
addition NN 0 1 1 O
interfere RB 0 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
modulation NN 0 1 13 O
of IN 0 0 12 O
allergic JJ 0 1 6 O
reaction NN 0 1 1 O
and CC 0 0 12 O
lead NN 0 1 12 O
to TO 0 0 12 O
an DT 0 0 12 O
increased VBN 1 1 1 O
severity NN 0 1 6 O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
frequency NN 0 1 1 O
of IN 0 0 12 O
attacks NNS 1 1 12 O
. . 0 0 12 O

Due JJ 0 1 2 O
to TO 0 0 12 O
low JJ 0 1 1 O
systemic JJ 0 1 6 O
exposure NN 0 1 1 O
to TO 0 0 12 O
retapamulin VB 0 1 UNK B-Drug
following VBG 1 1 1 O
topical JJ 0 1 6 O
application NN 0 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
dosage JJ 0 1 0 O
adjustments NNS 1 1 1 O
for IN 0 0 12 O
retapamulin NN 0 1 UNK B-Drug
are VBP 1 0 12 O
unnecessary JJ 0 0 UNK O
when WRB 0 0 12 O
co NN 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
with IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
inhibitors NNS 1 1 14 O
such JJ 0 0 1 O
as IN 1 0 12 O
ketoconazole NN 0 1 16 B-Drug
. . 0 0 12 O

Ketorolac NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
highly RB 0 1 1 O
bound VBN 1 1 12 O
to TO 0 0 12 O
human JJ 0 1 1 O
plasma NN 0 1 14 O
protein NN 0 1 14 O
( ( 0 0 2 O
mean JJ 0 1 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
. . 0 0 12 O

Phenytoin NN 0 1 0 B-Drug

While IN 0 0 12 O
in IN 0 0 12 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
shown VBN 1 1 1 O
that DT 0 0 12 O
mirtazapine NN 0 1 0 B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
a DT 0 0 12 O
potent JJ 0 1 UNK O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
any DT 0 0 12 O
of IN 0 0 12 O
these DT 0 0 12 O
enzymes NNS 1 1 14 O
an DT 0 0 12 O
indication NN 0 1 1 O
that IN 0 0 12 O
mirtazapine NN 0 1 0 B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
likely JJ 0 1 12 O
to TO 0 0 12 O
have VB 0 0 12 O
a DT 0 0 12 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
inhibitory JJ 0 1 UNK O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
are VBP 1 0 12 O
substrates VBZ 0 1 UNK O
for IN 0 0 12 O
these DT 0 0 12 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
enzymes VBZ 0 1 14 O
the DT 0 0 12 O
concomitant NN 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
REMERON NNP 0 1 UNK B-Brand
SolTab NNP 0 0 UNK I-Brand
with IN 0 0 12 O
most JJS 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
these DT 0 0 12 O
enzymes NNS 1 1 14 O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
formally RB 0 0 1 O
studied VBN 1 0 1 O
. . 0 0 12 O

Adrenergic JJ 0 1 UNK B-Group
Agents NNS 0 1 2 I-Group
: : 0 0 2 O
Some DT 0 0 2 O
individuals NNS 1 1 1 O
receiving VBG 1 1 1 O
ZYVOX NNP 0 1 UNK B-Brand
may MD 0 0 1 O
experience VB 0 1 12 O
a DT 0 0 12 O
reversible JJ 0 1 3 O
enhancement NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
pressor NN 0 1 14 O
response NN 0 1 1 O
to TO 0 0 12 O
indirect VB 0 1 1 O
- : 0 0 2 O
acting VBG 1 1 12 O
sympathomimetic JJ 0 1 13 B-Group
agents NNS 1 1 1 I-Group
vasopressor NN 0 1 13 B-Group
or CC 0 0 12 O
dopaminergic JJ 0 1 UNK B-Group
agents NNS 1 1 1 I-Group
. . 0 0 12 O

Probenecid NN 0 1 UNK B-Drug
: : 0 0 2 O
The DT 0 0 2 O
oral JJ 0 1 6 O
combination NN 0 1 1 O
of IN 0 0 12 O
probenecid NN 0 1 13 B-Drug
before IN 0 1 12 O
intramuscular JJ 0 1 14 O
injection NN 0 1 3 O
of IN 0 0 12 O
PIPRACIL NNP 0 1 UNK B-Brand
produces VBZ 1 0 1 O
an DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
piperacillin JJ 0 1 16 B-Drug
peak JJ 0 1 1 O
serum JJ 0 1 14 O
level NN 0 1 1 O
of IN 0 0 12 O
about RB 0 1 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

WelChol NNP 0 1 UNK B-Brand
has VBZ 1 0 12 O
been VBN 1 0 12 O
studied VBN 1 0 1 O
in IN 0 0 12 O
several JJ 0 1 12 O
human JJ 0 1 1 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
in IN 0 0 12 O
which WDT 0 0 12 O
it PRP 0 0 12 O
was VBD 1 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
a DT 0 0 12 O
meal NN 0 1 12 O
and CC 0 0 12 O
the DT 0 0 12 O
test NN 0 1 1 O
drug NN 0 1 1 O
. . 0 0 12 O

No DT 0 0 2 O
trials NNS 1 1 1 O
specifically RB 0 0 1 O
examining VBG 1 1 UNK O
potential JJ 0 1 1 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
Natrecor NNP 0 1 UNK B-Brand
were VBD 1 0 12 O
conducted VBN 1 1 1 O
although IN 0 0 12 O
many JJ 0 0 12 O
concomitant JJ 0 1 6 O
drugs NNS 1 1 6 O
were VBD 1 0 12 O
used VBN 1 1 12 O
in IN 0 0 12 O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
clinical JJ 0 1 6 O
studies NNS 1 1 1 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
WelChol NNP 0 1 UNK B-Brand
with IN 0 0 12 O
atorvastatin JJ 0 1 0 B-Drug
lovastatin NN 0 1 13 B-Drug
or CC 0 0 12 O
simvastatin NN 0 1 0 B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
lipid JJ 0 1 14 O
- : 0 0 2 O
lowering VBG 1 1 UNK O
activity NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
HMG NNP 0 0 UNK B-Group
- : 0 0 2 O
CoA NNP 0 0 UNK I-Group
reductase NN 0 1 UNK I-Group
inhibitor NN 0 1 14 I-Group
. . 0 0 12 O

Methotrexate NN 0 1 0 B-Drug
: : 0 0 2 O
In IN 0 0 2 O
an DT 0 0 12 O
interaction NN 0 1 UNK O
study NN 0 1 1 O
of IN 0 0 12 O
rheumatoid JJ 0 0 6 O
arthritis NN 0 1 6 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
methotrexate JJ 0 1 16 B-Drug
CELEBREX NNP 0 1 UNK B-Brand
did VBD 1 0 12 O
not RB 0 1 12 O
have VB 0 0 12 O
a DT 0 0 12 O
significant JJ 0 1 1 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
methotrexate NN 0 1 16 B-Drug
. . 0 0 12 O

Drug NNP 0 1 2 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
with IN 0 0 12 O
decitabine NN 0 1 13 B-Drug
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
conducted VBN 1 1 1 O
. . 0 0 12 O

Therefore RB 0 0 1 O
if IN 0 0 12 O
concomitant JJ 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
these DT 0 0 12 O
agents NNS 1 1 1 O
is VBZ 1 0 12 O
indicated JJ 0 1 1 O
because IN 0 0 12 O
of IN 0 0 12 O
demonstrated JJ 0 0 1 O
hypokalemia NN 0 1 14 O
they PRP 0 0 12 O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
with IN 0 0 12 O
caution NN 0 0 1 O
and CC 0 0 12 O
with IN 0 0 12 O
frequent JJ 0 1 1 O
monitoring NN 0 1 1 O
of IN 0 0 12 O
serum JJ 0 1 14 O
potassium NN 0 1 14 O
. . 0 0 12 O

However RB 0 0 1 O
at IN 0 0 12 O
that DT 0 0 12 O
time NN 0 1 12 O
the DT 0 0 12 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
diazepam NN 0 1 0 B-Drug
were VBD 1 0 12 O
below IN 0 0 12 O
the DT 0 0 12 O
therapeutic JJ 0 1 6 O
interval NN 0 1 1 O
and CC 0 0 12 O
thus RB 0 0 1 O
this DT 0 0 12 O
interaction NN 0 1 UNK O
is VBZ 1 0 12 O
unlikely JJ 0 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
of IN 0 0 12 O
clinical JJ 0 1 6 O
relevance NN 0 1 UNK O
. . 0 0 12 O

Drugs NNS 0 1 2 O
That WDT 0 0 2 O
Inhibit NNP 0 1 UNK O
CYP9A9 NNP 0 0 UNK O
( ( 0 0 2 O
Ketoconazole NNP 0 1 UNK B-Drug
) ) 0 0 2 O
CYP9A9 NNP 0 0 UNK O
is VBZ 1 0 12 O
a DT 0 0 12 O
major JJ 0 1 1 O
metabolic JJ 0 1 6 O
pathway NN 0 1 UNK O
for IN 0 0 12 O
elimination NN 0 1 UNK O
of IN 0 0 12 O
eszopiclone NN 0 1 13 B-Drug
. . 0 0 12 O

Cyclosporine NN 0 1 UNK B-Drug
: : 0 0 2 O
Elevated VBN 0 1 7 O
serum NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
cyclosporine NN 0 1 14 B-Drug
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
with IN 0 0 12 O
concomitant JJ 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
cyclosporine NN 0 1 14 B-Drug
with IN 0 0 12 O
other JJ 0 0 12 O
members NNS 1 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
quinolone NN 0 1 UNK B-Group
class NN 0 1 12 I-Group
. . 0 0 12 O

At IN 0 0 2 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
postdose VBP 0 1 UNK O
a DT 0 0 12 O
similar JJ 0 1 1 O
proportion NN 0 1 UNK O
of IN 0 0 12 O
patients NNS 1 1 6 O
treated VBN 1 1 1 O
with IN 0 0 12 O
methotrexate NN 0 1 16 B-Drug
alone RB 0 1 12 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
and CC 0 0 12 O
subsequently RB 0 0 1 O
treated VBN 1 1 1 O
with IN 0 0 12 O
methotrexate NN 0 1 16 B-Drug
co NNS 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
with IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
of IN 0 0 12 O
rofecoxib NN 0 1 16 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
had VBD 1 0 12 O
methotrexate JJ 0 1 16 B-Drug
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
below IN 0 0 12 O
the DT 0 0 12 O
measurable JJ 0 1 1 O
limit NN 0 1 1 O
( ( 0 0 2 O
9 CD 0 0 2 O
ng RB 0 1 13 O
/ NNP 0 0 2 O
mL NN 0 1 14 O
) ) 0 0 2 O
. . 0 0 12 O

Liver NNP 0 1 7 O
Function NNP 0 1 2 O
Tests VBZ 0 1 UNK O
: : 0 0 2 O
Elevations NNS 0 1 UNK O
of IN 0 0 12 O
AST NNP 0 1 13 O
( ( 0 0 2 O
SGOT NNP 0 0 14 O
) ) 0 0 2 O
ALT NNP 0 1 13 O
( ( 0 0 2 O
SGPT NNP 0 0 14 O
) ) 0 0 2 O
or CC 0 0 12 O
LDH NNP 0 1 14 O
were VBD 1 0 12 O
experienced VBN 1 0 12 O
by IN 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
in IN 0 0 12 O
9 CD 0 0 2 O
patients NNS 1 1 6 O
treated VBN 1 1 1 O
with IN 0 0 12 O
Soriatane NNP 0 1 UNK B-Brand
. . 0 0 12 O

Nephrotoxicity NN 0 1 UNK O
and CC 0 0 12 O
ototoxicity NN 0 1 UNK O
were VBD 1 0 12 O
not RB 0 1 12 O
noted VBN 1 0 1 O
when WRB 0 0 12 O
ceftazidime NN 0 1 14 B-Drug
was VBD 1 0 12 O
given VBN 1 1 12 O
alone RB 0 1 12 O
in IN 0 0 12 O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
. . 0 0 12 O

Enoxaparin NNP 0 1 0 B-Drug
dosed VBD 1 1 14 O
as IN 1 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg VBZ 0 1 18 O
subcutaneous JJ 0 1 14 O
injection NN 0 1 3 O
q9h NN 0 1 UNK O
for IN 0 0 12 O
four CD 0 1 12 O
doses NNS 1 1 6 O
did VBD 1 0 12 O
not RB 0 1 12 O
alter VB 0 1 13 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
eptifibatide NN 0 1 13 B-Drug
or CC 0 0 12 O
the DT 0 0 12 O
level NN 0 1 1 O
of IN 0 0 12 O
platelet NN 0 1 14 O
aggregation NN 0 1 UNK O
in IN 0 0 12 O
healthy JJ 0 1 12 O
adults NNS 1 1 13 O
. . 0 0 12 O

Increasing VBG 0 1 2 O
the DT 0 0 12 O
felbamate NN 0 1 13 B-Drug
dose NN 0 1 6 O
to TO 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
in IN 0 0 12 O
six CD 0 1 12 O
of IN 0 0 12 O
these DT 0 0 12 O
subjects NNS 1 1 UNK O
increased VBD 1 1 1 O
the DT 0 0 12 O
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
phenytoin NN 0 1 16 B-Drug
Cmin NNP 0 1 UNK O
to TO 0 0 12 O
9 CD 0 0 2 O
9 CD 0 0 2 O
micrograms NNS 1 1 14 O
/ JJ 0 0 2 O
mL NN 0 1 14 O
. . 0 0 12 O

Agents NNS 0 1 2 O
that WDT 0 0 12 O
are VBP 1 0 12 O
CYP NNP 0 1 UNK O
inducers NNS 1 1 UNK O
that WDT 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
found VBN 1 1 12 O
or CC 0 0 12 O
are VBP 1 0 12 O
expected VBN 1 1 12 O
to TO 0 0 12 O
decrease VB 0 1 1 O
plasma JJ 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
EQUETROTM NNP 0 0 UNK B-Brand
are VBP 1 0 12 O
the DT 0 0 12 O
following JJ 0 1 1 O
: : 0 0 2 O
Cisplatin NNP 0 1 0 B-Drug
doxorubicin VBZ 0 1 13 B-Drug
HCL NNP 0 0 0 I-Drug
felbamate NN 0 1 13 B-Drug
rifampin NN 0 1 16 B-Drug
phenobarbital JJ 0 1 16 B-Drug
Phenytoin NNP 0 1 0 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
primidone NN 0 1 13 B-Drug
methsuximide NN 0 1 UNK B-Drug
and CC 0 0 12 O
theophylline NN 0 1 16 B-Drug
Thus RB 0 0 1 O
if IN 0 0 12 O
a DT 0 0 12 O
patient NN 0 1 6 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
titrated VBN 1 1 14 O
to TO 0 0 12 O
a DT 0 0 12 O
stable JJ 0 1 1 O
dosage NN 0 1 0 O
on IN 0 0 12 O
EQUETROTM NNP 0 0 UNK B-Brand
and CC 0 0 12 O
then RB 0 1 12 O
begins VBZ 1 1 12 O
a DT 0 0 12 O
course NN 0 1 12 O
of IN 0 0 12 O
treatment NN 0 1 6 O
with IN 0 0 12 O
one CD 0 1 12 O
of IN 0 0 12 O
these DT 0 0 12 O
CYP9A9 NNP 0 0 UNK O
inducers NNS 1 1 UNK O
it PRP 0 0 12 O
is VBZ 1 0 12 O
reasonable JJ 0 0 1 O
to TO 0 0 12 O
expect VB 0 0 12 O
that IN 0 0 12 O
a DT 0 0 12 O
dose JJ 0 1 6 O
increase NN 0 1 1 O
for IN 0 0 12 O
EQUETROTM NNP 0 0 UNK B-Brand
may MD 0 0 1 O
be VB 0 0 12 O
necessary JJ 0 0 1 O
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
that IN 0 0 12 O
glucose NN 0 1 14 O
tests NNS 1 1 1 O
based VBN 1 1 1 O
on IN 0 0 12 O
enzymatic JJ 0 1 UNK O
glucose JJ 0 1 14 O
oxidase NN 0 1 13 O
reactions NNS 1 1 1 O
( ( 0 0 2 O
such JJ 0 0 1 O
as IN 1 0 12 O
Clinistix NNP 0 0 UNK O
** NNP 0 0 2 O
or CC 0 0 12 O
Tes NNP 0 1 UNK O
- : 0 0 2 O
Tape NNP 0 1 2 O
** NNP 0 0 2 O
) ) 0 0 2 O
be VB 0 0 12 O
used VBN 1 1 12 O
. . 0 0 12 O

Bosentan NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
CYP9C9 NNP 0 0 UNK O
and CC 0 0 12 O
CYP9A9 NNP 0 0 UNK O
. . 0 0 12 O

However RB 0 0 1 O
patients NNS 1 1 6 O
on IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
may MD 0 0 1 O
show VB 0 1 12 O
elevations NNS 1 1 1 O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
concentrations NNS 1 1 13 O
after IN 0 0 12 O
initiation NN 0 1 1 O
of IN 0 0 12 O
therapy NN 0 1 6 O
with IN 0 0 12 O
FLOLAN NNP 0 1 UNK B-Brand
which WDT 0 0 12 O
may MD 0 0 1 O
be VB 0 0 12 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
prone VBP 0 1 13 O
to TO 0 0 12 O
digoxin VB 0 1 14 B-Drug
toxicity NN 0 1 6 O
. . 0 0 12 O

Concurrent NNP 0 1 13 O
use NN 0 1 1 O
of IN 0 0 12 O
erythromycin NN 0 1 0 B-Drug
and CC 0 0 12 O
ergotamine NN 0 1 UNK B-Drug
or CC 0 0 12 O
dihydroergotamine NN 0 1 UNK B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
associated VBN 1 1 1 O
in IN 0 0 12 O
some DT 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
acute JJ 0 1 6 O
ergot FW 0 1 UNK O
toxicity NN 0 1 6 O
characterized VBN 1 1 1 O
by IN 0 0 12 O
severe JJ 0 1 6 O
peripheral JJ 0 1 6 O
vasospasm NN 0 1 8 O
and CC 0 0 12 O
dysesthesia NN 0 1 UNK O
. . 0 0 12 O

Salt NNP 0 1 UNK O
substitutes VBZ 1 0 13 O
containing VBG 1 1 1 O
potassium NN 0 1 14 B-Drug
should MD 0 0 12 O
also RB 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
with IN 0 0 12 O
caution NN 0 0 1 O
. . 0 0 12 O

Thiazides NNS 0 1 UNK B-Group
: : 0 0 2 O
Thiazides NNS 0 1 UNK B-Group
are VBP 1 0 12 O
known VBN 1 1 12 O
to TO 0 0 12 O
induce VB 0 1 6 O
hypercalcemia NN 0 1 8 O
by IN 0 0 12 O
the DT 0 0 12 O
reduction NN 0 1 1 O
of IN 0 0 12 O
calcium NN 0 1 14 O
excretion NN 0 1 14 O
in IN 0 0 12 O
urine NN 0 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
average JJ 0 1 1 O
increase NN 0 1 1 O
was VBD 1 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

The DT 0 0 2 O
use NN 0 1 1 O
of IN 0 0 12 O
MAO NNP 0 1 14 B-Group
inhibitors NNS 1 1 14 I-Group
or CC 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
with IN 0 0 12 O
hydrocodone NN 0 1 UNK B-Drug
preparations NNS 1 1 13 O
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
either CC 0 1 12 O
the DT 0 0 12 O
antidepressant NN 0 1 6 B-Group
or CC 0 0 12 O
hydrocodone NN 0 1 UNK B-Drug
. . 0 0 12 O

Paclitaxel NNP 0 1 UNK B-Drug
- : 0 0 2 O
In IN 0 0 2 O
one CD 0 1 12 O
report NN 0 1 1 O
L NNP 0 1 2 B-Drug
- : 0 0 2 O
glutamine NN 0 1 13 I-Drug
at IN 0 0 12 O
a DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
grams NNS 1 1 3 O
three CD 0 1 12 O
times NNS 1 1 12 O
daily RB 0 1 12 O
given VBN 1 1 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
after IN 0 0 12 O
receiving VBG 1 1 1 O
paclitaxel NN 0 1 13 B-Drug
appeared VBD 1 1 12 O
to TO 0 0 12 O
prevent VB 0 1 1 O
the DT 0 0 12 O
development NN 0 1 1 O
of IN 0 0 12 O
myalgia NN 0 1 8 O
and CC 0 0 12 O
arthralgia JJ 0 1 13 O
adverse JJ 0 0 1 O
reactions NNS 1 1 1 O
of IN 0 0 12 O
paclitaxel NN 0 1 13 B-Drug
. . 0 0 12 O

In IN 0 0 2 O
a DT 0 0 12 O
study NN 0 1 1 O
involving VBG 1 1 1 O
9 CD 0 0 2 O
adult NN 0 1 12 O
volunteers NNS 1 1 UNK O
TORADOLORAL NNP 0 0 UNK O
was VBD 1 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
warfarin VBP 0 1 14 B-Drug
causing VBG 1 1 1 O
no DT 0 0 12 O
significant JJ 0 1 1 O
changes NNS 1 1 1 O
in IN 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
or CC 0 0 12 O
pharmacodynamics NNS 0 1 UNK O
of IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
. . 0 0 12 O

However RB 0 0 1 O
the DT 0 0 12 O
metabolic JJ 0 1 6 O
clearance NN 0 1 16 O
of IN 0 0 12 O
mexiletine NN 0 1 16 B-Drug
in IN 0 0 12 O
the DT 0 0 12 O
extensive JJ 0 1 1 O
metabolizer NN 0 0 UNK O
phenotype NN 0 1 UNK O
decreased VBN 1 1 1 O
by IN 0 0 12 O
about IN 0 1 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
making VBG 1 1 12 O
the DT 0 0 12 O
poor JJ 0 1 12 O
and CC 0 0 12 O
extensive JJ 0 1 1 O
metabolizer NN 0 0 UNK O
groups NNS 1 1 1 O
indistinguishable JJ 0 0 UNK O
. . 0 0 12 O

Rarely RB 0 1 UNK O
salicylate JJ 0 1 13 B-Group
toxicity NN 0 1 6 O
may MD 0 0 1 O
occur VB 0 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
who WP 0 0 12 O
discontinue VBP 0 1 1 O
steroids NNS 1 1 6 B-Group
after IN 0 0 12 O
concurrent JJ 0 1 1 O
high JJ 0 1 1 O
- : 0 0 2 O
dose JJ 0 1 6 O
aspirin JJ 0 1 14 B-Brand
therapy NN 0 1 6 O
. . 0 0 12 O

Sever NNP 0 1 UNK O
neurologic JJ 0 1 6 O
signs NNS 1 1 12 O
including VBG 1 1 1 O
coma NN 0 1 6 O
have VBP 0 0 12 O
occurred VBN 1 1 1 O
with IN 0 0 12 O
concurrent NN 0 1 1 O
use NN 0 1 1 O
of IN 0 0 12 O
carbamazepine NN 0 1 16 B-Drug
. . 0 0 12 O

Acetaminophen NN 0 1 0 B-Drug
: : 0 0 2 O
In IN 0 0 2 O
normal JJ 0 1 1 O
volunteers NNS 1 1 UNK O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
diflunisal NN 0 1 13 B-Drug
and CC 0 0 12 O
acetaminophen NN 0 1 16 B-Drug
resulted VBD 1 1 1 O
in IN 0 0 12 O
an DT 0 0 12 O
approximate JJ 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
increase NN 0 1 1 O
in IN 0 0 12 O
plasma JJ 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
acetaminophen NN 0 1 16 B-Drug
. . 0 0 12 O

Both DT 0 0 2 O
groups NNS 1 1 1 O
of IN 0 0 12 O
agents NNS 1 1 1 O
lower JJR 1 1 1 O
blood NN 0 1 6 O
levels NNS 1 1 1 O
and CC 0 0 12 O
efficacy NN 0 1 UNK O
of IN 0 0 12 O
amphetamines NNS 1 1 14 B-Group
. . 0 0 12 O

In IN 0 0 2 O
a DT 0 0 12 O
parallel JJ 0 1 UNK O
group NN 0 1 12 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
study NN 0 1 1 O
comparing VBG 1 1 UNK O
the DT 0 0 12 O
intravenous JJ 0 1 14 O
prodrug JJ 0 1 UNK O
form NN 0 1 1 O
of IN 0 0 12 O
valdecoxib NN 0 1 13 B-Drug
at IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
BID NNP 0 0 11 O
( ( 0 0 2 O
n=9 NN 0 1 UNK O
) ) 0 0 2 O
vs NN 1 0 2 O
placebo NN 0 1 13 O
( ( 0 0 2 O
n=9 JJ 0 1 UNK O
) ) 0 0 2 O
valdecoxib NN 0 1 13 B-Drug
had VBD 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
in IN 0 0 12 O
vitro NN 0 1 UNK O
aspirin SYM 0 1 14 B-Brand
- : 0 0 2 O
mediated VBN 1 1 13 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
arachidonate JJ 0 1 UNK O
- : 0 0 2 O
or CC 0 0 12 O
collagen VB 0 1 13 O
- : 0 0 2 O
stimulated VBN 1 1 13 O
platelet NN 0 1 14 O
aggregation NN 0 1 UNK O
. . 0 0 12 O

Drug NNP 0 1 2 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
shown VBN 1 1 1 O
that IN 0 0 12 O
esomeprazole NN 0 1 16 B-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
have VB 0 0 12 O
any DT 0 0 12 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
warfarin NNS 0 1 14 B-Drug
quinidine VBP 0 1 16 B-Drug
clarithromycin NN 0 1 13 B-Drug
or CC 0 0 12 O
amoxicillin NN 0 1 0 B-Drug
. . 0 0 12 O

When WRB 0 0 12 O
duloxetine NN 0 1 0 B-Drug
was VBD 1 0 12 O
administered VBN 1 1 1 O
( ( 0 0 2 O
at IN 0 0 12 O
a DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
BID NNP 0 0 11 O
) ) 0 0 2 O
in IN 0 0 12 O
conjunction NN 0 1 1 O
with IN 0 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
9 CD 0 0 2 O
- : 0 0 2 O
mg NN 0 1 0 O
dose NN 0 1 6 O
of IN 0 0 12 O
desipramine NN 0 1 16 B-Drug
a DT 0 0 12 O
CYP9D9 NNP 0 0 UNK O
substrate NN 0 1 UNK O
the DT 0 0 12 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
desipramine NN 0 1 16 B-Drug
increased VBD 1 1 1 O
9 CD 0 0 2 O
- : 0 0 2 O
fold NN 0 1 3 O
. . 0 0 12 O

SERUM NNP 0 1 UNK O
LEVELS NNP 0 1 UNK O
OF NNP 0 0 11 O
PHENYTOIN NNP 0 1 UNK B-Drug
SHOULD NNP 0 0 UNK O
BE NNP 0 0 11 O
DETERMINED NNP 0 1 UNK O
ON NNP 0 0 11 O
DIFFERENT NNP 0 1 UNK O
DAYS NNP 0 1 11 O
FOR NNP 0 0 11 O
EVIDENCE NNP 0 1 11 O
OF NNP 0 0 11 O
AN NNP 0 0 11 O
INCREASE NNP 0 1 UNK O
OR NNP 0 0 11 O
FOR IN 0 0 11 O
A NNP 0 0 2 O
CONTINUING NNP 0 1 UNK O
RISE NNP 0 0 UNK O
IN NNP 0 0 11 O
LEVELS NNP 0 1 UNK O
. . 0 0 12 O

Although IN 0 0 12 O
such PDT 0 0 1 O
a DT 0 0 12 O
risk NN 0 1 1 O
is VBZ 1 0 12 O
not RB 0 1 12 O
verified VBN 1 1 1 O
for IN 0 0 12 O
roxithromycin JJ 0 1 UNK B-Drug
combination NN 0 1 1 O
of IN 0 0 12 O
roxithromycin NN 0 1 UNK B-Drug
with IN 0 0 12 O
such JJ 0 0 1 O
drugs NNS 1 1 6 O
is VBZ 1 0 12 O
not RB 0 1 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
clinical JJ 0 1 6 O
significance NN 0 1 13 O
of IN 0 0 12 O
this DT 0 0 12 O
interaction NN 0 1 UNK O
is VBZ 1 0 12 O
not RB 0 1 12 O
known VBN 1 1 12 O
; : 0 0 2 O

Patients NNS 0 1 7 O
/ VBP 0 0 2 O
Guardians NNPS 0 1 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
given VBN 1 1 12 O
the DT 0 0 12 O
following JJ 0 1 1 O
information NN 0 1 1 O
: : 0 0 2 O
i NN 0 1 12 O
. . 0 0 12 O

Antidepressants NNS 0 1 UNK B-Group
tricyclic JJ 0 0 14 B-Group
Amphetamines NNPS 0 1 UNK B-Group
may MD 0 0 1 O
enhance VB 0 1 UNK O
the DT 0 0 12 O
activity NN 0 1 1 O
of IN 0 0 12 O
tricyclic JJ 0 0 14 B-Drug
antidepressants NNS 1 1 13 I-Drug
or CC 0 0 12 O
sympathomimetic JJ 0 1 13 B-Group
agents NNS 1 1 1 I-Group
; : 0 0 2 O

chloral JJ 0 1 16 B-Drug
hydrate NN 0 1 16 I-Drug
* NN 0 0 2 O
; : 0 0 2 O

DOSTINEX NNP 0 1 UNK B-Brand
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
D9 NNP 0 1 UNK O
- : 0 0 2 O
antagonists NNS 1 1 13 O
such JJ 0 0 1 O
as IN 1 0 12 O
phenothiazines NNS 1 1 UNK B-Group
butyrophenones NNS 0 1 UNK B-Group
thioxanthines NNS 0 0 UNK B-Group
or CC 0 0 12 O
metoclopramide NN 0 1 16 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
pressor NN 0 1 14 O
effects NNS 1 1 1 O
of IN 0 0 12 O
ERGOMAR NNP 0 1 UNK B-Brand
and CC 0 0 12 O
other JJ 0 0 12 O
vasoconstrictor NN 0 1 UNK B-Group
drugs NNS 1 1 6 I-Group
can MD 0 0 12 O
combine VB 0 1 UNK O
to TO 0 0 12 O
cause VB 0 1 12 O
dangerous JJ 0 1 UNK O
hypertension NN 0 1 6 O
. . 0 0 12 O

Ethinyl NNP 0 0 UNK B-Drug
estradiol NN 0 1 13 I-Drug

Effect NN 0 1 UNK O
of IN 0 0 12 O
Probenecid NNP 0 1 UNK B-Drug
: : 0 0 2 O
Probenecid NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
a DT 0 0 12 O
blocker NN 0 0 3 O
of IN 0 0 12 O
renal JJ 0 1 6 O
tubular JJ 0 1 3 O
secretion NN 0 1 14 O
. . 0 0 12 O

Lotensin NNP 0 1 UNK B-Brand
has VBZ 1 0 12 O
been VBN 1 0 12 O
used VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
beta NN 0 1 16 B-Group
- : 0 0 2 O
adrenergic JJ 0 1 UNK I-Group
- : 0 0 2 O
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
calcium JJ 0 1 14 B-Group
- : 0 0 2 O
channel NN 0 1 1 I-Group
- : 0 0 2 O
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
diuretics NNS 1 1 14 B-Group
digoxin NN 0 1 14 B-Drug
and CC 0 0 12 O
hydralazine NN 0 1 14 B-Drug
without IN 0 0 12 O
evidence NN 0 1 1 O
of IN 0 0 12 O
clinically RB 0 0 6 O
important JJ 0 1 1 O
adverse JJ 0 0 1 O
interactions NNS 1 1 UNK O
. . 0 0 12 O

Drugs NNS 0 1 2 O
that WDT 0 0 12 O
may MD 0 0 1 O
have VB 0 0 12 O
their PRP$ 0 0 12 O
plasma JJ 0 1 14 O
concentration NN 0 1 1 O
altered VBN 1 1 1 O
by IN 0 0 12 O
Gleevec NNP 0 1 UNK B-Brand
Gleevec NNP 0 1 UNK B-Brand
increases VBZ 1 1 1 O
the DT 0 0 12 O
mean JJ 0 1 12 O
cmax NN 0 1 UNK O
and CC 0 0 12 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
simvastatin NN 0 1 0 B-Drug
( ( 0 0 2 O
CYP9A9 NNP 0 0 UNK O
substrate NN 0 1 UNK O
) ) 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
fold NN 0 1 3 O
respectively RB 0 0 1 O
suggesting VBG 1 1 1 O
an DT 0 0 12 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
the DT 0 0 12 O
CYP9A9 NNP 0 0 UNK O
by IN 0 0 12 O
Gleevec NNP 0 1 UNK B-Brand
. . 0 0 12 O

Careful JJ 0 1 UNK O
monitoring NN 0 1 1 O
of IN 0 0 12 O
phenytoin JJ 0 1 16 B-Drug
concentrations NNS 1 1 13 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
DIFLUCAN NNP 0 1 UNK B-Brand
and CC 0 0 12 O
phenytoin NN 0 1 16 B-Drug
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O

Consequently RB 0 0 1 O
the DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
VERSED NNP 0 1 15 B-Brand
Syrup NNP 0 1 2 I-Brand
should MD 0 0 12 O
be VB 0 0 12 O
adjusted VBN 1 1 1 O
according VBG 1 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
type NN 0 1 1 O
and CC 0 0 12 O
amount NN 0 1 1 O
of IN 0 0 12 O
concomitant JJ 0 1 6 O
medications NNS 1 1 6 O
administered VBN 1 1 1 O
and CC 0 0 12 O
the DT 0 0 12 O
desired JJ 0 1 1 O
clinical JJ 0 1 6 O
response NN 0 1 1 O
. . 0 0 12 O

Lymphocytopenia NNP 0 1 UNK O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
CAMPTOSAR NNP 0 1 UNK B-Brand
and CC 0 0 12 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
possible JJ 0 1 1 O
that IN 0 0 12 O
the DT 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
dexamethasone NN 0 1 16 B-Drug
as IN 1 0 12 O
antiemetic JJ 0 1 14 O
prophylaxis NN 0 1 6 O
may MD 0 0 1 O
have VB 0 0 12 O
enhanced VBN 1 1 1 O
the DT 0 0 12 O
likelihood NN 0 1 1 O
of IN 0 0 12 O
this DT 0 0 12 O
effect NN 0 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
addition NN 0 1 1 O
reduced VBN 1 1 1 O
kidney NN 0 1 6 O
and CC 0 0 12 O
liver NN 0 1 6 O
function NN 0 1 1 O
secondary JJ 0 1 1 O
to TO 0 0 12 O
PROLEUKIN NNP 0 1 UNK B-Brand
treatment NN 0 1 6 O
may MD 0 0 1 O
delay VB 0 1 1 O
elimination NN 0 1 UNK O
of IN 0 0 12 O
concomitant JJ 0 1 6 O
medications NNS 1 1 6 O
and CC 0 0 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
adverse JJ 0 0 1 O
events NNS 1 1 12 O
from IN 0 0 12 O
those DT 0 0 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

Naproxen NN 0 1 0 B-Drug
: : 0 0 2 O
The DT 0 0 2 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
diflunisal NN 0 1 13 B-Drug
and CC 0 0 12 O
naproxen NN 0 1 16 B-Drug
in IN 0 0 12 O
normal JJ 0 1 1 O
volunteers NNS 1 1 UNK O
had VBD 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
naproxen NN 0 1 16 B-Drug
but CC 0 0 12 O
significantly RB 0 0 1 O
decreased VBD 1 1 1 O
the DT 0 0 12 O
urinary JJ 0 1 6 O
excretion NN 0 1 14 O
of IN 0 0 12 O
naproxen NN 0 1 16 B-Drug
and CC 0 0 12 O
its PRP$ 1 0 12 O
glucuronide NN 0 1 UNK O
metabolite NN 0 1 UNK O
. . 0 0 12 O

CONTRAINDICATED NNS 0 1 UNK O
due JJ 0 1 1 O
to TO 0 0 12 O
potential JJ 0 1 1 O
for IN 0 0 12 O
serious JJ 0 1 12 O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
life NN 0 1 12 O
- : 0 0 2 O
threatening VBG 1 0 12 O
reactions NNS 1 1 1 O
such JJ 0 0 1 O
as IN 1 0 12 O
cardiac JJ 0 1 6 O
arrhythmias NN 1 1 6 O
. . 0 0 12 O

decrease VB 0 1 1 O
the DT 0 0 12 O
ED9 NNP 0 0 UNK O
of IN 0 0 12 O
MIVACRON NNP 0 1 UNK B-Brand
by IN 0 0 12 O
as RB 0 0 12 O
much JJ 0 0 12 O
as IN 1 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
( ( 0 0 2 O
see VB 0 1 12 O
CLINICAL NNP 0 1 11 O
PHARMACOLOGY NNP 0 1 UNK O
: : 0 0 2 O
Pharmacodynamics NNS 0 1 UNK O
and CC 0 0 12 O
Individualization NNP 0 0 UNK O
of IN 0 0 12 O
Dosages NNP 0 1 UNK O
) ) 0 0 2 O
. . 0 0 12 O

The DT 0 0 2 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
inhibit VBP 0 1 13 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
9D9 CD 0 0 UNK O
include VBP 0 1 1 O
some DT 0 0 12 O
that WDT 0 0 12 O
are VBP 1 0 12 O
not RB 0 1 12 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
the DT 0 0 12 O
enzyme NN 0 1 14 O
( ( 0 0 2 O
quinidine NN 0 1 16 B-Drug
; : 0 0 2 O

The DT 0 0 2 O
disposition NN 0 1 1 O
of IN 0 0 12 O
theophylline NN 0 1 16 B-Drug
was VBD 1 0 12 O
not RB 0 1 12 O
altered VBN 1 1 1 O
by IN 0 0 12 O
concomitant JJ 0 1 6 O
cetirizine JJ 0 1 13 B-Drug
administration NN 0 1 1 O
. . 0 0 12 O

If IN 0 0 12 O
pregnancy NN 0 1 6 O
occurs VBZ 1 1 1 O
while IN 0 0 12 O
taking VBG 1 0 12 O
AMEVIVE NNP 0 1 UNK B-Brand
continued VBN 1 1 12 O
use NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
drug NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
assessed VBN 1 1 1 O
. . 0 0 12 O

This DT 0 0 2 O
decrease NN 0 1 1 O
in IN 0 0 12 O
bioavailability NN 0 1 UNK O
was VBD 1 0 12 O
about RB 0 1 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
when WRB 0 0 12 O
gabapentin NN 0 1 0 B-Drug
was VBD 1 0 12 O
administered VBN 1 1 1 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
after IN 0 0 12 O
Maalox NNP 0 1 0 B-Brand
. . 0 0 12 O

Terfenadine NN 0 1 UNK B-Drug
: : 0 0 2 O
No DT 0 0 2 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
changes NNS 1 1 1 O
occurred VBD 1 1 1 O
in IN 0 0 12 O
heart NN 0 1 12 O
rate NN 0 1 1 O
or CC 0 0 12 O
corrected VBN 1 1 1 O
QT JJ 0 1 13 O
intervals NNS 1 1 1 O
or CC 0 0 12 O
in IN 0 0 12 O
terfenadine JJ 0 1 UNK B-Drug
metabolite NN 0 1 UNK O
or CC 0 0 12 O
lomefloxacin JJ 0 1 UNK B-Drug
pharmacokinetics NNS 0 1 UNK O
during IN 0 0 12 O
concurrent JJ 0 1 1 O
administration NN 0 1 1 O
of IN 0 0 12 O
lomefloxacin NN 0 1 UNK B-Drug
and CC 0 0 12 O
terfenadine NN 0 1 UNK B-Drug
at IN 0 0 12 O
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
in IN 0 0 12 O
9 CD 0 0 2 O
healthy JJ 0 1 12 O
males NNS 1 1 UNK O
. . 0 0 12 O

Acetylsalicylic NNP 0 0 UNK B-Drug
acid NN 0 1 14 I-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
alter VB 0 1 13 O
the DT 0 0 12 O
clearance NN 0 1 16 O
( ( 0 0 2 O
pharmacokinetics NNS 0 1 UNK O
) ) 0 0 2 O
of IN 0 0 12 O
iloprost NN 0 1 13 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
dose NN 0 1 6 O
resulted VBD 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
systemic JJ 0 1 6 O
exposure NN 0 1 1 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
times NNS 1 1 12 O
the DT 0 0 12 O
human JJ 0 1 1 O
plasma NN 0 1 14 O
area NN 0 1 12 O
- : 0 0 2 O
under IN 0 0 12 O
- : 0 0 2 O
the DT 0 0 12 O
- : 0 0 2 O
curve NN 0 1 13 O
( ( 0 0 2 O
AUC NNP 0 1 UNK O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
) ) 0 0 2 O
based VBN 1 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
maximum JJ 0 1 1 O
human JJ 0 1 1 O
dose NN 0 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
. . 0 0 12 O

A DT 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
once RB 0 0 12 O
- : 0 0 2 O
daily JJ 0 1 12 O
dose NN 0 1 6 O
was VBD 1 0 12 O
not RB 0 1 12 O
studied VBN 1 0 1 O
but CC 0 0 12 O
would MD 0 0 12 O
be VB 0 0 12 O
expected VBN 1 1 12 O
to TO 0 0 12 O
increase VB 0 1 1 O
aliskiren JJ 0 1 13 B-Drug
blood NN 0 1 6 O
levels NNS 1 1 1 O
further RBR 1 1 1 O
. . 0 0 12 O

This DT 0 0 2 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
with IN 0 0 12 O
Benedict NNP 0 0 UNK O
and CC 0 0 12 O
Fehling NNP 0 0 UNK O
s JJ 0 1 12 O
solutions NNS 1 1 UNK O
and CC 0 0 12 O
also RB 0 0 12 O
with IN 0 0 12 O
Clinitest NNP 0 1 UNK O
tablets NNS 1 1 3 O
. . 0 0 12 O

Concurrent JJ 0 1 13 O
administration NN 0 1 1 O
of IN 0 0 12 O
vasopressor NN 0 1 13 B-Group
drugs NNS 1 1 6 I-Group
( ( 0 0 2 O
for IN 0 0 12 O
the DT 0 0 12 O
treatment NN 0 1 6 O
of IN 0 0 12 O
hypotension NN 0 1 6 O
related VBN 1 1 1 O
to TO 0 0 12 O
obstetric VB 0 1 6 O
blocks NNS 1 1 3 O
) ) 0 0 2 O
and CC 0 0 12 O
ergot $ 0 1 UNK B-Group
- : 0 0 2 O
type NN 0 1 1 I-Group
oxytocic IN 0 1 13 I-Group
drugs NNS 1 1 6 I-Group
may MD 0 0 1 O
cause VB 0 1 12 O
severe JJ 0 1 6 O
persistent JJ 0 1 1 O
hypertension NN 0 1 6 O
or CC 0 0 12 O
cerebrovascular JJ 0 1 8 O
accidents NNS 1 1 1 O
. . 0 0 12 O

Prothrombin NNP 0 1 7 O
time NN 0 1 12 O
was VBD 1 0 12 O
not RB 0 1 12 O
affected VBN 1 1 1 O
by IN 0 0 12 O
levetiracetam NN 0 1 16 B-Drug
. . 0 0 12 O

Metformin NN 0 1 0 B-Drug
: : 0 0 2 O
In IN 0 0 2 O
healthy JJ 0 1 12 O
subjects NNS 1 1 UNK O
given VBN 1 1 12 O
single JJ 0 1 12 O
9 CD 0 0 2 O
mg JJ 0 1 0 O
doses NNS 1 1 6 O
of IN 0 0 12 O
cephalexin NN 0 1 16 B-Drug
and CC 0 0 12 O
metformin NN 0 1 0 B-Drug
plasma NN 0 1 14 O
metformin NN 0 1 0 B-Drug
mean NN 0 1 12 O
cmax NN 0 1 UNK O
and CC 0 0 12 O
AUC NNP 0 1 UNK O
increased VBN 1 1 1 O
by IN 0 0 12 O
an DT 0 0 12 O
average NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
respectively RB 0 0 1 O
and CC 0 0 12 O
metformin JJ 0 1 0 B-Drug
mean JJ 0 1 12 O
renal JJ 0 1 6 O
clearance NN 0 1 16 O
decreased VBN 1 1 1 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

The DT 0 0 2 O
risk NN 0 1 1 O
of IN 0 0 12 O
this DT 0 0 12 O
interaction NN 0 1 UNK O
may MD 0 0 1 O
be VB 0 0 12 O
reduced VBN 1 1 1 O
if IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
is VBZ 1 0 12 O
given VBN 1 1 12 O
as IN 1 0 12 O
capsules NNS 1 1 3 O
. . 0 0 12 O

This DT 0 0 2 O
effect NN 0 1 1 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
attributed VBN 1 1 1 O
to TO 0 0 12 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
renal JJ 0 1 6 O
prostaglandin NN 0 1 13 O
synthesis NN 0 1 UNK O
by IN 0 0 12 O
ibuprofen NN 0 1 0 B-Drug
. . 0 0 12 O

Theophylline NN 0 1 UNK B-Drug
: : 0 0 2 O
As IN 0 0 2 O
with IN 0 0 12 O
some DT 0 0 12 O
other JJ 0 0 12 O
quinolones NNS 0 1 13 B-Group
concurrent JJ 0 1 1 O
administration NN 0 1 1 O
of IN 0 0 12 O
ciprofloxacin NN 0 1 0 B-Drug
with IN 0 0 12 O
theophylline NN 0 1 16 B-Drug
may MD 0 0 1 O
lead VB 0 1 12 O
to TO 0 0 12 O
elevated JJ 0 1 1 O
serum JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
theophylline NN 0 1 16 B-Drug
and CC 0 0 12 O
prolongation NN 0 1 6 O
of IN 0 0 12 O
its PRP$ 1 0 12 O
elimination NN 0 1 UNK O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
. . 0 0 12 O

The DT 0 0 2 O
effect NN 0 1 1 O
of IN 0 0 12 O
induction NN 0 1 1 O
or CC 0 0 12 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
other JJ 0 0 12 O
pathways NNS 1 1 13 O
on IN 0 0 12 O
exposure NN 0 1 1 O
to TO 0 0 12 O
alosetron VB 0 1 UNK B-Drug
and CC 0 0 12 O
its PRP$ 1 0 12 O
metabolites NNS 1 1 UNK O
is VBZ 1 0 12 O
not RB 0 1 12 O
known VBN 1 1 12 O
. . 0 0 12 O

- : 0 0 2 O
Lofexidine NN 0 1 UNK B-Drug
may MD 0 0 1 O
enhance VB 0 1 UNK O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
anti JJ 0 0 3 B-Group
- : 0 0 2 O
hypertensive JJ 0 1 6 I-Group
drug NN 0 1 1 I-Group
therapy NN 0 1 6 O

Norpace NN 0 1 0 B-Brand
does VBZ 1 0 12 O
not RB 0 1 12 O
increase VB 0 1 1 O
serum NN 0 1 14 O
digoxin NN 0 1 14 B-Drug
levels NNS 1 1 1 O
. . 0 0 12 O

No DT 0 0 2 O
dosage NN 0 1 0 O
adjustment NN 0 1 1 O
for IN 0 0 12 O
montelukast NN 0 1 16 B-Drug
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O

WelChol NNP 0 1 UNK B-Brand
decreased VBD 1 1 1 O
the DT 0 0 12 O
Cmax NNP 0 1 UNK O
and CC 0 0 12 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
sustained VBN 1 1 1 O
- : 0 0 2 O
release NN 0 1 12 O
verapamil NN 0 1 0 B-Drug
( ( 0 0 2 O
Calan NNP 0 1 UNK B-Brand
SR NNP 0 1 2 I-Brand
) ) 0 0 2 O
by IN 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
respectively RB 0 0 1 O
. . 0 0 12 O

Doses NNS 0 1 0 O
of IN 0 0 12 O
these DT 0 0 12 O
and CC 0 0 12 O
perhaps RB 0 0 12 O
other JJ 0 0 12 O
medications NNS 1 1 6 O
may MD 0 0 1 O
need VB 0 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
adjusted VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
who WP 0 0 12 O
successfully RB 0 0 1 O
quit VBP 0 1 12 O
smoking NN 0 1 12 O
. . 0 0 12 O

Fatal JJ 0 1 UNK O
cardiac JJ 0 1 6 O
arrests NNS 1 1 UNK O
have VBP 0 0 12 O
occurred VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
both DT 0 0 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

When WRB 0 0 12 O
lansoprazole NN 0 1 16 B-Drug
was VBD 1 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
theophylline NN 0 1 16 B-Drug
( ( 0 0 2 O
CYP9A9 NNP 0 0 UNK O
CYP9A NNP 0 0 UNK O
) ) 0 0 2 O
a DT 0 0 12 O
minor JJ 0 1 1 O
increase NN 0 1 1 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
in IN 0 0 12 O
the DT 0 0 12 O
clearance NN 0 1 16 O
of IN 0 0 12 O
theophylline NN 0 1 16 B-Drug
was VBD 1 0 12 O
seen VBN 1 1 12 O
. . 0 0 12 O

Lansoprazole NNP 0 1 0 B-Drug
has VBZ 1 0 12 O
also RB 0 0 12 O
been VBN 1 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
have VB 0 0 12 O
no DT 0 0 12 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
interaction NN 0 1 UNK O
with IN 0 0 12 O
amoxicillin NN 0 1 0 B-Drug
. . 0 0 12 O

Steady JJ 0 1 UNK O
state NN 0 1 1 O
plasma NN 0 1 14 O
digitoxin NN 0 1 UNK B-Drug
concentrations NNS 1 1 13 O
did VBD 1 0 12 O
not RB 0 1 12 O
appear VB 0 1 12 O
to TO 0 0 12 O
change VB 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
appropriate JJ 0 1 1 O
doses NNS 1 1 6 O
for IN 0 0 12 O
this DT 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
respect NN 0 1 1 O
to TO 0 0 12 O
efficacy NN 0 1 UNK O
and CC 0 0 12 O
safety NN 0 1 1 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
established VBN 1 1 1 O
. . 0 0 12 O

Bexarotene NNP 0 1 UNK B-Drug
oxidative JJ 0 1 UNK O
metabolites NNS 1 1 UNK O
appear VBP 0 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
formed VBN 1 1 UNK O
by IN 0 0 12 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
9A9 CD 0 0 UNK O
. . 0 0 12 O

If IN 0 0 12 O
intravenous JJ 0 1 14 O
pentamidine NN 0 1 14 B-Drug
is VBZ 1 0 12 O
required VBN 1 1 1 O
to TO 0 0 12 O
treat VB 0 1 12 O
Pneumocystis NNP 0 1 14 O
carinii NN 0 0 14 O
pneumonia NN 0 1 6 O
treatment NN 0 1 6 O
with IN 0 0 12 O
HIVID NNP 0 1 UNK B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
interrupted VBN 1 1 12 O
. . 0 0 12 O

Carbamazepine NN 0 1 UNK B-Drug

Dextromethorphan NN 0 1 UNK B-Drug
: : 0 0 2 O
Dextromethorphan NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
primarily RB 0 0 1 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
CYP NNP 0 1 UNK O
9D9 CD 0 0 UNK O
and CC 0 0 12 O
to TO 0 0 12 O
a DT 0 0 12 O
lesser JJR 1 1 1 O
extent NN 0 1 1 O
by IN 0 0 12 O
9A9 CD 0 0 UNK O
. . 0 0 12 O

MAO NNP 0 1 14 B-Group
- : 0 0 2 O
A DT 0 0 2 I-Group
inhibitors NNS 1 1 14 I-Group
reduce VB 0 0 1 O
sumatriptan JJ 0 1 16 B-Drug
clearance NN 0 1 16 O
significantly RB 0 0 1 O
increasing VBG 1 1 1 O
systemic JJ 0 1 6 O
exposure NN 0 1 1 O
. . 0 0 12 O

Other JJ 0 0 2 O
concomitant JJ 0 1 6 O
therapy NN 0 1 6 O
Although IN 0 0 12 O
specific JJ 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
were VBD 1 0 12 O
not RB 0 1 12 O
performed VBN 1 1 1 O
finasteride JJ 0 1 16 B-Drug
doses NNS 1 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
or CC 0 0 12 O
more JJR 0 1 12 O
were VBD 1 0 12 O
concomitantly RB 0 0 14 O
used VBN 1 1 12 O
in IN 0 0 12 O
clinical JJ 0 1 6 O
studies NNS 1 1 1 O
with IN 0 0 12 O
acetaminophen JJ 0 1 16 B-Drug
acetylsalicylic JJ 0 0 UNK B-Drug
acid NN 0 1 14 I-Drug
a DT 0 0 12 O
- : 0 0 2 O
blockers NNS 1 0 6 O
analgesics NNS 1 1 14 B-Group
angiotensin VBP 0 1 UNK B-Group
- : 0 0 2 O
converting VBG 1 0 UNK I-Group
enzyme JJ 0 1 14 I-Group
ACE NNP 0 1 13 I-Group
inhibitors NNS 1 1 14 I-Group
anticonvulsants NNS 1 1 13 B-Group
benzodiazepines NNS 1 1 14 B-Group
beta NN 0 1 16 B-Group
blockers NNS 1 0 6 I-Group
calcium VBP 0 1 14 B-Group
- : 0 0 2 O
channel NN 0 1 1 I-Group
blockers NNS 1 0 6 I-Group
cardiac VBP 0 1 6 O
nitrates NNS 1 1 14 B-Group
diuretics NNS 1 1 14 B-Group
H9 NNP 0 0 UNK B-Group
antagonists VBZ 0 1 13 I-Group
HMG NNP 0 0 UNK B-Group
- : 0 0 2 O
CoA NNP 0 0 UNK I-Group
reductase NN 0 1 UNK I-Group
inhibitors NNS 1 1 14 I-Group
prostaglandin VBP 0 1 13 B-Group
synthetase JJ 0 1 UNK I-Group
inhibitors NNS 1 1 14 I-Group
( ( 0 0 2 O
also RB 0 0 12 O
referred VBN 1 1 1 O
to TO 0 0 12 O
as IN 1 0 12 O
NSAIDs NNP 0 1 UNK B-Group
) ) 0 0 2 O
and CC 0 0 12 O
quinolone $ 0 1 UNK B-Group
anti SYM 0 0 3 I-Group
- : 0 0 2 O
infectives NNS 0 0 UNK I-Group
without IN 0 0 12 O
evidence NN 0 1 1 O
of IN 0 0 12 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
adverse JJ 0 0 1 O
interactions NNS 1 1 UNK O
. . 0 0 12 O

Barbiturates NNS 0 1 UNK B-Group
carbamazepine VBP 0 1 16 B-Drug
and CC 0 0 12 O
phenytoin VBP 0 1 16 B-Drug
decrease VB 0 1 1 O
the DT 0 0 12 O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
of IN 0 0 12 O
doxycycline NN 0 1 0 B-Drug
. . 0 0 12 O

Rifampin NNP 0 1 0 B-Drug
an DT 0 0 12 O
inducer NN 0 1 UNK O
of IN 0 0 12 O
drug NN 0 1 1 O
metabolism NN 0 1 16 O
decreased VBD 1 1 1 O
the DT 0 0 12 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
losartan NN 0 1 0 B-Drug
and CC 0 0 12 O
its PRP$ 1 0 12 O
active JJ 0 1 1 O
metabolite NN 0 1 UNK O
. . 0 0 12 O

If IN 0 0 12 O
concomitant JJ 0 1 6 O
treatment NN 0 1 6 O
with IN 0 0 12 O
sumatriptan NN 0 1 16 B-Drug
and CC 0 0 12 O
an DT 0 0 12 O
SSRI NNP 0 1 UNK B-Group
is VBZ 1 0 12 O
clinically RB 0 0 6 O
warranted JJ 0 0 1 O
appropriate JJ 0 1 1 O
observation NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
patient NN 0 1 6 O
is VBZ 1 0 12 O
advised VBN 1 0 12 O
. . 0 0 12 O

In IN 0 0 2 O
controlled JJ 0 1 1 O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
of IN 0 0 12 O
AUGMENTIN NNP 0 1 UNK B-Brand
XR NNP 0 1 0 I-Brand
9 CD 0 0 2 O
patients NNS 1 1 6 O
received VBD 1 1 12 O
concomitant JJ 0 1 6 O
allopurinol NN 0 1 13 B-Drug
and CC 0 0 12 O
AUGMENTIN NNP 0 1 UNK B-Brand
XR NNP 0 1 0 I-Brand
. . 0 0 12 O

This DT 0 0 2 O
interaction NN 0 1 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
kept VBN 1 1 12 O
in IN 0 0 12 O
mind NN 0 1 12 O
when WRB 0 0 12 O
Gantanol NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
given VBN 1 1 12 O
to TO 0 0 12 O
patients NNS 1 1 6 O
already RB 0 0 12 O
on IN 0 0 12 O
anticoagulant JJ 0 1 13 O
therapy NN 0 1 6 O
and CC 0 0 12 O
the DT 0 0 12 O
coagulation NN 0 1 14 O
time NN 0 1 12 O
should MD 0 0 12 O
be VB 0 0 12 O
reassessed VBN 1 0 15 O
. . 0 0 12 O

In IN 0 0 2 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
concurrent JJ 0 1 1 O
therapy NN 0 1 6 O
with IN 0 0 12 O
clonidine NN 0 1 0 B-Drug
if IN 0 0 12 O
therapy NN 0 1 6 O
is VBZ 1 0 12 O
to TO 0 0 12 O
be VB 0 0 12 O
discontinued VBN 1 1 1 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
suggested VBN 1 1 12 O
that IN 0 0 12 O
ZEBETA NNP 0 1 UNK B-Brand
be VB 0 0 12 O
discontinued VBN 1 1 1 O
for IN 0 0 12 O
several JJ 0 1 12 O
days NNS 1 1 12 O
before IN 0 1 12 O
the DT 0 0 12 O
withdrawal NN 0 1 1 O
of IN 0 0 12 O
clonidine NN 0 1 0 B-Drug
. . 0 0 12 O

In IN 0 0 2 O
some DT 0 0 12 O
patients NNS 1 1 6 O
this DT 0 0 12 O
may MD 0 0 1 O
lead VB 0 1 12 O
to TO 0 0 12 O
reduced JJ 0 1 1 O
clearance NN 0 1 16 O
prolongation NN 0 1 6 O
of IN 0 0 12 O
plasma NN 0 1 14 O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
and CC 0 0 12 O
enhanced JJ 0 1 1 O
effects NNS 1 1 1 O
of IN 0 0 12 O
caffeine NN 0 1 6 B-Drug
and CC 0 0 12 O
theobromine NN 0 1 UNK B-Drug
. . 0 0 12 O

The DT 0 0 2 O
median JJ 0 1 1 O
duration NN 0 1 1 O
of IN 0 0 12 O
action NN 0 1 13 O
of IN 0 0 12 O
ZEMURON NNP 0 1 UNK B-Brand
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
administered VBD 1 1 1 O
after IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NNP 0 1 18 O
dose NN 0 1 6 O
of IN 0 0 12 O
succinylcholine NN 0 1 16 B-Drug
when WRB 0 0 12 O
T NNP 0 1 2 O
9 CD 0 0 2 O
returned VBD 1 1 12 O
to TO 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
of IN 0 0 12 O
control NN 0 1 1 O
was VBD 1 0 12 O
9 CD 0 0 2 O
minutes NNS 1 1 12 O
( ( 0 0 2 O
range NN 0 1 1 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
n=9 NN 0 1 UNK O
) ) 0 0 2 O
vs NN 1 0 2 O
. . 0 0 12 O

When WRB 0 0 12 O
these DT 0 0 12 O
products NNS 1 1 1 O
are VBP 1 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
or CC 0 0 12 O
other JJ 0 0 12 O
suitable JJ 0 1 1 O
coagulation NN 0 1 14 O
tests NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
closely RB 0 0 1 O
monitored VBN 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
clinical JJ 0 1 6 O
significance NN 0 1 13 O
of IN 0 0 12 O
this DT 0 0 12 O
finding NN 0 1 12 O
is VBZ 1 0 12 O
unknown JJ 0 1 12 O
; : 0 0 2 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interactions NNP 0 1 UNK O
No NNP 0 0 2 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
changes NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
results NNS 1 1 1 O
of IN 0 0 12 O
clinical JJ 0 1 6 O
laboratory NN 0 1 1 O
tests NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O

see VB 0 1 12 O
DOSAGE NNP 0 1 UNK O
AND NNP 0 0 11 O
ADMINISTRATION NNP 0 1 11 O
) ) 0 0 2 O
. . 0 0 12 O

The DT 0 0 2 O
extent NN 0 1 1 O
to TO 0 0 12 O
which WDT 0 0 12 O
SSRI NNP 0 1 UNK B-Group
- : 0 0 2 O
TCA NNP 0 1 13 B-Group
interactions NNS 1 1 UNK O
may MD 0 0 1 O
pose VB 0 0 UNK O
clinical JJ 0 1 6 O
problems NNS 1 1 1 O
will MD 0 0 12 O
depend VB 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
degree NN 0 1 1 O
of IN 0 0 12 O
inhibition NN 0 1 13 O
and CC 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
SSRI NNP 0 1 UNK B-Group
involved VBN 1 1 12 O
. . 0 0 12 O

The DT 0 0 2 O
potential NN 0 1 1 O
for IN 0 0 12 O
binding NN 0 1 1 O
of IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
if IN 0 0 12 O
given VBN 1 1 12 O
concomitantly RB 0 0 14 O
is VBZ 1 0 12 O
present JJ 0 1 1 O
. . 0 0 12 O

Diabetics NNS 0 1 UNK O
should MD 0 0 12 O
discuss VB 0 1 12 O
the DT 0 0 12 O
use NN 0 1 1 O
of IN 0 0 12 O
these DT 0 0 12 O
supplements NNS 1 1 6 O
with IN 0 0 12 O
their PRP$ 0 0 12 O
physicians NNS 1 1 6 O
and CC 0 0 12 O
note NN 0 1 12 O
if IN 0 0 12 O
the DT 0 0 12 O
supplements NNS 1 1 6 O
affect VBP 0 1 1 O
their PRP$ 0 0 12 O
glycemic JJ 0 1 14 O
control NN 0 1 1 O
. . 0 0 12 O

Monoamine NNP 0 1 UNK B-Group
oxidase NN 0 1 13 I-Group
MAO NNP 0 1 14 I-Group
inhibitors NNS 1 1 14 I-Group
prolong RB 0 0 13 O
and CC 0 0 12 O
intensify VB 0 0 UNK O
the DT 0 0 12 O
anticholinergic JJ 0 1 13 O
effects NNS 1 1 1 O
of IN 0 0 12 O
antihistamines NNS 1 1 UNK B-Group
. . 0 0 12 O

Safety NN 0 1 UNK O
and CC 0 0 12 O
effectiveness NN 0 1 UNK O
in IN 0 0 12 O
children NNS 1 1 12 O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
established VBN 1 1 1 O
. . 0 0 12 O

This DT 0 0 2 O
suggests VBZ 1 1 1 O
the DT 0 0 12 O
existence NN 0 1 13 O
of IN 0 0 12 O
a DT 0 0 12 O
recirculation NN 0 0 UNK O
pathway NN 0 1 UNK O
for IN 0 0 12 O
meloxicam NN 0 1 13 B-Drug
in IN 0 0 12 O
the DT 0 0 12 O
gastrointestinal JJ 0 1 6 O
tract NN 0 1 6 O
. . 0 0 12 O

Patients NNS 0 1 7 O
receiving VBG 1 1 1 O
narrow JJ 0 1 3 O
therapeutic JJ 0 1 6 O
ratio NN 0 1 1 O
drugs NNS 1 1 6 O
or CC 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
that IN 0 0 12 O
require VBP 0 0 1 O
careful JJ 0 1 12 O
titration NN 0 1 14 O
should MD 0 0 12 O
be VB 0 0 12 O
followed VBN 1 1 12 O
closely RB 0 0 1 O
; : 0 0 2 O

If IN 0 0 12 O
TYKERB NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
inhibit VBP 0 1 13 O
Pgp NNP 0 1 UNK O
increased VBD 1 1 1 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
lapatinib NN 0 1 13 B-Drug
are VBP 1 0 12 O
likely JJ 0 1 12 O
and CC 0 0 12 O
caution NN 0 0 1 O
should MD 0 0 12 O
be VB 0 0 12 O
exercised VBN 1 1 1 O
. . 0 0 12 O

rash NN 0 1 6 O

- : 0 0 2 O
Alcohol NN 0 1 2 B-Drug
barbiturates VBZ 0 1 14 B-Group
or CC 0 0 12 O
narcotics NNS 1 1 1 B-Group
: : 0 0 2 O
Potentiation NN 0 1 UNK O
of IN 0 0 12 O
otthostatic JJ 0 0 UNK O
hypotension NN 0 1 6 O
may MD 0 0 1 O
occur VB 0 1 1 O

Selective JJ 0 1 7 B-Group
serotonin NN 0 1 13 I-Group
reuptake NN 0 1 13 I-Group
inhibitors NNS 1 1 14 I-Group
( ( 0 0 2 O
SSRIs NNP 0 1 UNK B-Group
) ) 0 0 2 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
fluoxetine NN 0 1 16 B-Drug
fluvoxamine NN 0 1 16 B-Drug
paroxetine NN 0 1 16 B-Drug
sertraline NN 0 1 16 B-Drug
) ) 0 0 2 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
rarely RB 0 1 UNK O
to TO 0 0 12 O
cause VB 0 1 12 O
weakness NN 0 1 6 O
hyperreflexia NN 0 1 8 O
and CC 0 0 12 O
incoordination NN 0 1 UNK O
when WRB 0 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
HTv NN 0 0 UNK O
agonists NNS 1 1 UNK O
. . 0 0 12 O

Coadministration NN 0 1 UNK O
of IN 0 0 12 O
esomeprazole JJ 0 1 16 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
and CC 0 0 12 O
diazepam VB 0 1 0 B-Drug
a DT 0 0 12 O
CYP9C9 NNP 0 0 UNK O
substrate NN 0 1 UNK O
resulted VBD 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
decrease NN 0 1 1 O
in IN 0 0 12 O
clearance NN 0 1 16 O
of IN 0 0 12 O
diazepam NN 0 1 0 B-Drug
. . 0 0 12 O

9 CD 0 0 2 O
- : 0 0 2 O
adrenergic NN 0 1 UNK O
receptor NN 0 1 14 O
antagonism NN 0 1 UNK O
aripiprazole NN 0 1 16 B-Drug
has VBZ 1 0 12 O
the DT 0 0 12 O
potential JJ 0 1 1 O
to TO 0 0 12 O
enhance VB 0 1 UNK O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
certain JJ 0 1 1 O
antihypertensive JJ 0 1 14 B-Group
agents NNS 1 1 1 I-Group
. . 0 0 12 O

Although IN 0 0 12 O
the DT 0 0 12 O
clinical JJ 0 1 6 O
significance NN 0 1 13 O
of IN 0 0 12 O
these DT 0 0 12 O
effects NNS 1 1 1 O
is VBZ 1 0 12 O
not RB 0 1 12 O
known VBN 1 1 12 O
caution NN 0 0 1 O
is VBZ 1 0 12 O
advised VBN 1 0 12 O
in IN 0 0 12 O
the DT 0 0 12 O
co NN 0 1 12 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
beta JJ 0 1 16 B-Group
- : 0 0 2 O
agonists NNS 1 1 UNK I-Group
with IN 0 0 12 O
non JJ 0 1 1 B-Group
- : 0 0 2 O
potassium NN 0 1 14 I-Group
sparing VBG 1 0 6 I-Group
diuretics NNS 1 1 14 I-Group
. . 0 0 12 O

Excessive JJ 0 1 UNK O
neuromuscular JJ 0 1 6 O
weakness NN 0 1 6 O
may MD 0 0 1 O
be VB 0 0 12 O
exacerbated VBN 1 1 1 O
by IN 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
another DT 0 0 12 O
botulinum NN 0 1 13 B-Group
toxin NN 0 1 14 I-Group
prior RB 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
resolution NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
previously RB 0 0 1 O
administered VBN 1 1 1 O
botulinum NN 0 1 13 B-Group
toxin NN 0 1 14 I-Group
. . 0 0 12 O

Digoxin NN 0 1 0 B-Drug
: : 0 0 2 O
There EX 0 0 12 O
was VBD 1 0 12 O
a DT 0 0 12 O
slight JJ 0 1 3 O
increase NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
area NN 0 1 12 O
under IN 0 0 12 O
the DT 0 0 12 O
curve NN 0 1 13 O
( ( 0 0 2 O
AUC NNP 0 1 UNK O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
and CC 0 0 12 O
mean JJ 0 1 12 O
peak JJ 0 1 1 O
drug NN 0 1 1 O
concentration NN 0 1 1 O
( ( 0 0 2 O
Cmax NNP 0 1 UNK O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
with IN 0 0 12 O
the DT 0 0 12 O
co NN 0 1 12 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
sitagliptin NN 0 1 13 B-Drug
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
. . 0 0 12 O

Time NNP 0 1 2 O
to TO 0 0 12 O
reach VB 0 1 12 O
Cmax NNP 0 1 UNK O
is VBZ 1 0 12 O
also RB 0 0 12 O
prolonged VBN 1 1 6 O
by IN 0 0 12 O
9 CD 0 0 2 O
hour NN 0 1 12 O
. . 0 0 12 O

Administration NN 0 1 UNK O
of IN 0 0 12 O
quinolones NNS 0 1 13 B-Group
with IN 0 0 12 O
antacids NNS 1 1 14 B-Group
containing VBG 1 1 1 O
aluminum NN 0 1 16 B-Drug
magnesium NN 0 1 14 B-Drug
or CC 0 0 12 O
calcium NN 0 1 14 B-Drug
with IN 0 0 12 O
sucralfate NN 0 1 0 B-Drug
with IN 0 0 12 O
metal JJ 0 1 3 O
cations NNS 1 1 UNK O
such JJ 0 0 1 O
as IN 1 0 12 O
iron NN 0 1 3 B-Drug
or CC 0 0 12 O
with IN 0 0 12 O
multivitamins NNS 1 1 14 B-Group
containing VBG 1 1 1 O
iron NN 0 1 3 B-Drug
or CC 0 0 12 O
zinc NN 0 1 14 B-Drug
or CC 0 0 12 O
with IN 0 0 12 O
formulations NNS 1 1 UNK O
containing VBG 1 1 1 O
divalent NN 0 0 UNK O
and CC 0 0 12 O
trivalent JJ 0 0 UNK O
cations NNS 1 1 UNK O
such JJ 0 0 1 O
as IN 1 0 12 O
VIDEX NNP 0 1 UNK B-Brand
( ( 0 0 2 O
didanosine NN 0 1 16 B-Drug
) ) 0 0 2 O
chewable JJ 0 0 16 O
/ NN 0 0 2 O
buffered VBD 1 1 16 O
tablets NNS 1 1 3 O
or CC 0 0 12 O
the DT 0 0 12 O
pediatric JJ 0 1 6 O
powder NN 0 1 3 O
for IN 0 0 12 O
oral JJ 0 1 6 O
solution NN 0 1 1 O
may MD 0 0 1 O
substantially RB 0 0 1 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
absorption NN 0 1 1 O
of IN 0 0 12 O
quinolones NNS 0 1 13 B-Group
resulting VBG 1 1 1 O
in IN 0 0 12 O
systemic JJ 0 1 6 O
concentrations NNS 1 1 13 O
considerably RB 0 0 1 O
lower JJR 1 1 1 O
than IN 0 0 12 O
desired VBN 1 1 1 O
. . 0 0 12 O

When WRB 0 0 12 O
given VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
felodipine NN 0 1 13 B-Drug
the DT 0 0 12 O
tacrolimus NN 0 1 16 B-Drug
blood NN 0 1 6 O
concentration NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
followed VBN 1 1 12 O
and CC 0 0 12 O
the DT 0 0 12 O
tacrolimus NN 0 1 16 O
dose NN 0 1 6 O
may MD 0 0 1 O
need VB 0 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
adjusted VBN 1 1 1 O
. . 0 0 12 O

However RB 0 0 1 O
in IN 0 0 12 O
another DT 0 0 12 O
study NN 0 1 1 O
in IN 0 0 12 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
butorphanol NN 0 1 13 B-Drug
were VBD 1 0 12 O
significantly RB 0 0 1 O
altered VBN 1 1 1 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
decrease NN 0 1 1 O
in IN 0 0 12 O
AUC NNP 0 1 UNK O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
decrease NN 0 1 1 O
in IN 0 0 12 O
Cmax NNP 0 1 UNK O
) ) 0 0 2 O
when WRB 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
mg NN 0 1 0 O
dose NN 0 1 6 O
of IN 0 0 12 O
STADOL NNP 0 1 UNK B-Brand
NS NNP 0 1 13 I-Brand
was VBD 1 0 12 O
administered VBN 1 1 1 O
9 CD 0 0 2 O
minute NN 0 1 12 O
after IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
mg NN 0 1 0 O
dose NN 0 1 6 O
of IN 0 0 12 O
sumatriptan JJ 0 1 16 B-Drug
nasal NN 0 1 6 O
spray NN 0 1 3 O
. . 0 0 12 O

This DT 0 0 2 O
may MD 0 0 1 O
lead VB 0 1 12 O
to TO 0 0 12 O
reduced JJ 0 1 1 O
clearance NN 0 1 16 O
of IN 0 0 12 O
caffeine NN 0 1 6 B-Drug
and CC 0 0 12 O
a DT 0 0 12 O
prolongation NN 0 1 6 O
of IN 0 0 12 O
its PRP$ 1 0 12 O
plasma NN 0 1 14 O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
. . 0 0 12 O

Micro NNP 0 1 2 O
- : 0 0 2 O
dosed VBD 1 1 14 O
Progesterone JJ 0 1 UNK B-Drug
Preparations NNS 0 1 UNK O
: : 0 0 2 O
Micro NNP 0 1 2 O
- : 0 0 2 O
dosed VBD 1 1 14 O
progesterone NN 0 1 13 B-Drug
preparations NNS 1 1 13 O
( ( 0 0 2 O
minipills NNS 0 1 UNK O
that WDT 0 0 12 O
do VBP 0 0 12 O
not RB 0 1 12 O
contain VB 0 1 UNK O
an DT 0 0 12 O
estrogen NN 0 1 6 B-Group
) ) 0 0 2 O
may MD 0 0 1 O
be VB 0 0 12 O
an DT 0 0 12 O
inadequate JJ 0 1 1 O
method NN 0 1 13 O
of IN 0 0 12 O
contraception NN 0 1 13 O
during IN 0 0 12 O
Accutane NNP 0 1 UNK B-Brand
therapy NN 0 1 6 O
. . 0 0 12 O

Cephalosporins NNP 0 1 15 B-Group
- : 0 0 2 O
Cephalosporins VBZ 0 1 15 B-Group
containing VBG 1 1 1 O
side NN 0 1 3 O
chains NNS 1 1 UNK O
of IN 0 0 12 O
N NNP 0 1 2 O
- : 0 0 2 O
methylthiotetrazole NN 0 0 UNK O
( ( 0 0 2 O
cefmenoxime JJ 0 1 UNK B-Drug
cefoperazone NN 0 1 UNK B-Drug
cefotetan NN 0 1 14 B-Drug
cefamandole NN 0 1 UNK B-Drug
latamoxef NN 0 1 UNK B-Drug
) ) 0 0 2 O
or CC 0 0 12 O
methylthiadiazole NN 0 0 UNK O
( ( 0 0 2 O
cefazolin NN 0 1 14 B-Drug
) ) 0 0 2 O
can MD 0 0 12 O
cause VB 0 1 12 O
vitamin JJ 0 1 6 O
K NNP 0 1 2 O
deficiency NN 0 1 6 O
and CC 0 0 12 O
hypoprothrombinemia NN 0 1 UNK O
. . 0 0 12 O

Garlic NNP 0 1 UNK O
Capsules NNP 0 1 0 O
Garlic NNP 0 1 UNK O
capsules NNS 1 1 3 O
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
while IN 0 0 12 O
taking VBG 1 0 12 O
saquinavir NN 0 1 13 B-Drug
( ( 0 0 2 O
FORTOVASE NNP 0 1 UNK B-Brand
) ) 0 0 2 O
as IN 1 0 12 O
the DT 0 0 12 O
sole JJ 0 1 UNK O
protease NN 0 1 13 B-Group
inhibitor NN 0 1 14 I-Group
due JJ 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
decreased JJ 0 1 1 O
saquinavir NN 0 1 13 B-Drug
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
. . 0 0 12 O

Interactions NNS 0 1 UNK O
between IN 0 0 12 O
ZADAXIN NNP 0 1 UNK B-Brand
and CC 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
fully RB 0 0 1 O
evaluated VBN 1 1 1 O
. . 0 0 12 O

Abacavir NNP 0 1 UNK B-Drug
has VBZ 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetic JJ 0 1 UNK O
properties NNS 1 1 UNK O
of IN 0 0 12 O
ethanol NN 0 1 1 B-Drug
. . 0 0 12 O

Spontaneous JJ 0 1 7 O
reports NNS 1 1 1 O
of IN 0 0 12 O
serotonin JJ 0 1 13 O
syndrome NN 0 1 6 O
associated VBN 1 1 1 O
with IN 0 0 12 O
co NN 0 1 12 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
ZYVOX NNP 0 1 UNK B-Brand
and CC 0 0 12 O
serotonergic JJ 0 0 UNK B-Group
agents NNS 1 1 1 I-Group
including VBG 1 1 1 O
antidepressants NNS 1 1 13 B-Group
such JJ 0 0 1 O
as IN 1 0 12 O
selective JJ 0 1 13 B-Group
serotonin NN 0 1 13 I-Group
reuptake NN 0 1 13 I-Group
inhibitors NNS 1 1 14 I-Group
( ( 0 0 2 O
SSRIs NNP 0 1 UNK B-Group
) ) 0 0 2 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
. . 0 0 12 O

One CD 0 1 2 O
animal NN 0 1 13 O
in IN 0 0 12 O
the DT 0 0 12 O
high JJ 0 1 1 O
dose NN 0 1 6 O
group NN 0 1 12 O
developed VBD 1 0 1 O
a DT 0 0 12 O
B NNP 0 0 2 O
- : 0 0 2 O
cell NN 0 1 1 O
lymphoma NN 0 1 6 O
that WDT 0 0 12 O
was VBD 1 0 12 O
detected VBN 1 1 1 O
after IN 0 0 12 O
9 CD 0 0 2 O
weeks NNS 1 1 12 O
of IN 0 0 12 O
dosing NN 0 0 14 O
. . 0 0 12 O

In IN 0 0 2 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
indicate VBP 0 0 1 O
CYP9A9 NNP 0 0 UNK O
isoform NN 0 1 UNK O
and CC 0 0 12 O
CYP9A9 NNP 0 0 UNK O
isoform NN 0 1 UNK O
mediate NN 0 1 UNK O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
levobupivacaine NN 0 1 UNK B-Drug
to TO 0 0 12 O
desbutyl VB 0 0 UNK B-Drug_n
levobupivacaine NN 0 1 UNK I-Drug_n
and CC 0 0 12 O
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
hydroxy NN 0 1 14 I-Drug_n
levobupivacaine NN 0 1 UNK I-Drug_n
respectively RB 0 0 1 O
. . 0 0 12 O

Increases NNS 0 1 UNK O
in IN 0 0 12 O
serum NN 0 1 14 O
creatinine NN 0 1 14 O
have VBP 0 0 12 O
occurred VBN 1 1 1 O
when WRB 0 0 12 O
CEFOTAN NNP 0 1 UNK B-Brand
was VBD 1 0 12 O
given VBN 1 1 12 O
alone RB 0 1 12 O
. . 0 0 12 O

Thus RB 0 0 1 O
when WRB 0 0 12 O
ibuprofen NN 0 1 0 B-Drug
and CC 0 0 12 O
lithium NN 0 1 16 B-Drug
are VBP 1 0 12 O
administered VBN 1 1 1 O
concurrently RB 0 0 1 O
subjects NNS 1 1 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
observed VBN 1 1 1 O
carefully RB 0 0 12 O
for IN 0 0 12 O
signs NNS 1 1 12 O
of IN 0 0 12 O
lithium NN 0 1 16 B-Drug
toxicity NN 0 1 6 O
. . 0 0 12 O

Verapamil NN 0 1 0 B-Drug
: : 0 0 2 O
Concomitant JJ 0 1 UNK O
use NN 0 1 1 O
of IN 0 0 12 O
verapamil NN 0 1 0 B-Drug
is VBZ 1 0 12 O
contraindicated VBN 1 1 14 O
. . 0 0 12 O

In IN 0 0 2 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
shown VBN 1 1 1 O
that DT 0 0 12 O
mirtazapine NN 0 1 0 B-Drug
is VBZ 1 0 12 O
a DT 0 0 12 O
substrate NN 0 1 UNK O
for IN 0 0 12 O
several JJ 0 1 12 O
of IN 0 0 12 O
these DT 0 0 12 O
enzymes NNS 1 1 14 O
including VBG 1 1 1 O
9D9 CD 0 0 UNK O
9A9 CD 0 0 UNK O
and CC 0 0 12 O
9A9 CD 0 0 UNK O
. . 0 0 12 O

Hyperpyrexia NNP 0 1 UNK O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
when WRB 0 0 12 O
amitriptyline NN 0 1 16 B-Drug
HCl NNP 0 0 14 I-Drug
is VBZ 1 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
anticholinergic JJ 0 1 13 B-Drug
agents NNS 1 1 1 O
or CC 0 0 12 O
with IN 0 0 12 O
neuroleptic JJ 0 1 13 B-Drug
drugs NNS 1 1 6 O
particularly RB 0 0 1 O
during IN 0 0 12 O
hot JJ 0 1 3 O
weather NN 0 1 13 O
. . 0 0 12 O

In IN 0 0 2 O
vitro JJ 0 1 UNK O
propranolol NN 0 1 16 B-Drug
appears VBZ 1 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
displaced VBN 1 1 1 O
from IN 0 0 12 O
its PRP$ 1 0 12 O
binding VBG 1 1 1 O
sites NNS 1 1 1 O
by IN 0 0 12 O
diltiazem NN 0 1 0 B-Drug
. . 0 0 12 O

Increased VBN 0 1 7 O
plasma NN 0 1 14 O
HDL NNP 0 1 14 O
and CC 0 0 12 O
HDL9 NNP 0 0 UNK O
cholesterol NN 0 1 6 O
subfraction NN 0 0 UNK O
concentrations NNS 1 1 13 O
reduced VBD 1 1 1 O
LDL NNP 0 0 14 O
cholesterol NN 0 1 6 O
concentration NN 0 1 1 O
increased VBD 1 1 1 O
triglyceride JJ 0 1 14 O
levels NNS 1 1 1 O
. . 0 0 12 O

Pre NNP 0 1 2 O
- : 0 0 2 O
treatment NN 0 1 6 O
with IN 0 0 12 O
the DT 0 0 12 O
CYP9A9 NNP 0 0 UNK O
inducer NN 0 1 UNK O
rifampicin NN 0 1 UNK B-Drug
decreased VBD 1 1 1 O
erlotinib JJ 0 1 13 B-Drug
AUC NNP 0 1 UNK O
by IN 0 0 12 O
about IN 0 1 12 O
9 CD 0 0 2 O
/ JJ 0 0 2 O
9 CD 0 0 2 O
. . 0 0 12 O

Triprolidine NN 0 1 UNK B-Drug
may MD 0 0 1 O
effect NN 0 1 1 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
drugs NNS 1 1 6 O
in IN 0 0 12 O
the DT 0 0 12 O
liver NN 0 1 6 O
. . 0 0 12 O

Long RB 0 1 2 O
Acting VBG 0 1 UNK O
Nitrates NNS 0 1 UNK B-Group
: : 0 0 2 O
Nifedipine NN 0 1 0 B-Drug
may MD 0 0 1 O
be VB 0 0 12 O
safely RB 0 0 UNK O
co JJ 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
with IN 0 0 12 O
nitrates NNS 1 1 14 B-Group
but CC 0 0 12 O
there EX 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
no DT 0 0 12 O
controlled JJ 0 1 1 O
studies NNS 1 1 1 O
to TO 0 0 12 O
evaluate VB 0 1 1 O
the DT 0 0 12 O
antianginal JJ 0 1 UNK O
effectiveness NN 0 1 UNK O
of IN 0 0 12 O
this DT 0 0 12 O
combination NN 0 1 1 O
. . 0 0 12 O

Standard NNP 0 1 2 O
therapy NN 0 1 6 O
includes VBZ 1 1 1 O
antibiotics NNS 1 1 6 B-Group
such JJ 0 0 1 O
as IN 1 0 12 O
penicillin NN 0 1 14 B-Drug
and CC 0 0 12 O
gentamicin NN 0 1 14 B-Drug
; : 0 0 2 O

Diuretics NNS 0 1 UNK B-Group
: : 0 0 2 O
Etodolac NNP 0 1 UNK O
has VBZ 1 0 12 O
no DT 0 0 12 O
apparent JJ 0 1 1 O
pharmacokinetic JJ 0 1 UNK O
interaction NN 0 1 UNK O
when WRB 0 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
furosemide NN 0 1 0 B-Drug
or CC 0 0 12 O
hydrochlorothiazide NN 0 1 0 B-Drug
. . 0 0 12 O

For IN 0 0 2 O
these DT 0 0 12 O
reasons NNS 1 1 12 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
felt VBN 0 1 12 O
that IN 0 0 12 O
in IN 0 0 12 O
most JJS 0 0 12 O
subjects NNS 1 1 UNK O
who WP 0 0 12 O
have VBP 0 0 12 O
had VBD 1 0 12 O
an DT 0 0 12 O
unsatisfactory JJ 0 1 13 O
lipid JJ 0 1 14 O
response NN 0 1 1 O
to TO 0 0 12 O
either DT 0 1 12 O
drug NN 0 1 1 O
alone RB 0 1 12 O
the DT 0 0 12 O
possible JJ 0 1 1 O
benefits NNS 1 1 1 O
of IN 0 0 12 O
combined JJ 0 1 1 O
therapy NN 0 1 6 O
with IN 0 0 12 O
lovastatin NN 0 1 13 B-Drug
and CC 0 0 12 O
a DT 0 0 12 O
fibrate NN 0 0 UNK B-Group
do NN 0 0 12 O
not RB 0 1 12 O
outweigh VB 0 0 1 O
the DT 0 0 12 O
risks NNS 1 1 1 O
of IN 0 0 12 O
severe JJ 0 1 6 O
myopathy JJ 0 1 8 O
rhabdomyolysis NN 0 1 8 O
and CC 0 0 12 O
acute JJ 0 1 6 O
renal JJ 0 1 6 O
failure NN 0 1 1 O
. . 0 0 12 O

antiarrhythmic JJ 0 1 14 B-Group
agents NNS 1 1 1 I-Group
concentration NN 0 1 1 O

The DT 0 0 2 O
Cmax NNP 0 1 UNK O
of IN 0 0 12 O
norethindrone NN 0 1 13 B-Drug
was VBD 1 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
higher JJR 1 1 1 O
when WRB 0 0 12 O
it PRP 0 0 12 O
was VBD 1 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
gabapentin NN 0 1 0 B-Drug
; : 0 0 2 O

Coadministered NNP 0 0 UNK O
Concentration NNP 0 1 UNK O
Concentration NNP 0 1 UNK O

decreased JJ 0 1 1 O
levels NNS 1 1 1 O
of IN 0 0 12 O
anti JJ 0 0 3 O
- : 0 0 2 O
factor NN 0 1 1 O
Xa NN 0 1 UNK O
and CC 0 0 12 O
antithrombin JJ 0 1 14 B-Drug
III NNP 0 1 2 I-Drug
decreased VBD 1 1 1 O
antithrombin JJ 0 1 14 B-Drug
III NNP 0 1 2 I-Drug
activity NN 0 1 1 O
; : 0 0 2 O

Genitourinary JJ 0 1 7 O
: : 0 0 2 O
Urinary JJ 0 1 7 O
frequency NN 0 1 1 O
( ( 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
; : 0 0 2 O

In IN 0 0 2 O
addition NN 0 1 1 O
there EX 0 0 12 O
was VBD 1 0 12 O
no DT 0 0 12 O
pharmacodynamic JJ 0 1 UNK O
interaction NN 0 1 UNK O
as IN 1 0 12 O
a DT 0 0 12 O
result NN 0 1 1 O
of IN 0 0 12 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
zaleplon NN 0 1 13 B-Drug
and CC 0 0 12 O
venlafaxine NN 0 1 16 B-Drug
ER NNP 0 1 2 O
. . 0 0 12 O

Macrolides NNS 0 1 UNK B-Group
: : 0 0 2 O
Clinical JJ 0 1 7 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
indicate VBP 0 0 1 O
that IN 0 0 12 O
erythromycin NN 0 1 0 B-Drug
and CC 0 0 12 O
clarithromycin NN 0 1 13 B-Drug
can MD 0 0 12 O
exert VB 0 1 13 O
an DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
terfenadine NN 0 1 UNK B-Drug
metabolism NN 0 1 16 O
by IN 0 0 12 O
a DT 0 0 12 O
mechanism NN 0 1 13 O
which WDT 0 0 12 O
may MD 0 0 1 O
be VB 0 0 12 O
similar JJ 0 1 1 O
to TO 0 0 12 O
that DT 0 0 12 O
of IN 0 0 12 O
ketoconazole NN 0 1 16 B-Drug
but CC 0 0 12 O
to TO 0 0 12 O
a DT 0 0 12 O
lesser JJR 1 1 1 O
extent NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
clinical JJ 0 1 6 O
relevance NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
potential JJ 0 1 1 O
effect NN 0 1 1 O
of IN 0 0 12 O
grepafloxacin NN 0 1 UNK B-Drug
on IN 0 0 12 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
C.P.A NNP 0 0 UNK O
. . 0 0 12 O
substrates NNS 1 1 UNK O
is VBZ 1 0 12 O
not RB 0 1 12 O
known VBN 1 1 12 O
. . 0 0 12 O

A DT 0 0 2 O
similar JJ 0 1 1 O
association NN 0 1 1 O
though IN 0 0 12 O
less JJR 0 1 12 O
marked VBN 1 1 1 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
suggested VBN 1 1 12 O
with IN 0 0 12 O
barbiturates NNS 1 1 14 B-Group
phenylbutazone VBP 0 1 UNK B-Drug
phenytoin JJ 0 1 16 B-Drug
sodium NN 0 1 14 I-Drug
carbamazepine NN 0 1 16 B-Drug
griseofulvin NN 0 1 UNK B-Drug
topiramate NN 0 1 16 B-Drug
and CC 0 0 12 O
possibly RB 0 1 12 O
with IN 0 0 12 O
ampicillin NN 0 1 0 B-Drug
and CC 0 0 12 O
tetracyclines NNS 1 1 13 B-Group
9 CD 0 0 2 O
. . 0 0 12 O

During IN 0 0 2 O
transfer NN 0 1 1 O
to TO 0 0 12 O
oral VB 0 1 6 O
amiodarone CD 0 1 0 B-Drug
the DT 0 0 12 O
dose NN 0 1 6 O
levels NNS 1 1 1 O
of IN 0 0 12 O
previously RB 0 0 1 O
administered VBN 1 1 1 O
agents NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
reduced VBN 1 1 1 O
by IN 0 0 12 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
several JJ 0 1 12 O
days NNS 1 1 12 O
after IN 0 0 12 O
the DT 0 0 12 O
addition NN 0 1 1 O
of IN 0 0 12 O
oral JJ 0 1 6 O
amiodarone NN 0 1 0 B-Drug
. . 0 0 12 O

Effects NNS 0 1 UNK O
of IN 0 0 12 O
Other JJ 0 0 2 O
Drugs NNP 0 1 2 O
on IN 0 0 12 O
Aliskiren NNP 0 1 UNK B-Drug
Based VBD 0 1 2 O
on IN 0 0 12 O
in IN 0 0 12 O
- : 0 0 2 O
vitro NN 0 1 UNK O
studies NNS 1 1 1 O
aliskiren VBP 0 1 13 B-Drug
is VBZ 1 0 12 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
CYP NNP 0 1 UNK O
9A9 CD 0 0 UNK O
. . 0 0 12 O

WARFARIN NN 0 1 UNK B-Drug
: : 0 0 2 O
Co NNP 0 1 2 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
and CC 0 0 12 O
cerivastatin NN 0 1 UNK B-Drug
to TO 0 0 12 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
did VBD 1 0 12 O
not RB 0 1 12 O
result VB 0 1 1 O
in IN 0 0 12 O
any DT 0 0 12 O
changes NNS 1 1 1 O
in IN 0 0 12 O
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
or CC 0 0 12 O
clotting VBG 1 1 14 O
factor NN 0 1 1 O
VII NNP 0 1 2 O
when WRB 0 0 12 O
compared VBN 1 1 1 O
to TO 0 0 12 O
co VB 0 1 12 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
and CC 0 0 12 O
placebo NN 0 1 13 O
. . 0 0 12 O

Therefore RB 0 0 1 O
when WRB 0 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
pantoprazole JJ 0 1 16 B-Drug
adjustment NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
dosage NN 0 1 0 O
of IN 0 0 12 O
pantoprazole NN 0 1 16 B-Drug
or CC 0 0 12 O
of IN 0 0 12 O
such JJ 0 0 1 O
drugs NNS 1 1 6 O
may MD 0 0 1 O
not RB 0 1 12 O
be VB 0 0 12 O
necessary JJ 0 0 1 O
. . 0 0 12 O

Noncardioselective JJ 0 0 UNK B-Group
beta NN 0 1 16 I-Group
- : 0 0 2 O
blockers NNS 1 0 6 I-Group
( ( 0 0 2 O
nadolol JJ 0 1 0 B-Drug
porpranolol NN 0 0 UNK O
timolol NN 0 1 16 B-Drug
) ) 0 0 2 O
may MD 0 0 1 O
exacerbate VB 0 1 UNK O
rebound NN 0 0 3 O
hypertension NN 0 1 6 O
when WRB 0 0 12 O
guanfacine NN 0 1 13 B-Drug
is VBZ 1 0 12 O
withdrawn VBN 1 1 1 O
. . 0 0 12 O

Single NNP 0 1 2 O
dose VBD 0 1 6 O
pharmacokinetic JJ 0 1 UNK O
studies NNS 1 1 1 O
demonstrated VBD 1 0 1 O
that IN 0 0 12 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
rivastigmine NN 0 1 16 B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
significantly RB 0 0 1 O
affected VBN 1 1 1 O
by IN 0 0 12 O
concurrent JJ 0 1 1 O
administration NN 0 1 1 O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
warfarin NN 0 1 14 B-Drug
diazepam NN 0 1 0 B-Drug
or CC 0 0 12 O
fluoxetine NN 0 1 16 B-Drug
. . 0 0 12 O

No DT 0 0 2 O
Information NNP 0 1 2 O
Provided VBD 0 1 2 O

Phenytoin NNP 0 1 0 B-Drug
is VBZ 1 0 12 O
extensively RB 0 0 1 O
bound VBN 1 1 12 O
to TO 0 0 12 O
serum VB 0 1 14 O
plasma JJ 0 1 14 O
proteins NNS 1 1 14 O
and CC 0 0 12 O
is VBZ 1 0 12 O
prone JJ 0 1 13 O
to TO 0 0 12 O
competitive JJ 0 1 UNK O
displacement NN 0 1 1 O
. . 0 0 12 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interactions VBZ 0 1 UNK O
A NNP 0 0 2 O
false JJ 0 1 13 O
- : 0 0 2 O
positive JJ 0 1 1 O
reaction NN 0 1 1 O
for IN 0 0 12 O
ketones NNS 1 1 14 O
in IN 0 0 12 O
the DT 0 0 12 O
urine NN 0 1 6 O
may MD 0 0 1 O
occur VB 0 1 1 O
with IN 0 0 12 O
tests NNS 1 1 1 O
using VBG 1 1 1 O
nitroprusside RB 0 1 14 B-Drug
but CC 0 0 12 O
not RB 0 1 12 O
with IN 0 0 12 O
those DT 0 0 12 O
using VBG 1 1 1 O
nitroferricyanide RB 0 1 UNK B-Drug
. . 0 0 12 O

Phenobarbital NNP 0 1 0 B-Drug
which WDT 0 0 12 O
induces VBZ 1 1 UNK O
hepatic JJ 0 1 14 O
metabolism NN 0 1 16 O
decreased VBD 1 1 1 O
the DT 0 0 12 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
montelukast NN 0 1 16 B-Drug
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
following VBG 1 1 1 O
a DT 0 0 12 O
single JJ 0 1 12 O
9 CD 0 0 2 O
- : 0 0 2 O
mg NN 0 1 0 O
dose NN 0 1 6 O
of IN 0 0 12 O
montelukast NN 0 1 16 B-Drug
. . 0 0 12 O

Sumatriptan NNP 0 1 UNK B-Drug
and CC 0 0 12 O
D.H.E NNP 0 1 UNK B-Brand
9 CD 0 0 2 I-Brand
( ( 0 0 2 O
dihydroergotamine JJ 0 1 UNK B-Drug
mesylate NN 0 1 16 I-Drug
) ) 0 0 2 O
Injection NNP 0 1 7 O
USP NNP 0 1 UNK O
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
taken VBN 1 1 12 O
within IN 0 0 1 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
of IN 0 0 12 O
each DT 0 0 12 O
other JJ 0 0 12 O
. . 0 0 12 O

Patients NNS 0 1 7 O
who WP 0 0 12 O
are VBP 1 0 12 O
receiving VBG 1 1 1 O
CYLERT NNP 0 1 UNK B-Brand
concurrently RB 0 0 1 O
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
especially RB 0 0 12 O
drugs NNS 1 1 6 O
with IN 0 0 12 O
CNS NNP 0 1 6 O
activity NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
carefully RB 0 0 12 O
. . 0 0 12 O

Drug NN 0 1 2 O
/ NNS 0 0 2 O
Food NNP 0 1 2 O
Interactions NNPS 0 1 UNK O
The DT 0 0 2 O
bioavailability NN 0 1 UNK O
( ( 0 0 2 O
AUC NNP 0 1 UNK O
) ) 0 0 2 O
of IN 0 0 12 O
deferasirox NN 0 1 13 B-Drug
was VBD 1 0 12 O
variably RB 0 0 UNK O
increased VBN 1 1 1 O
when WRB 0 0 12 O
taken VBN 1 1 12 O
with IN 0 0 12 O
a DT 0 0 12 O
meal NN 0 1 12 O
. . 0 0 12 O

Cevimeline NN 0 1 UNK B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
caution NN 0 0 1 O
to TO 0 0 12 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
beta JJ 0 1 16 B-Group
adrenergic JJ 0 1 UNK I-Group
antagonists NNS 1 1 13 I-Group
because IN 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
possibility NN 0 1 1 O
of IN 0 0 12 O
conduction NN 0 1 6 O
disturbances NNS 1 1 6 O
. . 0 0 12 O

Intravenous JJ 0 1 7 O
ranitidine NN 0 1 0 B-Drug
was VBD 1 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
double VB 0 1 3 O
the DT 0 0 12 O
bioavailability NN 0 1 UNK O
of IN 0 0 12 O
oral JJ 0 1 6 O
alendronate NN 0 1 16 B-Drug
. . 0 0 12 O

ethacrynic JJ 0 0 16 B-Drug
acid NN 0 1 14 I-Drug
; : 0 0 2 O

The DT 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
guanfacine NN 0 1 13 B-Drug
concomitantly RB 0 0 14 O
with IN 0 0 12 O
known VBN 1 1 12 O
microsomal JJ 0 1 UNK O
enzyme NN 0 1 14 O
inducer NN 0 1 UNK O
( ( 0 0 2 O
phenobarbital JJ 0 1 16 B-Drug
or CC 0 0 12 O
phenytoin NN 0 1 16 B-Drug
) ) 0 0 2 O
to TO 0 0 12 O
two CD 0 1 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
renal JJ 0 1 6 O
impairment NN 0 1 16 O
reportedly RB 0 0 12 O
resulted VBD 1 1 1 O
in IN 0 0 12 O
significant JJ 0 1 1 O
reductions NNS 1 1 1 O
in IN 0 0 12 O
elimination NN 0 1 UNK O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
and CC 0 0 12 O
plasma JJ 0 1 14 O
concentration NN 0 1 1 O
. . 0 0 12 O

When WRB 0 0 12 O
paroxetine NN 0 1 16 B-Drug
a DT 0 0 12 O
potent JJ 0 1 UNK O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
CYP9D9 NNP 0 0 UNK O
was VBD 1 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
with IN 0 0 12 O
BROVANA NNP 0 1 UNK B-Brand
at IN 0 0 12 O
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
exposure NN 0 1 1 O
to TO 0 0 12 O
either DT 0 1 12 O
drug NN 0 1 1 O
was VBD 1 0 12 O
not RB 0 1 12 O
altered VBN 1 1 1 O
. . 0 0 12 O

Hyperglycemia NNP 0 1 7 O
has VBZ 1 0 12 O
also RB 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
CAMPTOSAR NNP 0 1 UNK B-Brand
. . 0 0 12 O

Although IN 0 0 12 O
no DT 0 0 12 O
interaction NN 0 1 UNK O
between IN 0 0 12 O
MAO NNP 0 1 14 B-Group
inhibitors NNS 1 1 14 I-Group
and CC 0 0 12 O
Levo NNP 0 1 15 B-Brand
- : 0 0 2 O
Dromoran NN 0 0 UNK I-Brand
has VBZ 1 0 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
not RB 0 1 12 O
recommended VBN 1 1 1 O
for IN 0 0 12 O
use NN 0 1 1 O
with IN 0 0 12 O
MAO NNP 0 1 14 B-Group
inhibitors NNS 1 1 14 I-Group
. . 0 0 12 O

During IN 0 0 2 O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
hypoglycemia NN 0 1 6 O
and CC 0 0 12 O
hyperglycemia NN 0 1 14 O
were VBD 1 0 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
diabetic JJ 0 1 6 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
oral JJ 0 1 6 O
hypoglycemics NNS 0 1 14 B-Group
. . 0 0 12 O

- : 0 0 2 O
Digoxin NN 0 1 0 B-Drug
: : 0 0 2 O
Interaction NN 0 1 2 O
studies NNS 1 1 1 O
in IN 0 0 12 O
humans NNS 1 1 UNK O
have VBP 0 0 12 O
shown VBN 1 1 1 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
blood NN 0 1 6 O
levels NNS 1 1 1 O
. . 0 0 12 O

However RB 0 0 1 O
there EX 0 0 12 O
are VBP 1 0 12 O
limited VBN 1 1 1 O
in IN 0 0 12 O
vivo NN 0 1 13 O
data NNS 0 1 1 O
suggesting VBG 1 1 1 O
a DT 0 0 12 O
modest JJ 0 1 1 O
CYP9D9 NNP 0 0 UNK O
inhibitory NN 0 1 UNK O
effect NN 0 1 1 O
for IN 0 0 12 O
escitalopram NN 0 1 0 B-Drug
i.e. JJ 0 1 1 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
escitalopram NN 0 1 0 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
) ) 0 0 2 O
with IN 0 0 12 O
the DT 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressant JJ 0 1 6 I-Group
desipramine NN 0 1 16 B-Drug
( ( 0 0 2 O
single JJ 0 1 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
) ) 0 0 2 O
a DT 0 0 12 O
substrate NN 0 1 UNK O
for IN 0 0 12 O
CYP9D9 NNP 0 0 UNK O
resulted VBD 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
increase NN 0 1 1 O
in IN 0 0 12 O
Cmax NNP 0 1 UNK O
and CC 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
increase NN 0 1 1 O
in IN 0 0 12 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
desipramine NN 0 1 16 B-Drug
. . 0 0 12 O

In IN 0 0 2 O
those DT 0 0 12 O
patients NNS 1 1 6 O
in IN 0 0 12 O
whom WP 0 0 12 O
renal JJ 0 1 6 O
insufficiency NN 0 1 6 O
was VBD 1 0 12 O
documented VBN 1 1 1 O
however RB 0 0 12 O
the DT 0 0 12 O
recommendation NN 0 1 1 O
to TO 0 0 12 O
lower VB 0 1 1 O
the DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
allopurinol NN 0 1 13 B-Drug
was VBD 1 0 12 O
not RB 0 1 12 O
followed VBN 1 1 12 O
. . 0 0 12 O

( ( 0 0 2 O
Effects NNS 0 1 UNK O
may MD 0 0 1 O
be VB 0 0 12 O
decreased VBN 1 1 1 O
when WRB 0 0 12 O
used VBN 1 1 12 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
thiazide JJ 0 1 UNK B-Group
diuretics NNS 1 1 14 I-Group
; : 0 0 2 O

ALLEGRA NNP 0 1 UNK B-Brand
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
taken VBN 1 1 12 O
closely RB 0 0 1 O
in IN 0 0 12 O
time NN 0 1 12 O
with IN 0 0 12 O
aluminum NN 0 1 16 B-Drug
and CC 0 0 12 O
magnesium NN 0 1 14 B-Drug
containing NN 0 1 1 O
antacids NNS 1 1 14 B-Group
. . 0 0 12 O

The DT 0 0 2 O
AUC NNP 0 1 UNK O
and CC 0 0 12 O
Cmax NNP 0 1 UNK O
of IN 0 0 12 O
both CC 0 0 12 O
the DT 0 0 12 O
R NNP 0 1 2 O
and CC 0 0 12 O
S NNP 0 1 2 O
isomers NNS 1 1 UNK O
of IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
were VBD 1 0 12 O
unaffected VBN 0 1 UNK O
by IN 0 0 12 O
concurrent JJ 0 1 1 O
dosing NN 0 0 14 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
cerivastatin NN 0 1 UNK B-Drug
sodium NN 0 1 14 I-Drug
. . 0 0 12 O

Resins NNS 0 1 UNK B-Group
: : 0 0 2 O
Since IN 0 1 2 O
bile NN 0 1 6 B-Group
acid IN 0 1 14 I-Group
sequestrants NNS 0 0 UNK I-Group
may MD 0 0 1 O
bind VB 0 1 UNK O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
given VBN 1 1 12 O
concurrently RB 0 0 1 O
patients NNS 1 1 6 O
should MD 0 0 12 O
take VB 0 1 12 O
TRICOR NNP 0 1 UNK B-Brand
at IN 0 0 12 O
least JJS 0 1 12 O
9 CD 0 0 2 O
hour NN 0 1 12 O
before IN 0 1 12 O
or CC 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
after IN 0 0 12 O
a DT 0 0 12 O
bile JJ 0 1 6 B-Group
acid NN 0 1 14 I-Group
binding VBG 1 1 1 I-Group
resin NN 0 1 UNK I-Group
to TO 0 0 12 O
avoid VB 0 0 12 O
impeding VBG 1 0 UNK O
its PRP$ 1 0 12 O
absorption NN 0 1 1 O
. . 0 0 12 O

Healthcare NNP 0 1 2 O
prescribers NNS 0 0 UNK O
are VBP 1 0 12 O
advised VBN 1 0 12 O
to TO 0 0 12 O
consult VB 0 1 1 O
the DT 0 0 12 O
package NN 0 1 13 O
inserts NNS 1 1 UNK O
of IN 0 0 12 O
medication NN 0 1 6 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
oral JJ 0 1 6 O
contraceptives NNS 1 1 13 B-Group
. . 0 0 12 O

This DT 0 0 2 O
interaction NN 0 1 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
given VBN 1 1 12 O
consideration NN 0 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
VIOXX NNP 0 1 UNK B-Brand
concomitantly RB 0 0 14 O
with IN 0 0 12 O
ACE NNP 0 1 13 B-Group
inhibitors NNS 1 1 14 I-Group
. . 0 0 12 O

FLEXERIL NN 0 1 0 B-Brand
may MD 0 0 1 O
have VB 0 0 12 O
life NN 0 1 12 O
- : 0 0 2 O
threatening JJ 0 0 12 O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
MAO NNP 0 1 14 B-Group
inhibitors NNS 1 1 14 I-Group
. . 0 0 12 O

Concomitant NNP 0 1 UNK O
use NN 0 1 1 O
of IN 0 0 12 O
antihistamines NNS 1 1 UNK B-Group
with IN 0 0 12 O
alcohol NN 0 1 1 B-Drug
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
barbiturates NNS 1 1 14 B-Group
or CC 0 0 12 O
other JJ 0 0 12 O
central JJ 0 1 1 B-Group
nervous JJ 0 1 6 I-Group
system NN 0 1 1 I-Group
depressants NNS 1 0 13 I-Group
may MD 0 0 1 O
have VB 0 0 12 O
an DT 0 0 12 O
additive JJ 0 1 16 O
effect NN 0 1 1 O
. . 0 0 12 O

Antiepileptic JJ 0 1 UNK B-Group
Drugs NNS 0 1 2 I-Group
: : 0 0 2 O
Sporadic JJ 0 1 UNK O
cases NNS 1 1 UNK O
of IN 0 0 12 O
seizures NNS 1 1 6 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
during IN 0 0 12 O
concomitant JJ 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
TORADOL NNP 0 1 UNK B-Brand
and CC 0 0 12 O
antiepileptic JJ 0 1 UNK B-Group
drugs NNS 1 1 6 I-Group
( ( 0 0 2 O
phenytoin VB 0 1 16 B-Drug
carbamazepine NN 0 1 16 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

Atovaquone NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
highly RB 0 1 1 O
bound VBN 1 1 12 O
to TO 0 0 12 O
plasma VB 0 1 14 O
protein NN 0 1 14 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
. . 0 0 12 O

While IN 0 0 12 O
no DT 0 0 12 O
clinical JJ 0 1 6 O
studies NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
conducted VBN 1 1 1 O
to TO 0 0 12 O
evaluate VB 0 1 1 O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
grepafloxacin NN 0 1 UNK B-Drug
on IN 0 0 12 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
C.P.A NNP 0 0 UNK O
. . 0 0 12 O

Substances NNS 0 1 UNK O
that WDT 0 0 12 O
are VBP 1 0 12 O
inducers NNS 1 1 UNK O
of IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
activity NN 0 1 1 O
increase NN 0 1 1 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
gefitinib NN 0 1 UNK B-Drug
and CC 0 0 12 O
decrease VB 0 1 1 O
its PRP$ 1 0 12 O
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
. . 0 0 12 O

In IN 0 0 2 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
were VBD 1 0 12 O
conducted VBN 1 1 1 O
to TO 0 0 12 O
investigate VB 0 1 1 O
the DT 0 0 12 O
potential NN 0 1 1 O
of IN 0 0 12 O
gabapentin NN 0 1 0 B-Drug
to TO 0 0 12 O
inhibit VB 0 1 13 O
the DT 0 0 12 O
major JJ 0 1 1 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
enzymes VBZ 0 1 14 O
( ( 0 0 2 O
CYP9A9 NNP 0 0 UNK O
CYP9A9 NNP 0 0 UNK O
CYP9C9 NNP 0 0 UNK O
CYP9C9 NNP 0 0 UNK O
CYP9D9 NNP 0 0 UNK O
CYP9E9 NNP 0 0 UNK O
and CC 0 0 12 O
CYP9A9 NNP 0 0 UNK O
) ) 0 0 2 O
that WDT 0 0 12 O
mediate VBP 0 1 UNK O
drug NN 0 1 1 O
and CC 0 0 12 O
xenobiotic JJ 0 1 UNK O
metabolism NN 0 1 16 O
using VBG 1 1 1 O
isoform JJ 0 1 UNK O
selective JJ 0 1 13 O
marker NN 0 1 13 O
substrates NNS 1 1 UNK O
and CC 0 0 12 O
human JJ 0 1 1 O
liver NN 0 1 6 O
microsomal JJ 0 1 UNK O
preparations NNS 1 1 13 O
. . 0 0 12 O

A DT 0 0 2 O
possible JJ 0 1 1 O
interaction NN 0 1 UNK O
between IN 0 0 12 O
glyburide NN 0 1 16 B-Drug
and CC 0 0 12 O
ciprofloxacin VB 0 1 0 B-Drug
a DT 0 0 12 O
fluoroquinolone NN 0 1 UNK B-Group
antibiotic NN 0 1 6 I-Group
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
resulting VBG 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
potentiation NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
hypoglycemic JJ 0 1 14 O
action NN 0 1 13 O
of IN 0 0 12 O
glyburide NN 0 1 16 B-Drug
. . 0 0 12 O

Antibiotics NNS 0 1 7 B-Group
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
erythromycin NN 0 1 0 B-Drug
trimethoprim NN 0 1 16 B-Drug
and CC 0 0 12 O
sulfamethoxazole JJ 0 1 13 B-Drug
amoxicillin NN 0 1 0 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

The DT 0 0 2 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
Exjade NNP 0 1 UNK B-Brand
and CC 0 0 12 O
vitamin NNP 0 1 6 B-Drug
C NNP 0 0 2 I-Drug
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
formally RB 0 0 1 O
studied VBN 1 0 1 O
. . 0 0 12 O

The DT 0 0 2 O
induction NN 0 1 1 O
dose NN 0 1 6 O
requirements NNS 1 1 1 O
of IN 0 0 12 O
DIPRIVAN NNP 0 1 UNK B-Brand
Injectable NNP 0 1 UNK O
Emulsion NNP 0 1 UNK O
may MD 0 0 1 O
be VB 0 0 12 O
reduced VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
intramuscular JJ 0 1 14 O
or CC 0 0 12 O
intravenous JJ 0 1 14 O
premedication NN 0 1 UNK O
particularly RB 0 0 1 O
with IN 0 0 12 O
narcotics NNS 1 1 1 B-Group
( ( 0 0 2 O
eg JJ 0 1 UNK O
morphine NN 0 1 14 B-Drug
meperidine NN 0 1 16 B-Drug
and CC 0 0 12 O
fentanyl JJ 0 1 14 B-Drug
etc NN 0 1 12 O
. . 0 0 12 O
) ) 0 0 2 O

Hematology NN 0 1 7 O
: : 0 0 2 O
TAXOL NNP 0 1 UNK B-Brand
therapy NN 0 1 6 O
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
to TO 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
baseline JJ 0 1 1 O
neutrophil JJ 0 1 14 O
counts NNS 1 1 1 O
of IN 0 0 12 O
less JJR 0 1 12 O
than IN 0 0 12 O
9 CD 0 0 2 O
9 CD 0 0 2 O
cells NNS 1 1 6 O
/ JJ 0 0 2 O
mm9 NN 0 0 UNK O
. . 0 0 12 O

Studies NNS 0 1 2 O
in IN 0 0 12 O
humans NNS 1 1 UNK O
show VBP 0 1 12 O
that IN 0 0 12 O
the DT 0 0 12 O
absorption NN 0 1 1 O
of IN 0 0 12 O
chlorothiazide NN 0 1 16 B-Drug
as IN 1 0 12 O
reflected VBN 1 1 UNK O
in IN 0 0 12 O
urinary JJ 0 1 6 O
excretion NN 0 1 14 O
is VBZ 1 0 12 O
markedly RB 0 1 1 O
decreased VBN 1 1 1 O
even RB 0 0 12 O
when WRB 0 0 12 O
administered VBD 1 1 1 O
one CD 0 1 12 O
hour NN 0 1 12 O
before IN 0 1 12 O
colestipol JJ 0 1 13 B-Drug
hydrochloride NN 0 1 0 I-Drug
. . 0 0 12 O

Concurrent JJ 0 1 13 O
administration NN 0 1 1 O
of IN 0 0 12 O
low JJ 0 1 1 O
- : 0 0 2 O
dose NN 0 1 6 O
dopamine NN 0 1 14 B-Drug
HCl NNP 0 0 14 I-Drug
and CC 0 0 12 O
diuretic JJ 0 1 14 B-Group
agents NNS 1 1 1 I-Group
may MD 0 0 1 O
produce VB 0 0 1 O
an DT 0 0 12 O
additive JJ 0 1 16 O
or CC 0 0 12 O
potentiating VBG 1 0 UNK O
effect NN 0 1 1 O
on IN 0 0 12 O
urine JJ 0 1 6 O
flow NN 0 1 1 O
. . 0 0 12 O

Increased VBN 0 1 7 O
anticoagulation NN 0 1 14 O
effects NNS 1 1 1 O
due JJ 0 1 1 O
to TO 0 0 12 O
a DT 0 0 12 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
with IN 0 0 12 O
erythromycin NN 0 1 0 B-Drug
may MD 0 0 1 O
be VB 0 0 12 O
more JJR 0 1 12 O
pronounced JJ 0 0 12 O
in IN 0 0 12 O
the DT 0 0 12 O
elderly JJ 0 1 12 O
. . 0 0 12 O

Quinolones NNS 0 1 UNK B-Group
form NN 0 1 1 O
chelates VBZ 1 1 UNK O
with IN 0 0 12 O
alkaline JJ 0 1 14 O
earth NN 0 1 13 O
and CC 0 0 12 O
transition NN 0 1 1 O
metals NNS 1 1 13 O
. . 0 0 12 O

In IN 0 0 2 O
the DT 0 0 12 O
same JJ 0 1 12 O
study NN 0 1 1 O
it PRP 0 0 12 O
was VBD 1 0 12 O
shown VBN 1 1 1 O
that IN 0 0 12 O
didanosine NN 0 1 16 B-Drug
and CC 0 0 12 O
stavudine NN 0 1 13 B-Drug
had VBD 1 0 12 O
no DT 0 0 12 O
significant JJ 0 1 1 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
intracellular JJ 0 1 UNK O
phosphorylation NN 0 1 UNK O
of IN 0 0 12 O
zalcitabine NN 0 1 UNK B-Drug
in IN 0 0 12 O
peripheral JJ 0 1 6 O
blood NN 0 1 6 O
mononuclear NN 0 1 14 O
cells NNS 1 1 6 O
. . 0 0 12 O

Impaired NNP 0 1 UNK O
renal JJ 0 1 6 O
function NN 0 1 1 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
described VBN 1 1 1 O
in IN 0 0 12 O
bone NN 0 1 6 O
marrow NN 0 1 6 O
transplant NN 0 1 6 O
patients NNS 1 1 6 O
who WP 0 0 12 O
were VBD 1 0 12 O
conditioned VBN 1 1 UNK O
with IN 0 0 12 O
high JJ 0 1 1 O
- : 0 0 2 O
dose RB 0 1 6 O
intravenous JJ 0 1 14 O
melphalan NN 0 1 13 B-Drug
and CC 0 0 12 O
who WP 0 0 12 O
subsequently RB 0 0 1 O
received VBD 1 1 12 O
cyclosporin NN 0 1 14 B-Drug
to TO 0 0 12 O
prevent VB 0 1 1 O
graft NN 0 1 6 O
- : 0 0 2 O
versus NN 0 0 1 O
- : 0 0 2 O
host NN 0 1 12 O
disease NN 0 1 6 O

Platelet NN 0 1 7 B-Group
inhibitors NNS 1 1 14 I-Group
: : 0 0 2 O
Drugs NNS 0 1 2 O
such JJ 0 0 1 O
as IN 1 0 12 O
acetylsalicylic JJ 0 0 UNK B-Drug
acid NN 0 1 14 I-Drug
dextran NN 0 1 14 B-Drug
phenylbutazone NN 0 1 UNK B-Drug
ibuprofen NN 0 1 0 B-Drug
indomethacin JJ 0 1 14 B-Drug
dipyridamole JJ 0 1 0 B-Drug
hydroxychloroquine NN 0 1 16 B-Drug
and CC 0 0 12 O
others NNS 0 1 12 O
that WDT 0 0 12 O
interfere VBP 0 1 UNK O
with IN 0 0 12 O
platelet NN 0 1 14 O
- : 0 0 2 O
aggregation NN 0 1 UNK O
reactions NNS 1 1 1 O
( ( 0 0 2 O
the DT 0 0 12 O
main JJ 0 1 12 O
hemostatic JJ 0 1 14 O
defense NN 0 1 UNK O
of IN 0 0 12 O
heparinized JJ 0 0 UNK O
patients NNS 1 1 6 O
) ) 0 0 2 O
may MD 0 0 1 O
induce VB 0 1 6 O
bleeding VBG 1 1 6 O
and CC 0 0 12 O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
with IN 0 0 12 O
caution NN 0 0 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
heparin JJ 0 1 14 B-Drug
sodium NN 0 1 14 I-Drug
. . 0 0 12 O

Although IN 0 0 12 O
the DT 0 0 12 O
clinical JJ 0 1 6 O
significance NN 0 1 13 O
is VBZ 1 0 12 O
not RB 0 1 12 O
known VBN 1 1 12 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
not RB 0 1 12 O
recommended VBN 1 1 1 O
that IN 0 0 12 O
cefditoren NN 0 1 UNK B-Drug
pivoxil NN 0 0 UNK I-Drug
be VB 0 0 12 O
taken VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
H9 NNP 0 0 UNK B-Group
receptor NN 0 1 14 I-Group
antagonists NNS 1 1 13 I-Group
. . 0 0 12 O

Use NNP 0 1 2 O
lowest JJS 1 1 13 O
possible JJ 0 1 1 O
dose NN 0 1 6 O
of IN 0 0 12 O
atorvastatin NN 0 1 0 B-Drug
with IN 0 0 12 O
careful JJ 0 1 12 O
monitoring NN 0 1 1 O
or CC 0 0 12 O
consider VB 0 1 12 O
HMG NNP 0 0 UNK B-Group
- : 0 0 2 O
CoA NNP 0 0 UNK I-Group
reductase NN 0 1 UNK I-Group
inhibitors NNS 1 1 14 I-Group
that WDT 0 0 12 O
are VBP 1 0 12 O
not RB 0 1 12 O
primarily RB 0 0 1 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
such JJ 0 0 1 O
as IN 1 0 12 O
pravastatin NN 0 1 16 B-Drug
fluvastatin NN 0 1 13 B-Drug
or CC 0 0 12 O
rosuvastatin NN 0 1 16 B-Drug
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
CRIXIVAN NNP 0 1 UNK B-Brand
. . 0 0 12 O

There EX 0 0 12 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
little JJ 0 1 12 O
experience NN 0 1 12 O
with IN 0 0 12 O
the DT 0 0 12 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
TAMBOCOR NNP 0 1 UNK B-Brand
and CC 0 0 12 O
either DT 0 1 12 O
disopyramide NN 0 1 16 B-Drug
or CC 0 0 12 O
verapamil NN 0 1 0 B-Drug
. . 0 0 12 O

Protein NNP 0 1 2 O
Binding NNP 0 1 UNK O
: : 0 0 2 O
Entacapone NN 0 1 0 B-Drug
is VBZ 1 0 12 O
highly RB 0 1 1 O
protein JJ 0 1 14 O
bound NN 0 1 12 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
. . 0 0 12 O

There EX 0 0 12 O
is VBZ 1 0 12 O
one CD 0 1 12 O
report NN 0 1 1 O
suggesting VBG 1 1 1 O
that IN 0 0 12 O
the DT 0 0 12 O
concomitant NN 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
trazodone NN 0 1 0 B-Drug
hydrochloride NN 0 1 0 I-Drug
( ( 0 0 2 O
Desyrel NNP 0 1 0 B-Brand
) ) 0 0 2 O
and CC 0 0 12 O
buspirone $ 0 1 16 B-Drug
HCl NNP 0 0 14 I-Drug
may MD 0 0 1 O
have VB 0 0 12 O
caused VBN 1 1 1 O
9 CD 0 0 2 O
- : 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
fold JJ 0 1 3 O
elevations NNS 1 1 1 O
on IN 0 0 12 O
SGPT NNP 0 0 14 O
( ( 0 0 2 O
ALT NNP 0 1 13 O
) ) 0 0 2 O
in IN 0 0 12 O
a DT 0 0 12 O
few JJ 0 1 12 O
patients NNS 1 1 6 O
. . 0 0 12 O

Tetracycline VB 0 1 0 B-Drug
a DT 0 0 12 O
bacteriostatic JJ 0 0 UNK B-Group
antibiotic NN 0 1 6 I-Group
may MD 0 0 1 O
antagonize VB 0 0 UNK O
the DT 0 0 12 O
bactercidal JJ 0 0 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
penicillin NN 0 1 14 B-Drug
and CC 0 0 12 O
concurrent NN 0 1 1 O
use NN 0 1 1 O
of IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
. . 0 0 12 O

Because IN 0 0 12 O
of IN 0 0 12 O
possible JJ 0 1 1 O
clinical JJ 0 1 6 O
significance NN 0 1 13 O
the DT 0 0 12 O
two CD 0 1 12 O
drugs NNS 1 1 6 O
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
concurrently RB 0 0 1 O
. . 0 0 12 O

Nicotine NN 0 1 7 B-Drug
: : 0 0 2 O
Nicotine NN 0 1 7 B-Drug
may MD 0 0 1 O
provoke VB 0 0 UNK O
vasoconstriction NN 0 1 UNK O
in IN 0 0 12 O
some DT 0 0 12 O
patients NNS 1 1 6 O
predisposing VBG 1 1 UNK O
to TO 0 0 12 O
a DT 0 0 12 O
greater JJR 1 1 1 O
ischemic JJ 0 1 6 O
response NN 0 1 1 O
to TO 0 0 12 O
ergot VB 0 1 UNK B-Drug
therapy NN 0 1 6 O
. . 0 0 12 O

XENICAL RB 0 1 UNK B-Brand
inhibited JJ 0 1 13 O
absorption NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
vitamin NN 0 1 6 B-Drug
E NNP 0 0 2 I-Drug
acetate NN 0 1 14 I-Drug
supplement NN 0 1 1 O
by IN 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

Probenecid NNP 0 1 UNK B-Drug
depresses VBZ 1 0 UNK O
tubular JJ 0 1 3 O
secretion NN 0 1 14 O
of IN 0 0 12 O
certain JJ 0 1 1 O
weak JJ 0 1 12 O
acids NNS 1 1 14 O
such JJ 0 0 1 O
as IN 1 0 12 O
PAH NNP 0 1 UNK B-Drug
. . 0 0 12 O

Desloratadine NNP 0 1 UNK B-Drug
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
Hydroxydesloratadine NN 0 0 UNK I-Drug_n

Drug NNP 0 1 2 O
- : 0 0 2 O
Drug NN 0 1 2 O
Interactions NNS 0 1 UNK O
: : 0 0 2 O
The DT 0 0 2 O
pharmacokinetic JJ 0 1 UNK O
and CC 0 0 12 O
pharmacodynamic JJ 0 1 UNK O
interactions NNS 1 1 UNK O
between IN 0 0 12 O
UROXATRAL NNP 0 1 UNK B-Brand
and CC 0 0 12 O
other JJ 0 0 12 O
alpha JJ 0 1 1 B-Group
- : 0 0 2 O
blockers NNS 1 0 6 I-Group
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
determined VBN 1 1 1 O
. . 0 0 12 O

Coadministration NN 0 1 UNK O
of IN 0 0 12 O
both DT 0 0 12 O
drugs NNS 1 1 6 O
should MD 0 0 12 O
proceed VB 0 0 1 O
with IN 0 0 12 O
caution NN 0 0 1 O
. . 0 0 12 O

Antipyrine NN 0 1 UNK B-Drug
: : 0 0 2 O
Because IN 0 0 12 O
atorvastatin NN 0 1 0 B-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
affect VB 0 1 1 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
antipyrine JJ 0 1 UNK B-Drug
interactions NNS 1 1 UNK O
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 B-Drug
metabolized VBN 1 1 UNK O
via IN 0 0 1 O
the DT 0 0 12 O
same JJ 0 1 12 O
cytochrome NN 0 1 UNK O
isozymes NNS 0 1 UNK O
are VBP 1 0 12 O
not RB 0 1 12 O
expected VBN 1 1 12 O
. . 0 0 12 O

If IN 0 0 12 O
leprosy JJ 0 1 13 O
- : 0 0 2 O
associated VBN 1 1 1 O
inflammatory JJ 0 1 6 O
reactions NNS 1 1 1 O
develop VBP 0 0 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
being VBG 1 0 12 O
treated VBN 1 1 1 O
with IN 0 0 12 O
dapsone NN 0 1 13 B-Drug
and CC 0 0 12 O
clofazimine NN 0 1 UNK B-Drug
it PRP 0 0 12 O
is VBZ 1 0 12 O
still RB 0 0 12 O
advisable JJ 0 0 UNK O
to TO 0 0 12 O
continue VB 0 1 12 O
treatment NN 0 1 6 O
with IN 0 0 12 O
both DT 0 0 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

Consider VB 0 1 2 O
additive JJ 0 1 16 O
sedative JJ 0 1 6 O
effects NNS 1 1 1 O
and CC 0 0 12 O
confusional JJ 0 1 13 O
states NNS 1 1 1 O
to TO 0 0 12 O
emerge VB 0 0 UNK O
if IN 0 0 12 O
chlorprothixene NN 0 1 UNK B-Drug
is VBZ 1 0 12 O
given VBN 1 1 12 O
with IN 0 0 12 O
benzodiazepines NNS 1 1 14 B-Group
or CC 0 0 12 O
barbituates NNS 0 0 UNK B-Group
. . 0 0 12 O

Coadministration NN 0 1 UNK O
of IN 0 0 12 O
valdecoxib NN 0 1 13 B-Drug
with IN 0 0 12 O
doses NNS 1 1 6 O
higher JJR 1 1 1 O
than IN 0 0 12 O
9 CD 0 0 2 O
mg JJ 0 1 0 O
QD NNP 0 1 13 O
omeprazole NN 0 1 0 B-Drug
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
studied VBN 1 0 1 O
. . 0 0 12 O

Nateglinide NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
highly RB 0 1 1 O
bound VBN 1 1 12 O
to TO 0 0 12 O
plasma VB 0 1 14 O
proteins NNS 1 1 14 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
mainly RB 0 0 1 O
albumin NN 0 1 14 O
. . 0 0 12 O

Warfarin NNP 0 1 0 B-Drug
- : 0 0 2 O
Vitamin NNP 0 1 2 B-Group
K NNP 0 1 2 I-Group
can MD 0 0 12 O
antagonize VB 0 0 UNK O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
warfarin NN 0 1 14 B-Drug

- : 0 0 2 O
Ethotoin NN 0 1 UNK B-Drug
( ( 0 0 2 O
e.g. VB 0 0 UNK O
Peganone NNP 0 1 UNK B-Brand
) ) 0 0 2 O
or CC 0 0 12 O

Cyclosporine NNP 0 1 UNK B-Drug
hexobarbital NN 0 1 UNK B-Drug
and CC 0 0 12 O
phenytoin NN 0 1 16 B-Drug
concentrations NNS 1 1 13 O
. . 0 0 12 O

Monoamine NNP 0 1 UNK B-Group
oxidase NN 0 1 13 I-Group
MAO NNP 0 1 14 I-Group
inhibitors NNS 1 1 14 I-Group
: : 0 0 2 O
See VB 0 1 2 O
CONTRAINDICATIONS NNP 0 1 0 O
. . 0 0 12 O

Coadministration NN 0 1 UNK O
of IN 0 0 12 O
amprenavir NN 0 1 13 B-Drug
and CC 0 0 12 O
methadone NN 0 1 6 B-Drug
as RB 0 0 12 O
compared VBN 1 1 1 O
to TO 0 0 12 O
a DT 0 0 12 O
non JJ 0 1 1 O
- : 0 0 2 O
matched VBN 1 1 1 O
historicalcontrol NN 0 0 UNK O
group NN 0 1 12 O
resulted VBD 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
decrease NN 0 1 1 O
in IN 0 0 12 O
serum NN 0 1 14 O
amprenavir NN 0 1 13 B-Drug
AUC NNP 0 1 UNK O
Cmax NNP 0 1 UNK O
andCmin VBZ 0 0 UNK O
respectively RB 0 0 1 O
. . 0 0 12 O

Flecainide NNP 0 1 0 B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
extensively RB 0 0 1 O
bound IN 0 1 12 O
to TO 0 0 12 O
plasma VB 0 1 14 O
proteins NNS 1 1 14 O
. . 0 0 12 O

and CC 0 0 12 O
calcium NN 0 1 14 B-Group
channel NN 0 1 1 I-Group
antagonists VBZ 0 1 13 I-Group
e.g. VBP 0 0 UNK O
verapamil NN 0 1 0 B-Drug
) ) 0 0 2 O
CYP9A9 NNP 0 0 UNK O
inducers NNS 1 1 UNK O
( ( 0 0 2 O
omeprazole NN 0 1 0 B-Drug
) ) 0 0 2 O
and CC 0 0 12 O
CYP9A9 NNP 0 0 UNK O
inhibitors NNS 1 1 14 O
( ( 0 0 2 O
furafylline NN 0 1 UNK B-Drug
and CC 0 0 12 O
clarithromycin NN 0 1 13 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

No DT 0 0 2 O
specific JJ 0 1 1 O
pharmacokinetic NN 0 1 UNK O
or CC 0 0 12 O
other JJ 0 0 12 O
formal JJ 0 1 1 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
were VBD 1 0 12 O
conducted VBN 1 1 1 O
. . 0 0 12 O

Drug NN 0 1 2 O
interactions NNS 1 1 UNK O
caused VBN 1 1 1 O
by IN 0 0 12 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
P NNP 0 1 2 O
- : 0 0 2 O
glycoprotein NN 0 1 UNK O
- : 0 0 2 O
mediated VBN 1 1 13 O
drug NN 0 1 1 O
clearance NN 0 1 16 O
or CC 0 0 12 O
CYP NNP 0 1 UNK O
- : 0 0 2 O
mediated VBN 1 1 13 O
drug NN 0 1 1 O
clearance NN 0 1 16 O
with IN 0 0 12 O
the DT 0 0 12 O
listed VBN 1 1 1 O
isoforms NNS 0 1 UNK O
are VBP 1 0 12 O
unlikely JJ 0 1 12 O
. . 0 0 12 O

Based VBN 0 1 2 O
on IN 0 0 12 O
total JJ 0 1 1 O
ertapenem JJ 0 1 16 B-Drug
concentrations NNS 1 1 13 O
probenecid VBP 0 1 13 B-Drug
increased VBD 1 1 1 O
the DT 0 0 12 O
AUC NNP 0 1 UNK O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
reduced VBD 1 1 1 O
the DT 0 0 12 O
plasma NN 0 1 14 O
and CC 0 0 12 O
renal JJ 0 1 6 O
clearances NNS 1 1 UNK O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
respectively RB 0 0 1 O
. . 0 0 12 O

There EX 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reports NNS 1 1 1 O
of IN 0 0 12 O
positive JJ 0 1 1 O
test NN 0 1 1 O
results NNS 1 1 1 O
using VBG 1 1 1 O
the DT 0 0 12 O
Bio NNP 0 1 UNK O
- : 0 0 2 O
Rad NNP 0 1 13 O
Laboratories NNPS 0 1 2 O
Platelia NNP 0 0 UNK O
Aspergillus NNP 0 1 UNK O
EIA NNP 0 1 13 O
test NN 0 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
piperacillin NN 0 1 16 B-Drug
/ NNP 0 0 2 O
tazobactam NN 0 1 13 B-Drug
injection NN 0 1 3 O
who WP 0 0 12 O
were VBD 1 0 12 O
subsequently RB 0 0 1 O
found VBN 1 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
free JJ 0 1 12 O
of IN 0 0 12 O
Aspergillus NNP 0 1 UNK O
infection NN 0 1 6 O
. . 0 0 12 O

However RB 0 0 1 O
in IN 0 0 12 O
a DT 0 0 12 O
well NN 0 1 12 O
- : 0 0 2 O
controlled VBN 1 1 1 O
study NN 0 1 1 O
of IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
lymphoma NN 0 1 6 O
on IN 0 0 12 O
combination NN 0 1 1 O
therapy NN 0 1 6 O
allopurinol NN 0 1 13 B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
marrow JJ 0 1 6 O
toxicity NN 0 1 6 O
of IN 0 0 12 O
patients NNS 1 1 6 O
treated VBN 1 1 1 O
with IN 0 0 12 O
cyclophosphamide JJ 0 1 14 B-Drug
doxorubicin NN 0 1 13 B-Drug
bleomycin NN 0 1 13 B-Drug
procarbazine NN 0 1 13 B-Drug
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
mechlorethamine NN 0 1 13 B-Drug
. . 0 0 12 O

Nephrotoxicity NN 0 1 UNK O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
following VBG 1 1 1 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
aminoglycoside JJ 0 1 14 B-Group
antibiotics NNS 1 1 6 I-Group
and CC 0 0 12 O
cephalosporin NN 0 1 13 B-Group
antibiotics NNS 1 1 6 I-Group
. . 0 0 12 O

Serious JJ 0 1 UNK O
toxicity NN 0 1 6 O
may MD 0 0 1 O
result VB 0 1 1 O
if IN 0 0 12 O
dextromethorphan NN 0 1 16 B-Drug
is VBZ 1 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
monoamine JJ 0 1 13 B-Group
oxidase NN 0 1 13 I-Group
inhibitors NNS 1 1 14 I-Group
( ( 0 0 2 O
MAOIs NNP 0 1 UNK B-Group
) ) 0 0 2 O
. . 0 0 12 O

Inhibits NNS 0 1 UNK O
CYP9A9 NNP 0 0 UNK O
( ( 0 0 2 O
weak JJ 0 1 12 O
) ) 0 0 2 O
9B9 CD 0 0 UNK O
( ( 0 0 2 O
weak JJ 0 1 12 O
) ) 0 0 2 O
9C9 CD 0 0 UNK O
( ( 0 0 2 O
weak JJ 0 1 12 O
) ) 0 0 2 O
9A9 CD 0 0 UNK O
( ( 0 0 2 O
weak JJ 0 1 12 O
) ) 0 0 2 O
. . 0 0 12 O

In IN 0 0 2 O
case NN 0 1 12 O
of IN 0 0 12 O
theophylline NN 0 1 16 B-Drug
toxicity NN 0 1 6 O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
elevated VBN 1 1 1 O
serum JJ 0 1 14 O
theophylline NN 0 1 16 B-Drug
levels NNS 1 1 1 O
the DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
theophylline NN 0 1 16 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
reduced VBN 1 1 1 O
while IN 0 0 12 O
the DT 0 0 12 O
patient NN 0 1 6 O
is VBZ 1 0 12 O
receiving VBG 1 1 1 O
concomitant JJ 0 1 6 O
erythromycin JJ 0 1 0 B-Drug
therapy NN 0 1 6 O
. . 0 0 12 O

Avoid NNP 0 0 2 O
dong JJ 0 0 UNK O
quai NN 0 0 UNK O
and CC 0 0 12 O
black JJ 0 1 3 O
cohosh NN 0 0 UNK O
( ( 0 0 2 O
have VBP 0 0 12 O
estrogen VBN 0 1 6 O
activity NN 0 1 1 O
) ) 0 0 2 O
. . 0 0 12 O

Other JJ 0 0 2 O
drugs NNS 1 1 6 O
that IN 0 0 12 O
increase NN 0 1 1 O
gastrointestinal JJ 0 1 6 O
motility NN 0 1 6 O
may MD 0 0 1 O
produce VB 0 0 1 O
similar JJ 0 1 1 O
effects NNS 1 1 1 O
. . 0 0 12 O

No DT 0 0 2 O
data NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
level NN 0 1 1 O
of IN 0 0 12 O
circulating VBG 1 1 13 O
catecholamines NNS 1 1 14 O
after IN 0 0 12 O
apraclonidine NN 0 1 16 B-Drug
withdrawal NN 0 1 1 O
are VBP 1 0 12 O
available JJ 0 1 1 O
. . 0 0 12 O

Although IN 0 0 12 O
no DT 0 0 12 O
clinical JJ 0 1 6 O
studies NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
conducted VBN 1 1 1 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
likely JJ 0 1 12 O
that IN 0 0 12 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
levobupivacaine NN 0 1 UNK B-Drug
may MD 0 0 1 O
be VB 0 0 12 O
affected VBN 1 1 1 O
by IN 0 0 12 O
the DT 0 0 12 O
known VBN 1 1 12 O
CYP9A9 NNP 0 0 UNK O
inducers NNS 1 1 UNK O
( ( 0 0 2 O
such JJ 0 0 1 O
as IN 1 0 12 O
phenytoin JJ 0 1 16 B-Drug
phenobarbital JJ 0 1 16 B-Drug
rifampin NN 0 1 16 B-Drug
) ) 0 0 2 O
CYP9A9 NNP 0 0 UNK O
inhibitors NNS 1 1 14 O
( ( 0 0 2 O
azole JJ 0 1 UNK O
antimycotics NNS 1 0 UNK O
e.g. JJ 0 0 UNK O
ketoconazole NN 0 1 16 B-Drug
; : 0 0 2 O

Tetracycline VB 0 1 0 B-Group
a DT 0 0 12 O
bacteriostatic JJ 0 0 UNK O
antibiotic NN 0 1 6 B-Group
may MD 0 0 1 O
antagonize VB 0 0 UNK O
the DT 0 0 12 O
bactericidal JJ 0 1 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
penicillin NN 0 1 14 B-Drug
and CC 0 0 12 O
concurrent NN 0 1 1 O
use NN 0 1 1 O
of IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
. . 0 0 12 O

Because IN 0 0 12 O
cholestyramine JJ 0 1 13 B-Drug
binds NNS 1 1 UNK O
bile JJ 0 1 6 O
acids NNS 1 1 14 O
cholestyramine VBP 0 1 13 B-Drug
resin NN 0 1 UNK B-Group
may MD 0 0 1 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
normal JJ 0 1 1 O
fat JJ 0 1 3 O
digestion NN 0 1 UNK O
and CC 0 0 12 O
absorption NN 0 1 1 O
and CC 0 0 12 O
thus RB 0 0 1 O
may MD 0 0 1 O
prevent VB 0 1 1 O
absorption NN 0 1 1 O
of IN 0 0 12 O
fat JJ 0 1 3 B-Group
soluble JJ 0 1 16 I-Group
vitamins NNS 1 1 6 I-Group
such JJ 0 0 1 O
as IN 1 0 12 O
A NNP 0 0 2 O
D NNP 0 1 2 O
E NNP 0 0 2 O
and CC 0 0 12 O
K NNP 0 1 2 O
. . 0 0 12 O

Drugs NNS 0 1 2 O
which WDT 0 0 12 O
inhibit VBP 0 1 13 O
CYP9D9 NNP 0 0 UNK O
and CC 0 0 12 O
CYP9A9 NNP 0 0 UNK O
/ NNP 0 0 2 O
9 CD 0 0 2 O
also RB 0 0 12 O
inhibit VBP 0 1 13 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
cevimeline NN 0 1 13 B-Drug
. . 0 0 12 O

No DT 0 0 2 O
dosage NN 0 1 0 O
adjustment NN 0 1 1 O
is VBZ 1 0 12 O
required VBN 1 1 1 O
for IN 0 0 12 O
Fluvoxamine NNP 0 1 UNK B-Drug
Tablets NNP 0 1 0 O
. . 0 0 12 O

Hypoglycemics NNS 0 1 UNK B-Group
and CC 0 0 12 O
endocrine JJ 0 1 6 O
drugs NNS 1 1 6 O
. . 0 0 12 O

use NN 0 1 1 O
potassium NN 0 1 14 B-Drug
supplements NNS 1 1 6 O
if IN 0 0 12 O
necessary JJ 0 0 1 O
. . 0 0 12 O

Infusion NN 0 1 UNK O
requirements NNS 1 1 1 O
of IN 0 0 12 O
NIMBEX NNP 0 1 UNK B-Brand
in IN 0 0 12 O
patients NNS 1 1 6 O
administered JJ 0 1 1 O
succinylcholine JJ 0 1 16 B-Drug
prior NN 0 1 1 O
to TO 0 0 12 O
infusions NNS 1 1 14 O
of IN 0 0 12 O
NIMBEX NNP 0 1 UNK B-Brand
were VBD 1 0 12 O
comparable JJ 0 0 1 O
to TO 0 0 12 O
or CC 0 0 12 O
slightly RB 0 1 3 O
greater JJR 1 1 1 O
than IN 0 0 12 O
when WRB 0 0 12 O
succinylcholine NN 0 1 16 B-Drug
was VBD 1 0 12 O
not RB 0 1 12 O
administered VBN 1 1 1 O
. . 0 0 12 O

- : 0 0 2 O
Procainamide NN 0 1 0 B-Drug
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
Pronestyl NNP 0 1 0 B-Brand
) ) 0 0 2 O
or CC 0 0 12 O

Lithium NNP 0 1 UNK B-Drug
- : 0 0 2 O
A DT 0 0 2 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
study NN 0 1 1 O
of IN 0 0 12 O
eplerenone NN 0 1 13 B-Drug
with IN 0 0 12 O
lithium NN 0 1 16 B-Drug
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
conducted VBN 1 1 1 O
. . 0 0 12 O

An DT 0 0 2 O
alternative JJ 0 1 1 O
non NN 0 1 1 O
- : 0 0 2 O
CYP9A9 NNP 0 0 UNK O
substrate VBP 0 1 UNK O
hypnotic JJ 0 1 13 B-Group
agent NN 0 1 1 I-Group
may MD 0 0 1 O
be VB 0 0 12 O
considered VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
CYP9A9 NNP 0 0 UNK O
inducers NNS 1 1 UNK O
such JJ 0 0 1 O
as IN 1 0 12 O
rifampin NN 0 1 16 B-Drug
phenytoin NN 0 1 16 B-Drug
carbamazepine NN 0 1 16 B-Drug
and CC 0 0 12 O
phenobarbital NN 0 1 16 B-Drug
. . 0 0 12 O

Binding VBG 0 1 UNK O
to TO 0 0 12 O
Serum NNP 0 1 7 O
Proteins NNP 0 1 UNK O
: : 0 0 2 O
The DT 0 0 2 O
following JJ 0 1 1 O
agents NNS 1 1 1 O
may MD 0 0 1 O
either VB 0 1 12 O
inhibit VB 0 1 13 O
levothyroxine JJ 0 1 0 B-Drug
sodium NN 0 1 14 I-Drug
binding NN 0 1 1 O
to TO 0 0 12 O
serum VB 0 1 14 O
proteins NNS 1 1 14 O
or CC 0 0 12 O
alter VB 0 1 13 O
the DT 0 0 12 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
serum NN 0 1 14 O
binding VBG 1 1 1 O
proteins NNS 1 1 14 O
: : 0 0 2 O
androgens NNS 1 1 13 B-Group
and CC 0 0 12 O
related JJ 0 1 1 O
anabolic JJ 0 1 13 B-Group
hormones NNS 1 1 13 I-Group
asparaginase NN 0 1 13 B-Drug
clofibrate NN 0 1 UNK B-Drug
estrogens NNS 1 1 16 B-Group
and CC 0 0 12 O
estrogen SYM 0 1 6 B-Group
- : 0 0 2 O
containing VBG 1 1 1 I-Group
compounds NNS 1 1 13 I-Group
9 CD 0 0 2 B-Drug
- : 0 0 2 O
fluorouracil NN 0 1 13 I-Drug
furosemide JJ 0 1 0 B-Drug
glucocorticoids NNS 1 1 UNK B-Group
meclofenamic JJ 0 0 UNK B-Drug
acid JJ 0 1 14 I-Drug
mefenamic JJ 0 0 UNK B-Drug
acid NN 0 1 14 I-Drug
methadone NN 0 1 6 B-Drug
perphenazine NN 0 1 13 B-Drug
phenylbutazone NN 0 1 UNK B-Drug
phenytoin NN 0 1 16 B-Drug
salicylates VBZ 0 1 13 B-Group
tamoxifen NNS 0 1 0 B-Drug
. . 0 0 12 O

Potassium NNP 0 1 14 B-Group
- : 0 0 2 O
sparing VBG 1 0 6 I-Group
diuretics NNS 1 1 14 I-Group
( ( 0 0 2 O
spironolactone NN 0 1 0 B-Drug
amiloride RB 0 1 16 B-Drug
triamterene NN 0 1 13 B-Drug
and CC 0 0 12 O
others NNS 0 1 12 O
) ) 0 0 2 O
or CC 0 0 12 O
potassium JJ 0 1 14 B-Drug
supplements NNS 1 1 6 O
can MD 0 0 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
hyperkalemia NN 0 1 14 O
. . 0 0 12 O

Tricyclic JJ 0 0 UNK B-Group
antidepressants NNS 1 1 13 I-Group
( ( 0 0 2 O
amitriptyline JJ 0 1 16 B-Drug
imipramine NN 0 1 0 B-Drug
nortriptyline NN 0 1 16 B-Drug
) ) 0 0 2 O
: : 0 0 2 O
Metabolism NN 0 1 UNK O
may MD 0 0 1 O
be VB 0 0 12 O
inhibited VBN 1 1 13 O
by IN 0 0 12 O
combination NN 0 1 1 B-Group
hormonal JJ 0 1 6 I-Group
contraceptives NNS 1 1 13 I-Group
increasing VBG 1 1 1 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
antidepressant NN 0 1 6 B-Group
; : 0 0 2 O

Amantadine NN 0 1 UNK B-Drug
: : 0 0 2 O
Population NNP 0 1 UNK O
pharmacokinetic JJ 0 1 UNK O
analysis NN 0 1 1 O
suggests VBZ 1 1 1 O
that IN 0 0 12 O
amantadine NN 0 1 16 B-Drug
is VBZ 1 0 12 O
unlikely JJ 0 1 12 O
to TO 0 0 12 O
alter VB 0 1 13 O
the DT 0 0 12 O
oral JJ 0 1 6 O
clearance NN 0 1 16 O
of IN 0 0 12 O
pramipexole NN 0 1 16 B-Drug
( ( 0 0 2 O
N= NNP 0 1 UNK O
9 CD 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

The DT 0 0 2 O
combined VBN 1 1 1 O
use NN 0 1 1 O
of IN 0 0 12 O
fluconazole NN 0 1 0 B-Drug
at IN 0 0 12 O
doses NNS 1 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
or CC 0 0 12 O
greater JJR 1 1 1 O
with IN 0 0 12 O
terfenadine NN 0 1 UNK B-Drug
is VBZ 1 0 12 O
contraindicated VBN 1 1 14 O
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
not RB 0 1 12 O
known VBN 1 1 12 O
if IN 0 0 12 O
fulvestrant NN 0 1 13 B-Drug
is VBZ 1 0 12 O
excreted VBN 1 1 UNK O
in IN 0 0 12 O
human JJ 0 1 1 O
milk NN 0 1 3 O
. . 0 0 12 O

Therefore RB 0 0 1 O
a DT 0 0 12 O
lower JJR 1 1 1 O
total JJ 0 1 1 O
daily JJ 0 1 12 O
dosage NN 0 1 0 O
of IN 0 0 12 O
INDOCIN NNP 0 1 UNK B-Brand
may MD 0 0 1 O
produce VB 0 0 1 O
a DT 0 0 12 O
satisfactory JJ 0 1 1 O
therapeutic JJ 0 1 6 O
effect NN 0 1 1 O
. . 0 0 12 O

However RB 0 0 1 O
other JJ 0 0 12 O
published VBN 1 1 UNK O
reports NNS 1 1 1 O
describe RBR 0 0 1 O
modest JJ 0 1 1 O
elevations NNS 1 1 1 O
( ( 0 0 2 O
less JJR 0 1 12 O
than IN 0 0 12 O
two CD 0 1 12 O
- : 0 0 2 O
fold NN 0 1 3 O
) ) 0 0 2 O
of IN 0 0 12 O
clozapine NN 0 1 13 B-Drug
and CC 0 0 12 O
metabolite JJ 0 1 UNK O
concentrations NNS 1 1 13 O
when WRB 0 0 12 O
clozapine NN 0 1 13 B-Drug
was VBD 1 0 12 O
taken VBN 1 1 12 O
with IN 0 0 12 O
paroxetine JJ 0 1 16 B-Drug
fluoxetine NN 0 1 16 B-Drug
and CC 0 0 12 O
sertraline NN 0 1 16 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
blood NN 0 1 6 O
pressure NN 0 1 1 O
effect NN 0 1 1 O
of IN 0 0 12 O
SULAR NNP 0 1 UNK B-Brand
tended VBD 1 0 1 O
to TO 0 0 12 O
be VB 0 0 12 O
greater JJR 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
on IN 0 0 12 O
atenolol NN 0 1 0 B-Drug
than IN 0 0 12 O
in IN 0 0 12 O
patients NNS 1 1 6 O
on IN 0 0 12 O
no DT 0 0 12 O
other JJ 0 0 12 O
antihypertensive JJ 0 1 14 B-Group
therapy NN 0 1 6 O
. . 0 0 12 O

Although IN 0 0 12 O
these DT 0 0 12 O
results NNS 1 1 1 O
do VBP 0 0 12 O
not RB 0 1 12 O
indicate VB 0 0 1 O
a DT 0 0 12 O
significant JJ 0 1 1 O
interaction NN 0 1 UNK O
between IN 0 0 12 O
TORADOL NNP 0 1 UNK B-Brand
and CC 0 0 12 O
warfarin NN 0 1 14 B-Drug
or CC 0 0 12 O
heparin VB 0 1 14 B-Drug
the DT 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
TORADOL NNP 0 1 UNK B-Brand
to TO 0 0 12 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
anticoagulants NNS 1 1 13 B-Group
should MD 0 0 12 O
be VB 0 0 12 O
done VBN 1 0 12 O
extremely RB 0 1 12 O
cautiously RB 0 0 UNK O
and CC 0 0 12 O
patients NNS 1 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
closely RB 0 0 1 O
monitored VBN 1 1 1 O
. . 0 0 12 O

Substances NNS 0 1 UNK O
that WDT 0 0 12 O
inhibit VBP 0 1 13 O
the DT 0 0 12 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
isoenzyme NN 0 1 13 O
( ( 0 0 2 O
CYP9A9 NNP 0 0 UNK O
) ) 0 0 2 O
activity NN 0 1 1 O
may MD 0 0 1 O
decrease VB 0 1 1 O
metabolism NN 0 1 16 O
and CC 0 0 12 O
increase VB 0 1 1 O
imatinib JJ 0 1 16 B-Drug
concentrations NNS 1 1 13 O
. . 0 0 12 O

Allopurinol NN 0 1 0 B-Drug
: : 0 0 2 O
Increased VBN 0 1 7 O
possibility NN 0 1 1 O
of IN 0 0 12 O
skin JJ 0 1 3 O
rash NN 0 1 6 O
particularly RB 0 0 1 O
in IN 0 0 12 O
hyperuricemic JJ 0 1 UNK O
patients NNS 1 1 6 O
may MD 0 0 1 O
occur VB 0 1 1 O
. . 0 0 12 O

Bile NNP 0 1 7 B-Group
acid NN 0 1 14 I-Group
binding VBG 1 1 1 I-Group
resins NNS 1 1 UNK I-Group
may MD 0 0 1 O
also RB 0 0 12 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
absorption NN 0 1 1 O
of IN 0 0 12 O
oral JJ 0 1 6 O
phosphate NN 0 1 14 B-Drug
supplements NNS 1 1 6 O
and CC 0 0 12 O
hydrocortisone NN 0 1 14 B-Drug
. . 0 0 12 O

Similarly RB 0 0 1 O
ethanol NN 0 1 1 B-Drug
decreased VBD 1 1 1 O
the DT 0 0 12 O
rate NN 0 1 1 O
of IN 0 0 12 O
elimination NN 0 1 UNK O
of IN 0 0 12 O
Antizol NNP 0 1 UNK B-Brand
( ( 0 0 2 O
by IN 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
by IN 0 0 12 O
the DT 0 0 12 O
same JJ 0 1 12 O
mechanism NN 0 1 13 O
. . 0 0 12 O

No DT 0 0 2 O
change NN 0 1 1 O
in IN 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
either DT 0 1 12 O
drug NN 0 1 1 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
use NN 0 1 1 O
of IN 0 0 12 O
FLUDARA NNP 0 1 UNK B-Brand
FOR NNP 0 0 11 O
INJECTION NNP 0 1 UNK O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
pentostatin NN 0 1 13 B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
recommended VBN 1 1 1 O
due JJ 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
severe JJ 0 1 6 O
pulmonary JJ 0 1 6 O
toxicity NN 0 1 6 O
. . 0 0 12 O

Concomitant JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
probenecid NN 0 1 13 B-Drug
doubled VBD 1 1 12 O
the DT 0 0 12 O
AUC NNP 0 1 UNK O
for IN 0 0 12 O
cefprozil NN 0 1 UNK B-Drug
. . 0 0 12 O

In IN 0 0 2 O
addition NN 0 1 1 O
certain JJ 0 1 1 O
drugs NNS 1 1 6 O
inhibit VBP 0 1 13 O
the DT 0 0 12 O
activity NN 0 1 1 O
of IN 0 0 12 O
this DT 0 0 12 O
isozyme NN 0 1 UNK O
and CC 0 0 12 O
make VB 0 1 12 O
normal JJ 0 1 1 O
metabolizers NNS 0 0 UNK O
resemble JJ 0 0 UNK O
poor JJ 0 1 12 O
metabolizers NNS 0 0 UNK O
. . 0 0 12 O

The DT 0 0 2 O
finding NN 0 1 12 O
that WDT 0 0 12 O
metoclopramide NN 0 1 16 B-Drug
releases VBZ 1 1 UNK O
catecholamines NNS 1 1 14 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
essential JJ 0 1 13 O
hypertension NN 0 1 6 O
suggests VBZ 1 1 1 O
that IN 0 0 12 O
it PRP 0 0 12 O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
cautiously RB 0 0 UNK O
if IN 0 0 12 O
at IN 0 0 12 O
all DT 0 0 12 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
monoamine NN 0 1 13 B-Group
oxi SYM 0 1 UNK I-Group
- : 0 0 2 O
dase NN 0 0 UNK I-Group
inhibitors NNS 1 1 14 I-Group
. . 0 0 12 O

The DT 0 0 2 O
absorption NN 0 1 1 O
of IN 0 0 12 O
oral JJ 0 1 6 O
medications NNS 1 1 6 O
may MD 0 0 1 O
be VB 0 0 12 O
decreased VBN 1 1 1 O
during IN 0 0 12 O
the DT 0 0 12 O
concurrent NN 0 1 1 O
use NN 0 1 1 O
of IN 0 0 12 O
scopolamine NN 0 1 14 B-Drug
because IN 0 0 12 O
of IN 0 0 12 O
decreased JJ 0 1 1 O
gastric JJ 0 1 6 O
motility NN 0 1 6 O
and CC 0 0 12 O
delayed VBN 1 1 1 O
gastric JJ 0 1 6 O
emptying NN 0 1 13 O
. . 0 0 12 O

Limited JJ 0 1 2 O
clinical JJ 0 1 6 O
data NNS 0 1 1 O
in IN 0 0 12 O
angina NN 0 1 6 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
concomitant JJ 0 1 6 O
bepridil NN 0 1 UNK B-Drug
hydrochloride NN 0 1 0 I-Drug
and CC 0 0 12 O
digoxin NN 0 1 14 B-Drug
therapy NN 0 1 6 O
indicate VBP 0 0 1 O
no DT 0 0 12 O
discernible JJ 0 1 UNK O
changes NNS 1 1 1 O
in IN 0 0 12 O
serum NN 0 1 14 O
digoxin NN 0 1 14 O
levels NNS 1 1 1 O
. . 0 0 12 O

although IN 0 0 12 O
combinations NNS 1 1 1 O
are VBP 1 0 12 O
sometimes RB 0 1 12 O
used VBN 1 1 12 O
for IN 0 0 12 O
therapeutic JJ 0 1 6 O
advantage NN 0 0 UNK O
when WRB 0 0 12 O
used VBN 1 1 12 O
concurrently RB 0 0 1 O
patient JJ 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
closely RB 0 0 1 O
monitored VBN 1 1 1 O
. . 0 0 12 O

Acetazolamide NNP 0 1 0 B-Drug
may MD 0 0 1 O
elevate VB 0 1 1 O
cyclosporine NN 0 1 14 B-Drug
levels NNS 1 1 1 O
. . 0 0 12 O

Interactions NNS 0 1 UNK O
between IN 0 0 12 O
COPAXONE NNP 0 1 UNK B-Brand
and CC 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
fully RB 0 0 1 O
evaluated VBN 1 1 1 O
. . 0 0 12 O

Fulvestrant NNP 0 1 UNK B-Drug
was VBD 1 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
an DT 0 0 12 O
increased JJ 0 1 1 O
incidence NN 0 1 6 O
of IN 0 0 12 O
fetal JJ 0 1 6 O
variations NNS 1 1 1 O
in IN 0 0 12 O
rabbits NNS 1 1 UNK O
( ( 0 0 2 O
backwards NNS 0 1 3 O
displacement NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
pelvic JJ 0 1 6 O
girdle NN 0 1 13 O
and CC 0 0 12 O
9 CD 0 0 2 O
pre NN 0 1 1 O
- : 0 0 2 O
sacral JJ 0 1 8 O
vertebrae NN 1 1 13 O
at IN 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
/ NNP 0 0 2 O
day NN 0 1 12 O
IM NNP 0 1 11 O
; : 0 0 2 O

Cardiovascular JJ 0 1 7 O
agents NNS 1 1 1 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
atenolol NN 0 1 0 B-Drug
hydrochlorothiazide NN 0 1 0 B-Drug
propranolol NN 0 1 16 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

Endocrine NNP 0 1 7 O
Function NNP 0 1 2 O
HMG NNP 0 0 UNK B-Group
- : 0 0 2 O
CoA NNP 0 0 UNK I-Group
reductase NN 0 1 UNK I-Group
inhibitors NNS 1 1 14 I-Group
interfere RB 0 1 UNK O
with IN 0 0 12 O
cholesterol NN 0 1 6 O
synthesis NN 0 1 UNK O
and CC 0 0 12 O
theoretically RB 0 0 UNK O
might MD 0 0 12 O
blunt VB 0 1 3 O
adrenal JJ 0 0 6 O
and CC 0 0 12 O
/ JJ 0 0 2 O
or CC 0 0 12 O
gonadal JJ 0 1 13 O
steroid JJ 0 1 6 O
production NN 0 1 1 O
. . 0 0 12 O

Amprenavir NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
an DT 0 0 12 O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
C.P.A NNP 0 0 UNK O
. . 0 0 12 O
metabolism NN 0 1 16 O
and CC 0 0 12 O
therefore RB 0 0 1 O
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
medications NNS 1 1 6 O
with IN 0 0 12 O
narrow JJ 0 1 3 O
therapeutic JJ 0 1 6 O
windows NNS 1 1 3 O
that WDT 0 0 12 O
are VBP 1 0 12 O
substrates NNS 1 1 UNK O
of IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
. . 0 0 12 O

. . 0 0 12 O

No DT 0 0 2 O
data NN 0 1 1 O
are VBP 1 0 12 O
available JJ 0 1 1 O
regarding VBG 1 0 1 O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
have VBP 0 0 12 O
renal JJ 0 1 6 O
clearance NN 0 1 16 O
mechanisms NNS 1 1 UNK O
similar JJ 0 1 1 O
to TO 0 0 12 O
that DT 0 0 12 O
of IN 0 0 12 O
lamivudine NN 0 1 16 B-Drug
. . 0 0 12 O

Erythromycin NNP 0 1 0 B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
significantly RB 0 0 1 O
alter VB 0 1 13 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
nonsedating VBG 0 0 UNK O
antihistamines NNS 1 1 UNK B-Group
terfenadine NN 0 1 UNK B-Drug
and CC 0 0 12 O
astemizole NN 0 1 UNK B-Drug
when WRB 0 0 12 O
taken VBN 1 1 12 O
concomitantly RB 0 0 14 O
. . 0 0 12 O

Food NNP 0 1 2 O
Interaction NN 0 1 2 O
: : 0 0 2 O
Oral JJ 0 1 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
ACEON NNP 0 1 UNK B-Brand
Tablets NNP 0 1 0 O
with IN 0 0 12 O
food NN 0 1 12 O
does VBZ 1 0 12 O
not RB 0 1 12 O
significantly RB 0 0 1 O
lower JJR 1 1 1 O
the DT 0 0 12 O
rate NN 0 1 1 O
or CC 0 0 12 O
extent NN 0 1 1 O
of IN 0 0 12 O
perindopril JJ 0 1 UNK B-Drug
absorption NN 0 1 1 O
relative NN 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
fasted VBN 1 1 UNK O
state NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
single JJ 0 1 12 O
- : 0 0 2 O
dose JJ 0 1 6 O
nature NN 0 1 1 O
of IN 0 0 12 O
this DT 0 0 12 O
study NN 0 1 1 O
and CC 0 0 12 O
the DT 0 0 12 O
lack NN 0 1 1 O
of IN 0 0 12 O
correlation NN 0 1 1 O
between IN 0 0 12 O
glyburide JJ 0 1 16 B-Drug
blood NN 0 1 6 O
levels NNS 1 1 1 O
and CC 0 0 12 O
pharmaco VB 0 0 UNK O
- : 0 0 2 O
dynamic JJ 0 1 1 O
effects NNS 1 1 1 O
makes VBZ 1 1 12 O
the DT 0 0 12 O
clinical JJ 0 1 6 O
significance NN 0 1 13 O
of IN 0 0 12 O
this DT 0 0 12 O
interaction NN 0 1 UNK O
uncertain NN 0 1 1 O
. . 0 0 12 O

Sulfonamides NNS 0 1 15 B-Group
can MD 0 0 12 O
also RB 0 0 12 O
displace VB 0 0 13 O
methotrexate NN 0 1 16 B-Drug
from IN 0 0 12 O
plasma NN 0 1 14 O
protein NN 0 1 14 O
- : 0 0 2 O
binding NN 0 1 1 O
sites NNS 1 1 1 O
thus RB 0 0 1 O
increasing VBG 1 1 1 O
free JJ 0 1 12 O
methotrexate NN 0 1 16 B-Drug
concentrations NNS 1 1 13 O
. . 0 0 12 O

Griseofulvin NN 0 1 UNK B-Drug
: : 0 0 2 O
Griseofulvin NNP 0 1 UNK B-Drug
may MD 0 0 1 O
induce VB 0 1 6 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
combination NN 0 1 1 B-Group
hormonal JJ 0 1 6 I-Group
contraceptives NNS 1 1 13 I-Group
causing VBG 1 1 1 O
menstrual JJ 0 1 6 O
changes NNS 1 1 1 O
; : 0 0 2 O

Heparin NN 0 1 0 B-Drug
: : 0 0 2 O
No DT 0 0 2 O
human JJ 0 1 1 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
with IN 0 0 12 O
heparin NN 0 1 14 B-Drug
were VBD 1 0 12 O
conducted VBN 1 1 1 O
. . 0 0 12 O

Patients NNS 0 1 7 O
should MD 0 0 12 O
be VB 0 0 12 O
followed VBN 1 1 12 O
carefully RB 0 0 12 O
to TO 0 0 12 O
detect VB 0 1 UNK O
side JJ 0 1 3 O
reactions NNS 1 1 1 O
or CC 0 0 12 O
unusual JJ 0 1 12 O
manifestations NNS 1 1 6 O
of IN 0 0 12 O
drug NN 0 1 1 O
idiosyncrasy NN 0 1 UNK O
. . 0 0 12 O

A DT 0 0 2 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
study NN 0 1 1 O
was VBD 1 0 12 O
performed VBN 1 1 1 O
in IN 0 0 12 O
which WDT 0 0 12 O
ERBITUX NNP 0 1 UNK B-Brand
was VBD 1 0 12 O
administered VBN 1 1 1 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
irinotecan JJ 0 1 13 B-Drug
. . 0 0 12 O

Do NNP 0 0 2 O
not RB 0 1 12 O
mix VB 0 1 3 O
TORADOL NNP 0 1 UNK B-Brand
and CC 0 0 12 O
morphine NN 0 1 14 B-Drug
in IN 0 0 12 O
the DT 0 0 12 O
same JJ 0 1 12 O
syringe NN 0 1 3 O
. . 0 0 12 O

Antihypertensives NNS 0 1 UNK B-Drug
: : 0 0 2 O
Amiodarone NN 0 1 0 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
with IN 0 0 12 O
caution NN 0 0 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
- : 0 0 2 O
receptor NN 0 1 14 B-Drug
blocking VBG 1 1 UNK O
agents NNS 1 1 1 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
propranolol NN 0 1 16 B-Drug
a DT 0 0 12 O
CYP9A9 NNP 0 0 UNK B-Drug
inhibitor NN 0 1 14 O
) ) 0 0 2 O
or CC 0 0 12 O
calcium JJ 0 1 14 B-Drug
channel NN 0 1 1 I-Drug
antagonists NNS 1 1 13 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
verapamil NN 0 1 0 B-Drug
a DT 0 0 12 O
CYP9A9 NNP 0 0 UNK B-Drug
substrate NN 0 1 UNK O
and CC 0 0 12 O
diltiazem VB 0 1 0 B-Drug
a DT 0 0 12 O
CYP9A9 NNP 0 0 UNK B-Drug
inhibitor NN 0 1 14 O
) ) 0 0 2 O
because IN 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
possible JJ 0 1 1 O
potentiation NN 0 1 UNK O
of IN 0 0 12 O
bradycardia NN 0 1 8 O
sinus NN 0 1 6 O
arrest NN 0 1 12 O
and CC 0 0 12 O
AV NNP 0 0 13 O
block NN 0 1 3 O
; : 0 0 2 O

At IN 0 0 2 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
g NN 0 1 16 O
dose JJ 0 1 6 O
sulfamethoxazole NN 0 1 13 B-Drug
produced VBD 1 0 1 O
a DT 0 0 12 O
slight JJ 0 1 3 O
but CC 0 0 12 O
significant JJ 0 1 1 O
increase NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
of IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
but CC 0 0 12 O
did VBD 1 0 12 O
not RB 0 1 12 O
produce VB 0 0 1 O
a DT 0 0 12 O
corresponding JJ 0 0 1 O
decrease NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
metabolic JJ 0 1 6 O
clearance NN 0 1 16 O
rate NN 0 1 1 O
. . 0 0 12 O

No DT 0 0 2 O
formal JJ 0 1 1 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
between IN 0 0 12 O
Neulasta NNP 0 1 UNK B-Brand
and CC 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
have VBP 0 0 12 O
been VBN 1 0 12 O
performed VBN 1 1 1 O
. . 0 0 12 O

Acromegalic JJ 0 0 UNK O
patients NNS 1 1 6 O
with IN 0 0 12 O
diabetes NNS 0 1 6 O
mellitus VBP 0 0 6 O
being VBG 1 0 12 O
treated VBN 1 1 1 O
with IN 0 0 12 O
insulin NN 0 1 14 B-Drug
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
oral JJ 0 1 6 O
hypoglycemic JJ 0 1 14 B-Group
agents NNS 1 1 1 O
may MD 0 0 1 O
require VB 0 0 1 O
dose JJ 0 1 6 O
reductions NNS 1 1 1 O
of IN 0 0 12 O
these DT 0 0 12 O
therapeutic JJ 0 1 6 O
agents NNS 1 1 1 O
after IN 0 0 12 O
the DT 0 0 12 O
initiation NN 0 1 1 O
of IN 0 0 12 O
therapy NN 0 1 6 O
with IN 0 0 12 O
SOMAVERT NNP 0 1 UNK B-Brand
. . 0 0 12 O

Phenytoin NN 0 1 0 B-Drug

Non NNP 0 1 2 B-Group
- : 0 0 2 O
steroidal NN 0 1 UNK I-Group
Anti NNP 0 0 UNK I-Group
- : 0 0 2 O
inflammatory NN 0 1 6 I-Group
Drugs NNS 0 1 2 I-Group
: : 0 0 2 O
In IN 0 0 2 O
some DT 0 0 12 O
patients NNS 1 1 6 O
the DT 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
non JJ 0 1 1 B-Group
- : 0 0 2 O
steroidal NN 0 1 UNK I-Group
anti SYM 0 0 3 I-Group
- : 0 0 2 O
inflammatory JJ 0 1 6 I-Group
agent NN 0 1 1 I-Group
can MD 0 0 12 O
reduce VB 0 0 1 O
the DT 0 0 12 O
diuretic JJ 0 1 14 O
natriuretic JJ 0 1 UNK O
and CC 0 0 12 O
antihypertensive JJ 0 1 14 O
effects NNS 1 1 1 O
of IN 0 0 12 O
loop NN 0 1 3 B-Group
potassium NN 0 1 14 B-Group
- : 0 0 2 O
sparing NN 0 0 6 I-Group
and CC 0 0 12 O
thiazide JJ 0 1 UNK B-Group
diuretics NNS 1 1 14 I-Group
. . 0 0 12 O

Furosemide NN 0 1 0 B-Drug
: : 0 0 2 O
Clinical JJ 0 1 7 O
studies NNS 1 1 1 O
as RB 0 0 12 O
well RB 0 1 12 O
as IN 1 0 12 O
post NN 0 1 12 O
marketing NN 0 1 UNK O
observations NNS 1 1 1 O
have VBP 0 0 12 O
shown VBN 1 1 1 O
that IN 0 0 12 O
NSAIDs NNP 0 1 UNK B-Group
can MD 0 0 12 O
reduce VB 0 0 1 O
the DT 0 0 12 O
natriuretic JJ 0 1 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
furosemide NN 0 1 0 B-Drug
and CC 0 0 12 O
thiazides NNS 1 1 UNK B-Group
in IN 0 0 12 O
some DT 0 0 12 O
patients NNS 1 1 6 O
. . 0 0 12 O

In IN 0 0 2 O
a DT 0 0 12 O
pharmacokinetic JJ 0 1 UNK O
study NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
chronic JJ 0 1 6 O
hepatitis NN 0 1 6 O
C NNP 0 0 2 O
patients NNS 1 1 6 O
concomitantly RB 0 0 14 O
receiving VBG 1 1 1 O
methadone NN 0 1 6 B-Drug
treatment NN 0 1 6 O
with IN 0 0 12 O
PEG NNP 0 0 14 B-Brand
- : 0 0 2 O
Intron NNP 0 1 UNK I-Brand
once RB 0 0 12 O
weekly VBD 0 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
weeks NNS 1 1 12 O
was VBD 1 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
a DT 0 0 12 O
mean JJ 0 1 12 O
increase NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
in IN 0 0 12 O
methadone NN 0 1 6 B-Drug
AUC NNP 0 1 UNK O
; : 0 0 2 O

Any DT 0 0 UNK O
agent NN 0 1 1 O
that IN 0 0 12 O
alters NNS 0 1 UNK O
thyroid VBP 0 1 6 O
hormone NN 0 1 6 O
synthesis NN 0 1 UNK O
secretion NN 0 1 14 O
distribution NN 0 1 1 O
effect NN 0 1 1 O
on IN 0 0 12 O
target NN 0 1 1 O
tissues NNS 1 1 6 O
metabolism NN 0 1 16 O
or CC 0 0 12 O
elimination NN 0 1 UNK O
may MD 0 0 1 O
alter VB 0 1 13 O
the DT 0 0 12 O
optimal JJ 0 1 1 O
therapeutic JJ 0 1 6 O
dose NN 0 1 6 O
of IN 0 0 12 O
levothyroxine JJ 0 1 0 B-Drug
sodium NN 0 1 14 O
. . 0 0 12 O

Close JJ 0 1 2 O
supervision NN 0 1 1 O
and CC 0 0 12 O
careful JJ 0 1 12 O
adjustment NN 0 1 1 O
of IN 0 0 12 O
dosage NN 0 1 0 O
is VBZ 1 0 12 O
required VBN 1 1 1 O
when WRB 0 0 12 O
this DT 0 0 12 O
drug NN 0 1 1 O
is VBZ 1 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
anticholinergic JJ 0 1 13 B-Group
drugs NNS 1 1 6 I-Group
. . 0 0 12 O

During IN 0 0 2 O
controlled VBN 1 1 1 O
hypotensive JJ 0 1 14 O
anesthesia NN 0 1 6 O
using VBG 1 1 1 O
labetalol JJ 0 1 0 B-Drug
HCl NNP 0 0 14 I-Drug
in IN 0 0 12 O
association NN 0 1 1 O
with IN 0 0 12 O
halothane NN 0 1 13 B-Drug
high JJ 0 1 1 O
concentrations NNS 1 1 13 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
or CC 0 0 12 O
above IN 0 1 12 O
) ) 0 0 2 O
of IN 0 0 12 O
halothane NN 0 1 13 B-Drug
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
because IN 0 0 12 O
the DT 0 0 12 O
degree NN 0 1 1 O
of IN 0 0 12 O
hypotension NN 0 1 6 O
will MD 0 0 12 O
be VB 0 0 12 O
increased VBN 1 1 1 O
and CC 0 0 12 O
because IN 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
possibility NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
large JJ 0 1 3 O
reduction NN 0 1 1 O
in IN 0 0 12 O
cardiac JJ 0 1 6 O
output NN 0 1 1 O
and CC 0 0 12 O
an DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
central JJ 0 1 1 O
venous JJ 0 1 6 O
pressure NN 0 1 1 O
. . 0 0 12 O

Monitoring NN 0 1 UNK O
of IN 0 0 12 O
disopyramide JJ 0 1 16 B-Drug
plasma NN 0 1 14 O
levels NNS 1 1 1 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
in IN 0 0 12 O
such JJ 0 0 1 O
concurrent NN 0 1 1 O
use NN 0 1 1 O
to TO 0 0 12 O
avoid VB 0 0 12 O
ineffective JJ 0 1 UNK O
therapy NN 0 1 6 O
. . 0 0 12 O

Furthermore RB 0 0 1 O
rifampin NN 0 1 16 B-Drug
phenytoin NN 0 1 16 B-Drug
phenobarbital NN 0 1 16 B-Drug
and CC 0 0 12 O
other JJ 0 0 12 O
inducers NNS 1 1 UNK O
of IN 0 0 12 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
9A9 CD 0 0 UNK O
may MD 0 0 1 O
cause VB 0 1 12 O
a DT 0 0 12 O
reduction NN 0 1 1 O
in IN 0 0 12 O
plasma JJ 0 1 14 O
bexarotene NN 0 1 UNK B-Drug
concentrations NNS 1 1 13 O
. . 0 0 12 O

( ( 0 0 2 O
Effectiveness NN 0 1 UNK O
may MD 0 0 1 O
be VB 0 0 12 O
decreased VBN 1 1 1 O
when WRB 0 0 12 O
used VBN 1 1 12 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
thiazide JJ 0 1 UNK B-Group
diuretics NNS 1 1 14 I-Group
because IN 0 0 12 O
of IN 0 0 12 O
alkalinization NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
urine NN 0 1 6 O
. . 0 0 12 O
) ) 0 0 2 O

Administration NN 0 1 UNK O
of IN 0 0 12 O
eplerenone NN 0 1 13 B-Drug
with IN 0 0 12 O
other JJ 0 0 12 O
CYP9A9 NNP 0 0 UNK O
inhibitors NNS 1 1 14 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
erythromycin RB 0 1 0 B-Drug
9 CD 0 0 2 O
mg NNS 0 1 0 O
BID NNP 0 0 11 O
verapamil VBZ 0 1 0 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
QD NNP 0 1 13 O
saquinavir VBD 0 1 13 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
TID NNP 0 1 15 O
fluconazole VBD 0 1 0 B-Drug
9 CD 0 0 2 O
mg NNS 0 1 0 O
QD NNP 0 1 13 O
) ) 0 0 2 O
resulted VBD 1 1 1 O
in IN 0 0 12 O
increases NNS 1 1 1 O
in IN 0 0 12 O
Cmax NNP 0 1 UNK O
of IN 0 0 12 O
eplerenone NN 0 1 13 B-Drug
ranging VBG 1 1 1 O
from IN 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
fold NN 0 1 3 O
and CC 0 0 12 O
AUC NNP 0 1 UNK O
from IN 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
fold NN 0 1 3 O
. . 0 0 12 O

pyrazolones NNS 0 1 UNK B-Group
; : 0 0 2 O

Guardians NNS 0 1 UNK O
of IN 0 0 12 O
children NNS 1 1 12 O
who WP 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
prescribed VBN 1 1 1 O
FORADIL NNP 0 1 UNK B-Brand
should MD 0 0 12 O
be VB 0 0 12 O
alerted VBN 1 1 12 O
to TO 0 0 12 O
the DT 0 0 12 O
general JJ 0 1 1 O
concern NN 0 1 1 O
regarding VBG 1 0 1 O
asthma NN 0 1 6 O
therapy NN 0 1 6 O
compliance NN 0 1 1 O
especially RB 0 0 12 O
neglect JJ 0 1 1 O
of IN 0 0 12 O
anti JJ 0 0 3 O
- : 0 0 2 O
inflammatory NN 0 1 6 O
therapy NN 0 1 6 O
and CC 0 0 12 O
overuse NN 0 0 UNK O
of IN 0 0 12 O
short JJ 0 1 12 B-Group
- : 0 0 2 O
acting VBG 1 1 12 I-Group
beta9 SYM 0 0 UNK I-Group
- : 0 0 2 O
agonists NNS 1 1 UNK I-Group
. . 0 0 12 O

Plasma NNP 0 1 UNK O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
cyclosporine NN 0 1 14 B-Drug
should MD 0 0 12 O
therefore RB 0 0 1 O
be VB 0 0 12 O
closely RB 0 0 1 O
monitored JJ 0 1 1 O
and CC 0 0 12 O
its PRP$ 1 0 12 O
dosage NN 0 1 0 O
reduced VBN 1 1 1 O
accordingly RB 0 0 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
treated VBN 1 1 1 O
with IN 0 0 12 O
nicardipine NN 0 1 16 B-Drug
. . 0 0 12 O

In IN 0 0 2 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
an DT 0 0 12 O
anticonvulsant NN 0 1 14 B-Group
( ( 0 0 2 O
eg JJ 0 1 UNK O
valproic NN 0 0 16 B-Drug
acid NN 0 1 14 I-Drug
carbamazepine NN 0 1 16 B-Drug
phenobarbital NN 0 1 16 B-Drug
or CC 0 0 12 O
phenytoin NN 0 1 16 B-Drug
) ) 0 0 2 O
the DT 0 0 12 O
concomitant NN 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
Mefloquine NNP 0 1 UNK B-Drug
may MD 0 0 1 O
reduce VB 0 0 1 O
seizure NN 0 1 6 O
control NN 0 1 1 O
by IN 0 0 12 O
lowering VBG 1 1 UNK O
the DT 0 0 12 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
anticonvulsant NN 0 1 14 B-Group
. . 0 0 12 O

When WRB 0 0 12 O
such JJ 0 0 1 O
combined VBN 1 1 1 O
therapy NN 0 1 6 O
is VBZ 1 0 12 O
contemplated VBN 1 0 UNK O
the DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
one CD 0 1 12 O
or CC 0 0 12 O
both DT 0 0 12 O
agents NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
reduced VBN 1 1 1 O
. . 0 0 12 O

Ritonavir NN 0 1 0 B-Drug

Effect NN 0 1 UNK O
of IN 0 0 12 O
Sensipar NNP 0 1 UNK B-Brand
on IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
: : 0 0 2 O
Drugs NNS 0 1 2 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
9D9 CD 0 0 UNK O
( ( 0 0 2 O
CYP9D9 NNP 0 0 UNK O
) ) 0 0 2 O
: : 0 0 2 O
Sensipar NN 0 1 UNK B-Brand
is VBZ 1 0 12 O
a DT 0 0 12 O
strong JJ 0 1 12 O
in IN 0 0 12 O
vitro JJ 0 1 UNK O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
CYP9D9 NNP 0 0 UNK O
. . 0 0 12 O

Increased VBN 0 1 7 O
nephrotoxicity NN 0 1 UNK O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
following VBG 1 1 1 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
cephalosporins NNS 1 1 14 B-Group
and CC 0 0 12 O
aminoglycoside JJ 0 1 14 B-Group
antibiotics NNS 1 1 6 I-Group
. . 0 0 12 O

phenyramidol NN 0 1 UNK B-Drug_n
; : 0 0 2 O

Methenamine NNP 0 1 UNK B-Drug
therapy NN 0 1 6 O
Urinary NNP 0 1 7 O
excretion NN 0 1 14 O
of IN 0 0 12 O
amphetamines NNS 1 1 14 B-Group
is VBZ 1 0 12 O
increased VBN 1 1 1 O
and CC 0 0 12 O
efficacy NN 0 1 UNK O
is VBZ 1 0 12 O
reduced VBN 1 1 1 O
by IN 0 0 12 O
acidifying VBG 1 0 13 O
agents NNS 1 1 1 O
used VBN 1 1 12 O
in IN 0 0 12 O
methenamine JJ 0 1 13 B-Drug
therapy NN 0 1 6 O
. . 0 0 12 O

Because IN 0 0 12 O
ondansetron NN 0 1 16 B-Drug
is VBZ 1 0 12 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
hepatic JJ 0 1 14 O
cytochrome NN 0 1 UNK O
P NNP 0 1 2 O
- : 0 0 2 O
9 CD 0 0 2 O
drug NN 0 1 1 O
- : 0 0 2 O
metabolizing NN 0 0 UNK O
enzymes NNS 1 1 14 O
( ( 0 0 2 O
CYP9A9 NNP 0 0 UNK O
CYP9D9 NNP 0 0 UNK O
CYP9A9 NNP 0 0 UNK O
) ) 0 0 2 O
inducers NNS 1 1 UNK O
or CC 0 0 12 O
inhibitors NNS 1 1 14 O
of IN 0 0 12 O
these DT 0 0 12 O
enzymes NNS 1 1 14 O
may MD 0 0 1 O
change VB 0 1 1 O
the DT 0 0 12 O
clearance NN 0 1 16 O
and CC 0 0 12 O
hence RB 0 0 1 O
the DT 0 0 12 O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
of IN 0 0 12 O
ondansetron NN 0 1 16 B-Drug
. . 0 0 12 O

9 CD 0 0 2 O
. . 0 0 12 O

Isoflurane NNP 0 1 UNK B-Drug
and CC 0 0 12 O
enflurane NN 0 1 UNK B-Drug
( ( 0 0 2 O
administered VBN 1 1 1 O
with IN 0 0 12 O
nitrous JJ 0 1 UNK B-Drug
oxide JJ 0 1 14 I-Drug
/ NN 0 0 2 O
oxygen NN 0 1 3 B-Drug
to TO 0 0 12 O
achieve VB 0 0 1 O
9 CD 0 0 2 O
M.C NNP 0 1 UNK O
. . 0 0 12 O

Daily JJ 0 1 2 O
doses NNS 1 1 6 O
of IN 0 0 12 O
sulfasalazine NN 0 1 0 B-Drug
9 CD 0 0 2 O
g NN 0 1 16 O
( ( 0 0 2 O
maximum JJ 0 1 1 O
9 CD 0 0 2 O
g NN 0 1 16 O
) ) 0 0 2 O
and CC 0 0 12 O
weekly JJ 0 1 12 O
doses NNS 1 1 6 O
of IN 0 0 12 O
methotrexate NN 0 1 16 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
( ( 0 0 2 O
maximum JJ 0 1 1 O
9 CD 0 0 2 O
mg NN 0 1 0 O
) ) 0 0 2 O
were VBD 1 0 12 O
administered VBN 1 1 1 O
alone RB 0 1 12 O
or CC 0 0 12 O
in IN 0 0 12 O
combination NN 0 1 1 O
to TO 0 0 12 O
9 CD 0 0 2 O
rheumatoid NNS 0 0 6 O
arthritis NN 0 1 6 O
patients NNS 1 1 6 O
in IN 0 0 12 O
two CD 0 1 12 O
controlled VBD 1 1 1 O
9 CD 0 0 2 O
- : 0 0 2 O
week NN 0 1 12 O
clinical JJ 0 1 6 O
studies NNS 1 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
: : 0 0 2 O
Studies NNS 0 1 2 O
in IN 0 0 12 O
human JJ 0 1 1 O
liver NN 0 1 6 O
microsomes NNS 1 1 UNK O
showed VBD 1 1 12 O
that IN 0 0 12 O
vardenafil NN 0 1 UNK B-Drug
is VBZ 1 0 12 O
metabolized VBN 1 1 UNK O
primarily RB 0 0 1 O
by IN 0 0 12 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
( ( 0 0 2 O
CYP NNP 0 1 UNK O
) ) 0 0 2 O
isoforms VBZ 0 1 UNK O
9A9 CD 0 0 UNK O
/ NN 0 0 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
to TO 0 0 12 O
a DT 0 0 12 O
lesser JJR 1 1 1 O
degree NN 0 1 1 O
by IN 0 0 12 O
CYP9C9 NNP 0 0 UNK O
. . 0 0 12 O

Probenecid NNS 0 1 UNK B-Drug
: : 0 0 2 O
May NNP 0 1 2 O
decrease VB 0 1 1 O
renal JJ 0 1 6 O
tubular JJ 0 1 3 O
secretion NN 0 1 14 O
of IN 0 0 12 O
ampicillin NN 0 1 0 B-Drug
resulting VBG 1 1 1 O
in IN 0 0 12 O
increased VBN 1 1 1 O
blood NN 0 1 6 O
levels NNS 1 1 1 O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
ampicillin JJ 0 1 0 B-Drug
toxicity NN 0 1 6 O
. . 0 0 12 O

Aminosalicylic NNP 0 0 UNK B-Drug
acid NN 0 1 14 I-Drug
may MD 0 0 1 O
decrease VB 0 1 1 O
the DT 0 0 12 O
amount NN 0 1 1 O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
( ( 0 0 2 O
Lanoxin NNP 0 1 0 B-Brand
Lanoxicaps NNP 0 1 UNK B-Drug
) ) 0 0 2 O
that WDT 0 0 12 O
gets VBZ 1 0 12 O
absorbed VBN 1 0 3 O
into IN 0 0 12 O
your PRP$ 0 0 12 O
body NN 0 1 3 O
. . 0 0 12 O

In IN 0 0 2 O
vitro JJ 0 1 UNK O
drug NN 0 1 1 O
metabolism NN 0 1 16 O
studies NNS 1 1 1 O
indicate VBP 0 0 1 O
that IN 0 0 12 O
Starlix NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
predominantly RB 0 0 1 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
the DT 0 0 12 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
isozyme NN 0 1 UNK O
CYP9C9 NNP 0 0 UNK O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
and CC 0 0 12 O
to TO 0 0 12 O
a DT 0 0 12 O
lesser JJR 1 1 1 O
extent NN 0 1 1 O
CYP9A9 NNP 0 0 UNK O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
. . 0 0 12 O

Concurrent NNP 0 1 13 O
use NN 0 1 1 O
of IN 0 0 12 O
flurbiprofen NN 0 1 16 B-Drug
and CC 0 0 12 O
aspirin NN 0 1 14 B-Brand
is VBZ 1 0 12 O
therefore RB 0 0 1 O
not RB 0 1 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O

Of IN 0 0 2 O
the DT 0 0 12 O
9 CD 0 0 2 O
patients NNS 1 1 6 O
who WP 0 0 12 O
had VBD 1 0 12 O
potassium NN 0 1 14 B-Group
depleting VBG 1 1 UNK I-Group
diuretics NNS 1 1 14 I-Group
added VBD 1 1 12 O
to TO 0 0 12 O
their PRP$ 0 0 12 O
concomitant JJ 0 1 6 O
medications NNS 1 1 6 O
in IN 0 0 12 O
the DT 0 0 12 O
DIAMOND NNP 0 1 UNK O
trials NNS 1 1 1 O
the DT 0 0 12 O
patients NNS 1 1 6 O
on IN 0 0 12 O
TIKOSYN NNP 0 1 UNK B-Brand
had VBD 1 0 12 O
a DT 0 0 12 O
non JJ 0 1 1 O
- : 0 0 2 O
significantly RB 0 0 1 O
reduced VBN 1 1 1 O
relative JJ 0 1 1 O
risk NN 0 1 1 O
for IN 0 0 12 O
death NN 0 1 12 O
of IN 0 0 12 O
9 CD 0 0 2 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
CI NNP 0 1 UNK O
9 CD 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

Inhibitors NNS 0 1 7 O
Of IN 0 0 2 O
Endogenous NNP 0 1 UNK O
Prostaglandin NNP 0 1 UNK O
Synthesis NNP 0 1 UNK O
It PRP 0 0 12 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
that IN 0 0 12 O
indomethacin NN 0 1 14 B-Drug
may MD 0 0 1 O
reduce VB 0 0 1 O
the DT 0 0 12 O
antihypertensive JJ 0 1 14 O
effect NN 0 1 1 O
of IN 0 0 12 O
captopril NN 0 1 0 B-Drug
especially RB 0 0 12 O
in IN 0 0 12 O
cases NNS 1 1 UNK O
of IN 0 0 12 O
low JJ 0 1 1 O
renin NN 0 1 UNK O
hypertension NN 0 1 6 O
. . 0 0 12 O

reliable JJ 0 1 UNK O
estimates NNS 1 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
prevalence NN 0 1 UNK O
of IN 0 0 12 O
reduced JJ 0 1 1 O
P9 NNP 0 1 UNK O
9D9 CD 0 0 UNK O
isozyme NN 0 1 UNK O
activity NN 0 1 1 O
among IN 0 0 12 O
Asian JJ 0 1 2 O
African NNP 0 1 UNK O
and CC 0 0 12 O
other JJ 0 0 12 O
populations NNS 1 1 UNK O
are VBP 1 0 12 O
not RB 0 1 12 O
yet RB 0 0 12 O
available JJ 0 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
some DT 0 0 12 O
patients NNS 1 1 6 O
a DT 0 0 12 O
disulfiram JJ 0 1 13 B-Drug
- : 0 0 2 O
like IN 0 0 12 O
reaction NN 0 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
produced VBN 1 0 1 O
by IN 0 0 12 O
the DT 0 0 12 O
ingestion NN 0 1 14 O
of IN 0 0 12 O
alcohol NN 0 1 1 B-Drug
. . 0 0 12 O

Therefore RB 0 0 1 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
should MD 0 0 12 O
elapse VB 0 1 UNK O
between IN 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
cholestyramine NN 0 1 13 B-Drug
and CC 0 0 12 O
thyroid JJ 0 1 6 B-Group
hormones NNS 1 1 13 I-Group
. . 0 0 12 O

The DT 0 0 2 O
possibility NN 0 1 1 O
of IN 0 0 12 O
altered JJ 0 1 1 O
safety NN 0 1 1 O
and CC 0 0 12 O
efficacy NN 0 1 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
when WRB 0 0 12 O
Ponstel NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
used VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

Thus RB 0 0 1 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
oral JJ 0 1 6 O
anticoagulants NNS 1 1 13 B-Group
and CC 0 0 12 O
Fluvoxamine NNP 0 1 UNK B-Drug
Tablets NNP 0 1 0 O
should MD 0 0 12 O
have VB 0 0 12 O
their PRP$ 0 0 12 O
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
monitored VBN 1 1 1 O
and CC 0 0 12 O
their PRP$ 0 0 12 O
anticoagulant NN 0 1 13 B-Group
dose NN 0 1 6 O
adjusted VBN 1 1 1 O
accordingly RB 0 0 1 O
. . 0 0 12 O

The DT 0 0 2 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
estazolam NN 0 1 13 B-Drug
( ( 0 0 2 O
Cmax NNP 0 1 UNK O
and CC 0 0 12 O
AUC NNP 0 1 UNK O
) ) 0 0 2 O
were VBD 1 0 12 O
not RB 0 1 12 O
affected VBN 1 1 1 O
during IN 0 0 12 O
multiple JJ 0 1 1 O
- : 0 0 2 O
dose JJ 0 1 6 O
fluoxetine NN 0 1 16 B-Drug
suggesting VBG 1 1 1 O
no DT 0 0 12 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
pharmacokinetic JJ 0 1 UNK O
interaction NN 0 1 UNK O
. . 0 0 12 O

Since IN 0 1 2 O
bacteriostatic JJ 0 0 UNK O
drugs NNS 1 1 6 O
such JJ 0 0 1 O
as IN 1 0 12 O
the DT 0 0 12 O
tetracycline JJ 0 1 0 B-Group
class NN 0 1 12 I-Group
of IN 0 0 12 O
antibiotics NNS 1 1 6 B-Group
may MD 0 0 1 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
bactericidal JJ 0 1 UNK O
action NN 0 1 13 O
of IN 0 0 12 O
penicillins NNS 1 1 14 B-Group
it PRP 0 0 12 O
is VBZ 1 0 12 O
not RB 0 1 12 O
advisable JJ 0 0 UNK O
to TO 0 0 12 O
administer VB 0 1 1 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
concomitantly RB 0 0 14 O
. . 0 0 12 O

The DT 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
local JJ 0 1 12 O
anesthetic JJ 0 1 13 B-Group
solutions NNS 1 1 UNK I-Group
containing VBG 1 1 1 O
epinephrine NN 0 1 14 B-Drug
or CC 0 0 12 O
norepinephrine NN 0 1 14 B-Drug
to TO 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
monoamine JJ 0 1 13 B-Group
oxidase NN 0 1 13 I-Group
inhibitors NNS 1 1 14 I-Group
or CC 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
may MD 0 0 1 O
produce VB 0 0 1 O
severe JJ 0 1 6 O
prolonged VBN 1 1 6 O
hypertension NN 0 1 6 O
. . 0 0 12 O

however RB 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
such JJ 0 0 1 O
combined JJ 0 1 1 O
therapy NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
closely RB 0 0 1 O
for IN 0 0 12 O
early JJ 0 1 12 O
evidence NN 0 1 1 O
of IN 0 0 12 O
neurological JJ 0 1 6 O
toxicity NN 0 1 6 O
and CC 0 0 12 O
treatment NN 0 1 6 O
discontinued VBN 1 1 1 O
promptly RB 0 0 12 O
if IN 0 0 12 O
such JJ 0 0 1 O
signs NNS 1 1 12 O
appear VBP 0 1 12 O
. . 0 0 12 O

Consequently RB 0 0 1 O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
which WDT 0 0 12 O
are VBP 1 0 12 O
highly RB 0 1 1 O
protein JJ 0 1 14 O
bound NN 0 1 12 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
anticoagulants NNS 1 1 13 B-Group
) ) 0 0 2 O
would MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
expected VBN 1 1 12 O
. . 0 0 12 O

Patients NNS 0 1 7 O
on IN 0 0 12 O
thyroid JJ 0 1 6 O
replacement NN 0 1 1 O
therapy NN 0 1 6 O
may MD 0 0 1 O
require VB 0 0 1 O
higher JJR 1 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
thyroid JJ 0 1 6 B-Group
hormone NN 0 1 6 I-Group
. . 0 0 12 O

When WRB 0 0 12 O
introducing VBG 1 1 UNK O
additives NNS 1 1 13 O
use VBP 0 1 1 O
aseptic JJ 0 1 13 O
technique NN 0 1 1 O
mix NN 0 1 3 O
thoroughly RB 0 0 12 O
and CC 0 0 12 O
do VB 0 0 12 O
not RB 0 1 12 O
store VB 0 1 UNK O
. . 0 0 12 O

Combination NNP 0 1 UNK O
therapy NN 0 1 6 O
with IN 0 0 12 O
Cerezyme NNP 0 1 UNK B-Brand
( ( 0 0 2 O
imiglucerase NN 0 1 13 B-Drug
) ) 0 0 2 O
and CC 0 0 12 O
ZAVESCA NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
not RB 0 1 12 O
indicated VBN 1 1 1 O
. . 0 0 12 O

Metformin NN 0 1 0 B-Drug
: : 0 0 2 O
In IN 0 0 2 O
a DT 0 0 12 O
single JJ 0 1 12 O
- : 0 0 2 O
dose JJ 0 1 6 O
interaction NN 0 1 UNK O
study NN 0 1 1 O
in IN 0 0 12 O
NIDDM NNP 0 1 UNK O
subjects NNS 1 1 UNK O
decreases VBZ 1 1 UNK O
in IN 0 0 12 O
glyburide NN 0 1 16 B-Drug
AUC NNP 0 1 UNK O
and CC 0 0 12 O
Cmax NNP 0 1 UNK O
were VBD 1 0 12 O
observed VBN 1 1 1 O
but CC 0 0 12 O
were VBD 1 0 12 O
highly RB 0 1 1 O
variable JJ 0 1 1 O
. . 0 0 12 O

Other JJ 0 0 2 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O

Anticoagulants NNS 0 1 UNK B-Group
( ( 0 0 2 O
Oral NNP 0 1 2 O
) ) 0 0 2 O
: : 0 0 2 O
In IN 0 0 2 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
oral JJ 0 1 6 O
anticoagulants NNS 1 1 13 B-Group
the DT 0 0 12 O
coagulation NN 0 1 14 O
times NNS 1 1 12 O
were VBD 1 0 12 O
increased VBN 1 1 1 O
in IN 0 0 12 O
some DT 0 0 12 O
cases NNS 1 1 UNK O
. . 0 0 12 O

Several JJ 0 1 2 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
completed VBN 1 1 12 O
with IN 0 0 12 O
both DT 0 0 12 O
INVIRASE NNP 0 1 UNK B-Brand
and CC 0 0 12 O
FORTOVASE NNP 0 1 UNK B-Brand
. . 0 0 12 O

Additive JJ 0 1 UNK O
CNS NNP 0 1 6 O
depression NN 0 1 6 O
may MD 0 0 1 O
occur VB 0 1 1 O
when WRB 0 0 12 O
antihistamines NNS 1 1 UNK B-Group
are VBP 1 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
other JJ 0 0 12 O
CNS NNP 0 1 6 B-Group
depressants NNS 1 0 13 I-Group
including VBG 1 1 1 O
barbiturates NNS 1 1 14 B-Group
tranquilizers NNS 1 1 13 B-Group
and CC 0 0 12 O
alcohol NN 0 1 1 B-Drug
. . 0 0 12 O

Saquinavir NN 0 1 UNK B-Drug

. . 0 0 12 O

Taking VBG 0 0 UNK O
a DT 0 0 12 O
rauwolfia NN 0 1 UNK B-Group
alkaloid NN 0 1 UNK I-Group
while IN 0 0 12 O
you PRP 0 0 12 O
are VBP 1 0 12 O
taking VBG 1 0 12 O
or CC 0 0 12 O
within IN 0 0 1 O
9 CD 0 0 2 O
weeks NNS 1 1 12 O
of IN 0 0 12 O
taking VBG 1 0 12 O
MAO NNP 0 1 14 B-Group
inhibitors NNS 1 1 14 I-Group
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
central JJ 0 1 1 O
nervous JJ 0 1 6 O
system NN 0 1 1 O
depression NN 0 1 6 O
or CC 0 0 12 O
may MD 0 0 1 O
cause VB 0 1 12 O
a DT 0 0 12 O
severe JJ 0 1 6 O
high JJ 0 1 1 O
blood NN 0 1 6 O
pressure NN 0 1 1 O
reaction NN 0 1 1 O
. . 0 0 12 O

When WRB 0 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
food NN 0 1 12 O
or CC 0 0 12 O
milk NN 0 1 3 O
there EX 0 0 12 O
is VBZ 1 0 12 O
more RBR 0 1 12 O
rapid JJ 0 1 1 O
absorption NN 0 1 1 O
; : 0 0 2 O

Methenamine JJ 0 1 UNK B-Drug
therapy NN 0 1 6 O
: : 0 0 2 O
Urinary JJ 0 1 7 O
excretion NN 0 1 14 O
of IN 0 0 12 O
amphetamines NNS 1 1 14 B-Group
is VBZ 1 0 12 O
increased VBN 1 1 1 O
and CC 0 0 12 O
efficacy NN 0 1 UNK O
is VBZ 1 0 12 O
reduced VBN 1 1 1 O
by IN 0 0 12 O
acidifying VBG 1 0 13 B-Group
agents NNS 1 1 1 I-Group
used VBN 1 1 12 O
in IN 0 0 12 O
methenamine JJ 0 1 13 B-Drug
therapy NN 0 1 6 O
. . 0 0 12 O

Coadministration NN 0 1 UNK O
of IN 0 0 12 O
NIZORAL NNP 0 1 UNK B-Brand
Tablets NNP 0 1 0 O
and CC 0 0 12 O
drugs NNS 1 1 6 O
primarily RB 0 0 1 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
the DT 0 0 12 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
9A9 CD 0 0 UNK O
enzyme NN 0 1 14 O
system NN 0 1 1 O
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
increased JJ 0 1 1 O
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
the DT 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
could MD 0 0 12 O
increase VB 0 1 1 O
or CC 0 0 12 O
prolong VB 0 0 13 O
both DT 0 0 12 O
therapeutic JJ 0 1 6 O
and CC 0 0 12 O
adverse JJ 0 0 1 O
effects NNS 1 1 1 O
. . 0 0 12 O

Important NNP 0 1 UNK O
Non NNP 0 1 2 O
- : 0 0 2 O
Thalidomide NNP 0 1 UNK B-Drug
Drug NNP 0 1 2 O
Interactions NNP 0 1 UNK O
Drugs NNP 0 1 2 O
That IN 0 0 2 O
Interfere NNP 0 1 UNK O
with IN 0 0 12 O
Hormonal NNP 0 1 UNK B-Group
Contraceptives NNS 0 1 UNK I-Group
: : 0 0 2 O
Concomitant NNP 0 1 UNK O
use NN 0 1 1 O
of IN 0 0 12 O
HIV NNP 0 1 6 B-Group
- : 0 0 2 O
protease NN 0 1 13 I-Group
inhibitors NNS 1 1 14 I-Group
griseofulvin VBP 0 1 UNK B-Drug
modafinil NN 0 1 16 B-Drug
penicillins NNS 1 1 14 B-Group
rifampin VBP 0 1 16 B-Drug
rifabutin JJ 0 1 13 B-Drug
phenytoin JJ 0 1 16 B-Drug
carbamazepine NN 0 1 16 B-Drug
or CC 0 0 12 O
certain JJ 0 1 1 O
herbal JJ 0 1 6 O
supplements NNS 1 1 6 O
such JJ 0 0 1 O
as IN 1 0 12 O
St NNP 0 1 2 O
. . 0 0 12 O

Phenytoin NN 0 1 0 B-Drug
: : 0 0 2 O
In IN 0 0 2 O
9 CD 0 0 2 O
normal JJ 0 1 1 O
- : 0 0 2 O
weight NN 0 1 3 O
subjects NNS 1 1 UNK O
receiving VBG 1 1 1 O
XENICAL JJ 0 1 UNK B-Brand
9 CD 0 0 2 O
mg NN 0 1 0 O
three CD 0 1 12 O
times NNS 1 1 12 O
a DT 0 0 12 O
day NN 0 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
XENICAL RB 0 1 UNK B-Brand
did VBD 1 0 12 O
not RB 0 1 12 O
alter VB 0 1 13 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
9 CD 0 0 2 O
- : 0 0 2 O
mg NN 0 1 0 O
dose NN 0 1 6 O
of IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
. . 0 0 12 O

Treatment JJ 0 1 7 O
experience NN 0 1 12 O
with IN 0 0 12 O
ZETIA NNP 0 1 UNK B-Brand
in IN 0 0 12 O
the DT 0 0 12 O
pediatric JJ 0 1 6 O
population NN 0 1 13 O
is VBZ 1 0 12 O
limited VBN 1 1 1 O
to TO 0 0 12 O
9 CD 0 0 2 O
patients NNS 1 1 6 O
( ( 0 0 2 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
years NNS 1 1 12 O
) ) 0 0 2 O
in IN 0 0 12 O
the DT 0 0 12 O
sitosterolemia NN 0 1 UNK O
study NN 0 1 1 O
and CC 0 0 12 O
9 CD 0 0 2 O
patients NNS 1 1 6 O
( ( 0 0 2 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
years NNS 1 1 12 O
) ) 0 0 2 O
in IN 0 0 12 O
the DT 0 0 12 O
HoFH NNP 0 0 UNK O
study NN 0 1 1 O
. . 0 0 12 O

Since IN 0 1 2 O
Celontin NNP 0 1 UNK B-Brand
( ( 0 0 2 O
methsuximide NN 0 1 UNK B-Drug
) ) 0 0 2 O
may MD 0 0 1 O
interact VB 0 0 UNK O
with IN 0 0 12 O
concurrently RB 0 0 1 O
administered VBN 1 1 1 O
antiepileptic JJ 0 1 UNK B-Group
drugs NNS 1 1 6 I-Group
periodic JJ 0 1 1 O
serum VBP 0 1 14 O
level JJ 0 1 1 O
determinations NNS 1 1 UNK O
of IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
may MD 0 0 1 O
be VB 0 0 12 O
necessary JJ 0 0 1 O
( ( 0 0 2 O
eg JJ 0 1 UNK O
methsuximide NN 0 1 UNK B-Drug
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
and CC 0 0 12 O
phenobarbital NN 0 1 16 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

Aspirin NN 0 1 0 B-Brand
: : 0 0 2 O
Concomitant JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
diclofenac NN 0 1 16 B-Drug
and CC 0 0 12 O
aspirin NN 0 1 14 B-Brand
is VBZ 1 0 12 O
not RB 0 1 12 O
recommended VBN 1 1 1 O
because IN 0 0 12 O
diclofenac NN 0 1 16 B-Drug
is VBZ 1 0 12 O
displaced VBN 1 1 1 O
from IN 0 0 12 O
its PRP$ 1 0 12 O
binding NN 0 1 1 O
sites NNS 1 1 1 O
during IN 0 0 12 O
the DT 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
aspirin JJ 0 1 14 B-Brand
resulting VBG 1 1 1 O
in IN 0 0 12 O
lower JJR 1 1 1 O
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
peak VBP 0 1 1 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
and CC 0 0 12 O
AUC NNP 0 1 UNK O
values NNS 1 1 1 O
. . 0 0 12 O

No DT 0 0 2 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
effect NN 0 1 1 O
of IN 0 0 12 O
famotidine JJ 0 1 0 B-Drug
valproate NN 0 1 16 B-Drug
or CC 0 0 12 O
lithium NN 0 1 16 B-Drug
was VBD 1 0 12 O
seen VBN 1 1 12 O
on IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
aripiprazole NN 0 1 16 B-Drug
( ( 0 0 2 O
see VB 0 1 12 O
CLINICAL NNP 0 1 11 O
PHARMACOLOGY NNP 0 1 UNK O
: : 0 0 2 O
Drug NNP 0 1 2 O
- : 0 0 2 O
Drug NNP 0 1 2 O
Interactions NNP 0 1 UNK O
) ) 0 0 2 O
. . 0 0 12 O

Since IN 0 1 2 O
the DT 0 0 12 O
renal JJ 0 1 6 O
excretion NN 0 1 14 O
of IN 0 0 12 O
unchanged JJ 0 1 1 O
dasatinib NN 0 1 13 B-Drug
and CC 0 0 12 O
its PRP$ 1 0 12 O
metabolites NNS 1 1 UNK O
is VBZ 1 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
a DT 0 0 12 O
decrease NN 0 1 1 O
in IN 0 0 12 O
total JJ 0 1 1 O
body NN 0 1 3 O
clearance NN 0 1 16 O
is VBZ 1 0 12 O
not RB 0 1 12 O
expected VBN 1 1 12 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
renal JJ 0 1 6 O
insufficiency NN 0 1 6 O
. . 0 0 12 O

Nevertheless RB 0 0 1 O
caution NN 0 0 1 O
is VBZ 1 0 12 O
indicated VBN 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
co NN 0 1 12 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
TCAs NNP 0 1 UNK B-Group
with IN 0 0 12 O
any DT 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
SSRIs NNP 0 1 UNK B-Group
and CC 0 0 12 O
also RB 0 0 12 O
in IN 0 0 12 O
switching VBG 1 1 UNK O
from IN 0 0 12 O
one CD 0 1 12 O
class NN 0 1 12 O
to TO 0 0 12 O
the DT 0 0 12 O
other JJ 0 0 12 O
. . 0 0 12 O

efavirenz DT 0 1 13 B-Drug
concentration NN 0 1 1 O

Methyprylon NNP 0 1 UNK B-Drug
may MD 0 0 1 O
interact VB 0 0 UNK O
with IN 0 0 12 O
other JJ 0 0 12 O
addictive JJ 0 1 UNK O
medications NNS 1 1 6 O
in IN 0 0 12 O
that DT 0 0 12 O
it PRP 0 0 12 O
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
likelyhood NN 0 0 UNK O
of IN 0 0 12 O
addiction NN 0 1 12 O
and CC 0 0 12 O
abuse NN 0 1 12 O
. . 0 0 12 O

Antacids NNS 0 1 UNK B-Group
or CC 0 0 12 O
sucralfate VB 0 1 0 B-Drug
substantially RB 0 0 1 O
interfere RB 0 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
absorption NN 0 1 1 O
of IN 0 0 12 O
some DT 0 0 12 O
quinolones NNS 0 1 13 B-Group
resulting VBG 1 1 1 O
in IN 0 0 12 O
low JJ 0 1 1 O
urine NN 0 1 6 O
levels NNS 1 1 1 O
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
believed VBN 1 0 12 O
that IN 0 0 12 O
the DT 0 0 12 O
toxicity NN 0 1 6 O
may MD 0 0 1 O
have VB 0 0 12 O
resulted VBN 1 1 1 O
from IN 0 0 12 O
a DT 0 0 12 O
previously RB 0 0 1 O
unrecognized JJ 0 0 UNK O
interaction NN 0 1 UNK O
between IN 0 0 12 O
isoniazid NN 0 1 13 B-Drug
and CC 0 0 12 O
acetaminophen NN 0 1 16 B-Drug
and CC 0 0 12 O
a DT 0 0 12 O
molecular JJ 0 1 1 O
basis NN 0 1 1 O
for IN 0 0 12 O
this DT 0 0 12 O
interaction NN 0 1 UNK O
has VBZ 1 0 12 O
been VBN 1 0 12 O
proposed VBN 1 1 UNK O
. . 0 0 12 O

Ezetimibe NNP 0 1 0 B-Drug
crossed VBD 1 1 12 O
the DT 0 0 12 O
placenta NN 0 1 6 O
when WRB 0 0 12 O
pregnant JJ 0 1 13 O
rats NNS 1 1 UNK O
and CC 0 0 12 O
rabbits NNS 1 1 UNK O
were VBD 1 0 12 O
given VBN 1 1 12 O
multiple JJ 0 1 1 O
oral JJ 0 1 6 O
doses NNS 1 1 6 O
. . 0 0 12 O

Clarithromycin NN 0 1 UNK B-Drug

Subsequent JJ 0 1 13 O
adjustment NN 0 1 1 O
of IN 0 0 12 O
doses NNS 1 1 6 O
of IN 0 0 12 O
mercaptopurine NN 0 1 13 B-Drug
or CC 0 0 12 O
azathioprine NN 0 1 13 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
made VBN 1 1 12 O
on IN 0 0 12 O
the DT 0 0 12 O
basis NN 0 1 1 O
of IN 0 0 12 O
therapeutic JJ 0 1 6 O
response NN 0 1 1 O
and CC 0 0 12 O
the DT 0 0 12 O
appearance NN 0 1 12 O
of IN 0 0 12 O
toxic JJ 0 1 1 O
effects NNS 1 1 1 O
. . 0 0 12 O

Likewise RB 0 0 1 O
gabapentin NN 0 1 0 B-Drug
pharmacokinetics NNS 0 1 UNK O
were VBD 1 0 12 O
unaltered VBN 0 1 UNK O
by IN 0 0 12 O
carbamazepine JJ 0 1 16 B-Drug
administration NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
magnitude NN 0 1 UNK O
of IN 0 0 12 O
these DT 0 0 12 O
effects NNS 1 1 1 O
may MD 0 0 1 O
depend VB 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
duration NN 0 1 1 O
of IN 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
volatile JJ 0 1 UNK O
agents NNS 1 1 1 O
. . 0 0 12 O

Until IN 0 0 2 O
specific JJ 0 1 1 O
compatibility NN 0 1 UNK O
data NNS 0 1 1 O
are VBP 1 0 12 O
available JJ 0 1 1 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
not RB 0 1 12 O
recommended VBN 1 1 1 O
that IN 0 0 12 O
DOXIL NNP 0 1 UNK B-Brand
be VB 0 0 12 O
mixed VBN 1 1 3 O
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

In IN 0 0 2 O
patients NNS 1 1 6 O
using VBG 1 1 1 O
cardiac JJ 0 1 6 B-Group
glycosides NNS 1 1 13 I-Group
( ( 0 0 2 O
digoxin NN 0 1 14 B-Drug
and CC 0 0 12 O
others NNS 0 1 12 O
) ) 0 0 2 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
calcium NN 0 1 14 O
potassium NN 0 1 14 O
and CC 0 0 12 O
magnesium NN 0 1 14 O
must MD 0 0 12 O
be VB 0 0 12 O
carefully RB 0 0 12 O
monitored VBN 1 1 1 O
. . 0 0 12 O

Weak NNP 0 1 UNK O
inhibitory JJ 0 1 UNK O
effects NNS 1 1 1 O
toward IN 0 0 12 O
other JJ 0 0 12 O
isoforms NNS 0 1 UNK O
( ( 0 0 2 O
CYP9C9 NNP 0 0 UNK O
9C9 CD 0 0 UNK O
9C9 CD 0 0 UNK O
9D9 CD 0 0 UNK O
9A9 CD 0 0 UNK O
) ) 0 0 2 O
were VBD 1 0 12 O
found VBN 1 1 12 O
but CC 0 0 12 O
Ki NNP 0 0 UNK O
values NNS 1 1 1 O
were VBD 1 0 12 O
in IN 0 0 12 O
excess NN 0 1 1 O
of IN 0 0 12 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
achieved VBD 1 0 1 O
following VBG 1 1 1 O
dosing NN 0 0 14 O
. . 0 0 12 O

HMG NNP 0 0 UNK B-Group
- : 0 0 2 O
CoA NNP 0 0 UNK I-Group
Reductase NNP 0 1 UNK I-Group
Inhibitors NNS 0 1 7 I-Group
: : 0 0 2 O
lovastatin NN 0 1 13 B-Drug
simvastatin NN 0 1 0 B-Drug
WARNING NNP 0 1 11 O
potential NN 0 1 1 O
for IN 0 0 12 O
serious JJ 0 1 12 O
reactions NNS 1 1 1 O
such JJ 0 0 1 O
as IN 1 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
myopathy JJ 0 1 8 O
including VBG 1 1 1 O
rhabdomyolysis NN 0 1 8 O
. . 0 0 12 O

Discontinuing VBG 0 1 UNK O
colestipol NN 0 1 13 B-Drug
hydrochloride NN 0 1 0 I-Drug
could MD 0 0 12 O
pose VB 0 0 UNK O
a DT 0 0 12 O
hazard NN 0 1 13 O
to TO 0 0 12 O
health NN 0 1 1 O
if IN 0 0 12 O
a DT 0 0 12 O
potentially RB 0 0 1 O
toxic JJ 0 1 1 O
drug NN 0 1 1 O
that WDT 0 0 12 O
is VBZ 1 0 12 O
significantly RB 0 0 1 O
bound VBN 1 1 12 O
to TO 0 0 12 O
the DT 0 0 12 O
resin NN 0 1 UNK B-Group
has VBZ 1 0 12 O
been VBN 1 0 12 O
titrated VBN 1 1 14 O
to TO 0 0 12 O
a DT 0 0 12 O
maintenance NN 0 1 1 O
level NN 0 1 1 O
while IN 0 0 12 O
the DT 0 0 12 O
patient NN 0 1 6 O
was VBD 1 0 12 O
taking VBG 1 0 12 O
colestipol JJ 0 1 13 B-Drug
hydrochloride NN 0 1 0 I-Drug
. . 0 0 12 O

Given VBN 0 1 2 O
the DT 0 0 12 O
anticonvulsant JJ 0 1 14 O
properties NNS 1 1 UNK O
of IN 0 0 12 O
carbamazepine NN 0 1 16 B-Drug
EQUETROTM NNP 0 0 UNK B-Brand
may MD 0 0 1 O
reduce VB 0 0 1 O
the DT 0 0 12 O
thyroid NN 0 1 6 O
function NN 0 1 1 O
as IN 1 0 12 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
with IN 0 0 12 O
other JJ 0 0 12 O
anticonvulsants NNS 1 1 13 B-Group
. . 0 0 12 O

Additionally RB 0 0 1 O
anti JJ 0 0 3 B-Group
- : 0 0 2 O
malarial JJ 0 1 UNK I-Group
drugs NNS 1 1 6 I-Group
such JJ 0 0 1 O
as IN 1 0 12 O
chloroquine NN 0 1 13 B-Drug
and CC 0 0 12 O
mefloquine NN 0 1 13 B-Drug
may MD 0 0 1 O
antagonize VB 0 0 UNK O
the DT 0 0 12 O
activity NN 0 1 1 O
of IN 0 0 12 O
carbamazepine NN 0 1 16 B-Drug
. . 0 0 12 O

Accordingly RB 0 0 1 O
renal JJ 0 1 6 O
function NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
closely RB 0 0 1 O
monitored VBN 1 1 1 O
in IN 0 0 12 O
these DT 0 0 12 O
patients NNS 1 1 6 O
and CC 0 0 12 O
in IN 0 0 12 O
the DT 0 0 12 O
event NN 0 1 12 O
of IN 0 0 12 O
relevant JJ 0 1 1 O
significant JJ 0 1 1 O
changes NNS 1 1 1 O
in IN 0 0 12 O
laboratory NN 0 1 1 O
parameters NNS 1 1 1 O
bezafibrate VBP 0 1 UNK B-Drug
should MD 0 0 12 O
if IN 0 0 12 O
necessary JJ 0 0 1 O
be VB 0 0 12 O
discontinued VBN 1 1 1 O

Although IN 0 0 12 O
the DT 0 0 12 O
mechanism NN 0 1 13 O
of IN 0 0 12 O
interaction NN 0 1 UNK O
between IN 0 0 12 O
fenoprofen NN 0 1 UNK B-Drug
and CC 0 0 12 O
aspirin NN 0 1 14 B-Brand
is VBZ 1 0 12 O
not RB 0 1 12 O
totally RB 0 0 12 O
known VBN 1 1 12 O
enzyme JJ 0 1 14 O
induction NN 0 1 1 O
and CC 0 0 12 O
displacement NN 0 1 1 O
of IN 0 0 12 O
fenoprofen NN 0 1 UNK B-Drug
from IN 0 0 12 O
plasma JJ 0 1 14 O
albumin NN 0 1 14 O
binding NN 0 1 1 O
sites NNS 1 1 1 O
are VBP 1 0 12 O
possibilities NNS 1 1 1 O
. . 0 0 12 O

Metopirone NN 0 1 UNK B-Brand
inhibits VBZ 1 1 UNK O
the DT 0 0 12 O
glucuronidation NN 0 1 UNK O
of IN 0 0 12 O
acetaminophen NN 0 1 16 B-Drug
and CC 0 0 12 O
could MD 0 0 12 O
possibly RB 0 1 12 O
potentiate VB 0 0 UNK O
acetaminophen NN 0 1 16 B-Drug
toxicity NN 0 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
other JJ 0 0 12 O
potassium NN 0 1 14 B-Group
- : 0 0 2 O
sparing VBG 1 0 6 I-Group
antihypertensives NNS 1 1 14 I-Group
with IN 0 0 12 O
NSAIDs NNP 0 1 UNK B-Group
has VBZ 1 0 12 O
been VBN 1 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
reduce VB 0 0 1 O
the DT 0 0 12 O
antihypertensive JJ 0 1 14 O
effect NN 0 1 1 O
in IN 0 0 12 O
some DT 0 0 12 O
patients NNS 1 1 6 O
and CC 0 0 12 O
result NN 0 1 1 O
in IN 0 0 12 O
severe JJ 0 1 6 O
hyperkalemia NN 0 1 14 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
impaired JJ 0 1 6 O
renal JJ 0 1 6 O
function NN 0 1 1 O
. . 0 0 12 O

decreased VBN 1 1 1 O
pregnanediol JJ 0 1 UNK O
excretion NN 0 1 14 O
; : 0 0 2 O

. . 0 0 12 O

Colchicine NNP 0 1 0 B-Drug
is VBZ 1 0 12 O
inhibited VBN 1 1 13 O
by IN 0 0 12 O
acidifying VBG 1 0 13 B-Group
agents NNS 1 1 1 I-Group
. . 0 0 12 O

Pretreatment NN 0 1 UNK O
of IN 0 0 12 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
with IN 0 0 12 O
multiple JJ 0 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
rifampin NN 0 1 16 B-Drug
followed VBN 1 1 12 O
by IN 0 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
Gleevec NNP 0 1 UNK B-Brand
increased VBD 1 1 1 O
Gleevec NNP 0 1 UNK B-Brand
oral JJ 0 1 6 O
- : 0 0 2 O
dose JJ 0 1 6 O
clearance NN 0 1 16 O
by IN 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
fold NN 0 1 3 O
which WDT 0 0 12 O
significantly RB 0 0 1 O
( ( 0 0 2 O
p JJ 0 1 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
decreased VBN 1 1 1 O
mean JJ 0 1 12 O
cmax NN 0 1 UNK O
and CC 0 0 12 O
AUC NNP 0 1 UNK O
( ( 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

Electrolyte NNP 0 1 UNK O
Disturbances VBZ 0 1 UNK O
Patients NNS 0 1 7 O
with IN 0 0 12 O
hypokalemia NN 0 1 14 O
or CC 0 0 12 O
hypomagnesemia NN 0 1 8 O
should MD 0 0 12 O
have VB 0 0 12 O
the DT 0 0 12 O
condition NN 0 1 1 O
corrected VBD 1 1 1 O
whenever WRB 0 0 12 O
possible JJ 0 1 1 O
before IN 0 1 12 O
being VBG 1 0 12 O
treated VBN 1 1 1 O
with IN 0 0 12 O
Cordarone NNP 0 1 UNK B-Drug
I.V. NNP 0 1 UNK I-Drug
as IN 1 0 12 O
these DT 0 0 12 O
disorders NNS 1 1 6 O
can MD 0 0 12 O
exaggerate VB 0 1 UNK O
the DT 0 0 12 O
degree NN 0 1 1 O
of IN 0 0 12 O
QTc NNP 0 0 14 O
prolongation NN 0 1 6 O
and CC 0 0 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
potential JJ 0 1 1 O
for IN 0 0 12 O
TdP NNP 0 0 UNK O
. . 0 0 12 O

Caution NN 0 0 UNK O
is VBZ 1 0 12 O
therefore RB 0 0 1 O
advised JJ 0 0 12 O
when WRB 0 0 12 O
administering VBG 1 1 1 O
PEGANONE NNP 0 1 UNK B-Brand
to TO 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
coumarin JJ 0 1 UNK B-Group
anticoagulants NNS 1 1 13 I-Group
. . 0 0 12 O

Therefore NNP 0 0 1 O
administration NN 0 1 1 O
of IN 0 0 12 O
quinolones NNS 0 1 13 B-Group
with IN 0 0 12 O
antacids NNS 1 1 14 B-Group
containing VBG 1 1 1 O
calcium NN 0 1 14 B-Drug
magnesium NN 0 1 14 B-Drug
or CC 0 0 12 O
aluminum NN 0 1 16 B-Drug
; : 0 0 2 O

The DT 0 0 2 O
mechanism NN 0 1 13 O
for IN 0 0 12 O
this DT 0 0 12 O
interaction NN 0 1 UNK O
probably RB 0 1 12 O
is VBZ 1 0 12 O
adsorption NN 0 1 UNK O
of IN 0 0 12 O
nitrofurantoin NN 0 1 0 B-Drug
onto IN 0 0 3 O
the DT 0 0 12 O
surface NN 0 1 3 O
of IN 0 0 12 O
magnesium NN 0 1 14 B-Drug
trisilicate NN 0 0 UNK I-Drug
. . 0 0 12 O

If IN 0 0 12 O
you PRP 0 0 12 O
are VBP 1 0 12 O
taking VBG 1 0 12 O
a DT 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressant JJ 0 1 6 I-Group
talk NN 0 1 12 O
to TO 0 0 12 O
your PRP$ 0 0 12 O
doctor NN 0 1 12 O
before IN 0 1 12 O
taking VBG 1 0 12 O
this DT 0 0 12 O
medicine NN 0 1 6 O
. . 0 0 12 O

Calcium NNP 0 1 7 B-Group
channel NN 0 1 1 I-Group
blockers NNS 1 0 6 I-Group
may MD 0 0 1 O
also RB 0 0 12 O
have VB 0 0 12 O
an DT 0 0 12 O
additive JJ 0 1 16 O
effect NN 0 1 1 O
when WRB 0 0 12 O
given VBN 1 1 12 O
with IN 0 0 12 O
TENORMIN NNP 0 1 UNK B-Brand
. . 0 0 12 O

The DT 0 0 2 O
fraction NN 0 1 1 O
of IN 0 0 12 O
STADOL NNP 0 1 UNK B-Brand
NS NNP 0 1 13 I-Brand
absorbed VBD 1 0 3 O
is VBZ 1 0 12 O
unaffected VBN 0 1 UNK O
by IN 0 0 12 O
the DT 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
nasal JJ 0 1 6 B-Group
vasoconstrictor NN 0 1 UNK I-Group
( ( 0 0 2 O
oxymetazoline JJ 0 1 16 B-Drug
) ) 0 0 2 O
but CC 0 0 12 O
the DT 0 0 12 O
rate NN 0 1 1 O
of IN 0 0 12 O
absorption NN 0 1 1 O
is VBZ 1 0 12 O
decreased VBN 1 1 1 O
. . 0 0 12 O

indinavir NN 0 1 16 B-Drug
concentration NN 0 1 1 O

However RB 0 0 1 O
because IN 0 0 12 O
some DT 0 0 12 O
quinolones NNS 0 1 13 B-Group
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
enhance VB 0 1 UNK O
the DT 0 0 12 O
anticoagulant JJ 0 1 13 O
effects NNS 1 1 1 O
of IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
or CC 0 0 12 O
its PRP$ 1 0 12 O
derivatives NNS 1 1 13 O
in IN 0 0 12 O
patients NNS 1 1 6 O
the DT 0 0 12 O
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
or CC 0 0 12 O
other JJ 0 0 12 O
suitable JJ 0 1 1 O
coagulation NN 0 1 14 O
test NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
closely RB 0 0 1 O
monitored VBN 1 1 1 O
if IN 0 0 12 O
a DT 0 0 12 O
quinolone NN 0 1 UNK B-Group
antimicrobial NN 0 1 14 I-Group
is VBZ 1 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
or CC 0 0 12 O
its PRP$ 1 0 12 O
derivatives NNS 1 1 13 O
. . 0 0 12 O

However RB 0 0 1 O
because IN 0 0 12 O
bleeding NN 0 1 6 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
when WRB 0 0 12 O
ibuprofen NN 0 1 0 B-Drug
and CC 0 0 12 O
other JJ 0 0 12 O
nonsteroidal JJ 0 0 14 B-Group
anti SYM 0 0 3 I-Group
- : 0 0 2 O
inflammatory NN 0 1 6 I-Group
agents NNS 1 1 1 I-Group
have VBP 0 0 12 O
been VBN 1 0 12 O
administered VBN 1 1 1 O
to TO 0 0 12 O
patients NNS 1 1 6 O
on IN 0 0 12 O
coumarin JJ 0 1 UNK B-Group
- : 0 0 2 O
type NN 0 1 1 I-Group
anticoagulants VBZ 0 1 13 I-Group
the DT 0 0 12 O
physician NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
cautious JJ 0 0 UNK O
when WRB 0 0 12 O
administering VBG 1 1 1 O
ibuprofen NN 0 1 0 B-Drug
to TO 0 0 12 O
patients NNS 1 1 6 O
on IN 0 0 12 O
anticoagulants NNS 1 1 13 B-Group
. . 0 0 12 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interactions NNP 0 1 UNK O
Phenytoin NNP 0 1 0 B-Drug
may MD 0 0 1 O
decrease VB 0 1 1 O
serum JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
9 CD 0 0 2 O
. . 0 0 12 O

vi NN 0 1 13 O
. . 0 0 12 O

Increased VBN 0 1 7 O
thyroid JJ 0 1 6 O
- : 0 0 2 O
binding NN 0 1 1 O
globulin NN 0 1 14 O
( ( 0 0 2 O
TBG NNP 0 1 UNK O
) ) 0 0 2 O
leading VBG 1 1 1 O
to TO 0 0 12 O
increased VBN 1 1 1 O
circulating VBG 1 1 13 O
total JJ 0 1 1 O
thyroid JJ 0 1 6 O
hormone NN 0 1 6 O
levels NNS 1 1 1 O
as IN 1 0 12 O
measured VBN 1 1 1 O
by IN 0 0 12 O
protein NN 0 1 14 O
- : 0 0 2 O
bound NN 0 1 12 O
iodine NN 0 1 14 O
( ( 0 0 2 O
PBI NNP 0 1 UNK O
) ) 0 0 2 O
T9 NNP 0 1 13 O
levels NNS 1 1 1 O
( ( 0 0 2 O
by IN 0 0 12 O
column NN 0 1 1 O
or CC 0 0 12 O
by IN 0 0 12 O
radioimmunoassay NN 0 1 UNK O
) ) 0 0 2 O
or CC 0 0 12 O
T9 NNP 0 1 13 O
levels NNS 1 1 1 O
by IN 0 0 12 O
radioimmunoassay NN 0 1 UNK O
. . 0 0 12 O

In IN 0 0 2 O
some DT 0 0 12 O
cases NNS 1 1 UNK O
the DT 0 0 12 O
onset NN 0 1 6 O
of IN 0 0 12 O
the DT 0 0 12 O
injection NN 0 1 3 O
site NN 0 1 12 O
reaction NN 0 1 1 O
either RB 0 1 12 O
occurred VBD 1 1 1 O
during IN 0 0 12 O
a DT 0 0 12 O
prolonged JJ 0 1 6 O
infusion NN 0 1 14 O
or CC 0 0 12 O
was VBD 1 0 12 O
delayed VBN 1 1 1 O
by IN 0 0 12 O
a DT 0 0 12 O
week NN 0 1 12 O
to TO 0 0 12 O
ten VB 0 1 12 O
days NNS 1 1 12 O
. . 0 0 12 O

In IN 0 0 2 O
a DT 0 0 12 O
large JJ 0 1 3 O
compassionate NN 0 1 UNK O
use NN 0 1 1 O
program NN 0 1 1 O
Mexitil NNP 0 1 UNK B-Brand
has VBZ 1 0 12 O
been VBN 1 0 12 O
used VBN 1 1 12 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
commonly RB 0 0 UNK O
employed VBN 1 1 1 O
antianginal JJ 0 1 UNK O
antihypertensive NN 0 1 14 B-Group
and CC 0 0 12 O
anticoagulant JJ 0 1 13 B-Group
drugs NNS 1 1 6 I-Group
without IN 0 0 12 O
observed JJ 0 1 1 O
interactions NNS 1 1 UNK O
. . 0 0 12 O

If IN 0 0 12 O
antacid JJ 0 1 UNK B-Group
therapy NN 0 1 6 O
is VBZ 1 0 12 O
needed VBN 1 1 12 O
the DT 0 0 12 O
antacid NN 0 1 UNK O
dose NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
at IN 0 0 12 O
least JJS 0 1 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
prior RB 0 1 1 O
to TO 0 0 12 O
or CC 0 0 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
after IN 0 0 12 O
the DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
SPRYCEL NNP 0 1 UNK B-Brand
. . 0 0 12 O

In IN 0 0 2 O
clinical JJ 0 1 6 O
studies NNS 1 1 1 O
the DT 0 0 12 O
concurrent JJ 0 1 1 O
administration NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
ASMANEX NNP 0 1 UNK B-Brand
TWISTHALER NNP 0 0 UNK I-Brand
inhaler NN 0 1 0 O
and CC 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
commonly RB 0 0 UNK O
used VBN 1 1 12 O
in IN 0 0 12 O
the DT 0 0 12 O
treatment NN 0 1 6 O
of IN 0 0 12 O
asthma NN 0 1 6 O
was VBD 1 0 12 O
not RB 0 1 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
any DT 0 0 12 O
unusual JJ 0 1 12 O
adverse JJ 0 0 1 O
events NNS 1 1 12 O
. . 0 0 12 O

Ketoconazole NNP 0 1 UNK B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
once RB 0 0 12 O
daily JJ 0 1 12 O
) ) 0 0 2 O
produced VBD 1 0 1 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
fold JJ 0 1 3 O
increase NN 0 1 1 O
in IN 0 0 12 O
vardenafil JJ 0 1 UNK B-Drug
AUC NNP 0 1 UNK O
and CC 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
fold JJ 0 1 3 O
increase NN 0 1 1 O
in IN 0 0 12 O
Cmax NNP 0 1 UNK O
when WRB 0 0 12 O
co NN 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
with IN 0 0 12 O
Vardenafil NNP 0 1 UNK B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
) ) 0 0 2 O
in IN 0 0 12 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
. . 0 0 12 O

Propranolol NNP 0 1 0 B-Drug
attenuated VBD 1 1 UNK O
the DT 0 0 12 O
heart NN 0 1 12 O
rate NN 0 1 1 O
increase NN 0 1 1 O
following VBG 1 1 1 O
administration NN 0 1 1 O
of IN 0 0 12 O
immediate JJ 0 1 1 O
release NN 0 1 12 O
nisoldipine NN 0 1 13 B-Drug
. . 0 0 12 O

. . 0 0 12 O

Montelukast NNP 0 1 0 B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
other JJ 0 0 12 O
therapies NNS 1 1 6 O
routinely RB 0 0 1 O
used VBN 1 1 12 O
in IN 0 0 12 O
the DT 0 0 12 O
prophylaxis NN 0 1 6 O
and CC 0 0 12 O
chronic JJ 0 1 6 O
treatment NN 0 1 6 O
of IN 0 0 12 O
asthma NN 0 1 6 O
with IN 0 0 12 O
no DT 0 0 12 O
apparent JJ 0 1 1 O
increase NN 0 1 1 O
in IN 0 0 12 O
adverse JJ 0 0 1 O
reactions NNS 1 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
another DT 0 0 12 O
study NN 0 1 1 O
with IN 0 0 12 O
intravenous JJ 0 1 14 O
administration NN 0 1 1 O
of IN 0 0 12 O
midazolam JJ 0 1 16 B-Drug
Aprepitant NNP 0 1 UNK B-Drug
was VBD 1 0 12 O
given VBN 1 1 12 O
as IN 1 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
on IN 0 0 12 O
Day NNP 0 1 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
on IN 0 0 12 O
Days NNP 0 1 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
and CC 0 0 12 O
midazolam $ 0 1 16 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
IV NNP 0 1 2 O
was VBD 1 0 12 O
given VBN 1 1 12 O
prior RB 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
day NN 0 1 12 O
regimen NNS 0 1 6 O
of IN 0 0 12 O
Aprepitant NNP 0 1 UNK B-Drug
and CC 0 0 12 O
on IN 0 0 12 O
Days NNP 0 1 2 O
9 CD 0 0 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
. . 0 0 12 O

Since IN 0 1 2 O
this DT 0 0 12 O
could MD 0 0 12 O
be VB 0 0 12 O
explained VBN 1 0 12 O
either RB 0 1 12 O
by IN 0 0 12 O
enhanced JJ 0 1 1 O
absorption NN 0 1 1 O
or CC 0 0 12 O
by IN 0 0 12 O
an DT 0 0 12 O
alteration NN 0 1 1 O
of IN 0 0 12 O
hepatic JJ 0 1 14 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
labetalol JJ 0 1 0 B-Drug
HCl NNP 0 0 14 I-Drug
special JJ 0 1 12 O
care NN 0 1 12 O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
in IN 0 0 12 O
establishing VBG 1 1 UNK O
the DT 0 0 12 O
dose NN 0 1 6 O
required VBN 1 1 1 O
for IN 0 0 12 O
blood NN 0 1 6 O
pressure NN 0 1 1 O
control NN 0 1 1 O
in IN 0 0 12 O
such JJ 0 0 1 O
patients NNS 1 1 6 O
. . 0 0 12 O

Omeprazole NN 0 1 0 B-Drug
: : 0 0 2 O
Omeprazole NNP 0 1 0 B-Drug
is VBZ 1 0 12 O
a DT 0 0 12 O
CYP NNP 0 1 UNK O
9A9 CD 0 0 UNK O
substrate NN 0 1 UNK O
and CC 0 0 12 O
CYP NNP 0 1 UNK O
9C9 CD 0 0 UNK O
substrate NN 0 1 UNK O
and CC 0 0 12 O
inhibitor NN 0 1 14 O
. . 0 0 12 O

The DT 0 0 2 O
interaction NN 0 1 UNK O
of IN 0 0 12 O
Streptase NNP 0 1 UNK B-Brand
Streptokinase NNP 0 1 15 B-Drug
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
well RB 0 1 12 O
studied VBN 1 0 1 O
. . 0 0 12 O

It PRP 0 0 12 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
that IN 0 0 12 O
Itraconazole NNP 0 1 UNK B-Drug
enhances VBZ 1 1 UNK O
the DT 0 0 12 O
anticoagulant JJ 0 1 13 O
effect NN 0 1 1 O
of IN 0 0 12 O
coumarin NN 0 1 UNK B-Group
- : 0 0 2 O
like IN 0 0 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

Caution NN 0 0 UNK O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
when WRB 0 0 12 O
administering VBG 1 1 1 O
substrates NNS 1 1 UNK O
of IN 0 0 12 O
CYP9B9 NNP 0 0 UNK O
and CC 0 0 12 O
CYP9C9 NNP 0 0 UNK O
with IN 0 0 12 O
NEXAVAR NNP 0 1 UNK B-Brand
. . 0 0 12 O

Elevated VBN 0 1 7 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
theophylline NN 0 1 16 B-Drug
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
with IN 0 0 12 O
concomitant NN 0 1 6 O
quinolone NN 0 1 UNK B-Group
use NN 0 1 1 O
. . 0 0 12 O

Lansoprazole JJ 0 1 0 B-Drug
causes VBZ 1 1 6 O
a DT 0 0 12 O
profound NN 0 1 1 O
and CC 0 0 12 O
long JJ 0 1 12 O
lasting JJ 0 0 1 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
gastric JJ 0 1 6 O
acid JJ 0 1 14 O
secretion NN 0 1 14 O
; : 0 0 2 O

serum NN 0 1 14 O
magnesium NN 0 1 14 O
levels NNS 1 1 1 O
may MD 0 0 1 O
increase VB 0 1 1 O
in IN 0 0 12 O
uremic JJ 0 0 13 O
patients NNS 1 1 6 O
) ) 0 0 2 O
Serum NNP 0 1 7 O
protein SYM 0 1 14 O
- : 0 0 2 O
bound NN 0 1 12 O
iodine NN 0 1 14 O
( ( 0 0 2 O
PBI NNP 0 1 UNK O
) ) 0 0 2 O
levels NNS 1 1 1 O
( ( 0 0 2 O
may MD 0 0 1 O
be VB 0 0 12 O
decreased VBN 1 1 1 O
) ) 0 0 2 O
Thiazides NNP 0 1 UNK B-Group
should MD 0 0 12 O
be VB 0 0 12 O
discontinued VBN 1 1 1 O
before IN 0 1 12 O
carrying VBG 1 1 12 O
out RP 0 1 12 O
tests NNS 1 1 1 O
for IN 0 0 12 O
parathyroid JJ 0 1 14 O
function NN 0 1 1 O
. . 0 0 12 O

Indocyanine NNP 0 0 UNK B-Drug_n
green NN 0 1 3 I-Drug_n
as IN 1 0 12 O
an DT 0 0 12 O
index NN 0 1 1 O
of IN 0 0 12 O
hepatic JJ 0 1 14 O
drug NN 0 1 1 O
extraction NN 0 1 1 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
tested VBN 1 1 1 O
and CC 0 0 12 O
no DT 0 0 12 O
significant JJ 0 1 1 O
effects NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
found VBN 1 1 12 O
. . 0 0 12 O

Neuromuscular JJ 0 1 UNK B-Group
Blockers NNS 0 0 UNK I-Group
: : 0 0 2 O
In IN 0 0 2 O
one CD 0 1 12 O
study NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
PRECEDEX NNP 0 1 UNK B-Brand
for IN 0 0 12 O
9 CD 0 0 2 O
minutes NNS 1 1 12 O
at IN 0 0 12 O
a DT 0 0 12 O
plasma JJ 0 1 14 O
concentration NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
( ( 0 0 2 O
one CD 0 1 12 O
) ) 0 0 2 O
ng NN 0 1 13 O
/ NNP 0 0 2 O
mL NN 0 1 14 O
resulted VBD 1 1 1 O
in IN 0 0 12 O
no DT 0 0 12 O
clinically RB 0 0 6 O
meaningful JJ 0 1 1 O
increases NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
magnitude NN 0 1 UNK O
or CC 0 0 12 O
neuromuscular JJ 0 1 6 O
blockade NN 0 1 1 O
associated VBN 1 1 1 O
with IN 0 0 12 O
rocuronium NN 0 1 16 B-Drug
administration NN 0 1 1 O
. . 0 0 12 O

Cold NNP 0 1 UNK O
and CC 0 0 12 O
flu JJ 0 1 6 O
remedies NNS 1 0 6 O
. . 0 0 12 O

Corticotropin NNP 0 1 UNK B-Drug
may MD 0 0 1 O
accentuate VB 0 0 UNK O
the DT 0 0 12 O
electrolyte JJ 0 1 14 O
loss NN 0 1 1 O
associated VBN 1 1 1 O
with IN 0 0 12 O
diuretic JJ 0 1 14 B-Drug
therapy NN 0 1 6 O
. . 0 0 12 O

Trimethoprim VB 0 1 0 B-Drug
given VBN 1 1 12 O
at IN 0 0 12 O
a DT 0 0 12 O
common JJ 0 1 1 O
clinical JJ 0 1 6 O
dosage NN 0 1 0 O
increased VBD 1 1 1 O
the DT 0 0 12 O
phenytoin NN 0 1 16 B-Drug
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
decreased VBD 1 1 1 O
the DT 0 0 12 O
phenytoin NN 0 1 16 B-Drug
metabolic JJ 0 1 6 O
clearance NN 0 1 16 O
rate NN 0 1 1 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

Because IN 0 0 12 O
prostaglandins NNS 1 1 UNK O
play VBP 0 1 13 O
an DT 0 0 12 O
important JJ 0 1 1 O
role NN 0 1 1 O
in IN 0 0 12 O
hemostasis NN 0 1 UNK O
and CC 0 0 12 O
NSAIDs NNP 0 1 UNK B-Group
affect VBP 0 1 1 O
platelet NN 0 1 14 O
function NN 0 1 1 O
as IN 1 0 12 O
well RB 0 1 12 O
concurrent JJ 0 1 1 O
therapy NN 0 1 6 O
with IN 0 0 12 O
all DT 0 0 12 O
NSAIDs NNP 0 1 UNK B-Group
including VBG 1 1 1 O
diclofenac NN 0 1 16 B-Drug
and CC 0 0 12 O
warfarin NN 0 1 14 B-Drug
requires VBZ 1 0 1 O
close JJ 0 1 12 O
monitoring NN 0 1 1 O
of IN 0 0 12 O
patients NNS 1 1 6 O
to TO 0 0 12 O
be VB 0 0 12 O
certain JJ 0 1 1 O
that IN 0 0 12 O
no DT 0 0 12 O
change NN 0 1 1 O
in IN 0 0 12 O
their PRP$ 0 0 12 O
anticoagulant JJ 0 1 13 B-Group
dosage NN 0 1 0 O
is VBZ 1 0 12 O
required VBN 1 1 1 O
. . 0 0 12 O

Therefore RB 0 0 1 O
caution NN 0 0 1 O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
when WRB 0 0 12 O
administering VBG 1 1 1 O
MEPRON NNP 0 1 UNK B-Brand
concurrently RB 0 0 1 O
with IN 0 0 12 O
other JJ 0 0 12 O
highly RB 0 1 1 O
plasma JJ 0 1 14 O
protein NN 0 1 14 O
- : 0 0 2 O
bound NN 0 1 12 O
drugs NNS 1 1 6 O
with IN 0 0 12 O
narrow JJ 0 1 3 O
therapeutic JJ 0 1 6 O
indices NNS 1 1 UNK O
as IN 1 0 12 O
competition NN 0 1 12 O
for IN 0 0 12 O
binding VBG 1 1 1 O
sites NNS 1 1 1 O
may MD 0 0 1 O
occur VB 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
incidence NN 0 1 6 O
of IN 0 0 12 O
upper JJ 0 1 3 O
gastrointestinal JJ 0 1 6 O
events NNS 1 1 12 O
in IN 0 0 12 O
patients NNS 1 1 6 O
concomitantly RB 0 0 14 O
taking VBG 1 0 12 O
aspirin NN 0 1 14 B-Brand
or CC 0 0 12 O
NSAIDs NNP 0 1 UNK B-Group
was VBD 1 0 12 O
similar JJ 0 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
ibandronate JJ 0 1 13 B-Drug
9 CD 0 0 2 O
mg JJ 0 1 0 O
daily JJ 0 1 12 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
once RB 0 0 12 O
monthly JJ 0 1 1 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
. . 0 0 12 O

Mephenytoin NNP 0 1 UNK B-Drug
may MD 0 0 1 O
also RB 0 0 12 O
affect VB 0 1 1 O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
which WDT 0 0 12 O
include VBP 0 1 1 O
some DT 0 0 12 O
steroid JJ 0 1 6 B-Group
medications NNS 1 1 6 I-Group
warfarin VBP 0 1 14 B-Drug
certain JJ 0 1 1 O
heart NN 0 1 12 O
medicines NNS 1 1 6 O
birth IN 0 1 12 O
control NN 0 1 1 O
pills NNS 1 1 6 O
anti VBP 0 0 3 B-Group
- : 0 0 2 O
infective JJ 0 0 13 I-Group
medicines NNS 1 1 6 I-Group
furosemide RB 0 1 0 B-Drug
and CC 0 0 12 O
theophylline JJ 0 1 16 B-Drug
Please NNP 0 0 2 O
note NN 0 1 12 O
that IN 0 0 12 O
Mephenytoin NNP 0 1 UNK B-Drug
may MD 0 0 1 O
interact VB 0 0 UNK O
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
are VBP 1 0 12 O
not RB 0 1 12 O
listed VBN 1 1 1 O
here RB 0 0 12 O
. . 0 0 12 O

The DT 0 0 2 O
clearance NN 0 1 16 O
of IN 0 0 12 O
theophylline NN 0 1 16 B-Drug
was VBD 1 0 12 O
decreased VBN 1 1 1 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
- : 0 0 2 O
fold NN 0 1 3 O
. . 0 0 12 O

It PRP 0 0 12 O
may MD 0 0 1 O
also RB 0 0 12 O
interact VB 0 0 UNK O
with IN 0 0 12 O
thiazides NNS 1 1 UNK B-Group
( ( 0 0 2 O
increased VBN 1 1 1 O
thrombocytopenia NN 0 1 14 O
) ) 0 0 2 O
cyclosporine NN 0 1 14 B-Drug
( ( 0 0 2 O
increased JJ 0 1 1 O
nephrotoxicity NN 0 1 UNK O
) ) 0 0 2 O
sulfonylurea NN 0 1 UNK B-Group
agents NNS 1 1 1 I-Group
( ( 0 0 2 O
increased VBN 1 1 1 O
hypoglycemic JJ 0 1 14 O
response NN 0 1 1 O
) ) 0 0 2 O
warfarin NN 0 1 14 B-Drug
( ( 0 0 2 O
increased VBN 1 1 1 O
anticoagulant RB 0 1 13 O
effect NN 0 1 1 O
) ) 0 0 2 O
methotrexate NN 0 1 16 B-Drug
( ( 0 0 2 O
decreased JJ 0 1 1 O
renal JJ 0 1 6 O
excretion NN 0 1 14 O
of IN 0 0 12 O
methotrexate NN 0 1 16 B-Drug
) ) 0 0 2 O
phenytoin NN 0 1 16 B-Drug
( ( 0 0 2 O
decreased VBN 1 1 1 O
hepatic JJ 0 1 14 O
clearance NN 0 1 16 O
of IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

Concomitant JJ 0 1 UNK O
Administration NNP 0 1 UNK O
with IN 0 0 12 O
Racemic NNP 0 1 UNK O
Citalopram NNP 0 1 0 B-Drug
Citalopram NNP 0 1 0 B-Drug
- : 0 0 2 O
Since IN 0 1 2 O
escitalopram NN 0 1 0 B-Drug
is VBZ 1 0 12 O
the DT 0 0 12 O
active JJ 0 1 1 O
isomer NN 0 1 UNK O
of IN 0 0 12 O
racemic JJ 0 1 14 O
citalopram NN 0 1 16 B-Drug
( ( 0 0 2 O
Celexa NNP 0 1 0 B-Brand
) ) 0 0 2 O
the DT 0 0 12 O
two CD 0 1 12 O
agents NNS 1 1 1 O
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
coadministered VBN 0 0 UNK O
. . 0 0 12 O

Saquinavir NN 0 1 UNK B-Drug

Additional JJ 0 1 2 O
animals NNS 1 1 12 O
in IN 0 0 12 O
both DT 0 0 12 O
dose JJ 0 1 6 O
groups NNS 1 1 1 O
developed VBD 1 0 1 O
B NNP 0 0 2 O
- : 0 0 2 O
cell NN 0 1 1 O
hyperplasia NN 0 1 13 O
of IN 0 0 12 O
the DT 0 0 12 O
spleen NN 0 1 6 O
and CC 0 0 12 O
lymph NN 0 1 6 O
nodes NNS 1 1 1 O
. . 0 0 12 O

Although IN 0 0 12 O
additional JJ 0 1 1 O
specific JJ 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
were VBD 1 0 12 O
not RB 0 1 12 O
performed VBN 1 1 1 O
montelukast NN 0 1 16 B-Drug
was VBD 1 0 12 O
used VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
a DT 0 0 12 O
wide JJ 0 1 3 O
range NN 0 1 1 O
of IN 0 0 12 O
commonly RB 0 0 UNK O
prescribed VBN 1 1 1 O
drugs NNS 1 1 6 O
in IN 0 0 12 O
clinical JJ 0 1 6 O
studies NNS 1 1 1 O
without IN 0 0 12 O
evidence NN 0 1 1 O
of IN 0 0 12 O
clinical JJ 0 1 6 O
adverse JJ 0 0 1 O
interactions NNS 1 1 UNK O
. . 0 0 12 O

Drugs NNS 0 1 2 O
That WDT 0 0 2 O
Interfere NNP 0 1 UNK O
With IN 0 0 2 O
Hemostasis NNP 0 1 UNK O
( ( 0 0 2 O
NSAIDs NNP 0 1 UNK B-Group
Aspirin NNP 0 1 0 B-Brand
Warfarin NNP 0 1 0 B-Drug
etc FW 0 1 12 O
. . 0 0 12 O
) ) 0 0 2 O

In IN 0 0 2 O
a DT 0 0 12 O
study NN 0 1 1 O
in IN 0 0 12 O
which WDT 0 0 12 O
the DT 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
clonazepam NN 0 1 0 B-Drug
orally RB 0 1 14 O
disintegrating VBG 1 1 16 O
tablet NN 0 1 16 O
was VBD 1 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
and CC 0 0 12 O
without IN 0 0 12 O
propantheline NN 0 1 13 B-Drug
( ( 0 0 2 O
an DT 0 0 12 O
anticholinergic NN 0 1 13 B-Group
agent NN 0 1 1 I-Group
with IN 0 0 12 O
multiple JJ 0 1 1 O
effects NNS 1 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
GI NNP 0 1 6 O
tract NN 0 1 6 O
) ) 0 0 2 O
to TO 0 0 12 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
the DT 0 0 12 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
clonazepam NN 0 1 0 B-Drug
was VBD 1 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
lower JJR 1 1 1 O
and CC 0 0 12 O
the DT 0 0 12 O
Cmax NNP 0 1 UNK O
of IN 0 0 12 O
clonazepam NN 0 1 0 B-Drug
was VBD 1 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
lower JJR 1 1 1 O
when WRB 0 0 12 O
the DT 0 0 12 O
orally RB 0 1 14 O
disintegrating VBG 1 1 16 O
tablet NN 0 1 16 O
was VBD 1 0 12 O
given VBN 1 1 12 O
with IN 0 0 12 O
propantheline NN 0 1 13 B-Drug
compared VBN 1 1 1 O
to TO 0 0 12 O
when WRB 0 0 12 O
it PRP 0 0 12 O
was VBD 1 0 12 O
given VBN 1 1 12 O
alone RB 0 1 12 O
. . 0 0 12 O

Trileptal NNP 0 1 UNK B-Brand
dose NN 0 1 6 O
( ( 0 0 2 O
mg JJ 0 1 0 O
/ NNP 0 0 2 O
day NN 0 1 12 O
) ) 0 0 2 O

However RB 0 0 1 O
it PRP 0 0 12 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
established VBN 1 1 1 O
that IN 0 0 12 O
acitretin NN 0 1 13 B-Drug
interferes NNS 0 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
contraceptive JJ 0 1 13 O
effect NN 0 1 1 O
of IN 0 0 12 O
microdosed JJ 0 0 UNK O
progestin NN 0 1 UNK B-Drug
minipill NN 0 1 UNK O
preparations NNS 1 1 13 O
. . 0 0 12 O

The DT 0 0 2 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
rimantadine NN 0 1 13 B-Drug
were VBD 1 0 12 O
assessed VBN 1 1 1 O
on IN 0 0 12 O
days NNS 1 1 12 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
. . 0 0 12 O

Coadministration NN 0 1 UNK O
of IN 0 0 12 O
TRITEC NNP 0 1 UNK B-Brand
with IN 0 0 12 O
clarithromycin NN 0 1 13 B-Drug
resulted VBN 1 1 1 O
in IN 0 0 12 O
increased JJ 0 1 1 O
plasma NN 0 1 14 O
ranitidine NN 0 1 0 B-Drug
concentrations NNS 1 1 13 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
increased VBD 1 1 1 O
plasma JJ 0 1 14 O
bismuth NN 0 1 16 O
trough IN 0 1 3 O
concentrations NNS 1 1 13 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
and CC 0 0 12 O
increased VBD 1 1 1 O
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
hydroxy NN 0 1 14 I-Drug_n
- : 0 0 2 O
clarithromycin NN 0 1 13 I-Drug_n
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
. . 0 0 12 O

In IN 0 0 2 O
a DT 0 0 12 O
study NN 0 1 1 O
in IN 0 0 12 O
which WDT 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
active JJ 0 1 1 O
RA NNP 0 1 13 O
were VBD 1 0 12 O
treated VBN 1 1 1 O
for IN 0 0 12 O
up RB 0 0 12 O
to TO 0 0 12 O
9 CD 0 0 2 O
weeks NNS 1 1 12 O
with IN 0 0 12 O
concurrent JJ 0 1 1 O
Kineret NNP 0 1 UNK B-Brand
and CC 0 0 12 O
etanercept VBD 0 1 13 B-Drug
therapy NN 0 1 6 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
rate NN 0 1 1 O
of IN 0 0 12 O
serious JJ 0 1 12 O
infections NNS 1 1 6 O
was VBD 1 0 12 O
observed VBN 1 1 1 O
which WDT 0 0 12 O
was VBD 1 0 12 O
higher JJR 1 1 1 O
than IN 0 0 12 O
that DT 0 0 12 O
observed VBD 1 1 1 O
with IN 0 0 12 O
etanercept JJ 0 1 13 B-Drug
alone RB 0 1 12 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
. . 0 0 12 O

These DT 0 0 1 O
above IN 0 1 12 O
findings NNS 1 1 1 O
are VBP 1 0 12 O
summarized VBN 1 0 1 O
in IN 0 0 12 O
TABLE NNP 0 1 UNK O
9 CD 0 0 2 O
. . 0 0 12 O

To TO 0 0 2 O
minimize VB 0 0 1 O
CNS NNP 0 1 6 O
depression NN 0 1 6 O
and CC 0 0 12 O
possible JJ 0 1 1 O
potentiation NN 0 1 UNK O
barbiturates NNS 1 1 14 B-Group
antihistamines VBP 0 1 UNK B-Group
narcotics NNS 1 1 1 B-Group
hypotensive JJ 0 1 14 B-Group
agents NNS 1 1 1 I-Group
or CC 0 0 12 O
phenothiazines NNS 1 1 UNK B-Group
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
with IN 0 0 12 O
caution NN 0 0 1 O
. . 0 0 12 O

Concomitant JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
fenofibrate NN 0 1 16 B-Drug
( ( 0 0 2 O
equivalent JJ 0 1 1 O
to TO 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
TRICOR NNP 0 1 UNK B-Brand
) ) 0 0 2 O
with IN 0 0 12 O
atorvastatin NN 0 1 0 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
) ) 0 0 2 O
once RB 0 0 12 O
daily JJ 0 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
resulted VBD 1 1 1 O
in IN 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
decrease NN 0 1 1 O
( ( 0 0 2 O
range NN 0 1 1 O
from IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
decrease NN 0 1 1 O
to TO 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
increase NN 0 1 1 O
) ) 0 0 2 O
in IN 0 0 12 O
atorvastatin NN 0 1 0 B-Drug
AUC NNP 0 1 UNK O
values VBZ 1 1 1 O
in IN 0 0 12 O
9 CD 0 0 2 O
healthy JJ 0 1 12 O
males NNS 1 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
addition NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
kg JJ 0 1 18 O
/ NNP 0 0 2 O
day NN 0 1 12 O
of IN 0 0 12 O
cromolyn NN 0 1 16 B-Drug
sodium NN 0 1 14 I-Drug
( ( 0 0 2 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
times NNS 1 1 12 O
the DT 0 0 12 O
maximum NN 0 1 1 O
recommended VBD 1 1 1 O
daily JJ 0 1 12 O
inhalation NN 0 1 16 O
dose NN 0 1 6 O
in IN 0 0 12 O
adults NNS 1 1 13 O
on IN 0 0 12 O
a DT 0 0 12 O
mg NN 0 1 0 O
/ NN 0 0 2 O
m9 JJ 0 1 UNK O
basis NN 0 1 1 O
) ) 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
kg JJ 0 1 18 O
/ NNP 0 0 2 O
day NN 0 1 12 O
of IN 0 0 12 O
isoproterenol NN 0 1 13 B-Drug
( ( 0 0 2 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
times NNS 1 1 12 O
the DT 0 0 12 O
maximum NN 0 1 1 O
recommended VBD 1 1 1 O
daily JJ 0 1 12 O
inhalation NN 0 1 16 O
dose NN 0 1 6 O
in IN 0 0 12 O
adults NNS 1 1 13 O
on IN 0 0 12 O
a DT 0 0 12 O
mg NN 0 1 0 O
/ NN 0 0 2 O
m9 JJ 0 1 UNK O
basis NN 0 1 1 O
) ) 0 0 2 O
appears VBZ 1 1 12 O
to TO 0 0 12 O
have VB 0 0 12 O
increased VBN 1 1 1 O
the DT 0 0 12 O
incidence NN 0 1 6 O
of IN 0 0 12 O
both DT 0 0 12 O
resorptions NNS 1 1 UNK O
and CC 0 0 12 O
malformations NNS 1 1 8 O
. . 0 0 12 O

This DT 0 0 2 O
may MD 0 0 1 O
indicate VB 0 0 1 O
that IN 0 0 12 O
ibuprofen NN 0 1 0 B-Drug
could MD 0 0 12 O
enhance VB 0 1 UNK O
the DT 0 0 12 O
toxicity NN 0 1 6 O
of IN 0 0 12 O
methotrexate NN 0 1 16 B-Drug
. . 0 0 12 O

Drugs NNS 0 1 2 O
that WDT 0 0 12 O
cause VBP 0 1 12 O
significant JJ 0 1 1 O
sustained JJ 0 1 1 O
elevation NN 0 1 1 O
in IN 0 0 12 O
gastric JJ 0 1 6 O
pH NN 0 1 14 O
( ( 0 0 2 O
histamine JJ 0 1 UNK B-Group
H9 NNP 0 0 UNK I-Group
- : 0 0 2 O
receptor NN 0 1 14 I-Group
antagonists NNS 1 1 13 I-Group
such JJ 0 0 1 O
as IN 1 0 12 O
ranitidine NN 0 1 0 B-Drug
or CC 0 0 12 O
cimetidine NN 0 1 13 B-Drug
) ) 0 0 2 O
may MD 0 0 1 O
reduce VB 0 0 1 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
IRESSA NNP 0 1 UNK B-Brand
and CC 0 0 12 O
therefore RB 0 0 1 O
potentially RB 0 0 1 O
may MD 0 0 1 O
reduce VB 0 0 1 O
efficacy NN 0 1 UNK O
. . 0 0 12 O

Intestinal JJ 0 1 UNK B-Group
adsorbents NNS 1 1 UNK I-Group
( ( 0 0 2 O
e. JJ 0 0 1 O
g. NNS 0 1 13 O
charcoal NN 0 1 3 B-Drug
) ) 0 0 2 O
and CC 0 0 12 O
digestive JJ 0 1 16 B-Group
enzyme NN 0 1 14 I-Group
preparations NNS 1 1 13 I-Group
containing VBG 1 1 1 O
carbohydrate NN 0 1 13 O
- : 0 0 2 O
splitting NN 0 1 13 O
enzymes NNS 1 1 14 O
( ( 0 0 2 O
e. JJ 0 0 1 O
g. NN 0 1 13 O
amylase NN 0 1 14 B-Drug
pancreatin NN 0 1 UNK B-Drug
) ) 0 0 2 O
may MD 0 0 1 O
reduce VB 0 0 1 O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
Acarbose NNP 0 1 UNK B-Drug
and CC 0 0 12 O
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
taken VBN 1 1 12 O
concomitantly RB 0 0 14 O
. . 0 0 12 O

In IN 0 0 2 O
an DT 0 0 12 O
emergency NN 0 1 1 O
situation NN 0 0 12 O
when WRB 0 0 12 O
opioid JJ 0 1 13 O
analgesia NN 0 1 6 O
must MD 0 0 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
to TO 0 0 12 O
a DT 0 0 12 O
patient NN 0 1 6 O
receiving VBG 1 1 1 O
REVIA NNP 0 1 UNK B-Brand
the DT 0 0 12 O
amount NN 0 1 1 O
of IN 0 0 12 O
opioid NN 0 1 13 B-Group
required VBN 1 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
greater JJR 1 1 1 O
than IN 0 0 12 O
usual JJ 0 1 12 O
and CC 0 0 12 O
the DT 0 0 12 O
resulting VBG 1 1 1 O
respiratory JJ 0 1 6 O
depression NN 0 1 6 O
may MD 0 0 1 O
be VB 0 0 12 O
deeper JJR 1 1 12 O
and CC 0 0 12 O
more JJR 0 1 12 O
prolonged NNS 0 1 6 O
. . 0 0 12 O

Free JJ 0 1 2 O
T9 NNP 0 1 13 O
resin NN 0 1 UNK O
uptake NN 0 1 14 O
is VBZ 1 0 12 O
decreased VBN 1 1 1 O
reflecting VBG 1 1 1 O
the DT 0 0 12 O
elevated JJ 0 1 1 O
TBG NNP 0 1 UNK O
; : 0 0 2 O

Data NNS 0 1 2 O
from IN 0 0 12 O
in IN 0 0 12 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
of IN 0 0 12 O
alprazolam JJ 0 1 0 B-Drug
suggest VBP 0 1 1 O
a DT 0 0 12 O
possible JJ 0 1 1 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
with IN 0 0 12 O
alprazolam NN 0 1 0 B-Drug
for IN 0 0 12 O
the DT 0 0 12 O
following NN 0 1 1 O
: : 0 0 2 O
sertraline NN 0 1 16 B-Drug
and CC 0 0 12 O
paroxetine NN 0 1 16 B-Drug
. . 0 0 12 O

When WRB 0 0 12 O
ZETIA NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
an DT 0 0 12 O
HMG NNP 0 0 UNK B-Group
- : 0 0 2 O
CoA NNP 0 0 UNK I-Group
reductase NN 0 1 UNK I-Group
inhibitor NN 0 1 14 I-Group
in IN 0 0 12 O
a DT 0 0 12 O
woman NN 0 1 12 O
of IN 0 0 12 O
childbearing VBG 0 0 UNK O
potential JJ 0 1 1 O
refer NN 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
pregnancy NN 0 1 6 O
category NN 0 1 16 O
and CC 0 0 12 O
package NN 0 1 13 O
labeling NN 0 1 UNK O
for IN 0 0 12 O
the DT 0 0 12 O
HMG NNP 0 0 UNK B-Drug
- : 0 0 2 O
CoA NNP 0 0 UNK I-Drug
reductase NN 0 1 UNK I-Drug
inhibitor NN 0 1 14 I-Drug
. . 0 0 12 O

Co NNP 0 1 2 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
SUTENT NNP 0 1 0 B-Brand
with IN 0 0 12 O
inducers NNS 1 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
CYP9A9 NNP 0 0 UNK O
family NN 0 1 12 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
dexamethasone NN 0 1 16 B-Drug
phenytoin NN 0 1 16 B-Drug
carbamazepine NN 0 1 16 B-Drug
rifampin NN 0 1 16 B-Drug
rifabutin NN 0 1 13 B-Drug
rifapentin NN 0 0 UNK B-Drug
phenobarbital JJ 0 1 16 B-Drug
St. NNP 0 1 2 O
Johns NNP 0 0 UNK O
Wort NNP 0 0 UNK O
) ) 0 0 2 O
may MD 0 0 1 O
decrease VB 0 1 1 O
sunitinib JJ 0 1 13 B-Drug
concentrations NNS 1 1 13 O
. . 0 0 12 O

Dose NNP 0 1 7 O
reduction NN 0 1 1 O
of IN 0 0 12 O
CRIXIVAN NNP 0 1 UNK B-Brand
to TO 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
every DT 0 0 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
when WRB 0 0 12 O
administering VBG 1 1 1 O
itraconazole RB 0 1 0 B-Drug
concurrently RB 0 0 1 O
. . 0 0 12 O

Blood NN 0 1 2 O
Sugar NN 0 1 UNK O
: : 0 0 2 O
Some DT 0 0 2 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
retinoids NNS 0 1 UNK B-Group
have VBP 0 0 12 O
experienced VBN 1 0 12 O
problems NNS 1 1 1 O
with IN 0 0 12 O
blood NN 0 1 6 O
sugar NN 0 1 3 O
control NN 0 1 1 O
. . 0 0 12 O

Results NNS 0 1 2 O
from IN 0 0 12 O
existing VBG 1 1 1 O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
suggest VBP 0 1 1 O
no DT 0 0 12 O
significant JJ 0 1 1 O
interactions NNS 1 1 UNK O
between IN 0 0 12 O
COPAXONE NNP 0 1 UNK B-Brand
and CC 0 0 12 O
other JJ 0 0 12 O
therapies NNS 1 1 6 O
commonly RB 0 0 UNK O
used VBN 1 1 12 O
in IN 0 0 12 O
MS NNP 0 1 2 O
patients NNS 1 1 6 O
including VBG 1 1 1 O
the DT 0 0 12 O
concurrent NN 0 1 1 O
use NN 0 1 1 O
of IN 0 0 12 O
corticosteroids NNS 1 1 14 B-Group
for IN 0 0 12 O
up IN 0 0 12 O
to TO 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
. . 0 0 12 O

Praziquantel NN 0 1 UNK B-Drug
: : 0 0 2 O
In IN 0 0 2 O
the DT 0 0 12 O
fed NN 0 1 12 O
state NN 0 1 1 O
praziquantel NN 0 1 13 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
) ) 0 0 2 O
increased VBD 1 1 1 O
mean JJ 0 1 12 O
maximum JJ 0 1 1 O
plasma NN 0 1 14 O
concentration NN 0 1 1 O
and CC 0 0 12 O
area NN 0 1 12 O
under IN 0 0 12 O
the DT 0 0 12 O
curve NN 0 1 13 O
of IN 0 0 12 O
albendazole JJ 0 1 13 B-Drug
sulfoxide NN 0 1 UNK I-Drug
by IN 0 0 12 O
about IN 0 1 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
in IN 0 0 12 O
healthy JJ 0 1 12 O
subjects NNS 1 1 UNK O
( ( 0 0 2 O
n=9 NN 0 1 UNK O
) ) 0 0 2 O
compared VBN 1 1 1 O
with IN 0 0 12 O
a DT 0 0 12 O
separate JJ 0 1 1 O
group NN 0 1 12 O
of IN 0 0 12 O
subjects NNS 1 1 UNK O
( ( 0 0 2 O
n=9 NN 0 1 UNK O
) ) 0 0 2 O
given VBN 1 1 12 O
albendazole JJ 0 1 13 B-Drug
alone RB 0 1 12 O
. . 0 0 12 O

- : 0 0 2 O
Reduced VBN 0 1 UNK O
serum JJ 0 1 14 O
folate NN 0 1 14 O
concentration NN 0 1 1 O

Folic NNP 0 0 0 B-Drug
acid NN 0 1 14 I-Drug
in IN 0 0 12 O
large JJ 0 1 3 O
amounts NNS 1 1 1 O
may MD 0 0 1 O
counteract VB 0 0 UNK O
the DT 0 0 12 O
antiepileptic JJ 0 1 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
phenobarbital JJ 0 1 16 B-Drug
phenytoin NN 0 1 16 B-Drug
and CC 0 0 12 O
primidone NN 0 1 13 B-Drug
and CC 0 0 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
frequency NN 0 1 1 O
of IN 0 0 12 O
seizures NNS 1 1 6 O
in IN 0 0 12 O
susceptible JJ 0 1 1 O
pediatric JJ 0 1 6 O
patients NNS 1 1 6 O
. . 0 0 12 O

Similarly RB 0 0 1 O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
on IN 0 0 12 O
phenobarbital JJ 0 1 16 B-Drug
valproic NN 0 0 16 B-Drug
acid NN 0 1 14 I-Drug
and CC 0 0 12 O
sodium NN 0 1 14 O
plasma NN 0 1 14 O
valproate NN 0 1 16 B-Drug
concentrations NNS 1 1 13 O
are VBP 1 0 12 O
unpredictable JJ 0 0 UNK O

The DT 0 0 2 O
most RBS 0 0 12 O
significant JJ 0 1 1 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
following VBG 1 1 1 O
administration NN 0 1 1 O
of IN 0 0 12 O
Cerebyx NNP 0 1 UNK B-Brand
are VBP 1 0 12 O
expected VBN 1 1 12 O
to TO 0 0 12 O
occur VB 0 1 1 O
with IN 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
interact VBP 0 0 UNK O
with IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
. . 0 0 12 O

Experience NN 0 1 UNK O
with IN 0 0 12 O
nonsteroidal JJ 0 0 14 B-Group
anti SYM 0 0 3 I-Group
- : 0 0 2 O
inflammatory NN 0 1 6 I-Group
drugs NNS 1 1 6 I-Group
( ( 0 0 2 O
NSAIDs NNP 0 1 UNK B-Group
) ) 0 0 2 O
suggests VBZ 1 1 1 O
the DT 0 0 12 O
potential NN 0 1 1 O
for IN 0 0 12 O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
furosemide NN 0 1 0 B-Drug
and CC 0 0 12 O
ACE NNP 0 1 13 B-Group
inhibitors NNS 1 1 14 I-Group
. . 0 0 12 O

therefore RB 0 0 1 O
close JJ 0 1 12 O
monitoring NN 0 1 1 O
of IN 0 0 12 O
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
and CC 0 0 12 O
adjustment NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
anticoagulant JJ 0 1 13 B-Group
dose NN 0 1 6 O
may MD 0 0 1 O
be VB 0 0 12 O
necessary JJ 0 0 1 O
when WRB 0 0 12 O
Tagamet NNP 0 1 0 B-Brand
is VBZ 1 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
. . 0 0 12 O

Tetracycline VB 0 1 0 B-Drug
a DT 0 0 12 O
bacteriostatic JJ 0 0 UNK B-Group
antibiotic NN 0 1 6 I-Group
may MD 0 0 1 O
antagonize VB 0 0 UNK O
the DT 0 0 12 O
bactericidal JJ 0 1 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
penicillin NN 0 1 14 B-Drug
and CC 0 0 12 O
concurrent NN 0 1 1 O
use NN 0 1 1 O
of IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
. . 0 0 12 O

dietary JJ 0 1 6 O
deficiencies NNS 1 1 13 O
; : 0 0 2 O

increased VBN 1 1 1 O
plasminogen NN 0 1 14 O
antigen NN 0 1 14 O
and CC 0 0 12 O
activity NN 0 1 1 O
. . 0 0 12 O

- : 0 0 2 O
Valproic NN 0 0 UNK B-Drug
acid NN 0 1 14 I-Drug
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
Depakene NNP 0 1 UNK B-Brand
) ) 0 0 2 O
Use NNP 0 1 2 O
of IN 0 0 12 O
sulfapyridine NN 0 1 UNK B-Drug
with IN 0 0 12 O
these DT 0 0 12 O
medicines NNS 1 1 6 O
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
chance NN 0 1 12 O
of IN 0 0 12 O
side JJ 0 1 3 O
effects NNS 1 1 1 O
affecting VBG 1 1 1 O
the DT 0 0 12 O
liver NN 0 1 6 O

Aspirin NN 0 1 0 B-Brand
: : 0 0 2 O
Ketoprofen NNP 0 1 UNK B-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
alter VB 0 1 13 O
aspirin JJ 0 1 14 B-Brand
absorption NN 0 1 1 O
; : 0 0 2 O

A DT 0 0 2 O
variety NN 0 1 1 O
of IN 0 0 12 O
toxic JJ 0 1 1 O
neurological JJ 0 1 6 O
effects NNS 1 1 1 O
and CC 0 0 12 O
malignant JJ 0 1 6 O
hyperpyrexia NN 0 1 UNK O
can MD 0 0 12 O
occur VB 0 1 1 O
sometimes RB 0 1 12 O
with IN 0 0 12 O
fatal JJ 0 1 13 O
results NNS 1 1 1 O
. . 0 0 12 O

Combination NN 0 1 UNK O
of IN 0 0 12 O
amiodarone NN 0 1 0 B-Drug
with IN 0 0 12 O
other JJ 0 0 12 O
antiarrhythmic JJ 0 1 14 B-Drug
therapy NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
reserved VBN 1 0 UNK O
for IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
life NN 0 1 12 O
- : 0 0 2 O
threatening VBG 1 0 12 O
ventricular JJ 0 1 8 O
arrhythmias NNS 1 1 6 O
who WP 0 0 12 O
are VBP 1 0 12 O
incompletely RB 0 0 6 O
responsive JJ 0 1 1 O
to TO 0 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
agent NN 0 1 1 O
or CC 0 0 12 O
incompletely RB 0 0 6 O
responsive JJ 0 1 1 O
to TO 0 0 12 O
amiodarone VB 0 1 0 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
mean JJ 0 1 12 O
percentage NN 0 1 1 O
increase NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
glipizide NN 0 1 0 B-Drug
AUC NNP 0 1 UNK O
after IN 0 0 12 O
fluconazole JJ 0 1 0 B-Drug
administration NN 0 1 1 O
was VBD 1 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
( ( 0 0 2 O
range NN 0 1 1 O
: : 0 0 2 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

Treatment NN 0 1 7 O
with IN 0 0 12 O
entacapone NN 0 1 13 B-Drug
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
levodopa JJ 0 1 UNK B-Drug
/ NNP 0 0 2 O
dopa NN 0 1 14 B-Group
decarboxylase NN 0 1 UNK I-Group
inhibitor NN 0 1 14 I-Group
does VBZ 1 0 12 O
not RB 0 1 12 O
change VB 0 1 1 O
these DT 0 0 12 O
effects NNS 1 1 1 O
. . 0 0 12 O

This DT 0 0 2 O
interaction NN 0 1 UNK O
was VBD 1 0 12 O
not RB 0 1 12 O
accompanied VBN 1 0 12 O
by IN 0 0 12 O
ECG NNP 0 1 6 O
changes NNS 1 1 1 O
and CC 0 0 12 O
its PRP$ 1 0 12 O
clinical JJ 0 1 6 O
significance NN 0 1 13 O
is VBZ 1 0 12 O
not RB 0 1 12 O
known VBN 1 1 12 O
. . 0 0 12 O

Coadministration NN 0 1 UNK O
with IN 0 0 12 O
compounds NNS 1 1 13 O
that WDT 0 0 12 O
are VBP 1 0 12 O
potent JJ 0 1 UNK O
inducers NNS 1 1 UNK O
of IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
( ( 0 0 2 O
eg JJ 0 1 UNK O
phenobarbital NN 0 1 16 B-Drug
phenytoin NN 0 1 16 B-Drug
dexamethasone NN 0 1 16 B-Drug
carbamazepine NN 0 1 16 B-Drug
) ) 0 0 2 O
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
decreased JJ 0 1 1 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
saquinavir NN 0 1 13 B-Drug
. . 0 0 12 O

Therefore RB 0 0 1 O
esomeprazole NN 0 1 16 B-Drug
may MD 0 0 1 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
absorption NN 0 1 1 O
of IN 0 0 12 O
drugs NNS 1 1 6 O
where WRB 0 0 12 O
gastric NN 0 1 6 O
pH NN 0 1 14 O
is VBZ 1 0 12 O
an DT 0 0 12 O
important JJ 0 1 1 O
determinant NN 0 1 UNK O
of IN 0 0 12 O
bioavailability NN 0 1 UNK O
( ( 0 0 2 O
eg JJ 0 1 UNK O
ketoconazole NN 0 1 16 B-Drug
iron NN 0 1 3 B-Drug
salts NNS 1 1 13 O
and CC 0 0 12 O
digoxin NN 0 1 14 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

Digitalis NNS 0 1 15 B-Group
: : 0 0 2 O
Thyroid NNP 0 1 7 B-Group
preparations NNS 1 1 13 I-Group
may MD 0 0 1 O
potentiate VB 0 0 UNK O
the DT 0 0 12 O
toxic JJ 0 1 1 O
effects NNS 1 1 1 O
of IN 0 0 12 O
digitalis NN 0 1 14 B-Group
. . 0 0 12 O

These DT 0 0 1 O
compounds NNS 1 1 13 O
interfere RB 0 1 UNK O
with IN 0 0 12 O
chemical JJ 0 1 13 O
color NN 0 1 3 O
development NN 0 1 1 O
essential JJ 0 1 13 O
to TO 0 0 12 O
the DT 0 0 12 O
analytical JJ 0 1 UNK O
procedures NNS 1 1 1 O
. . 0 0 12 O

- : 0 0 2 O
Antihypertensives NNS 0 1 UNK B-Group
: : 0 0 2 O
Bumetanide NNP 0 1 UNK B-Drug
may MD 0 0 1 O
potentiate VB 0 0 UNK O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
various JJ 0 1 1 O
antihypertensive JJ 0 1 14 B-Group
drugs NNS 1 1 6 I-Group
necessitating VBG 1 0 1 O
a DT 0 0 12 O
reduction NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
dosage NN 0 1 0 O
of IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

Toxicology NNP 0 1 7 O
studies NNS 1 1 1 O
of IN 0 0 12 O
heroin NN 0 1 13 B-Drug_n
- : 0 0 2 O
related JJ 0 1 1 O
deaths NNS 1 1 UNK O
reveal VBP 0 1 12 O
frequent JJ 0 1 1 O
involvement NN 0 1 1 O
of IN 0 0 12 O
other JJ 0 0 12 O
central JJ 0 1 1 B-Group
nervous JJ 0 1 6 I-Group
system NN 0 1 1 I-Group
depressants NNS 1 0 13 I-Group
including VBG 1 1 1 O
alcohol NN 0 1 1 B-Drug
benzodiazepines NNS 1 1 14 B-Group
such JJ 0 0 1 O
as IN 1 0 12 O
diazepam NN 0 1 0 B-Drug
( ( 0 0 2 O
Valium NNP 0 1 0 B-Brand
) ) 0 0 2 O
and CC 0 0 12 O
to TO 0 0 12 O
a DT 0 0 12 O
rising VBG 1 0 12 O
degree NN 0 1 1 O
methadone NN 0 1 6 B-Drug
. . 0 0 12 O

9 CD 0 0 2 O
. . 0 0 12 O

Increases NNS 0 1 UNK O
in IN 0 0 12 O
INR NNP 0 1 13 O
and CC 0 0 12 O
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
may MD 0 0 1 O
lead VB 0 1 12 O
to TO 0 0 12 O
abnormal JJ 0 1 6 O
bleeding NN 0 1 6 O
and CC 0 0 12 O
even RB 0 0 12 O
death NN 0 1 12 O
. . 0 0 12 O

Lithium NN 0 1 UNK B-Drug
: : 0 0 2 O
Ibuprofen NNP 0 1 0 B-Drug
produced VBD 1 0 1 O
an DT 0 0 12 O
elevation NN 0 1 1 O
of IN 0 0 12 O
plasma JJ 0 1 14 O
lithium NN 0 1 16 B-Drug
levels NNS 1 1 1 O
and CC 0 0 12 O
a DT 0 0 12 O
reduction NN 0 1 1 O
in IN 0 0 12 O
renal JJ 0 1 6 O
lithium NN 0 1 16 B-Drug
clearance NN 0 1 16 O
in IN 0 0 12 O
a DT 0 0 12 O
study NN 0 1 1 O
of IN 0 0 12 O
eleven JJ 0 1 UNK O
normal JJ 0 1 1 O
volunteers NNS 1 1 UNK O
. . 0 0 12 O

nc9 RB 0 0 UNK O
9 CD 0 0 2 O
% NN 0 0 18 O
decrease NN 0 1 1 O
[ NNP 0 0 2 O
CI NNP 0 1 UNK O
: : 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
decrease NN 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
decrease NN 0 1 1 O
] NN 0 0 2 O

Digoxin NN 0 1 0 B-Drug
: : 0 0 2 O
A DT 0 0 2 O
controlled VBN 1 1 1 O
pharmacokinetic NN 0 1 UNK O
study NN 0 1 1 O
has VBZ 1 0 12 O
shown VBN 1 1 1 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
plasma NN 0 1 14 O
digoxin NN 0 1 14 B-Drug
concentrations NNS 1 1 13 O
when WRB 0 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
ACEON NNP 0 1 UNK B-Brand
Tablets NNP 0 1 0 O
but CC 0 0 12 O
an DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
on IN 0 0 12 O
the DT 0 0 12 O
plasma JJ 0 1 14 O
concentration NN 0 1 1 O
of IN 0 0 12 O
perindopril JJ 0 1 UNK B-Drug
/ NNP 0 0 2 O
perindoprilat NN 0 1 UNK B-Drug_n
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
excluded VBN 1 1 1 O
. . 0 0 12 O

vardenafil NN 0 1 UNK B-Drug
concentration NN 0 1 1 O

Midazolam NNP 0 1 0 B-Drug
Synergism NNP 0 1 UNK O

Concomitant NNP 0 1 UNK O
use NN 0 1 1 O
of IN 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
with IN 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
can MD 0 0 12 O
inhibit VB 0 1 13 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
9D9 CD 0 0 UNK O
may MD 0 0 1 O
require VB 0 0 1 O
lower JJR 1 1 1 O
doses NNS 1 1 6 O
than IN 0 0 12 O
usually RB 0 1 12 O
prescribed VBN 1 1 1 O
for IN 0 0 12 O
either CC 0 1 12 O
the DT 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressant NN 0 1 6 I-Group
or CC 0 0 12 O
the DT 0 0 12 O
other JJ 0 0 12 O
drug NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
following NN 0 1 1 O
are VBP 1 0 12 O
examples NNS 1 1 UNK O
of IN 0 0 12 O
substances NNS 1 1 1 O
that WDT 0 0 12 O
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
blood NN 0 1 6 O
- : 0 0 2 O
glucose JJ 0 1 14 O
- : 0 0 2 O
lowering VBG 1 1 UNK O
effect NN 0 1 1 O
and CC 0 0 12 O
susceptibility NN 0 1 6 O
to TO 0 0 12 O
hypoglycemia NN 0 1 6 O
: : 0 0 2 O
oral JJ 0 1 6 O
antidiabetic JJ 0 1 13 B-Group
products NNS 1 1 1 I-Group
ACE NNP 0 1 13 B-Group
inhibitors NNS 1 1 14 I-Group
disopyramide VBP 0 1 16 B-Drug
fibrates NNS 0 1 UNK B-Group
fluoxetine VBP 0 1 16 B-Drug
monoamine JJ 0 1 13 B-Group
oxidase NN 0 1 13 I-Group
MAO NNP 0 1 14 I-Group
inhibitors NNS 1 1 14 I-Group
propoxyphene VBP 0 1 16 B-Drug
salicylates NNS 1 1 13 B-Group
somatostatin VBP 0 1 14 B-Group
analog NN 0 1 UNK I-Group
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
octreotide NN 0 1 14 B-Drug
) ) 0 0 2 O
sulfonamide NN 0 1 UNK B-Group
antibiotics NNS 1 1 6 I-Group
. . 0 0 12 O

A DT 0 0 2 O
decrease NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
dosage NN 0 1 0 O
may MD 0 0 1 O
be VB 0 0 12 O
necessary JJ 0 0 1 O
when WRB 0 0 12 O
patient NN 0 1 6 O
becomes VBZ 1 0 12 O
euthyroid JJ 0 1 14 O
. . 0 0 12 O

Patients NNS 0 1 7 O
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
for IN 0 0 12 O
signs NNS 1 1 12 O
of IN 0 0 12 O
withdrawal NN 0 1 1 O
and CC 0 0 12 O
their PRP$ 0 0 12 O
methadone NN 0 1 6 B-Drug
dose NN 0 1 6 O
increased VBD 1 1 1 O
as RB 0 0 12 O
required VBN 1 1 1 O
to TO 0 0 12 O
alleviate VB 0 0 1 O
withdrawal NN 0 1 1 O
symptoms NNS 1 1 6 O
. . 0 0 12 O

Ephedrine NN 0 1 UNK B-Drug
: : 0 0 2 O
Ephedrine NN 0 1 UNK B-Drug
may MD 0 0 1 O
enhance VB 0 1 UNK O
the DT 0 0 12 O
metabolic JJ 0 1 6 O
clearance NN 0 1 16 O
of IN 0 0 12 O
corticosteroids NNS 1 1 14 B-Group
resulting VBG 1 1 1 O
in IN 0 0 12 O
decreased VBN 1 1 1 O
blood NN 0 1 6 O
levels NNS 1 1 1 O
and CC 0 0 12 O
lessened VBD 1 0 UNK O
physiologic JJ 0 1 6 O
activity NN 0 1 1 O
thus RB 0 0 1 O
requiring VBG 1 0 1 O
an DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
corticosteroid JJ 0 1 UNK B-Group
dosage NN 0 1 0 O
. . 0 0 12 O

Synergism NN 0 1 UNK O
has VBZ 1 0 12 O
been VBN 1 0 12 O
shown VBN 1 1 1 O
between IN 0 0 12 O
halothane NN 0 1 13 B-Drug
anesthesia NN 0 1 6 O
and CC 0 0 12 O
intravenously RB 0 0 14 O
administered VBN 1 1 1 O
labetalol JJ 0 1 0 B-Drug
HCl NNP 0 0 14 I-Drug
. . 0 0 12 O

CONTRAINDICATED NNS 0 1 UNK O
due JJ 0 1 1 O
to TO 0 0 12 O
potential JJ 0 1 1 O
for IN 0 0 12 O
serious JJ 0 1 12 O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
life NN 0 1 12 O
- : 0 0 2 O
threatening VBG 1 0 12 O
reactions NNS 1 1 1 O
such JJ 0 0 1 O
as IN 1 0 12 O
acute JJ 0 1 6 O
ergot FW 0 1 UNK O
toxicity NN 0 1 6 O
characterized VBN 1 1 1 O
by IN 0 0 12 O
peripheral JJ 0 1 6 O
vasospasm NN 0 1 8 O
and CC 0 0 12 O
ischemia NN 0 1 8 O
of IN 0 0 12 O
the DT 0 0 12 O
extremities NNS 1 1 6 O
and CC 0 0 12 O
other JJ 0 0 12 O
tissues NNS 1 1 6 O
. . 0 0 12 O

Thus RB 0 0 1 O
if IN 0 0 12 O
such JJ 0 0 1 O
treatment NN 0 1 6 O
is VBZ 1 0 12 O
essential JJ 0 1 13 O
the DT 0 0 12 O
possibility NN 0 1 1 O
of IN 0 0 12 O
increased VBN 1 1 1 O
risk NN 0 1 1 O
relative NN 0 1 1 O
to TO 0 0 12 O
benefits NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
. . 0 0 12 O

Quinidine NNP 0 1 0 B-Drug
verapamil NN 0 1 0 B-Drug
amiodarone NN 0 1 0 B-Drug
propafenone NN 0 1 16 B-Drug
indomethacin JJ 0 1 14 B-Drug
itraconazole JJ 0 1 0 B-Drug
alprazolam NN 0 1 0 B-Drug
and CC 0 0 12 O
spironolactone NN 0 1 0 B-Drug
raise VB 0 0 12 O
the DT 0 0 12 O
serum NN 0 1 14 O
digoxin NN 0 1 14 B-Drug
concentration NN 0 1 1 O
due JJ 0 1 1 O
to TO 0 0 12 O
a DT 0 0 12 O
reduction NN 0 1 1 O
in IN 0 0 12 O
clearance NN 0 1 16 O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
in IN 0 0 12 O
volume NN 0 1 1 O
of IN 0 0 12 O
distribution NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
drug NN 0 1 1 O
with IN 0 0 12 O
the DT 0 0 12 O
implication NN 0 0 UNK O
that IN 0 0 12 O
digitalis JJ 0 1 14 B-Group
intoxication NN 0 1 6 O
may MD 0 0 1 O
result VB 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
effect NN 0 1 1 O
was VBD 1 0 12 O
present JJ 0 1 1 O
for IN 0 0 12 O
at IN 0 0 12 O
least JJS 0 1 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
after IN 0 0 12 O
the DT 0 0 12 O
last JJ 0 1 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
bupropion NN 0 1 16 B-Drug
. . 0 0 12 O

All DT 0 0 2 O
elevations NNS 1 1 1 O
resolved VBD 1 1 1 O
9 CD 0 0 2 O
with IN 0 0 12 O
continuation NN 0 0 1 O
of IN 0 0 12 O
both DT 0 0 12 O
drugs NNS 1 1 6 O
and CC 0 0 12 O
9 CD 0 0 2 O
after IN 0 0 12 O
discontinuation NN 0 1 6 O
of IN 0 0 12 O
leflunomide NN 0 1 13 B-Drug
. . 0 0 12 O

Although IN 0 0 12 O
no DT 0 0 12 O
clinical JJ 0 1 6 O
drug NN 0 1 1 O
- : 0 0 2 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
conducted VBN 1 1 1 O
to TO 0 0 12 O
date NN 0 1 12 O
on IN 0 0 12 O
the DT 0 0 12 O
basis NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
in IN 0 0 12 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
cytochrome VBP 0 1 UNK O
p9 JJ 0 1 UNK O
inhibitors NNS 1 1 14 O
and CC 0 0 12 O
inducers NNS 1 1 UNK O
are VBP 1 0 12 O
unlikely JJ 0 1 12 O
to TO 0 0 12 O
affect VB 0 1 1 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
clofarabine NN 0 1 13 B-Drug
. . 0 0 12 O

Unless IN 0 0 UNK O
really RB 0 0 12 O
needed VBN 1 1 12 O
agents NNS 1 1 1 O
which WDT 0 0 12 O
may MD 0 0 1 O
enhance VB 0 1 UNK O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
hemorrhage NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
discontinued VBN 1 1 1 O
prior JJ 0 1 1 O
to TO 0 0 12 O
initiation NN 0 1 1 O
of IN 0 0 12 O
Lovenox NNP 0 1 0 B-Brand
Injection NNP 0 1 7 O
therapy NN 0 1 6 O
. . 0 0 12 O

Diuretics NNS 0 1 UNK B-Group
: : 0 0 2 O
Patients NNS 0 1 7 O
on IN 0 0 12 O
diuretics NNS 1 1 14 B-Group
especially RB 0 0 12 O
those DT 0 0 12 O
with IN 0 0 12 O
intravascular JJ 0 1 8 O
volume NN 0 1 1 O
depletion NN 0 1 1 O
may MD 0 0 1 O
occasionally RB 0 1 12 O
experience VB 0 1 12 O
an DT 0 0 12 O
excessive JJ 0 1 1 O
reduction NN 0 1 1 O
of IN 0 0 12 O
blood NN 0 1 6 O
pressure NN 0 1 1 O
after IN 0 0 12 O
initiation NN 0 1 1 O
of IN 0 0 12 O
therapy NN 0 1 6 O
with IN 0 0 12 O
fosinopril JJ 0 1 13 B-Drug
sodium NN 0 1 14 I-Drug
. . 0 0 12 O

Warfarin NN 0 1 0 B-Drug
: : 0 0 2 O
Concomitant JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
daptomycin NN 0 1 16 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
once RB 0 0 12 O
every DT 0 0 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
) ) 0 0 2 O
and CC 0 0 12 O
warfarin $ 0 1 14 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
single JJ 0 1 12 O
oral JJ 0 1 6 O
dose NN 0 1 6 O
) ) 0 0 2 O
had VBD 1 0 12 O
no DT 0 0 12 O
significant JJ 0 1 1 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
either DT 0 1 12 O
drug NN 0 1 1 O
and CC 0 0 12 O
the DT 0 0 12 O
INR NNP 0 1 13 O
was VBD 1 0 12 O
not RB 0 1 12 O
significantly RB 0 0 1 O
altered VBN 1 1 1 O
. . 0 0 12 O

Glucose NN 0 1 7 O
: : 0 0 2 O
Some DT 0 0 2 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
Accutane NNP 0 1 UNK B-Brand
have VBP 0 0 12 O
experienced VBN 1 0 12 O
problems NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
control NN 0 1 1 O
of IN 0 0 12 O
their PRP$ 0 0 12 O
blood NN 0 1 6 O
sugar NN 0 1 3 O
. . 0 0 12 O

Vitamin FW 0 1 2 B-Group
A DT 0 0 2 I-Group
: : 0 0 2 O
Because IN 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
relationship NN 0 1 12 O
of IN 0 0 12 O
Accutane NNP 0 1 UNK B-Brand
to TO 0 0 12 O
vitamin VB 0 1 6 B-Group
A NNP 0 0 2 I-Group
patients NNS 1 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
advised VBN 1 0 12 O
against IN 0 0 12 O
taking VBG 1 0 12 O
vitamin JJ 0 1 6 B-Group
supplements NNS 1 1 6 I-Group
containing VBG 1 1 1 O
vitamin NN 0 1 6 B-Group
A DT 0 0 2 I-Group
to TO 0 0 12 O
avoid VB 0 0 12 O
additive JJ 0 1 16 O
toxic NN 0 1 1 O
effects NNS 1 1 1 O

ACE NNP 0 1 13 B-Group
inhibitors NNS 1 1 14 I-Group
Reports NNP 0 1 2 O
suggest VBP 0 1 1 O
that IN 0 0 12 O
NSAIDs NNP 0 1 UNK B-Group
may MD 0 0 1 O
diminish VB 0 1 UNK O
the DT 0 0 12 O
antihypertensive JJ 0 1 14 O
effect NN 0 1 1 O
of IN 0 0 12 O
angiotensin NN 0 1 UNK B-Group
- : 0 0 2 O
converting VBG 1 0 UNK I-Group
enzyme JJ 0 1 14 I-Group
ACE NNP 0 1 13 I-Group
inhibitors NNS 1 1 14 I-Group
. . 0 0 12 O

Concurrent NNP 0 1 13 O
use NN 0 1 1 O
of IN 0 0 12 O
these DT 0 0 12 O
agents NNS 1 1 1 O
should MD 0 0 12 O
generally RB 0 0 1 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
. . 0 0 12 O

This DT 0 0 2 O
appears VBZ 1 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
the DT 0 0 12 O
only JJ 0 1 12 O
clinically RB 0 0 6 O
relevant JJ 0 1 1 O
interaction NN 0 1 UNK O
of IN 0 0 12 O
this DT 0 0 12 O
kind NN 0 1 12 O
with IN 0 0 12 O
Mefloquine NNP 0 1 UNK B-Drug
although IN 0 0 12 O
theoretically RB 0 0 UNK O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
known VBN 1 1 12 O
to TO 0 0 12 O
alter VB 0 1 13 O
cardiac JJ 0 1 6 O
conduction NN 0 1 6 O
( ( 0 0 2 O
eg JJ 0 1 UNK O
anti SYM 0 0 3 B-Drug
- : 0 0 2 O
arrhythmic JJ 0 0 UNK I-Drug
or CC 0 0 12 O
beta SYM 0 1 16 B-Group
- : 0 0 2 O
adrenergic JJ 0 1 UNK I-Group
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
calcium JJ 0 1 14 B-Group
channel NN 0 1 1 I-Group
blockers NNS 1 0 6 I-Group
antihistamines NNS 1 1 UNK B-Group
or CC 0 0 12 O
H9 NNP 0 0 UNK B-Group
- : 0 0 2 O
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
and CC 0 0 12 O
phenothiazines NNS 1 1 UNK B-Group
) ) 0 0 2 O
might MD 0 0 12 O
also RB 0 0 12 O
contribute VB 0 1 UNK O
to TO 0 0 12 O
a DT 0 0 12 O
prolongation NN 0 1 6 O
of IN 0 0 12 O
the DT 0 0 12 O
QTc NNP 0 0 14 O
interval NN 0 1 1 O
. . 0 0 12 O

Nevertheless RB 0 0 1 O
caution NN 0 0 1 O
is VBZ 1 0 12 O
indicated VBN 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
co NN 0 1 12 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
T.A NNP 0 1 UNK B-Group
with IN 0 0 12 O
any DT 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
SSRIs NNP 0 1 UNK B-Group
and CC 0 0 12 O
also RB 0 0 12 O
in IN 0 0 12 O
switching VBG 1 1 UNK O
from IN 0 0 12 O
one CD 0 1 12 O
class NN 0 1 12 O
to TO 0 0 12 O
the DT 0 0 12 O
other JJ 0 0 12 O
. . 0 0 12 O

Drugs NNS 0 1 2 O
that WDT 0 0 12 O
may MD 0 0 1 O
decrease VB 0 1 1 O
imatinib VB 0 1 16 B-Drug
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
: : 0 0 2 O
Substances NNS 0 1 UNK O
that WDT 0 0 12 O
are VBP 1 0 12 O
inducers NNS 1 1 UNK O
of IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
activity NN 0 1 1 O
may MD 0 0 1 O
increase VB 0 1 1 O
metabolism NN 0 1 16 O
and CC 0 0 12 O
decrease NN 0 1 1 O
imatinib NN 0 1 16 B-Drug
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
. . 0 0 12 O

In IN 0 0 2 O
this DT 0 0 12 O
study NN 0 1 1 O
there EX 0 0 12 O
was VBD 1 0 12 O
no DT 0 0 12 O
evidence NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
blunting NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
antihypertensive JJ 0 1 14 O
action NN 0 1 13 O
of IN 0 0 12 O
VASOTEC NNP 0 1 UNK B-Brand
. . 0 0 12 O

If IN 0 0 12 O
signs NNS 1 1 12 O
of IN 0 0 12 O
folate JJ 0 1 14 O
deficiency NN 0 1 6 O
develop VB 0 0 1 O
pyrimethamine NN 0 1 16 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
discontinued VBN 1 1 1 O
. . 0 0 12 O

PEGASYS NNP 0 1 UNK B-Brand
should MD 0 0 12 O
be VB 0 0 12 O
assumed VBN 1 1 1 O
to TO 0 0 12 O
have VB 0 0 12 O
abortifacient JJ 0 1 UNK O
potential NN 0 1 1 O
. . 0 0 12 O

John NNP 0 0 19 O
wort NN 0 0 UNK O
) ) 0 0 2 O
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
formation NN 0 1 1 O
of IN 0 0 12 O
dapsone NN 0 1 13 B-Drug_n
hydroxylamine NN 0 1 UNK I-Drug_n
a DT 0 0 12 O
metabolite NN 0 1 UNK O
of IN 0 0 12 O
dapsone NN 0 1 13 B-Drug
associated VBN 1 1 1 O
with IN 0 0 12 O
hemolysis NN 0 1 13 O
. . 0 0 12 O

Thus RB 0 0 1 O
results NNS 1 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
DST NNP 0 1 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
interpreted VBN 1 1 UNK O
with IN 0 0 12 O
caution NN 0 0 1 O
in IN 0 0 12 O
these DT 0 0 12 O
patients NNS 1 1 6 O
. . 0 0 12 O

Sedatives NNS 0 1 UNK B-Group
/ VBP 0 0 2 O
Hypnotics NNS 0 1 UNK B-Group
: : 0 0 2 O
triazolam NN 0 1 13 B-Drug
midazolam NN 0 1 16 B-Drug
CONTRAINDICATED NNP 0 1 UNK O
due JJ 0 1 1 O
to TO 0 0 12 O
potential JJ 0 1 1 O
for IN 0 0 12 O
serious JJ 0 1 12 O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
life NN 0 1 12 O
- : 0 0 2 O
threatening VBG 1 0 12 O
reactions NNS 1 1 1 O
such JJ 0 0 1 O
as IN 1 0 12 O
prolonged JJ 0 1 6 O
or CC 0 0 12 O
increased JJ 0 1 1 O
sedation NN 0 1 6 O
or CC 0 0 12 O
respiratory NN 0 1 6 O
depression NN 0 1 6 O
. . 0 0 12 O

Neuroleptic JJ 0 1 UNK B-Group
Drugs NNP 0 1 2 I-Group
- : 0 0 2 O
L NNP 0 1 2 B-Drug
- : 0 0 2 O
phenylalanine NN 0 1 UNK I-Drug
may MD 0 0 1 O
potentiate VB 0 0 UNK O
the DT 0 0 12 O
tardive JJ 0 0 UNK O
dyskinesia NN 0 1 6 O
side NN 0 1 3 O
reactions NNS 1 1 1 O
of IN 0 0 12 O
neuroleptic JJ 0 1 13 B-Group
drugs NNS 1 1 6 I-Group
if IN 0 0 12 O
used VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
them PRP 0 0 12 O
. . 0 0 12 O

Serum NNP 0 1 7 O
Amylase NNP 0 1 14 O
An DT 0 0 2 O
apparent JJ 0 1 1 O
decrease NN 0 1 1 O
in IN 0 0 12 O
serum JJ 0 1 14 O
amylase NN 0 1 14 O
activity NN 0 1 1 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
administered JJ 0 1 1 O
EXTRANEAL NNP 0 1 UNK B-Brand
. . 0 0 12 O

Ketoconazole NNP 0 1 UNK B-Drug
: : 0 0 2 O
Co NNP 0 1 2 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
bosentan $ 0 1 13 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
b.i.d NN 0 1 UNK O
. . 0 0 12 O
and CC 0 0 12 O
ketoconazole VB 0 1 16 B-Drug
a DT 0 0 12 O
potent JJ 0 1 UNK O
CYP9A9 NNP 0 0 UNK O
inhibitor NN 0 1 14 O
increased VBD 1 1 1 O
the DT 0 0 12 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
bosentan NN 0 1 13 B-Drug
by IN 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
- : 0 0 2 O
fold NN 0 1 3 O
. . 0 0 12 O

sildenafil NN 0 1 16 B-Drug
concentration NN 0 1 1 O

Antacid NNS 0 1 UNK B-Group
: : 0 0 2 O
When WRB 0 0 12 O
atorvastatin NN 0 1 0 B-Drug
and CC 0 0 12 O
Maalox NNP 0 1 0 B-Brand
TC NNP 0 1 13 I-Brand
suspension NN 0 1 3 O
were VBD 1 0 12 O
coadministered VBN 0 0 UNK O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
atorvastatin NN 0 1 0 B-Drug
decreased VBD 1 1 1 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

Due JJ 0 1 2 O
to TO 0 0 12 O
wide JJ 0 1 3 O
interindividual JJ 0 0 UNK O
variability NN 0 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
dose JJ 0 1 6 O
adjustment NN 0 1 1 O
required VBN 1 1 1 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
that IN 0 0 12 O
cyclosporine NN 0 1 14 B-Drug
concentrations NNS 1 1 13 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
closely RB 0 0 1 O
after IN 0 0 12 O
initiation NN 0 1 1 O
of IN 0 0 12 O
carvedilol NN 0 1 16 B-Drug
therapy NN 0 1 6 O
and CC 0 0 12 O
that IN 0 0 12 O
the DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
cyclosporine NN 0 1 14 B-Drug
be VB 0 0 12 O
adjusted VBN 1 1 1 O
as IN 1 0 12 O
appropriate NN 0 1 1 O
. . 0 0 12 O

Furthermore RB 0 0 1 O
whenever WRB 0 0 12 O
one CD 0 1 12 O
of IN 0 0 12 O
these DT 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
is VBZ 1 0 12 O
withdrawn VBN 1 1 1 O
from IN 0 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
therapy NN 0 1 6 O
an DT 0 0 12 O
increased VBN 1 1 1 O
dose NN 0 1 6 O
of IN 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressant NN 0 1 6 I-Group
may MD 0 0 1 O
be VB 0 0 12 O
required VBN 1 1 1 O
. . 0 0 12 O

CANCIDAS NNP 0 1 UNK B-Brand
has VBZ 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
itraconazole JJ 0 1 0 B-Drug
amphotericin NN 0 1 14 B-Drug
B NNP 0 0 2 I-Drug
or CC 0 0 12 O
the DT 0 0 12 O
active JJ 0 1 1 O
metabolite NN 0 1 UNK O
of IN 0 0 12 O
mycophenolate NN 0 1 0 O
. . 0 0 12 O

Phenytoin NN 0 1 0 B-Drug
increases VBZ 1 1 1 O
the DT 0 0 12 O
clearance NN 0 1 16 O
of IN 0 0 12 O
busulfan NN 0 1 13 B-Drug
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
or CC 0 0 12 O
more JJR 0 1 12 O
possibly RB 0 1 12 O
due JJ 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
induction NN 0 1 1 O
of IN 0 0 12 O
glutathione NN 0 1 13 O
- : 0 0 2 O
S NNP 0 1 2 O
- : 0 0 2 O
transferase NN 0 1 14 O
. . 0 0 12 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interaction NNP 0 1 2 O
After IN 0 0 2 O
treatment NN 0 1 6 O
with IN 0 0 12 O
ampicillin PDT 0 1 0 B-Drug
a DT 0 0 12 O
false JJ 0 1 13 O
- : 0 0 2 O
positive JJ 0 1 1 O
reaction NN 0 1 1 O
for IN 0 0 12 O
glucose NN 0 1 14 O
in IN 0 0 12 O
the DT 0 0 12 O
urine NN 0 1 6 O
may MD 0 0 1 O
occur VB 0 1 1 O
with IN 0 0 12 O
copper NN 0 1 3 B-Drug_n
sulfate NN 0 1 14 I-Drug_n
tests NNS 1 1 1 O
( ( 0 0 2 O
Benedicts NNPS 0 0 UNK O
solution NN 0 1 1 O
Fehlings NNPS 0 0 UNK O
solution NN 0 1 1 O
or CC 0 0 12 O
Clinitest NNP 0 1 UNK O
tablets NNS 1 1 3 O
) ) 0 0 2 O
but CC 0 0 12 O
not RB 0 1 12 O
with IN 0 0 12 O
enzyme NNS 0 1 14 O
based VBN 1 1 1 O
tests NNS 1 1 1 O
such JJ 0 0 1 O
as IN 1 0 12 O
Clinistix NNP 0 0 UNK O
and CC 0 0 12 O
Glucose NNP 0 1 7 O
Enzymatic NNP 0 1 UNK O
Test NNP 0 1 2 O
Strip NNP 0 1 UNK O
USP NNP 0 1 UNK O
. . 0 0 12 O

Nevertheless RB 0 0 1 O
there EX 0 0 12 O
may MD 0 0 1 O
be VB 0 0 12 O
the DT 0 0 12 O
potential JJ 0 1 1 O
for IN 0 0 12 O
clinically RB 0 0 6 O
important JJ 0 1 1 O
alterations NNS 1 1 1 O
of IN 0 0 12 O
blood NN 0 1 6 O
levels NNS 1 1 1 O
of IN 0 0 12 O
coadministered JJ 0 0 UNK O
drugs NNS 1 1 6 O
. . 0 0 12 O

Coadministration NN 0 1 UNK O
of IN 0 0 12 O
alosetron NN 0 1 UNK B-Drug
and CC 0 0 12 O
strong JJ 0 1 12 O
CYP9A9 NNP 0 0 UNK O
inhibitors NNS 1 1 14 O
such JJ 0 0 1 O
as IN 1 0 12 O
clarithromycin NN 0 1 13 B-Drug
telithromycin NN 0 1 UNK B-Drug
protease NN 0 1 13 B-Group
inhibitors NNS 1 1 14 I-Group
voriconazole VBP 0 1 14 B-Drug
and CC 0 0 12 O
itraconazole NN 0 1 0 B-Drug
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
evaluated VBN 1 1 1 O
but CC 0 0 12 O
should MD 0 0 12 O
be VB 0 0 12 O
undertaken VBN 1 0 1 O
with IN 0 0 12 O
caution NN 0 0 1 O
because IN 0 0 12 O
of IN 0 0 12 O
similar JJ 0 1 1 O
potential JJ 0 1 1 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
. . 0 0 12 O

Fulminant JJ 0 0 UNK O
rhabdomyolysis NN 0 1 8 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
seen VBN 1 1 12 O
as RB 0 0 12 O
early JJ 0 1 12 O
as IN 1 0 12 O
three CD 0 1 12 O
weeks NNS 1 1 12 O
after IN 0 0 12 O
initiation NN 0 1 1 O
of IN 0 0 12 O
combined JJ 0 1 1 O
therapy NN 0 1 6 O
with IN 0 0 12 O
another DT 0 0 12 O
fibrate NN 0 0 UNK B-Group
and CC 0 0 12 O
lovastatin NN 0 1 13 B-Drug
but CC 0 0 12 O
may MD 0 0 1 O
be VB 0 0 12 O
seen VBN 1 1 12 O
after IN 0 0 12 O
several JJ 0 1 12 O
months NNS 1 1 12 O
. . 0 0 12 O

HMG NNP 0 0 UNK B-Group
- : 0 0 2 O
CoA NNP 0 0 UNK I-Group
Reductase NNP 0 1 UNK I-Group
Inhibitors NNS 0 1 7 I-Group
: : 0 0 2 O
Inhibitors NNS 0 1 7 B-Group
of IN 0 0 12 I-Group
HMG NNP 0 0 UNK I-Group
- : 0 0 2 O
CoA NNP 0 0 UNK I-Group
reductase NN 0 1 UNK I-Group
may MD 0 0 1 O
cause VB 0 1 12 O
myopathy NN 0 1 8 O
which WDT 0 0 12 O
is VBZ 1 0 12 O
manifested VBN 1 1 UNK O
as IN 1 0 12 O
muscle NN 0 1 6 O
pain NN 0 1 6 O
or CC 0 0 12 O
weakness NN 0 1 6 O
associated VBN 1 1 1 O
with IN 0 0 12 O
elevated JJ 0 1 1 O
levels NNS 1 1 1 O
of IN 0 0 12 O
CPK NNP 0 0 15 O
. . 0 0 12 O

There EX 0 0 12 O
is VBZ 1 0 12 O
limited JJ 0 1 1 O
experience NN 0 1 12 O
with IN 0 0 12 O
use NN 0 1 1 O
of IN 0 0 12 O
retinal JJ 0 1 6 O
tamponades NNS 1 1 UNK O
in IN 0 0 12 O
conjunction NN 0 1 1 O
with IN 0 0 12 O
the DT 0 0 12 O
Vitrasert NNP 0 1 UNK B-Brand
Implant NNP 0 1 UNK O
. . 0 0 12 O

A DT 0 0 2 O
dose JJ 0 1 6 O
adjustment NN 0 1 1 O
is VBZ 1 0 12 O
not RB 0 1 12 O
needed VBN 1 1 12 O
when WRB 0 0 12 O
zidovudine NN 0 1 13 B-Drug
is VBZ 1 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
VIRACEPT NNP 0 1 UNK B-Brand
. . 0 0 12 O

Prothrombin NNP 0 1 7 O
times NNS 1 1 12 O
were VBD 1 0 12 O
not RB 0 1 12 O
affected VBN 1 1 1 O
by IN 0 0 12 O
tiagabine NN 0 1 13 B-Drug
. . 0 0 12 O

Drug NN 0 1 2 O
Name NN 0 1 2 O

Myocardial JJ 0 1 7 O
injury NN 0 1 6 O
including VBG 1 1 1 O
myocardial JJ 0 1 6 O
infarction NN 0 1 6 O
myocarditis NN 0 1 8 O
ventricular JJ 0 1 8 O
hypokinesia NN 0 1 UNK O
and CC 0 0 12 O
severe JJ 0 1 6 O
rhabdomyolysis NN 0 1 8 O
appear VBP 0 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
increased VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
PROLEUKIN NNP 0 1 UNK B-Brand
and CC 0 0 12 O
interferon VB 0 1 14 B-Drug
- : 0 0 2 O
alfa NN 0 1 16 I-Drug
concurrently RB 0 0 1 O
. . 0 0 12 O

Nevirapine NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
principally RB 0 0 UNK O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
the DT 0 0 12 O
liver NN 0 1 6 O
via IN 0 0 1 O
the DT 0 0 12 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
isoenzymes VBZ 0 1 14 O
9A9 CD 0 0 UNK O
and CC 0 0 12 O
9B9 CD 0 0 UNK O
. . 0 0 12 O

Hepatic JJ 0 1 7 O
: : 0 0 2 O
There EX 0 0 12 O
is VBZ 1 0 12 O
limited JJ 0 1 1 O
evidence NN 0 1 1 O
that IN 0 0 12 O
the DT 0 0 12 O
myelotoxicity NN 0 0 UNK O
of IN 0 0 12 O
TAXOL NNP 0 1 UNK B-Brand
may MD 0 0 1 O
be VB 0 0 12 O
exacerbated VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
serum JJ 0 1 14 O
total JJ 0 1 1 O
bilirubin NN 0 1 14 O
9 CD 0 0 2 O
times NNS 1 1 12 O
ULN NNP 0 1 UNK O
. . 0 0 12 O

At IN 0 0 2 O
higher JJR 1 1 1 O
than IN 0 0 12 O
recommended VBN 1 1 1 O
doses NNS 1 1 6 O
VIOXX NNP 0 1 UNK B-Brand
9 CD 0 0 2 O
mg NN 0 1 0 O
administered VBN 1 1 1 O
once RB 0 0 12 O
daily JJ 0 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
increased VBD 1 1 1 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
as IN 1 0 12 O
measured VBN 1 1 1 O
by IN 0 0 12 O
AUC9 NNP 0 0 UNK O
- : 0 0 2 O
9hr CD 0 0 UNK O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
methotrexate JJ 0 1 16 B-Drug
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
week NN 0 1 12 O
for IN 0 0 12 O
rheumatoid JJ 0 0 6 O
arthritis NN 0 1 6 O
. . 0 0 12 O

Betaseron NNP 0 1 UNK B-Brand
administration NN 0 1 1 O
to TO 0 0 12 O
three CD 0 1 12 O
cancer NN 0 1 6 O
patients NNS 1 1 6 O
over IN 0 1 12 O
a DT 0 0 12 O
dose JJ 0 1 6 O
range NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
to TO 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
led VBD 1 1 12 O
to TO 0 0 12 O
a DT 0 0 12 O
dose JJ 0 1 6 O
- : 0 0 2 O
dependent JJ 0 1 1 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
antipyrine NN 0 1 UNK B-Drug
elimination.9 IN 0 1 UNK O
The DT 0 0 2 O
effect NN 0 1 1 O
of IN 0 0 12 O
alternate JJ 0 1 1 O
- : 0 0 2 O
day NN 0 1 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
of IN 0 0 12 O
Betaseron NNP 0 1 UNK B-Brand
on IN 0 0 12 O
drug NN 0 1 1 O
metabolism NN 0 1 16 O
in IN 0 0 12 O
MS NNP 0 1 2 O
patients NNS 1 1 6 O
is VBZ 1 0 12 O
unknown JJ 0 1 12 O
. . 0 0 12 O

Drugs NNS 0 1 2 O
Metabolized VBN 0 1 UNK O
by IN 0 0 12 O
CYP9A NNP 0 0 UNK O
: : 0 0 2 O
Results NNS 0 1 2 O
of IN 0 0 12 O
in IN 0 0 12 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
demonstrate VBP 0 0 1 O
that IN 0 0 12 O
duloxetine NN 0 1 0 B-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
inhibit VB 0 1 13 O
or CC 0 0 12 O
induce VB 0 1 6 O
CYP9A NNP 0 0 UNK O
activity NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
use NN 0 1 1 O
of IN 0 0 12 O
Adenocard NNP 0 1 UNK B-Brand
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
digitalis NN 0 1 14 B-Group
may MD 0 0 1 O
be VB 0 0 12 O
rarely RB 0 1 UNK O
associated VBN 1 1 1 O
with IN 0 0 12 O
ventricular JJ 0 1 8 O
fibrillation NN 0 1 6 O
. . 0 0 12 O

A DT 0 0 2 O
study NN 0 1 1 O
in IN 0 0 12 O
rats NNS 1 1 UNK O
to TO 0 0 12 O
assess VB 0 1 1 O
the DT 0 0 12 O
carcinogenic JJ 0 1 UNK O
potential NN 0 1 1 O
of IN 0 0 12 O
ribavirin NN 0 1 13 B-Drug
is VBZ 1 0 12 O
ongoing VBG 0 1 1 O
. . 0 0 12 O

Studies NNS 0 1 2 O
in IN 0 0 12 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
have VBP 0 0 12 O
shown VBN 1 1 1 O
that IN 0 0 12 O
Acarbose NNP 0 1 UNK B-Drug
has VBZ 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
either CC 0 1 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
or CC 0 0 12 O
pharmacodynamics NNS 0 1 UNK O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
nifedipine JJ 0 1 0 B-Drug
propranolol NN 0 1 16 B-Drug
or CC 0 0 12 O
ranitidine NN 0 1 0 B-Drug
. . 0 0 12 O

In IN 0 0 2 O
vitro JJ 0 1 UNK O
binding NN 0 1 1 O
studies NNS 1 1 1 O
with IN 0 0 12 O
human JJ 0 1 1 O
serum NN 0 1 14 O
proteins NNS 1 1 14 O
indicate VBP 0 0 1 O
that IN 0 0 12 O
glipizide NN 0 1 0 B-Drug
binds VBZ 1 1 UNK O
differently RB 0 0 UNK O
than IN 0 0 12 O
tolbutamide RB 0 1 UNK B-Drug
and CC 0 0 12 O
does VBZ 1 0 12 O
not RB 0 1 12 O
interact VB 0 0 UNK O
with IN 0 0 12 O
salicylate NN 0 1 13 B-Group
or CC 0 0 12 O
dicumarol NN 0 1 UNK B-Drug
. . 0 0 12 O

The DT 0 0 2 O
pressor NN 0 1 14 O
effects NNS 1 1 1 O
of IN 0 0 12 O
catecholamines NNS 1 1 14 B-Group
such JJ 0 0 1 O
as IN 1 0 12 O
dopamine NN 0 1 14 B-Drug
or CC 0 0 12 O
norepinephrine NN 0 1 14 B-Drug
are VBP 1 0 12 O
enhanced VBN 1 1 1 O
by IN 0 0 12 O
Bretylium NNP 0 1 UNK B-Drug
Tosylate NNP 0 0 UNK I-Drug
. . 0 0 12 O

When WRB 0 0 12 O
you PRP 0 0 12 O
are VBP 1 0 12 O
using VBG 1 1 1 O
idoxuridine NN 0 1 UNK B-Drug
it PRP 0 0 12 O
is VBZ 1 0 12 O
especially RB 0 0 12 O
important JJ 0 1 1 O
that IN 0 0 12 O
your PRP$ 0 0 12 O
health NN 0 1 1 O
care NN 0 1 12 O
professional NN 0 1 1 O
know VBP 0 0 12 O
if IN 0 0 12 O
you PRP 0 0 12 O
are VBP 1 0 12 O
using VBG 1 1 1 O
the DT 0 0 12 O
following NN 0 1 1 O
: : 0 0 2 O
Eye NNP 0 1 2 O
product NN 0 1 1 O
containing VBG 1 1 1 O
boric JJ 0 1 UNK B-Drug
acid NN 0 1 14 I-Drug
. . 0 0 12 O

Caution NN 0 0 UNK O
is VBZ 1 0 12 O
advised VBN 1 0 12 O
nonetheless RB 0 0 UNK O
since IN 0 1 12 O
interactions NNS 1 1 UNK O
have VBP 0 0 12 O
been VBN 1 0 12 O
seen VBN 1 1 12 O
with IN 0 0 12 O
other JJ 0 0 12 O
nonsteroidal JJ 0 0 14 O
agents NNS 1 1 1 O
of IN 0 0 12 O
this DT 0 0 12 O
class NN 0 1 12 O
. . 0 0 12 O

Agents NNS 0 1 2 O
that WDT 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
found VBN 1 1 12 O
or CC 0 0 12 O
are VBP 1 0 12 O
expected VBN 1 1 12 O
to TO 0 0 12 O
have VB 0 0 12 O
decreased VBN 1 1 1 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
presence NN 0 1 1 O
of IN 0 0 12 O
EQUETROTM NNP 0 0 UNK B-Brand
due JJ 0 1 1 O
to TO 0 0 12 O
induction NN 0 1 1 O
of IN 0 0 12 O
CYP NNP 0 1 UNK O
enzymes NNS 1 1 14 O
are VBP 1 0 12 O
the DT 0 0 12 O
following JJ 0 1 1 O
: : 0 0 2 O
Acetaminophen NNP 0 1 0 B-Drug
alprazolam VBZ 0 1 0 B-Drug
amitriptyline JJ 0 1 16 B-Drug
bupropion NN 0 1 16 B-Drug
buspirone NN 0 1 16 B-Drug
citalopram NN 0 1 16 B-Drug
clobazam NN 0 1 13 B-Drug
clonazepam NN 0 1 0 B-Drug
clozapine NN 0 1 13 B-Drug
cyclosporin NN 0 1 14 B-Drug
delavirdine NN 0 1 13 B-Drug
desipramine NN 0 1 16 B-Drug
diazepam NN 0 1 0 B-Drug
dicumarol NN 0 1 UNK B-Drug
doxycycline NN 0 1 0 B-Drug
ethosuximide NN 0 1 13 B-Drug
felbamate VBP 0 1 13 B-Drug
felodipine JJ 0 1 13 B-Drug
glucocorticoids NNS 1 1 UNK B-Group
haloperidol VBD 0 1 16 B-Drug
itraconazole JJ 0 1 0 B-Drug
lamotrigine JJ 0 1 0 B-Drug
levothyroxine NN 0 1 0 B-Drug
lorazepam NN 0 1 0 B-Drug
methadone NN 0 1 6 B-Drug
midazolam NN 0 1 16 B-Drug
mirtazapine NN 0 1 0 B-Drug
nortriptyline JJ 0 1 16 B-Drug
olanzapine JJ 0 1 16 B-Drug
oral JJ 0 1 6 O
contraceptives NNS 1 1 13 B-Group
( ( 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
oxcarbazepine NN 0 1 16 B-Drug
Phenytoin NNP 0 1 0 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
praziquantel NN 0 1 13 B-Drug
protease NN 0 1 13 B-Group
inhibitors NNS 1 1 14 I-Group
quetiapine VBP 0 1 16 B-Drug
risperidone NN 0 1 0 B-Drug
theophylline NN 0 1 16 B-Drug
topiramate NN 0 1 16 B-Drug
tiagabine NN 0 1 13 B-Drug
tramadol NN 0 1 16 B-Drug
triazolam NN 0 1 13 B-Drug
valproate NN 0 1 16 B-Drug
warfarin NN 0 1 14 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
ziprasidone NN 0 1 16 B-Drug
and CC 0 0 12 O
zonisamide NN 0 1 16 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
saquinavir NN 0 1 13 B-Drug
is VBZ 1 0 12 O
mediated VBN 1 1 13 O
by IN 0 0 12 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
specific JJ 0 1 1 O
isoenzyme NN 0 1 13 O
CYP9A9 NNP 0 0 UNK O
responsible JJ 0 1 1 O
for IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
of IN 0 0 12 O
the DT 0 0 12 O
hepatic JJ 0 1 14 O
metabolism NN 0 1 16 O
. . 0 0 12 O

Benzylpenicillin NNP 0 1 UNK B-Drug
ampicillin NN 0 1 0 B-Drug
oxacillin NN 0 1 14 B-Drug
chlortetracycline NN 0 1 UNK B-Drug
doxycycline NN 0 1 0 B-Drug
cephalothin NN 0 1 UNK B-Drug
erythromycin NN 0 1 0 B-Drug
and CC 0 0 12 O
sulfamethoxazole NN 0 1 13 B-Drug
have VBP 0 0 12 O
no DT 0 0 12 O
influence NN 0 0 UNK O
in IN 0 0 12 O
vitro NN 0 1 UNK O
on IN 0 0 12 O
the DT 0 0 12 O
protein NN 0 1 14 O
binding NN 0 1 1 O
of IN 0 0 12 O
diclofenac NN 0 1 16 B-Drug
in IN 0 0 12 O
human JJ 0 1 1 O
serum NN 0 1 14 O
. . 0 0 12 O

Inhibition NN 0 1 UNK O
of IN 0 0 12 O
renal JJ 0 1 6 O
lithium NN 0 1 16 B-Drug
clearance NN 0 1 16 O
leading VBG 1 1 1 O
to TO 0 0 12 O
increases NNS 1 1 1 O
in IN 0 0 12 O
plasma JJ 0 1 14 O
lithium NN 0 1 16 B-Drug
concentrations NNS 1 1 13 O
has VBZ 1 0 12 O
also RB 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
. . 0 0 12 O

Drugs NNS 0 1 2 O
other JJ 0 0 12 O
than IN 0 0 12 O
those DT 0 0 12 O
listed VBN 1 1 1 O
here RB 0 0 12 O
may MD 0 0 1 O
also RB 0 0 12 O
interact VB 0 0 UNK O
with IN 0 0 12 O
glimepiride NN 0 1 16 B-Drug
or CC 0 0 12 O
affect VB 0 1 1 O
your PRP$ 0 0 12 O
condition NN 0 1 1 O
. . 0 0 12 O

Although IN 0 0 12 O
clinical JJ 0 1 6 O
evidence NN 0 1 1 O
to TO 0 0 12 O
date NN 0 1 12 O
has VBZ 1 0 12 O
not RB 0 1 12 O
demonstrated VBN 1 0 1 O
renal JJ 0 1 6 O
precipitation NN 0 1 1 O
of IN 0 0 12 O
oxypurines NNS 0 1 UNK O
in IN 0 0 12 O
patients NNS 1 1 6 O
either CC 0 1 12 O
on IN 0 0 12 O
allopurinol JJ 0 1 13 B-Drug
alone CD 0 1 12 O
or CC 0 0 12 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
uricosuric JJ 0 0 UNK B-Group
agents NNS 1 1 1 I-Group
the DT 0 0 12 O
possibility NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
kept VBN 1 1 12 O
in IN 0 0 12 O
mind NN 0 1 12 O
. . 0 0 12 O

It PRP 0 0 12 O
may MD 0 0 1 O
also RB 0 0 12 O
interact VB 0 0 UNK O
with IN 0 0 12 O
amantadine NN 0 1 16 B-Drug
or CC 0 0 12 O
other JJ 0 0 12 O
anticholinergic JJ 0 1 13 B-Group
drugs NNS 1 1 6 I-Group
or CC 0 0 12 O
MAOIs NNP 0 1 UNK B-Group
which WDT 0 0 12 O
may MD 0 0 1 O
intensify VB 0 0 UNK O
the DT 0 0 12 O
anticholinergic JJ 0 1 13 O
action NN 0 1 13 O
. . 0 0 12 O

Phenobarbital NN 0 1 0 B-Drug
: : 0 0 2 O
Decreases VBZ 0 1 UNK O
aspirin JJ 0 1 14 B-Brand
effectiveness NN 0 1 UNK O
by IN 0 0 12 O
enzyme JJ 0 1 14 O
induction NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
adverse JJ 0 0 1 O
experience NN 0 1 12 O
profile NN 0 1 1 O
seen VBN 1 1 12 O
with IN 0 0 12 O
KEMSTROTM NNP 0 0 UNK B-Brand
was VBD 1 0 12 O
similar JJ 0 1 1 O
to TO 0 0 12 O
that DT 0 0 12 O
seen VBN 1 1 12 O
with IN 0 0 12 O
baclofen JJ 0 1 0 B-Drug
tablets NNS 1 1 3 O
. . 0 0 12 O

When WRB 0 0 12 O
the DT 0 0 12 O
rapid JJ 0 1 1 O
onset NN 0 1 6 O
of IN 0 0 12 O
a DT 0 0 12 O
concomitant NN 0 1 6 O
orally RB 0 1 14 O
administered VBN 1 1 1 O
agent NN 0 1 1 O
is VBZ 1 0 12 O
a DT 0 0 12 O
critical JJ 0 1 1 O
determinant NN 0 1 UNK O
of IN 0 0 12 O
effectiveness NN 0 1 UNK O
( ( 0 0 2 O
such JJ 0 0 1 O
as IN 1 0 12 O
analgesics NNS 1 1 14 B-Group
) ) 0 0 2 O
the DT 0 0 12 O
agent NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
at IN 0 0 12 O
least JJS 0 1 12 O
9 CD 0 0 2 O
hour NN 0 1 12 O
prior RB 0 1 1 O
to TO 0 0 12 O
or CC 0 0 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
after IN 0 0 12 O
SYMLIN NNP 0 1 UNK B-Brand
injection NN 0 1 3 O
. . 0 0 12 O

Clinically RB 0 0 7 O
relevant JJ 0 1 1 O
interactions NNS 1 1 UNK O
of IN 0 0 12 O
pantoprazole NN 0 1 16 B-Drug
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
with IN 0 0 12 O
the DT 0 0 12 O
same JJ 0 1 12 O
metabolic JJ 0 1 6 O
pathways NNS 1 1 13 O
are VBP 1 0 12 O
not RB 0 1 12 O
expected VBN 1 1 12 O
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
suggested VBN 1 1 12 O
that IN 0 0 12 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
dopamine JJ 0 1 14 B-Drug
HCl NNP 0 0 14 I-Drug
alternatives NNS 1 1 UNK O
to TO 0 0 12 O
phenytoin VB 0 1 16 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
if IN 0 0 12 O
anticonvulsant JJ 0 1 14 B-Group
therapy NN 0 1 6 O
is VBZ 1 0 12 O
needed VBN 1 1 12 O
. . 0 0 12 O

When WRB 0 0 12 O
atropine NN 0 1 14 B-Drug
and CC 0 0 12 O
pralidoxime NN 0 1 13 B-Drug
are VBP 1 0 12 O
used VBN 1 1 12 O
together RB 0 1 12 O
the DT 0 0 12 O
signs NNS 1 1 12 O
of IN 0 0 12 O
atropinization NN 0 1 UNK O
( ( 0 0 2 O
flushing VBG 1 1 13 O
mydriasis NN 0 1 13 O
tachycardia NN 0 1 8 O
dryness NN 0 1 6 O
of IN 0 0 12 O
the DT 0 0 12 O
mouth NN 0 1 3 O
and CC 0 0 12 O
nose RB 0 1 3 O
) ) 0 0 2 O
may MD 0 0 1 O
occur VB 0 1 1 O
earlier JJR 1 1 12 O
than IN 0 0 12 O
might MD 0 0 12 O
be VB 0 0 12 O
expected VBN 1 1 12 O
than IN 0 0 12 O
when WRB 0 0 12 O
atropine NN 0 1 14 B-Drug
is VBZ 1 0 12 O
used VBN 1 1 12 O
alone RB 0 1 12 O
because IN 0 0 12 O
pralidoxime NN 0 1 13 B-Drug
may MD 0 0 1 O
potentiate VB 0 0 UNK O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
atropine NN 0 1 14 B-Drug
. . 0 0 12 O

decreased VBN 1 1 1 O
antithrombin JJ 0 1 14 O
9 CD 0 0 2 O
; : 0 0 2 O

In IN 0 0 2 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
with IN 0 0 12 O
human JJ 0 1 1 O
liver NN 0 1 6 O
microsomes NNS 1 1 UNK O
indicate VBP 0 0 1 O
that IN 0 0 12 O
bortezomib NN 0 1 13 B-Drug
is VBZ 1 0 12 O
primarily RB 0 0 1 O
a DT 0 0 12 O
substrate NN 0 1 UNK O
for IN 0 0 12 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
9A9 CD 0 0 UNK O
9C9 CD 0 0 UNK O
and CC 0 0 12 O
9A9 CD 0 0 UNK O
. . 0 0 12 O

Narcotic JJ 0 1 UNK B-Group
analgesics NNS 1 1 14 I-Group
may MD 0 0 1 O
potentiate VB 0 0 UNK O
the DT 0 0 12 O
hypotensive JJ 0 1 14 O
effects NNS 1 1 1 O
of IN 0 0 12 O
clonidine NN 0 1 0 B-Drug
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
unknown JJ 0 1 12 O
how WRB 0 0 12 O
the DT 0 0 12 O
effect NN 0 1 1 O
seen VBN 1 1 12 O
in IN 0 0 12 O
these DT 0 0 12 O
in IN 0 0 12 O
vitro NN 0 1 UNK O
studies NNS 1 1 1 O
translates VBZ 1 1 UNK O
into IN 0 0 12 O
clinical JJ 0 1 6 O
consequences NNS 1 1 UNK O
. . 0 0 12 O

Thus RB 0 0 1 O
if IN 0 0 12 O
a DT 0 0 12 O
patient NN 0 1 6 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
titrated VBN 1 1 14 O
to TO 0 0 12 O
a DT 0 0 12 O
stable JJ 0 1 1 O
dosage NN 0 1 0 O
of IN 0 0 12 O
EQUETROTM NNP 0 0 UNK B-Brand
and CC 0 0 12 O
then RB 0 1 12 O
begins VBZ 1 1 12 O
a DT 0 0 12 O
course NN 0 1 12 O
of IN 0 0 12 O
treatment NN 0 1 6 O
with IN 0 0 12 O
one CD 0 1 12 O
of IN 0 0 12 O
these DT 0 0 12 O
CYP9A9 NNP 0 0 UNK O
or CC 0 0 12 O
epoxide VB 0 1 UNK O
hydrolase NN 0 1 UNK O
inhibitors NNS 1 1 14 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
reasonable JJ 0 0 1 O
to TO 0 0 12 O
expect VB 0 0 12 O
that IN 0 0 12 O
a DT 0 0 12 O
dose JJ 0 1 6 O
reduction NN 0 1 1 O
for IN 0 0 12 O
EQUETROTM NNP 0 0 UNK B-Brand
may MD 0 0 1 O
be VB 0 0 12 O
necessary JJ 0 0 1 O
. . 0 0 12 O

Use NNP 0 1 2 O
caution NN 0 0 1 O
when WRB 0 0 12 O
giving VBG 1 1 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
together RB 0 1 12 O
especially RB 0 0 12 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
hepatic JJ 0 1 14 O
or CC 0 0 12 O
cardiac JJ 0 1 6 O
disease NN 0 1 6 O
. . 0 0 12 O

Anafranil NNP 0 1 UNK B-Brand
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
with IN 0 0 12 O
MAO NNP 0 1 14 B-Group
inhibitors NNS 1 1 14 I-Group
. . 0 0 12 O

Patients NNS 0 1 7 O
taking VBG 1 0 12 O
digoxin NN 0 1 14 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
appropriately RB 0 0 1 O
. . 0 0 12 O

Ergot NNP 0 1 UNK O
derivatives NNS 1 1 13 O
: : 0 0 2 O
dihydroergotamine NN 0 1 UNK B-Drug
ergonovine NN 0 1 UNK B-Drug
ergotamine NN 0 1 UNK B-Drug
methylergonovine NN 0 1 16 B-Drug

Injection NN 0 1 7 O
There EX 0 0 12 O
is VBZ 1 0 12 O
inadequate JJ 0 1 1 O
systematic JJ 0 1 UNK O
experience NN 0 1 12 O
with IN 0 0 12 O
the DT 0 0 12 O
use NN 0 1 1 O
of IN 0 0 12 O
baclofen NN 0 1 0 B-Drug
injection NN 0 1 3 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
other JJ 0 0 12 O
medications NNS 1 1 6 O
to TO 0 0 12 O
predict VB 0 0 UNK O
specific JJ 0 1 1 O
drug NN 0 1 1 O
- : 0 0 2 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
. . 0 0 12 O

Interactions NNS 0 1 UNK O
may MD 0 0 1 O
occur VB 0 1 1 O
with IN 0 0 12 O
the DT 0 0 12 O
following NN 0 1 1 O
: : 0 0 2 O
adrenocorticoids NNS 0 0 UNK O
( ( 0 0 2 O
cortisone SYM 0 1 6 O
- : 0 0 2 O
like IN 0 0 12 O
medicine NN 0 1 6 O
) ) 0 0 2 O
anticoagulants NNS 1 1 13 B-Group
( ( 0 0 2 O
blood NN 0 1 6 B-Group
thinners NNS 1 1 14 I-Group
) ) 0 0 2 O
carbamazepine VBP 0 1 16 B-Drug
corticotropin NN 0 1 13 B-Drug
( ( 0 0 2 O
barbiturates NNS 1 1 14 B-Group
may MD 0 0 1 O
decrease VB 0 1 1 O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
these DT 0 0 12 O
medicines NNS 1 1 6 O
) ) 0 0 2 O
central JJ 0 1 1 B-Group
nervous JJ 0 1 6 I-Group
system NN 0 1 1 I-Group
CNS NNP 0 1 6 I-Group
depressants NNS 1 0 13 I-Group
( ( 0 0 2 O
using VBG 1 1 1 O
these DT 0 0 12 O
medicines NNS 1 1 6 O
with IN 0 0 12 O
barbiturates NNS 1 1 14 B-Group
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
increased JJ 0 1 1 O
CNS NNP 0 1 6 O
depressant NN 0 0 UNK O
effects NNS 1 1 1 O
) ) 0 0 2 O
divalproex VBP 0 1 16 B-Drug
sodium JJ 0 1 14 I-Drug
valproic NN 0 0 16 B-Drug
acid NN 0 1 14 I-Drug
( ( 0 0 2 O
using VBG 1 1 1 O
these DT 0 0 12 O
medicines NNS 1 1 6 O
with IN 0 0 12 O
barbiturates NNS 1 1 14 B-Group
may MD 0 0 1 O
change VB 0 1 1 O
the DT 0 0 12 O
amount NN 0 1 1 O
of IN 0 0 12 O
either DT 0 1 12 O
medicine NN 0 1 6 O
that IN 0 0 12 O
you PRP 0 0 12 O
need VBP 0 1 12 O
to TO 0 0 12 O
take VB 0 1 12 O
) ) 0 0 2 O
and CC 0 0 12 O
oral JJ 0 1 6 O
contraceptives NNS 1 1 13 B-Group
containing VBG 1 1 1 O
estrogens NNS 1 1 16 B-Group
( ( 0 0 2 O
barbiturates NNS 1 1 14 B-Group
may MD 0 0 1 O
decrease VB 0 1 1 O
the DT 0 0 12 O
effectiveness NN 0 1 UNK O
of IN 0 0 12 O
these DT 0 0 12 O
oral JJ 0 1 6 O
contraceptives NNS 1 1 13 B-Group
and CC 0 0 12 O
you PRP 0 0 12 O
may MD 0 0 1 O
need VB 0 1 12 O
to TO 0 0 12 O
change VB 0 1 1 O
to TO 0 0 12 O
a DT 0 0 12 O
different JJ 0 1 1 O
type NN 0 1 1 O
of IN 0 0 12 O
birth NN 0 1 12 O
control NN 0 1 1 O
) ) 0 0 2 O
. . 0 0 12 O

There EX 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
case NN 0 1 12 O
reports NNS 1 1 1 O
of IN 0 0 12 O
increased VBN 1 1 1 O
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
levels NNS 1 1 1 O
of IN 0 0 12 O
quinidine NN 0 1 16 B-Drug
procainamide NN 0 1 16 B-Drug
and CC 0 0 12 O
phenytoin NN 0 1 16 B-Drug
during IN 0 0 12 O
concomitant JJ 0 1 6 O
therapy NN 0 1 6 O
with IN 0 0 12 O
amiodarone NN 0 1 0 B-Drug
. . 0 0 12 O

These DT 0 0 1 O
reports NNS 1 1 1 O
are VBP 1 0 12 O
more RBR 0 1 12 O
frequent JJ 0 1 1 O
for IN 0 0 12 O
women NNS 1 1 UNK O
who WP 0 0 12 O
use VBP 0 1 1 O
only RB 0 1 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
method NN 0 1 13 O
of IN 0 0 12 O
contraception NN 0 1 13 O
. . 0 0 12 O

Therefore RB 0 0 1 O
smaller JJR 1 1 3 O
ALFENTA NNP 0 1 UNK B-Brand
doses NNS 1 1 6 O
will MD 0 0 12 O
be VB 0 0 12 O
required VBN 1 1 1 O
with IN 0 0 12 O
prolonged JJ 0 1 6 O
administration NN 0 1 1 O
and CC 0 0 12 O
the DT 0 0 12 O
duration NN 0 1 1 O
of IN 0 0 12 O
action NN 0 1 13 O
of IN 0 0 12 O
ALFENTA NNP 0 1 UNK B-Brand
my PRP$ 0 0 12 O
be VB 0 0 12 O
extended VBN 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
Factrel NNP 0 1 UNK B-Brand
test NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
conducted VBN 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
absence NN 0 1 1 O
of IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
which WDT 0 0 12 O
directly RB 0 1 1 O
affect VBP 0 1 1 O
the DT 0 0 12 O
pituitary JJ 0 1 6 O
secretion NN 0 1 14 O
of IN 0 0 12 O
the DT 0 0 12 O
gonadotropins NNS 1 1 UNK O
. . 0 0 12 O

Warfarin NN 0 1 0 B-Drug
: : 0 0 2 O
Quinolones NNS 0 1 UNK B-Group
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
enhance VB 0 1 UNK O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
oral JJ 0 1 6 O
anticoagulant JJ 0 1 13 B-Group
warfarin NN 0 1 14 B-Drug
or CC 0 0 12 O
its PRP$ 1 0 12 O
derivatives NNS 1 1 13 O
. . 0 0 12 O

Because IN 0 0 12 O
bupropion NN 0 1 16 B-Drug
is VBZ 1 0 12 O
extensively RB 0 0 1 O
metabolized VBN 1 1 UNK O
the DT 0 0 12 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
may MD 0 0 1 O
affect VB 0 1 1 O
its PRP$ 1 0 12 O
clinical JJ 0 1 6 O
activity NN 0 1 1 O
. . 0 0 12 O

Administration NN 0 1 UNK O
of IN 0 0 12 O
non JJ 0 1 1 B-Group
- : 0 0 2 O
steroidal NN 0 1 UNK I-Group
anti SYM 0 0 3 I-Group
- : 0 0 2 O
inflammatory NN 0 1 6 I-Group
drugs NNS 1 1 6 I-Group
concomitantly RB 0 0 14 O
with IN 0 0 12 O
cyclosporine NN 0 1 14 B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
an DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
cyclosporine JJ 0 1 14 B-Drug
- : 0 0 2 O
induced JJ 0 1 6 O
toxicity NN 0 1 6 O
possibly RB 0 1 12 O
due JJ 0 1 1 O
to TO 0 0 12 O
decreased JJ 0 1 1 O
synthesis NN 0 1 UNK O
of IN 0 0 12 O
renal JJ 0 1 6 O
prostacyclin NN 0 1 UNK O
. . 0 0 12 O

See VB 0 1 2 O
CLINICAL NNP 0 1 11 O
PHARMACOLOGY NNP 0 1 UNK O
. . 0 0 12 O

Monoamine NNP 0 1 UNK B-Group
oxidase NN 0 1 13 I-Group
MAO NNP 0 1 14 I-Group
inhibitors NNS 1 1 14 I-Group
such JJ 0 0 1 O
as IN 1 0 12 O
isocarboxazid NN 0 1 UNK B-Drug
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
Marplan NNP 0 1 UNK B-Brand
) ) 0 0 2 O
phenelzine NN 0 1 16 B-Drug
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
Nardil NNP 0 1 UNK B-Brand
) ) 0 0 2 O
procarbazine NN 0 1 13 B-Drug
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
Matulane NNP 0 1 UNK B-Brand
) ) 0 0 2 O
selegiline NN 0 1 13 B-Drug
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
Eldepryl NNP 0 1 0 B-Brand
) ) 0 0 2 O
and CC 0 0 12 O
tranylcypromine NN 0 1 13 B-Drug
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
Parnate NNP 0 1 UNK B-Brand
) ) 0 0 2 O
: : 0 0 2 O
Using VBG 0 1 2 O
these DT 0 0 12 O
medicines NNS 1 1 6 O
with IN 0 0 12 O
L NNP 0 1 2 B-Drug
- : 0 0 2 O
tryptophan NN 0 1 UNK I-Drug
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
chance NN 0 1 12 O
of IN 0 0 12 O
side JJ 0 1 3 O
effects NNS 1 1 1 O
. . 0 0 12 O

Loratadine NNP 0 1 UNK B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
once RB 0 0 12 O
daily JJ 0 1 12 O
) ) 0 0 2 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
therapeutic JJ 0 1 6 O
doses NNS 1 1 6 O
of IN 0 0 12 O
erythromycin JJ 0 1 0 B-Drug
cimetidine NN 0 1 13 B-Drug
and CC 0 0 12 O
ketoconazole NN 0 1 16 B-Drug
in IN 0 0 12 O
controlled JJ 0 1 1 O
clinical JJ 0 1 6 O
pharmacology NN 0 1 UNK O
studies NNS 1 1 1 O
in IN 0 0 12 O
adult NN 0 1 12 O
volunteers NNS 1 1 UNK O
. . 0 0 12 O

No DT 0 0 2 O
increase NN 0 1 1 O
in IN 0 0 12 O
mortality NN 0 1 13 O
was VBD 1 0 12 O
observed VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
digoxin NN 0 1 14 B-Drug
as IN 1 0 12 O
concomitant JJ 0 1 6 O
medication NN 0 1 6 O
. . 0 0 12 O

In IN 0 0 2 O
drug NN 0 1 1 O
- : 0 0 2 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
the DT 0 0 12 O
recommended JJ 0 1 1 O
clinical JJ 0 1 6 O
dose NN 0 1 6 O
of IN 0 0 12 O
montelukast NN 0 1 16 B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
have VB 0 0 12 O
clinically RB 0 0 6 O
important JJ 0 1 1 O
effects NNS 1 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
following JJ 0 1 1 O
drugs NNS 1 1 6 O
: : 0 0 2 O
theophylline NN 0 1 16 B-Drug
prednisone NN 0 1 0 B-Drug
prednisolone NN 0 1 0 B-Drug
oral JJ 0 1 6 O
contraceptives NNS 1 1 13 B-Group
( ( 0 0 2 O
norethindrone RB 0 1 13 B-Drug
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
ethinyl VBP 0 0 13 B-Drug
estradiol $ 0 1 13 I-Drug
9 CD 0 0 2 O
mcg NN 0 1 0 O
) ) 0 0 2 O
terfenadine NN 0 1 UNK B-Drug
digoxin NN 0 1 14 B-Drug
and CC 0 0 12 O
warfarin NN 0 1 14 B-Drug
. . 0 0 12 O

As IN 0 0 2 O
with IN 0 0 12 O
other JJ 0 0 12 O
agents NNS 1 1 1 O
which WDT 0 0 12 O
prolong VBP 0 0 13 O
ECG NNP 0 1 6 O
intervals NNS 1 1 1 O
caution NN 0 0 1 O
should MD 0 0 12 O
be VB 0 0 12 O
exercised VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
drugs NNS 1 1 6 O
which WDT 0 0 12 O
prolong VBP 0 0 13 O
ECG NNP 0 1 6 O
intervals NNS 1 1 1 O
particularly RB 0 0 1 O
QTc NNP 0 0 14 O
. . 0 0 12 O

Nervous JJ 0 1 UNK O
System NN 0 1 2 O
: : 0 0 2 O
Although IN 0 0 12 O
the DT 0 0 12 O
occurrence NN 0 1 1 O
of IN 0 0 12 O
peripheral JJ 0 1 6 O
neuropathy NN 0 1 6 O
is VBZ 1 0 12 O
frequent JJ 0 1 1 O
the DT 0 0 12 O
development NN 0 1 1 O
of IN 0 0 12 O
severe JJ 0 1 6 O
symptomatology NN 0 0 6 O
is VBZ 1 0 12 O
unusual JJ 0 1 12 O
and CC 0 0 12 O
requires VBZ 1 0 1 O
a DT 0 0 12 O
dose JJ 0 1 6 O
reduction NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
for IN 0 0 12 O
all DT 0 0 12 O
subsequentcourses NNS 0 0 UNK O
of IN 0 0 12 O
TAXOL NNP 0 1 UNK B-Brand
. . 0 0 12 O

DRUG NN 0 1 11 O
/ NNP 0 0 2 O
LABORATORY NNP 0 1 11 O
TEST NNP 0 1 11 O
INTERACTIONS NNP 0 1 UNK O
9 CD 0 0 2 O
. . 0 0 12 O

Antacids NNS 0 1 UNK B-Group
: : 0 0 2 O
The DT 0 0 2 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
antacids NNS 1 1 14 B-Group
has VBZ 1 0 12 O
no DT 0 0 12 O
apparent JJ 0 1 1 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
extent NN 0 1 1 O
of IN 0 0 12 O
absorption NN 0 1 1 O
of IN 0 0 12 O
Lodine NNP 0 1 UNK B-Brand
. . 0 0 12 O

While IN 0 0 12 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
not RB 0 1 12 O
known VBN 1 1 12 O
whether IN 0 0 12 O
this DT 0 0 12 O
interaction NN 0 1 UNK O
occurs VBZ 1 1 1 O
with IN 0 0 12 O
fibrates NNS 0 1 UNK B-Group
other JJ 0 0 12 O
than IN 0 0 12 O
gemfibrozil JJ 0 1 16 B-Drug
myopathy NN 0 1 8 O
and CC 0 0 12 O
rhabdomyolysis NN 0 1 8 O
have VBP 0 0 12 O
occasionally RB 0 1 12 O
been VBN 1 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
the DT 0 0 12 O
use NN 0 1 1 O
of IN 0 0 12 O
fibrates NNS 0 1 UNK B-Group
alone RB 0 1 12 O
including VBG 1 1 1 O
clofibrate NN 0 1 UNK B-Drug
. . 0 0 12 O

This DT 0 0 2 O
interaction NN 0 1 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
given VBN 1 1 12 O
consideration NN 0 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
NSAIDs NNP 0 1 UNK B-Group
concomitantly RB 0 0 14 O
with IN 0 0 12 O
ACE NNP 0 1 13 B-Group
inhibitors NNS 1 1 14 I-Group
. . 0 0 12 O

Carbamazepine NN 0 1 UNK B-Drug
: : 0 0 2 O
Coadministration NN 0 1 UNK O
of IN 0 0 12 O
carbamazepine NN 0 1 16 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg RB 0 1 0 O
BID NNP 0 0 11 O
) ) 0 0 2 O
a DT 0 0 12 O
potent JJ 0 1 UNK O
CYP9A9 NNP 0 0 UNK O
inducer NN 0 1 UNK O
with IN 0 0 12 O
aripiprazole NN 0 1 16 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg RB 0 1 0 O
QD NNP 0 1 13 O
) ) 0 0 2 O
resulted VBD 1 1 1 O
in IN 0 0 12 O
an DT 0 0 12 O
approximate JJ 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
decrease NN 0 1 1 O
in IN 0 0 12 O
Cmax NNP 0 1 UNK O
and CC 0 0 12 O
AUC NNP 0 1 UNK O
values NNS 1 1 1 O
of IN 0 0 12 O
both DT 0 0 12 O
aripiprazole JJ 0 1 16 B-Drug
and CC 0 0 12 O
its PRP$ 1 0 12 O
active JJ 0 1 1 O
metabolite NN 0 1 UNK O
dehydro NN 0 0 UNK B-Drug_n
- : 0 0 2 O
aripiprazole NN 0 1 16 I-Drug_n
. . 0 0 12 O

9 CD 0 0 2 O
years NNS 1 1 12 O
of IN 0 0 12 O
age NN 0 1 12 O
and CC 0 0 12 O
9 CD 0 0 2 O
patients NNS 1 1 6 O
were VBD 1 0 12 O

Because IN 0 0 12 O
of IN 0 0 12 O
possible JJ 0 1 1 O
additive JJ 0 1 16 O
effects NNS 1 1 1 O
with IN 0 0 12 O
other JJ 0 0 12 O
carbonic JJ 0 1 13 B-Group
anhydrase NN 0 0 13 I-Group
inhibitors NNS 1 1 14 I-Group
concomitant VBP 0 1 6 O
use NN 0 1 1 O
is VBZ 1 0 12 O
not RB 0 1 12 O
advisable JJ 0 0 UNK O
. . 0 0 12 O

- : 0 0 2 O
Quinidine NN 0 1 0 B-Drug
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
Quinidex NNP 0 1 UNK B-Brand
) ) 0 0 2 O
or CC 0 0 12 O

Careful JJ 0 1 UNK O
monitoring NN 0 1 1 O
of IN 0 0 12 O
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
DIFLUCAN NNP 0 1 UNK B-Brand
and CC 0 0 12 O
coumarin VB 0 1 UNK B-Group
- : 0 0 2 O
type NN 0 1 1 I-Group
anticoagulants NNS 1 1 13 I-Group
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O

Because IN 0 0 12 O
heparin JJ 0 1 14 B-Drug
aspirin NN 0 1 14 B-Brand
or CC 0 0 12 O
Activase NNP 0 1 UNK B-Brand
may MD 0 0 1 O
cause VB 0 1 12 O
bleeding VBG 1 1 6 O
complications NNS 1 1 6 O
careful JJ 0 1 12 O
monitoring NN 0 1 1 O
for IN 0 0 12 O
bleeding NN 0 1 6 O
is VBZ 1 0 12 O
advised VBN 1 0 12 O
especially RB 0 0 12 O
at IN 0 0 12 O
arterial JJ 0 1 6 O
puncture NN 0 1 3 O
sites NNS 1 1 1 O
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
not RB 0 1 12 O
to TO 0 0 12 O
exceed VB 0 0 UNK O
a DT 0 0 12 O
single JJ 0 1 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
dose NN 0 1 6 O
of IN 0 0 12 O
Vardenafil NNP 0 1 UNK B-Drug
in IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
hour NN 0 1 12 O
period NN 0 1 1 O
when WRB 0 0 12 O
used VBN 1 1 12 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
erythromycin NN 0 1 0 B-Drug
. . 0 0 12 O

No DT 0 0 2 O
clinical JJ 0 1 6 O
or CC 0 0 12 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
study NN 0 1 1 O
was VBD 1 0 12 O
conducted VBN 1 1 1 O
with IN 0 0 12 O
dolasetron NN 0 1 0 B-Drug
. . 0 0 12 O

Liver NNP 0 1 7 O
Function NNP 0 1 2 O
Tests VBZ 0 1 UNK O
: : 0 0 2 O
Since IN 0 1 2 O
elevations NNS 1 1 1 O
of IN 0 0 12 O
liver NN 0 1 6 O
enzymes NNS 1 1 14 O
have VBP 0 0 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
during IN 0 0 12 O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
and CC 0 0 12 O
hepatitis NN 0 1 6 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
pretreatment NN 0 1 UNK O
and CC 0 0 12 O
follow VB 0 1 12 O
- : 0 0 2 O
up RB 0 0 12 O
liver IN 0 1 6 O
function NN 0 1 1 O
tests NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
performed VBN 1 1 1 O
at IN 0 0 12 O
weekly JJ 0 1 12 O
or CC 0 0 12 O
biweekly JJ 0 1 UNK O
intervals NNS 1 1 1 O
until IN 0 0 12 O
the DT 0 0 12 O
response NN 0 1 1 O
to TO 0 0 12 O
Accutane NNP 0 1 UNK B-Brand
has VBZ 1 0 12 O
been VBN 1 0 12 O
established VBN 1 1 1 O

Potentiation NN 0 1 UNK O
of IN 0 0 12 O
coumarin NN 0 1 UNK B-Group
- : 0 0 2 O
type NN 0 1 1 I-Group
anticoagulants NNS 1 1 13 I-Group
has VBZ 1 0 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
with IN 0 0 12 O
prolongation NN 0 1 6 O
of IN 0 0 12 O
the DT 0 0 12 O
prothrombin NN 0 1 14 O
time NN 0 1 12 O
/ NNP 0 0 2 O
INR NNP 0 1 13 O
. . 0 0 12 O

Lithium NN 0 1 UNK B-Drug
: : 0 0 2 O
NSAIDs NN 0 1 UNK B-Group
have VBP 0 0 12 O
produced VBN 1 0 1 O
an DT 0 0 12 O
elevation NN 0 1 1 O
of IN 0 0 12 O
plasma JJ 0 1 14 O
lithium NN 0 1 16 B-Drug
levels NNS 1 1 1 O
and CC 0 0 12 O
a DT 0 0 12 O
reduction NN 0 1 1 O
in IN 0 0 12 O
renal JJ 0 1 6 O
lithium NN 0 1 16 B-Drug
clearance NN 0 1 16 O
. . 0 0 12 O

There EX 0 0 12 O
were VBD 1 0 12 O
no DT 0 0 12 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
for IN 0 0 12 O
any DT 0 0 12 O
of IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O

Two CD 0 1 2 O
percent NN 0 1 1 O
of IN 0 0 12 O
patients NNS 1 1 6 O
treated VBN 1 1 1 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
Kineret NNP 0 1 UNK B-Brand
and CC 0 0 12 O
etanercept VB 0 1 13 B-Drug
developed VBN 1 0 1 O
neutropenia NN 0 1 14 O
( ( 0 0 2 O
ANC NNP 0 1 13 O
9 CD 0 0 2 O
x NNP 0 0 10 O
9 CD 0 0 2 O
/ NNP 0 0 2 O
L NNP 0 1 2 O
) ) 0 0 2 O
. . 0 0 12 O

Colchicine NN 0 1 0 B-Drug
may MD 0 0 1 O
increase VB 0 1 1 O
sensitivity NN 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
CNS NNP 0 1 6 B-Group
depressants NNS 1 0 13 I-Group
. . 0 0 12 O

thyroid JJ 0 1 6 B-Group
drugs NNS 1 1 6 I-Group
; : 0 0 2 O

Particular JJ 0 0 UNK O
caution NN 0 0 1 O
is VBZ 1 0 12 O
necessary JJ 0 0 1 O
when WRB 0 0 12 O
using VBG 1 1 1 O
ROMAZICON NNP 0 1 UNK B-Brand
in IN 0 0 12 O
cases NNS 1 1 UNK O
of IN 0 0 12 O
mixed JJ 0 1 3 O
drug NN 0 1 1 O
overdosage NN 0 0 UNK O
since IN 0 1 12 O
the DT 0 0 12 O
toxic NN 0 1 1 O
effects NNS 1 1 1 O
( ( 0 0 2 O
such JJ 0 0 1 O
as IN 1 0 12 O
convulsions NNS 1 1 13 O
and CC 0 0 12 O
cardiac JJ 0 1 6 O
dysrhythmias NN 0 1 13 O
) ) 0 0 2 O
of IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
taken VBN 1 1 12 O
in IN 0 0 12 O
overdose JJ 0 1 6 O
( ( 0 0 2 O
especially RB 0 0 12 O
cyclic JJ 0 1 13 B-Group
antidepressants NNS 1 1 13 I-Group
) ) 0 0 2 O
may MD 0 0 1 O
emerge VB 0 0 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
reversal NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
benzodiazepine NN 0 1 14 B-Group
effect NN 0 1 1 O
by IN 0 0 12 O
flumazenil NN 0 1 13 B-Drug
. . 0 0 12 O

Norepinephrine NN 0 1 UNK B-Drug
: : 0 0 2 O
Amphetamines NNS 0 1 UNK B-Group
enhance VB 0 1 UNK O
the DT 0 0 12 O
adrenergic JJ 0 1 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
norepinephrine NN 0 1 14 B-Drug
. . 0 0 12 O

In IN 0 0 2 O
patients NNS 1 1 6 O
with IN 0 0 12 O
mild JJ 0 1 6 O
to TO 0 0 12 O
moderate VB 0 1 1 O
hypertension NN 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg JJ 0 1 0 O
daily NN 0 1 12 O
of IN 0 0 12 O
VIOXX NNP 0 1 UNK B-Brand
with IN 0 0 12 O
the DT 0 0 12 O
ACE NNP 0 1 13 B-Group
inhibitor NN 0 1 14 I-Group
benazepril VBD 0 1 13 B-Drug
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
for IN 0 0 12 O
9 CD 0 0 2 O
weeks NNS 1 1 12 O
was VBD 1 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
an DT 0 0 12 O
average JJ 0 1 1 O
increase NN 0 1 1 O
in IN 0 0 12 O
mean JJ 0 1 12 O
arterial JJ 0 1 6 O
pressure NN 0 1 1 O
of IN 0 0 12 O
about IN 0 1 12 O
9 CD 0 0 2 O
mm NNS 0 0 18 O
Hg NNP 0 1 14 O
compared VBN 1 1 1 O
to TO 0 0 12 O
ACE NNP 0 1 13 B-Group
inhibitor NN 0 1 14 I-Group
alone RB 0 1 12 O
. . 0 0 12 O

In IN 0 0 2 O
this DT 0 0 12 O
formal JJ 0 1 1 O
interaction NN 0 1 UNK O
study NN 0 1 1 O
TAMBOCOR NNP 0 1 UNK B-Brand
and CC 0 0 12 O
propranolol NNS 0 1 16 B-Drug
were VBD 1 0 12 O
each DT 0 0 12 O
found VBN 1 1 12 O
to TO 0 0 12 O
have VB 0 0 12 O
negative JJ 0 1 1 O
inotropic NN 0 0 14 O
effects NNS 1 1 1 O
; : 0 0 2 O

Antiarrhythmics NNS 0 1 UNK B-Group
: : 0 0 2 O
bepridil NN 0 1 UNK B-Drug
lidocaine NN 0 1 14 B-Drug
( ( 0 0 2 O
systemic JJ 0 1 6 O
) ) 0 0 2 O
and CC 0 0 12 O
quinidine VB 0 1 16 B-Drug

To TO 0 0 2 O
avoid VB 0 0 12 O
potentiation NN 0 1 UNK O
the DT 0 0 12 O
physician JJ 0 1 6 O
wishing NN 0 1 UNK O
to TO 0 0 12 O
terminate VB 0 1 1 O
treatment NN 0 1 6 O
with IN 0 0 12 O
Isocarboxazid NNP 0 1 UNK B-Drug
and CC 0 0 12 O
begin VB 0 1 12 O
therapy NN 0 1 6 O
with IN 0 0 12 O
another DT 0 0 12 O
agent NN 0 1 1 O
should MD 0 0 12 O
allow VB 0 1 1 O
for IN 0 0 12 O
an DT 0 0 12 O
interval NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
. . 0 0 12 O

Because IN 0 0 12 O
of IN 0 0 12 O
foscarnets NNS 0 0 UNK B-Drug
tendency VBP 0 0 1 O
to TO 0 0 12 O
cause VB 0 1 12 O
renal JJ 0 1 6 O
impairment NN 0 1 16 O
the DT 0 0 12 O
use NN 0 1 1 O
of IN 0 0 12 O
FOSCAVIR NNP 0 1 UNK B-Brand
should MD 0 0 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
potentially RB 0 0 1 O
nephrotoxic JJ 0 1 UNK O
drugs NNS 1 1 6 O
such JJ 0 0 1 O
as IN 1 0 12 O
aminoglycosides NNS 0 1 13 B-Group
amphotericin VBP 0 1 14 B-Drug
B NNP 0 0 2 I-Drug
and CC 0 0 12 O
intravenous JJ 0 1 14 O
pentamidine NN 0 1 14 B-Drug
unless IN 0 0 12 O
the DT 0 0 12 O
potential JJ 0 1 1 O
benefits NNS 1 1 1 O
outweigh VBP 0 0 1 O
the DT 0 0 12 O
risks NNS 1 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
patient NN 0 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
interval NN 0 1 1 O
between IN 0 0 12 O
the DT 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
COLESTID NNP 0 1 UNK B-Brand
Tablets NNP 0 1 0 O
and CC 0 0 12 O
any DT 0 0 12 O
other JJ 0 0 12 O
medication NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
as RB 0 0 12 O
long RB 0 1 12 O
as IN 1 0 12 O
possible JJ 0 1 1 O
. . 0 0 12 O

Monitor NNP 0 1 2 O
salicylate NN 0 1 13 B-Group
levels NNS 1 1 1 O
or CC 0 0 12 O
the DT 0 0 12 O
therapeutic JJ 0 1 6 O
effect NN 0 1 1 O
for IN 0 0 12 O
which WDT 0 0 12 O
aspirin NN 0 1 14 B-Brand
is VBZ 1 0 12 O
given VBN 1 1 12 O
; : 0 0 2 O

periodic JJ 0 1 1 O
monitoring NN 0 1 1 O
of IN 0 0 12 O
anticonvulsant JJ 0 1 14 B-Group
plasma NN 0 1 14 O
levels NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
conducted VBN 1 1 1 O
. . 0 0 12 O

Clinical JJ 0 1 7 O
trials NNS 1 1 1 O
have VBP 0 0 12 O
indicated VBN 1 1 1 O
that IN 0 0 12 O
Pulmozyme NNP 0 1 UNK B-Brand
can MD 0 0 12 O
be VB 0 0 12 O
effectively RB 0 0 1 O
and CC 0 0 12 O
safely RB 0 0 UNK O
used VBN 1 1 12 O
in IN 0 0 12 O
conjunction NN 0 1 1 O
with IN 0 0 12 O
standard JJ 0 1 1 O
cystic JJ 0 1 6 O
fibrosis NN 0 1 6 O
therapies NNS 1 1 6 O
including VBG 1 1 1 O
oral JJ 0 1 6 O
inhaled VBN 1 1 14 O
and CC 0 0 12 O
/ CD 0 0 2 O
or CC 0 0 12 O
parenteral JJ 0 1 14 O
antibiotics NNS 1 1 6 B-Group
bronchodilators NNS 1 1 14 B-Group
enzyme VBP 0 1 14 O
supplements NNS 1 1 6 O
vitamins VBZ 0 1 6 B-Group
oral JJ 0 1 6 O
or CC 0 0 12 O
inhaled JJ 0 1 14 O
corticosteroids NNS 1 1 14 B-Group
and CC 0 0 12 O
analgesics NNS 1 1 14 B-Group
. . 0 0 12 O

Non NNP 0 1 2 B-Group
- : 0 0 2 O
selective JJ 0 1 13 I-Group
monoamine NN 0 1 13 I-Group
oxidase NN 0 1 13 I-Group
MAO NNP 0 1 14 I-Group
inhibitors NNS 1 1 14 I-Group
- : 0 0 2 O
including VBG 1 1 1 O
phenelzine JJ 0 1 16 B-Drug
sulfate NN 0 1 14 I-Drug
tranylcypromine NN 0 1 13 B-Drug
sulfate NN 0 1 14 I-Drug
and CC 0 0 12 O
pargyline NN 0 1 UNK B-Drug
HC9 NNP 0 1 UNK O
. . 0 0 12 O

No DT 0 0 2 O
formal JJ 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
performed VBN 1 1 1 O
to TO 0 0 12 O
assess VB 0 1 1 O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
SYMLIN NNP 0 1 UNK B-Brand
on IN 0 0 12 O
the DT 0 0 12 O
kinetics NNS 0 1 UNK O
of IN 0 0 12 O
oral JJ 0 1 6 O
antidiabetic JJ 0 1 13 B-Group
agents NNS 1 1 1 I-Group
. . 0 0 12 O

Diphenhydramine NN 0 1 0 B-Drug
: : 0 0 2 O
Diphenhydramine NN 0 1 0 B-Drug
is VBZ 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
be VB 0 0 12 O
a DT 0 0 12 O
weak JJ 0 1 12 O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
aldehyde JJ 0 1 UNK O
oxidase NN 0 1 13 O
in IN 0 0 12 O
rat NN 0 1 13 O
liver NN 0 1 6 O
but CC 0 0 12 O
its PRP$ 1 0 12 O
inhibitory JJ 0 1 UNK O
effects NNS 1 1 1 O
in IN 0 0 12 O
human JJ 0 1 1 O
liver NN 0 1 6 O
are VBP 1 0 12 O
not RB 0 1 12 O
known VBN 1 1 12 O
. . 0 0 12 O

- : 0 0 2 O
Dantrolene NN 0 1 UNK B-Drug
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
Dantrium NNP 0 1 UNK B-Brand
) ) 0 0 2 O
or CC 0 0 12 O

Drugs NNS 0 1 2 O
and CC 0 0 12 O
foods NNS 1 1 1 O
that WDT 0 0 12 O
raise VBP 0 0 12 O
urine JJ 0 1 6 O
pH NN 0 1 14 O
will MD 0 0 12 O
increase VB 0 1 1 O
renal JJ 0 1 6 O
clearance NN 0 1 16 O
and CC 0 0 12 O
urinary JJ 0 1 6 O
excretion NN 0 1 14 O
of IN 0 0 12 O
salicylic JJ 0 1 UNK B-Drug
acid NN 0 1 14 I-Drug
thus RB 0 0 1 O
lowering VBG 1 1 UNK O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
; : 0 0 2 O

Frequent NNP 0 1 2 O
prothrombin NN 0 1 14 O
determinations NNS 1 1 UNK O
are VBP 1 0 12 O
advisable JJ 0 0 UNK O
until IN 0 0 12 O
it PRP 0 0 12 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
determined VBN 1 1 1 O
definitely RB 0 1 UNK O
that IN 0 0 12 O
the DT 0 0 12 O
prothrombin NN 0 1 14 O
level NN 0 1 1 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
stabilized VBN 1 1 1 O
. . 0 0 12 O

Aprepitant NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
a DT 0 0 12 O
substrate NN 0 1 UNK O
for IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
; : 0 0 2 O

Because IN 0 0 12 O
elderly JJ 0 1 12 O
patients NNS 1 1 6 O
are VBP 1 0 12 O
more RBR 0 1 12 O
likely JJ 0 1 12 O
to TO 0 0 12 O
have VB 0 0 12 O
decreased VBN 1 1 1 O
renal JJ 0 1 6 O
function NN 0 1 1 O
care NN 0 1 12 O
should MD 0 0 12 O
be VB 0 0 12 O
taken VBN 1 1 12 O
in IN 0 0 12 O
dose JJ 0 1 6 O
selection NN 0 1 UNK O
and CC 0 0 12 O
it PRP 0 0 12 O
may MD 0 0 1 O
be VB 0 0 12 O
useful JJ 0 1 UNK O
to TO 0 0 12 O
monitor VB 0 1 1 O
renal JJ 0 1 6 O
function NN 0 1 1 O
. . 0 0 12 O

Corticotropin NNP 0 1 UNK B-Drug
may MD 0 0 1 O
accentuate VB 0 0 UNK O
the DT 0 0 12 O
electrolyte JJ 0 1 14 O
loss NN 0 1 1 O
associated VBN 1 1 1 O
with IN 0 0 12 O
diuretic JJ 0 1 14 B-Group
therapy NN 0 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
vasodilating VBG 0 0 UNK O
effects NNS 1 1 1 O
of IN 0 0 12 O
isosorbide JJ 0 1 16 B-Drug
dinitrate NN 0 0 0 I-Drug
may MD 0 0 1 O
be VB 0 0 12 O
additive JJ 0 1 16 O
with IN 0 0 12 O
those DT 0 0 12 O
of IN 0 0 12 O
other JJ 0 0 12 O
vasodilators NNS 1 1 13 B-Group
. . 0 0 12 O

Pantoprazole NNP 0 1 0 B-Drug
is VBZ 1 0 12 O
metabolized VBN 1 1 UNK O
through IN 0 0 12 O
the DT 0 0 12 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
system NN 0 1 1 O
primarily RB 0 0 1 O
the DT 0 0 12 O
CYP9C9 NNP 0 0 UNK O
and CC 0 0 12 O
CYP9A9 NNP 0 0 UNK O
isozymes NNS 0 1 UNK O
and CC 0 0 12 O
subsequently RB 0 0 1 O
undergoes JJ 0 0 UNK O
Phase NNP 0 1 UNK O
II NNP 0 0 2 O
conjugation NN 0 1 14 O
. . 0 0 12 O

These DT 0 0 1 O
events NNS 1 1 12 O
required VBD 1 1 1 O
medical JJ 0 1 1 O
intervention NN 0 1 1 O
in IN 0 0 12 O
some DT 0 0 12 O
patients NNS 1 1 6 O
. . 0 0 12 O

Methadone NN 0 1 0 B-Drug

Menstrual JJ 0 1 UNK O
cycle NN 0 1 1 O
irregularities NNS 1 1 1 O
were VBD 1 0 12 O
accompanied VBN 1 0 12 O
by IN 0 0 12 O
both DT 0 0 12 O
a DT 0 0 12 O
decrease NN 0 1 1 O
and CC 0 0 12 O
delay NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
peak NN 0 1 1 O
9b CD 0 0 UNK O
- : 0 0 2 O
estradiol NN 0 1 13 O
and CC 0 0 12 O
progesterone NN 0 1 13 O
levels NNS 1 1 1 O
following VBG 1 1 1 O
administration NN 0 1 1 O
of IN 0 0 12 O
PEGASYS NNP 0 1 UNK B-Brand
to TO 0 0 12 O
female VB 0 1 12 O
monkeys NNS 1 1 UNK O
. . 0 0 12 O

Whether IN 0 0 12 O
this DT 0 0 12 O
interaction NN 0 1 UNK O
also RB 0 0 12 O
occurs VBZ 1 1 1 O
with IN 0 0 12 O
the DT 0 0 12 O
intravenous JJ 0 1 14 O
topical JJ 0 1 6 O
or CC 0 0 12 O
vaginal JJ 0 1 6 O
preparations NNS 1 1 13 O
of IN 0 0 12 O
miconazole NN 0 1 16 B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
known VBN 1 1 12 O
. . 0 0 12 O

. . 0 0 12 O

Ethinyl NNP 0 0 UNK B-Drug
estradiol NN 0 1 13 I-Drug
: : 0 0 2 O
Substrate NN 0 1 UNK O
of IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
( ( 0 0 2 O
major JJ 0 1 1 O
) ) 0 0 2 O
9A9 CD 0 0 UNK O
- : 0 0 2 O
9 CD 0 0 2 O
( ( 0 0 2 O
minor JJ 0 1 1 O
) ) 0 0 2 O
; : 0 0 2 O

Caution NN 0 0 UNK O
is VBZ 1 0 12 O
advised VBN 1 0 12 O
when WRB 0 0 12 O
administering VBG 1 1 1 O
VERSED NNP 0 1 15 B-Brand
Syrup NNP 0 1 2 I-Brand
to TO 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
these DT 0 0 12 O
medications NNS 1 1 6 O
and CC 0 0 12 O
if IN 0 0 12 O
necessary JJ 0 0 1 O
dose NN 0 1 6 O
adjustments NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
. . 0 0 12 O

Low JJ 0 1 2 O
initial JJ 0 1 1 O
dosing NN 0 0 14 O
and CC 0 0 12 O
small JJ 0 1 12 O
gradual JJ 0 1 1 O
dose NN 0 1 6 O
increases NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
employed VBN 1 1 1 O
. . 0 0 12 O

Dexamethasone NN 0 1 0 B-Drug
is VBZ 1 0 12 O
a DT 0 0 12 O
moderate JJ 0 1 1 O
inducer NN 0 1 UNK O
of IN 0 0 12 O
CYP NNP 0 1 UNK O
9A9 CD 0 0 UNK O
. . 0 0 12 O

anticholinergics NNS 1 1 13 B-Group
or CC 0 0 12 O
other JJ 0 0 12 O
medications NNS 1 1 6 O
with IN 0 0 12 O
anticholinergic JJ 0 1 13 O
activity NN 0 1 1 O
- : 0 0 2 O
anticholinergic JJ 0 1 13 O
effects NNS 1 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
potentiated VBN 1 0 UNK O
when WRB 0 0 12 O
these DT 0 0 12 O
medications NNS 1 1 6 O
are VBP 1 0 12 O
used VBN 1 1 12 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
diphenidol NN 0 1 UNK B-Drug
; : 0 0 2 O

When WRB 0 0 12 O
these DT 0 0 12 O
products NNS 1 1 1 O
are VBP 1 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
prothrombin VBP 0 1 14 O
or CC 0 0 12 O
other JJ 0 0 12 O
suitable JJ 0 1 1 O
coagulation NN 0 1 14 O
tests NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
closely RB 0 0 1 O
. . 0 0 12 O

- : 0 0 2 O
a DT 0 0 12 O
phenothiazine NN 0 1 UNK B-Group
such JJ 0 0 1 O
as IN 1 0 12 O
chlorpromazine NN 0 1 16 B-Drug
( ( 0 0 2 O
Thorazine NNP 0 1 UNK B-Brand
) ) 0 0 2 O
fluphenazine NN 0 1 13 B-Drug
( ( 0 0 2 O
Prolixin NNP 0 1 UNK B-Brand
Permitil NNP 0 1 UNK B-Brand
) ) 0 0 2 O
prochlorperazine NN 0 1 16 B-Drug
( ( 0 0 2 O
Compazine NNP 0 1 0 B-Brand
) ) 0 0 2 O
promethazine NN 0 1 16 B-Drug
( ( 0 0 2 O
Phenergan NNP 0 1 0 B-Brand
) ) 0 0 2 O
and CC 0 0 12 O
others NNS 0 1 12 O
; : 0 0 2 O

Accelerated NNP 0 1 UNK O
prothrombin NN 0 1 14 O
time NN 0 1 12 O
partial JJ 0 1 1 O
thromboplastin NN 0 1 14 O
time NN 0 1 12 O
and CC 0 0 12 O
platelet VB 0 1 14 O
aggregation NN 0 1 UNK O
time NN 0 1 12 O
; : 0 0 2 O

Given VBN 0 1 2 O
the DT 0 0 12 O
primary JJ 0 1 1 O
CNS NNP 0 1 6 O
effects NNS 1 1 1 O
of IN 0 0 12 O
Anafranil NNP 0 1 UNK B-Brand
caution NN 0 0 1 O
is VBZ 1 0 12 O
advised VBN 1 0 12 O
in IN 0 0 12 O
using VBG 1 1 1 O
it PRP 0 0 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
other JJ 0 0 12 O
CNS NNP 0 1 6 O
- : 0 0 2 O
active JJ 0 1 1 O
drugs NNS 1 1 6 O
. . 0 0 12 O

In IN 0 0 2 O
the DT 0 0 12 O
case NN 0 1 12 O
of IN 0 0 12 O
severe JJ 0 1 6 O
neutropenia NN 0 1 14 O
( ( 0 0 2 O
9 CD 0 0 2 O
cells NNS 1 1 6 O
/ JJ 0 0 2 O
mm9 NN 0 0 UNK O
for IN 0 0 12 O
seven CD 0 1 12 O
days NNS 1 1 12 O
or CC 0 0 12 O
more JJR 0 1 12 O
) ) 0 0 2 O
during IN 0 0 12 O
a DT 0 0 12 O
course NN 0 1 12 O
of IN 0 0 12 O
TAXOL NNP 0 1 UNK B-Brand
therapy VBD 0 1 6 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
reduction NN 0 1 1 O
in IN 0 0 12 O
dose NN 0 1 6 O
for IN 0 0 12 O
subsequent JJ 0 1 1 O
courses NNS 1 1 1 O
of IN 0 0 12 O
therapy NN 0 1 6 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O

Patients NNS 0 1 7 O
using VBG 1 1 1 O
cardiovascular JJ 0 1 6 O
drugs NNS 1 1 6 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
IOPIDINE NNP 0 1 UNK B-Brand
9 CD 0 0 2 O
% NN 0 0 18 O
Ophthalmic NNP 0 1 7 O
Solution NNP 0 1 2 O
should MD 0 0 12 O
have VB 0 0 12 O
pulse NN 0 1 3 O
and CC 0 0 12 O
blood NN 0 1 6 O
pressures NNS 1 1 1 O
frequently RB 0 1 1 O
monitored VBD 1 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
EM NNP 0 0 13 O
individuals NNS 1 1 1 O
treated VBD 1 1 1 O
with IN 0 0 12 O
paroxetine NN 0 1 16 B-Drug
or CC 0 0 12 O
fluoxetine VB 0 1 16 B-Drug
the DT 0 0 12 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
atomoxetine NN 0 1 13 B-Drug
is VBZ 1 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
- : 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
fold NN 0 1 3 O
and CC 0 0 12 O
Css NNP 0 1 UNK O
max NN 0 0 3 O
is VBZ 1 0 12 O
about IN 0 1 12 O
9 CD 0 0 2 O
- : 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
fold NN 0 1 3 O
greater JJR 1 1 1 O
than IN 0 0 12 O
atomoxetine VB 0 1 13 B-Drug
alone JJ 0 1 12 O
. . 0 0 12 O

An DT 0 0 2 O
increase NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
in IN 0 0 12 O
the DT 0 0 12 O
mean JJ 0 1 12 O
AUC NNP 0 1 UNK O
and CC 0 0 12 O
increases NNS 1 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
respectively RB 0 0 1 O
in IN 0 0 12 O
the DT 0 0 12 O
mean JJ 0 1 12 O
T NNP 0 1 2 O
max NN 0 0 3 O
and CC 0 0 12 O
mean JJ 0 1 12 O
C NNP 0 0 2 O
max NN 0 0 3 O
were VBD 1 0 12 O
noted VBN 1 0 1 O
in IN 0 0 12 O
9 CD 0 0 2 O
study NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
individuals NNS 1 1 1 O
. . 0 0 12 O

Nasal NNP 0 1 7 O
Spray NNP 0 1 2 O
: : 0 0 2 O
Formal JJ 0 1 2 O
studies NNS 1 1 1 O
designed VBN 1 1 UNK O
to TO 0 0 12 O
evaluate VB 0 1 1 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
Calcitonin NNP 0 1 UNK B-Drug
salmon NNS 0 1 16 I-Drug
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
done VBN 1 0 12 O
. . 0 0 12 O

- : 0 0 2 O
Anabolic NN 0 1 UNK B-Group
steroids NNS 1 1 6 I-Group
( ( 0 0 2 O
nandrolone JJ 0 1 UNK B-Drug
[ NNP 0 0 2 O
e.g. NN 0 0 UNK O
Anabolin NNP 0 0 UNK B-Brand
] NNP 0 0 2 O
oxandrolone NN 0 1 13 B-Drug
[ NNP 0 0 2 O
e.g. VBZ 0 0 UNK O
Anavar NNP 0 1 UNK B-Brand
] NNP 0 0 2 O
oxymetholone NN 0 1 UNK B-Drug
[ NNP 0 0 2 O
e.g. VBZ 0 0 UNK O
Anadrol NNP 0 1 UNK B-Brand
] NNP 0 0 2 O
stanozolol VBD 0 1 13 B-Drug
[ NNP 0 0 2 O
e.g. FW 0 0 UNK O
Winstrol NNP 0 1 UNK B-Brand
] NNP 0 0 2 O
) ) 0 0 2 O
or CC 0 0 12 O

In IN 0 0 2 O
addition NN 0 1 1 O
results NNS 1 1 1 O
from IN 0 0 12 O
regression NN 0 1 UNK O
analyses NNS 1 1 UNK O
of IN 0 0 12 O
patient JJ 0 1 6 O
pharmacokinetic JJ 0 1 UNK O
data NNS 0 1 1 O
suggest VBP 0 1 1 O
that IN 0 0 12 O
co SYM 0 1 12 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
other JJ 0 0 12 O
inducers NNS 1 1 UNK O
of IN 0 0 12 O
drug NN 0 1 1 O
clearance NN 0 1 16 O
( ( 0 0 2 O
efavirenz JJ 0 1 13 B-Drug
nevirapine NN 0 1 13 B-Drug
phenytoin NN 0 1 16 B-Drug
dexamethasone NN 0 1 16 B-Drug
or CC 0 0 12 O
carbamazepine NN 0 1 16 B-Drug
) ) 0 0 2 O
with IN 0 0 12 O
CANCIDAS NNP 0 1 UNK B-Brand
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
clinically RB 0 0 6 O
meaningful JJ 0 1 1 O
reductions NNS 1 1 1 O
in IN 0 0 12 O
caspofungin NN 0 1 14 B-Drug
concentrations NNS 1 1 13 O
. . 0 0 12 O

Anticoagulants NNS 0 1 UNK B-Group
( ( 0 0 2 O
such JJ 0 0 1 O
as IN 1 0 12 O
heparin NN 0 1 14 B-Drug
and CC 0 0 12 O
vitamin NN 0 1 6 B-Group
K NNP 0 1 2 I-Group
antagonists NNS 1 1 13 I-Group
) ) 0 0 2 O
and CC 0 0 12 O
drugs NNS 1 1 6 O
that IN 0 0 12 O
alter NN 0 1 13 O
platelet NN 0 1 14 O
function NN 0 1 1 O
( ( 0 0 2 O
such JJ 0 0 1 O
as IN 1 0 12 O
acetylsalicylic JJ 0 0 UNK B-Drug
acid JJ 0 1 14 I-Drug
dipyridamole NN 0 1 0 B-Drug
and CC 0 0 12 O
GP NNP 0 1 UNK O
IIb NNP 0 0 UNK O
/ NNP 0 0 2 O
IIIa NNP 0 0 UNK O
inhibitors NNS 1 1 14 O
) ) 0 0 2 O
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
bleeding VBG 1 1 6 O
if IN 0 0 12 O
administered VBN 1 1 1 O
prior RB 0 1 1 O
to TO 0 0 12 O
during IN 0 0 12 O
or CC 0 0 12 O
after IN 0 0 12 O
TNKase NNP 0 1 UNK B-Brand
therapy NN 0 1 6 O
. . 0 0 12 O

In IN 0 0 2 O
post NN 0 1 12 O
- : 0 0 2 O
marketing NN 0 1 UNK O
experience NN 0 1 12 O
bleeding VBG 1 1 6 O
events NNS 1 1 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
predominantly RB 0 0 1 O
in IN 0 0 12 O
the DT 0 0 12 O
elderly JJ 0 1 12 O
in IN 0 0 12 O
association NN 0 1 1 O
with IN 0 0 12 O
increases NNS 1 1 1 O
in IN 0 0 12 O
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
VIOXX NNP 0 1 UNK B-Brand
concurrently RB 0 0 1 O
with IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
. . 0 0 12 O

Available JJ 0 1 UNK O
data NNS 0 1 1 O
are VBP 1 0 12 O
not RB 0 1 12 O
sufficient JJ 0 1 1 O
however RB 0 0 12 O
to TO 0 0 12 O
predict VB 0 0 UNK O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
concomitant JJ 0 1 6 O
medication NN 0 1 6 O
on IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
impaired JJ 0 1 6 O
ventricular JJ 0 1 8 O
function NN 0 1 1 O
or CC 0 0 12 O
cardiac JJ 0 1 6 O
conduction NN 0 1 6 O
abnormalities NNS 1 1 6 O
. . 0 0 12 O

Nelfinavir NNP 0 1 UNK B-Drug
M9 NNP 0 1 UNK O

The DT 0 0 2 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
Metopirone NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
accelerated VBN 1 1 1 O
by IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
; : 0 0 2 O

Although IN 0 0 12 O
no DT 0 0 12 O
drug NN 0 1 1 O
- : 0 0 2 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
conducted VBN 1 1 1 O
in IN 0 0 12 O
vivo NN 0 1 13 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
expected VBN 1 1 12 O
that IN 0 0 12 O
no DT 0 0 12 O
significant JJ 0 1 1 O
interaction NN 0 1 UNK O
would MD 0 0 12 O
occur VB 0 1 1 O
when WRB 0 0 12 O
nitazoxanide NN 0 1 13 B-Drug
is VBZ 1 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
with IN 0 0 12 O
drugs NNS 1 1 6 O
that IN 0 0 12 O
either DT 0 1 12 O
are VBP 1 0 12 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
or CC 0 0 12 O
inhibit VB 0 1 13 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
enzymes NNS 1 1 14 O
. . 0 0 12 O

The DT 0 0 2 O
inhibiting JJ 0 1 UNK O
effects NNS 1 1 1 O
of IN 0 0 12 O
anticholinergic JJ 0 1 13 B-Group
drugs NNS 1 1 6 I-Group
on IN 0 0 12 O
gastric JJ 0 1 6 O
hydrochloric JJ 0 0 16 O
acid NN 0 1 14 O
secretion NN 0 1 14 O
are VBP 1 0 12 O
antagonized VBN 1 0 UNK O
by IN 0 0 12 O
agents NNS 1 1 1 O
used VBN 1 1 12 O
to TO 0 0 12 O
treat VB 0 1 12 O
achlorhydria NNS 0 1 13 O
and CC 0 0 12 O
those DT 0 0 12 O
used VBN 1 1 12 O
to TO 0 0 12 O
test VB 0 1 1 O
gastric JJ 0 1 6 O
secretion NN 0 1 14 O
. . 0 0 12 O

Antacids NNS 0 1 UNK B-Group
or CC 0 0 12 O
H $ 0 1 2 B-Group
9 CD 0 0 2 I-Group
- : 0 0 2 O
receptor NN 0 1 14 I-Group
antagonists NNS 1 1 13 I-Group
: : 0 0 2 O
The DT 0 0 2 O
effect NN 0 1 1 O
of IN 0 0 12 O
increased VBN 1 1 1 O
gastric JJ 0 1 6 O
pH NN 0 1 14 O
on IN 0 0 12 O
the DT 0 0 12 O
bioavailability NN 0 1 UNK O
of IN 0 0 12 O
ceftibuten NN 0 1 UNK B-Drug
was VBD 1 0 12 O
evaluated VBN 1 1 1 O
in IN 0 0 12 O
9 CD 0 0 2 O
healthy JJ 0 1 12 O
adult NN 0 1 12 O
volunteers NNS 1 1 UNK O
. . 0 0 12 O

Several JJ 0 1 2 O
studies NNS 1 1 1 O
demonstrate VBP 0 0 1 O
a DT 0 0 12 O
decrease NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
bioavailability NN 0 1 UNK O
of IN 0 0 12 O
methyldopa NN 0 1 13 B-Drug
when WRB 0 0 12 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
ingested VBN 1 1 14 O
with IN 0 0 12 O
ferrous JJ 0 1 14 B-Drug
sulfate NN 0 1 14 I-Drug
or CC 0 0 12 O
ferrous JJ 0 1 14 B-Drug
gluconate NN 0 1 14 I-Drug
. . 0 0 12 O

The DT 0 0 2 O
clinical JJ 0 1 6 O
significance NN 0 1 13 O
of IN 0 0 12 O
this DT 0 0 12 O
interaction NN 0 1 UNK O
is VBZ 1 0 12 O
not RB 0 1 12 O
known VBN 1 1 12 O
; : 0 0 2 O

In IN 0 0 2 O
amiodarone CD 0 1 0 B-Drug
- : 0 0 2 O
treated VBN 1 1 1 O
patients NNS 1 1 6 O
who WP 0 0 12 O
require VBP 0 0 1 O
additional JJ 0 1 1 O
antiarrhythmic JJ 0 1 14 B-Drug
therapy NN 0 1 6 O
the DT 0 0 12 O
initial JJ 0 1 1 O
dose NN 0 1 6 O
of IN 0 0 12 O
such JJ 0 0 1 O
agents NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
approximately RB 0 1 1 O
half NN 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
usual JJ 0 1 12 O
recommended VBD 1 1 1 O
dose NN 0 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
interaction NN 0 1 UNK O
of IN 0 0 12 O
CYLERT NNP 0 1 UNK B-Brand
( ( 0 0 2 O
pemoline NN 0 1 13 B-Drug
) ) 0 0 2 O
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
studied VBN 1 0 1 O
in IN 0 0 12 O
humans NNS 1 1 UNK O
. . 0 0 12 O

Patients NNS 0 1 7 O
receiving VBG 1 1 1 O
beta SYM 0 1 16 B-Group
- : 0 0 2 O
adrenergic JJ 0 1 UNK I-Group
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
along IN 0 0 12 O
with IN 0 0 12 O
either DT 0 1 12 O
oral JJ 0 1 6 O
or CC 0 0 12 O
intravenous JJ 0 1 14 O
calcium NN 0 1 14 B-Group
antagonists NNS 1 1 13 I-Group
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
for IN 0 0 12 O
possible JJ 0 1 1 O
atrioventricular JJ 0 0 8 O
conduction NN 0 1 6 O
disturbances NNS 1 1 6 O
left VBD 1 1 12 O
ventricular JJ 0 1 8 O
failure NN 0 1 1 O
and CC 0 0 12 O
hypotension NN 0 1 6 O
. . 0 0 12 O

Exjade NN 0 1 UNK B-Brand
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
combined VBN 1 1 1 O
with IN 0 0 12 O
other JJ 0 0 12 O
iron NN 0 1 3 O
chelator NN 0 1 UNK O
therapies NNS 1 1 6 O
as IN 1 0 12 O
safety NN 0 1 1 O
of IN 0 0 12 O
such JJ 0 0 1 O
combinations NNS 1 1 1 O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
established VBN 1 1 1 O
. . 0 0 12 O

Platelet NNP 0 1 7 O
function NN 0 1 1 O
studies NNS 1 1 1 O
in IN 0 0 12 O
these DT 0 0 12 O
patients NNS 1 1 6 O
have VBP 0 0 12 O
not RB 0 1 12 O
demonstrated VBN 1 0 1 O
any DT 0 0 12 O
significant JJ 0 1 1 O
platelet NN 0 1 14 O
dysfunction NN 0 1 6 O
. . 0 0 12 O

Use NNP 0 1 2 O
of IN 0 0 12 O
potassium NN 0 1 14 B-Group
- : 0 0 2 O
sparing NN 0 0 6 I-Group
diuretics NNS 1 1 14 I-Group
( ( 0 0 2 O
spironolactone NN 0 1 0 B-Drug
amiloride RB 0 1 16 B-Drug
triamterene NN 0 1 13 B-Drug
and CC 0 0 12 O
others NNS 0 1 12 O
) ) 0 0 2 O
potassium NN 0 1 14 B-Drug
supplements NNS 1 1 6 O
or CC 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
capable JJ 0 1 UNK O
of IN 0 0 12 O
increasing VBG 1 1 1 O
serum JJ 0 1 14 O
potassium NN 0 1 14 O
( ( 0 0 2 O
indomethacin JJ 0 1 14 B-Drug
heparin NN 0 1 14 B-Drug
cyclosporine NN 0 1 14 B-Drug
and CC 0 0 12 O
others NNS 0 1 12 O
) ) 0 0 2 O
can MD 0 0 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
hyperkalemia NN 0 1 14 O
. . 0 0 12 O

In IN 0 0 2 O
a DT 0 0 12 O
separate JJ 0 1 1 O
study NN 0 1 1 O
baboons NNS 1 1 UNK O
given VBN 1 1 12 O
9 CD 0 0 2 O
doses NNS 1 1 6 O
of IN 0 0 12 O
alefacept NN 0 1 UNK B-Drug
at IN 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NN 0 0 2 O
kg NN 0 1 18 O
every DT 0 0 12 O
9 CD 0 0 2 O
weeks NNS 1 1 12 O
were VBD 1 0 12 O
found VBN 1 1 12 O
to TO 0 0 12 O
have VB 0 0 12 O
centroblast VBN 0 1 UNK O
proliferation NN 0 1 1 O
in IN 0 0 12 O
B NNP 0 0 2 O
- : 0 0 2 O
cell NN 0 1 1 O
dependent JJ 0 1 1 O
areas NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
germinal JJ 0 0 8 O
centers NNS 1 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
spleen NN 0 1 6 O
following VBG 1 1 1 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
day NN 0 1 12 O
washout IN 0 1 3 O
period NN 0 1 1 O
. . 0 0 12 O

Usage NN 0 1 UNK O
with IN 0 0 12 O
Alcohol NNP 0 1 2 B-Drug
: : 0 0 2 O
Due JJ 0 1 2 O
to TO 0 0 12 O
the DT 0 0 12 O
potential JJ 0 1 1 O
for IN 0 0 12 O
increased JJ 0 1 1 O
CNS NNP 0 1 6 O
depressants NNS 1 0 13 O
effects NNS 1 1 1 O
alcohol NN 0 1 1 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
with IN 0 0 12 O
caution NN 0 0 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
who WP 0 0 12 O
are VBP 1 0 12 O
currently RB 0 1 12 O
receiving VBG 1 1 1 O
pentazocine NN 0 1 UNK B-Drug
. . 0 0 12 O

This DT 0 0 2 O
interference NN 0 1 13 O
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
an DT 0 0 12 O
apparent JJ 0 1 1 O
factor NN 0 1 1 O
concentration NN 0 1 1 O
that WDT 0 0 12 O
is VBZ 1 0 12 O
lower JJR 1 1 1 O
than IN 0 0 12 O
the DT 0 0 12 O
true JJ 0 1 12 O
concentration NN 0 1 1 O
. . 0 0 12 O

For IN 0 0 2 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
both DT 0 0 12 O
therapies NNS 1 1 6 O
standard VBP 0 1 1 O
monitoring NN 0 1 1 O
of IN 0 0 12 O
tacrolimus JJ 0 1 16 B-Drug
blood NN 0 1 6 O
concentrations NNS 1 1 13 O
and CC 0 0 12 O
appropriate JJ 0 1 1 O
tacrolimus NN 0 1 16 B-Drug
dosage NN 0 1 0 O
adjustments NNS 1 1 1 O
are VBP 1 0 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O

- : 0 0 2 O
did VBD 1 0 12 O
not RB 0 1 12 O
cause VB 0 1 12 O
any DT 0 0 12 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
change NN 0 1 1 O
in IN 0 0 12 O
plasma JJ 0 1 14 O
profiles NNS 1 1 UNK O
of IN 0 0 12 O
prednisone NN 0 1 0 B-Drug
or CC 0 0 12 O
prednisolone NN 0 1 0 B-Drug
following VBG 1 1 1 O
administration NN 0 1 1 O
of IN 0 0 12 O
either DT 0 1 12 O
oral JJ 0 1 6 O
prednisone NN 0 1 0 B-Drug
or CC 0 0 12 O
intravenous JJ 0 1 14 O
prednisolone NN 0 1 0 B-Drug
. . 0 0 12 O

Paroxetine NN 0 1 0 B-Drug
: : 0 0 2 O
Coadministration NN 0 1 UNK O
of IN 0 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
Sonata NNP 0 1 UNK B-Brand
9 CD 0 0 2 O
mg NN 0 1 0 O
and CC 0 0 12 O
paroxetine NN 0 1 16 B-Drug
9 CD 0 0 2 O
mg JJ 0 1 0 O
daily RB 0 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
did VBD 1 0 12 O
not RB 0 1 12 O
produce VB 0 0 1 O
any DT 0 0 12 O
interaction NN 0 1 UNK O
on IN 0 0 12 O
psychomotor NN 0 0 13 O
performance NN 0 1 13 O
. . 0 0 12 O

Therefore RB 0 0 1 O
monitoring NN 0 1 1 O
of IN 0 0 12 O
theophylline JJ 0 1 16 B-Drug
plasma NN 0 1 14 O
levels NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
and CC 0 0 12 O
dosage NN 0 1 0 O
of IN 0 0 12 O
theophylline NN 0 1 16 B-Drug
adjusted VBN 1 1 1 O
as IN 1 0 12 O
required VBN 1 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
demonstrated VBN 1 0 1 O
that IN 0 0 12 O
efavirenz VBZ 0 1 13 B-Drug
inhibits NNS 0 1 UNK O
9C9 CD 0 0 UNK O
9C9 CD 0 0 UNK O
and CC 0 0 12 O
9A9 CD 0 0 UNK O
isozymes NNS 0 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
range NN 0 1 1 O
of IN 0 0 12 O
observed JJ 0 1 1 O
efavirenz JJ 0 1 13 B-Drug
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
. . 0 0 12 O

Greater NNP 0 1 UNK O
fecal JJ 0 1 6 O
blood NN 0 1 6 O
loss NN 0 1 1 O
results NNS 1 1 1 O
from IN 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
both DT 0 0 12 O
drugs NNS 1 1 6 O
than IN 0 0 12 O
from IN 0 0 12 O
either CC 0 1 12 O
drug NN 0 1 1 O
alone RB 0 1 12 O
. . 0 0 12 O

Dose NNP 0 1 7 O
reduction NN 0 1 1 O
of IN 0 0 12 O
CRIXIVAN NNP 0 1 UNK B-Brand
to TO 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
every DT 0 0 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
should MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
when WRB 0 0 12 O
taking VBG 1 0 12 O
delavirdine NN 0 1 13 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
three CD 0 1 12 O
times NNS 1 1 12 O
a DT 0 0 12 O
day NN 0 1 12 O
. . 0 0 12 O

Digitalis NNP 0 1 15 B-Group
Glycosides NNP 0 1 UNK I-Group
: : 0 0 2 O
Therapeutic JJ 0 1 UNK O
effects NNS 1 1 1 O
of IN 0 0 12 O
digitalis NNS 0 1 14 B-Group
glycosides NNS 1 1 13 I-Group
may MD 0 0 1 O
be VB 0 0 12 O
reduced VBN 1 1 1 O
. . 0 0 12 O

N=9 NNP 0 1 UNK O
) ) 0 0 2 O
are VBP 1 0 12 O
identical JJ 0 1 1 O
whether IN 0 0 12 O
the DT 0 0 12 O
drugs NNS 1 1 6 O
are VBP 1 0 12 O
administered VBN 1 1 1 O
alone RB 0 1 12 O
or CC 0 0 12 O
together RB 0 1 12 O
. . 0 0 12 O

Occasionally RB 0 1 13 O
TAXOL NNP 0 1 UNK B-Brand
infusions NNS 1 1 14 O
must MD 0 0 12 O
be VB 0 0 12 O
interrupted VBN 1 1 12 O
or CC 0 0 12 O
discontinued VBN 1 1 1 O
because IN 0 0 12 O
of IN 0 0 12 O
initial JJ 0 1 1 O
or CC 0 0 12 O
recurrent JJ 0 1 6 O
hypertension NN 0 1 6 O
. . 0 0 12 O

Sulfamethizole NNP 0 1 UNK B-Drug
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
barbiturates NNS 1 1 14 B-Group
tolbutamide IN 0 1 UNK B-Drug
and CC 0 0 12 O
uricosurics NNS 0 0 UNK B-Group
. . 0 0 12 O

CONTRAINDICATED NNS 0 1 UNK O
due JJ 0 1 1 O
to TO 0 0 12 O
potential JJ 0 1 1 O
for IN 0 0 12 O
serious JJ 0 1 12 O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
life NN 0 1 12 O
- : 0 0 2 O
threatening VBG 1 0 12 O
reactions NNS 1 1 1 O
such JJ 0 0 1 O
as IN 1 0 12 O
prolonged JJ 0 1 6 O
or CC 0 0 12 O
increased JJ 0 1 1 O
sedation NN 0 1 6 O
or CC 0 0 12 O
respiratory NN 0 1 6 O
depression NN 0 1 6 O
. . 0 0 12 O

indinavir JJ 0 1 16 B-Drug
concentration NN 0 1 1 O
ritonavir NN 0 1 16 B-Drug
concentration NN 0 1 1 O

Phenobarbital NNP 0 1 0 B-Drug
( ( 0 0 2 O
Primidone NNP 0 1 UNK B-Drug
) ) 0 0 2 O
: : 0 0 2 O
Population NN 0 1 UNK O
pharmacokinetic JJ 0 1 UNK O
analyses NNS 1 1 UNK O
indicate VBP 0 0 1 O
that IN 0 0 12 O
tiagabine JJ 0 1 13 B-Drug
clearance NN 0 1 16 O
is VBZ 1 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
greater JJR 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
phenobarbital JJ 0 1 16 B-Drug
( ( 0 0 2 O
primidone NN 0 1 13 B-Drug
) ) 0 0 2 O
with IN 0 0 12 O
or CC 0 0 12 O
without IN 0 0 12 O
other JJ 0 0 12 O
enzyme JJ 0 1 14 O
- : 0 0 2 O
inducing NN 0 1 6 O
AEDs NNP 0 1 UNK B-Group
. . 0 0 12 O

The DT 0 0 2 O
addition NN 0 1 1 O
of IN 0 0 12 O
sodium NN 0 1 14 B-Drug
bicarbonate NN 0 1 14 I-Drug
to TO 0 0 12 O
parenteral JJ 0 1 14 O
solutions NNS 1 1 UNK O
containing VBG 1 1 1 O
calcium NN 0 1 14 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
except IN 0 0 12 O
where WRB 0 0 12 O
compatibility NN 0 1 UNK O
has VBZ 1 0 12 O
been VBN 1 0 12 O
previously RB 0 0 1 O
established VBN 1 1 1 O
. . 0 0 12 O

Caution NN 0 0 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
taken VBN 1 1 12 O
when WRB 0 0 12 O
ENABLEX NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
used VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
medications NNS 1 1 6 O
that WDT 0 0 12 O
are VBP 1 0 12 O
predominantly RB 0 0 1 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
CYP9D9 NNP 0 0 UNK O
and CC 0 0 12 O
which WDT 0 0 12 O
have VBP 0 0 12 O
a DT 0 0 12 O
narrow JJ 0 1 3 O
therapeutic JJ 0 1 6 O
window NN 0 1 3 O
such JJ 0 0 1 O
as IN 1 0 12 O
flecainide JJ 0 1 16 B-Drug
thioridazine NN 0 1 13 B-Drug
and CC 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
( ( 0 0 2 O
see VB 0 1 12 O
CLINICAL NNP 0 1 11 O
PHARMACOLOGY NNP 0 1 UNK O
) ) 0 0 2 O
. . 0 0 12 O

However RB 0 0 1 O
norepinephrine NN 0 1 14 B-Drug
may MD 0 0 1 O
still RB 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
effectively RB 0 0 1 O
. . 0 0 12 O

SIDE NNP 0 1 11 O
EFFECTS NNP 0 1 UNK O
( ( 0 0 2 O
KEMSTRO NNP 0 1 UNK B-Brand
) ) 0 0 2 O
The DT 0 0 2 O
most RBS 0 0 12 O
common JJ 0 1 1 O
adverse JJ 0 0 1 O
reaction NN 0 1 1 O
during IN 0 0 12 O
treatment NN 0 1 6 O
with IN 0 0 12 O
baclofen NN 0 1 0 B-Drug
is VBZ 1 0 12 O
transient JJ 0 1 1 O
drowsiness NN 0 1 13 O
( ( 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
. . 0 0 12 O

Among IN 0 0 UNK O
these DT 0 0 12 O
patients NNS 1 1 6 O
the DT 0 0 12 O
incidence NN 0 1 6 O
of IN 0 0 12 O
upper JJ 0 1 3 O
gastrointestinal JJ 0 1 6 O
adverse JJ 0 0 1 O
experiences NNS 1 1 12 O
in IN 0 0 12 O
the DT 0 0 12 O
patients NNS 1 1 6 O
treated VBN 1 1 1 O
with IN 0 0 12 O
Ibandronate NNP 0 1 UNK B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
once RB 0 0 12 O
monthly RB 0 1 1 O
was VBD 1 0 12 O
similar JJ 0 1 1 O
to TO 0 0 12 O
that DT 0 0 12 O
in IN 0 0 12 O
patients NNS 1 1 6 O
treated VBN 1 1 1 O
with IN 0 0 12 O
Ibandronate NNP 0 1 UNK B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
once RB 0 0 12 O
daily RB 0 1 12 O
. . 0 0 12 O

The DT 0 0 2 O
changes NNS 1 1 1 O
in IN 0 0 12 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
were VBD 1 0 12 O
within IN 0 0 1 O
the DT 0 0 12 O
range NN 0 1 1 O
of IN 0 0 12 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
achieved VBN 1 0 1 O
in IN 0 0 12 O
adequate NN 0 1 1 O
and CC 0 0 12 O
well RB 0 1 12 O
- : 0 0 2 O
controlled VBN 1 1 1 O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
. . 0 0 12 O

AXERT NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
not RB 0 1 12 O
known VBN 1 1 12 O
to TO 0 0 12 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
commonly RB 0 0 UNK O
employed VBN 1 1 1 O
clinical JJ 0 1 6 O
laboratory NN 0 1 1 O
tests NNS 1 1 1 O
. . 0 0 12 O

- : 0 0 2 O
Indomethacin NN 0 1 0 B-Drug
: : 0 0 2 O
Indomethacin JJ 0 1 0 B-Drug
blunts NNS 0 1 UNK O
the DT 0 0 12 O
increases NNS 1 1 1 O
in IN 0 0 12 O
urine JJ 0 1 6 O
volume NN 0 1 1 O
and CC 0 0 12 O
sodium NN 0 1 14 O
excretion NN 0 1 14 O
seen VBN 1 1 12 O
during IN 0 0 12 O
bumetanide JJ 0 1 16 B-Drug
treatment NN 0 1 6 O
and CC 0 0 12 O
inhibits VBZ 1 1 UNK O
the DT 0 0 12 O
bumetanide NN 0 1 16 B-Drug
- : 0 0 2 O
induced JJ 0 1 6 O
increase NN 0 1 1 O
in IN 0 0 12 O
plasma JJ 0 1 14 O
renin NN 0 1 UNK O
activity NN 0 1 1 O
. . 0 0 12 O

This DT 0 0 2 O
diminution NN 0 1 1 O
is VBZ 1 0 12 O
not RB 0 1 12 O
sufficient JJ 0 1 1 O
to TO 0 0 12 O
preclude VB 0 0 UNK O
effectiveness NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
pressor NN 0 1 14 O
agent NN 0 1 1 O
for IN 0 0 12 O
therapeutic JJ 0 1 6 O
use NN 0 1 1 O
. . 0 0 12 O
) ) 0 0 2 O

Because IN 0 0 12 O
candesartan NN 0 1 16 B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
significantly RB 0 0 1 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
the DT 0 0 12 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
system NN 0 1 1 O
and CC 0 0 12 O
at IN 0 0 12 O
therapeutic JJ 0 1 6 O
concentrations NNS 1 1 13 O
has VBZ 1 0 12 O
no DT 0 0 12 O
effects NNS 1 1 1 O
on IN 0 0 12 O
P9 NNP 0 1 UNK O
enzymes NNS 1 1 14 O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
inhibit VBP 0 1 13 O
or CC 0 0 12 O
are VBP 1 0 12 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
those DT 0 0 12 O
enzymes NNS 1 1 14 O
would MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
expected VBN 1 1 12 O
. . 0 0 12 O

THE DT 0 0 11 O
POTENTIATING NNP 0 0 UNK O
ACTION NNP 0 1 UNK O
OF NNP 0 0 11 O
HYDROXYZINE NNP 0 1 UNK B-Drug
MUST NNP 0 0 11 O
BE NNP 0 0 11 O
CONSIDERED VBN 0 1 UNK O
WHEN NNP 0 0 UNK O
THE NNP 0 0 11 O
DRUG NNP 0 1 11 O
IS NNP 0 0 11 O
USED NNP 0 1 11 O
IN NNP 0 0 11 O
CONJUNCTION NNP 0 1 UNK O
WITH NNP 0 0 11 O
CENTRAL NNP 0 1 UNK B-Group
NERVOUS NNP 0 1 UNK I-Group
SYSTEM NNP 0 1 11 I-Group
DEPRESSANTS NNP 0 0 UNK I-Group
SUCH NNP 0 0 11 O
AS IN 0 0 11 O
NARCOTICS NNP 0 1 UNK B-Group
NON NNP 0 1 UNK B-Group
- : 0 0 2 O
NARCOTIC NN 0 1 UNK I-Group
ANALGESICS NNP 0 1 UNK I-Group
AND NNP 0 0 11 O
BARBITURATES NNP 0 1 UNK B-Group
. . 0 0 12 O

Azlocillin NNP 0 1 UNK B-Drug
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
amikacin JJ 0 1 0 B-Drug
ciprofloxacin NN 0 1 0 B-Drug
gentamicin NN 0 1 14 B-Drug
netilmicin NN 0 1 UNK B-Drug
or CC 0 0 12 O
tobramycin NN 0 1 16 B-Drug
. . 0 0 12 O

No DT 0 0 2 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
performed VBN 1 1 1 O
. . 0 0 12 O

Concomitant NNP 0 1 UNK O
use NN 0 1 1 O
of IN 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
cytochrome JJ 0 1 UNK O
P9IID9 NNP 0 0 UNK O
may MD 0 0 1 O
require VB 0 0 1 O
lower JJR 1 1 1 O
doses NNS 1 1 6 O
than IN 0 0 12 O
usually RB 0 1 12 O
prescribed VBN 1 1 1 O
for IN 0 0 12 O
either CC 0 1 12 O
the DT 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressant NN 0 1 6 I-Group
or CC 0 0 12 O
the DT 0 0 12 O
other JJ 0 0 12 O
drug NN 0 1 1 O
. . 0 0 12 O

Vitamin NNP 0 1 2 B-Group
D NNP 0 1 2 I-Group
: : 0 0 2 O
The DT 0 0 2 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
any DT 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
vitamin NN 0 1 6 B-Group
D NNP 0 1 2 I-Group
analogues NNS 1 1 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
as IN 1 0 12 O
this DT 0 0 12 O
could MD 0 0 12 O
create VB 0 1 13 O
possible JJ 0 1 1 O
additive JJ 0 1 16 O
effects NNS 1 1 1 O
and CC 0 0 12 O
hypercalcemia NN 0 1 8 O
. . 0 0 12 O

The DT 0 0 2 O
clinical JJ 0 1 6 O
relevance NN 0 1 UNK O
of IN 0 0 12 O
these DT 0 0 12 O
increases NNS 1 1 1 O
is VBZ 1 0 12 O
not RB 0 1 12 O
known VBN 1 1 12 O
. . 0 0 12 O

Caution NN 0 0 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
exercised VBN 1 1 1 O
with IN 0 0 12 O
simultaneous JJ 0 1 13 O
use NN 0 1 1 O
of IN 0 0 12 O
clonidine NN 0 1 0 B-Drug
and CC 0 0 12 O
other JJ 0 0 12 O
similar JJ 0 1 1 O
pharmacologic NN 0 1 14 O
agents NNS 1 1 1 O

Concurrent JJ 0 1 13 O
administration NN 0 1 1 O
of IN 0 0 12 O
etanercept NN 0 1 13 B-Drug
( ( 0 0 2 O
another DT 0 0 12 O
TNF NNP 0 1 UNK O
- : 0 0 2 O
blocking VBG 1 1 UNK O
agent NN 0 1 1 O
) ) 0 0 2 O
and CC 0 0 12 O
anakinra $ 0 1 13 B-Drug
( ( 0 0 2 O
an DT 0 0 12 O
interleukin NN 0 1 13 B-Group
- : 0 0 2 O
9 CD 0 0 2 I-Group
antagonist NN 0 1 13 I-Group
) ) 0 0 2 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
an DT 0 0 12 O
increased VBN 1 1 1 O
risk NN 0 1 1 O
of IN 0 0 12 O
serious JJ 0 1 12 O
infections NNS 1 1 6 O
and CC 0 0 12 O
increased VBD 1 1 1 O
risk NN 0 1 1 O
of IN 0 0 12 O
neutropenia NN 0 1 14 O
and CC 0 0 12 O
no DT 0 0 12 O
additional JJ 0 1 1 O
benefit NN 0 1 1 O
compared VBN 1 1 1 O
to TO 0 0 12 O
these DT 0 0 12 O
medicinal JJ 0 0 16 O
products NNS 1 1 1 O
alone RB 0 1 12 O
. . 0 0 12 O

When WRB 0 0 12 O
CANCIDAS NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
with IN 0 0 12 O
inducers NNS 1 1 UNK O
of IN 0 0 12 O
drug NN 0 1 1 O
clearance NN 0 1 16 O
such JJ 0 0 1 O
as IN 1 0 12 O
efavirenz JJ 0 1 13 B-Drug
nevirapine JJ 0 1 13 B-Drug
phenytoin NN 0 1 16 B-Drug
dexamethasone NN 0 1 16 B-Drug
or CC 0 0 12 O
carbamazepine NN 0 1 16 B-Drug
use NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
daily JJ 0 1 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
of IN 0 0 12 O
CANCIDAS NNP 0 1 UNK B-Brand
should MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O

Glyburide NN 0 1 0 B-Drug
: : 0 0 2 O
An DT 0 0 2 O
increased VBN 1 1 1 O
risk NN 0 1 1 O
of IN 0 0 12 O
elevated VBN 1 1 1 O
liver NN 0 1 6 O
aminotransferases NNS 1 1 UNK O
was VBD 1 0 12 O
observed VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
concomitant JJ 0 1 6 O
therapy NN 0 1 6 O
with IN 0 0 12 O
glyburide NN 0 1 16 B-Drug
. . 0 0 12 O

Antacids NNS 0 1 UNK B-Group
and CC 0 0 12 O
sucralfate NN 0 1 0 B-Drug
: : 0 0 2 O
Sucralfate NN 0 1 0 B-Drug
and CC 0 0 12 O
antacids NNS 1 1 14 B-Group
containing VBG 1 1 1 O
magnesium NN 0 1 14 B-Drug
or CC 0 0 12 O
aluminum NN 0 1 16 B-Drug
as RB 0 0 12 O
well RB 0 1 12 O
as IN 1 0 12 O
formulations NNS 1 1 UNK O
containing VBG 1 1 1 O
divalent NN 0 0 UNK O
and CC 0 0 12 O
trivalent JJ 0 0 UNK O
cations NNS 1 1 UNK O
such JJ 0 0 1 O
as IN 1 0 12 O
Videx NNP 0 1 UNK B-Brand
( ( 0 0 2 O
didanosine NN 0 1 16 B-Drug
) ) 0 0 2 O
chewable JJ 0 0 16 O
/ NN 0 0 2 O
buffered VBD 1 1 16 O
tablets NNS 1 1 3 O
or CC 0 0 12 O
the DT 0 0 12 O
pediatric JJ 0 1 6 O
powder NN 0 1 3 O
for IN 0 0 12 O
oral JJ 0 1 6 O
solution NN 0 1 1 O
can MD 0 0 12 O
form VB 0 1 1 O
chelation NN 0 1 UNK O
complexes NNS 1 1 1 O
with IN 0 0 12 O
lomefloxacin NN 0 1 UNK B-Drug
and CC 0 0 12 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
its PRP$ 1 0 12 O
bioavailability NN 0 1 UNK O
. . 0 0 12 O

oral JJ 0 1 6 O
contraceptives NNS 1 1 13 B-Group
; : 0 0 2 O

Urinary JJ 0 1 7 O
alkalinizing VBG 1 0 UNK O
agents NNS 1 1 1 O
( ( 0 0 2 O
acetazolamide IN 0 1 0 B-Drug
some DT 0 0 12 O
thiazides NNS 1 1 UNK B-Group
) ) 0 0 2 O
increase VBP 0 1 1 O
the DT 0 0 12 O
concentration NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
non JJ 0 1 1 O
- : 0 0 2 O
ionized JJ 0 1 14 O
species NNS 1 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
amphetamine NN 0 1 13 B-Drug
molecule NN 0 1 UNK O
thereby RB 0 0 UNK O
decreasing VBG 1 1 1 O
urinary JJ 0 1 6 O
excretion NN 0 1 14 O
. . 0 0 12 O

The DT 0 0 2 O
clinical JJ 0 1 6 O
significance NN 0 1 13 O
of IN 0 0 12 O
this DT 0 0 12 O
reduction NN 0 1 1 O
is VBZ 1 0 12 O
not RB 0 1 12 O
known VBN 1 1 12 O
hence NN 0 0 1 O
zalcitabine NN 0 1 UNK B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
recommended VBN 1 1 1 O
to TO 0 0 12 O
be VB 0 0 12 O
ingested VBN 1 1 14 O
simultaneously RB 0 1 13 O
with IN 0 0 12 O
magnesium NN 0 1 14 B-Drug
/ NN 0 0 2 O
aluminum NN 0 1 16 B-Drug
- : 0 0 2 O
containing NN 0 1 1 O
antacids NNS 1 1 14 B-Group
. . 0 0 12 O

Bacteriostatic JJ 0 0 UNK B-Group
Antibiotics NNS 0 1 7 I-Group
: : 0 0 2 O
Chloramphenicol NNP 0 1 UNK B-Drug
erythromycins VBZ 0 1 UNK B-Drug
sulfonamides NNS 1 1 13 B-Group
or CC 0 0 12 O
tetracyclines NNS 1 1 13 B-Group
may MD 0 0 1 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
bactericidal JJ 0 1 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
penicillins NNS 1 1 14 B-Group
. . 0 0 12 O

Caution NN 0 0 UNK O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
during IN 0 0 12 O
the DT 0 0 12 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
any DT 0 0 12 O
of IN 0 0 12 O
these DT 0 0 12 O
with IN 0 0 12 O
alprazolam NN 0 1 0 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
neuromuscular JJ 0 1 6 O
blocking VBG 1 1 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
MIVACRON NNP 0 1 UNK B-Brand
may MD 0 0 1 O
be VB 0 0 12 O
enhanced VBN 1 1 1 O
by IN 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
reduce VB 0 0 1 O
plasma JJ 0 1 14 O
cholinesterase NN 0 1 UNK O
activity NN 0 1 1 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
chronically RB 0 0 6 O
administered VBN 1 1 1 O
oral JJ 0 1 6 O
contraceptives NNS 1 1 13 B-Group
glucocorticoids NNS 1 1 UNK B-Group
or CC 0 0 12 O
certain JJ 0 1 1 O
monoamine JJ 0 1 13 B-Group
oxidase NN 0 1 13 I-Group
inhibitors NNS 1 1 14 I-Group
) ) 0 0 2 O
or CC 0 0 12 O
by IN 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
irreversibly RB 0 0 UNK O
inhibit VBP 0 1 13 O
plasma JJ 0 1 14 O
cholinesterase NN 0 1 UNK O
. . 0 0 12 O
Resistance NN 0 1 UNK O
to TO 0 0 12 O
the DT 0 0 12 O
neuromuscular JJ 0 1 6 O
blocking VBG 1 1 UNK O
action NN 0 1 13 O
of IN 0 0 12 O
nondepolarizing VBG 0 0 UNK O
neuromuscular JJ 0 1 6 B-Group
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
has VBZ 1 0 12 O
been VBN 1 0 12 O
demonstrated VBN 1 0 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
chronically RB 0 0 6 O
administered VBN 1 1 1 O
phenytoin NN 0 1 16 B-Drug
or CC 0 0 12 O
carbamazepine NN 0 1 16 B-Drug
. . 0 0 12 O

Antacids NNS 0 1 UNK B-Group
: : 0 0 2 O
Concomitant NNP 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
magnesium NN 0 1 14 B-Drug
hydroxide NN 0 1 14 I-Drug
and CC 0 0 12 O
aluminum NN 0 1 16 B-Drug
hydroxide NN 0 1 14 I-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
rate NN 0 1 1 O
or CC 0 0 12 O
extent NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
absorption NN 0 1 1 O
of IN 0 0 12 O
ketoprofen NN 0 1 UNK B-Drug
administered VBN 1 1 1 O
as IN 1 0 12 O
Orudis NNP 0 1 UNK B-Brand
. . 0 0 12 O

Reductions NNS 0 1 UNK O
in IN 0 0 12 O
serum NN 0 1 14 O
endogenous JJ 0 1 14 O
vitamin NN 0 1 6 O
D NNP 0 1 2 O
concentrations NNS 1 1 13 O
have VBP 0 0 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
following VBG 1 1 1 O
the DT 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
to TO 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
ketoconazole VB 0 1 16 B-Drug
for IN 0 0 12 O
a DT 0 0 12 O
week NN 0 1 12 O
to TO 0 0 12 O
healthy JJ 0 1 12 O
men NNS 0 1 13 O
. . 0 0 12 O

Tadalafil NNP 0 1 UNK B-Drug
dose NN 0 1 6 O
should MD 0 0 12 O
not RB 0 1 12 O
exceed VB 0 0 UNK O
a DT 0 0 12 O
maximum NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
in IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
hour NN 0 1 12 O
period NN 0 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
concomitant JJ 0 1 6 O
indinavir JJ 0 1 16 B-Drug
therapy NN 0 1 6 O
. . 0 0 12 O

Lopinavir NN 0 1 UNK B-Drug

If IN 0 0 12 O
concomitant JJ 0 1 6 O
treatment NN 0 1 6 O
with IN 0 0 12 O
AXERT NNP 0 1 UNK B-Brand
and CC 0 0 12 O
an DT 0 0 12 O
SSRI NNP 0 1 UNK B-Group
is VBZ 1 0 12 O
clinically RB 0 0 6 O
warranted JJ 0 0 1 O
appropriate JJ 0 1 1 O
observation NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
patient NN 0 1 6 O
is VBZ 1 0 12 O
advised VBN 1 0 12 O
. . 0 0 12 O

Because IN 0 0 12 O
of IN 0 0 12 O
profound NN 0 1 1 O
and CC 0 0 12 O
long JJ 0 1 12 O
lasting JJ 0 0 1 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
gastric JJ 0 1 6 O
acid JJ 0 1 14 O
secretion NN 0 1 14 O
pantoprazole NN 0 1 16 B-Drug
may MD 0 0 1 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
absorption NN 0 1 1 O
of IN 0 0 12 O
drugs NNS 1 1 6 O
where WRB 0 0 12 O
gastric NN 0 1 6 O
pH NN 0 1 14 O
is VBZ 1 0 12 O
an DT 0 0 12 O
important JJ 0 1 1 O
determinant NN 0 1 UNK O
of IN 0 0 12 O
their PRP$ 0 0 12 O
bioavailability NN 0 1 UNK O
( ( 0 0 2 O
eg JJ 0 1 UNK O
ketoconazole NN 0 1 16 B-Drug
ampicillin NN 0 1 0 B-Drug
esters NNS 1 1 UNK O
and CC 0 0 12 O
iron NN 0 1 3 B-Drug
salts NNS 1 1 13 O
) ) 0 0 2 O
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
that IN 0 0 12 O
glucose NN 0 1 14 O
tests NNS 1 1 1 O
based VBN 1 1 1 O
on IN 0 0 12 O
enzymatic JJ 0 1 UNK O
glucose JJ 0 1 14 O
oxidase NN 0 1 13 O
reactions NNS 1 1 1 O
( ( 0 0 2 O
such JJ 0 0 1 O
as IN 1 0 12 O
Clinistix NNP 0 0 UNK O
or CC 0 0 12 O
Tes NNP 0 1 UNK O
- : 0 0 2 O
Tape NN 0 1 2 O
) ) 0 0 2 O
be VB 0 0 12 O
used VBN 1 1 12 O
. . 0 0 12 O

Ondansetron NNP 0 1 0 B-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
itself PRP 0 0 UNK O
appear VBP 0 1 12 O
to TO 0 0 12 O
induce VB 0 1 6 O
or CC 0 0 12 O
inhibit VB 0 1 13 O
the DT 0 0 12 O
cytochrome NN 0 1 UNK O
P NNP 0 1 2 O
- : 0 0 2 O
9 CD 0 0 2 O
drug NN 0 1 1 O
- : 0 0 2 O
metabolizing NN 0 0 UNK O
enzyme JJ 0 1 14 O
system NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
liver NN 0 1 6 O
. . 0 0 12 O

When WRB 0 0 12 O
such JJ 0 0 1 O
drugs NNS 1 1 6 O
are VBP 1 0 12 O
administered VBN 1 1 1 O
to TO 0 0 12 O
a DT 0 0 12 O
patient NN 0 1 6 O
receiving VBG 1 1 1 O
MICRONASE NNP 0 1 UNK B-Brand
the DT 0 0 12 O
patient NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
observed VBN 1 1 1 O
closely RB 0 0 1 O
for IN 0 0 12 O
hypoglycemia NN 0 1 6 O
. . 0 0 12 O

All DT 0 0 2 O
animals NNS 1 1 12 O
in IN 0 0 12 O
the DT 0 0 12 O
study NN 0 1 1 O
were VBD 1 0 12 O
positive JJ 0 1 1 O
for IN 0 0 12 O
an DT 0 0 12 O
endemic JJ 0 0 13 O
primate NN 0 1 UNK O
gammaherpes NNS 0 0 UNK O
virus NN 0 1 6 O
also RB 0 0 12 O
known VBN 1 1 12 O
as IN 1 0 12 O
lymphocryptovirus NN 0 1 UNK O
( ( 0 0 2 O
LCV NNP 0 0 UNK O
) ) 0 0 2 O
. . 0 0 12 O

Consequently RB 0 0 1 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
drugs NNS 1 1 6 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
these DT 0 0 12 O
two CD 0 1 12 O
isoenzymes NNS 0 1 14 O
will MD 0 0 12 O
be VB 0 0 12 O
decreased VBN 1 1 1 O
when WRB 0 0 12 O
TRACLEER NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
. . 0 0 12 O

. . 0 0 12 O

Therefore IN 0 0 1 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
critically RB 0 0 1 O
important JJ 0 1 1 O
for IN 0 0 12 O
women NNS 1 1 UNK O
of IN 0 0 12 O
childbearing VBG 0 0 UNK O
potential JJ 0 1 1 O
to TO 0 0 12 O
select VB 0 1 1 O
and CC 0 0 12 O
commit VB 0 1 UNK O
to TO 0 0 12 O
use VB 0 1 1 O
9 CD 0 0 2 O
forms NNS 1 1 1 O
of IN 0 0 12 O
effective JJ 0 1 1 O
contraception NN 0 1 13 O
simultaneously RB 0 1 13 O
at IN 0 0 12 O
least JJS 0 1 12 O
9 CD 0 0 2 O
of IN 0 0 12 O
which WDT 0 0 12 O
must MD 0 0 12 O
be VB 0 0 12 O
a DT 0 0 12 O
primary JJ 0 1 1 O
form NN 0 1 1 O
unless IN 0 0 12 O
absolute JJ 0 1 1 O
abstinence NN 0 1 UNK O
is VBZ 1 0 12 O
the DT 0 0 12 O
chosen JJ 0 1 12 O
method NN 0 1 13 O
or CC 0 0 12 O
the DT 0 0 12 O
patient NN 0 1 6 O
has VBZ 1 0 12 O
undergone RP 0 0 1 O
a DT 0 0 12 O
hysterectomy NN 0 1 6 O

Drugs NNS 0 1 2 O
Eliminated VBN 0 1 UNK O
by IN 0 0 12 O
Active NNP 0 1 2 O
Tubular NNP 0 1 UNK O
Secretion NN 0 1 UNK O
: : 0 0 2 O
Although IN 0 0 12 O
studies NNS 1 1 1 O
to TO 0 0 12 O
assess VB 0 1 1 O
drug NN 0 1 1 O
- : 0 0 2 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
Sanctura NNP 0 1 UNK B-Brand
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
conducted VBN 1 1 1 O
Sanctura NNP 0 1 UNK B-Brand
has VBZ 1 0 12 O
the DT 0 0 12 O
potential NN 0 1 1 O
for IN 0 0 12 O
pharmacokinetic JJ 0 1 UNK O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
are VBP 1 0 12 O
eliminated VBN 1 1 UNK O
by IN 0 0 12 O
active JJ 0 1 1 O
tubular JJ 0 1 3 O
secretion NN 0 1 14 O
( ( 0 0 2 O
e.g JJ 0 0 UNK O
. . 0 0 12 O
digoxin NN 0 1 14 B-Drug
procainamide IN 0 1 16 B-Drug
pancuronium NN 0 1 16 B-Drug
morphine NN 0 1 14 B-Drug
vancomycin NN 0 1 14 B-Drug
metformin NN 0 1 0 B-Drug
and CC 0 0 12 O
tenofovir NN 0 1 16 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

These DT 0 0 1 O
recommendations NNS 1 1 1 O
are VBP 1 0 12 O
based VBN 1 1 1 O
on IN 0 0 12 O
either DT 0 1 12 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
or CC 0 0 12 O
predicted VBN 1 1 1 O
interactions NNS 1 1 UNK O
due JJ 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
expected VBN 1 1 12 O
magnitude NN 0 1 UNK O
of IN 0 0 12 O
interaction NN 0 1 UNK O
and CC 0 0 12 O
potential NN 0 1 1 O
for IN 0 0 12 O
serious JJ 0 1 12 O
events NNS 1 1 12 O
or CC 0 0 12 O
loss NN 0 1 1 O
of IN 0 0 12 O
efficacy NN 0 1 UNK O
. . 0 0 12 O

Aprepitant NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
also RB 0 0 12 O
an DT 0 0 12 O
inducer NN 0 1 UNK O
of IN 0 0 12 O
CYP9C9 NNP 0 0 UNK O
. . 0 0 12 O

Theophylline NN 0 1 UNK B-Drug
: : 0 0 2 O
Grepafloxacin NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
a DT 0 0 12 O
competitive JJ 0 1 UNK O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
theophylline NN 0 1 16 B-Drug
. . 0 0 12 O

Therefore RB 0 0 1 O
close JJ 0 1 12 O
monitoring NN 0 1 1 O
of IN 0 0 12 O
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
and CC 0 0 12 O
adjustment NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
anticoagulant JJ 0 1 13 B-Group
dose NN 0 1 6 O
may MD 0 0 1 O
be VB 0 0 12 O
necessary JJ 0 0 1 O
when WRB 0 0 12 O
EULEXIN NNP 0 1 UNK B-Brand
Capsules NNP 0 1 0 O
are VBP 1 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
. . 0 0 12 O

H9 NNP 0 0 UNK B-Group
and CC 0 0 12 O
H9 NNP 0 0 UNK B-Group
Blockers NNP 0 0 UNK I-Group
- : 0 0 2 O
Although IN 0 0 12 O
not RB 0 1 12 O
reported VBN 1 1 1 O
L NNP 0 1 2 B-Drug
- : 0 0 2 O
histidine NN 0 1 13 I-Drug
via IN 0 0 1 O
its PRP$ 1 0 12 O
metabolism NN 0 1 16 O
to TO 0 0 12 O
histamine VB 0 1 UNK O
might MD 0 0 12 O
decrease VB 0 1 1 O
the DT 0 0 12 O
efficacy NN 0 1 UNK O
of IN 0 0 12 O
H9 NNP 0 0 UNK B-Group
and CC 0 0 12 O
H9 NNP 0 0 UNK B-Group
blockers NNS 1 0 6 I-Group
. . 0 0 12 O

Cyclosporine NN 0 1 UNK B-Drug
: : 0 0 2 O
The DT 0 0 2 O
total JJ 0 1 1 O
ezetimibe JJ 0 1 16 B-Drug
level NN 0 1 1 O
increased VBD 1 1 1 O
9 CD 0 0 2 O
- : 0 0 2 O
fold NN 0 1 3 O
in IN 0 0 12 O
one CD 0 1 12 O
renal JJ 0 1 6 O
transplant NN 0 1 6 O
patient NN 0 1 6 O
receiving VBG 1 1 1 O
multiple JJ 0 1 1 O
medications NNS 1 1 6 O
including VBG 1 1 1 O
cyclosporine NN 0 1 14 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
potentiation NN 0 1 UNK O
resulted VBD 1 1 1 O
from IN 0 0 12 O
a DT 0 0 12 O
CNS NNP 0 1 6 O
pharmacodynamic JJ 0 1 UNK O
interaction NN 0 1 UNK O
; : 0 0 2 O

ATROVENT NNP 0 1 0 B-Brand
Inhalation NNP 0 1 7 O
Aerosol NNP 0 1 7 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
used VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
including VBG 1 1 1 O
sympathomimetic JJ 0 1 13 B-Group
bronchodilators NNS 1 1 14 I-Group
methylxanthines NNS 0 1 UNK B-Group
and CC 0 0 12 O
steroids NNS 1 1 6 B-Group
commonly RB 0 0 UNK O
used VBN 1 1 12 O
in IN 0 0 12 O
the DT 0 0 12 O
treatment NN 0 1 6 O
of IN 0 0 12 O
chronic JJ 0 1 6 O
obstructive JJ 0 1 6 O
pulmonary JJ 0 1 6 O
disease NN 0 1 6 O
. . 0 0 12 O

No DT 0 0 2 O
significant JJ 0 1 1 O
drug NN 0 1 1 O
- : 0 0 2 O
drug NN 0 1 1 O
pharmacokinetic JJ 0 1 UNK O
interactions NNS 1 1 UNK O
have VBP 0 0 12 O
been VBN 1 0 12 O
found VBN 1 1 12 O
in IN 0 0 12 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
with IN 0 0 12 O
hydrochlorothiazide JJ 0 1 0 B-Drug
digoxin NN 0 1 14 B-Drug
warfarin NN 0 1 14 B-Drug
cimetidine NN 0 1 13 B-Drug
and CC 0 0 12 O
phenobarbital NN 0 1 16 B-Drug
. . 0 0 12 O

Minor NNP 0 1 2 O
symptoms NNS 1 1 6 O
such JJ 0 0 1 O
as IN 1 0 12 O
flushing VBG 1 1 13 O
skin JJ 0 1 3 O
reactions NNS 1 1 1 O
dyspnea VBP 0 1 8 O
hypotension NN 0 1 6 O
or CC 0 0 12 O
tachycardia VB 0 1 8 O
do VBP 0 0 12 O
not RB 0 1 12 O
require VB 0 0 1 O
interruption NN 0 1 1 O
of IN 0 0 12 O
therapy NN 0 1 6 O
. . 0 0 12 O

Interactions NNS 0 1 UNK O
with IN 0 0 12 O
Other JJ 0 0 2 O
CNS JJ 0 1 6 O
Agents NNS 0 1 2 O
: : 0 0 2 O
Concurrent NNP 0 1 13 O
use NN 0 1 1 O
of IN 0 0 12 O
Levo NNP 0 1 15 B-Brand
- : 0 0 2 O
Dromoran NN 0 0 UNK I-Brand
with IN 0 0 12 O
all DT 0 0 12 O
central JJ 0 1 1 B-Group
nervous JJ 0 1 6 I-Group
system NN 0 1 1 I-Group
depressants NNS 1 0 13 I-Group
( ( 0 0 2 O
eg JJ 0 1 UNK O
alcohol NN 0 1 1 B-Drug
sedatives NNS 1 1 6 B-Group
hypnotics VBP 0 1 13 B-Group
other JJ 0 0 12 O
opioids NNS 0 1 14 B-Group
general JJ 0 1 1 O
anesthetics NNS 1 1 13 B-Group
barbiturates VBZ 0 1 14 B-Group
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
phenothiazines VBZ 0 1 UNK B-Group
tranquilizers NNS 1 1 13 B-Group
skeletal JJ 0 1 13 B-Group
muscle NN 0 1 6 I-Group
relaxants NNS 1 0 13 I-Group
and CC 0 0 12 O
antihistamines NNS 1 1 UNK B-Group
) ) 0 0 2 O
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
additive JJ 0 1 16 O
central JJ 0 1 1 O
nervous JJ 0 1 6 O
system NN 0 1 1 O
depressant JJ 0 0 UNK O
effects NNS 1 1 1 O
. . 0 0 12 O

Fentanyl NN 0 1 0 B-Drug

Thiazide IN 0 1 UNK B-Group
diuretics NNS 1 1 14 I-Group
may MD 0 0 1 O
accentuate VB 0 0 UNK O
the DT 0 0 12 O
orthostatic JJ 0 1 8 O
hypotension NN 0 1 6 O
that WDT 0 0 12 O
may MD 0 0 1 O
occur VB 0 1 1 O
with IN 0 0 12 O
phenothiazines NNS 1 1 UNK B-Group
. . 0 0 12 O

( ( 0 0 2 O
b NN 0 0 16 O
) ) 0 0 2 O
Plasma NNP 0 1 UNK O
and CC 0 0 12 O
urinary JJ 0 1 6 O
gonadotropin NN 0 1 13 O
levels NNS 1 1 1 O
are VBP 1 0 12 O
decreased VBN 1 1 1 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
LH NNP 0 1 13 O
FSH NNP 0 0 14 O
) ) 0 0 2 O
. . 0 0 12 O

9 CD 0 0 2 O

Effect NN 0 1 UNK O
of IN 0 0 12 O
AEDs NNP 0 1 UNK B-Group
in IN 0 0 12 O
Pediatric NNP 0 1 7 O
Patients NNPS 0 1 7 O
There EX 0 0 12 O
was VBD 1 0 12 O
about IN 0 1 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
increase NN 0 1 1 O
of IN 0 0 12 O
apparent JJ 0 1 1 O
total NN 0 1 1 O
body NN 0 1 3 O
clearance NN 0 1 16 O
of IN 0 0 12 O
levetiracetam NN 0 1 16 B-Drug
when WRB 0 0 12 O
it PRP 0 0 12 O
was VBD 1 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
with IN 0 0 12 O
enzyme JJ 0 1 14 O
- : 0 0 2 O
inducing NN 0 1 6 O
AEDs NNP 0 1 UNK B-Group
. . 0 0 12 O

Caspofungin NN 0 1 0 B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
a DT 0 0 12 O
substrate NN 0 1 UNK O
for IN 0 0 12 O
P NNP 0 1 2 O
- : 0 0 2 O
glycoprotein NN 0 1 UNK O
and CC 0 0 12 O
is VBZ 1 0 12 O
a DT 0 0 12 O
poor JJ 0 1 12 O
substrate NN 0 1 UNK O
for IN 0 0 12 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
enzymes NNS 1 1 14 O
. . 0 0 12 O

Trilostane NN 0 1 UNK B-Drug
may MD 0 0 1 O
interact VB 0 0 UNK O
with IN 0 0 12 O
aminoglutethimide NN 0 1 UNK B-Drug
or CC 0 0 12 O
mitotane NN 0 1 13 B-Drug
( ( 0 0 2 O
causing VBG 1 1 1 O
too RB 0 0 12 O
great JJ 0 1 12 O
a DT 0 0 12 O
decrease NN 0 1 1 O
in IN 0 0 12 O
adrenal JJ 0 0 6 O
function NN 0 1 1 O
) ) 0 0 2 O
. . 0 0 12 O

Although IN 0 0 12 O
clinical JJ 0 1 6 O
studies NNS 1 1 1 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
conducted VBN 1 1 1 O
in IN 0 0 12 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
of IN 0 0 12 O
iloprost NN 0 1 13 B-Drug
indicate VBP 0 0 1 O
that IN 0 0 12 O
no DT 0 0 12 O
relevant JJ 0 1 1 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
drug NN 0 1 1 O
metabolism NN 0 1 16 O
would MD 0 0 12 O
be VB 0 0 12 O
expected VBN 1 1 12 O
. . 0 0 12 O

Caution NN 0 0 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
if IN 0 0 12 O
naproxen DT 0 1 16 B-Drug
is VBZ 1 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
methotrexate NN 0 1 16 B-Drug
. . 0 0 12 O

use NN 0 1 1 O
potassium NN 0 1 14 B-Drug
supplements NNS 1 1 6 O
if IN 0 0 12 O
necessary JJ 0 0 1 O
. . 0 0 12 O

Methotrexate NN 0 1 0 B-Drug
: : 0 0 2 O
Caution NN 0 0 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
if IN 0 0 12 O
diflunisal NN 0 1 13 B-Drug
is VBZ 1 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
methotrexate NN 0 1 16 B-Drug
. . 0 0 12 O

Trimethoprim NNP 0 1 0 B-Drug
Alone NNP 0 1 UNK O
or CC 0 0 12 O
in IN 0 0 12 O
Combination NNP 0 1 UNK O
with IN 0 0 12 O
Sulfamethoxazole NNP 0 1 0 B-Drug
: : 0 0 2 O
Concomitant NNP 0 1 UNK O
use NN 0 1 1 O
of IN 0 0 12 O
trimethoprim JJ 0 1 16 B-Drug
alone NN 0 1 12 O
or CC 0 0 12 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
sulfamethoxazole NN 0 1 13 B-Drug
is VBZ 1 0 12 O
contraindicated VBN 1 1 14 O
. . 0 0 12 O

Probenecid NN 0 1 UNK B-Drug
: : 0 0 2 O
As IN 0 0 2 O
with IN 0 0 12 O
other JJ 0 0 12 O
b SYM 0 0 16 B-Group
- : 0 0 2 O
lactams VBZ 0 1 UNK I-Group
the DT 0 0 12 O
renal JJ 0 1 6 O
excretion NN 0 1 14 O
of IN 0 0 12 O
cephalexin NN 0 1 16 B-Drug
is VBZ 1 0 12 O
inhibited VBN 1 1 13 O
by IN 0 0 12 O
probenecid NN 0 1 13 B-Drug
. . 0 0 12 O

This DT 0 0 2 O
effect NN 0 1 1 O
is VBZ 1 0 12 O
small JJ 0 1 12 O
with IN 0 0 12 O
occasional JJ 0 1 12 O
doses NNS 1 1 6 O
of IN 0 0 12 O
antacids NNS 1 1 14 B-Group
but CC 0 0 12 O
may MD 0 0 1 O
be VB 0 0 12 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
when WRB 0 0 12 O
antacids NNS 1 1 14 B-Group
are VBP 1 0 12 O
used VBN 1 1 12 O
on IN 0 0 12 O
a DT 0 0 12 O
continuous JJ 0 1 1 O
schedule NN 0 1 12 O
. . 0 0 12 O

Since IN 0 1 2 O
INVIRASE NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
ritonavir NN 0 1 16 B-Drug
the DT 0 0 12 O
ritonavir NN 0 1 16 B-Drug
label NN 0 1 13 O
should MD 0 0 12 O
be VB 0 0 12 O
reviewed VBN 1 1 1 O
for IN 0 0 12 O
additional JJ 0 1 1 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
coadministered VBN 0 0 UNK O
. . 0 0 12 O

Interactions NNS 0 1 UNK O
between IN 0 0 12 O
Leukine NNP 0 1 UNK B-Brand
and CC 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
fully RB 0 0 1 O
evaluated VBN 1 1 1 O
. . 0 0 12 O

This DT 0 0 2 O
inhibition NN 0 1 13 O
can MD 0 0 12 O
result VB 0 1 1 O
in IN 0 0 12 O
unexpectedly RB 0 0 UNK O
high JJ 0 1 1 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 B-Drug
which WDT 0 0 12 O
are VBP 1 0 12 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
those DT 0 0 12 O
CYP9 NNP 0 0 UNK O
enzymes NNS 1 1 14 O
. . 0 0 12 O

nc9 RB 0 0 UNK O
9 CD 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
decrease NN 0 1 1 O
[ NNP 0 0 2 O
CI NNP 0 1 UNK O
: : 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
decrease NN 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
decrease NN 0 1 1 O
] NN 0 0 2 O

Because IN 0 0 12 O
alosetron NN 0 1 UNK B-Drug
is VBZ 1 0 12 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
a DT 0 0 12 O
variety NN 0 1 1 O
of IN 0 0 12 O
hepatic JJ 0 1 14 O
CYP NNP 0 1 UNK O
drug NN 0 1 1 O
- : 0 0 2 O
metabolizing NN 0 0 UNK O
enzymes VBZ 0 1 14 O
inducers NNS 1 1 UNK O
or CC 0 0 12 O
inhibitors NNS 1 1 14 O
of IN 0 0 12 O
these DT 0 0 12 O
enzymes NNS 1 1 14 O
may MD 0 0 1 O
change VB 0 1 1 O
the DT 0 0 12 O
clearance NN 0 1 16 O
of IN 0 0 12 O
alosetron NN 0 1 UNK B-Drug
. . 0 0 12 O

Therefore RB 0 0 1 O
proton JJ 0 1 14 B-Group
pump NN 0 1 3 I-Group
inhibitors NNS 1 1 14 I-Group
should MD 0 0 12 O
be VB 0 0 12 O
taken VBN 1 1 12 O
at IN 0 0 12 O
least JJS 0 1 12 O
9 CD 0 0 2 O
minutes NNS 1 1 12 O
prior RB 0 1 1 O
to TO 0 0 12 O
sucralfate VB 0 1 0 B-Drug
. . 0 0 12 O

Rabbits NNS 0 1 UNK O
failed VBD 1 1 12 O
to TO 0 0 12 O
maintain VB 0 1 1 O
pregnancy NN 0 1 6 O
when WRB 0 0 12 O
dosed VBN 1 1 14 O
with IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
kg JJ 0 1 18 O
/ NNP 0 0 2 O
day NN 0 1 12 O
fulvestrant JJ 0 1 13 B-Drug
IM NNP 0 1 11 O
( ( 0 0 2 O
twice RB 0 1 12 O
the DT 0 0 12 O
human JJ 0 1 1 O
dose NN 0 1 6 O
on IN 0 0 12 O
BSA NNP 0 0 13 O
) ) 0 0 2 O
during IN 0 0 12 O
the DT 0 0 12 O
period NN 0 1 1 O
of IN 0 0 12 O
organogenesis NN 0 1 UNK O
. . 0 0 12 O

There EX 0 0 12 O
was VBD 1 0 12 O
a DT 0 0 12 O
small JJ 0 1 12 O
decrease NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
clearance NN 0 1 16 O
of IN 0 0 12 O
cetirizine NN 0 1 13 B-Drug
caused VBN 1 1 1 O
by IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
mg NN 0 1 0 O
dose NN 0 1 6 O
of IN 0 0 12 O
theophylline NN 0 1 16 B-Drug
; : 0 0 2 O

clinical JJ 0 1 6 O
implications NNS 1 0 UNK O
are VBP 1 0 12 O
unclear JJ 0 0 1 O
. . 0 0 12 O

No DT 0 0 2 O
formal JJ 0 1 1 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
conducted VBN 1 1 1 O
. . 0 0 12 O

Nelfinavir NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
an DT 0 0 12 O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
CYP9A NNP 0 0 UNK O
( ( 0 0 2 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
9A CD 0 1 UNK O
) ) 0 0 2 O
. . 0 0 12 O

The DT 0 0 2 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
bosentan NN 0 1 13 B-Drug
and CC 0 0 12 O
cyclosporine VB 0 1 14 B-Drug
A NNP 0 0 2 I-Drug
is VBZ 1 0 12 O
contraindicated VBN 1 1 14 O
. . 0 0 12 O

Plasma NNP 0 1 UNK O
concentrations NNS 1 1 13 O
and CC 0 0 12 O
effects NNS 1 1 1 O
potentially RB 0 0 1 O
increased VBD 1 1 1 O
or CC 0 0 12 O
decreased VBN 1 1 1 O
by IN 0 0 12 O
SUSTIVA NNP 0 1 UNK B-Brand
. . 0 0 12 O

This DT 0 0 2 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
with IN 0 0 12 O
Benedict NNP 0 0 UNK O
and CC 0 0 12 O
Fehling NNP 0 0 UNK O
s JJ 0 1 12 O
solutions NNS 1 1 UNK O
but CC 0 0 12 O
not RB 0 1 12 O
with IN 0 0 12 O
the DT 0 0 12 O
glucose JJ 0 1 14 O
enzymatic JJ 0 1 UNK O
test NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
reddish JJ 0 0 3 O
color NN 0 1 3 O
is VBZ 1 0 12 O
due JJ 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
formation NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
nonabsorbable JJ 0 0 UNK O
complex NN 0 1 1 O
between IN 0 0 12 O
cefdinir NN 0 1 UNK B-Drug
or CC 0 0 12 O
its PRP$ 1 0 12 O
breakdown JJ 0 1 1 O
products NNS 1 1 1 O
and CC 0 0 12 O
iron NN 0 1 3 B-Drug
in IN 0 0 12 O
the DT 0 0 12 O
gastrointestinal JJ 0 1 6 O
tract NN 0 1 6 O
. . 0 0 12 O

This DT 0 0 2 O
is VBZ 1 0 12 O
typical JJ 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
interaction NN 0 1 UNK O
of IN 0 0 12 O
meperidine NN 0 1 16 B-Drug
and CC 0 0 12 O
MAOIs NNP 0 1 UNK B-Group
. . 0 0 12 O

Drug NN 0 1 2 O
Interactions NNS 0 1 UNK O
: : 0 0 2 O
The DT 0 0 2 O
use NN 0 1 1 O
of IN 0 0 12 O
ZEMURON NNP 0 1 UNK B-Brand
( ( 0 0 2 O
rocuronium VB 0 1 16 B-Drug
bromide NN 0 1 16 I-Drug
) ) 0 0 2 O
Injection NN 0 1 7 O
before IN 0 1 12 O
succinylcholine NN 0 1 16 B-Drug
for IN 0 0 12 O
the DT 0 0 12 O
purpose NN 0 1 1 O
of IN 0 0 12 O
attenuating VBG 1 1 UNK O
some DT 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
side NN 0 1 3 O
effects NNS 1 1 1 O
of IN 0 0 12 O
succinylcholine NN 0 1 16 B-Drug
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
studied VBN 1 0 1 O
. . 0 0 12 O

Digoxin NN 0 1 0 B-Drug
: : 0 0 2 O
Enoxacin NN 0 1 UNK B-Drug
may MD 0 0 1 O
raise VB 0 0 12 O
serum NN 0 1 14 O
digoxin NN 0 1 14 B-Drug
levels NNS 1 1 1 O
in IN 0 0 12 O
some DT 0 0 12 O
individuals NNS 1 1 1 O
. . 0 0 12 O

Coadministration NN 0 1 UNK O
of IN 0 0 12 O
valdecoxib NN 0 1 13 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
BID NNP 0 0 11 O
( ( 0 0 2 O
day NN 0 1 12 O
9 CD 0 0 2 O
) ) 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
QD NNP 0 1 13 O
( ( 0 0 2 O
days NNS 1 1 12 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
) ) 0 0 2 O
with IN 0 0 12 O
glyburide NN 0 1 16 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
glyburide RB 0 1 16 B-Drug
BID NNP 0 0 11 O
) ) 0 0 2 O
resulted VBD 1 1 1 O
in IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
increase NN 0 1 1 O
in IN 0 0 12 O
glyburide JJ 0 1 16 B-Drug
AUC9 NNP 0 0 UNK O
- : 0 0 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
increase NN 0 1 1 O
in IN 0 0 12 O
glyburide JJ 0 1 16 B-Drug
Cmax NNP 0 1 UNK O
leading VBG 1 1 1 O
to TO 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
decrease NN 0 1 1 O
in IN 0 0 12 O
glucose JJ 0 1 14 O
AUC9 NNP 0 0 UNK O
- : 0 0 2 O
9 CD 0 0 2 O
. . 0 0 12 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interactions NNP 0 1 UNK O
Salicylate NNP 0 1 UNK B-Group
competes VBZ 1 0 UNK O
with IN 0 0 12 O
thyroid JJ 0 1 6 O
hormone NN 0 1 6 O
for IN 0 0 12 O
binding VBG 1 1 1 O
to TO 0 0 12 O
plasma VB 0 1 14 O
proteins NNS 1 1 14 O
which WDT 0 0 12 O
may MD 0 0 1 O
be VB 0 0 12 O
reflected VBN 1 1 UNK O
in IN 0 0 12 O
a DT 0 0 12 O
depressed JJ 0 1 12 O
plasma NN 0 1 14 O
T9 NNP 0 1 13 O
value NN 0 1 1 O
in IN 0 0 12 O
some DT 0 0 12 O
patients NNS 1 1 6 O
; : 0 0 2 O

The DT 0 0 2 O
following JJ 0 1 1 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
have VBP 0 0 12 O
been VBN 1 0 12 O
identified VBN 1 1 1 O
involving VBG 1 1 1 O
NIZORAL NNP 0 1 UNK B-Brand
Tablets NNPS 0 1 0 O
and CC 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
the DT 0 0 12 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
9A9 CD 0 0 UNK O
enzyme NN 0 1 14 O
system NN 0 1 1 O
: : 0 0 2 O
Ketoconazole NNP 0 1 UNK B-Drug
tablets NNS 1 1 3 O
inhibit VBP 0 1 13 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
terfenadine NN 0 1 UNK B-Drug
resulting VBG 1 1 1 O
in IN 0 0 12 O
an DT 0 0 12 O
increased JJ 0 1 1 O
plasma NN 0 1 14 O
concentration NN 0 1 1 O
of IN 0 0 12 O
terfenadine NN 0 1 UNK B-Drug
and CC 0 0 12 O
a DT 0 0 12 O
delay NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
elimination NN 0 1 UNK O
of IN 0 0 12 O
its PRP$ 1 0 12 O
acid JJ 0 1 14 O
metabolite NN 0 1 UNK O
. . 0 0 12 O

In IN 0 0 2 O
addition NN 0 1 1 O
administration NN 0 1 1 O
of IN 0 0 12 O
Sonata NNP 0 1 UNK B-Brand
to TO 0 0 12 O
a DT 0 0 12 O
patient NN 0 1 6 O
taking VBG 1 0 12 O
another DT 0 0 12 O
drug NN 0 1 1 O
that WDT 0 0 12 O
is VBZ 1 0 12 O
highly RB 0 1 1 O
protein JJ 0 1 14 O
bound NN 0 1 12 O
should MD 0 0 12 O
not RB 0 1 12 O
cause VB 0 1 12 O
transient JJ 0 1 1 O
increase NN 0 1 1 O
in IN 0 0 12 O
free JJ 0 1 12 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
the DT 0 0 12 O
other JJ 0 0 12 O
drug NN 0 1 1 O
. . 0 0 12 O

cmaxSS NN 0 0 UNK O
( ( 0 0 2 O
Peak NNP 0 1 2 O
plasma VBZ 0 1 14 O
concentration NN 0 1 1 O
) ) 0 0 2 O

Drugs NNS 0 1 2 O
that WDT 0 0 12 O
are VBP 1 0 12 O
Metabolized VBN 0 1 UNK O
by IN 0 0 12 O
and CC 0 0 12 O
/ NNP 0 0 2 O
or CC 0 0 12 O
Inhibit NNP 0 1 UNK O
Cytochrome NNP 0 1 UNK O
P9 NNP 0 1 UNK O
Enzymes NNP 0 1 7 O
Many NNP 0 0 UNK O
drugs NNS 1 1 6 O
are VBP 1 0 12 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
and CC 0 0 12 O
/ NNP 0 0 2 O
or CC 0 0 12 O
inhibit RB 0 1 13 O
various JJ 0 1 1 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
enzymes VBZ 0 1 14 O
e.g. RB 0 0 UNK O
9D9 CD 0 0 UNK O
9A9 CD 0 0 UNK O
9A9 CD 0 0 UNK O
etc NN 0 1 12 O
. . 0 0 12 O

The DT 0 0 2 O
CNS NNP 0 1 6 O
- : 0 0 2 O
depressant JJ 0 0 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
propoxyphene NN 0 1 16 B-Drug
is VBZ 1 0 12 O
additive JJ 0 1 16 O
with IN 0 0 12 O
that DT 0 0 12 O
of IN 0 0 12 O
other JJ 0 0 12 O
CNS NNP 0 1 6 B-Group
depressants NNS 1 0 13 I-Group
including VBG 1 1 1 O
alcohol NN 0 1 1 B-Drug
. . 0 0 12 O

Dose NNP 0 1 7 O
of IN 0 0 12 O
AED NNP 0 1 UNK B-Group
( ( 0 0 2 O
mg JJ 0 1 0 O
/ NNP 0 0 2 O
day NN 0 1 12 O
) ) 0 0 2 O

Coumarin JJ 0 1 UNK B-Group
Anticoagulants NNS 0 1 UNK I-Group
: : 0 0 2 O
There EX 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
rare JJ 0 1 12 O
reports NNS 1 1 1 O
of IN 0 0 12 O
increased VBN 1 1 1 O
prothrombin NN 0 1 14 O
time NN 0 1 12 O
in IN 0 0 12 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
coumarin JJ 0 1 UNK B-Group
anticoagulants NNS 1 1 13 I-Group
to TO 0 0 12 O
whom WP 0 0 12 O
nifedipine NN 0 1 0 B-Drug
was VBD 1 0 12 O
administered VBN 1 1 1 O
. . 0 0 12 O

9% CD 0 0 UNK O

However RB 0 0 1 O
severe JJ 0 1 6 O
reactions NNS 1 1 1 O
such JJ 0 0 1 O
as IN 1 0 12 O
hypotension NN 0 1 6 O
requiring VBG 1 0 1 O
treatment NN 0 1 6 O
dyspnea NN 0 1 8 O
requiring VBG 1 0 1 O
bronchodilators NNS 1 1 14 B-Group
angioedema VBP 0 1 16 O
or CC 0 0 12 O
generalized VBN 1 1 6 O
urticaria JJ 0 1 13 O
require NN 0 0 1 O
immediate JJ 0 1 1 O
discontinuation NN 0 1 6 O
of IN 0 0 12 O
TAXOL NNP 0 1 UNK B-Brand
and CC 0 0 12 O
aggressive JJ 0 1 1 O
symptomatic JJ 0 1 6 O
therapy NN 0 1 6 O
. . 0 0 12 O

Monitoring NN 0 1 UNK O
of IN 0 0 12 O
plasma JJ 0 1 14 O
phenytoin JJ 0 1 16 B-Drug
concentrations NNS 1 1 13 O
may MD 0 0 1 O
be VB 0 0 12 O
helpful JJ 0 1 12 O
when WRB 0 0 12 O
possible JJ 0 1 1 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
are VBP 1 0 12 O
suspected VBN 1 1 12 O
. . 0 0 12 O

Aminoglutethimide NN 0 1 UNK B-Drug
: : 0 0 2 O
Aminoglutethimide NNP 0 1 UNK B-Drug
may MD 0 0 1 O
diminish VB 0 1 UNK O
adrenal JJ 0 0 6 O
suppression NN 0 1 1 O
by IN 0 0 12 O
corticosteroids NNS 1 1 14 B-Group
. . 0 0 12 O

Therefore RB 0 0 1 O
the DT 0 0 12 O
potential JJ 0 1 1 O
exists NNS 0 1 UNK O
for IN 0 0 12 O
interaction NN 0 1 UNK O
between IN 0 0 12 O
carbamazepine NN 0 1 16 B-Drug
and CC 0 0 12 O
any DT 0 0 12 O
agent NN 0 1 1 O
that WDT 0 0 12 O
induces VBZ 1 1 UNK O
CYP9A9 NNP 0 0 UNK O
. . 0 0 12 O

Because IN 0 0 12 O
dexfenfluramine NN 0 1 UNK B-Drug
is VBZ 1 0 12 O
a DT 0 0 12 O
serotonin JJ 0 1 13 O
releaser NN 0 0 UNK O
and CC 0 0 12 O
reuptake VB 0 1 13 O
inhibitor NN 0 1 14 O
dexfenfluramine NN 0 1 UNK B-Drug
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
a DT 0 0 12 O
MAO NNP 0 1 14 B-Group
inhibitor NN 0 1 14 I-Group
. . 0 0 12 O

In IN 0 0 2 O
some DT 0 0 12 O
patients NNS 1 1 6 O
the DT 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
non JJ 0 1 1 B-Group
- : 0 0 2 O
steroidal NN 0 1 UNK I-Group
anti SYM 0 0 3 I-Group
- : 0 0 2 O
inflammatory JJ 0 1 6 I-Group
agent NN 0 1 1 I-Group
can MD 0 0 12 O
reduce VB 0 0 1 O
the DT 0 0 12 O
diuretic JJ 0 1 14 O
natriuretic JJ 0 1 UNK O
and CC 0 0 12 O
antihypertensive JJ 0 1 14 O
effects NNS 1 1 1 O
of IN 0 0 12 O
loop NN 0 1 3 B-Group
potassium NN 0 1 14 B-Group
- : 0 0 2 O
sparing NN 0 0 6 I-Group
and CC 0 0 12 O
thiazide JJ 0 1 UNK B-Group
diuretics NNS 1 1 14 I-Group
. . 0 0 12 O

Although IN 0 0 12 O
beta SYM 0 1 16 B-Group
- : 0 0 2 O
adrenergic JJ 0 1 UNK I-Group
blockers NNS 1 0 6 I-Group
or CC 0 0 12 O
calcium NN 0 1 14 B-Group
channel NN 0 1 1 I-Group
blockers NNS 1 0 6 I-Group
and CC 0 0 12 O
digoxin NN 0 1 14 B-Drug
may MD 0 0 1 O
be VB 0 0 12 O
useful JJ 0 1 UNK O
in IN 0 0 12 O
combination NN 0 1 1 O
to TO 0 0 12 O
control VB 0 1 1 O
atrial JJ 0 1 8 O
fibrillation NN 0 1 6 O
their PRP$ 0 0 12 O
additive JJ 0 1 16 O
effects NNS 1 1 1 O
on IN 0 0 12 O
AV NNP 0 0 13 O
node JJ 0 1 1 O
conduction NN 0 1 6 O
can MD 0 0 12 O
result VB 0 1 1 O
in IN 0 0 12 O
advanced JJ 0 1 1 O
or CC 0 0 12 O
complete JJ 0 1 1 O
heart NN 0 1 12 O
block NN 0 1 3 O
. . 0 0 12 O

The DT 0 0 2 O
pharmacokinetic JJ 0 1 UNK O
parameters NNS 1 1 1 O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
are VBP 1 0 12 O
not RB 0 1 12 O
significantly RB 0 0 1 O
modified VBN 1 1 16 O
by IN 0 0 12 O
SKELID NNP 0 1 UNK B-Brand
coadministration NN 0 1 UNK O
. . 0 0 12 O

DIAGNOSTIC NNP 0 1 11 O
INTERFERENCE NNP 0 1 UNK O
With IN 0 0 2 O
expected VBN 1 1 12 O
physiologic JJ 0 1 6 O
effects NNS 1 1 1 O
: : 0 0 2 O
Blood NN 0 1 2 O
and CC 0 0 12 O
urine JJ 0 1 6 O
glucose NN 0 1 14 O
levels NNS 1 1 1 O
( ( 0 0 2 O
usually RB 0 1 12 O
only RB 0 1 12 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
a DT 0 0 12 O
predisposition NN 0 1 UNK O
for IN 0 0 12 O
glucose JJ 0 1 14 O
intolerance NN 0 1 6 O
) ) 0 0 2 O
and CC 0 0 12 O
Serum NNP 0 1 7 O
bilirubin NN 0 1 14 O
levels NNS 1 1 1 O
( ( 0 0 2 O
by IN 0 0 12 O
displacement NN 0 1 1 O
from IN 0 0 12 O
albumin JJ 0 1 14 O
binding NN 0 1 1 O
) ) 0 0 2 O
and CC 0 0 12 O
Serum NNP 0 1 7 O
calcium NN 0 1 14 O
levels NNS 1 1 1 O
( ( 0 0 2 O
thiazide IN 0 1 UNK B-Group
diuretics NNS 1 1 14 I-Group
should MD 0 0 12 O
be VB 0 0 12 O
discontinued VBN 1 1 1 O
before IN 0 1 12 O
parathyroid JJ 0 1 14 O
- : 0 0 2 O
function NN 0 1 1 O
tests NNS 1 1 1 O
are VBP 1 0 12 O
carried VBN 1 1 12 O
out IN 0 1 12 O
) ) 0 0 2 O
and CC 0 0 12 O
Serum NNP 0 1 7 O
uric JJ 0 0 14 O
acid NN 0 1 14 O
levels NNS 1 1 1 O
( ( 0 0 2 O
may MD 0 0 1 O
be VB 0 0 12 O
increased VBN 1 1 1 O
) ) 0 0 2 O
Serum NNP 0 1 7 O
magnesium NN 0 1 14 O
potassium NN 0 1 14 O
and CC 0 0 12 O
sodium NN 0 1 14 O
levels NNS 1 1 1 O
( ( 0 0 2 O
may MD 0 0 1 O
be VB 0 0 12 O
decreased VBN 1 1 1 O
; : 0 0 2 O

. . 0 0 12 O

Animal NNP 0 1 UNK O
studies NNS 1 1 1 O
also RB 0 0 12 O
suggest VBP 0 1 1 O
an DT 0 0 12 O
increased JJ 0 1 1 O
potential NN 0 1 1 O
for IN 0 0 12 O
seizures NNS 1 1 6 O
when WRB 0 0 12 O
these DT 0 0 12 O
two CD 0 1 12 O
drugs NNS 1 1 6 O
are VBP 1 0 12 O
given VBN 1 1 12 O
concomitantly RB 0 0 14 O
. . 0 0 12 O

In IN 0 0 2 O
vivo JJ 0 1 13 O
drug NN 0 1 1 O
- : 0 0 2 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
conducted VBN 1 1 1 O
in IN 0 0 12 O
normal JJ 0 1 1 O
volunteer NN 0 1 13 O
subjects NNS 1 1 UNK O
showed VBD 1 1 12 O
that IN 0 0 12 O
terbinafine NN 0 1 16 B-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
affect VB 0 1 1 O
the DT 0 0 12 O
clearance NN 0 1 16 O
of IN 0 0 12 O
antipyrine NN 0 1 UNK B-Drug
or CC 0 0 12 O
digoxin NN 0 1 14 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
most RBS 0 0 12 O
commonly JJ 0 0 UNK O
occurring VBG 1 1 1 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
are VBP 1 0 12 O
listed VBN 1 1 1 O
below IN 0 0 12 O
: : 0 0 2 O
- : 0 0 2 O
Drugs NNS 0 1 2 O
that WDT 0 0 12 O
may MD 0 0 1 O
increase VB 0 1 1 O
plasma NN 0 1 14 O
phenytoin JJ 0 1 16 B-Drug
concentrations NNS 1 1 13 O
include VBP 0 1 1 O
: : 0 0 2 O
acute JJ 0 1 6 O
alcohol NN 0 1 1 B-Drug
intake VB 0 1 3 O
amiodarone NN 0 1 0 B-Drug
chboramphenicol NN 0 0 UNK O
chlordiazepoxide NN 0 1 16 B-Drug
cimetidine NN 0 1 13 B-Drug
diazepam NN 0 1 0 B-Drug
dicumarol NN 0 1 UNK B-Drug
disulfiram NN 0 1 13 B-Drug
estrogens VBZ 0 1 16 B-Group
ethosuximide JJ 0 1 13 B-Drug
fluoxetine NN 0 1 16 B-Drug
H9 NNP 0 0 UNK B-Group
- : 0 0 2 O
antagonists NNS 1 1 13 I-Group
halothane VBP 0 1 13 B-Drug
isoniazid JJ 0 1 13 B-Drug
methylphenidate NN 0 1 16 B-Drug
phenothiazines NNS 1 1 UNK B-Group
phenylbutazone NN 0 1 UNK B-Drug
salicylates VBZ 0 1 13 B-Group
succinimides NNS 0 1 13 B-Group
sulfonamides NNS 1 1 13 B-Group
tolbutamide IN 0 1 UNK B-Drug
trazodone NN 0 1 0 B-Drug

NSAIDs NNP 0 1 UNK B-Group
may MD 0 0 1 O
decrease VB 0 1 1 O
the DT 0 0 12 O
hemodynamic JJ 0 1 8 O
effects NNS 1 1 1 O
of IN 0 0 12 O
hydralazine NN 0 1 14 B-Drug
; : 0 0 2 O

Anticholinergic JJ 0 1 UNK B-Group
agents NNS 1 1 1 I-Group
may MD 0 0 1 O
potentially RB 0 0 1 O
alter VB 0 1 13 O
the DT 0 0 12 O
absorption NN 0 1 1 O
of IN 0 0 12 O
some DT 0 0 12 O
concomitantly RB 0 0 14 O
administered VBN 1 1 1 O
drugs NNS 1 1 6 O
due JJ 0 1 1 O
to TO 0 0 12 O
anticholinergic JJ 0 1 13 O
effects NNS 1 1 1 O
on IN 0 0 12 O
gastrointestinal JJ 0 1 6 O
motility NN 0 1 6 O
. . 0 0 12 O

Motility NN 0 1 UNK O
agents NNS 1 1 1 O

Corticosteroids NNS 0 1 UNK B-Group
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
clearance NN 0 1 16 O
of IN 0 0 12 O
chronic JJ 0 1 6 O
high JJ 0 1 1 O
dose NN 0 1 6 O
aspirin NN 0 1 14 B-Brand
. . 0 0 12 O

Therefore RB 0 0 1 O
when WRB 0 0 12 O
concomitant NN 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
thiabendazole NN 0 1 UNK B-Drug
and CC 0 0 12 O
xanthine JJ 0 1 UNK B-Group
derivatives NNS 1 1 13 I-Group
is VBZ 1 0 12 O
anticipated VBN 1 1 1 O
it PRP 0 0 12 O
may MD 0 0 1 O
be VB 0 0 12 O
necessary JJ 0 0 1 O
to TO 0 0 12 O
monitor VB 0 1 1 O
blood NN 0 1 6 O
levels NNS 1 1 1 O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
reduce VB 0 0 1 O
the DT 0 0 12 O
dosage NN 0 1 0 O
of IN 0 0 12 O
such JJ 0 0 1 O
compounds NNS 1 1 13 O
. . 0 0 12 O

Limited VBN 0 1 2 O
PK NNP 0 0 UNK O
and CC 0 0 12 O
/ NNP 0 0 2 O
or CC 0 0 12 O
PD NNP 0 0 13 O
studies NNS 1 1 1 O
investigating VBG 1 1 UNK O
possible JJ 0 1 1 O
interactions NNS 1 1 UNK O
between IN 0 0 12 O
anagrelide NN 0 1 13 B-Drug
and CC 0 0 12 O
other JJ 0 0 12 O
medicinal JJ 0 0 16 O
products NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
conducted VBN 1 1 1 O
. . 0 0 12 O

This DT 0 0 2 O
suggests VBZ 1 1 1 O
that IN 0 0 12 O
an DT 0 0 12 O
interaction NN 0 1 UNK O
of IN 0 0 12 O
aripiprazole NN 0 1 16 B-Drug
with IN 0 0 12 O
inhibitors NNS 1 1 14 O
or CC 0 0 12 O
inducers NNS 1 1 UNK O
of IN 0 0 12 O
these DT 0 0 12 O
enzymes NNS 1 1 14 O
or CC 0 0 12 O
other JJ 0 0 12 O
factors NNS 1 1 1 O
like IN 0 0 12 O
smoking NN 0 1 12 O
is VBZ 1 0 12 O
unlikely JJ 0 1 12 O
. . 0 0 12 O

In IN 0 0 2 O
addition NN 0 1 1 O
levetiracetam NN 0 1 16 B-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
affect VB 0 1 1 O
the DT 0 0 12 O
in IN 0 0 12 O
vitro JJ 0 1 UNK O
glucuronidation NN 0 1 UNK O
of IN 0 0 12 O
valproic JJ 0 0 16 B-Drug
acid NN 0 1 14 I-Drug
. . 0 0 12 O

Androgens NNS 0 1 UNK B-Group
may MD 0 0 1 O
increase VB 0 1 1 O
sensitivity NN 0 1 1 O
to TO 0 0 12 O
oral JJ 0 1 6 O
anticoagulahts NNS 0 0 UNK O
. . 0 0 12 O

d LS 0 1 16 B-Drug
- : 0 0 2 O
amphetamine NN 0 1 13 I-Drug
with IN 0 0 12 O
desipramine NN 0 1 16 B-Drug
or CC 0 0 12 O
protriptyline NN 0 1 UNK B-Drug
and CC 0 0 12 O
possibly RB 0 1 12 O
other JJ 0 0 12 O
tricyclics NNS 1 1 UNK B-Group
cause VBP 0 1 12 O
striking VBG 1 1 12 O
and CC 0 0 12 O
sustained JJ 0 1 1 O
increases NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
concentration NN 0 1 1 O
of IN 0 0 12 O
d JJ 0 1 16 B-Drug
- : 0 0 2 O
amphetamine NN 0 1 13 I-Drug
in IN 0 0 12 O
the DT 0 0 12 O
brain NN 0 1 6 O
; : 0 0 2 O

Several JJ 0 1 2 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
block VB 0 1 3 O
the DT 0 0 12 O
pharmacologic JJ 0 1 14 O
effects NNS 1 1 1 O
of IN 0 0 12 O
guanethidine JJ 0 1 UNK B-Drug
clonidine NN 0 1 0 B-Drug
or CC 0 0 12 O
similar JJ 0 1 1 O
agents NNS 1 1 1 O
and CC 0 0 12 O
such JJ 0 0 1 O
an DT 0 0 12 O
effect NN 0 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
anticipated VBN 1 1 1 O
with IN 0 0 12 O
CMI NNP 0 0 13 B-Drug
because IN 0 0 12 O
of IN 0 0 12 O
its PRP$ 1 0 12 O
structural JJ 0 1 1 O
similarity NN 0 1 UNK O
to TO 0 0 12 O
other JJ 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
. . 0 0 12 O

The DT 0 0 2 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
a DT 0 0 12 O
potent JJ 0 1 UNK O
CYP9A9 NNP 0 0 UNK O
enzyme NN 0 1 14 O
inducer NN 0 1 UNK O
although IN 0 0 12 O
not RB 0 1 12 O
posing VBG 1 0 UNK O
a DT 0 0 12 O
safety NN 0 1 1 O
concern NN 0 1 1 O
thus RB 0 0 1 O
could MD 0 0 12 O
lead VB 0 1 12 O
to TO 0 0 12 O
ineffectiveness VB 0 1 UNK O
of IN 0 0 12 O
zaleplon NN 0 1 13 B-Drug
. . 0 0 12 O

Ethinyl NNP 0 0 UNK B-Drug
estradiol NN 0 1 13 I-Drug
and CC 0 0 12 O
Norethindrone NN 0 1 UNK B-Drug

Diphenhydramine NNP 0 1 0 B-Drug
hydrochloride NN 0 1 0 I-Drug
has VBZ 1 0 12 O
additive JJ 0 1 16 O
effects NNS 1 1 1 O
with IN 0 0 12 O
alcohol NN 0 1 1 B-Drug
and CC 0 0 12 O
other JJ 0 0 12 O
CNS NNP 0 1 6 B-Group
depressants NNS 1 0 13 I-Group
( ( 0 0 2 O
hypnotics NNS 1 1 13 B-Group
sedatives VBZ 0 1 6 B-Group
tranquilizers NNS 1 1 13 B-Group
etc FW 0 1 12 O
) ) 0 0 2 O
. . 0 0 12 O

Trecator NN 0 1 UNK B-Brand
has VBZ 1 0 12 O
been VBN 1 0 12 O
found VBN 1 1 12 O
to TO 0 0 12 O
temporarily RB 0 0 1 O
raise VB 0 0 12 O
serum JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
isoniazid NN 0 1 13 B-Drug
. . 0 0 12 O

Digitalis NNS 0 1 15 B-Group
: : 0 0 2 O
Immediate NNP 0 1 UNK O
Release NNP 0 1 2 O
Capsules NNP 0 1 0 O
: : 0 0 2 O
Since IN 0 1 2 O
there EX 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
isolated VBN 1 1 1 O
reports NNS 1 1 1 O
of IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
elevated JJ 0 1 1 O
digoxin NN 0 1 14 B-Drug
levels NNS 1 1 1 O
and CC 0 0 12 O
there EX 0 0 12 O
is VBZ 1 0 12 O
a DT 0 0 12 O
possible JJ 0 1 1 O
interaction NN 0 1 UNK O
between IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
and CC 0 0 12 O
nifedipine NN 0 1 0 B-Drug
it PRP 0 0 12 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
that IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
levels NNS 1 1 1 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
when WRB 0 0 12 O
initiating VBG 1 1 1 O
adjusting NN 0 0 1 O
and CC 0 0 12 O
discontinuing VBG 1 1 6 O
nifedipine NN 0 1 0 B-Drug
to TO 0 0 12 O
avoid VB 0 0 12 O
possible JJ 0 1 1 O
over IN 0 1 12 O
- : 0 0 2 O
or CC 0 0 12 O
under IN 0 0 12 O
- : 0 0 2 O
digitalization NN 0 1 UNK O
. . 0 0 12 O

Drugs NNS 0 1 2 O
with IN 0 0 12 O
parasympathomimetic JJ 0 1 UNK O
effects NNS 1 1 1 O
administered VBN 1 1 1 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
cevimeline NN 0 1 13 B-Drug
can MD 0 0 12 O
be VB 0 0 12 O
expected VBN 1 1 12 O
to TO 0 0 12 O
have VB 0 0 12 O
additive JJ 0 1 16 O
effects NNS 1 1 1 O
. . 0 0 12 O

Prednisolone NN 0 1 UNK B-Drug
: : 0 0 2 O
Ethinyl NNP 0 0 UNK B-Drug
estradiol NN 0 1 13 I-Drug
may MD 0 0 1 O
inhibit VB 0 1 13 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
prednisolone NN 0 1 0 B-Drug
leading VBG 1 1 1 O
to TO 0 0 12 O
increased VBN 1 1 1 O
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
. . 0 0 12 O

The DT 0 0 2 O
rate NN 0 1 1 O
of IN 0 0 12 O
metabolism NN 0 1 16 O
and CC 0 0 12 O
the DT 0 0 12 O
leukopenic JJ 0 1 UNK O
activity NN 0 1 1 O
of IN 0 0 12 O
cyclophosphamide NN 0 1 14 B-Drug
reportedly RB 0 0 12 O
are VBP 1 0 12 O
increased VBN 1 1 1 O
by IN 0 0 12 O
chronic JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
high JJ 0 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
phenobarbital NN 0 1 16 B-Drug
. . 0 0 12 O

Nelfinavir NN 0 1 UNK B-Drug

Careful JJ 0 1 UNK O
monitoring NN 0 1 1 O
is VBZ 1 0 12 O
advisable JJ 0 0 UNK O
when WRB 0 0 12 O
GH NNP 0 1 13 B-Drug
is VBZ 1 0 12 O
administered VBN 1 1 1 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
known VBN 1 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
CP9 NNP 0 0 UNK O
liver NN 0 1 6 O
enzymes NNS 1 1 14 O
. . 0 0 12 O

Most JJS 0 0 2 O
who WP 0 0 12 O
take VBP 0 1 12 O
EPA NNP 0 0 UNK B-Drug
supplements NNS 1 1 6 O
and CC 0 0 12 O
the DT 0 0 12 O
above JJ 0 1 12 O
drugs NNS 1 1 6 O
or CC 0 0 12 O
herbs NNS 1 1 UNK O
do VBP 0 0 12 O
not RB 0 1 12 O
suffer VB 0 1 12 O
from IN 0 0 12 O
these DT 0 0 12 O
problems NNS 1 1 1 O
and CC 0 0 12 O
if IN 0 0 12 O
they PRP 0 0 12 O
occur VBP 0 1 1 O
they PRP 0 0 12 O
are VBP 1 0 12 O
rare JJ 0 1 12 O
. . 0 0 12 O

Acetazolamide NNP 0 1 0 B-Drug
decreases VBZ 1 1 UNK O
urinary JJ 0 1 6 O
excretion NN 0 1 14 O
of IN 0 0 12 O
amphetamine NN 0 1 13 B-Drug
and CC 0 0 12 O
may MD 0 0 1 O
enhance VB 0 1 UNK O
the DT 0 0 12 O
magnitude NN 0 1 UNK O
and CC 0 0 12 O
duration NN 0 1 1 O
of IN 0 0 12 O
their PRP$ 0 0 12 O
effect NN 0 1 1 O
. . 0 0 12 O

Interactions NNS 0 1 UNK O
between IN 0 0 12 O
Betaseron NNP 0 1 UNK B-Brand
and CC 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
fully RB 0 0 1 O
evaluated VBN 1 1 1 O
. . 0 0 12 O

No DT 0 0 2 O
drug NN 0 1 1 O
- : 0 0 2 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
in IN 0 0 12 O
human JJ 0 1 1 O
subjects NNS 1 1 UNK O
have VBP 0 0 12 O
been VBN 1 0 12 O
conducted VBN 1 1 1 O
. . 0 0 12 O

Tricyclic JJ 0 0 UNK B-Group
antidepressants NNS 1 1 13 I-Group
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
blunt VB 0 1 3 O
the DT 0 0 12 O
hypotensive JJ 0 1 14 O
effect NN 0 1 1 O
of IN 0 0 12 O
systemic JJ 0 1 6 O
clonidine NN 0 1 0 B-Drug
. . 0 0 12 O
It PRP 0 0 12 O
is VBZ 1 0 12 O
not RB 0 1 12 O
known VBN 1 1 12 O
whether IN 0 0 12 O
the DT 0 0 12 O
concurrent NN 0 1 1 O
use NN 0 1 1 O
of IN 0 0 12 O
these DT 0 0 12 O
agents NNS 1 1 1 O
with IN 0 0 12 O
ALPHAGAN NNP 0 1 0 B-Brand
P NNP 0 1 2 I-Brand
in IN 0 0 12 O
humans NNS 1 1 UNK O
can MD 0 0 12 O
lead VB 0 1 12 O
to TO 0 0 12 O
resulting VBG 1 1 1 O
interference NN 0 1 13 O
with IN 0 0 12 O
the DT 0 0 12 O
IOP NNP 0 1 UNK O
lowering VBG 1 1 UNK O
effect NN 0 1 1 O
. . 0 0 12 O

Corticosteroids NNP 0 1 UNK B-Group
Methylxanthines NNP 0 1 UNK B-Group
and CC 0 0 12 O
Diuretics NNPS 0 1 UNK B-Group
: : 0 0 2 O
Concomitant JJ 0 1 UNK O
treatment NN 0 1 6 O
with IN 0 0 12 O
xanthine JJ 0 1 UNK B-Group
derivatives NNS 1 1 13 I-Group
steroids NNS 1 1 6 B-Group
or CC 0 0 12 O
diuretics NNS 1 1 14 B-Group
may MD 0 0 1 O
potentiate VB 0 0 UNK O
a DT 0 0 12 O
possible JJ 0 1 1 O
hypokalemic JJ 0 1 8 O
effect NN 0 1 1 O
of IN 0 0 12 O
beta9 NN 0 0 UNK B-Group
- : 0 0 2 O
agonists NNS 1 1 UNK I-Group
. . 0 0 12 O

During IN 0 0 2 O
maintenance NN 0 1 1 O
of IN 0 0 12 O
anesthesia NN 0 1 6 O
or CC 0 0 12 O
sedation NN 0 1 6 O
the DT 0 0 12 O
rate NN 0 1 1 O
of IN 0 0 12 O
DIPRIVAN NNP 0 1 UNK B-Brand
Injectable NNP 0 1 UNK O
Emulsion NNP 0 1 UNK O
administration NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
adjusted VBN 1 1 1 O
according VBG 1 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
desired VBN 1 1 1 O
level NN 0 1 1 O
of IN 0 0 12 O
anesthesia NN 0 1 6 O
or CC 0 0 12 O
sedation NN 0 1 6 O
and CC 0 0 12 O
may MD 0 0 1 O
be VB 0 0 12 O
reduced VBN 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
presence NN 0 1 1 O
of IN 0 0 12 O
supplemental JJ 0 1 1 O
analgesic JJ 0 1 13 B-Group
agents NNS 1 1 1 I-Group
( ( 0 0 2 O
eg RB 0 1 UNK O
nitrous JJ 0 1 UNK B-Drug
oxide NN 0 1 14 I-Drug
or CC 0 0 12 O
opioids NNS 0 1 14 B-Group
) ) 0 0 2 O
. . 0 0 12 O

Due JJ 0 1 2 O
to TO 0 0 12 O
a DT 0 0 12 O
theoretical JJ 0 1 UNK O
risk NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
pharmacodynamic JJ 0 1 UNK O
interaction NN 0 1 UNK O
use NN 0 1 1 O
of IN 0 0 12 O
ergotamine JJ 0 1 UNK B-Drug
- : 0 0 2 O
containing NN 0 1 1 O
or CC 0 0 12 O
ergot VB 0 1 UNK B-Group
- : 0 0 2 O
type NN 0 1 1 I-Group
medications NNS 1 1 6 I-Group
( ( 0 0 2 O
like IN 0 0 12 O
dihydroergotamine NN 0 1 UNK B-Drug
or CC 0 0 12 O
methysergide NN 0 1 UNK B-Drug
) ) 0 0 2 O
and CC 0 0 12 O
FROVA NNP 0 1 UNK B-Brand
within IN 0 0 1 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
of IN 0 0 12 O
each DT 0 0 12 O
other JJ 0 0 12 O
should MD 0 0 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
( ( 0 0 2 O
see VB 0 1 12 O
a DT 0 0 12 O
href= JJ 0 0 UNK O
frova_od.htm NN 0 1 UNK O
# # 0 0 2 O
CI NNP 0 1 UNK O
CONTRAINDICATIONS NNP 0 1 0 O
) ) 0 0 2 O
. . 0 0 12 O

Lithium NNP 0 1 UNK B-Drug
- : 0 0 2 O
Coadministration NN 0 1 UNK O
of IN 0 0 12 O
racemic JJ 0 1 14 O
citalopram NN 0 1 16 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
) ) 0 0 2 O
and CC 0 0 12 O
lithium NN 0 1 16 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mmol NNS 0 1 13 O
/ JJ 0 0 2 O
day NN 0 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
) ) 0 0 2 O
had VBD 1 0 12 O
no DT 0 0 12 O
significant JJ 0 1 1 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
citalopram NN 0 1 16 B-Drug
or CC 0 0 12 O
lithium NN 0 1 16 B-Drug
. . 0 0 12 O

This DT 0 0 2 O
could MD 0 0 12 O
lead VB 0 1 12 O
to TO 0 0 12 O
decreased JJ 0 1 1 O
salicylate NN 0 1 13 B-Group
serum NN 0 1 14 O
levels NNS 1 1 1 O
or CC 0 0 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
salicylate JJ 0 1 13 B-Group
toxicity NN 0 1 6 O
when WRB 0 0 12 O
corticosteroid NN 0 1 UNK B-Drug
is VBZ 1 0 12 O
withdrawn VBN 1 1 1 O
. . 0 0 12 O

Accordingly RB 0 0 1 O
when WRB 0 0 12 O
diflunisal NN 0 1 13 B-Drug
is VBZ 1 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
oral JJ 0 1 6 O
anticoagulants NNS 1 1 13 B-Group
the DT 0 0 12 O
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
should MD 0 0 12 O
be VB 0 0 12 O
closely RB 0 0 1 O
monitored VBN 1 1 1 O
during IN 0 0 12 O
and CC 0 0 12 O
for IN 0 0 12 O
several JJ 0 1 12 O
days NNS 1 1 12 O
after IN 0 0 12 O
concomitant JJ 0 1 6 O
drug NN 0 1 1 O
administration NN 0 1 1 O
. . 0 0 12 O

Therefore RB 0 0 1 O
if IN 0 0 12 O
concomitant JJ 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
these DT 0 0 12 O
agents NNS 1 1 1 O
is VBZ 1 0 12 O
indicated JJ 0 1 1 O
because IN 0 0 12 O
of IN 0 0 12 O
demonstrated JJ 0 0 1 O
hypokalemia NN 0 1 14 O
they PRP 0 0 12 O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
with IN 0 0 12 O
caution NN 0 0 1 O
and CC 0 0 12 O
with IN 0 0 12 O
frequent JJ 0 1 1 O
monitoring NN 0 1 1 O
of IN 0 0 12 O
serum JJ 0 1 14 O
potassium NN 0 1 14 O
. . 0 0 12 O

Interactions NNS 0 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
drugs NNS 1 1 6 O
listed VBN 1 1 1 O
below RB 0 0 12 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
with IN 0 0 12 O
azithromycin NN 0 1 0 B-Drug
; : 0 0 2 O

Currently RB 0 1 2 O
there EX 0 0 12 O
are VBP 1 0 12 O
no DT 0 0 12 O
safety NN 0 1 1 O
and CC 0 0 12 O
efficacy NN 0 1 UNK O
data NNS 0 1 1 O
available JJ 0 1 1 O
from IN 0 0 12 O
the DT 0 0 12 O
use NN 0 1 1 O
of IN 0 0 12 O
this DT 0 0 12 O
combination NN 0 1 1 O
. . 0 0 12 O

therefore RB 0 0 1 O
periodic JJ 0 1 1 O
liver NN 0 1 6 O
function NN 0 1 1 O
testing VBG 1 1 1 O
( ( 0 0 2 O
transaminases NNS 1 1 14 O
bilirubin NN 0 1 14 O
and CC 0 0 12 O
alkaline JJ 0 1 14 O
phosphatase NN 0 1 14 O
) ) 0 0 2 O
should MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
. . 0 0 12 O

Theophylline NN 0 1 UNK B-Drug
: : 0 0 2 O
Ethinyl NNP 0 0 UNK B-Drug
estradiol NN 0 1 13 I-Drug
may MD 0 0 1 O
inhibit VB 0 1 13 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
theophylline NN 0 1 16 B-Drug
leading VBG 1 1 1 O
to TO 0 0 12 O
increased VBN 1 1 1 O
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
. . 0 0 12 O

Antihypertensive JJ 0 1 7 B-Group
Medications NNS 0 1 7 I-Group
and CC 0 0 12 O
Vasodilators NNS 0 1 UNK B-Group
: : 0 0 2 O
The DT 0 0 2 O
following JJ 0 1 1 O
adverse JJ 0 0 1 O
events NNS 1 1 12 O
were VBD 1 0 12 O
experienced VBN 1 0 12 O
more JJR 0 1 12 O
commonly RB 0 0 UNK O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
concomitant JJ 0 1 6 O
antihypertensive JJ 0 1 14 B-Group
medications NNS 1 1 6 I-Group
or CC 0 0 12 O
vasodilators NNS 1 1 13 B-Group
( ( 0 0 2 O
n JJ 0 1 12 O
= NNP 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
compared VBN 1 1 1 O
to TO 0 0 12 O
patients NNS 1 1 6 O
not RB 0 1 12 O
receiving VBG 1 1 1 O
these DT 0 0 12 O
concomitant JJ 0 1 6 O
drugs NNS 1 1 6 O
( ( 0 0 2 O
n JJ 0 1 12 O
= NNP 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
: : 0 0 2 O
hypotension NN 0 1 6 O
9 CD 0 0 2 O
% NN 0 0 18 O
vs JJ 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
myocardial JJ 0 1 6 O
infarction NN 0 1 6 O
9 CD 0 0 2 O
% NN 0 0 18 O
vs JJ 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
serious JJ 0 1 12 O
pneumonia NN 0 1 6 O
9 CD 0 0 2 O
% NN 0 0 18 O
vs JJ 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
serious JJ 0 1 12 O
falls VBZ 1 1 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
vs JJ 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
bone NN 0 1 6 O
and CC 0 0 12 O
joint JJ 0 1 1 O
injuries NNS 1 1 6 O
9 CD 0 0 2 O
% NN 0 0 18 O
vs JJ 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

These DT 0 0 1 O
reactions NNS 1 1 1 O
include VBP 0 1 1 O
fever JJ 0 1 6 O
chills NNS 1 1 6 O
nausea IN 0 1 6 O
vomiting VBG 1 1 6 O
pruritus NN 0 1 8 O
rash NN 0 1 6 O
diarrhea NN 0 1 6 O
hypotension NN 0 1 6 O
edema NN 0 1 6 O
and CC 0 0 12 O
oliguria NN 0 1 8 O
. . 0 0 12 O

Diabetics NNS 0 1 UNK O
who WP 0 0 12 O
take VBP 0 1 12 O
EPA NNP 0 0 UNK B-Drug
supplements NNS 1 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
by IN 0 0 12 O
their PRP$ 0 0 12 O
physicians NNS 1 1 6 O
. . 0 0 12 O

HMG NNP 0 0 UNK B-Drug
- : 0 0 2 O
CoA NNP 0 0 UNK I-Drug
Reductase NNP 0 1 UNK I-Drug
Inhibitors NNS 0 1 7 I-Drug
: : 0 0 2 O
Simvastatin NNP 0 1 0 B-Drug
( ( 0 0 2 O
CYP9A9 NNP 0 0 UNK B-Drug
substrate NN 0 1 UNK O
) ) 0 0 2 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
amiodarone NN 0 1 0 B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
reports NNS 1 1 1 O
of IN 0 0 12 O
myopathy JJ 0 1 8 O
/ JJ 0 0 2 O
rhabdomyolysis NN 0 1 8 O
. . 0 0 12 O

Drugs NNS 0 1 2 O
Metabolized VBN 0 1 UNK O
by IN 0 0 12 O
P9IID9 NNP 0 0 UNK O
A NNP 0 0 2 O
subset NN 0 1 UNK O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
to TO 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
of IN 0 0 12 O
the DT 0 0 12 O
population NN 0 1 13 O
has VBZ 1 0 12 O
reduced VBN 1 1 1 O
activity NN 0 1 1 O
of IN 0 0 12 O
certain JJ 0 1 1 O
drug NN 0 1 1 O
metabolizing VBG 1 0 UNK O
enzymes NNS 1 1 14 O
such JJ 0 0 1 O
as IN 1 0 12 O
the DT 0 0 12 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
isoenzyme NN 0 1 13 O
P9IID9 NNP 0 0 UNK O
. . 0 0 12 O

Cimetidine NN 0 1 0 B-Drug

Immunosuppressive JJ 0 1 UNK B-Group
Drugs NNP 0 1 2 I-Group
Fibric NNP 0 0 UNK B-Group
Acid NNP 0 1 2 I-Group
Derivatives NNP 0 1 UNK I-Group
Niacin NNP 0 1 0 B-Drug
( ( 0 0 2 O
Nicotinic NNP 0 1 UNK B-Drug
Acid NNP 0 1 2 I-Drug
Erythromycin NNP 0 1 0 B-Drug
Azole NNP 0 1 UNK B-Group
Antifungals NNS 0 1 UNK I-Group
: : 0 0 2 O
Skeletal JJ 0 1 UNK O
Muscle NNP 0 1 2 O
. . 0 0 12 O

Catecholamine NNP 0 1 UNK O
- : 0 0 2 O
depleting NN 0 1 UNK O
drugs NNS 1 1 6 O
( ( 0 0 2 O
eg FW 0 1 UNK O
reserpine NN 0 1 UNK B-Drug
) ) 0 0 2 O
may MD 0 0 1 O
have VB 0 0 12 O
an DT 0 0 12 O
additive JJ 0 1 16 O
effect NN 0 1 1 O
when WRB 0 0 12 O
given VBN 1 1 12 O
with IN 0 0 12 O
beta JJ 0 1 16 B-Group
- : 0 0 2 O
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
. . 0 0 12 O

macrolide NN 0 1 UNK B-Group
antibiotics NNS 1 1 6 I-Group
e.g. VBP 0 0 UNK O
erythromycin NN 0 1 0 B-Drug
; : 0 0 2 O

- : 0 0 2 O
Reduced VBN 0 1 UNK O
response NN 0 1 1 O
to TO 0 0 12 O
metyrapone CD 0 1 13 O
test NN 0 1 1 O

The DT 0 0 2 O
clinical JJ 0 1 6 O
relevance NN 0 1 UNK O
of IN 0 0 12 O
this DT 0 0 12 O
interaction NN 0 1 UNK O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
established VBN 1 1 1 O
. . 0 0 12 O

Non NNP 0 1 2 B-Drug
- : 0 0 2 O
pegylated VBD 0 0 UNK I-Drug
interferon NN 0 1 14 I-Drug
alfa NN 0 1 16 I-Drug
- : 0 0 2 O
9a CD 0 1 UNK I-Drug
treatment NN 0 1 6 O
of IN 0 0 12 O
pregnant JJ 0 1 13 O
Rhesus NNP 0 1 UNK O
monkeys NN 1 1 UNK O
at IN 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
times NNS 1 1 12 O
the DT 0 0 12 O
human JJ 0 1 1 O
weekly JJ 0 1 12 O
dose NN 0 1 6 O
resulted VBD 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
statistically RB 0 1 1 O
significant JJ 0 1 1 O
increase NN 0 1 1 O
in IN 0 0 12 O
abortions NNS 1 1 UNK O
. . 0 0 12 O

Anticoagulants NNS 0 1 UNK B-Group
: : 0 0 2 O
While IN 0 0 12 O
studies NNS 1 1 1 O
have VBP 0 0 12 O
not RB 0 1 12 O
shown VBN 1 1 1 O
diclofenac NN 0 1 16 B-Drug
to TO 0 0 12 O
interact VB 0 0 UNK O
with IN 0 0 12 O
anticoagulants NNS 1 1 13 B-Group
of IN 0 0 12 I-Group
the DT 0 0 12 I-Group
warfarin NN 0 1 14 I-Group
type NN 0 1 1 I-Group
caution NN 0 0 1 O
should MD 0 0 12 O
be VB 0 0 12 O
exercised VBN 1 1 1 O
nonetheless RB 0 0 UNK O
since IN 0 1 12 O
interactions NNS 1 1 UNK O
have VBP 0 0 12 O
been VBN 1 0 12 O
seen VBN 1 1 12 O
with IN 0 0 12 O
other JJ 0 0 12 O
NSAIDs NNP 0 1 UNK B-Group
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
not RB 0 1 12 O
known VBN 1 1 12 O
whether IN 0 0 12 O
other JJ 0 0 12 O
progestational JJ 0 0 UNK B-Group
contraceptives NNS 1 1 13 I-Group
such JJ 0 0 1 O
as IN 1 0 12 O
implants NNS 1 1 6 O
and CC 0 0 12 O
injectables NNS 0 1 UNK O
are VBP 1 0 12 O
adequate JJ 0 1 1 O
methods NNS 1 1 1 O
of IN 0 0 12 O
contraception NN 0 1 13 O
during IN 0 0 12 O
acitretin JJ 0 1 13 B-Drug
therapy NN 0 1 6 O
. . 0 0 12 O

Marked VBN 0 1 2 O
symptomatic JJ 0 1 6 O
orthostatic JJ 0 1 8 O
hypotension NN 0 1 6 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
when WRB 0 0 12 O
calcium NN 0 1 14 B-Group
channel NN 0 1 1 I-Group
blockers NNS 1 0 6 I-Group
and CC 0 0 12 O
organic JJ 0 1 13 O
nitrates NNS 1 1 14 B-Group
were VBD 1 0 12 O
used VBN 1 1 12 O
in IN 0 0 12 O
combination NN 0 1 1 O
. . 0 0 12 O

Examples NNS 0 1 UNK O
of IN 0 0 12 O
Drugs NNP 0 1 2 O
in IN 0 0 12 O
Which NNP 0 0 UNK O
Plasma NNP 0 1 UNK O
Concentrations NNP 0 1 UNK O
May NNP 0 1 2 O
Be NNP 0 0 UNK O
Increased VBN 0 1 7 O
By IN 0 0 2 O
Co NNP 0 1 2 O
- : 0 0 2 O
administration NN 0 1 1 O
With IN 0 0 2 O
Nevirapine NNP 0 1 UNK B-Drug

Three CD 0 1 2 O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
have VBP 0 0 12 O
investigated VBN 1 1 1 O
Simulect NNP 0 1 UNK B-Brand
use NN 0 1 1 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
triple JJ 0 1 3 O
- : 0 0 2 O
therapy NN 0 1 6 O
regimens NNS 1 1 UNK O
. . 0 0 12 O

Phenytoin NN 0 1 0 B-Drug
: : 0 0 2 O
DIFLUCAN NN 0 1 UNK B-Brand
increases VBZ 1 1 1 O
the DT 0 0 12 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
. . 0 0 12 O

HIV NNP 0 1 6 B-Group
Protease NNP 0 1 UNK I-Group
Inhibitors NNS 0 1 7 I-Group
: : 0 0 2 O
The DT 0 0 2 O
effect NN 0 1 1 O
of IN 0 0 12 O
amprenavir NN 0 1 13 B-Drug
on IN 0 0 12 O
total JJ 0 1 1 O
drug NN 0 1 1 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
other JJ 0 0 12 O
HIV NNP 0 1 6 B-Group
protease NN 0 1 13 I-Group
inhibitors NNS 1 1 14 I-Group
in IN 0 0 12 O
subjects NNS 1 1 UNK O
receiving VBG 1 1 1 O
both DT 0 0 12 O
agents NNS 1 1 1 O
was VBD 1 0 12 O
evaluated VBN 1 1 1 O
using VBG 1 1 1 O
comparisons NNS 1 1 1 O
to TO 0 0 12 O
historical JJ 0 1 1 O
data NNS 0 1 1 O
. . 0 0 12 O

May NNP 0 1 2 O
interact NN 0 0 UNK O
with IN 0 0 12 O
wthionamide NN 0 0 UNK O
( ( 0 0 2 O
Trecator NNP 0 1 UNK B-Brand
- : 0 0 2 O
SC NN 0 1 2 I-Brand
) ) 0 0 2 O
and CC 0 0 12 O
isoniazid NN 0 1 13 B-Drug
( ( 0 0 2 O
Nydrazid NNP 0 1 UNK B-Brand
) ) 0 0 2 O
. . 0 0 12 O

Digoxin NN 0 1 0 B-Drug
: : 0 0 2 O
Digoxin NN 0 1 0 B-Drug
concentrations NNS 1 1 13 O
are VBP 1 0 12 O
increased VBN 1 1 1 O
by IN 0 0 12 O
about RB 0 1 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
when WRB 0 0 12 O
digoxin NN 0 1 14 B-Drug
and CC 0 0 12 O
carvedilol NN 0 1 16 B-Drug
are VBP 1 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
. . 0 0 12 O

Non NNP 0 1 2 B-Group
- : 0 0 2 O
steroidal NN 0 1 UNK I-Group
Anti NNP 0 0 UNK I-Group
- : 0 0 2 O
inflammatory NN 0 1 6 I-Group
Agents NNS 0 1 2 I-Group
: : 0 0 2 O
In IN 0 0 2 O
some DT 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
compromised JJ 0 0 1 O
renal JJ 0 1 6 O
function NN 0 1 1 O
who WP 0 0 12 O
are VBP 1 0 12 O
being VBG 1 0 12 O
treated VBN 1 1 1 O
with IN 0 0 12 O
nonsteroidal JJ 0 0 14 B-Group
anti SYM 0 0 3 I-Group
- : 0 0 2 O
inflammatory NN 0 1 6 I-Group
drugs NNS 1 1 6 I-Group
the DT 0 0 12 O
co NN 0 1 12 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
enalapril NN 0 1 0 B-Drug
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
further JJ 0 1 1 O
deterioration NN 0 1 1 O
of IN 0 0 12 O
renal JJ 0 1 6 O
function NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
use NN 0 1 1 O
of IN 0 0 12 O
ROMAZICON NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
not RB 0 1 12 O
recommended VBN 1 1 1 O
in IN 0 0 12 O
epileptic JJ 0 1 13 O
patients NNS 1 1 6 O
who WP 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
receiving VBG 1 1 1 O
benzodiazepine NN 0 1 14 O
treatment NN 0 1 6 O
for IN 0 0 12 O
a DT 0 0 12 O
prolonged JJ 0 1 6 O
period NN 0 1 1 O
. . 0 0 12 O

Monoamine NNP 0 1 UNK B-Group
oxidase NN 0 1 13 I-Group
inhibitors NNS 1 1 14 I-Group
or CC 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
may MD 0 0 1 O
potentiate VB 0 0 UNK O
the DT 0 0 12 O
action NN 0 1 13 O
of IN 0 0 12 O
sympathomimetic JJ 0 1 13 B-Group
amines NNS 1 1 13 I-Group
. . 0 0 12 O

Clarithromycin NNP 0 1 UNK B-Drug
exposure NN 0 1 1 O
was VBD 1 0 12 O
significantly RB 0 0 1 O
decreased VBN 1 1 1 O
by IN 0 0 12 O
nevirapine NN 0 1 13 B-Drug
; : 0 0 2 O

Geriatric NNP 0 1 7 O
Use NNP 0 1 2 O
Younger NNP 0 1 UNK O
patients NNS 1 1 6 O
have VBP 0 0 12 O
higher JJR 1 1 1 O
virologic JJ 0 1 UNK O
response NN 0 1 1 O
rates NNS 1 1 1 O
than IN 0 0 12 O
older JJR 1 1 12 O
patients NNS 1 1 6 O
. . 0 0 12 O

Increased VBN 0 1 7 O
thyroid JJ 0 1 6 O
- : 0 0 2 O
binding NN 0 1 1 O
globulin NN 0 1 14 O
( ( 0 0 2 O
TBG NNP 0 1 UNK O
) ) 0 0 2 O
levels NNS 1 1 1 O
leading VBG 1 1 1 O
to TO 0 0 12 O
increased VBN 1 1 1 O
circulating VBG 1 1 13 O
total JJ 0 1 1 O
thyroid JJ 0 1 6 O
hormone NN 0 1 6 O
levels NNS 1 1 1 O
as IN 1 0 12 O
measured VBN 1 1 1 O
by IN 0 0 12 O
protein NN 0 1 14 O
- : 0 0 2 O
bound NN 0 1 12 O
iodine NN 0 1 14 B-Drug
( ( 0 0 2 O
PBI NNP 0 1 UNK O
) ) 0 0 2 O
T9 NNP 0 1 13 O
levels NNS 1 1 1 O
( ( 0 0 2 O
by IN 0 0 12 O
column NN 0 1 1 O
or CC 0 0 12 O
by IN 0 0 12 O
radioimmunoassay NN 0 1 UNK O
) ) 0 0 2 O
or CC 0 0 12 O
T9 NNP 0 1 13 O
levels NNS 1 1 1 O
by IN 0 0 12 O
radioimmunoassay NN 0 1 UNK O
. . 0 0 12 O

Dantrium NN 0 1 UNK B-Brand
is VBZ 1 0 12 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
the DT 0 0 12 O
liver NN 0 1 6 O
and CC 0 0 12 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
theoretically RB 0 0 UNK O
possible JJ 0 1 1 O
that IN 0 0 12 O
its PRP$ 1 0 12 O
metabolism NN 0 1 16 O
may MD 0 0 1 O
be VB 0 0 12 O
enhanced VBN 1 1 1 O
by IN 0 0 12 O
drugs NNS 1 1 6 O
known VBN 1 1 12 O
to TO 0 0 12 O
induce VB 0 1 6 O
hepatic JJ 0 1 14 O
microsomal NN 0 1 UNK O
enzymes NNS 1 1 14 O
. . 0 0 12 O

Phenytoin NN 0 1 0 B-Drug
: : 0 0 2 O
Population NNP 0 1 UNK O
pharmacokinetic JJ 0 1 UNK O
analyses NNS 1 1 UNK O
indicate VBP 0 0 1 O
that IN 0 0 12 O
tiagabine JJ 0 1 13 B-Drug
clearance NN 0 1 16 O
is VBZ 1 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
greater JJR 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
phenytoin NN 0 1 16 B-Drug
with IN 0 0 12 O
or CC 0 0 12 O
without IN 0 0 12 O
other JJ 0 0 12 O
enzyme JJ 0 1 14 O
- : 0 0 2 O
inducing NN 0 1 6 O
AEDs NNP 0 1 UNK B-Group
. . 0 0 12 O

Decreases NNS 0 1 UNK O
in IN 0 0 12 O
TBg NNP 0 1 UNK O
concentrations NNS 1 1 13 O
are VBP 1 0 12 O
observed VBN 1 1 1 O
in IN 0 0 12 O
nephrosis NN 0 1 13 O
acromegaly NN 0 1 13 O
and CC 0 0 12 O
after IN 0 0 12 O
androgen NN 0 1 13 B-Group
or CC 0 0 12 O
corticosteroid JJ 0 1 UNK B-Group
therapy NN 0 1 6 O
. . 0 0 12 O

As IN 0 0 2 O
a DT 0 0 12 O
moderate JJ 0 1 1 O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
aprepitant NN 0 1 13 B-Drug
can MD 0 0 12 O
increase VB 0 1 1 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
coadministered JJ 0 0 UNK O
medicinal JJ 0 0 16 O
products NNS 1 1 1 O
that WDT 0 0 12 O
are VBP 1 0 12 O
metabolized VBN 1 1 UNK O
through IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
. . 0 0 12 O

quinidine NN 0 1 16 B-Drug
; : 0 0 2 O

As IN 0 0 2 O
a DT 0 0 12 O
false JJ 0 1 13 O
- : 0 0 2 O
negative JJ 0 1 1 O
result NN 0 1 1 O
may MD 0 0 1 O
occur VB 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
ferricyanide JJ 0 1 UNK O
test NN 0 1 1 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
that IN 0 0 12 O
either CC 0 1 12 O
the DT 0 0 12 O
glucose JJ 0 1 14 O
oxidase NN 0 1 13 O
or CC 0 0 12 O
hexokinase NN 0 1 UNK O
method NN 0 1 13 O
be VB 0 0 12 O
used VBN 1 1 12 O
to TO 0 0 12 O
determine VB 0 0 1 O
blood NN 0 1 6 O
/ NNP 0 0 2 O
plasma NN 0 1 14 O
glucose NN 0 1 14 O
levels NNS 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
cefditoren JJ 0 1 UNK B-Drug
pivoxil NN 0 0 UNK I-Drug
. . 0 0 12 O

Effect NN 0 1 UNK O
of IN 0 0 12 O
aprepitant NN 0 1 13 B-Drug
on IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
other JJ 0 0 12 O
agents NNS 1 1 1 O

with IN 0 0 12 O
sucralfate NN 0 1 0 B-Drug
; : 0 0 2 O

For IN 0 0 2 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
monoamine JJ 0 1 13 B-Group
oxidase NN 0 1 13 I-Group
inhibitors NNS 1 1 14 I-Group
see VBP 0 1 12 O
CONTRAINDICATIONS NNP 0 1 0 O
. . 0 0 12 O

The DT 0 0 2 O
binding NN 0 1 1 O
of IN 0 0 12 O
thyroxine NN 0 1 14 O
by IN 0 0 12 O
thyroxine JJ 0 1 14 O
- : 0 0 2 O
binding NN 0 1 1 O
prealbumin NN 0 1 UNK O
( ( 0 0 2 O
TBPA NNP 0 1 UNK O
) ) 0 0 2 O
is VBZ 1 0 12 O
inhibited VBN 1 1 13 O
by IN 0 0 12 O
salicylates NNS 1 1 13 B-Group

Efavirenz NNP 0 1 UNK B-Drug

Anticonvulsants NNS 0 1 UNK B-Group
( ( 0 0 2 O
carbamazepine JJ 0 1 16 B-Drug
felbamate NN 0 1 13 B-Drug
phenobarbital JJ 0 1 16 B-Drug
phenytoin NN 0 1 16 B-Drug
topiramate NN 0 1 16 B-Drug
) ) 0 0 2 O
: : 0 0 2 O
Increase VB 0 1 2 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
ethinyl JJ 0 0 13 B-Drug
estradiol NN 0 1 13 I-Drug
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
some DT 0 0 12 O
progestins NNS 1 1 UNK B-Group
leading VBG 1 1 1 O
to TO 0 0 12 O
possible JJ 0 1 1 O
decrease NN 0 1 1 O
in IN 0 0 12 O
contraceptive JJ 0 1 13 O
effectiveness NN 0 1 UNK O
. . 0 0 12 O

Patients NNS 0 1 7 O
who WP 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
treated VBN 1 1 1 O
with IN 0 0 12 O
MAO NNP 0 1 14 B-Group
inhibitors NNS 1 1 14 I-Group
within IN 0 0 1 O
two CD 0 1 12 O
to TO 0 0 12 O
three CD 0 1 12 O
weeks NNS 1 1 12 O
prior RB 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
dopamine JJ 0 1 14 B-Drug
HCl NNP 0 0 14 I-Drug
should MD 0 0 12 O
receive VB 0 1 1 O
initial JJ 0 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
dopamine NN 0 1 14 B-Drug
HCl NNP 0 0 14 I-Drug
no RB 0 0 12 O
greater JJR 1 1 1 O
than IN 0 0 12 O
one CD 0 1 12 O
- : 0 0 2 O
tenth NN 0 1 12 O
( ( 0 0 2 O
9 CD 0 0 2 O
/ RB 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
of IN 0 0 12 O
the DT 0 0 12 O
usual JJ 0 1 12 O
dose NN 0 1 6 O
. . 0 0 12 O

Because IN 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
serious JJ 0 1 12 O
ventricular JJ 0 1 8 O
arrhythmias NN 1 1 6 O
and CC 0 0 12 O
sudden JJ 0 1 12 O
death NN 0 1 12 O
potentially RB 0 0 1 O
associated VBN 1 1 1 O
with IN 0 0 12 O
elevated JJ 0 1 1 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
thioridazine NN 0 1 13 B-Drug
Duloxetine NNP 0 1 0 B-Drug
and CC 0 0 12 O
thioridazine NN 0 1 13 B-Drug
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
. . 0 0 12 O

Concomitant JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
drugs NNS 1 1 6 O
known VBN 1 1 12 O
to TO 0 0 12 O
inhibit VB 0 1 13 O
the DT 0 0 12 O
activity NN 0 1 1 O
of IN 0 0 12 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
isozymes NNS 0 1 UNK O
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
plasma JJ 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
clozapine NN 0 1 13 B-Drug
. . 0 0 12 O

Ganciclovir NN 0 1 UNK B-Drug
: : 0 0 2 O
The DT 0 0 2 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
foscarnet NN 0 1 16 B-Drug
and CC 0 0 12 O
ganciclovir NN 0 1 14 B-Drug
were VBD 1 0 12 O
not RB 0 1 12 O
altered VBN 1 1 1 O
in IN 0 0 12 O
9 CD 0 0 2 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
either CC 0 1 12 O
concomitant JJ 0 1 6 O
therapy NN 0 1 6 O
or CC 0 0 12 O
daily JJ 0 1 12 O
alternating VBG 1 1 3 O
therapy NN 0 1 6 O
for IN 0 0 12 O
maintenance NN 0 1 1 O
of IN 0 0 12 O
CMV NNP 0 0 14 O
disease NN 0 1 6 O
. . 0 0 12 O

9 CD 0 0 2 O
minutes NNS 1 1 12 O
( ( 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
n=9 NN 0 1 UNK O
) ) 0 0 2 O
without IN 0 0 12 O
succinylcholine NN 0 1 16 B-Drug
. . 0 0 12 O

This DT 0 0 2 O
response NN 0 1 1 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
attributed VBN 1 1 1 O
to TO 0 0 12 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
renal JJ 0 1 6 O
prostaglandin NN 0 1 13 O
synthesis NN 0 1 UNK O
. . 0 0 12 O

Reductions NNS 0 1 UNK O
in IN 0 0 12 O
serum NN 0 1 14 O
endogenous JJ 0 1 14 O
vitamin NN 0 1 6 O
D NNP 0 1 2 O
concentrations NNS 1 1 13 O
have VBP 0 0 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
following VBG 1 1 1 O
the DT 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
to TO 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
ketoconazole VB 0 1 16 B-Drug
for IN 0 0 12 O
a DT 0 0 12 O
week NN 0 1 12 O
to TO 0 0 12 O
healthy JJ 0 1 12 O
men NNS 0 1 13 O
. . 0 0 12 O

Increased VBN 0 1 7 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
terfenadine JJ 0 1 UNK B-Drug
astemizole NN 0 1 UNK B-Drug
and CC 0 0 12 O
cisapride NN 0 1 UNK B-Drug
cause NN 0 1 12 O
QT NNP 0 1 13 O
prolongation NN 0 1 6 O
and CC 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
torsades NNS 0 0 13 O
de FW 0 1 2 O
pointes FW 0 0 UNK O
- : 0 0 2 O
type NN 0 1 1 O
ventricular JJ 0 1 8 O
tachycardia NN 0 1 8 O
sometimes RB 0 1 12 O
fatal JJ 0 1 13 O
. . 0 0 12 O

AUCss NNP 0 0 UNK O
( ( 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
9h CD 0 0 UNK O
) ) 0 0 2 O
( ( 0 0 2 O
Extent NNP 0 1 UNK O
of IN 0 0 12 O
systemic JJ 0 1 6 O
exposure NN 0 1 1 O
) ) 0 0 2 O

Alpha NNP 0 1 2 B-Group
- : 0 0 2 O
blockers NNS 1 0 6 I-Group
: : 0 0 2 O
When WRB 0 0 12 O
Vardenafil NNP 0 1 UNK B-Drug
9 CD 0 0 2 O
or CC 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
was VBD 1 0 12 O
given VBN 1 1 12 O
to TO 0 0 12 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
either CC 0 1 12 O
simultaneously RB 0 1 13 O
or CC 0 0 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
after IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
dose NN 0 1 6 O
of IN 0 0 12 O
terazosin NN 0 1 0 B-Drug
significant JJ 0 1 1 O
hypotension NN 0 1 6 O
developed VBD 1 0 1 O
in IN 0 0 12 O
a DT 0 0 12 O
substantial JJ 0 0 1 O
number NN 0 1 1 O
of IN 0 0 12 O
subjects NNS 1 1 UNK O
. . 0 0 12 O

Ketoconazole NNP 0 1 UNK B-Drug
- : 0 0 2 O
Combined JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
racemic JJ 0 1 14 O
citalopram NN 0 1 16 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
) ) 0 0 2 O
and CC 0 0 12 O
ketoconazole $ 0 1 16 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
) ) 0 0 2 O
decreased VBD 1 1 1 O
the DT 0 0 12 O
Cmax NNP 0 1 UNK O
and CC 0 0 12 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
ketoconazole NN 0 1 16 B-Drug
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
respectively RB 0 0 1 O
and CC 0 0 12 O
did VBD 1 0 12 O
not RB 0 1 12 O
significantly RB 0 0 1 O
affect VBP 0 1 1 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
citalopram NN 0 1 16 B-Drug
. . 0 0 12 O

Aspirin NNP 0 1 0 B-Brand
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
cautiously RB 0 0 UNK O
in IN 0 0 12 O
conjunction NN 0 1 1 O
with IN 0 0 12 O
corticosteroids NNS 1 1 14 B-Group
in IN 0 0 12 O
patients NNS 1 1 6 O
suffering VBG 1 1 12 O
from IN 0 0 12 O
hypoprothrombinemia NN 0 1 UNK O
. . 0 0 12 O

Phenothiazine NNP 0 1 UNK B-Group
- : 0 0 2 O
related JJ 0 1 1 I-Group
compounds NNS 1 1 13 I-Group
and CC 0 0 12 O
beta SYM 0 1 16 B-Group
- : 0 0 2 O
adrenergic JJ 0 1 UNK I-Group
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
may MD 0 0 1 O
have VB 0 0 12 O
additive JJ 0 1 16 O
hypotensite NN 0 0 UNK O
effects NNS 1 1 1 O
due JJ 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
each DT 0 0 12 O
other JJ 0 0 12 O
metabolism NN 0 1 16 O
. . 0 0 12 O

Based VBN 0 1 2 O
on IN 0 0 12 O
clinical JJ 0 1 6 O
and CC 0 0 12 O
pharmacokinetic JJ 0 1 UNK O
results NNS 1 1 1 O
from IN 0 0 12 O
the DT 0 0 12 O
ATAC NNP 0 1 UNK O
trial NN 0 1 12 O
tamoxifen NN 0 1 0 B-Drug
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
anastrozole NN 0 1 16 B-Drug
( ( 0 0 2 O
see VB 0 1 12 O
CLINICAL NNP 0 1 11 O
PHARMACOLOGY NNP 0 1 UNK O
Drug NNP 0 1 2 O
Interactions NNP 0 1 UNK O
and CC 0 0 12 O
CLINICAL NNP 0 1 11 O
PHARMACOLOGY NNP 0 1 UNK O
- : 0 0 2 O
Clinical JJ 0 1 7 O
Studies NNP 0 1 2 O
- : 0 0 2 O
Adjuvant JJ 0 1 UNK O
Treatment NN 0 1 7 O
of IN 0 0 12 O
Breast NNP 0 1 7 O
Cancer NNP 0 1 7 O
in IN 0 0 12 O
Postmenopausal NNP 0 1 UNK O
Women NNP 0 1 2 O
subsections NNS 1 1 UNK O
) ) 0 0 2 O
. . 0 0 12 O

Isoproterenol NNP 0 1 UNK B-Drug
alone RB 0 1 12 O
at IN 0 0 12 O
a DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
kg JJ 0 1 18 O
/ JJ 0 0 2 O
day NN 0 1 12 O
( ( 0 0 2 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
times NNS 1 1 12 O
the DT 0 0 12 O
maximum NN 0 1 1 O
recommended VBD 1 1 1 O
daily JJ 0 1 12 O
inhalation NN 0 1 16 O
dose NN 0 1 6 O
in IN 0 0 12 O
adults NNS 1 1 13 O
on IN 0 0 12 O
a DT 0 0 12 O
mg NN 0 1 0 O
/ NN 0 0 2 O
m9 JJ 0 1 UNK O
basis NN 0 1 1 O
) ) 0 0 2 O
increased VBD 1 1 1 O
both DT 0 0 12 O
resorptions NNS 1 1 UNK O
and CC 0 0 12 O
malformations NNS 1 1 8 O
. . 0 0 12 O

Amprenavir NNP 0 1 UNK B-Drug
inhibits VBZ 1 1 UNK O
CYP9A9 NNP 0 0 UNK O
. . 0 0 12 O

Probenecid NN 0 1 UNK B-Drug
: : 0 0 2 O
Concomitant JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
TORADOL NNP 0 1 UNK B-Brand
ORAL NNP 0 1 UNK O
and CC 0 0 12 O
probenecid NN 0 1 13 B-Drug
resulted VBD 1 1 1 O
in IN 0 0 12 O
decreased JJ 0 1 1 O
clearance NN 0 1 16 O
of IN 0 0 12 O
ketorolac NN 0 1 16 B-Drug
and CC 0 0 12 O
significant JJ 0 1 1 O
increases NNS 1 1 1 O
in IN 0 0 12 O
ketorolac NN 0 1 16 B-Drug
plasma NN 0 1 14 O
levels NNS 1 1 1 O
( ( 0 0 2 O
total JJ 0 1 1 O
AUC NNP 0 1 UNK O
increased VBD 1 1 1 O
approximately RB 0 1 1 O
threefold VBN 0 0 UNK O
from IN 0 0 12 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
m NNS 0 1 2 O
g JJ 0 1 16 O
/ NNP 0 0 2 O
h NN 0 1 16 O
/ NNP 0 0 2 O
mL NN 0 1 14 O
) ) 0 0 2 O
and CC 0 0 12 O
terminal JJ 0 1 1 O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
increased VBD 1 1 1 O
approximately RB 0 1 1 O
twofold VBN 0 0 UNK O
from IN 0 0 12 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
. . 0 0 12 O

Lithium NN 0 1 UNK B-Drug
: : 0 0 2 O
Lithium NN 0 1 UNK B-Drug
toxicity NN 0 1 6 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
lithium NN 0 1 16 B-Drug
concomitantly RB 0 0 14 O
with IN 0 0 12 O
drugs NNS 1 1 6 O
which WDT 0 0 12 O
cause VBP 0 1 12 O
elimination NN 0 1 UNK O
of IN 0 0 12 O
sodium NN 0 1 14 O
including VBG 1 1 1 O
ACE NNP 0 1 13 B-Group
inhibitors NNS 1 1 14 I-Group
. . 0 0 12 O

Phenothiazines NNS 0 1 UNK B-Group
and CC 0 0 12 O
butyrophenones NNS 0 1 UNK B-Group
may MD 0 0 1 O
reduce VB 0 0 1 O
or CC 0 0 12 O
reverse VB 0 1 1 O
the DT 0 0 12 O
pressor NN 0 1 14 O
effect NN 0 1 1 O
of IN 0 0 12 O
epinephrine NN 0 1 14 B-Drug
. . 0 0 12 O

Special JJ 0 1 2 O
care NN 0 1 12 O
is VBZ 1 0 12 O
required VBN 1 1 1 O
if IN 0 0 12 O
this DT 0 0 12 O
drug NN 0 1 1 O
is VBZ 1 0 12 O
given VBN 1 1 12 O
to TO 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
ganglion NN 0 1 8 B-Group
blocking VBG 1 1 UNK I-Group
compounds NNS 1 1 13 I-Group
because IN 0 0 12 O
a DT 0 0 12 O
critical JJ 0 1 1 O
fall NN 0 1 12 O
in IN 0 0 12 O
blood NN 0 1 6 O
pressure NN 0 1 1 O
may MD 0 0 1 O
occur VB 0 1 1 O
. . 0 0 12 O

rifabutin NN 0 1 13 B-Drug
concentration NN 0 1 1 O

( ( 0 0 2 O
Concurrent NNP 0 1 13 O
use NN 0 1 1 O
with IN 0 0 12 O
thiazide JJ 0 1 UNK B-Group
diuretics NNS 1 1 14 I-Group
may MD 0 0 1 O
intensify VB 0 0 UNK O
electrolyte JJ 0 1 14 O
imbalance NN 0 1 6 O
particularly RB 0 0 1 O
hypokalemia NN 0 1 14 O
. . 0 0 12 O
) ) 0 0 2 O

This DT 0 0 2 O
is VBZ 1 0 12 O
especially RB 0 0 12 O
important JJ 0 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
who WP 0 0 12 O
may MD 0 0 1 O
use VB 0 1 1 O
alcohol NN 0 1 1 B-Drug
excessively RB 0 1 3 O
. . 0 0 12 O

SPIRIVA NNP 0 1 0 B-Brand
has VBZ 1 0 12 O
been VBN 1 0 12 O
used VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
commonly RB 0 0 UNK O
used VBN 1 1 12 O
in IN 0 0 12 O
COPD NNP 0 1 6 O
without IN 0 0 12 O
increases NNS 1 1 1 O
in IN 0 0 12 O
adverse JJ 0 0 1 O
drug NN 0 1 1 O
reactions NNS 1 1 1 O
. . 0 0 12 O

death NN 0 1 12 O
cardiac NN 0 1 6 O
arrest NN 0 1 12 O
and CC 0 0 12 O
ventricular JJ 0 1 8 O
arrhythmia NN 0 1 6 O
including VBG 1 1 1 O
torsades NNS 0 0 13 O
de IN 0 1 2 O
pointes NNS 0 0 UNK O
. . 0 0 12 O

If IN 0 0 12 O
a DT 0 0 12 O
patient NN 0 1 6 O
requires VBZ 1 0 1 O
TIKOSYN NNP 0 1 UNK B-Brand
and CC 0 0 12 O
anti SYM 0 0 3 B-Group
- : 0 0 2 O
ulcer JJ 0 1 6 I-Group
therapy NN 0 1 6 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
suggested VBN 1 1 12 O
that IN 0 0 12 O
omeprazole JJ 0 1 0 B-Drug
ranitidine NN 0 1 0 B-Drug
or CC 0 0 12 O
antacids NNS 1 1 14 B-Group
( ( 0 0 2 O
aluminum NN 0 1 16 B-Drug
and CC 0 0 12 O
magnesium NN 0 1 14 B-Drug
hydroxides NNS 1 1 UNK I-Drug
) ) 0 0 2 O
be VB 0 0 12 O
used VBN 1 1 12 O
as IN 1 0 12 O
alternatives NNS 1 1 UNK O
to TO 0 0 12 O
cimetidine VB 0 1 13 B-Drug
as IN 1 0 12 O
these DT 0 0 12 O
agents NNS 1 1 1 O
have VBP 0 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetic JJ 0 1 UNK O
profile NN 0 1 1 O
of IN 0 0 12 O
TIKOSYN NNP 0 1 UNK B-Brand
. . 0 0 12 O

Nonsteroidal NNP 0 0 UNK B-Group
Anti NNP 0 0 UNK I-Group
- : 0 0 2 O
inflammatory NN 0 1 6 I-Group
Drugs NNP 0 1 2 I-Group
( ( 0 0 2 O
NSAIDs NNP 0 1 UNK B-Group
) ) 0 0 2 O
: : 0 0 2 O
The DT 0 0 2 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
nonsteroidal JJ 0 0 14 B-Group
anti JJ 0 0 3 I-Group
inflammatory JJ 0 1 6 I-Group
drug NN 0 1 1 I-Group
with IN 0 0 12 O
a DT 0 0 12 O
quinolone NN 0 1 UNK B-Group
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
risks NNS 1 1 1 O
of IN 0 0 12 O
CNS NNP 0 1 6 O
stimulation NN 0 1 6 O
and CC 0 0 12 O
convulsions NNS 1 1 13 O
. . 0 0 12 O

Moreover RB 0 0 1 O
as IN 1 0 12 O
noted VBN 1 0 1 O
with IN 0 0 12 O
alprazolam PDT 0 1 0 B-Drug
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
fluvoxamine NN 0 1 16 B-Drug
may MD 0 0 1 O
even RB 0 0 12 O
be VB 0 0 12 O
more RBR 0 1 12 O
pronounced JJ 0 0 12 O
when WRB 0 0 12 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
administered VBN 1 1 1 O
at IN 0 0 12 O
higher JJR 1 1 1 O
doses NNS 1 1 6 O
. . 0 0 12 O

In IN 0 0 2 O
extremely RB 0 1 12 O
acidic JJ 0 1 UNK O
conditions NNS 1 1 1 O
Duloxetine NNP 0 1 0 B-Drug
unprotected VBN 0 0 UNK O
by IN 0 0 12 O
the DT 0 0 12 O
enteric JJ 0 1 14 O
coating NN 0 1 UNK O
may MD 0 0 1 O
undergo VB 0 0 1 O
hydrolysis NN 0 1 UNK O
to TO 0 0 12 O
form VB 0 1 1 O
naphthol NN 0 1 UNK O
. . 0 0 12 O

Patients NNS 0 1 7 O
on IN 0 0 12 O
rifampin NN 0 1 16 B-Drug
should MD 0 0 12 O
receive VB 0 1 1 O
9 CD 0 0 2 O
mg NN 0 1 0 O
of IN 0 0 12 O
CANCIDAS NNP 0 1 UNK B-Brand
daily RB 0 1 12 O
. . 0 0 12 O

This DT 0 0 2 O
information NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
when WRB 0 0 12 O
changing VBG 1 1 1 O
from IN 0 0 12 O
intravenous JJ 0 1 14 O
amiodarone NN 0 1 0 B-Drug
to TO 0 0 12 O
oral JJ 0 1 6 O
amiodarone NN 0 1 0 B-Drug
. . 0 0 12 O

No DT 0 0 2 O
information NN 0 1 1 O
is VBZ 1 0 12 O
available JJ 0 1 1 O
. . 0 0 12 O

Fulvestrant NNP 0 1 UNK B-Drug
was VBD 1 0 12 O
not RB 0 1 12 O
mutagenic JJ 0 1 UNK O
or CC 0 0 12 O
clastogenic JJ 0 1 UNK O
in IN 0 0 12 O
multiple JJ 0 1 1 O
in IN 0 0 12 O
vitro NN 0 1 UNK O
tests NNS 1 1 1 O
with IN 0 0 12 O
and CC 0 0 12 O
without IN 0 0 12 O
the DT 0 0 12 O
addition NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
mammalian JJ 0 1 UNK O
liver NN 0 1 6 O
metabolic JJ 0 1 6 O
activation NN 0 1 13 O
factor NN 0 1 1 O
( ( 0 0 2 O
bacterial JJ 0 1 6 O
mutation NN 0 1 13 O
assay NN 0 1 14 O
in IN 0 0 12 O
strains NNS 1 1 6 O
of IN 0 0 12 O
Salmonella NNP 0 1 UNK O
typhimurium NN 0 0 UNK O
and CC 0 0 12 O
Escherichia NNP 0 1 14 O
coli VBP 0 0 14 O
in IN 0 0 12 O
vitro NN 0 1 UNK O
cytogenetics NNS 0 1 16 O
study VBP 0 1 1 O
in IN 0 0 12 O
human JJ 0 1 1 O
lymphocytes NNS 1 1 14 O
mammalian JJ 0 1 UNK O
cell NN 0 1 1 O
mutation NN 0 1 13 O
assay VBP 0 1 14 O
in IN 0 0 12 O
mouse NN 0 1 UNK O
lymphoma NN 0 1 6 O
cells NNS 1 1 6 O
and CC 0 0 12 O
in IN 0 0 12 O
vivo JJ 0 1 13 O
micronucleus JJ 0 1 UNK O
test NN 0 1 1 O
in IN 0 0 12 O
rat NN 0 1 13 O
. . 0 0 12 O

This DT 0 0 2 O
resulted VBD 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
decrease NN 0 1 1 O
in IN 0 0 12 O
t9 JJ 0 1 13 O
/ JJ 0 0 2 O
9 CD 0 0 2 O
from IN 0 0 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
to TO 0 0 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
and CC 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
reduction NN 0 1 1 O
in IN 0 0 12 O
AUC NNP 0 1 UNK O
. . 0 0 12 O

Inhibition NN 0 1 UNK O
of IN 0 0 12 O
CYP9D9 NNP 0 0 UNK O
was VBD 1 0 12 O
observed VBN 1 1 1 O
with IN 0 0 12 O
an DT 0 0 12 O
apparent JJ 0 1 1 O
Ki NNP 0 0 UNK O
of IN 0 0 12 O
9 CD 0 0 2 O
uM JJ 0 0 UNK O
indicating VBG 1 0 1 O
that DT 0 0 12 O
pramipexole NN 0 1 16 B-Drug
will MD 0 0 12 O
not RB 0 1 12 O
inhibit VB 0 1 13 O
CYP NNP 0 1 UNK O
enzymes NNS 1 1 14 O
at IN 0 0 12 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
observed VBD 1 1 1 O
following VBG 1 1 1 O
the DT 0 0 12 O
highest JJS 1 1 1 O
recommended JJ 0 1 1 O
clinical JJ 0 1 6 O
dose NN 0 1 6 O
( ( 0 0 2 O
9 CD 0 0 2 O
mg RB 0 1 0 O
tid NN 0 1 13 O
) ) 0 0 2 O
. . 0 0 12 O

Disulfiram NNP 0 1 UNK B-Drug
alone RB 0 1 12 O
in IN 0 0 12 O
the DT 0 0 12 O
rat NN 0 1 13 O
diet NN 0 1 6 O
did VBD 1 0 12 O
not RB 0 1 12 O
lead VB 0 1 12 O
to TO 0 0 12 O
such JJ 0 0 1 O
tumors NNS 1 1 6 O
. . 0 0 12 O

Ketoconazole NNP 0 1 UNK B-Drug
: : 0 0 2 O
Ketoconazole NNP 0 1 UNK B-Drug
may MD 0 0 1 O
inhibit VB 0 1 13 O
both DT 0 0 12 O
synthetic JJ 0 1 3 O
and CC 0 0 12 O
catabolic JJ 0 1 14 O
enzymes NNS 1 1 14 O
of IN 0 0 12 O
vitamin NN 0 1 6 B-Group
D NNP 0 1 2 I-Group
. . 0 0 12 O

Concomitant NNP 0 1 UNK O
use NN 0 1 1 O
of IN 0 0 12 O
other JJ 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
HT9B NNP 0 0 UNK O
/ VBZ 0 0 2 O
9D CD 0 0 UNK O
agonists NNS 1 1 UNK O
within IN 0 0 1 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
of IN 0 0 12 O
FROVA NNP 0 1 UNK B-Brand
treatment NN 0 1 6 O
is VBZ 1 0 12 O
not RB 0 1 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
bioavailability NN 0 1 UNK O
of IN 0 0 12 O
SKELID NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
decreased VBN 1 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
by IN 0 0 12 O
calcium NN 0 1 14 B-Drug
when WRB 0 0 12 O
calcium NN 0 1 14 B-Drug
and CC 0 0 12 O
SKELID NNP 0 1 UNK B-Brand
are VBP 1 0 12 O
administered VBN 1 1 1 O
at IN 0 0 12 O
the DT 0 0 12 O
same JJ 0 1 12 O
time NN 0 1 12 O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
by IN 0 0 12 O
some DT 0 0 12 O
aluminum NN 0 1 16 B-Drug
- : 0 0 2 O
or CC 0 0 12 O
magnesium VB 0 1 14 B-Drug
- : 0 0 2 O
containing VBG 1 1 1 O
antacids NNS 1 1 14 B-Drug
when WRB 0 0 12 O
administered VBD 1 1 1 O
9 CD 0 0 2 O
hour NN 0 1 12 O
before IN 0 1 12 O
SKELID NNP 0 1 UNK B-Brand
. . 0 0 12 O

In IN 0 0 2 O
a DT 0 0 12 O
study NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
HIV NNP 0 1 6 O
- : 0 0 2 O
infected JJ 0 1 6 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
methadone NN 0 1 6 B-Drug
- : 0 0 2 O
maintenance NN 0 1 1 O
therapy NN 0 1 6 O
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
and CC 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
daily RB 0 1 12 O
) ) 0 0 2 O
with IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
of IN 0 0 12 O
ZIAGEN NNP 0 1 UNK B-Brand
twice JJ 0 1 12 O
daily RB 0 1 12 O
( ( 0 0 2 O
twice RB 0 1 12 O
the DT 0 0 12 O
currently RB 0 1 12 O
recommended VBN 1 1 1 O
dose NN 0 1 6 O
) ) 0 0 2 O
oral JJ 0 1 6 O
methadone JJ 0 1 6 B-Drug
clearance NN 0 1 16 O
increased VBD 1 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
CI NNP 0 1 UNK O
9 CD 0 0 2 O
% NN 0 0 18 O
to TO 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
. . 0 0 12 O

In IN 0 0 2 O
vitro JJ 0 1 UNK O
data NNS 0 1 1 O
in IN 0 0 12 O
human JJ 0 1 1 O
plasma NN 0 1 14 O
indicate VBP 0 0 1 O
that IN 0 0 12 O
doxazosin NN 0 1 13 B-Drug
mesylate NN 0 1 16 I-Drug
has VBZ 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
protein NN 0 1 14 O
binding NN 0 1 1 O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
warfarin NN 0 1 14 B-Drug
phenytoin NN 0 1 16 B-Drug
or CC 0 0 12 O
indomethacin NN 0 1 14 B-Drug
. . 0 0 12 O

Cimetidine NNP 0 1 0 B-Drug
increased VBD 1 1 1 O
AUC NNP 0 1 UNK O
by IN 0 0 12 O
about RB 0 1 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
but CC 0 0 12 O
caused VBD 1 1 1 O
no DT 0 0 12 O
change NN 0 1 1 O
in IN 0 0 12 O
Cmax NNP 0 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
interaction NN 0 1 UNK O
of IN 0 0 12 O
Retavase NNP 0 1 0 B-Brand
with IN 0 0 12 O
other JJ 0 0 12 O
cardioactive JJ 0 0 UNK O
drugs NNS 1 1 6 O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
studied VBN 1 0 1 O
. . 0 0 12 O

Acitretin NN 0 1 UNK B-Drug
: : 0 0 2 O
Interferes VBZ 0 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
contraceptive JJ 0 1 13 O
effect NN 0 1 1 O
of IN 0 0 12 O
microdosed VBN 0 0 UNK O
progestin NN 0 1 UNK B-Group
- : 0 0 2 O
containing NN 0 1 1 O
minipill NN 0 1 UNK O
preparations NNS 1 1 13 O
. . 0 0 12 O

Deferasirox NNP 0 1 UNK B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
taken VBN 1 1 12 O
on IN 0 0 12 O
an DT 0 0 12 O
empty JJ 0 1 3 O
stomach NN 0 1 6 O
9 CD 0 0 2 O
minutes NNS 1 1 12 O
before IN 0 1 12 O
eating NN 0 1 12 O
. . 0 0 12 O

Acidifying VBG 0 0 UNK B-Group
agents NNS 1 1 1 I-Group
: : 0 0 2 O
Gastrointestinal NNP 0 1 7 B-Group
acidifying VBG 1 0 13 I-Group
agents NNS 1 1 1 I-Group
( ( 0 0 2 O
guanethidine JJ 0 1 UNK B-Drug
reserpine NN 0 1 UNK B-Drug
glutamic JJ 0 0 14 B-Drug
acid NN 0 1 14 I-Drug
HCl NNP 0 0 14 I-Drug
ascorbic JJ 0 0 16 B-Drug
acid NN 0 1 14 I-Drug
fruit NN 0 1 13 O
juices NNS 1 1 UNK O
etc FW 0 1 12 O
. . 0 0 12 O
) ) 0 0 2 O
lower JJR 1 1 1 O
absorption NN 0 1 1 O
of IN 0 0 12 O
amphetamines NNS 1 1 14 B-Group
. . 0 0 12 O

Pharmacodynamic JJ 0 1 UNK O
Interactions NNS 0 1 UNK O
: : 0 0 2 O
The DT 0 0 2 O
CNS NNP 0 1 6 O
- : 0 0 2 O
depressant JJ 0 0 UNK O
action NN 0 1 13 O
of IN 0 0 12 O
the DT 0 0 12 O
benzodiazepine JJ 0 1 14 B-Group
class NN 0 1 12 I-Group
of IN 0 0 12 O
drugs NNS 1 1 6 O
may MD 0 0 1 O
be VB 0 0 12 O
potentiated VBN 1 0 UNK O
by IN 0 0 12 O
alcohol NN 0 1 1 B-Drug
narcotics NNS 1 1 1 B-Group
barbiturates VBZ 0 1 14 B-Group
nonbarbiturate JJ 0 0 UNK B-Group
hypnotics NNS 1 1 13 I-Group
antianxiety NN 0 0 0 B-Group
agents VBZ 0 1 1 I-Group
the DT 0 0 12 O
phenothiazines NNS 1 1 UNK B-Group
thioxanthene NN 0 1 UNK B-Group
and CC 0 0 12 O
butyrophenone NN 0 1 UNK B-Group
classes NNS 1 1 UNK I-Group
of IN 0 0 12 I-Group
antipsychotic JJ 0 1 UNK I-Group
agents NNS 1 1 1 I-Group
monoamine JJ 0 1 13 B-Group
oxidase NN 0 1 13 I-Group
inhibitors NNS 1 1 14 I-Group
and CC 0 0 12 O
the DT 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
and CC 0 0 12 O
by IN 0 0 12 O
other JJ 0 0 12 O
anticonvulsant JJ 0 1 14 B-Group
drugs NNS 1 1 6 I-Group
. . 0 0 12 O

morphine NN 0 1 14 B-Drug
theophylline NN 0 1 16 B-Drug
aminophylline NN 0 1 13 B-Drug
succinylcholine NN 0 1 16 B-Drug
reserpine NN 0 1 UNK B-Drug
and CC 0 0 12 O
phenothiazine VB 0 1 UNK B-Group
- : 0 0 2 O
type NN 0 1 1 I-Group
tranquilizers NNS 1 1 13 I-Group
should MD 0 0 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
organophosphate JJ 0 1 13 O
poisoning NN 0 1 13 O
. . 0 0 12 O

MAO JJ 0 1 14 B-Group
Inhibitors NNS 0 1 7 I-Group
: : 0 0 2 O
The DT 0 0 2 O
pressor NN 0 1 14 O
effect NN 0 1 1 O
of IN 0 0 12 O
sympathomimetic JJ 0 1 13 B-Group
pressor NN 0 1 14 I-Group
amines NNS 1 1 13 I-Group
is VBZ 1 0 12 O
markedly RB 0 1 1 O
potentiated VBN 1 0 UNK O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
monoamine JJ 0 1 13 B-Group
oxidase NN 0 1 13 I-Group
inhibitors NNS 1 1 14 I-Group
( ( 0 0 2 O
MAOI NNP 0 1 UNK B-Group
) ) 0 0 2 O
. . 0 0 12 O

Amiodarone NNP 0 1 0 B-Drug
taken VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
increases VBZ 1 1 1 O
the DT 0 0 12 O
serum NN 0 1 14 O
digoxin NN 0 1 14 B-Drug
concentration NN 0 1 1 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
after IN 0 0 12 O
one CD 0 1 12 O
day NN 0 1 12 O
. . 0 0 12 O

In IN 0 0 2 O
addition NN 0 1 1 O
studies NNS 1 1 1 O
in IN 0 0 12 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
have VBP 0 0 12 O
shown VBN 1 1 1 O
that IN 0 0 12 O
TIKOSYN NNP 0 1 UNK B-Brand
does VBZ 1 0 12 O
not RB 0 1 12 O
affect VB 0 1 1 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
or CC 0 0 12 O
pharmacodynamics NNS 0 1 UNK O
of IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
or CC 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
propranolol NN 0 1 16 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
twice RB 0 1 12 O
daily RB 0 1 12 O
) ) 0 0 2 O
phenytoin VBP 0 1 16 B-Drug
theophylline NN 0 1 16 B-Drug
or CC 0 0 12 O
oral JJ 0 1 6 O
contraceptives NNS 1 1 13 B-Group
. . 0 0 12 O

Concomitant JJ 0 1 UNK O
treatment NN 0 1 6 O
with IN 0 0 12 O
methylxanthines NNS 0 1 UNK B-Group
( ( 0 0 2 O
aminophylline JJ 0 1 13 B-Drug
theophylline NN 0 1 16 B-Drug
) ) 0 0 2 O
steroids NNS 1 1 6 B-Group
or CC 0 0 12 O
diuretics NNS 1 1 14 B-Group
may MD 0 0 1 O
potentiate VB 0 0 UNK O
any DT 0 0 12 O
hypokalemic JJ 0 1 8 O
effect NN 0 1 1 O
of IN 0 0 12 O
adrenergic JJ 0 1 UNK B-Group
agonists NNS 1 1 UNK I-Group
. . 0 0 12 O

Cimetidine NN 0 1 0 B-Drug
increased VBD 1 1 1 O
the DT 0 0 12 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
epirubicin NN 0 1 13 B-Drug
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interactions NNPS 0 1 UNK O
The DT 0 0 2 O
urine NN 0 1 6 O
of IN 0 0 12 O
patients NNS 1 1 6 O
who WP 0 0 12 O
take VBP 0 1 12 O
Lodine NNP 0 1 UNK B-Brand
can MD 0 0 12 O
give VB 0 1 12 O
a DT 0 0 12 O
false JJ 0 1 13 O
- : 0 0 2 O
positive JJ 0 1 1 O
reaction NN 0 1 1 O
for IN 0 0 12 O
urinary JJ 0 1 6 O
bilirubin NN 0 1 14 O
( ( 0 0 2 O
urobilin JJ 0 1 UNK O
) ) 0 0 2 O
due JJ 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
presence NN 0 1 1 O
of IN 0 0 12 O
phenolic JJ 0 1 UNK O
metabolites NNS 1 1 UNK O
of IN 0 0 12 O
etodolac NN 0 1 13 B-Drug
. . 0 0 12 O

Benazepril NNP 0 1 UNK B-Drug
like IN 0 0 12 O
other JJ 0 0 12 O
ACE NNP 0 1 13 B-Group
inhibitors NNS 1 1 14 I-Group
has VBZ 1 0 12 O
had VBD 1 0 12 O
less JJR 0 1 12 O
than IN 0 0 12 O
additive JJ 0 1 16 O
effects NNS 1 1 1 O
with IN 0 0 12 O
beta NN 0 1 16 B-Group
- : 0 0 2 O
adrenergic JJ 0 1 UNK I-Group
blockers NNS 1 0 6 I-Group
presumably RB 0 0 12 O
because IN 0 0 12 O
both DT 0 0 12 O
drugs NNS 1 1 6 O
lower JJR 1 1 1 O
blood NN 0 1 6 O
pressure NN 0 1 1 O
by IN 0 0 12 O
inhibiting VBG 1 1 UNK O
parts NNS 1 1 3 O
of IN 0 0 12 O
the DT 0 0 12 O
renin NN 0 1 UNK O
- : 0 0 2 O
angiotensin NN 0 1 UNK O
system NN 0 1 1 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
desirable JJ 0 0 UNK O
to TO 0 0 12 O
monitor VB 0 1 1 O
TCA NNP 0 1 13 B-Group
plasma NN 0 1 14 O
levels NNS 1 1 1 O
whenever WRB 0 0 12 O
a DT 0 0 12 O
TCA NNP 0 1 13 B-Group
is VBZ 1 0 12 O
going VBG 1 0 12 O
to TO 0 0 12 O
be VB 0 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
with IN 0 0 12 O
another DT 0 0 12 O
drug NN 0 1 1 O
known VBN 1 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
an DT 0 0 12 O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
P9 NNP 0 1 UNK O
9D9 CD 0 0 UNK O
. . 0 0 12 O

Estrogens NNS 0 1 0 B-Group
including VBG 1 1 1 O
oral JJ 0 1 6 O
contraceptives NNS 1 1 13 B-Group
: : 0 0 2 O
Estrogens NNS 0 1 0 B-Group
may MD 0 0 1 O
decrease VB 0 1 1 O
the DT 0 0 12 O
hepatic JJ 0 1 14 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
certain JJ 0 1 1 O
corticosteroids NNS 1 1 14 B-Group
thereby RB 0 0 UNK O
increasing VBG 1 1 1 O
their PRP$ 0 0 12 O
effect NN 0 1 1 O
. . 0 0 12 O

Cyclosporine NN 0 1 UNK B-Drug
: : 0 0 2 O
Elevated VBN 0 1 7 O
serum NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
cyclosporine NN 0 1 14 B-Drug
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
with IN 0 0 12 O
concomitant JJ 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
cyclosporine NN 0 1 14 B-Drug
with IN 0 0 12 O
other JJ 0 0 12 O
members NNS 1 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
quinolone NN 0 1 UNK B-Group
class NN 0 1 12 I-Group
. . 0 0 12 O

Therefore RB 0 0 1 O
if IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
is VBZ 1 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
VAPRISOL NNP 0 1 UNK B-Brand
the DT 0 0 12 O
clinician NN 0 1 13 O
should MD 0 0 12 O
be VB 0 0 12 O
alert JJ 0 1 12 O
to TO 0 0 12 O
the DT 0 0 12 O
possibility NN 0 1 1 O
of IN 0 0 12 O
increases NNS 1 1 1 O
in IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
levels NNS 1 1 1 O
. . 0 0 12 O

Caution NN 0 0 UNK O
is VBZ 1 0 12 O
advised VBN 1 0 12 O
when WRB 0 0 12 O
beginning VBG 1 1 12 O
discontinuing VBG 1 1 6 O
or CC 0 0 12 O
changing VBG 1 1 1 O
the DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
DIAMOX NNP 0 1 UNK B-Brand
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
primidone NN 0 1 13 B-Drug
. . 0 0 12 O

Digoxin NN 0 1 0 B-Drug
: : 0 0 2 O
Meloxicam NNP 0 1 UNK B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
once RB 0 0 12 O
daily JJ 0 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
did VBD 1 0 12 O
not RB 0 1 12 O
alter VB 0 1 13 O
the DT 0 0 12 O
plasma NN 0 1 14 O
concentration NN 0 1 1 O
profile NN 0 1 1 O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
after IN 0 0 12 O
b SYM 0 0 16 O
- : 0 0 2 O
acetyldigoxin NN 0 1 UNK O
administration NN 0 1 1 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
at IN 0 0 12 O
clinical JJ 0 1 6 O
doses NNS 1 1 6 O
. . 0 0 12 O

Nelfinavir NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
metabolized VBN 1 1 UNK O
in IN 0 0 12 O
proof NN 0 1 1 O
by IN 0 0 12 O
C.P.A NNP 0 0 UNK O
. . 0 0 12 O

Drugs NNS 0 1 2 O
which WDT 0 0 12 O
may MD 0 0 1 O
potentiate VB 0 0 UNK O
the DT 0 0 12 O
myeloproliferative JJ 0 1 8 O
effects NNS 1 1 1 O
of IN 0 0 12 O
Leukine NNP 0 1 UNK B-Brand
such JJ 0 0 1 O
as IN 1 0 12 O
lithium NN 0 1 16 B-Drug
and CC 0 0 12 O
corticosteroids NNS 1 1 14 B-Group
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
with IN 0 0 12 O
caution NN 0 0 1 O
. . 0 0 12 O

In IN 0 0 2 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
shown VBN 1 1 1 O
no DT 0 0 12 O
binding VBG 1 1 1 O
displacement NN 0 1 1 O
between IN 0 0 12 O
entacapone NN 0 1 13 B-Drug
and CC 0 0 12 O
other JJ 0 0 12 O
highly RB 0 1 1 O
bound IN 0 1 12 O
drugs NNS 1 1 6 O
such JJ 0 0 1 O
as IN 1 0 12 O
warfarin JJ 0 1 14 B-Drug
salicylic JJ 0 1 UNK B-Drug
acid NN 0 1 14 I-Drug
phenylbutazone NN 0 1 UNK B-Drug
and CC 0 0 12 O
diazepam NN 0 1 0 B-Drug
. . 0 0 12 O

Cimetidine NNP 0 1 0 B-Drug
caffeine NN 0 1 6 B-Drug
and CC 0 0 12 O
erythromycin NN 0 1 0 B-Drug
may MD 0 0 1 O
increase VB 0 1 1 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
Clozapine NNP 0 1 0 B-Drug
potentially RB 0 0 1 O
resulting VBG 1 1 1 O
in IN 0 0 12 O
adverse JJ 0 0 1 O
effects NNS 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
action NN 0 1 13 O
of IN 0 0 12 O
colchicine NN 0 1 0 B-Drug
is VBZ 1 0 12 O
potentiated VBN 1 0 UNK O
by IN 0 0 12 O
alkalinizing VBG 1 0 UNK B-Group
agents NNS 1 1 1 I-Group
. . 0 0 12 O

No DT 0 0 2 O
interaction NN 0 1 UNK O
was VBD 1 0 12 O
noted VBN 1 0 1 O
with IN 0 0 12 O
the DT 0 0 12 O
MAO NNP 0 1 14 B-Group
- : 0 0 2 O
B NNP 0 0 2 I-Group
inhibitor NN 0 1 14 I-Group
selegiline NN 0 1 13 B-Drug
in IN 0 0 12 O
two CD 0 1 12 O
multiple JJ 0 1 1 O
- : 0 0 2 O
dose JJ 0 1 6 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
when WRB 0 0 12 O
entacapone NN 0 1 13 B-Drug
was VBD 1 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
a DT 0 0 12 O
levodopa JJ 0 1 UNK B-Drug
/ NN 0 0 2 O
dopa NN 0 1 14 B-Group
decarboxylase NN 0 1 UNK I-Group
inhibitor NN 0 1 14 I-Group
( ( 0 0 2 O
n=9 JJ 0 1 UNK O
) ) 0 0 2 O
. . 0 0 12 O

Therefore RB 0 0 1 O
close JJ 0 1 12 O
monitoring NN 0 1 1 O
of IN 0 0 12 O
serum JJ 0 1 14 O
cyclosporin NN 0 1 14 B-Drug
level NN 0 1 1 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
and CC 0 0 12 O
if IN 0 0 12 O
necessary JJ 0 0 1 O
chloroquine NN 0 1 13 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
discontinued VBN 1 1 1 O
. . 0 0 12 O

Oral JJ 0 1 2 O
anticoagulants NNS 1 1 13 B-Group
decreased VBN 1 1 1 O
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
response NN 0 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
addition NN 0 1 1 O
certain JJ 0 1 1 O
drugs NNS 1 1 6 O
inhibit VBP 0 1 13 O
the DT 0 0 12 O
activity NN 0 1 1 O
of IN 0 0 12 O
this DT 0 0 12 O
isozyme NN 0 1 UNK O
and CC 0 0 12 O
make VB 0 1 12 O
normal JJ 0 1 1 O
metabolizers NNS 0 0 UNK O
resemble JJ 0 0 UNK O
poor JJ 0 1 12 O
metabolizers NNS 0 0 UNK O
. . 0 0 12 O

The DT 0 0 2 O
effects NNS 1 1 1 O
of IN 0 0 12 O
allopurinol NN 0 1 13 B-Drug
on IN 0 0 12 O
didanosine NN 0 1 16 B-Drug
pharmacokinetics NNS 0 1 UNK O
in IN 0 0 12 O
subjects NNS 1 1 UNK O
with IN 0 0 12 O
normal JJ 0 1 1 O
renal JJ 0 1 6 O
function NN 0 1 1 O
are VBP 1 0 12 O
not RB 0 1 12 O
known VBN 1 1 12 O
. . 0 0 12 O

Wait $ 0 1 UNK O
9 CD 0 0 2 O
weeks NNS 1 1 12 O
after IN 0 0 12 O
stopping VBG 1 1 12 O
escitalopram NN 0 1 0 B-Drug
before IN 0 1 12 O
starting VBG 1 1 12 O
a DT 0 0 12 O
non JJ 0 1 1 B-Group
- : 0 0 2 O
selective JJ 0 1 13 I-Group
MAO NNP 0 1 14 I-Group
inhibitor NN 0 1 14 I-Group
. . 0 0 12 O

Other JJ 0 0 2 O
Cardiovascular JJ 0 1 7 O
Agents NNS 0 1 2 O
: : 0 0 2 O
Enalapril NNP 0 1 0 B-Drug
and CC 0 0 12 O
enalapril RB 0 1 0 B-Drug
IV NNP 0 1 2 O
have VBP 0 0 12 O
been VBN 1 0 12 O
used VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
beta NN 0 1 16 B-Group
adrenergic SYM 0 1 UNK I-Group
- : 0 0 2 O
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
methyldopa JJ 0 1 13 B-Drug
nitrates NNS 1 1 14 B-Group
calcium VBP 0 1 14 B-Group
- : 0 0 2 O
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
hydralazine JJ 0 1 14 B-Drug
prazosin NN 0 1 16 B-Drug
and CC 0 0 12 O
digoxin NN 0 1 14 B-Drug
without IN 0 0 12 O
evidence NN 0 1 1 O
of IN 0 0 12 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
adverse JJ 0 0 1 O
interactions NNS 1 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
combined VBN 1 1 1 O
use NN 0 1 1 O
of IN 0 0 12 O
fluconazole NN 0 1 0 B-Drug
with IN 0 0 12 O
cisapride NN 0 1 UNK B-Drug
is VBZ 1 0 12 O
contraindicated VBN 1 1 14 O
. . 0 0 12 O

Saquinavir NNP 0 1 UNK B-Drug
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
Cmax NNP 0 1 UNK O
A.C. NNP 0 0 UNK O
and CC 0 0 12 O
Cmin NNP 0 1 UNK O
were VBD 1 0 12 O
increased VBN 1 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
decreased VBD 1 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
decreased VBD 1 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
respectively RB 0 0 1 O
by IN 0 0 12 O
concomitant JJ 0 1 6 O
amprenavir NN 0 1 13 B-Drug
. . 0 0 12 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
test NN 0 1 1 O
interactions NNS 1 1 UNK O
Anabolic NNP 0 1 UNK B-Drug
steroids NNS 1 1 6 I-Drug
may MD 0 0 1 O
decrease VB 0 1 1 O
levels NNS 1 1 1 O
of IN 0 0 12 O
thyroxine NN 0 1 14 O
- : 0 0 2 O
binding NN 0 1 1 O
globulin NN 0 1 14 O
resulting VBG 1 1 1 O
in IN 0 0 12 O
decreased JJ 0 1 1 O
total JJ 0 1 1 O
T9 NNP 0 1 13 O
serum NN 0 1 14 O
levels NNS 1 1 1 O
and CC 0 0 12 O
increased VBD 1 1 1 O
resin NNS 0 1 UNK O
uptake NN 0 1 14 O
of IN 0 0 12 O
T9 NNP 0 1 13 O
and CC 0 0 12 O
T9 NNP 0 1 13 O
. . 0 0 12 O

Table JJ 0 1 UNK O
9 CD 0 0 2 O
Changes NNS 0 1 2 O
in IN 0 0 12 O
Desloratadine NNP 0 1 UNK B-Drug
and CC 0 0 12 O
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
Hydroxydesloratadine NN 0 0 UNK I-Drug_n
Pharmacokinetics NNPS 0 1 UNK O
in IN 0 0 12 O
Healthy NNP 0 1 2 O
Male NNP 0 1 2 O
and CC 0 0 12 O
Female NNP 0 1 2 O
Volunteers NNP 0 1 UNK O

Coadministration NN 0 1 UNK O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
influence VB 0 0 UNK O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
levetiracetam NN 0 1 16 B-Drug
. . 0 0 12 O

Depending VBG 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
fraction NN 0 1 1 O
of IN 0 0 12 O
drug NN 0 1 1 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
P9 NNP 0 1 UNK O
9D9 CD 0 0 UNK O
the DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
plasma JJ 0 1 14 O
concentration NN 0 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
small JJ 0 1 12 O
or CC 0 0 12 O
quite JJ 0 0 12 O
large JJ 0 1 3 O
( ( 0 0 2 O
9 CD 0 0 2 O
fold JJ 0 1 3 O
increase NN 0 1 1 O
in IN 0 0 12 O
plasma JJ 0 1 14 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
TCA NNP 0 1 13 B-Group
) ) 0 0 2 O
. . 0 0 12 O

CPK NN 0 0 15 O
: : 0 0 2 O
Some DT 0 0 2 O
patients NNS 1 1 6 O
undergoing VBG 1 0 6 O
vigorous JJ 0 0 1 O
physical JJ 0 1 1 O
activity NN 0 1 1 O
while IN 0 0 12 O
on IN 0 0 12 O
Accutane NNP 0 1 UNK B-Brand
therapy NN 0 1 6 O
have VBP 0 0 12 O
experienced VBN 1 0 12 O
elevated VBN 1 1 1 O
CPK NNP 0 0 15 O
levels NNS 1 1 1 O
; : 0 0 2 O

Pharmacokinetic JJ 0 1 UNK O
studies NNS 1 1 1 O
document VBP 0 1 1 O
no DT 0 0 12 O
clinically RB 0 0 6 O
relevant JJ 0 1 1 O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
other JJ 0 0 12 O
agents NNS 1 1 1 O
given VBN 1 1 12 O
concomitantly RB 0 0 14 O
including VBG 1 1 1 O
thiazide IN 0 1 UNK B-Group
diuretics NNS 1 1 14 I-Group
digoxin NN 0 1 14 B-Drug
and CC 0 0 12 O
cimetidine NN 0 1 13 B-Drug
. . 0 0 12 O

Drugs NNS 0 1 2 O
Metabolized VBN 0 1 UNK O
by IN 0 0 12 O
Cytochrome NNP 0 1 UNK O
P9D9 NNP 0 0 UNK O
- : 0 0 2 O
In IN 0 0 2 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
did VBD 1 0 12 O
not RB 0 1 12 O
reveal VB 0 1 12 O
an DT 0 0 12 O
inhibitory JJ 0 1 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
escitalopram NN 0 1 0 B-Drug
on IN 0 0 12 O
CYP9D9 NNP 0 0 UNK O
. . 0 0 12 O

Co NNP 0 1 2 O
- : 0 0 2 O
administration NN 0 1 1 O
with IN 0 0 12 O
efavirenz JJ 0 1 13 B-Drug
or CC 0 0 12 O
fluconazole JJ 0 1 0 B-Drug
had VBD 1 0 12 O
a DT 0 0 12 O
modest JJ 0 1 1 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
azithromycin NN 0 1 0 B-Drug
. . 0 0 12 O

Although IN 0 0 12 O
there EX 0 0 12 O
are VBP 1 0 12 O
no DT 0 0 12 O
study NN 0 1 1 O
data NNS 0 1 1 O
to TO 0 0 12 O
evaluate VB 0 1 1 O
the DT 0 0 12 O
possibility NN 0 1 1 O
nitric JJ 0 0 13 B-Group
oxide RB 0 1 14 I-Group
donor JJ 0 1 1 I-Group
compounds NNS 1 1 13 I-Group
including VBG 1 1 1 O
sodium NN 0 1 14 B-Drug
nitroprusside NN 0 1 14 I-Drug
and CC 0 0 12 O
nitroglycerin NN 0 1 14 B-Drug
may MD 0 0 1 O
have VB 0 0 12 O
an DT 0 0 12 O
additive JJ 0 1 16 O
effect NN 0 1 1 O
with IN 0 0 12 O
INOmax NNP 0 1 UNK B-Brand
on IN 0 0 12 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
developing VBG 1 0 1 O
methemoglobinemia NN 0 1 13 O
. . 0 0 12 O

Both DT 0 0 2 O
groups NNS 1 1 1 O
of IN 0 0 12 O
agents NNS 1 1 1 O
lower JJR 1 1 1 O
blood NN 0 1 6 O
levels NNS 1 1 1 O
and CC 0 0 12 O
efficacy NN 0 1 UNK O
of IN 0 0 12 O
amphetamines NNS 1 1 14 B-Group
. . 0 0 12 O

Saquinavir NN 0 1 UNK B-Drug
: : 0 0 2 O
The DT 0 0 2 O
combination NN 0 1 1 O
of IN 0 0 12 O
HIVID NNP 0 1 UNK B-Drug
saquinavir NN 0 1 13 B-Drug
and CC 0 0 12 O
ZDV NNP 0 1 UNK B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
studied VBN 1 0 1 O
( ( 0 0 2 O
as IN 1 0 12 O
triple JJ 0 1 3 O
combination NN 0 1 1 O
) ) 0 0 2 O
in IN 0 0 12 O
adults NNS 1 1 13 O
. . 0 0 12 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interactions NNS 0 1 UNK O
: : 0 0 2 O
The DT 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
CEFOTAN NNP 0 1 UNK B-Brand
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
false JJ 0 1 13 O
positive JJ 0 1 1 O
reaction NN 0 1 1 O
for IN 0 0 12 O
glucose NN 0 1 14 O
in IN 0 0 12 O
the DT 0 0 12 O
urine JJ 0 1 6 O
using VBG 1 1 1 O
Clinitest NNP 0 1 UNK O
Benedicts NNPS 0 0 UNK O
solution NN 0 1 1 O
or CC 0 0 12 O
Fehlings NNP 0 0 UNK O
solution NN 0 1 1 O
. . 0 0 12 O

Cimetidine NNP 0 1 0 B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
bioavailability NN 0 1 UNK O
of IN 0 0 12 O
labetalol JJ 0 1 0 B-Drug
HCl NNP 0 0 14 I-Drug
. . 0 0 12 O

dermatitis NN 0 1 13 O

In IN 0 0 2 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
a DT 0 0 12 O
potent JJ 0 1 UNK O
CYP9A9 NNP 0 0 UNK O
inducer NN 0 1 UNK O
such JJ 0 0 1 O
as IN 1 0 12 O
rifampicin NN 0 1 UNK B-Drug
or CC 0 0 12 O
phenytoin VB 0 1 16 B-Drug
a DT 0 0 12 O
dose JJ 0 1 6 O
increase NN 0 1 1 O
to TO 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
daily RB 0 1 12 O
should MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
absence NN 0 1 1 O
of IN 0 0 12 O
severe JJ 0 1 6 O
adverse JJ 0 0 1 O
drug NN 0 1 1 O
reaction NN 0 1 1 O
and CC 0 0 12 O
clinical JJ 0 1 6 O
response NN 0 1 1 O
and CC 0 0 12 O
adverse JJ 0 0 1 O
events NNS 1 1 12 O
should MD 0 0 12 O
be VB 0 0 12 O
carefully RB 0 0 12 O
monitored VBN 1 1 1 O
( ( 0 0 2 O
see VB 0 1 12 O
CLINICAL NNP 0 1 11 O
PHARMACOLOGY NNP 0 1 UNK O
- : 0 0 2 O
Pharmacokinetics NNPS 0 1 UNK O
- : 0 0 2 O
Drug NNP 0 1 2 O
- : 0 0 2 O
Drug NN 0 1 2 O
Interactions NNS 0 1 UNK O
and CC 0 0 12 O
DOSAGE NNP 0 1 UNK O
AND NNP 0 0 11 O
ADMINISTRATION NNP 0 1 11 O
- : 0 0 2 O
Dosage NN 0 1 UNK O
Adjustment NNP 0 1 UNK O
sections NNS 1 1 1 O
) ) 0 0 2 O
. . 0 0 12 O

Therefore RB 0 0 1 O
when WRB 0 0 12 O
Hydrochlorothiazide NNP 0 1 0 B-Drug
and CC 0 0 12 O
non SYM 0 1 1 B-Group
- : 0 0 2 O
steroidal NN 0 1 UNK I-Group
anti SYM 0 0 3 I-Group
- : 0 0 2 O
inflammatory NN 0 1 6 I-Group
agents NNS 1 1 1 I-Group
are VBP 1 0 12 O
used VBN 1 1 12 O
concomitantly RB 0 0 14 O
the DT 0 0 12 O
patient NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
observed VBN 1 1 1 O
closely RB 0 0 1 O
to TO 0 0 12 O
determine VB 0 0 1 O
if IN 0 0 12 O
the DT 0 0 12 O
desired JJ 0 1 1 O
effect NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
diuretic JJ 0 1 14 B-Group
is VBZ 1 0 12 O
obtained VBN 1 1 1 O
. . 0 0 12 O

Other JJ 0 0 2 O
CNS NNP 0 1 6 B-Group
depressant NN 0 0 UNK I-Group
drugs NNS 1 1 6 I-Group
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
with IN 0 0 12 O
caution NN 0 0 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
fenfluramine JJ 0 1 UNK B-Drug
since IN 0 1 12 O
the DT 0 0 12 O
effects NNS 1 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
additive JJ 0 1 16 O
. . 0 0 12 O

The DT 0 0 2 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
inhibit VBP 0 1 13 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
9D9 CD 0 0 UNK O
include VBP 0 1 1 O
some DT 0 0 12 O
that WDT 0 0 12 O
are VBP 1 0 12 O
not RB 0 1 12 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
the DT 0 0 12 O
enzyme NN 0 1 14 O
( ( 0 0 2 O
quinidine NN 0 1 16 B-Drug
; : 0 0 2 O

Separating VBG 0 1 UNK O
the DT 0 0 12 O
doses NNS 1 1 6 O
of IN 0 0 12 O
antacid NN 0 1 UNK B-Group
and CC 0 0 12 O
lomefloxacin NN 0 1 UNK B-Drug
minimizes NNS 0 0 UNK O
this DT 0 0 12 O
decrease NN 0 1 1 O
in IN 0 0 12 O
bioavailability NN 0 1 UNK O
; : 0 0 2 O

however RB 0 0 12 O
no DT 0 0 12 O
specific JJ 0 1 1 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
performed VBN 1 1 1 O
to TO 0 0 12 O
evaluate VB 0 1 1 O
potential JJ 0 1 1 O
drug NN 0 1 1 O
- : 0 0 2 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
. . 0 0 12 O

Veratrum NNP 0 1 UNK B-Group
alkaloids NNS 1 1 13 I-Group
: : 0 0 2 O
Amphetamines NNS 0 1 UNK B-Group
inhibit VBP 0 1 13 O
the DT 0 0 12 O
hypotensive JJ 0 1 14 O
effect NN 0 1 1 O
of IN 0 0 12 O
veratrum NN 0 1 UNK B-Group
alkaloids NNS 1 1 13 I-Group
. . 0 0 12 O

Flucytosine NN 0 1 UNK B-Drug
: : 0 0 2 O
while IN 0 0 12 O
a DT 0 0 12 O
synergistic JJ 0 1 UNK O
relationship NN 0 1 12 O
with IN 0 0 12 O
amphotericin NN 0 1 14 B-Drug
B NNP 0 0 2 I-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
concomitant JJ 0 1 6 O
use NN 0 1 1 O
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
toxicity NN 0 1 6 O
of IN 0 0 12 O
flucytosine NN 0 1 13 B-Drug
by IN 0 0 12 O
possibly RB 0 1 12 O
increasing VBG 1 1 1 O
its PRP$ 1 0 12 O
cellular JJ 0 1 13 O
uptake NN 0 1 14 O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
impairing VBG 1 1 UNK O
its PRP$ 1 0 12 O
renal JJ 0 1 6 O
excretion NN 0 1 14 O
. . 0 0 12 O

An DT 0 0 2 O
interaction NN 0 1 UNK O
study NN 0 1 1 O
with IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
showed VBD 1 1 12 O
no DT 0 0 12 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
effect NN 0 1 1 O
of IN 0 0 12 O
anastrozole NN 0 1 16 B-Drug
on IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
pharmacokinetics NNS 0 1 UNK O
or CC 0 0 12 O
anticoagulant JJ 0 1 13 O
activity NN 0 1 1 O
. . 0 0 12 O

Ranitidine NNP 0 1 0 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
twice RB 0 1 12 O
daily RB 0 1 12 O
did VBD 1 0 12 O
not RB 0 1 12 O
interact VB 0 0 UNK O
significantly RB 0 0 1 O
with IN 0 0 12 O
nisoldipine NN 0 1 13 B-Drug
( ( 0 0 2 O
AUC NNP 0 1 UNK O
was VBD 1 0 12 O
decreased VBN 1 1 1 O
by IN 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
. . 0 0 12 O

Careful JJ 0 1 UNK O
observation NN 0 1 1 O
is VBZ 1 0 12 O
required VBN 1 1 1 O
when WRB 0 0 12 O
amantadine NN 0 1 16 B-Drug
is VBZ 1 0 12 O
administered VBN 1 1 1 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
central JJ 0 1 1 B-Group
nervous JJ 0 1 6 I-Group
system NN 0 1 1 I-Group
stimulants NNS 1 1 13 I-Group
. . 0 0 12 O

Carbamazepine NNP 0 1 UNK B-Drug_n
epoxide VBP 0 1 UNK I-Drug_n
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
Cmin NNP 0 1 UNK O
concentrations NNS 1 1 13 O
increased VBD 1 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
from IN 0 0 12 O
9 CD 0 0 2 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
9 CD 0 0 2 O
micrograms NNS 1 1 14 O
/ JJ 0 0 2 O
mL NN 0 1 14 O
with IN 0 0 12 O
the DT 0 0 12 O
addition NN 0 1 1 O
of IN 0 0 12 O
felbamate NN 0 1 13 B-Drug
. . 0 0 12 O

Coadministration NN 0 1 UNK O
of IN 0 0 12 O
VIDEX NNP 0 1 UNK B-Brand
with IN 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
are VBP 1 0 12 O
known VBN 1 1 12 O
to TO 0 0 12 O
cause VB 0 1 12 O
pancreatitis NN 0 1 6 O
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
this DT 0 0 12 O
toxicity NN 0 1 6 O
( ( 0 0 2 O
see VB 0 1 12 O
WARNINGS NNP 0 1 UNK O
) ) 0 0 2 O
and CC 0 0 12 O
should MD 0 0 12 O
be VB 0 0 12 O
done VBN 1 0 12 O
with IN 0 0 12 O
extreme JJ 0 1 1 O
caution NN 0 0 1 O
only RB 0 1 12 O
if IN 0 0 12 O
other JJ 0 0 12 O
alternatives NNS 1 1 UNK O
are VBP 1 0 12 O
not RB 0 1 12 O
available JJ 0 1 1 O
and CC 0 0 12 O
only RB 0 1 12 O
if IN 0 0 12 O
clearly RB 0 0 12 O
indicated VBN 1 1 1 O
. . 0 0 12 O

These DT 0 0 1 O
doses NNS 1 1 6 O
are VBP 1 0 12 O
lower JJR 1 1 1 O
than IN 0 0 12 O
the DT 0 0 12 O
therapeutic JJ 0 1 6 O
doses NNS 1 1 6 O
for IN 0 0 12 O
both DT 0 0 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

There EX 0 0 12 O
is VBZ 1 0 12 O
no DT 0 0 12 O
known JJ 0 1 12 O
drug NN 0 1 1 O
interference NN 0 1 13 O
with IN 0 0 12 O
standard JJ 0 1 1 O
clinical JJ 0 1 6 O
laboratory NN 0 1 1 O
tests NNS 1 1 1 O
. . 0 0 12 O

Digitalis NNP 0 1 15 B-Group
glycosides NNS 1 1 13 I-Group
: : 0 0 2 O
amphotericin NN 0 1 14 B-Drug
B NNP 0 0 2 I-Drug
- : 0 0 2 O
induced JJ 0 1 6 O
hypokalemia NN 0 1 14 O
may MD 0 0 1 O
potentiate VB 0 0 UNK O
digitalis NN 0 1 14 B-Group
toxicity NN 0 1 6 O
. . 0 0 12 O

Administration NN 0 1 UNK O
of IN 0 0 12 O
repeat NN 0 1 12 O
doses NNS 1 1 6 O
of IN 0 0 12 O
FACTIVE NNP 0 1 UNK B-Brand
had VBD 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
repeat NN 0 1 12 O
dose JJ 0 1 6 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
theophylline NN 0 1 16 B-Drug
digoxin NN 0 1 14 B-Drug
or CC 0 0 12 O
an DT 0 0 12 O
ethinylestradiol JJ 0 1 UNK B-Drug
/ NN 0 0 2 O
levonorgestrol NN 0 0 UNK O
oral JJ 0 1 6 O
contraceptive JJ 0 1 13 B-Group
product NN 0 1 1 I-Group
in IN 0 0 12 O
healthy JJ 0 1 12 O
subjects NNS 1 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
safety NN 0 1 1 O
and CC 0 0 12 O
efficacy NN 0 1 UNK O
of IN 0 0 12 O
PROLEUKIN NNP 0 1 UNK B-Brand
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
any DT 0 0 12 O
antineoplastic JJ 0 1 13 B-Group
agents NNS 1 1 1 I-Group
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
established VBN 1 1 1 O
. . 0 0 12 O

Clinically RB 0 0 7 O
or CC 0 0 12 O
potentially RB 0 0 1 O
significant JJ 0 1 1 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
between IN 0 0 12 O
DIFLUCAN NNP 0 1 UNK B-Brand
and CC 0 0 12 O
the DT 0 0 12 O
following JJ 0 1 1 O
agents NNS 1 1 1 O
/ VBP 0 0 2 O
classes NNS 1 1 UNK O
have VBP 0 0 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
a DT 0 0 12 O
similar JJ 0 1 1 O
study NN 0 1 1 O
attempting VBG 1 1 12 O
to TO 0 0 12 O
replicate VB 0 1 UNK O
this DT 0 0 12 O
finding NN 0 1 12 O
no DT 0 0 12 O
interactive JJ 0 1 1 O
effect NN 0 1 1 O
on IN 0 0 12 O
hepatic JJ 0 1 14 O
transaminases NNS 1 1 14 O
was VBD 1 0 12 O
identified VBN 1 1 1 O
. . 0 0 12 O

Opioids NNS 0 1 UNK B-Group
are VBP 1 0 12 O
strong JJ 0 1 12 O
central JJ 0 1 1 B-Group
nervous JJ 0 1 6 I-Group
system NN 0 1 1 I-Group
depressants NNS 1 0 13 I-Group
but CC 0 0 12 O
regular JJ 0 1 12 O
users NNS 1 1 UNK O
develop VBP 0 0 1 O
physiological JJ 0 1 13 O
tolerance NN 0 1 1 O
allowing VBG 1 1 1 O
gradually RB 0 0 1 O
increased VBN 1 1 1 O
dosages NNS 1 1 14 O
. . 0 0 12 O

- : 0 0 2 O
did VBD 1 0 12 O
not RB 0 1 12 O
change VB 0 1 1 O
the DT 0 0 12 O
pharmacokinetic JJ 0 1 UNK O
profile NN 0 1 1 O
of IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
( ( 0 0 2 O
a DT 0 0 12 O
substrate NN 0 1 UNK O
of IN 0 0 12 O
cytochromes NNS 1 1 UNK O
P9 NNP 0 1 UNK O
9A9 CD 0 0 UNK O
and CC 0 0 12 O
9C9 CD 0 0 UNK O
) ) 0 0 2 O
or CC 0 0 12 O
influence VB 0 0 UNK O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
9 CD 0 0 2 O
- : 0 0 2 O
mg NN 0 1 0 O
oral JJ 0 1 6 O
dose NN 0 1 6 O
of IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
on IN 0 0 12 O
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
or CC 0 0 12 O
the DT 0 0 12 O
INR NNP 0 1 13 O
( ( 0 0 2 O
International NNP 0 1 UNK O
Normalized NNP 0 1 UNK O
Ratio NNP 0 1 2 O
) ) 0 0 2 O
. . 0 0 12 O

FREQUENT NNP 0 1 11 O
PROTHROMBIN NNP 0 1 UNK O
TIME NNP 0 1 11 O
/ NNP 0 0 2 O
INR NNP 0 1 13 O
DETERMINATIONS NNP 0 1 UNK O
ARE NNP 0 0 UNK O
ADVISABLE NNP 0 0 UNK O
UNTIL NNP 0 0 11 O
IT NNP 0 0 UNK O
HAS NNP 0 0 11 O
BEEN NNP 0 0 11 O
DEFINITELY NNP 0 1 UNK O
DETERMINED NNP 0 1 UNK O
THAT IN 0 0 11 O
THE NNP 0 0 11 O
PROTHROMBIN NNP 0 1 UNK O
TIME NNP 0 1 11 O
/ NNP 0 0 2 O
INR NNP 0 1 13 O
HAS NNP 0 0 11 O
STABILIZED NNP 0 1 UNK O
. . 0 0 12 O

Therefore RB 0 0 1 O
patients NNS 1 1 6 O
without IN 0 0 12 O
a DT 0 0 12 O
functioning NN 0 1 1 O
thyroid JJ 0 1 6 B-Group
gland NN 0 1 6 O
who WP 0 0 12 O
are VBP 1 0 12 O
on IN 0 0 12 O
thyroid JJ 0 1 6 O
replacement NN 0 1 1 O
therapy NN 0 1 6 O
may MD 0 0 1 O
need VB 0 1 12 O
to TO 0 0 12 O
increase VB 0 1 1 O
their PRP$ 0 0 12 O
thyroid NN 0 1 6 O
dose NN 0 1 6 O
if IN 0 0 12 O
estrogens NNS 1 1 16 B-Group
or CC 0 0 12 O
estrogen VB 0 1 6 B-Group
- : 0 0 2 O
containing VBG 1 1 1 O
oral JJ 0 1 6 O
contraceptives NNS 1 1 13 B-Group
are VBP 1 0 12 O
given VBN 1 1 12 O
. . 0 0 12 O

Beta NNP 0 1 2 B-Group
adrenergic JJ 0 1 UNK I-Group
agonists NNS 1 1 UNK I-Group
should MD 0 0 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
caution NN 0 0 1 O
to TO 0 0 12 O
patients NNS 1 1 6 O
being VBG 1 0 12 O
treated VBN 1 1 1 O
with IN 0 0 12 O
monoamine JJ 0 1 13 B-Group
oxidase NN 0 1 13 I-Group
inhibitors NNS 1 1 14 I-Group
or CC 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
since IN 0 1 12 O
the DT 0 0 12 O
action NN 0 1 13 O
of IN 0 0 12 O
beta NN 0 1 16 B-Group
adrenergic JJ 0 1 UNK I-Group
agonists NNS 1 1 UNK I-Group
on IN 0 0 12 O
the DT 0 0 12 O
vascular JJ 0 1 6 O
system NN 0 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
potentiated VBN 1 0 UNK O
. . 0 0 12 O

The DT 0 0 2 O
anesthesiologist NN 0 1 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
informed VBN 1 1 12 O
when WRB 0 0 12 O
a DT 0 0 12 O
patient NN 0 1 6 O
is VBZ 1 0 12 O
receiving VBG 1 1 1 O
labetalol JJ 0 1 0 B-Drug
HCl NNP 0 0 14 I-Drug
. . 0 0 12 O

The DT 0 0 2 O
following JJ 0 1 1 O
similar JJ 0 1 1 O
changes NNS 1 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
expected VBN 1 1 12 O
with IN 0 0 12 O
larger JJR 1 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
estrogen NN 0 1 6 B-Group
: : 0 0 2 O
- : 0 0 2 O
Increased VBD 0 1 7 O
sulfobromophthalein JJ 0 1 UNK O
retention NN 0 1 1 O

Protease NN 0 1 UNK B-Group
inhibitors NNS 1 1 14 I-Group
: : 0 0 2 O
Amprenavir NNP 0 1 UNK B-Drug
lopinavir VBZ 0 1 13 B-Drug
nelfinavir JJ 0 1 16 B-Drug
and CC 0 0 12 O
ritonavir NNS 0 1 16 B-Drug
have VBP 0 0 12 O
been VBN 1 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
decrease VB 0 1 1 O
plasma JJ 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
combination NN 0 1 1 B-Group
hormonal JJ 0 1 6 I-Group
contraceptives NNS 1 1 13 I-Group
; : 0 0 2 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
desirable JJ 0 0 UNK O
to TO 0 0 12 O
monitor VB 0 1 1 O
TCA NNP 0 1 13 B-Group
plasma NN 0 1 14 O
levels NNS 1 1 1 O
whenever WRB 0 0 12 O
an DT 0 0 12 O
agent NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressant JJ 0 1 6 I-Group
class NN 0 1 12 I-Group
including VBG 1 1 1 O
Anafranil NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
going VBG 1 0 12 O
to TO 0 0 12 O
be VB 0 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
with IN 0 0 12 O
another DT 0 0 12 O
drug NN 0 1 1 O
known VBN 1 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
an DT 0 0 12 O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
P9 NNP 0 1 UNK O
9D9 CD 0 0 UNK O
( ( 0 0 2 O
and CC 0 0 12 O
/ NNP 0 0 2 O
or CC 0 0 12 O
P9 NNP 0 1 UNK O
9A9 CD 0 0 UNK O
) ) 0 0 2 O
. . 0 0 12 O

- : 0 0 2 O
Increased VBD 0 1 7 O
thyroid JJ 0 1 6 O
- : 0 0 2 O
binding NN 0 1 1 O
globulin NN 0 1 14 O
( ( 0 0 2 O
TBG NNP 0 1 UNK O
) ) 0 0 2 O
leading VBG 1 1 1 O
to TO 0 0 12 O
in IN 0 0 12 O
- : 0 0 2 O
creased VBD 1 0 UNK O
circulating VBG 1 1 13 O
total JJ 0 1 1 O
thyroid JJ 0 1 6 O
hormone NN 0 1 6 O
; : 0 0 2 O

Therefore RB 0 0 1 O
increased VBD 1 1 1 O
monitoring NN 0 1 1 O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
when WRB 0 0 12 O
initiating VBG 1 1 1 O
adjusting NN 0 0 1 O
or CC 0 0 12 O
discontinuing VBG 1 1 6 O
COREG NNP 0 1 UNK B-Brand
. . 0 0 12 O

Until IN 0 0 2 O
data NNS 0 1 1 O
on IN 0 0 12 O
possible JJ 0 1 1 O
interactions NNS 1 1 UNK O
between IN 0 0 12 O
verapamil NN 0 1 0 B-Drug
and CC 0 0 12 O
disopyramide NN 0 1 16 B-Drug
phosphate NN 0 1 14 I-Drug
are VBP 1 0 12 O
obtained VBN 1 1 1 O
disopyramide RB 0 1 16 B-Drug
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
within IN 0 0 1 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
before IN 0 1 12 O
or CC 0 0 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
after IN 0 0 12 O
verapamil JJ 0 1 0 B-Drug
administration NN 0 1 1 O
. . 0 0 12 O

There EX 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
no DT 0 0 12 O
formal JJ 0 1 1 O
clinical JJ 0 1 6 O
studies NNS 1 1 1 O
to TO 0 0 12 O
evaluate VB 0 1 1 O
the DT 0 0 12 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
of IN 0 0 12 O
TAXOTERE NNP 0 1 UNK B-Brand
with IN 0 0 12 O
other JJ 0 0 12 O
medications NNS 1 1 6 O
. . 0 0 12 O

These DT 0 0 1 O
effects NNS 1 1 1 O
were VBD 1 0 12 O
not RB 0 1 12 O
observed VBN 1 1 1 O
when WRB 0 0 12 O
Vardenafil NNP 0 1 UNK B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
was VBD 1 0 12 O
taken VBN 1 1 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
before IN 0 1 12 O
the DT 0 0 12 O
NTG NNP 0 1 15 B-Drug
. . 0 0 12 O

Coadministration NN 0 1 UNK O
with IN 0 0 12 O
a DT 0 0 12 O
high JJ 0 1 1 O
dose NN 0 1 6 O
of IN 0 0 12 O
antacid NN 0 1 UNK B-Group
( ( 0 0 2 O
9 CD 0 0 2 O
mEq NN 0 1 14 O
) ) 0 0 2 O
results NNS 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
decrease NN 0 1 1 O
in IN 0 0 12 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
ranitidine NN 0 1 0 B-Drug
and CC 0 0 12 O
may MD 0 0 1 O
decrease VB 0 1 1 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
bismuth NN 0 1 16 O
from IN 0 0 12 O
TRITEC NNP 0 1 UNK B-Brand
. . 0 0 12 O

Therefore RB 0 0 1 O
if IN 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
these DT 0 0 12 O
agents NNS 1 1 1 O
is VBZ 1 0 12 O
indicated JJ 0 1 1 O
dosing NN 0 0 14 O
should MD 0 0 12 O
be VB 0 0 12 O
separated VBN 1 1 3 O
by IN 0 0 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
. . 0 0 12 O

Interference NN 0 1 UNK O
of IN 0 0 12 O
MPAG NNP 0 0 UNK B-Drug_n
hydrolysis NN 0 1 UNK O
may MD 0 0 1 O
lead VB 0 1 12 O
to TO 0 0 12 O
less JJR 0 1 12 O
MPA NNP 0 0 UNK B-Drug_n
available JJ 0 1 1 O
for IN 0 0 12 O
absorption NN 0 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
patients NNS 1 1 6 O
who WP 0 0 12 O
have VBP 0 0 12 O
received VBN 1 1 12 O
muscle NN 0 1 6 B-Group
relaxants NNS 1 0 13 I-Group
doxapram VBP 0 1 UNK B-Drug
may MD 0 0 1 O
temporarily RB 0 0 1 O
mask VB 0 1 3 O
the DT 0 0 12 O
residual JJ 0 1 1 O
effects NNS 1 1 1 O
of IN 0 0 12 O
muscle NN 0 1 6 B-Group
relaxant NN 0 0 0 I-Group
drugs NNS 1 1 6 I-Group
. . 0 0 12 O

ALIMTA NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
primarily RB 0 0 1 O
eliminated VBN 1 1 UNK O
unchanged JJ 0 1 1 O
renally RB 0 0 14 O
as IN 1 0 12 O
a DT 0 0 12 O
result NN 0 1 1 O
of IN 0 0 12 O
glomerular JJ 0 1 UNK O
filtration NN 0 1 3 O
and CC 0 0 12 O
tubular JJ 0 1 3 O
secretion NN 0 1 14 O
. . 0 0 12 O

Imipramine NN 0 1 UNK B-Drug
: : 0 0 2 O
Coadministration NN 0 1 UNK O
of IN 0 0 12 O
single JJ 0 1 12 O
doses NNS 1 1 6 O
of IN 0 0 12 O
Sonata NNP 0 1 UNK B-Brand
9 CD 0 0 2 O
mg NN 0 1 0 O
and CC 0 0 12 O
imipramine VB 0 1 0 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
produced VBN 1 0 1 O
additive JJ 0 1 16 O
effects NNS 1 1 1 O
on IN 0 0 12 O
decreased JJ 0 1 1 O
alertness NN 0 1 UNK O
and CC 0 0 12 O
impaired JJ 0 1 6 O
psychomotor NN 0 0 13 O
performance NN 0 1 13 O
for IN 0 0 12 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
after IN 0 0 12 O
administration NN 0 1 1 O
. . 0 0 12 O

Drugs NNS 0 1 2 O
That WDT 0 0 2 O
Are VBP 0 0 UNK O
Mainly RB 0 0 UNK O
Metabolized VBN 0 1 UNK O
by IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O

If IN 0 0 12 O
ZEMURON NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
administered VBN 1 1 1 O
following VBG 1 1 1 O
administration NN 0 1 1 O
of IN 0 0 12 O
succinylcholine NN 0 1 16 B-Drug
it PRP 0 0 12 O
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
given VBN 1 1 12 O
until IN 0 0 12 O
recovery NN 0 1 1 O
from IN 0 0 12 O
succinylcholine NN 0 1 16 B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
. . 0 0 12 O

GI NNP 0 1 6 O
Motility NNP 0 1 UNK O
Agent NNP 0 1 UNK O
: : 0 0 2 O
cisapride NN 0 1 UNK B-Drug
* NN 0 0 2 O
CONTRAINDICATED NNP 0 1 UNK O
due JJ 0 1 1 O
to TO 0 0 12 O
potential JJ 0 1 1 O
for IN 0 0 12 O
serious JJ 0 1 12 O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
life NN 0 1 12 O
- : 0 0 2 O
threatening VBG 1 0 12 O
reactions NNS 1 1 1 O
such JJ 0 0 1 O
as IN 1 0 12 O
cardiac JJ 0 1 6 O
arrhythmias NN 1 1 6 O
. . 0 0 12 O

Due JJ 0 1 2 O
to TO 0 0 12 O
the DT 0 0 12 O
considerable JJ 0 0 1 O
variability NN 0 1 UNK O
of IN 0 0 12 O
these DT 0 0 12 O
interactions NNS 1 1 UNK O
the DT 0 0 12 O
dosage NN 0 1 0 O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
individualized VBN 1 1 UNK O
when WRB 0 0 12 O
patients NNS 1 1 6 O
receive VBP 0 1 1 O
these DT 0 0 12 O
medications NNS 1 1 6 O
concurrently RB 0 0 1 O
. . 0 0 12 O

Because IN 0 0 12 O
there EX 0 0 12 O
is VBZ 1 0 12 O
a DT 0 0 12 O
theoretical JJ 0 1 UNK O
basis NN 0 1 1 O
that IN 0 0 12 O
these DT 0 0 12 O
effects NNS 1 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
additive JJ 0 1 16 O
use NN 0 1 1 O
of IN 0 0 12 O
ergotamine JJ 0 1 UNK B-Drug
- : 0 0 2 O
containing NN 0 1 1 O
or CC 0 0 12 O
ergot VB 0 1 UNK B-Group
- : 0 0 2 O
type NN 0 1 1 I-Group
medications NNS 1 1 6 I-Group
( ( 0 0 2 O
like IN 0 0 12 O
dihydroergotamine NN 0 1 UNK B-Drug
or CC 0 0 12 O
methysergide NN 0 1 UNK B-Drug
) ) 0 0 2 O
and CC 0 0 12 O
AXERT NNP 0 1 UNK B-Brand
within IN 0 0 1 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
of IN 0 0 12 O
each DT 0 0 12 O
other JJ 0 0 12 O
should MD 0 0 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
. . 0 0 12 O

Furthermore IN 0 0 1 O
it PRP 0 0 12 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
proposed VBN 1 1 UNK O
that IN 0 0 12 O
isoniazid NN 0 1 13 B-Drug
resulted VBD 1 1 1 O
In IN 0 0 2 O
induction NN 0 1 1 O
of IN 0 0 12 O
P NNP 0 1 2 O
- : 0 0 2 O
9IIE9 CD 0 0 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
patients NNS 1 1 6 O
liver WDT 0 1 6 O
which WDT 0 0 12 O
in IN 0 0 12 O
turn NN 0 1 12 O
resulted VBN 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
greater JJR 1 1 1 O
proportion NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
ingested JJ 0 1 14 O
acetaminophen NN 0 1 16 B-Drug
being VBG 1 0 12 O
converted VBN 1 0 1 O
to TO 0 0 12 O
the DT 0 0 12 O
toxic NN 0 1 1 O
metabolites NNS 1 1 UNK O
. . 0 0 12 O

Combination NNP 0 1 UNK O
therapy NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
caution NN 0 0 1 O
especially RB 0 0 12 O
in IN 0 0 12 O
immunocompromised JJ 0 1 13 O
patients NNS 1 1 6 O
. . 0 0 12 O

Epinephrine NNP 0 1 0 B-Drug
also RB 0 0 12 O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
cautiously RB 0 0 UNK O
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
( ( 0 0 2 O
e.g. NN 0 0 UNK O
digitalis RB 0 1 14 B-Group
glycosides NNS 1 1 13 B-Group
) ) 0 0 2 O
that WDT 0 0 12 O
sensitize VBP 0 0 UNK O
the DT 0 0 12 O
myocardium NN 0 1 8 O
to TO 0 0 12 O
the DT 0 0 12 O
actions NNS 1 1 UNK O
of IN 0 0 12 O
sympathomimetic JJ 0 1 13 B-Group
drugs NNS 1 1 6 I-Group
. . 0 0 12 O

Co NNP 0 1 2 O
- : 0 0 2 O
medications NNS 1 1 6 O
that IN 0 0 12 O
induce VBP 0 1 6 O
CYP NNP 0 1 UNK O
9A9 CD 0 0 UNK O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
rifampicin NN 0 1 UNK B-Drug
phenytoin NN 0 1 16 B-Drug
carbamazepine NN 0 1 16 B-Drug
phenobarbital NN 0 1 16 B-Drug
or CC 0 0 12 O
St. NNP 0 1 2 O
John NNP 0 0 19 O
wort NN 0 0 UNK O
) ) 0 0 2 O
may MD 0 0 1 O
significantly RB 0 0 1 O
decrease VB 0 1 1 O
exposure NN 0 1 1 O
to TO 0 0 12 O
exemestane VB 0 1 13 B-Drug
. . 0 0 12 O

However RB 0 0 1 O
prudent JJ 0 0 1 O
medical JJ 0 1 1 O
practice NN 0 1 UNK O
dictates NNS 1 0 UNK O
careful JJ 0 1 12 O
monitoring NN 0 1 1 O
of IN 0 0 12 O
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
in IN 0 0 12 O
all DT 0 0 12 O
patients NNS 1 1 6 O
treated VBN 1 1 1 O
with IN 0 0 12 O
azithromycin NN 0 1 0 B-Drug
and CC 0 0 12 O
warfarin NN 0 1 14 B-Drug
concomitantly RB 0 0 14 O
. . 0 0 12 O

Nevirapine NN 0 1 UNK B-Drug

Tricyclic JJ 0 0 UNK B-Group
antidepressants NNS 1 1 13 I-Group
may MD 0 0 1 O
potentiate VB 0 0 UNK O
the DT 0 0 12 O
cardiovascular JJ 0 1 6 O
effects NNS 1 1 1 O
of IN 0 0 12 O
adreneric JJ 0 0 UNK O
agents NNS 1 1 1 O
. . 0 0 12 O

Carbamazepine NNP 0 1 UNK B-Drug
clonazepam NN 0 1 0 B-Drug
ethosuximide NN 0 1 13 B-Drug

It PRP 0 0 12 O
is VBZ 1 0 12 O
not RB 0 1 12 O
known VBN 1 1 12 O
which WDT 0 0 12 O
drug NN 0 1 1 O
clearance NN 0 1 16 O
mechanism NN 0 1 13 O
involved VBN 1 1 12 O
in IN 0 0 12 O
caspofungin JJ 0 1 14 B-Drug
disposition NN 0 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
inducible JJ 0 1 14 O
. . 0 0 12 O

Methotrexate NN 0 1 0 B-Drug
: : 0 0 2 O
An DT 0 0 2 O
increased VBN 1 1 1 O
risk NN 0 1 1 O
of IN 0 0 12 O
hepatitis NN 0 1 6 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
result VB 0 1 1 O
from IN 0 0 12 O
combined VBN 1 1 1 O
use NN 0 1 1 O
of IN 0 0 12 O
methotrexate NN 0 1 16 B-Drug
and CC 0 0 12 O
etretinate NN 0 1 UNK B-Drug
. . 0 0 12 O

Rifabutin NN 0 1 UNK B-Drug

In IN 0 0 2 O
the DT 0 0 12 O
warfarin NN 0 1 14 B-Drug
study NN 0 1 1 O
vardenafil NN 0 1 UNK B-Drug
had VBD 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
or CC 0 0 12 O
other JJ 0 0 12 O
pharmacodynamic JJ 0 1 UNK O
parameters NNS 1 1 1 O
. . 0 0 12 O

However RB 0 0 1 O
on IN 0 0 12 O
the DT 0 0 12 O
basis NN 0 1 1 O
of IN 0 0 12 O
available JJ 0 1 1 O
data NNS 0 1 1 O
no DT 0 0 12 O
dosage NN 0 1 0 O
adjustment NN 0 1 1 O
for IN 0 0 12 O
ondansetron NN 0 1 16 B-Drug
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
for IN 0 0 12 O
patients NNS 1 1 6 O
on IN 0 0 12 O
these DT 0 0 12 O
drugs.9 NNS 0 1 UNK O
9 CD 0 0 2 O
Tramadol NNP 0 1 0 B-Drug
: : 0 0 2 O
Although IN 0 0 12 O
no DT 0 0 12 O
pharmacokinetic JJ 0 1 UNK O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
between IN 0 0 12 O
ondansetron NN 0 1 16 B-Drug
and CC 0 0 12 O
tramadol NN 0 1 16 B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
data NNS 0 1 1 O
from IN 0 0 12 O
9 CD 0 0 2 O
small JJ 0 1 12 O
studies NNS 1 1 1 O
indicate VBP 0 0 1 O
that IN 0 0 12 O
ondansetron NN 0 1 16 B-Drug
may MD 0 0 1 O
be VB 0 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
an DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
patient NN 0 1 6 O
controlled VBN 1 1 1 O
administration NN 0 1 1 O
of IN 0 0 12 O
tramadol JJ 0 1 16 B-Drug
.9 FW 0 0 18 O
9 CD 0 0 2 O
Chemotherapy NN 0 1 7 O
: : 0 0 2 O
Tumor NN 0 1 7 O
response NN 0 1 1 O
to TO 0 0 12 O
chemotherapy VB 0 1 6 O
in IN 0 0 12 O
the DT 0 0 12 O
P NNP 0 1 2 O
9 CD 0 0 2 O
mouse NN 0 1 UNK O
leukemia NN 0 1 6 O
model NN 0 1 UNK O
is VBZ 1 0 12 O
not RB 0 1 12 O
affected VBN 1 1 1 O
by IN 0 0 12 O
ondansetron NN 0 1 16 B-Drug
. . 0 0 12 O

No DT 0 0 2 O
formal JJ 0 1 1 O
clinical JJ 0 1 6 O
studies NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
conducted VBN 1 1 1 O
to TO 0 0 12 O
assess VB 0 1 1 O
if IN 0 0 12 O
there EX 0 0 12 O
is VBZ 1 0 12 O
an DT 0 0 12 O
interactive JJ 0 1 1 O
effect NN 0 1 1 O
on IN 0 0 12 O
bone NN 0 1 6 O
loss NN 0 1 1 O
between IN 0 0 12 O
systemic JJ 0 1 6 B-Group
corticosteroids NNS 1 1 14 I-Group
and CC 0 0 12 O
Accutane NNP 0 1 UNK B-Brand
. . 0 0 12 O

INDOCIN NNP 0 1 UNK B-Brand
can MD 0 0 12 O
reduce VB 0 0 1 O
the DT 0 0 12 O
antihypertensive JJ 0 1 14 O
effects NNS 1 1 1 O
of IN 0 0 12 O
captopril NN 0 1 0 B-Drug
and CC 0 0 12 O
losartan NN 0 1 0 B-Drug
. . 0 0 12 O

Amphotericin NNP 0 1 0 B-Drug
Foscarnet NNP 0 1 0 B-Drug
and CC 0 0 12 O
Aminoglycosides NNP 0 1 UNK B-Group
: : 0 0 2 O
Drugs NNS 0 1 2 O
such JJ 0 0 1 O
as IN 1 0 12 O
amphotericin JJ 0 1 14 B-Drug
foscarnet NN 0 1 16 B-Drug
and CC 0 0 12 O
aminoglycosides NNS 0 1 13 B-Group
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
developing VBG 1 0 1 O
peripheral JJ 0 1 6 O
neuropathy NN 0 1 6 O
or CC 0 0 12 O
other JJ 0 0 12 O
HIVID NNP 0 1 UNK B-Drug
- : 0 0 2 O
associated JJ 0 1 1 O
adverse JJ 0 0 1 O
events NNS 1 1 12 O
by IN 0 0 12 O
interfering VBG 1 1 13 O
with IN 0 0 12 O
the DT 0 0 12 O
renal JJ 0 1 6 O
clearance NN 0 1 16 O
of IN 0 0 12 O
zalcitabine NN 0 1 UNK B-Drug
( ( 0 0 2 O
thereby RB 0 0 UNK O
raising VBG 1 0 UNK O
systemic JJ 0 1 6 O
exposure NN 0 1 1 O
) ) 0 0 2 O
. . 0 0 12 O

Clinical JJ 0 1 7 O
studies NNS 1 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
strong JJ 0 1 12 O
CYP NNP 0 1 UNK O
9A9 CD 0 0 UNK O
inhibitors NNS 1 1 14 O
on IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
fulvestrant NN 0 1 13 B-Drug
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
performed VBN 1 1 1 O
. . 0 0 12 O

Rifampin NN 0 1 0 B-Drug

Limited JJ 0 1 2 O
clinical JJ 0 1 6 O
experience NN 0 1 12 O
indicates VBZ 1 0 1 O
that IN 0 0 12 O
requirements NNS 1 1 1 O
for IN 0 0 12 O
volatile JJ 0 1 UNK B-Group
inhalation NN 0 1 16 I-Group
anesthetics NNS 1 1 13 I-Group
are VBP 1 0 12 O
reduced VBN 1 1 1 O
by IN 0 0 12 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
for IN 0 0 12 O
the DT 0 0 12 O
first JJ 0 1 12 O
sixty NN 0 1 12 O
( ( 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
minutes NNS 1 1 12 O
following VBG 1 1 1 O
ALFENTA NNP 0 1 UNK B-Brand
induction NN 0 1 1 O
The DT 0 0 2 O
concomitant NN 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
erythromycin NN 0 1 0 B-Drug
with IN 0 0 12 O
ALFENTA NNP 0 1 UNK B-Brand
can MD 0 0 12 O
significantly RB 0 0 1 O
inhibit VB 0 1 13 O
ALFENTA NNP 0 1 UNK B-Brand
clearance NN 0 1 16 O
and CC 0 0 12 O
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
prolonged JJ 0 1 6 O
or CC 0 0 12 O
delayed JJ 0 1 1 O
respiratory NN 0 1 6 O
depression NN 0 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
pressor NN 0 1 14 O
response NN 0 1 1 O
of IN 0 0 12 O
adrenergic JJ 0 1 UNK B-Group
agents NNS 1 1 1 I-Group
may MD 0 0 1 O
also RB 0 0 12 O
be VB 0 0 12 O
potentiated VBN 1 0 UNK O
by IN 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
. . 0 0 12 O

In IN 0 0 2 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
demonstrated VBD 1 0 1 O
that IN 0 0 12 O
the DT 0 0 12 O
plasma NN 0 1 14 O
protein NN 0 1 14 O
binding NN 0 1 1 O
of IN 0 0 12 O
des NNS 1 0 13 B-Drug
- : 0 0 2 O
ciclesonide NN 0 1 13 I-Drug
was VBD 1 0 12 O
not RB 0 1 12 O
affected VBN 1 1 1 O
by IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
or CC 0 0 12 O
salicylic JJ 0 1 UNK B-Drug
acid NN 0 1 14 I-Drug
indicating VBG 1 0 1 O
no DT 0 0 12 O
potential NN 0 1 1 O
for IN 0 0 12 O
protein NN 0 1 14 O
binding VBG 1 1 1 O
- : 0 0 2 O
based VBN 1 1 1 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
urinary JJ 0 1 6 O
excretion NN 0 1 14 O
of IN 0 0 12 O
meclofenamate NN 0 1 UNK B-Drug
sodium NN 0 1 14 I-Drug
is VBZ 1 0 12 O
unaffected VBN 0 1 UNK O
by IN 0 0 12 O
aspirin NN 0 1 14 B-Brand
indicating VBG 1 0 1 O
no DT 0 0 12 O
change NN 0 1 1 O
in IN 0 0 12 O
meclofenamate NN 0 1 UNK B-Drug
sodium NN 0 1 14 I-Drug
absorption NN 0 1 1 O
. . 0 0 12 O

however RB 0 0 12 O
the DT 0 0 12 O
clinical JJ 0 1 6 O
significance NN 0 1 13 O
is VBZ 1 0 12 O
unknown JJ 0 1 12 O
. . 0 0 12 O

Most JJS 0 0 2 O
cases NNS 1 1 UNK O
of IN 0 0 12 O
serious JJ 0 1 12 O
or CC 0 0 12 O
fatal JJ 0 1 13 O
adverse JJ 0 0 1 O
events NNS 1 1 12 O
involving VBG 1 1 1 O
Levo NNP 0 1 15 B-Brand
- : 0 0 2 O
Dromoran NN 0 0 UNK I-Brand
reported VBD 1 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
manufacturer NN 0 1 1 O
or CC 0 0 12 O
the DT 0 0 12 O
FDA NNP 0 1 UNK O
have VBP 0 0 12 O
involved VBN 1 1 12 O
either CC 0 1 12 O
the DT 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
large JJ 0 1 3 O
initial JJ 0 1 1 O
doses NNS 1 1 6 O
or CC 0 0 12 O
too RB 0 0 12 O
frequent JJ 0 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
the DT 0 0 12 O
drug NN 0 1 1 O
to TO 0 0 12 O
nonopioid VB 0 1 UNK O
tolerant JJ 0 1 1 O
patients NNS 1 1 6 O
or CC 0 0 12 O
the DT 0 0 12 O
simultaneous JJ 0 1 13 O
administration NN 0 1 1 O
of IN 0 0 12 O
levorphanol NN 0 1 UNK B-Drug
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
affecting VBG 1 1 1 O
respiration NN 0 1 6 O
. . 0 0 12 O

Most JJS 0 0 2 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
of IN 0 0 12 O
plasma NN 0 1 14 O
doxazosin NN 0 1 13 B-Drug
is VBZ 1 0 12 O
protein JJ 0 1 14 O
bound NN 0 1 12 O
. . 0 0 12 O

Antacids NNS 0 1 UNK B-Group
may MD 0 0 1 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
absorption NN 0 1 1 O
of IN 0 0 12 O
LEVSIN NNP 0 1 UNK B-Brand
. . 0 0 12 O

Patients NNS 0 1 7 O
receiving VBG 1 1 1 O
high JJ 0 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
salicylates NNS 1 1 13 B-Group
concomitantly RB 0 0 14 O
with IN 0 0 12 O
furosemide NN 0 1 0 B-Drug
as IN 1 0 12 O
in IN 0 0 12 O
rheumatic JJ 0 0 6 O
disease NN 0 1 6 O
may MD 0 0 1 O
experience VB 0 1 12 O
salicylate JJ 0 1 13 B-Group
toxicity NN 0 1 6 O
at IN 0 0 12 O
lower JJR 1 1 1 O
doses NNS 1 1 6 O
because IN 0 0 12 O
of IN 0 0 12 O
competitive JJ 0 1 UNK O
renal JJ 0 1 6 O
excretory NN 0 0 UNK O
sites NNS 1 1 1 O
. . 0 0 12 O

Depending VBG 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
fraction NN 0 1 1 O
of IN 0 0 12 O
drug NN 0 1 1 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
P9 NNP 0 1 UNK O
9D9 CD 0 0 UNK O
the DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
plasma JJ 0 1 14 O
concentration NN 0 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
small JJ 0 1 12 O
or CC 0 0 12 O
quite JJ 0 0 12 O
large JJ 0 1 3 O
( ( 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
fold JJ 0 1 3 O
increase NN 0 1 1 O
in IN 0 0 12 O
plasma JJ 0 1 14 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
TCA NNP 0 1 13 B-Group
) ) 0 0 2 O
. . 0 0 12 O

Antidiabetic JJ 0 1 UNK B-Group
drugs NNS 1 1 6 I-Group
( ( 0 0 2 O
oral JJ 0 1 6 O
agents NNS 1 1 1 O
and CC 0 0 12 O
insulin NN 0 1 14 B-Drug
) ) 0 0 2 O
: : 0 0 2 O
hypoglycemia NN 0 1 6 O
or CC 0 0 12 O
hyperglycemia NN 0 1 14 O
; : 0 0 2 O

Indomethacin NNP 0 1 0 B-Drug
- : 0 0 2 O
Concomitant NNP 0 1 UNK O
use NN 0 1 1 O
of IN 0 0 12 O
L NNP 0 1 2 B-Drug
- : 0 0 2 O
glutamine NN 0 1 13 I-Drug
and CC 0 0 12 O
indomethacin NN 0 1 14 B-Drug
may MD 0 0 1 O
ameliorate VB 0 0 6 O
increased VBD 1 1 1 O
intestinal JJ 0 1 13 O
permeability NN 0 1 UNK O
caused VBN 1 1 1 O
by IN 0 0 12 O
indomethacin NN 0 1 14 B-Drug
. . 0 0 12 O

An DT 0 0 2 O
additive JJ 0 1 16 O
hypotensive NN 0 1 14 O
effect NN 0 1 1 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
with IN 0 0 12 O
the DT 0 0 12 O
combination NN 0 1 1 O
of IN 0 0 12 O
systemic JJ 0 1 6 O
clonidine NN 0 1 0 B-Drug
and CC 0 0 12 O
neuroleptic JJ 0 1 13 B-Group
therapy NN 0 1 6 O
. . 0 0 12 O

No DT 0 0 2 O
adjustment NN 0 1 1 O
of IN 0 0 12 O
dosage NN 0 1 0 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
in IN 0 0 12 O
such JJ 0 0 1 O
patients NNS 1 1 6 O
. . 0 0 12 O

In IN 0 0 2 O
rats NNS 1 1 UNK O
increased VBD 1 1 1 O
incidences NNS 1 1 UNK O
of IN 0 0 12 O
common JJ 0 1 1 O
fetal JJ 0 1 6 O
skeletal JJ 0 1 13 O
findings NNS 1 1 1 O
( ( 0 0 2 O
extra JJ 0 0 3 O
pair NN 0 1 UNK O
of IN 0 0 12 O
thoracic JJ 0 0 8 O
ribs NNS 1 1 3 O
unossified JJ 0 0 UNK O
cervical JJ 0 1 6 O
vertebral JJ 0 1 8 O
centra NN 1 1 15 O
shortened VBD 1 1 1 O
ribs NNS 1 1 3 O
) ) 0 0 2 O
were VBD 1 0 12 O
observed VBN 1 1 1 O
at IN 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
/ NNP 0 0 2 O
day NN 0 1 12 O
( ( 0 0 2 O
~9 JJ 0 0 UNK O
times NNS 1 1 12 O
the DT 0 0 12 O
human JJ 0 1 1 O
exposure NN 0 1 1 O
at IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
daily RB 0 1 12 O
based VBN 1 1 1 O
on IN 0 0 12 O
AUC9 NNP 0 0 UNK O
- : 0 0 2 O
9hr CD 0 0 UNK O
for IN 0 0 12 O
total JJ 0 1 1 O
ezetimibe NN 0 1 16 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

A DT 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
mg NN 0 1 0 O
Vardenafil NNP 0 1 UNK B-Drug
dose NN 0 1 6 O
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
exceeded VBN 1 0 UNK O
when WRB 0 0 12 O
used VBN 1 1 12 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
once RB 0 0 12 O
daily JJ 0 1 12 O
ketoconazole NN 0 1 16 B-Drug
. . 0 0 12 O

Alprazolam NNS 0 1 0 B-Drug
: : 0 0 2 O
When WRB 0 0 12 O
fluvoxamine NN 0 1 16 B-Drug
maleate NN 0 1 16 I-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg RB 0 1 0 O
qd NN 0 1 14 O
) ) 0 0 2 O
and CC 0 0 12 O
alprazolam NN 0 1 0 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
q.d NN 0 0 UNK O
. . 0 0 12 O
were VBD 1 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
to TO 0 0 12 O
steady JJ 0 1 1 O
state NN 0 1 1 O
plasma NN 0 1 14 O
concentration NN 0 1 1 O
and CC 0 0 12 O
other JJ 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
parameters NNS 1 1 1 O
( ( 0 0 2 O
AUC NNP 0 1 UNK O
Cmax NNP 0 1 UNK O
T9 NNP 0 1 13 O
/ NNP 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
of IN 0 0 12 O
alprazolam NN 0 1 0 B-Drug
were VBD 1 0 12 O
approximately RB 0 1 1 O
twice JJ 0 1 12 O
those DT 0 0 12 O
observed JJ 0 1 1 O
when WRB 0 0 12 O
alprazolam NN 0 1 0 B-Drug
was VBD 1 0 12 O
administered VBN 1 1 1 O
alone RB 0 1 12 O
; : 0 0 2 O

Because IN 0 0 12 O
the DT 0 0 12 O
tetracyclines NNS 1 1 13 B-Group
have VBP 0 0 12 O
been VBN 1 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
depress VB 0 0 13 O
plasma JJ 0 1 14 O
prothrombin NN 0 1 14 O
activity NN 0 1 1 O
patients NNS 1 1 6 O
who WP 0 0 12 O
are VBP 1 0 12 O
on IN 0 0 12 O
anticoagulant JJ 0 1 13 B-Group
therapy NN 0 1 6 O
may MD 0 0 1 O
require VB 0 0 1 O
downward JJ 0 1 3 O
adjustment NN 0 1 1 O
of IN 0 0 12 O
their PRP$ 0 0 12 O
anticoagulant JJ 0 1 13 B-Group
dosage NN 0 1 0 O
. . 0 0 12 O

As IN 0 0 2 O
a DT 0 0 12 O
result NN 0 1 1 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
are VBP 1 0 12 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
these DT 0 0 12 O
enzyme NNS 0 1 14 O
systems NNS 1 1 1 O
may MD 0 0 1 O
have VB 0 0 12 O
lower JJR 1 1 1 O
than IN 0 0 12 O
expected VBN 1 1 12 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
when WRB 0 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
nevirapine NN 0 1 13 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
difficulty NN 0 1 1 O
in IN 0 0 12 O
achieving VBG 1 0 1 O
adequate JJ 0 1 1 O
sedation NN 0 1 6 O
may MD 0 0 1 O
have VB 0 0 12 O
been VBN 1 0 12 O
the DT 0 0 12 O
result NN 0 1 1 O
of IN 0 0 12 O
decreased JJ 0 1 1 O
absorption NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
sedatives NNS 1 1 6 B-Group
due JJ 0 1 1 O
to TO 0 0 12 O
both DT 0 0 12 O
the DT 0 0 12 O
gastrointestinal JJ 0 1 6 O
effects NNS 1 1 1 O
and CC 0 0 12 O
stimulant JJ 0 1 13 O
effects NNS 1 1 1 O
of IN 0 0 12 O
methylphenidate NN 0 1 16 B-Drug
. . 0 0 12 O

Pharmacokinetics NNS 0 1 UNK O
were VBD 1 0 12 O
assessed VBN 1 1 1 O
in IN 0 0 12 O
two CD 0 1 12 O
of IN 0 0 12 O
these DT 0 0 12 O
trials NNS 1 1 1 O
. . 0 0 12 O

Combination NN 0 1 UNK O
Therapy NN 0 1 2 O
: : 0 0 2 O
Any DT 0 0 UNK O
form NN 0 1 1 O
of IN 0 0 12 O
therapy NN 0 1 6 O
which WDT 0 0 12 O
adds VBZ 1 1 UNK O
to TO 0 0 12 O
the DT 0 0 12 O
stress NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
patient NN 0 1 6 O
interferes VBZ 1 1 UNK O
with IN 0 0 12 O
nutrition NN 0 1 1 O
or CC 0 0 12 O
depresses VBZ 1 0 UNK O
bone CD 0 1 6 O
marrow NN 0 1 6 O
function NN 0 1 1 O
will MD 0 0 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
toxicity NN 0 1 6 O
of IN 0 0 12 O
Floxuridine NNP 0 1 UNK B-Drug
. . 0 0 12 O

Halothane NNP 0 1 UNK B-Drug
has VBZ 1 0 12 O
little RB 0 1 12 O
or CC 0 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
ED9 NNP 0 0 UNK O
but CC 0 0 12 O
may MD 0 0 1 O
prolong VB 0 0 13 O
the DT 0 0 12 O
duration NN 0 1 1 O
of IN 0 0 12 O
action NN 0 1 13 O
and CC 0 0 12 O
decrease VB 0 1 1 O
the DT 0 0 12 O
average JJ 0 1 1 O
infusion NN 0 1 14 O
requirement NN 0 1 1 O
by IN 0 0 12 O
as RB 0 0 12 O
much JJ 0 0 12 O
as IN 1 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

In IN 0 0 2 O
general JJ 0 1 1 O
if IN 0 0 12 O
a DT 0 0 12 O
patient NN 0 1 6 O
shows VBZ 1 1 12 O
no DT 0 0 12 O
signs NNS 1 1 12 O
of IN 0 0 12 O
sedation NN 0 1 6 O
within IN 0 0 1 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
after IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
mg NN 0 1 0 O
dose NN 0 1 6 O
of IN 0 0 12 O
flumazenil NN 0 1 13 B-Drug
serious JJ 0 1 12 O
resedation NN 0 0 UNK O
at IN 0 0 12 O
a DT 0 0 12 O
later JJ 1 1 12 O
time NN 0 1 12 O
is VBZ 1 0 12 O
unlikely JJ 0 1 12 O
. . 0 0 12 O

Ocupress NN 0 1 UNK B-Brand
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
with IN 0 0 12 O
caution NN 0 0 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
who WP 0 0 12 O
are VBP 1 0 12 O
receiving VBG 1 1 1 O
a DT 0 0 12 O
beta NN 0 1 16 B-Group
- : 0 0 2 O
adrenergic NN 0 1 UNK I-Group
blocking VBG 1 1 UNK I-Group
agent NN 0 1 1 I-Group
orally RB 0 1 14 O
because IN 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
potential NN 0 1 1 O
for IN 0 0 12 O
additive JJ 0 1 16 O
effects NNS 1 1 1 O
on IN 0 0 12 O
systemic JJ 0 1 6 O
beta NN 0 1 16 O
- : 0 0 2 O
blockade NN 0 1 1 O
. . 0 0 12 O

INDOCIN NNP 0 1 UNK B-Brand
and CC 0 0 12 O
potassium NN 0 1 14 B-Group
- : 0 0 2 O
sparing VBG 1 0 6 I-Group
diuretics NNS 1 1 14 I-Group
each DT 0 0 12 O
may MD 0 0 1 O
be VB 0 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
increased JJ 0 1 1 O
serum NN 0 1 14 O
potassium NN 0 1 14 O
levels NNS 1 1 1 O
. . 0 0 12 O

Drug NNP 0 1 2 O
- : 0 0 2 O
Drug NN 0 1 2 O
Interactions NNS 0 1 UNK O
: : 0 0 2 O
No DT 0 0 2 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
have VBP 0 0 12 O
been VBN 1 0 12 O
found VBN 1 1 12 O
with IN 0 0 12 O
theophylline NN 0 1 16 B-Drug
at IN 0 0 12 O
a DT 0 0 12 O
low JJ 0 1 1 O
dose NN 0 1 6 O
azithromycin NN 0 1 0 B-Drug
pseudoephedrine JJ 0 1 16 B-Drug
ketoconazole NN 0 1 16 B-Drug
or CC 0 0 12 O
erythromycin NN 0 1 0 B-Drug
. . 0 0 12 O

and CC 0 0 12 O
disulfiram NN 0 1 13 B-Drug
When WRB 0 0 12 O
amitriptyline NN 0 1 16 B-Drug
HCl NNP 0 0 14 I-Drug
is VBZ 1 0 12 O
given VBN 1 1 12 O
with IN 0 0 12 O
anticholinergic JJ 0 1 13 B-Drug
agents NNS 1 1 1 O
or CC 0 0 12 O
sympathomimetic JJ 0 1 13 B-Drug
drugs NNS 1 1 6 O
including VBG 1 1 1 O
epinephrine NN 0 1 14 B-Drug
combined VBN 1 1 1 O
with IN 0 0 12 O
local JJ 0 1 12 O
anesthetics NNS 1 1 13 B-Drug
close JJ 0 1 12 O
supervision NN 0 1 1 O
and CC 0 0 12 O
careful JJ 0 1 12 O
adjustment NN 0 1 1 O
of IN 0 0 12 O
dosages NNS 1 1 14 O
are VBP 1 0 12 O
required VBN 1 1 1 O
. . 0 0 12 O

Terfenadine NN 0 1 UNK B-Drug
: : 0 0 2 O
Because IN 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
occurrence NN 0 1 1 O
of IN 0 0 12 O
serious JJ 0 1 12 O
cardiac JJ 0 1 6 O
dysrhythmias NN 0 1 13 O
secondary JJ 0 1 1 O
to TO 0 0 12 O
prolongation NN 0 1 6 O
of IN 0 0 12 O
the DT 0 0 12 O
QTc NNP 0 0 14 O
interval NN 0 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
azole JJ 0 1 UNK B-Group
antifungals NNS 1 1 UNK I-Group
in IN 0 0 12 O
conjunction NN 0 1 1 O
with IN 0 0 12 O
terfenadine JJ 0 1 UNK B-Drug
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
performed VBN 1 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
vitro JJ 0 1 UNK O
displacement NN 0 1 1 O
studies NNS 1 1 1 O
with IN 0 0 12 O
highly RB 0 1 1 O
protein JJ 0 1 14 O
- : 0 0 2 O
bound NN 0 1 12 O
drugs NNS 1 1 6 O
such JJ 0 0 1 O
as IN 1 0 12 O
furosemide JJ 0 1 0 B-Drug
propranolol NN 0 1 16 B-Drug
captopril NN 0 1 0 B-Drug
nicardipine NN 0 1 16 B-Drug
pravastatin NN 0 1 16 B-Drug
glyburide NN 0 1 16 B-Drug
warfarin NN 0 1 14 B-Drug
phenytoin NN 0 1 16 B-Drug
acetylsalicylic JJ 0 0 UNK B-Drug
acid NN 0 1 14 I-Drug
tolbutamide NN 0 1 UNK B-Drug
and CC 0 0 12 O
metformin NN 0 1 0 B-Drug
showed VBD 1 1 12 O
no DT 0 0 12 O
influence NN 0 0 UNK O
on IN 0 0 12 O
the DT 0 0 12 O
extent NN 0 1 1 O
of IN 0 0 12 O
nateglinide JJ 0 1 13 B-Drug
protein NN 0 1 14 O
binding NN 0 1 1 O
. . 0 0 12 O

Patients NNS 0 1 7 O
treated VBN 1 1 1 O
with IN 0 0 12 O
TENORMIN NNP 0 1 UNK B-Brand
plus CC 0 1 16 O
a DT 0 0 12 O
catecholamine JJ 0 1 14 O
depletor NN 0 0 UNK O
should MD 0 0 12 O
therefore RB 0 0 1 O
be VB 0 0 12 O
closely RB 0 0 1 O
observed VBN 1 1 1 O
for IN 0 0 12 O
evidence NN 0 1 1 O
of IN 0 0 12 O
hypotension NN 0 1 6 O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
marked VBN 1 1 1 O
bradycardia IN 0 1 8 O
which WDT 0 0 12 O
may MD 0 0 1 O
produce VB 0 0 1 O
vertigo JJ 0 1 6 O
syncope NN 0 1 8 O
or CC 0 0 12 O
postural JJ 0 1 13 O
hypotension NN 0 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
similarity NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
TYSABRI NNP 0 1 UNK B-Brand
- : 0 0 2 O
associated JJ 0 1 1 O
adverse JJ 0 0 1 O
event NN 0 1 12 O
profile NN 0 1 1 O
between IN 0 0 12 O
Study NNP 0 1 2 O
9 CD 0 0 2 O
( ( 0 0 2 O
without IN 0 0 12 O
co NN 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
AVONEX NNP 0 1 UNK B-Brand
) ) 0 0 2 O
and CC 0 0 12 O
Study $ 0 1 2 O
9 CD 0 0 2 O
( ( 0 0 2 O
with IN 0 0 12 O
co NN 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
AVONEX NNP 0 1 UNK B-Brand
) ) 0 0 2 O
indicates VBZ 1 0 1 O
that IN 0 0 12 O
this DT 0 0 12 O
alteration NN 0 1 1 O
in IN 0 0 12 O
clearance NN 0 1 16 O
does VBZ 1 0 12 O
not RB 0 1 12 O
necessitate JJ 0 0 UNK O
reduction NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
TYSABRI NNP 0 1 UNK B-Brand
dose NN 0 1 6 O
to TO 0 0 12 O
maintain VB 0 1 1 O
safety NN 0 1 1 O
General NNP 0 1 2 O
) ) 0 0 2 O
. . 0 0 12 O

A DT 0 0 2 O
conservative JJ 0 0 12 O
approach NN 0 1 1 O
to TO 0 0 12 O
dosing VBG 1 0 14 O
felodipine NN 0 1 13 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
taken VBN 1 1 12 O
. . 0 0 12 O

In IN 0 0 2 O
vitro NN 0 1 UNK O
and CC 0 0 12 O
in IN 0 0 12 O
vivo JJ 0 1 13 O
studies NNS 1 1 1 O
have VBP 0 0 12 O
shown VBN 1 1 1 O
that IN 0 0 12 O
esomeprazole NN 0 1 16 B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
likely JJ 0 1 12 O
to TO 0 0 12 O
inhibit VB 0 1 13 O
CYPs NNP 0 1 UNK O
9A9 CD 0 0 UNK O
9A9 CD 0 0 UNK O
9C9 CD 0 0 UNK O
9D9 CD 0 0 UNK O
9E9 CD 0 0 UNK O
and CC 0 0 12 O
9A9 CD 0 0 UNK O
. . 0 0 12 O

Oral JJ 0 1 2 O
hypoglycemic JJ 0 1 14 B-Group
agents NNS 1 1 1 I-Group
Oxandrolone VBP 0 1 UNK B-Drug
may MD 0 0 1 O
inhibit VB 0 1 13 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
oral JJ 0 1 6 O
hypoglycemic JJ 0 1 14 B-Group
agents NNS 1 1 1 I-Group
. . 0 0 12 O

- : 0 0 2 O
Phenytoin NN 0 1 0 B-Drug
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
Dilantin NNP 0 1 0 B-Brand
) ) 0 0 2 O
Use NNP 0 1 2 O
of IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
with IN 0 0 12 O
sulfapyridine NN 0 1 UNK B-Drug
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
chance NN 0 1 12 O
of IN 0 0 12 O
side JJ 0 1 3 O
effects NNS 1 1 1 O
affecting VBG 1 1 1 O
the DT 0 0 12 O
liver NN 0 1 6 O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
the DT 0 0 12 O
side JJ 0 1 3 O
effects NNS 1 1 1 O
of IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug

Such JJ 0 0 1 O
an DT 0 0 12 O
interaction NN 0 1 UNK O
can MD 0 0 12 O
potentially RB 0 0 1 O
lead VB 0 1 12 O
to TO 0 0 12 O
higher JJR 1 1 1 O
free JJ 0 1 12 O
fractions NNS 1 1 1 O
of IN 0 0 12 O
either DT 0 1 12 O
tiagabine NN 0 1 13 B-Drug
or CC 0 0 12 O
the DT 0 0 12 O
competing JJ 0 0 UNK O
drug NN 0 1 1 O
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
desirable JJ 0 0 UNK O
to TO 0 0 12 O
monitor VB 0 1 1 O
TCA NNP 0 1 13 B-Group
plasma NN 0 1 14 O
levels NNS 1 1 1 O
whenever WRB 0 0 12 O
a DT 0 0 12 O
TCA NNP 0 1 13 B-Group
is VBZ 1 0 12 O
going VBG 1 0 12 O
to TO 0 0 12 O
be VB 0 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
with IN 0 0 12 O
another DT 0 0 12 O
drug NN 0 1 1 O
known VBN 1 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
an DT 0 0 12 O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
P9 NNP 0 1 UNK O
9D9 CD 0 0 UNK O
. . 0 0 12 O

Beta NNP 0 1 2 B-Group
- : 0 0 2 O
adrenergic NN 0 1 UNK I-Group
Blocking VBG 0 1 UNK I-Group
Agents NNS 0 1 2 I-Group
: : 0 0 2 O
The DT 0 0 2 O
effect NN 0 1 1 O
of IN 0 0 12 O
flurbiprofen NN 0 1 16 B-Drug
on IN 0 0 12 O
blood NN 0 1 6 O
pressure NN 0 1 1 O
response NN 0 1 1 O
to TO 0 0 12 O
propranolol VB 0 1 16 B-Drug
and CC 0 0 12 O
atenolol VB 0 1 0 B-Drug
was VBD 1 0 12 O
evaluated VBN 1 1 1 O
in IN 0 0 12 O
men NNS 0 1 13 O
with IN 0 0 12 O
mild NN 0 1 6 O
uncomplicated JJ 0 1 1 O
hypertension NN 0 1 6 O
( ( 0 0 2 O
n JJ 0 1 12 O
= NNP 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

Repeating VBG 0 1 UNK O
the DT 0 0 12 O
study NN 0 1 1 O
with IN 0 0 12 O
9 CD 0 0 2 O
healthy JJ 0 1 12 O
male NN 0 1 12 O
volunteers NNS 1 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
absence NN 0 1 1 O
of IN 0 0 12 O
glibenclamide NN 0 1 UNK B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
detect VB 0 1 UNK O
an DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
acitretin NN 0 1 13 B-Drug
on IN 0 0 12 O
glucose JJ 0 1 14 O
tolerance NN 0 1 1 O
. . 0 0 12 O

vasopressors NNS 1 1 UNK B-Group
such JJ 0 0 1 O
as IN 1 0 12 O
dopamine NN 0 1 14 B-Drug
and CC 0 0 12 O
isoproterenol NN 0 1 13 B-Drug
; : 0 0 2 O

If IN 0 0 12 O
labetalol JJ 0 1 0 B-Drug
HCl NNP 0 0 14 I-Drug
is VBZ 1 0 12 O
used VBN 1 1 12 O
with IN 0 0 12 O
nitroglycerin JJ 0 1 14 B-Drug
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
angina JJ 0 1 6 O
pectoris JJ 0 0 8 O
additional JJ 0 1 1 O
antihypertensive JJ 0 1 14 O
effects NNS 1 1 1 O
may MD 0 0 1 O
occur VB 0 1 1 O
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
presently RB 0 1 1 O
not RB 0 1 12 O
known VBN 1 1 12 O
whether IN 0 0 12 O
these DT 0 0 12 O
same JJ 0 1 12 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
occur VBP 0 1 1 O
with IN 0 0 12 O
dirithromycin NN 0 1 UNK B-Drug
. . 0 0 12 O

No DT 0 0 2 O
evidence NN 0 1 1 O
of IN 0 0 12 O
fetal JJ 0 1 6 O
toxicity NN 0 1 6 O
including VBG 1 1 1 O
adverse JJ 0 0 1 O
effects NNS 1 1 1 O
on IN 0 0 12 O
immune JJ 0 1 6 O
system NN 0 1 1 O
development NN 0 1 1 O
was VBD 1 0 12 O
observed VBN 1 1 1 O
in IN 0 0 12 O
any DT 0 0 12 O
of IN 0 0 12 O
these DT 0 0 12 O
animals NNS 1 1 12 O
. . 0 0 12 O

Drug NNP 0 1 2 O
- : 0 0 2 O
Drug NN 0 1 2 O
Interactions NNS 0 1 UNK O
Between NNP 0 0 2 O
Keppra NNP 0 1 0 B-Brand
And CC 0 0 2 O
Other JJ 0 0 2 O
Antiepileptic NNP 0 1 UNK B-Group
Drugs NNP 0 1 2 I-Group
( ( 0 0 2 O
AEDs NNP 0 1 UNK B-Group
) ) 0 0 2 O
Phenytoin NNP 0 1 0 B-Drug
Keppra NNP 0 1 0 B-Brand
( ( 0 0 2 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
daily RB 0 1 12 O
) ) 0 0 2 O
had VBD 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetic JJ 0 1 UNK O
disposition NN 0 1 1 O
of IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
refractory JJ 0 1 6 O
epilepsy NN 0 1 13 O
. . 0 0 12 O

. . 0 0 12 O

Such JJ 0 0 1 O
occurrences NNS 1 1 UNK O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
when WRB 0 0 12 O
propoxyphene NN 0 1 16 B-Drug
was VBD 1 0 12 O
administered VBN 1 1 1 O
to TO 0 0 12 O
patients NNS 1 1 6 O
on IN 0 0 12 O
antidepressants NNS 1 1 13 B-Group
anticonvulsants NNS 1 1 13 B-Group
or CC 0 0 12 O
warfarin SYM 0 1 14 B-Drug
- : 0 0 2 O
like IN 0 0 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

glutethimide NN 0 1 13 B-Drug
; : 0 0 2 O

Except IN 0 0 UNK O
in IN 0 0 12 O
life NN 0 1 12 O
- : 0 0 2 O
threatening JJ 0 0 12 O
situations NNS 1 0 UNK O
avoid VBP 0 0 12 O
this DT 0 0 12 O
combination NN 0 1 1 O
. . 0 0 12 O

Anticholinergic NNP 0 1 UNK B-Group
drugs NNS 1 1 6 I-Group
in IN 0 0 12 O
the DT 0 0 12 O
presence NN 0 1 1 O
of IN 0 0 12 O
increased JJ 0 1 1 O
intraocular JJ 0 1 13 O
pressure NN 0 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
hazardous JJ 0 1 13 O
when WRB 0 0 12 O
taken VBN 1 1 12 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
agents NNS 1 1 1 O
such JJ 0 0 1 O
as IN 1 0 12 O
corti NN 0 0 13 O
costeroids.. NN 0 0 UNK O

An DT 0 0 2 O
increase NN 0 1 1 O
in IN 0 0 12 O
intracellular JJ 0 1 UNK O
levels NNS 1 1 1 O
of IN 0 0 12 O
methotrexate NN 0 1 16 B-Drug
was VBD 1 0 12 O
observed VBN 1 1 1 O
in IN 0 0 12 O
vitro NN 0 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
presence NN 0 1 1 O
of IN 0 0 12 O
teniposide NN 0 1 UNK B-Drug
. . 0 0 12 O

In IN 0 0 2 O
opioid JJ 0 1 13 B-Group
- : 0 0 2 O
dependent NN 0 1 1 O
patients NNS 1 1 6 O
mixed JJ 0 1 3 B-Group
agonist JJ 0 1 14 I-Group
antagonist JJ 0 1 13 I-Group
analgesics NNS 1 1 14 I-Group
may MD 0 0 1 O
precipitate VB 0 1 13 O
withdrawal NN 0 1 1 O
symptoms NNS 1 1 6 O
. . 0 0 12 O

There EX 0 0 12 O
was VBD 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
bleeding NN 0 1 6 O
time NN 0 1 12 O
PT NNP 0 1 2 O
or CC 0 0 12 O
aPTT NN 0 1 UNK O
. . 0 0 12 O

Nabilone NN 0 1 UNK B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
have VB 0 0 12 O
an DT 0 0 12 O
additive JJ 0 1 16 O
CNS NNP 0 1 6 O
depressant NN 0 0 UNK O
effect NN 0 1 1 O
when WRB 0 0 12 O
given VBN 1 1 12 O
with IN 0 0 12 O
either DT 0 1 12 O
diazepam NN 0 1 0 B-Drug
secobarbitone NN 0 0 UNK B-Brand
sodium NN 0 1 14 I-Brand
alcohol NN 0 1 1 B-Drug
or CC 0 0 12 O
codeine NN 0 1 0 B-Drug
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
desirable JJ 0 0 UNK O
to TO 0 0 12 O
monitor VB 0 1 1 O
TCA NNP 0 1 13 B-Group
plasma NN 0 1 14 O
levels NNS 1 1 1 O
whenever WRB 0 0 12 O
a DT 0 0 12 O
TCA NNP 0 1 13 B-Group
is VBZ 1 0 12 O
going VBG 1 0 12 O
to TO 0 0 12 O
be VB 0 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
with IN 0 0 12 O
another DT 0 0 12 O
drug NN 0 1 1 O
known VBN 1 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
an DT 0 0 12 O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
P9 NNP 0 1 UNK O
9D9 CD 0 0 UNK O
. . 0 0 12 O

Patients NNS 0 1 7 O
taking VBG 1 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
are VBP 1 0 12 O
substrates NNS 1 1 UNK O
of IN 0 0 12 O
CYP9 NNP 0 0 UNK O
9A9 CD 0 0 UNK O
especially RB 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
renal JJ 0 1 6 O
and CC 0 0 12 O
/ JJ 0 0 2 O
or CC 0 0 12 O
hepatic JJ 0 1 14 O
impairment NN 0 1 16 O
may MD 0 0 1 O
require VB 0 0 1 O
dosage NN 0 1 0 O
adjustment NN 0 1 1 O
when WRB 0 0 12 O
starting VBG 1 1 12 O
or CC 0 0 12 O
stopping VBG 1 1 12 O
concomitantly RB 0 0 14 O
administered VBN 1 1 1 O
diltiazem NN 0 1 0 B-Drug
in IN 0 0 12 O
order NN 0 1 1 O
to TO 0 0 12 O
maintain VB 0 1 1 O
optimum JJ 0 1 1 O
therapeutic JJ 0 1 6 O
blood NN 0 1 6 O
levels NNS 1 1 1 O
. . 0 0 12 O

Certain NNP 0 1 UNK O
drugs NNS 1 1 6 O
tend VBP 0 0 12 O
to TO 0 0 12 O
produce VB 0 0 1 O
hyperglycemia NN 0 1 14 O
and CC 0 0 12 O
may MD 0 0 1 O
lead VB 0 1 12 O
to TO 0 0 12 O
loss NN 0 1 1 O
of IN 0 0 12 O
control NN 0 1 1 O
. . 0 0 12 O

When WRB 0 0 12 O
Bezalip NNP 0 1 UNK B-Brand
or CC 0 0 12 O
Bezalip NNP 0 1 UNK B-Brand
retard NN 0 1 13 I-Brand
is VBZ 1 0 12 O
used VBN 1 1 12 O
at IN 0 0 12 O
the DT 0 0 12 O
same JJ 0 1 12 O
time NN 0 1 12 O
as IN 1 0 12 O
other JJ 0 0 12 O
medicines NNS 1 1 6 O
or CC 0 0 12 O
substances VBZ 0 1 1 O
the DT 0 0 12 O
following JJ 0 1 1 O
interactions NNS 1 1 UNK O
must MD 0 0 12 O
be VB 0 0 12 O
taken VBN 1 1 12 O
into IN 0 0 12 O
account NN 0 1 1 O
: : 0 0 2 O
- : 0 0 2 O
Bezalip NN 0 1 UNK B-Brand
and CC 0 0 12 O
Bezalip NNP 0 1 UNK B-Brand
retard NN 0 1 13 I-Brand
may MD 0 0 1 O
enhance VB 0 1 UNK O
the DT 0 0 12 O
action NN 0 1 13 O
of IN 0 0 12 O
anticoagulants NNS 1 1 13 B-Group
of IN 0 0 12 I-Group
the DT 0 0 12 I-Group
coumarin NN 0 1 UNK I-Group
type NN 0 1 1 I-Group
. . 0 0 12 O

Although IN 0 0 12 O
results NNS 1 1 1 O
have VBP 0 0 12 O
varied VBN 1 1 1 O
from IN 0 0 12 O
study NN 0 1 1 O
to TO 0 0 12 O
study VB 0 1 1 O
effects NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
shown VBN 1 1 1 O
on IN 0 0 12 O
furosemide JJ 0 1 0 B-Drug
- : 0 0 2 O
stimulated VBN 1 1 13 O
diuresis NN 0 1 14 O
natriuresis NN 0 1 UNK O
and CC 0 0 12 O
kaliuresis NN 0 0 UNK O
. . 0 0 12 O

drugs NNS 1 1 6 O
affecting VBG 1 1 1 O
blood NN 0 1 6 O
elements NNS 1 1 1 O
; : 0 0 2 O

- : 0 0 2 O
When WRB 0 0 12 O
Bezalip NNP 0 1 UNK B-Brand
or CC 0 0 12 O
Bezalip NNP 0 1 UNK B-Brand
retard NN 0 1 13 I-Brand
is VBZ 1 0 12 O
used VBN 1 1 12 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
anion NN 0 1 14 B-Group
- : 0 0 2 O
exchange NN 0 1 1 I-Group
resins NNS 1 1 UNK I-Group
( ( 0 0 2 O
e.g NN 0 0 UNK O
. . 0 0 12 O
cholestryramine NN 0 0 UNK B-Drug
) ) 0 0 2 O
an DT 0 0 12 O
interval NN 0 1 1 O
of IN 0 0 12 O
at IN 0 0 12 O
least JJS 0 1 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
should MD 0 0 12 O
be VB 0 0 12 O
maintained VBN 1 1 1 O
between IN 0 0 12 O
the DT 0 0 12 O
two CD 0 1 12 O
medicines NNS 1 1 6 O
since IN 0 1 12 O
the DT 0 0 12 O
absorption NN 0 1 1 O
of IN 0 0 12 O
Bezalip NNP 0 1 UNK B-Brand
or CC 0 0 12 O
Bezalip NNP 0 1 UNK B-Brand
retard NN 0 1 13 I-Brand
is VBZ 1 0 12 O
impaired JJ 0 1 6 O

Glyburide NN 0 1 0 B-Drug
: : 0 0 2 O
Glyburide NNP 0 1 0 B-Drug
is VBZ 1 0 12 O
a DT 0 0 12 O
CYP NNP 0 1 UNK O
9C9 CD 0 0 UNK O
substrate NN 0 1 UNK O
. . 0 0 12 O

Coadministration NN 0 1 UNK O
of IN 0 0 12 O
methyldopa NN 0 1 13 B-Drug
with IN 0 0 12 O
ferrous JJ 0 1 14 B-Drug
sulfate NN 0 1 14 I-Drug
or CC 0 0 12 O
ferrous JJ 0 1 14 B-Drug
gluconate NN 0 1 14 I-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O

Coadministration NN 0 1 UNK O
in IN 0 0 12 O
HIV NNP 0 1 6 O
- : 0 0 2 O
infected JJ 0 1 6 O
individuals NNS 1 1 1 O
with IN 0 0 12 O
a DT 0 0 12 O
history NN 0 1 12 O
of IN 0 0 12 O
injection NN 0 1 3 O
drug NN 0 1 1 O
use NN 0 1 1 O
resulted VBD 1 1 1 O
in IN 0 0 12 O
decreased JJ 0 1 1 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
methadone NN 0 1 6 B-Drug
and CC 0 0 12 O
signs NNS 1 1 12 O
of IN 0 0 12 O
opiate NN 0 1 6 B-Group
withdrawal NN 0 1 1 O
. . 0 0 12 O

Quinolones NNS 0 1 UNK B-Group
including VBG 1 1 1 O
norfloxacin NN 0 1 UNK B-Drug
may MD 0 0 1 O
enhance VB 0 1 UNK O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
oral JJ 0 1 6 O
anticoagulants NNS 1 1 13 B-Group
including VBG 1 1 1 O
warfarin NN 0 1 14 B-Drug
or CC 0 0 12 O
its PRP$ 1 0 12 O
derivatives NNS 1 1 13 O
or CC 0 0 12 O
similar JJ 0 1 1 O
agents NNS 1 1 1 O
. . 0 0 12 O

Antacids NNS 0 1 UNK B-Group
containing VBG 1 1 1 O
magnesium NN 0 1 14 B-Drug
aluminum NN 0 1 16 B-Drug
or CC 0 0 12 O
calcium NN 0 1 14 B-Drug
; : 0 0 2 O

Treatment NN 0 1 7 O
with IN 0 0 12 O
ZETIA NNP 0 1 UNK B-Brand
in IN 0 0 12 O
children NNS 1 1 12 O
( ( 0 0 2 O
< $ 0 0 16 O
9 CD 0 0 2 O
years NNS 1 1 12 O
) ) 0 0 2 O
is VBZ 1 0 12 O
not RB 0 1 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O

Concurrent JJ 0 1 13 O
administration NN 0 1 1 O
of IN 0 0 12 O
HEXALEN NNP 0 1 UNK B-Brand
and CC 0 0 12 O
antidepressants NNS 1 1 13 B-Group
of IN 0 0 12 I-Group
the DT 0 0 12 I-Group
MAO NNP 0 1 14 I-Group
inhibitor NN 0 1 14 I-Group
class NN 0 1 12 I-Group
may MD 0 0 1 O
cause VB 0 1 12 O
severe JJ 0 1 6 O
orthostatic JJ 0 1 8 O
hypotension.Cimetidine NN 0 1 UNK O
an DT 0 0 12 O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
microsomal JJ 0 1 UNK O
drug NN 0 1 1 O
metabolism NN 0 1 16 O
increased VBD 1 1 1 O
altretamine JJ 0 1 UNK B-Drug
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
and CC 0 0 12 O
toxicity NN 0 1 6 O
in IN 0 0 12 O
a DT 0 0 12 O
rat NN 0 1 13 O
model NN 0 1 UNK O
. . 0 0 12 O

Rifabutin NN 0 1 UNK B-Drug

In IN 0 0 2 O
patients NNS 1 1 6 O
the DT 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
with IN 0 0 12 O
dofetilide NN 0 1 13 B-Drug
was VBD 1 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
a DT 0 0 12 O
higher JJR 1 1 1 O
occurrence NN 0 1 1 O
of IN 0 0 12 O
torsade NN 0 0 13 O
de FW 0 1 2 O
pointes NNS 0 0 UNK O
. . 0 0 12 O

Epinephrine NN 0 1 0 B-Drug
may MD 0 0 1 O
antagonize VB 0 0 UNK O
the DT 0 0 12 O
neuron NN 0 1 13 O
blockade NN 0 1 1 O
produced VBN 1 0 1 O
by IN 0 0 12 O
guanethidine NN 0 1 UNK B-Drug
resulting VBG 1 1 1 O
in IN 0 0 12 O
decreased JJ 0 1 1 O
antihypertensive JJ 0 1 14 O
effect NN 0 1 1 O
and CC 0 0 12 O
requiring VBG 1 0 1 O
increased JJ 0 1 1 O
dosage NN 0 1 0 O
of IN 0 0 12 O
the DT 0 0 12 O
latter NN 0 0 UNK O
. . 0 0 12 O

Reproductive JJ 0 1 UNK O
findings NNS 1 1 1 O
occur VBP 0 1 1 O
at IN 0 0 12 O
lower JJR 1 1 1 O
doses NNS 1 1 6 O
in IN 0 0 12 O
combination NN 0 1 1 O
therapy NN 0 1 6 O
compared VBN 1 1 1 O
to TO 0 0 12 O
monotherapy VB 0 0 14 O
. . 0 0 12 O

Estrogen NN 0 1 7 B-Group
increased VBD 1 1 1 O
levels NNS 1 1 1 O
of IN 0 0 12 O
corticosteroid NN 0 1 UNK O
- : 0 0 2 O
binding NN 0 1 1 O
globulin NN 0 1 14 O
thereby RB 0 0 UNK O
increasing VBG 1 1 1 O
the DT 0 0 12 O
bound NN 0 1 12 O
( ( 0 0 2 O
inactive JJ 0 1 1 O
) ) 0 0 2 O
fraction NN 0 1 1 O
; : 0 0 2 O

There EX 0 0 12 O
is VBZ 1 0 12 O
one CD 0 1 12 O
report NN 0 1 1 O
of IN 0 0 12 O
cardiopulmonary JJ 0 1 6 O
arrest NN 0 1 12 O
with IN 0 0 12 O
full JJ 0 1 12 O
recovery NN 0 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
patient NN 0 1 6 O
who WP 0 0 12 O
was VBD 1 0 12 O
taking VBG 1 0 12 O
a DT 0 0 12 O
beta NN 0 1 16 B-Group
blocker NN 0 0 3 I-Group
( ( 0 0 2 O
propranolol NN 0 1 16 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

All DT 0 0 2 O
subjects NNS 1 1 UNK O
received VBN 1 1 12 O
glipizide JJ 0 1 0 B-Drug
alone RB 0 1 12 O
and CC 0 0 12 O
following VBG 1 1 1 O
treatment NN 0 1 6 O
with IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
of IN 0 0 12 O
fluconazole NN 0 1 0 B-Drug
as IN 1 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
daily JJ 0 1 12 O
oral JJ 0 1 6 O
dose NN 0 1 6 O
for IN 0 0 12 O
seven CD 0 1 12 O
days NNS 1 1 12 O
. . 0 0 12 O

- : 0 0 2 O
Lithium NN 0 1 UNK B-Drug
: : 0 0 2 O
Generally RB 0 0 1 O
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
given VBN 1 1 12 O
with IN 0 0 12 O
diuretics NNS 1 1 14 B-Group
. . 0 0 12 O

There EX 0 0 12 O
also RB 0 0 12 O
was VBD 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
exposure NN 0 1 1 O
to TO 0 0 12 O
and CC 0 0 12 O
the DT 0 0 12 O
excretion NN 0 1 14 O
of IN 0 0 12 O
the DT 0 0 12 O
primary JJ 0 1 1 O
metabolite NN 0 1 UNK O
ucb JJ 0 0 UNK O
L9 NNP 0 1 UNK O
. . 0 0 12 O

In IN 0 0 2 O
patients NNS 1 1 6 O
given VBN 1 1 12 O
very RB 0 1 12 O
high JJ 0 1 1 O
doses NNS 1 1 6 O
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
) ) 0 0 2 O
of IN 0 0 12 O
aspirin JJ 0 1 14 B-Brand
daily JJ 0 1 12 O
increases NNS 1 1 1 O
in IN 0 0 12 O
serum JJ 0 1 14 O
salicylate NN 0 1 13 B-Group
levels NNS 1 1 1 O
were VBD 1 0 12 O
seen VBN 1 1 12 O
when WRB 0 0 12 O
nizatidine JJ 0 1 13 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
b.i.d. NN 0 1 14 O
was VBD 1 0 12 O
administered VBN 1 1 1 O
concurrently RB 0 0 1 O
. . 0 0 12 O

Nondepolarizing VBG 0 0 UNK B-Group
Muscle NN 0 1 2 I-Group
Relaxants NNS 0 0 UNK I-Group
: : 0 0 2 O
In IN 0 0 2 O
postmarketing VBG 0 0 UNK O
experience NN 0 1 12 O
there RB 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reports NNS 1 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
possible JJ 0 1 1 O
interaction NN 0 1 UNK O
between IN 0 0 12 O
TORADOLIV NNP 0 0 UNK O
/ NNP 0 0 2 O
IM NNP 0 1 11 O
and CC 0 0 12 O
nondepolarizing JJ 0 0 UNK B-Group
muscle NN 0 1 6 I-Group
relaxants NNS 1 0 13 I-Group
that WDT 0 0 12 O
resulted VBD 1 1 1 O
in IN 0 0 12 O
apnea NN 0 1 6 O
. . 0 0 12 O

If IN 0 0 12 O
the DT 0 0 12 O
drugs NNS 1 1 6 O
are VBP 1 0 12 O
used VBN 1 1 12 O
together RB 0 1 12 O
caution NN 0 0 1 O
should MD 0 0 12 O
be VB 0 0 12 O
exercised VBN 1 1 1 O
because RB 0 0 12 O
unexpected JJ 0 1 12 O
hypotension NN 0 1 6 O
could MD 0 0 12 O
result VB 0 1 1 O
from IN 0 0 12 O
beta NN 0 1 16 O
- : 0 0 2 O
blocker NN 0 0 3 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
the DT 0 0 12 O
sympathetic JJ 0 0 13 O
reflex NN 0 1 6 O
response NN 0 1 1 O
to TO 0 0 12 O
fenoldopam VB 0 1 13 B-Drug
. . 0 0 12 O

Sulfoxone NN 0 1 UNK B-Drug
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
barbiturates NNS 1 1 14 B-Group
tolbutamide IN 0 1 UNK B-Drug
and CC 0 0 12 O
uricosurics NNS 0 0 UNK B-Group
. . 0 0 12 O

The DT 0 0 2 O
inhibitory JJ 0 1 UNK O
potential NN 0 1 1 O
of IN 0 0 12 O
ciclesonide NN 0 1 13 B-Drug
on IN 0 0 12 O
CYP9 NNP 0 0 UNK O
isoenzymes NNS 0 1 14 O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
studied VBN 1 0 1 O
. . 0 0 12 O

ritonavir NN 0 1 16 B-Drug
concentration NN 0 1 1 O

These DT 0 0 1 O
doses NNS 1 1 6 O
were VBD 1 0 12 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
times NNS 1 1 12 O
( ( 0 0 2 O
mouse NN 0 1 UNK O
) ) 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
times NNS 1 1 12 O
( ( 0 0 2 O
rat NN 0 1 13 O
) ) 0 0 2 O
the DT 0 0 12 O
human JJ 0 1 1 O
AUC NNP 0 1 UNK O
( ( 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
based VBN 1 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
maximum NN 0 1 1 O
recommended VBD 1 1 1 O
human JJ 0 1 1 O
dose NN 0 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
. . 0 0 12 O

There EX 0 0 12 O
are VBP 1 0 12 O
reports NNS 1 1 1 O
of IN 0 0 12 O
enhanced VBN 1 1 1 O
as RB 0 0 12 O
well RB 0 1 12 O
as IN 1 0 12 O
diminished JJ 0 1 1 O
effects NNS 1 1 1 O
of IN 0 0 12 O
anticoagulants NNS 1 1 13 B-Group
when WRB 0 0 12 O
given VBN 1 1 12 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
corticosteroids NNS 1 1 14 B-Group
. . 0 0 12 O

In IN 0 0 2 O
normal JJ 0 1 1 O
volunteers NNS 1 1 UNK O
receiving VBG 1 1 1 O
indomethacin VBP 0 1 14 B-Drug
the DT 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
diflunisal NN 0 1 13 B-Drug
decreased VBN 1 1 1 O
the DT 0 0 12 O
renal JJ 0 1 6 O
clearance NN 0 1 16 O
and CC 0 0 12 O
significantly RB 0 0 1 O
increased VBD 1 1 1 O
the DT 0 0 12 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
indomethacin NN 0 1 14 B-Drug
. . 0 0 12 O

By IN 0 0 2 O
decreasing VBG 1 1 1 O
the DT 0 0 12 O
gastrointestinal JJ 0 1 6 O
absorption NN 0 1 1 O
of IN 0 0 12 O
primidone NN 0 1 13 B-Drug
DIAMOX NNP 0 1 UNK B-Brand
may MD 0 0 1 O
decrease VB 0 1 1 O
serum JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
primidone NN 0 1 13 B-Drug
and CC 0 0 12 O
its PRP$ 1 0 12 O
metabolites NNS 1 1 UNK O
with IN 0 0 12 O
a DT 0 0 12 O
consequent NN 0 1 UNK O
possible JJ 0 1 1 O
decrease NN 0 1 1 O
in IN 0 0 12 O
anticonvulsant JJ 0 1 14 O
effect NN 0 1 1 O
. . 0 0 12 O

Coadministration NN 0 1 UNK O
of IN 0 0 12 O
oral JJ 0 1 6 O
contraceptives NNS 1 1 13 B-Group
increased VBD 1 1 1 O
the DT 0 0 12 O
maximum JJ 0 1 1 O
plasma JJ 0 1 14 O
concentration NN 0 1 1 O
of IN 0 0 12 O
alprazolam NN 0 1 0 B-Drug
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
decreased VBN 1 1 1 O
clearance NN 0 1 16 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
increased VBD 1 1 1 O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

( ( 0 0 2 O
Concurrent NNP 0 1 13 O
use NN 0 1 1 O
with IN 0 0 12 O
thiazide JJ 0 1 UNK B-Group
diuretics NNS 1 1 14 I-Group
may MD 0 0 1 O
enhance VB 0 1 UNK O
the DT 0 0 12 O
possibility NN 0 1 1 O
of IN 0 0 12 O
digitalis JJ 0 1 14 B-Group
toxicity NN 0 1 6 O
associated VBN 1 1 1 O
with IN 0 0 12 O
hypokalemia NN 0 1 14 O
. . 0 0 12 O
) ) 0 0 2 O

This DT 0 0 2 O
time NN 0 1 12 O
window NN 0 1 3 O
is VBZ 1 0 12 O
different JJ 0 1 1 O
than IN 0 0 12 O
for IN 0 0 12 O
other JJ 0 0 12 O
oral JJ 0 1 6 O
formulations NNS 1 1 UNK O
of IN 0 0 12 O
ciprofloxacin NN 0 1 0 B-Drug
which WDT 0 0 12 O
are VBP 1 0 12 O
usually RB 0 1 12 O
administered VBN 1 1 1 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
before IN 0 1 12 O
or CC 0 0 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
after IN 0 0 12 O
antacids NNS 1 1 14 B-Group
. . 0 0 12 O

Therefore RB 0 0 1 O
unless IN 0 0 12 O
otherwise RB 0 0 1 O
specified VBN 1 1 13 O
appropriate JJ 0 1 1 O
dosage NN 0 1 0 O
adjustments NNS 1 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
necessary JJ 0 0 1 O
. . 0 0 12 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interactions NNP 0 1 UNK O
Effect NNP 0 1 UNK O
on IN 0 0 12 O
Blood NNP 0 1 2 O
Coagulation NN 0 1 7 O
: : 0 0 2 O
Diclofenac NNP 0 1 UNK B-Drug
increases VBZ 1 1 1 O
platelet VB 0 1 14 O
aggregation NN 0 1 UNK O
time NN 0 1 12 O
but CC 0 0 12 O
does VBZ 1 0 12 O
not RB 0 1 12 O
affect VB 0 1 1 O
bleeding VBG 1 1 6 O
time NN 0 1 12 O
plasma JJ 0 1 14 O
thrombin NN 0 1 14 O
clotting VBG 1 1 14 O
time NN 0 1 12 O
plasma JJ 0 1 14 O
fibrinogen NN 0 1 14 O
or CC 0 0 12 O
factors NNS 1 1 1 O
V NNP 0 0 2 O
and CC 0 0 12 O
VII NNP 0 1 2 O
to TO 0 0 12 O
XII VB 0 0 13 O
. . 0 0 12 O

No DT 0 0 2 O
Important NNP 0 1 UNK O
Interactions NNS 0 1 UNK O
To TO 0 0 2 O
Date NNP 0 1 2 O
Levosimendan NNP 0 1 UNK B-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
have VB 0 0 12 O
clinically RB 0 0 6 O
important JJ 0 1 1 O
pharmacokinetic JJ 0 1 UNK O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
captopril NN 0 1 0 B-Drug
beta SYM 0 1 16 B-Group
- : 0 0 2 O
blockers NNS 1 0 6 I-Group
felodipine VBP 0 1 13 B-Drug
digoxin NN 0 1 14 B-Drug
warfarin NN 0 1 14 B-Drug
isosorbide JJ 0 1 16 B-Drug
mononitrate NN 0 0 0 I-Drug
carvedilol NN 0 1 16 B-Drug
ethanol NN 0 1 1 B-Drug
or CC 0 0 12 O
itraconazole NN 0 1 0 B-Drug
. . 0 0 12 O

clinical JJ 0 1 6 O
significance NN 0 1 13 O
unknown NN 0 1 12 O
. . 0 0 12 O

9 CD 0 0 2 O
. . 0 0 12 O

Lithium NNP 0 1 UNK B-Drug
generally RB 0 0 1 O
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
given VBN 1 1 12 O
with IN 0 0 12 O
diuretics NNS 1 1 14 B-Group
because IN 0 0 12 O
they PRP 0 0 12 O
reduce VB 0 0 1 O
its PRP$ 1 0 12 O
renal JJ 0 1 6 O
clearance NN 0 1 16 O
and CC 0 0 12 O
add VB 0 1 12 O
a DT 0 0 12 O
high JJ 0 1 1 O
risk NN 0 1 1 O
of IN 0 0 12 O
lithium NN 0 1 16 B-Drug
toxicity NN 0 1 6 O
. . 0 0 12 O

NSAIDs NNP 0 1 UNK B-Group
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
with IN 0 0 12 O
caution NN 0 0 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
cyclosporine NN 0 1 14 B-Drug
and CC 0 0 12 O
renal JJ 0 1 6 O
function NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
carefully RB 0 0 12 O
monitored VBN 1 1 1 O
. . 0 0 12 O

These DT 0 0 1 O
results NNS 1 1 1 O
are VBP 1 0 12 O
consistent JJ 0 1 1 O
with IN 0 0 12 O
the DT 0 0 12 O
in IN 0 0 12 O
vitro NN 0 1 UNK O
finding NN 0 1 12 O
that IN 0 0 12 O
neither DT 0 0 12 O
isotretinoin NN 0 1 13 B-Drug
nor CC 0 0 12 O
its PRP$ 1 0 12 O
metabolites NNS 1 1 UNK O
induce VBP 0 1 6 O
or CC 0 0 12 O
inhibit VBP 0 1 13 O
the DT 0 0 12 O
activity NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
CYP NNP 0 1 UNK O
9C9 CD 0 0 UNK O
human JJ 0 1 1 O
hepatic JJ 0 1 14 O
P9 NNP 0 1 UNK O
enzyme NN 0 1 14 O
. . 0 0 12 O

Administration NN 0 1 UNK O
of IN 0 0 12 O
diltiazem JJ 0 1 0 B-Drug
hydrochloride NN 0 1 0 I-Drug
concomitantly RB 0 0 14 O
with IN 0 0 12 O
propranolol NN 0 1 16 B-Drug
in IN 0 0 12 O
five CD 0 1 12 O
normal JJ 0 1 1 O
volunteers NNS 1 1 UNK O
resulted VBD 1 1 1 O
in IN 0 0 12 O
increased JJ 0 1 1 O
propranolol NN 0 1 16 B-Drug
levels NNS 1 1 1 O
in IN 0 0 12 O
all DT 0 0 12 O
subjects NNS 1 1 UNK O
and CC 0 0 12 O
bioavailability NN 0 1 UNK O
of IN 0 0 12 O
propranolol NN 0 1 16 B-Drug
was VBD 1 0 12 O
increased VBN 1 1 1 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

However RB 0 0 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
treated VBN 1 1 1 O
with IN 0 0 12 O
oral JJ 0 1 6 O
carbonic JJ 0 1 13 B-Group
anhydrase NN 0 0 13 I-Group
inhibitors NNS 1 1 14 I-Group
rare JJ 0 1 12 O
instances NNS 1 1 UNK O
of IN 0 0 12 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
have VBP 0 0 12 O
occurred VBN 1 1 1 O
with IN 0 0 12 O
high JJ 0 1 1 O
- : 0 0 2 O
dose JJ 0 1 6 O
salicylate JJ 0 1 13 B-Drug
therapy NN 0 1 6 O
. . 0 0 12 O

Other JJ 0 0 2 O
Concomitant NNP 0 1 UNK O
Therapy NNP 0 1 2 O
In IN 0 0 2 O
healthy JJ 0 1 12 O
subjects NNS 1 1 UNK O
there EX 0 0 12 O
were VBD 1 0 12 O
no DT 0 0 12 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
interactions NNS 1 1 UNK O
when WRB 0 0 12 O
felodipine NN 0 1 13 B-Drug
was VBD 1 0 12 O
given VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
indomethacin NN 0 1 14 B-Drug
or CC 0 0 12 O
spironolactone NN 0 1 0 B-Drug
. . 0 0 12 O

Paroxetine NNP 0 1 0 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg RB 0 1 0 O
QD NNP 0 1 13 O
) ) 0 0 2 O
increased VBD 1 1 1 O
the DT 0 0 12 O
concentration NN 0 1 1 O
of IN 0 0 12 O
duloxetine NN 0 1 0 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg RB 0 1 0 O
QD NNP 0 1 13 O
) ) 0 0 2 O
by IN 0 0 12 O
about IN 0 1 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
greater JJR 1 1 1 O
degrees NNS 1 1 1 O
of IN 0 0 12 O
inhibition NN 0 1 13 O
are VBP 1 0 12 O
expected VBN 1 1 12 O
with IN 0 0 12 O
higher JJR 1 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
paroxetine NN 0 1 16 B-Drug
. . 0 0 12 O

9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
The DT 0 0 2 O
following JJ 0 1 1 O
precautions NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
kept VBN 1 1 12 O
in IN 0 0 12 O
mind NN 0 1 12 O
in IN 0 0 12 O
the DT 0 0 12 O
treatment NN 0 1 6 O
of IN 0 0 12 O
anticholinesterase NN 0 1 UNK O
poisoning VBG 1 1 13 O
although IN 0 0 12 O
they PRP 0 0 12 O
do VBP 0 0 12 O
not RB 0 1 12 O
bear VB 0 1 12 O
directly RB 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
use NN 0 1 1 O
of IN 0 0 12 O
pralidoxime NN 0 1 13 B-Drug
: : 0 0 2 O
since IN 0 1 12 O
barbiturates NNS 1 1 14 B-Group
are VBP 1 0 12 O
potentiated VBN 1 0 UNK O
by IN 0 0 12 O
the DT 0 0 12 O
anticholinesterases NNS 1 1 UNK B-Group
they PRP 0 0 12 O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
cautiously RB 0 0 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
treatment NN 0 1 6 O
of IN 0 0 12 O
convulsions NNS 1 1 13 O
; : 0 0 2 O

Drug NNP 0 1 2 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
with IN 0 0 12 O
other JJ 0 0 12 O
anticonvulsants NNS 1 1 13 B-Group
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
conducted VBN 1 1 1 O
. . 0 0 12 O

N=9 NNP 0 1 UNK O
) ) 0 0 2 O
. . 0 0 12 O

thrombocytopenia NN 0 1 14 O

in IN 0 0 12 O
one CD 0 1 12 O
man NN 0 1 12 O
the DT 0 0 12 O
C NNP 0 0 2 O
max NN 0 0 3 O
of IN 0 0 12 O
terfenadine NN 0 1 UNK B-Drug
was VBD 1 0 12 O
9 CD 0 0 2 O
ng JJ 0 1 13 O
/ NNP 0 0 2 O
mL NN 0 1 14 O
with IN 0 0 12 O
terfenadine JJ 0 1 UNK B-Drug
alone NN 0 1 12 O
and CC 0 0 12 O
9 CD 0 0 2 O
ng JJ 0 1 13 O
/ NNP 0 0 2 O
mL NN 0 1 14 O
with IN 0 0 12 O
terfenadine JJ 0 1 UNK B-Drug
plus CC 0 1 16 O
dirithromycin NN 0 1 UNK B-Drug
. . 0 0 12 O

When WRB 0 0 12 O
a DT 0 0 12 O
diuretic NN 0 1 14 B-Group
is VBZ 1 0 12 O
added VBN 1 1 12 O
to TO 0 0 12 O
the DT 0 0 12 O
therapy NN 0 1 6 O
of IN 0 0 12 O
a DT 0 0 12 O
patient NN 0 1 6 O
receiving VBG 1 1 1 O
PRINIVIL NNP 0 1 UNK B-Brand
an DT 0 0 12 O
additional JJ 0 1 1 O
antihypertensive JJ 0 1 14 O
effect NN 0 1 1 O
is VBZ 1 0 12 O
usually RB 0 1 12 O
observed VBN 1 1 1 O
. . 0 0 12 O

Cimetidine NN 0 1 0 B-Drug
: : 0 0 2 O
Concomitant JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
cimetidine JJ 0 1 13 B-Drug
QID NNP 0 1 15 O
did VBD 1 0 12 O
not RB 0 1 12 O
alter VB 0 1 13 O
the DT 0 0 12 O
single JJ 0 1 12 O
- : 0 0 2 O
dose JJ 0 1 6 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
meloxicam NN 0 1 13 B-Drug
. . 0 0 12 O

Other JJ 0 0 2 O
drugs NNS 1 1 6 O
eliminated VBN 1 1 UNK O
via IN 0 0 1 O
renal JJ 0 1 6 O
secretion NN 0 1 14 O
: : 0 0 2 O
Population NNP 0 1 UNK O
pharmacokinetic JJ 0 1 UNK O
analysis NN 0 1 1 O
suggests VBZ 1 1 1 O
that IN 0 0 12 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
are VBP 1 0 12 O
secreted VBN 1 1 14 O
by IN 0 0 12 O
the DT 0 0 12 O
cationic JJ 0 1 UNK O
transport NN 0 1 1 O
system NN 0 1 1 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
cimetidine NN 0 1 13 B-Drug
ranitidine NN 0 1 0 B-Drug
diltiazem NN 0 1 0 B-Drug
triamterene NN 0 1 13 B-Drug
verapamil FW 0 1 0 B-Drug
quinidine NN 0 1 16 B-Drug
and CC 0 0 12 O
quinine NN 0 1 16 B-Drug
) ) 0 0 2 O
decreases VBZ 1 1 UNK O
the DT 0 0 12 O
oral JJ 0 1 6 O
clearance NN 0 1 16 O
of IN 0 0 12 O
pramipexole NN 0 1 16 B-Drug
by IN 0 0 12 O
about IN 0 1 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
while IN 0 0 12 O
those DT 0 0 12 O
secreted VBN 1 1 14 O
by IN 0 0 12 O
the DT 0 0 12 O
anionic JJ 0 1 UNK O
transport NN 0 1 1 O
system NN 0 1 1 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
cephalosporins NNS 1 1 14 B-Group
penicillins NNS 1 1 14 B-Group
indomethacin JJ 0 1 14 B-Drug
hydrochlorothiazide NN 0 1 0 B-Drug
and CC 0 0 12 O
chlorpropamide NN 0 1 13 B-Drug
) ) 0 0 2 O
are VBP 1 0 12 O
likely JJ 0 1 12 O
to TO 0 0 12 O
have VB 0 0 12 O
little JJ 0 1 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
oral JJ 0 1 6 O
clearance NN 0 1 16 O
of IN 0 0 12 O
pramipexole NN 0 1 16 B-Drug
. . 0 0 12 O

CNS NNP 0 1 6 O
Drugs NNP 0 1 2 O
- : 0 0 2 O
Given VBN 0 1 2 O
the DT 0 0 12 O
primary JJ 0 1 1 O
CNS NNP 0 1 6 O
effects NNS 1 1 1 O
of IN 0 0 12 O
escitalopram JJ 0 1 0 B-Drug
caution NN 0 0 1 O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
when WRB 0 0 12 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
taken VBN 1 1 12 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
other JJ 0 0 12 O
centrally RB 0 0 UNK O
acting VBG 1 1 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

dosage NN 0 1 0 O
adjustments NNS 1 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
necessary JJ 0 0 1 O
. . 0 0 12 O
) ) 0 0 2 O

Methotrexate NN 0 1 0 B-Drug
: : 0 0 2 O
Concomitant JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
methotrexate NN 0 1 16 B-Drug
and CC 0 0 12 O
some DT 0 0 12 O
NSAIDs NNP 0 1 UNK B-Group
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
reduce VB 0 0 1 O
the DT 0 0 12 O
clearance NN 0 1 16 O
of IN 0 0 12 O
methotrexate NN 0 1 16 B-Drug
enhancing VBG 1 1 1 O
the DT 0 0 12 O
toxicity NN 0 1 6 O
of IN 0 0 12 O
methotrexate NN 0 1 16 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
local JJ 0 1 12 O
anesthetic JJ 0 1 13 B-Group
solutions NNS 1 1 UNK I-Group
containing VBG 1 1 1 O
epinephrine NN 0 1 14 B-Drug
or CC 0 0 12 O
norepinephrine NN 0 1 14 B-Drug
to TO 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
monoamine JJ 0 1 13 B-Group
oxidase NN 0 1 13 I-Group
inhibitors NNS 1 1 14 I-Group
or CC 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
may MD 0 0 1 O
produce VB 0 0 1 O
severe JJ 0 1 6 O
prolonged VBN 1 1 6 O
hypertension NN 0 1 6 O
. . 0 0 12 O

A DT 0 0 2 O
small JJ 0 1 12 O
number NN 0 1 1 O
of IN 0 0 12 O
patients NNS 1 1 6 O
received VBN 1 1 12 O
epirubicin SYM 0 1 13 B-Drug
- : 0 0 2 O
based VBN 1 1 1 O
chemotherapy NN 0 1 6 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
radiation NN 0 1 1 O
therapy NN 0 1 6 O
but CC 0 0 12 O
had VBD 1 0 12 O
chemotherapy NN 0 1 6 O
interrupted VBN 1 1 12 O
in IN 0 0 12 O
order NN 0 1 1 O
to TO 0 0 12 O
avoid VB 0 0 12 O
potential JJ 0 1 1 O
overlapping VBG 1 1 1 O
toxicities NNS 1 1 UNK O
. . 0 0 12 O

Drug NN 0 1 2 O
interactions NNS 1 1 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
kept VBN 1 1 12 O
in IN 0 0 12 O
mind NN 0 1 12 O
when WRB 0 0 12 O
METROGEL NNP 0 1 UNK B-Brand
( ( 0 0 2 O
metronidazole JJ 0 1 0 B-Drug
gel NN 0 1 3 O
) ) 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
is VBZ 1 0 12 O
prescribed VBN 1 1 1 O
for IN 0 0 12 O
patients NNS 1 1 6 O
who WP 0 0 12 O
are VBP 1 0 12 O
receiving VBG 1 1 1 O
anticoagulant JJ 0 1 13 O
treatment NN 0 1 6 O
although IN 0 0 12 O
they PRP 0 0 12 O
are VBP 1 0 12 O
less RBR 0 1 12 O
likely JJ 0 1 12 O
to TO 0 0 12 O
occur VB 0 1 1 O
with IN 0 0 12 O
topical JJ 0 1 6 O
metronidazole NN 0 1 0 B-Drug
administration NN 0 1 1 O
because IN 0 0 12 O
of IN 0 0 12 O
low JJ 0 1 1 O
absorption NN 0 1 1 O
. . 0 0 12 O

Adjustment NN 0 1 UNK O
of IN 0 0 12 O
adenosine JJ 0 1 14 B-Drug
dosage NN 0 1 0 O
may MD 0 0 1 O
be VB 0 0 12 O
necessary JJ 0 0 1 O
. . 0 0 12 O

Hormonal NNP 0 1 UNK O
contraceptives NNS 1 1 13 B-Group
Co NNP 0 1 2 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
Trileptal NNP 0 1 UNK B-Brand
with IN 0 0 12 O
an DT 0 0 12 O
oral JJ 0 1 6 O
contraceptive NN 0 1 13 B-Group
has VBZ 1 0 12 O
been VBN 1 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
influence VB 0 0 UNK O
the DT 0 0 12 O
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
the DT 0 0 12 O
two CD 0 1 12 O
hormonal JJ 0 1 6 O
components NNS 1 1 1 O
ethinylestradiol FW 0 1 UNK B-Drug
( ( 0 0 2 O
EE NNP 0 0 UNK O
) ) 0 0 2 O
and CC 0 0 12 O
levonorgestrel $ 0 1 13 B-Drug
( ( 0 0 2 O
LNG NNP 0 0 UNK O
) ) 0 0 2 O
. . 0 0 12 O

and CC 0 0 12 O
Videx NNP 0 1 UNK B-Brand
( ( 0 0 2 O
Didanosine NNP 0 1 0 B-Drug
) ) 0 0 2 O
chewable JJ 0 0 16 O
/ NN 0 0 2 O
buffered VBD 1 1 16 O
tablets NNS 1 1 3 O
or CC 0 0 12 O
the DT 0 0 12 O
pediatric JJ 0 1 6 O
powder NN 0 1 3 O
for IN 0 0 12 O
oral JJ 0 1 6 O
solution NN 0 1 1 O
may MD 0 0 1 O
substantially RB 0 0 1 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
absorption NN 0 1 1 O
of IN 0 0 12 O
quinolones NNS 0 1 13 B-Group
resulting VBG 1 1 1 O
in IN 0 0 12 O
systemic JJ 0 1 6 O
levels NNS 1 1 1 O
considerably RB 0 0 1 O
lower JJR 1 1 1 O
than IN 0 0 12 O
desired VBN 1 1 1 O
. . 0 0 12 O

Celecoxib NNP 0 1 UNK B-Drug
metabolism NN 0 1 16 O
is VBZ 1 0 12 O
predominantly RB 0 0 1 O
mediated VBN 1 1 13 O
via IN 0 0 1 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
9C9 CD 0 0 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
liver NN 0 1 6 O
. . 0 0 12 O

This DT 0 0 2 O
may MD 0 0 1 O
indicate VB 0 0 1 O
that IN 0 0 12 O
they PRP 0 0 12 O
could MD 0 0 12 O
enhance VB 0 1 UNK O
the DT 0 0 12 O
toxicity NN 0 1 6 O
of IN 0 0 12 O
methotrexate NN 0 1 16 B-Drug
. . 0 0 12 O

Animal JJ 0 1 UNK O
experience NN 0 1 12 O
indicates VBZ 1 0 1 O
that IN 0 0 12 O
clorazepate NN 0 1 16 B-Drug
dipotassium NN 0 0 16 I-Drug
prolongs VBZ 1 0 UNK O
the DT 0 0 12 O
sleeping NN 0 1 12 O
time NN 0 1 12 O
after IN 0 0 12 O
hexobarbital NN 0 1 UNK B-Drug
or CC 0 0 12 O
after IN 0 0 12 O
ethyl JJ 0 0 13 B-Drug
alcohol NN 0 1 1 I-Drug
increases VBZ 1 1 1 O
the DT 0 0 12 O
inhibitory JJ 0 1 UNK O
effects NNS 1 1 1 O
of IN 0 0 12 O
chlorpromazine NN 0 1 16 B-Drug
but CC 0 0 12 O
does VBZ 1 0 12 O
not RB 0 1 12 O
exhibit VB 0 1 1 O
monoamine JJ 0 1 13 O
oxidase NN 0 1 13 O
inhibition NN 0 1 13 O
. . 0 0 12 O

There EX 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
a DT 0 0 12 O
number NN 0 1 1 O
of IN 0 0 12 O
reports NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
post NN 0 1 12 O
- : 0 0 2 O
marketing NN 0 1 UNK O
experience NN 0 1 12 O
of IN 0 0 12 O
coma NN 0 1 6 O
and CC 0 0 12 O
death NN 0 1 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
the DT 0 0 12 O
concomitant NN 0 1 6 O
intravenous JJ 0 1 14 O
misuse NN 0 1 UNK O
of IN 0 0 12 O
buprenorphine NN 0 1 13 B-Drug
and CC 0 0 12 O
benzodiazepines NNS 1 1 14 B-Drug
by IN 0 0 12 O
addicts NNS 1 1 UNK O
. . 0 0 12 O

Antihypertensive JJ 0 1 7 B-Group
medications NNS 1 1 6 I-Group
other JJ 0 0 12 O
especially RB 0 0 12 O
diazoxide VBP 0 1 16 B-Drug
or CC 0 0 12 O
preanesthetic JJ 0 0 UNK O
and CC 0 0 12 O
anesthetic JJ 0 1 13 O
agents NNS 1 1 1 O
used VBN 1 1 12 O
in IN 0 0 12 O
surgery NN 0 1 6 O
or CC 0 0 12 O
skeletal JJ 0 1 13 B-Group
- : 0 0 2 O
muscle NN 0 1 6 I-Group
relaxants NNS 1 0 13 I-Group
nondepolarizing VBG 0 0 UNK O
used VBN 1 1 12 O
in IN 0 0 12 O
surgery NN 0 1 6 O

As IN 0 0 2 O
a DT 0 0 12 O
result NN 0 1 1 O
when WRB 0 0 12 O
giving VBG 1 1 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
concomitantly RB 0 0 14 O
plasma VBP 0 1 14 O
warfarin JJ 0 1 14 B-Drug
levels NNS 1 1 1 O
may MD 0 0 1 O
change VB 0 1 1 O
with IN 0 0 12 O
the DT 0 0 12 O
potential NN 0 1 1 O
for IN 0 0 12 O
increases NNS 1 1 1 O
in IN 0 0 12 O
coagulation NN 0 1 14 O
time NN 0 1 12 O
. . 0 0 12 O

Cimetidine NN 0 1 0 B-Drug
: : 0 0 2 O
Albendazole NNP 0 1 UNK B-Drug
sulfoxide NN 0 1 UNK I-Drug
concentrations NNS 1 1 13 O
in IN 0 0 12 O
bile NN 0 1 6 O
and CC 0 0 12 O
cystic JJ 0 1 6 O
fluid NN 0 1 3 O
were VBD 1 0 12 O
increased VBN 1 1 1 O
( ( 0 0 2 O
about IN 0 1 12 O
9 CD 0 0 2 O
- : 0 0 2 O
fold NN 0 1 3 O
) ) 0 0 2 O
in IN 0 0 12 O
hydatid JJ 0 1 UNK O
cyst NN 0 1 6 O
patients NNS 1 1 6 O
treated VBN 1 1 1 O
with IN 0 0 12 O
cimetidine NN 0 1 13 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
/ NNP 0 0 2 O
day NN 0 1 12 O
) ) 0 0 2 O
( ( 0 0 2 O
n=9 NN 0 1 UNK O
) ) 0 0 2 O
compared VBN 1 1 1 O
with IN 0 0 12 O
albendazole NN 0 1 13 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
/ NNP 0 0 2 O
day NN 0 1 12 O
) ) 0 0 2 O
alone RB 0 1 12 O
( ( 0 0 2 O
n=9 JJ 0 1 UNK O
) ) 0 0 2 O
. . 0 0 12 O

Although IN 0 0 12 O
there EX 0 0 12 O
may MD 0 0 1 O
be VB 0 0 12 O
decreased VBN 1 1 1 O
zalcitabine NN 0 1 UNK B-Drug
activity NN 0 1 1 O
because IN 0 0 12 O
of IN 0 0 12 O
lessened JJ 0 0 UNK O
active JJ 0 1 1 O
metabolite NN 0 1 UNK O
formation NN 0 1 1 O
the DT 0 0 12 O
clinical JJ 0 1 6 O
relevance NN 0 1 UNK O
of IN 0 0 12 O
these DT 0 0 12 O
in IN 0 0 12 O
vitro NN 0 1 UNK O
results NNS 1 1 1 O
are VBP 1 0 12 O
not RB 0 1 12 O
known VBN 1 1 12 O
. . 0 0 12 O

dextran NN 0 1 14 B-Drug
; : 0 0 2 O

Catecholamine NNP 0 1 UNK O
- : 0 0 2 O
depleting VBG 1 1 UNK O
drugs NNS 1 1 6 O
e.g. JJ 0 0 UNK O
reserpine NN 0 1 UNK B-Drug
may MD 0 0 1 O
have VB 0 0 12 O
an DT 0 0 12 O
additive JJ 0 1 16 O
effect NN 0 1 1 O
when WRB 0 0 12 O
given VBN 1 1 12 O
with IN 0 0 12 O
beta NN 0 1 16 B-Group
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
. . 0 0 12 O

Where WRB 0 0 2 O
this DT 0 0 12 O
is VBZ 1 0 12 O
not RB 0 1 12 O
possible JJ 0 1 1 O
minoxidil NNS 0 1 16 B-Drug
therapy NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
started VBN 1 1 12 O
in IN 0 0 12 O
the DT 0 0 12 O
hospital NN 0 1 12 O
and CC 0 0 12 O
the DT 0 0 12 O
patient NN 0 1 6 O
should MD 0 0 12 O
remain VB 0 0 12 O
institutionalized JJ 0 1 UNK O
until IN 0 0 12 O
severe JJ 0 1 6 O
orthostatic JJ 0 1 8 O
effects NNS 1 1 1 O
are VBP 1 0 12 O
no RB 0 0 12 O
longer RBR 0 1 12 O
present JJ 0 1 1 O
or CC 0 0 12 O
the DT 0 0 12 O
patient NN 0 1 6 O
has VBZ 1 0 12 O
learned VBN 1 1 12 O
to TO 0 0 12 O
avoid VB 0 0 12 O
activities NNS 1 1 1 O
that WDT 0 0 12 O
provoke VBD 0 0 UNK O
them PRP 0 0 12 O
. . 0 0 12 O

. . 0 0 12 O

Thus RB 0 0 1 O
there EX 0 0 12 O
may MD 0 0 1 O
be VB 0 0 12 O
a DT 0 0 12 O
potential JJ 0 1 1 O
for IN 0 0 12 O
drug NN 0 1 1 O
- : 0 0 2 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

Plasma NNP 0 1 UNK O
exposure NN 0 1 1 O
of IN 0 0 12 O
diazepam NN 0 1 0 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg RB 0 1 0 O
BID NNP 0 0 11 O
) ) 0 0 2 O
was VBD 1 0 12 O
increased VBN 1 1 1 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
following VBG 1 1 1 O
administration NN 0 1 1 O
of IN 0 0 12 O
valdecoxib NN 0 1 13 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg RB 0 1 0 O
BID NNP 0 0 11 O
) ) 0 0 2 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
while IN 0 0 12 O
plasma JJ 0 1 14 O
exposure NN 0 1 1 O
of IN 0 0 12 O
valdecoxib NN 0 1 13 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg RB 0 1 0 O
BID NNP 0 0 11 O
) ) 0 0 2 O
was VBD 1 0 12 O
not RB 0 1 12 O
substantially RB 0 0 1 O
increased VBN 1 1 1 O
following VBG 1 1 1 O
administration NN 0 1 1 O
of IN 0 0 12 O
diazepam NN 0 1 0 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg RB 0 1 0 O
BID NNP 0 0 11 O
) ) 0 0 2 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
. . 0 0 12 O

- : 0 0 2 O
Estrogens NNS 0 1 0 B-Group
( ( 0 0 2 O
female JJ 0 1 12 O
hormones NNS 1 1 13 O
) ) 0 0 2 O
or CC 0 0 12 O

Lomefloxacin NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
unlikely JJ 0 1 12 O
to TO 0 0 12 O
have VB 0 0 12 O
a DT 0 0 12 O
significant JJ 0 1 1 O
effect NN 0 1 1 O
on IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
metabolism NN 0 1 16 O
. . 0 0 12 O

Isoproterenol NNP 0 1 UNK B-Drug
hydrochloride NN 0 1 0 I-Drug
injection NN 0 1 3 O
and CC 0 0 12 O
epinephrine NN 0 1 14 B-Drug
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
simultaneously RB 0 1 13 O
because IN 0 0 12 O
both DT 0 0 12 O
drugs NNS 1 1 6 O
are VBP 1 0 12 O
direct JJ 0 1 1 O
cardiac JJ 0 1 6 O
stimulants NNS 1 1 13 O
and CC 0 0 12 O
their PRP$ 0 0 12 O
combined JJ 0 1 1 O
effects NNS 1 1 1 O
may MD 0 0 1 O
induce VB 0 1 6 O
serious JJ 0 1 12 O
arrhythmias NNS 1 1 6 O
. . 0 0 12 O

Drug NN 0 1 2 O
Interactions NNS 0 1 UNK O
: : 0 0 2 O
a DT 0 0 12 O
. . 0 0 12 O
Drugs NNP 0 1 2 O
Enhancing NNP 0 1 2 O
Heparin NNP 0 1 0 B-Drug
Effect NNP 0 1 UNK O
: : 0 0 2 O
Oral JJ 0 1 2 O
anticoagulants NNS 1 1 13 B-Group
: : 0 0 2 O
Heparin NNP 0 1 0 B-Drug
sodium NN 0 1 14 I-Drug
may MD 0 0 1 O
prolong VB 0 0 13 O
the DT 0 0 12 O
one CD 0 1 12 O
- : 0 0 2 O
stage NN 0 1 12 O
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
. . 0 0 12 O

An DT 0 0 2 O
alternative JJ 0 1 1 O
confirmatory NN 0 1 14 O
method NN 0 1 13 O
should MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
to TO 0 0 12 O
verify VB 0 1 UNK O
positive JJ 0 1 1 O
results NNS 1 1 1 O
. . 0 0 12 O

Steady JJ 0 1 UNK O
- : 0 0 2 O
state NN 0 1 1 O
plasma NN 0 1 14 O
felbamate NN 0 1 13 B-Drug
concentrations NNS 1 1 13 O
were VBD 1 0 12 O
found VBN 1 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
lower JJR 1 1 1 O
than IN 0 0 12 O
the DT 0 0 12 O
mean JJ 0 1 12 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
a DT 0 0 12 O
group NN 0 1 12 O
of IN 0 0 12 O
newly RB 0 1 12 O
diagnosed VBN 1 1 6 O
subjects NNS 1 1 UNK O
with IN 0 0 12 O
epilepsy NN 0 1 13 O
also RB 0 0 12 O
receiving VBG 1 1 1 O
9 CD 0 0 2 O
mg NN 0 1 0 O
of IN 0 0 12 O
felbamate NN 0 1 13 B-Drug
a DT 0 0 12 O
day NN 0 1 12 O
. . 0 0 12 O

. . 0 0 12 O

9 CD 0 0 2 O
. . 0 0 12 O

Meloxicam NNP 0 1 UNK B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
have VB 0 0 12 O
a DT 0 0 12 O
significant JJ 0 1 1 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
single JJ 0 1 12 O
doses NNS 1 1 6 O
of IN 0 0 12 O
methotrexate NN 0 1 16 B-Drug
. . 0 0 12 O

Because IN 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
potential NN 0 1 1 O
for IN 0 0 12 O
ARAVA NNP 0 1 UNK B-Brand
levels NNS 1 1 1 O
to TO 0 0 12 O
continue VB 0 1 12 O
to TO 0 0 12 O
increase VB 0 1 1 O
with IN 0 0 12 O
multiple JJ 0 1 1 O
dosing VBG 1 0 14 O
caution NN 0 0 1 O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
if IN 0 0 12 O
patients NNS 1 1 6 O
are VBP 1 0 12 O
to TO 0 0 12 O
be VB 0 0 12 O
receiving VBG 1 1 1 O
both DT 0 0 12 O
ARAVA NNP 0 1 UNK B-Brand
and CC 0 0 12 O
rifampin NN 0 1 16 B-Drug
. . 0 0 12 O

Central NNP 0 1 2 B-Group
Nervous NNP 0 1 UNK I-Group
System NNP 0 1 2 I-Group
Depressants VBZ 0 0 UNK I-Group
: : 0 0 2 O
The DT 0 0 2 O
concomitant NN 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
DURAGESIC NNP 0 1 UNK B-Brand
( ( 0 0 2 O
fentanyl VB 0 1 14 B-Drug
transdermal JJ 0 1 14 O
system NN 0 1 1 O
) ) 0 0 2 O
with IN 0 0 12 O
other JJ 0 0 12 O
central JJ 0 1 1 B-Group
nervous JJ 0 1 6 I-Group
system NN 0 1 1 I-Group
depressants NNS 1 0 13 I-Group
including VBG 1 1 1 O
but CC 0 0 12 O
not RB 0 1 12 O
limited VBN 1 1 1 O
to TO 0 0 12 O
other JJ 0 0 12 O
opioids JJ 0 1 14 B-Group
sedatives NNS 1 1 6 B-Group
hypnotics NNS 1 1 13 B-Group
tranquilizers NNS 1 1 13 B-Group
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
benzodiazepines NNS 1 1 14 B-Group
) ) 0 0 2 O
general JJ 0 1 1 O
anesthetics NNS 1 1 13 B-Group
phenothiazines NNS 1 1 UNK B-Group
skeletal JJ 0 1 13 B-Group
muscle NN 0 1 6 I-Group
relaxants NNS 1 0 13 I-Group
and CC 0 0 12 O
alcohol NN 0 1 1 B-Drug
may MD 0 0 1 O
cause VB 0 1 12 O
respiratory NN 0 1 6 O
depression NN 0 1 6 O
hypotension NN 0 1 6 O
and CC 0 0 12 O
profound JJ 0 1 1 O
sedation NN 0 1 6 O
or CC 0 0 12 O
potentially RB 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
coma NN 0 1 6 O
or CC 0 0 12 O
death NN 0 1 12 O
. . 0 0 12 O

Acetaminophen NNP 0 1 0 B-Drug
had VBD 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
diflunisal NN 0 1 13 B-Drug
. . 0 0 12 O

In IN 0 0 2 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
in IN 0 0 12 O
human JJ 0 1 1 O
liver NN 0 1 6 O
microsomes NNS 1 1 UNK O
indicate VBP 0 0 1 O
that IN 0 0 12 O
ertapenem NN 0 1 16 B-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
inhibit VB 0 1 13 O
metabolism NN 0 1 16 O
mediated VBN 1 1 13 O
by IN 0 0 12 O
any DT 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
following JJ 0 1 1 O
six CD 0 1 12 O
cytochrome JJ 0 1 UNK O
p9 NN 0 1 UNK O
( ( 0 0 2 O
CYP NNP 0 1 UNK O
) ) 0 0 2 O
isoforms NNS 0 1 UNK O
: : 0 0 2 O
9A9 CD 0 0 UNK O
9C9 CD 0 0 UNK O
9C9 CD 0 0 UNK O
9D9 CD 0 0 UNK O
9E9 CD 0 0 UNK O
and CC 0 0 12 O
9A9 CD 0 0 UNK O
. . 0 0 12 O

Isocarboxazid NNP 0 1 UNK B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
caution NN 0 0 1 O
to TO 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
Antabuse NNP 0 1 UNK B-Brand
( ( 0 0 2 O
disulfiram JJ 0 1 13 B-Drug
Wyeth NNP 0 1 UNK O
- : 0 0 2 O
Ayerst NNP 0 1 UNK O
Laboratories NNPS 0 1 2 O
) ) 0 0 2 O
. . 0 0 12 O

Cholestyramine NNP 0 1 UNK B-Drug
and CC 0 0 12 O
colestipol NN 0 1 13 B-Drug
resins NNS 1 1 UNK B-Group
: : 0 0 2 O
Absorption NN 0 1 UNK O
of IN 0 0 12 O
hydrochlorothiazide NN 0 1 0 B-Drug
is VBZ 1 0 12 O
impaired VBN 1 1 6 O
in IN 0 0 12 O
the DT 0 0 12 O
presence NN 0 1 1 O
of IN 0 0 12 O
anionic JJ 0 1 UNK B-Group
exchange NN 0 1 1 I-Group
resins NNS 1 1 UNK I-Group
. . 0 0 12 O

The DT 0 0 2 O
effect NN 0 1 1 O
on IN 0 0 12 O
other JJ 0 0 12 O
progestational JJ 0 0 UNK B-Group
contraceptives NNS 1 1 13 I-Group
( ( 0 0 2 O
eg JJ 0 1 UNK O
implants NNS 1 1 6 O
injectables NNS 0 1 UNK O
) ) 0 0 2 O
is VBZ 1 0 12 O
unknown JJ 0 1 12 O
. . 0 0 12 O

Aspirin NNS 0 1 0 B-Brand
: : 0 0 2 O
When WRB 0 0 12 O
Lodine NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
aspirin NN 0 1 14 B-Brand
its PRP$ 1 0 12 O
protein NN 0 1 14 O
binding NN 0 1 1 O
is VBZ 1 0 12 O
reduced VBN 1 1 1 O
although IN 0 0 12 O
the DT 0 0 12 O
clearance NN 0 1 16 O
of IN 0 0 12 O
free JJ 0 1 12 O
etodolac NN 0 1 13 B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
altered VBN 1 1 1 O
. . 0 0 12 O

Anticoagulants NNS 0 1 UNK B-Drug
: : 0 0 2 O
Potentiation NN 0 1 UNK O
of IN 0 0 12 O
warfarin JJ 0 1 14 B-Drug
- : 0 0 2 O
type NN 0 1 1 O
( ( 0 0 2 O
CYP9C9 NNP 0 0 UNK B-Drug
and CC 0 0 12 O
CYP9A9 NNP 0 0 UNK B-Drug
substrate NN 0 1 UNK O
) ) 0 0 2 O
anticoagulant NN 0 1 13 B-Drug
response NN 0 1 1 O
is VBZ 1 0 12 O
almost RB 0 1 12 O
always RB 0 1 12 O
seen VBN 1 1 12 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
amiodarone NN 0 1 0 B-Drug
and CC 0 0 12 O
can MD 0 0 12 O
result VB 0 1 1 O
in IN 0 0 12 O
serious JJ 0 1 12 O
or CC 0 0 12 O
fatal JJ 0 1 13 O
bleeding NN 0 1 6 O
. . 0 0 12 O

Effect NN 0 1 UNK O

co SYM 0 1 12 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
may MD 0 0 1 O
produce VB 0 0 1 O
a DT 0 0 12 O
synergistic JJ 0 1 UNK O
anticonvulsant JJ 0 1 14 O
action NN 0 1 13 O
. . 0 0 12 O

Furosemide NNP 0 1 0 B-Drug
has VBZ 1 0 12 O
a DT 0 0 12 O
tendency NN 0 0 1 O
to TO 0 0 12 O
antagonize VB 0 0 UNK O
the DT 0 0 12 O
skeletal JJ 0 1 13 O
muscle NN 0 1 6 O
relaxing VBG 1 1 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
tubocurarine NN 0 1 UNK B-Drug
and CC 0 0 12 O
may MD 0 0 1 O
potentiate VB 0 0 UNK O
the DT 0 0 12 O
action NN 0 1 13 O
of IN 0 0 12 O
succinylcholine NN 0 1 16 B-Drug
. . 0 0 12 O

Digoxin NNP 0 1 0 B-Drug
Nimodipine NNP 0 1 0 B-Drug
and CC 0 0 12 O
Losartan NNP 0 1 0 B-Drug
: : 0 0 2 O
Bosentan NNP 0 1 UNK B-Drug
has VBZ 1 0 12 O
no DT 0 0 12 O
significant JJ 0 1 1 O
pharmacokinetic JJ 0 1 UNK O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
and CC 0 0 12 O
nimodipine NN 0 1 16 B-Drug
and CC 0 0 12 O
losartan NN 0 1 0 B-Drug
has VBZ 1 0 12 O
no DT 0 0 12 O
significant JJ 0 1 1 O
effect NN 0 1 1 O
on IN 0 0 12 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
bosentan NN 0 1 13 B-Drug
. . 0 0 12 O

Ketoconazole NNP 0 1 UNK B-Drug
at IN 0 0 12 O
9 CD 0 0 2 O
mg JJ 0 1 0 O
daily RB 0 1 12 O
( ( 0 0 2 O
the DT 0 0 12 O
maximum NN 0 1 1 O
approved VBD 1 1 1 O
prescription NN 0 1 0 O
dose NN 0 1 6 O
) ) 0 0 2 O
co NN 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
with IN 0 0 12 O
TIKOSYN NNP 0 1 UNK B-Brand
( ( 0 0 2 O
9 CD 0 0 2 O
mcg RB 0 1 0 O
BID NNP 0 0 11 O
) ) 0 0 2 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
increase VB 0 1 1 O
dofetilide NN 0 1 13 B-Drug
Cmax NNP 0 1 UNK O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
in IN 0 0 12 O
males NNS 1 1 UNK O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
in IN 0 0 12 O
females NNS 1 1 UNK O
and CC 0 0 12 O
AUC NNP 0 1 UNK O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
in IN 0 0 12 O
males NNS 1 1 UNK O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
in IN 0 0 12 O
females NNS 1 1 UNK O
. . 0 0 12 O

Phenytoin NN 0 1 0 B-Drug
: : 0 0 2 O
Amphetamines NNS 0 1 UNK B-Group
may MD 0 0 1 O
delay VB 0 1 1 O
intestinal JJ 0 1 13 O
absorption NN 0 1 1 O
of IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
; : 0 0 2 O

A DT 0 0 2 O
clinical JJ 0 1 6 O
study NN 0 1 1 O
in IN 0 0 12 O
healthy JJ 0 1 12 O
male NN 0 1 12 O
volunteers NNS 1 1 UNK O
( ( 0 0 2 O
n=9 NN 0 1 UNK O
) ) 0 0 2 O
demonstrated VBD 1 0 1 O
that IN 0 0 12 O
mixing VBG 1 1 UNK O
NovoLog NNP 0 1 UNK B-Brand
with IN 0 0 12 O
NPH NNP 0 1 14 B-Drug
human JJ 0 1 1 I-Drug
insulin NN 0 1 14 I-Drug
immediately RB 0 1 12 O
before IN 0 1 12 O
injection NN 0 1 3 O
produced VBD 1 0 1 O
some DT 0 0 12 O
attenuation NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
peak JJ 0 1 1 O
concentration NN 0 1 1 O
of IN 0 0 12 O
NovoLog NNP 0 1 UNK B-Brand
but CC 0 0 12 O
that IN 0 0 12 O
the DT 0 0 12 O
time NN 0 1 12 O
to TO 0 0 12 O
peak VB 0 1 1 O
and CC 0 0 12 O
the DT 0 0 12 O
total JJ 0 1 1 O
bioavailability NN 0 1 UNK O
of IN 0 0 12 O
NovoLog NNP 0 1 UNK B-Brand
were VBD 1 0 12 O
not RB 0 1 12 O
significantly RB 0 0 1 O
affected VBN 1 1 1 O
. . 0 0 12 O

These DT 0 0 1 O
include VBP 0 1 1 O
sympathomimetic JJ 0 1 13 B-Group
bronchodilators NNS 1 1 14 I-Group
methylxanthines NNS 0 1 UNK B-Group
and CC 0 0 12 O
oral JJ 0 1 6 O
and CC 0 0 12 O
inhaled JJ 0 1 14 O
steroids NNS 1 1 6 B-Group
. . 0 0 12 O

Antibiotics NNS 0 1 7 B-Group
: : 0 0 2 O
In IN 0 0 2 O
vitro NN 0 1 UNK O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
in IN 0 0 12 O
vivo JJ 0 1 13 O
data NNS 0 1 1 O
show VBP 0 1 12 O
that IN 0 0 12 O
clarithromycin NN 0 1 13 B-Drug
erythromycin NN 0 1 0 B-Drug
and CC 0 0 12 O
troleandomycin NN 0 1 UNK B-Drug
markedly RB 0 1 1 O
inhibit VBZ 0 1 13 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
cisapride NN 0 1 UNK B-Drug
which WDT 0 0 12 O
can MD 0 0 12 O
result VB 0 1 1 O
in IN 0 0 12 O
an DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
plasma JJ 0 1 14 O
cisapride NN 0 1 UNK B-Drug
levels NNS 1 1 1 O
and CC 0 0 12 O
prolongation NN 0 1 6 O
of IN 0 0 12 O
the DT 0 0 12 O
QT NNP 0 1 13 O
interval NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
ECG NNP 0 1 6 O
. . 0 0 12 O

Dexamethasone NN 0 1 0 B-Drug
: : 0 0 2 O
Steady JJ 0 1 UNK O
- : 0 0 2 O
state NN 0 1 1 O
trough IN 0 1 3 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
albendazole JJ 0 1 13 B-Drug
sulfoxide NN 0 1 UNK I-Drug
were VBD 1 0 12 O
about RB 0 1 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
higher JJR 1 1 1 O
when WRB 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
dexamethasone NN 0 1 16 B-Drug
was VBD 1 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
each DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
albendazole NN 0 1 13 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
/ NNP 0 0 2 O
day NN 0 1 12 O
) ) 0 0 2 O
in IN 0 0 12 O
eight CD 0 1 12 O
neurocysticercosis NN 0 1 13 O
patients NNS 1 1 6 O
. . 0 0 12 O

Leukocyte JJ 0 1 7 B-Drug_n
transfusions NNS 1 1 6 I-Drug_n
: : 0 0 2 O
acute NN 0 1 6 O
pulmonary JJ 0 1 6 O
toxicity NN 0 1 6 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
intravenous JJ 0 1 14 O
amphotericin NN 0 1 14 B-Drug
B NNP 0 0 2 I-Drug
and CC 0 0 12 O
leukocyte JJ 0 1 14 B-Drug_n
transfusions NNS 1 1 6 I-Drug_n
. . 0 0 12 O

There EX 0 0 12 O
was VBD 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
representative JJ 0 1 1 O
drugs NNS 1 1 6 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
CYP NNP 0 1 UNK O
9C9 CD 0 0 UNK O
CYP NNP 0 1 UNK O
9C9 CD 0 0 UNK O
CYP NNP 0 1 UNK O
9D9 CD 0 0 UNK O
or CC 0 0 12 O
CYP NNP 0 1 UNK O
9A9 CD 0 0 UNK O
. . 0 0 12 O

Concurrent NNP 0 1 13 O
use NN 0 1 1 O
of IN 0 0 12 O
macrolides NNS 0 1 13 B-Group
and CC 0 0 12 O
warfarin NN 0 1 14 B-Drug
in IN 0 0 12 O
clinical JJ 0 1 6 O
practice NN 0 1 UNK O
has VBZ 1 0 12 O
been VBN 1 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
increased JJ 0 1 1 O
anticoagulant JJ 0 1 13 O
effects NNS 1 1 1 O
. . 0 0 12 O

Generally RB 0 0 1 O
this DT 0 0 12 O
phenomenon NN 0 1 1 O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
other JJ 0 0 12 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
events NNS 1 1 12 O
. . 0 0 12 O

Appropriate NNP 0 1 2 O
laboratory NN 0 1 1 O
testing NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
prior JJ 0 1 1 O
to TO 0 0 12 O
initiating VBG 1 1 1 O
combination NN 0 1 1 O
therapy NN 0 1 6 O
with IN 0 0 12 O
Amprenavir NNP 0 1 UNK B-Drug
and CC 0 0 12 O
ritonavir NN 0 1 16 B-Drug
and CC 0 0 12 O
at IN 0 0 12 O
periodic JJ 0 1 1 O
intervals NNS 1 1 1 O
or CC 0 0 12 O
if IN 0 0 12 O
any DT 0 0 12 O
clinical JJ 0 1 6 O
signs NNS 1 1 12 O
or CC 0 0 12 O
symptoms NNS 1 1 6 O
of IN 0 0 12 O
hyperlipidemia NN 0 1 14 O
or CC 0 0 12 O
elevated VBN 1 1 1 O
liver JJ 0 1 6 O
function NN 0 1 1 O
tests NNS 1 1 1 O
occur VBP 0 1 1 O
during IN 0 0 12 O
therapy NN 0 1 6 O
. . 0 0 12 O

There EX 0 0 12 O
is VBZ 1 0 12 O
evidence NN 0 1 1 O
that IN 0 0 12 O
meropenem NN 0 1 14 B-Drug
may MD 0 0 1 O
reduce VB 0 0 1 O
serum NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
valproic NN 0 0 16 B-Drug
acid NN 0 1 14 I-Drug
to TO 0 0 12 O
subtherapeutic JJ 0 0 14 O
levels NNS 1 1 1 O
( ( 0 0 2 O
therapeutic JJ 0 1 6 O
range NN 0 1 1 O
considered VBN 1 1 1 O
to TO 0 0 12 O
be VB 0 0 12 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
g NNS 0 1 16 O
/ JJ 0 0 2 O
mL JJ 0 1 14 O
total JJ 0 1 1 O
valproate NN 0 1 16 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

Although IN 0 0 12 O
there EX 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
no DT 0 0 12 O
formal JJ 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
other JJ 0 0 12 O
than IN 0 0 12 O
with IN 0 0 12 O
antipyrine NN 0 1 UNK B-Drug
based VBN 1 1 1 O
on IN 0 0 12 O
these DT 0 0 12 O
in IN 0 0 12 O
vivo NN 0 1 13 O
and CC 0 0 12 O
in IN 0 0 12 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
unlikely JJ 0 1 12 O
that IN 0 0 12 O
co SYM 0 1 12 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
dose NN 0 1 6 O
of IN 0 0 12 O
ARIMIDEX NNP 0 1 UNK B-Brand
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
will MD 0 0 12 O
result VB 0 1 1 O
in IN 0 0 12 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
drug NN 0 1 1 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
- : 0 0 2 O
mediated VBD 1 1 13 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
the DT 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

Increased VBN 0 1 7 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
diazepam NN 0 1 0 B-Drug
were VBD 1 0 12 O
observed VBN 1 1 1 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
after IN 0 0 12 O
dosing VBG 1 0 14 O
and CC 0 0 12 O
onwards NNS 0 0 UNK O
. . 0 0 12 O

The DT 0 0 2 O
extent NN 0 1 1 O
to TO 0 0 12 O
which WDT 0 0 12 O
SSRI NNP 0 1 UNK B-Group
- : 0 0 2 O
TCA NNP 0 1 13 B-Group
interactions NNS 1 1 UNK O
may MD 0 0 1 O
pose VB 0 0 UNK O
clinical JJ 0 1 6 O
problems NNS 1 1 1 O
will MD 0 0 12 O
depend VB 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
degree NN 0 1 1 O
of IN 0 0 12 O
inhibition NN 0 1 13 O
and CC 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
SSRI NNP 0 1 UNK B-Group
involved VBN 1 1 12 O
. . 0 0 12 O

When WRB 0 0 12 O
such JJ 0 0 1 O
drugs NNS 1 1 6 O
are VBP 1 0 12 O
administered VBN 1 1 1 O
to TO 0 0 12 O
a DT 0 0 12 O
patient NN 0 1 6 O
receiving VBG 1 1 1 O
Acarbose NNP 0 1 UNK B-Drug
the DT 0 0 12 O
patient NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
closely RB 0 0 1 O
observed VBN 1 1 1 O
for IN 0 0 12 O
loss NN 0 1 1 O
of IN 0 0 12 O
blood NN 0 1 6 O
glucose NN 0 1 14 O
control NN 0 1 1 O
. . 0 0 12 O

methadone NN 0 1 6 B-Drug
concentration NN 0 1 1 O

Concurrent JJ 0 1 13 O
administration NN 0 1 1 O
of IN 0 0 12 O
oxyphenbutazone NN 0 1 UNK B-Drug
and CC 0 0 12 O
androgens NNS 1 1 13 B-Group
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
elevated JJ 0 1 1 O
serum NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
oxyphenbutazone NN 0 1 UNK B-Drug
. . 0 0 12 O

Nonsteroidal NNP 0 0 UNK B-Group
anti SYM 0 0 3 I-Group
- : 0 0 2 O
inflammatory NN 0 1 6 I-Group
agents NNS 1 1 1 I-Group

Ezetimibe NNP 0 1 0 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
during IN 0 0 12 O
pregnancy NN 0 1 6 O
only RB 0 1 12 O
if IN 0 0 12 O
the DT 0 0 12 O
potential JJ 0 1 1 O
benefit NN 0 1 1 O
justifies VBZ 1 1 UNK O
the DT 0 0 12 O
risk NN 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
fetus NN 0 1 13 O
. . 0 0 12 O

In IN 0 0 2 O
the DT 0 0 12 O
absence NN 0 1 1 O
of IN 0 0 12 O
formal JJ 0 1 1 O
clinical JJ 0 1 6 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
caution VBP 0 0 1 O
should MD 0 0 12 O
be VB 0 0 12 O
exercised VBN 1 1 1 O
when WRB 0 0 12 O
administering VBG 1 1 1 O
TAXOL NNP 0 1 UNK B-Brand
concomitantly RB 0 0 14 O
with IN 0 0 12 O
known VBN 1 1 12 O
substrates NNS 1 1 UNK O
or CC 0 0 12 O
inhibitors NNS 1 1 14 O
of IN 0 0 12 O
the DT 0 0 12 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
isoenzymes VBZ 0 1 14 O
CYP9C9 NNP 0 0 UNK O
and CC 0 0 12 O
CYP9A9 NNP 0 0 UNK O
. . 0 0 12 O

Doses NNS 0 1 0 O
of IN 0 0 12 O
vitamin NN 0 1 6 B-Drug
C NNP 0 0 2 I-Drug
up RB 0 0 12 O
to TO 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
were VBD 1 0 12 O
allowed VBN 1 1 12 O
in IN 0 0 12 O
clinical JJ 0 1 6 O
studies NNS 1 1 1 O
without IN 0 0 12 O
negative JJ 0 1 1 O
consequences NNS 1 1 UNK O
. . 0 0 12 O

Clindamycin NNP 0 1 0 B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
have VB 0 0 12 O
neuromuscular JJ 0 1 6 O
blocking VBG 1 1 UNK O
properties NNS 1 1 UNK O
that WDT 0 0 12 O
may MD 0 0 1 O
enhance VB 0 1 UNK O
the DT 0 0 12 O
action NN 0 1 13 O
of IN 0 0 12 O
other JJ 0 0 12 O
neuromuscular JJ 0 1 6 B-Group
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
. . 0 0 12 O

In IN 0 0 2 O
psoriatic JJ 0 0 13 O
arthritis NN 0 1 6 O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
concomitant JJ 0 1 6 O
medications NNS 1 1 6 O
included VBD 1 1 1 O
MTX NNP 0 1 UNK B-Drug
in IN 0 0 12 O
approximately RB 0 1 1 O
half NN 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
patients NNS 1 1 6 O
as RB 0 0 12 O
well RB 0 1 12 O
as IN 1 0 12 O
nonsteroidal JJ 0 0 14 B-Group
anti IN 0 0 3 I-Group
- : 0 0 2 O
inflammatory NN 0 1 6 I-Group
agents NNS 1 1 1 I-Group
folic JJ 0 0 14 B-Drug
acid NN 0 1 14 I-Drug
and CC 0 0 12 O
corticosteroids NNS 1 1 14 B-Group
. . 0 0 12 O

Concurrent NN 0 1 13 O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
sequential JJ 0 1 1 O
systemic NN 0 1 6 O
or CC 0 0 12 O
topical JJ 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
other JJ 0 0 12 O
potentially RB 0 0 1 O
neurotoxic JJ 0 1 UNK O
and CC 0 0 12 O
/ JJ 0 0 2 O
or CC 0 0 12 O
nephrotoxic JJ 0 1 UNK O
drugs NNS 1 1 6 O
such JJ 0 0 1 O
as IN 1 0 12 O
amphotericin NN 0 1 14 B-Drug
B NNP 0 0 2 I-Drug
aminoglycosides VBZ 0 1 13 B-Group
bacitracin NN 0 1 16 B-Drug
polymyxin NN 0 1 16 B-Drug
B NNP 0 0 2 I-Drug
colistin NN 0 1 13 B-Drug
viomycin NN 0 1 UNK B-Drug
or CC 0 0 12 O
cisplatin NN 0 1 14 B-Drug
when WRB 0 0 12 O
indicated JJ 0 1 1 O
requires VBZ 1 0 1 O
careful JJ 0 1 12 O
monitoring NN 0 1 1 O
. . 0 0 12 O

Although IN 0 0 12 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
CYP NNP 0 1 UNK O
9A9 CD 0 0 UNK O
/ VBD 0 0 2 O
9 CD 0 0 2 O
by IN 0 0 12 O
OXC NNP 0 0 UNK B-Drug
and CC 0 0 12 O
MHD NNP 0 0 UNK B-Drug_n
did VBD 1 0 12 O
occur VB 0 1 1 O
at IN 0 0 12 O
high JJ 0 1 1 O
concentrations NNS 1 1 13 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
not RB 0 1 12 O
likely JJ 0 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
of IN 0 0 12 O
clinical JJ 0 1 6 O
significance NN 0 1 13 O
. . 0 0 12 O

This DT 0 0 2 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
demonstrated VBN 1 0 1 O
in IN 0 0 12 O
vitro NN 0 1 UNK O
; : 0 0 2 O

Potential NNP 0 1 UNK O
for IN 0 0 12 O
Other JJ 0 0 2 O
Drugs NNP 0 1 2 O
to TO 0 0 12 O
Affect NNP 0 1 UNK O
INVEGA NNP 0 1 UNK B-Brand
Paliperidone NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
a DT 0 0 12 O
substrate NN 0 1 UNK O
of IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
CYP9A9 NNP 0 0 UNK O
CYP9C9 NNP 0 0 UNK O
and CC 0 0 12 O
CYP9C9 NNP 0 0 UNK O
so RB 0 1 12 O
that IN 0 0 12 O
an DT 0 0 12 O
interaction NN 0 1 UNK O
with IN 0 0 12 O
inhibitors NNS 1 1 14 O
or CC 0 0 12 O
inducers NNS 1 1 UNK O
of IN 0 0 12 O
these DT 0 0 12 O
isozymes NNS 0 1 UNK O
is VBZ 1 0 12 O
unlikely JJ 0 1 12 O
. . 0 0 12 O

Digitalis NNP 0 1 15 B-Group
glycosides NNS 1 1 13 I-Group
enhanced VBD 1 1 1 O
possibility NN 0 1 1 O
of IN 0 0 12 O
arrhythmias NN 1 1 6 O
or CC 0 0 12 O
digitalis JJ 0 1 14 B-Group
toxicity NN 0 1 6 O
associated VBN 1 1 1 O
with IN 0 0 12 O
hypokalemia NN 0 1 14 O
. . 0 0 12 O

In IN 0 0 2 O
vitro JJ 0 1 UNK O
metabolism NN 0 1 16 O
studies NNS 1 1 1 O
have VBP 0 0 12 O
suggested VBN 1 1 12 O
that IN 0 0 12 O
decitabine NN 0 1 13 B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
a DT 0 0 12 O
substrate NN 0 1 UNK O
for IN 0 0 12 O
the DT 0 0 12 O
human JJ 0 1 1 O
liver NN 0 1 6 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
enzymes VBZ 0 1 14 O
. . 0 0 12 O

No DT 0 0 2 O
significant JJ 0 1 1 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
studies NNS 1 1 1 O
of IN 0 0 12 O
candesartan NN 0 1 16 B-Drug
cilexetil NN 0 0 16 I-Drug
given VBN 1 1 12 O
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
such JJ 0 0 1 O
as IN 1 0 12 O
glyburide JJ 0 1 16 B-Drug
nifedipine NN 0 1 0 B-Drug
digoxin NN 0 1 14 B-Drug
warfarin NN 0 1 14 B-Drug
hydrochlorothiazide NN 0 1 0 B-Drug
and CC 0 0 12 O
oral JJ 0 1 6 O
contraceptives NNS 1 1 13 B-Group
in IN 0 0 12 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
or CC 0 0 12 O
given VBN 1 1 12 O
with IN 0 0 12 O
enalapril NN 0 1 0 B-Drug
to TO 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
heart NN 0 1 12 O
failure NN 0 1 1 O
( ( 0 0 2 O
NYHA NNP 0 0 UNK O
class NN 0 1 12 O
II NNP 0 0 2 O
and CC 0 0 12 O
III NNP 0 1 2 O
) ) 0 0 2 O
. . 0 0 12 O

Because IN 0 0 12 O
pergolide JJ 0 1 13 B-Drug
mesylate NN 0 1 16 I-Drug
is VBZ 1 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
bound NN 0 1 12 O
to TO 0 0 12 O
plasma VB 0 1 14 O
proteins NNS 1 1 14 O
caution NN 0 0 1 O
should MD 0 0 12 O
be VB 0 0 12 O
exercised VBN 1 1 1 O
if IN 0 0 12 O
pergolide JJ 0 1 13 B-Drug
mesylate NN 0 1 16 I-Drug
is VBZ 1 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
known VBN 1 1 12 O
to TO 0 0 12 O
affect VB 0 1 1 O
protein NN 0 1 14 O
binding NN 0 1 1 O
. . 0 0 12 O

( ( 0 0 2 O
Thiazides NNS 0 1 UNK B-Group
may MD 0 0 1 O
decrease VB 0 1 1 O
arterial JJ 0 1 6 O
responsiveness NN 0 1 UNK O
to TO 0 0 12 O
norepinephrine VB 0 1 14 B-Drug
. . 0 0 12 O

SKELAXIN NNP 0 1 UNK B-Brand
may MD 0 0 1 O
enhance VB 0 1 UNK O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
alcohol NN 0 1 1 B-Drug
barbiturates NNS 1 1 14 B-Group
and CC 0 0 12 O
other JJ 0 0 12 O
CNS NNP 0 1 6 B-Group
depressants NNS 1 0 13 I-Group
. . 0 0 12 O

Concurrent JJ 0 1 13 O
administration NN 0 1 1 O
of IN 0 0 12 O
vasopressor NN 0 1 13 B-Group
drugs NNS 1 1 6 I-Group
( ( 0 0 2 O
for IN 0 0 12 O
the DT 0 0 12 O
treatment NN 0 1 6 O
of IN 0 0 12 O
hypotension NN 0 1 6 O
related VBN 1 1 1 O
to TO 0 0 12 O
obstetric VB 0 1 6 O
blocks NNS 1 1 3 O
) ) 0 0 2 O
and CC 0 0 12 O
ergot $ 0 1 UNK B-Group
- : 0 0 2 O
type NN 0 1 1 I-Group
oxytocic IN 0 1 13 I-Group
drugs NNS 1 1 6 I-Group
may MD 0 0 1 O
cause VB 0 1 12 O
severe JJ 0 1 6 O
persistent JJ 0 1 1 O
hypertension NN 0 1 6 O
or CC 0 0 12 O
cerebrovascular JJ 0 1 8 O
accidents NNS 1 1 1 O
. . 0 0 12 O

Drugs NNS 0 1 2 O
with IN 0 0 12 O
a DT 0 0 12 O
Narrow NNP 0 1 UNK O
Therapeutic NNP 0 1 UNK O
Index NNP 0 1 2 O
Digoxin NNP 0 1 0 B-Drug
: : 0 0 2 O
Sonata NNP 0 1 UNK B-Brand
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
) ) 0 0 2 O
did VBD 1 0 12 O
not RB 0 1 12 O
affect VB 0 1 1 O
the DT 0 0 12 O
pharmacokinetic JJ 0 1 UNK O
or CC 0 0 12 O
pharmacodynamic JJ 0 1 UNK O
profile NN 0 1 1 O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
q9h NN 0 1 UNK O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
) ) 0 0 2 O
. . 0 0 12 O

Concomitant JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
drugs NNS 1 1 6 O
known VBN 1 1 12 O
to TO 0 0 12 O
induce VB 0 1 6 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
enzymes NNS 1 1 14 O
may MD 0 0 1 O
decrease VB 0 1 1 O
the DT 0 0 12 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
clozapine NN 0 1 13 B-Drug
. . 0 0 12 O

( ( 0 0 2 O
The DT 0 0 2 O
two CD 0 1 12 O
drugs NNS 1 1 6 O
were VBD 1 0 12 O
administered VBN 1 1 1 O
in IN 0 0 12 O
opposite JJ 0 1 UNK O
nostrils NNS 1 1 UNK O
. . 0 0 12 O
) ) 0 0 2 O

There EX 0 0 12 O
are VBP 1 0 12 O
no DT 0 0 12 O
controlled JJ 0 1 1 O
studies NNS 1 1 1 O
documenting VBG 1 1 UNK O
the DT 0 0 12 O
use NN 0 1 1 O
of IN 0 0 12 O
ZEMURON NNP 0 1 UNK B-Brand
before IN 0 1 12 O
or CC 0 0 12 O
after IN 0 0 12 O
other JJ 0 0 12 O
nondepolarizing JJ 0 0 UNK B-Group
muscle NN 0 1 6 I-Group
relaxants NNS 1 0 13 I-Group
. . 0 0 12 O

Therefore RB 0 0 1 O
diphenoxylate NN 0 1 16 B-Drug
has VBZ 1 0 12 O
the DT 0 0 12 O
potential JJ 0 1 1 O
to TO 0 0 12 O
prolong VB 0 0 13 O
the DT 0 0 12 O
biological JJ 0 1 13 O
half NN 0 1 12 O
- : 0 0 2 O
lives NNS 1 1 12 O
of IN 0 0 12 O
drugs NNS 1 1 6 O
for IN 0 0 12 O
which WDT 0 0 12 O
the DT 0 0 12 O
rate NN 0 1 1 O
of IN 0 0 12 O
elimination NN 0 1 UNK O
is VBZ 1 0 12 O
dependent JJ 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
microsomal JJ 0 1 UNK O
drug NN 0 1 1 O
metabolizing VBG 1 0 UNK O
enzyme NN 0 1 14 O
system NN 0 1 1 O
. . 0 0 12 O

Nevertheless RB 0 0 1 O
caution NN 0 0 1 O
is VBZ 1 0 12 O
indicated VBN 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
TCAs NNP 0 1 UNK B-Group
with IN 0 0 12 O
any DT 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
SSRIs NNP 0 1 UNK B-Group
and CC 0 0 12 O
also RB 0 0 12 O
in IN 0 0 12 O
switching VBG 1 1 UNK O
from IN 0 0 12 O
one CD 0 1 12 O
class NN 0 1 12 O
to TO 0 0 12 O
the DT 0 0 12 O
other JJ 0 0 12 O
. . 0 0 12 O

Nafazodone CD 0 0 UNK B-Drug
fluvoxamine JJ 0 1 16 B-Drug
cimetidine NN 0 1 13 B-Drug
( ( 0 0 2 O
consider VB 0 1 12 O
Xanax NNP 0 1 0 B-Brand
dose VB 0 1 6 O
reduction NN 0 1 1 O
) ) 0 0 2 O
. . 0 0 12 O

Zalcitabine NNP 0 1 UNK B-Drug
inhibited VBD 1 1 13 O
lamivudine JJ 0 1 16 B-Drug
phosphorylation NN 0 1 UNK O
at IN 0 0 12 O
high JJ 0 1 1 O
concentration NN 0 1 1 O
ratios NNS 1 1 UNK O
( ( 0 0 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
) ) 0 0 2 O
; : 0 0 2 O

Co NNP 0 1 2 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
SUTENT NNP 0 1 0 B-Brand
with IN 0 0 12 O
strong JJ 0 1 12 O
inhibitors NNS 1 1 14 O
of IN 0 0 12 O
the DT 0 0 12 O
CYP9A9 NNP 0 0 UNK O
family NN 0 1 12 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
ketoconazole NN 0 1 16 B-Drug
itraconazole NN 0 1 0 B-Drug
clarithromycin NN 0 1 13 B-Drug
atazanavir NN 0 1 13 B-Drug
indinavir NN 0 1 16 B-Drug
nefazodone NN 0 1 16 B-Drug
nelfinavir JJ 0 1 16 B-Drug
ritonavir NN 0 1 16 B-Drug
saquinavir NN 0 1 13 B-Drug
telithromycin JJ 0 1 UNK B-Drug
voriconizole NN 0 0 UNK B-Drug
) ) 0 0 2 O
may MD 0 0 1 O
increases VB 1 1 1 O
sunitinib JJ 0 1 13 B-Drug
concentrations NNS 1 1 13 O
. . 0 0 12 O

Because IN 0 0 12 O
many JJ 0 0 12 O
drugs NNS 1 1 6 O
are VBP 1 0 12 O
excreted VBN 1 1 UNK O
in IN 0 0 12 O
human JJ 0 1 1 O
milk NN 0 1 3 O
and CC 0 0 12 O
because IN 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
potential NN 0 1 1 O
for IN 0 0 12 O
serious JJ 0 1 12 O
adverse JJ 0 0 1 O
reactions NNS 1 1 1 O
from IN 0 0 12 O
FASLODEX NNP 0 1 UNK B-Brand
in IN 0 0 12 O
nursing VBG 1 1 12 O
infants NNS 1 1 6 O
a DT 0 0 12 O
decision NN 0 1 12 O
should MD 0 0 12 O
be VB 0 0 12 O
made VBN 1 1 12 O
whether IN 0 0 12 O
to TO 0 0 12 O
discontinue VB 0 1 1 O
nursing NN 0 1 12 O
or CC 0 0 12 O
to TO 0 0 12 O
discontinue VB 0 1 1 O
the DT 0 0 12 O
drug NN 0 1 1 O
taking VBG 1 0 12 O
into IN 0 0 12 O
account NN 0 1 1 O
the DT 0 0 12 O
importance NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
drug NN 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
mother NN 0 1 12 O
. . 0 0 12 O

Other JJ 0 0 2 O
drugs NNS 1 1 6 O
Drug NNP 0 1 2 O
interactions NNS 1 1 UNK O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
with IN 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
erythromycin NN 0 1 0 B-Drug
and CC 0 0 12 O
other JJ 0 0 12 O
medications NNS 1 1 6 O
including VBG 1 1 1 O
cyclosporine JJ 0 1 14 B-Drug
hexobarbital JJ 0 1 UNK B-Drug
carbamazepine NN 0 1 16 B-Drug
alfentanil NN 0 1 UNK B-Drug
disopyramide NN 0 1 16 B-Drug
phenytoin NN 0 1 16 B-Drug
bromocriptine NN 0 1 16 B-Drug
valproate NN 0 1 16 B-Drug
astemizole NN 0 1 UNK B-Drug
and CC 0 0 12 O
lovastatin NN 0 1 13 B-Drug
. . 0 0 12 O

Because IN 0 0 12 O
tetracyclines NNS 1 1 13 B-Group
have VBP 0 0 12 O
been VBN 1 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
depress VB 0 0 13 O
plasma JJ 0 1 14 O
prothrombin NN 0 1 14 O
activity NN 0 1 1 O
patients NNS 1 1 6 O
who WP 0 0 12 O
are VBP 1 0 12 O
on IN 0 0 12 O
anticoagulant JJ 0 1 13 B-Group
therapy NN 0 1 6 O
may MD 0 0 1 O
require VB 0 0 1 O
downward JJ 0 1 3 O
adjustment NN 0 1 1 O
of IN 0 0 12 O
their PRP$ 0 0 12 O
anticoagulant JJ 0 1 13 B-Group
dosage NN 0 1 0 O
. . 0 0 12 O

Warfarin NN 0 1 0 B-Drug
: : 0 0 2 O
Atorvastatin NNP 0 1 0 B-Drug
had VBD 1 0 12 O
no DT 0 0 12 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
effect NN 0 1 1 O
on IN 0 0 12 O
prothrombin NN 0 1 14 O
time NN 0 1 12 O
when WRB 0 0 12 O
administered VBN 1 1 1 O
to TO 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
chronic JJ 0 1 6 O
warfarin NN 0 1 14 B-Drug
treatment NN 0 1 6 O
. . 0 0 12 O

Some DT 0 0 2 O
drugs NNS 1 1 6 B-Drug
/ JJ 0 0 2 O
substances NNS 1 1 1 O
are VBP 1 0 12 O
known VBN 1 1 12 O
to TO 0 0 12 O
accelerate VB 0 1 UNK O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
amiodarone NN 0 1 0 B-Drug
by IN 0 0 12 O
stimulating VBG 1 1 1 O
the DT 0 0 12 O
synthesis NN 0 1 UNK O
of IN 0 0 12 O
CYP9A9 NNP 0 0 UNK B-Drug
( ( 0 0 2 O
enzyme JJ 0 1 14 O
induction NN 0 1 1 O
) ) 0 0 2 O
. . 0 0 12 O

Because IN 0 0 12 O
escitalopram NN 0 1 0 B-Drug
is VBZ 1 0 12 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
multiple JJ 0 1 1 O
enzyme JJ 0 1 14 O
systems NNS 1 1 1 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
enzyme NN 0 1 14 O
may MD 0 0 1 O
not RB 0 1 12 O
appreciably VB 0 0 UNK O
decrease NN 0 1 1 O
escitalopram JJ 0 1 0 B-Drug
clearance NN 0 1 16 O
. . 0 0 12 O

Lapatinib NNP 0 1 UNK B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
significantly RB 0 0 1 O
inhibit VB 0 1 13 O
the DT 0 0 12 O
following JJ 0 1 1 O
enzymes NNS 1 1 14 O
in IN 0 0 12 O
human JJ 0 1 1 O
liver NN 0 1 6 O
microsomes NNS 1 1 UNK O
: : 0 0 2 O
CYP9A9 NNP 0 0 UNK O
CYP9C9 NNP 0 0 UNK O
CYP9C9 NNP 0 0 UNK O
and CC 0 0 12 O
CYP9D9 NNP 0 0 UNK O
or CC 0 0 12 O
UGT NNP 0 1 UNK O
enzymes NNS 1 1 14 O
in IN 0 0 12 O
vitro NN 0 1 UNK O
however RB 0 0 12 O
the DT 0 0 12 O
clinical JJ 0 1 6 O
significance NN 0 1 13 O
is VBZ 1 0 12 O
unknown JJ 0 1 12 O
. . 0 0 12 O

The DT 0 0 2 O
overall JJ 0 1 1 O
toxicity NN 0 1 6 O
profile NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
combination NN 0 1 1 O
revealed VBD 1 1 12 O
an DT 0 0 12 O
increased JJ 0 1 1 O
incidence NN 0 1 6 O
of IN 0 0 12 O
gastrointestinal JJ 0 1 6 O
adverse JJ 0 0 1 O
events NNS 1 1 12 O
especially RB 0 0 12 O
nausea VBP 0 1 6 O
when WRB 0 0 12 O
compared VBN 1 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
incidence NN 0 1 6 O
associated VBN 1 1 1 O
with IN 0 0 12 O
either DT 0 1 12 O
drug NN 0 1 1 O
administered VBD 1 1 1 O
alone RB 0 1 12 O
. . 0 0 12 O

The DT 0 0 2 O
possible JJ 0 1 1 O
adverse JJ 0 0 1 O
effects NNS 1 1 1 O
of IN 0 0 12 O
ZINECARD NNP 0 1 UNK B-Brand
on IN 0 0 12 O
the DT 0 0 12 O
fertility NN 0 1 6 O
of IN 0 0 12 O
humans NNS 1 1 UNK O
and CC 0 0 12 O
experimental JJ 0 1 UNK O
animals NNS 1 1 12 O
male NN 0 1 12 O
or CC 0 0 12 O
female NN 0 1 12 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
adequately RB 0 0 1 O
studied VBN 1 0 1 O
. . 0 0 12 O

CONTRAINDICATED NNS 0 1 UNK O
due JJ 0 1 1 O
to TO 0 0 12 O
potential JJ 0 1 1 O
for IN 0 0 12 O
serious JJ 0 1 12 O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
life NN 0 1 12 O
- : 0 0 2 O
threatening VBG 1 0 12 O
reactions NNS 1 1 1 O
such JJ 0 0 1 O
as IN 1 0 12 O
cardiac JJ 0 1 6 O
arrhythmias NN 1 1 6 O
. . 0 0 12 O

Animal NNP 0 1 UNK O
studies NNS 1 1 1 O
also RB 0 0 12 O
suggest VBP 0 1 1 O
an DT 0 0 12 O
increased JJ 0 1 1 O
potential NN 0 1 1 O
for IN 0 0 12 O
seizures NNS 1 1 6 O
when WRB 0 0 12 O
these DT 0 0 12 O
9 CD 0 0 2 O
drugs NNS 1 1 6 O
are VBP 1 0 12 O
given VBN 1 1 12 O
concomitantly RB 0 0 14 O
. . 0 0 12 O

Little NNP 0 1 2 O
or CC 0 0 12 O
no DT 0 0 12 O
change NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
either DT 0 1 12 O
drug NN 0 1 1 O
was VBD 1 0 12 O
observed VBN 1 1 1 O
when WRB 0 0 12 O
VIRACEPT NNP 0 1 UNK B-Brand
was VBD 1 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
lamivudine NN 0 1 16 B-Drug
or CC 0 0 12 O
stavudine NN 0 1 13 B-Drug
. . 0 0 12 O

Cyclophosphamide NNP 0 1 UNK B-Drug
used VBD 1 1 12 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
Cerubidine NNP 0 1 UNK B-Brand
may MD 0 0 1 O
also RB 0 0 12 O
result VB 0 1 1 O
in IN 0 0 12 O
increased JJ 0 1 1 O
cardiotoxicity NN 0 1 UNK O
. . 0 0 12 O

In IN 0 0 2 O
order NN 0 1 1 O
to TO 0 0 12 O
avoid VB 0 0 12 O
lithium JJ 0 1 16 B-Drug
intoxication NN 0 1 6 O
lithium NN 0 1 16 B-Drug
plasma NN 0 1 14 O
levels NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
closely RB 0 0 1 O
. . 0 0 12 O

Interaction NN 0 1 2 O
with IN 0 0 12 O
Food NNP 0 1 2 O
See NNP 0 1 2 O
CLINICAL NNP 0 1 11 O
PHARMACOLOGY NNP 0 1 UNK O
Pharmacokinetics NNP 0 1 UNK O
and CC 0 0 12 O
Metabolism NNP 0 1 UNK O
. . 0 0 12 O

Ketoconazole NNP 0 1 UNK B-Drug
: : 0 0 2 O
Co NNP 0 1 2 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
twice RB 0 1 12 O
- : 0 0 2 O
daily JJ 0 1 12 O
ketoconazole NN 0 1 16 B-Drug
with IN 0 0 12 O
aliskiren NNS 0 1 13 B-Drug
resulted VBN 1 1 1 O
in IN 0 0 12 O
an DT 0 0 12 O
approximate JJ 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
increase NN 0 1 1 O
in IN 0 0 12 O
plasma JJ 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
aliskiren NN 0 1 13 B-Drug
. . 0 0 12 O

Example JJ 0 1 UNK O
inducers NNS 1 1 UNK O
include VBP 0 1 1 O
aminoglutethimide JJ 0 1 UNK B-Drug
carbamazepine JJ 0 1 16 B-Drug
nafcillin NN 0 1 14 B-Drug
nevirapine JJ 0 1 13 B-Drug
phenobarbital JJ 0 1 16 B-Drug
phenytoin NN 0 1 16 B-Drug
and CC 0 0 12 O
rifamycins NNS 0 1 UNK B-Group
. . 0 0 12 O

Commonly RB 0 0 UNK O
used VBN 1 1 12 O
drugs NNS 1 1 6 O
such JJ 0 0 1 O
as IN 1 0 12 O
phenylpropanolamine NN 0 1 UNK B-Drug
and CC 0 0 12 O
pseudoephedrine NN 0 1 16 B-Drug
have VBP 0 0 12 O
been VBN 1 0 12 O
specifically RB 0 0 1 O
studied VBN 1 0 1 O
. . 0 0 12 O

Sympathomimetics NNS 0 1 UNK B-Group
: : 0 0 2 O
Metolazone NN 0 1 UNK B-Drug
may MD 0 0 1 O
decrease VB 0 1 1 O
arterial JJ 0 1 6 O
responsiveness NN 0 1 UNK O
to TO 0 0 12 O
norepinephrine VB 0 1 14 B-Drug
but CC 0 0 12 O
this DT 0 0 12 O
diminution NN 0 1 1 O
is VBZ 1 0 12 O
not RB 0 1 12 O
sufficient JJ 0 1 1 O
to TO 0 0 12 O
preclude VB 0 0 UNK O
effectiveness NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
pressor NN 0 1 14 O
agent NN 0 1 1 O
for IN 0 0 12 O
therapeutic JJ 0 1 6 O
use NN 0 1 1 O
. . 0 0 12 O

Felbamate NNP 0 1 UNK B-Drug
treatment NN 0 1 6 O
resulted VBD 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
decrease NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
gestodene NN 0 1 UNK B-Drug
AUC NNP 0 1 UNK O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
but CC 0 0 12 O
no DT 0 0 12 O
clinically RB 0 0 6 O
relevant JJ 0 1 1 O
effect NN 0 1 1 O
was VBD 1 0 12 O
observed VBN 1 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetic JJ 0 1 UNK O
parameters NNS 1 1 1 O
of IN 0 0 12 O
ethinyl JJ 0 0 13 B-Drug
estradiol NN 0 1 13 I-Drug
. . 0 0 12 O

If IN 0 0 12 O
concomitant JJ 0 1 6 O
treatment NN 0 1 6 O
with IN 0 0 12 O
sumatriptan NN 0 1 16 B-Drug
and CC 0 0 12 O
an DT 0 0 12 O
SSRI NNP 0 1 UNK B-Group
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
fluoxetine NN 0 1 16 B-Drug
fluvoxamine NN 0 1 16 B-Drug
paroxetine NN 0 1 16 B-Drug
sertraline NN 0 1 16 B-Drug
citalopram NN 0 1 16 B-Drug
escitalopram NN 0 1 0 B-Drug
) ) 0 0 2 O
is VBZ 1 0 12 O
clinically RB 0 0 6 O
warranted JJ 0 0 1 O
appropriate JJ 0 1 1 O
observation NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
patient NN 0 1 6 O
is VBZ 1 0 12 O
advised VBN 1 0 12 O
. . 0 0 12 O

Valproate NNP 0 1 0 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
twice RB 0 1 12 O
daily RB 0 1 12 O
did VBD 1 0 12 O
not RB 0 1 12 O
modify VB 0 1 UNK O
the DT 0 0 12 O
rate NN 0 1 1 O
or CC 0 0 12 O
extent NN 0 1 1 O
of IN 0 0 12 O
levetiracetam JJ 0 1 16 B-Drug
absorption NN 0 1 1 O
or CC 0 0 12 O
its PRP$ 1 0 12 O
plasma JJ 0 1 14 O
clearance NN 0 1 16 O
or CC 0 0 12 O
urinary JJ 0 1 6 O
excretion NN 0 1 14 O
. . 0 0 12 O

This DT 0 0 2 O
observed JJ 0 1 1 O
increase NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
bioavailability NN 0 1 UNK O
of IN 0 0 12 O
fexofenadine NN 0 1 16 B-Drug
may MD 0 0 1 O
be VB 0 0 12 O
due JJ 0 1 1 O
to TO 0 0 12 O
transport VB 0 1 1 O
- : 0 0 2 O
related JJ 0 1 1 O
effects NNS 1 1 1 O
such JJ 0 0 1 O
as IN 1 0 12 O
p JJ 0 1 2 O
- : 0 0 2 O
glycoprotein NN 0 1 UNK O
. . 0 0 12 O
in IN 0 0 12 O
vivo NN 0 1 13 O
animal NN 0 1 13 O
studies NNS 1 1 1 O
also RB 0 0 12 O
suggest VBP 0 1 1 O
that IN 0 0 12 O
in IN 0 0 12 O
addition NN 0 1 1 O
to TO 0 0 12 O
enhancing VBG 1 1 1 O
absorption NN 0 1 1 O
ketoconazole NN 0 1 16 B-Drug
decreases VBZ 1 1 UNK O
fexofenadine JJ 0 1 16 B-Drug
gastrointestinal JJ 0 1 6 O
secretion NN 0 1 14 O
while IN 0 0 12 O
erythromycin NN 0 1 0 B-Drug
may MD 0 0 1 O
also RB 0 0 12 O
decrease VB 0 1 1 O
biliary JJ 0 1 8 O
excretion NN 0 1 14 O
. . 0 0 12 O

9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O

Intravenous JJ 0 1 7 O
Adenocard NNP 0 1 UNK B-Brand
( ( 0 0 2 O
adenosine NN 0 1 14 B-Drug
) ) 0 0 2 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
effectively RB 0 0 1 O
administered VBN 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
presence NN 0 1 1 O
of IN 0 0 12 O
other JJ 0 0 12 O
cardioactive JJ 0 0 UNK O
drugs NNS 1 1 6 O
such JJ 0 0 1 O
as IN 1 0 12 O
quinidine NN 0 1 16 B-Drug
beta NN 0 1 16 B-Group
- : 0 0 2 O
adrenergic JJ 0 1 UNK I-Group
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
calcium JJ 0 1 14 B-Group
channel NNS 0 1 1 I-Group
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
and CC 0 0 12 O
angiotensin NN 0 1 UNK B-Group
converting VBG 1 0 UNK I-Group
enzyme JJ 0 1 14 I-Group
inhibitors NNS 1 1 14 I-Group
without IN 0 0 12 O
any DT 0 0 12 O
change NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
adverse JJ 0 0 1 O
reaction NN 0 1 1 O
profile NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
effect NN 0 1 1 O
of IN 0 0 12 O
administering VBG 1 1 1 O
different JJ 0 1 1 O
botulinum NN 0 1 13 B-Group
neurotoxin NN 0 1 UNK I-Group
serotypes NNS 0 1 UNK O
at IN 0 0 12 O
the DT 0 0 12 O
same JJ 0 1 12 O
time NN 0 1 12 O
or CC 0 0 12 O
within IN 0 0 1 O
less JJR 0 1 12 O
than IN 0 0 12 O
9 CD 0 0 2 O
months NNS 1 1 12 O
of IN 0 0 12 O
each DT 0 0 12 O
other JJ 0 0 12 O
is VBZ 1 0 12 O
unknown JJ 0 1 12 O
. . 0 0 12 O

The DT 0 0 2 O
effects NNS 1 1 1 O
of IN 0 0 12 O
ERGOMAR NNP 0 1 UNK B-Brand
may MD 0 0 1 O
be VB 0 0 12 O
potentiated VBN 1 0 UNK O
by IN 0 0 12 O
triacetyloleandomycin NN 0 1 UNK B-Drug
which WDT 0 0 12 O
inhibits VBZ 1 1 UNK O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
ergotamine NN 0 1 UNK B-Drug
. . 0 0 12 O

. . 0 0 12 O

Aprepitant NNP 0 1 UNK B-Drug
increased VBD 1 1 1 O
the DT 0 0 12 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
midazolam NN 0 1 16 B-Drug
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
on IN 0 0 12 O
Day NNP 0 1 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
decreased VBD 1 1 1 O
the DT 0 0 12 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
midazolam NN 0 1 16 B-Drug
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
on IN 0 0 12 O
Day NNP 0 1 2 O
9 CD 0 0 2 O
relative NN 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
dosing NN 0 0 14 O
of IN 0 0 12 O
Aprepitant NNP 0 1 UNK B-Drug
on IN 0 0 12 O
Days NNP 0 1 2 O
9 CD 0 0 2 O
through IN 0 0 12 O
9 CD 0 0 2 O
. . 0 0 12 O

( ( 0 0 2 O
e NN 0 0 16 O
) ) 0 0 2 O
There EX 0 0 12 O
may MD 0 0 1 O
be VB 0 0 12 O
small JJ 0 1 12 O
changes NNS 1 1 1 O
in IN 0 0 12 O
coagulation NN 0 1 14 O
factors NNS 1 1 1 O
. . 0 0 12 O

Antitubercular JJ 0 1 UNK O
drugs NNS 1 1 6 O
: : 0 0 2 O
Serum NNP 0 1 7 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
isoniazid NN 0 1 13 B-Drug
may MD 0 0 1 O
be VB 0 0 12 O
decreased VBN 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
daily JJ 0 1 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
ENABLEX NNP 0 1 UNK B-Brand
should MD 0 0 12 O
not RB 0 1 12 O
exceed VB 0 0 UNK O
9 CD 0 0 2 O
mg NNS 0 1 0 O
when WRB 0 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
potent JJ 0 1 UNK O
CYP9A9 NNP 0 0 UNK O
inhibitors NNS 1 1 14 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
ketoconazole NN 0 1 16 B-Drug
itraconazole NN 0 1 0 B-Drug
ritonavir NN 0 1 16 B-Drug
nelfinavir JJ 0 1 16 B-Drug
clarithromycin NN 0 1 13 B-Drug
and CC 0 0 12 O
nefazadone NN 0 0 UNK O
) ) 0 0 2 O
. . 0 0 12 O

Therefore RB 0 0 1 O
the DT 0 0 12 O
potential NN 0 1 1 O
for IN 0 0 12 O
such JJ 0 0 1 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
AZOPT NNP 0 1 UNK B-Brand
( ( 0 0 2 O
brinzolamide IN 0 1 16 B-Drug
ophthalmic JJ 0 1 6 O
suspension NN 0 1 3 O
) ) 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

Probenecid NNP 0 1 UNK B-Drug
Prolonged NNP 0 1 7 O
action NN 0 1 13 O
of IN 0 0 12 O
etomidate NN 0 1 14 B-Drug

The DT 0 0 2 O
possibility NN 0 1 1 O
of IN 0 0 12 O
hypotensive JJ 0 1 14 O
effects NNS 1 1 1 O
with IN 0 0 12 O
enalapril NN 0 1 0 B-Drug
or CC 0 0 12 O
enalaprilat NN 0 1 16 B-Drug
can MD 0 0 12 O
be VB 0 0 12 O
minimized VBN 1 0 1 O
by IN 0 0 12 O
either DT 0 1 12 O
discontinuing VBG 1 1 6 O
the DT 0 0 12 O
diuretic JJ 0 1 14 B-Drug
or CC 0 0 12 O
increasing VBG 1 1 1 O
the DT 0 0 12 O
salt NN 0 1 3 O
intake VB 0 1 3 O
prior JJ 0 1 1 O
to TO 0 0 12 O
initiation NN 0 1 1 O
of IN 0 0 12 O
treatment NN 0 1 6 O
with IN 0 0 12 O
enalapril NN 0 1 0 B-Drug
or CC 0 0 12 O
enalaprilat NN 0 1 16 B-Drug
. . 0 0 12 O

Diphenoxylate NNP 0 1 UNK B-Drug
HCl NNP 0 0 14 I-Drug
and CC 0 0 12 O
atropine JJ 0 1 14 B-Drug
sulfate NN 0 1 14 I-Drug
may MD 0 0 1 O
interact VB 0 0 UNK O
with IN 0 0 12 O
MAO NNP 0 1 14 B-Group
inhibitors NNS 1 1 14 I-Group
In IN 0 0 2 O
studies NNS 1 1 1 O
with IN 0 0 12 O
male JJ 0 1 12 O
rats NNS 1 1 UNK O
diphenoxylate VBP 0 1 16 B-Drug
hydrochloride NN 0 1 0 I-Drug
was VBD 1 0 12 O
found VBN 1 1 12 O
to TO 0 0 12 O
inhibit VB 0 1 13 O
the DT 0 0 12 O
hepatic JJ 0 1 14 O
microsomal NN 0 1 UNK O
enzyme NN 0 1 14 O
system NN 0 1 1 O
at IN 0 0 12 O
a DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
kg JJ 0 1 18 O
/ NNP 0 0 2 O
day NN 0 1 12 O
. . 0 0 12 O

Patients NNS 0 1 7 O
on IN 0 0 12 O
oral JJ 0 1 6 O
antidiabetic JJ 0 1 13 B-Group
agents NNS 1 1 1 I-Group
receiving VBG 1 1 1 O
VELCADE NNP 0 1 UNK B-Brand
treatment NN 0 1 6 O
may MD 0 0 1 O
require VB 0 0 1 O
close JJ 0 1 12 O
monitoring NN 0 1 1 O
of IN 0 0 12 O
their PRP$ 0 0 12 O
blood NN 0 1 6 O
glucose NN 0 1 14 O
levels NNS 1 1 1 O
and CC 0 0 12 O
adjustment NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
their PRP$ 0 0 12 O
antidiabetic JJ 0 1 13 B-Group
medication NN 0 1 6 I-Group
. . 0 0 12 O

Oral JJ 0 1 2 O
doses NNS 1 1 6 O
of IN 0 0 12 O
Antizol NNP 0 1 UNK B-Brand
( ( 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
) ) 0 0 2 O
via IN 0 0 1 O
alcohol NN 0 1 1 O
dehydrogenase NN 0 1 14 O
inhibition NN 0 1 13 O
significantly RB 0 0 1 O
reduced VBD 1 1 1 O
the DT 0 0 12 O
rate NN 0 1 1 O
of IN 0 0 12 O
elimination NN 0 1 UNK O
of IN 0 0 12 O
ethanol NN 0 1 1 B-Drug
( ( 0 0 2 O
by IN 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
given VBN 1 1 12 O
to TO 0 0 12 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
in IN 0 0 12 O
moderate JJ 0 1 1 O
doses NNS 1 1 6 O
. . 0 0 12 O

Interactions NNS 0 1 UNK O
may MD 0 0 1 O
also RB 0 0 12 O
occur VB 0 1 1 O
with IN 0 0 12 O
the DT 0 0 12 O
following NN 0 1 1 O
: : 0 0 2 O
anti JJ 0 0 3 B-Group
- : 0 0 2 O
depressants NNS 1 0 13 I-Group
/ VBP 0 0 2 O
anti JJ 0 0 3 B-Group
- : 0 0 2 O
anxiety NN 0 1 6 I-Group
drugs NNS 1 1 6 I-Group
drugs NNS 1 1 6 O
used VBN 1 1 12 O
to TO 0 0 12 O
treat VB 0 1 12 O
an DT 0 0 12 O
overactive JJ 0 1 UNK O
thyroid NN 0 1 6 O
beta NN 0 1 16 B-Group
- : 0 0 2 O
blockers NNS 1 0 6 I-Group
( ( 0 0 2 O
e.g. VB 0 0 UNK O
propranolol NN 0 1 16 B-Drug
) ) 0 0 2 O
sparfloxacin NN 0 1 UNK B-Drug
grepafloxacin JJ 0 1 UNK B-Drug
guanethidine NN 0 1 UNK B-Drug
guanadrel NN 0 1 UNK B-Drug
metrizamide NN 0 1 UNK B-Drug
cabergoline NN 0 1 13 B-Drug
lithium NN 0 1 16 B-Drug
narcotic JJ 0 1 6 B-Group
pain NN 0 1 6 O
medication NN 0 1 6 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
codeine NN 0 1 0 B-Drug
) ) 0 0 2 O
drugs NNS 1 1 6 O
used VBN 1 1 12 O
to TO 0 0 12 O
aid VB 0 1 1 O
sleep JJ 0 1 12 O
drowsiness NN 0 1 13 O
- : 0 0 2 O
causing NN 0 1 1 O
antihistamines NNS 1 1 UNK B-Group
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
diphenhydramine NN 0 1 16 B-Drug
) ) 0 0 2 O
any DT 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
may MD 0 0 1 O
make VB 0 1 12 O
you PRP 0 0 12 O
drowsy VB 0 1 6 O
. . 0 0 12 O

When WRB 0 0 12 O
Itraconazole NNP 0 1 UNK B-Drug
was VBD 1 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
phenytoin JJ 0 1 16 B-Drug
rifampin NN 0 1 16 B-Drug
or CC 0 0 12 O
H9antagonists NNS 0 0 UNK O
reduced VBD 1 1 1 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
itraconazole NN 0 1 0 B-Drug
were VBD 1 0 12 O
reported VBN 1 1 1 O
. . 0 0 12 O

No DT 0 0 2 O
data NN 0 1 1 O
are VBP 1 0 12 O
available JJ 0 1 1 O
for IN 0 0 12 O
the DT 0 0 12 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
INVIRASE NNP 0 1 UNK B-Brand
/ NNP 0 0 2 O
ritonavir NN 0 1 16 B-Drug
or CC 0 0 12 O
FORTOVASE NNP 0 1 UNK B-Brand
/ NNP 0 0 2 O
ritonavir NN 0 1 16 B-Drug
and CC 0 0 12 O
garlic JJ 0 1 UNK O
capsules NNS 1 1 3 O
. . 0 0 12 O

Atromid NNP 0 1 UNK B-Brand
- : 0 0 2 O
S NN 0 1 2 I-Brand
may MD 0 0 1 O
displace VB 0 0 13 O
acidic JJ 0 1 UNK O
drugs NNS 1 1 6 O
such JJ 0 0 1 O
as IN 1 0 12 O
phenytoin NN 0 1 16 B-Drug
or CC 0 0 12 O
tolbutamide NN 0 1 UNK B-Drug
from IN 0 0 12 O
their PRP$ 0 0 12 O
binding NN 0 1 1 O
sites NNS 1 1 1 O
. . 0 0 12 O

Oral JJ 0 1 2 O
contraceptives NNS 1 1 13 B-Group
may MD 0 0 1 O
be VB 0 0 12 O
less RBR 0 1 12 O
effective JJ 0 1 1 O
while IN 0 0 12 O
you PRP 0 0 12 O
are VBP 1 0 12 O
taking VBG 1 0 12 O
lymecycline NN 0 1 UNK B-Drug
. . 0 0 12 O

Mixtures NNS 0 1 UNK O
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
intravenously RB 0 0 14 O
. . 0 0 12 O

These DT 0 0 1 O
effects NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
with IN 0 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
itraconazole NN 0 1 0 B-Drug
( ( 0 0 2 O
a DT 0 0 12 O
potent NN 0 1 UNK O
CYP9A9 NNP 0 0 UNK B-Drug
inhibitor NN 0 1 14 O
) ) 0 0 2 O
. . 0 0 12 O

decreased VBN 1 1 1 O
pharmacologic JJ 0 1 14 O
effect NN 0 1 1 O
of IN 0 0 12 O
aspirin NN 0 1 14 B-Brand
. . 0 0 12 O

Potentiation NN 0 1 UNK O
occurs VBZ 1 1 1 O
with IN 0 0 12 O
ganglionic JJ 0 1 UNK B-Group
or CC 0 0 12 O
peripheral JJ 0 1 6 B-Group
adrenergic JJ 0 1 UNK I-Group
blocking VBG 1 1 UNK I-Group
drugs NNS 1 1 6 I-Group
. . 0 0 12 O

bromelains NNS 0 1 UNK B-Drug
; : 0 0 2 O

There EX 0 0 12 O
was VBD 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
dose NN 0 1 6 O
or CC 0 0 12 O
multiple JJ 0 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
MYCAMINE NNP 0 1 UNK B-Brand
on IN 0 0 12 O
mycophenolate NN 0 1 0 B-Drug
mofetil NNS 0 0 16 I-Drug
cyclosporine VBP 0 1 14 B-Drug
tacrolimus IN 0 1 16 B-Drug
prednisolone NN 0 1 0 B-Drug
and CC 0 0 12 O
fluconazole JJ 0 1 0 B-Drug
pharmacokinetics NNS 0 1 UNK O
. . 0 0 12 O

Blood NN 0 1 2 O
levels NNS 1 1 1 O
of IN 0 0 12 O
hydrodolasetron NN 0 1 UNK B-Drug_n
increased VBD 1 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
when WRB 0 0 12 O
dolasetron NN 0 1 0 B-Drug
was VBD 1 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
cimetidine NN 0 1 13 B-Drug
( ( 0 0 2 O
nonselective JJ 0 0 UNK O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
cytochrome NN 0 1 UNK O
P NNP 0 1 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
and CC 0 0 12 O
decreased VBD 1 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
with IN 0 0 12 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
rifampin NN 0 1 16 B-Drug
( ( 0 0 2 O
potent JJ 0 1 UNK O
inducer NN 0 1 UNK O
of IN 0 0 12 O
cytochrome NN 0 1 UNK O
P NNP 0 1 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
. . 0 0 12 O

. . 0 0 12 O

Drugs NNS 0 1 2 O
Metabolized VBN 0 1 UNK O
by IN 0 0 12 O
Cytochrome NNP 0 1 UNK O
P9 NNP 0 1 UNK O
Enzymes NNP 0 1 7 O
The DT 0 0 2 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
study NN 0 1 1 O
evaluating VBG 1 1 1 O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
grepafloxacin NN 0 1 UNK B-Drug
on IN 0 0 12 O
theophylline NN 0 1 16 B-Drug
indicates VBZ 1 0 1 O
that IN 0 0 12 O
grepafloxacin NN 0 1 UNK B-Drug
inhibits NNS 0 1 UNK O
theophylline VBP 0 1 16 B-Drug
metabolism NN 0 1 16 O
which WDT 0 0 12 O
is VBZ 1 0 12 O
mediated VBN 1 1 13 O
by IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
. . 0 0 12 O

No DT 0 0 2 O
abortifacient NN 0 1 UNK O
or CC 0 0 12 O
teratogenic JJ 0 1 UNK O
effects NNS 1 1 1 O
were VBD 1 0 12 O
observed VBN 1 1 1 O
in IN 0 0 12 O
cynomolgus JJ 0 1 UNK O
monkeys NNS 1 1 UNK O
following VBG 1 1 1 O
intravenous JJ 0 1 14 O
bolus JJ 0 1 14 O
injections NNS 1 1 6 O
of IN 0 0 12 O
AMEVIVE NNP 0 1 UNK B-Brand
administered VBD 1 1 1 O
weekly JJ 0 1 12 O
during IN 0 0 12 O
the DT 0 0 12 O
period NN 0 1 1 O
of IN 0 0 12 O
organogenesis NN 0 1 UNK O
to TO 0 0 12 O
gestation NN 0 1 6 O
. . 0 0 12 O

DIPRIVAN NNP 0 1 UNK B-Brand
Injectable JJ 0 1 UNK O
Emulsion NN 0 1 UNK O
does VBZ 1 0 12 O
not RB 0 1 12 O
cause VB 0 1 12 O
a DT 0 0 12 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
change NN 0 1 1 O
in IN 0 0 12 O
onset JJ 0 1 6 O
intensity NN 0 1 1 O
or CC 0 0 12 O
duration NN 0 1 1 O
of IN 0 0 12 O
action NN 0 1 13 O
of IN 0 0 12 O
the DT 0 0 12 O
commonly NN 0 0 UNK O
used VBD 1 1 12 O
neuromuscular JJ 0 1 6 B-Group
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
( ( 0 0 2 O
eg JJ 0 1 UNK O
succinylcholine NN 0 1 16 B-Drug
and CC 0 0 12 O
nondepolarizing JJ 0 0 UNK B-Group
muscle NN 0 1 6 I-Group
relaxants NNS 1 0 13 I-Group
) ) 0 0 2 O
. . 0 0 12 O

In IN 0 0 2 O
a DT 0 0 12 O
crossover NN 0 1 UNK O
study NN 0 1 1 O
in IN 0 0 12 O
9 CD 0 0 2 O
pediatric JJ 0 1 6 O
patients NNS 1 1 6 O
I.V NNP 0 1 UNK O
. . 0 0 12 O

Concurrent NNP 0 1 13 O
use NN 0 1 1 O
of IN 0 0 12 O
tetracyclines NNS 1 1 13 B-Group
with IN 0 0 12 O
oral JJ 0 1 6 O
contraceptives NNS 1 1 13 B-Group
may MD 0 0 1 O
render VB 0 0 13 O
oral JJ 0 1 6 O
contraceptives NNS 1 1 13 B-Group
less RBR 0 1 12 O
effective JJ 0 1 1 O
. . 0 0 12 O

Anticholinergic JJ 0 1 UNK B-Group
agents NNS 1 1 1 I-Group
may MD 0 0 1 O
potentially RB 0 0 1 O
alter VB 0 1 13 O
the DT 0 0 12 O
absorption NN 0 1 1 O
of IN 0 0 12 O
some DT 0 0 12 O
concomitantly RB 0 0 14 O
administered VBN 1 1 1 O
drugs NNS 1 1 6 O
due JJ 0 1 1 O
to TO 0 0 12 O
effects NNS 1 1 1 O
on IN 0 0 12 O
gastrointestinal JJ 0 1 6 O
motility NN 0 1 6 O
. . 0 0 12 O

You PRP 0 0 2 O
can MD 0 0 12 O
not RB 0 1 12 O
take VB 0 1 12 O
mazindol NN 0 1 UNK B-Drug
if IN 0 0 12 O
you PRP 0 0 12 O
have VBP 0 0 12 O
taken VBN 1 1 12 O
a DT 0 0 12 O
monoamine JJ 0 1 13 B-Group
oxidase NN 0 1 13 I-Group
inhibitor NN 0 1 14 I-Group
( ( 0 0 2 O
MAOI NNP 0 1 UNK B-Group
) ) 0 0 2 O
such JJ 0 0 1 O
as IN 1 0 12 O
isocarboxazid NN 0 1 UNK B-Drug
( ( 0 0 2 O
Marplan NNP 0 1 UNK B-Brand
) ) 0 0 2 O
tranylcypromine NN 0 1 13 B-Drug
( ( 0 0 2 O
Parnate NNP 0 1 UNK B-Brand
) ) 0 0 2 O
or CC 0 0 12 O
phenelzine NN 0 1 16 B-Drug
( ( 0 0 2 O
Nardil NNP 0 1 UNK B-Brand
) ) 0 0 2 O
in IN 0 0 12 O
the DT 0 0 12 O
last JJ 0 1 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
. . 0 0 12 O

Other JJ 0 0 2 O
drugs NNS 1 1 6 O
which WDT 0 0 12 O
may MD 0 0 1 O
enhance VB 0 1 UNK O
the DT 0 0 12 O
neuromuscular JJ 0 1 6 O
blocking VBG 1 1 UNK O
action NN 0 1 13 O
of IN 0 0 12 O
nondepolarizing VBG 0 0 UNK O
agents NNS 1 1 1 O
such JJ 0 0 1 O
as IN 1 0 12 O
NUROMAX NNP 0 1 UNK B-Brand
include VBP 0 1 1 O
certain JJ 0 1 1 O
antibiotics NNS 1 1 6 B-Group
( ( 0 0 2 O
e. JJ 0 0 1 O
g. NN 0 1 13 O
aminoglycosides NNS 0 1 13 B-Group
tetracyclines NNS 1 1 13 B-Group
bacitracin VBP 0 1 16 B-Group
polymyxins NNS 1 1 UNK B-Group
lincomycin JJ 0 1 UNK B-Drug
clindamycin NN 0 1 0 B-Drug
colistin NN 0 1 13 B-Drug
and CC 0 0 12 O
sodium NN 0 1 14 B-Drug
colistimethate NN 0 1 13 I-Drug
) ) 0 0 2 O
magnesium NN 0 1 14 B-Drug
salts NNS 1 1 13 O
lithium JJ 0 1 16 B-Drug
local JJ 0 1 12 O
anesthetics NNS 1 1 13 B-Group
procainamide NN 0 1 16 B-Drug
and CC 0 0 12 O
quinidine NN 0 1 16 B-Drug
. . 0 0 12 O

- : 0 0 2 O
Mercaptopurine NN 0 1 UNK B-Drug
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
Purinethol NNP 0 1 UNK B-Brand
) ) 0 0 2 O
or CC 0 0 12 O

In IN 0 0 2 O
vivo JJ 0 1 13 O
studies NNS 1 1 1 O
: : 0 0 2 O
Cytochrome NNP 0 1 UNK O
P9 NNP 0 1 UNK O
Inhibitors NNS 0 1 7 O

Clinical JJ 0 1 7 O
experience NN 0 1 12 O
with IN 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
bosentan NN 0 1 13 B-Drug
and CC 0 0 12 O
warfarin NN 0 1 14 B-Drug
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
pulmonary JJ 0 1 6 O
arterial JJ 0 1 6 O
hypertension NN 0 1 6 O
did VBD 1 0 12 O
not RB 0 1 12 O
show VB 0 1 12 O
clinically RB 0 0 6 O
relevant JJ 0 1 1 O
changes NNS 1 1 1 O
in IN 0 0 12 O
INR NNP 0 1 13 O
or CC 0 0 12 O
warfarin NN 0 1 14 B-Drug
dose NN 0 1 6 O
( ( 0 0 2 O
baseline NN 0 1 1 O
vs. FW 0 1 2 O
end NN 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
clinical JJ 0 1 6 O
studies NNS 1 1 1 O
) ) 0 0 2 O
and CC 0 0 12 O
the DT 0 0 12 O
need NN 0 1 12 O
to TO 0 0 12 O
change VB 0 1 1 O
the DT 0 0 12 O
warfarin NN 0 1 14 B-Drug
dose NN 0 1 6 O
during IN 0 0 12 O
the DT 0 0 12 O
trials NNS 1 1 1 O
due JJ 0 1 1 O
to TO 0 0 12 O
changes NNS 1 1 1 O
in IN 0 0 12 O
INR NNP 0 1 13 O
or CC 0 0 12 O
due JJ 0 1 1 O
to TO 0 0 12 O
adverse JJ 0 0 1 O
events NNS 1 1 12 O
was VBD 1 0 12 O
similar JJ 0 1 1 O
among IN 0 0 12 O
bosentan JJ 0 1 13 B-Drug
- : 0 0 2 O
and CC 0 0 12 O
placebo VB 0 1 13 O
- : 0 0 2 O
treated JJ 0 1 1 O
patients NNS 1 1 6 O
. . 0 0 12 O

Such JJ 0 0 1 O
individuals NNS 1 1 1 O
are VBP 1 0 12 O
referred VBN 1 1 1 O
to TO 0 0 12 O
as IN 1 0 12 O
poor JJ 0 1 12 O
metabolizers NNS 0 0 UNK O
of IN 0 0 12 O
drugs NNS 1 1 6 O
such JJ 0 0 1 O
as IN 1 0 12 O
debrisoquin NN 0 1 UNK B-Drug
dextromethorphan IN 0 1 16 B-Drug
the DT 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
and CC 0 0 12 O
clozapine NN 0 1 13 B-Drug
. . 0 0 12 O

Data NNP 0 1 2 O
suggest NN 0 1 1 O
that IN 0 0 12 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
oral JJ 0 1 6 O
ketoconazole NN 0 1 16 B-Drug
and CC 0 0 12 O
cisapride NN 0 1 UNK B-Drug
can MD 0 0 12 O
result VB 0 1 1 O
in IN 0 0 12 O
prolongation NN 0 1 6 O
of IN 0 0 12 O
the DT 0 0 12 O
QT NNP 0 1 13 O
interval NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
ECG NNP 0 1 6 O
. . 0 0 12 O

They PRP 0 0 12 O
may MD 0 0 1 O
be VB 0 0 12 O
administered VBN 1 1 1 O
alternately RB 0 0 UNK O
when WRB 0 0 12 O
the DT 0 0 12 O
preceding VBG 1 1 1 O
effect NN 0 1 1 O
of IN 0 0 12 O
other JJ 0 0 12 O
such JJ 0 0 1 O
drug NN 0 1 1 O
has VBZ 1 0 12 O
subsided VBN 1 0 3 O
. . 0 0 12 O

Renal JJ 0 1 7 O
clearance NN 0 1 16 O
measurements NNS 1 1 1 O
of IN 0 0 12 O
PAH NNP 0 1 UNK B-Drug
can MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
made VBN 1 1 12 O
with IN 0 0 12 O
any DT 0 0 12 O
significant JJ 0 1 1 O
accuracy NN 0 1 UNK O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
sulfonamides NNS 1 1 13 B-Group
procaine NN 0 1 UNK B-Drug
or CC 0 0 12 O
thiazolesulfone NN 0 0 UNK B-Drug
. . 0 0 12 O

Clinical JJ 0 1 7 O
significance NN 0 1 13 O
of IN 0 0 12 O
reduced JJ 0 1 1 O
efavirenz JJ 0 1 13 B-Drug
concentrations NNS 1 1 13 O
unknown JJ 0 1 12 O
. . 0 0 12 O

In IN 0 0 2 O
clinical JJ 0 1 6 O
studies NNS 1 1 1 O
performed VBN 1 1 1 O
with IN 0 0 12 O
Fondaparinux NNP 0 1 UNK B-Drug
the DT 0 0 12 O
concomitant NN 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
oral JJ 0 1 6 O
anticoagulants NNS 1 1 13 B-Group
( ( 0 0 2 O
warfarin NN 0 1 14 B-Drug
) ) 0 0 2 O
platelet NN 0 1 14 B-Group
inhibitors NNS 1 1 14 I-Group
( ( 0 0 2 O
acetylsalicylic JJ 0 0 UNK B-Drug
acid NN 0 1 14 I-Drug
) ) 0 0 2 O
NSAIDs NNP 0 1 UNK B-Group
( ( 0 0 2 O
piroxicam NN 0 1 13 B-Drug
) ) 0 0 2 O
and CC 0 0 12 O
digoxin NN 0 1 14 B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
significantly RB 0 0 1 O
affect VBP 0 1 1 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
/ VBP 0 0 2 O
pharmacodynamics NNS 0 1 UNK O
of IN 0 0 12 O
fondaparinux JJ 0 1 16 B-Drug
sodium NN 0 1 14 I-Drug
. . 0 0 12 O

Other JJ 0 0 2 O
nonsteroidal JJ 0 0 14 B-Group
anti SYM 0 0 3 I-Group
- : 0 0 2 O
inflammatory NN 0 1 6 I-Group
drugs NNS 1 1 6 I-Group
that WDT 0 0 12 O
inhibit VBP 0 1 13 O
prostaglandin JJ 0 1 13 O
synthesis NN 0 1 UNK O
have VBP 0 0 12 O
been VBN 1 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
thiazide JJ 0 1 UNK B-Group
diuretics NNS 1 1 14 I-Group
in IN 0 0 12 O
some DT 0 0 12 O
studies NNS 1 1 1 O
and CC 0 0 12 O
with IN 0 0 12 O
potassium NN 0 1 14 B-Group
- : 0 0 2 O
sparing NN 0 0 6 I-Group
diuretics NNS 1 1 14 I-Group
. . 0 0 12 O

The DT 0 0 2 O
effects NNS 1 1 1 O
seen VBN 1 1 12 O
are VBP 1 0 12 O
poorly RB 0 1 1 O
understood JJ 0 1 12 O
and CC 0 0 12 O
depend VBP 0 1 1 O
upon IN 0 0 12 O
a DT 0 0 12 O
variety NN 0 1 1 O
of IN 0 0 12 O
factors NNS 1 1 1 O
such JJ 0 0 1 O
as IN 1 0 12 O
dose NN 0 1 6 O
and CC 0 0 12 O
type NN 0 1 1 O
of IN 0 0 12 O
thyroid JJ 0 1 6 B-Group
preparations NNS 1 1 13 I-Group
and CC 0 0 12 O
endocrine JJ 0 1 6 O
status NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
patient NN 0 1 6 O
. . 0 0 12 O

Patients NNS 0 1 7 O
receiving VBG 1 1 1 O
antihistamines NNS 1 1 UNK B-Group
should MD 0 0 12 O
be VB 0 0 12 O
advised VBN 1 0 12 O
against IN 0 0 12 O
the DT 0 0 12 O
concurrent NN 0 1 1 O
use NN 0 1 1 O
of IN 0 0 12 O
other JJ 0 0 12 O
CNS NNP 0 1 6 B-Group
depressant NN 0 0 UNK I-Group
drugs NNS 1 1 6 I-Group
. . 0 0 12 O

No DT 0 0 2 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
changes NNS 1 1 1 O
to TO 0 0 12 O
lamivudine VB 0 1 16 B-Drug
or CC 0 0 12 O
zidovudine VB 0 1 13 B-Drug
pharmacokinetics NNS 0 1 UNK O
were VBD 1 0 12 O
observed VBN 1 1 1 O
following VBG 1 1 1 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
abacavir NN 0 1 16 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
effects NNS 1 1 1 O
of IN 0 0 12 O
fulvestrant NN 0 1 13 B-Drug
on IN 0 0 12 O
the DT 0 0 12 O
fertility NN 0 1 6 O
of IN 0 0 12 O
female JJ 0 1 12 O
rats NNS 1 1 UNK O
appear VBP 0 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
consistent JJ 0 1 1 O
with IN 0 0 12 O
its PRP$ 1 0 12 O
anti JJ 0 0 3 O
- : 0 0 2 O
estrogenic JJ 0 1 UNK O
activity NN 0 1 1 O
. . 0 0 12 O

Although IN 0 0 12 O
the DT 0 0 12 O
pattern NN 0 1 3 O
of IN 0 0 12 O
use NN 0 1 1 O
for IN 0 0 12 O
oral JJ 0 1 6 O
allopurinol NN 0 1 13 B-Drug
includes VBZ 1 1 1 O
longer JJR 1 1 12 O
term NN 0 1 1 O
therapy NN 0 1 6 O
particularly RB 0 0 1 O
for IN 0 0 12 O
gout NN 0 1 6 O
and CC 0 0 12 O
renal JJ 0 1 6 O
calculi NN 1 1 8 O
the DT 0 0 12 O
experience NN 0 1 12 O
gained VBD 1 1 12 O
may MD 0 0 1 O
be VB 0 0 12 O
relevant JJ 0 1 1 O
. . 0 0 12 O

Therefore RB 0 0 1 O
careful JJ 0 1 12 O
monitoring NN 0 1 1 O
is VBZ 1 0 12 O
advised VBN 1 0 12 O
. . 0 0 12 O

Gastroparesis NNP 0 1 7 O
( ( 0 0 2 O
gastric JJ 0 1 6 O
stasis NN 0 1 6 O
) ) 0 0 2 O
may MD 0 0 1 O
be VB 0 0 12 O
responsible JJ 0 1 1 O
for IN 0 0 12 O
poor JJ 0 1 12 O
diabetic JJ 0 1 6 O
control NN 0 1 1 O
in IN 0 0 12 O
some DT 0 0 12 O
patients NNS 1 1 6 O
. . 0 0 12 O

. . 0 0 12 O

N=9 NNP 0 1 UNK O
) ) 0 0 2 O
decreases VBZ 1 1 UNK O
hydrocodone NN 0 1 UNK B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
; : 0 0 2 O

Antacids NNS 0 1 UNK B-Group
: : 0 0 2 O
Concomitant NNP 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
antacids NNS 1 1 14 B-Group
may MD 0 0 1 O
reduce VB 0 0 1 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
diflunisal NN 0 1 13 B-Drug
. . 0 0 12 O

Therefore RB 0 0 1 O
if IN 0 0 12 O
an DT 0 0 12 O
inhibitor NN 0 1 14 O
or CC 0 0 12 O
an DT 0 0 12 O
inducer NN 0 1 UNK O
of IN 0 0 12 O
CYP9C9 NNP 0 0 UNK O
is VBZ 1 0 12 O
started VBN 1 1 12 O
or CC 0 0 12 O
stopped VBN 1 1 12 O
during IN 0 0 12 O
treatment NN 0 1 6 O
with IN 0 0 12 O
rosiglitazone NN 0 1 16 B-Drug
changes NNS 1 1 1 O
in IN 0 0 12 O
diabetes NNS 0 1 6 O
treatment NN 0 1 6 O
may MD 0 0 1 O
be VB 0 0 12 O
needed VBN 1 1 12 O
based VBN 1 1 1 O
upon IN 0 0 12 O
clinical JJ 0 1 6 O
response NN 0 1 1 O
. . 0 0 12 O

FORADIL NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
not RB 0 1 12 O
meant VBN 1 1 12 O
to TO 0 0 12 O
relieve VB 0 1 6 O
acute JJ 0 1 6 O
asthma NN 0 1 6 O
or CC 0 0 12 O
COPD NNP 0 1 6 O
symptoms NNS 1 1 6 O
and CC 0 0 12 O
extra JJ 0 0 3 O
doses NNS 1 1 6 O
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
for IN 0 0 12 O
that DT 0 0 12 O
purpose NN 0 1 1 O
. . 0 0 12 O

After IN 0 0 2 O
9 CD 0 0 2 O
days NNS 1 1 12 O
of IN 0 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
administration NN 0 1 1 O
mean VBP 0 1 12 O
trough IN 0 1 3 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
clozapine NN 0 1 13 B-Drug
and CC 0 0 12 O
its PRP$ 1 0 12 O
metabolites NNS 1 1 UNK O
N NNP 0 1 2 B-Drug_n
- : 0 0 2 O
desmethylclozapine NN 0 0 UNK I-Drug_n
and CC 0 0 12 O
clozapine NN 0 1 13 B-Drug_n
N NNP 0 1 2 I-Drug_n
- : 0 0 2 O
oxide NN 0 1 14 I-Drug_n
were VBD 1 0 12 O
elevated VBN 1 1 1 O
with IN 0 0 12 O
fluvoxamine NN 0 1 16 B-Drug
by IN 0 0 12 O
about IN 0 1 12 O
three CD 0 1 12 O
- : 0 0 2 O
fold NN 0 1 3 O
compared VBN 1 1 1 O
to TO 0 0 12 O
baseline VB 0 1 1 O
concentrations NNS 1 1 13 O
. . 0 0 12 O

Since IN 0 1 2 O
a DT 0 0 12 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
interaction NN 0 1 UNK O
may MD 0 0 1 O
be VB 0 0 12 O
anticipated VBN 1 1 1 O
alternative JJ 0 1 1 O
antihypertensive JJ 0 1 14 B-Drug
therapy NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
in IN 0 0 12 O
these DT 0 0 12 O
patients NNS 1 1 6 O
. . 0 0 12 O

Plasma NNP 0 1 UNK O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
quinolone NN 0 1 UNK B-Group
antibiotics NNS 1 1 6 I-Group
are VBP 1 0 12 O
decreased VBN 1 1 1 O
when WRB 0 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
antacids NNS 1 1 14 B-Group
containing VBG 1 1 1 O
magnesium NN 0 1 14 B-Drug
calcium NN 0 1 14 B-Drug
or CC 0 0 12 O
aluminum NN 0 1 16 B-Drug
. . 0 0 12 O

Cimetidine NNP 0 1 0 O
Co NNP 0 1 2 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
felodipine NN 0 1 13 B-Drug
with IN 0 0 12 O
cimetidine NN 0 1 13 B-Drug
( ( 0 0 2 O
a DT 0 0 12 O
non NN 0 1 1 O
- : 0 0 2 O
specific JJ 0 1 1 O
CYP NNP 0 1 UNK O
- : 0 0 2 O
9 CD 0 0 2 O
inhibitor NN 0 1 14 O
) ) 0 0 2 O
resulted VBD 1 1 1 O
in IN 0 0 12 O
an DT 0 0 12 O
increase NN 0 1 1 O
of IN 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
in IN 0 0 12 O
the DT 0 0 12 O
AUC NNP 0 1 UNK O
and CC 0 0 12 O
the DT 0 0 12 O
Cmax NNP 0 1 UNK O
of IN 0 0 12 O
felodipine NN 0 1 13 B-Drug
. . 0 0 12 O

Drugs NNS 0 1 2 O
Decreasing VBG 0 1 UNK O
Heparin NNP 0 1 0 B-Drug
Effect NNP 0 1 UNK O
: : 0 0 2 O
Digitalis NNP 0 1 15 B-Group
tetracyclines NNS 1 1 13 B-Group
nicotine NN 0 1 6 B-Drug
or CC 0 0 12 O
antihistamines NNS 1 1 UNK B-Group
may MD 0 0 1 O
partially RB 0 0 1 O
counteract VB 0 0 UNK O
the DT 0 0 12 O
anticoagulant JJ 0 1 13 O
action NN 0 1 13 O
of IN 0 0 12 O
heparin NN 0 1 14 B-Drug
sodium NN 0 1 14 I-Drug
. . 0 0 12 O

Preliminary JJ 0 1 2 O
studies NNS 1 1 1 O
indicate VBP 0 0 1 O
that IN 0 0 12 O
the DT 0 0 12 O
concomitant NN 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
dobutamine NN 0 1 14 B-Drug
and CC 0 0 12 O
nitroprusside JJ 0 1 14 B-Drug
results NNS 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
higher JJR 1 1 1 O
cardiac JJ 0 1 6 O
output NN 0 1 1 O
and CC 0 0 12 O
usually RB 0 1 12 O
a DT 0 0 12 O
lower JJR 1 1 1 O
pulmonary JJ 0 1 6 O
wedge NN 0 1 3 O
pressure NN 0 1 1 O
than IN 0 0 12 O
when WRB 0 0 12 O
either DT 0 1 12 O
drug NN 0 1 1 O
is VBZ 1 0 12 O
used VBN 1 1 12 O
alone RB 0 1 12 O
. . 0 0 12 O

Use NNP 0 1 2 O
of IN 0 0 12 O
a DT 0 0 12 O
nonhormonal JJ 0 0 UNK B-Group
contraceptive JJ 0 1 13 I-Group
product NN 0 1 1 I-Group
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O

Ranitidine NNP 0 1 0 B-Drug
produced VBD 1 0 1 O
smaller JJR 1 1 3 O
non JJ 0 1 1 O
- : 0 0 2 O
significant JJ 0 1 1 O
increases NNS 1 1 1 O
. . 0 0 12 O

InjectionSite JJ 0 0 UNK O
Reaction NN 0 1 UNK O
: : 0 0 2 O
Injection NNP 0 1 7 O
site NN 0 1 12 O
reactions NNS 1 1 1 O
including VBG 1 1 1 O
reactions NNS 1 1 1 O
secondary JJ 0 1 1 O
to TO 0 0 12 O
extravasation VB 0 1 8 O
were VBD 1 0 12 O
usually RB 0 1 12 O
mild JJ 0 1 6 O
and CC 0 0 12 O
consisted VBN 1 1 1 O
of IN 0 0 12 O
erythema NN 0 1 8 O
tenderness NN 0 1 6 O
skin JJ 0 1 3 O
discoloration NN 0 1 6 O
or CC 0 0 12 O
swelling VBG 1 1 6 O
at IN 0 0 12 O
the DT 0 0 12 O
injection NN 0 1 3 O
site NN 0 1 12 O
. . 0 0 12 O

Accordingly RB 0 0 1 O
careful JJ 0 1 12 O
patient JJ 0 1 6 O
monitoring NN 0 1 1 O
and CC 0 0 12 O
dose JJ 0 1 6 O
adjustment NN 0 1 1 O
of IN 0 0 12 O
metformin NN 0 1 0 B-Drug
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
concomitantly RB 0 0 14 O
taking VBG 1 0 12 O
cephalexin NN 0 1 16 B-Drug
and CC 0 0 12 O
metformin NN 0 1 0 B-Drug
. . 0 0 12 O

Nifedipine NNP 0 1 0 B-Drug
AUC NNP 0 1 UNK O
and CC 0 0 12 O
Cmax NNP 0 1 UNK O
were VBD 1 0 12 O
increased VBN 1 1 1 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
respectively RB 0 0 1 O
in IN 0 0 12 O
the DT 0 0 12 O
presence NN 0 1 1 O
of IN 0 0 12 O
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
MYCAMINE NNP 0 1 UNK B-Brand
compared VBN 1 1 1 O
with IN 0 0 12 O
nifedipine JJ 0 1 0 B-Drug
alone NN 0 1 12 O
. . 0 0 12 O

chlordiazepoxide NN 0 1 16 B-Drug
; : 0 0 2 O

Consequently RB 0 0 1 O
the DT 0 0 12 O
combination NN 0 1 1 O
of IN 0 0 12 O
methotrexate NN 0 1 16 B-Drug
with IN 0 0 12 O
acitretin NN 0 1 13 B-Drug
is VBZ 1 0 12 O
also RB 0 0 12 O
contraindicated VBN 1 1 14 O
. . 0 0 12 O

If IN 0 0 12 O
chlorprothixene NN 0 1 UNK B-Drug
is VBZ 1 0 12 O
given VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
opioids NNS 0 1 14 B-Group
the DT 0 0 12 O
opioid NN 0 1 13 B-Group
dose NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
reduced VBN 1 1 1 O
( ( 0 0 2 O
by IN 0 0 12 O
approx NN 0 0 3 O
. . 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
because IN 0 0 12 O
chlorprothixene NN 0 1 UNK B-Drug
amplifies VBZ 1 0 UNK O
the DT 0 0 12 O
therapeutic JJ 0 1 6 O
actions NNS 1 1 UNK O
and CC 0 0 12 O
side JJ 0 1 3 O
- : 0 0 2 O
effects NNS 1 1 1 O
of IN 0 0 12 O
opioids NNS 0 1 14 B-Group
massively RB 0 1 1 O
. . 0 0 12 O

These DT 0 0 1 O
data NNS 0 1 1 O
indicate VBP 0 0 1 O
that IN 0 0 12 O
levetiracetam NN 0 1 16 B-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
influence VB 0 0 UNK O
the DT 0 0 12 O
plasma NN 0 1 14 O
concentration NN 0 1 1 O
of IN 0 0 12 O
other JJ 0 0 12 O
AEDs NNP 0 1 UNK B-Group
and CC 0 0 12 O
that IN 0 0 12 O
these DT 0 0 12 O
AEDs NNP 0 1 UNK B-Group
do VBP 0 0 12 O
not RB 0 1 12 O
influence VB 0 0 UNK O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
levetiracetam NN 0 1 16 B-Drug
. . 0 0 12 O

Aspirin NNP 0 1 0 B-Brand
/ NNP 0 0 2 O
Nonsteroidal NNP 0 0 UNK B-Group
Antiinflammatory NNP 0 1 UNK I-Group
Drugs NNP 0 1 2 I-Group
( ( 0 0 2 O
NSAIDs NNP 0 1 UNK B-Group
) ) 0 0 2 O

In IN 0 0 2 O
the DT 0 0 12 O
large JJ 0 1 3 O
placebo NN 0 1 13 O
- : 0 0 2 O
controlled VBN 1 1 1 O
osteoporosis NN 0 1 6 O
Treatment NNP 0 1 7 O
Study NNP 0 1 2 O
aspirin NN 0 1 14 B-Brand
and CC 0 0 12 O
nonsteroidal JJ 0 0 14 B-Group
anti NN 0 0 3 I-Group
- : 0 0 2 O
inflammatory NN 0 1 6 I-Group
drugs NNS 1 1 6 I-Group
were VBD 1 0 12 O
taken VBN 1 1 12 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
of IN 0 0 12 O
the DT 0 0 12 O
9 CD 0 0 2 O
patients NNS 1 1 6 O
. . 0 0 12 O

Therefore RB 0 0 1 O
monitoring NN 0 1 1 O
of IN 0 0 12 O
blood NN 0 1 6 O
glucose NN 0 1 14 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
when WRB 0 0 12 O
these DT 0 0 12 O
agents NNS 1 1 1 O
are VBP 1 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
. . 0 0 12 O

Sertraline NN 0 1 0 B-Drug

Phenytoin NN 0 1 0 B-Drug
: : 0 0 2 O
Serum NNP 0 1 7 O
phenytoin NN 0 1 16 B-Drug
levels NNS 1 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
increased VBN 1 1 1 O
by IN 0 0 12 O
aspirin NN 0 1 14 B-Brand
. . 0 0 12 O

The DT 0 0 2 O
bioavailability NN 0 1 UNK O
of IN 0 0 12 O
perindoprilat NN 0 1 UNK B-Drug_n
was VBD 1 0 12 O
reduced VBN 1 1 1 O
by IN 0 0 12 O
diuretics NNS 1 1 14 B-Group
however RB 0 0 12 O
and CC 0 0 12 O
this DT 0 0 12 O
was VBD 1 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
a DT 0 0 12 O
decrease NN 0 1 1 O
in IN 0 0 12 O
plasma JJ 0 1 14 O
ACE NNP 0 1 13 O
inhibition NN 0 1 13 O
. . 0 0 12 O

No DT 0 0 2 O
interaction NN 0 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressant JJ 0 1 6 I-Group
imipramine NN 0 1 0 B-Drug
was VBD 1 0 12 O
shown VBN 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
- : 0 0 2 O
dose NN 0 1 6 O
study NN 0 1 1 O
with IN 0 0 12 O
entacapone NN 0 1 13 B-Drug
without IN 0 0 12 O
coadministered JJ 0 0 UNK O
levodopa NN 0 1 UNK B-Drug
/ NNP 0 0 2 O
dopa VBZ 0 1 14 B-Group
- : 0 0 2 O
decarboxylase NN 0 1 UNK I-Group
inhibitor NN 0 1 14 I-Group
. . 0 0 12 O

Although IN 0 0 12 O
deferasirox NN 0 1 13 B-Drug
has VBZ 1 0 12 O
a DT 0 0 12 O
lower JJR 1 1 1 O
affinity NN 0 1 UNK O
for IN 0 0 12 O
aluminum NN 0 1 16 B-Drug
than IN 0 0 12 O
for IN 0 0 12 O
iron NN 0 1 3 B-Drug
Exjade NNP 0 1 UNK B-Brand
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
taken VBN 1 1 12 O
with IN 0 0 12 O
aluminum NN 0 1 16 B-Drug
- : 0 0 2 O
containing NN 0 1 1 O
antacid JJ 0 1 UNK B-Group
preparations NNS 1 1 13 I-Group
. . 0 0 12 O

Short NNP 0 1 2 O
- : 0 0 2 O
term NN 0 1 1 O
controlled VBD 1 1 1 O
studies NNS 1 1 1 O
failed VBD 1 1 12 O
to TO 0 0 12 O
show VB 0 1 12 O
that IN 0 0 12 O
taking VBG 1 0 12 O
the DT 0 0 12 O
drug NN 0 1 1 O
significantly RB 0 0 1 O
affects VBZ 1 1 1 O
prothrombin JJ 0 1 14 O
times NNS 1 1 12 O
when WRB 0 0 12 O
administered VBN 1 1 1 O
to TO 0 0 12 O
individuals NNS 1 1 1 O
on IN 0 0 12 O
coumarin NN 0 1 UNK B-Group
- : 0 0 2 O
type NN 0 1 1 I-Group
anticoagulants NNS 1 1 13 I-Group
. . 0 0 12 O

In IN 0 0 2 O
a DT 0 0 12 O
formal JJ 0 1 1 O
study NN 0 1 1 O
benzodiazepines NNS 1 1 14 B-Group
were VBD 1 0 12 O
shown VBN 1 1 1 O
not RB 0 1 12 O
to TO 0 0 12 O
affect VB 0 1 1 O
Mexitil NNP 0 1 UNK B-Brand
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
. . 0 0 12 O

The DT 0 0 2 O
appropriate JJ 0 1 1 O
doses NNS 1 1 6 O
for IN 0 0 12 O
this DT 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
respect NN 0 1 1 O
to TO 0 0 12 O
efficacy NN 0 1 UNK O
and CC 0 0 12 O
safety NN 0 1 1 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
established VBN 1 1 1 O
. . 0 0 12 O

Oral JJ 0 1 2 O
Contraceptives NNS 0 1 UNK B-Group
: : 0 0 2 O
Given VBN 0 1 2 O
the DT 0 0 12 O
different JJ 0 1 1 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
Myfortic NNP 0 1 UNK B-Brand
and CC 0 0 12 O
oral JJ 0 1 6 O
contraceptives NNS 1 1 13 B-Group
no DT 0 0 12 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
between IN 0 0 12 O
these DT 0 0 12 O
two CD 0 1 12 O
classes NNS 1 1 UNK O
of IN 0 0 12 O
drug NN 0 1 1 O
is VBZ 1 0 12 O
expected VBN 1 1 12 O
. . 0 0 12 O

When WRB 0 0 12 O
used VBN 1 1 12 O
concomitantly RB 0 0 14 O
anesthetics NNS 1 1 13 B-Group
and CC 0 0 12 O
calcium NN 0 1 14 B-Group
channel NN 0 1 1 I-Group
blockers NNS 1 0 6 I-Group
should MD 0 0 12 O
be VB 0 0 12 O
titrated VBN 1 1 14 O
carefully RB 0 0 12 O
. . 0 0 12 O

Coadministration NN 0 1 UNK O
with IN 0 0 12 O
acetaminophen NN 0 1 16 B-Drug
reduced VBD 1 1 1 O
the DT 0 0 12 O
peak JJ 0 1 1 O
concentration NN 0 1 1 O
and CC 0 0 12 O
AUC NNP 0 1 UNK O
values NNS 1 1 1 O
for IN 0 0 12 O
rimantadine NN 0 1 13 B-Drug
by IN 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
however RB 0 0 12 O
possible JJ 0 1 1 O
that IN 0 0 12 O
concomitant JJ 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
other JJ 0 0 12 O
known VBN 1 1 12 O
photosensitizing VBG 1 1 UNK B-Group
agents NNS 1 1 1 I-Group
such JJ 0 0 1 O
as IN 1 0 12 O
griseofulvin JJ 0 1 UNK B-Drug
thiazide IN 0 1 UNK B-Group
diuretics NNS 1 1 14 I-Group
sulfonylureas JJ 0 1 UNK B-Group
phenothiazines NNS 1 1 UNK B-Group
sulfonamides NNS 1 1 13 B-Group
and CC 0 0 12 O
tetracyclines NNS 1 1 13 B-Group
might MD 0 0 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
photosensitivity NN 0 1 UNK O
reaction NN 0 1 1 O
of IN 0 0 12 O
actinic JJ 0 1 13 O
keratoses NNS 0 1 UNK O
treated VBN 1 1 1 O
with IN 0 0 12 O
the DT 0 0 12 O
LEVULAN NNP 0 1 UNK B-Brand
KERASTICK NNP 0 0 UNK I-Brand
for IN 0 0 12 O
Topical NNP 0 1 7 O
Solution NNP 0 1 2 O
. . 0 0 12 O

Digoxin NN 0 1 0 B-Drug
: : 0 0 2 O
Concomitant JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
erythromycin NN 0 1 0 B-Drug
and CC 0 0 12 O
digoxin NN 0 1 14 B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
result VB 0 1 1 O
in IN 0 0 12 O
elevated JJ 0 1 1 O
digoxin NN 0 1 14 B-Drug
serum NN 0 1 14 O
levels NNS 1 1 1 O
. . 0 0 12 O

9 CD 0 0 2 O
. . 0 0 12 O

Warfarin NN 0 1 0 B-Drug
: : 0 0 2 O
Anticoagulant JJ 0 1 UNK O
activity NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
particularly RB 0 0 1 O
in IN 0 0 12 O
the DT 0 0 12 O
first JJ 0 1 12 O
few JJ 0 1 12 O
days NNS 1 1 12 O
after IN 0 0 12 O
initiating VBG 1 1 1 O
or CC 0 0 12 O
changing VBG 1 1 1 O
VIOXX NNP 0 1 UNK B-Brand
therapy NN 0 1 6 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
warfarin NN 0 1 14 B-Drug
or CC 0 0 12 O
similar JJ 0 1 1 O
agents NNS 1 1 1 O
since IN 0 1 12 O
these DT 0 0 12 O
patients NNS 1 1 6 O
are VBP 1 0 12 O
at IN 0 0 12 O
an DT 0 0 12 O
increased VBN 1 1 1 O
risk NN 0 1 1 O
of IN 0 0 12 O
bleeding VBG 1 1 6 O
complications NNS 1 1 6 O
. . 0 0 12 O

- : 0 0 2 O
Etretinate NN 0 1 UNK B-Drug
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
Tegison NNP 0 1 UNK B-Brand
) ) 0 0 2 O
or CC 0 0 12 O

Cyclosporine NN 0 1 UNK B-Drug
: : 0 0 2 O
Modest JJS 0 1 UNK O
increases NNS 1 1 1 O
in IN 0 0 12 O
mean JJ 0 1 12 O
trough IN 0 1 3 O
cyclosporine JJ 0 1 14 B-Drug
concentrations NNS 1 1 13 O
were VBD 1 0 12 O
observed VBN 1 1 1 O
following VBG 1 1 1 O
initiation NN 0 1 1 O
of IN 0 0 12 O
carvedilol NN 0 1 16 B-Drug
treatment NN 0 1 6 O
in IN 0 0 12 O
9 CD 0 0 2 O
renal JJ 0 1 6 O
transplant NN 0 1 6 O
patients NNS 1 1 6 O
suffering VBG 1 1 12 O
from IN 0 0 12 O
chronic JJ 0 1 6 O
vascular JJ 0 1 6 O
rejection NN 0 1 1 O
. . 0 0 12 O

If IN 0 0 12 O
a DT 0 0 12 O
diuretic NN 0 1 14 B-Group
is VBZ 1 0 12 O
also RB 0 0 12 O
used VBN 1 1 12 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
lithium JJ 0 1 16 B-Drug
toxicity NN 0 1 6 O
may MD 0 0 1 O
be VB 0 0 12 O
increased VBN 1 1 1 O
. . 0 0 12 O

Caution NN 0 0 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
exercised VBN 1 1 1 O
when WRB 0 0 12 O
Methergine NNP 0 1 0 B-Brand
( ( 0 0 2 O
methylergonovine JJ 0 1 16 B-Drug
maleate NN 0 1 16 I-Drug
) ) 0 0 2 O
is VBZ 1 0 12 O
used VBN 1 1 12 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
other JJ 0 0 12 O
vasoconstrictors NNS 1 1 UNK B-Group
or CC 0 0 12 O
ergot JJ 0 1 UNK B-Group
alkaloids NNS 1 1 13 I-Group
. . 0 0 12 O

However RB 0 0 1 O
since IN 0 1 12 O
there EX 0 0 12 O
is VBZ 1 0 12 O
an DT 0 0 12 O
increased JJ 0 1 1 O
risk NN 0 1 1 O
of IN 0 0 12 O
bleeding VBG 1 1 6 O
with IN 0 0 12 O
Xigris NNP 0 1 UNK B-Brand
caution NN 0 0 1 O
should MD 0 0 12 O
be VB 0 0 12 O
employed VBN 1 1 1 O
when WRB 0 0 12 O
Xigris NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
used VBN 1 1 12 O
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
that IN 0 0 12 O
affect JJ 0 1 1 O
hemostasis NN 0 1 UNK O
. . 0 0 12 O

Dosage NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
anticoagulant NN 0 1 13 B-Group
may MD 0 0 1 O
have VB 0 0 12 O
to TO 0 0 12 O
be VB 0 0 12 O
decreased VBN 1 1 1 O
in IN 0 0 12 O
order NN 0 1 1 O
to TO 0 0 12 O
maintain VB 0 1 1 O
desired JJ 0 1 1 O
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
. . 0 0 12 O

Therefore RB 0 0 1 O
when WRB 0 0 12 O
central JJ 0 1 1 B-Group
nervous JJ 0 1 6 I-Group
system NN 0 1 1 I-Group
depressants NNS 1 0 13 I-Group
are VBP 1 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
hydroxyzine VB 0 1 16 B-Drug
their PRP$ 0 0 12 O
dosage NN 0 1 0 O
should MD 0 0 12 O
be VB 0 0 12 O
reduced VBN 1 1 1 O
. . 0 0 12 O

A DT 0 0 2 O
variety NN 0 1 1 O
of IN 0 0 12 O
neurological JJ 0 1 6 O
toxic NN 0 1 1 O
effects NNS 1 1 1 O
and CC 0 0 12 O
malignant JJ 0 1 6 O
hyperpyrexia NN 0 1 UNK O
can MD 0 0 12 O
occur VB 0 1 1 O
sometimes RB 0 1 12 O
with IN 0 0 12 O
fatal JJ 0 1 13 O
results NNS 1 1 1 O
. . 0 0 12 O

Thiazides NNS 0 1 UNK B-Group
may MD 0 0 1 O
decrease VB 0 1 1 O
arterial JJ 0 1 6 O
responsiveness NN 0 1 UNK O
to TO 0 0 12 O
norepinephrine VB 0 1 14 B-Drug
. . 0 0 12 O

Conversion NN 0 1 UNK O
could MD 0 0 12 O
be VB 0 0 12 O
affected VBN 1 1 1 O
by IN 0 0 12 O
alterations NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
level NN 0 1 1 O
of IN 0 0 12 O
phosphatase NN 0 1 14 O
activity NN 0 1 1 O
but CC 0 0 12 O
given VBN 1 1 12 O
the DT 0 0 12 O
abundance NN 0 1 UNK O
and CC 0 0 12 O
wide JJ 0 1 3 O
distribution NN 0 1 1 O
of IN 0 0 12 O
phosphatases NNS 1 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
body NN 0 1 3 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
unlikely JJ 0 1 12 O
that IN 0 0 12 O
drugs NNS 1 1 6 O
would MD 0 0 12 O
affect VB 0 1 1 O
this DT 0 0 12 O
activity NN 0 1 1 O
enough RB 0 0 12 O
to TO 0 0 12 O
affect VB 0 1 1 O
conversion NN 0 1 13 O
of IN 0 0 12 O
fosphenytoin NN 0 1 16 B-Drug
to TO 0 0 12 O
phenytoin VB 0 1 16 B-Drug
. . 0 0 12 O

Ketoconazole NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
a DT 0 0 12 O
potent JJ 0 1 UNK O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
the DT 0 0 12 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
9A9 CD 0 0 UNK O
enzyme NN 0 1 14 O
system NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
effect NN 0 1 1 O
of IN 0 0 12 O
TORADOL NNP 0 1 UNK B-Brand
on IN 0 0 12 O
plasma NN 0 1 14 O
lithium NN 0 1 16 B-Drug
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
studied VBN 1 0 1 O
but CC 0 0 12 O
cases NNS 1 1 UNK O
of IN 0 0 12 O
increased JJ 0 1 1 O
lithium NN 0 1 16 B-Drug
plasma NN 0 1 14 O
levels NNS 1 1 1 O
during IN 0 0 12 O
TORADOL NNP 0 1 UNK B-Brand
therapy NN 0 1 6 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
. . 0 0 12 O

Potential NNP 0 1 UNK O
for IN 0 0 12 O
Duloxetine NNP 0 1 0 B-Drug
to TO 0 0 12 O
Affect VB 0 1 UNK O
Other JJ 0 0 2 O
Drugs NNS 0 1 2 O
: : 0 0 2 O
Drugs NNS 0 1 2 O
Metabolized VBN 0 1 UNK O
by IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
: : 0 0 2 O
In IN 0 0 2 O
vitro JJ 0 1 UNK O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
demonstrate VBP 0 0 1 O
that IN 0 0 12 O
duloxetine NN 0 1 0 B-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
induce VB 0 1 6 O
CYP9A9 NNP 0 0 UNK O
activity NN 0 1 1 O
and CC 0 0 12 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
unlikely JJ 0 1 12 O
to TO 0 0 12 O
have VB 0 0 12 O
a DT 0 0 12 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
substrates NNS 1 1 UNK O
. . 0 0 12 O

Anticholinesterases NNS 0 1 UNK B-Group
: : 0 0 2 O
Concurrent NNP 0 1 13 O
use NN 0 1 1 O
of IN 0 0 12 O
procaine NN 0 1 UNK B-Drug
hydrochloride NN 0 1 0 I-Drug
and CC 0 0 12 O
anticholinesterase NN 0 1 UNK B-Group
agents NNS 1 1 1 I-Group
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
increased JJ 0 1 1 O
systemic JJ 0 1 6 O
toxicity NN 0 1 6 O
since IN 0 1 12 O
anticholinesterases NNS 1 1 UNK B-Group
inhibit VBP 0 1 13 O
the DT 0 0 12 O
breakdown NN 0 1 1 O
of IN 0 0 12 O
procaine JJ 0 1 UNK B-Drug
hydrochloride NN 0 1 0 I-Drug
. . 0 0 12 O

The DT 0 0 2 O
threohydrobupropion NN 0 1 UNK B-Drug_n
metabolite NN 0 1 UNK O
of IN 0 0 12 O
bupropion NN 0 1 16 B-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
appear VB 0 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
produced VBN 1 0 1 O
by IN 0 0 12 O
the DT 0 0 12 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
isoenzymes NNS 0 1 14 O
. . 0 0 12 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interactions NNP 0 1 UNK O
Corticosteroids NNP 0 1 UNK B-Group
may MD 0 0 1 O
affect VB 0 1 1 O
the DT 0 0 12 O
nitrobluetetrazolium JJ 0 0 UNK O
test NN 0 1 1 O
for IN 0 0 12 O
bacterial JJ 0 1 6 O
infection NN 0 1 6 O
and CC 0 0 12 O
produce VB 0 0 1 O
false JJ 0 1 13 O
- : 0 0 2 O
negative JJ 0 1 1 O
results NNS 1 1 1 O

Ketoconazole NNP 0 1 UNK B-Drug
tablets NNS 1 1 3 O
may MD 0 0 1 O
alter VB 0 1 13 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
cyclosporine NN 0 1 14 B-Drug
tacrolimus NN 0 1 16 B-Drug
and CC 0 0 12 O
methylprednisolone NN 0 1 16 B-Drug
resulting VBG 1 1 1 O
in IN 0 0 12 O
elevated VBN 1 1 1 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
the DT 0 0 12 O
latter JJ 0 0 UNK O
drugs NNS 1 1 6 O
. . 0 0 12 O

Carcinogenesis NNP 0 1 UNK O
Mutagenesis NNP 0 1 UNK O
Impairment NNP 0 1 UNK O
of IN 0 0 12 O
Fertility NNP 0 1 7 O
Carcinogenesis NNP 0 1 UNK O
PEGASYS NNP 0 1 UNK B-Brand
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
tested VBN 1 1 1 O
for IN 0 0 12 O
its PRP$ 1 0 12 O
carcinogenic JJ 0 1 UNK O
potential NN 0 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
vitro JJ 0 1 UNK O
raloxifene NN 0 1 13 B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
affect VB 0 1 1 O
the DT 0 0 12 O
binding NN 0 1 1 O
of IN 0 0 12 O
warfarin JJ 0 1 14 B-Drug
phenytoin NN 0 1 16 B-Drug
or CC 0 0 12 O
tamoxifen NN 0 1 0 B-Drug
. . 0 0 12 O

Anticoagulant JJ 0 1 UNK B-Brand
therapy NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
particularly RB 0 0 1 O
during IN 0 0 12 O
the DT 0 0 12 O
first JJ 0 1 12 O
few JJ 0 1 12 O
weeks NNS 1 1 12 O
after IN 0 0 12 O
initiating VBG 1 1 1 O
therapy NN 0 1 6 O
with IN 0 0 12 O
BEXTRA NNP 0 1 UNK B-Brand
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
warfarin NN 0 1 14 B-Drug
or CC 0 0 12 O
similar JJ 0 1 1 O
agents NNS 1 1 1 O
. . 0 0 12 O

Therophylline NN 0 0 UNK O
: : 0 0 2 O
A DT 0 0 2 O
recent JJ 0 1 12 O
study NN 0 1 1 O
has VBZ 1 0 12 O
shown VBN 1 1 1 O
that IN 0 0 12 O
concomitan JJ 0 0 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
isoniazid NN 0 1 13 B-Drug
and CC 0 0 12 O
theophylline NN 0 1 16 B-Drug
may MD 0 0 1 O
cause VB 0 1 12 O
elevated JJ 0 1 1 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
theophylline NN 0 1 16 B-Drug
and CC 0 0 12 O
in IN 0 0 12 O
some DT 0 0 12 O
instances NNS 1 1 UNK O
a DT 0 0 12 O
slight JJ 0 1 3 O
decrease NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
elimination NN 0 1 UNK O
of IN 0 0 12 O
isoniazid NN 0 1 13 B-Drug
. . 0 0 12 O

Even RB 0 0 UNK O
though IN 0 0 12 O
such JJ 0 0 1 O
interactions NNS 1 1 UNK O
were VBD 1 0 12 O
not RB 0 1 12 O
seen VBN 1 1 12 O
during IN 0 0 12 O
clinical JJ 0 1 6 O
studies NNS 1 1 1 O
with IN 0 0 12 O
nicardipine JJ 0 1 16 B-Drug
HCl NNP 0 0 14 I-Drug
an DT 0 0 12 O
increased JJ 0 1 1 O
volume NN 0 1 1 O
of IN 0 0 12 O
circulating VBG 1 1 13 O
fluids NNS 1 1 6 O
might MD 0 0 12 O
be VB 0 0 12 O
required VBN 1 1 1 O
if IN 0 0 12 O
such JJ 0 0 1 O
an DT 0 0 12 O
interaction NN 0 1 UNK O
were VBD 1 0 12 O
to TO 0 0 12 O
occur VB 0 1 1 O
. . 0 0 12 O

However RB 0 0 1 O
the DT 0 0 12 O
extent NN 0 1 1 O
of IN 0 0 12 O
biotransformation NN 0 1 UNK O
of IN 0 0 12 O
perindopril NN 0 1 UNK B-Drug
to TO 0 0 12 O
the DT 0 0 12 O
active JJ 0 1 1 O
metabolite NN 0 1 UNK O
perindoprilat NN 0 1 UNK B-Drug_n
is VBZ 1 0 12 O
reduced VBN 1 1 1 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
resulting VBG 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
reduction NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
plasma NN 0 1 14 O
ACE NNP 0 1 13 O
inhibition NN 0 1 13 O
curve NN 0 1 13 O
of IN 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
probably RB 0 1 12 O
clinically RB 0 0 6 O
insignificant JJ 0 0 1 O
. . 0 0 12 O

CNS NNP 0 1 6 O
Acting NNP 0 1 UNK O
Drugs NNP 0 1 2 O
: : 0 0 2 O
Given VBN 0 1 2 O
the DT 0 0 12 O
primary JJ 0 1 1 O
CNS NNP 0 1 6 O
effects NNS 1 1 1 O
of IN 0 0 12 O
Duloxetine NNP 0 1 0 B-Drug
it PRP 0 0 12 O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
with IN 0 0 12 O
caution NN 0 0 1 O
when WRB 0 0 12 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
taken VBN 1 1 12 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
or CC 0 0 12 O
substituted VBN 1 0 UNK O
for IN 0 0 12 O
other JJ 0 0 12 O
centrally RB 0 0 UNK O
acting VBG 1 1 12 O
drugs NNS 1 1 6 O
including VBG 1 1 1 O
those DT 0 0 12 O
with IN 0 0 12 O
a DT 0 0 12 O
similar JJ 0 1 1 O
mechanism NN 0 1 13 O
of IN 0 0 12 O
action NN 0 1 13 O
. . 0 0 12 O

Investigations NNS 0 1 UNK O
into IN 0 0 12 O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
acitretin NN 0 1 13 B-Drug
on IN 0 0 12 O
the DT 0 0 12 O
protein NN 0 1 14 O
binding NN 0 1 1 O
of IN 0 0 12 O
anticoagulants NNS 1 1 13 B-Group
of IN 0 0 12 I-Group
the DT 0 0 12 I-Group
coumarin NN 0 1 UNK I-Group
type NN 0 1 1 I-Group
( ( 0 0 2 O
warfarin NN 0 1 14 B-Drug
) ) 0 0 2 O
revealed VBD 1 1 12 O
no DT 0 0 12 O
interaction NN 0 1 UNK O
. . 0 0 12 O

Propranolol NNS 0 1 0 B-Drug
: : 0 0 2 O
May NNP 0 1 2 O
decrease NN 0 1 1 O
aspirins VBZ 0 1 UNK B-Brand
anti JJ 0 0 3 O
- : 0 0 2 O
inflammatory JJ 0 1 6 O
action NN 0 1 13 O
by IN 0 0 12 O
competing VBG 1 0 UNK O
for IN 0 0 12 O
the DT 0 0 12 O
same JJ 0 1 12 O
receptors NNS 1 1 13 O
. . 0 0 12 O

Therefore RB 0 0 1 O
use NN 0 1 1 O
of IN 0 0 12 O
zidovudine NN 0 1 13 B-Drug
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
ZERIT NNP 0 1 UNK B-Brand
should MD 0 0 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
. . 0 0 12 O

Serum NNP 0 1 7 O
digitalis NN 0 1 14 B-Group
levels NNS 1 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
decreased VBN 1 1 1 O
in IN 0 0 12 O
hyperthyroidism NN 0 1 6 O
or CC 0 0 12 O
when WRB 0 0 12 O
a DT 0 0 12 O
hypothyroid JJ 0 1 6 O
patient NN 0 1 6 O
becomes VBZ 1 0 12 O
euthyroid JJ 0 1 14 O
. . 0 0 12 O

The DT 0 0 2 O
clinical JJ 0 1 6 O
significance NN 0 1 13 O
of IN 0 0 12 O
these DT 0 0 12 O
changes NNS 1 1 1 O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
adequately RB 0 0 1 O
studied VBN 1 0 1 O
. . 0 0 12 O

Olanzapine NN 0 1 0 B-Drug
: : 0 0 2 O
Coadministration NN 0 1 UNK O
of IN 0 0 12 O
eszopiclone NN 0 1 13 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
and CC 0 0 12 O
olanzapine JJ 0 1 16 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
produced VBD 1 0 1 O
a DT 0 0 12 O
decrease NN 0 1 1 O
in IN 0 0 12 O
DSST NNP 0 1 UNK O
scores NNS 1 1 1 O
. . 0 0 12 O

Diagnostic JJ 0 1 7 O
dip NN 0 1 3 O
- : 0 0 2 O
stick NN 0 1 3 O
methodology NN 0 1 UNK O
used VBN 1 1 12 O
to TO 0 0 12 O
detect VB 0 1 UNK O
ketone NN 0 1 13 O
bodies NNS 1 1 1 O
in IN 0 0 12 O
urine NN 0 1 6 O
has VBZ 1 0 12 O
resulted VBN 1 1 1 O
in IN 0 0 12 O
false JJ 0 1 13 O
- : 0 0 2 O
positive JJ 0 1 1 O
findings NNS 1 1 1 O
in IN 0 0 12 O
some DT 0 0 12 O
patients NNS 1 1 6 O
treated VBN 1 1 1 O
with IN 0 0 12 O
Lodine NNP 0 1 UNK B-Brand
. . 0 0 12 O

Possible JJ 0 1 2 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
of IN 0 0 12 O
HUMORSOL NNP 0 1 UNK B-Brand
with IN 0 0 12 O
succinylcholine NN 0 1 16 B-Drug
or CC 0 0 12 O
with IN 0 0 12 O
other JJ 0 0 12 O
anticholinesterase NN 0 1 UNK B-Group
agents NNS 1 1 1 I-Group
. . 0 0 12 O

The DT 0 0 2 O
pharmacokinetics NNS 0 1 UNK O
and CC 0 0 12 O
protein NN 0 1 14 O
binding NN 0 1 1 O
of IN 0 0 12 O
fosphenytoin NN 0 1 16 B-Drug
phenytoin NN 0 1 16 B-Drug
and CC 0 0 12 O
diazepam NN 0 1 0 B-Drug
were VBD 1 0 12 O
not RB 0 1 12 O
altered VBN 1 1 1 O
when WRB 0 0 12 O
diazepam NN 0 1 0 B-Drug
and CC 0 0 12 O
Cerebyx NNP 0 1 UNK B-Brand
were VBD 1 0 12 O
concurrently RB 0 0 1 O
administered VBN 1 1 1 O
in IN 0 0 12 O
single JJ 0 1 12 O
submaximal JJ 0 0 UNK O
doses NNS 1 1 6 O
. . 0 0 12 O

Drug NN 0 1 2 O
Interactions NNS 0 1 UNK O
with IN 0 0 12 O
Beta NNP 0 1 2 B-Group
- : 0 0 2 O
Blockers NNS 0 0 UNK I-Group
: : 0 0 2 O
Concomitant NNP 0 1 UNK O
use NN 0 1 1 O
of IN 0 0 12 O
fenoldopam NN 0 1 13 B-Drug
with IN 0 0 12 O
beta NN 0 1 16 B-Group
- : 0 0 2 O
blockers NNS 1 0 6 I-Group
should MD 0 0 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
. . 0 0 12 O

Warfarin NN 0 1 0 B-Drug
: : 0 0 2 O
Anticoagulant JJ 0 1 UNK O
activity NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
particularly RB 0 0 1 O
in IN 0 0 12 O
the DT 0 0 12 O
first JJ 0 1 12 O
few JJ 0 1 12 O
days NNS 1 1 12 O
after IN 0 0 12 O
initiating VBG 1 1 1 O
or CC 0 0 12 O
changing VBG 1 1 1 O
MOBIC NNP 0 1 UNK B-Brand
therapy NN 0 1 6 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
warfarin NN 0 1 14 B-Drug
or CC 0 0 12 O
similar JJ 0 1 1 O
agents NNS 1 1 1 O
since IN 0 1 12 O
these DT 0 0 12 O
patients NNS 1 1 6 O
are VBP 1 0 12 O
at IN 0 0 12 O
an DT 0 0 12 O
increased VBN 1 1 1 O
risk NN 0 1 1 O
of IN 0 0 12 O
bleeding NN 0 1 6 O
. . 0 0 12 O

Clinical JJ 0 1 7 O
studies NNS 1 1 1 O
in IN 0 0 12 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
show VBP 0 1 12 O
that IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
CANCIDAS NNP 0 1 UNK B-Brand
are VBP 1 0 12 O
not RB 0 1 12 O
altered VBN 1 1 1 O
by IN 0 0 12 O
itraconazole JJ 0 1 0 B-Drug
amphotericin NN 0 1 14 B-Drug
B NNP 0 0 2 I-Drug
mycophenolate NN 0 1 0 B-Drug
nelfinavir NN 0 1 16 B-Drug
or CC 0 0 12 O
tacrolimus NN 0 1 16 B-Drug
. . 0 0 12 O

May NNP 0 1 2 O
lead NN 0 1 12 O
to TO 0 0 12 O
loss NN 0 1 1 O
of IN 0 0 12 O
virologic JJ 0 1 UNK O
response NN 0 1 1 O
and CC 0 0 12 O
possible JJ 0 1 1 O
resistance NN 0 1 1 O
to TO 0 0 12 O
CRIXIVAN NNP 0 1 UNK B-Brand
or CC 0 0 12 O
to TO 0 0 12 O
the DT 0 0 12 O
class NN 0 1 12 O
of IN 0 0 12 O
protease NN 0 1 13 B-Group
inhibitors NNS 1 1 14 I-Group
. . 0 0 12 O

Other JJ 0 0 2 O
plasma JJ 0 1 14 O
proteins NNS 1 1 14 O
may MD 0 0 1 O
be VB 0 0 12 O
increased VBN 1 1 1 O
( ( 0 0 2 O
angiotensinogen JJ 0 1 UNK O
/ NNP 0 0 2 O
renin NN 0 1 UNK O
substrate NN 0 1 UNK O
alpha SYM 0 1 1 O
- : 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
antitrypsin NN 0 1 UNK O
ceruloplasmin NN 0 1 14 O
) ) 0 0 2 O
. . 0 0 12 O

CYP9A9 JJ 0 0 UNK O
Inhibitors NNS 0 1 7 O
: : 0 0 2 O
Ketoconazole NNP 0 1 UNK B-Drug
an DT 0 0 12 O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
the DT 0 0 12 O
drug NN 0 1 1 O
metabolizing VBG 1 0 UNK O
enzyme JJ 0 1 14 O
CYP9A9 NNP 0 0 UNK O
significantly RB 0 0 1 O
increased VBD 1 1 1 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
tolterodine NN 0 1 16 B-Drug
when WRB 0 0 12 O
coadministered VBN 0 0 UNK O
to TO 0 0 12 O
subjects NNS 1 1 UNK O
who WP 0 0 12 O
were VBD 1 0 12 O
poor JJ 0 1 12 O
metabolizers NNS 0 0 UNK O
( ( 0 0 2 O
see VB 0 1 12 O
CLINICAL NNP 0 1 11 O
PHARMACOLOGY NNP 0 1 UNK O
Variability NNP 0 1 UNK O
in IN 0 0 12 O
Metabolism NNP 0 1 UNK O
and CC 0 0 12 O
Drug NNP 0 1 2 O
- : 0 0 2 O
Drug NNP 0 1 2 O
Interactions NNP 0 1 UNK O
) ) 0 0 2 O
. . 0 0 12 O

Cisapride NNP 0 1 0 B-Drug
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
known VBN 1 1 12 O
to TO 0 0 12 O
prolong VB 0 0 13 O
the DT 0 0 12 O
QT NNP 0 1 13 O
interval NN 0 1 1 O
: : 0 0 2 O
certain JJ 0 1 1 O
antiarrhythmics NNS 1 1 UNK B-Group
including VBG 1 1 1 O
those DT 0 0 12 O
of IN 0 0 12 O
Class NNP 0 1 2 O
IA NNP 0 1 2 O
( ( 0 0 2 O
such JJ 0 0 1 O
as IN 1 0 12 O
quinidine NN 0 1 16 B-Drug
and CC 0 0 12 O
procainamide NN 0 1 16 B-Drug
) ) 0 0 2 O
and CC 0 0 12 O
Class NNP 0 1 2 O
III NNP 0 1 2 O
( ( 0 0 2 O
such JJ 0 0 1 O
as IN 1 0 12 O
sotalol NN 0 1 16 B-Drug
) ) 0 0 2 O
; : 0 0 2 O

therefore RB 0 0 1 O
these DT 0 0 12 O
combinations NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
with IN 0 0 12 O
caution NN 0 0 1 O
. . 0 0 12 O

Dosage NN 0 1 UNK O
adjustments NNS 1 1 1 O
of IN 0 0 12 O
other JJ 0 0 12 O
antihypertensives NNS 1 1 14 B-Group
may MD 0 0 1 O
be VB 0 0 12 O
necessary JJ 0 0 1 O
. . 0 0 12 O

The DT 0 0 2 O
pharmacokinetic JJ 0 1 UNK O
interactions NNS 1 1 UNK O
listed VBN 1 1 1 O
below IN 0 0 12 O
are VBP 1 0 12 O
potentially RB 0 0 1 O
clinically RB 0 0 6 O
important JJ 0 1 1 O
. . 0 0 12 O

There EX 0 0 12 O
are VBP 1 0 12 O
reports NNS 1 1 1 O
of IN 0 0 12 O
enhanced VBN 1 1 1 O
as RB 0 0 12 O
well RB 0 1 12 O
as IN 1 0 12 O
diminished JJ 0 1 1 O
effects NNS 1 1 1 O
of IN 0 0 12 O
anticoagulant NN 0 1 13 B-Group
when WRB 0 0 12 O
given VBN 1 1 12 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
corticosteroids NNS 1 1 14 B-Group
. . 0 0 12 O

Other JJ 0 0 2 O
Chemotherapy NNP 0 1 7 O
Agents NNS 0 1 2 O
In IN 0 0 2 O
a DT 0 0 12 O
separate JJ 0 1 1 O
study NN 0 1 1 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
lapatinib NN 0 1 13 B-Drug
with IN 0 0 12 O
capecitabine NN 0 1 13 B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
meaningfully RB 0 0 UNK O
alter VB 0 1 13 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
either DT 0 1 12 O
agent NN 0 1 1 O
( ( 0 0 2 O
or CC 0 0 12 O
the DT 0 0 12 O
metabolites NNS 1 1 UNK O
of IN 0 0 12 O
capecitabine NN 0 1 13 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

The DT 0 0 2 O
mean JJ 0 1 12 O
clearances NNS 1 1 UNK O
of IN 0 0 12 O
dofetilide NN 0 1 13 B-Drug
were VBD 1 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
lower JJR 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
on IN 0 0 12 O
thiazide JJ 0 1 UNK B-Group
diuretics NNS 1 1 14 I-Group
and CC 0 0 12 O
inhibitors NNS 1 1 14 O
of IN 0 0 12 O
tubular JJ 0 1 3 O
organic JJ 0 1 13 O
cation NN 0 1 UNK O
transport NN 0 1 1 O
respectively RB 0 0 1 O
. . 0 0 12 O

Both DT 0 0 2 O
hypo SYM 0 0 13 O
- : 0 0 2 O
and CC 0 0 12 O
hyperglycemic JJ 0 0 13 O
effects NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
. . 0 0 12 O

Selegiline NNP 0 1 UNK B-Drug
- : 0 0 2 O
L NNP 0 1 2 B-Drug
- : 0 0 2 O
phenylalanine NN 0 1 UNK I-Drug
and CC 0 0 12 O
the DT 0 0 12 O
selective JJ 0 1 13 B-Group
MAO NNP 0 1 14 I-Group
inhibitor NN 0 1 14 I-Group
selegiline NN 0 1 13 B-Drug
may MD 0 0 1 O
have VB 0 0 12 O
synergistic JJ 0 1 UNK O
antidepressant NN 0 1 6 O
activity NN 0 1 1 O
if IN 0 0 12 O
used VBN 1 1 12 O
concomitantly RB 0 0 14 O
. . 0 0 12 O

The DT 0 0 2 O
concentration NN 0 1 1 O
of IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
falls NNS 1 1 12 O
to TO 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
within IN 0 0 1 O
five CD 0 1 12 O
weeks NNS 1 1 12 O
according VBG 1 1 1 O
to TO 0 0 12 O
an DT 0 0 12 O
experiment NN 0 1 UNK O
published VBN 1 1 UNK O
in IN 0 0 12 O
9 CD 0 0 2 O
by IN 0 0 12 O
the DT 0 0 12 O
same JJ 0 1 12 O
two CD 0 1 12 O
scientists NNS 1 1 UNK O
that WDT 0 0 12 O
tried VBD 1 0 12 O
and CC 0 0 12 O
failed VBD 1 1 12 O
to TO 0 0 12 O
elucidate VB 0 0 UNK O
the DT 0 0 12 O
mechanism NN 0 1 13 O
behind IN 0 0 12 O
this DT 0 0 12 O
interaction NN 0 1 UNK O
. . 0 0 12 O

Therefore RB 0 0 1 O
when WRB 0 0 12 O
meclofenamate NN 0 1 UNK B-Drug
sodium NN 0 1 14 I-Drug
is VBZ 1 0 12 O
given VBN 1 1 12 O
to TO 0 0 12 O
a DT 0 0 12 O
patient NN 0 1 6 O
receiving VBG 1 1 1 O
warfarin VBD 0 1 14 B-Drug
the DT 0 0 12 O
dosage NN 0 1 0 O
of IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
reduced VBN 1 1 1 O
to TO 0 0 12 O
prevent VB 0 1 1 O
excessive JJ 0 1 1 O
prolongation NN 0 1 6 O
of IN 0 0 12 O
the DT 0 0 12 O
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
. . 0 0 12 O

There EX 0 0 12 O
is VBZ 1 0 12 O
no DT 0 0 12 O
evidence NN 0 1 1 O
in IN 0 0 12 O
animal NN 0 1 13 O
or CC 0 0 12 O
human JJ 0 1 1 O
studies NNS 1 1 1 O
that WDT 0 0 12 O
TORADOL NNP 0 1 UNK B-Brand
induces VBZ 1 1 UNK O
or CC 0 0 12 O
inhibits VBZ 1 1 UNK O
hepatic JJ 0 1 14 O
enzymes NNS 1 1 14 O
capable JJ 0 1 UNK O
of IN 0 0 12 O
metabolizing VBG 1 0 UNK O
itself PRP 0 0 UNK O
or CC 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O

Another DT 0 0 2 O
study NN 0 1 1 O
showed VBD 1 1 12 O
that IN 0 0 12 O
alosetron NN 0 1 UNK B-Drug
had VBD 1 0 12 O
no DT 0 0 12 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
effect NN 0 1 1 O
on IN 0 0 12 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
the DT 0 0 12 O
oral JJ 0 1 6 O
contraceptive NN 0 1 13 B-Group
agents NNS 1 1 1 I-Group
ethinyl VBP 0 0 13 B-Drug
estradiol NN 0 1 13 I-Drug
and CC 0 0 12 O
levonorgestrel NN 0 1 13 B-Drug
( ( 0 0 2 O
CYP9A9 NNP 0 0 UNK O
substrates VBZ 0 1 UNK O
) ) 0 0 2 O
. . 0 0 12 O

Magnesium NN 0 1 7 B-Drug
: : 0 0 2 O
Magnesium NNP 0 1 7 B-Drug
- : 0 0 2 O
containing NN 0 1 1 O
preparations NNS 1 1 13 O
( ( 0 0 2 O
eg JJ 0 1 UNK O
antacids NNS 1 1 14 B-Group
) ) 0 0 2 O
may MD 0 0 1 O
cause VB 0 1 12 O
hypermagnesemia NN 0 1 13 O
and CC 0 0 12 O
should MD 0 0 12 O
therefore VB 0 0 1 O
not RB 0 1 12 O
be VB 0 0 12 O
taken VBN 1 1 12 O
during IN 0 0 12 O
therapy NN 0 1 6 O
with IN 0 0 12 O
vitamin NN 0 1 6 B-Group
D NNP 0 1 2 I-Group
by IN 0 0 12 O
patients NNS 1 1 6 O
on IN 0 0 12 O
chronic JJ 0 1 6 O
renal JJ 0 1 6 O
dialysis NN 0 1 6 O
. . 0 0 12 O

Two CD 0 1 2 O
of IN 0 0 12 O
9 CD 0 0 2 O
subjects NNS 1 1 UNK O
dosed VBD 1 1 14 O
simultaneously RB 0 1 13 O
with IN 0 0 12 O
Vardenafil NNP 0 1 UNK B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
and CC 0 0 12 O
tamsulosin NN 0 1 16 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
experienced VBD 1 0 12 O
a DT 0 0 12 O
standing VBG 1 1 12 O
systolic JJ 0 1 8 O
blood NN 0 1 6 O
pressure NN 0 1 1 O
below IN 0 0 12 O
9 CD 0 0 2 O
mm NN 0 0 18 O
Hg NNP 0 1 14 O
. . 0 0 12 O

In IN 0 0 2 O
vitro NNP 0 1 UNK O
data NNS 0 1 1 O
suggest VBP 0 1 1 O
that IN 0 0 12 O
itraconazole NN 0 1 0 B-Drug
also RB 0 0 12 O
markedly RB 0 1 1 O
inhibits VBZ 1 1 UNK O
the DT 0 0 12 O
biotransformation NN 0 1 UNK O
system NN 0 1 1 O
mainly RB 0 0 1 O
responsible JJ 0 1 1 O
for IN 0 0 12 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
cisapride NN 0 1 UNK B-Drug
; : 0 0 2 O

Limited VBN 0 1 2 O
data NNS 0 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
known VBN 1 1 12 O
enzyme JJ 0 1 14 O
inducers NNS 1 1 UNK O
( ( 0 0 2 O
phenytoin JJ 0 1 16 B-Drug
phenobarbital JJ 0 1 16 B-Drug
carbamazepine NN 0 1 16 B-Drug
) ) 0 0 2 O
indicate VBP 0 0 1 O
only RB 0 1 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
increase NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
rate NN 0 1 1 O
of IN 0 0 12 O
flecainide JJ 0 1 16 B-Drug
elimination NN 0 1 UNK O
. . 0 0 12 O

Pletal NN 0 1 UNK B-Brand
does VBZ 1 0 12 O
not RB 0 1 12 O
however RB 0 0 12 O
appear VBP 0 1 12 O
to TO 0 0 12 O
cause VB 0 1 12 O
increased JJ 0 1 1 O
blood NN 0 1 6 O
levels NNS 1 1 1 O
of IN 0 0 12 O
drugs NNS 1 1 6 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
as IN 1 0 12 O
it PRP 0 0 12 O
had VBD 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
lovastatin NN 0 1 13 B-Drug
a DT 0 0 12 O
drug NN 0 1 1 O
with IN 0 0 12 O
metabolism NN 0 1 16 O
very RB 0 1 12 O
sensitive JJ 0 1 1 O
to TO 0 0 12 O
C.P.A NNP 0 0 UNK O
. . 0 0 12 O
inhibition NN 0 1 13 O
. . 0 0 12 O

Furosemide NN 0 1 0 B-Drug
: : 0 0 2 O
Clinical JJ 0 1 7 O
studies NNS 1 1 1 O
as RB 0 0 12 O
well RB 0 1 12 O
as IN 1 0 12 O
random NN 0 1 13 O
observations NNS 1 1 1 O
have VBP 0 0 12 O
shown VBN 1 1 1 O
that IN 0 0 12 O
ibuprofen NN 0 1 0 B-Drug
can MD 0 0 12 O
reduce VB 0 0 1 O
the DT 0 0 12 O
natriuretic JJ 0 1 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
furosemide NN 0 1 0 B-Drug
and CC 0 0 12 O
thiazides NNS 1 1 UNK B-Group
in IN 0 0 12 O
some DT 0 0 12 O
patients NNS 1 1 6 O
. . 0 0 12 O

In IN 0 0 2 O
oral JJ 0 1 6 O
( ( 0 0 2 O
gavage NN 0 1 14 O
) ) 0 0 2 O
fertility NN 0 1 6 O
studies NNS 1 1 1 O
of IN 0 0 12 O
ezetimibe NN 0 1 16 B-Drug
conducted VBN 1 1 1 O
in IN 0 0 12 O
rats NNS 1 1 UNK O
there EX 0 0 12 O
was VBD 1 0 12 O
no DT 0 0 12 O
evidence NN 0 1 1 O
of IN 0 0 12 O
reproductive JJ 0 1 13 O
toxicity NN 0 1 6 O
at IN 0 0 12 O
doses VBZ 1 1 6 O
up RB 0 0 12 O
to TO 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
kg JJ 0 1 18 O
/ NNP 0 0 2 O
day NN 0 1 12 O
in IN 0 0 12 O
male NN 0 1 12 O
or CC 0 0 12 O
female JJ 0 1 12 O
rats NNS 1 1 UNK O
( ( 0 0 2 O
~9 JJ 0 0 UNK O
times NNS 1 1 12 O
the DT 0 0 12 O
human JJ 0 1 1 O
exposure NN 0 1 1 O
at IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
daily RB 0 1 12 O
based VBN 1 1 1 O
on IN 0 0 12 O
AUC9 NNP 0 0 UNK O
- : 0 0 2 O
9hr CD 0 0 UNK O
for IN 0 0 12 O
total JJ 0 1 1 O
ezetimibe NN 0 1 16 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

Beta NNP 0 1 2 B-Group
- : 0 0 2 O
blockers NNS 1 0 6 I-Group
clonidine VBP 0 1 0 B-Drug
lithium NN 0 1 16 B-Drug
salts NNS 1 1 13 O
and CC 0 0 12 O
alcohol NN 0 1 1 B-Drug
may MD 0 0 1 O
either VB 0 1 12 O
potentiate NN 0 0 UNK O
or CC 0 0 12 O
weaken VB 0 0 UNK O
the DT 0 0 12 O
blood NN 0 1 6 O
- : 0 0 2 O
glucose JJ 0 1 14 O
- : 0 0 2 O
lowering VBG 1 1 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
insulin NN 0 1 14 B-Drug
. . 0 0 12 O

Plenaxis NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
highly RB 0 1 1 O
bound VBN 1 1 12 O
to TO 0 0 12 O
plasma VB 0 1 14 O
proteins NNS 1 1 14 O
( ( 0 0 2 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
. . 0 0 12 O

Ketorolac NNP 0 1 UNK B-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
alter VB 0 1 13 O
digoxin NN 0 1 14 B-Drug
protein NN 0 1 14 O
binding NN 0 1 1 O
. . 0 0 12 O

Significant NNP 0 1 2 O
pharmacokinetic JJ 0 1 UNK O
interactions NNS 1 1 UNK O
mediated VBN 1 1 13 O
by IN 0 0 12 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
CYP NNP 0 1 UNK O
isoenzymes NNS 0 1 14 O
therefore RB 0 0 1 O
appear VBP 0 1 12 O
unlikely JJ 0 1 12 O
. . 0 0 12 O

However RB 0 0 1 O
in IN 0 0 12 O
a DT 0 0 12 O
drug NN 0 1 1 O
- : 0 0 2 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
study NN 0 1 1 O
mean VBP 0 1 12 O
levonorgesterol NN 0 0 UNK B-Drug
AUC NNP 0 1 UNK O
was VBD 1 0 12 O
decreased VBN 1 1 1 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
when WRB 0 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
mycophenolate NN 0 1 0 B-Drug
mofetil NN 0 0 16 I-Drug
. . 0 0 12 O

Since IN 0 1 2 O
platinum NN 0 1 UNK O
containing NN 0 1 1 O
species NNS 1 1 1 O
are VBP 1 0 12 O
eliminated VBN 1 1 UNK O
primarily RB 0 0 1 O
through IN 0 0 12 O
the DT 0 0 12 O
kidney NN 0 1 6 O
clearance NN 0 1 16 O
of IN 0 0 12 O
these DT 0 0 12 O
products NNS 1 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
decreased VBN 1 1 1 O
by IN 0 0 12 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
potentially RB 0 0 1 O
nephrotoxic JJ 0 1 UNK O
compounds NNS 1 1 13 O
; : 0 0 2 O

Therefore RB 0 0 1 O
when WRB 0 0 12 O
initiating VBG 1 1 1 O
pressor NN 0 1 14 O
therapy NN 0 1 6 O
in IN 0 0 12 O
these DT 0 0 12 O
patients NNS 1 1 6 O
the DT 0 0 12 O
initial JJ 0 1 1 O
dose NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
small JJ 0 1 12 O
and CC 0 0 12 O
used VBN 1 1 12 O
with IN 0 0 12 O
due JJ 0 1 1 O
caution NN 0 0 1 O
. . 0 0 12 O

Corticosteroids NNS 0 1 UNK B-Group
: : 0 0 2 O
A DT 0 0 2 O
relationship NN 0 1 12 O
of IN 0 0 12 O
functional JJ 0 1 1 O
antagonism NN 0 1 UNK O
exists VBZ 1 1 UNK O
between IN 0 0 12 O
vitamin NN 0 1 6 B-Group
D NNP 0 1 2 I-Group
analogues VBZ 0 1 UNK I-Group
which WDT 0 0 12 O
promote VBP 0 1 1 O
calcium NN 0 1 14 O
absorption NN 0 1 1 O
and CC 0 0 12 O
corticosteroids NNS 1 1 14 B-Group
which WDT 0 0 12 O
inhibit VBP 0 1 13 O
calcium JJ 0 1 14 O
absorption NN 0 1 1 O
. . 0 0 12 O

Therefore DT 0 0 1 O
caution NN 0 0 1 O
is VBZ 1 0 12 O
advised VBN 1 0 12 O
if IN 0 0 12 O
the DT 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
loxapine NN 0 1 16 B-Drug
and CC 0 0 12 O
CNS NNP 0 1 6 O
- : 0 0 2 O
active JJ 0 1 1 O
drugs NNS 1 1 6 O
is VBZ 1 0 12 O
required VBN 1 1 1 O
. . 0 0 12 O

Additive JJ 0 1 UNK O
adverse JJ 0 0 1 O
effects NNS 1 1 1 O
resulting VBG 1 1 1 O
from IN 0 0 12 O
cholinergic NN 0 1 13 O
blockade NN 0 1 1 O
may MD 0 0 1 O
occur VB 0 1 1 O
when WRB 0 0 12 O
LEVSIN NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
other JJ 0 0 12 O
antimuscarinics NNS 0 1 13 B-Group
amantadine VBP 0 1 16 B-Drug
haloperidol JJ 0 1 16 B-Drug
phenothiazines NNS 1 1 UNK B-Group
monoamine JJ 0 1 13 B-Group
oxidase NN 0 1 13 I-Group
MAO NNP 0 1 14 I-Group
inhibitors NNS 1 1 14 I-Group
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
or CC 0 0 12 O
some DT 0 0 12 O
antihistamines NNS 1 1 UNK B-Group
. . 0 0 12 O

Sedatives NNS 0 1 UNK B-Group
and CC 0 0 12 O
tranquilizers NNS 1 1 13 B-Group
( ( 0 0 2 O
e.g. VB 0 0 UNK O
diazepam NN 0 1 0 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

Close JJ 0 1 2 O
supervision NN 0 1 1 O
and CC 0 0 12 O
careful JJ 0 1 12 O
adjustment NN 0 1 1 O
of IN 0 0 12 O
dosage NN 0 1 0 O
are VBP 1 0 12 O
required VBN 1 1 1 O
when WRB 0 0 12 O
this DT 0 0 12 O
drug NN 0 1 1 O
is VBZ 1 0 12 O
given VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
anticholinergic NN 0 1 13 B-Group
or CC 0 0 12 O
sympathomimetic JJ 0 1 13 B-Group
drugs NNS 1 1 6 I-Group
. . 0 0 12 O

Drugs NNS 0 1 2 O
that WDT 0 0 12 O
reportedly RB 0 0 12 O
may MD 0 0 1 O
increase VB 0 1 1 O
oral JJ 0 1 6 O
anticoagulant JJ 0 1 13 B-Group
response NN 0 1 1 O
ie NN 0 0 1 O
increased VBD 1 1 1 O
prothrombin JJ 0 1 14 O
response NN 0 1 1 O
in IN 0 0 12 O
man NN 0 1 12 O
include VBP 0 1 1 O
: : 0 0 2 O
alcohol NN 0 1 1 B-Drug
* NN 0 0 2 O
; : 0 0 2 O
allopurinol CC 0 1 13 B-Drug
; : 0 0 2 O
aminosalicylic JJ 0 0 UNK B-Drug
acid NN 0 1 14 I-Drug
; : 0 0 2 O
amiodarone NN 0 1 0 B-Drug
; : 0 0 2 O
anabolic JJ 0 1 13 B-Group
steroids NNS 1 1 6 I-Group
; : 0 0 2 O
antibiotics NNS 1 1 6 B-Group
; : 0 0 2 O
bromelains NNS 0 1 UNK B-Drug
; : 0 0 2 O
chloral JJ 0 1 16 B-Drug
hydrate NN 0 1 16 I-Drug
* NN 0 0 2 O
; : 0 0 2 O
chlorpropamide NN 0 1 13 B-Drug
; : 0 0 2 O
chymotrypsin NN 0 1 UNK B-Drug
; : 0 0 2 O
cimetidine NN 0 1 13 B-Drug
; : 0 0 2 O
cinchophen NN 0 1 UNK B-Drug
; : 0 0 2 O
clofibrate NN 0 1 UNK B-Drug
; : 0 0 2 O
dextran NN 0 1 14 B-Drug
; : 0 0 2 O
dextrothyroxine NN 0 1 UNK B-Drug
; : 0 0 2 O
diazoxide NN 0 1 16 B-Drug
; : 0 0 2 O
dietary JJ 0 1 6 O
deficiencies NNS 1 1 13 O
; : 0 0 2 O
diflunisal NN 0 1 13 B-Drug
; : 0 0 2 O
disulfiram NN 0 1 13 B-Drug
; : 0 0 2 O
drugs NNS 1 1 6 O
affecting VBG 1 1 1 O
blood NN 0 1 6 O
elements NNS 1 1 1 O
; : 0 0 2 O
ethacrynic JJ 0 0 16 B-Drug
acid NN 0 1 14 I-Drug
; : 0 0 2 O
fenoprofen CC 0 1 UNK B-Drug
; : 0 0 2 O
glucagon NN 0 1 14 B-Drug
; : 0 0 2 O
hepatotoxic JJ 0 1 UNK O
drugs NNS 1 1 6 O
; : 0 0 2 O
ibuprofen NN 0 1 0 B-Drug
; : 0 0 2 O
indomethacin NN 0 1 14 B-Drug
; : 0 0 2 O
influenza JJ 0 1 6 B-Group
virus NN 0 1 6 I-Group
vaccine NN 0 1 6 I-Group
; : 0 0 2 O
inhalation NN 0 1 16 O
anesthetics NNS 1 1 13 B-Group
; : 0 0 2 O
mefenamic JJ 0 0 UNK B-Drug
acid NN 0 1 14 I-Drug
; : 0 0 2 O
methyldopa CC 0 1 13 B-Drug
; : 0 0 2 O
methylphenidate NN 0 1 16 B-Drug
; : 0 0 2 O
metronidazole CC 0 1 0 B-Drug
; : 0 0 2 O
miconazole NN 0 1 16 B-Drug
; : 0 0 2 O
monoamine JJ 0 1 13 B-Group
oxidase NN 0 1 13 I-Group
inhibitors NNS 1 1 14 I-Group
; : 0 0 2 O
nalidixic JJ 0 0 UNK B-Drug
acid NN 0 1 14 I-Drug
; : 0 0 2 O
naproxen CC 0 1 16 B-Drug
; : 0 0 2 O
oxolinic JJ 0 1 UNK B-Drug
acid NN 0 1 14 I-Drug
; : 0 0 2 O
oxyphenbutazone NN 0 1 UNK B-Drug
; : 0 0 2 O
pentoxifylline NN 0 1 16 B-Drug
; : 0 0 2 O
phenylbutazone NN 0 1 UNK B-Drug
; : 0 0 2 O
phenyramidol CC 0 1 UNK B-Drug_n
; : 0 0 2 O
phenytoin NN 0 1 16 B-Drug
; : 0 0 2 O
prolonged VBN 1 1 6 O
hot JJ 0 1 3 O
weather NN 0 1 13 O
; : 0 0 2 O
prolonged JJ 0 1 6 B-Group
narcotics NNS 1 1 1 I-Group
; : 0 0 2 O
pyrazolones NNS 0 1 UNK B-Group
; : 0 0 2 O
quinidine NN 0 1 16 B-Drug
; : 0 0 2 O
quinine NN 0 1 16 B-Drug
; : 0 0 2 O
ranitidine JJ 0 1 0 B-Drug
* NN 0 0 2 O
; : 0 0 2 O
salicylates VBZ 0 1 13 B-Group
; : 0 0 2 O
sulfinpyrazone NN 0 1 13 B-Drug
; : 0 0 2 O
sulfonamides NNS 1 1 13 B-Group
long RB 0 1 12 O
acting VBG 1 1 12 O
; : 0 0 2 O
sulindac NN 0 1 13 B-Drug
; : 0 0 2 O
thyroid CC 0 1 6 B-Group
drugs NNS 1 1 6 I-Group
; : 0 0 2 O
tolbutamide NN 0 1 UNK B-Drug
; : 0 0 2 O
triclofos CC 0 1 UNK B-Drug
sodium NN 0 1 14 I-Drug
; : 0 0 2 O
trimethoprim CC 0 1 16 B-Drug
/ JJ 0 0 2 O
sulfamethoxazole NN 0 1 13 B-Drug
; : 0 0 2 O
unreliable JJ 0 1 1 O
prothrombin NN 0 1 14 O
time NN 0 1 12 O
determinations NNS 1 1 UNK O
; : 0 0 2 O
warfarin CC 0 1 14 B-Drug
sodium JJ 0 1 14 I-Drug
overdosage NN 0 0 UNK O
. . 0 0 12 O

The DT 0 0 2 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
benzodiazepines NNS 1 1 14 B-Group
are VBP 1 0 12 O
unaltered VBN 0 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
presence NN 0 1 1 O
of IN 0 0 12 O
flumazenil NN 0 1 13 B-Drug
and CC 0 0 12 O
vice NN 0 1 UNK O
versa NN 0 0 UNK O
. . 0 0 12 O

. . 0 0 12 O

The DT 0 0 2 O
patient NN 0 1 6 O
was VBD 1 0 12 O
also RB 0 0 12 O
chronically RB 0 0 6 O
receiving VBG 1 1 1 O
phenytoin NN 0 1 16 B-Drug
phenobarbital JJ 0 1 16 B-Drug
digoxin NN 0 1 14 B-Drug
and CC 0 0 12 O
levothyroxine JJ 0 1 0 B-Drug
sodium NN 0 1 14 I-Drug
. . 0 0 12 O

The DT 0 0 2 O
dosage NN 0 1 0 O
of IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
or CC 0 0 12 O
others NNS 0 1 12 O
with IN 0 0 12 O
a DT 0 0 12 O
similar JJ 0 1 1 O
metabolism NN 0 1 16 O
may MD 0 0 1 O
need VB 0 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
modified VBN 1 1 16 O
if IN 0 0 12 O
they PRP 0 0 12 O
are VBP 1 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
nilutamide NN 0 1 UNK B-Drug
. . 0 0 12 O

. . 0 0 12 O

Consequently RB 0 0 1 O
caution NN 0 0 1 O
is VBZ 1 0 12 O
advised VBN 1 0 12 O
if IN 0 0 12 O
the DT 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
REVIA NNP 0 1 UNK B-Brand
and CC 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
is VBZ 1 0 12 O
required VBN 1 1 1 O
. . 0 0 12 O

Therefore RB 0 0 1 O
cyclosporine JJ 0 1 14 B-Drug
serum NN 0 1 14 O
levels NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
and CC 0 0 12 O
appropriate JJ 0 1 1 O
cyclosporine NN 0 1 14 B-Drug
dosage NN 0 1 0 O
adjustments NNS 1 1 1 O
made VBD 1 1 12 O
when WRB 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
are VBP 1 0 12 O
used VBN 1 1 12 O
concomitantly RB 0 0 14 O
. . 0 0 12 O

In IN 0 0 2 O
diabetic JJ 0 1 6 O
patients NNS 1 1 6 O
the DT 0 0 12 O
metabolic JJ 0 1 6 O
effects NNS 1 1 1 O
of IN 0 0 12 O
androgens NNS 1 1 13 B-Group
may MD 0 0 1 O
decrease VB 0 1 1 O
blood NN 0 1 6 O
glucose NN 0 1 14 O
and CC 0 0 12 O
therefore RB 0 0 1 O
insulin NN 0 1 14 B-Drug
requirements NNS 1 1 1 O
. . 0 0 12 O

Because IN 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
possible JJ 0 1 1 O
additive JJ 0 1 16 O
effects NNS 1 1 1 O
of IN 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
may MD 0 0 1 O
depress VB 0 0 13 O
the DT 0 0 12 O
nervous JJ 0 1 6 O
system NN 0 1 1 O
ethanol NN 0 1 1 B-Drug
or CC 0 0 12 O
triazolam NN 0 1 13 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
cautiously RB 0 0 UNK O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
tiagabine NN 0 1 13 B-Drug
. . 0 0 12 O

Therefore RB 0 0 1 O
chloroprocaine NN 0 1 13 B-Drug
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
in IN 0 0 12 O
any DT 0 0 12 O
condition NN 0 1 1 O
in IN 0 0 12 O
which WDT 0 0 12 O
a DT 0 0 12 O
sulfonamide JJ 0 1 UNK B-Group
drug NN 0 1 1 I-Group
is VBZ 1 0 12 O
being VBG 1 0 12 O
employed VBN 1 1 1 O
. . 0 0 12 O

Patients NNS 0 1 7 O
receiving VBG 1 1 1 O
medications NNS 1 1 6 O
that WDT 0 0 12 O
interfere VBP 0 1 UNK O
with IN 0 0 12 O
platelet NN 0 1 14 O
function NN 0 1 1 O
or CC 0 0 12 O
coagulation NN 0 1 14 O
should MD 0 0 12 O
have VB 0 0 12 O
more RBR 0 1 12 O
frequent JJ 0 1 1 O
laboratory NN 0 1 1 O
monitoring NN 0 1 1 O
for IN 0 0 12 O
thrombocytopenia NN 0 1 14 O
. . 0 0 12 O

indinavir NN 0 1 16 B-Drug
concentration NN 0 1 1 O

In IN 0 0 2 O
EMs NNP 0 0 UNK O
selective JJ 0 1 13 O
inhibitors NNS 1 1 14 O
of IN 0 0 12 O
CYP9D9 NNP 0 0 UNK O
increase NN 0 1 1 O
atomoxetine NN 0 1 13 B-Drug
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
to TO 0 0 12 O
exposures NNS 1 1 UNK O
similar JJ 0 1 1 O
to TO 0 0 12 O
those DT 0 0 12 O
observed VBN 1 1 1 O
in IN 0 0 12 O
PMs NNP 0 1 UNK O
. . 0 0 12 O

There EX 0 0 12 O
is VBZ 1 0 12 O
no DT 0 0 12 O
clinical JJ 0 1 6 O
experience NN 0 1 12 O
to TO 0 0 12 O
date NN 0 1 12 O
on IN 0 0 12 O
the DT 0 0 12 O
use NN 0 1 1 O
of IN 0 0 12 O
Femara NNP 0 1 UNK B-Brand
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
other JJ 0 0 12 O
anticancer NN 0 0 UNK O
agents NNS 1 1 1 O
. . 0 0 12 O

- : 0 0 2 O
adrenergic NN 0 1 UNK B-Group
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
: : 0 0 2 O
Hyperthyroidism NN 0 1 7 O
may MD 0 0 1 O
cause VB 0 1 12 O
an DT 0 0 12 O
increased JJ 0 1 1 O
clearance NN 0 1 16 O
of IN 0 0 12 O
beta NN 0 1 16 O
ratio NN 0 1 1 O
. . 0 0 12 O

Digitalis NNS 0 1 15 B-Group
: : 0 0 2 O
Vitamin NNP 0 1 2 B-Group
D NNP 0 1 2 I-Group
dosage NN 0 1 0 O
must MD 0 0 12 O
be VB 0 0 12 O
determined VBN 1 1 1 O
with IN 0 0 12 O
care NN 0 1 12 O
in IN 0 0 12 O
patients NNS 1 1 6 O
undergoing VBG 1 0 6 O
treatment NN 0 1 6 O
with IN 0 0 12 O
digitalis NN 0 1 14 B-Group
as IN 1 0 12 O
hypercalcemia NN 0 1 8 O
in IN 0 0 12 O
such JJ 0 0 1 O
patients NNS 1 1 6 O
may MD 0 0 1 O
precipitate VB 0 1 13 O
cardiac JJ 0 1 6 O
arrhythmias NN 1 1 6 O
. . 0 0 12 O

In IN 0 0 2 O
patients NNS 1 1 6 O
who WP 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
be VB 0 0 12 O
well RB 0 1 12 O
controlled VBN 1 1 1 O
on IN 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
receiving VBG 1 1 1 O
concurrent JJ 0 1 1 O
cimetidine NN 0 1 13 B-Drug
therapy NN 0 1 6 O
discontinuation NN 0 1 6 O
of IN 0 0 12 O
cimetidine NN 0 1 13 B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
decrease VB 0 1 1 O
established VBN 1 1 1 O
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
serum NN 0 1 14 O
tricyclic JJ 0 0 14 B-Group
antidepressant NN 0 1 6 I-Group
levels NNS 1 1 1 O
and CC 0 0 12 O
compromise VB 0 1 1 O
their PRP$ 0 0 12 O
therapeutic JJ 0 1 6 O
effects NNS 1 1 1 O
. . 0 0 12 O

- : 0 0 2 O
Drugs NN 0 1 2 O
with IN 0 0 12 O
ototoxic JJ 0 1 UNK O
potential NN 0 1 1 O
: : 0 0 2 O
Especially RB 0 0 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
presence NN 0 1 1 O
of IN 0 0 12 O
impaired JJ 0 1 6 O
renal JJ 0 1 6 O
function NN 0 1 1 O
the DT 0 0 12 O
use NN 0 1 1 O
of IN 0 0 12 O
parenterally RB 0 0 UNK O
administered VBN 1 1 1 O
bumetanide NN 0 1 16 B-Drug
in IN 0 0 12 O
patients NNS 1 1 6 O
to TO 0 0 12 O
whom WP 0 0 12 O
aminoglycoside IN 0 1 14 B-Group
antibiotics NNS 1 1 6 I-Group
are VBP 1 0 12 O
also RB 0 0 12 O
being VBG 1 0 12 O
given VBN 1 1 12 O
should MD 0 0 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
except IN 0 0 12 O
in IN 0 0 12 O
life NN 0 1 12 O
- : 0 0 2 O
threatening JJ 0 0 12 O
conditions NNS 1 1 1 O
. . 0 0 12 O

INDOCIN NNP 0 1 UNK B-Brand
reduces VBZ 1 0 UNK O
basal NN 0 1 6 O
plasma JJ 0 1 14 O
renin NN 0 1 UNK O
activity NN 0 1 1 O
( ( 0 0 2 O
PRA NNP 0 1 UNK O
) ) 0 0 2 O
as RB 0 0 12 O
well RB 0 1 12 O
as IN 1 0 12 O
those DT 0 0 12 O
elevations NNS 1 1 1 O
of IN 0 0 12 O
PRA NNP 0 1 UNK O
induced VBN 1 1 6 O
by IN 0 0 12 O
furosemide JJ 0 1 0 B-Drug
administration NN 0 1 1 O
or CC 0 0 12 O
salt NN 0 1 3 O
or CC 0 0 12 O
volume NN 0 1 1 O
depletion NN 0 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
evaluating VBG 1 1 1 O
the DT 0 0 12 O
minimum JJ 0 1 1 O
inhibitory JJ 0 1 UNK O
concentration NN 0 1 1 O
( ( 0 0 2 O
MIC NNP 0 1 13 O
) ) 0 0 2 O
of IN 0 0 12 O
vancomycin NN 0 1 14 B-Drug
cefazolin NN 0 1 14 B-Drug
ampicillin NN 0 1 0 B-Drug
ampicillin NN 0 1 0 B-Drug
/ NNP 0 0 2 O
flucoxacillin NN 0 0 UNK O
ceftazidime NN 0 1 14 B-Drug
gentamicin NN 0 1 14 B-Drug
and CC 0 0 12 O
amphotericin NN 0 1 14 B-Drug
demonstrated VBD 1 0 1 O
no DT 0 0 12 O
evidence NN 0 1 1 O
of IN 0 0 12 O
incompatibility NN 0 1 13 O
of IN 0 0 12 O
these DT 0 0 12 O
antibiotics NNS 1 1 6 B-Group
with IN 0 0 12 O
EXTRANEAL NNP 0 1 UNK B-Brand
. . 0 0 12 O

Pharmacological JJ 0 1 UNK O
/ NNP 0 0 2 O
Pharmacodynamic NNP 0 1 UNK O
Interactions NNP 0 1 UNK O
with IN 0 0 12 O
Carbamazepine NNP 0 1 UNK B-Drug
Concomitant NNP 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
carbamazepine NN 0 1 16 B-Drug
and CC 0 0 12 O
lithium NN 0 1 16 B-Drug
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
neurotoxic JJ 0 1 UNK O
side NN 0 1 3 O
effects NNS 1 1 1 O
. . 0 0 12 O

Multiple NNP 0 1 2 O
dose JJ 0 1 6 O
studies NNS 1 1 1 O
of IN 0 0 12 O
ezetimibe NN 0 1 16 B-Drug
given VBN 1 1 12 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
HMG NNP 0 0 UNK B-Group
- : 0 0 2 O
CoA NNP 0 0 UNK I-Group
reductase NN 0 1 UNK I-Group
inhibitors NNS 1 1 14 I-Group
( ( 0 0 2 O
statins NNS 1 1 UNK B-Group
) ) 0 0 2 O
in IN 0 0 12 O
rats NNS 1 1 UNK O
and CC 0 0 12 O
rabbits NNS 1 1 UNK O
during IN 0 0 12 O
organogenesis NN 0 1 UNK O
result NN 0 1 1 O
in IN 0 0 12 O
higher JJR 1 1 1 O
ezetimibe NN 0 1 16 B-Drug
and CC 0 0 12 O
statin NN 0 1 14 O
exposures NNS 1 1 UNK O
. . 0 0 12 O

In IN 0 0 2 O
addition NN 0 1 1 O
new JJ 0 1 12 O
cases NNS 1 1 UNK O
of IN 0 0 12 O
diabetes NNS 0 1 6 O
have VBP 0 0 12 O
been VBN 1 0 12 O
diagnosed VBN 1 1 6 O
during IN 0 0 12 O
Accutane NNP 0 1 UNK B-Brand
therapy CC 0 1 6 O
although IN 0 0 12 O
no DT 0 0 12 O
causal NN 0 1 UNK O
relationship NN 0 1 12 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
established VBN 1 1 1 O

cimetidine NN 0 1 13 B-Drug
; : 0 0 2 O

Drugs NNS 0 1 2 O
which WDT 0 0 12 O
inhibit VBP 0 1 13 O
this DT 0 0 12 O
metabolic JJ 0 1 6 O
pathway NN 0 1 UNK O
may MD 0 0 1 O
have VB 0 0 12 O
a DT 0 0 12 O
profound JJ 0 1 1 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
clearance NN 0 1 16 O
of IN 0 0 12 O
alprazolam NN 0 1 0 B-Drug
. . 0 0 12 O

Triazolam NNP 0 1 UNK B-Drug
- : 0 0 2 O
Combined JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
racemic JJ 0 1 14 O
citalopram NN 0 1 16 B-Drug
( ( 0 0 2 O
titrated VBN 1 1 14 O
to TO 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
) ) 0 0 2 O
and CC 0 0 12 O
the DT 0 0 12 O
CYP9A9 NNP 0 0 UNK O
substrate NN 0 1 UNK O
triazolam NN 0 1 13 B-Drug
( ( 0 0 2 O
single JJ 0 1 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
) ) 0 0 2 O
did VBD 1 0 12 O
not RB 0 1 12 O
significantly RB 0 0 1 O
affect VBP 0 1 1 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
either DT 0 1 12 O
citalopram NN 0 1 16 B-Drug
or CC 0 0 12 O
triazolam NN 0 1 13 B-Drug
. . 0 0 12 O

Antagonism NN 0 1 UNK O
between IN 0 0 12 O
lincomycin NN 0 1 UNK B-Drug
and CC 0 0 12 O
erythromycin NN 0 1 0 B-Drug
in IN 0 0 12 O
vitro NN 0 1 UNK O
has VBZ 1 0 12 O
been VBN 1 0 12 O
demonstrated VBN 1 0 1 O
. . 0 0 12 O

Drug NNP 0 1 2 O
- : 0 0 2 O
Drug NN 0 1 2 O
Interactions NNS 0 1 UNK O
Albuterol NNP 0 1 0 B-Drug
- : 0 0 2 O
STRATTERA NN 0 1 UNK B-Brand
should MD 0 0 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
caution NN 0 0 1 O
to TO 0 0 12 O
patients NNS 1 1 6 O
being VBG 1 0 12 O
treated VBN 1 1 1 O
with IN 0 0 12 O
systemically RB 0 0 UNK O
- : 0 0 2 O
administered VBN 1 1 1 O
( ( 0 0 2 O
oral JJ 0 1 6 O
or CC 0 0 12 O
intravenous JJ 0 1 14 O
) ) 0 0 2 O
albuterol NN 0 1 0 B-Drug
( ( 0 0 2 O
or CC 0 0 12 O
other JJ 0 0 12 O
beta9 JJ 0 0 UNK B-Group
agonists NNS 1 1 UNK I-Group
) ) 0 0 2 O
because IN 0 0 12 O
the DT 0 0 12 O
action NN 0 1 13 O
of IN 0 0 12 O
albuterol NN 0 1 0 B-Drug
on IN 0 0 12 O
the DT 0 0 12 O
cardiovascular JJ 0 1 6 O
system NN 0 1 1 O
can MD 0 0 12 O
be VB 0 0 12 O
potentiated VBN 1 0 UNK O
resulting VBG 1 1 1 O
in IN 0 0 12 O
increases NNS 1 1 1 O
in IN 0 0 12 O
heart NN 0 1 12 O
rate NN 0 1 1 O
and CC 0 0 12 O
blood NN 0 1 6 O
pressure NN 0 1 1 O
. . 0 0 12 O

Serum NNP 0 1 7 O
samples NNS 1 1 UNK O
from IN 0 0 12 O
patients NNS 1 1 6 O
treated VBN 1 1 1 O
with IN 0 0 12 O
cefoxitin NN 0 1 13 B-Drug
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
analyzed VBN 1 1 13 O
for IN 0 0 12 O
creatinine NN 0 1 14 O
if IN 0 0 12 O
withdrawn VBN 1 1 1 O
within IN 0 0 1 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
of IN 0 0 12 O
drug NN 0 1 1 O
administration NN 0 1 1 O
. . 0 0 12 O

Renal JJ 0 1 7 O
clearance NN 0 1 16 O
of IN 0 0 12 O
ucb JJ 0 0 UNK O
L9 NNP 0 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
presence NN 0 1 1 O
of IN 0 0 12 O
probenecid NN 0 1 13 B-Drug
decreased VBD 1 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
probably RB 0 1 12 O
related VBN 1 1 1 O
to TO 0 0 12 O
competitive JJ 0 1 UNK O
inhibition NN 0 1 13 O
of IN 0 0 12 O
tubular JJ 0 1 3 O
secretion NN 0 1 14 O
of IN 0 0 12 O
ucb JJ 0 0 UNK O
L9 NNP 0 1 UNK O
. . 0 0 12 O

Iron NNP 0 1 2 B-Drug
salts NNS 1 1 13 O
may MD 0 0 1 O
reduce VB 0 0 1 O
the DT 0 0 12 O
bioavailability NN 0 1 UNK O
of IN 0 0 12 O
carbidopa NN 0 1 13 B-Drug
and CC 0 0 12 O
levodopa NN 0 1 UNK B-Drug
. . 0 0 12 O

Hypotension NN 0 1 7 O
was VBD 1 0 12 O
more RBR 0 1 12 O
likely JJ 0 1 12 O
to TO 0 0 12 O
occur VB 0 1 1 O
if IN 0 0 12 O
the DT 0 0 12 O
calcium NN 0 1 14 B-Group
antagonist NN 0 1 13 I-Group
were VBD 1 0 12 O
a DT 0 0 12 O
dihydropyridine JJ 0 1 UNK B-Group
derivative JJ 0 1 13 I-Group
e.g. NN 0 0 UNK O
nifedipine NN 0 1 0 B-Drug
while IN 0 0 12 O
left VBD 1 1 12 O
ventricular JJ 0 1 8 O
failure NN 0 1 1 O
and CC 0 0 12 O
AV NNP 0 0 13 O
conduction NN 0 1 6 O
disturbances NNS 1 1 6 O
including VBG 1 1 1 O
complete JJ 0 1 1 O
heart NN 0 1 12 O
block NN 0 1 3 O
were VBD 1 0 12 O
more RBR 0 1 12 O
likely JJ 0 1 12 O
to TO 0 0 12 O
occur VB 0 1 1 O
with IN 0 0 12 O
either DT 0 1 12 O
verapamil NN 0 1 0 B-Drug
or CC 0 0 12 O
diltiazem NN 0 1 0 B-Drug
. . 0 0 12 O

MAO NNP 0 1 14 B-Group
inhibitors NNS 1 1 14 I-Group
MAOI NNP 0 1 UNK B-Group
antidepressants NNS 1 1 13 I-Group
as RB 0 0 12 O
well RB 0 1 12 O
as IN 1 0 12 O
a DT 0 0 12 O
metabolite NN 0 1 UNK O
of IN 0 0 12 O
furazolidone NN 0 1 UNK B-Drug
slow JJ 0 1 12 O
amphetamine NN 0 1 13 B-Drug
metabolism NN 0 1 16 O
. . 0 0 12 O

Appropriate JJ 0 1 2 O
doses NNS 1 1 6 O
for IN 0 0 12 O
this DT 0 0 12 O
combination NN 0 1 1 O
are VBP 1 0 12 O
not RB 0 1 12 O
established VBN 1 1 1 O
. . 0 0 12 O

a DT 0 0 12 O
reduction NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
usual JJ 0 1 12 O
anticoagulant JJ 0 1 13 B-Group
dosage NN 0 1 0 O
may MD 0 0 1 O
be VB 0 0 12 O
required VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
both DT 0 0 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

Caution NN 0 0 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
taken VBN 1 1 12 O
in IN 0 0 12 O
concurrent NN 0 1 1 O
or CC 0 0 12 O
serial JJ 0 1 1 O
use NN 0 1 1 O
of IN 0 0 12 O
other JJ 0 0 12 O
neurotoxic JJ 0 1 UNK O
and CC 0 0 12 O
/ JJ 0 0 2 O
or CC 0 0 12 O
nephrotoxic JJ 0 1 UNK O
drugs NNS 1 1 6 O
because IN 0 0 12 O
of IN 0 0 12 O
possible JJ 0 1 1 O
enhancement NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
nephrotoxicity NN 0 1 UNK O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
ototoxicity NN 0 1 UNK O
of IN 0 0 12 O
neomycin NN 0 1 16 B-Drug
. . 0 0 12 O

Phenytoin NN 0 1 0 B-Drug
: : 0 0 2 O
If IN 0 0 12 O
acitretin NN 0 1 13 B-Drug
is VBZ 1 0 12 O
given VBN 1 1 12 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
phenytoin VB 0 1 16 B-Drug
the DT 0 0 12 O
protein NN 0 1 14 O
binding NN 0 1 1 O
of IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
may MD 0 0 1 O
be VB 0 0 12 O
reduced VBN 1 1 1 O
. . 0 0 12 O

Phenytoin NNP 0 1 0 B-Drug
Carbamazepine NNP 0 1 UNK B-Drug
and CC 0 0 12 O
Rifampicin NNP 0 1 UNK B-Drug
: : 0 0 2 O
In IN 0 0 2 O
patients NNS 1 1 6 O
treated VBN 1 1 1 O
with IN 0 0 12 O
potent JJ 0 1 UNK O
inducers NNS 1 1 UNK O
of IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
( ( 0 0 2 O
i.e. FW 0 1 1 O
phenytoin FW 0 1 16 B-Drug
carbamazepine NN 0 1 16 B-Drug
and CC 0 0 12 O
rifampicin NN 0 1 UNK B-Drug
) ) 0 0 2 O
the DT 0 0 12 O
clearance NN 0 1 16 O
of IN 0 0 12 O
ondansetron NN 0 1 16 B-Drug
was VBD 1 0 12 O
significantly RB 0 0 1 O
increased VBN 1 1 1 O
and CC 0 0 12 O
ondansetron RB 0 1 16 B-Drug
blood NN 0 1 6 O
concentrations NNS 1 1 13 O
were VBD 1 0 12 O
decreased VBN 1 1 1 O
. . 0 0 12 O

However RB 0 0 1 O
one CD 0 1 12 O
subject NN 0 1 UNK O
showed VBD 1 1 12 O
an DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
INR NNP 0 1 13 O
from IN 0 0 12 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
. . 0 0 12 O

The DT 0 0 2 O
risks NNS 1 1 1 O
of IN 0 0 12 O
using VBG 1 1 1 O
Anafranil NNP 0 1 UNK B-Brand
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
systematically RB 0 0 UNK O
evaluated VBN 1 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
healthy JJ 0 1 12 O
subjects NNS 1 1 UNK O
no DT 0 0 12 O
significant JJ 0 1 1 O
drug NN 0 1 1 O
- : 0 0 2 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
was VBD 1 0 12 O
observed VBN 1 1 1 O
when WRB 0 0 12 O
Norpace NNP 0 1 0 B-Brand
was VBD 1 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
either DT 0 1 12 O
propranolol NN 0 1 16 B-Drug
or CC 0 0 12 O
diazepam NN 0 1 0 B-Drug
. . 0 0 12 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interactions NNP 0 1 UNK O
Methyldopa NNP 0 1 UNK B-Drug
may MD 0 0 1 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
measurement NN 0 1 1 O
of IN 0 0 12 O
: : 0 0 2 O
urinary JJ 0 1 6 O
uric JJ 0 0 14 O
acid NN 0 1 14 O
by IN 0 0 12 O
the DT 0 0 12 O
phosphotungstate NN 0 0 UNK O
method NN 0 1 13 O
serum NN 0 1 14 O
creatinine NN 0 1 14 O
by IN 0 0 12 O
the DT 0 0 12 O
alkaline NN 0 1 14 O
picrate NN 0 1 UNK O
method NN 0 1 13 O
and CC 0 0 12 O
SGOT NNP 0 0 14 O
by IN 0 0 12 O
colorimetric JJ 0 1 UNK O
methods NNS 1 1 1 O
. . 0 0 12 O

Since IN 0 1 2 O
PLETAL NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
extensively RB 0 0 1 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
cytochrome NN 0 1 UNK O
P NNP 0 1 2 O
- : 0 0 2 O
9 CD 0 0 2 O
isoenzymes NNS 0 1 14 O
caution NN 0 0 1 O
should MD 0 0 12 O
be VB 0 0 12 O
exercised VBN 1 1 1 O
when WRB 0 0 12 O
PLETAL NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
inhibitors NNS 1 1 14 O
of IN 0 0 12 O
C.P.A NNP 0 0 UNK O
. . 0 0 12 O
such JJ 0 0 1 O
as IN 1 0 12 O
ketoconazole NN 0 1 16 B-Drug
and CC 0 0 12 O
erythromycin NN 0 1 0 B-Drug
or CC 0 0 12 O
inhibitors NNS 1 1 14 O
of IN 0 0 12 O
CYP9C9 NNP 0 0 UNK O
such JJ 0 0 1 O
as IN 1 0 12 O
omeprazole NN 0 1 0 B-Drug
. . 0 0 12 O

Laboratory NN 0 1 2 O
Tests NNS 0 1 UNK O
There EX 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reports NNS 1 1 1 O
of IN 0 0 12 O
false JJ 0 1 13 O
- : 0 0 2 O
positive JJ 0 1 1 O
urine JJ 0 1 6 O
screening NN 0 1 1 O
tests NNS 1 1 1 O
for IN 0 0 12 O
tetrahydrocannabinol NN 0 1 UNK B-Drug
( ( 0 0 2 O
THC NNP 0 1 UNK B-Drug
) ) 0 0 2 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
most JJS 0 0 12 O
proton JJ 0 1 14 B-Group
pump NN 0 1 3 I-Group
inhibitors NNS 1 1 14 I-Group
including VBG 1 1 1 O
pantoprazole NN 0 1 16 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
possibility NN 0 1 1 O
of IN 0 0 12 O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
administered VBN 1 1 1 O
concurrently RB 0 0 1 O
should MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
particularly RB 0 0 1 O
when WRB 0 0 12 O
their PRP$ 0 0 12 O
main JJ 0 1 12 O
route NN 0 1 12 O
of IN 0 0 12 O
elimination NN 0 1 UNK O
is VBZ 1 0 12 O
active JJ 0 1 1 O
renal JJ 0 1 6 O
secretion NN 0 1 14 O
via IN 0 0 1 O
the DT 0 0 12 O
organic JJ 0 1 13 O
cationic NN 0 1 UNK O
transport NN 0 1 1 O
system NN 0 1 1 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
trimethoprim NN 0 1 16 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

Mutagenicity NN 0 1 UNK O
studies NNS 1 1 1 O
were VBD 1 0 12 O
conducted VBN 1 1 1 O
in IN 0 0 12 O
vitro NN 0 1 UNK O
and CC 0 0 12 O
in IN 0 0 12 O
vivo NN 0 1 13 O
; : 0 0 2 O

Warfarin NN 0 1 0 B-Drug
: : 0 0 2 O
The DT 0 0 2 O
effects NNS 1 1 1 O
of IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
and CC 0 0 12 O
NSAIDs NNP 0 1 UNK B-Group
on IN 0 0 12 O
GI NNP 0 1 6 O
bleeding VBG 1 1 6 O
are VBP 1 0 12 O
synergistic JJ 0 1 UNK O
such JJ 0 0 1 O
that IN 0 0 12 O
users NNS 1 1 UNK O
of IN 0 0 12 O
both DT 0 0 12 O
drugs NNS 1 1 6 O
together RB 0 1 12 O
have VBP 0 0 12 O
a DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
serious JJ 0 1 12 O
GI NNP 0 1 6 O
bleeding NN 0 1 6 O
higher JJR 1 1 1 O
than IN 0 0 12 O
users NNS 1 1 UNK O
of IN 0 0 12 O
either DT 0 1 12 O
drug NN 0 1 1 O
alone RB 0 1 12 O
. . 0 0 12 O

The DT 0 0 2 O
use NN 0 1 1 O
of IN 0 0 12 O
codeine NN 0 1 0 B-Drug
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
additive JJ 0 1 16 O
CNS NNP 0 1 6 O
depressant NN 0 0 UNK O
effects NNS 1 1 1 O
when WRB 0 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
alcohol NN 0 1 1 B-Drug
antihistamines NNS 1 1 UNK B-Group
psychotropics NNS 0 1 UNK B-Group
or CC 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
that IN 0 0 12 O
produce VBP 0 0 1 O
CNS NNP 0 1 6 O
depression NN 0 1 6 O
. . 0 0 12 O

Ampicillin NNP 0 1 0 B-Drug
/ NNP 0 0 2 O
Amoxicillin NNP 0 1 0 B-Drug
: : 0 0 2 O
An DT 0 0 2 O
increase NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
frequency NN 0 1 1 O
of IN 0 0 12 O
skin NN 0 1 3 O
rash NN 0 1 6 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
among IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
ampicillin NN 0 1 0 B-Drug
or CC 0 0 12 O
amoxicillin NN 0 1 0 B-Drug
concurrently RB 0 0 1 O
with IN 0 0 12 O
allopurinol NNS 0 1 13 B-Drug
compared VBN 1 1 1 O
to TO 0 0 12 O
patients NNS 1 1 6 O
who WP 0 0 12 O
are VBP 1 0 12 O
not RB 0 1 12 O
receiving VBG 1 1 1 O
both DT 0 0 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
contribution NN 0 1 1 O
of IN 0 0 12 O
each DT 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
treatments NNS 1 1 6 O
to TO 0 0 12 O
this DT 0 0 12 O
adverse JJ 0 0 1 O
reaction NN 0 1 1 O
is VBZ 1 0 12 O
unknown JJ 0 1 12 O
but CC 0 0 12 O
the DT 0 0 12 O
possibility NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
can MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
excluded VBN 1 1 1 O
. . 0 0 12 O

Dose NNP 0 1 7 O
reduction NN 0 1 1 O
or CC 0 0 12 O
interruption NN 0 1 1 O
of IN 0 0 12 O
TARCEVA NNP 0 1 UNK B-Brand
should MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
if IN 0 0 12 O
changes NNS 1 1 1 O
in IN 0 0 12 O
liver NN 0 1 6 O
function NN 0 1 1 O
are VBP 1 0 12 O
severe JJ 0 1 6 O
. . 0 0 12 O

Effects NNS 0 1 UNK O
of IN 0 0 12 O
Felbatol NNP 0 1 UNK B-Brand
on IN 0 0 12 O
Low NNP 0 1 2 O
- : 0 0 2 O
Dose NNP 0 1 7 O
Combination NNP 0 1 UNK B-Group
Oral NNP 0 1 2 I-Group
Contraceptives VBZ 0 1 UNK I-Group
A NNP 0 0 2 O
group NN 0 1 12 O
of IN 0 0 12 O
9 CD 0 0 2 O
nonsmoking VBG 0 0 UNK O
healthy JJ 0 1 12 O
white JJ 0 1 3 O
female NN 0 1 12 O
volunteers NNS 1 1 UNK O
established VBN 1 1 1 O
on IN 0 0 12 O
an DT 0 0 12 O
oral JJ 0 1 6 O
contraceptive JJ 0 1 13 B-Group
regimen NNS 0 1 6 O
containing VBG 1 1 1 O
9 CD 0 0 2 O
mg JJ 0 1 0 O
ethinyl NN 0 0 13 B-Drug
estradiol NN 0 1 13 I-Drug
and CC 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
gestodene NN 0 1 UNK B-Drug
for IN 0 0 12 O
at IN 0 0 12 O
least JJS 0 1 12 O
9 CD 0 0 2 O
months NNS 1 1 12 O
received VBD 1 1 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
of IN 0 0 12 O
felbamate NN 0 1 13 B-Drug
from IN 0 0 12 O
midcycle NN 0 1 UNK O
( ( 0 0 2 O
day NN 0 1 12 O
9 CD 0 0 2 O
) ) 0 0 2 O
to TO 0 0 12 O
midcycle VB 0 1 UNK O
( ( 0 0 2 O
day NN 0 1 12 O
9 CD 0 0 2 O
) ) 0 0 2 O
of IN 0 0 12 O
two CD 0 1 12 O
consecutive JJ 0 1 1 O
oral JJ 0 1 6 O
contraceptive NN 0 1 13 B-Group
cycles NNS 1 1 1 O
. . 0 0 12 O

Immunologic NN 0 1 UNK O

One CD 0 1 2 O
study NN 0 1 1 O
at IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
mg JJ 0 1 0 O
daily JJ 0 1 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
fluconazole NN 0 1 0 B-Drug
failed VBD 1 1 12 O
to TO 0 0 12 O
demonstrate VB 0 0 1 O
a DT 0 0 12 O
prolongation NN 0 1 6 O
in IN 0 0 12 O
QTc NNP 0 0 14 O
interval NN 0 1 1 O
. . 0 0 12 O

Drug NN 0 1 2 O
exposure NN 0 1 1 O
in IN 0 0 12 O
rodent NN 0 1 UNK O
pups NNS 1 0 UNK O
from IN 0 0 12 O
fulvestrant JJ 0 1 13 B-Drug
- : 0 0 2 O
treated VBD 1 1 1 O
lactating JJ 0 1 13 O
dams NN 1 1 UNK O
was VBD 1 0 12 O
estimated VBN 1 1 1 O
as IN 1 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
of IN 0 0 12 O
the DT 0 0 12 O
administered VBN 1 1 1 O
dose NN 0 1 6 O
. . 0 0 12 O

This DT 0 0 2 O
interaction NN 0 1 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
given VBN 1 1 12 O
consideration NN 0 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
CELEBREX NNP 0 1 UNK B-Brand
concomitantly RB 0 0 14 O
with IN 0 0 12 O
ACE NNP 0 1 13 B-Group
- : 0 0 2 O
inhibitors NNS 1 1 14 I-Group
. . 0 0 12 O

similar JJ 0 1 1 O
events NNS 1 1 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
other JJ 0 0 12 O
psychotropic NN 0 1 13 B-Group
drugs NNS 1 1 6 I-Group
or CC 0 0 12 O
even RB 0 0 12 O
Clozapine NNP 0 1 0 B-Drug
by IN 0 0 12 O
itself PRP 0 0 UNK O
. . 0 0 12 O

Cephalosporins NNS 0 1 15 B-Group
are VBP 1 0 12 O
known VBN 1 1 12 O
to TO 0 0 12 O
occasionally RB 0 1 12 O
induce VB 0 1 6 O
a DT 0 0 12 O
positive JJ 0 1 1 O
direct JJ 0 1 1 O
Coombs NNP 0 1 19 O
test NN 0 1 1 O
. . 0 0 12 O

there EX 0 0 12 O
was VBD 1 0 12 O
no DT 0 0 12 O
alteration NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
either DT 0 1 12 O
drug NN 0 1 1 O
. . 0 0 12 O

Amantadine NNP 0 1 UNK B-Drug
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
and CC 0 0 12 O
MAOIs NNP 0 1 UNK B-Group
may MD 0 0 1 O
increase VB 0 1 1 O
anticholinergic JJ 0 1 13 O
effect NN 0 1 1 O
of IN 0 0 12 O
clidinium NN 0 1 UNK B-Drug
. . 0 0 12 O

The DT 0 0 2 O
interaction NN 0 1 UNK O
of IN 0 0 12 O
Exjade NNP 0 1 UNK B-Brand
with IN 0 0 12 O
hydroxyurea NN 0 1 14 B-Drug
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
formally RB 0 0 1 O
studied VBN 1 0 1 O
. . 0 0 12 O

Table JJ 0 1 UNK O
9 CD 0 0 2 O
Potential JJ 0 1 UNK O
Drug NNP 0 1 2 O
Interactions NNS 0 1 UNK O
: : 0 0 2 O
Use NN 0 1 2 O
With IN 0 0 2 O
Caution NNP 0 0 UNK O
Dose NNP 0 1 7 O
Adjustment NNP 0 1 UNK O
of IN 0 0 12 O
Co NNP 0 1 2 O
- : 0 0 2 O
administered VBN 1 1 1 O
Drug NNP 0 1 2 O
May NNP 0 1 2 O
Be NNP 0 0 UNK O
Needed VBN 0 1 UNK O
due JJ 0 1 1 O
to TO 0 0 12 O
Possible JJ 0 1 2 O
Decrease NNP 0 1 7 O
in IN 0 0 12 O
Clinical NNP 0 1 7 O
Effect NNP 0 1 UNK O

however RB 0 0 12 O
in IN 0 0 12 O
some DT 0 0 12 O
patients NNS 1 1 6 O
there EX 0 0 12 O
were VBD 1 0 12 O
decreases VBZ 1 1 UNK O
up IN 0 0 12 O
to TO 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
of IN 0 0 12 O
ethinyl JJ 0 0 13 B-Drug
estradiol NN 0 1 13 I-Drug
and CC 0 0 12 O
levonorgestrel NN 0 1 13 B-Drug
levels NNS 1 1 1 O
. . 0 0 12 O

Since IN 0 1 2 O
fondaparinux JJ 0 1 16 B-Drug
sodium NN 0 1 14 I-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
bind VB 0 1 UNK O
significantly RB 0 0 1 O
to TO 0 0 12 O
plasma VB 0 1 14 O
proteins NNS 1 1 14 O
other JJ 0 0 12 O
than IN 0 0 12 O
ATIII NNP 0 1 UNK O
no DT 0 0 12 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
by IN 0 0 12 O
protein NN 0 1 14 O
- : 0 0 2 O
binding NN 0 1 1 O
displacement NN 0 1 1 O
are VBP 1 0 12 O
expected VBN 1 1 12 O
. . 0 0 12 O

Drug NN 0 1 2 O
Interactions NNS 0 1 UNK O
: : 0 0 2 O
Women NNS 0 1 2 O
on IN 0 0 12 O
oral JJ 0 1 6 O
contraceptives NNS 1 1 13 B-Group
have VBP 0 0 12 O
shown VBN 1 1 1 O
a DT 0 0 12 O
significant JJ 0 1 1 O
increase NN 0 1 1 O
in IN 0 0 12 O
plasma JJ 0 1 14 O
vitamin FW 0 1 6 B-Group
A DT 0 0 2 I-Group
levels NNS 1 1 1 O
. . 0 0 12 O

This DT 0 0 2 O
transient JJ 0 1 1 O
hypotensive JJ 0 1 14 O
response NN 0 1 1 O
is VBZ 1 0 12 O
not RB 0 1 12 O
a DT 0 0 12 O
contraindication NN 0 1 14 O
to TO 0 0 12 O
further JJ 0 1 1 O
doses NNS 1 1 6 O
which WDT 0 0 12 O
can MD 0 0 12 O
be VB 0 0 12 O
given VBN 1 1 12 O
without IN 0 0 12 O
difficulty NN 0 1 1 O
once IN 0 0 12 O
the DT 0 0 12 O
blood NN 0 1 6 O
pressure NN 0 1 1 O
has VBZ 1 0 12 O
increased VBN 1 1 1 O
after IN 0 0 12 O
volume NN 0 1 1 O
expansion NN 0 0 UNK O
. . 0 0 12 O

If IN 0 0 12 O
diuretics NNS 1 1 14 B-Group
can MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
interrupted VBN 1 1 12 O
close RB 0 1 12 O
medical JJ 0 1 1 O
supervision NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
provided VBN 1 1 1 O
with IN 0 0 12 O
the DT 0 0 12 O
first JJ 0 1 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
ACEON NNP 0 1 UNK B-Brand
Tablets NNP 0 1 0 O
for IN 0 0 12 O
at IN 0 0 12 O
least JJS 0 1 12 O
two CD 0 1 12 O
hours NNS 1 1 12 O
and CC 0 0 12 O
until IN 0 0 12 O
blood NN 0 1 6 O
pressure NN 0 1 1 O
has VBZ 1 0 12 O
stabilized VBN 1 1 1 O
for IN 0 0 12 O
another DT 0 0 12 O
hour NN 0 1 12 O
. . 0 0 12 O

H9 NNP 0 0 UNK B-Group
Blockers NNP 0 0 UNK I-Group
and CC 0 0 12 O
Proton NNP 0 1 UNK B-Group
Pump NNP 0 1 2 I-Group
Inhibitors NNP 0 1 7 I-Group
( ( 0 0 2 O
PPIs NNP 0 1 UNK B-Group
) ) 0 0 2 O

Immunodeficiencies NNS 0 1 UNK O
associated VBN 1 1 1 O
with IN 0 0 12 O
sulphasalazine JJ 0 1 UNK B-Drug
therapy NN 0 1 6 O
in IN 0 0 12 O
inflammatory JJ 0 1 6 O
arthritis NN 0 1 6 O
. . 0 0 12 O

This DT 0 0 2 O
increase NN 0 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
clinically RB 0 0 6 O
relevant JJ 0 1 1 O
as IN 1 0 12 O
adverse JJ 0 0 1 O
experiences NNS 1 1 12 O
are VBP 1 0 12 O
related VBN 1 1 1 O
to TO 0 0 12 O
dose VB 0 1 6 O
and CC 0 0 12 O
exposure NN 0 1 1 O
; : 0 0 2 O

alcohol NN 0 1 1 B-Drug
* NN 0 0 2 O
; : 0 0 2 O

Such JJ 0 0 1 O
individuals NNS 1 1 1 O
are VBP 1 0 12 O
referred VBN 1 1 1 O
to TO 0 0 12 O
as IN 1 0 12 O
poor JJ 0 1 12 O
metabolizers NNS 0 0 UNK O
of IN 0 0 12 O
drugs NNS 1 1 6 O
such JJ 0 0 1 O
as IN 1 0 12 O
debrisoquin NN 0 1 UNK B-Drug
dextromethorphan NN 0 1 16 B-Drug
and CC 0 0 12 O
the DT 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
. . 0 0 12 O

Rifabutin NN 0 1 UNK B-Drug
: : 0 0 2 O
There EX 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reports NNS 1 1 1 O
of IN 0 0 12 O
uveitis NN 0 1 13 O
in IN 0 0 12 O
patients NNS 1 1 6 O
to TO 0 0 12 O
whom WP 0 0 12 O
fluconazole NN 0 1 0 B-Drug
and CC 0 0 12 O
rifabutin NN 0 1 13 B-Drug
were VBD 1 0 12 O
coadministered VBN 0 0 UNK O
. . 0 0 12 O

No DT 0 0 2 O
formal JJ 0 1 1 O
drug NN 0 1 1 O
/ NNP 0 0 2 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
with IN 0 0 12 O
Plenaxis NNP 0 1 UNK B-Brand
were VBD 1 0 12 O
performed VBN 1 1 1 O
. . 0 0 12 O

Caution NN 0 0 UNK O
should MD 0 0 12 O
also RB 0 0 12 O
be VB 0 0 12 O
taken VBN 1 1 12 O
in IN 0 0 12 O
concurrent NN 0 1 1 O
or CC 0 0 12 O
serial JJ 0 1 1 O
use NN 0 1 1 O
of IN 0 0 12 O
other JJ 0 0 12 O
aminoglycosides NNS 0 1 13 B-Group
and CC 0 0 12 O
polymyxins NNS 1 1 UNK B-Group
because IN 0 0 12 O
they PRP 0 0 12 O
may MD 0 0 1 O
enhance VB 0 1 UNK O
neomycin JJ 0 1 16 O
nephrotoxicity NN 0 1 UNK O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
ototoxicity NN 0 1 UNK O
and CC 0 0 12 O
potentiate NN 0 0 UNK O
neomycin NNS 0 1 16 B-Drug
sulfate VBP 0 1 14 I-Drug
neuromuscular JJ 0 1 6 O
blocking NN 0 1 UNK O
effects NNS 1 1 1 O
. . 0 0 12 O

in IN 0 0 12 O
vitro JJ 0 1 UNK O
Gleevec NNP 0 1 UNK B-Brand
inhibits NNS 0 1 UNK O
acetaminophen VBP 0 1 16 O
O NNP 0 1 2 O
- : 0 0 2 O
glucuronidation NN 0 1 UNK O
( ( 0 0 2 O
Ki NNP 0 0 UNK O
value NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
M NNP 0 1 2 O
) ) 0 0 2 O
at IN 0 0 12 O
therapeutic JJ 0 1 6 O
levels NNS 1 1 1 O
. . 0 0 12 O

Antacids NNS 0 1 UNK B-Group
: : 0 0 2 O
Concomitant NNP 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
antacids NNS 1 1 14 B-Group
containing VBG 1 1 1 O
magnesium NN 0 1 14 B-Drug
or CC 0 0 12 O
aluminum NN 0 1 16 B-Drug
with IN 0 0 12 O
VIDEX NNP 0 1 UNK B-Brand
Chewable NNP 0 0 0 O
/ NNP 0 0 2 O
Dispersible NNP 0 0 UNK O
Buffered NNP 0 1 UNK O
Tablets NNP 0 1 0 O
or CC 0 0 12 O
Pediatric NNP 0 1 7 O
Powder NNP 0 1 2 O
for IN 0 0 12 O
Oral NNP 0 1 2 O
Solution NNP 0 1 2 O
may MD 0 0 1 O
potentiate VB 0 0 UNK O
adverse JJ 0 0 1 O
events NNS 1 1 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
the DT 0 0 12 O
antacid JJ 0 1 UNK B-Group
components NNS 1 1 1 O
. . 0 0 12 O

b SYM 0 0 16 B-Group
- : 0 0 2 O
Adrenergic JJ 0 1 UNK I-Group
Blocking VBG 0 1 UNK I-Group
Agents NNS 0 1 2 I-Group
: : 0 0 2 O
Actions NNS 0 1 UNK O
of IN 0 0 12 O
some DT 0 0 12 O
of IN 0 0 12 O
beta JJ 0 1 16 B-Group
- : 0 0 2 O
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
may MD 0 0 1 O
be VB 0 0 12 O
impaired VBN 1 1 6 O
when WRB 0 0 12 O
hypothyroid JJ 0 1 6 O
patients NNS 1 1 6 O
become VBP 0 0 12 O
euthyroid JJ 0 1 14 O
. . 0 0 12 O

Therefore RB 0 0 1 O
EXTREME JJ 0 1 UNK O
CAUTION NNP 0 0 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
exercised VBN 1 1 1 O
when WRB 0 0 12 O
administering VBG 1 1 1 O
dopamine NN 0 1 14 B-Drug
HCl NNP 0 0 14 I-Drug
to TO 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
cyclopropane NN 0 1 UNK B-Drug
or CC 0 0 12 O
halogenated VBN 0 0 UNK B-Group
hydrocarbon NN 0 1 13 I-Group
anesthetics NNS 1 1 13 I-Group
. . 0 0 12 O

Pregnancies NNS 0 1 UNK O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
by IN 0 0 12 O
users NNS 1 1 UNK O
of IN 0 0 12 O
combined JJ 0 1 1 B-Group
hormonal JJ 0 1 6 I-Group
contraceptives NNS 1 1 13 I-Group
who WP 0 0 12 O
also RB 0 0 12 O
used VBD 1 1 12 O
some DT 0 0 12 O
form NN 0 1 1 O
of IN 0 0 12 O
St. NNP 0 1 2 O
Johns NNP 0 0 UNK O
Wort NNP 0 0 UNK O
. . 0 0 12 O

Therefore IN 0 0 1 O
it PRP 0 0 12 O
can MD 0 0 12 O
prolong VB 0 0 13 O
bleeding JJ 0 1 6 O
time NN 0 1 12 O
by IN 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
minutes NNS 1 1 12 O
from IN 0 0 12 O
baseline NN 0 1 1 O
values NNS 1 1 1 O
. . 0 0 12 O

This DT 0 0 2 O
effect NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
kept VBN 1 1 12 O
in IN 0 0 12 O
mind NN 0 1 12 O
when WRB 0 0 12 O
bleeding VBG 1 1 6 O
times NNS 1 1 12 O
are VBP 1 0 12 O
determined VBN 1 1 1 O
. . 0 0 12 O

Quinidine NN 0 1 0 B-Drug
: : 0 0 2 O
Immediate NNP 0 1 UNK O
Release NNP 0 1 2 O
Capsules NNP 0 1 0 O
: : 0 0 2 O
There EX 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
rare JJ 0 1 12 O
reports NNS 1 1 1 O
of IN 0 0 12 O
an DT 0 0 12 O
interaction NN 0 1 UNK O
between IN 0 0 12 O
quinidine NN 0 1 16 B-Drug
and CC 0 0 12 O
nifedipine NN 0 1 0 B-Drug
( ( 0 0 2 O
with IN 0 0 12 O
a DT 0 0 12 O
decreased JJ 0 1 1 O
plasma NN 0 1 14 O
level NN 0 1 1 O
of IN 0 0 12 O
quinidine NN 0 1 16 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

In IN 0 0 2 O
addition NN 0 1 1 O
CNS NNP 0 1 6 O
toxicity NN 0 1 6 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
( ( 0 0 2 O
confusion NN 0 1 1 O
disorientation NN 0 1 6 O
respiratory NN 0 1 6 O
depression NN 0 1 6 O
apnea NN 0 1 6 O
seizures NNS 1 1 6 O
) ) 0 0 2 O
following VBG 1 1 1 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
cimetidine NN 0 1 13 B-Drug
with IN 0 0 12 O
opioid JJ 0 1 13 B-Group
analgesics NNS 1 1 14 I-Group
; : 0 0 2 O

Alternatively RB 0 0 UNK O
provide VB 0 1 1 O
medical JJ 0 1 1 O
supervision NN 0 1 1 O
for IN 0 0 12 O
at IN 0 0 12 O
least JJS 0 1 12 O
one CD 0 1 12 O
hour NN 0 1 12 O
after IN 0 0 12 O
the DT 0 0 12 O
initial JJ 0 1 1 O
dose NN 0 1 6 O
. . 0 0 12 O

Theophylline NNP 0 1 UNK B-Drug
VIOXX NNP 0 1 UNK B-Brand
9 CD 0 0 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
administered VBN 1 1 1 O
once RB 0 0 12 O
daily JJ 0 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
increased VBD 1 1 1 O
plasma JJ 0 1 14 O
theophylline NN 0 1 16 B-Drug
concentrations NNS 1 1 13 O
( ( 0 0 2 O
AUC NNP 0 1 UNK O
( ( 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
) ) 0 0 2 O
) ) 0 0 2 O
by IN 0 0 12 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
in IN 0 0 12 O
healthy JJ 0 1 12 O
subjects NNS 1 1 UNK O
administered VBD 1 1 1 O
a DT 0 0 12 O
single JJ 0 1 12 O
9 CD 0 0 2 O
- : 0 0 2 O
mg NN 0 1 0 O
dose NN 0 1 6 O
of IN 0 0 12 O
theophylline NN 0 1 16 B-Drug
. . 0 0 12 O

Saquinavir NN 0 1 UNK B-Drug

As IN 0 0 2 O
noted VBN 1 0 1 O
below IN 0 0 12 O
a DT 0 0 12 O
sub JJ 0 1 1 O
- : 0 0 2 O
for IN 0 0 12 O
fluvoxamine NN 0 1 16 B-Drug
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
alprazolam PDT 0 1 0 B-Drug
a DT 0 0 12 O
drug NN 0 1 1 O
that WDT 0 0 12 O
is VBZ 1 0 12 O
known VBN 1 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
the DT 0 0 12 O
IIIA9 NNP 0 0 UNK O
isozyme NN 0 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
clinical JJ 0 1 6 O
relevance NN 0 1 UNK O
of IN 0 0 12 O
this DT 0 0 12 O
in IN 0 0 12 O
vitro NN 0 1 UNK O
finding NN 0 1 12 O
is VBZ 1 0 12 O
unknown JJ 0 1 12 O
. . 0 0 12 O

The DT 0 0 2 O
effect NN 0 1 1 O
on IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
was VBD 1 0 12 O
explored VBN 1 0 1 O
further RB 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
clinical JJ 0 1 6 O
interaction NN 0 1 UNK O
study NN 0 1 1 O
with IN 0 0 12 O
theophylline NN 0 1 16 B-Drug
and CC 0 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
metabolism NN 0 1 16 O
was VBD 1 0 12 O
observed VBN 1 1 1 O
. . 0 0 12 O

Aspirin NNP 0 1 0 B-Brand
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
cautiously RB 0 0 UNK O
in IN 0 0 12 O
conjunction NN 0 1 1 O
with IN 0 0 12 O
cortico JJ 0 0 UNK B-Group
- : 0 0 2 O
steroids NNS 1 1 6 I-Group
in IN 0 0 12 O
patients NNS 1 1 6 O
suffering VBG 1 1 12 O
from IN 0 0 12 O
hypopro JJ 0 0 UNK O
- : 0 0 2 O
thrombinemia NN 0 0 UNK O
. . 0 0 12 O

While IN 0 0 12 O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
chronic JJ 0 1 6 O
phenytoin NN 0 1 16 B-Drug
or CC 0 0 12 O
carbamazepine NN 0 1 16 B-Drug
therapy NN 0 1 6 O
on IN 0 0 12 O
the DT 0 0 12 O
action NN 0 1 13 O
of IN 0 0 12 O
NIMBEX NNP 0 1 UNK B-Brand
are VBP 1 0 12 O
unknown JJ 0 1 12 O
slightly RB 0 1 3 O
shorter JJR 1 1 UNK O
durations NNS 1 1 1 O
of IN 0 0 12 O
neuromuscular JJ 0 1 6 O
block NN 0 1 3 O
may MD 0 0 1 O
be VB 0 0 12 O
anticipated VBN 1 1 1 O
and CC 0 0 12 O
infusion NN 0 1 14 O
rate NN 0 1 1 O
requirements NNS 1 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
higher JJR 1 1 1 O
. . 0 0 12 O

Depending VBG 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
traction NN 0 1 13 O
of IN 0 0 12 O
drug NN 0 1 1 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
P9 NNP 0 1 UNK O
9D9 CD 0 0 UNK O
the DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
plasma JJ 0 1 14 O
concentration NN 0 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
small JJ 0 1 12 O
or CC 0 0 12 O
quite JJ 0 0 12 O
large JJ 0 1 3 O
( ( 0 0 2 O
9 CD 0 0 2 O
fold JJ 0 1 3 O
increase NN 0 1 1 O
in IN 0 0 12 O
plasma JJ 0 1 14 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
TCA NNP 0 1 13 B-Group
) ) 0 0 2 O
. . 0 0 12 O

The DT 0 0 2 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
irbesartan NNS 0 1 16 B-Drug
were VBD 1 0 12 O
not RB 0 1 12 O
affected VBN 1 1 1 O
by IN 0 0 12 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
nifedipine NN 0 1 0 B-Drug
or CC 0 0 12 O
hydrochlorothiazide NN 0 1 0 B-Drug

Bile NNP 0 1 7 B-Group
acid NN 0 1 14 I-Group
sequestrants NNS 0 0 UNK I-Group
have VBP 0 0 12 O
been VBN 1 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
bind VB 0 1 UNK O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
given VBN 1 1 12 O
concurrently RB 0 0 1 O
. . 0 0 12 O

Diuretics NNS 0 1 UNK B-Group
: : 0 0 2 O
Diclofenac NNP 0 1 UNK B-Drug
and CC 0 0 12 O
other JJ 0 0 12 O
NSAIDs NNP 0 1 UNK B-Group
can MD 0 0 12 O
inhibit VB 0 1 13 O
the DT 0 0 12 O
activity NN 0 1 1 O
of IN 0 0 12 O
diuretics NNS 1 1 14 B-Group
. . 0 0 12 O

Caution NN 0 0 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
exercised VBN 1 1 1 O
with IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
when WRB 0 0 12 O
treating VBG 1 1 6 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
TAXOTERE NNP 0 1 UNK B-Brand
as IN 1 0 12 O
there EX 0 0 12 O
is VBZ 1 0 12 O
a DT 0 0 12 O
potential JJ 0 1 1 O
for IN 0 0 12 O
a DT 0 0 12 O
significant JJ 0 1 1 O
interaction NN 0 1 UNK O
. . 0 0 12 O

Nevirapine NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
known VBN 1 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
an DT 0 0 12 O
inducer NN 0 1 UNK O
of IN 0 0 12 O
these DT 0 0 12 O
enzymes NNS 1 1 14 O
. . 0 0 12 O

Potent JJ 0 1 UNK O
inhibitors NNS 1 1 14 O
of IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
( ( 0 0 2 O
below IN 0 0 12 O
) ) 0 0 2 O
increase VB 0 1 1 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
myopathy NN 0 1 8 O
by IN 0 0 12 O
reducing VBG 1 1 1 O
the DT 0 0 12 O
elimination NN 0 1 UNK O
of IN 0 0 12 O
lovastatin NN 0 1 13 B-Drug
. . 0 0 12 O

Potential NNP 0 1 UNK O
for IN 0 0 12 O
Interaction NNP 0 1 2 O
with IN 0 0 12 O
Monoamine NNP 0 1 UNK B-Group
Oxidase NNP 0 1 UNK I-Group
Inhibitors NNP 0 1 7 I-Group

Therefore RB 0 0 1 O
there EX 0 0 12 O
is VBZ 1 0 12 O
a DT 0 0 12 O
potential JJ 0 1 1 O
for IN 0 0 12 O
an DT 0 0 12 O
interaction NN 0 1 UNK O
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
are VBP 1 0 12 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
CYP NNP 0 1 UNK O
9A9 CD 0 0 UNK O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
amitriptyline NN 0 1 16 B-Drug
tacrine NN 0 1 UNK B-Drug
and CC 0 0 12 O
zileuton NN 0 1 13 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interactions NNP 0 1 UNK O
Naproxen NNP 0 1 0 B-Drug
may MD 0 0 1 O
decrease VB 0 1 1 O
platelet VB 0 1 14 O
aggregation NN 0 1 UNK O
and CC 0 0 12 O
prolong JJ 0 0 13 O
bleeding NN 0 1 6 O
time NN 0 1 12 O
. . 0 0 12 O

Although IN 0 0 12 O
increased VBN 1 1 1 O
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
( ( 0 0 2 O
C NNP 0 0 2 O
max NN 0 0 3 O
and CC 0 0 12 O
AUC NNP 0 1 UNK O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
hrs NN 1 0 16 O
) ) 0 0 2 O
of IN 0 0 12 O
desloratadine NN 0 1 UNK B-Drug
and CC 0 0 12 O
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
hydroxydesloratadine NN 0 0 UNK I-Drug_n
were VBD 1 0 12 O
observed VBN 1 1 1 O
there EX 0 0 12 O
were VBD 1 0 12 O
no DT 0 0 12 O
clinically RB 0 0 6 O
relevant JJ 0 1 1 O
changes NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
safety NN 0 1 1 O
profile NN 0 1 1 O
of IN 0 0 12 O
desloratadine NN 0 1 UNK B-Drug
as IN 1 0 12 O
assessed VBN 1 1 1 O
by IN 0 0 12 O
electrocardiographic JJ 0 1 8 O
parameters NNS 1 1 1 O
( ( 0 0 2 O
including VBG 1 1 1 O
the DT 0 0 12 O
corrected VBN 1 1 1 O
QT NNP 0 1 13 O
interval NN 0 1 1 O
) ) 0 0 2 O
clinical JJ 0 1 6 O
laboratory NN 0 1 1 O
tests NNS 1 1 1 O
vital JJ 0 1 1 O
signs NNS 1 1 12 O
and CC 0 0 12 O
adverse JJ 0 0 1 O
events NNS 1 1 12 O
. . 0 0 12 O

Dosage NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
anticoagulant NN 0 1 13 B-Group
may MD 0 0 1 O
require VB 0 0 1 O
reduction NN 0 1 1 O
in IN 0 0 12 O
order NN 0 1 1 O
to TO 0 0 12 O
maintain VB 0 1 1 O
satisfactory JJ 0 1 1 O
therapeutic JJ 0 1 6 O
hypoprothrombinemia NN 0 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
mean JJ 0 1 12 O
AUC NNP 0 1 UNK O
values NNS 1 1 1 O
of IN 0 0 12 O
EE NNP 0 0 UNK O
were VBD 1 0 12 O
decreased VBN 1 1 1 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
[ JJ 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
CI NNP 0 1 UNK O
: : 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
] NN 0 0 2 O
in IN 0 0 12 O
one CD 0 1 12 O
study NN 0 1 1 O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
[ JJ 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
CI NNP 0 1 UNK O
: : 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
] NN 0 0 2 O
in IN 0 0 12 O
another DT 0 0 12 O
study NN 0 1 1 O
[ VBD 0 0 2 O
9 CD 0 0 2 O
9 CD 0 0 2 O
] NN 0 0 2 O
. . 0 0 12 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interactions VBZ 0 1 UNK O
A NNP 0 0 2 O
false JJ 0 1 13 O
positive JJ 0 1 1 O
reaction NN 0 1 1 O
for IN 0 0 12 O
glucose NN 0 1 14 O
in IN 0 0 12 O
the DT 0 0 12 O
urine NN 0 1 6 O
may MD 0 0 1 O
occur VB 0 1 1 O
with IN 0 0 12 O
Benedicts NNP 0 0 UNK O
solution NN 0 1 1 O
Fehlings NNP 0 0 UNK O
solution NN 0 1 1 O
or CC 0 0 12 O
with IN 0 0 12 O
CLINITEST NNP 0 1 UNK O
tablets NNS 1 1 3 O
but CC 0 0 12 O
not RB 0 1 12 O
with IN 0 0 12 O
enzyme SYM 0 1 14 O
- : 0 0 2 O
based VBN 1 1 1 O
tests NNS 1 1 1 O
such JJ 0 0 1 O
as IN 1 0 12 O
CLINISTIX NNP 0 0 UNK O
. . 0 0 12 O

AZOPT NNP 0 1 UNK B-Brand
( ( 0 0 2 O
brinzolamide IN 0 1 16 B-Drug
ophthalmic JJ 0 1 6 O
suspension NN 0 1 3 O
) ) 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
contains VBZ 1 1 1 O
a DT 0 0 12 O
carbonic JJ 0 1 13 B-Group
anhydrase NN 0 0 13 I-Group
inhibitor NN 0 1 14 I-Group
. . 0 0 12 O

This DT 0 0 2 O
may MD 0 0 1 O
potentiate VB 0 0 UNK O
and CC 0 0 12 O
prolong VB 0 0 13 O
hypnotic JJ 0 1 13 O
and CC 0 0 12 O
sedative JJ 0 1 6 O
effects NNS 1 1 1 O
especially RB 0 0 12 O
with IN 0 0 12 O
repeated JJ 0 1 1 O
dosing NN 0 0 14 O
or CC 0 0 12 O
chronic JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
these DT 0 0 12 O
agents NNS 1 1 1 O
. . 0 0 12 O

No DT 0 0 2 O
specific JJ 0 1 1 O
studies NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
performed VBN 1 1 1 O
and CC 0 0 12 O
caution NN 0 0 1 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O

Reductions NNS 0 1 UNK O
in IN 0 0 12 O
serum NN 0 1 14 O
endogenous JJ 0 1 14 O
vitamin NN 0 1 6 O
D NNP 0 1 2 O
concentrations NNS 1 1 13 O
have VBP 0 0 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
following VBG 1 1 1 O
the DT 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
to TO 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
ketoconazole VB 0 1 16 B-Drug
for IN 0 0 12 O
a DT 0 0 12 O
week NN 0 1 12 O
to TO 0 0 12 O
healthy JJ 0 1 12 O
men NNS 0 1 13 O
. . 0 0 12 O

If IN 0 0 12 O
this DT 0 0 12 O
is VBZ 1 0 12 O
not RB 0 1 12 O
possible JJ 0 1 1 O
the DT 0 0 12 O
starting VBG 1 1 12 O
dose NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
reduced VBN 1 1 1 O
and CC 0 0 12 O
the DT 0 0 12 O
patient NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
observed VBN 1 1 1 O
closely RB 0 0 1 O
for IN 0 0 12 O
several JJ 0 1 12 O
hours NNS 1 1 12 O
following VBG 1 1 1 O
an DT 0 0 12 O
initial JJ 0 1 1 O
dose NN 0 1 6 O
and CC 0 0 12 O
until IN 0 0 12 O
blood NN 0 1 6 O
pressure NN 0 1 1 O
has VBZ 1 0 12 O
stabilized VBN 1 1 1 O
( ( 0 0 2 O
see VB 0 1 12 O
DOSAGE NNP 0 1 UNK O
AND NNP 0 0 11 O
ADMINISTRATION NNP 0 1 11 O
. . 0 0 12 O
) ) 0 0 2 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interactions NNP 0 1 UNK O
There EX 0 0 12 O
are VBP 1 0 12 O
no DT 0 0 12 O
known JJ 0 1 12 O
interactions NNS 1 1 UNK O
between IN 0 0 12 O
MIRAPEX NNP 0 1 UNK B-Brand
and CC 0 0 12 O
laboratory NN 0 1 1 O
tests NNS 1 1 1 O
. . 0 0 12 O

dosage NN 0 1 0 O
adjustments NNS 1 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
necessary JJ 0 0 1 O
. . 0 0 12 O

In IN 0 0 2 O
particular JJ 0 0 1 O
convulsions NNS 1 1 13 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
when WRB 0 0 12 O
ethionamide NN 0 1 UNK B-Drug
is VBZ 1 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
cycloserine NN 0 1 UNK B-Drug
and CC 0 0 12 O
special JJ 0 1 12 O
care NN 0 1 12 O
should MD 0 0 12 O
be VB 0 0 12 O
taken VBN 1 1 12 O
when WRB 0 0 12 O
the DT 0 0 12 O
treatment NN 0 1 6 O
regimen NN 0 1 6 O
includes VBZ 1 1 1 O
both DT 0 0 12 O
of IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

Pramipexole NN 0 1 0 B-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
inhibit VB 0 1 13 O
CYP NNP 0 1 UNK O
enzymes NNS 1 1 14 O
CYPIA9 NNP 0 0 UNK O
CYP9C9 NNP 0 0 UNK O
CYP9CI9 NNP 0 0 UNK O
CYP9EI NNP 0 0 UNK O
and CC 0 0 12 O
CYP9A9 NNP 0 0 UNK O
. . 0 0 12 O

Certain NNP 0 1 UNK O
endocrine NN 0 1 6 O
and CC 0 0 12 O
liver JJ 0 1 6 O
function NN 0 1 1 O
tests NNS 1 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
affected VBN 1 1 1 O
by IN 0 0 12 O
estrogen NN 0 1 6 B-Group
- : 0 0 2 O
containing VBG 1 1 1 O
oral JJ 0 1 6 O
contraceptives NNS 1 1 13 B-Group
. . 0 0 12 O

When WRB 0 0 12 O
given VBN 1 1 12 O
concurrently RB 0 0 1 O
the DT 0 0 12 O
following JJ 0 1 1 O
drugs NNS 1 1 6 O
may MD 0 0 1 O
interact VB 0 0 UNK O
with IN 0 0 12 O
thiazide JJ 0 1 UNK B-Group
diuretics NNS 1 1 14 I-Group
. . 0 0 12 O

Increased VBN 0 1 7 O
plasma NN 0 1 14 O
HDL NNP 0 1 14 O
and CC 0 0 12 O
HDL9 NNP 0 0 UNK O
cholesterol NN 0 1 6 O
subfraction NN 0 0 UNK O
concentrations NNS 1 1 13 O
reduced VBD 1 1 1 O
LDL NNP 0 0 14 O
cholesterol NN 0 1 6 O
concentration NN 0 1 1 O
increased VBD 1 1 1 O
triglyceride JJ 0 1 14 O
levels NNS 1 1 1 O
. . 0 0 12 O

Potassium NN 0 1 14 B-Drug
Supplements NNS 0 1 UNK O
and CC 0 0 12 O
Potassium NNP 0 1 14 B-Group
- : 0 0 2 O
Sparing VBG 0 0 UNK I-Group
Diuretics NNS 0 1 UNK I-Group
: : 0 0 2 O
UNIVASC NN 0 1 UNK B-Brand
can MD 0 0 12 O
increase VB 0 1 1 O
serum JJ 0 1 14 O
potassium NN 0 1 14 O
because IN 0 0 12 O
it PRP 0 0 12 O
decreases VBZ 1 1 UNK O
aldosterone JJ 0 1 UNK O
secretion NN 0 1 14 O
. . 0 0 12 O

INOmax NNP 0 1 UNK B-Brand
has VBZ 1 0 12 O
been VBN 1 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
tolazoline JJ 0 1 UNK B-Drug
dopamine NN 0 1 14 B-Drug
dobutamine NN 0 1 14 B-Drug
steroids NNS 1 1 6 B-Group
surfactant NN 0 1 14 B-Drug
and CC 0 0 12 O
high JJ 0 1 1 O
- : 0 0 2 O
frequency NN 0 1 1 O
ventilation NN 0 1 3 O
. . 0 0 12 O

Co NNP 0 1 2 O
- : 0 0 2 O
administration NN 0 1 1 O
with IN 0 0 12 O
antifungal JJ 0 1 14 B-Group
agents NNS 1 1 1 I-Group
such JJ 0 0 1 O
as IN 1 0 12 O
ketoconazole NN 0 1 16 B-Drug
or CC 0 0 12 O
itraconazole NN 0 1 0 B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O

Table JJ 0 1 UNK O
9 CD 0 0 2 O

Doxylamine NNP 0 1 UNK B-Drug
may MD 0 0 1 O
enhance VB 0 1 UNK O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
epinephrine NN 0 1 14 B-Drug
. . 0 0 12 O

There EX 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reports NNS 1 1 1 O
of IN 0 0 12 O
theophylline JJ 0 1 16 B-Drug
- : 0 0 2 O
related JJ 0 1 1 O
side NN 0 1 3 O
- : 0 0 2 O
effects NNS 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
on IN 0 0 12 O
concomitant JJ 0 1 6 O
theophylline NN 0 1 16 B-Drug
- : 0 0 2 O
quinolone NN 0 1 UNK B-Group
therapy NN 0 1 6 O
. . 0 0 12 O

Isoflurane NNP 0 1 UNK B-Drug
potentiates VBZ 1 0 UNK O
the DT 0 0 12 O
muscle NN 0 1 6 O
relaxant JJ 0 0 0 O
effect NN 0 1 1 O
of IN 0 0 12 O
all DT 0 0 12 O
muscle NN 0 1 6 B-Group
relaxants NNS 1 0 13 I-Group
most RBS 0 0 12 O
notably RB 0 0 1 O
nondepolarizing JJ 0 0 UNK B-Group
muscle NN 0 1 6 I-Group
relaxants NNS 1 0 13 I-Group
and CC 0 0 12 O
MAC NNP 0 1 UNK O
( ( 0 0 2 O
minimum JJ 0 1 1 O
alveolar JJ 0 1 8 O
concentration NN 0 1 1 O
) ) 0 0 2 O
is VBZ 1 0 12 O
reduced VBN 1 1 1 O
by IN 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
N NNP 0 1 2 O
9O CD 0 0 UNK O
. . 0 0 12 O

Beta NNP 0 1 2 B-Group
- : 0 0 2 O
adrenergic NN 0 1 UNK I-Group
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
should MD 0 0 12 O
be VB 0 0 12 O
withdrawn VBN 1 1 1 O
at IN 0 0 12 O
least JJS 0 1 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
before IN 0 1 12 O
conducting VBG 1 1 UNK O
an DT 0 0 12 O
arbutamine JJ 0 1 UNK B-Drug
- : 0 0 2 O
mediated JJ 0 1 13 O
stress JJ 0 1 1 O
test NN 0 1 1 O
. . 0 0 12 O

Other JJ 0 0 2 O
drugs NNS 1 1 6 O
which WDT 0 0 12 O
may MD 0 0 1 O
enhance VB 0 1 UNK O
the DT 0 0 12 O
neuromuscular JJ 0 1 6 O
blocking VBG 1 1 UNK O
action NN 0 1 13 O
of IN 0 0 12 O
nondepolarizing VBG 0 0 UNK B-Group
agents NNS 1 1 1 I-Group
such JJ 0 0 1 O
as IN 1 0 12 O
NIMBEX NNP 0 1 UNK B-Brand
include VBP 0 1 1 O
certain JJ 0 1 1 O
antibiotics NNS 1 1 6 B-Group
( ( 0 0 2 O
e. JJ 0 0 1 O
g. NN 0 1 13 O
aminoglycosides NNS 0 1 13 B-Group
tetracyclines NNS 1 1 13 B-Group
bacitracin VBP 0 1 16 B-Drug
polymyxins NNS 1 1 UNK B-Group
lincomycin JJ 0 1 UNK B-Drug
clindamycin NN 0 1 0 B-Drug
colistin NN 0 1 13 B-Drug
and CC 0 0 12 O
sodium NN 0 1 14 B-Drug
colistemethate NN 0 0 UNK I-Drug
) ) 0 0 2 O
magnesium NN 0 1 14 B-Group
salts NNS 1 1 13 O
lithium JJ 0 1 16 B-Drug
local JJ 0 1 12 O
anesthetics NNS 1 1 13 B-Group
procainamide NN 0 1 16 B-Drug
and CC 0 0 12 O
quinidine NN 0 1 16 B-Drug
. . 0 0 12 O

Because IN 0 0 12 O
dopamine NN 0 1 14 B-Drug
is VBZ 1 0 12 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
monoamine JJ 0 1 13 O
oxidase NN 0 1 13 O
MAO NNP 0 1 14 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
this DT 0 0 12 O
enzyme JJ 0 1 14 O
prolongs NNS 0 0 UNK O
and CC 0 0 12 O
potentiates VBZ 1 0 UNK O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
dopamine NN 0 1 14 B-Drug
. . 0 0 12 O

Temporary JJ 0 1 2 O
dosage NN 0 1 0 O
adjustment NN 0 1 1 O
of IN 0 0 12 O
antimyasthenics NNS 0 0 UNK O
may MD 0 0 1 O
be VB 0 0 12 O
required VBN 1 1 1 O
. . 0 0 12 O

Aprepitant NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
a DT 0 0 12 O
substrate NN 0 1 UNK O
for IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
; : 0 0 2 O

Patients NNS 0 1 7 O
taking VBG 1 0 12 O
isoniazid NN 0 1 13 B-Drug
when WRB 0 0 12 O
disulfiram NN 0 1 13 B-Drug
is VBZ 1 0 12 O
given VBN 1 1 12 O
should MD 0 0 12 O
be VB 0 0 12 O
observed VBN 1 1 1 O
for IN 0 0 12 O
the DT 0 0 12 O
appearance NN 0 1 12 O
of IN 0 0 12 O
unsteady JJ 0 1 3 O
gait NN 0 1 6 O
or CC 0 0 12 O
marked VBN 1 1 1 O
changes NNS 1 1 1 O
in IN 0 0 12 O
mental JJ 0 1 1 O
status NN 0 1 1 O
; : 0 0 2 O

co SYM 0 1 12 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
phenobarbital NN 0 1 16 B-Drug
may MD 0 0 1 O
produce VB 0 0 1 O
a DT 0 0 12 O
synergistic JJ 0 1 UNK O
anticonvulsant JJ 0 1 14 O
action NN 0 1 13 O
. . 0 0 12 O

Established VBN 0 1 UNK O
Drug NNP 0 1 2 O
Interactions NNP 0 1 UNK O
( ( 0 0 2 O
continued VBN 1 1 12 O
) ) 0 0 2 O

They PRP 0 0 12 O
should MD 0 0 12 O
be VB 0 0 12 O
observed VBN 1 1 1 O
closely RB 0 0 1 O
particularly RB 0 0 1 O
if IN 0 0 12 O
renal JJ 0 1 6 O
function NN 0 1 1 O
is VBZ 1 0 12 O
impaired VBN 1 1 6 O
. . 0 0 12 O

After IN 0 0 2 O
the DT 0 0 12 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
9 CD 0 0 2 O
mg JJ 0 1 0 O
oral JJ 0 1 6 O
ketoconazole NN 0 1 16 B-Drug
twice RB 0 1 12 O
daily RB 0 1 12 O
and CC 0 0 12 O
one CD 0 1 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
dose NN 0 1 6 O
of IN 0 0 12 O
loratadine NN 0 1 0 B-Drug
to TO 0 0 12 O
9 CD 0 0 2 O
subjects NNS 1 1 UNK O
the DT 0 0 12 O
AUC NNP 0 1 UNK O
and CC 0 0 12 O
Cmax NNP 0 1 UNK O
of IN 0 0 12 O
loratadine NN 0 1 0 B-Drug
averaged VBD 1 1 18 O
9 CD 0 0 2 O
% NN 0 0 18 O
( ( 0 0 2 O
9 CD 0 0 2 O
S.D NNP 0 1 UNK O
. . 0 0 12 O
) ) 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
( ( 0 0 2 O
9 CD 0 0 2 O
S.D NNP 0 1 UNK O
. . 0 0 12 O
) ) 0 0 2 O
respectively RB 0 0 1 O
of IN 0 0 12 O
those DT 0 0 12 O
obtained VBN 1 1 1 O
after IN 0 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
treatment NN 0 1 6 O
with IN 0 0 12 O
placebo NN 0 1 13 O
. . 0 0 12 O

. . 0 0 12 O

Beta NNP 0 1 2 B-Group
- : 0 0 2 O
blocking VBG 1 1 UNK I-Group
Agents NNS 0 1 2 I-Group
: : 0 0 2 O
The DT 0 0 2 O
concomitant NN 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
Bepridil NNP 0 1 UNK B-Drug
and CC 0 0 12 O
beta SYM 0 1 16 B-Group
- : 0 0 2 O
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
has VBZ 1 0 12 O
been VBN 1 0 12 O
well RB 0 1 12 O
tolerated VBN 1 0 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
stable JJ 0 1 1 O
angina NN 0 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
effectiveness NN 0 1 UNK O
and CC 0 0 12 O
safety NN 0 1 1 O
of IN 0 0 12 O
ZETIA NNP 0 1 UNK B-Brand
were VBD 1 0 12 O
similar JJ 0 1 1 O
between IN 0 0 12 O
these DT 0 0 12 O
patients NNS 1 1 6 O
and CC 0 0 12 O
younger JJR 1 1 12 O
subjects NNS 1 1 UNK O
. . 0 0 12 O

Serious JJ 0 1 UNK O
anticholinergic NN 0 1 13 O
symptoms NNS 1 1 6 O
( ( 0 0 2 O
severe JJ 0 1 6 O
dry JJ 0 1 3 O
mouth NN 0 1 3 O
urinary JJ 0 1 6 O
retention NN 0 1 1 O
blurred VBD 1 1 3 O
vision NN 0 1 1 O
) ) 0 0 2 O
have VBP 0 0 12 O
been VBN 1 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
elevations NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
serum NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
when WRB 0 0 12 O
cimetidine NN 0 1 13 B-Drug
is VBZ 1 0 12 O
added VBN 1 1 12 O
to TO 0 0 12 O
the DT 0 0 12 O
drug NN 0 1 1 O
regimen NNS 0 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
magnitude NN 0 1 UNK O
of IN 0 0 12 O
interaction NN 0 1 UNK O
at IN 0 0 12 O
other JJ 0 0 12 O
doses NNS 1 1 6 O
is VBZ 1 0 12 O
not RB 0 1 12 O
known VBN 1 1 12 O
. . 0 0 12 O

The DT 0 0 2 O
mechanism NN 0 1 13 O
underlying VBG 1 0 1 O
many JJ 0 0 12 O
of IN 0 0 12 O
these DT 0 0 12 O
events NNS 1 1 12 O
is VBZ 1 0 12 O
unknown JJ 0 1 12 O
but CC 0 0 12 O
may MD 0 0 1 O
represent VB 0 1 1 O
increased JJ 0 1 1 O
hypotension NN 0 1 6 O
. . 0 0 12 O

Patients NNS 0 1 7 O
receiving VBG 1 1 1 O
rifabutin NN 0 1 13 B-Drug
and CC 0 0 12 O
fluconazole JJ 0 1 0 B-Drug
concomitantly RB 0 0 14 O
should MD 0 0 12 O
be VB 0 0 12 O
carefully RB 0 0 12 O
monitored VBN 1 1 1 O
. . 0 0 12 O

9 CD 0 0 2 O
hours NNS 1 1 12 O
. . 0 0 12 O

In IN 0 0 2 O
nine CD 0 1 12 O
otherwise RB 0 0 1 O
healthy JJ 0 1 12 O
subjects NNS 1 1 UNK O
with IN 0 0 12 O
epilepsy NN 0 1 13 O
ingesting VBG 1 1 UNK O
carbamazepine VBP 0 1 16 B-Drug
the DT 0 0 12 O
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
trough NN 0 1 3 O
( ( 0 0 2 O
Cmin NNP 0 1 UNK O
) ) 0 0 2 O
carbamazepine NN 0 1 16 B-Drug
concentration NN 0 1 1 O
was VBD 1 0 12 O
9 CD 0 0 2 O
9 CD 0 0 2 O
micrograms NNS 1 1 14 O
/ JJ 0 0 2 O
mL NN 0 1 14 O
. . 0 0 12 O

Based VBN 0 1 2 O
on IN 0 0 12 O
this DT 0 0 12 O
reported VBN 1 1 1 O
activity NN 0 1 1 O
they PRP 0 0 12 O
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
given VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
Coly NNP 0 1 UNK B-Brand
- : 0 0 2 O
Mycin NNP 0 0 UNK I-Brand
M NNP 0 1 2 I-Brand
Parenteral NNP 0 1 UNK O
except IN 0 0 12 O
with IN 0 0 12 O
the DT 0 0 12 O
greatest JJS 1 1 UNK O
caution NN 0 0 1 O
. . 0 0 12 O

Digoxin NN 0 1 0 B-Drug
: : 0 0 2 O
Studies NNS 0 1 2 O
of IN 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
flurbiprofen NN 0 1 16 B-Drug
and CC 0 0 12 O
digoxin NN 0 1 14 B-Drug
to TO 0 0 12 O
healthy JJ 0 1 12 O
men NNS 0 1 13 O
( ( 0 0 2 O
n= IN 0 1 UNK O
9 CD 0 0 2 O
) ) 0 0 2 O
did VBD 1 0 12 O
not RB 0 1 12 O
show VB 0 1 12 O
a DT 0 0 12 O
change NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
steady JJ 0 1 1 O
state NN 0 1 1 O
serum NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
either DT 0 1 12 O
drug NN 0 1 1 O
. . 0 0 12 O

Caution NN 0 0 UNK O
is VBZ 1 0 12 O
advised VBN 1 0 12 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
chronic JJ 0 1 6 O
concomitant NN 0 1 6 O
therapy NN 0 1 6 O
. . 0 0 12 O

